Download - Cryptococcosis: a deadly fungal disease

Final ProgramInterscience Conference on Antimicrobial Agents and ChemotherapyASM’s Premier Annual Conference on InfectiousDiseases and Antimicrobial AgentsMoscone Convention Center | San Francisco, CAwww.icaac.org

Clinical TrialTranslationalResearchTherapeuticOFFICIAL PEER-REVIEWEDHIGHLIGHTS FROM THE52 nd Interscience ConferenceSeptember 9 - 12, 2012COMING THIS NOVEMBEROfficial Peer-Reviewed HighlightsWant to know more?Peer-ReviewedHighlightsINFECTIOUS DISEASEon Antimicrobial Agents andChemotherapyUpdatesScan for theICAAC 2011 editionDistribution of this independent reportis supported byInfectious Disease Genomics: Individual Variability,New OpportunititesTechnological advances now enable comparisons of more than a half amillion genetic variants in subjects with disease and population controls.A large number of novel genetic loci involved in susceptibility to commonimmune-related diseases, such as rheumatoid arthritis and inflammatorybowel disease, have been identified through genome-wide associationstudies. More recently, this methodology has been successfully applied toidentify loci involved in infectious disease susceptibility [Vannberg FO et al.Immunol Rev 2011]. See page 4.ALSO IN THIS ISSUE Hot Topics in Vaccines Clinical Trial Highlights – The ScienceSan Francisco, California, USABehind Infectious Disease Novel Approaches to Antibacterial Drug DiscoveryProduced by:Distribution supported by:

Table of ContentsICAAC Program Committee . ..............................4Welcome Letter . ........................................5Corporate Supporters . ...................................6ICAAC Mobile App . .....................................6Schedule-at-a-Glance . ...................................7ICAAC Awards and Lectures . .............................8Opening Keynote Session . .............................8ICAAC Lecture . .....................................8Cubist-ICAAC Award and Lecture . .....................8ICAAC Program Committee Awards . ....................9ICAAC Young Investigator Awards . ....................10Poster Walks . .........................................11Grant and Travel Grant Recipients . .......................13ICAAC ID Fellows Grant Program . ....................13ASM Infectious Diseases (ID) Fellow Travel Grants ......14ASM Student and Post-Doctoral Fellow Travel Grants . . . . 15American Society for Microbiology Products and Services . . . . 17Career Connections . .................................17ASM Journals . .................................... 17ASM Press Bookstore . ...............................17Membership . .......................................17Press Room and ICAAC Live . .........................17Convention Center Floor Plans . ..........................18Hotel Information . .....................................20Hotel Map . ............................................21Shuttle Information . ...................................22General Information . ...................................23Abstract Compilations . ..............................23Abstracts on CD-ROM .............................. 23Americans with Disabilities Act . ..................... 23ATM Machines . .....................................23Badge Policies . .................................... 23Business Center . ....................................24Cameras and Recordings . ........................... 24Certificate of Attendance . ........................... 24Child Safety . ...................................... 24Coat and Baggage Check . ........................... 24Cooperating Organizations . ...........................24E-Central . .........................................24Exhibit Hall . .......................................25ExpoCard . .........................................25First Aid . ..........................................25Food and Beverage Services . ......................... 25Future Meetings Booth . ..............................25Housing . ..........................................25Information Booths . ................................ 25Lost and Found . ................................... 26Messages . ......................................... 26Multimedia Sales . ...................................26Nursing Room . .....................................26Parking . .......................................... 26Poster Information . ................................ 26Poster Walks . ......................................26Program Changes . ..................................26Registration Hours . .................................26Satellite Symposia . ................................ 26Sessions and Room Capacity . .........................26Shipping . ......................................... 27Shuttle Service . ....................................27Smoking Policy . ................................... 27Speaker Ready Room . .............................. 27Telephone Numbers . .................................27Transportation . .....................................27Continuing Education . ..................................28Glossary . .............................................30Scientific Sessions . .................................... 31Workshops . ........................................31Sunday . ...........................................37Monday . ...........................................71Tuesday . .........................................127Wednesday . .......................................183Indices . ............................................ 207Abstract Authors Index . ............................207Keyword Index . ...................................261Program Grid . .....................................279Late-breakers . ...................................... 295Late-breaker Presentations . .........................295Late-breaker Abstracts ............................ .305Late-breaker Author Index . .........................339Late-breaker Keyword Index . ........................345ICAAC Headquarters:American Society for MicrobiologyMeetings & Exhibits1752 N Street, NWWashington, DC 20036-2904Telephone: (202) 737-3600Fax: (202) 942-9340E-mail: icaac@asmusa.orgInternet: www.icaac.orgCopyright © 2012 American Society for MicrobiologyPrinted in the United States of AmericaISBN: 978-1-55581-873-9ISSN: 0733-6373Final Program3

ICAAC 2012 Program CommitteeM. Lindsay Grayson, MD, ChairAustin Hospital, Melbourne, AustraliaCraig E. Rubens, MD, PhD, Vice ChairSeattle Children’s Hospital Research Institute, Seattle, WAJudith A. Aberg, MDNew York University School of Medicine, New York, NYDavid Michael Aronoff, MDUniversity of Michigan Health System, Ann Arbor, MIEmily Blumberg, MDUniversity of Pennsylvania, Philadelphia, PAGuy Boivin, MDLaval University, Quebec, CanadaRobert A. Bonomo, MDVA Medical Center, Cleveland, OHPatricia A. Bradford, PhDAstraZeneca Pharmaceuticals, Waltham, MAAngela M. Caliendo, MD, PhDEmory University Hospital, Atlanta, GAKaren Carroll, MDJohns Hopkins University School of Medicine, Baltimore, MDMorven S. Edwards, MDBaylor College of Medicine, Houston, TXJoseph J. Eron, Jr., MDUniversity of North Carolina, Chapel Hill, NCNiels Fridmodt-Moller, MDStatens Serum Institute, Copenhagen, DenmarkCarlo Giaquinto, MDUniversity of Padova, Padova, ItalyLoreen Herwaldt, MDUniversity of Iowa College of Medicine, Iowa City, IAStephen G. Jenkins, PhDWeill Cornell Medical College, New York, NYJohn A. Jernigan, MDCenters for Disease Control and Prevention, Atlanta, GAKevin C. Kain, MDUniversity of Toronto, Toronto, CanadaLaurent Kaiser, MDUniversity Hospitals of Geneva, Geneva, SwitzerlandAlan Magill, MDWalter Reed Army Medical Institute of Research, Silver Spring, MDLesley McGee, PhDCenters for Disease Control and Prevention, Atlanta, GAJean-Michel Molina, MD, PhDHospital Saint Louis, Paris, FrancePatrice Nordmann, PhDHospital Bicetre, Paris, FranceMalcolm G. P. Page, PhDBasilea Pharmaceuticia, Basel, SwitzerlandRobin Patel, MDMayo Clinic College of Medicine, Rochester, MNJohn Perfect, MDDuke University Medical Center, Durham, NCLaura J.V. Piddock, PhDUniversity of Birmingham, Birmingham, United KingdomLiise-anne Pirofski, MDAlbert Einstein College of Medicine, Bronx, NYJohann Pitout, MDCalgary Laboratory Services, Calgary, CanadaDidier Pittet, MDUniversity of Geneva, Geneva, SwitzerlandMichael J. Pucci, PhDAchillion Pharmaceuticals, New Haven, CTVincent Racaniello, PhDColumbia University Medical Center, New York, NYJesús Rodriguez Baño, MD, PhDHospital Universitario Virgen Macarena, Sevilla, SpainKeith A. Rodvold, PhDUniversity of Illinois, Chicago, ILWing-Hong Seto, MDQueen Mary Hospital, Hong Kong, ChinaShiranee Sriskandan, FRCP, PhDImperial College Faculty of Medicine, London, United KingdomTania C. Sorrell, MDUniversity of Sydney, Westmead, Australia4 September 9-12 |

Dear Colleagues,Welcome to San Francisco! On behalf of the Program Committee for the 52nd InterscienceConference on Antimicrobial Agents and Chemotherapy, we invite you to take full advantageof all that ICAAC has to offer. Scheduled throughout the four days of ICAAC, the premierconference on antimicrobial agents and infectious diseases, is a line-up of oral and posterpresentations showcasing the latest-breaking science and lectures from top researchers fromaround the globe.M. Lindsay GraysonCraig E. RubensThe ICAAC Program Committee has designed a program of the highest quality to facilitate theexchange of new information among healthcare professionals, particularly physicians, clinicalmicrobiologists, researchers, pharmacists and trainees specializing in infectious diseases. Twohundred and fifty-five sessions have been scheduled including: the Opening Keynote session,covering cutting edge issues related to diagnostics, viral hepatitis, and new drug discovery;the ICAAC Lecture “Fungal Disease in the 21st Century”; the Cubist-ICAAC Award Lecture“Antiviral Chemotherapy: Astonishing Progress and Formidable Pushback—The Ying and Yangof Host-Viral Interactions”; ten interactive symposia; 36 Meet-the-Experts sessions; and 70didactic symposia. In addition, on Sunday afternoon there will be a Poster Summary reportingon Early New Antimicrobial Agents and a Literature Review to provide an update on infectiousdiseases. From over 1,700 accepted abstract submissions, the Program Committee has organized107 poster sessions, 26 slide sessions and seven state-of-the-art mini-lectures. Late-breakerabstracts will be presented during applicable slide and poster sessions rather than in separateLate-breaker sessions. The Late-breaker abstracts and presentation times have been printed onpage 295 of this and are posted online at www.icaac.org.The complement of abstract sessions and invited sessions allow for the presentation of new andimportant developments in the therapy, prevention, pathogenesis, epidemiology, immunologyand diagnosis of both established and emerging infectious diseases. Detailed sessiondescriptions are included in this Final Program. The Program Committee welcomes yourfeedback regarding all aspects of the meeting. This feedback will be used to plan future ICAACsthat meet all of your expectations. Surveys for individual sessions are available at E-Central.These surveys will also be available online for one year after the meeting. In addition, you willreceive via e-mail, an evaluation survey composed of questions that cover many aspects of theconference. Your responses are vital in assisting the Program Committee with their preparationsfor ICAAC 2013, which will be held September 10-13, 2013, in Denver, CO.We hope that you enjoy your time in San Francisco and at ICAAC 2012. We are certain youwill return home with new information that you can immediately put to use in your offices,classrooms and laboratories to improve healthcare and the management of infectious diseases.M. Lindsay Grayson, MD Craig E. Rubens, MD, PhDChair, ICAAC Program CommitteeVice-Chair, ICAAC Program CommitteeFinal Program5

ICAAC 2012 SupportersICAAC would like to acknowledge the following companies for their supportof ICAAC 2012. On behalf of our leadership, we thank them for theircontinued commitment and appreciate their generous contributions.Booth 1001Aisle SignsICAAC 2012 Peer Reviewed Highlights ReportBooth 700Abstracts on CD-ROMiPostersBooth 1300ExpocardsID Fellows Grant ProgramBooth 1101ID Fellows Grant ProgramBooth 1301ID Fellows Grant ProgramID Fellows Grant ProgramNOWAVAILABLE!INTRODUCINGTHE ICAAC2012 APP!ICAAC 2012Scan above using your device’sbarcode scanner applicationfor easy download.DOWNLOADING THE APP IS EASYFor iPhone, iPod Touch, and iPad users:From your handheld device, go to the iTunes App Store and search for “ICAAC” or “ICAAC2012” to locate the app. Click on the “free” button, which will take you to the installscreen. Next, download the ICAAC 2012 App as you would any other application fromthe iTunes App Store. It’s that easy.For BlackBerry, Android, and all other web-enabled smartphones:Point your browser to m.core-apps.com/TriStar-ICAAC12. On this web-based mobilesite, you will be directed to the proper download version for your device type.Get 24-hour access to unique,on-the-go meeting information,maps, and networking.Features include:Interactive program & course schedulesCustomizable calendar & itinerary builderExhibitor listing with interactive booth mapSocial media interactionMeeting alertsThe ICAAC 2012 App is compatible with iPhone, BlackBerry, and Android smartphones, as well as iPad and most tablets.6 September 9-12 |

Schedule-at-a-GlanceSaturday Sunday Monday Tuesday WednesdaySeptember 8 September 9 September 10 September 11 September 12Registration 12:00 p.m. - 5:00 p.m. 6:30 a.m. - 5:00 p.m. 6:30 a.m. - 5:00 p.m. 6:30 a.m. - 5:00 p.m. 6:30 a.m. - 9:00 a.m.Workshops*8:30 a.m. - 4:30 p.m.Infectious Diseases101 for FellowsAges 18-887:00 a.m. - 9:00 a.m.Keynote Session9:30 a.m. - 11:30 a.m.Meet-the-Experts 7:00 a.m. - 8:15 a.m. 7:00 a.m. - 8:15 a.m. 7:00 a.m. - 8:15 a.m.5:45 p.m. - 7:00 p.m. 5:45 p.m. - 7:00 p.m.Symposia 4:00 p.m. - 6:00 p.m. 8:30 a.m. - 10:30 a.m. 8:30 a.m. - 10:30 a.m. 9:15 a.m. - 11:15 a.m.11:15 a.m. - 12:45 p.m. 11:15 a.m. - 12:45 p.m.2:00 p.m. - 4:00 p.m. 2:00 p.m. - 4:00 p.m.Slide Sessions 4:00 p.m. - 6:30 p.m. 8:30 a.m. - 11:00 a.m. 8:30 a.m. - 11:00 a.m. 9:15 a.m. - 11:45 a.m.1:30 p.m. - 4:00 p.m. 1:30 p.m. - 4:00 p.m.Poster Sessions 11:30 a.m. - 1:30 p.m. 11:15 a.m. - 1:15 p.m. 11:15 a.m. - 1:15 p.m. 9:15 a.m. - 11:15 a.m.Exhibits and Posters 11:30 a.m. - 4:30 p.m. 10:30 a.m. - 4:30 p.m. 10:30 a.m. - 4:30 p.m.Special Lectures and 1:45 p.m. - 3:45 p.m. 4:30 p.m. - 5:30 p.m. 4:30 p.m. - 5:30 p.m. 8:00 a.m. - 9:00 a.m.Award Presentations Literature Review ICAAC Lecture Cubist-ICAAC Plenary SessionSession & PosterAward LectureSummary SessionCommercially-Supported Educational ActivitiesSatellite Symposia After 5:00 p.m. After 7:00 p.m. After 7:00 p.m. After 7:00 p.m.*Registration for workshops begins at 7:30 a.m.Final Program7

ICAAC Awards and LecturesKeynote SessionSunday, September 9 | 9:30 a.m. - 11:30 a.m. | Hall EICAAC LectureMonday, September 10 | 4:30 p.m.– 5:30 p.m. | Room 103Emerging New Issues in the Management ofHepatitis C InfectionCharles M. Rice, PhDThe Rockefeller Univ., New York-Presbyterian Hosp.,Weill Cornell Med. Coll., New York, NYFungal Disease in the 21st CenturyArturo Casadevall, MD, PhDAlbert Einstein Coll. of Med., Bronx, NYThe Impact of Emerging New Diagnostic LaboratoryTechniques on Clinical Infectious DiseaseFranklin R. Cockerill III, MDMayo Clinic, Rochester, MNProspects for New AntibioticsChristopher T. Walsh, PhDHarvard Med. Sch., Boston, MACubist-ICAAC Award and LectureTuesday, September 11 | 4:30 p.m. - 5:30 p.m. | Room 103Supported by Cubist PharmaceuticalsAntiviral Chemotherapy: Astonishing Progress and Formidable Pushback—The Ying and Yang of Host-Viral InteractionsLawrence Corey, MDFred Hutchinson Cancer Research Center, Seattle, WAASM’s premier award honoring outstanding accomplishment in antimicrobial research is presented to Lawrence Corey. Aninternationally renowned expert in virology, immunology and vaccine development, Corey’s research focuses on herpes viruses,HIV, and other viral infections, particularly those associated with cancer.Corey is the President and Director of the Fred Hutchinson Cancer Research Center. He earned his bachelor’s and medical degrees from theUniversity of Michigan, and completed infectious diseases training at the University of Washington School of Medicine. He joined the facultyof the University of Washington in 1978, where he remains today as a Professor of Laboratory Medicine and holder of the Lawrence CoreyEndowed Chair in Medical Virology. Corey is also an infectious disease physician at Seattle Cancer Care Alliance and the principal investigatorof the Hutchinson Center-based HIV Vaccine Trials Network (HVTN), an international collaboration of scientists and institutions thatcombines clinical trials and laboratory-based studies to accelerate the development of HIV vaccines.Corey will deliver the Cubist-ICAAC Award Lecture, “Antiviral Chemotherapy: Astonishing Progress and Formidable Pushback—The Yingand Yang of Host-Viral Interactions,” on September 11 at 4:30 p.m.8 September 9-12 |

ICAAC Program Committee Awards PresentationWill be honored during the ICAAC Lecture.Monday, September 10 | 4:30 p.m. – 5:30 p.m. | Room 103These awards were established for the purpose of encouraging the presentation of qualityresearch through outstanding abstract preparation. Following the review of all submittedabstracts, the ICAAC Program Committee has a meeting to discuss the most interestingsubmissions and is pleased to announce the following six recipients. You are encouraged toattend their presentations.Pathogenesis of Microbial DiseasesAna García-Reyne, MD, PhDUniv. Hosp. 12 Octubre, Madrid, SpainInfluence of Cytomegalovirus (CMV) Disease in the Development of Cardiac AllograftVasculopathy (CAV) in Heart Transplants Recipients (HTR) through the Applicationof the New ISHLT (International Society of Heart Transplantation) CoronaryAngiographic CriteriaSlide Session 116, Presentation T-1071Epidemiology of InfectionDavid J. Templeton, PhDKirby Inst., Univ. of New South Wales, Sydney, AustraliaPrevalence and Correlates of Vaccine-Preventable Anal Human Papillomavirus Genotypesin Australian Homosexual MenPoster Session 027, Presentation L2-301Therapy and Prevention of Microbial DiseaseAu H. Duong, BSUniv. California San Francisco, San Francisco, CAEfficacy of Human Intravenous Immunoglobulin (IVIG) for the Treatment of LethalNecrotizing Pneumonia Caused by Hypervirulent Community-Associated Methicillin-Resistant Staphylococcus aureusSlide Session 196, Presentation B-1735Clinical Microbiology and DiagnosisStefano Giulieri, MDUniv. of Lausanne, Lausanne, SwitzerlandIs CSF Lactate the Best Parameter for Discriminating Bacterial from Viral CommunityAcquired Meningitis?Slide Session 158, Presentation L1-1221Resistance: Mechanisms and ConsequencesAlicia E. Farinati, Sr., MDSalvador Univ., Buenos Aires, ArgentinaPrevalence of Naturally Occurring Hepatitis C Virus (HCV) Variants with PrimaryResistance to the Direct-Acting Antivirals (DAA): Analysis of 722 Complete GenomeSequences and 307 NS3/4A and NS5B Partial SequencesSlide session 160, Presentation V-1237Immunology of InfectionEmmanuel Faure, PhDLille 2 Univ. Hosp., Lille, FranceIPAF-Inflammasome Null Mice are Protected from Pseudomonas aeruginosa-InducedAcute Lung InfectionPoster Session 005, Presentation B-060Final Program9

ICAAC Awards and Lectures continued…ICAAC Young Investigator AwardeesWill be honored during the Cubist-ICAAC Lecture.Tuesday, September 11 | 4:30 p.m. - 5:30 p.m. | Room 103The 2012 ICAAC Young Investigator Awards recognize and reward five early-career scientists fortheir research excellence and potential in microbiology and infectious diseases. Two awards havebeen supported by Merck, U.S. Human Health Division since 1983, while two are sponsored bythe ASM. In 2007, an additional award from Merck, U.S. Human Health Division was addedto recognize excellence in HIV research. William P. Hanage and David M. Tobin are the 2012laureates for the Merck-sponsored awards, and Andrew Lee Lovering and María SoledadRamírez are the 2012 laureates for the ASM-sponsored awards. Mario L. Santiago is the2012 laureate for the Merck-sponsored award for HIV research.William P. Hanage, PhDHarvard School of Public Health, Boston, MAHonored for his work studying the epidemiology andevolution of infectious disease, Hanage received hisPhD from Imperial College London where he studiedhost microbial interactions. Hanage continued to theUniversity of Oxford and later Imperial College London,where he studied the molecular epidemiology of bacterial pathogens.Especially interested in subjects that combine clinical importancewith fundamental biological questions, Hanage looks at questionslike how pathogens respond to novel selective pressures in the formof antimicrobials and vaccines.Andrew Lee Lovering, PhDUniversity of Birmingham, Edgbaston, Birmingham, United KingdomLovering is recognized for his seminal work on thestructural biology and biochemistry of the proteins thatsynthesize and modify cell walls in bacteria. Loveringearned his PhD in Biosciences from Birmingham University,where he used x-ray crystallography to detail themechanism of action of two enzymes involved in cancer therapies—one a bacterial nitroreductase used in gene therapy of solid tumors,and the other a target for a cell differentiation approach tacklingacute myeloid leukemia. He then took a postdoctoral position at theUniversity of British Columbia working on antibacterial research.Lovering now focuses on deciphering the molecular basis of bacterialpredation by Bdellovibrio bacteriovorus, a phenomenon that may leadto its exploitation as a “living antibiotic.”Mario L. Santiago, PhDUniversity of Colorado, DenverSantiago’s outstanding work in virology includes fieldbasedHIV epidemiology studies and manipulating innateimmunity in his efforts to explore innovative new waysto approach the challenge of the HIV vaccine. Beforereceiving his PhD in Microbiology at the University of Alabama-Birmingham, Santiago worked at the NIH-sponsored TropicalMedicine Research Center in the Philippines and as a FogartyAIDS International Research fellow at Brown University. Hecompleted postdoctoral fellowships at the University of Alabama-Birmingham and the University of California, San Francisco.He now works on the interplay between innate retroviral restrictionand adaptive immunity in mice, monkeys and humans, with aconceptual focus on HIV vaccine development, host genetics ofretrovirus resistance, and interferon-based antiretroviral therapy.David M. Tobin, PhDDuke University School of Medicine, Durham, NCTobin is recognized for his work in infectious diseasetherapeutics. He received his PhD at the Universityof California, San Francisco, where he defined the roleof a set of TRPV-related ion channels in behaviors.He completed his postdoctoral studies at the Universityof Washington, developing a genetic screen in zebrafish to probethe host genetic determinants of susceptibility to mycobacterialinfection. Tobin currently studies the host response to mycobacterialinfection using zebrafish, bacterial, and human genetics.María Soledad Ramírez, PhDNational Scientific and Technical Research Council (CONICET),Buenos Aires, ArgentinaRamírez is honored for her outstanding work in thearea of integron participation in gene capture anddissemination. Before earning her PhD at the Universityof Buenos Aires, Ramírez underwent clinical researchtraining at the Fundación Favaloro. After receiving her PhD,Ramírez received a CONICET Postdoctoral Fellowship, followedby a Fulbright-CONICET Research Fellowship. She has extensiveexperience in the study of the mechanisms of antimicrobialresistance, both in the biochemical characterization and the geneticanalysis of the structures associated with the encoding genes.10 September 9-12 |

Poster Walk PresentationsPoster Walk presentations, selected by the ICAAC ProgramCommittee, are designed to give poster presenters an opportunityto give brief informal presentations and answer questions ontheir research. Lead by pioneers in the field, these topic-basedwalks will tour the Poster Hall discussing the most intriguingposters and latest discoveries from particular areas of interest.Poster Walks will take place in Halls A-C.Sunday, September 9 | 11:30 a.m. – 12:30 p.m.Antibiotic Use and ResistanceConvener:Stephan Harbarth, MD, MSUniv. of Geneva Hosp., Geneva, SwitzerlandPresentations:Do Antibiotic Combinations with Rifampin for OsteoarticularInfections Protect against Clostridium difficile-Associated Colitis?C. Landelle; Univ. of Geneva Hosp., Geneva, SwitzerlandOutcome of Appropriate Empiric Combination versusMonotherapy for Pseudomonas aeruginosa BacteremiaD. R. Bowers; St. Luke’s Episcopal Hosp., Univ. of Houston, Houston, TXClinical Impact of KPC Status and Appropriate Treatment amongEnterobacteriaceae (EB) and Pseudomonas aeruginosa (Pae) in aMulticenter Matched Control Cohort Study in ColombiaV. M. Blanco; CIDEIM, Cali, Colombia, Univ. del Valle, Cali, ColombiaInadequate Antibiotic Therapy is Associated with DecreasedSurvival in Patients with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Bloodstream InfectionsN. F. Dewhurst; St. Michael’s Hosp., Toronto, Canada, Univ. of Toronto,Toronto, CanadaControl of the Prescription of Carbapenems in a French Hospital:Impact of the Hospital Antibiotic Management TeamC. Couzigou; Hosp. Saint-Joseph, Paris, FranceSunday, September 9 | 12:30 p.m.- 1:30 p.m.The HIV Poster RoundsConveners:Joseph Eron, Jr., MDUniv. of North Carolina, Chapel Hill, NCEfficacy and Use of PI vs EFV in Treatment Naive HIV+Men and WomenJ. Patel; Rush Univ. Med. Ctr., Chicago, ILSafety and Efficacy of Once Daily Raltegravir to EnhanceAdherence and Efficacy of HAART in Vulnerable HIV-InfectedPatientsK. Stewart; Univ. of Saskatchewan, Saskatoon, CanadaPreemptive Therapy Prevents Cytomegalovirus End-OrganDisease in Treatment-Naïve Patients With AdvancedHIV-1 InfectionD. Mizushima; Natl. Ctr. for Global Hlth. and Med., Tokyo, JapanGenotypic Algorithm for Predicting Elvitegravir Susceptibility:Clinical Validation and Correlation with PhenotypeM. Haddad; Monogram Biosciences, South San Francisco, CAPersistent Low-Level Viraemia in HIV-1-Infected Patients: SwissHIV Cohort StudyN. Boillat Blanco; Univ., Lausanne, SwitzerlandMonday, September 10 | 11:15 a.m.-12:15 p.m.Daily Infection Prevention and Control IssuesConvener:Loreen Herwaldt, MDUniv. of Iowa, Coll. of Med., Iowa City, IAPresentations:Prosthetic Joint Infection (PJI) Should Be Considered InProsthetic Failure Within 2 Years of ImplantationM. E. Portillo; Reference Lab. of Catalunya, Barcelona, SpainHospital-Acquired Influenza in an Australian SentinelSurveillance SystemN. Macesic; Alfred Hlth., Melbourne, AustraliaRapid Screening Tests for MRSA Did Not Decrease PostoperativeMRSA Infections in Patients with Inflammatory Bowel Disease(IBD)Y. Takahashi; Hyogo Coll. of Med., Nishinomiya, JapanWhat to Breathe? Performance Analysis of Air Samplers inOperating RoomsL. Ummels; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, NetherlandsCharacteristics of Septic Arthritis: A Retrospective StudyOver 11 YearsL. N. Walti; Univ. Hosp., Lausanne, SwitzerlandJean-Michel G. Molina, MDSaint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, FrancePresentations:Impact of Seven Nucleotide Polymorphisms and Haplotypesof CYP2B6 on Plasma Efavirenz Level in HIV/TuberculosisCo-Infected Thai Patients Receiving RifampicinS. Sungkanuparph; Faculty of Med. Ramathibodi Hosp., Mahidol Univ.,Bangkok, ThailandFinal Program11

Poster Walk Presentations continued…Monday, September 10 | 12:15 p.m. - 1:15 p.m.Resistance Genes Have No Boundaries!Conveners:Lesley McGee, PhDCDC, Atlanta, GAJohann D. Pitout, MDUniv. of Calgary, Calgary, CanadaPresentations:Molecular Characterization of Multidrug-ResistantMycobacterium tuberculosis from Asian CountriesC. Nakajima; Hokkaido Univ. Res. Ctr. for Zoonosis Control, Sapporo,JapanExtended-Spectrum Beta-Lactamase (ESBL) Producing Gram-Negative Bacteria from Pets, Buffalos and Psittacines, BrazilL. Barbato; USP, São Paulo, BrazilAccessory Gene Regulator (AGR) Function, rpoB Mutationsand Vancomycin (VA) Susceptibility in Methicillin-ResistantStaphylococcus aureus (MRSA) Blood IsolatesM. Camoez; Hosp. Univ Bellvitge. UB. IDIBELL, Barcelona, SpainLack of Impact of Infant PCV Vaccination on Rates of AdultInvasive Pneumococcal Disease in Ontario, CanadaK. Wong; Mount Sinai Hosp., Toronto, CanadaCurrent Status of Group B Streptococci (GBS) in Japan -Penicillin-ResistantGBS is Emerging in Japan?H. Mikamo; Aichi Med. Univ., Aichi, JapanDissemination of Diverse Plasmids Bearing blaKPC AmongCarbapenem-Resistant Enterobacteriaceae (CRE) Different fromKlebsiella spp. in a Hospital System in ClevelandF. Perez; VAMC, CWRU, Cleveland, OHTuesday, September 11 | 11:15 a.m. - 12:15 p.m.New Developments in TransplantationConvener:Emily A. Blumberg, MDPerelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PAPresentations:Refractory KPC Carbapenemase-Producing Klebsiella pneumoniaeBacteremia is Tolerated by Solid Organ Transplant Patients(SOT Pts)C. Clancy; Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PAChronic High EBV Load Carriage has Low Predictive Value toDetect Post-Transplant Lymphoproliferative Disorder (PTLD)in Solid-Organ Transplant RecipientsC. Gardiol; Univ. Hosp. Ctr. of Lausanne, Lausanne, SwitzerlandRisk Factors and Outcomes of Bacteremia Caused byDrug-Resistant ESKAPE Pathogens in Solid Organ Transplant(SOT) RecipientsM. Bodro; IDIBELL Biomedical Res. Inst., Hosp. Llobregat, Barcelona, SpainThe Molecular Epidemiology of a Respiratory Syncytial VirusOutbreak Among Oncology and Hematopoietic Stem CellTransplant (HSCT) PatientsH. Y. Chu; Univ. of Washington, Seattle, WADiagnosis of Invasive Aspergillosis and Mucormycosis Guidedby PCR Assays from Bronchoalveolar Lavage Fluid in AllogenicStem Cell RecipientsH. Lellek; Univ. Hosp. Hamburg-Eppendorf, Hamburg, GermanyTuesday, September 11 | 12:15 p.m. - 1:15 p.m.Fungal Infections at the BedsideConvener:John Perfect, MDDuke Univ. Med. Ctr., Durham, NCPresentations:The Clinical Course Following the Use of Corticosteroids forSymptomatic Relief of Primary Pulmonary Coccidioidomycosis inImmunocompetent PersonsN. Azadeh; Mayo Clinic, Phoenix, AZEffectiveness of Posaconazole Vs Fluconazole as AntifungalProphylaxis in Hematology-Oncology Patients at DukeUniversity Hospital (DUH) 2004-2010H. C. Kung; Duke Clinical Res. Inst., Durham, NCPilot Prospective Study of High Dose (10 mg/kg/d) LiposomalAmphotericin B (L-AmB) for the Initial Treatment ofMucormycosis: AMBIZYGO TrialF. Lanternier; Hosp. Necker Enfants Malades, Paris, France; Inst. Pasteur,Paris, FranceSystemic Candidiasis Increased Mortality in ICU InfectedPatients with CirrhosisH. Dupont; Pole d’Anesthesie-Reanimation, CHU d’Amiens, Amiens,FranceThe Tolerability of Amphotericin B Lipid ComplexFormulation in Patients With Severe Infusion Reactionsto Liposomal Amphotericin BD. Farmakiotis; MD Anderson Cancer Ctr., Houston, TX12 September 9-12 |

ICAAC ID Fellows Grant ProgramSupported by educational grants from ASM, Gilead US, Pfizer Australia, and 3M.The American Society for Microbiology has long been committed to the educational development of young professionals within theinfectious disease arena. This year, the ASM is please to host again the ID fellows Grant Program supported by educational grantsfrom ASM, Gilead US, Pfizer Australia, and 3M. This program offers ID Fellows a unique opportunity to attend ICAAC 2012 andparticipate in an educational experience specifically tailored to their educational development needs. This select group of Fellowswas nominated by their Program Directors and will have the opportunity to hear a targeted keynote talk and an overview of recommendedsessions for attendance, interact with ICAAC Program Committee members and ASM Officers, and be offered personalizedattention and daily discussion.ICAAC 2012 ID Fellows Grant Program Recipients:Albornoz, Ezequiel, Inst. Natl. de Enfermedades Infecciosas ANLIS Dr. G. Malbran,Buenos Aires, ArgentinaPoster Session 087, Presentation C2-701Alraddadi, Basem, Tufts Med. Ctr., Medford, MAPoster Session 113, Presentation T-1025Beyda, Nicholas, Univ. of Houston Coll. of Pharmacy, Houston, TXPoster Session 028, Presentation M-316Bhalla, Preeti, Oregon Hlth. & Sci. Univ., Portland, ORPoster Session 029, Presentation T-345Bhalodi, Amira, Hartford Hosp., Hartford, CTPoster Session 003, Presentation A-020; Poster Session 083, Presentation A-625; Poster Session 163,Presentation A-1287Bhargava, Ashish, Detroit Med. Ctr., Wayne State Univ., Detroit, MIPoster Session 008, Presentation C2-096Briggs, Heather, Univ. of Texas Hlth. Sci. Ctr. at San Antonio, TXPoster Session 172, Presentation D-1449Butterfield, Jill, Albany Coll. of Pharmacy and Hlth. Sci., Albany, NYPoster Session 082, Presentation A-606Chen, Hong, Ctr. for Hlth. Protection, Hong Kong, ChinaPoster Session 021, Presentation K-243Cheng, Ying, Natl. Inst. for Communicable Disease Control and Prevention, Sklid, ChinaPoster Session 105, Presentation K-936Chu, Helen, Univ. of Washington, Seattle, WAPoster Session 029, Presentation T-353Commons, Robert, Royal Darwin Hosp., Northern Territory, AustraliaPoster Session 165, Presentation B-1313Dilworth, Thomas, Univ. of New Mexico Coll. of Pharmacy, Albuquerque, NMPoster Session 174, Presentation E-1472Frere, Julie, CHU Sainte-Justine, Montreal, CanadaPoster Session 178, Presentation G3-1554Gillis, Louise-Marie, Univ. of Pittsburgh Med. Ctr., Pittsburgh, PAPoster Session 094, Presentation E-786; Poster Session 183, Presentation K-1605Gillman, Jason, UT Southwestern Med. Ctr., Dallas, TexasPoster Session 029, Presentation T-357Goldblatt, Jennifer, Imperial Coll. London, London, United KingdomPoster Session 165, Presentation B-1311Housman, Seth, Ctr. Anti-Infect. Res. & Devel., Hartford Hosp., Hartford, CTPoster Session 003, Presentation A-022Jaber, Mohammad, Chu Sainte Justine, Montreal, QC, CanadaPoster Session 030, Presentation V-376Jacobson, Shauna, West Virginia Univ. Hosp., Morgantown, WVPoster Session 105, Presentation K-928Karadag Oncel, Eda, Hacettepe Univ. Med. Faculty, Ankara, TurkeyPoster Session 240, Presentation A-1941Kasper, Douglas, Med. Coll. of Wisconsin, Milwuakee, WIPoster Session 090, Presentation D-728Kelesidis, Theodoros, David Geffen Sch. of Med., Los Angeles, CAPoster Session 024, Presentation K-280; Poster Session 169, Presentation C2-1401Kestler Hernandez, Martha, Hosp. Gen. Univ. Gregorio Marañon, Madrid, SpainPoster Session 023, Presentation K-263; Poster Session 106, Presentation K-940Kwa, Andrea, Univ. of Pittsburgh, Pittsburgh, PAPoster Session 015, Presentation E-195; Poster Session 094, Presentation E-791;Poster Session 174, Presentation E-1476Lee, Yu-Mi, Asan Med. Ctr., Seoul, Korea, Republic ofPoster Session 091, Presentation D-741Lee, Yeon Joo, Memorial Sloan-Kettering Cancer Ctr., New York, NYPoster Session 029, Presentation T-361Leistner, Rasmus, Charité Univ., Berlin, GermanyPoster Session 181, Presentation K-1592Luther, Megan, Veterans Affarirs Med. Ctr., Providence, RIPoster Session 173, Presentations E-1464, E-1469Phee, Lynette, Barts Hlth. NHS Trust, London, United KingdomPoster Session 092, Presentation D-761; Poster Session 094, Presentation E-797Pittet, Laure, Univ. Hosp. of Geneva, SwitzerlandPoster Session 178, Presentation G3-1556Pupaibool, Jakrapun, Mayo Clinic, Rochester, MNPoster Session 096, Presentation F-813Rao, Gauri, SUNY, Buffalo, NYPoster Session 004, Presentation A-024; Poster Session 094, Presentation E-785Rao, Krishna, Univ. of Michigan Hlth. Systems, Ann Arbor, MIPoster Session 105, Presentation K-926Reuland, Elien Ascelijn, VU Univ. Med. Ctr., Amsterdam, NetherlandsPoster Session 009, Presentation C2-104Sadarangani, Manish, Univ. of British Columbia and BC Children’s Hosp.,Vancouver, CanadaPoster Session 178, Presentations G3-1542, G3-1544Satyanarayana, Gowri, Beth Israel Deaconess Med. Ctr., Boston, MAPoster Session 029, Presentation T-354Schmitt, Bryan, Mayo Clinic, Rochester, MISlide Session 201, Presentation D-1774Sharff, Katie, Oregon Hlth. and Sci. Univ., Portland, ORPoster Session 171, Presentation D-1432Sheth, Prameet, Univ. of Toronto, Toronto, CanadaPoster Session 008, Presentation C2-089Soltani, Banafsheh, Temple Univ. Hosp., Philadelphia, PAPoster Session 188, Presentation L1-1656Soon, Rachel L., Univ. at Buffalo, Buffalo, NYPoster Session 015, Presentation E-201; Poster Session 082, Presentation A-605;Slide Session 200, Presentation A-1762Stevens, Vanessa, SUNY Buffalo Sch. of Pharmacy and Pharmacutical Sci., Buffalo, NYPoster Session 082, Presentation A-617Suwantarat, Nuntra, Case Western Reserve Univ., Cleveland, OHPoster Session 087, Presentation C2-686Final Program13

ID Fellows Grant Program Recipients continued…Teh, Benjamin, Royal Melbourne Hosp., Parkville, AustraliaPoster Session 113, Presentation T-1027Tulliano, Gianfranco, NYU School of Medicine, New York, NYPoster Session 024, Presentation K-273Werth, Brian, Wayne State Univ., Detroit, MIPoster Session 083, Presentation A-627Williamson, Deborah, Department of Clin. Microbiology, Auckland, New ZealandPoster Session 178, Presentation G3-1555; Slide Session 237, Presentation C2-1908Wilmer, Amanda, Univ. of British Columbia, Vancouver, British Columbia, CanadaPoster Session 011, Presentation D-161; Poster Session 182, Presentation K-1593Wongkulab, Panuwat, Chiang Mai Univ., Chiang Mai, ThailandPoster Session 170, Presentation D-1406Xu, Hua, ShanDong Provincial Hosp., Jinan, ChinaPoster Session 023, Presentation K-268Zhou, Qing, Zhongshan Hosp. Fudan Univ., Shanghai, ChinaPoster Session 023, Presentation K-269Zimmerman, Ofer, Tel Aviv Sourasky Med. Ctr., Tel Aviv, IsraelSlide Session 115, Presentation M-1059> ASM Infectious Diseases (ID) Fellow Travel GrantsThe ASM ID Fellows Travel Grant program was established to support the travel of ID Fellows to the annual InterscienceConference on Antimicrobial Agents and Chemotherapy. The ICAAC Program Committee is pleased to announce that thefollowing individuals were awarded travel grants. All of this year’s recipients have been designated as George McCrackenInfectious Disease Fellows, in recognition of Dr. McCracken’s efforts to facilitate financial support for these grants.ICAAC 2012 George McCracken ID Fellows Grant Recipients:Achermann, Yvonne, Univ. Hosp. Zurich, SwitzerlandSlide Session 129, Presentation K-1125Albur, Mahableshwar, North Bristol NHS Trust, Bristol, United KingdomPoster Session 092, Presentation D-763; Poster Session 094, Presentation E-793Amit, Sharon, Tel-Aviv Sourasky Med. Ctr., Tel-Aviv, IsraelPoster Session 184, Presentation K-1609Asuphon, Orarik, Nareasuan Univ. Meung Pitsanulok, Phayao, ThailandPoster Session 162, Presentation A-1279Ballesté Delpierre, Clara, Ctr. en Salut Internacional de Barcelona, Barcelona, SpainPoster Session 087, Presentation C2-696Cubero, Meritxell, Hosp. Univ. de Bellvitge, Barcelona, SpainPoster Session 087, Presentation C2-690Daniels, Kelly, The Univ. of Texas, San Antonio, TXPoster Session 026, Presentation L1-297Duval, Raphael, Univ. de Lorraine, Nancy, FrancePoster Session 177, Presentation F-1527Espinal, Paula, Hosp. Clinic-CEK, Barcelona, SpainPoster Session 016, Presentation, B-1327; Slide Session 236, Presentation C2-1900Farmakiotis, Dimitrios, Baylor Coll. of Med., MD Anderson Cancer Ctr., Houston, TXPoster Session 191, Presentation M-1705Ghebremedhin, Beniam, Med. Mirobiol., Magdeburg, GermanyPoster Session 009, Presentation C2-108Girometti, Nicolo, Policlinico S. Orsola-Malpighi, Bologna, ItalyPoster Session 184, Presentation K-1619Gomez, Sonia Alejandra, ANLIS-Dr Carlos G. Malbran, Buenos Aires, ArgentinaPoster Session 008, Presentation C2-084Goncalves Quiles, Milene, Federal Univ. of Sao Paulo, BrazilPoster Session 170, Presentation D-1412Hung, Wei-Chun, Niigata Univ. Graduate Sch. of Med. and Dental Sciences, Niigata, JapanPoster Session 166, Presentation C1-1340Khan, Adnan, Univ. of Karachi, Karachi, PakistanPoster Session 243, Presentation C2-1981Kim, Chung-Jong, Seoul Natl. Univ. Hosp., Seoul, Korea, Republic ofPoster Session 104, Presentation K-908King, Travis, Univ. of Mississippi Med. Ctr., Jackson, MIPoster Session 111, Presentation M-968Macesic, Nenad, Alfred Hlth., Prahran, AustraliaPoster Session 108, Presentation K-952Moon, Song Mi, Asan Med. Ctr., Seoul, Korea, Republic ofSlide Session 160, Presentation V-1239Morency-Potvin, Philippe, Univ. de Montreal, Montreal, CanadaPoster Session 090, Presentation D-730Munier, Anne-Lise, Hosp. Saint Louis, Paris, FrancePoster Session 019, Presentation H-219; Poster Session 169, Presentation C2-1399Munita, Jose, Univ. of Texas at Houston Med. Sch., Houston, TXPoster Session 166, Presentation C1-1345Muvunyi, Mambo-Claude, National Univ. of Rwanda, National ReferenceLaboratory, Huye, RwandaPoster Session 092, Presentation D-775Pascual, Vanesa, Hosp. Univ. Mutua de Terrassa, Barcelona, SpainPoster Session 184, Presentation K-1621Pino, Marylu, Facultad de Farmacia y Bioquimica, Buenos Aires, ArgentinaSlide Session 047, Presentation C1-466; Poster Session 086, Presentation C1-678Pouch, Stephanie, NY Presbyterian, Columbia Univ. Med. Ctr., NYPoster Session 113, Presentations T-1034, T-1036Seyedmousavi Tasieh, Seyedmojtaba, Radboud Univ. Nijmegen Med. Ctr.,Nijmegen, NetherlandsPoster Session 111, Presentation M-989Shahrooei, Mohammad, Lab. for Experimental and Clin. Microbio., Leuven, BelgiumPoster Session 252, Presentation K-2094Shallcross, Laura, Univ. College London, London, United KingdomPoster Session 186, Presentation L1-1645Sivagnanam, Shobini, Nepean Hosp., Sydney, AustraliaPoster Session 190, Presentation M-1680Sole Guiu, Mar, CRESIB, Barcelona, SpainPoster Session 006, Presentation C1-075Tamayo-Legorreta, Elsa, Natl. Inst. Public Hlth., Cuernavaca, Morelos, MexicoPoster Session 006, Presentation C1-069Tsai, MaoSong, Natl. Taiwan Univ. Hosp., Taipei, Taiwan, Province of ChinaPoster Session 180, Presentation H-1578Valerio, Maricela, Hosp. Gen. Gregorio Marañon, Madrid, SpainSlide Session 159, Presentation M-1232; Poster Session 190, Presentation M-1684Vila, Xavier, Hosp. Clinic, Barcelona, SpainPoster Session 249, Presentation F-206814 September 9-12 |

George McCracken ID Fellows Grant Recipients continued…Wainaina, Jane, Med. Col. of Wisconsin, Milwaukee, WIPoster Session 011, Presentation D-153Xue, Bai, Inst. for Clin. PharmacoDynamics (ICPD), Latham, NYPoster Session 161, Presentations A-1261, A-1263Yakubchyk, Yury, SUNY Stony Brook, SBUMC Pediatric ID, Stony Brook, NYPoster Session 112, Presentation P-997Yoshizumi, Ayumi, Toho Univ., Ota-ku, Tokyo, JapanPoster Session 006, Presentation C1-077Zainah, Hadeel, Henry Ford Hosp., Detroit, MIPoster Session 191, Presentation M-1716> ASM Student & Post-Doctoral Fellow Travel GrantsThe ASM Student and Post-Doctoral Travel Grant program was established to support the travel of students and fellowsto ASM meetings. Recipients are selected by the ICAAC Program Committee on the basis of the scientific quality oftheir submitted abstracts.ICAAC 2012 Student and Post-Doctoral Travel Grant Recipients:Baietto, Lorena, Univ. of Turin, Turin, ItalySlide Session 200, Presentation A-1769; Poster Session 090, Presentation A-1937Berti, Andrew, Univ. of Wisconsin, Sch. of Pharmacy, Madison, WIPoster Session 174, Presentation E-1482Blanco, Victor M., Intl. Ctr. for Med. Res. and Training (CIDEIM), Cali, ColombiaPoster Session 092, Presentation D-747; Poster Session 104, Presentation K-903;Poster Session 255, Presentation L2-2108Casapao, Anthony, Wayne State Univ., Anti-Infective Res. Lab., Detroit, MIPoster Session 024, Presentation K-275; Poster Session 106, Presentation K-946;Slide Session 129, Presentation K-1123Chan, Albert, UCLA, Los Angeles, CAPoster Session 177, Presentation F-1534Cotton, Gemma, Univ. of Lincoln, Lincoln, United KingdomPoster Session 246, Presentation F-2001Denisuik, Andrew, Univ. of Manitoba, Winnipeg, CanadaPoster Session 009, Presentation C2-103; Poster Session 015, Presentation E-194Deslouches, Berthony, Univ. of Pittsburgh, Ctr. for Vaccine Res., Pittsburgh, PAPoster Session 249, Presentation F-2061Dumkow, Lisa, Henry Ford Hosp., Detroit, MIPoster Session 020, Presentation K-240Fehlberg, Lorena Cristina, Univ. Federal de São Paulo, São Paulo, BrazilPoster Session 090, Presentation D-731; Slide Session 156, Presentation C1-1207Finn, Talya, Tel Aviv Med. Ctr., Tel Aviv, IsraelPoster Session 111, Presentation M-985Ghantoji, Shashank, MD Anderson Cancer Ctr., Houston, TXPoster Session 105, Presentation K-934Grare, Marion, Lab. de Bactériologie-Hygiène, Toulouse, FrancePoster Session 092, Presentation D-758; Poster Session 177, Presentation F-1527Hall, Ashley, Wayne State Univ., Detroit, MIPoster Session 082, Presentations A-601, A-602Heimann, Sebastian, Univ. Hosp. of Cologne, Clinic I for Internal Med., Div. ofInfectious Disease, Cologne, GermanySlide Session 159, Presentation M-1230; Poster Session 191, Presentation M-1706Hoenigl, Martin, Med. Univ. of Graz, Section of Infectious Diseases, Graz, AustriaPoster Session 170, Presentation D-1404; Poster Session 112, Presentation P-1009Huang, En, The Ohio State Univ., Columbus, OHPoster Session 176, Presentation F-1508Lin, Yu-Tzu, Dept. of Clin.Lab. Sci.and Med. Biotechnology, Taipei, Taiwan,Province of ChinaPoster Session 166, Presentation C1-1339Ly, Neang, Univ. of Buffalo, Buffalo, NYPoster Session 003, Presentation A-016Mahajan, Sminil, UT MD Anderson Cancer Ctr., Houston, TXSlide Session 117, Presentation V-1075Martins Bispo, Paulo Jose, Federal Univ. of Sao Paulo, Sao Paulo, BrazilPoster Session 169, Presentation C2-1400; Poster Session 174, Presentation E-1481Maya, Juan J., Intl. Natl. Ctr. for Med. Res. and Training, Cali, ColombiaPoster Session 092, Presentation D-747; Poster Session 104, Presentation K-903;Poster Sesion 255, Presentation L2-2108Melchers, Maria, Radboud Univ. Nijmegen Med. Centre, Nijmegen, NetherlandsPoster Session 015, Presentation E-190; Poster Session 094, Presentation E-803Milillo, Michael, Walter Reed Army Inst. of Res., Silver Spring, MDSlide Session 237, Presentation C2-1914Montassier, Emmanuel, UFR Med., Univ. of Nantes, Nantes, FrancePoster Session 025, Presentation L1-285; Poster Session 172, Presentation D-1458;Poster Session 186, Presentation L1-1642Muraleedharan, Chithra, Oakland Univ., Rochester, MIPoster Session 088, Presentation C2-703Nair, Rajeshwari, Univ. of Iowa, Coralville, IAPoster Session 169, Presentation C2-1384Peterson, Eliza, Univ. of North Carolina, Chapel Hill, NCPoster Session 177, Presentation F-1535Rogers, Benjamin, The Univ. of Queensland, Herston, Brisbane, AustraliaPoster Session 087, Presentation C2-689Rojo, Andrea, Clin. Univ. de Navarra, Pamplona, SpainPoster Session 171, Presentations D-1439, D-1440Ryan, Keenan, Univ. of New Mexico Coll. of Pharmacy, Albuquerque, NMSlide Session 197, Presentation C1-1742Serrano-Villar, Sergio, Hosp. Univ. Ramón y Cajal, Madrid, SpainPoster Session 018, Presentation H-217; Poster Session 179, Presentation H-1567Simner, Patricia, Mayo Clinic, Rochester, MNPoster Session 190, Presentation M-1691Trang, Michael, Univ. at Buffalo, Buffalo, NYPoster Session 003, Presentation A-012Trivedi, Ashit, Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TNPoster Session 161, Presentation A-1267Walti, Laura, CHUV, Lausanne, SwitzerlandPoster Session 012, Presentation D-168; Poster Session 022, Presentation K-250;Poster Session 250, Presentation K-2073Wendel, Sarah, Natl. Inst. of Allergy and Infectious Diseases, Natl. Inst. of Hlth.,Baltimore, MDPoster Session 180, Presentation H-1580Winkler, Marisa, Case Western Reserve Univ., Cleveland, OHSlide Session 047, Presentation C1-463; Slide Session 156, Presentation C1-1209Zhao, Yuyun, Tsinghua Univ., Beijing, ChinaPoster Session 246, Presentation F-2002Final Program15

16 September 9-12 |

American Society for MicrobiologyProducts and ServicesASM Career ConnectionsASM Career Connections will be onsite at ICAAC. Leverage your meeting attendance bysearching job postings and applying for jobs as a candidate, or post job openings and contactqualified candidates as an employer. Identify candidates and employers attending the meeting andschedule onsite interviews. Learn more at www.asmcareerconnections.org.ASM JournalsASM journals, available in both online and print formats, remain a critical source of high-qualityclinical microbial content. Our journals are some of the most-cited serials within their disciplines,covering antimicrobial agents, immunology, chemotherapy, clinical microbiology, molecularbiology, pharmacology, virology, and more.For more information about publishing in an ASM journal, please visit the ASM Journals Booth#1513 in the Exhibit Hall. Additional submission information is available on the Authors tab atwww.journals.asm.org.ASM Press BookstoreASM Press, the book publishing division of the American Society for Microbiology, will beselling a broad selection of textbooks, references, manuals, and general interest titles in the ASMPress Bookstore, located in the main entrance of the South Lobby. ASM Members receive a20-50% discount on all purchases made at the meeting. Non-members receive a 10% discounton all purchases made at the meeting.MembershipAdvance with ASM MembershipIn 2013 ASM will change its member categories to address the needs of an increasingly diversescientific audience—including infectious disease and other clinical professionals. For moreinformation about the new member types and benefits, visit asm.org/advance or stop by theMembership Booth (#1106) on the exhibit floor. ICAAC attendees can join or renew for 2013onsite. For additional information on membership in ASM, call (202) 942-9319 or e-mailmembership@asmusa.org.Press Room and ICAAC LiveMedia representatives interested in obtaining releases on selected papers and schedulinginterviews can do so in the Press Room, Esplanade Ballroom 301. Daily press conferences andmedia interviews of researchers will also take place as part of ICAAC Live in EsplanadeBallroom 303. ICAAC Live will be moderated by Dr. Jeff Fox, Features Editor for Microbemagazine. The ICAAC Live schedule and live webcasts of interviews are available athttp://www.microbeworld.org/icaaclive. All registered attendees of ICAAC are invitedto attend the ICAAC Live interviews.Final Program17

Convention Center Maps18 September 9-12 |

Final Program19

ICAAC 2012 Hotel Information1. Hotel Abri127 Ellis StreetSan Francisco, CA 94102(415) 392-88002. Courtyard by Marriott Downtown299 Second StreetSan Francisco, CA 94105(415) 947-07003. Fairmont San Francisco950 Mason StreetSan Francisco, CA 94108(415) 772-50004. Galleria Park Hotel, a Joie De VivreHotel191 Sutter StreetSan Francisco, CA 94104(415) 781-30605. Grand Hyatt San Francisco345 Stockton StreetSan Francisco, CA 94108(415) 398-12346. Handlery Union Square Hotel351 Geary StreetSan Francisco, CA 94102(415) 781-78007. Hilton San Francisco Union Square333 O’Farrell StreetSan Francisco, CA 94102(415) 771-14008. Holiday Inn Civic Center50 8th StreetSan Francisco, CA 94103(415) 626-61039. InterContinental San Francisco888 Howard StreetSan Francisco, CA 94103(415) 616-650010. JW Marriott San Francisco Union Square500 Post StreetSan Francisco, CA 94102(415) 771-860011. King George Hotel334 Mason StreetSan Francisco, CA 94102(415) 781-505012. Marriott Union Square-San Francisco480 Sutter StreetSan Francisco, CA 94108(415) 398-890013. Hotel Nikko San Francisco222 Mason StreetSan Francisco, CA 94102(415) 394-111114. Palace Hotel2 New Montgomery StreetSan Francisco, CA 94105(415) 512-111115. Hotel Palomar12 4th StreetSan Francisco, CA 94503(415) 348-111116. Parc 55 Wyndham San Francisco –Union Square55 Cyril Magnin StreetSan Francisco, CA 94102(415) 392-800017. The Powell Hotel28 Cyril Magnin StreetSan Francisco, CA 94102(415) 398-320018. San Francisco Marriott Marquis55 4th StreetSan Francisco, CA 94102(415) 896-160019. Serrano Hotel (Kimpton)405 Taylor StreetSan Francisco, CA 94102(415) 885-250020. Sir Francis Drake Hotel (Kimpton)450 Powell StreetSan Francisco, CA 94102(415) 392-775521. Hotel Union Square114 Powell StreetSan Francisco, CA 94102(415) 397-300022. Villa Florence Hotel225 Powell StreetSan Francisco, CA 94102(415) 397-770023. W San Francisco181 3rd StreetSan Francisco, CA 94103(415) 777-530024. The Westin San Francisco Market Street50 Third StreetSan Francisco, CA 94103(415) 974-640025. The Westin St. Francis335 Powell StreetSan Francisco, CA 94102(415) 397-700020 September 9-12 |

Shuttle InformationComplimentary shuttle service is provided between the MosconeConvention Center and the official ICAAC hotels. Shuttle informationsigns will be posted in the lobby of each hotel. Check the sign in yourhotel lobby for additional information and changes.>>>Hotels and Boarding LocationsPlease allow for adequate travel time to accommodate for possibledelays due to distance, traffic conditions, etc.Route #1 ........................ Boarding LocationHilton Union Square San Francisco .....Curbside on Taylor StreetHoliday Inn Civic Center ..............Curbside on 8th StreetHotel Nikko ..........................At Hilton Union SquareKing George Hotel ...................At Hilton Union SquareSerrano Hotel ........................At Hilton Union SquareVilla Florence Hotel ..................At Hilton Union SquareService every 15-20 minutes at all times.Route #2 ........................ Boarding LocationGalleria Park Hotel ...................At Westin St. FrancisGrand Hyatt San Francisco ............At Westin St. FrancisHandlery Union Square ...............At Westin St. FrancisJW Marriott San Francisco Union Sq. . . . At Westin St. FrancisMarriott Union Square ................At Westin St. FrancisSir Francis Drake ......................At Westin St. FrancisWestin St. Francis .....................Curbside on PostService every 15-20 minutes at all times.Route #3 ........................ Boarding LocationFairmont San Francisco ................Curbside on MasonService every 15-20 minutes at all times.The following hotels are located within walkingdistance of Moscone Convention Center, therefore,shuttle service is NOT provided.Hotel AbriCourtyard by Marriott DowntownHotel PalomarHotel Union SquareInterContinental San FranciscoMarriott Marquis San FranciscoPalace - Luxury StarwoodParc 55 WyndhamPowell HotelW Hotel San FranciscoWestin San Francisco Market StreetConvention Center Shuttle Hours MosconeConvention CenterService is every 15-20 minutes at all times.Saturday, September 8 ................7:30 a.m. – 5:30 p.m.*Sunday, September 9 .................6:00 a.m. – 7:00 p.m.*Monday, September 10 ...............6:00 a.m. – 7:30 p.m.*Tuesday, September 11 ...............6:00 a.m. – 7:30 p.m.*Wednesday, September 12 ............6:30 a.m. – 12:30 p.m.**Indicates last time shuttle departs Moscone ConventionCenter returning to hotels. Last shuttle departs hotelscoming to Moscone approximately 45 minutes prior to this time.Satellite Symposia Shuttle HoursSymposia will be located at the Marriott Marquis and theIntercontinental. SHUTTLE SERVICE WILL NOT BEPROVIDED.If you have questions about the shuttleor if you need to make an advancereservation for a wheelchair-accessibleshuttle, please see the supervisor at theMoscone Convention Center or callKUSHNER & ASSOCIATES at(310) 274-8819 ext. 213.22 September 9-12 |

General Information for ICAAC 2012Abstract CompilationsExhibiting companies that distribute abstract compilations onsiteof any of the ICAAC 2012 abstract presentations must havereceived prior approval from the Program Committee and ASM.Compilations most accurately reflect the abstracts and cannotcontain promotional information. Pre-approved distribution isallowed from a specially designated literature rack in Halls A-Cat the Poster Information booth. Abstract compilations distributedin an unapproved area will be removed by ASM staff.Abstracts on CD-ROMSupported by Merck & Co, Inc.All ICAAC 2012 Abstracts have been compiled on a fullysearchable CD-ROM that will be included in each registrationbag.Americans with Disabilities ActSpecial Services at Moscone North and SouthPersons requiring special services at the convention center(wheelchair-accessible transportation, sign interpreters, etc.)are asked to stop by ASM Headquarters in Room 220. Sincerequests were due as part of the registration process, on-siterequests will be fulfilled based on availability.ATMThere is an ATM located in Moscone North near the entranceto Hall D, and one in Moscone South outside of Hall B.Badge PoliciesFor security reasons, all attendees are required to wear a badgeto attend sessions or enter the Exhibit Hall. Please note thatbadges are the property of ASM and must be relinquished at anytime at the request of ASM staff or security.Attendee Badges> Access into all scientific sessions> Access to the Exhibit Hall and Poster Sessions duringoperating hours> Unlimited use of the courtesy shuttle> Access to Continuing Education CreditsGuest Badges> Access to the Exhibit Hall and Poster Sessions duringoperating hours> Unlimited use of the courtesy shuttle> Attendees wearing guest badges will not be permitted intoscientific session rooms.Exhibitor Badges> Entrance into the Exhibit Hall during installation anddismantling hours> Entrance into the Hall 2 hours before the Hall opens andone hour after it closes> Unlimited use of the courtesy shuttle> Attendees wearing exhibitor badges will not be permitted intoscientific session rooms.Press Badges> Access into all scientific sessions> Access to the Exhibit Hall and Poster Sessions duringoperating hours> Unlimited use of the courtesy shuttle> To receive continuing education credit, members of thepress must register for the meeting and pay the appropriateregistration feeBadge Replacement PolicyReplacement badges are $100. Please return any foundbadges to the Registration Assistance Counter located inHall A-B, Exhibit Level of Moscone Convention CenterSouth.Security and Badge Duplication or SharingStrict badge policies are in effect for ICAAC to providea safe and secure meeting. Photocopying, duplicating, orsharing badges to avoid paying meeting registration fees isstrictly prohibited. Security will be closely examining badgesand anyone possessing a fraudulent meeting badge will beescorted from the premises.Final Program23

General Information continued…Business CenterThe Business Center in Moscone South offers numerous services,including digital printing, packing & shipping, packagingmaterials, and last-minute office supplies, to meet your needs.LocationMoscone South, near the entrance to Hall CPhone: (415) 974-4067Fax: (415) 974-4052Hours:Sunday, September 9 > 10:30 a.m. – 4:30 p.m.Monday, September 10 > 9:30 a.m. – 4:30 p.m.Tuesday, September 11 > 9:30 a.m. – 4:30 p.m.Wednesday, September 12 > 9:00 a.m. – 12:00 p.m.Cameras and RecordingCassette recorders, cameras (including camera phones, and videocameras) are NOT allowed in session rooms or in the exhibitand poster areas. Attendees who wish to purchase a digital recordingof a session may stop by the Multimedia Booth locatedin the South Lobby.Certificate of AttendanceA Certificate of Attendance will be available beginning Monday,September 10 at all attendee registration counters.Child SafetyChildren are not permitted entry into session rooms. Also,children under the age of 18 are not permitted on the ExhibitHall floor during setup or dismantling hours. During scheduledshow hours, exceptions are made when parents or guardianscomplete and sign a Minor Release Form. This form is availablein the ICAAC Information Booth in the South Lobby and inthe ICAAC Headquarters Office in Room 220. Strollers are notallowed in the Exhibit Hall and may be checked at the coat andbaggage check.Coat and Baggage CheckA coat and baggage check is located on the Mezzanine level, justbelow the South Lobby.Hours:Sunday, September 9 > 7:00 a.m. – 6:30 p.m.Monday, September 10 > 7:00 a.m. – 7:00 p.m.Tuesday, September 11 > 7:00 a.m. – 7:00 p.m.Wednesday, September 12 > 7:00 a.m. – 12:00 p.m.Cooperating Organizations> American Society of Tropical Medicine and Hygiene(ASTMH)> European Organisation for Research and Treatment ofCancer (EORTC-IDG)> European Society of Clinical Microbiology and InfectiousDiseases (ESCMID)> Global Chinese Association of Clinical Microbiology andInfectious Diseases (GCACMID)> Infectious Diseases Society of America (IDSA)> Infectious Diseases Society of Obstetrics and Gynecology(IDSOG)> International Antiviral Society-USA (IAS-USA)> International Society of Anti-Infective Pharmacology(ISAP)> International Society of Chemotherapy (ISC)> Mycology Study Group (MSG)> Pediatric Infectious Diseases Society (PIDS)> Society of Infectious Diseases Pharmacists (SIDP)> Surgical Infection Society (SIS)E-CentralThe following services and information are available:> Obtain a continuing education certificate> ASM CE Portal access> Locate presenters, sessions and topics> E-mail accessLocations :E -Central #1 | Hall E FoyerSaturday, September 8 > 12:00 p.m. – 5:00 p.m.Sunday, September 9 > 6:30 a.m. – 6:30 p.m.Monday, September 10 > 6:30 a.m. – 7:00 p.m.Tuesday, September 11 > 6:30 a.m. – 7:00 p.m.Wednesday, September 12 > 6:30 a.m. – 12:00 p.m.E-Central #2 | Halls A-CSunday, September 9 > 11:30 a.m. – 4:30 p.m.Monday, September 10 > 10:30 a.m. – 4:30 p.m.Tuesday, September 11 > 10:30 a.m. – 4:30 p.m.24 September 9-12 |

Exhibit HallOutside of the educational sessions, the Exhibit Hall is the mostexciting place to be! With more than 70 exhibitors assembled inThe Moscone Center for one of the largest exhibitions in antimicrobialagents and chemotherapy. These exhibitors will havethe latest in the field of infectious disease from vaccines, diagnosticequipment and services, scientific publications, research,and new drugs and the latest information on existing drugs.Please schedule time to walk through the Exhibit Hall and takeadvantage of this rare grouping of exhibitors. The Exhibit Hallis located in Moscone South A-C.The Exhibit Hall is open:Sunday, September 9 > 11:30 a.m. – 4:30 p.m.Monday, September 10 > 10:30 a.m. – 4:30 p.m.Tuesday, September 11 > 10:30 a.m. – 4:30 p.m.Exhibit Hall Attractions:> Poster Sessions> Poster Walks> iPosters> E-Central> Food CourtRefer to the Meeting & Exhibit Guide for detailed informationon specific exhibitors, their products and locations, as well as additionalinformation on their industry-sponsored symposia.ExpoCardSupported by Elsevier – Clinical Key.The ExpoCard has your name, address, and demographic informationelectronically encoded. Several services are accessiblewhen the ExpoCard is used:In the Exhibit Hall: the ExpoCard serves as an electronic businesscard, allowing you to easily and quickly leave your addressinformation for follow-up with companies exhibiting productsthat interest you.E-Central: you may gain access to the services outlined on page24 with the swipe of your ExpoCard.First AidA First Aid Station will be staffed at Moscone Center in Hall CFoyer during meeting hours. If you feel ill or need a place to liedown, go to the First Aid Station. In case of a medical emergencyat Moscone Center, please dial 511 from any house phone.Food and BeverageFull service food stands will be available Saturday–Tuesday,throughout Moscone North and South.Future Meetings BoothA bulletin board for posting notices concerning future meetingswill be located at the Future Meetings Booth in the SouthLobby. Announcements displayed elsewhere will be discarded.HousingAny changes to hotel reservations should be made directlywith the hotel. If you have any problems with your reservationor need to change hotels, please visit the Housing AssistanceCounter located at Registration Assistance in Halls A-C.Information BoothThe ICAAC Information Booth will be located in the SouthLobby.The following information will be available:> Meeting Information> Approved Affiliated Events> Program Changes and Updates> Minor Release Forms for Exhibit Hall Entrance> Satellite Symposia InformationFinal Program25

General Information continued…Lost and FoundUnattended personal belongings will be removed and taken tothe ICAAC Headquarters Office located in Room 220.MessagesMail and other forms of communication can be directed to theindividual at the hotel where he or she is registered.Multimedia SalesDigital recordings from ICAAC sessions are available forpurchase in the South Lobby at the multimedia sales booth.Nursing RoomA Nursing Room will be available for use during ICAAC 2012.Please visit Headquarters in Room 220 for additional information.ParkingMoscone Center encourages the use of public transit first.However, parking facilities do exist close to Moscone. For moreinformation about nearby garages as well as a parking map,please visit www.moscone.com/directions/parking.shtml.Poster InformationCall4PostersThe Call4Posters Booth is located outside Halls A-C.iPostersiPosters is a free of charge service that allows you to includeyour poster in the online poster database. iPosters onlineposter database will be available for viewing during andafter the meeting. iPosters kiosks for poster viewing andprinting will be available on-site in Halls A-C. To includeyour poster in this educational database, please go to www.call4posters.com/icaac or visit the iPosters kiosks locatedin Halls A-C, where staff will be available to accept electronicsubmissions of your final poster. Attendees can viewiPosters online by visiting the iPosters kiosks.Poster StorageComplimentary poster storage, for posters and poster containersonly, will be located inside Halls A-C. Posters notremoved from the Poster Storage area will be discarded at theconclusion of the meeting. All items are stored at your ownrisk. ASM is not responsible for lost or stolen items.Poster WalksPoster Walk presentations, selected by the ICAAC ProgramCommittee, are designed to give poster presenters an opportunityto give brief informal presentations and answer questions ontheir research. Lead by pioneers in the field, these topic-basedwalks will tour the Poster Hall discussing the most intriguingposters and latest discoveries from particular areas of interest.Poster Walks will take place in Halls A-C. For more informationsee page 11.Program ChangesDaily updates and changes to the Final Program will be reflectedin the ICAAC 2012 Mobile App.Registration HoursSaturday, September 8 > 12:00 p.m. – 5:00 p.m.Sunday, September 9 > 6:30 a.m. – 5:00 p.m.Monday, September 10 > 6:30 a.m. – 5:00 p.m.Tuesday, September 11 > 6:30 a.m. – 5:00 p.m.Wednesday, September 12 > 6:30 a.m. – 9:00 a.m.Satellite SymposiaSatellite Symposia are non-commercially-focused scientificsessions developed by organizing agencies and supported byICAAC exhibiting companies. Satellite Symposia are not partof the official ICAAC program. Details about the satellitesymposia can be found in the ICAAC Meeting & ExhibitGuide located in each registration bag.Sessions and Room CapacityAll scientific sessions will be held at Moscone North and South.A map of Moscone Center is located in the Meeting & ExhibitGuide and this Final Program. Poster Sessions will be held inHalls A-C Sunday, September 9 – Wednesday, September 12.An ICAAC 2012 attendee badge is required to access thePoster Sessions.The ICAAC Program Committee attempts to determine thepopularity and estimated attendance level for each session.Please accept our apologies in advance should the demandexceed the number of seats in a particular session. For safetyreasons, ASM must adhere to all room capacity regulationsprescribed by the Moscone Convention Center and the FireMarshall of California. Attendance is on a first-come, firstservedbasis. ASM requests that attendees use every availableseat before resorting to standing. Sitting in aisles is a hazard, andASM requests that you not do so.26 September 9-12 |

ShippingIf you need to have a package shipped from San Francisco,please visit your hotel’s business center or the Business Centerin Moscone South near the entrance to Hall C.Shuttle ServicePlease see page 22 for complete shuttle details including boardinglocations and hours of operation. A shuttle bus flyer andsignage will also be placed in each hotel.Smoking PolicySmoking is prohibited in all areas of the Moscone Center.Speaker Ready RoomSpeakers may preview their presentation in the Speaker ReadyRoom in Room 204 of the Moscone Center.ASM requests that speakers submit their electronic presentationfiles to the AV operator in the Speaker Ready Room at least 4hours prior to their presentation time.Hours:Saturday, September 8 > 7:30 a.m. – 5:00 p.m.Sunday, September 9 > 6:00 a.m. – 7:00 p.m.Monday, September 10 > 6:00 a.m. – 6:00 p.m.Tuesday, September 11 > 6:00 a.m. – 6:00 p.m.Wednesday, September 12 > 6:00 a.m. – 9:30 a.m.Telephone NumbersICAAC Headquarters Office — 415-978-3700First Aid — 415-974-4090Press Room — 415-978-3709Shuttle Bus — 310-274-8819, ext. 213TransportationAirportsSan Francisco International Airport (SFO) offers non-stopflights to more than 31 international points on 29 internationalcarriers. The Bay Area’s largest airport offers serviceto more than 70 non-stop cities in the U.S. on 16 domesticairlines.Public Transportation from the Airport> BART Rapid Rail: BART operates rapid rail serviceto northern San Mateo County, San Francisco and theEast Bay directly from SFO. The SFO BART Station islocated on the Departures/Ticketing Level of the InternationalTerminal (Boarding Area G side). BART is easilyaccessed from any terminal by riding SFO’s AirTrain tothe Garage G/BART Station stop. There is no charge toboard AirTrain. BART provides a connection to Caltrainat the Millbrae station.> Caltrain Commuter Rail: Caltrain provides rail servicebetween San Francisco and San Jose, with weekdaycommute-hour service to Gilroy. BART connects SFO tothe Caltrain rail system at the Millbrae Station. Weekdayexpress trains serve select stations during commute hours.> SamTrans Public Bus Service: SamTrans provides 24-hour service connecting SFO to San Mateo County andparts of San Francisco and Palo Alto.Shuttle from the AirportCharter services are available to most Bay Area locationsand must be pre-arranged with the service operator. Charterpick-up areas are located in the courtyards on the Arrivals/Baggage Claim Level. Please visit www.flysfo.com for a listof operators serving SFO.Taxicabs from the AirportTaxis depart from the designated taxi zones located at theroadway center islands, on the Arrivals/Baggage Claim Levelof all terminals. Uniformed taxi coordinators are stationed atthe taxi zones from 7:00 a.m. to 1:00 a.m. to assist passengerswith questions or concerns.Taxi Service24-hour dependable service is available to and from all destinations.Taxi cabs are also easily accessible at the MosconeCenter, major hotels, and other downtown locations.Final Program27

Continuing Education InformationIntended AudienceThe ICAAC 2012 is designed to meet the needs of health careprofessionals, particularly physicians, clinical microbiologists,researchers, and pharmacists, specializing in infectious diseases.Current trends will be covered regarding:> Antimicrobial Resistance> Clinical Trials> Community-Acquired Infections> Epidemiology> HIV/AIDS and other Retroviruses> Laboratory Diagnostics> Microbial Pathogenesis> Mycology> Nosocomial Infections> Parasitology> Pharmacology> Susceptibility Studies> Vaccines and Immunology> VirologyObjectivesParticipation in the ICAAC 2012 should allow attendees to:> Investigate the pathogenesis and epidemiology of old andnew microbes;> Utilize new data from the research of basic microbiologicalsciences related to human disease to improve theirclinical practice and patient outcomes;> Evaluate the spread of infectious diseases throughout theworld;> Review state-of-the-art developments in the field, includingtimely reviews of recent advances in clinical care andresearch and original reports of clinical, translational, andbasic research;> Identify the most recent trends in health care management;> Incorporate the knowledge gained to assist with bridgingany gaps among the fields of infectious diseases clinicalpractice, clinical research, epidemiological and healthservices research, translational research, and basic research;> Recognize and better understand recent new antimicrobialagents;> Understand and discuss updates on clinical diagnoses,preventative modalities and therapeutics;> Analyze the developing resistance of pathogens to diversetherapeutics; and> Engage in networking and collaboration among cliniciansand investigators to facilitate advances in the prevention,diagnosis, and treatment of infectious diseases.Continuing Education (CE) CreditThe following session types will offer continuing education credit.Session TypeContact Hours orAMA PRA Category1 Credits per sessionKeynote Session, PosterSummary and Literature Review > 2Interactive Symposia andSymposia > 1.5 - 2Slide Sessions > 2.5Meet-the-Experts > 1.25ICAAC Lecture andPlenary Session > 1Workshops (Full-Day) > 7Workshops (Half-Day) > 3.5Continuing Medical EducationThe France Foundation is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuingmedical education for physicians.The France Foundation designates this live activity for amaximum of 33.25 AMA PRA Category 1 Credits. Physiciansshould claim only the credit commensurate with theextent of their participation in the activity.The American Medical Association (AMA) has determinedthat physicians not licensed in the U.S. who participate inthis CME activity are eligible for AMA PRA Category 1Credits.Diplomates of the American Board of Medical Microbiology,Diplomates of the American Board of Medical LaboratoryImmunology, and Registrants of the National Registryof Certified Microbiologists who are MDs and DOs mayearn AMA PRA Category 1 Credits toward recertification.All other Diplomates and Registrants may claim Participation,CA or FL credits toward recertification. Each professionalshould claim credit commensurate with their level ofparticipation in the activity.28 September 9-12 |

Continuing Pharmacy EducationThe France Foundation is accredited by the AccreditationCouncil for Pharmacy Education as a provider of continuingpharmacy education and will award up to 33.25 contacthours or 3.325 CEUs to pharmacists who attend the activitiesand complete the registration and evaluation forms.All sessions at ICAAC 2012 are knowledge-based activities.Sessions approved for CE credit will have a correspondingUniversal Activity Number (UAN).California Clinical Laboratory Scientists (CLS)ASM is accredited by the California Department of HealthServices to offer continuing education for California ClinicalLaboratory Scientists. All sessions designated for CMEcredit will also qualify for California CE credit toward CLSlicense renewal.Florida Clinical Laboratory PersonnelASM is accredited by the Florida Department of Health tooffer continuing education for Florida Clinical LaboratoryPersonnel. All sessions designated for CME credit will alsoqualify for Florida CE credit toward license renewal.Other CE LicensesYou may obtain a Participation Statement of Credit by completingthe activity evaluation. This is a detailed statementthat documents your participation in the activity.Education DisclaimerThe primary purpose of the sessions at ICAAC 2012 is education. Informationpresented, as well as publications, technologies, products, and/or servicesdiscussed, are intended to inform you about the knowledge, techniques,and experiences of professionals who are willing to share such informationwith colleagues. A diversity of professional opinions exists in the fields discussedat ICAAC and the views of the ICAAC faculty are offered solely foreducational purposes. Faculty’s views neither represent those of ASM norconstitute endorsement by the association. The ASM disclaims any and allliabilities for damages to any individual attending ICAAC and for all claimswhich may result from the use of this information, publications, technologies,products, and/or services at ICAAC.DisclosureThe France Foundation adheres to ACCME Essential Areas, Standards,and Policies regarding industry support of continuing medical education.Disclosure of the planning committee, content reviewers, and faculty’scommercial relationships will be made known at the activity. Speakers arerequired to openly disclose any limitations of data and/or any discussionof any off-label, experimental, or investigational uses of drugs or devices intheir presentations. A listing of faculty disclosures is available in the OnlineProgram Planner and will be made available at the start of each session. Thispolicy is intended to make you aware of faculty disclosure so that you mayform your own judgments about material discussed during ICAAC.If you have concerns (e.g., commercially-biased presentations, promotionalmaterials distributed by presenters and/or participants, etc.), please visit theICAAC Headquarters Office and ask to speak to an ASM staff person sothat ASM can respond immediately to your concerns.The planners, reviewers, editors, staff, CME committee, or other membersat The France Foundation who control content have no relevant financialrelationships to disclose.Claim CE CreditsTo claim credits for the ICAAC 2012, visit the ASM CE Portal,http://ce.asm.org.The ASM CE Portal allows individuals to:> Evaluate the activities they attend,> Print their own CE or participation certificate for the activity,> Browse the library of available ASM CE activities,> Participate in online learning activities.How to Claim CE Credit1. Keep your badge! You will need your registration confirmationnumber or badge ID to claim your credits.2. Login to the CE Portal with your ASM eStore user name andpassword. If you do not have a user name and password, selectthe “Need Help Logging In?” link.3. Once logged in, you will be directed to your “My Activities”page.4. Click on the “Claim Credits for Live Meetings” button on theright side of the screen.5. Select “ICAAC 2012” under the Available Activities table.If you are claiming credit for a workshop, please select“Workshops –ICAAC 2012.”6. On the Activities Overview Page, scroll to the bottom of the pageto enter your badge ID. The badge ID may be obtained from yourprinted badge or from your emailed confirmation letter.7. Choose what type of credit you would like to claim. TheICAAC 2012 offers five types of continuing education credit.Please choose the certificate that is applicable to your needs:- Continuing Medical Education (CME) certificate- Continuing Pharmacy Education (CPE) certificate- Florida (FL) certificate- California (CA) certificate- Participation certificate> After selecting your certificate type you will be directed to the“Claim Credits” page. Select each session attended, indicatehow many credits you are requesting, and complete the evaluationfor each session. (To view more sessions please click thepage numbers at the bottom of the Claim Credits screen. Donot press Next until you have finished claiming credits for allyour sessions.)8. Once you have claimed credit for ALL of your sessions, you mayreview your credits summary and print your certificate.When completing your online evaluation, PLEASE DO NOTPRESS PRINT until you have entered your information foreach session attended at ICAAC. Once you print, your Statementof Credit is considered final and sessions cannot be addedor changed.Please email cmeservices@asmusa.org with questions or visit theICAAC Headquarters Office.Final Program29

Icon legend >>>>>>> GlossaryContinuing education available for physicians, microbiologists, and othersContinuing education available for pharmacistsRecipient of an ICAAC Program Committee AwardConveners Conveners are invited faculty who have contributed to theplanning of an invited symposium or interactive cases and serve as achair.Interactive Symposia Seven invited symposia have been scheduledthat involve the audience in their own learning. Faculty present clinicalcase studies and pose relevant questions. Using hand-held keypads, theaudience participants select a response, and the audience’s collectivedata are then displayed. Subsequently, there is an open discussion of theresponses.Late-Breaker Presentations Late-breaker presentations highlightbreak-through scientific research results only recently discoveredsince the original ICAAC abstract submission deadline. Late-breakerabstracts have been added to previously programmed slide and postersessions as appropriate. Please see page 295 for details.Literature Review Scheduled for Sunday afternoon, the conveners ofthis session present a general overview of the past year’s most noteworthypublications related to infectious diseases. Abstracts of the articlesdiscussed are posted at www.icaac.org.Meet-the-Experts Thirty-six clinically-oriented Meet-the-Expertssessions are scheduled. These sessions permit attendees to interactdirectly with two specialists on a topic. After short presentations, theexperts open the session for questions and answers during this 1-1/4hour session.Moderators Moderators are selected individuals who serve as chairsof abstract slide sessions.Poster Sessions Eighty-five percent of accepted abstracts will be presentedas posters, on display in Exhibit Hall, Halls A-C from Sunday– Wednesday. Each poster stays on display for an entire day, and eachpresenter is available at his or her poster for a two hour time period,as published. Specially-designed literature racks provided by ASM arelocated near the Poster Information booth, where exhibiting companiesmay place their pre-approved abstract and poster compilations.Poster Summary Session This session on new drugs will be held Sundayafternoon. The conveners of this session review all poster presentationsthat deal with new drug research and present an overview of thedata presented. This session consistently receives outstanding reviews.Poster Walks Poster Walk presentations are selected by the ICAACProgram Committee are designed to give poster presenters an opportunityto discuss informally their research with colleagues. These brieforal presentations allow poster presenters to present their research andanswer questions from the audience. Poster walks will take place inExhibit Hall, Halls A-C.Slide Sessions Fifteen percent of this year’s accepted abstracts arescheduled for slide (PowerPoint) presentation.State-of-the-Art Mini-Lecture Seven slide sessions include a 30-minute,invited State-of-the-Art Mini-Lecture to complement the abstractpresentations by offering attendees an overview, background, or summaryof the science in that slide session.Symposia Symposia are classic 1 ½ - 2 hour sessions in which threeto four speakers, invited by the ICAAC Program Committee, discussthe topic at hand. A number of symposia conclude with a 30-minuteroundtable discussion to allow for additional audience participation.Topical Categories To assist you with your use of the Final Program,please note the following topical categories that are referenced in parenthesesfollowing session numbers.A1. Antimicrobial PharmacokineticsA2. Antimicrobial PharmacodynamicsB. Therapy in Animal Models, Pathogenesis of Infectious Diseases,Molecular Basis for Pathogenicity, and Host DefensesC1. Antibacterials: Mechanisms of Action, Biochemistry andGenetics of Resistance (Antibacterial, not Viral or Fungal)C2. Antibacterials: Surveys and/or Molecular Epidemiology ofResistance and Resistance Genes, Strains or Serotypes(Bacterial, not Viral or Fungal Resistance)D. Laboratory Tests for Diagnosing Infections; Methods forAntibacterial Susceptibility TestingE. In Vitro Antibacterial Susceptibility Studies and Drug-Combination InteractionsF1. New Antimicrobial Agents (i.e. pre-US IND or prior to thestart of any clinical therapeutic studies)F2. New Research Technologies and Methodologies (in early stagesof drug discovery)G1. Bacterial, Viral and Other Vaccine Development TrialsG2. Antigen Discovery or Delivery and Adjuvants or Immunomodulatorsto Augment Immune ResponsesG3. Studies Relating to Aspects of Pediatric InfectionsH1. HIV Epidemiology, Natural History, Pathogenesis and HIV-Related Morbidities Including Outcomes and PharmacoepidemiologicalStudiesH2. Antiretroviral Agents for Treatment and Prevention IncludingPreclinical and All Phases of Clinical Trials and resistanceH3. Co-Infections in HIV (eg HCV, HBV, Other Agents)K. Healthcare-Associated and Surgical Infections and ClinicalEpidemiologyL1. Clinical Trials of Adults with Community-Acquired InfectionsL2. STD, Urinary Tract and Ob-Gyn InfectionsM. Mycology, Including Resistance and Mechanisms of Action ofAntifungalsP. Global Health, Travel Medicine and ParasitologyT. Transplantation Infectious DiseasesV. Virology (Non-HIV), Including Resistance, and Non-HIVViral Opportunistic Infections in HIV-Infected Patients30 September 9-12 |

Saturday> 8:30 a.m. - 12:00 p.m.Workshops52-01 Basics of Pharmacokinetics andPharmacodynamics of Anti-Infective AgentsEsplanade Ballroom 30652-03 Introduction to PK/PD Modeling ofAnti-InfectiveAgentsEsplanade Ballroom 305> 8:30 a.m. - 4:30 p.m.Workshops52-05 PK/PD Full-Day WorkshopCombining 52-01 and 52-0252-06 PK/PD Full-Day WorkshopCombining 52-03 and 52-0452-07 PK/PD Full-Day WorkshopCombining 52-04 and 52-0152-08 PK/PD Full-Day WorkshopCombining 52-03 and 52-0252-10 Antibiotic Resistance Among BacterialPathogens: Mechanisms, Detection, andMolecular EpidemiologyEsplanade Ballroom 30752-11 Antimicrobial Stewardship in HospitalsEsplanade Ballroom 30452-12 A Year in Review: Critical Analysis andApplication of Infectious Diseases PracticeGuidelines and Pharmacotherapy LiteratureEsplanade Ballroom 30852-13 New Clinical Microbiology Diagnostics:What is (or Could be) in Your Lab?Esplanade Ballroom 30952-14 Transplant Infectious Diseases:Prevention and Resistance: Challengesfor the 21st CenturyEsplanade Ballroom 310> 1:00 p.m. - 4:30 p.m.Workshops52-02 Clinical Relevance of Pharmacokineticsand Pharmacodynamics of Anti-InfectiveAgentsEsplanade Ballroom 30652-04 Advanced PK/PD Modeling of Anti-Infective Agents with Practical ExamplesEsplanade Ballroom 305> Saturday/Sunday Schedule at-a-GlanceSunday> 7:00 a.m. - 9:00 a.m.Interactive ID Fellows Session001 Infectious Diseases 101: For FellowsAge 18-88Room 104> 9:30 a.m. - 11:30 a.m.Keynote Session002 Opening Keynote SessionHall E> 11:30 a.m. - 12:30 p.m.Poster WalkAntibiotic Use and ResistanceHalls A-C> 11:30 a.m. - 1:30 p.m.Poster Sessions003 (A) PK/PD of Carbapenems With orWithout Beta-Lactamase InhibitorsHalls A-C004 (A) Polymyxins and Aminoglycosides:Optimizing PK/PD and DosingHalls A-C005 (B) Immune Response to MicrobialInfectionHalls A-C006 (C1) Carbapenemases and ExpandedSpectrum-Lactamases: Enterobacteriaceae,S. aeruginosa, A. bumanniiHalls A-C007 (C2) AmpCs: Not Going Away!Halls A-C008 (C2) Carbapenemases: Will TheyEver End!Halls A-C009 (C2) ESBLs: Still RelevantHalls A-C010 (C2) Multi-Center Surveillance StudiesHalls A-C011 (D) Clostridium difficile DiagnosticsHalls A-C012 (D) Diagnosis of Infections ofImplantable Devices and BiofilmsHalls A-C013 (D) Diagnosis of Respiratory TractInfectionsHalls A-C014 (D) Serologic Methods for Detection ofInfectious DiseasesHalls A-C015 (E) In Vitro Activity of Beta-LactamaseInhibitor CombinationsHalls A-C016 (E) In Vitro Activity of FluoroquinolonesHalls A-C017 (H) Adherence to HIV Therapy and CareHalls A-C018 (H) Hepatitis B and C Coinfection inHIVHalls A-C019 (H) Opportunistic Infections and Co-Morbid Conditions in HIV-IHalls A-C020 (K) Antibiotic Stewardship and UsageHalls A-C021 (K) Infection Control and theEnvironmentHalls A-C022 (K) Prosthetic Joint InfectionsHalls A-C023 (K) Surgical Site InfectionsHalls A-C024 (K) Vancomyoin-Resistant EnterococciHalls A-C025 (L1) Antimicrobial Stewardship andOPATHalls A-C026 (L1) Respiratory Tract InfectionHalls A-C027 (L2) Studies in Sexually TransmittedInfectionHalls A-C028 (M) Fungal EpidemiologyHalls A-C029 (T) Infections in Transplant Recipients:Viruses and FungiHalls A-C030 (V) Non-HIV VirologyHalls A-C> 12:30 p.m. - 1:30 p.m.Poster WalkThe HIV Poster RoundsHalls A-C> 1:45 p.m. - 3:45 p.m.Literature Review031 Literature ReviewRoom 103Poster Summary Session032 (F) Early New Antimicrobial AgentsRoom 104Saturday/Sunday

Saturday/Sunday Schedule at-a-Glance continued…> 4:00 p.m. - 6:00 p.m.Interactive Symposia033 (P) What’s Hot Where it’s Hot:Interactive Cases in Tropical MedicineRoom 103034 (V, D) Transplantation and the IDPhysician: Management Strategies forthe 21st CenturyRoom 104Symposia035 (A) Pharmacodynamics of AntifungalAgentsEsplanade Ballroom 306036 (B) Microbial Factors Modulating HostResponses: New FrontiersEsplanade Ballroom 309037 (C1) Multidrug Resistance in EmergingCountriesEsplanade Ballroom 302038 (C2) Whole Genome Sequencing andMolecular Epidemiology: The New Frontier?Esplanade Ballroom 308039 (D) Best Practices: Diagnosis of ViralCauses of HepatitisEsplanade Ballroom 305040 (E, C2) Origins and Ecology ofAntibiotic ResistanceEsplanade Ballroom 310041 (F) New Treatments for Mycobacteriumtuberculosis InfectionsRoom 122042 (G) Vaccine Conquests and ChallengesRoom 120043 (H) Update on HIV-AssociatedCo-MorbiditiesRoom 121044 (L) An Update on Novel & ImportantTickborne DiseasesRoom 102045 (L2) An Update on Perinatal InfectionsRoom 130046 (M) Mycology 2012: Top PapersRoom 132> 4:00 p.m. - 6:30 p.m.Slide Session047 (C1) Structure/FunctionEsplanade Ballroom 300048 (K) Difficulties of Clostridium difficileRoom 254

ICAAC 2012 WORKSHOPSWorkshopsAll workshops will be held in the Moscone South (Convention Center).------------------------------------------------------------------------52-01Basics of Pharmacokinetics and Pharmacodynamics ofAnti-Infective AgentsSaturday, 8:30 a.m. - 12:00 p.m. . ... Esplanade Ballroom 306UAN: 0391-9999-12-179-L04-PConveners:Johan W. Mouton, MD, PhD - ProfessorRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.Hartmut Derendorf, PhD - Distinguished ProfessorUniv. of Florida, Gainesville, FL.Faculty:Hartmut Derendorf, PhD - Distinguished ProfessorUniv. of Florida, Gainesville, FL.Johan W. Mouton, MD, PhD - ProfessorRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.William A. Craig, MD - Emeritus ProfessorUniv. of Wisconsin, Madison, WI.Alasdair P. MacGowan, MD - Professor of Clinical Microbiology andAntimicrobial TherapeuticsBristol Ctr. for Antimicrobial Res. and Evaluation, Bristol, United Kingdom.Ursula Theuretzbacher, PhD - PrincipalCtr. for Anti-Infective Agents, Vienna, Austria.Roger L. Nation, PhD - Professor of Drug Disposition and DynamicsMonash Univ., Melbourne, Australia.Objectives: Upon completion of this Workshop, the participant should beable to:> Identify pharmacokinetic and pharmacodynamic concepts of antimicrobialefficacy;> Apply in vitro models and animal models in pharmacodynamic research;> Recognize the limitations and use of serum and tissue concentrations;> Calculate pharmacokinetic and pharmacodynamic parameters and interpretthe results; and> Assess drug resistance in vitro.Intended Audience: Medical microbiologists, infectious diseases specialists,pharmacologists, drug development scientists, and other interested.Course Level: Beginning------------------------------------------------------------------------52-02Clinical Relevance of Pharmacokinetics and Pharmacodynamicsof Anti-Infective AgentsSaturday, 1:00 p.m. - 4:30 p.m. . .... Esplanade Ballroom 306UAN: 0391-9999-12-180-L04-PConveners:Johan W. Mouton, MD, PhD - ProfessorRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.Ursula Theuretzbacher, PhD - PrincipalCtr. for Anti-Infective Agents, Vienna, Austria.Faculty:Johan W. Mouton, MD, PhD - ProfessorRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.Markus Zeitlinger, MD - Assoc. ProfessorMed. Univ. of Vienna, Vienna, Austria.Sujata M. Bhavnani, PharmD - Vice-President, Translational MedicineInst. for Clinical Pharmacodynamics, Latham, NY.David R. Andes, MD - Associate ProfessorUniv. of Wisconsin, Madison, WI.Ursula Theuretzbacher, PhD - PrincipalCtr. for Anti-Infective Agents, Vienna, Austria.Paul M. Tulkens, MD - ProfessorUniv. Louvain, Bruxelles, Belgium.Objectives: Upon completion of this Workshop, the participant should beable to:> Gain insight in the clinical significance of PK/PD modeling ofantimicrobials;> Extrapolate preclinical PK/PD information into clinical drugdevelopment;> Determine PK/PD of antibacterials and antifungals;> Assess drug exposure at the site of infection; and> Recognize and evaluate clinical drug resistance.Intended Audience: Infectious diseases specialists, pharmacologists, medicalmicrobiologists, clinical drug development specialists, and others interested.Course Level: BeginningFinal Program31

Saturday WORKSHOPS------------------------------------------------------------------------52-03Introduction to PK/PD Modeling of Anti-InfectiveAgentsSaturday, 8:30 a.m. - 12:00 p.m. . ... Esplanade Ballroom 305UAN: 0391-9999-12-181-L04-PConveners:Vincent Tam, PharmD - Associate ProfessorUniv. of Houston Coll. of Pharmacy, Houston, TX.Alexander A. Vinks, PharmD, PhD - ProfessorUniv. of Cincinnati, Cincinnati, OH.Faculty:Alasdair P. MacGowan, MD - Professor of Clinical Microbiology and AntimicrobialTherapeuticsBristol Ctr. for Antimicrobial Res. and Evaluation, Bristol, United Kingdom.Vincent H. Tam, PharmD - Associate ProfessorUniv. of Houston Coll. of Pharmacy, Houston, TX.Alexander A. Vinks, PharmD, PhD - ProfessorUniv. of Cincinnati, Cincinnati, OH.Alan Forrest, PharmD - Research Professor; Senior Director PharmacometricsSUNY Univ. of Buffalo, Buffalo, NY.Sujata M. Bhavnani, PharmD - Vice-President, Translational MedicineInst. for Clinical Pharmacodynamics, Latham, NY.Jared L. Crandon, PharmD - Associate DirectorHartford Hosp., Hartford, CT.Objectives: Upon completion of this Workshop, the participant should beable to:> Apply MIC based PK/PD modeling in vitro and in animals;> Perform PK/PD analysis based on kill curves;> Employ population PK/PD of anti-infective agents;> Design and evaluate Monte Carlo Simulations; and> Integrate preclinical and clinical PK/PD.Intended Audience: Drug development specialists, pharmacologists, medicalmicrobiologists, infectious diseases specialists, and others interested.Course Level: Intermediate------------------------------------------------------------------------52-04Advanced PK/PD Modeling of Anti-Infective Agentswith Practical ExamplesSaturday, 1:00 p.m. - 4:30 p.m. . .... Esplanade Ballroom 305UAN: 0391-9999-12-182-L04-PConveners:George L. Drusano, MD - ProfessorUniv. of Florida, Orlando, FL.Hartmut Derendorf, PhD - Distinguished ProfessorUniv. of Florida, Gainesville, FL.Faculty:Hartmut Derendorf, PhD - Distinguished ProfessorUniv. of Florida, Gainesville, FL.Alan Forrest, Pharm D - Research Professor; Senior Director, PharmacometricsSUNY Univ. of Buffalo, Buffalo, NY.Jurgen Bulitta, PhD - Senior Research Fellow & Adjunct Assistant ProfessorMonash Univ., Buffalo, NY.George Drusano, MD - ProfessorUniv. of Florida, Gainesville, FL.Objectives: Upon completion of this Workshop, the participant should beable to:> Employ sophisticated kill curve modeling;> Design PK/PD models to predict and avoid resistance development;> Integrate modeling and simulation in to the overall drug developmentactivities; and> Identify the integration of preclinical and clinical PK/PD to streamlinedecision making in drug development.Intended Audience: Pharmacometricians, PK/PD analysts, and drug developmentspecialists.Course Level: Advanced------------------------------------------------------------------------52-05PK/PD Full-Day Workshop Combining 52-01 and 52-02Saturday, 8:30 a.m. - 4:30 p.m.------------------------------------------------------------------------52-06PK/PD Full-Day Workshop Combining 52-03 and 52-04Saturday, 8:30 a.m. - 4:30 p.m.------------------------------------------------------------------------52-07PK/PD Full-Day Workshop Combining 52-04 and 52-01Saturday, 8:30 a.m. - 4:30 p.m.------------------------------------------------------------------------52-08PK/PD Full-Day Workshop Combining 52-03 and 52-02Saturday, 8:30 a.m. - 4:30 p.m.32September 9-12 |

ICAAC 2012 WORKSHOPS------------------------------------------------------------------------52-10Antibiotic Resistance Among Bacterial Pathogens:Mechanisms, Detection, and Molecular EpidemiologySaturday, 8:30: a.m. - 4:30 p.m. . .... Esplanade Ballroom 307UAN: 0391-9999-12-183-L04-PConveners:Stephen G. Jenkins, PhD - Professor of Pathology and Laboratory MedicineWeill Cornell Med. Coll., New York, NY.Stephen M. Brecher, PhD - Director of MicrobiologyVA Boston Healthcare System, West Roxbury, MA.Faculty:Stephen G. Jenkins, PhD - Professor of Pathology and Laboratory MedicineWeill Cornell Med. Coll., New York, NY.Stephen M. Brecher, PhD - Director of MicrobiologyVA Boston Healthcare System, West Roxbury, MA.Audrey N. Schuetz, MD, MPH - Assistant Professor of Pathology and LaboratoryMedicineWeill Cornell Med. Coll., New York, NY.David P. Nicolau, PharmD - Dir., Ctr for Anti-Infective Res & DevHartford Hosp., Ctr. for Anti-Infective Res. and Dev., Hartford, CT.Objectives: Upon completion of this Workshop, the participant should beable to:> Describe the nuances and problems associated with susceptibility testingof staphylococci;> Recognize the problems associated with detection of antibiotic resistancein Enterobacteriaceae and other gram-negative pathogens, and methodsemployed to overcome such difficulties;> Detect Clostridium difficile with significantly increased accuracy;> Describe how to use molecular typing tools in the clinical laboratory tosolve epidemiologic problems; and> Explain the PK/PD parameters used to evaluate antimicrobial agents inthe light of evolving resistance.Intended Audience: Clinical microbiologists, infectious disease physicians,clinical pharmacists with expertise and interest in infectious diseases, andinfection control practitioners.Course Level: Intermediate------------------------------------------------------------------------52-11Antimicrobial Stewardship in HospitalsSaturday, 8:30 a.m. - 4:30 p.m. . .... Esplanade Ballroom 304UAN: 0391-9999-12-184-L04-PDeveloped in Cooperation with ESCMID Study Group for Antibiotic Policies(ESGAP)Conveners:Inge C. Gyssens, MD, PhD - ProfessorRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.Richard H. Drew, PharmD, MS - Professor of Pharmacy, Associate Professorof MedicineDuke Univ. Med. Ctr., Durham, NC.Faculty:Stephan Harbarth, MD, MS - Associate ProfessorHôpitaux Univ. de Genève, Geneva, Switzerland.Inge C. Gyssens, MD, PhD - ProfessorRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.Elizabeth S. D. Ashley, PharmD - Associate Director of Clinical PharmacyServicesUniv. of Rochester Med. Ctr., Rochester, NY.Robert Gaynes, MD - ProfessorEmory Univ. Sch. of Med., Atlanta, GA.Richard H. Drew, PharmD, MS - Professor of Pharmacy, Associate Professorof MedicineDuke Univ. Med. Ctr., Durham, NC.Harold C. Standiford, MD - Clinical Professor of MedicineUniv. of Maryland Sch. of Med., Baltimore, MD.Objectives: Upon completion of this Workshop, the participant should beable to:> Select proper measurement units to describe the volume of antimicrobialuse;> Interpret antimicrobial use data locally and within a multicenter network(Benchmarking);> Choose and to apply an audit methodology for monitoring the quality ofantimicrobial prescriptions;> Identify possible intervention strategies and their relative advantages anddisadvantages which could be implemented in a hospital;> Identify the electronic antimicrobial drug prescribing aids and the advantagesand disadvantages of each;> Describe how an individual hospital can determine if its antimicrobialmanagement program was economically successful and if it had an impacton bacterial resistance;> Describe the use of biomarkers of infection that may be useful to guidethe duration of therapy; and> Describe the elements needed to launch a stewardship program in communityhospitals.Intended Audience: Infectious diseases pharmacists, infection controlpractitioners involved in antimicrobial management, and infectious diseasesphysicians.Course Level: IntermediateFinal Program33

Saturday WORKSHOPS------------------------------------------------------------------------52-12A Year in Review: Critical Analysis and Application ofInfectious Diseases Practice Guidelines and PharmacotherapyLiteratureSaturday, 8:30 a.m. - 4:30 p.m. . .... Esplanade Ballroom 308UAN: 0391-9999-12-185-L04-PConveners:Scott J. Bergman, PharmD - Associate ProfessorSouthern Illinois Univ. Edwardsville, Springfield, IL.Jeannie McKinnon, PharmD - PharmacistMayo Clinic, Jacksonville, FL.Punit J. Shah, PharmD - Infectious Diseases Pharmacy ResidentSt. John’s Hosp., Springfield, IL.Faculty:Jessica Cottreau, Pharm D - Assistant ProfessorUniv. of Houston, Houston, TX.Ian McNicholl, PharmD - Clinical Associate ProfessorUniv. of California, San Francisco, CA.Russell Lewis, PharmD - Senior ResearcherS’Orsola-Malpighi Hosp., Univ. of Bologna, Bologna, Italy.Christopher R. Frei, PharmD, MS - Assistant ProfessorThe Univ. of Texas at Austin and The Univ. of Texas Hlth. Sci. Ctr. at SanAntonio, Austin, TX.David J. Weber, MD, MPH - Professor of Medicine, Pediatrics &EpidemiologyUniv. of North Carolina, Chapel Hill, NC.Ellie J. C. Goldstein, MD - DirectorR.M. Alden Res. Lab., Santa Monica, CA.Objectives: Upon completion of this Workshop, the participant should beable to:> Summarize the most relevant infectious diseases practice guidelinespublished in the last year;> Discuss the recent literature surrounding anti-infective therapy and howthis may influence treatment guidelines and clinical practice;> Assess the efficacy, safety, and economics of anti-infective therapy recommended;and> Develop evidence-based treatment strategies for patients with infections.Intended Audience: Physicians, pharmacists, microbiologists, and industryscientists.Course Level: Intermediate------------------------------------------------------------------------52-13New Clinical Microbiology Diagnostics: What is (orCould be) in Your Lab?Saturday, 8:30 a.m. - 4:30 p.m. . .... Esplanade Ballroom 309UAN: 0391-9999-12-186-L04-PConveners:Robin Patel, MD - Professor of Medicine and MicrobiologyMayo Clinic, Rochester, MN.Karen C. Carroll, MD - Professor of PathologyJohns Hopkins Univ. Sch. of Med., Baltimore, MD.Faculty:Robin Patel, MD - Professor of Medicine and MicorbiologyMayo Clinic, Rochester, MN.Karen C. Carroll, MD - Professor of PathologyJohns Hopkins Univ. Sch. of Med., Baltimore, MD.Alexandra Valsamakis, MD, PhD - Associate ProfessorJohns Hopkins Univ. Sch. of Med., Baltimore, MD.Nathan A. Ledeboer, PhD - Assistant Professor of PathologyMed. Coll. of Wisconsin, Milwaukee, WI.Esther Babady, PhD - Assistant Director of MicrobiologyMem. Sloan-Kettering Cancer Ctr., New York, NY.Objectives: Upon completion of this Workshop, the participant should beable to:> State the potential benefits to patient care (if any) realized by adopting thediscussed technologies;> Discuss the strengths and limitations of the discussed diagnostic tests;> Apply the discussed diagnostic techniques to their clinical practice; and> Assess workflow changes, if any, surrounding use of these new technologies.Intended Audience: Clinical microbiologists, infectious diseases clinicians,laboratory technologists, and industry.Course Level: Intermediate34September 9-12 |

ICAAC 2012 WORKSHOPS------------------------------------------------------------------------52-14Transplant Infectious Diseases: Prevention andResistance: Challenges for the 21st CenturySaturday, 8:30 a.m. - 4:30 p.m. . .... Esplanade Ballroom 310UAN: 0391-9999-12-187-L04-PDeveloped in Cooperation with the International Society of Heart and LungTransplantation (ISHLT)Conveners:Emily A. Blumberg, MD - Professor of MedicinePerelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.Lara Danziger-Isakov, MD, MPH - Assistant Professor of PediatricsCleveland Clinic Lerner Coll. of Med., Case Western Reserve Univ.,Cleveland, OH.Faculty:Atul Humar, MD - Professor, Director Alberta Transplant InstituteUniv. of Alberta, Edmonton, Canada.Shahid Husain, MS, MBBS, MD - Associate Professor of Medicine , Directorof Transplant Infectious DiseasesUniv. of Toronto, Toronto, Canada.Lara Danziger-Isakov, MD, MPH - Assistant Professor of PediatricsCleveland Clinic Lerner Coll. of Med., Case Western Reserve Univ.,Cleveland, OH.David R. Snydman, MD, FACP, FIDSA - Chief, Division of GeographicMedicine and Infectious DiseasesTufts Univ., Sch. of Med., Boston, MA.Todd D. Barton, MD - Associate Professor of Clinical MedicinePerelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.Ajit P. Limaye, MD - ProfessorUniv. of Washington, Seattle, WA.Laurent Kaiser, MD - Professor, Head of the Laboratory of clinical virologyUniv. Hosp. of Geneva, Geneva, Switzerland.Emily A. Blumberg, MD - Professor of MedicinePerelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.Wing Hong Seto, MD - Director, WHO Collaborating Centre for InfectionControlHosp. Authority, Hong Kong, China.Guy Boivin, MD - ProfessorCHUL, Quebec, Canada.Objectives: Upon completion of this Workshop, the participant should beable to:> Determine the impact of antimicrobials on prevention of infection;> Identify adjunctive prevention strategies, including immunization andinfection control strategies;> Appraise the impact of viral infections on transplant outcomes; and> Assess issues related to diagnosis and treatment for multiple difficult totreat infections in transplant recipients, including resistant viruses,bacteria and mycobacteria.Intended Audience: Infectious diseases physicians, pharmacists, and microbiologistsworking in diagnostics. The audience may include those alreadyworking in transplantation as well as those who are familiar with infectiousdiseases but not with transplant specific issues.Course Level: IntermediateFinal Program35

NOTES36September 9-12 |

SUNDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------001Interactive ID Fellows SessionInfectious Diseases 101: For Fellows Age 18-88Sunday, 7:00 a.m.–9:00 a.m. ..................... Room 104UAN: 0391-9999-12-033-L04-Pconveners:Didier Pittet, MD, MS - Professor of MedicineUniv. of Geneva Hosp., Geneva, Switzerland.David Aronoff, MD - Associate ProfessorUniv. of Michigan, Ann Arbor, MI.Speakers:001 Treatment Challenges in Multidrug-Resistant InfectionsYohei Doi, MD, PhDUniv. of Pittsburgh Med. Ctr., Pittsburgh, PA.002 Important Topics in VaccinesKathryn M. Edwards, MDVanderbilt Univ., Nashville, TN.003 Treating HIV Infection in 2012Joel Gallant, MD - Professor of Medicine & Epidemiology, Associate Director,John Hopkins AIDS ServiceJohns Hopkins Univ. Sch. of Med., Baltimore.004 Important Issues in Global HealthDavid Heymann, MD - ProfessorImperial Coll., London, United Kingdom.Objectives: Upon completion of this Interactive ID Fellows Session, theparticipant should be able to:> Integrate new knowledge regarding vaccine-preventable infections intotheir practice or research;> Identify critical knowledge gaps in microbiology, infectious diseases andinfection prevention;> Discuss global burden of diseases and global health; and> Discuss novel diagnostic and therapeutic aspects of infectious diseases.------------------------------------------------------------------------002Keynote SessionOpening Keynote SessionSunday, 9:30 a.m.–11:30 a.m. ........................Hall EUAN: 0391-9999-12-034-L04-PSpeakers:9:30 a.m.005 Emerging New Issues in the Management of Hepatitis C InfectionCharles M. Rice, PhD - Maurice R. and Corinne P. Greenberg Professor;Head, Laboratory of Virology and Infectious DiseaseThe Rockefeller Univ., New York-Presbyterian Hosp., Weill Cornell Med.Coll., New York, NY.9:30 a.m.006 The Impact of Emerging New Diagnostic Laboratory Techniqueson Clinical Infectious DiseaseFranklin R. Cockerill, III, MD - Ann and Leo Markin Professor of Microbiologyand Medicine, Mayo Graduate School of Medicine; Chair, Department ofLaboratory Medicine and PathologyMayo Clinic, Rochester, MN.9:30 a.m.007 Prospects for New AntibioticsChristopher T. Walsh, PhD - Hamilton Kuhn ProfessorHarvard Med. Sch., Boston, MA.Objectives: Upon completion of this Keynote Session, the participant shouldhave a greater understanding regarding emerging new issues related to:> The pathogenesis and management of hepatitis C;> Emerging new technologies in diagnostic microbiology and their likelyimpact on clinical infectious diseases; and> The development of new classes of antimicrobial agents.Intended Audience: Clinicians, scientists, researchers, microbiologists,virologists, pharmacists and public health physicians.Level: All Levels------------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALK Antibiotic Use and Resistance | Sunday, September 9, 11:30 a.m. – 12:30 p.m. | Halls A-CConvener:Stephan Harbarth, MD, MS - ProfessorUniv. of Geneva Hosp., Geneva, Switzerland.Presentations:Do Antibiotic Combinations with Rifampin for Osteoarticular Infections Protect against Clostridium difficile-Associated Colitis?C. Landelle; Univ. of Geneva Hosp., Geneva, Switzerland.Outcome of Appropriate Empiric Combination versus Monotherapy for Pseudomonas aeruginosa BacteremiaD. R. Bowers; St. Luke’s Episcopal Hosp., Univ. of Houston, Houston, TX.Clinical Impact of KPC Status and Appropriate Treatment among Enterobacteriaceae (EB) and Pseudomonas aeruginosa (Pae) in a MulticenterMatched Control Cohort Study in ColombiaV. M. Blanco; CIDEIM, Cali, Colombia.Inadequate Antibiotic Therapy is Associated with Decreased Survival in Patients with Extended-Spectrum Beta-Lactamase-ProducingEnterobacteriaceae Bloodstream InfectionsN. F. Dewhurst; St. Michael’s Hosp., Univ. of Toronto, Toronto, Canada.Control of the Prescription of Carbapenems in a French Hospital: Impact of the Hospital Antibiotic Management TeamC. Couzigou; Hosp. Saint Joseph, Paris, France.Final Program37

Sunday SCIENTIFIC SESSIONS------------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALK The HIV Poster Rounds | Sunday, September 9, 12:30 p.m. – 1:30 p.m. | Halls A-CConveners:Joseph Eron, Jr., MD - Professor of MedicineUniv. of North Carolina, Chapel Hill, NC.Jean-Michel G. Molina, MD - ProfessorSaint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, France.Presentations:Impact of Seven Nucleotide Polymorphisms and Haplotypes of CYP2B6 on Plasma Efavirenz Level in HIV/Tuberculosis Co-InfectedThai Patients Receiving RifampicinS. Sungkanuparph; Faculty of Med. Ramathibodi Hosp., Mahidol Univ., Bangkok, Thailand.Efficacy and Use of PI vs EFV in Treatment Naive HIV+ Men and WomenJ. Patel; Rush Univ. Med. Ctr., Chicago, IL.Safety and Efficacy of Once Daily Raltegravir to Enhance Adherence and Efficacy of HAART in Vulnerable HIV-Infected PatientsK. Stewart; Univ. of Saskatchewan, Saskatoon, Canada.Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients With Advanced HIV-1 InfectionD. Mizushima; Natl. Ctr. for Global Hlth. and Med., Tokyo, Japan.Genotypic Algorithm for Predicting Elvitegravir Susceptibility: Clinical Validation and Correlation with PhenotypeM. Haddad; Monogram Biosciences, South San Francisco, CA.Persistent Low-Level Viraemia in HIV-1-Infected Patients: Swiss HIV Cohort StudyN. Boillat Blanco; Univ., Lausanne, Switzerland.------------------------------------------------------------------------003(A)Poster SessionPK/PD of Carbapenems With or Without Beta-LactamaseInhibitorsSunday, 11:30 a.m.–1:30 p.m. .................. Halls A-CPresentations:A-008 MK-7655, A Novel -Lactamase Inhibitor (BLI), Elicits aProlonged Post-Inhibitor Effect in P. aeruginosaK. Young 1 , M. Motyl 1 , M. Rizk 2 , J. Deane 3 , D. Sahm 3 , M. Knechtel 4 , G.Zuerenko 5 , C. Pillar 4 , D. Shinabarger 4 ; 1 Merck Res. Lab., Kenilworth, NJ,2Merck Res. Lab., West Point, PA, 3 Eurofins, Global Central Lab., Chantilly,VA, 4 Micromyx, Kalamazoo, MI, 5 Micromyx, Kalmazoo, MI.A-009 A Phase I Study Evaluating the Single-Dose Safety, Tolerability,and Pharmacokinetics of an Intravenous Beta-LactamaseInhibitor in Healthy Elderly Male, Elderly Female and YoungFemale VolunteersP. Jumes 1 , M. L. Rizk 1 , M. Gutierrez 2 , X. Li 1 , S. A. Stoch 1 , J. A. Wagner1, J. R. Butterton 1 ; 1 Merck Sharp & Dohme Corp., Whitehouse Station, NJ,2Comprehensive Phase One, Miramar, FL.A-010 Pharmacokinetics of MK-7655, a Novel Beta-Lactamase Inhibitor(BLI), in Combination with Imipenem/Cilastatin (IPM/CIL) in Subjects with Impaired Renal FunctionM. L. Rizk 1 , P. Jumes 1 , K. Lassetter 2 , T. Marbury 3 , E. Mangin 1 , Y. Liu 1 , J.Wagner 1 , J. Butterton 1 ; 1 Merck Sharp & Dohme Corp., Whitehouse Station,NJ, 2 Clinical Pharmacology of Miami, Miami, FL, 3 The Orlando ClinicalRes. Ctr., Orlando, FL.A-011 Synergistic Prevention of Resistance by Meropenem (MER)Combined with Tobramycin (TOB) against a HypermutatingPseudomonas aeruginosa (PA) StrainJ. B. Bulitta 1 , R. E. D’Hondt 2 , A. Oliver 3 , A. Mena 3 , C. B. Landersdorfer 1 ,D. Brown 4 , B. VanScoy 4 , R. Kulawy 4 , A. Louie 4 , G. L. Drusano 4 ; 1 Ctr. forMed. Use and Safety, Monash Univ., Melbourne, Australia, 2 Ordway Res.Inst., Albany, NY, 3 Hosp. Univ. Son Espases, Palma de Mallorca, Spain, 4 Inst.for Therapeutic Innovation, Univ. Florida, Albany, NY.A-012 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluationof the Efficacy & Efficiency (Ef ) of Meropenem (M) DosingRegimensM. Trang, A. Forrest; SUNY Sch. of Pharmacy, Buffalo, NY.A-013 Impact of Various Conditions on the Efficacy of Dual CarbapenemTherapy against KPC Producing Klebsiella pneumoniaeD. E. Wiskirchen 1 , J. L. Crandon 2 , D. P. Nicolau 2 ; 1 Univ. of St. Joseph,Sch. of Pharm., Hartford, CT, 2 Ctr. Anti-Infect. Res. & Devel., HartfordHosp., Hartford, CT.A-014 Impact of Resistance Mechanisms on Predicting In Vivo Activityof Carbapenems against Klebsiella pneumoniae with SimilarMICsM. Hagihara 1 , J. L. Crandon 1 , C. Urban 2 , D. P. Nicolau 1 ; 1 Ctr. Anti-Infect.Res. & Dev., Hartford Hosp., Hartford, CT, 2 Infect. Dis. Res. Lab, New YorkHosp. Queens, Flushing, NY.A-015 KPC Presence in Pseudomonas aeruginosa (PSA) has MinimalImpact on the In Vivo Efficacy of Carbapenem TherapyM. Haihara 1,2 , J. L. Crandon 1 , C. Urban 3 , D. P. Nicolau 1 ; 1 Ctr. Anti-Infect.Res. and Dev., Hartford Hosp., Hartford, CT, 2 Aichi Med. Univ., Aichi,Japan, 3 Infec Dis. Res. Lab., New York Hosp. Queens, Flushing, NY.38September 9-12 |

SUNDAY SCIENTIFIC SESSIONSA-016 Comparison of Methods for Doripenem (D) PopulationPharmacodynamic (PPD) Analysis & Optimization of DosingRegimens Using Monte Carlo Simulation (MCS)N. S. Ly, G. G. Rao, R. L. Soon, L. Wollenberg, K. Yang, B. T. Tsuji,A. Forrest; SUNY, Buffalo, NY.A-017 Pharmacokinetics and Pharmacodynamics of Doripenem inObese, Hospitalized PatientsM. B. Kays 1 , S. C. Cheatham 2 , M. R. Fleming 3 , J. M. Juenke 4 , C. E. K.Chung 1 ; 1 Purdue Univ. Coll. of Pharmacy, Indianapolis, IN, 2 St. FrancisHosp., Indianapolis, IN, 3 Methodist Dallas Med. Ctr., Dallas, TX, 4 ARUP,Salt Lake City, UT.A-018 Pharmacokinetics and Monte Carlo Simulations ofDoripenem in Patients with Febrile NeutropeniaG. E. Stein, G. Kulhanek, C. Smith, J. Kuti, D. Nicolau, A. Scharmen,C. Farnum, M. Tran, A. Kalra, D. Havlichek; Michigan State Univ.,East Lansing, MI.A-019 PK/PD Target Attainment of Doripenem in PediatricPatients Using Monte-Carlo SimulationY. Matsuo, M. Tsuji, T. Ishibashi, T. Katsube, T. Wajima; Shionogi & Co.Ltd., Osaka, Japan.A-020 Comparative Pharmacokinetics (PK) of Doripenem (DOR)in Infected Patients Treated In- and Out-Side the Intensive CareUnit (ICU)A. A. Bhalodi 1 , R. A. Keel 1 , R. Quintiliani 2 , T. P. Lodise 3 , D. P. Nicolau 1 ,J. L. Kuti 1 ; 1 Ctr. for Anti-Infect. Res. & Dev., Harford Hosp., Hartford, CT,2CT Multispecialty Group, Hartford Hosp., Hartford, CT, 3 Albany Coll. ofPharmacy and Hlth. Sci., Albany, NY.A-021 Population Pharmacokinetics (PopPK) of Imipenem (IMP)in Intensive Care Unit (ICU) Patients with Ventilator-AssociatedPneumonia (VAP)C. Couffignal 1,2 , O. Pajot 3 , L. Massias 1 , L. Armand-lefevre 1 , A. Foucrier 1 ,C. Laouénan 1,2 , M. Wolff 1,4 , F. Mentré 1,2 ; 1 AP-HP, Hop BICHAT, Paris,France, 2 Univ. Paris Diderot, Sorbonne Paris Cité and Inserm, UMR 738,Paris, France, 3 Hop V Dupouy, Argenteuil, France, 4 Univ. Paris Diderot,Sorbonne Paris Cité, EA 3964, Paris, France.A-022 In Vitro Pharmacodynamics (IVPD) of Human SimulatedExposures of Ampicillin/Sulbactam (SAM), Doripenem (DOR),or Tigecycline (TGC) Alone and in Combination against Multidrug-Resistant(MDR) Acinetobacter baumanii (ACB)S. T. Housman, M. Hagihara, D. P. Nicolau, J. L. Kuti; Ctr. Anti-Infect.Res. & Devel., Hartford Hosp., Hartford, CT.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------004(A)Poster SessionPolymyxins and Aminoglycosides: Optimizing PK/PDand DosingSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:A-023 In Vitro Pharmacodynamics of Polymyxin B (PMB) andTigecycline (TGC) Alone and in Combination against Multidrug-Resistant(MDR) Acinetobacter baumannii (ACB)M. Hagihara 1,2 , S. T. Housman 1 , D. P. Nicolau 1 , J. L. Kuti 1 ; 1 Ctr. Anti-Infect. Res. and Dev., Hartford Hosp., Hartford, CT, 2 Aichi Med. Univ.,Aichi, Japan.A-024 Polymyxin B (PB) in Combination (Combo) with Doripenem(D) against Acinetobacter baumannii (Ab) Demonstrates HighSynergy and Suppression of ResistanceG. G. Rao 1 , N. S. Ly 1 , R. L. Soon 1 , M. D. San Roman 1 , P. A. Kelchlin 1 , P.N. Holden 1 , P. Bergen 2 , J. B. Bulitta 2,1 , A. Forrest 1 , R. L. Nation 2 , J. Li 2 ,B. T. Tsuji 1 ; 1 SUNY, Buffalo, NY, 2 Monash Univ., Melbourne, Australia.A-025 Pulmonary Target Delivery of Polymyxin B for EnhancedEfficacyJ. He, K. Abdelraouf, K. R. Ledesma, D. S. L. Chow, V. H. Tam; Univ. ofHouston, Houston, TX.A-026 Clinical Pharmacokinetics of Intravenous Polymyxin B1 and B2C. J. Kubin 1 , E. Broun 1 , K. M. Abildskov 1 , J. Horan 2 , T. A. Thomas 1 , M. T.Yin 1 , S. Cremers 1 ; 1 Columbia Univ. Med. Ctr., New York, NY, 2 Duke Univ.,Durham, NC.A-027 Steady-State (SS) Pharmacokinetics (PK) of Polymyxin B (PB)in Critically Ill PatientsA. M. Sandri 1,2 , C. B. Landersdorfer 3 , J. Jacob 4 , M. M. Boniatti 5 , M. G.Dalarosa 5 , D. R. Falci 5 , T. F. Behle 6 , J. Wang 4 , A. Forrest 7 , R. L. Nation 4 ,A. P. Zavascki 1,6 , J. Li 4 ; 1 Univ. Federal do Rio Grande do Sul, Porto Alegre,Brazil, 2 Hosp. Sao Lucas da PUCRS, Porto Alegre, Brazil, 3 Ctr. for Med. Use& Safety, Monash Univ., Melbourne, Australia, 4 Monash Inst. of PharmaceuticalSci., Monash Univ., Melbourne, Australia, 5 Hosp. Nossa Senhorada Conceição, Porto Alegre, Brazil, 6 Hosp. de Clín. de Porto Alegre, PortoAlegre, Brazil, 7 Sch. of Pharmacy & Pharmaceutical Sci., SUNY, Buffalo,NY.A-028 Pharmacokinetics and Renal Disposition of Polymyxin BK. Abdelraouf, J. He, K. R. Ledesma, M. Hu, V. H. Tam; Univ. of Houston,Houston, TX.A-029 Polymyxin B Dosing Adjustment in Renal InsufficiencyV. H. Tam, J. He, K. Abdelraouf, K. R. Ledesma, M. Hu; Univ. of Houston,Houston, TX.A-030 Colistin, Tigecycline and Daptomycin CombinationsImproves Bacterial Kill of Acinetobacter baumanniiP. Komp Lindgren 1 , H. Seifert 2 , O. Cars 1 ; 1 ARunit, Uppsala, Sweden,2IMMIH, Cologne, Germany.A-031 Synergistic Killing of Colistin (COL) Combination (COM-BO) Therapy against Multidrug-Resistant (MDR) Acinetobacterbaumannii (Ab) in Mouse Lung and Thigh Infection ModelsH. J. Lee 1 , J. Wang 1 , C. Ku 1 , B. T. Tsuji 2 , A. Forrest 2 , J. B. Bulitta 1,2 , J. Li1, R. L. Nation 1 ; 1 Monash Univ., Melbourne, Australia, 2 Univ. at Buffalo,Buffalo, NY.A-032 Optimal Design (OD) of a Colistin Sparse Sampling Schedulefor Individual PK-Parameter EstimationA. N. Kristoffersson, J. Nyberg, L. E. Friberg; Uppsala Univ., Uppsala,Sweden.A-033 Whole Body Physiologically-Based PharmacokineticModel of Colistin and Colistimethate Sodium (CMS) inHealthy VolunteersS. Bouchene 1 , L. E. Friberg 1 , S. Björkman 1 , W. Couet 2 , M. O. Karlsson 1 ;1Uppsala Univ., Uppsala, Sweden, 2 Poitiers Univ., Poitiers, France.Final Program39

Sunday SCIENTIFIC SESSIONSA-034 Risk Factors for and Incidence of NephrotoxicityAssociated with Intravenous Colistin in the Modern Era:A Systematic ReviewH. Pulluru, K. S. Kaye, J. M. Pogue, D. Marchaim, K. Hayakawa; DetroitMed. Ctr., Wayne State Univ., Detroit, MI.A-035 Pharmacokinetics of Colistin Methanesulfonate and Colistinafter Lung Transplantion in Cystic Fibrosis PatientsN. Grégoire 1 , F. Périn-Dureau 2 , P. Gobin 3 , C. Cerf 4 , D. Grenet 2 ,F. Parquin 2 , O. Mimoz 3 , W. Couet 1,5 ; 1 Univ. of Poitiers, Poitiers, France,2Hosp. Foch, Suresnes, France, 3 CHU Poitiers, Poitiers, France, 4 Hosp.Foch, Suresnes, France, 5 Inserm, Poitiers, France.A-036 Plasma Pharmacokinetics and Sputum Concentrations ofColistin After Nebulisation or Intravenous Administrationof Colistin Methansulphonate (CMS) to Ambulatories CysticFibrosis PatientsS. Marchand 1 , A. Henriet 2 , N. Grégoire 1 , P. Gobin 1 , P. Diot 2 , W. Couet 1,3 ;1Univ. of Poitiers, Poitiers, France, 2 CHU Tours, Tours, France, 3 Inserm,Poitiers, France.A-037 Plasma Pharmacokinetics and Epithelial Lining Fluid (ELF)Concentrations of Colistin after Nebulisation or IntravenousAdministration of Colistin Methanesulfonate (CMS) in CriticalCare PatientsM. Boisson 1 , S. Marchand 2 , N. Grégoire 2 , P. Gobin 1 , O. Mimoz 1 , W.Couet 2,3 ; 1 CHU Poitiers, Poitiers, France, 2 Univ. of Poitiers, Poitiers, France,3Inserm, Poitiers, France.A-038 Penetration of Arbekacin Sulfate to the Lung TissueY. Funatsu, N. Hasegawa, H. Nahmgunn, H. Fujiwara, T. Asami,T. Betsuyaku, S. Iwata; Keio Univ., Shinjuku-Ku, Japan.A-039 Pharmacologic Assessment of Guidelines on GentamicinUse in Infective EndocarditisG. Beraud, A. Elsendoorn, C. Landron, C. Plouzeau, G. Le Moal, C. Godet,C. Burucoa, F. Roblot; Univ. Hosp. of Poitiers, Poitiers, France.A-040 Plazomicin (PLZ) Compared with Cefepime, Ciprofloxacin,Meropenem, Piperacillin-Tazobactam and Aminoglycosides forthe Empiric Treatment of Gram-Negative, including Multidrug-Resistant (MDR), Pathogens Causing Infections in HospitalsS. Zelenitsky 1 , R. Ariano 2 , C. Lawson 1 , G. Zhanel 1 ; 1 Univ. of Manitoba,Winnipeg, Canada, 2 St. Boniface Gen. Hosp., Winnipeg, Canada.A-041 Pharmacodynamics of Plazomicin in a Neutropenic MurinePneumonia Model against Klebsiella pneumoniae (Kpn)A. Louie 1 , S. Fikes 1 , W. Liu 1 , B. VanScoy 1 , R. Cirz 2 , G. Drusano 1 ; 1 Univ.of Florida, Orlando, FL, 2 Achaogen, Inc., South San Francisco, CA.A-042 Dose-Response Efficacy of Plazomicin in the Treatment ofMurine Pneumonia Due to 7 Strains of Klebsiella pneumoniae(Kpn) Including Strains Resistant to Legacy AminoglycosidesA. Louie 1 , W. Liu 1 , S. Fikes 1 , B. VanScoy 1 , R. Cirz 2 , R. Cass 2 , J. McKinnell2 , P. Nordmann 3 , G. Drusano 1 ; 1 Univ. of Florida, Orlando, FL, 2 Achaogen,Inc., South San Francisco, CA, 3 South Paris Med. Sch., Hosp. Bicetre,Paris, France.----------------------------------------------------------------------------------005(B)Poster SessionImmune Response to Microbial InfectionSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:B-043 Staphylococcus aureus Nasal Carriage Might be Associated withVitamin D Receptor Polymorphisms in Type 2 DiabetesD. Dimopoulou, I. Messaritakis, G. Samonis, G. Goulielmos, J. Papadakis,G. Brentzos, C. Choulaki, M. Fragaki, A. Valachis, D. P. Kofteridis; Univ.Hosp. of Heraklion, Heraklion, Greece.B-044 Pattern Recognition Receptor Polymorphisms and the Susceptibilityto Complicated Skin and Skin Structure InfectionsM. H. T. Stappers 1,2 , Y. Thys 1,3 , M. Oosting 1 , T. S. Plantinga 1 , M. Ioana 1 ,P. Reimnitz 4 , J. W. Mouton 1,2 , M. G. Netea 1 , L. A. B. Joosten 1 , I. C.Gyssens 1,2,3 ; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands,2 Canisius Wilhelmina Hosp., Nijmegen, Netherlands, 3 Hasselt Univ.,Diepenbeek, Belgium, 4 Bayer Healthcare Pharmaceuticals, Wuppertal,Germany.B-045 Role of Mannose-Binding Lectin (MBL) in Hospitalized-Children Infected with H1N1 2009 Virus in ArgentinaS. D. Ruvinsky, J. Gurevich, A. Monaco, G. Perez, L. Sen, R. Bologna, A.Mangano; Hosp. de Pediatria Dr. Juan P. Garrahan, Buenos Aires, Argentina.B-046 Immunization of Rats with Recombinant Lactococcus lactisExpressing ClfA Protects from Staphylococcus aureus ExperimentalEndocarditis Induced by Low-Grade BacteremiaT. R. Veloso, Y. A. Que, M. Giddey, J. Vouillamoz, P. Moreillon, J. Entenza;Univ. of Lausanne, Lausanne, Switzerland.B-047 Leptin-Stat3 Signaling Axis Enhances Colonic InflammationDuring Clostridium difficile InfectionWithdrawnB-048 Macrolides Inhibit Fusobacterium nucleatum-InducedMUC5AC Induction in Human Airway Epithelial CellsK. Nagaoka, K. Yanagihara, Y. Harada, K. Yamada, Y. Migiyama, Y.Morinaga, S. Kohno; Nagasaki Univ. Hosp., Nagasaki, Japan.B-049 Azithromycin Inhibit Muc5ac Induction by Multidrug-Resistant Acinetobacter baumannii in Airway Epithelial CellsK. Yamada, K. Yanagihara, Y. Harada, Y. Migiyama, K. Nagaoka, Y.Morinaga, K. Izumikawa, H. Kakeya, Y. Yamamoto, S. Kohno; NagasakiUniv., Nagasaki, Japan.B-050 Lung Sensitization by Candida Albicans Protects fromPseudomonas aeruginosa-Induced Lung Injury ThroughExpression of Antimicrobial PeptidesJ. B. Méar 1 , E. Faure 1 , E. Kipnis 1 , P. Gosset 2 , G. Schurtz 1 , K. Faure 1 , B.Guery 1 ; 1 Faculte de Med. de Lille, Lille, France, 2 Inserm U1019, Team 8,Lille, France.B-051 Natural Killer Cells are Critical in Controlling Pseudomonasaeruginosa Strain PAO1 in a Mice Pneumonia Infection ModelA. H. Broquet 1 , A. Roquilly 1,2 , C. Jacqueline 1 , J. Caillon 1 , G. Potel 1 , K.Asehnoune 1,2 ; 1 UPRES EA3826, Nantes, France, 2 CHU Nantes, Pôle AnesthésieRéanimations, Service d’Anesthésie Réanimation Chirurgicale, HôtelDieu, Nantes, France.40September 9-12 |

SUNDAY SCIENTIFIC SESSIONSB-052 T-Cells from Chronic Bone Infection Show Reduced Proliferationand a High Proportion of CD28 Negative CD4 T-CellsG. Kumar 1 , M. Ticchioni 2 , E. Bernard 2 , C. Trojani 2 , P. Roger 2 ; 1 Univ. ofNice Sophia Antipolis, Nice, France, 2 Hopital L’Archet 1, Nice, France.B-053 Keyhole Limpet Hemocyanin (KLH) N-Glycans Share SimilarStructural Features with Saccharides of Schistosoma, Trypanosoma,Leishmania, Cryptococcus, Aspergillis, Candida, E. coli,Salmonella, Clostridium and Hepatitis C Virus (HCV)J. S. Sundsmo, H. Chow, M. Sagermann; Stellar Biotechnologies, Inc., PortHueneme, CA.B-054 Monophosphoryl Lipid a Modulates the Cross-Talk BetweenDendritic Cells and Natural Killer Cells in a Murine Model ofHemorrhage-Induced Immune DysfunctionA. Roquilly, A. Broquet, C. Jacqueline, R. Cinotti, X. Ambrosi, G. Potel, J.Caillon, K. Asehnoune; Univ. de Nantes, Laboratoire EA UPRES 3826,Nantes, France.B-055 Endotoxemia in Humans Induces Alterations in the T-CellCompartment and is Associated with Impaired Production ofProinflammatory CytokinesA. Ronit, R. P. Plovsing, J. C. Gaardbo, R. M. Berg, H. J. Hartling, H.Ullum, K. Moller, S. D. Poulsen; Copenhagen Univ. Hosp. Rigshospitalet,Osterbro, Denmark.B-056 Critical Roles of IL-17 in Lethality of Community-AssociatedMRSA Pneumonia in MiceY. Shibue 1,2 , S. Kimura 1 , C. Kajiwara 1 , K. Tateda 1 , M. Nishimura 2 , K.Yamaguchi 1 ; 1 Toho Univ. Faculty of Med., Tokyo, Japan, 2 Hokkaido Univ.Sch. of Med., Hokkaido, Japan.B-057 Chemokine Induction of Biofilm in Staphylococcus aureusS. C. Yung, K. Chen, P. M. Murphy; NIH, Bethesda, MD.B-058 Distinctive Cytokines as Biomarkers Predicting Fatal Outcomeof Severe Staphylococcus aureus Bacteremia in MiceS. van den Berg 1 , J. D. Laman 1 , L. Boon 2 , M. T. ten Kate 1 , G. J. de Knegt 1 ,R. M. Verdijk 1 , H. A. Verbrugh 1 , J. L. Nouwen 1 , I. A. Bakker-Woudenberg 1 ; 1 Erasmus Univ. Med. Ctr., Rotterdam, Netherlands, 2 BiocerosBV, Utrecht, Netherlands.B-059 Modulation of Inflammatory Mediators MicroRNA-21 andMicroRNA-19b in Human Coronavirus-229E Infected CellsA. R. Collins, SUNY at Buffalo, Buffalo, NY.B-060 IPAF-Inflammasome Null Mice are Protected fromPseudomonas aeruginosa-Induced Acute Lung InfectionE. Faure, J. Mear, B. Guery, K. Faure, E. Kipnis; Lille 2 Univ. Hosp., Lille,France.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------006(C1)Poster SessionCarbapenemases and Expanded Spectrum. Lactamases:Enterobacteriaceae, S. aeruginosa, A. bumanniiSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:C1-061 Characterization of OXA-204, a Carbapenem-HydrolyzingClass D Beta-Lactamase from a Klebsiella pneumoniae ClinicalIsolateL. Poirel, A. Potron, P. Nordmann; Hosp. de Bicetre, Le Kremlin Bicetre,France.C1-062 Intercontinental Transfer of an OXA-48-Producing Multi-Resistant Klebsiella pneumoniaeB. A. Espedido 1,2 , J. A. Steen 3,4 , I. B. Gosbell 1,2,5 , H. Ziochos 5 , M. A.Cooper 4 , S. M. Grimmond 3,4 , S. J. van Hal 1,5 , S. O. Jenson 1,2 ; 1 ARMEG,SoM, Univ. W. Sydney, Liverpool, Australia, 2 Ingham Inst. Applied Med.Res., Liverpool, Australia, 3 Qld Ctr. for Med. Genomics, Univ. Qld, Brisbane,Australia, 4 Inst. Mol. Biosc. Univ. Qld, Brisbane, Australia, 5 SydneySouth West Pathology Service, NSW Pathology, Liverpool, Australia.C1-063 Emergence of OXA-232, a Carbapenem-Hydrolyzing ClassD-Lactamase from Indian IsolatesL. Poirel, E. Rondinaud, A. Potron, P. Nordmann; Hosp. de Bicetre, LeKremlin Bicetre, France.C1-064 A Direct-Link Between blaNDM-1 Harbouring PlasmidsIsolated in Chennai, India and pNDM-HK Isolated in Hong KongM. A. Toleman 1 , M. D. Krepps 2 , H. S. Gibbons 2 , T. R. Walsh 1 ; 1 CardiffUniv., Cardiff, United Kingdom, 2 U.S. Army Edgewood Biological ChemicalCtr., Baltimore, MD.C1-065 Biochemical Characterization of the Metallo-Beta-LactamaseIMP-30K. M. Pegg 1 , E. M. Liu 2 , P. Oelschlaeger 2 ; 1 California State PolytechnicUniv., Pomona, CA, 2 Western Univ. of Hlth. Sci., Pomona, CA.C1-066 Covalent Docking and Molecular Dynamics of Serine ActiveCarbapenemasesT. Naas 1 , P. Nordmann 1 , B. I. Iorga 2 ; 1 INSERM U914, Le Kremlin Bicetre,France, 2 ICSN, CNRS UPR 2301, Gif-sur-Yvette, France.C1-067 Characterization of Pseudomonas aeruginosa Clinical Isolatesfrom Mexico Producing Novel Carbapenemases (ß-LactamasesGes-19 and Ges-20, and Imp-36)J. Silva-Sanchez 1 , H. Barrios 1 , U. Garza-Ramos 1 , A. Sánchez 1 , F. Reyna 1 ,J. C. Catalan 1 , R. Morfin 2 , E. Rodriguez 2 , P. Volkow 3 , P. Cornejo 3 , M.Vázquez 4 , V. Rodríguez 4 , J. Gaytan 5 , I. G. Lorenzo 5 , R. Gonzalez 6 , L.Vazquez 6 ; 1 INSP, Cuernavaca, Mexico, 2 Hosp. Civil de Guadalajara, Jalisco,Mexico, 3 Inst. Natl. de Cancerología, DF, Mexico, 4 Inst. Natl. de Cardiología,DF, Mexico, 5 Hosp. de Infectología CMN La Raza, DF, Mexico, 6 UMAE.IMSS #71, Torreon, Mexico.C1-068 Characterization of OXA-210, a Novel Carbapenem-HydrolyzingClass D-Lactamase from Pseudomonas aeruginosaJ. H. Lee, J. J. Lee, X. Wu, B. Selenge, S. H. Lee; Myongji Univ., Yongin,Korea, Republic of.C1-069 Identification of Carbapenemase OXA-23 Group inAcinetobacter baumannii: OXA-239, a Novel OxacillinaseIdentified in MexicoE. M. Tamayo-Legorreta 1 , H. Barrios 1 , U. Garza-Ramos 1 , A. Sanchez 1 ,A. Galicia 2 , A. Meza 3 , J. Silva-Sanchez 1 ; 1 Inst. Natl. de Salud Publ.a, Cuernavaca,Mexico, 2 Hosp. de Oncologia, IMSS-CMN-Siglo XXI, DF, Mexico,3Hosp. de Cardiologia, IMSS-CMN-Siglo XXI, DF, Mexico.Final Program41

Sunday SCIENTIFIC SESSIONSC1-070 OXA-237, a Novel Class D Beta-Lactamase Involved inResistance to Carbapenems in Acinetobacter baumanniiP. G. Higgins 1 , F. J. Perez-Llarena 2 , E. Zander 1 , A. Fernandez 2 , G. Bou 2 ,H. Seifert 1 ; 1 Univ. of Cologne, Cologne, Germany, 2 C.H.Univ. A Coruña,A Coruña, Spain.C1-071 Endemicity of GES-Type Carbapenemase amongAcinetobacter baumannii Clinical Isolates in KuwaitR. Bonnin 1 , V. Rotimi 2 , P. Nordmann 1 , M. Al Hubail 2 , N. Al Sweih 3 , L.Poirel 1 ; 1 Hosp. de Bicetre, Le Kremlin Bicetre, France, 2 Faculty of Med.,Kuwait-City, Kuwait, 3 Hosp. de Bicetre, Kuwait-City, Kuwait.C1-072 Role of Position 169 in Penicillin-Hydrolysis Activity ofClass A ESBLsT. Naas 1 , B. I. Iorga 2 , L. Djamdjian 1 , P. Nordmann 1 ; 1 INSERM U914, LeKremlin Bicetre, France, 2 ICSN, CNRS UPR 2301, Gif-Yvette, France.C1-073 N148G and -S Substitutions in ADC-7-Lactamase ofAcinetobacter baumannii (ACB) Cause Selective Changes inSubstrate and Inhibitor SpecificityB. C. Conklin, M. J. Skalweit; VAMC/CWRU, Cleveland, OH.C1-074 Description of Novel Allelic Variants of the ChromosomalGene Blaoxa-114-Like in Achromobacter xylosoxidans ClinicalIsolatesG. Traglia 1 , M. Almuzara 2 , A. K. Merkier 1 , M. Papalia 2 , M. Radice 2 ,C. Vay 2 , D. Centrón 1 , M. Ramirez 1 ; 1 Sch. of Med., Buenos Aires, Argentina,2 Facultad de Farmacia y Bioquimica, Buenos Aires, Argentina.C1-075 CMY-88: A Novel Chromosomally-Encoded Cephamycinasein an Escherichia coli Clinical IsolateM. Solé 1 , N. Cobos 2 , I. Roca 1 , J. Martínez 2 , J. Vila 1 ; 1 CRESIB-Hosp.Clinic/UB, Barcelona, Spain, 2 Hosp. Clinic/UB, Barcelona, Spain.C1-076 The Contribution of Ambler Position P167 in Ceftazidime(TAZ) Resistance in PenI of Burkholderia pseudomallei (Bp)K. M. Papp-Wallace 1 , M. Nukaga 2 , R. A. Bonomo 1 ; 1 LSCDVAMC &CWRU, Cleveland, OH, 2 Josai Intl. Univ., Togane City, Chiba, Japan.C1-077 Kinetic Characterization of a Novel VIM (VIM-28) Metallo-Beta-Lactamase in Pseudomonas aeruginosa Isolates from EgyptA. Yoshizumi 1 , Y. Ishii 1 , T. S. El-Mahdy 2 , N. D. Hanson 3 , K. Tateda 1 ;1Toho Univ., Tokyo, Japan, 2 Helwan Univ., Cairo, Egypt, 3 Creighton Univ.,Omaha, NE.C1-078 Rapid Detection of Carbapenemase Production inPseudomonasP. Nordmann, L. Poirel, L. Dortet; Hosp. de Bicetre, Le Kremlin Bicetre,France.------------------------------------------------------------------------007(C2)Poster SessionAmpCs: Not Going Away!Sunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:C2-079 Identification of Plasmid Mediated AmpC-Lactamases inClinical Isolates of Escherichia coli and Klebsiella pneumoniae at aTertiary Hospital of Muscat, OmanWithdrawnC2-080 Detection of Clonally-Related Escherichia coli IsolatesProducing Different CMY-Lactamases from a Cystic FibrosisPatientL. Cremet 1 , N. Caroff 1 , C. Giraudeau 2 , A. Reynaud 1 , J. Caillon 1 ,S. Corvec 1 ; 1 Univ., Nantes, France, 2 Nantes Hosp., Nantes, France.C2-081 Genotyping Plasmid Mediated ampC Genes By Real-TimePCR and High Resolution Melt AnalysisB. Y. Y. Tse 1 , G. L. Vanstone 2 , I. Balakrishnan 2 ; 1 Univ. Coll., London,United Kingdom, 2 Royal Free Hosp., London, United Kingdom.C2-082 Plasmid-Mediated AmpC-Lactamases: Moving FromHospitals to the Community?A. Conen 1 , R. Frei 2,3 , H. Adler 2 , C. A. Fux 1 , A. F. Widmer 3 ; 1 InfectiousDiseases and Hosp. Epidemiology, Aarau, Switzerland, 2 Clinical Microbiol.,Basel, Switzerland, 3 Infectious Diseases and Hosp. Epidemiology, Basel,Switzerland.------------------------------------------------------------------------008(C2)Poster SessionCarbapenemases: Will They Ever End!Sunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:C2-083 A Novel IMP Metallo--Lactamase, IMP-38, from an Outbreakof a K. pneumonia Clone Strain in a University Hospital inCentral ChinaW. Liu, Z. Jian, H. Li, Y. Li, Y. Li, Y. Liu, X. Gu, W. Peng; Xiangya Hosp.,Central South Univ., Changsha, China.C2-084 Klebsiella pneumoniae Producing a New Variant Derived fromOXA-163: Case ReportS. Gomez, F. Pasteran, D. Faccone, M. Bettiol, O. Veliz, M. Rapoport, B.Gatti, A. Petroni, A. Corso; INEI-ANLIS-MALBRAN, Buenos Aires,Argentina.C2-085 Emergence of Serratia marcescens Harbouring the Class ACarbapenemase SME in CanadaL. F. Mataseje 1 , D. A. Boyd 1 , M. Imperial 2 , B. Lefebvre 3 , P. Van Caeseele 4 ,B. Willey 5 , M. R. Mulvey 1 ; 1 Natl. Microbiol. Lab., Winnipeg, Canada,2BCCDC, Vancouver, Canada, 3 Lab. de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Canada, 4 Natl. Microbiol. Lab., Cadam Provincial Lab.,Canada, 5 Mount Sinai Hosp., Toronto, Canada.C2-086 Emergence of Polymyxin B-Resistant KPC-2-ProducingKlebsiella pneumoniae ST11 Clone in an University Hospital inBrazilL. N. Andrade 1 , L. Vitali 2 , G. G. Gaspar 2 , R. Martinez 2 , A. C. Darini 1 ;1Faculdade de Ciências Farmacêuticas de Ribeirão Preto - USP, RibeirãoPreto, Brazil, 2 Hosp. das Clínicas - Faculdade de Med. de Ribeirão Preto -USP, Ribeirão Preto, Brazil.C2-087 Fosfomycin Susceptibility of BlaKPC-2 in BrazilF. F. Tuon 1 , J. L. L. Rocha 2 , J. Camilotti 1 , M. S. Formighieri 1 , S. Sfair 1 , M.B. Bertoldi 1 , J. K. Palmeiro 3 , L. M. Dalla-Costa 3 ; 1 Hosp. Univ. Evangélicode Curitiba, Curitiba, Brazil, 2 Frischmann Aisengart/DASA MedicinaDiagnóstica, Curitiba, Brazil, 3 Hosp. de Clínicas, Univ. Federal do Paraná(UFPR), Curitiba, Brazil.42September 9-12 |

SUNDAY SCIENTIFIC SESSIONSC2-088 Two Cases of NDM-Producing Klebsiella pneumoniae:Transmission or Coincidence - If the Molecular Biology isSurprising, Do You Trust the Epidemiology?D. Morris 1 , K. Burns 2 , C. Collins 2 , V. Passet 3 , S. Brisse 3 , M. Cormican 1 ;1Natl. Univ. of Ireland, Galway, Ireland, 2 Beaumont Hosp., Dublin, Ireland,3Institut Pasteur, Paris, France.C2-089 Surveillance of KPC-Producing Enterobacteriaceae in ON,Canada, 2008-2011N. Tijet, P. M. Sheth, O. Lastovetska, C. Chung, S. Lo, D. J. Farrell, D. E.Low, S. N. Patel, R. G. Melano; Publ. Hlth. Ontario Lab., Toronto, Canada.C2-090 Detection of IMP-27 Metallo-ß-Lactamase in Proteusmirabilis, ON, CanadaN. Tijet, S. Lo, H. Siebert, M. MacNeill, P. Rawte, D. J. Farrell, D. E. Low,S. N. Patel, R. G. Melano; Publ. Hlth. Ontario Lab., Toronto, Canada.C2-091 Persistence Of NDM-1-Producing Enterobacteria Over a6-Month Period in a French Community PatientC. Arpin 1 , P. Noury 2 , F. M’Zali 1 , C. Andre 1 , L. Coulange 1 , C. Quentin 1 ;1UMR CNRS 5234, Univ. de Bordeaux 2, Bordeaux, France, 2 Lab. EXA-LAB, Villenave d’Ornon, France.C2-092 Dissemination of Diverse Plasmids Bearing bla KPCAmongCarbapenem-Resistant Enterobacteriaceae (CRE) Different fromKlebsiella spp. in a Hospital System in ClevelandS. Ruiz 1 , F. Perez 2 , A. M. Hujer 2 , S. Rudin 2 , S. H. Marshall 2 , S. Bajaksouszian3 , M. V. Villegas 1 , R. A. Bonomo 2 , M. R. Jacobs 3 ; 1 CIDEIM, Cali,Colombia, 2 VAMC, Cleveland, OH, 3 CWRU, Cleveland, OH.C2-093 Emergence of Four Different OXA-48-Type Carbapenemase-Producing Enterobacteriaceae Species Isolated in One PatientA. Mischnik, N. T. Mutters, S. Klein, B. Lehner, S. Zimmermann; HeidelbergUniv. Hosp., Heidelberg, Germany.C2-094 Emergence of MDR KPC-2-Producing Escherichia coli in ItalyA. Piazza 1 , M. Caltagirone 1 , V. Repetto 1 , E. Nucleo 1 , M. Spalla, 1 , M.Balzaretti 2 , E. Casari 3 , L. Pagani 1 , R. Migliavacca 1 ; 1 Univ. of Pavia, Pavia,Italy, 2 ASP Piero Redaelli, Milan, Italy, 3 IRCCS Clinical Inst. Humanitas,Rozzano, Italy.C2-095 Assessing the Prevalence of Enterobacteriaceae HarboringKlebsiella pneumoniae Carbapenemases (KPC) in MarylandJ. K. Johnson 1 , L. E. Wilson 2 , L. Zhao 1 , K. A. Thom 1 , A. D. Harris 1 ,Maryland MDRO Prevention Collaborative; 1 Univ. of Maryland, Baltimore,Baltimore, 2 Maryland Dept. of Hlth. and Mental Hygiene, Baltimore.C2-096 Epidemiology of Carbapenem-Resistant Enterobacteriaceae(CRE) Colonization Among Patients with Exposure to Long-Term Acute Care Centers (LTACs)A. Bhargava 1 , K. Hayakawa 1 , K. C. Alluri 2 , S. Haider 2 , S. Datla 3 , S. Diviti 2 ,V. Kuchipudi 2 , K. Muppavarapu 2 , D. Marchaim 1 , T. Chopra 1 , K. Kaye 1 ;1WSU, Detroit, MI, 2 Detroit Med. Ctr., Detroit, MI, 3 DMC, Detroit, MI.C2-097 Carbapenem-Nonsusceptible Enterobacteriaceae Infection:Impact of Carbapenemases Production and In Vitro Susceptibilityto Tigecycline and Colistin on MortalityU. Wu 1 , J. Wang 1 , Y. Chen 1 , C. Yang 2 , C. Lin 3 , S. Chang 1 ; 1 Natl. TaiwanUniv. Hosp., Taipei, Taiwan, 2 Far Eastern Mem. Hosp., Taipei, Taiwan, 3 Natl.Taiwan Univ. Hosp., Yun-Lin Branch, Dao-Liou, Taiwan.C2-098 Whole Genome Sequencing to Track a Hospital Outbreak ofCarbapenem-Resistant Klebsiella pneumoniaeWithdrawnLate-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------009(C2)Poster SessionESBLs: Still RelevantSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:C2-099 In Vitro Activity of Tigecycline against Enterobacteriaceaewith Emphasis on ESBL Producing Isolates in India and Israel:Test 2007-2012M. Renteria, S. Bouchillon, B. Johnson, M. Hackel, J. Johnson; IHMA, Inc.,Schaumburg, IL.C2-100 Trends in Susceptibility and ESBL Production for Escherichiacoli from Intra-Abdominal Infections: SMART 2002-2011S. Lob, S. Bouchillon, M. Hackel, D. Hoban, A. Johnson, R. Badal; IHMA,Inc., Schaumburg, IL.C2-101 Extended Spectrum Beta-Lactamases and Class I Integron:Multidrug Modulators in Clinical Isolates of Escherichia coli andSalmonella spp from Eastern Cape, South AfricaM. A. Bisi-Johnson 1,2 , C. L. Obi 1 , T. Hattori 3 , K. A. Baba 4 , S. D. Vasaikar 1 ,I. Morobe 1 ; 1 Walter Sisulu Univ., Mthatha, South Africa, 2 Obafemi AwolowoUniv., Ile-Ife, Nigeria, 3 Tohoku Univ., Sendai, Japan, 4 Univ. of Pretoria,Pretoria, South Africa.C2-102 Molecular Epidemiology and Antimicrobial Resistance ofEscherichia coli Infections in East London, UKH. Ciesielczuk 1 , D. W. Wareham 1 , R. Hope 2 , N. Woodford 2,1 ; 1 QueenMary’s Coll. Univ. of London, London, United Kingdom, 2 Hlth. ProtectionAgency, London, United Kingdom.C2-103 Dramatic Increase in the Prevalence of ESBL-ProducingEscherichia coli (EC) in Canadian Hospitals Over a 5-Year PeriodA. Denisuik 1 , P. Simner 2 , F. Tailor 1 , H. Adam 1,3 , P. Lagacé-Wiens 1,3 , M.Mulvey 1,4 , M. Baxterer 1 , D. J. Hoban 1,3 , G. G. Zhanel 1 ; 1 Univ. of Manitoba,Winnipeg, Canada, 2 Mayo Clinic, Rochester, MN, 3 Diagnostic Services ofManitoba, Winnipeg, Canada, 4 Natl. Microbiol. Lab., Winnipeg, Canada.C2-104 High Prevalence of ESBL-Producing Enterobacteriaceae(ESBL-E) in the Dutch CommunityE. A. Reuland 1 , N. Al Naiemi 1,2 , M. C. Rijnsburger 1 , M. Van Keulen 1 ,P. H. M. Savelkoul 1 , P. J. M. Elders 1 , C. M. J. Vandenbroucke-Grauls 1 ;1VU Univ. Med. Ctr., Amsterdam, Netherlands, 2 Lab. for Med. Microbiol.,Enschede, Netherlands.C2-105 Emergence of ESBL-Producing Enterobacter cloacae in aUniversity Hospital in Northern SpainJ. Calvo, M. Cano, M. Aranzamendi, E. Román, B. Ruiz, L. Martinez-Martinez; Hosp. Univ. Marqués de Valdecilla, Santander, Spain.C2-106 Complex Class 1 Integrons Harboring blaCTX-M-2 Genesin Different Clinical Enterobacteriaceae Species from a Hospital inBrazilM. Dropa, L. C. Balsalobre, N. Lincopan, G. R. Matte, M. H. Matte; Univ.of Sao Paulo, Sao Paulo, Brazil.C2-107 Prevalence of ESBL-Producing E. coli and K. pneumoniae inFecal Carriage in Children in Guinea-BissauJ. Isendahl 1 , A. Turlej-Rogacka 1 , A. Rodrigues 2 , C. Manjuba 3 , C. Giske 1 , P.Nauclér 1 ; 1 Karolinska Inst., Stockholm, Sweden, 2 Natl. Inst. of Publ. Hlth. inGuinea-Bissau, Bissau, Guinea-Bissau, 3 Natl. Hosp. Simão Mendes, Bissau,Guinea-Bissau.Final Program43

Sunday SCIENTIFIC SESSIONSC2-108 ESBL-Producing Klebsiella pneumoniae Isolates of DifferentPhylogenetic Lineages from Southwest NigeriaB. Ghebremedhin 1 , I. Aibinuer 2 , T. Odugbemier 2 , W. Koenig 1 ; 1 ClinicalMicrobiol., Magdeburg, Germany, 2 Med. Microbiol. & Parasitol., Lagos,Nigeria.C2-109 Transmission Dynamics of ESBL-Producing E. coli Clones inRehabilitation WardsA. Adler 1 , M. Gniadkowski 2 , A. Baraniak 2 , R. Izdebski 2 , J. Fiett 2 ,W. Hryniewicz 2 , S. Malhotra-Kumar 3 , H. Goossens 3 , C. Lammens 3 ,Y. Lerman 1 , M. Kazma 1 , T. Kotlovsky 1 , Y. Carmeli 1 , MOSAR WP5 &WP2 study groups; 1 Tel-Aviv Med. Ctr., Tel-Aviv, Israel, 2 Warsaw Natl.Med. Inst., Warsaw, Poland, 3 Univ. of Antwerp, Antwerp, Belgium.C2-110 Molecular Epidemiology of ESBL-Producing Escherichia colifrom Community Onset and Hospital Associated Blood StreamInfections in BucharestA. Hristea 1 , I. D. Olaru 2 , M. Popoiu 2 , M. Nica, 3,4 , M. Buzea 5 , M. Ion 2 ,S. Adams-Sapper 6 , L. W. Riley 6 ; 1 Natl. Inst. of Infectious Diseases, Univ. ofMed. and Pharmacy, Bucharest, Romania, 2 Natl. Inst. of Infectious Diseases,Bucharest, Romania, 3 Victor Babes Hosp. of Tropical and Infectious Disease,Bucharest, Romania, 4 Univ. of Med. and Pharmacy, Bucharest, Romania,5Univ. Emergency Hosp. Elias, Bucharest, Romania, 6 Univ. of California,Berkeley, CA.C2-111 High Prevalence of CTX-M-15 Escherichia coli ST131Causing Community-Onset Healthcare Associated BacteremicUrinary Tract Infection in SpainI. Merino 1 , E. Cercenado 2 , N. Benito 3 , M. Pallarés 4 , J. Gómez 5 ,M. Xercavins 6 , L. Martínez-Martínez 7 , M. De Cueto 8 , E. Shaw 9 ,J. Horcajada 9 , R. Cantón 1 , P. Ruiz-Garbajosa 1 , ITUBRAS-GEIH-SEIMCGroup; 1 Hosp. Ramón y Cajal, Madrid, Spain, 2 Hosp. Gregorio Marañón,Madrid, Spain, 3 Hosp. Santa Creu i Sant Pau, Barcelona, Spain, 4 ComplexoHosp. Pontevedra, Pontevedra, Spain, 5 Lab. de Referència de Catalunya,Barcelona, Spain, 6 Hosp. Mútua de Terrassa, Terrassa, Spain, 7 Hosp. Marquésde Valdecilla, Madrid, Spain, 8 Hosp. Virgen Macarena, Sevilla, Spain, 9 Hosp.del Mar, Barcelona, Spain.C2-112 Community-Associated Extended-Spectrum--Lactamase(ESBL)-Producing Escherichia coli Infection in the United StatesY. Doi 1 , Y. Park 2 , J. I. Rivera 1 , J. M. Adams-Haduch 1 , A. Hingwe 3 , M.C. Kilayko 4 , J. S. Lewis, Jr 5 , W. J. Howard 6 , L. E. Johnson 3 , E. Sordillo 4 ,B. Poskly 4 , J. H. Jorgensen 5 , S. S. Richter 7 , K. A. Shutt 1 , D. L. Paterson 8 ;1Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA, 2 Gachon Univ. Gil Hosp.,Incheon, Korea, Republic of, 3 Henry Ford Hosp., Detroit, MI, 4 St. Luke’sRoosevelt Hosp. Ctr., New York, NY, 5 Univ. of Texas Hlth. Sci. Ctr., SanAntonio, TX, 6 Univ. of Iowa Hlth. Care, Iowa City, IA, 7 Cleveland Clinic,Cleveland, OH, 8 Univ. of Queensland, Brisbane, Australia.C2-113 Risk Factors and Molecular Epidemiology of Extended-Spectrum-Lactamases-Producing Escherichia coli in UrinaryTract Infections in a Mexican Naval HospitalM. D. Alcántar-Curiel 1 , H. J. Varona-Bobadilla 2 , C. Gayosso-Vázquez 1 ,M. D. Jarillo-Quijada 1 , M. Frías-Mendivil 3 , L. Sanjuan-Padrón 2 , J. I.Santos-Preciado 1 ; 1 Univ. Nacional Autónoma de México (UNAM), MéxicoD.F., Mexico, 2 Hosp. Gen. Naval de Alta Especialidad (HOSGENAES),México D.F., Mexico, 3 Escuela Nacional de Enfermeria, UNAM, MéxicoD.F., Mexico.C2-114 Molecular Characteristics of Extended-Spectrum-Lactamases in Clinical Isolates of Escherichia coli at a JapaneseTertiary HospitalH. Yano, S. Endo, H. Kanamori, S. Inomata, R. Kakuta, N. Ishibashier,T. Aoyagi, M. Hatta, Y. Gu, M. Yamada, K. Tokuda, H. Kunishima, M.Kitagawa, Y. Hirakata, M. Kaku; Tohoku Univ. Graduate Sch. of Med.,Sendai, Japan.C2-115 Evaluation of bla CTXM14 andbla CTXM15Identifies DifferentialGene Expression Among Sequence Type 131 (ST131) andNon-ST131 (NST131) E. coli (Ec)C. Geyer 1 , S. Weissman 2 , P. Hawkey 3 , N. D. Hanson 1 ; 1 Creighton Univ.,Omaha, NE, 2 Univ. of WA, Seattle, WA, 3 Univ. of Birm, Edgbaston, UnitedKingdom.C2-116 Characterization of Extended-Spectrum Cephalosporins-Resistant (ESC-R) Escherichia coli (Ec) Isolates Detected in Bern,SwitzerlandM. Hilty, S. Aebi, S. Droz, V. Perreten, K. Mühlemann, A. Endimiani; Univ.of Bern, Bern, Switzerland.C2-117 Clonal Dissemination of Extended Spectrum Beta-LactamaseProducing E. coli and Klebiellae among Patients Presentingto Community Hospitals in Southeastern United StatesL. F. Chen 1 , B. Nicholson 2 , A. Keiger 2 , C. W. Woods 2 , D. J. Sexton 1 , D. J.Anderson 1 ; 1 Duke Univ. Med. Ctr., Durham, NC, 2 Durham VA Med. Ctr.,Durham, NC.C2-118 High Prevalence of ST131 Strains among Escherichia coliUrinary Isolates with Decreased Carbapenem Susceptibilities inSouthern TaiwanJ. Yan 1 , J. Wu 2 ; 1 Natl. Cheng Kung Univ. Coll. of Med. and Hosp., Tainan,Taiwan, 2 Natl. Cheng Kung Univ. Coll. of Med., Tainan, Taiwan.C2-119 Changes In Dominant Extended Spectrum-LactamaseProducing E. coli in a Nursing Home Over a Seven Year PeriodC. Ludden 1 , E. Mc Garry 1 , B. Hanahoe 2 , M. Cormican 1,2 , D. Morris 1 ;1Natl. Univ. of Ireland, Galway, Galway, Ireland, 2 Univ. Hosp. Galway,Galway, Ireland.C2-122 E. coli O25b:ST131 Accounts for a Significantly HigherProportion of Nursing Home Isolates Compared with HospitalIsolates of CTX-M Producing E. coliC. Ludden 1 , F. Boyle 1 , B. Hanahoe 2 , B. Kanagaratnam 1 , M. Cormican 1,2 ,D. Morris 1 ; 1 Natl. Univ. of Ireland, Galway, Ireland, 2 Galway Univ. Hosp.,Galway, Ireland.C2-120 Global Susceptibility and ESBL+ Rates of K. pneumoniaefrom Intra-Abdominal Infections: SMART 2011R. Badal 1 , S. Bouchillon 1 , M. Hackel 1 , D. Hoban 1 , A. Johnson 1 ,S. Hawser 2 ; 1 IHMA, Inc., Schaumburg, IL, 2 IHMA Europe, Sarl,Epalinges, Switzerland.C2-121 Point Prevalence and Genetic Characterization of Extended-Spectrum-Lactamase Genes Harbored by Invasive Isolates ofEnterobacteriaceae in a Teaching Hospital in Lagos, NigeriaM. A. Raji 1,2 , O. Ojemhen 3 , U. Umejiburu 4 , W. Jamal 5 , O. Rotimi 5 ; 1 LagosState Univ. Coll. of Med., I, Lagos State, Nigeria, 2 Lagos State Univ. TeachingHosp.,, Ikeja, Nigeria, 3 Lagos State Univ. Teaching Hosp.,, Lagos State,Nigeria, 4 Lagos State Univ. Coll. of Med., Lagos State, Nigeria, 5 Faculty ofMed., Kuwait Univ., Kuwait, United Arab Emirates.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.44September 9-12 |

SUNDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------010(C2)Poster SessionMulti-Center Surveillance StudiesSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:C2-123 Ceftaroline Activity Tested against Pathogens AssociatedWith Acute Bacterial Skin and Skin Structure Infections (ABSS-SI) Isolated From Latin American Medical Centers (2010)D. J. Biedenbach, H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc.,N Liberty, IA.C2-124 Antimicrobial Activity of Ceftaroline and ComparatorAgents Tested against Contemporary (2010) Pathogens Associatedwith Acute Bacterial Skin and Skin Structure Infections(ABSSSI) Isolated from the Asia-Pacific Region (APAC) andSouth Africa (SAF)P. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., NLiberty, IA.C2-125 Comparative In Vitro Activity of Sitafloxacin (SIT) Relativeto Other Fluoroquinolones against Clinically Important BacteriaIsolated in Asia and EuropeJ. Deane, A. Simenauer, D. Sahm; Eurofins, Chantilly, VA.C2-126 In Vitro Activity of Ceftaroline against Staphylococcus aureus(SA) from Consecutive U.S. Nationwide Surveillance Program2009 and 2011G. Doern 1 , S. Richter 2 , K. Heilmann 1 , C. Dohrn 1 , F. Riahi 1 , D. Diekema 1 ;1Univ. of Iowa, Iowa City, IA, 2 Cleveland Clinic, Cleveland, OH.C2-127 Comparative In Vitro Activity of Ceftaroline, Daptomycin,Linezolid, and Vancomycin against 512 Bacteremic Methicillin-Resistant Staphylococcus aureus Isolated Over a Period of 9 Years(2004-2012) in Madrid, SpainE. Cercenado, B. Gama, C. Sánchez-Carrillo, M. Marín, M. Rodríguez-Créixe, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.C2-128 A Five Year Comparison of Vancomycin (VAN) and Oritavancin(ORI) In Vitro Activities against StaphylococciJ. Deane 1 , A. Simenauer 1 , G. Moeck 2 , F. F. Arhin 2 , D. Sahm 1 ; 1 Eurofins,Chantilly, VA, 2 The Med. Company, Parsippany, NJ.C2-129 Antimicrobial Susceptibility of S. aureus from USA HospitalsAccording to the Site of Infection: Data from the CeftarolineAWARE Surveillance Program (2008-2011)H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA.C2-130 Activity of Ceftaroline Tested against Staphylococcus Collectedfrom a Nationwide Study in Spain, 2010E. Cercenado, B. Gama, O. Cuevas, M. Marín, E. Bouza, StaphylococcusStudy Group; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.C2-131 Ceftaroline and Comparator Agent Activity against Contemporary(2010) Staphylococcus aureus Isolates from Asia-Pacific(APAC) Region and South Africa HospitalsP. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., Inc., NLiberty, IA.C2-132 Oritavancin Activity Tested against Staphylococcus aureusand-Hemolytic Streptococci Causing Skin and Skin StructureInfections in the USA (2010−2012)R. E. Mendes, H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., N Liberty, IA.C2-133 Monitoring Cross-Resistance Trends Between Tigecyclineand Minocycline in Gram-Positive Blood Isolates (Test 2008 -2011)S. Hawser 1 , C. Zampaloni 1 , F. Monti 1 , S. Bouchillon 2 ; 1 IHMA Europe Sàrl,Epalinges, Switzerland, 2 IHMA, Inc., Schaumburg, IL.C2-134 Comparative In Vitro Activity of Dalbavancin (DAL) andOther Gram-Positive Agents against a Recent Collection ofEuropean Bacterial IsolatesJ. Deane 1 , A. Simenauer 1 , M. Dunne 2 , B. P. Goldstein 3 , D. Sahm 1 ;1Eurofins Medinet, Chantilly, VA, 2 Durata Therapeutics, Morristown, NJ,3None, Morristown, NJ.C2-135 Antimicrobial Susceptibility of 27,123 Pathogens Isolatedfrom Patients in Canadian Hospitals: CANWARD Study 2007-2011G. G. Zhanel 1 , H. Adam 2 , M. Baxter 1 , K. Nichol 2 , A. Denisuik 1 , P.Lagace-Wiens 2 , A. Walkty 2 , J. A. Karlowsky 2 , F. Schweizer 1 , CanadianAntimicrobial Resistance Alliance-CARA, D. J. Hoban 2 ; 1 Univ. ofManitoba, Winnipeg, Canada, 2 Diagnostic Services of Manitoba, Winnipeg,Canada.C2-136 Emerging Markets Resistance Surveillance (EMRS) ProgramReport for Eastern European (EEU) NationsR. N. Jones, M. G. Stilwell, R. K. Flamm, H. S. Sader; JMI Lab., N Liberty, IA.C2-137 Nationwide Surveillance on the Antimicrobial Resistanceamong Blood Isolates Causing Bacteremia: A 2011 Korean Networkfor Study on Infectious Diseases (KONSID) StudyK. Huh, S. Y. Park, S. Y. Cho, C. I. Kang, D. R. Chung, N. Y. Lee, K. R.Peck, J. H. Song, Korean Network for Study on Infectious Diseases (KON-SID); Samsung Med. Ctr., Seoul, Korea, Republic of.C2-138 Update of Dalbavancin (DAL) Activity in the USA: Reportfrom the SENTRY Program (2011)R. N. Jones R. K. Flamm, H. S. Sader; JMI Lab., N Liberty, IA.C2-139 Linezolid Experience and Accurate Determination of Resistance(LEADER) Program for 2011: USA Surveillance ReportJ. E. Ross, R. E. Mendes, R. K. Flamm, R. N. Jones; JMI Lab., N Liberty, IA.C2-140 Trends in Activity of Tigecycline against Bacteroides spp. fromCardiovascular Sources (TEST 2008 - 2011)S. Hawser 1 , C. Zampaloni 1 , F. Monti 1 , S. Bouchillon 2 ; 1 IHMA EuropeSàrl, Epalinges, Switzerland, 2 IHMA, Inc., Schaumburg, IL.C2-141 Comparison of Tigecycline Activity against Aerobic Intra-Abdominal Pathogens in Eastern and Western EuropeanCountries: TEST 2008-2011S. Lob, S. Bouchillon, M. Hackel, D. Hoban, J. Johnson; IHMA, Inc.,Schaumburg, IL.C2-142 In Vitro Activity of Tedizolid and Radezolid against Linezolid-ResistantGram-Positive Clinical Isolates with GeneticallyCharacterized Resistance MechanismsE. Cercenado, M. Marín, B. Gama, C. Iglesias, E. Bouza; Hosp. Gen. Univ.Gregorio Marañón, Madrid, Spain.Final Program45

Sunday SCIENTIFIC SESSIONSC2-143 Susceptibility of Gram-Positive Wound Pathogens in EasternEurope: A Multi-Year Update of the TEST StudyM. Hackel 1 , S. Bouchillon 1 , D. Hoban 1 , R. Badal 1 , J. Johnson 1 , S. Hawser 2 ;1IHMA, Inc., Schaumburg, IL, 2 IHMA Europe Sàrl, Epalinges, Switzerland.C2-144 Monitoring of Tigecycline In Vitro Activity in NosocomialPneumonia Isolates from North American Intensive Care Units:TEST Data 2006-2011D. Hoban, M. Hackel, R. Badal, S. Bouchillon, B. Johnson; IHMA, Inc.,Schaumburg, IL.C2-145 Activity of Ceftaroline (CPT) and Comparator Agents Testedagainst Contemporary (2010) Pathogens Commonly Associatedwith Respiratory Tract Infections (RTI) in Asia-Pacific (APAC)Countries and South Africa (SAF)D. J. Biedenbach, R. K. Flamm, D. J. Farrell, H. S. Sader, R. N. Jones; JMILab., N Liberty, IA.C2-146 Antimicrobial Activity of Ceftaroline Tested against BacteriaCollected from Patients with Community-Acquired RespiratoryTract Infections (CARTI) in the USA (2008-2011)R. N. Jones, R. K. Flamm, P. R. Rhomberg, H. S. Sader; JMI Lab., Inc., NLiberty, IA.C2-147 Extended-Spectrum ß-Lactamase (ESBL) In Vitro Activityin Urinary Tract Infections: European TEST Program Results,2004-2011S. Bouchillon, M. Hackel, B. Johnson, D. Hoban, J. Johnson; IHMA, Inc.,Schaumburg, IL.C2-148 Epidemiology and Antimicrobial Susceptibility of PathogensAssociated with Bacterial Empyema: TEST 2004-2011S. Bouchillon, R. Badal, B. Johnson, M. Hackel, D. Hoban; IHMA, Inc.,Schaumburg, IL.C2-149 In Vitro Activity of Ceftazidime-Avibactam (formerlyCAZ104) against Gram-Negative Pathogens Isolated from Patientsin Canadian Hospitals in 2009-2011: CANWARD SurveillanceStudyP. Lagacé-Wiens, H. Adam, A. Denisuik, J. Karlowsky, A. Walkty, D. Hoban,G. G. Zhanel; Univ. of Manitoba, Winnipeg, Canada.C2-150 In Vitro Activity of Tigecycline and Comparators againstGram-Negatives in Africa-Middle East: TEST 2007-2012M. Renteria 1 , S. Bouchillon 1 , B. Johnson 1 , M. Hackel 1 , N. Raghubir 2 ;1IHMA, Inc., Schaumburg, IL, 2 Pfizer, Inc., Dubai, United Arab Emirates.C2-151 Dynamics of Susceptibility to Tigecycline and to an ExtendedPanel of Antimicrobials of Gram-Positive and Gram-NegativeBacteria in Portugal (2005-2011)C. Silva-Costa, A. Friaes, M. D. Pinho, M. Ramirez, J. Melo-Cristino;Faculdade de Med. de Lisboa, Lisboa, Portugal.C2-152 Enterobacteriaceae in the UK and Ireland 2011: Susceptibilityto Old and New AgentsR. Reynolds 1 , S. Mushtaq 2 , A. Kidney 3 , BSAC Working Party on ResistanceSurveillance; 1 Southmead Hosp., Bristol, United Kingdom, 2 Hlth. ProtectionAgency, London, United Kingdom, 3 Quotient Bioresearch, Microbiol.,Fordham, United Kingdom.----------------------------------------------------------------------------------011(D)Poster SessionClostridium difficile DiagnosticsSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:D-153 Evaluation of the Accuracy and Cost Effectiveness of Strategiesof Testing for Clostridium difficileJ. N. Wainaina 1 , M. A. Beilke 1 , T. Wisniewski 2 , J. Winner 2 , P. Sohnle 1 ;1Clement J. Zablocki Med. Ctr., Med. Coll. of Wisconsin, Milwaukee, WI,2Clement J. Zablocki Med. Ctr., Milwaukee, WI.D-154 Does a Rapid Diagnosis of Clostridium difficile Infection (CDI)Impact on Quality of Patient’s Management?F. Barbut 1,2 , C. Eckert 1,2 , L. Surgers 1 , V. Lalande 1 , for the GRCn°2EPIDIFF; 1 Hosp. Saint-Antoine, Paris, France, 2 Univ. Pierre et Marie Curie,Paris, France.D-155 The Efficient Use of Laboratory Testing in Support of Clostridiumdifficile Infection, Diagnosis, and Prevention: ComparingAntigen, Nucleic Acid Amplification, and GDH: What is theMost Efficient Testing Algorithm?M. J. Bankowski 1,2 , A. Hose 1 , A. LeClaire 1 , T. Goo 1 , T. Koyamatsu 1 , W.Kim 1 ; 1 Diagnostic Lab. Services (The Queen’s Med. Ctr.), Aiea, HI, 2 JohnA. Burns Sch. of Med., Honolulu, HI.D-156 Evaluation of a New Glutamatedehydrogenase Immuno Assayin a Two Step Algorithm for the Diagnosis of Clostridium difficileInfectionJ. Van Broeck, E. R. Icyeza, M. Delmée; Univ. Catholique de Louvain, Brussels,Belgium.D-157 Performances of a New Test to Detect GDH in Stool SamplesC. Eckert 1,2 , C. Rambaud 1,2 , V. Lalande 3,2 , F. Barbut 1,2 ; 1 Saint-AntoineHosp., Paris, France, 2 UPMC Univ. Paris 06, GRC n°2, Epidiff, Paris,France, 3 Saint-Antoine Hosp., AP-HP, Paris, France.D-158 Development and Evaluation of a Double Multiplex Real-Time PCR Method for Simultaneous Identification and ToxigenicType Characterization of C. difficile from Stool SamplesA. Kilic 1,2 , M. J. Alam 2 , N. L. Tisdel 3 , D. N. Shah 2,3 , M. Yapar 1 , T. M.Lasco 3 , K. W. Garey 2,3 ; 1 Gulhane Military Med. Academy, Ankara, Turkey,2Univ. of Houston Coll. of Pharmacy, Houston, TX, 3 St Luke’s EpiscopalHosp., Houston, TX.D-159 Improvement in Patient Management through the Use of aClostridium difficile PCR Real-Time Stand Alone Test in AcuteHospital SettingE. Casari 1 , A. Ferrario 1 , C. De Luca 1 , M. Calabrò 1 , S. Allibardi 2 , M.Lagioia 1 ; 1 IRCCS Ist. Clinico Humanitas, Rozzano (Milan), Italy, 2 CepheidEurope, Milano, Italy.D-160 Clinical Validation of Clostidium difficile Infection (CDI)Diagnostics: Importance of Toxin DetectionT. D. Planche 1 , K. A. Davies 2 , P. Coen 3 , D. Crook 4 , N. Shetty 3 , M.Wrener 3 , M. H. Wilcox 2 ; 1 St. George’s, Univ. of London, London, UnitedKingdom, 2 Leeds Teaching Hosp. NHS Trust, Leeds, United Kingdom,3UCLH NHS Fndn. Trust, London, United Kingdom, 4 Oxford RadcliffeNHS Trust, Oxford, United Kingdom.46September 9-12 |

SUNDAY SCIENTIFIC SESSIONSD-161 PCR Assay to Detect Clostridium difficile tcdC Mutants isValuable in Characterizing Hospital EpidemiologyA. Wilmer 1 , E. Lloyd-Smith 2 , V. Leung 2 , T. Wong 1 , G. Ritchie 3 , S. Champagne3 , M. Romney 3 ; 1 Univ. of British Columbia, Vancouver, Canada, 2 St.Paul’s Hosp., Vancouver, Canada, 3 St. Paul’s Hosp., Vancouver, Canada.D-162 Elevated Fecal Lactoferrin Levels Correlate with the Presenceof Clostridium difficile ToxinH. R. Totty 1 , J. H. Boone 1 , R. J. Carman 1 , T. M. Kerkering 2 , D. M. Lyerly 1 ;1Techlab, Inc., Blacksburg, VA, 2 Carilion Clinic, Roanoke, VA.D-163 Higher Lactoferrin, Increased WBC, Stool Toxin and 027Infection are Associated with More Severe C. difficile DiseaseJ. H. Boone 1 , C. McCoy 1 , J. DiPersio 2 , M. Tan 2 , S. Salstrom 2 , K.Wickham 1 , R. Carman 1 , D. Lyerly 1 ; 1 TechLab, Inc., Blacksburg, VA,2Summa Hlth. System, Akron, OH.------------------------------------------------------------------------012(D)Poster SessionDiagnosis of Infections of Implantable Devices andBiofilmsSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:D-164 A Novel, Direct Susceptibility Testing Method of VascularProsthetic Grafts by E-TestsL. Stecken 1 , A. San Miguel 1 , F. M’zali 2 , A. Quinart 1 , X. Berard 1 , F.Sztark 1 ; 1 Bordeaux Teaching Hosp., Bordeaux, France, 2 Univ. of Bordeaux,Bordeaux, France.D-165 Sonication of Cardiac Devices and their Components: Microbiologicaland Pathogenetic Implication in Cardiac DeviceInfectionsA. Oliva 1 , B. Nguyen 1 , M. T. Mascellino 1 , M. Iannetta 1 , A. D’Abramo 1 ,V. Malagnino 1 , A. Ciccaglioni 1 , V. Vullo 1 , C. M. Mastroianni 2 ; 1 SapienzaUniv., Rome, Italy, 2 Sapienza Univ., Latina, Italy.D-166 Diagnosis of Venous Access Port Colonization Requires Culturesfrom Multiple SitesM. Guembe, P. Martín-Rabadán, A. Echenagusia, F. Camúñez, G. Rodríguez-Rosales,G. Simó, M. Echenagusia, E. Bouza; Hosp. G.U. GregorioMarañón, Univ. of Madrid, Madrid, Spain.D-167 Diagnosis of Intravascular Catheter Colonization and CentralVenous Catheter-Related Infection: A Prospective Comparison ofthe Roll-Plate and Sonication Technique in 975 Central VenousCathetersS. Erb, K. Schrengenberger, M. Dangel, R. Frei, A. F. Widmer; Univ. Hosp.of Basel, Switzerland, Basel, Switzerland.D-168 Sonication of Cerebrospinal Fluid Catheter Tips for ImprovedDetection of Microorganism in Device Associated InfectionsL. N. Walti 1 , G. Jost 2 , L. Mariani 2 , A. Trampuz 1 ; 1 Univ. Hosp., Lausanne,Switzerland, 2 Univ. Hosp., Basel, Switzerland.D-169 Diagnostic Tests for Prosthetic Joint Infection (PJI)M. Fernandez-Sampedro 1 , C. Fariñas-Alvarez 2 , C. Salas-Venero 1 , M.Sumillera 1 , M. Fakkas Fernández 1 , J. Gómez-Román 1 , L. Martínez-Martínez1 , M. Fariñas 1 ; 1 Valdecilla Univ. Hosp., Santander, Spain, 2 SierrallanaHosp., Torrelavega, Spain.D-170 Anaerobic Thioglycollate Broth Culture for Recovery ofPropionibacterium Acnes (PA) from Shoulder Fluid and TissueSpecimensS. K. Shannon, J. Mandrekar, D. R. Gustafson, S. L. Rucinski, A. L. Dailey,R. E. Segner, M. K. Burman, K. J. Boelman, D. T. Lynch, J. E. Rosenblatt, R.Patel; Mayo Clinic, Rochester, MN.D-171 Detection of Biofilm Formation Among the Clinical Isolatesof Acinetobacter baumaniiA. Hassan; Natl. Univ. of Scienecs and Technology, Army Med. Coll.,Rawalpindi, Pakistan.----------------------------------------------------------------------------------013(D)Poster SessionDiagnosis of Respiratory Tract InfectionsSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:D-172 Genomic Load from Sputum to Diagnose PneumococcalPneumoniaW. C. Albrich 1,2 , S. A. Madhi 2,3 , P. V. Adrian 2,3 , P. Zhaoer 4 , M. Sidhu 5 , J.Telles 6 , G. Paranhos-Baccala 6 , K. U. Jansen 4 , G. Vernet 6 , K. P. Klugman 2,7 ;1Kantonsspital Aarau, Aarau, Switzerland, 2 Vaccine Preventable Diseases& Respiratory and Meningeal Pathogens Res. Unit, MRC, Univ. of theWitwatersrand, Johannesburg, South Africa, 3 Natl. Inst. for CommunicableDiseases, Faculty of Hlth. Sci., Johannesburg, South Africa, 4 Pfizer VaccineRes., Pearl River, NY, 5 Pfizer, Pearl River, NY, 6 Emerging Pathogens Lab.,Fondation Mérieux, Lyon, France, 7 Rollins Sch. of Publ. Hlth. & Div. ofInfect. Dis., Emory Univ., Atlanta, GA.D-173 Multiplex PCR on Bronchoalveolar Lavage (BAL) MarkedlyImproves the Microbiological Documentation of Severe Pneumoniafor Patients with Ongoing Antimicrobial TreatmentJ. Baudel, J. Tankovic, F. Carrat, R. Dahoumane, A. Galbois, H. Ait Oufella,G. Offenstadt, B. Guidet, E. Maury; Univ. Hosp. Saint-Antoine, Paris,France.D-174 Direct Comparison of Real-Time PCR Using Roche AnalyteSpecific Reagents with Shell Vial Culture for Detection of Cytomegalovirusin Lower Respiratory SpecimensK. R. Hawkins 1 , M. J. Binnicker 2 , B. S. Pritt 2 ; 1 Univ. of Warwick, Norfolk,United Kingdom, 2 Mayo Clinic, Rochester, MN.D-175 Dichromatic at-a-Glance Real-Time PCR Discriminationof Macrolide Sensitive/Resistant Mycoplasma pneumoniae fromClinical SpecimensI. Miyata, I. Miyairi; Natl. Ctr. for Child Hlth. and Dev., Tokyo, Japan.D-176 Diagnosis of Respiratory Infections Due to Mycoplasmapneumoniae: Serology or PCR?S. Sunder, D. Bouvet, M. Alves, F. Bastides, C. De Gialluly, R. Quentin, A.Goudeau, L. Bernard; CHRU de Tours, Tours, France.D-177 Multiplex Real-Time PCR: Efficacy in Diagnosis and Treatmentof Lower Respiratory Tract InfectionsH. Chaussade, D. Bouvet, S. Sunder, G. Gras, A. Goudeau, L. Bernard;CHRU de Tours, Tours, France.Final Program47

Sunday SCIENTIFIC SESSIONSD-178 Comparative Evaluation of 8 Commercial Multiplex PCR Kitsfor the Diagnosis of Respiratory InfectionM. Lardeux 1 , S. Pillet 1 , J. Dina 2 , F. Grattard 1 , P. O. Verhoeven 1 , J. Legoff 3 , A.Vabret 2 , B. Pozzetto 1 ; 1 Univ. Hosp. of Saint Etienne, Saint Etienne, France,2Univ. Hosp. of Caen, Caen, France, 3 Saint-Louis Hosp., Paris, France.D-179 Prevalence of Respiratory Viruses in the Community ofNorthern Saxony and Saxony-Anhalt, GermanyN. H. Zaiss, M. Kunze, G. Ackermann; Alphaomega Labor, Delitzsch,Germany.D-180 Prognostic Value of Serum Albumin Levels at Admission inHospitalized Adults with Community-Acquired PneumoniaD. Viasus, C. Garcia-Vidal, J. Dorca, F. Gudiol, J. Carratalà; Hosp. de Bellvitge- IDIBELL, Univ. of Barcelona, Barcelona, Spain.D-181 Prevalence of Bacterial Otitis Media and Antimicrobial SusceptibilityPattern in EthiopiaD. S. Fentaw 1 , Y. Bekele 2 , T. Getachew 3 ; 1 UIO, Oslo, Norway, 2 AHRI, AddisAbaba, Ethiopia, 3 EHNRI, Addis Ababa, Ethiopia.------------------------------------------------------------------------014(D)Poster SessionSerologic Methods for Detection of Infectious DiseasesSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:D-182 Optimal Cutoff Value of Serum Adenosine Deaminase Activityfor Diagnosing Acute Scrub TyphusJ. Lee 1 , J. Cho 2 , E. Choi 3 ; 1 Inst. of Wonkwang Med. Sci., Iksan, Korea, Republicof, 2 Wonkwang Univ. Hosp., Iksan, Korea, Republic of, 3 MirawomenPedriatric Hosp., Iksan, Korea, Republic of.D-183 Diagnostic Cutoffs for Increases and Absolute Values of ImmunoglobulinG Antibodies against Pertussis ToxinS. C. de Greeff 1 , P. Teunis 1 , H. E. de Melker 1 , F. R. Mooi 1 , D. Notermans 1 ,B. Elvers 1 , J. F. P. Schellekens 2 ; 1 Natl. Inst. for Publ. Hlth. and the Environment,Bilthoven, Netherlands, 2 Lab. for Infectious Diseases, Groningen,Netherlands.D-184 A Comparison of Three Anti-HEV IgG EIA ScreeningKits and One Confirmatory Immunodot Assay in Blood DonorSamples in SwitzerlandA. Schnegg 1 , P. Bürgisser 2 , C. André 2 , A. Kenfak-Foguena 2 , G. Canellini 3 ,D. Moradpour 2 , M. Cavassini 2 , K. E. Darling 2 ; 1 Univ. of Lausanne, Lausanne,Switzerland, 2 Ctr. Hosp. Univ. Vaudois, Univ. of Lausanne, Lausanne,Switzerland, 3 Service Régional Vaudois de Transfusion Sanguine, Epalinges,Switzerland.D-185 Optimizing the Positive Predictive Value of the Focus HSV-2ELISA in Hepatitis C Infected Veterans at the Jackson VAMCM. Burton 1 , E. Swiatlo 1 , I. Sunesara 2 , A. Penman 2 , C. Young 1 , E. W.Hook, III 3 ; 1 G.V. Sonny Montgomery VAMC, Jackson, 2 Univ. of MississippiMed. Ctr., Jackson, 3 Univ. of Alabama, Birmingham, AL.----------------------------------------------------------------------------------015(E)Poster SessionIn Vitro Activity of Beta-Lactamase InhibitorCombinationsSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:E-186 Antimicrobial Activity of Ceftaroline-Avibactam (CPA)Tested against Contemporary Clinical Isolates from USA MedicalCenters (2011)H. S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., NLiberty, IA.E-187 Avibactam Reverts the Ceftazidime (CAZ) MIC 90of a RecentSet of European Clinical Isolates of Gram-Negative BacteriaBack to the Epidemiological Cut-Off Value (ECOFF)R. K. Flamm 1 , W. W. Nichols 2 , H. S. Sader 1 , R. N. Jones 1 ; 1 JMI Lab., NLiberty, IA, 2 AstraZeneca Pharmaceuticals LP, Waltham, MA.E-188 Quality Control Parameters for Ceftaroline-Avibactam DiskDiffusion, Anaerobic Broth Microdilution and Agar DilutionQuality ControlS. D. Brown, M. M. Traczewski; Clinical Microbiol. Inst., Inc., Wilsonville,OR.E-189 Antimicrobial Spectrum and Potency of Ceftaroline-AvibactamTested against ESBL-Phenotype and Carbapenem-ResistantEnterobacteriaceae Collected from USA Hospitals (2009-2011)H. S. Sader, M. Castanheira, R. K. Flamm, R. N. Jones; JMI Lab., Inc., NLiberty, IA.E-190 In Vitro Activity of Ceftazidime Alone and in Combinationwith Avibactam against Resistant Pseudomonas aeruginosa andEnterobacteriaceaeM. J. B. Melchers 1 , C. H. van Mil 2 , J. W. Mouton 1 ; 1 Radboud Univ.Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 Canisius Wilhelmina Hosp.,Nijmegen, Netherlands.E-191 In Vitro Activity of Ceftaroline-Avibactam against FrequentlyIsolated Bacterial Pathogens from Patients in Canadian HospitalsJ. Karlowsky 1 , A. Walkty 1 , M. Baxter 2 , H. Adam 1 , P. Lagace-Wiens 1 ,D. Hoban 1 , G. G. Zhanel 2 ; 1 Diagnostic Services of Manitoba, Winnipeg,Canada, 2 Univ. of Manitoba, Winnipeg, Canada.E-192 Activity of MK-7655 with Imipenem vs.-LactamaseProducersD. M. Livermore, M. Warner, S. Mushtaq; UK Hlth. Protection Agency,London, United Kingdom.E-193 Antimicrobial Activity of BAL30072, Alone and in Combinationwith Meropenem Tested against Gram-Negative BacteriaCausing Serious Infections in Hospitals from China, India, LatinAmerica and South East Asia-PacificP. R. Rhomberg, K. A. Fedler, R. K. Flamm, R. N. Jones, H. S. Sader; JMILab., Inc., N Liberty, IA.48September 9-12 |

SUNDAY SCIENTIFIC SESSIONSE-194 Avibactam (NXL104) in Combination with Select-Lactamsand Meropenem Greatly Improves In Vitro Activity againstESBL-, AmpC-, and KPC-Producing Escherichia coli (EC) andKlebsiella pneumoniae (KPN) from Canadian HospitalsA. Denisuik 1 , F. Tailor 1 , P. Lagacé-Wiens 1,2 , H. J. Adam 1,2 , D. J. Hoban 1,2 ,G. G. Zhanel 1 , The Canadian Antimicrobial Resistance Alliance (CARA);1Univ. of Manitoba, Winnipeg, Canada, 2 Diagnostic Services of Manitoba,Winnipeg, Canada.E-195 In Vitro Activity of Piperacillin-Tazobactam (PT) in Combination(combi) with Various Antibiotics (ABX) against ExtremeDrug-Resistant (XDR) Enterobacteriaceae (EB) with ReducedSusceptibilities to Polymyxin B (PB)T. P. Lim 1,2 , S. Sasikala 1 , W. Lee 1 , N. Tahir 1 , Y. Cai 1 , T. H. Koh 1 , T. Y.Tan 3 , L. Y. Hsu 2 , T. T. Tan 1 , A. L. Kwa 1 ; 1 Singapore Gen. Hosp., Singapore,Singapore, 2 Natl. Univ. Hosp. System, Singapore, Singapore, 3 Changi Gen.Hosp., Singapore, Singapore.E-196 In Vitro Susceptibility Among Enterobacteriaceae to a Novel-Lactam/-Lactam Inhibitor Combination: Cefpime-TazobactamA. Manoharan, M. Sugumar, G. S. Barla, D. Kumar, D. Mathai; ChristianMed. Coll., Vellore, Tamil Nadu, India.E-197 Utilizing Population Analysis to Investigate Piperacillin/Tazobactam Differences Between Broth Microdilution and AgarDilution for a Set of Escherichia coliC. Shubert 1 , J. Slaughter 1 , D. Creely 1 , G. Zambardi 2 , D. Shortridge 1 ;1bioMerieux, Inc., Hazelwood, MO, 2 bioMerieux, Inc., La Balme, France.E-198 In Vitro Activity of Ceftolozane Alone and in Combinationwith Tazobactam against Extended Spectrum Beta-LactamaseHarbouring EnterobacteriaceaeM. J. B. Melchers 1 , C. H. van Mil 2 , J. W. Mouton 1 ; 1 Radboud Univ.Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 Canisius Wilhelmina Hosp.,Nijmegen, Netherlands.E-199 Activity of the Novel Antimicrobial Ceftolozane/TazobactamTested against Contemporary Clinical Strains from USA Hospitals(2011)H. S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., NLiberty, IA.E-200 In Vitro Activity of Ceftolozane/Tazobactam Tested against1,705 Gram-Negative Pathogens Isolated from Patients inCanadian Hospitals in 2011: CANWARD Surveillance StudyG. G. Zhanel 1 , H. Adam 2,1 , A. Walkty 2 , P. R. S. Lagace-Wiens 2 ,D. J. Hoban 2,1 , J. A. Karlowsky 2 ; 1 Univ. of Manitoba, Winnipeg, Canada,2Diagnostic Services of Manitoba, Winnipeg, Canada.E-201 In Vitro Pharmacodynamics (PD) of Ceftolozane (TOL)/Tazobactam (TAZ) against-Lactamase (BL) ProducingEschericia coli (Ec)R. L. Soon, A. Forrest, P. N. Holden, P. Kelchlin, B. T. Tsuji; Univ. atBuffalo, Buffalo, NY.E-202 In Vitro Imipenem -Sulbactam Activity against Multidrug-Resistant Acinetobacter baumannii Complex (ABC) by Time-KillAssayM. G. Quinteros, A. Miquelarena, Jr, A. Dorronzoro, J, J. Toran, M. Santalucía,Jr, A. E. Farinati; Salvador Univ., Buenos Aires, Argentina.------------------------------------------------------------------------016(E)Poster SessionIn Vitro Activity of FluoroquinolonesSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:E-203 In Vitro Bactericidal Activity of KPI-10, a Next GenerationFluoroquinolone (FQ), against FQ-Susceptible (FQ-S) and FQ-Resistant (FQ-R) Gram-Negative and Gram-Positive IsolatesC. Jacqueline 1 , C. Desessard 2 , M. Davieau 1 , Y. Ge 3 , G. Potel 1 , J. Caillon 1 ;1UPRES EA 3826, Nantes, France, 2 Atlangram, Nantes, France, 3 KalidexPharmaceuticals Inc, Menlo Park, CA.E-204 Ozenoxacin. Activity against Gram-Positive Bacteria (GPB)Causing Skin and Soft Tissue Infections (SSTI) Collected in2009-10I. Morrissey 1 , R. Janes 1 , J. Dallow 1 , A. Leakey 1 , A. Guglietta 2 , D.Gargallo-Viola 2 ; 1 Quotient Bioresearch, Ltd., Fordham, United Kingdom,2Ferrer, R&D Ctr., Barcelona, Spain.E-205 Ozenoxacin: Characterization of Variables that May InfluenceSusceptibility Testing, Including MIC and MBC ValuesM. Tato 1 , Y. López 2 , A. Moreno-Bofarull 1 , M. I. Morosinier 1 , D.Gargallo-Viola 3 , A. Guglietta 3 , J. Vila 2 , R. Cantón 1 ; 1 Ramón y Cajal Univ.Hosp., Madrid, Spain, 2 Hosp. Clinic, Barcelona, Spain, 3 Ferrer, R&D Ctr.,Barcelona, Spain.E-206 In Vitro Activity of Nemonoxacin, a Novel QuinoloneAntibiotic, against Chlamydia trachomatisK. Chotikanatis, S. A. Kohlhoff, M. R. Hammerschlag; SUNY DownstateMed. Ctr., Brooklyn, NY.E-207 Activity of the Novel Fluoroquinolone KPI-10 vs. AtypicalBacteriaP. B. Eckburg 1 , Y. Ge 1 , H. Windsor 2 , M. Donati 3 , R. Cevenini 3 ; 1 KalidexPharmaceuticals, Inc., Menlo Park, CA, 2 Mycoplasma Experience, Ltd.,Reigate, United Kingdom, 3 Univ. of Bologna, Bologna, Italy.E-208 Characterization and In Vitro Activity of Delafloxacin (DLX)against Isolates from a Phase 2 Study of Acute Bacterial Skin andSkin Structure Infections (ABSSSI)L. E. Lawrence 1 , S. Hopkins 1 , D. Sahm 2 , J. Deane 2 , J. Longcor 1 ; 1 Rib-XPharmaceuticals Inc., New Haven, CT, 2 Eurofins Medinet, Chantilly, VA.E-209 In Vitro Activity of Sitafloxacin against Multidrug-Resistant(MDR) Acinetobacter baumanniiV. Thamlikitkul, S. Tiengrim; Siriraj Hosp., Bangkok, Thailand.E-210 Ozenoxacin: Bactericidal Activity against Gram-PositiveBacteriaI. Morrissey 1 , R. Janes, MRes 1 , J. Dallow 1 , A. Leakey 1 , A. Guglietta 2 , D.Gargallo-Viola 2 ; 1 Quotient Bioresearch, Ltd., Fordham, United Kingdom,2Ferrer, R&D Ctr., Barcelona, Spain.Final Program49

Sunday SCIENTIFIC SESSIONS------------------------------------------------------------------------017(H)Poster SessionAdherence to HIV Therapy and CareSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:H-211 Association Between Selective Adherence to AntiretroviralTherapy and Hospitalization Risk in an HIV PopulationC. Cohen 1 , K. Davis 2 , J. Meyers 2 ; 1 Community Res. Initiative of New England,Boston, MA, 2 RTI Hlth. Solutions, Research Triangle Park, NC.H-212 Affects on Medication Adherence in HIV-Infected Patientsby a Part D Style Medication Therapy Management (MTM)ProgramC. Holtzer, Holtzer, E. Ndzerem, C. Higgs; Ramsell Corp., Oakland, CA.H-213 Barriers to Healthcare Engagement in Hospitalized HIV-Infected PatientsA. P. Liappis 1,2 , B. Yoon 1 , S. D. McIntosh 1,2 , A. D. Castel 2 , S. Silver 2 , P.J. Poppen 2 ; 1 VA Med. Ctr., Washington, DC, 2 George Washington Univ.,Washington, DC.------------------------------------------------------------------------018(H, V)Poster SessionHepatitis B and C Coinfection in HIVSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:H-214 Genotyping and Phylogenetic Analysis of HCV Isolatesamong People Living with HIV/AIDS in CameroonM. Djuidje Ngounoue 1,2 , A. Djikeng 3 , D. Spiro 4 , P. F. Moundipa 1 , L.Kaptue 5,2 ; 1 Univ. of Yaounde I, Yaounde, Cameroon, 2 Cameroon Natl. EthicsCommittee, Yaoundé, Cameroon, 3 Biosciences central and eastern Africa(BECA) and Intl. Livestock Res. Inst. (ILRI), Nairobi, Kenya, 4 Natl. Inst. ofHlth. (NIAID/NIH/DHHS), Bethesda, 5 Univ. des Montagnes, Bangangté,Cameroon.H-215 Prevalence of Genotypic Resistance of Hepatitis C Virus toProtease Inhibitors in HIV-Infected Patients In TaiwanS. Chang, Z. Yang, W. Liu, C. Hung, S. Chang; Natl. Taiwan Univ. Hosp.,Taipei, Taiwan.H-216 A Comparative Meta-Analysis Report of Retreatment withPegylated Interferon and Ribavirin in HIV-HCV CoinfectedPatientsM. Bassoer 1 , S. G. Parisi 1 , C. Mengoli 1 , M. Fiscon 1 , M. Cruciani 2 , S. Nardi 2 ,G. Palù 1 ; 1 Padova Univ., Padova, Italy, 2 ULSS20, Verona, Italy.H-217 Neutropenia During Therapy with PegIFN and RBV and theRisk of Infections in HIV-Infected Subjects with Chronic HepatitisC (CHC)S. Serrano-Villar, C. Quereda, A. Moreno, M. Pérez-Elías, J. Martín, J.Casado, F. Dronda, E. Navas, J. Hermida, S. Moreno; Hosp. Ramón y Cajal,Madrid, Spain.H-218 Clinical and Virologic Outcomes after Switch to Tenofovir/Lamivudine of HIV-Infected Patients with Hepatitis B Virus(HBV) Resistance to Lamivudine in an Hyperendemic Area forHBV InfectionK. Lee, S. Chang, Y. Su, W. Liu, C. Hung, S. Chang; Natl. Taiwan Univ.Hosp., Taipei, Taiwan.------------------------------------------------------------------------019(H)Poster SessionOpportunistic Infections and Co-Morbid Conditions inHIV-ISunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:H-219 Risk Factors of Invasive Pneumococcal Disease in HIV-Infected Patients in France from 2000-2011A. Munier 1 , V. De Lastours 1 , R. Porcher 1 , E. Varon 2 , J. Donay 1 , J. Molina 1 ;1Saint-Louis Hosp., Paris, France, 2 HEGP Hosp., Paris, France.H-220 Cryptococcal Meningitis in Patients with AIDS: ClinicalExperience in a Tertiary Care Teaching Hospital of PanamaE. González, A. B. Arauz, A. Rodriguez-French; Hosp. Santo Tomás,Panama, Panama.H-221 Hepatotoxicity Related to Use of Trimethoprim-Sulfamethoxazolein Treatment of Pneumocystis jirovecii Pneumonia in HIV-Infected Patients: Incidence and Associated FactorsJ. Yang, K. Lee, M. Tsai, C. Hung, S. Chang; Natl. Taiwan Univ. Hosp.,Taipei, Taiwan.H-222 Leishmaniasis as Cause of Immune Activation in HIV-InfectedPatientsJ. L. Casado, M. Abad, M. Del Palacio, M. J. Perez-Elías, A. Moreno, S.Moreno, A. Vallejo; Ramon y Cajal Hosp., Madrid, Spain.H-223 AIDS Related Toxoplasmic Encephalitis in the Era of AntiretroviralTherapy in JapanT. Kobayashi, K. Watanabe, K. Nishijima, H. Gatanaga, Y. Kikuchi, S. Oka;Natl. Ctr. for Global Hlth. and Med., Shinjuku-ku, Japan.H-224 Preemptive Therapy Prevents Cytomegalovirus End-Organ Diseasein Treatment-Naïve Patients with Advanced HIV-1 InfectionD. Mizushima, T. Nishijima, H. Gatanaga, K. Tsukada, K. Teruya,Y. Kikuchi, S. Oka; Natl. Ctr. for Global Hlth. and Med., Tokyo, Japan.H-225 Impact of an Antimicrobial Stewardship Team (AST) in theManagement of Hospitalized Patients with HIVA. Kunapuli, J. Nagel, T. Gandhi; Univ. of Michigan, Ann Arbor, MI.H-226 Etiologies of Pulmonary Complications of HIV-InfectedPatients in Taiwan in the Era of Combination AntiretroviralTherapy: A Prospective Observational StudyK. Lee 1 , D. Ji 2 , C. Hung 1 , S. Chang 1 ; 1 Natl. Taiwan Univ. Hosp., Taipei,Taiwan, 2 Ctr.s for Disease Control, Taipei, Taiwan.H-227 Etiology and Prognostic Factors of HIV-Infected PatientsAdmitted to an Intensive Care Unit in a 20-year PeriodA. Santos 1 , S. Xerinda 1 , C. Alves 1 , P. Figueiredo 1 , R. Poinhos 2 , M. Santos 1 ,A. Sarmento 1 ; 1 Hosp. S. João, Porto, Portugal, 2 Faculdade Ciências Nutrição,Porto, Portugal.50September 9-12 |

SUNDAY SCIENTIFIC SESSIONSH-228 In-Hospital Mortality from Acute Myocardial Infarction: HIVSero-Positive vs. Sero-Negative IndividualsD. D. Pearce 1 , C. Ani 2 , Y. Espinosa-Silva 3 , R. Clark 3 , K. Fatima 3 , M.Rahman 3 , E. Diebolt 3 , B. Ovbiagele 4 ; 1 Loma Linda Univ., Loma Linda,CA, 2 Charles Drew Univ., Compton, CA, 3 Western Univ. of Hlth. Sci., Coll.of Osteopathic Med. of the Pacific, Pomona, CA, 4 Univ. of California, SanDiego, San Diego, CA.H-229 Early Onset and Late Diagnosis of CAD in HIV+ PersonsC. Kaiser 1 , T. Chin 1 , S. Napravnik 2 , L. Yang 1 , M. Tipton 2 , J. Eron 2 , C.Hicks 1 ; 1 Duke Univ. Med. Ctr., Durham, NC, 2 UNC, Chapel Hill, NC.H-230 Comparison of Predicted Cardiovascular Disease Risk BetweenHIV-Infected and Non-Infected KoreansS. Kim, Y. Kim, M. Kim, J. Song, D. Oh, J. Ahn, N. Ku, H. Kim, S. Jeong,S. Han, C. Kim, Y. Song, J. Choi, J. Kim; Yonsei Univ. Coll. of Med., Seoul,Korea, Republic of.H-231 An Observational Study of Bone Status in HIV-InfectedPatientsL. Lemeunier 1 , N. Viget 1 , E. Biver 2 , B. Cortet 2 , E. Senneville 1 ; 1 TourcoingHosp., Tourcoing, France, 2 CHRU Lille, Lille, France.H-232 Psychiatric Disorders among HIV Patients in Southern Israel:A Comparison between African-Origin and Caucasian PopulationsI. Dotan, R. Toledano, D. Buskila, F. Schlaeffer, R. Smolyakov, L. Saidel-Odes, V. Novack, A. Borer, K. Riesenberg; Soroka Univ. Med. Ctr. (SUMC)and Faculty of Hlth. Sci., Ben Gurion Univ. of the Negev, Beer Sheva, Israel.------------------------------------------------------------------------020(K)Poster SessionAntibiotic Stewardship and UsageSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:K-233 Regional Antibiogram (ABG) of ESKAPE Pathogens: A NewDirection for Resistance Trends in Antimicrobial Stewardship(AMS)A. R. Caffrey 1,2 , H. J. Morrill 3 , K. M. Babcock 3 , J. Dworkin 4 , K. L.LaPlante 3,2 ; 1 Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI, 2 Univ.of Rhode Island, Coll. of Pharmacy, Kingston, RI, 3 Providence VA ID Res.Program, Providence, RI, 4 Brown Univ., Providence, RI.K-234 Control of the Prescription of Carbapenems in a French Hospital:Impact of the Hospital Antibiotic Management TeamC. Couzigou, J. C. Nguyen, B. Vidal, I. Tersen, J. Loriau, M. D. Kitzis;Hosp. Saint-Joseph, Paris, France.K-235 The Role of an Anti-Microbial Stewardship Program (ASP) inan Adult Renal DepartmentY. Cai, ASP Team (SGH), M. P. Chlebicki, A. L. Kwa; Singapore Gen.Hosp., Singapore, Singapore.K-236 Little Steps Towards Infection Control: Where There is a Will,There is a Way- Even in the NDM-1 Era!!A. Ghafur, V. P. R. Lakshmi, K. Chandra, S. Bharadwaj, M. Anna; ApolloHosp., Chennai, India.K-237 How Carbapenems are Used in French Health-Care Settingsin 2011?R. Gauzit 1 , Y. Pean 2 , S. Alfandari 3 , J. Bru 4 , J. P. Bedos 5 , C. Rabaud 6 , J.Robert 7 , SPILF, ONERBA; 1 Hotel-Dieu, Paris, France, 2 L’IMM, Paris,France, 3 CH, Tourcoing, France, 4 CH, Annecy, France, 5 CH, Versailles,France, 6 CHU, Nancy, France, 7 Faculte P&M Curie, Paris, France.K-238 Optimal Antibiotic Treatment in Hospitals- Meta-Analysisand ModelsP. Abel Zur Wiesch 1 , R. D. Kouyos 2 , S. Abel 1 , L. Laser 3 , S. Bonhoeffer 3 ;1Brigham and Women’s Hosp., Harvard Med. Sch., Boston, MA, 2 PrincetonUniv., Princeton, NJ, 3 ETH Zurich, Zurich, Switzerland.K-239 Costs of Outpatient Parenteral Antibiotic Therapy (OPAT)for the Management of Gram+ Acute Bacterial Skin and SoftTissue Infections (abSSTIs)A. Khachatryan 1 , V. Ektare 1 , M. Xue 1 , M. Dunne 2 , J. Stephens 1 ;1Pharmerit Intl., Bethesda, 2 Durata Therapeutics, Morristown, NJ.K-240 Implementation of a Collaborative Antimicrobial CultureFollow-Up Program in the Emergency Department (ED)L. E. Dumkow 1 , R. M. Chambers 1 , N. C. MacDonald 1 , J. J. Carreno 1,2 , M.K. Malhotra 1 , S. L. Davis 1,2 ; 1 Henry Ford Hosp., Detroit, MI, 2 Wayne StateUniv., Detroit, MI.K-241 Impact of a Pharmacy Driven Intervention to Reduce Time toInitiation of Empiric Antibiotic Therapy in Bacteremic PatientsT. E. Bias 1,2 , W. Vincent 2,1 , N. Trustman 2 , L. Berkowitz 1 , V. Venugopalan 1,2 ;1The Brooklyn Hosp. Ctr., Brooklyn, NY, 2 Arnold & Marie Schwartz Coll.of Pharmacy and Hlth. Sci. Long Island Univ., Brooklyn, NY.K-242 Early Intervention of Piperacillin/Tazobactam in the Accidentand Emergency Department at Sultan Qaboos UniversityHospital in Oman: A Boon or an Anathema?R. Vaishnav 1 , R. S. H. Al-Buridi 2,3 ; 1 Coll. of Med. & Hlth. Sci., SultanQaboos Univ., Al-Khod, Muscat, Oman, 2 Coll. of Med. & Hlth. Sci.,Al-Khod, Muscat, Oman, 3 Coll. of Med. & Hlth. Sci., Sultan QaboosUniv., Muscat, Oman.------------------------------------------------------------------------021(K)Poster SessionInfection Control and the EnvironmentSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:K-243 Will Environmental Disinfection Decrease Healthcare-Associated Infection (HAI)?: A Systematic ReviewH. Chen 1 , C. Yau 1 , A. Wong 1 , P. Ching 2 , W. Seto 2 ; 1 CHP, HKSAR, HongKong, 2 WHO Collaborative Ctr., HKSAR, Hong Kong.K-244 What to Breath?: Performance Analysis of Air Samplers inOperating RoomsL. Ummels 1 , D. Van de Vegt 1 , A. Voss 1,2 , J. Hopman 1 ; 1 Radboud Univ.Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 Canisius Wilhemina Hosp.,Nijmegen, Netherlands.Final Program51

Sunday SCIENTIFIC SESSIONSK-245 The Effect of Copper-Coated Surfaces on the EnvironmentalContamination by Pathogenic Bacteria in a Greek ICU: A ComparativeTrialM. Souli 1 , A. Antoniadou 1 , M. Droggari 1 , I. Mavrou 1 , A. Antonopoulou 1 ,G. Poulakou 1 , E. Papadomichelakis 1 , P. Efstathiou 2 , H. Giamarellou 3 , A.Armaganidis 1 , G. Petrikkos 1 ; 1 Univ. Gen. Hosp. ATTIKON, Chaidari,Greece, 2 Hellenic Copper Dev. Inst., Athens, Greece, 3 Hygeia Hosp., Marousi,Greece.K-246 Burden of Environmental Contamination by PathogenicBacteria in an ICU SettingM. Souli 1 , A. Antoniadou 1 , T. Panagea 1 , G. Petrikkos 1 , H. Giamarellou 2 ,A. Armaganidis 1 ; 1 Univ. Gen. Hosp. ATTIKON, Chaidari, Greece, 2 HygeiaHosp., Marousi, Greece.------------------------------------------------------------------------022(K)Poster SessionProsthetic Joint InfectionsSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:K-247 Targeted Use of Vancomycin (VAN) Perioperative Prophylaxisin Revision Total Knee Arthroplasty (RTKA) Reduces SurgicalSite Infections (SSI)C. Liu, L. Block, A. Kakis A. Nichols, S. Takemoto, K. Bozic; Univ. of California,San Francisco, CA.K-248 Characteristics of Prosthetic Joint Infections Leading toBacteremiaF. A. Dauchy 1 , H. Dutronc 1 , S. Lawson-Ayayi 2 , P. Hofmann 1 , T. Fabre 1 ,B. de Barbeyrac 1 , M. Dupon 1 ; 1 Bordeaux Univ. Hosp., Bordeaux, France,2INSERM U897, ISPED, Bordeaux, France.K-249 Not Following the Surgical Zimmerli’S Algorithm in Patientswith Methicillin-Susceptible S. aureus Prosthetic Joint Infection(Hip and Knee) is a Risk Factor for Treatment Failure at Long-Term Follow UpA. Bouaziz 1 , I. Uçkay 2 , S. Lustig 1 , A. Boibieux 1 , D. Lew 2 , P. Hoffmeyer 2 ,P. Neyret 1 , C. Chidiac 1 , T. Ferr y 1 ; 1 Hospices Civils de Lyon, Lyon, France,2Hosp. Univ. de Genève, Geneva, Switzerland.K-250 Infection and Functional Outcome of Hip and Knee ProstheticJoint Infection: A Retrospective Multicenter StudyL. N. Walti 1 , C. Cattelan 2 , R. Baalbaki 1 , M. Veuthey 1 , S. Meriem 1 , O.Borens 1 , A. Trampuz 1 ; 1 Univ. Hosp., Lausanne, Switzerland, 2 Univ. Hosp.,Basel, Switzerland.K-251 Impact of Interdisciplinary Septic Unit: On TreatmentOutcome of Hip and Knee Prosthetic Joint InfectionT. Tkhilaishvili, L. N. Walti, R. Balbaaki, M. Veuthey, S. Meriem, O.Borens, A. Trampuz; Univ. Hosp., Lausanne, Switzerland.K-252 Tissue Expander-Related Infections: Perioperative andEmpiric Antimicrobial TherapyG. M. Viola, K. V. Rolston, D. P. Baumann; MD Anderson Cancer Ctr.,Houston, TX.K-253 Microbiological Markers Suggesting High Inoculum Sizeat Time of Surgery are Risk Factors for Relapse in Patients withMethicillin-Susceptible or -Resistant S. aureus Prosthetic JointInfectionA. Bouaziz 1 , I. Uçkay 2 , S. Lustig 1 , A. Boibieux 1 , D. Lew 2 , P. Hoffmeyer 2 ,P. Neyret 1 , C. Chidiac 1 , T. Ferr y 1 ; 1 Hospices Civils de Lyon, Lyon, France,2Hosp. Univ. de Genève, Geneva, Switzerland.K-254 Infected Hip Hemiarthroplasties (IHHA) and Total HipArthroplasties (ITHA): Differences in Clinical Characteristicsand PrognosisJ. Lora-T, G. Euba, O. Murillo, A. Ribera, S. Pedrero, F. Tubau, M. Pujol, X.Cabo, J. Ariza; Hosp. U Bellvitge, Barcelone, Spain.K-255 Methicillin-Susceptible Staphylococcus aureus ST398: GeneticBackground Comparison Between Nasal Carriage and ProstheticJoint Infection IsolatesG. G. Aubin 1,2 , C. Lasserre 1,2 , N. Caroff 2 , D. Lepelletier 1,2 , A. Reynaud 1,2 ,J. Lavigne. 3 , S. Corvec 1,2 ; 1 Nantes Univ. Hosp., Nantes, France, 2 Med. Sch.,Nantes, France, 3 Montpellier Univ., Nîmes, France.K-256 Acute Prosthetic Joint Infections (PJI): Current Etiology,Treatment, Outcome and Functional ResultsN. Benito, M. Franco, M. Jordán, V. Pomar, J. López-Contreras, P. Coll, J.Monllau, M. Gurguí; Hosp. de la Santa Creu i Sant Pau, Barcelona, Spain.K-257 Risk Factors Associated with Unfavorable Clinical Outcome(UCO) During Hospitalization for Initial Treatment of PrimaryTotal Hip Arthroplasty Infection (PHAI) in BrazilJ. A. Matos, C. A. S. Schmaltz, N. M. Mesquita, I. Barauna, J. H. Carijó, R.W. Beranger; Inst. Nacional de Traumatologia e Ortopedia, Rio de Janeiro,Brazil.K-258 Prosthetic Joint Infection (PJI) Should be Considered inProsthetic Failure Within 2 Years of ImplantationM. E. Portillo 1 , A. Alier 2 , S. Martinez 2 , L. Sorli 2 , J. Horcajada 2 , M. Salvado1 , L. Puig 2 ; 1 Reference Lab. of Catalunya, Barcelona, Spain, 2 Hosp. delMar, Barcelona, Spain.------------------------------------------------------------------------023(K)Poster SessionSurgical Site InfectionsSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:K-259 Characterizing Staphylococcus aureus Infections FollowingElective Surgeries in U.S. HospitalsH. Yu, J. Mardekian, D. Strutton, D. Girgenti; Pfizer, Inc., Collegeville, PA.K-260 Utilising Routine Electronic Data to Develop Syndromic Surveillanceof Surgical Site Infections in Coronary Artery BypassGraft PatientsWithdrawnK-261 Microbiology of Postoperative Spine Infections: A RetrospectiveStudy of 239 CasesC. Liu, A. Abdul-Jabbar, S. Takemoto, S. Hu, S. Berven; Univ. of California,San Francisco, CA.K-262 Surgical-Site Infections Following Gender ReassignmentSurgeriesJ. J. Zhao, D. Marchaim, M. Palla, K. Hayakawa, R. Tansek, J. Moshos, A.Muthusamy, H. Kotra, P. R. Lephart, A. N. Wilson, K. S. Kaye; Wayne StateUniv., Detroit, MI.52September 9-12 |

SUNDAY SCIENTIFIC SESSIONSK-263 Risk Factors for Abdominal Prosthetic Aortic Graft Infections(APAGI)M. Kestler, P. Gijón, M. Izquierdo, A. Apodaka, T. Cervera, E. Bouza; Hosp.G. U. Gregorio Marañon., Univ. of Madrid, Madrid, Spain.K-264 A Prospective Study to Determine the Incidence and MicrobialEtiology of Surgical Site Infections at a Private Hospital inMumbai, IndiaWithdrawnK-265 Rapidly Growing Mycobacterial Infections ComplicatingLaparoscopic Adjustable Gastric BandingD. G. McLellan 1 , S. Watson 2 , J. Dyer 1 , V. D’Abrera 2 ; 1 Fremantle Hosp.,Fremantle, Australia, 2 St. John of God Healthcare Murdoch, Perth, Australia.K-266 Emergence of a Dominant Healthcare-Associated Clone ofMycobacterium abscessus subsp. bolletii at a Medical CenterA. Cheng, H. Sun, Y. Chuang, S. C. Chang, Y. C. Chen; Natl. Taiwan Univ.Hosp. and Far Eastern Mem. Hosp., Taipei, Taiwan.K-267 Success in Preventing Staphylococcus aureus Mediastinitis afterCoronary By-Pass SurgeryJ. Chapplain, M. Revest, E. Flecher, P. Donnio, C. Michelet, A. Leguerrier;Rennes Univ. Hosp., Rennes, France.K-268 Surgical Site Infection Surveillance of Esophageal and LungCancer in Thoracic SurgeryH. Xu, W. Li, Y. Wang, Q. Zhu, L. Jia, A. M. Gu; Provincial Hosp.Affiliated to Shandong Univ., Jinan, China.K-269 Effects of Antimicrobial-Coated Sutures in Reducing SurgicalSite Infection: A Meta-Analysis of Randomized Controlled TrialsQ. Zhou 1 , X. Gao 2 , B. Hu 2 ; 1 Zhongshan Hosp., Fudan Univ., Shanghai,China, 2 Zhongshan Hosp., Fudan Univ., Need, China.------------------------------------------------------------------------024(K)Poster SessionVancomyoin-Resistant EnterococciSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:K-270 Incidence of and Risk Factors for Patients in Intensive CareUnits to Acquire Infection or Colonization of Vancomycin-ResistantEnterococciS. Pan, J. Wang, Y. Chen, S. Chang; Natl. Taiwan Univ. Hosp., Taipei,Taiwan.K-271 De-Escalation of Broad Spectrum Antibiotics in EnterococcalBloodstream Infections According to VRE ColonizationE. Short 1 , M. Griffith 2,1 , J. Esterly 1,3 , M. Postelnick 1 ; 1 Northwestern Mem.Hosp., Chicago, IL, 2 Midwestern Univ., Downers Grove, IL, 3 Chicago StateUniv., Chicago, IL.K-272 The Impact of Different Antimicrobial Therapies on Clinicaland Fiscal Outcomes of Patients with Bacteremia Due toVancomycin-Resistant EnterococciK. Hayakawa, D. Marchaim, U. M. Gudur, D. Dalle, K. Alshabani, S.Mohin, F. Jaydev, P. R. Sundaragiri, P. Bathina, S. D. Rajuri, K. S. Muppavarapu,J. K. Khatri, P. R. Lephart, E. T. Martin, J. M. Pogue, M. J. Rybak, K. S.Kaye; Detroit Med. Ctr. (DMC), Wayne State Univ., Detroit, MI.K-273 Characteristics of Enterococcus Species Isolated from Patientsat a Solid Organ Transplant Unit in a Tertiary Care UniversityHospital Between 2000 and 2011G. Tulliano, P. M. Tierno, L. W. Teperman, R. A. Press, A. Safdar; NewYork Univ. Sch. of Med. and Langone Med. Ctr., New York, NY.K-274 An Analysis of the Use of Ampicillin for Urinary Tract InfectionsCaused by Vancomycin-Resistant EnterococcusJ. Shultz 1 , K. Klinker 1 , S. Borgert 1 , R. Ramphal 2 ; 1 Shands at the Univ. ofFlorida, Gainesville, FL, 2 Univ. of Florida, Gainesville, FL.K-275 High-Dose Daptomycin for Treatment of Enterococcal Infections:Multicenter, Retrospective StudyA. M. Casapao 1 , S. L. Davis 1 , D. P. Levine 2 , J. J. Zhao 2 , B. A. Potoski 3 , D.A. Goff 4 , C. W. Crank 5 , J. Segreti 5 , G. Sakoulas 6 , S. E. Cosgrove 7 , M. J.Rybak 1 ; 1 Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI, 2 DetroitMed. Ctr., Detroit, MI, 3 Univ. of Pittsburgh, Pittsburgh, PA, 4 Ohio StateUniv., Columbus, OH, 5 Rush Univ., Chicago, IL, 6 Univ. of California, LaJolla, CA, 7 Johns Hopkins, Baltimore, MD.K-276 Daptomycin (D) with or without Concomitant Beta-lactams(BL) for Vancomycin-Resistant Enterococcus (VRE) BacteremiaP. A. Moise 1 , K. C. Lamp 1 , D. D. DePestel 1 , M. J. Yoon 1 , M. Zervos2; 1 Cubist Pharmaceuticals, Lexington, MA, 2 Henry Ford Hlth. System,Detroit, MI.K-277 Daptomycin Experience for Enterococcal EndocarditisJ. C. Gallagher 1 , P. White 2 , J. Kishel 2 , T. Chung 2 ; 1 Temple Univ. Sch. ofPharmacy, Philadelphia, PA, 2 Cubist Pharmaceuticals, Lexington, MA.K-278 Identification of Risk Factors Associated with the Developmentof Daptomycin Nonsusceptible EnterococcusA. M. Pavell 1,2 , C. W. Crank 1 , S. Wang 1,2 , K. S. Singh 1 ; 1 Rush Univ. Med.Ctr., Chicago, IL, 2 Midwestern Univ., Downers Grove, IL.K-279 Reduced Daptomycin Susceptibility (MIC 3-4 mcg/ml)Among Vancomycin-Resistant Enterococci Blood-Stream IsolatesN. Pettit, B. Brielmaier, J. Pisano, E. Landon; Univ. of Chicago Med. Ctr.,Chicago, IL.K-280 Case Series of Daptomycin Nonsusceptible EnterococcusUrinary Tract Infections in a Tertiary CenterT. Kelesidis 1 , S. Tsiodras 2 , R. Humphries 1 ; 1 UCLA, Los Angeles, CA 2 Univ.of Athens Med Sch., Athens, Greece.K-281 Selection of Vancomycin Resistance from vanA-ContainingEnterococcus faecium Susceptible to VancomycinA. Loughborough 1 , B. M. Willey 1,2 , M. Kissoon 1 , S. Patel 3,4 , A. McGeer 1,4 ,D. E. Low 1,4,2 , S. M. Poutanen 1,2,4 ; 1 Mount Sinai Hosp., Toronto, Canada,2Univ. Hlth. Network, Toronto, Canada, 3 Publ. Hlth. Ontario, Toronto,Canada, 4 Univ. of Toronto, Toronto, Canada.Final Program53

Sunday SCIENTIFIC SESSIONS------------------------------------------------------------------------025(L1)Poster SessionAntimicrobial Stewardship and OPATSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:L1-282 Use of Conditional and Cumulative Susceptibility Reportingto Improve Antibiotic Prescribing and Rates of Initial AppropriateAntibiotic TherapyS. C. Cheatham 1 , S. S. Utley 1 , M. R. Fleming 2 ; 1 St. Francis Health, Indianapolis,IN, 2 Methodist Dallas Med. Ctr., Dallas, TX.L1-283 De-Escalation of Antibacterial Therapy in Urinary TractInfections: A Neglected Opportunity to Save Broad-SpectrumAgentsE. Montassier, E. Duchene, J. Caillon, G. Potel, E. Batard; Univ. de Nantes,Nantes, France.L1-284 The Incidence of Antimicrobial Associated Adverse EventsDuring Outpatient Parenteral Antimicrobial Therapy (OPAT): AOne Year Retrospective ReviewI. El Lakkis, J. Mackey, M. Albrecht, R. Jambeih, E. Ablah, M. Sandid, K.Konda, M. Assi; Univ. of Kansas Sch. of Med. Wichita, KS.L1-285 Antibiotic Consumption in the Emergency Department: A10-Year SurveyE. Montassier, D. Navas, N. Goffinet, C. Gras-Le Guen, G. Potel, E.Batard; Ctr. Hosp. Univ. de Nantes, Nantes, France.L1-286 Antibiotic Algorithm Use in Sepsis: Adherence and Effectivenessin the Emergency DepartmentT. C. Kam 1 , A. M. Cook 1 , J. L. Lock 1 , W. E. Swigart 1,2 , C. P. Bunce 1,3 ; 1 St.Vincent Hosp., Indianapolis, IN, 2 St. Vincent Emergency Physicians, Inc.,Indianapolis, IN, 3 Infectious Disease of Indiana, Carmel, IN.L1-287 A Comparison of Ertapenem Versus Ceftriaxone for theTreatment of Cellulitis in the OPAT SettingR. Santos 1 , A. Mayhew 1 , D. Andrews 2 , A. L. Chapman 2 , M. Torok 3 ;1Cambridge Univ. Hosp. NHS Fndn. Trust, Cambridge, United Kingdom,2Royal Hallamshire Hosp., Sheffield, United Kingdom, 3 Univ. of Cambridge,Cambridge, United Kingdom.L1-288 Outpatient Parenteral Antibiotic Therapy (OPAT): Experiencefrom a UK Teaching HospitalS. V. Coggle 1 , E. Nickerson 1 , T. Gouliouris 1 , T. Corrah 1 , A. Mayhew 1 , R.Santos 1 , S. H. Aliyu 1 , A. J. Carmichael 1 , M. E. Torok 2 ; 1 Cambridge Univ.Hosp. NHS Fndn. Trust, Cambridge, United Kingdom, 2 Univ. of Cambridge,Cambridge, United Kingdom.------------------------------------------------------------------------026(L1)Poster SessionRespiratory Tract InfectionSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:L1-289 In Routine Hospital Practice: Ertapenem in Comparison withOther Parenteral Antibiotics in the Treatment of Community-Acquired PneumoniaC. Hidalgo Tenorio, C. Santiago, A. Fernandez, C. Gil, V. Sotorrio, I. Sanchez,C. Merin, A. Caballero, R. Javier, J. Pasquau Liaño; Univ. Hosp Virgende las Nieves, Granada, Spain.L1-290 Inter-Country Differences in Microbiological Testing andDiagnoses for CAP in Hospitalized Patients: Results from theEuropean REACH StudyF. Blasi 1 , J. Garau 2 , J. Medina 3 , M. Ávila 4 , K. McBride 5 , H. Ostermann 6 ;1Univ.ersità degli Studi di Milano, Milan, Italy, 2 Hosp. Univ.ersitari Mutua deTerrassa, Barcelona, Spain, 3 AstraZeneca, Madrid, Spain, 4 AstraZeneca Europe,Zaventem, Belgium, 5 Instat Services, Inc., Chatham, NJ, 6 Univ. Hosp.Munich, Munich, Germany.L1-291 Better Impact of Combination Therapy with Macrolides inICU Patients with Community-Acquired PneumoniaJ. Y. Mootien, C. Fuchs, D. Narbey, M. Egard, P. Guiot; Hosp E. Muller,Mulhouse, France.L1-292 Clinical Response Rate at Day 4 of Therapy in HospitalizedAdult Patients with Community-Acquired Bacterial Pneumonia(CABP): An Interim Analysis of a Chart Review StudyR. Luo 1 , C. B. Lipkin 1 , F. R. Ernst 1 , X. Huang 2 ; 1 Premier, Charlotte, NC,2Forest Res. Inst., Jersey City, NJ.L1-293 Rainfall is a Risk Factor for Legionella pneumophila PneumoniaM. Labori, C. Garcia-Vidal, D. Viasus, L. Molero, D. Garcia-Somoza, J.Dorca, F. Gudiol , J. Carratala; Hosp. Univ. de Bellvitge, Barcelona, Spain.L1-294 A Phase 2, Multi-Dose, Double-Blind, Randomized, Multicenter,Comparative Study of Zabofloxacin vs Moxifloxacin in theTreatment of Mild to Moderate Community-Acquired PneumoniaD. Choi 1 , Y. S. Kim 2 , M. J. Kim 3 , K. R. Back 4 , C. H. Lim 1 , J. A. Rock 5 , S.K. Seoung 1 ; 1 Dong-Wha Pharm., Yongin-si, Gyunggi-do, Korea, Republicof, 2 Asan Med. Ctr., Pungnap 2-dong, Songpa-gu, Seoul, Korea, Republic of,3Korea Univ. Anam Hosp., Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, Korea,Republic of, 4 Samsung Med. Ctr., Irwon-dong, Gangnam-gu, Seoul, Korea,Republic of, 5 IASO Pharma Inc., San Diego, CA.L1-295 Is it Possible to Identify Legionella pneumophila Pneumoniafrom Initial Presentation on Emergency Room?C. Garcia-Vidal, D. Viasus, M. Labori, L. Molero, D. Garcia-Somoza, J.Dorca, F. Gudiol , J. Carratala; Hosp. Univ. De Bellvitge, Barcelona, Spain.L1-296 Dichotomy between In Vitro Activity and Clinical Outcome:Does Azithromycin (AZM) Demonstrate Clinical Efficacy inMacrolides Resistant Pneumococcal Pneumonia?K. Tateda, S. Kohno, M. Nagashima; AZM Studies Data Review Committee,Tokyo, Japan.L1-297 The Impact of Statins on the Incidence of Bacteremia andPneumonia in Military PersonnelK. R. Daniels 1 , I. A. Mansi 2 , J. P. Magulick 2 , C. U. Oramasionwu 3 , E. M.Mortensen 4 , M. V. Pugh 5 , C. R. Frei 1 ; 1 UT Austin & UT Hlth. Sci. Ctr.,San Antonio, TX, 2 San Antonio Military Med. Ctr., San Antonio, TX, 3 Univ.North Carolina, Chapel Hill, NC, 4 UT Southwestern, Dallas, TX, 5 VER-DICT, South TX Vet. Hlth. Care Syst, San Antonio, TX.L1-298 Usefulness of IDSA/ATS Guidelines Recommendations forDiagnostic Testing in Community-Acquired PneumoniaD. Viasus, C. Garcia-Vidal, J. Dorca, F. Gudiol, J. Carratalà; Hosp. deBellvitge - IDIBELL, Univ. of Barcelona, L`Hosp. de Llobregat, Barcelona,Spain.54September 9-12 |

SUNDAY SCIENTIFIC SESSIONSL1-299 A Randomized Comparative Study of 7-Days Courses ofFuzafungine vs. Fuzafungine and Clarithromycin in Patients withAcute LaryngitisV. V. Rafalskiy 1 , A. S. Gurevitch 2 , I. V. Otvagin 1 , E. V. Dovgan 1 ; 1 SmolenskState Med. Academy, Smolensk, Russian Federation, 2 Bryansk Clinical andDiagnostic Ctr., Bryansk, Russian Federation.L1-300 Effect of LactoBacillus Rhamnosus LGG and Bifidobacteriumanimalis ssp Lactis BB-12 on Health-Related Quality of Life inCollege Students with Upper Respiratory InfectionsT. J. Smith, D. Rigassio-Radler, R. Denmark, R. Touger-Decker; Univ. ofMed. and Dentistry of New Jersey, Newark, NJ.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------027(L2)Poster SessionStudies in Sexually Transmitted InfectionSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:L2-301 Prevalence and Correlates of Vaccine-Preventable Anal HumanPapillomavirus Genotypes in Australian Homosexual MenD. J. Templeton 1 , S. N. Tabrizi 2 , D. A. Machalek 1 , F. Jin 1 , I. M. Poynten 1 ,T. Tabone 2 , S. M. Garland 2 , R. J. Hillman 3 , C. K. Fairley 2 , J. Roberts 4 ,A. Farnsworth 4 , A. E. Grulich 1 , on behalf of the SPANC Research Team;1Kirby Inst., Univ. of New South Wales, Sydney, Australia, 2 Univ. of Melbourne,Melbourne, Australia, 3 Univ. of Sydney, Sydney, Australia, 4 DouglassHanly Moir, Sydney, Australia.L2-302 Oropharyngeal Squamous Cell Carcinoma and HumanPapillomavirus-Associated Cancers in WomenJ. Guillet 1 , S. Bevilacqua 2 , P. Bravetti 3 , J. Merlin 4 , T. May 2 , G. Dolivet 1 ;1Ctr. Alexis Vautrin, Vandoeuvre Les Nancy, France, 2 CHU Nancy, VandoeuvreLes Nancy, France, 3 Faculté d’Odontologie, Nancy, France, 4 FacultéPharmacie, Nancy, France.L2-303 Antimicrobial Susceptibility and Molecular Characterizationof Neisseria gonorrhoeae Strains Isolated in 2011 from Barcelona,SpainJ. Serra 1 , G. Roig 2 , R. Juve 3 , J. Gonzalez-Lopez 1 , C. Paz, Technician 1 ,D. Viu, Technician 1 , A. Andreuer 1 , M. Barberà 4 ; 1 Hosp. Vall d’Hebron,Barcelona, Spain, 2 Manso Primary Care Ctr., Barcelona, Spain, 3 MansoPrimary Care Ctr. 2, Barcelona, Spain, 4 Sexually Transmitted Infectious Unit,Barcelona, Spain.L2-304 Evaluation of HPV Infection in Adolescent Girls Aged 13-19YearsS. Esposito 1 , E. Tanzi 2 , V. Montinaro 1 , S. Bosari 1 , P. Bertuccio, BSc 3 , G.Rizzardini 4 , G. Tisi 5 , M. Tinelli 6 , N. Manca 7 , M. Gramegna 8 , G. Orlando 4 ,Valhidate Study Group; 1 Fondazione IRCCS Policlinico, Univ. degli Studidi Milano, Milan, Italy, 2 Univ. Milan, Milan, Italy, 3 Istituto di RicercheFarmacologiche Mario Negri, Milan, Italy, 4 Infectious Diseases II, L. SaccoUniv. Hosp, Milan, Italy, 5 Gynecol Oncol Unit, Univ. of Brescia, Brescia,Italy, 6 Infect Dis Unit, Lodi Hosp, Lodi, Italy, 7 Microbiol Unit, Brescia, Italy,8Hlth. Gen. Director, Regione Lombardia, Milan, Italy.L2-305 Once a Day Versus Twice a Day Sitafloxacin (STFX) forMicrobiological Cure of Women with Cervicitis by ChlamydiatrachomatisH. Mikamo, Y. Yamagishi; Aichi Med. Univ., Aichi, Japan.L2-306 Vaginitis Co-Infections Based on DNA Homology: 2 YrsExperience at a Tertiary Medical CenterA. Bhargava 1 , R. Mitchell 2 , T. Painter 2 , P. Lephart 2 , A. Salimnia 1 , N. Balic 1 ,M. Fairfax 1 , H. Salimnia 2 , J. Sobel 1 ; 1 WSU, Detroit, MI, 2 Detroit Med. Ctr.Univ. Lab., Detroit, MI.L2-307 Epidemiology of Genital Varicella Zoster and Herpes SimplexVirusesK. Choong 1 , C. Henderson 2 , J. M. Robson 2 ; 1 Nambour Hosp., Nambour,Australia, 2 Sullivan Nicolaides Pathology, Brisbane, Australia.L2-308 Genetic and Molecular Epidemiologic Correlates of CephalosporinResistance in Neisseria gonorrhoeae, California 2011S. Gose 1 , C. J. Kong 2 , S. Guerry 3 , M. Pandori 4 ; 1 Univ. of California,Berkeley, Berkeley, CA, 2 California Dept. of Publ. Health, Richmond, CA,3Los Angeles Dept. of Publ. Health, Los Angeles, CA, 4 San Francisco Dept.of Publ. Health, San Francisco, CA.L2-309 Molecular Epidemiology of Chlamydia trachomatis InfectionAmong Clients Seeking Voluntary Counseling and Testing forHIV in TaiwanP. Wu 1 , C. Yang 2 , S. Chang 3 , W. Liu 1 , C. Hung, MSc 1 ; 1 Natl. Taiwan Univ.Hosp., Taipei, Taiwan, 2 Far Eastern Mem. Hosp., New Taipei City, Taiwan,3Natl. Taiwan Univ. Coll. of Med., Taipei, Taiwan.L2-310 Effect of Sexual Intercourse on Vaginal Microbiome of InfertileCouples’ Women (Data of Illumina Sequencing)R. Mändar 1,2 , J. Truu 1,2 , N. Borovkova 1,2 , M. Punab 1,2,3 ; 1 Univ. of Tartu,Tartu, Estonia, 2 Competence Ctr. on Reproductive Med. and Biology, Tartu,Estonia, 3 Tartu Univ. Hosp., Tartu, Estonia.------------------------------------------------------------------------028(M)Poster SessionFungal EpidemiologySunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:M-311 Antifungal Susceptibility Profile and Predominance of Non-Candida albicans Isolates in Bloodstream Yeasts Isolated fromPeruvian PatientsB. Bustamante 1 , M. A. Martins 2 , L. X. Bonfietti 2 , M. W. Szeszs 2 , J.Jacobs 3 , M. S. C. Melhemer 2 ; 1 I Tropical Alexander von Humboldt-Univ.Peruana Cayetano Heredia, Lima, Peru, 2 Instituto Adolfo Lutz, Sao Paulo,Brazil, 3 Central Lab. of Clinical Biology, Dept. of Clinical Sci. TropicalPrince Leopold,, Amberes, Belgium.M-312 Increase of Candidemia Due to Non-albicans Candida Speciesin Oncohematological (OH) Patients in SpainI. Ruiz-Camps, Mireia Puig, Patricia Muñoz, Mario Fernández-Ruiz,Alberto Delgado-Iribarren, Maricela Valerio, José M Aguado; on behalfof CANDIPOP Project, GEIH-GEMICOMED (SEIMC) and REIPI.,Barcelona, Spain.M-313 The Epidemiology of Nosocomial Candidemia in Nonneutropenic,Nonintensive Care-Based PatientsA. T. L. Ong 1 , C. C. Blyth 2 , E. G. Playford 3 , S. C. Chen 1 , T. C. Sorrell 1 ;1Westmead Hosp., Sydney, Australia, 2 Univ. of Western Australia, Sydney,Australia, 3 Princess Alexandra Hosp., Brisbane, Australia.Final Program55

Sunday SCIENTIFIC SESSIONSM-314 Geographic Distribution and Co-Morbidities of CryptococcalMeningitis in the U.S., 1997-2009V. Pyrgos, A. E. Seitz , R. Prevots, P. R. Williamson; NIH, Bethesda, MD.M-315 Electronic Surveillance of Invasive Fungal Diseases in Hematology-OncologyPatients Using Natural Language Processing ofComputed Tomography Reports: Towards Real-Time ProspectiveSurveillanceM. Ananda-Rajah 1 , D. Martinez 2 , H. Suominen 3 , K. Thursky, FRACP 4 ,M. Slavin, FRACP 4 , L. Cavedon 2 ; 1 Alfred Hlth., Melbourne, Australia,2NICTA, Melbourne, Australia, 3 NICTA, Canberra, Australia, 4 MelbourneHlth., Melbourne, Australia.M-316 Molecular Epidemiology and Fluconazole Susceptibility ofCandida glabrata Candidemia at a University Affiliated MedicalCenterN. D. Beyda 1,2 , A. Kilic Scientist 1 , M. J. Alam 1 , T. M. Lasco 2 , K. W. Garey 1,2 ;1Univ. of Houston Coll. of Pharmacy, Houston, TX, 2 St. Luke’s EpiscopalHosp., Houston, TX.M-317 Candidemia in Internal Medicine Wards (iIMW): Epidemiology,Time to Initiate Antifungal Treatment and OutcomeM. Bassetti 1 , E. Righi 1 , E. Nicco 2 , L. Taramasso 2 , C. Viscoli 2 ; 1 SantaMaria Misericordia Hosp., Udine, Italy, 2 San Martino Hosp., Genova, Italy.M-318 National Surveillance of Fungemia in Denmark 2010-11M. C. Arendrup, Danish Fungaemia Study Group; Statens Serum Inst.,Copenhagen, Denmark.M-319 Continued Increase of Azole Resistance in Aspergillus fumigatus(Af ) in Dutch HospitalsD. Versteeg, E. Snelders, T. Rijs, BSc - research, W. Melchers, P. Verweij;Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.M-320 Development of Resistance to Agricultural Azole AntifungalCompounds: Emergence of Multidrug Cross-Resistance AmongHuman Fungal Pathogens Candida, Cryptococcus and AspergillusI. Faria-Ramos 1 , S. Farinha 1 , P. Tavares 1 , J. Maia 1 , E. Ricardo 1,2 , I. M.Miranda 1,2 , C. Pina-Vaz 1,2,3 , A. G. Rodrigues 1,2,3 ; 1 Univ. of Porto, Oporto,Portugal, 2 Cardiovascular Res. & Dev. Unit, Faculty of Med., Univ. of Porto,Porto, Portugal, 3 Hosp. S. João, Porto, Portugal.M-321 Population-Based Program of Aspergillus spp. AntifungalResistance in Spain (FILPOP STUDY )A. Alastruey-Izquierdo 1 , E. Mellado 1 , T. Pelaez 2 , J. Peman 3 , S. Zapico 4 ,M. Alvarez 5 , M. Cuenca-Estrella 1 , FILPOP Study Group; 1 Centro Nacionalde Microbiologia, ISCIII, Majadahonda. Madrid, Spain, 2 Hosp. GregorioMarañón, Madrid, Spain, 3 Hosp. La Fe, Valencia, Spain, 4 Hosp. de Donostia,Guipuzcoa, Spain, 5 Hosp. Central de Asturias, Oviedo, Spain.M-322 Epidemiology of Otomycosis in a Large Teaching HospitalOver a 24-Year Period: Is There Any Difference Between Adultand Pediatric Patients?T. Peláez, S. Álvarez-Pérez, L. Alcalá, B. Gama, BSc, F. Romero, E. Bouza;Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.M-323 Emerging Trends in Candidemia by C. glabrata: A Better Outcomein a Worse SettingWithdrawnM-324 Influence of Voriconazole (VRC) on Survival Outcome ofTrichosporonemia: Result Epidemiological Study in JapanI. Tokimatsu, H. Kushima, S. Toba, J. Kadota, Japan Trichosporonosis StudyGroup; Oita Univ. Faculty of Med., Yufu, Japan.M-325 Risk Factors and Epidemiology of Candidemia by CandidaguilliermondiiY. Yamagishi, H. Mikamo; Aichi Med. Univ., Aichi, Japan.M-326 The Defined Daily Dose (DDD) of Micafungin Usage Didn’tAffect Incidence of Candida parapsilosis Candidemia at TertiaryHospital in JapanY. Hirai, S. Asahata, Y. Ainoda, H. Konishi, K. Okada, T. Fujita, K. Totsuka;Tokyo Women’s Med. Univ., Tokyo, Japan.M-327 Species Distribution and Susceptibility Profile of YeastsIsolated from Blood Cultures: Preliminary Results of a MulticenterStudy for Latin AmericaS. Córdoba 1 , M. Melhem 2 , M. Dolande 3 , A. Puimé 4 , G. Martínez 5 , S.Zurita 6 , M. Cuenca-Estrella 7 , J. Rodríguez-Tudela 7 , J. Gabastou 8 , RLN;1INEI, Buenos Aires, Argentina, 2 IAL, SP, Brazil, 3 INHRR, Caracas,Venezuela, Bolivarian Republic of, 4 DLSP, Montevideo, Uruguay, 5 IPK,LH, Cuba, 6 INS, Lima, Peru, 7 ISC III, Majadahonda, Spain, 8 PAHO, SJO,Trinidad and Tobago.M-328 Investigation on Isolation of Trichosporon Species in ClinicalPracticeY. Yamagishi 1 , N. Kawasumi 1 , M. Hagihara 1 , T. Sugita 2 , H. Mikamo 1 ;1Aichi Med. Univ., Aichi, Japan, 2 Meiji Pharmaceutical Univ., Tokyo, Japan.M-329 Effect of Statin Use on the Outcomes of Adults withCandidemiaG. Cuervo, C. Garcia-Vidal, M. Nucci, F. Puchades, M. Fernandez-Ruiz, A.Mykietiuk, A. Manzur, C. Gudiol, J. Peman, J. Ayats, J. Carratala; Hosp. deBellvitge, Barcelona, Spain.M-330 New CLSI Clinical Breakpoints (CBPs) and EpidemiologicalCutoff Values (ECVs) Applied to Characterize Resistance (R) inthe SENTRY Antifungal Surveillance Program (2010-2011)M. A. Pfaller, S. A. Messer, R. N. Jones, M. Castanheira; JMI Lab., NLiberty, IA.M-331 In Vitro Activity of Isavuconazole against CryptococcusIsolates: A Pooled Analysis from 3 StudiesJ. I. Smart 1 , M. E. Jones 2 , L. L. Kovanda, N/A 1 ; 1 Astellas Pharma GlobalDev., Inc, Deerfield, IL, 2 Basilea Pharmaceutica Intl. Ltd., Basel, Switzerland.M-332 In Vitro Activity of Isavuconazole against a Worldwide Collectionof 237 Aspergillus Section Terrei Isolates and Comparedwith 7 Other Aspergillus Active Antifungal Drugs Tested withEUCAST and CLSI MethodologyJ. F. Meisant 1,2 , J. W. Mouton 2 , J. P. Bouchara 3 , A. Chakrabarti 4 , P.Gaustad 5 , J. V. Guinea-Ortega 6 , J. Houbraken 7 , R. A. Samson 7 , K. Grif 8 ,C. Lass-Floerl 9 , C. H. Klaassen 1 ; 1 Canisius-Wilhelmina Hosp., Nijmegen,Netherlands, 2 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands,3Univ. Angers, Angers, France, 4 Postgrad. Inst. Med.Res., Chandigarh, India,5Univ. Hosp. Oslo, Oslo, Norway, 6 Hosp. Gen. Univ. Gregorio Marañón,Madrid, Spain, 7 CBS-KNAW Fungal Biodiversity Ctr., Utrecht, Netherlands,8 Med. Univ. Innsbruck, Innsbruck, Austria, 9 Med. Univ. Innsbruck,Innsbruck, Austria.56September 9-12 |

SUNDAY SCIENTIFIC SESSIONSM-333 Absence of Pneumocystis DHPS Mutants in Brittany,Western FranceS. Le Gal 1 , F. Gangneux 2 , C. Damiani 3 , M. Virmaux 1 , A. Totet 3 , J.Gangneux 2 , G. Nevez 1 ; 1 Univ. de Brest, Brest, France, 2 Univ. de Rennes,Rennes, France, 3 Univ. de Picardie, Amiens, France.M-334 In Vitro Activity of Micafungin Compared with Five otherAntifungal Agents against 273 Prospectively Collected ClinicalAspergillus Isolates from The NetherlandsI. Curfs 1 , P. J. Haas. PhD 2 , M. Wolfhagen 3 , K. Verduin 4 , C. Bens 1 , C. H.Klaassen 1 , J. F. Meis 1,5 , Dutch Mica Study Group; 1 Canisius-WilhelminaHosp., Nijmegen, Netherlands, 2 Univ. Med. Ctr. Utrecht, Utrecht, Netherlands,3 Isala Hosp., Zwolle, Netherlands, 4 PAMM, Veldhoven, Netherlands,5Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.M-335 Investigation of Primary Clinical Samples of ImmunocompromisedPatients, Azole Resistant Clinical and EnvironmentalIsolates for Aspergillus Fumigatus Cyp51A Key Mutations UsingSensitive PCR Assays and Consecutive DNA Sequence AnalysisB. Spiess 1 , M. Reinwald 1 , S. J. Howard 2 , U. Gross 3 , O. Bader 3 , P. M. Rath 4 ,W. Seifarth 1 , S. Will, TA 1 , M. Lauten 5 , W. K. Hofmann 1 , D. Buchheidt 1 ;1Mannheim Univ. Hosp., 3rd Dept. of Internal Med., Mannheim, Germany,2Univ. of Liverpool, Translational Med., Liverpool, United Kingdom, 3 Inst.of Med. Microbiol., Göttingen Univ. Hosp., Göttingen, Germany, 4 Inst. ofMed. Microbiol., Essen Univ. Hosp., Essen, Germany, 5 Pediatric Hematologyand Oncology, Univ. Hosp. Schleswig-Holstein, Campus Lübeck, Lübeck,Germany.M-336 Molecular Epidemiology of Cryptococcosis in Thailand Revealeda Greater Genetic Diversity as Known Previously and thePresence of the Low Virulent Vancouver Island Outbreak C. gattiiGenotype VGIIbP. Ngamskulrungroj 1 , A. Chindamporn 2 , A. Chaiprasert 1 , N. Poonwan 3 , W.Meyer 4 ; 1 Faculty of Med. Siriraj Hosp. Mahidol Univ., Bangkok, Thailand,2Mycology Lab., Faculty of Med., Chulalongkorn Univ., Bangkok, Thailand,Bangkok, Thailand, 3 Mycology Lab., NIH, Nonthaburi, Thailand, Bangkok,Thailand, 4 Molecular Mycology Lab., CIDM, Westmead Millennium Inst.,Sydney Med. Sch.- Westmead Hosp., The Univ. of Sydney, Westmead,NSW, Australia, Westmead, Australia.M-337 Airway Invasive Pulmonary Aspergillosis (IPA) vs Angio-IPAHave Distinct Risk Factors and Outcomes in Lung TransplantRecipientsN. Singh 1 , M. Wagener 1 , J. Suarez 2 , R. Avery 3 , C. Lass Floerl 4 , A. C.Pasqualotto 5 , G. M. Lyon 6 , M. Barron 7 , S. Husain - 8 , J. G. Montoya 2 ;1UPitt, Pitt, PA, 2 Stanford, PaloAlto, CA, 3 CCF, Cleveland, OH,4U Innsbruck, Innsbruck, Austria, 5 UFCSPA, PortoAlegre, Brazil, 6 Emory U,Atlanta, GA, 7 U CO, Denver, CO, 8 UHN, Toronto, Canada.M-338 Fungiscope: A Global Database for Emerging Fungal InfectionsM. J. Vehreschild 1 , K. Wahlers 1 , A. Hamprecht 1 , G. Fischer 2 , S. de Hoog 3 ,J. Vehreschild 1 , M. Karthaus 4 , O. A. Cornely 1 , The Fungiscope ECMM/ISHAM Working Group; 1 Univ. Hosp. Cologne, Koeln, Germany, 2 Hlth.Authorities, Stuttgart, Germany, 3 CBS, Utrecht, Netherlands, 4 Klin. Neuperlach,Munich, Germany.M-339 Patterns and Dynamics of Colonization with Candida spp. inthe Neonatal Intensive Care Unit (NICU)E. Leibovitz, T. Taraboulos-Klein, I. Livshiz-Riven, A. Borer, E. Shani, A.Golan; Ben-Gurion Univ., Beer-Sheva, Israel.------------------------------------------------------------------------029(T, V)Poster SessionInfections in Transplant Recipients: Viruses and FungiSunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:T-340 Universal Prophylaxis vs Pre-Emptive Therapy in CMV HighRisk Transplant Recipients: Data from RESITRA-REIPI CohortY. Meije, J. Aguado, A. Moreno, J. Gavaldá, J. Cisneros, M. Gurguí,J. Carratalá, P. Muñoz, M. Montejo, M. Blanes, G. Bou, J. Pérez, J. Torre-Cisneros, A. Ramos, A. Pahissa, J. Fortún; GESITRA-REIPI, Spain, Spain.T-341 Plasma Exchange (PE) Therapy (Rituximab Apheresis) forRituximab (R) Induced Progressive Multifocal Leukoencephalopathy(PML) in Hematologic DisordersA. Burchardt 1 , S. Wienzek-Lischka 2 , H. Hackstein 2 , M. Rummel 1 ; 1 Hosp. ofJustus-Liebieg Univ., Giessen, Germany, 2 Transfusion Med., Justus-LiebiegUniv., Giessen, Germany.T-342 Central Nervous System Infections Due to Herpes Simplexand Varicella-Zoster Viruses in Natalizumab-Treated Patients:Post-Market Data from the FDA Adverse Event ReportingSystemA. Fine, A. Sorbello; U.S. FDA., Silver Spring, MD.T-343 Fungal Infections in Solid Organ Transplant Recipients in theSwiss Transplant Cohort StudyT. Lecompte 1 , C. Garzoni 2 , N. Mueller 3 , G. Kralidis 4 , O. Manuel 5 , M.Weiser 4 , C. Berger 3 , K. Boggian 6 , P. Meylan 5 , H. Hirsch 4 , D. Vu-Cantero 1 ,C. Van Delden 1 , STCS; 1 Univ. Hosp., Geneva, Switzerland, 2 Clinica Luganese,Lugano, Switzerland, 3 Univ. Hosp., Zurich, Switzerland, 4 Univ. Hosp.,Basel, Switzerland, 5 Univ. Hosp., Lausanne, Switzerland, 6 Cantonal Hosp.,St. Gallen, Switzerland.T-344 Incidence of Invasive Fungal Infections in Pediatric Hematologyand Oncology Patients in Period 2002 - 2010V. Chrenkova 1 , P. Hubacek, Ph.D. 2 , P. Sedlacek 2 , P. Keslova 2 , E. Kabickova 2 ,E. Mejstrikova 2 , V. Smelhaus 2 , E. Bebrova 2 , O. Nyc 2 , J. Stary 2 ; 1 MotolUniv. Hosp., Prague, Czech Republic, 2 Charles Univ. 2nd Faculty of Med.and Motol Univ. Hosp., Prague, Czech Republic.T-345 Cryptococcus gattii Infection in Solid Organ TransplantRecipients: Clinical Characteristics and OutcomesP. Bhalla, D.O. 1 , E. E. DeBess, DVM, MPVM 2 , L. N. Fitzgibbons, M.D. 3 ,K. L. Winthrop 1 , G. N. Forrest 1 , P. R. Cieslak 2 ; 1 Oregon Hlth. & Sci.Univ., Portland, OR, 2 Oregon Hlth. Authority, Publ. Hlth. Div., Portland,OR, 3 Kaiser Sacramento Med. Ctr., Northern California Kaiser Permanente,Sacramento, CA.T-346 Posaconazole (POS) Serum Troughs, Clinical Responses andTolerance among Cardiothoracic Transplant Patients (CT pts)R. K. Shields, M. H. Nguyen, E. J. Kwak, F. P. Silveira, C. J. Clancy; Univ. ofPittsburgh, Pittsburgh, PA.T-347 Diagnosis of Invasive Aspergillosis and Mucormycosis Guidedby PCR Assays from Bronchoalveolar Lavage Fluid in AllogenicStem Cell RecipientsH. Lellek 1 , R. Bialek 2 , H.Rohde, H.J.Baumann, H.K.Klose, S.Kluge,N.Kröger, H. Rohde 1 , H. Baumann 1 , H. Klose 1 , S. Kluge 1 , N. Kröger 1 ;1Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany, 2 Labor Dr Krause,Hamburg, Germany.Final Program57

Sunday SCIENTIFIC SESSIONST-348 Diseases Due to Scedosporium in the First Year FollowingTransplant (Tx) Often Stem from Colonization or Surgical Seeding,and are Associated with High MortalityL. Johnson, R. K. Shields, C. Clancy; Univ. of Pittsburgh, Pittsburgh, PA.T-349 The Epidemiology and Outcomes of Candidemia in HematopoieticCell TransplantationL. Gold J. Kriengkauykiat, B. Tegtmeier, S. Dadwal, J. Ito; City of Hope,Duarte, CA.T-350 Posaconazole (PCZ) Serum Levels for Treatment (Tx) andProphylaxis (Px) in Immunocompromised PatientsM. Rhee 1 , J. Ito 2 , S. Dadwal 2 , B. Tegtmeier 2 , J. Kriengkauykiat 2 ; 1 WesternUniv. of Hlth. Sci., Pomona, CA, 2 City of Hope, Duarte, CA.T-351 Human Herpesvirus Type-6 (HHV6) Reactivation in Patients(pts) with Unrelated Donor Hematopoietic Cell Transplantation(HCT): Comparison of Outcomes amongst Treated and UntreatedT. Bui, J. Kriengkauykiat, J. Ito, B. Tegtmeier, S. Dadwal; City of Hope,Duarte, CA.T-352 Chronic High EBV Load Carriage Has Low Predictive Valueto Detect Post-Transplant Lymphoproliferative Disorder (PTLD)in Solid-Organ Transplant RecipientsC. Gardiol, P. Meylan, M. Pascual, O. Manuel; Univ. Hosp. Ctr. of Lausanne,Lausanne, Switzerland.T-353 The Molecular Epidemiology of a Respiratory Syncytial VirusOutbreak Among Oncology and Hematopoietic Stem Cell Transplant(HSCT) PatientsH. Y. Chu, S. Podczervinski, J. Kuypers, A. P. Campbell, M. Boeckh, J.Englund, C. Casper; Univ. of Washington, Seattle, WA.T-354 BK Virus (BKV) Infection after Reduced Intensity DoubleUmbilical Cord Blood Stem-Cell Transplantation (dUCBT)G. Satyanarayana 1 , S. Hammond 2 , T. A. Broge Jr. 1 , R. Viscidi 3 , I. Politikos 1 ,I. J. Koralnik 1 , C. Cutler 4 , K. Ballen 5 , V. A. Boussiotis 1 , F. Marty 2 , S. Tan 1 ;1Beth Israel Deaconess Med. Ctr., Boston, MA, 2 Brigham and Women’sHosp., Boston, MA, 3 Johns Hopkins Univ., Baltimore, 4 Dana Farber CancerInst., Boston, MA, 5 Massachusetts Gen. Hosp., Boston, MA.T-355 CMV Antigenemia and Quantitative Viral Load Assessmentsin Hematopoietic Stem Cell Transplant RecipientsL. Cardeñoso 1 , B. Pinsky 2 , I. Lautenschlager 3 , S. Aslam 4 , B. Cobb 4 , R.Vilchez 4 , H. Hirsch 5 ; 1 Hosp. Univ.ersitario de la Princesa, Madrid, Spain,2Stanford Univ. Sch. of Med., Stanford, CA, 3 Helsinki Univ. Hosp., Univ. ofHelsinki, Helsinki, Finland, 4 Roche Molecular SysteInc., Pleasanton, CA,5Univ. of Basel, Basel, Switzerland.T-356 Letermovir (AIC246) for the Prevention of CMV InfectionsMeets Primary Endpoint in Phase 2b Trial in Human Blood PrecursorCell Transplant (HBPCT) RecipientsR. F. Chemaly 1 , G. Ehninger 2 , R. Champlin 1 , for the AIC246 Study Team,M. Richard 3 , H. Zimmermann 3 , P. Lischka 3 , S. Stoelben 3 , D. McCormick 3 ,H. Ruebsamen-Schaeff 3 ; 1 UT MD Anderson Cancer Ctr., Houston, TX,2Univ. Dresden, Dresden, Germany, 3 AiCuris GmbH & Co. KG, Wuppertal,Germany.T-357 Treatment of RSV in Adult Transplant Recipients with Palivizumab7.5mg/kg, Inhaled Ribavirin, IVIG, and SteroidsJ. Gillman, P. Mohazabnia, R. Portinari, Pharm.D, W. Tharpe, B. De Marco,F. Lee, B. M. Le; Univ. of Texas Southwestern Med. Ctr., Dallas, TX.T-358 Preemptive Therapy (PrT) for Cytomegalovirus (CMV)Posthematopoietic Cell Transplantation (HCT) is Associated withSignificant Morbidity and Resource UtilizationH. Mommeja-Marin, S. Godkin, T. Brundage, W. Painter, D. Margolskee;Chimerix, Durham, NC.T-359 Impact of Adjuvanted Pandemic (H1N1) 2009 Influenza Vaccineon Acute Rejection Rate and Long-Term Graft Outcomeafter Kidney Transplantation (KT)M. Fernández-Ruiz 1 , P. Arrazola 1 , F. López-Medrano 1 , J. M. Morales 1 ,A. Andrés 1 , J. Gavaldà 2 , J. M. Aguado 1 , C. Lumbreras 1 ; 1 Univ. Hosp. 12 deOctubre, Madrid, Spain, 2 Univ. Hosp. Vall d´Hebron, Barcelona, Spain.T-360 Risk Factors and Prognosis of BK Virus-Associated HemorrhagicCystitis Following Allogeneic Hematopoietic Stem CellTransplantationL. Gilis, N. Tedone, G. Billaud, M. Michallet, F. Ader; Hospices Civils deLyon, Lyon, France.T-361 BK Polyomavirus (BKV) IgG is a Predictor of High Level BKVViruria after Allogeneic Hematopoietic Stem Cell Transplantation(HSCT)Y. J. Lee 1 , D. Chung 1 , C. Figueroa 1 , I. Amigues 1 , T. Son 1 , J. Hester 2 , A.Jakubowski 1 , G. Papanicolaou 1 ; 1 Mem. Sloan-Kettering Cancer Ctr., NewYork, NY, 2 Viracor-IBT Lab., Lee’s Summit, MO.T-362 CMX001 is an Effective Treatment Option for RefractoryCMV Infection or Disease in HCT Recipients: A Single Center’sExperienceG. Papanicolaou 1 , H. Mommeja-Marin 2 , M. Anderson 2 , S. Godkin 2 , G.Chittick 2 , W. Painter 2 ; 1 Mem. Sloan Kettering Cancer Ctr., New York, NY,2Chimerix, Inc., Durham, NC.T-363 Molecular Decryption of a Group C Adenovirus Epidemic inPediatric Recipients of Hematopoietic Stem CellsL. Feghoul 1 , P. Roques 2 , J. Dalle 3 , J. Cherot 1 , M. Ouachée 1 , C. Doit 1 , M.Rodier 1 , A. Baruchel 3 , F. Simon 1 , J. Le Goff 1 ; 1 Univ. Paris Diderot, HôpitalSaint-Louis, APHP, Paris, France, 2 IMETI, CEA, Fontenay-aux-Roses,France, 3 Univ. Paris Diderot, Hôpital Robert Debré, APHP, Paris, France.T-364 Good Outcomes Among Hepatitis C (HCV)-Infected Heartand Lung Transplant Recipients: A Single-Center ExperienceM. Nguyen 1 , K. Chopra 1 , E. J. Kwak 1 , F. Silveira 1 , R. Abdel-Massih 2 , Y.Toyoda 2 , N. Shigemura 2 , J. Pilewski 1 , M. Crespo 2 , C. Bermudez 1 , J. Bahma 2 ,C. Clancy 2 ; 1 Univ. of Pittsburgh, Pittsburgh, PA, 2 Univ. of Pittsburgh and VAPittsburgh, Pittsburgh, PA.T-365 Looking into the Crystal Ball: Can We Foresee CMV?A. J. Jamal 1 , S. Husain 1,2 , Y. Li 1 , O. Famure 1 , J. S. Kim 1,2 ; 1 Univ. Hlth.Network, Toronto, Canada, 2 Univ. of Toronto, Toronto, Canada.T-366 Safety and Efficacy of a Strategy for Discontinuing PreemptiveGanciclovir Therapy after One Negative Antigenemia Test Resultin Kidney TransplantationS. Park, Y. Lee, H. Hong, H. Park, S. Moon, H. Sung, Y. Kim, D. Han, S.Park, J. Park, S. Kim, S. Choi, Y. Kim, J. Woo, S. Lee; Asan Med. Ctr., Seoul,Korea, Republic of.T-367 Acyclovir Resistant Herpes Simplex Virus (HSV) among HematopoieticStem Cell Transplant (HSCT) Recipients: Case-Case-Control InvestigationD. Patel 1 , D. Marchaim 2 , G. Marcus 2 , R. Gayathri 1 , P. R. Lephart 1 , C.Pranatharthi 1 ; 1 Wayne State Univ., Detroit, MI, 2 Assaf Harofeh Med. Ctr.,Zerifin, Israel.58September 9-12 |

SUNDAY SCIENTIFIC SESSIONST-368 Impact of Cytomegalovirus (CMV) Infection in RapidProgression to Fibrosis and 5-Year Mortality in Liver TransplantRecipients (LTR) Infected with Hepatitis C Virus (HCV)O. Len, M. Puig, L. Castells, N. Fernández-Sabé, A. García-Reyne, M.Montejo, R. Lara, G. Bou, J. Gavaldà, A. Pahissa; REIPI (Spanish Networkfor Res. in Infectious Diseases), Barcelona, Spain.T-369 Use of Electronic Estimation of Renal Function (eGFR) toGuide Valganciclovir (VGCV) Dosing in Solid-Organ TransplantRecipients (SOT-R) Commonly Results in Sub-TherapeuticGanciclovir (GCV) LevelsJ. Trevillyan 1 , P. Angus 1,2 , E. Shelton 1 , J. Whitlam 1 , F. Ierino 1,2 , J. Pavlovic 1 ,D. Gregory 1 , K. Urbancic 1 , J. Torresi 1,2 , A. Testro 1 , L. Grayson 1,2 ; 1 AustinHealth, Melbourne., Australia, 2 Melbourne Univ., Melbourne, Australia.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------030(V)Poster SessionNon HIV VirologySunday, 11:30 a.m.–1:30 p.m. .................... Halls A-CPresentations:V-370 Fluorescent Primuline Derivatives Inhibit Hepatitis C VirusNS3- Catalyzed RNA unwinding, Peptide Hydrolysis and ViralReplicase FormationJ. Ndjomou 1 , R. Kolli 1 , S. Mukherjee 1 , K. Li 2 , F. J. Schoenen 2 , D. N.Frick 1 ; 1 Univ. of Wisconsine, Milwaukee, WI, 2 Univ. of Kansas SpecializedChemistry Ctr., Lawrence, KS.V-371 Long-Term Follow-Up of Inner City Populations Treated forHCV InfectionH. Tossonian 1 , L. Gallagher 1 , S. Nouch 2 , F. Duncan 2 , O. Alenezi 1 , B.Conway 1 ; 1 Univ. of British Columbia, Vancouver, Canada, 2 Pender CommunityHlth. Ctr., Vancouver Coastal Hlth., Vancouver, Canada.V-372 Relationship Between Apolipoprotein E Genotypes and Anti-Viral Response in Hepatitis C Virus InfectionW. Lee, Y. Kim, K. Lee; Kyungpook Natl. Univ. Hosp., Daegu, Korea,Republic of.V-373 Virologic Response and Emergence of Mutant Strains onAntiviral Monotherapy and Combination Therapy in Hepatitis BVirus Related Chronic Liver DiseaseM. Srivastava, A. Jain, V. Dixit, S. Shukla, G. Nath; Inst. of Med. Sci.,BHU,Varanasi, India.V-374 A Cross-Sectional Survey of Genotypes and Viral Mutationsin Veterans with Chronic Hepatitis B InfectionM. Burton 1 , D. Sullivan 2 ; 1 G.V. Sonny Montgomery VAMC, Jackson, 2 Univ.of Mississippi Med. Ctr., Jackson, MS.V-375 Impact of Free HBV Vaccination and/or Healthcare WorkersTraining on Vaccine Acceptability in High Risk SubjectsO. Launay 1 , Y. Le Strat 2 , W. Tosini 3 , L. Kara 1 , S. Quelet 4 , S. Lévy 5 , E.Bouvet 3 , D. Lévy-Bruhl 2 , ANRSFORMVAC Study Group; 1 CIC de VaccinologieCochin Pasteur, Paris, France, 2 Institut de Veille Sanitaire, Paris,France, 3 Service des Maladies Infectieuses et Tropicales Hôpital Bichat,Paris, France, 4 Direction de l’action sociale, de l’enfance et de la Santé, Paris,France, 5 Ctr. Régional d’information et de Prévention du Sida, Paris, France.V-376 Hepatitis E Seroprevalence in an Immunocompromised PediatricPopulationM. J. Jaber, C. Buteau, C. Rousseau, S. Cellot, U. Halac, F. Alvarez; CHUSainte Justine, Montreal, Canada.V-377 HCV RNA Replication is Sensitive to Perturbations in DesmosterolHomeostasisV. A. Villareal 1 , M. A. Rodgers 1,2 , E. A. Schaefer 3 , L. F. Peng 3 , K. E. Corey 3 ,R. T. Chung 3 , P. L. Yang 1 ; 1 Harvard Med. Sch., Boston, MA, 2 USC, LosAngeles, CA, 3 Massachusetts Gen. Hosp., Boston, MA.V-378 Association Between Chemokine Receptor 5 Mutation andHepatitis C Infection Susceptibility and Outcomes in Shistosomiasis-InfectedPatientsWithdrawnV-379 The Seroprevalence of Hepatitis B and C in NortheasternRegion of TurkeyG. Arvas 1 , Y. Akkoyunlu 2 , B. Kaya 3 , I. Hakyemez 4 , M. Berktas 5 , T. Aslan 2 ;1Igdir Univ., Med. Technology Vocational and Training Sch., Igdir, Turkey,2Bezmialem Vakif Univ., Istanbul, Turkey, 3 Igdir State Hosp., Igdir, Turkey,4Abant Izzet Baysal Univ., Bolu, Turkey, 5 100. Yil Univ., Van, Turkey.V-380 Efficacy of Peramivir on the Outcome of Severe PneumococcalPneumonia Induced By Co-Infection with Influenza Virus inComparison with Oseltamivir in MiceA. Tanaka 1 , S. Nakamura 1 , N. Iwanaga 1 , T. Kajihara 1 , M. Kitano 2 , Y.Imamura 1 , T. Miyazaki 1 , M. Seki 3 , K. Izumikawa 1 , H. Kakeya 1 , Y. Yamamoto1 , K. Yanagihara 1 , T. Tashiro 1 , S. Kohno 1 ; 1 Nagasaki Univ. Hosp.,Nagasaki, Japan, 2 Shionogi & Co., LTD. Medicinal Res. Lab., Osaka, Japan,3Osaka Univ. Hosp., Suita, Japan.V-381 Genotypic Resistance Assessment in a Phase II Clinical StudyAssessing DAS181 Antiviral Activity against InfluenzaR. L. Sanders, C. Tjoeng, R. Moss; NexBio Inc., San Diego, CA.V-382 Inhibition of Clinical Isolates of Human Parainfluenza Virusby DAS181 in Cell Culture and in a Cotton Rat ModelJ. L. Hurwitz 1 , B. Jones 2 , R. Moss 3 , R. L. Sanders 3 ; 1 St. Judes Children’sRes. hospital, Memphis, TN, 2 St. Jude Children’s Res. Hosp., San Diego, CA,3NexBio Inc, San Diego, CA.V-383 Correlation of Housekeeping Gene Expression with RespiratorySwab Sample Quality in Healthy VolunteersJ. D. Hoopes 1 , R. Coon 2 , M. Balansay-Ames 2 , L. Hua 3 , M. Hughes 3 ,C. Myers 2 , D. Faix 2 , P. Blair 2 , J. Nguyen 1 , NIAID Influenza ResearchCollaboration; 1 Adamas Pharmaceuticals, Emeryville, CA, 2 Naval Hlth. Res.Ctr., San Diego, CA, 3 Harvard Sch. of Publ. Health, Boston, MA.V-384 Prevalence and Predictors for the Presence of HeterosubtypicAntibodies against Influenza A in HumansI. Kohler 1 , A. U. Scherrer 2 , B. Ledergerber 2 , H. F. Guenthard 2 , L. Hangartner1 ; 1 Univ. of Zurich, Zurich, Switzerland, 2 Univ. Hosp. Zurich, Zurich,Switzerland.V-385 Barrier-Forming Formulation Containing CetylpyridiniumChloride (fCPC) Possesses Anti-Infective Activity against InfluenzaVirusF. Esper 1 , P. K. Mukherjee 2 , A. M. Ghannoum 3 , R. A. Salata 1 , M. A.Ghannoum 4 ; 1 Univ. Hosp. Case Med. Ctr., Cleveland, OH, 2 Case WesternReserve Univ., Cleveland, OH, 3 Oasis Consumer Healthcare LLC, Cleveland,OH, 4 Univ. Hosp. Case Med. Ctr. and Case Western Reserve Univ.,Cleveland, OH.Final Program59

Sunday SCIENTIFIC SESSIONSV-386 Use of Data Integration of Alberta Laboratory (DIAL), AWeb-Based Platform, to Analyze Mixed Infections Among HumanMetapneumovirus and Other Respiratory Viruses Circulatingin Alberta, Canada (2009-2012)S. Fathima. 1 , J. May-Hadford 2 , B. Lee 3 , S. Mukhi 3,4 , S. J. Drews 1,5 ;1Provincial Lab. for Publ. Health, Calgary, Canada, 2 Publ. Hlth. Agency ofCanada, Calgary, Canada, 3 Univ. of Alberta, Calgary, Canada, 4 CanadianNetwork for Publ. Hlth. Intelligence, Winnipeg, Canada, 5 Univ. of Calgary,Calgary, Canada.V-387 Risk Factors for Infection with the Pandemic Influenza A/H1N1 Virus in the General Population: A Representative CohortStudy in FranceR. M. Delabre 1 , N. Lapidus 1 , N. Salez 2 , M. Leruez 3 , L. Andreoletti. 4 , A.Flahault 5 , X. De Lamballerie. 2 , F. Carrat. 1 ; 1 Inserm U707, Paris, France,2UMR-D 190, Aix-Marseille Univ. and IRD, Marseille, France, 3 Hosp.Necker, Paris, France, 4 Unité de Virologie Médicale et Moléculaire, CHU,ReiFrance, 5 EHESP, Rennes, France.V-388 Arbidol-Oseltamivir Combination Therapy for A InfluenzaVirus Infection in Cell Culture and in MiceI. A. Leneva 1 , I. Fedyakina 2 ; 1 The I. Mechnikov Res. Inst. of Vaccines andSera, Moscow, Russian Federation, 2 D.I. Ivanovsky Inst. of Virology, Moscow,Russian Federation.V-389 Influenza-Like Illness Hospitalizations with Prospective VirologicAssessment During a Mixed Influenza A and B SeasonR. Gilca 1 , R. Amini 2 , M. Douville-Fradet 1 , H. Charest 3 , J. Dubuque 4 , V.Lajoie 2 , N. Boulianne 1 , A. Thuot 5 , D. Lauzon 5 , A. Poirier 6 , D. Grimard 7 ,R. Savard 7 , E. Simoneau 8 , G. De Serres 1 ; 1 INSPQ, Quebec, Canada,2CHUL-CHUQ, Quebec, Canada, 3 INSPQ, Montreal, Canada, 4 MSSS,Montreal, Canada, 5 Hosp. Haut-Richelieu, Saint-Jean-sur-Richelieu, Canada,6 CSSSTR, Trois-Rivières, Canada, 7 Hôpital de Chicoutimi, Chicoutimi,Canada, 8 Cité de la santé, Laval, Canada.V-390 The Effectiveness of Neuraminidase Inhibitors for thePediatric Patients with InfluenzaK. Oda, Kawasaki Hosp., Okayama, Japan.V-391 AIC316, a Potent Non-Nucleosidic Inhibitor of HerpesSimplex Virus (HSV), Exhibits a Favorable Pharmacokinetic/Pharmacodynamic (PK/PD) Profile in a Successfully CompletedProof-of-Concept and Dose Finding TrialA. Birkmann, D. McCormick, B. Timmler, S. Stoelben, M. P. Richard,H. Zimmermann, H. Ruebsamen-Schaeff; AiCuris GmbH & Co. KG,Wuppertal, Germany.V-392 Novel Method for Generating Recombinant HumanCytomegalovirus (HCMV) Mutants with a Reporter Luciferasefor Drug Susceptibility TestingE. Drouot, J. Piret, G. Boivin; Laval Univ., Quebec, Canada.V-393 Relationship Between Cytomegalovirus (CMV) Infection ofPeripheral Blood Leukocytes (PBL) and Bone Marrow (BM) Cellsin Hematopoietic Stem Cell Transplant (HSCT) RecipientsA. Capobianchi, A. Iori, A. Micozzi, G. Torelli, C. Girmenia, S. Santilli, G.Antonelli, R. Foà, G. Gentile; Sapienza Univ., Rome, Italy.V-394 The Importance of Serum Adipokine Levels in Patients withCrimean-Congo Hemorrhagic FeverG. Yilmaz, A. Mentese , H. Yilmaz, I. Koksal; Karadeniz Technical Univ.Faculty of Med., Trabzon, Turkey.V-395 Blurred Vision and Myopic Shift in Puumala Virus Infectionare Independent of Disease SeverityG. Theiler, B. Langner-Wegscheider, I. Zollner-Schwetz, T. Valentin, M.Hönigl, R. Krause; Med. Univ. Graz, Graz, Austria.V-396 Modeling the Efficacy of Post-Event Mass Vaccination andAntiviral Prophylaxis and Treatment in Response to a SmallpoxOutbreakE. Graeden , K. Steinhouse, R. Fielding; Gryphon Scientific, Takoma Park.V-397 Efficacy and Safety of Acyclovir 5%/Hydrocortisone 1% Creamin Immunocompromised Patients with Recurrent Herpes SimplexLabialisS. K. Tyring 1 , T. Lin 2 , L. Handiwala 2 , J. T. Olin 2 , C. M. Hull 3 ; 1 Univ. ofTexas Med. Sch. at Houston, Houston, TX, 2 Valeant Pharmaceuticals NorthAmerica LLC, Bridgewater, NJ, 3 Univ. of Utah, Salt Lake City, UT.V-398 Comparison of Clinical Characteristics and Laboratory ValuesBetween PCR Confirmed H1N1 Influenza and PCR NegativeInfluenza Like IllnessesM. Hoenigl, J. Prattes, M. Drescher, K. Tovilo, K. Vander, H. Kessler, R. B.Raggam, T. Valentin J. Wagner, K. Seeber, I. Zollner-Schwetz, R. Krause, H.Flick; Med. Univ. of Graz, Austria, Graz, Austria.V-399 Immunomodulating Effect of Protease-Activated ReceptorType 1 (PAR-1) on Human Metapneumovirus InfectionL. Aerts 1 , M. Hamelin 1 , C. Rhéaume 1 , C. Couture 1 , B. Riteau 2 , G. Boivin 1 ;1Univ. Laval, Quebec, Canada, 2 Univ. C. Bernard, Lyon, France.V-400 First Prospective, Randomized, Clinical Study EvaluatingCombination of Oseltamivir Phosphate and Azithromycin ExtendedRelease Formulation for InfluenzaH. Kakeya 1 , M. Seki 2 , K. Izumikawa 1 , S. Kohno 1 ; 1 Nagasaki Univ. Hosp.,Nagasaki, Japan, 2 Osaka Univ. Hosp., Osaka, Japan.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.60September 9-12 |

SUNDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------031Literature ReviewLiterature ReviewSunday, 1:45 p.m.–3:45 p.m. .................... Room 103UAN: 0391-9999-12-035-L04-PConveners:Robert A. Bonomo, MD - ProfessorLouis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH.Jean-Michel G. Molina, MD - ProfessorSaint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, France.David Paterson, PhD - Professor of MedicineUniv. of Queensland Ctr. for Clinicial Res., Brisbane, Australia.Morven S. Edwards, MD - Professor of PediatricsBaylor Coll. of Med., Houston, TX.Emily Blumberg, MD - Professor of MedicineUniv. of Pennsylvania, Philadelphia, PA.Angela M. Caliendo, MD, PhD - ProfessorPath. and Lab. Med., Emory Univ. Hosp., Atlanta, GA.Objectives: Upon completion of this Literature Review, the participantshould be able to:> Review the past year’s most noteworthy publications;> Restate recent advances in infectious diseases epidemiology, pathogenesis,diagnostics, and therapeutics; and> Summarize and analyze recent advances relating to HIV infection.Intended Audience: All AttendeesLevel: Intermediate------------------------------------------------------------------------032Poster Summary SessionEarly New Antimicrobial AgentsSunday, 1:45 p.m.–3:45 p.m. .................... Room 104UAN: 0391-9999-12-036-L04-PDeveloped in Cooperation with the Japanese Antibiotic Research Association( JARA) and the Japanese Society for Chemotherapy ( JSC)Conveners:Michael J. Pucci, PhD - Excutive DirectorAchillion Pharmaceuticals, New Haven, CT.Malcolm G. P. Page, PhD - ProfessorBasilea Pharmaceutica, Basel, Switzerland.Kazuhiro Tateda, MD, PhD - ProfessorToho Univ. Sch. of Med., Tokyo, Japan.Objectives: Upon completion of this Poster Summary Session, the participantshould be able to:> Identify some key preclinical or early stage compounds in drug developmentthat have not yet entered therapeutic (Phase 2) clinical trials;> Describe selected new antimicrobial agents or new screening technologiesthat are being presented in Category F sessions at this meeting; and> Gain insights into the potential antibiotic pipeline for the near future.------------------------------------------------------------------------033(P)Interactive SymposiumWhat’s Hot Where It’s Hot: Interactive Cases inTropical MedicineSunday, 4:00 p.m.–6:00 p.m. .................... Room 103UAN: 0391-9999-12-037-L04-PDeveloped in Cooperation with the American Society of Tropical Medicine andHygiene (ASTHM)Conveners:Wesley C. Van Voorhis, MD, PhD - Professor of Medicine and Head ofAllergy and ID DivisionUniv. of Washington, Seattle, WA.Panelists:401 Stephen D. Shafran, MD - Professor and Director, Division of InfectiousDiseasesMedicine, Univ. of Alberta, Edmonton, Canada.402 Eric Caumes, MD - ProfessorHosp. Pitié-Salpêtrière, Univ. Pierre-et-Marie-Curie, Paris, France.403 Michael D. Libman, MD - Associate ProfessorMcGill Univ. Hlth. Ctr., Montreal, Canada.404 Andrea Boggild, MD - Associate ProfessorUniv. of Toronto, Toronto, Canada.406 Christina M. Coyle, MD, MS - Professor of Clinical MedicineAlbert Einstein Coll. of Med., Bronx, NY.Objectives: Upon completion of this Interactive Symposium Session, theparticipant should be able to:> Cite some of the latest significant literature of travelers medicine,parasitology, and tropical medicine;> Discuss the epidemiology of travelers’ illnesses and issues in managementand prevention of these illnesses; and> Discuss issues in management and prevention of common tropicalillnesses.Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists,and general physicians.Level: IntermediateFinal Program61

Sunday SCIENTIFIC SESSIONS------------------------------------------------------------------------034(V, D)Interactive SymposiumTransplantation and the ID Physician: ManagementStrategies for the 21st CenturySunday, 4:00 p.m.–6:00 p.m. .................... Room 104UAN: 0391-9999-12-038-L04-PConveners:Emily A. Blumberg, MD - Professor of MedicinePerelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.Jay A. Fishman, MD - Professor of MedicineMassachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA.Speakers:4:00 p.m.407 Viral Molecular Diagnostics: Pitfalls & ChallengesAjit P. Limaye, MD- ProfessorUniv. of Washington, Seattle, WA.4:30 p.m.408 Laboratory Monitoring for Fungi in Transplantation: Advantagesand LimitationsBarbara D. Alexander, MD, MHS - Associate Professor of Medicine andPathologyDuke Univ., Durham, NC.5:00 p.m.409 Functional Immune Assays and the Individualization of CareAtul Humar, MD - Professor, Director Alberta Transplant InstituteUniv. of Alberta, Edmonton, Canada.5:30 p.m.410 Immunologically Based Prophylactic Strategies in TransplantRecipientsJay A. Fishman, MD - Professor of MedicineMassachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA.Objectives: Upon completion of this Interactive Symposium Session, theparticipant should be able to:> Analyze the utility and limitations of viral diagnostics in transplantrecipients;> Assess the optimal use of fungal diagnostics in the management oftransplant recipients;> Identify when to use immune monitoring assays in transplant recipients;and> Demonstrate how diagnostic assays may impact on prophylactic strategiesin transplant recipients.Intended Audience: Physicians, pharmacists, and clinical microbiologists/virologists.Level: Intermediate------------------------------------------------------------------------035(A)SymposiumPharmacodynamics of Antifungal AgentsSunday, 4:00 p.m.–6:00 p.m. ....... Esplanade Ballroom 306UAN: 0391-9999-12-039-L04-PDeveloped in Cooperation with the International Society of Anti-Infective Pharmacology(ISAP)Conveners:David R. Andes, MD - ProfessorUniv. of Wisconsin, Madison, WI.William Hope, MD, PhD - Professor of Therapeutics and Infectious DiseasesThe Univ. of Liverpool, Liverpool, United Kingdom.Speakers:4:00 p.m.411 The Antifungal Pharmacodynamic Target: Impact of Organism,Host, and InfectionWilliam W. Hope, MD, PhD - Professor of Therapeutics and InfectiousDiseasesThe Univ. of Manchester, Manchester, United Kingdom.4:30 p.m.412 Antifungal Pharmacodynamics: Beyond CandidaNathan P. Wiederhold, PharmD - Associate ProfessorUniv. of Texas at Austin Coll. of Pharmacy, Univ. of Texas Hlth. Sci. Ctr.,San Antonio, TX.5:00 p.m.413 Analysis of Clinical Pharmacodynamic Data of AntifungalAgentsDavid R. Andes, MD - ProfessorUniv. of Wisconsin, Madison, WI.5:30 p.m.414 Using Pharmacodynamics to Set Antifungal SusceptibilityBreakpointsRussell Lewis, PharmD - Senior ResearcherUniv. of Bologna, Bologna, Italy.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Recognize the challenges in making dosage selections of antifungalagents;> Describe pharmacokinetic/pharmacodynamic methods involved in optimaldose selection; and> Identify issues and difficulties in estimating the optimal effect in vitro andin vivo of antifungal agents.Intended Audience: Physicians, pharmacists, and microbiologists.Level: Intermediate62September 9-12 |

SUNDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------036(B)SymposiumMicrobial Factors Modulating Host Responses: NewFrontiersSunday, 4:00 p.m.–6:00 p.m. ....... Esplanade Ballroom 309UAN: 0391-9999-12-040-L04-PConveners:Victor Nizet, MD - ProfessorUniv. of California, San Diego Sch. of Med. and Skaggs Sch. of Pharmacy &Pharmaceutical Sci., La Jolla, CA.Julie Magarian Blander, PhD - Associate ProfessorMount Sinai Sch. of Med., New York, NY.Speakers:4:00 p.m.415 A Commensal Microbe Coordinates Host Immunity to EstablishSymbiosisJune Round, PhD- Assistant Professor of Pathology, Division of Microbiologyand ImmunologyUniv. of Utah, Salt Lake City, UT.4:30 p.m.416 Food from the Fire: How the Host Response Feeds SalmonellaAndreas Baumler, PhD - ProfessorUniv. of California, Davis Sch. of Med., Davis, CA.5:00 p.m.417 Vita-PAMPs: Signatures of Microbial ViabilityJulie Magarian Blander, PhD - Associate ProfessorMount Sinai Sch. of Med., New York, NY.5:30 p.m.418 Bacterial Glycans and Glycosidases: That Subvert Host PhagocyteFunctionVictor Nizet, MD - ProfessorUniv. of California, San Diego, La Jolla, CA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe how the commensal flora of the human intestine shape developmentalaspects of the adaptive immune responses in both health andpathologies such as inflammatory bowel disease;> Identify how inflammatory responses induced by the intestinal pathogenSalmonella actually promote the pathogens own survival over the normalflora through unique metabolic adaptations;> Assess how the host innate immune system discriminates viable fromnonviable bacteria in order to mount a response only in the circumstanceof a true infectious threat; and> Describe how sugar molecules (glycans) on the surface of both bacterialand host cells regulate immune responses, and how streptococcal pathogenshave learned to mimic or degrade host sugars to avoid phagocytekilling.Intended Audience: Microbiologists and immunologists interested in hostpathogeninteractions and/or innate immunity, infectious disease physiciansand physicians-in-training, and pharmaceutical scientists interested in noveltargets for infectious disease therapeuticsLevel: Intermediate/Advanced------------------------------------------------------------------------037(C1)SymposiumMultidrug-Resistance in Emerging CountriesSunday, 4:00 p.m.–6:00 p.m. ....... Esplanade Ballroom 302UAN: 0391-9999-12-041-L04-PConveners:Patrice L. Nordmann, MD, PhD - ProfessorHosp. Bicetre, South Paris Med. Sch., Kremlin-Bicetre, France.Ana C. Gales, MD, PhD - Professor of MedicineUniv. Federal de São Paulo, Escola Paulista de Med. (UNIFESP, EPM), SãoPaulo, Brazil.Speakers:4:00 p.m.419 IndiaCamilla Rodrigues, MD - Consultant MicrobiologistHinduja Hosp., Mumbai, India.4:30 p.m.420 Bacterial Resistance: The Brazilian ScenarioAna C. Gales, MD, PhD - Professor of MedicineUniv. Federal de São Paulo, Escola Paulista de Med. (UNIFESP, EPM), SãoPaulo, Brazil.5:00 p.m.421 Bacterial Resistance: The South African ScenarioAdrian J. Brink, MD, MMed - DoctorAmpath Natl. Lab. Services, Milpark Hosp., Johannesburg, South Africa.5:30 p.m.422 Epidemiology and Characteristics of Antibacterial Resistancein ChinaYong-Hong Xiao, MD, PhD - ProfessorZhejiang Univ., Hangzhou, China.Objectives: Upon completion of this Symposium Session, participantsshould be able to:> Assess the extent of the antibiotic resistance problem in several emergingcountries;> Identify the main mechanisms of resistance behind resistance rates; and> Identify antibiotic resistance rates and first line therapy.Intended Audience: ID physicians, pharmacists, and industry clinicalmicrobiologists.Level: IntermediateFinal Program63

Sunday SCIENTIFIC SESSIONS------------------------------------------------------------------------038(C2)SymposiumWhole Genome Sequencing and MolecularEpidemiology: The New Frontier?Sunday, 4:00 p.m.–6:00 p.m. ....... Esplanade Ballroom 308UAN: 0391-9999-12-042-L04-PDeveloped in Cooperation with the European Society of Clinical Microbiologyand Infectious Diseases (ESCMID)Conveners:Mark J. Pallen, MD, PhD - ProfessorUniv. of Birmingham, Birmingham, United Kingdom.Johann Pitout, MD - ProfessorUniv. of Calgary, Calgary, Canada.Speakers:4:00 p.m.423 High-Throughput Sequencing and Molecular Epidemiology:Progress, Opportunities and ChallengesMark J. Pallen, MD, PhD - ProfessorUniv. of Birmingham, Birmingham, United Kingdom.4:30 p.m.424 Next Generation Sequencing Technology and Gram-Negatives:Escherichia coli O104:H4Nicholas J. Loman, MB BS, PhD - Research FellowUniv. of Birmingham, Birmingham, United Kingdom.5:00 p.m.425 Next Generation Sequencing Technology and Gram-Positives:Methicillin-Resistant Staphylococcus aureusPatrice Francois, PhD - MicrobiologistUniv. Hosp. of Geneva, Geneva, Switzerland.5:30 p.m.426 Clostridium difficile: Functional Genomics StudiesYung-Fu Chang, DVM, PhD - ProfessorCornell Univ., Ithaca, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the progress, opportunities and challenges of high-throughputsequencing in molecular epidemiology;> Recognize the role of next generation sequencing in the Escherichia coliO104:H4 outbreak;> Evaluate the role of next generation sequencing in the molecular epidemiologyof MRSA; and> Evaluate the role of next generation sequencing in the molecular epidemiologyof Clostridium difficile.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, clinical pathologists, medical technologists,and epidemiologists.Level: Advanced------------------------------------------------------------------------039(D)SymposiumBest Practices: Diagnosis of Viral Causes of HepatitisSunday, 4:00 p.m.–6:00 p.m. ....... Esplanade Ballroom 305UAN: 0391-9999-12-043-L04-PConveners:David A. Anderson, PhD - Deputy DirectorMacfarlane Burnet Inst. for Med. Res. and Publ. Hlth., Melbourne, Australia.Marie Landry, MD - ProfessorYale Univ. Sch. of Med. and Yale New Haven Hosp., New Haven, CT.Speakers:4:00 p.m.427 Hepatitis A and EDavid A. Anderson, PhD - Deputy DirectorMacfarlane Burnet Inst. for Med. Res. and Publ. Hlth., Melbourne, Australia.4:30 p.m.428 Diagnosis of Hepatitis B and Monitoring of Antiviral TherapyFabien Zoulim, MD, PhD - ProfessorINSERM, Lyon, France.5:00 p.m.429 Diagnostic Testing for Hepatitis C Virus in the Era of Direct-Acting Antiviral TherapyAlexandra Valsamakis, MD, PhD - Associate ProfessorJohns Hopkins Hosp., Baltimore.5:30 p.m.430 Herpes Viruses (CMV, EBV, HSV)Marie L. Landry, MD - ProfessorYale Univ. Sch. of Med. and Yale New Haven Hosp., New Haven, CT.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify the best tests to diagnose viral causes of hepatitis;> Describe the types and uses of nucleic acid tests for diagnosis and monitoringtreatment of viral hepatitis;> Describe the genetic markers that have been defined to be associated withinfection and treatment outcome; and> Assess the impact of viral genome variability on the clinical outcome ofchronic hepatitis.Intended Audience: Clinical microbiologists and infectious diseases clinicians.Level: Intermediate64September 9-12 |

SUNDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------040(E, C2)SymposiumOrigins and Ecology of Antibiotic ResistanceSunday, 4:00 p.m.–6:00 p.m. ....... Esplanade Ballroom 310UAN: 0391-9999-12-044-L04-PConveners:Laura V. Piddock, PhD- ProfessorUniv. of Birmingham, Birmingham, United Kingdom.Gautam Dantas, PhD - Assistant ProfessorWashington Univ. Sch. of Med., St. Louis, MO.Speakers:4:00 p.m.431 Antibiotic Resistance Genes in Probiotic FoodsGiorgio Giraffa, PhD - Research Centre DirectorConsiglio per la Ricerca e la Sperimentazione in Agricoltura, Lodi, Italy.4:30 p.m.432 Antibiotic Resistance Genes in Environmental BacteriaGautam Dantas, PhD - Assistant ProfessorWashington Univ. Sch. of Med., St. Louis, MO.5:00 p.m.433 Antibiotic Resistance in Commensal BacteriaBruno Fantin, MD, PhD - ProfessorUniv. Paris Diderot Med. Sch., Paris, France.5:30 p.m.434 Antibiotic Resistance Genes in Bacteria of Ancient OriginGerry Wright, PhD - ProfessorMcMaster Univ., Hamilton, Canada.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify the contribution of reservoirs of antibiotic resistance genes innon-pathogenic bacteria;> Describe the potential importance of antimicrobial resistance genes inprobiotic foods> Discuss the impact of antibiotic resistance genes in commensal microbiota;and> Discuss the types of antibitic resistance genes reported in bacteria ofancient origin.Intended Audience: Researchers and physicians wishing to broaden theirunderstanding of how antibiotic resistance genes arise and their prevalence inthe environment’s other than humans.Level: Beginning------------------------------------------------------------------------041(F)SymposiumNew Treatments for Mycobacterium tuberculosis InfectionsSunday, 4:00 p.m.– 6:00 p.m. .................... Room 122UAN: 0391-9999-12-045-L04-PConveners:Michael J. Pucci, PhD - Executive DirectorAchillion Pharmaceuticals, New Haven, CT.Carol A. Nacy, PhD - CEOSequella, Inc., Rockville, MD.Speakers:4:00 p.m.435 Discovery and Development of SQ609: A Novel Dipiperidine forTreatment of TB and TB MeningitisCarol A. Nacy, PhD - CEOSequella, Inc., Rockville, MD.4:30 p.m.436 Efficacy of Antimicrobial Peptoids against M. tuberculosisAnnelise E. Barron, Ph.D. - Associate ProfessorStanford Univ., Stanford, CA.5:00 p.m.437 Dry Powder Aerosols for Treatment of TuberculosisAnthony J. Hickey, PhD, DSc - Program Leader Inhalation TherapeuticsRes. Triangle Inst., ResearchTriangle Park, NC.5:30 p.m.438 TBA-354: A Next Generation Nitroimidazole for Treatment ofDrug- Sensitive and Drug-Resistant TuberculosisAnna M. Upton, PhD - Senior Project Leader, DiscoveryTB Alliance, New York, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the current need for new treatments for tuberculosis;> Gain insights into the drug discovery process for this disease; and> Discuss several early new approaches for future treatment of Mycobacteriumtuberculosis infections.Intended Audience: Microbiologists, pharmaceutical and academic scientists.Level: IntermediateFinal Program65

Sunday SCIENTIFIC SESSIONS------------------------------------------------------------------------042(G)SymposiumVaccine Conquests and ChallengesSunday, 4:00 p.m.–6:00 p.m. .................... Room 120UAN: 0391-9999-12-046-L04-PConveners:Andrew J. Pollard, FRCPCH PhD - ProfessorUniv. of Oxford, Oxford, United Kingdom.Janet A. Englund, MD - ProfessorUniv. of Washington, Seattle, WA.Speakers:4:00 p.m.439 Pneumococcal Conjugates: Impact of Expanded Valent VaccinesAnne Vergison, MD, PhD - Associate ProfessorULB-HUDERF, Brussels, Belgium.4:30 p.m.440 Meningococcal Conjugate Vaccines: Africa and BeyondAndrew J. Pollard, FRCPCH, PhD - ProfessorUniv. of Oxford, Oxford, United Kingdom.5:00 p.m.441 HPV Vaccine for Girls and Boys!Janet A. Englund, MD - ProfessorUniv. of Washington,Seattle Children’s Hosp., Seattle, WA.5:30 p.m.442 Global Measles: What’s Next?Jane F. Seward, MBBS, MPH - Deputy Director, Division of Viral DiseasesCDC, Atlanta, GA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the impact of expanded valent pneumococcal conjugate vaccines;> Discuss the impact of implementation of meningococcal conjugatevaccines in specific locales;> Discuss the expected outcomes after introduction of HPV vaccines inboys; and> Discuss goals by region, impact of importation and challenges remainingin global measles control.Intended Audience: Infectious disease physicians and physician extenders,public health officials and healthcare providers involved in vaccine development,advances and administration.Level: Intermediate------------------------------------------------------------------------043(H)SymposiumUpdate on HIV-Associated Co-MorbiditiesSunday, 4:00 p.m.– 6:00 p.m. .................... Room 121UAN: 0391-9999-12-047-L02-PConveners:Judith A. Aber, MD - Professor of Medicine; Director Division of InfectiousDiseases and ImmunologyNew York Univ. Sch. of Med., New York, NY.Esteban Martínez, MD - Associate Professor of MedicineUniv. of Barcelona, Barcelona, Spain.Speakers:4:00 p.m.443 Epidemiology and Outcomes of Organ Transplantation in HIVPeter Stock, MD, PhD - Professor of SurgeryUniv. of California San Francisco, San Francisco, CA.4:30 p.m.444 Central Nervous System Complications of HIVSerena S. Spudich, MD, MA - Associate ProfessorYale Univ. Sch. of Med., New Haven, CT.5:00 p.m.445 Syphilis and HIV: A Case Based DiscussionKimberly Workowski, MD - Professor of MedicineEmory Univ., Atlanta, GA.5:30 p.m.446 Update from the World AIDS ConferenceEsteban Martínez, MD - Associate Professor of MedicineUniv. of Barcelona, Barcelona, Spain.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the epidemiology and outcomes of persons with HIV infectionwho receive organ transplants;> Review current knowledge of CNS complications associated with HIVinfection; Identify the new diagnostic and treatment guidelines for ofsyphilis in HIV-infected persons; and> Review the data presented on co-morbidities at the World AIDSConference 2012.Intended Audience: HIV and HCV clinicians including MD, pharmacists,pharmacologists, physician extenders and other clinician, HIV and HCVclinical and translational s including those involved in all phases of antiviralresearch.Level: Intermediate66September 9-12 |

SUNDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------044(L)SymposiumAn Update on Novel & Important Tickborne DiseasesSunday, 4:00 p.m.– 6:00 p.m. .................... Room 102UAN: 0391-9999-12-048-L04-PConveners:Didier Raoult, MD, PhD - ProfessorWHO Collaborative Ctr. for Rickettsial Reference and Res., Marseille,France.Bobbi S. Pritt, MD - Laboratory DirectorMayo Clinic and Mayo Clinic Coll. of Med., Rochester, MN.Speakers:4:00 p.m.447 Emergence of a New Pathogenic Ehrlichia Species, Wisconsinand MinnesotaBobbi S. Pritt, MD - Associate ProfessorMayo Clinic and Mayo Clinic Coll. of Med., Rochester, MN.4:25 p.m.448 Human Infections Caused by Borrelia miyamotoiPeter J. Krause, MD - Senior Research ScientistYale Sch. of Publ. Hlth. and Yale Sch. of Med., New Haven, CT.4:50 p.m.449 Diverse Rickettsiae Across the GlobeDidier Raoult, MD, PhD - ProfessorWHO Collaborative Ctr. for Rickettsial Reference and Res., Marseille,France.5:15 p.m.450 Transfusion-Associated BabesiosisBarbara L. Herwaldt, MD, MPH - Medical EpidemiologistCDC, Atlanta, GA.5:40 p.m.451 Emergence of Deer Tick Virus as a Human PathogenGary P. Wormser, MD - ProfessorNew York Med. Coll., Valhalla, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify major tickborne pathogens;> Define diagnostic and therapeutic aspects of tickborne infections;> Analyze features of emerging deer tick virus encephalitis; and> Improve knowledge about new tick-associated infections.Intended Audience: Healthcare practitioners and investigators with aninterest in vector transmitted infections.Level: Intermediate------------------------------------------------------------------------045(L2)SymposiumAn Update on Perinatal InfectionsSunday, 4:00 p.m.– 6:00 p.m. .................... Room 130UAN: 0391-9999-12-049-L04-PDeveloped in Cooperation with the Infectious Diseases Society of Obstetrics andGynecology (IDSOG)Conveners:Catherine Nelson-Piercy, FRCP - PhysicianSt. Thomas’ Hosp., London, United Kingdom.Michael G. Gravett, MD - ProfessorUniv. of Washington Sch. of Med., Seattle, WA.Speakers:4:00 p.m.452 Safe Use of Antimicrobials in PregnancyCatherine Nelson-Piercy, FRCP - PhysicianSt. Thomas’ Hosp., London, United Kingdom.4:30 p.m.453 Influenza During PregnancyRichard Beigi, MD, MSc - PhysicianMagee-Womens Hosp. of the Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA.5:00 p.m.454 Beyone TORCH: The New Paradigm for Pesky Perinatal InfectionsMichael G. Gravett, MD - ProfessorUniv. of Washington Sch. of Med., Seattle, WA.5:30 p.m.455 Malaria and Other Parasitic Infections During PregnancyR. Philips Heine, MD - Associate ProfessorDuke Univ. Med. Ctr., Durham, NC.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Define important infections that complicate pregnancy;> Determine which antimicrobials are safe for use in pregnancy; and> Improve the care of pregnant women with infection or at risk forinfection.Intended Audience: Healthcare providers and investigators with an interestin perinatal maternal and child health.Level: IntermediateFinal Program67

Sunday SCIENTIFIC SESSIONS------------------------------------------------------------------------046(M)SymposiumMycology 2012: Top PapersSunday, 4:00 p.m.– 6:00 p.m. .................... Room 132UAN: 0391-9999-12-050-L04-PConvener:Dimitrios P. Kontoyiannis, MD - Frances King Black Endowed ProfessorUniv. of Texas MD Anderson Cancer Ctr., Houston, TX.Experts:456 Thomas F. Patterson, MD - Professor and Chief, Infectious DiseaseUniv. of Texas Hlth. Sci. Ctr., San Antonio, TX.457 David Denning, MD - ProfessorUniv. Hosp. of South Manchester, Manchester, United Kingdom.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Analyze major findings in fungal diseases;> Understand new insights into the diagnosis and management of invasivefungal infections; and> Identify epidemiology features and understand pathogenesis of invasivefungal infections.Intended Audience: Clinicians, trainees, mycologists and researchers.Level: Advanced------------------------------------------------------------------------047(C1)Slide SessionStructure/FunctionSunday, 4:00 p.m.–6:30 p.m. ....... Esplanade Ballroom 300UAN: 0391-9999-12-051-L04-PModerators:Timothy G. Palzkill, PhD - ProfessorBaylor Coll. of Med., Houston, TX.Laurent Poirel, PhD - Senior ScientistHop. de Bicetre, Le Kremlin Bicetre, France.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Identify molecular mechanisms of resistance;> Discuss the general properties that govern the relationship between antibioticand resistance proteins; and> Discuss the correlation of 3D structure with mechanistic activity of resistanceprotien.Presentations:4:00 p.m.C1-458 Structural and Functional Characterization of AminoglycosideN-Acetyltransferases AAC(6’)-Ig and -Ih from Acinetobacter sppP. J. Stogios, PhD - Research Scientist 1,2 , D. Meziane-Cherif, PhD - ResearchScientist 3 , E. Evdokimova, MSc - Research Technician 1,2 , A. Savchenko, PhD- Professor 1,2 , P. Courvalin, MD, FRCP - Professor 3 ; 1 Univ. of Toronto, Toronto,Canada, 2 Ctr. for Structural Genomics of Infectious Diseases, Toronto,Canada, 3 Inst. Pasteur, Paris, France.4:15 p.m.C1-459 Crystal Structure of the Class A Beta-Lactamase from Bacilluslicheniformis BS3 Inhibited by TazobactamP. Power, PhD - Researcher 1 , P. Mercuri, PhD - Researcher 2 , R. Herman,BSc - Research Assistant 2 , F. Kerff, PhD - Researcher 2 , G. Gutkind, PhD -Researcher 1 , M. Galleni, PhD - Researcher 2 , P. Charlier, PhD - Researcher 2 ,E. Sauvage, PhD - Researcher 2 ; 1 Univ. of Buenos Aires, Buenos Aires, Argentina,2 Univ. of Liege, Liege, Belgium.4:30 p.m.C1-460 Crystal Structures of the Pen-Lactamases of Burkholderiacepacia (Bc) and Burkholderia pseudomallei (Bp)K. M. Papp-Wallace, PhD - Research Scientist and Instructor 1 , R. A.Bonomo, MD - Professor 1 , N. Ohuchi, PhD - Research Associate 2 , M. Nukaga,PhD - Associate Professor 2 ; 1 Cleveland VAMC and CWRU, Cleveland,OH, 2 Josai Intl. Univ., Togane City, Chiba, Japan.4:45 p.m.C1-461 Evolutionary Mechanisms for Metallo-Beta-LactamasesM. R. Meini, BS - PhD, M. M. Gonzalez, BS - PhD, P. E. Tomatis, PhD -Research Assistant, A. J. Vila, ScD - Professor; IBR, Rosario, Argentina.5:00 p.m.C1-462 Structural and Biochemical Characterization of SubstrateSpecificity Determining Residues in CTX-M-14A. Cardenas, BS - Graduate Student, N. G. Brown, PhD - Research Associate,L. B. Horton, PhD - Research Associate, T. G. Palzkill, PhD - Professor;Baylor Coll. of Med., Houston, TX.5:15 p.m.C1-463 Unraveling a Final Common Pathway: The K234R Substitutionin SHV Mediates Amoxicillin/Clavulanic Acid (A/C)ResistanceM. L. Winkler, BA - Student 1 , E. Rodkey, BS - Student 1 , M. Taracila, MS- Research Assistant 1 , C. R. Bethel, MS - Research Assistant 2 , S. M. Drawz,PhD - Student 1 , K. Papp-Wallace, PhD - Investigator 2 , F. van den Akker,PhD - Professor 1 , R. A. Bonomo, MD - Professor 3 ; 1 CWRU, Cleveland, OH,2VAMC, Cleveland, OH, 3 CWRU, VAMC, Cleveland, OH.5:30 p.m.C1-464 Defining the Role of D179 in the Substrate Profile of KPC-2-LactamaseP. S. Levitt, B.A. - MD/PhD student 1 , K. M. Papp-Wallace, PhD - Instructor1,2, R. A. Bonomo, MD - Professor 3 ; 1 CWRU, Cleveland, OH, 2 ClevelandVAMC, Cleveland, OH, 3 VAMC, Cleveland, OH.5:45 p.m.C1-465 The Crystal Structure of the DIM-1 Metallo-Beta-Lactamasefrom Pseudomonas stutzeriM. P. S. Booth, PhD - Research Assistant 1 , L. Poirel, PhD - Associate Researcher2 , P. Nordmann, MD, PhD - Professor 2 , J. Spencer, PhD - Lecturer 1 ;1Univ. of Bristol, Bristol, United Kingdom, 2 Hosp. de Bicêtre, Paris, France.6:00 p.m.C1-466 INQ-1: Preliminary Characterization of a-Lactamase fromInquilinus limosusM. Pino, Lic. - Reseacher, P. Power, PhD - Reseacher, J. Di Conza, PhD -Professor, M. Ruggiero, Lic. - Researcher, G. Gutkind, PhD - Professor; Fac.Farm. y Bioq., UBA, Buenos Aires, Argentina.68September 9-12 |

SUNDAY SCIENTIFIC SESSIONS6:15 p.m.C1-467 Substrate Specificity in Class D-Lactamases: A StructureBased Comparison of OXA-1 and OXA-24 with Oxacillin BoundC. M. June, MS - Research Assistant 1 , B. C. Vallier, undergraduate - Student1, R. A. Bonomo, MD - Professor 2 , D. A. Leonard, PhD - Professor 1 , R. A.Powers, PhD - Professor 1 ; 1 Grand Valley State Univ., Allendale, MI, 2 ClevelandVAMC, Cleveland, OH.------------------------------------------------------------------------048(K)Slide SessionDifficulties of Clostridium difficileSunday, 4:00 p.m.–6:30 p.m. .................... Room 254UAN: 0391-9999-12-052-L04-PModerator:Dale N. Gerding, MDEdward Hines Jr. VA Hosp., Hines, IL.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Describe current epidemiology of Clostridium difficile stain type C;> Identify factors associated with outcome of C. difficile infection; and> Discuss clinical and economic consequences of vancomycin and fidaxomicinin the treatment of C. difficile infection.Presentations:4:00 p.m.State-of-the-Art Minilecture468 Update on C.difficile InfectionDale N. Gerding, MDEdward Hines Jr. VA Hosp., Hines, IL.4:30 p.m.K-469 Clostridium difficile Strain Types from United States HospitalsF. C. Tenover, PhD - Executive Director 1 , M. Donnellan, MS - ResearchAssistant 2 , I. A. Tickler, BS - Scientist 1 , D. H. Persing, MD, Ph.D. - ChiefMedical and Technology Officer 1 , R. V. Goering, Ph.D. - Professor 2 , HAI Consortium;1 Cepheid, Sunnyvale, CA, 2 Creighton Univ., Omaha, NE.5:00 p.m.K-471 A U.S. Based National Sentinel Surveillance Study for theSusceptibility and Epidemiology of Clostridium difficile AssociatedDiarrheal IsolatesD. R. Snydman, MD - Chief 1 , L. A. McDermott, MT (ASCP) - ResearchAssociate 1 , N. V. Jacobus, MS, MPH - Research Associate 1 , E. J. C. Goldstein,MD - Director 2 , L. Harrell, MD - Professor 3 , R. Patel, MD, FRCP, FIDSA,FACP - Chair, Division of Clinical Microbiology 4 , S. G. Jenkins, PhD - Professorof Pathology and Laboratory Medicine 5 , S. J. Johnson, MD, DTM&H- Staff Physician, Medicine Service 6 , D. N. Gerding, MD - Chief, MedicalService 6 ; 1 Tufts Med. Ctr., Boston, MA, 2 RM Alden Res. Lab., Culver City,CA, 3 Duke Univ., Durham, NC, 4 Mayo Clinic, Rochester, MN, 5 New YorkPresbyterian Hosp., NY, NY, 6 VA Chicago Hlth. Care System, Chicago, IL.5:15 p.m.K-472 Mortality of Nosocomial Clostridium difficile Infections: AMulticenter Cohort StudyM. Hensgens, MD 1 , A. Goorhuis, MD - PhD 2 , O. Dekkers, MD - PhD 1 ,B. van Benthem, PhD - PhD 3 , E. Kuijper, MD - PhD 1 ; 1 LUMC, Leiden,Netherlands, 2 AMC, Amsterdam, Netherlands, 3 Natl. Inst. for Publ. Hlth.and the Environment, Bilthoven, Netherlands.5:30 p.m.K-473 Clinical and Economic Consequences of Vancomycin andFidaxomicin for the Treatment of Clostridium difficile Infection inCanadaM. Wagner, PhD - Director, Research Application, L. Lavoie, PhD - SeniorResearch Application Associate, M. Goetghebeur, PhD - Vice-President Operations;BioMedCom Consultants Inc., Montreal, Canada.5:45 p.m.K-474 Genomic Stability of Clostridium difficile NAP1/027 within aHuman Gut ModelM. H. Wilcox, MD - Professor 1 , D. W. Eyre, BM, BCh - Research Fellow 2 ,R. Bowden, PhD - Senior Researcher 2 , W. N. Fawley, PhD - Researcher 1 , C.H. Chilton, Ph.D - Researcher 1 , J. Freeman, PhD - Researcher 1 , T. E. A. Peto,D.Phil - Professor 2 ; 1 Univ. of Leeds, Leeds Teaching Hosp. & HPA, Leeds,United Kingdom, 2 NIHR Oxford Biomedical Res. Ctr., Oxford, UnitedKingdom.4:45 p.m.K-470 Characterisation of Swine Isolates of Clostridium difficile inSpain: A Potential Source of Hypervirulent Multidrug-ResistantStrains?T. Pelaez, PhD - Professor 1 , L. Alcala, PharmD - Researcher 1 , J. L. Blanco,PhD - Professor 2 , M. Marin, PhD - Researcher 1 , A. Martin-Lopez, PhD -Researcher 1 , S. Alvarez-Perez, PhD - Researcher 2,3 , M. E. Garcia, PhD - Professor2 , E. Bouza, PhD - Professor 1 ; 1 Hosp. Gen. Gregorio Marañon, Madrid,Spain, 2 Facultad Veterinaria UCM, Madrid, Spain, 3 Hosp. Gen. GregorioMarañon, Madrid, Spain.Final Program69

NOTES70September 9-12 |

Monday Schedule at-a-Glance> 7:00 a.m. - 8:15 a.m.Meet-the-Experts049 (A) Surgical Prophylaxis: DosageRecommendations, Tissue Penetration, andPharmacokinetic ConsiderationsEsplanade Ballroom 305050 (D) Syphilis Diagnostics: TraditionalVersus “New” AlgorithmRoom 122051 (G) Antibiotic Shortages, AntibioticStewardship and the Sick ChildEsplanade Ballroom 309052 (H) How Do I Treat HCV in HIV/HCVCo-Infected Patients?Room 121053 (K) Infection Prevention and Control inLow- and -Middle-Resource SettingsEsplanade Ballroom 308054 (K) Top Papers in Infection Preventionand Control, 2011-2012Room 120066 (F) Host Defense (Antimicrobial)Peptides: Major Players in Health and NovelTherapeuticsEsplanade Ballroom 300067 (G) Hot Topics in VaccinesRoom 120068 (K) Preventing Spread of M. tuberculosis inHealthcare FacilitiesRoom 122069 (L) New Issues in the Management ofMDR/XDR TBEsplanade Ballroom 306070 (L1) New Insights in Diabetic FootInfections and OsteomyelitisRoom 121071 (L2) An Update on the Treatment andPrevention of UTIsRoom 102072 (M) Research in Mycology: Hot TopicsRoom 132> 8:30 a.m. - 11:00 a.m.Slide Session081 (C1) Carbapenemase in Enterobacteriaceaeand P. aeruginosaRoom 122> 11:15 a.m. - 1:15 p.m.Poster Sessions082 (A) Glycopeptides and Lipopeptides:What’s New in PK/PD and SafetyHalls A-C083 (A) Improving Pharmacodynamics ofBeta-Lactams and Beta-Lactamase InhibitorsHalls A-C084 (B) Antimicrobial Therapy in AnimalModels IHalls A-C085 (C1) Genetics and ResistanceHalls A-C086 (C1) Resistance by Efflux/QuinoloneResistanceHalls A-CMonday055 (L) Challenging Infections in OlderAdultsEsplanade Ballroom 310056 (L1) Difficult to Manage CutaneousInfections in Adults and ChildrenEsplanade Ballroom 302057 (M) Fungal Infections Involving the EyeRoom 102058 (P) Top Ten Papers in Travel and TropicalMedicineEsplanade Ballroom 306059 (V) Persistent Herpes Virus Viremia:What Does it Mean?Esplanade Ballroom 300> 8:30 a.m. - 10:30 a.m.Interactive Symposium060 (D) Cases in Clinical MicrobiologyRoom 103Symposia061 (A, L) Targeting Gram-NegativeSuperbugs with Polymyxins: From Lab-Benchto BedsideEsplanade Ballroom 305062 (B) Malnutrition, Microbiome & MucosalImmunityEsplanade Ballroom 308063 (B) Pathogenesis, Diagnosis andTreatment of Urinary Tract InfectionRoom 130064 (C1) Plasmid-Mediated QuinoloneResistanceEsplanade Ballroom 302065 (C2) Population Dynamics in StreptococcuspneumoniaeEsplanade Ballroom 310Slide Sessions073 (H) New Antiretroviral Therapy: Benchto BedsideRoom 104074 (K) Multidrug-Resistant Organisms:and Catheter-Related InfectionsRoom 254075 (P) Parasitology, Global Health and TravelMedicineEsplanade Ballroom 309> 11:15 a.m. -12:15 p.m.Poster WalkDaily Infection Prevention and Control IssuesHalls A-C> 11:15 a.m. - 12:45 p.m.Interactive Symposium076 (K) Challenges in Infection ControlRoom 104Symposia077 (G, H) Vaccine InnovationsEsplanade Ballroom 305078 (L, F) 50 Years of Fluoroquinolones: Past,Present and FutureRoom 132079 (L) An Update on StreptococcalPharyngitis and Rheumatic FeverEsplanade Ballroom 302080 (V, H) Hot Topics in Viral HepatitisRoom 130087 (C2) Diverse Resistance Issues inEnterobacteriaceaeHalls A-C088 (C2) Food, Animals and EnvironmentReservoirs for Gram-Negative OrganismsHalls A-C089 (C2) Pseudomonas aeruginosa: AnOverview of Survelliance DataHalls A-C090 (D) MALDI-ToF Mass Spectrometry andIdentification and Susceptibility TestingHalls A-C091 (D) Mycobacteria: Diagnostics andSusceptibility TestingHalls A-C092 (D) Phenotypic Susceptibility TestingMethodsHalls A-C093 (E) Cornucopia of in Vitro ActivityHalls A-C094 (E) In Vitro Activity Against Multidrug-Resistant Gram-Negative BacteriaHalls A-C095 (E) In Vitro Activity Versus AnaerobesHalls A-C096 (F) New Antifungal AgentsHalls A-C097 (F) New Antiviral AgentsHalls A-C098 (F) New Approaches in MycobacterialTherapyHalls A-C

Monday Schedule at-a-Glance continued…> 11:15 a.m. - 1:15 p.m.099 (F) Targeting the Bacterial Cell Wall: NewBeta-Lactams and Beta-Lactamase InhibitorCombinationsHalls A-C100 (G) Impact of Expanded Valent:Pneumococcal VaccinesHalls A-C101 (G) Updates in VaccinesHalls A-C102 (H) Antiretroviral Therapy OutcomesIncluding Select PopulationsHalls A-C103 (H) Safety and Toxicity of AntiretroviralTherapyHalls A-C104 (K) Blood Stream InfectionsHalls A-C105 (K) Clostridium difficile InfectionsHalls A-C106 (K) EndocarditisHalls A-C107 (K) Fungal InfectionsHalls A-C108 (K) InfluenzaHalls A-C109 (L1) An Update on TuberculosisHalls A-C110 (L1) Zoonotic InfectionsHalls A-C111 (M) Experimental MycologyHalls A-C112 (P) Global Health, Parasitology andTravel MedicineHalls A-C113 (T) Infections in Transplant Recipientsand Patients with MalignanciesHalls A-C> 12:15 p.m. - 1:15 p.m.Poster WalkResistance Genes Have No Boundaries!Halls A-C> 1:30 p.m. - 4:00 p.m.Slide Sessions114 (G) Vaccines: Innovations, Impact andSafetyRoom 121115 (M) Sleuthing in MycologyEsplanade Ballroom 310116 (T) Infections in Transplant RecipientsRoom 120117 (V) Respiratory Viruses and MeaslesEsplanade Ballroom 309> 2:00 p.m. - 4:00 p.m.Interactive Symposia118 (K) Evidence-Based Infection Preventionand Control: Answering Key QuestionsRoom 104119 (P) Clinical Problem Solving: InteractiveCases in Travel and Tropical MedicineRoom 103Symposia120 ICAAC LiveEsplanade Ballroom 303This Week in Microbiolgy with VincentRacaniello121 (A) Aerosol Drug Delivery: Getting Anti-Infective Agents to the LungRoom 130122 (B) Bacterial and Viral Infections inPatients Treated with Novel Biologic Agents:What Do I Need to Know?Esplanade Ballroom 300123 (C2) Antibiotic Combinations againstGram-Negatives in the XDR Era: From Benchto BedsideRoom 122124 (D) Epidemiology and Diagnosis ofFebrile Illness in the Era of Global ClimateChangeRoom 102125 (F) Alternative Approaches to InhibitingGram-Negative BacteriaEsplanade Ballroom 308126 (H) Current Issues in HIV-AssociatedOpportunistic DiseasesEsplanade Ballroom 306127 (L) New Issues in the Management ofMultidrug-Resistant (MDR) EndocarditisEsplanade Ballroom 305128 (M) Fungal Infections in High-RiskGroups: Current and Future Strategies forControlEsplanade Ballroom 302Slide Session129 (K) Staphylococcus aureus: Tough Bug,Tough TreatmentRoom 132> 4:30 p.m. - 5:30 p.m.ICAAC Lecture130 ICAAC LectureRoom 103> 5:45 p.m. - 7:00 p.m.Meet-the-Experts131 (A) Top Papers in Anti-Infective andAntiretroviral PK/PDEsplanade Ballroom 310132 (C2) Detecting, Controlling, and TreatingCarbapenemase-Producing EnterobacteriaceaeEsplanade Ballroom 302133 (D) MALDI-ToF and PCR/ESI MassSpectrometry: Implementation and Impact onPatient CareRoom 121134 (H, V) Prevention of Anal Cancer inHIV-Infection: From Early Detection toVaccinationEsplanade Ballroom 309136 (K) Preventing Line-AssociatedBloodstream Infection: Which Measures areEssential?Esplanade Ballroom 308137 (P) Controversies in Pre-TravelPreparationRoom 122138 (V, H) New Strategies for Transplantationof HIV Infected IndividualsEsplanade Ballroom 300> 5:45 p.m. - 7:15 p.m.Symposium130a ICAAC-GCACMID SymposiumRoom 102

MONDAY SCIENTIFIC SESSIONS----------------------------------------------------------------------------------049(A)Meet-the-ExpertsSurgical Prophylaxis: Dosage Recommendations, TissuePenetration, and Pharmacokinetic ConsiderationsMonday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 305UAN: 0391-9999-12-053-L04-PConvener:Joseph S. Solomkin, MD - Professor of SurgeryUniv. of Cincinnati Coll. of Med., Cincinnati, OH.Experts:475 Douglas N. Fish, PharmD - ProfessorUniv. of Colorado Sch. of Pharmacy, Aurora, CO.476 Kevin W. Garey, PharmD, MS - Associate Professor and ChairUniv. of Houston, Coll. of Pharmacy, Houston, TX.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> List the current dosage recommendations of antimicrobial agents commonlyused for surgical prophylaxis;> Describe the pharmacokinetic/pharmacodynamic and tissue penetrationconsiderations of antimicrobial agents for surgical prophylaxis; and> Evaluate current dosing recommendations for surgical prophylaxis inobese patients.Intended Audience: Physicians, pharmacists, and microbiologists.Level: Intermediate------------------------------------------------------------------------050(D)Meet-the-ExpertsSyphilis Diagnostics: Traditional Versus “New” AlgorithmMonday, 7:00 a.m.–8:15 a.m. .................... Room 122UAN: 0391-9999-12-054-L04-PExperts:477 Kimberly Workowski, MD - Professor of MedicineEmory Univ. Sch. of Med., Atlanta, GA.478 Khalil G. Ghanem, MD, PhD - Associate Professor of MedicineJohns Hopkins Univ. Sch. of Med., Baltimore, MD.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe the traditional and reverse sequence algorithm for the diagnosisof syphilis;> Identify the strengths and weaknesses of each approach; and> Assess the impact of the algorithm on patient care and public healthpractice.Intended Audience: Clinical microbiologists and infectious diseases clinicians.Level: Intermediate------------------------------------------------------------------------051(G)Meet-the-ExpertsAntibiotic Shortages, Antibiotic Stewardship and theSick ChildMonday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 309UAN: 0391-9999-12-055-L04-PExperts:479 Jason G. Newland, MD - Associate Professor of PediatricsUniv. of Missouri, Kansas City Sch. of Med. and Children’s Mercy Hosp.,Kansas City, MO.480 Mike Sharland, MD - ProfessorSt. George’s Hosp., London, United Kingdom.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discuss the basis for shortages of antibiotics employed in the care of sickchildren;> Assess the importance of antibiotic stewardship to the care of children;and> Apply principles of antibiotic stewardship relevant to the care of children.Intended Audience: Physicians, public health practitioners, epidemiologists,pharmacists and all with an interest in issues pertaining to antimicrobialstewardship and shortages.Level: Beginning/Intermediate------------------------------------------------------------------------052(H)Meet-the-ExpertsHow Do I Treat HCV in HIV/HCV Co-Infected Patients?Monday, 7:00 a.m.–8:15 a.m. .................... Room 121UAN: 0391-9999-12-056-L02-PExperts:481 Charles W. Flexner, MD - ProfessorJohns Hopkins Univ. Sch. of Med., Baltimore, MD.482 Vincent Soriano, MD, PhD - Associate Professor of MedicineHosp. Carlos III & Univ. Complutense of Madrid, Madrid, Spain.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Review recent data with direct acting anti-HCV drugs for the treatmentof HCV-infection;> Discuss the unsettled issues and pitfalls of using DAAs for the treatmentof HCV-infection in HIV-infected patients; and> Describe the most significant drug-drug interactions between anti-HCVand HIV drugs.Intended Audience: HIV treating physicians, ID professionals, clinicalvirologists, primary care physicians, hepatologists, pharmacologists, andindustry professionals.Level: Intermediate/AdvancedFinal Program71

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------053(K)Meet-the-ExpertsInfection Prevention and Control in Low- and Middle-Resource SettingsMonday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 308UAN: 0391-9999-12-057-L04-PExperts:483 Benedetta Allegranzi, MD – PhysicianWorld Health Organization, Geneva, Switzerland.484 Shaheen Mehtar, MD - ProfessorFac of Hlth. Sci., Stellenbosch Univ., Cape Town, South Africa.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Measure the importance of infection prevention in countries with limitedresources;> Discuss possible surveillance strategies to be implemented in countrieswith limited resources;> Identify the most frequent healthcare-associated infections in countrieswith limited resources; and> Discuss the barriers to infection control in countries with limited resources.Intended Audience: ID specialists, infection control professionals, hospitalepidemiologists, public health professionals, and hospital administrators.Level: Beginning/Intermediate------------------------------------------------------------------------054(K)Meet-the-ExpertsTop Papers in Infection Prevention and Control, 2011-2012Monday, 7:00 a.m.–8:15 a.m. .................... Room 120UAN: 0391-9999-12-058-L04-PExperts:485 Andreas Voss, MD, PhD - Professor of Infection ControlCanisius-Wilhelmina Hosp. & RUNMC, Nijmegen, Netherlands.486 Loreen Herwaldt, MD - Professor, Hospital EpidemiologistUniv. of Iowa Coll. of Med., Iowa City, IA.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Provide a critical review of recently published papers in the field;> Prioritize information in the literature; and> Summarize changes in practice and novel discoveries in the field.Intended Audience: ID specialists, infection control professionals, andhospital epidemiologists.Level: Beginning/Intermediate------------------------------------------------------------------------055(L)Meet-the-ExpertsChallenging Infections in Older AdultsMonday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 310UAN: 0391-9999-12-059-L04-PExperts:487 Ebbing Lautenbach, MD, MPH, MSCE - Professor of Medicine andEpidemiologyUniv. of Pennsylvania Sch. of Med., Philadelphia, PA.488 Preeti N. Malani, MD, MSJ - Associate ProfessorUniv. of Michigan, Ann Arbor, MI.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Identify important infectious diseases in older adults;> Describe the impact of infections on older adults; and> Improve their care of older adults with infections.Intended Audience: Healthcare providers and investigators interested ininfections of older adults.Level: Intermediate------------------------------------------------------------------------056(L1)Meet-the-ExpertsDifficult to Manage Cutaneous Infections in Adults andChildrenMonday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 302UAN: 0391-9999-12-060-L04-PExperts:489 John W. Baddley, MD, MSPH - Associate ProfessorUniv. of Alabama, Birmingham, AL.490 Clarence B. Creech, MD, MPH - Assistant ProfessorVanderbilt Univ. Sch. of Med., Nashville, TN.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discriminate important infections of skin and soft tissue;> Describe the approach to diagnosing and managing challenging skin andsoft tissue infections; and> Improve their care of patients with cutaneous infections.Intended Audience: Healthcare practitioners and investigators with aninterest in skin and soft tissue infections.Level: Intermediate72September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------057(M)Meet-the-ExpertsFungal Infections Involving the EyeMonday, 7:00 a.m.–8:15 a.m. .................... Room 102UAN: 0391-9999-12-061-L04-PExperts:491 Carol A. Kauffman, MD - ProfessorUniv. of Michigan, Ann Arbor, MI.492 Grant Comer, MD - Assistant ProfessorKellogg Eye Ctr., Ann Arbor, MI.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Apply the principles of PK/PD to antifungal drug use in eye infections;> Integrate, and interpret the results of, current diagnostics in the managementof eye infections;> Discuss the scope and presentations of the problem in a resource poorcountry; and> Apply this experience-based knowledge to clinical practice.Intended Audience: Mycology researchers, ID physicians and trainees.Level: Intermediate------------------------------------------------------------------------058(P)Meet-the-ExpertsTop Ten Papers in Travel and Tropical MedicineMonday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 306UAN: 0391-9999-12-062-L04-PDeveloped in Cooperation with the American Society of Tropical Medicine andHygiene (ASTMH)Experts:493 Eric Caumes, MD - ProfessorHosp. Pitié-Salpêtrière, Univ. Pierre-et-Marie-Curie, Paris, France.494 Phil Coyne, MD, MSPH - Assistant Professor, Tropical Public HealthUniformed Services Univ. of Hlth. Sci., Bethesda, MD.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Cite the latest significant literature on travel medicine;> Describe the epidemiology of travel related illnesses; and> Identify issues in prevention of these illnesses.Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists,and general physicians.Level: Intermediate------------------------------------------------------------------------059(V)Meet-the-ExpertsPersistent Herpes Virus Viremia: What Does it Mean?Monday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 300UAN: 0391-9999-12-063-L04-PExperts:494 Upton D. Allen, MD, MBBS - ProfessorHosp. for Sick Children, Univ. of Toronto, Toronto, Canada.495 Paul Griffiths, MD, DSc - ProfessorUniv. Coll. London, UCL Med. Sch., London, United Kingdom.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Identify what is a relevant persisting viremia for CMV and EBV;> Identify the clinical relevance of this viremia; and> Discuss the different monitoring tools and the treatment options.Intended Audience: Clinical microbiologists, ID physicians and transplantspecialists.Level: Intermediate/Advanced------------------------------------------------------------------------060(D)Interactive SymposiumCases in Clinical MicrobiologyMonday, 8:30 a.m.–10:30 a.m. .................. Room 103UAN: 0391-9999-12-064-L04-PConvener:Deirdre Church, MD, PhD, FRCPC - ProfessorUniv. of Calgary and Calgary Lab. Services, Calgary, Canada.Speakers:496 Cases 1 and 2Deirdre Church, MD, PhD, FRCPC - ProfessorUniv. of Calgary, Calgary Lab. Services, Calgary, Canada.497 Cases 3 and 4Duane W. Newton, PhD - Director, Clinical Microbiology LaboratoriesUniv. of Michigan Hosp. and Hlth. Ctr., Ann Arbor, MI.498 Cases 5 and 6Dominic E. Dwyer, MD - ProfessorWestmead Hosp. at the Univ. of Sydney, Sydney, Australia.499 Cases 7 and 8Guy Thwaites, MD, PhD - Consultant in Infectious Diseases and MicrobiologyKings Coll. London, London, United Kingdom.Objectives: Upon completion of this Interactive Symposium Session, theparticipant should be able to:> Describe the advantages and limitations of certain conventional andcontemporary diagnostic methods used for the identification of microbialpathogens;> Describe laboratory investigations in sick travelers returning from tropicalregions; and> Assess the laboratory approach to the diagnosis of infectious diseases.Final Program73

Monday SCIENTIFIC SESSIONSIntended Audience: Clinical microbiologists and infectious diseases clinicians.Level: Intermediate------------------------------------------------------------------------061(A, L)SymposiumTargeting Gram-Negative Superbugs with Polymyxins:From Lab-Bench to BedsideMonday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 305UAN: 0391-9999-12-065-L04-PDeveloped in Cooperation with the Society of Infectious Diseases Pharmacists(SIDP) and International Society Anti-Infective Pharmacology (ISAP)Conveners:Jian Li, PhD - Associate ProfessorMonash Inst. of Pharmaceutical Sci., Monash Univ., Parkville, Australia.Keith Kaye, MD, MPH - Professor of MedicineWayne State Univ. and Detroit Med. Ctr., Detroit, MI.Speakers:8:30 a.m.500 Mechanisms of Activity of Polymyxins and ResistanceJian Li, PhD - Associate ProfessorMonash Inst. of Pharmaceutical Sci., Monash Univ., Parkville, Australia.9:00 a.m.501 Polymyxin Therapy: What Does Combination Therapy Offer inthe Clinical Setting?Keith Kaye, MD, MPH - Professor of MedicineWayne State Univ. and Detroit Med. Ctr., Detroit, MI.9:30 a.m.502 Inhaled Polymyxins in Patients with Pneumonia and CysticFibrosisWilliam Couet, PhD - ProfessorUniv. de Poitiers, Poitiers, France.10:00 a.m.503 Polymyxin Nephrotoxicity: What Do We Know and How MightUnderstanding its Mechanism Help?Vincent H. Tam, PharmD - Associate ProfessorUniv. of Houston Coll. of Pharmacy, Houston, TX.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify the mechanisms of activity and resistance of polymyxin agents;> Recognize the role of inhaled polymyxins in patients with pneumonia andcystic fibrosis;> Evaluate recommendations for combination therapy with polymyxinagents; and> Describe the mechanisms of nephrotoxicity and dose-limiting adverseeffects of polymyxins.Intended Audience: Physicians, pharmacists, and microbiologists.Level: Intermediate------------------------------------------------------------------------062(B)SymposiumMalnutrition, Microbiome & Mucosal ImmunityMonday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 308UAN: 0391-9999-12-066-L04-PConveners:William A. Petri, Jr, MD, PhD - Professor and Chief, Division of InfectiousDiseasesUniv. of Virginia, Charlottesville, VA.Cecil Czerkinsky, DMD, PhD - ProfessorIntl. Vaccine Inst., Seoul, Korea, Republic of.Speakers:8:30 a.m.504 Characterization of the Immune System of Children in theDeveloping WorldMark M. Davis, PhD - Burt and Marion Avery Family Professor ofImmunologyStanford Univ., Palo Alto, CA.9:00 a.m.505 Growth and Malnutrition in Children in the GambiaAndrew M. Prentice, PhD - Director, MRC International Nutrition GroupLondon Sch. of Hygiene and Tropical Med., London, United Kingdom.9:30 a.m.506 Functional Studies of the Gut Microbiomes of Malawian TwinPairs Discordant for KwashiorkorMichelle I. Smith, PhD - Postdoctoral Research FellowWashington Univ., St. Louis, MO.10:00 a.m.507 Oral Polio Vaccine Failure in Bangladesh and its Relationship toMalnutrition and Tropical EnteropathyWilliam A. Petri, Jr., MD, PhD - Professor and Chief, Division of InfectiousDiseasesUniv. of Virginia, Charlottesville, VA.Objectives: Upon completion of this Workshop, the participant should beable to:> Discuss the broad concepts of induction of mucosal immunity, including therole of macro- and micronutrients, microbiome and vaccination strategies;> Assess how malnutrition is the most common cause of immunodeficiencyin children;> Describe tropical (aka environmental) enteropathy; andAssess how the microbiome enables nutrition.Intended Audience: Scientists, physicians and public health professionalsinterested in the immune system of the intestine and elucidation of how it isdifferent in children exposed to multiple enteric infections in the developingworld.Level: Intermediate/Advanced74September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------063(B)SymposiumPathogenesis, Diagnosis and Treatment of Urinary TractInfectionMonday, 8:30 a.m.–10:30 a.m. .................. Room 130UAN: 0391-9999-12-067-L04-PConveners:Scott J. Hultgren, PhD - Helen L. Stoever Professor of Molecular Microbiology;Director Center for Women’s Infectious Disease ResearchWashington Univ. Sch. of Med., St. Louis, MO.Thomas M. Hooton, MD - ProfessorUniv. of Miami Miller Sch. of Med., Miami, FL.Speakers:8:30 a.m.508 Innate Immunity, Genetics and Susceptibility to Urinary TractInfectionCatharina M. Svanborg, MD, PhD - ProfessorLund Univ., Lund, Sweden.8:50 a.m.509 The Pathogenesis of Chronic and Recurrent CystitisThomas J. Hannan, DVM, PhD - Research Instructor in ImmunobiologyWashington Univ. Sch. of Med., Saint Louis, MO.9:10 a.m.510 Global Spread of Multidrug-Resistance in UTIMarie-Helene Nicolas-Chanoine, MD, PhD - ProfessorHopital Beaujon, Clichy, France.9:30 a.m.511 Treatment Guidelines for UTIThomas M. Hooton, MD - Professor of Clinical MedicineUniv. of Miami, Miami, FL.9:50 a.m.512 Development of Novel Therapeutics for Treatment of UTIScott J. Hultgren, PhD - Helen L. Stoever Professor of Molecular Microbiology;Director, Center for Women’s Infectious Disease ResearchWashington Univ. Sch. of Med., St. Louis, MO.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the epidemiology of UTI and the increasing prevalence of MDRuropathogens;> Discuss basic concepts of innate immunity relevant to UTI;> Identify basic concepts of molecular pathogenesis of UTI;> Utilize recent guidelines for the treatment of UTI; and> Analyze novel approaches under study to prevent UTI.Intended Audience: Infectious disease scientist/clinician, urologist, internalmedicine, microbiologists, pediatricians, immunologists, and pharmacologists.Level: Advanced------------------------------------------------------------------------064(C1)SymposiumPlasmid-Mediated Quinolone ResistanceMonday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 302UAN: 0391-9999-12-068-L04-PConveners:Patricia Bradford, PhD - Associate ResearcherAstraZeneca Pharmaceuticals, Waltham, MA.Laurent Poirel, PhD - Senior ScientistHosp. Bicetre, South Paris Med. Sch., Kremlin-Bicetre, France.Speakers:8:30 a.m.513 QNR UpdateGeorge A. Jacoby, MD - Research AssociateLahey Clinic, Burlington, MA.9:00 a.m.514 The Genetics and Function of QepLaurent Poirel, PhD - Associate ResearcherHosp. Bicetre, South Paris Med. Sch., Kremlin-Bicetre, France.9:30 a.m.515 Genetics and Function of aac(6’)-Ib-crDavid C. Hooper, MD - ProfessorMassachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA.10:00 a.m.516 Epidemiology of Plasmid-Mediated Quinolone-ResistanceGenesLuis Martinez-Martinez, MD, PhD - ProfessorUniv. Hosp. Marqués de Valdecilla, Univ. of Cantabria, Santander, Spain.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Recognize the names of genes causing plasmid-mediated resistance(PMQR) to quinolones;> Review the mechanisms by which these elements cause resistance tofluoroquinolones;> Describe the fluoroquinolone antibiotics affected by these genes and theMIC values that might indicate the presence of a PMQR gene; and> Assess the spread of these genes both geographically and the scope ofbacterial pathogens involved.Intended Audience: Physicians and microbiologists.Level: IntermediateFinal Program75

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------065(C2)SymposiumPopulation Dynamics in Streptococcus pneumoniaeMonday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 310UAN: 0391-9999-12-069-L04-PConveners:Lesley McGee, PhD - Principal ScientistCDC, Atlanta, GA.Stephen D. Bentley, PhD - Principal ScientistWellcome Trust Sanger Inst., Hinxton, United Kingdom.Speakers:8:30 a.m.517 Status Update on Invasive Pneumococcal serotype and CloneDistribution Post-PCV13 in USABernard Beall, PhD - Head, Streptococcus LaboratoryCDC, Atlanta, GA.9:00 a.m.518 Viewing the Evolution of Pneumococci Through Their GenomeSequencesStephen D. Bentley, PhD - Principal ScientistWellcome Trust Sanger Inst., Hinxton, United Kingdom.9:30 a.m.519 Streptococcus pneumoniae: Virulence Factors and VariationTim J. Mitchell, PhD - ProfessorUniv. of Birmingham, Birmingham, United Kingdom.10:00 a.m.520 PneuCarriage Project: Identifying the Best Method(s) to DetectCarriage of Multiple Pneumococcal serotypesCatherine Satzke, PhD - Senior Research OfficerMurdoch Childrens Res. Inst., Melbourne, Australia.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Provide an update on the serotype and clonal distribution post-PCV13in USA;> Recognize the role of next generation sequencing in the molecularepidemiology of S. pneumoniae;> Describe the importance of different virulence factors in infections dueto S. pneumoniae; and> Recommend the most appropriate serotyping methodologies forStreptococcus pneumoniae.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, clinical pathologists, medical technologists,epidemiologists and research scientists.Level: Intermediate------------------------------------------------------------------------066(F)SymposiumHost Defense (Antimicrobial) Peptides: Major Playersin Health and Novel TherapeuticsMonday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 300UAN: 0391-9999-12-070-L04-PConveners:Michael J. Pucci, PhD - Executive DirectorAchillion Pharmaceuticals, Inc., New Haven, CT.Robert Hancock, PhD - ProfessorUniv. of British Columbia, Vancouver, Canada.Speakers:8:30 a.m.521 Development of Innate Defense Regulator Peptides as Therapiesfor Infections and InflammationRobert Hancock, PhD - ProfessorUniv. of British Columbia, Vancouver, Canada.9:00 a.m.522 Peptides in Health and DiseaseRichard L. Gallo, MD, PhD - ProfessorUniv. of California, San Diego, CA.9:30 a.m.523 Peptides as Components of Advanced AdjuvantsVolker Gerdts, DVM, PhD - Associate Director - ResearchVIDO-InterVac, Univ. of Saskatchewan, Saskatoon, Canada.10:00 a.m.524 Nonpeptidic mimics of Host Defense PeptidesRichard W. Scott, PhD - Vice President, ResearchPolyMedix, Inc., Radnor, PA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the role of host defense proteins in the disease process;> Discuss the use of host defense peptides and peptidomimetics in the treatmentof infections and inflammation; and> Gain an appreciation opportunities and challenges of peptides as antiinfectiveagents.Intended Audience: Microbiologists, pharmaceutical and academic scientists.Level: Intermediate76September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------067(G)SymposiumHot Topics in VaccinesMonday, 8:30 a.m.–10:30 a.m. .................. Room 120UAN: 0391-9999-12-071-L04-PDeveloped in Cooperation with the Pediatric Infectious Diseases Society (PIDS)Conveners:Sarah S. Long, MD - Professor of Pediatrics, Chief of Infectious DiseasesDrexel Univ. Coll. of Med., St. Christopher’s Hosp. for Children, Philadelphia,PA.Ron Dagan, MD - ProfessorBen-Gurion Univ. of the Negev and Soroka Univ. Med. Ctr., Beer-Sheva,Israel.Panelists:8:30 a.m.525 Carol J. Baker, MD - Professor of Pediatrics, Molecular Virology & MicrobiologyBaylor Coll. of Med., Houston, TX.9:00 a.m.526 Kathleen M. Neuzil, MD, MPH - Director, Vaccine Access and DeliveryPATH, Seattle, WA.9:30 a.m.527 Kathryn M. Edwards, MD - Professor of PediatricsVanderbilt Univ., Nashville, TN.10:00 a.m.528 Jan Bonhoeffer, MD - Assistant ProfessorBrighton Collaboration, Basel, Switzerland.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Analyze the year’s important advances and biomedical discoveries in vaccinology;> Assimilate the context of new scientific findings by discussion withexperts in the field;> Anticipate the potential impact of discoveries on the prevention of infection;and> Plan strategies to apply new advances to further discovery or clinicalpractice.Intended Audience: Infectious disease physicians and physician extenders,public health officials and healthcare providers involved in vaccine development,advances and administration.Level: Beginning/Intermediate------------------------------------------------------------------------068(K)SymposiumPreventing Spread of M. tuberculosis in HealthcareFacilitiesMonday, 8:30 a.m.–10:30 a.m. .................. Room 122UAN: 0391-9999-12-072-L04-PConveners:Loreen Herwaldt, MD - Professor, Hospital EpidemiologistUniv. of Iowa Coll. of Med., Iowa City, IA.Arthur L. Reingold, MD- Professor and ChairUniv. of California, Berkeley, CA.Speakers:8:30 a.m.529 TB Infection Control ReconsideredEdward Nardell, MD - Associate ProfessorHarvard Med. Sch., Harvard Sch. of Publ. Health, Brigham & Women’sHosp., Boston, MA.9:00 a.m.530 Rapid Diagnostics: State-of-the-ArtLucien Davis, MD - Assistant Professor of MedicineUniv. of California, San Francisco, CA.9:30 a.m.531 Thinking Out of the Box: Using Giant Gambian PouchedRats for Second-Line Screening in Low- and Medium-IncomeCountriesAmanda D. Mahoney, MSAPOPO, Warren, MI.10:00 a.m.532 Heathcare Worker’s Risk of Acquiring Tuberculosis and ScreeningHealthcare Workers for TuberculosisArthur L. Reingold, MD - Professor and ChairSch. of Publ. Health, Univ. of California, Berkeley, CA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe two approaches that will be essential for controlling spread of M.tuberculosis in the 21st century;> Describe the pros and cons of current rapid diagnostic tools;> Describe a possible method for second-line screening for M. tuberculosis inresource limited countries; and> Describe the pros and cons of different methods for screening healthcareworkers for tuberculosis.Intended Audience: Clinical microbiologists, especially those working withMycobacteria, infectious disease physicians, physicians and microbiologistsinvolved in infection prevention, and public health professionals.Level: All LevelsFinal Program77

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------069(L)SymposiumNew Issues in the Management of MDR/XDR TBMonday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 306UAN: 0391-9999-12-073-L04-PConveners:William Bishai, MD, PhD - Director of K-RITHKwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV (K-RITH) and JohnsHopkins Ctr. for Tuberculosis Res., Durban, South Africa.Shiranee Sriskandan, MD, PhD - ProfessorImperial Coll., London, United Kingdom.Speakers:8:30 a.m.533 MDR TB: View from the FrontlineWilliam R. Bishai, Doctor, MD, PhD - Director of K-RITHKwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV (K-RITH) and JohnsHopkins Ctr. for Tuberculosis Res., Durban, South Africa.8:50 a.m.534 New Diagnostics for MDR TBMark Perkins, MD - Chief Scientific OfficerFndn. for Innovative Diagnostics (FIND), Geneva, Switzerland.9:10 a.m.535 MDR TB: View from WHO and Updated RecommendedRegimenTBD9:30 a.m.536 Surgery for MDR and Difficult to Treat TBJohn D. Mitchell, MD - Associate ProfessorUniv. of Colorado Sch. of Med., Natl. Jewish Health, Denver, CO.9:50 a.m.537 New Drugs in the Clinical Pipeline for TBMel Spigelman, MD - President and Chief Executive OfficerGlobal Alliance for TB Drug Dev., New York, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify new diagnostic approaches for resistance testing in Mycobacteriumtuberculosis;> Identify internationally-accepted management standards for treating casesof MDR and XDR M. tuberculosis; and> Identify options for alternative medical and surgical options in difficult totreat cases.Intended Audience: Infectious diseases physicians, medical microbiologists,tropical ID, and pharmaceutical development.Level: Intermediate------------------------------------------------------------------------070(L1)SymposiumNew Insights in Diabetic Foot Infections and OsteomyelitisMonday, 8:30 a.m.–10:30 a.m. .................. Room 121UAN: 0391-9999-12-074-L04-PConveners:Anthony R. Berendt, BM, BCh, FRCP - Consultant PhysicianNuffield Orthopaedic Ctr., Headington, United Kingdom.Adolf W. Karchmer, MD - Professor of Medicine, Harvard Medical SchoolBeth Israel Deaconess Med. Ctr., Boston, MA.Speakers:8:30 a.m.538 Do Clinical Guideline Help Us Manage DFIs Caused byMultidrug-Resistant Organisms?Anthony R. Berendt, FRCP - Deputy Medical DirectorOxford Univ. Hosp. NHS Trust, Oxford, United Kingdom.8:55 a.m.539 Drug Dosing for Complicated DFIs: Maximizing PK/PDDavid P. Nicolau, PharmD - Dir., Ctr for Anti-Infective Res & DevHartford Hosp., Hartford, CT.9:20 a.m.540 New Diagnostic Approaches to Diabetic Foot OsteomyelitisBenjamin A. Lipsky, MD - Professor, Department of MedicineVA Puget Sound Healthcare System, Seattle, WA and Univ. of Washington,Seattle, WA.9:45 a.m.541 Medical Management of Osteomyelitis: How to PreventAmputationsAdolf W. Karchmer, MD - Professor of Medicine, Harvard Medical SchoolBeth Israel Deaconess Med. Ctr., Boston, MA.10:10 a.m.Roundtable DiscussionObjectives: Upon completion of this Symposium Session, the participantshould be able to:> Define the impact of multidrug resistant pathogens to the management ofdiabetic foot infections;> Analyze options for diagnosing bone infections in the diabetic foot;> Determine the optimal dosing for antimicrobials used in the treatment ofinfections in diabetic feet; and> Manage diabetic foot infections in a more rational way.Intended Audience: Healthcare providers and investigators interested indiabetic foot infections.Level: Intermediate78September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------071(L2)SymposiumAn Update on the Treatment and Prevention of UTIsMonday, 8:30 a.m.–10:30 a.m. .................. Room 102UAN: 0391-9999-12-075-L04-PConveners:Lindsay E. Nicolle, MD - ProfessorUniv. of Manitoba, Winnipeg, Canada.Suzanne E. Geerlings, MD, PhD - Infectious Disease SpecialistUniv. Med. Ctr. Utrecht, Utrecht, Netherlands.Speakers:8:30 a.m.542 Do Cranberries or Other Natural Products Prevent UTIs?Suzanne E. Geerlings, MD, PhD - Infectious Disease SpecialistAcademic Med. Ctr., Amsterdam, Netherlands.9:00 a.m.543 Empiric UTI Therapy in the Era of the ESBLsBarbara K. Hasse, MD - Attending PhysicianUniv. Hosp. Zurich, Zurich, Switzerland.9:30 a.m.544 Developments in Asymptomatic Bacteriuria and UTI in OlderPopulationsLindsay E. Nicolle, MD - ProfessorUniv. of Manitoba, Winnipeg, Canada.10:00 a.m.545 Effective Strategies to Prevent Catheter-Associated UTIsBarbara W. Trautner, MD, PhD - Associate ProfessorBaylor Coll. of Med., Houston, TX.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the role of cranberries and other natural products in UTIprevention;> Improve their care of patients with UTIs caused by multidrug resistantpathogens;> Analyze the state of knowledge regarding asymptomatic bacteriuria; and> Improve prevention of catheter related UTIs.Intended Audience: Healthcare practitioners and investigators interested inurinary tract infections.Level: Intermediate------------------------------------------------------------------------072(M)SymposiumResearch in Mycology: Hot TopicsMonday, 8:30 a.m.–10:30 a.m. .................. Room 132UAN: 0391-9999-12-076-L04-PConveners:Tania C. Sorrell, MB, BS, MD, FRACP - ProfessorUniv. of Sydney, Sydney, Australia.John Perfect, MD - Interim Chief, Division of Infectious Diseases andInternational HealthDuke Univ. Med. Ctr., Durham, NC.Speakers:8:30 a.m.546 Multicentre Collaborative Studies: How Do They Work and Why?Peter G. Pappas, MD - Professor of MedicineUniv. of Alabama, Birmingham, AL.9:00 a.m.547 Cell-Based Therapies for IFIs in Haematology PatientsDavid J. Gottlieb, MD PhD - ProfessorUniv. of Sydney, Sydney, Australia.9:30 a.m.548 What the Site of a Fungal Infection Means for OutcomeMichail Lionakis, MD, ScD - Assistant Clinical InvestigatorNIAID, Bethesda, MD.10:00 a.m.549 What are the Possibilities for Use of Radioimmunotherapy forFungal Infections: The Data and the RealityJoshua Nosanchuk, MD - Associate ProfessorAlbert Einstein Coll. of Med., Bronx, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Debate issues and participate constructively in planning and execution ofmulticentre collaborative studies;> Discuss the status and potential of two non-drug experimental approachesto therapy of invasive fungal infections; and> Translate information on the relationship between site of a fungal infectionand outcome into clinical practice.Intended Audience: Mycology researchers, ID physicians and trainees.Level: IntermediateFinal Program79

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------073(H)Slide SessionNew Antiretroviral Therapy: Bench to BedsideMonday, 8:30 a.m.–11:00 a.m. .................. Room 104UAN: 0391-9999-12-077-L04-PModerators:Douglas J. Ward, MD - PhysicianDupont Circle Physicians Group, Washington, DC.Joseph Eron, Jr., MD - Professor of MedicineUniv. of North Carolina, Chapel Hill, NC.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Describe mechanisms of action of new antiretroviral therapy;> Assess the antiretroviral response to fixed dose combination therapy; and> Discuss the advantages and disadvantages on switching antiretroviraltherapy.Presentations:8:30 a.m.H-550 Antiviral Characteristics of S/GSK1265744, an HIV IntegraseInhibitor (INI) Dosed by Oral or Long-Acting Parenteral InjectionT. Yoshinaga, PhD - Section Head 1 , M. Kobayashi, MS - Section Head 1 , T.Seki, PhD - Team Leader 1 , T. Kawasuji, MS - Section Head 1 , T. Taishi, MS -Team Leader 1 , A. Sato, PhD - Department Head 1 , T. Fujiwara, PhD - ProjectLeader 1 , B. Johns, PhD - Medicinal Chemist 2 , R. Hazen, PhD - Virology 2 ,R. Ferris, PhD - Virology 2 , M. Underwood, PhD - Virology 2 ; 1 Shionogi,Toyonaka, Japan, 2 GlaxoSmithKline, Research Triangle Park, NC.8:45 a.m.H-551 Antiviral Activity and In Vitro Mutation Development Pathwaysof MK-1439: A Novel Non-Nucleoside Reverse TranscriptaseInhibitorM. Lai, PhD- Program Lead 1 , M. Feng, MS - Research Assistant 1 , M. Lu,MS - Research Assistant 1 , E. Asante-Appiah, PhD - Program Lead 2 , P.Tawa, MS - Research Assistant 2 , M. Witmer, MS - Research Assistant 1 , D.DiStefano, MS - Program Lead 1 , E. Cauchon, MS - Research Assistant 3 , L.Campeau, PhD - Program Lead 4 , Y. Yan, PhD - Program Lead 1 , M. Miller,PhD - Program Lead 1 , D. Hazuda, PhD - Vice President 1 ; 1 Merck & Co.Inc., West Point, PA, 2 Merck & Co. Inc., Kenilworth, NJ, 3 Merck & Co.Inc., Pointe Claire, Canada, 4 Merck & Co. Inc., Rahway, NJ.9:00 a.m.H-552 Virological Profiling of GS-7340, a Next-Generation TenofovirProdrug with Superior Potency Over TDFC. Callebaut, PhD - Sr Scientist, N. Margot, MS - Associate Scientist, G.Stepan, BS - Associate Scientist, Y. Tian, PhD - Research Scientist, M. Miller,PhD - Sr Director; Gilead Sci., Foster City, CA.9:15 a.m.H-553 Preferential Expansion of Transitional (T TM) and CentralMemory (T CM) CD4 T-Cells following Adoptive Transfer of ZFNCCR5 Modified Autologous CD4 T-Cells (SB-728-T)J. Zeidan, PhD - Fellow 1 , R. Bordi, PhD - Fellow 1 , S. Deeks, MD - Professor2 , R. Mitsuyasu, MD - Professor 3 , J. Lalezari, MD - Director 4 , G. Lee,PhD - Assoc Director 5 , S. Wang, MD - Director 5 , W. W. Tang, MD - VP 5 ,G. Nichol, MD - EVP 5 , M. Giedlin, PhD - VP 5 , R. Sekaly, PhD - Director1, D. Ando, MD - CMO 5 ; 1 VGTI, Port St Lucie, FL, 2 UCSF, San Francisco,CA, 3 UCLA, Los Angeles, CA, 4 Quest Clin Res, San Francisco, CA, 5 SangamoBiosciences Inc, Richmond, CA.9:30 a.m.H-554 Albuvirtide, the First Long-Acting HIV Fusion Inhibitor,Suppressed Viral Replicaiton in HIV-Infected AdultsH. Wu, MD - Division Chief 1 , C. Yao, PhD - Medical Manager 2 , R. J. Lu,PhD - Vice President 2 , T. Zhang, MD - Professor 1 , M. X. Wang, PhD -Professor 1 , H. X. Zhao, MD - Professor 3 , H. Y. Peng, MS - Research Assistant4, Y. Xie, BS - Research Assistant 2 , W. J. Min, MS - Research Assistant 2 , H.Jiang, PhD - Professor 2 , C. J. Wang, PhD - Professor 2 , D. Xie, PhD - ChiefScientific Officer 2 , R. H. Jin, MD - Professor 1 ; 1 Beijing You’an Hosp., CapitalMed. Univ., Beijing, China, 2 Chongqing Frontier Biotechnologies Co. Ltd.,Chongqing, China, 3 Beijing Ditan Hosp., Capital Med. Univ., Beijing,China, 4 Beijing Kao Ke Rui Co., Beijing, China.9:45 a.m.H-555 Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from an Integrated Analysis of Phase 2 and 3 ClinicalTrialsD. Ward, MD - Owner 1 , G. Crofoot, MD - Owner 2 , D. Shamblaw, MD -Owner 3 , N. Bellos, MD - Owner 4 , C. Kinder, MD - Owner 5 , M. Rhee, MD- As. Dir. 6 ; 1 Dupont Cir Physicians Gr, Wash, DC, 2 Gordon E. Crofoot,MD, Houston, TX, 3 La Playa Med and Clin Res, San Diego, CA, 4 SouthwestInfectious Disease Clin Res., Dallas, TX, 5 Kinder Med Gr., Miami, FL,6Gilead, Foster City, CA.10:00 a.m.H-556 Switching to the Single-Tablet Regimen (STR) Emtricitabine/Rilpivirine/TenofovirDF (FTC/RPV/TDF) from a Ritonavir-BoostedProtease Inhibitor (PI+RTV) and Two NucleosideReverse Transcriptase Inhibitors Maintains HIV Suppression andis Well Tolerated in HIV-1 Subjects at Week 24 Regardless of Age:SPIRIT StudyD. Shamblaw, MD 1 , F. Palella, MD 2 , P. Ruane, MD 3 , P. Tebas 4 , B. Gazzard 5 ,M. Fisher 6 , J. van Lunzen 7 , J. Flamm 8 , R. Ebrahimi 9 , K. White 9 , H. Graham9, B. Guyer, PharmD 9 , T. Fralich 9 , S. K. Chuck 9 ; 1 La Playa Med. Group, SanDiego, CA, 2 Northwestern Univ. Feinberg Sch. of Med., Chicago, IL, 3 PeterJ. Ruane, MD, Inc., Los Angeles, CA, 4 Univ. of Penn., Philadelphia, PA,5Chelsea and Westminster Hosp., London, United Kingdom, 6 Brighton andSussex Univ. Hosp., Brighton, United Kingdom, 7 Univ. Med. Ctr Hamburg-Eppendorf, Hamburg, Germany, 8 Kaiser Permanente, Sacramento, CA,9Gilead Sci., Foster City, CA.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.80September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------074(K)Slide SessionMultidrug-Resistant Organisms and Catheter-RelatedInfectionsMonday, 8:30 a.m.–11:00 a.m. .................. Room 254UAN: 0391-9999-12-078-L04-PModerator:Sylvia Munoz-Price, MD - Associate Professor of MedicineJackson Mem. Hosp., Univ. of Miami, Miami, FL.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Understand the epidemiology of MDROs in longterm care facilities;> List factors associated with survival of Acinetobacter baumannii in desiccatingconditions; and> Describe successful approaches to treating meningitis caused by multidrugresistant Acinetobacter.Presentations:8:30 a.m.K-557 Prevention of Carbapenem-Resistant Enterobacteriaceae(CRE) Spread in Long-Term Acute Care Facilities (LTACF) Via aNational InterventionD. Ben-David, MD - Physician, S. Masarwa, MD - Nurse, A. Adler, MD- Microbiologist, S. Navon-Venezia, PhD - Microbiologist, G. Smollan, MD -Microbiologist, B. Rubinovitch, MD - Physician, Y. Carmeli, MD - Physician,M. J. Schwaber, MD - Physician; Natl. Ctr. for Infection Control (NCIF),Israel Ministry of Health, Tel Aviv, Israel.8:45 a.m.K-558 Prevalence and Risk Factors for Multidrug-Resistant Organismsin Long-Term Care FacilitiesC. J. Lim, BPharm - PhD Student 1,2 , A. C. Cheng, MPH, PhD - AssociateProfessor of Infectious Diseases Epidemiology 1,2 , J. Kennon - Manager of InfectionPrevention and Healthcare Epidemiology 2 , D. Spelman, MBBS, MPH - Headof Microbiology 2 , D. Hale, BAS - Scientist of Microbiology 2 , D. C. M. Kong,MPharm, PhD - Lecturer 1 , A. Y. Peleg, MBBS, PhD - Senior Lecturer 1,2 ;1Monash Univ., Melbourne, Australia, 2 Alfred Hlth., Melbourne, Australia.9:00 a.m.K-559 Experimental and Proteomics Approach to Understand theSurvival of Acinetobacter baumannii in Desiccation ConditionsC. Gayoso, PhD - Research Assistant, J. Mateos, PhD - Research Assistant, J.Méndez, MS - Student, P. Fernandez, PhD - Research Sssistant, M. Tomás,MD, PhD - Research Assistant, G. Bou, PhD; Univ. La Coruña, La Coruña,Spain.9:15 a.m.K-560 Prevalence of Extended Spectrum Beta-Lactamase-ProducingEnterobacteriaceae (ESBL-PE) in Chicken Meat and Food Handlersat a University Hospital KitchenA. Stewardson, MD - Fellow 1 , G. Renzi, MS - Scientist 1 , C. Vaudaux, MS- Food Safety Officer 1 , C. Brossier, RN - Research Nurse 1 , E. Fritsch, MD -Physician 1 , C. Bonfillon, MD - Physician 1 , D. Pittet, MD - Professor 1 , N.Maury, MS - Microbiologist 2 , P. Edder, MS - Chemist 2 , J. Schrenzel, MD- Professor 1 , S. Harbarth, MD - Professor 1 ; 1 Univ. of Geneva Hosp., Geneva,Switzerland, 2 Dept. of Consumer & Vet. Affairs, Geneva, Switzerland.9:30 a.m.K-561 Laboratory Investigation of the Nosocomial Transmission ofMultiple Multi-Resistant Gram Negative Bacilli at a CanadianHospital from a Patient Transferred from a Foreign HospitalJ. Ahmed-Bentley, MD - Microbiologist 1,2 , A. U. Chandran, MD - HospitalEpidemiologist 3,2 , A. M. Joffe, MD - Infectious diseases physician 3,2 , A. Wolfe,BSc (MLS) - ICP 3 , S. Manca, BSc (MLS) - ICP 3 , K. Ng, BSc (MLS) -Technologist 1 , D. French, MLT - Technologist 1 , D. Andrews, MLT - Technologist1 , T. Lloyd, MLT - Technologist 4 , G. Peirano, PhD - Post-doc 4 , J. Pitout,MD - Microbiologist 4,5 ; 1 DynaLIFEDX, Edmonton, Canada, 2 Univ. ofAlberta, Edmonton, Canada, 3 Royal Alexandra Hosp., Edmonton, Canada,4Calgary Lab. Services, Calgary, Canada, 5 Univ. of Calgary, Calgary, Canada.9:45 a.m.K-562 Successful Treatment of Extensive Drug-Resistant (XDR) A.baumannii Meningitis with Intraventricular (IVR) Colistin (CST)after Application of a Loading Dose: A Case SeriesI. Karaiskos, MD - Attending Physician, L. Galani, MD - Infectious Diseasespecialist, F. Baziaka, PhD - Attending Physician, E. Katsouda, PhD - Intensivist,H. Paskalis, MD - Intensivist, I. Ioannidis, PhD - Interventional Neuroradiology,A. Andreou, PhD - Neurosurgery, H. Giamarellou, PhD - Professorof Internal Medicine; Hygeia Hosp., Athens, Greece.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------075(P)Slide SessionParasitology, Global Health and Travel MedicineMonday, 8:30 a.m.–11:00 a.m. ..... Esplanade Ballroom 309UAN: 0391-9999-12-079-L04-PModerator:Kevin Kain, MD, FRCPC - Professor of MedicineUniv. of Toronto, Toronto, Canada.Objectives: Upon completion of this Slide Session, the participant should beable to:> Describe a new molecular mechanism of resistance in Trichmonas vaginalis;> Compare the predictive utility of different clinical and laboratory featuresof severe dengue;> Contrast the differences between policy recommendations and thepractice reality in malaria; and> Describe and recognize prognostic features severe malaria in non-immuneadults.Presentations:8:30 a.m.P-563 A Novel tvntr6 Polymorphism is Associated with Trichomonasvaginalis Metronidazole ResistanceS. E. Gygax, PhD - Director 1 , T. E. Miller, MS - Research Associate 1 ,P. Augostini, MS - Biologist 2 , M. E. Adelson, PhD - Vice President 1 ,E. Mordechai, PhD - CEO 1 , W. E. Secor, PhD - Research Microbiologist 2 ,D. W. Hilbert, PhD - Team Leader 1 ; 1 FEMERIS Women’s Hlth. Res. Ctr.,Med. Diagnostic Lab., L.L.C., Hamilton, NJ, 2 CDC, Atlanta, GA.Final Program81

Monday SCIENTIFIC SESSIONS8:45 a.m.P-564 Attitude of Doctors Towards Infectious Disease Subspecialist:A Report from South IndiaP. Senthur Nambi, MD- Dr, R. Gopalakrishnan, MD - Doctor, A. Ghafur,MD - Doctor, P. Vidyalakshmi, MD - Doctor, C. Ashwini, MD - Doctor, V.Ramasubramanian, MD - Doctor; Apollo Hosp., Chennai, India.9:00 a.m.P-565 Malaria Guidelines in India: Is it in Paper or in Practice?D. Sureshkumar, MD, MD- ID Fellow, K. Abdul Ghafur, MD - ID Consultant,V. Ramasubramanian, MD - ID Consultant, P. Vidyalakshmi, DNB -ID Fellow, A. Tayade, DNB - ID Fellow; Apolo Hosp., Tamilnadu, India.9:15 a.m.P-566 Hospitalized Adults with Measles in France in the 21 st CenturyJ. Stahl, MD- Professor 1 , M. Ojielska, MD - Assistant 2 , A. Dinh, MD - Assistant3 , V. Corbin, MD - Assistant 4 , E. Botelho-Nevers, MD - Assistant 5 ,C. Biron, MD - Assistant 6 , S. Perin, MD - Assistant 7 , S. Gallien, MD - Assistant8 , E. Curlier, MD - Assistant 9 , T. Fraisse, MD - Head of department 10 ,C. Rabaud, PhD - Professor 11 , Steering Comittee; 1 Univ. Hosp., Grenoble,France, 2 Univ. Hosp., Poitiers, France, 3 Univ. Hosp., Garches, France, 4 Univ.Hosp., Clermont-Ferrand, France, 5 Univ. Hosp., Marseille, France, 6 Univ.Hosp., Nantes, France, 7 Univ. Hosp., Dijon, France, 8 Univ. Hosp., Paris,France, 9 Univ. Hosp., Besançon, France, 10 Gen. Hosp., Alès, France, 11 Univ.Hosp., Nancy, France.9:30 a.m.P-567 Utility and Gaps of Warning Signs in Adult DengueT. Thein, Research Fellow, Y. Leo, MRCP, FRCP, FAMS - Clinical Director,C. F. Yung, PhD - Consultant, V. C. Gan, MD - Medical Officer, J. G. Wong,BS - Medical Statistician, D. C. Lye, MBBS, FRACP, FAMS - Consultant;Tan Tock Seng Hosp., Singapore, Singapore.9:45 a.m.P-568 Cerebral Malaria During Severe Imported Malaria in Adults:Clinical Features, Prognostic Indices and Brain ImagingV. Laurent, MD - Doctor 1 , F. Tubach, MD, PhD - Professor 2 , M. Wolff,MD - Professor 2 , J. P. Mira, MD, PhD - Professor 3 , J. F. Timsit, MD, PhD- Professor 4 , E. Azoulay, MD, PhD - Professor 5 , C. Roy, PhD - Assistant 2 , F.Bruneel, MD - Doctor 1 ; 1 Versailles Hosp., Versailles, France, 2 Bichat Hosp.APHP, Paris, France, 3 Cochin Hosp. APHP, Paris, France, 4 Grenoble Hosp.,Grenoble, France, 5 Saint Louis Hosp. APHP, Paris, France.10:00 a.m.P-569 Predictors of Bacteremia in Adult DengueY. Leo, FRCP - Associate Professor 1,2 , M. Yeang, NA - Medical Student 2 , C.Yung, MPH - Doctor 1 , T. Thein, MPH - Doctor 1 , D. Lye, FRACP - Doctor1,2; 1 Tan Tock Seng Hosp., Singapore, Singapore, 2 Natl. Univ. Singapore,Singapore.10:15 a.m.P-570 Severe Imported Malaria in Adults: Multicenter ProspectivePhysiopathological StudyF. Bruneel, MD - Doctor 1 , F. Tubach, MD, PhD - Professor 2 , J. P. Mira, MD,PhD - Professor 3 , M. G. Huisse, MD - Doctor 2 , S. Houze, MD - Doctor 2 ,S. Gibot, MD, PhD - Professor 4 , S. Matheron, MD - Professor 2 , M. Wolff,MD - Professor 2 , SIMA-P Study Group; 1 Versailles Hosp., Versailles, France,2Bichat Hosp. AP HP, Paris, France, 3 Cochin Hosp. AP HP, Paris, France,4Nancy Central Hosp., Nancy, France.------------------------------------------------------------------------076(K)Interactive SymposiumChallenges in Infection ControlMonday, 11:15 a.m.–12:45 p.m. ................. Room 104UAN: 0391-9999-12-080-L04-PConveners:Didier Pittet, MD, MS - Professor of MedicineUniv. of Geneva Hosp., Geneva, Switzerland.Jean-Francois Timsit, MD, PhD - ProfessorCHU A. Michallon, Univ. Joseph Fourier, Grenoble, France.Speakers:571 A) Reality Check for Mathematical Models: Is MRSADecolonization in the ICU a Viable Option? PROBen S. Cooper, PhD - Research FellowMahidol-Oxford Res. Unit, Bangkok, Thailand.572 A) Reality Check for Mathematical Models: Is MRSADecolonization in the ICU a Viable Option? CONStephan Harbarth, MD, MS - ProfessorUniv. of Geneva Hosp., Geneva, Switzerland.573 B) Do Bundles of Infection Prevention Measures ProduceSustained Reductions in Catheter-Associated BloodstreamInfections? PROTBD574 B) Do Bundles of Infection Prevention Measures Produce SustainedReductions in Catheter-Associated BloodstreamInfections? CONJean-Francois Timsit, MD, PhD - ProfessorCHU A. Michallon, Univ. Joseph Fourier, Grenoble, France.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the advantages/disadvantages of MRSA prevention strategies inthe ICU setting;> Describe the concept of mathematical modeling, including its value andshortcomings in infection control;> Identify the concept of bundles and its role to help improve processes ofcare and patient outcomes; and> Identify the most effective components to be included in infection controlbundles for a sustained effect.Intended Audience: ID specialists, infection control professionals, hospitalepidemiologists, public health professionals, and hospital administrators.Level: Beginning/Intermediate82September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------077(G, H)SymposiumVaccine InnovationsMonday, 11:15 a.m.–12:45 p.m. .... Esplanade Ballroom 305UAN: 0391-9999-12-081-L04-PConveners:Carlo Giaquinto, MD - Medical Doctor PaediatricianAzienda Ospedaliera-Univ., Padova, Italy.Richard Koup, MD - Senior InvestigatorNIH Vaccine Res. Ctr., Bethesda, MD.Speakers:11:15 a.m.575 Development of a Novel Multi-Antigen Vaccine to PreventStaphylococcus aureus Infection and DiseaseAnnaliesa S. Anderson, PhD - Senior Director Vaccine ResearchPfizer Vaccine Res., Pearl River, NY.11:45 a.m.576 A Universal Influenza Vaccine?Wendy A. Keitel, MD - Professor of Molecular Virology & Microbiologyand MedicineBaylor Coll. of Med., Houston, TX.12:15 p.m.577 A Vaccine for HIV-1: Harnessing Cross-Reactive AntibodiesRichard Koup, MD - Senior InvestigatorNIH Vaccine Res. Ctr., Bethesda, MD.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss progress toward and challenges remaining to development of avaccine to prevent HIV-1 infection;> Discuss progress toward and challenges remaining to develop aprophylactic Staphylococcus aureus vaccine; andDiscuss progress toward and challenges remaining to realization of auniversal vaccine for influenza.Intended Audience: All attendeesLevel: Intermediate------------------------------------------------------------------------078(L, F)Symposium50 Years of Fluoroquinolones: Past, Present and FutureMonday, 11:15 a.m.–12:45 p.m. ................. Room 132UAN: 0391-9999-12-082-L04-PDeveloped in Cooperation with the International Society of Chemotherapy (ISC)Conveners:David C. Hooper, MD - ProfessorHarvard Med. Sch., Boston, MA.Teresita Mazzei, MD - Professor of ChemotherapyUniv. of Florence, Florence, Italy.Speakers:11:15 a.m.578 New Novel Uses of Fluoroquinolones (Including Polyoma Virus,Leprosy, MTB)Ethan Rubinstein, MD - ProfessorUniv. of Manitoba, Winnipeg, Canada.11:45 a.m.579 Use and Abuse: Why, How and So What?Ian M. Gould, MD - DoctorAberdeen Royal Infirmary, Aberdeen, United Kingdom.12:15 p.m.580 New Quinolones: What’s on the Horizon?David C. Hooper, MD - ProfessorHarvard Med. Sch., Boston, MA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the fluoroquinolone drug class, including the emergence of resistance;> Describe how to effectively use fluoroquinolones for clinical care, includingboth efficacy and adverse reactions; and> Identify new fluoroquinolone agents that are under development.Intended Audience: Clinicians, scientists, researchers, microbiologists, andpharmacists.Level: All Levels------------------------------------------------------------------------079(L)SymposiumAn Update on Streptococcal Pharyngitis and RheumaticFeverMonday, 11:15 a.m.–12:45 p.m. .... Esplanade Ballroom 302UAN: 0391-9999-12-083-L04-PConveners:Shiranee Sriskandan, MD, PhD - ProfessorImperial Coll., London, United Kingdom.Andrew C. Steer, MD, PhD - Senior Research FellowUniv. of Melbourne and Royal Children’s Hosp., Melbourne, Australia.Speakers:11:15 a.m.581 Group A Streptococcus Pathogenesis in PharyngitisMichael Wessels, MD - ProfessorChildren’s Hosp. Boston, Harvard Med. Sch., Boston, MA.11:45 a.m.582 Update on Diagnosis and Management of Streptococcal PharyngitisStanford T. Shulman, MD - ProfessorNorthwestern Univ. Feinberg Sch. of Med., Chicago, IL.12:15 p.m.583 Rheumatic Fever 2012 and BeyondAndrew C. Steer, MD, PhD - Senior Research FellowUniv. of Melbourne and Royal Children’s Hosp., Melbourne, Australia.Final Program83

Monday SCIENTIFIC SESSIONSObjectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify key pathogenetic factors that enable S. pyogenes to cause pharyngealinfection;> Diagnose and manage Strep pharyngitis in the modern era; and> Discuss the epidemiology of strep pharyngitis and rheumatic fever.Intended Audience: Pediatric infectious diseases and outpatient IDspecialists.Level: Intermediate------------------------------------------------------------------------080(V, H)SymposiumHot Topics in Viral HepatitisMonday, 11:15 a.m.–12:45 p.m. ................. Room 130UAN: 0391-9999-12-084-L04-PConveners:Emily A. Blumberg, MD - Professor of MedicinePerelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.Jean-Michel G. Molina, MD - ProfessorHosp. Saint Louis and Univ. of Paris 7, Paris, France.Speakers:11:15 a.m.584 Hepatitis C: Impact of New and Future TherapeuticsNorah Terrault, MD, MPH - Professor of MedicineUniv. of California San Francisco, CA.11:45 a.m.585 Hepatitis B: Management of Mono and HIV Co-InfectedIndividualsDouglas T. Dieterich, MD - Professor of MedicineMount Sinai Sch. of Med., New York, NY.12:15 p.m.586 Epidemiology and Management of the Normal andImmunosuppressed Host with Hepatitis ENassim Kamar, MD, PhD - ProfessorToulouse Univ. Hosp., Toulouse, France.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Differentiate treatment options for Hepatitis B and C for unique patientpopulations including HIV coinfected patients and transplant recipients;> Formulate appropriate treatment plans for Hepatitis viruses in differentpatient populations, recognizing the impact of drug interactions; and> Describe the epidemiology of Hepatitis E and assess treatment optionsin normal and immunosuppressed hosts.Intended Audience: Physicians, pharmacists, and clinical microbiologists/virologists.Level: Intermediate------------------------------------------------------------------------081(C1)Slide SessionCarbapenemase in Enterobacteriaceae and P. aeruginosaMonday, 11:15 a.m.–12:45 p.m. ................. Room 122UAN: 0391-9999-12-085-L04-PModerators:Patrice Nordmann, MD - ProfessorHosp. Bicetre, Le-Kremlin-Bicetre, France.Mariana Castanheira, PhD - Associate DirectorJMI Lab., North Liberty, IA.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Discuss the most modern features of carbapenemases and their direction;> Decipher the genetics of carbapenemases; and> Explore the tools used to differentiate various carbapenemases.Presentations:11:15 a.m.C1-587 Rapid Detection of Carbapenemase-Producing EnterobacteriaceaeUsing a Totally Novel ApproachP. Nordmann, MD, PhD - Professor, L. Poirel, PhD - Associate Researcher, L.Dortet, PharmD - Assistant Professor; Hosp. de Bicetre, Le Kremlin Bicetre,France.11:25 a.m.C1-588 Integron and Species Diversity in a Long-Term Outbreak ofGIM-1-Carrying BacteriaA. F. Wendel, MD- Resident 1 , A. H. B. Brodner, MD - Resident 1 , B.Henrich, PhD - Professor 1 , R. Deenen, PhD - Research Assistant 2 , K. Köhrer,PhD - Professor 2 , S. Ressina, BSc - Student 1 , K. Pfeffer, MD - Professor 1 ,C. R. MacKenzie, MD - Professor 1 ; 1 Inst. of Med. Microbiol. and Hosp.Hygiene, Heinrich-Heine Univ., Düsseldorf, Germany, 2 Biologisch-MedizinischesForschungszentrum, Heinrich-Heine Univ., Düsseldorf, Germany.11:35 a.m.C1-589 Complete Nucleotide Sequence of blaKPC-4 and blaKPC-5Harboring IncN and IncX Plasmids Isolated in New JerseyL. Chen, PhD- Research Associate 1 , K. D. Chavda, MS - Research Associate 1 ,J. R. Mediavilla, MS - Research Associate 1 , H. S. Fraimow, MD - Professor 2 ,R. G. Melano, PhD - Professor 3 , B. N. Kreiswirth, PhD - Research Associate 1 ;1Publ. Hlth. Res Ins, Uni of Med & Den of NJ, Newark, NJ, 2 Cooper UniHosp, Camden, NJ, 3 Publ. Hlth. Ontario, Toronto, Canada.11:45 a.m.C1-590 ESBL-MBLs- Metallo-Beta-Lactamases with Extended-Spectrum Beta-Lactamase (ESBL) Phenotypes? Defining theRole of Arg228 in Vim-2 and Vim-24M. F. Mojica, MS - Research Assistant 1 , S. H. Marshall, MS - Research Assistant2 , C. J. Wallace, MS - Adjunct Professor 3 , C. R. Bethel, MS - ResearchAssistant 2 , M. A. Taracila, MS - Research Assistant 2 , M. V. Villegas, MD- Scientific Director 1 , R. A. Bonomo, MD - Professor 2 ; 1 CIDEIM, Cali,Colombia, 2 Cleveland VAMC, Cleveland, OH, 3 Lakeland Community Coll.,Kirtland, OH.84September 9-12 |

MONDAY SCIENTIFIC SESSIONS11:55 a.m.C1-591 Genetic Features of OXA-48-Producing EnterobacterialIsolatesL. Poirel, PhD - Associate Researcher, E. Rondinaud, PharmD - Resident, A.Potron, PharmD - Assistant Professor, P. Nordmann, MD, PhD - Professor;Hosp. de Bicetre, Le Kremlin Bicetre, France.12:05 p.m.C1-592 Whole Genome Sequencing and Analysis of 12 blaNDM-1Harbouring Isolates Including the Index Klebsiella pneumoniaeblaNDM-1 IsolateH. S. Gibbons, PhD - Group Leader 1 , M. D. Krepps, PhD - Research fellow1, T. R. Walsh, PhD - Prof 2 , M. A. Toleman, PhD - Senior Research Fellow 2 ;1US Army Edgewood Biological Chemical Ctr., Baltimore, MD, 2 CardiffUniv., Cardiff, United Kingdom.12:15 p.m.C1-593 Characterization of a Novel IMP-28 Metallo--Lactamasefrom a Spanish Klebsiella oxytoca IsolateF. Pérez-Llarena, PhD - Researcher 1 , A. Fernández, student - PhD Student1, L. Zamorano, PhD - Researcher 2 , F. Kerff, PhD - Researcher 3 , A. Beceiro,PhD - Researcher 1 , B. Aracil, PhD - Researcher 4 , E. Cercenado, PhD - Researcher5 , E. Miro, PhD - Researcher 6 , A. Oliver, PhD - Professor 2 , J. Oteo,PhD - Professor 4 , F. Navarro, PhD - Professor 6 , G. Bou, PhD - Professor 1 ;1Univ. La Coruña, La Coruña, Spain, 2 HU Son Espases, Palma de Mallorca,Spain, 3 Univ. de Liège, Liège, Belgium, 4 Ctr. Natl. de Microbiología, Madrid,Spain, 5 HGU Gregorio Marañón, Madrid, Spain, 6 Hosp. de la Santa Creu iSant Pa, Barcelona, Spain.12:25 p.m.C1-594 IMP-33, a New IMP Variant Detected in Pseudomonas aeruginosa(PSA) from ItalyL. M. Deshpande, PhD - RSc 1 , T. A. Davies, PhD - Principal Sci 2 , G. Blandino,BS - MT 3 , G. Nicoletti, PhD - Prof 3 , R. N. Jones, MD - CEO 1 , M.Castanheira, PhD - Dir 1 ; 1 JMI Lab., N Liberty, IA, 2 Jansen R&D, Raritan,NJ, 3 Univ. di Catania, Catania, Italy.12:35 p.m.C1-595 Biochemical Characterization of OXA-240, a Novel Class DCarbapenemase Identified in Pseudomonas aeruginosaJ. J. Lee, MS - Research Assistant, J. H. Lee, MS - Research Assistant, X. Wu,MS - Research Assistant, D. B. Kwon, MS - Research Assistant, S. H. Lee,PhD - Professor; Myongji Univ., Yongin, Korea, Republic of.------------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALKMonday, September 10 | 11:15 a.m.-12:15 p.m. | Halls A-CDaily Infection Prevention and Control IssuesConvener:Loreen Herwaldt, MD - Professor, Hospital EpidemiologistUniv. of Iowa Coll. of Med., Iowa City, IA.Presentations:Prosthetic Joint Infection (PJI) Should Be Considered In ProstheticFailure within 2 Years of ImplantationM. E. Portillo; Reference Lab. of Catalunya, Barcelona, Spain.Hospital-Acquired Influenza in an Australian Sentinel SurveillanceSystemN. Macesic; Alfred Health, Melbourne, Australia.Rapid Screening Tests for MRSA Did Not Decrease PostoperativeMRSA Infections in Patients with Inflammatory BowelDisease (IBD)Y. Takahashi; Hyogo Coll. of Med., Nishinomiya, Japan.What to breath? Performance analysis of Air Samplers in OperatingRoomsL. Ummels; Radboud Univ. Nijmegen Med. Ctr., Nijmegen,Netherlands.Characteristics of Septic Arthritis - A Retrospective Study Over11 YearsL. N. Walti; Univ. Hosp., Lausanne, Switzerland.Monday, September 10 | 12:15 p.m. - 1:15 p.m. | Halls A-CResistance Genes Have No Boundaries!Conveners:Lesley McGee, PhDCDC, Atlanta, GA.Johann D. Pitout, MDUniv. of Calgary, Calgary, Canada.Presentations:Molecular Characterization of Multidrug-Resistant Mycobacteriumtuberculosis from Asian CountriesC. Nakajima; Hokkaido Univ. Res. Ctr. for Zoonosis Control, Sapporo,Japan.Extended-Spectrum Beta-Lactamase (ESBL) Producing Gram-Negative Bacteria from Pets, Buffalos and Psittacines, BrazilL. Barbato; USP, São Paulo, Brazil.Accessory Gene Regulator (AGR) Function, rpoB Mutationsand Vancomycin (VA) Susceptibility in Methicillin-ResistantStaphylococcus aureus (MRSA) Blood IsolatesM. Camoez; Hosp. Univ Bellvitge. UB. IDIBELL, Barcelona,Spain.Lack of Impact of Infant PCV Vaccination on Rates of AdultInvasive Pneumococcal Disease in Ontario, CanadaK. Wong; Mount Sinai Hosp., Toronto, Canada.Current Status of Group B Streptococci (GBS) in Japan-Penicillin-resistant GBS is Emerging in Japan?H. Mikamo; Aichi Med. Univ., Aichi, Japan.Dissemination of Diverse Plasmids Bearing blaKPC AmongCarbapenem-Resistant Enterobacteriaceae (CRE) Different fromKlebsiella spp. in a Hospital System in ClevelandF. Perez; VAMC, Cleveland, OH, 3 CWRU, Cleveland, OH.Final Program85

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------082(A)Poster SessionGlycopeptides and Lipopeptides: What’s New in PK/PD and SafetyMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:A-596 Menadione-Dependent Small-Colony Variants of MRSA areHypersusceptible to-Lactams Intracellularly Due to CooperationBetween Vacuolar Acidic pH and Oxidant SpeciesL. G. Garcia 1 , S. Lemaire 1 , B. C. Kahl 2 , K. Becker 2 , R. A. Proctor 3 , P. M.Tulkens 1 , F. Van Bambeke 1 ; 1 Univ. Catholique de Louvain, Brussels, Belgium,2 Univ. Muenster, Muenster, Germany, 3 Univ. Wisconsin, Madison, WI.A-597 Activity of Antibiotics against a Normal Phenotype MRSAand its menD and hemB Mutants on Models of Bronchial EpithelialCells Expressing Wild-Type, F508del or No CFTRL. G. Garcia 1 , B. C. Kahl 2 , K. Becker 2 , R. A. Proctor 3 , O. Denis 4 , P. M.Tulkens 1 , F. Van Bambeke 1 ; 1 Univ. Catholique de Louvain, Brussels, Belgium,2 Univ. Muenster, Muenster, Germany, 3 Univ. Wisconsin, Madison, WI,4Univ. Libre de Bruxelles, Brussels, Belgium.A-598 Activity of Anti-Staphylococcal Antibiotics in an In VitroModel of Biofilm Using Clinical Isolates of S. aureusJ. Bauer 1 , M. Hallin 2 , O. Denis 2 , P. M. Tulkens 1 , F. Van Bambeke 1 ; 1 Univ.Catholique de Louvain, Brussels, Belgium, 2 Univ. Libre de Bruxelles, Brussels,Belgium.A-599 Influence of Oxidant Stress on the Activity of Antibioticsagainst the Extracellular and Intracellular (THP-1 cells) Forms ofS. aureus (SA) and its Small Colony Variants (SCV) MutantsL. G. Garcia 1 , S. Lemaire 1 , B. C. Kahl 2 , K. Becker 2 , R. A. Proctor 3 , P. M.Tulkens 1 , F. Van Bambeke 1 ; 1 Univ. Catholique de Louvain, Brussels, Belgium,2 Univ. Muenster, Muenster, Germany, 3 Univ. Wisconsin, Madison, WI.A-600 Evaluation of the Daptomycin (DAP) Mutant SelectionWindow in Vancomycin Resistant Enterococci (VRE) in a Pharmacokinetic/Pharmacodynamic(PK/PD) Model of SimulatedEndocardial Vegetations (SEV)B. J. Werth 1 , C. E. Ireland 1 , M. E. Steed 2 , M. J. Rybak 1 ; 1 Anti-InfectiveRes. Lab., Wayne State Univ., Detroit, MI, 2 Univ. Kansas Med. Ctr., KansasCity, KS.A-601 Evaluation of Daptomycin (DAP) Plus Ceftriaxone (CTX)against Vancomycin-Resistant Enterococcus faecium (VREFm) andfaecalis (VREFs) in an In Vitro Pharmacokinetic/Pharmacodynamic(PK/PD) Simulated Endocardial Vegetation (SEV) ModelA. D. Hall 1 , G. Sakoulas 2 , M. J. Rybak 1 ; 1 Wayne State Univ., Detroit, MI,2Univ of California San Diego, La Jolla, CA.A-602 A Preliminary Evaluation of the Novel Combination of DaptomycinPlus Fosfomycin (FOS) against Vancomycin-ResistantEnterococcus Using an In Vitro Pharmacokinetic/Pharmacodynamic(PK/PD) Bacteremia ModelA. D. Hall, B. J. Werth, J. P. McRoberts, M. J. Rybak; Wayne State Univ.,Detroit, MI.A-603 Evaluation of the Novel Combination of High Dose Daptomycin(HD-DAP) plus Trimethoprim/Sulfamethoxazole (TMP/SMX) against Daptomycin Non-susceptible (DNS) Methicillin-Resistant Staphylococcus aureus (MRSA) Using an In Vitro Pharmacokinetic/Pharmacodynamic(PK/PD) Model of SimulatedEndocardial Vegetations (SEVs)M. E. Steed, B. J. Werth , C. E. Ireland, M. J. Rybak; Anti-Infective Res.Lab., Wayne State Univ., Detroit, MI.A-604 Impact of High Dose Daptomycin in Preventing ResistanceDevelopment in Viridans Group StreptococciR. L. Akins; Univ. of Louisiana Monroe, Monroe, LA.A-605 Pharmacokinetic (PK) / Pharmacodynamic (PD) / Toxicodynamic(TD) Evaluation of Daptomycin (DAP) Efficacy & Safetyagainst Staphylococcus aureus (SA)R. L. Soon, S. J. Turner, A. Forrest, B. T. Tsuji, J. Brown ; Univ. at Buffalo,Buffalo, NY.A-606 Daptomycin (D) Pharmacokinetics (PK) and Pharmacodynamics(PD) in a Pooled Sample of Hemodialysis (HD) Patients(Pts)J. M. Butterfield 1 , N. Patel 1 , B. A. Mueller 2 , D. W. Grabe 1 , K. E. Cardone 1 ,N. N. Salama 3 , T. P. Lodise 1 ; 1 Albany Coll. of Pharmacy and Hlth. Sci., Albany,NY, 2 Univ. of Michigan Coll. of Pharmacy, Ann Arbor, MI, 3 St. LouisColl. of Pharmacy, St. Louis, MO.A-607 Optimal Loading Dose Regimen of Teicoplanin (TEIC) toAchieve Higher Trough Level (Cmin) in Patients with RenalDysfunctionT. Ueda, Y. Takesue, K. Nakajima, K. Ichki, M. Komastu, Y. Wada, T. Tsuchida,Y. Takahashi, M. Ishihara; Hyogo Coll. of Med., Nishinomiya, Japan.A-608 New Target Trough Level (Cmin) of Teicoplanin (TEIC) inPatients with Common MRSA InfectionsT. Ueda, Y. Takesue, K. Nakajima, K. Ichki, M. Komastu, Y. Wada, T. Tsuchida,Y. Takahashi, M. Ishihara; Hyogo Coll. of Med., Nishinomiya, Japan.A-609 Impact of High Inoculum of Heteroresistance Methicillin-Susceptible Staphylococcus aureus on the Activities of CefazolinAlone and in Combination with Vancomycin in an In Vitro PharmacodynamicModelV. Huang 1 , M. J. Zervos 2,3 ; 1 Mercer Univ. Coll. of Pharmacy and Hlth. Sci.,Atlanta, GA, 2 Henry Ford Hlth. System, Detroit, MI, 3 Wayne State Univ.Sch. of Med., Detroit, MI.A-610 Adjusted Vancomycin (VAN) Dosage to Reach an AUC/MIC Index 400 Did Not Improve the Outcome of ExperimentalEndocarditis (EE) Caused by Methicillin-Resistant Staphylococcusaureus (MRSA) Strains With Different VAN MICsJ. M. Miro, C. García-de-la-Maria, X. Castañeda, A. del-Rio, Y. Armero,C. Cervera, D. Soy, A. Moreno, J. M. Pericas, M. Almela, C. A. Mestres, C.Falces, S. Ninot, J. M. Gatell, F. Marco, Hospital Clinic Endocarditis StudyGroup; Hosp. Clinic, IDIBAPS, Barcelona, Spain.A-611 Population Pharmacokinetics (PK) of Vancomycin in HospitalizedPatientsA. Chaturvedula 1 , S. Mok 2 , M. Chesson 1 , M. J. Fossler 3 , J. T. Jacob 4 ;1Mercer Univ., Atlanta, GA, 2 Emory Healthcare, Atlanta, GA, 3 GlaxoSmith-Kline, Prince of Prussia, PA, 4 Emory Univ., Atlanta, GA.86September 9-12 |

MONDAY SCIENTIFIC SESSIONSA-612 Comparison of Vancomycin Dosing in Normal Body Habitus,Overweight, and Obese Pediatric PatientsM. P. Nelson 1,2 , D. E. Heble 2 , D. A. Hunstad 3 ; 1 Southern Illinois Univ.Edwardsville, Edwardsville, IL, 2 St. Louis Children’s Hosp., St. Louis, MO,3Washington Univ., St. Louis, MO.A-613 Comparing Outpatient Parenteral Antimicrobial Therapy(OPAT) for Methicillin-Sensitive Staphylococcus aureus (MSSA)Infection Using an In Vitro Pharmacodynamic Model (IPDM)H. Iacovides, C. Huang, S. Zelenitsky; Univ. of Manitoba, Winnipeg,Canada.A-614 Predictive Performance of Pharmacokinetic Models of OutpatientsReceiving Vancomycin Continuous InfusionsT. M. Ng 1 , W. P. Lim 1 , M. Chan 1 , D. C. Lye 1 , V. H. Tam 2 ; 1 Tan Tock SengHosp., Singapore, Singapore, 2 Univ. of Houston, Houston, TX.A-615 Vancomycin Dose and Duration of Therapy as Risk Factors forNephrotoxicity in Adult PatientsJ. Brown 1 , V. Stevens 1 , K. Brown 2 , N. Onufrak 1 ; 1 SUNY Buffalo Sch. ofPharmacy and Pharmaceutical Sci., Buffalo, NY, 2 Univ. of Rochester Med.Ctr., Rochester, NY.A-616 Vancomycin Nephrotoxicity With or Without Administrationof Intravenous Contrast MediaA. Lee 1 , J. Joo 2 , A. Jeng 2 , P. Chan 1 ; 1 Western Univ. of Hlth. Sci., Pomona,CA, 2 Olive View-UCLA Med. Ctr., Sylmar, CA.A-617 Average 24-Hour Area Under the Vancomycin (V) SerumConcentration-Time Curve (AUC), Degree of Nephrotoxicity(NT), and Need for DialysisV. Stevens 1 , N. Onufrak 1 , K. Brown 2 , J. Brown 1 ; 1 SUNY Buffalo Sch. ofPharmacy and Pharmaceutical Sci., Buffalo, NY, 2 Univ. of Rochester Med.Ctr., Rochester, NY.A-618 Weight-Based Maintenance Dosing of Vancomycin inHemodialysisD. Ezdon 1 , M. Brown 1,2 , M. Meshay 1 , A. Brophy 1,3 , R. Hickey 1,4 , S.Aggarwal 1,5 , R. Polisetty 1,6 , B. Cuhaci 5 , J. Mitchell 1 , H. P. Schlecht 1,5 ;1Hahnemann Univ. Hosp., Philadelphia, PA, 2 Nanticoke Mem. Hosp.,Seaford, DE, 3 Mercy St. Vincent Med. Ctr., Toledo, OH, 4 Hosp. of the Univ.of Pennsylvania, Philadelphia, PA, 5 Drexel Univ. Coll. of Med., Philadelphia,PA, 6 Midwestern Univ., Chicago Coll. of Pharmacy, Downers Grove, IL.A-619 Pharmacokinetics of Vancomycin in Patients UndergoingContinuous Venovenous HemodialysisG. P. Mascara 1 , R. Simpson 1 , R. L. McGill 1,2 , N. H. Chan-Tompkins 1 ;1Allegheny Gen. Hosp., Pittsburgh, PA, 2 Drexel Univ. Coll. of Med.,Pittsburgh, PA.A-620 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation ofOritavancin (ORI) against Staphylococcus aureus (SA) Using Datafrom a Murine-Thigh Infection ModelO. O. Okusanya 1 , D. Lehoux 2 , A. Forrest 1 , G. Moeck 2 , C. C. Bulik 1 , P. G.Ambrose 1 , S. M. Bhavnani 1 ; 1 ICPD, Latham, NY, 2 The Med. Company, St.Laurent, Canada.A-621 Effect of Telavancin (TEL) and Vancomycin (VAN) Clearanceon Staphylococcus aureus Activity in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model of Varying Renal FunctionW. Rose 1 , T. Liebenstein 2 , C. Vandevoorde 1 ; 1 Univ. of Wisconsin, Madison,WI, 2 Univ. of Wisconsin Hosp. and Clinics, Madison, WI.A-622 Comparative Activity of Telavancin (TLV) Combined withNafcillin (NAF), Imipenem (IMP), and Gentamicin (GEN)against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) ModelS. N. Leonard 1,2 , M. E. Supple 1 ; 1 Northeastern Univ., Boston, MA,2Brigham and Women’s Hosp., Boston, MA.A-623 A Single-Center, Randomized, Placebo- and Positive-Controlled,Parallel-Group Study of the Electrocardiographic Effectsof Dalbavancin in Healthy Male and Female SubjectsM. Dunne 1 , S. R. Moriarty 1 , C. R. Sprenger 2 ; 1 Durata Therapeutics, Morristown,NJ, 2 Cetero Res., Fargo, ND.------------------------------------------------------------------------083(A)Poster SessionImproving Pharmacodynamics of Beta-Lactams andBeta-Lactamase InhibitorsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:A-624 %fT>MIC Predicts Probability of Microbiological Outcomein the Treatment of Nosocomial Pneumonia by CeftobiproleA. E. Muller 1 , N. Punt 2 , J. W. Mouton 1 ; 1 UMC St Radboud, Nijmegen,Netherlands, 2 Medimatics, Maastricht, Netherlands.A-624a Monte Carlo Simulations Based on Phase 1 Studies PredictTarget Attainment of Ceftobiprole in Nosocomial PneumoniaPatients: A Validation StudyA. Muller 1 , A. H. Schmitt-Hoffmann 2 , N. Punt 3 , J. W. Mouton; 1 UMC StRadboud, Nijmegen, Netherlands, 2 Basilea Pharmaceutica Intl. Ltd, Basel,CH, Basel, Switzerland, 3 Medimatics, Maastricht, Netherlands.A-625 Efficacy of Ceftaroline Fosamil in the Staphylococcal MurinePneumonia ModelA. A. Bhalodi 1 , J. L. Crandon 1 , D. Biek 2 , D. P. Nicolau 1 ; 1 Ctr. for Anti-Infect.Res. & Dev., Hartford Hosp., Hartford, CT, 2 Cerexa, Inc., Oakland, CA.A-626 An Evaluation of Ceftaroline (CPT) and Daptomycin (DAP)or Vancomycin (VAN) Combination against an Isogenic Methicillin-ResistantStaphylococcus aureus (MRSA)/ Vancomycin IntermediateS. aureus (VISA) Pair in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) ModelB. J. Werth 1 , G. Sakoulas 2 , W. E. Rose 3 , M. J. Rybak 1 ; 1 Anti-Infective Res.Lab., Wayne State Univ, Detroit, MI, 2 Univ. of California, La Jolla, CA,3Univ. of Wisconsin-Madison, Madison, WI.A-627 Evaluation of Ceftaroline (CPT) Activity against HeteroresistantVancomycin Intermediate Staphylococcus aureus (hVISA)and VISA Methicillin-Resistant S. aureus (MRSA) Strains in anIn Vitro Pharmacokinetic/Pharmacodynamic(PK/PD) Model:Exploring the “Seesaw Effect”B. J. Werth 1 , M. E. Steed 2 , G. W. Kaatz 3,4 , M. J. Rybak 1 ; 1 Anti-infectiveRes. Lab., Wayne State Univ., Detroit, MI, 2 Univ. Kansas Med. Ctr., KansasCity, KS, 3 Wayne State Univ., Detroit, MI, 4 John D. Dingell VA Med. Ctr,Detroit, MI.Final Program87

Monday SCIENTIFIC SESSIONSA-628 Assessment of the Antistaphylococcal Effect of Ceftaroline inLong Duration Human Dose Simulations: Impact of MICK. E. Bowker, A. R. Noel, S. Tomaselli, D. L. Nicholls, A. P. MacGowan;Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.A-629 Pharmacodynamics of Ceftaroline against EnterobacteriaceaeK. E. Bowker, A. R. Noel, S. G. Tomaselli, D. L. Nicholls, A. P. MacGowan;Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.A-630 Efficacy of Humanized Ceftaroline-Fosamil/Avibactam Exposuresagainst Enterobacteriaceae Exhibiting MICs 1 μg/mLA. A. Bhalodi 1 , J. L. Crandon 1 , G. Williams 2 , D. P. Nicolau 1 ; 1 Ctr. forAnti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT, 2 Cerexa, Inc.,Oakland, CA.A-631 The Pharmacodynamics of Avibactam (NXL104) in Combinationwith Either Ceftaroline or Ceftazidime against BlactamaseProducing EnterobacteriaceaeA. R. Noel 1 , S. G. Tomaselli 1 , D. L. Nicholls 1 , K. E. Bowker 1 , G. Williams 2 ,A. P. MacGowan 1 ; 1 Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom,2 Cerexa Inc, Oakland, CA, USA, a wholly-owned subsidiary of ForestLab. Inc, Oakland, CA.A-632 In Vitro Efficacy of Simulated Human Exposures of Ceftazidime-Avibactamagainst Pseudomonas aeruginosa in a HollowFiber ModelV. Schuck, M. A. Tanudra, M. Beaudoin, K. Vishwanathan, W. Nichols;AstraZeneca, Waltham, MA.A-633 Comparative Efficacy of Human Simulated Exposures ofCeftazidime (CAZ) and Ceftazidime-Avibactam (CAZ-AVI)against Clinical Pseudomonas aeruginosa IsolatesJ. L. Crandon, M. Banevicius, D. P. Nicolau; Ctr. for Anti-Infect. Res. &Dev., Hartford Hosp., Hartford, CT.A-634 Population Pharmacokinetic Modeling of Ceftazidime (CAZ)and Avibactam (AVI) in Healthy Volunteers and Patients withComplicated Intra-Abdominal Infection (cIAI)J. Li 1 , W. Knebel 2 , M. Riggs 2 , D. Zhou 1 , W. Nichols 3 , S. Das 4 ; 1 Astra-Zeneca, Wilmington, DE, 2 Metrum Res Gp, Tariffville, CT, 3 AstraZeneca,Waltham, MA, 4 AstraZeneca, Alderley Park, United Kingdom.A-635 Evaluation of Ceftazidime-Avibactam (CAZ-AVI) DoseRegimens for Phase III Study in Patients with Different RenalFunctionJ. Li 1 , D. Zhou 1 , W. Nichols 2 , S. Das 3 ; 1 AstraZeneca, Wilmington, DE,2AstraZeneca, Waltham, MA, 3 AstraZeneca, Alderley Park, United Kingdom.A-636 Mathematical Modeling of Ceftazidime for High-Flux HemodialysisPatientsA. Loo 1,2 , M. Neely 3 , E. Anderson 2,4 , C. Ghossein 2,4 , M. Griffith 1,2 , M.Scheetz 1,2 ; 1 Midwestern Univ., Downers Grove, IL, 2 Northwestern Mem.Hosp., Chicago, IL, 3 USC Keck Sch. of Med., Los Angeles, CA, 4 NorthwesternUniv. Feinberg Sch. of Med., Chicago, IL.A-637 Standard Dosage Regimens of Broad-Spectrum Beta-Lactamsare Inadequate to Treat Difficult-to-Treat Pathogens in ObeseNon-Critically Ill PatientsM. C. Hites, F. Wolff, F. S. Taccone, E. Maillart, G. Deprez, J. Araci, R.Surin, F. Cotton, F. Jacobs; Erasme Hosp., Free Univ. of Brussels, Brussels,Belgium.A-638 Antibiotic Dosing in Adult Obese Patients: A Calculatorfor Betalactams, Aminosides, Glycopeptides and OtherAntimicrobial AgentsN. Lemaire, N. Gauthier, A. Le Joubioux, N. Van Grunderbeeck,S. Barrailler, B. Frimat; Lens Hosp., Lens, France.A-639 Integrating Pharmacodynamics and MIC Distributions toAssess Changing Activity of Amikacin, Cefepime, Ciprofloxacin,Colistin, Gentamicin, Meropenem and Piperacillin-Tazobactamagainst Clinical Strains of Pseudomonas aeruginosa in CanadianHospitals from 2007 to 2011S. Zelenitsky 1 , E. Rubinstein 1 , R. Ariano 2 , G. Zhanel 1 ; 1 Univ. of Manitoba,Winnipeg, Canada, 2 St. Boniface Gen. Hosp., Winnipeg, Canada.A-640 Steady-State Pharmacokinetics/Pharmacodynamics of Cefoperazone/Sulbactamin Hospital-Acquired Pneumonia PatientsCaused by Multidrug-Resistant Nonfermentative BacilliY. J. Zhou, Y. Y. Zhang, B. N. Guo, X. J. Wu, J. F. Wu, Y. C. Chen, J. C. Yu,X. Y. Ye, J. Zhang, Y. G. Shi, M. G. Wang; Huashan Hosp., Fudan Univ.,Shanghai, China.A-641 Safety and Pharmacokinetics (PK) of Intravenous (IV)Ceftolozane/Tazobactam (C/T) 3 G Every 8 Hours (Q8h) andCumulative Fraction of Response (CFR) in Plasma and EpithelialLining Fluid (ELF) in a Simulated Ventilator-Associated Pneumonia(VAP) PopulationB. Miller, G. Chandorkar, O. Umeh, I. Friedland, E. Hershberger; CubistPharmaceuticals, Lexington, MA.A-642 Pharmacodynamics of Piperacillin/Tazobactam (P/T) againstPseudomonas aeruginosa: Antibacterial Effect and Risk of Emergenceof ResistanceK. E. Bowker, A. R. Noel, S. G. Tomaselli, D. L. Nicholls, A. P. MacGowan;Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.A-643 Piperacillin-Tazobactam (PT) Extended Infusion (EI)Therapy to Treat Pulmonary Exacerbation in Patients with CysticFibrosis (CF)R. Kullar 1 , J. Garber 1 , A. Alhadab 1 , A. Olyaei 1 , G. Allada 2 , J. Gold 2 , M.Munar 1 ; 1 Oregon State Univ/Oregon Hlth. & Sci. Univ, Portland, OR,2Oregon Hlth. & Sci. Univ, Portland, OR.A-644 Optimization of Piperacillin/Tazobactam (Pip/Taz) DosingBased on Population Pharmacokinetics (PK) & Pharmacodynamics(PD)G. Durica, A. Forrest; SUNY Sch. of Pharmacy, Buffalo, NY.88September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------084(B)Poster SessionAntimicrobial Therapy in Animal Models IMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:B-645 Comparison of Six Generics Vancomycin (VAN) Products fromEurope and America in the Treatment of Methicillin-ResistantStaphylococcus aureus (MRSA) Experimental Endocarditis inRabbitsP. Tattevin 1 , A. Saleh-Mghir 2 , B. Davido 2 , I. Ghout 3 , L. Massias 4 , C.Garcia de la Maria 5 , C. Muller-Serieys 4 , J. M. Miro 5 , B. A. Diep 6 , A. Crémieux2 ; 1 Pontchaillou Univ. Hosp., Rennes, France, 2 Raymond Poincaré Univ.Hosp., Garches, France, 3 Ambroise Paré Univ. Hosp., Boulogne, France,4Bichat Univ. Hosp., Paris, France, 5 Univ. Hosp. Clinic-IDIBAPS, Barcelona,Spain, 6 SFGH, Univ. of California, San Francisco, CA.B-646 Relationship Between In Vitro Vancomycin Susceptibility inBiofilms and Treatment Outcomes in Experimental EndocarditisDue to Methicillin-Resistant Staphylococcus aureusW. Abdel Hady 1 , A. S. Bayer 1,2 , K. Seidl 1,3 , C. C. Nast 2,4 , A. R. Horswill5, Y. Q. Xiong 1 ; 1 LABioMed at Harbor-UCLA Med. Ctr., Torrance, CA,2David Geffen Sch. of Med. at UCLA, Los Angeles, CA, 3 Univ. of Zurich,Zurich, Switzerland, 4 Cedars-Sinai Med. Ctr., Los Angeles, CA, 5 Univ. ofIowa, Iowa City, IA.B-647 Efficacy of the Combinations of Fosfomycin with Daptomycinor Rifampin in an Experimental Foreign-Body Infection (FBI) byMethicillin-Resistant Staphylococcus aureus (MRSA)C. Garrigós, O. Murillo, J. Lora-Tamayo, M. Vivas, F. Tubau, Dr , J. Cabo,Dr , C. Cabellos, Dr , J. Ariza, Dr ; Hosp. Bellvitge, Barcelona, Spain.B-648 Effectiveness of Cloxacillin (CLO) Plus Vancomycin (VAN)Compared to CLO, VAN, and Daptomycin (DAP) in the Treatmentof Methicillin-Resistant (MRSA) or Methicillin-Susceptible(MSSA) Staphylococcus aureus in a Rabbit Model of ExperimentalEndocarditis (EE)X. Castañeda, C. García-de-la-Maria, A. del-Rio, D. Soy, Y. Armero, C.Cervera, A. Moreno, J. M. Pericas, M. Almela, C. A. Mestres, C. Falces,S. Ninot, J. M. Gatell, F. Marco, J. M. Miro, Hospital Clinic EndocarditisStudy Group; Hosp. Clinic - IDIBAPS, Barcelona, Spain.B-649 Addition of Daptomycin (D) to Levofloxacin (LVX) Increasedthe Efficacy of Levofloxacin Monotherapy against a Methicillin-Sensitive S. aureus (MSSA) Strain in Experimental Meningitisand Prevented Development of Levofloxacin-Induced ResistanceP. Cottagnoud 1 , M. Cottagnoud 2 , F. Acosta 2 , A. Bizzini 3 , S. Leib, 4 ; 1 KlinikSonnenhof, Bern, Switzerland, 2 Spitalnetzbern Ziegler, Bern, Switzerland,3CHUV, Lausanne, Switzerland, 4 Inst. für Infektionskrankheiten, Bern,Switzerland.B-650 Inter-Laboratory Comparison of Treatment Response in aMurine Model of Methicillin Resistant Staphylococcus aureus(MRSA) BacteremiaL. K. Najvar 1,2 , A. Ibrahim 3 , N. P. Wiederhold 4,1 , G. Luo 3 , R. A. Bocanegra1,2, T. Ghebremariam 3 , W. R. Kirkpatrick 1,2 , S. G. Filler 3 , T. F. Patterson1,2; 1 UTHSCSA, San Antonio, TX, 2 STVHCS, San Antonio, TX, 3 Harbor-UCLA, Torrance, CA, 4 UT Austin, Austin, TX.B-651 Linezolid (LZD) Prevents the Development of Lung Damagesin a Murine Model of Methicillin-Resistant Staphylococcus aureus(MRSA) Pneumonia (PN)C. Jacqueline, A. Broquet, A. Roquilly, M. Davieau, G. Potel, J. Caillon, K.Asehnoune; UPRES EA 3826, Nantes, France.B-652 Comparative Activities of Vancomycin, Tigecycline and RifampinAlone and in Combination in a Rat Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Foreign Body OsteomyelitisP. Vergidis, S. S. Schmidt, J. N. Mandrekar , J. M. Steckelberg, R. Patel;Mayo Clinic, Rochester, MN.B-653 Experimental Assessment of Calcium-Deficient ApatiteDelivering Daptomycin in Acute Osteomyelitis: A New EffectiveApproach?G. Amador 1 , H. Gautier 2 , C. Desessard 1 , V. Le Mabecque 1 , A. Miegeville 1 ,J. Bouler 2 , P. Weiss, DDS 2 , G. Potel 1 , J. Caillon 1 , C. Jacqueline 1 ; 1 EA3826,Med. Sch., Nantes, France, 2 INSERM U791, Nantes, France.B-654 Comparison of Linezolid and Daptomycin in an ExperimentalMurine Model of VRE Faecium Bacteremia: Emergence ofDaptomycin-Nonsusceptibility During Daptomycin TreatmentY. Q. Xiong, W. Abdel Hardy, S. J. Eells, A. S. Bayer, J. A. McKinnell; LABiomed Res. Inst., Torrance, CA.B-655 Murine Model of Acute Vancomycin-Resistant Enterococcal(VRE) BacteremiaY. Q. Xiong, W. Abdel Hardy, S. J. Eells, A. S. Bayer, J. A. McKinnell; LABiomed Res. Inst., Torrance, CA.B-656 In Vivo Antibacterial Activity of Alpha-Melanocyte StimulatingHormone against Staphylococcus aureusWithdrawnB-657 Effects of Dagibatran on a Murine Model of Staphylococcusaureus Hematogenous Pulmonary InfectionY. Morinaga, K. Yanagihara, N. Kaku, Y. Migiyama, Y. Harada, K. Nagaoka,K. Yamada, K. Izumikawa, H. Kakeya, Y. Yamamoto, S. Kohno; NagasakiUniv., Nagasaki, Japan.B-658 Experimental Study of the Efficacy of High Dose of Daptomycinin the Therapy of Cephalosporin-Resistant PneumococcalMeningitisM. Vivas, E. Force, C. Garrigós, F. Tubau, J. Liñares, I. Pelegrín, J. Ariza, C.Cabellos; Hosp. de Bellvitge, Hosp. del Llobregat, Spain.B-659 Synergism Between the Combination of Cpl-1 with Daptomycinor Vancomycin against Streptococcus pneumoniae in Mice withBacteremiaJ. Vouillamoz 1 , P. Moreillon 1 , M. Giddey 1 , V. A. Fischetti 2 , G. Resch 1 ;1Univ. of Lausanne, Lausanne, Switzerland, 2 The Rockefeller Univ., NewYork, NY.B-660 Impact of Reduced Susceptibility to Daptomycin in E. faeciumon the Activity of This Antibiotic In Vitro and In VivoC. Richaud 1 , F. Chau 1 , M. Sotier 2 , A. Bleibtreu 3 , B. Fantin 1 , V. Cattoir 4 ,A. Lefort 1 ; 1 EA 3964, Univ. Paris Diderot, Paris, France, 2 Lab de Toxicologieet Pharmacocinétique, Bichat Hosp., Paris, France, 3 UMR 722, Univ. ParisDiderot, Paris, France, 4 EA 4655, Univ. Caen Côte de Nacre, Caen, France.B-661 Prostaglandins Alter the Innate Immune Response to Group AStreptococcus InfectionWithdrawnFinal Program89

Monday SCIENTIFIC SESSIONSB-662 In Vitro Activity of Cadazolid (ACT-179811) against Clostridiumdifficile and in an In Vitro Gut Model of C. difficile infectionS. Baines, G. Crowther, S. Todhunter, J. Freeman, M. Wilcox; Leeds TeachingHosp. & Univ. of Leeds, Leeds, United Kingdom.B-663 Effects of Vancomycin and Huo Xiang Zheng Qi Liquid onClostridium difficile Infection in C57BL MiceM. Chen 1,2 , L. Zhai 1 , K. Schonning 3 , L. P. Andersen 1 , W. A. Alpizar 4 , O.D. Laerum 4 , A. Friis-Moeller 3 ; 1 Rigshospitalet, Copenhagen,, Denmark,2Sonderjylland Hosp., Aabenraa, Denmark, 3 Univ. Hosp. Hvidovre, Copenhagen,,Denmark, 4 The Finsen Ctr., Copenhagen,, Denmark.B-664 Efficacy Comparison between LFF571 and Fidaxomicin in theHamster Model of Clostridium difficile InfectionD. McKenney 1 , A. Williams 2 , M. LaMarche 2 , J. Praestgaard 3 , J. Leeds1; 1 Novartis Inst.s for BioMed. Res., Emeryville, CA, 2 Novartis Inst. forBioMed. Res., Cambridge, MA, 3 Novartis, East Hanover, NJ.------------------------------------------------------------------------085(C1)Poster SessionGenetics and ResistanceMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C1-665 High Levels of Mobile Quinolone Resistance Genes FoundNear a Waste Water Treatment Plant Serving Antibiotic ManufacturersC. Rutgersson 1 , C. Flach 1 , N. Marathe 1,2 , E. Kristiansson 3 , A. Janzon 1 , J.Fick 4 , Y. Shouche 2 , E. Moore 5 , D. G. J. Larsson 1 ; 1 Inst. for Neuroscienceand Physiology, Sahlgrenska Academy, Gothenburg Univ., Gothenburg,Sweden, 2 Natl. Ctr. for Cell Sci., Pune Univ., Pune, India, 3 Chalmers Univ. ofTech., Gothenburg, Sweden, 4 Umeå Univ., Umeå, Sweden, 5 The SahlgrenskaUniv. Hosp. Univ. of Gothenburg, Gothenburg, Sweden.C1-666 Regulation of Class 1 Integron Integrase Expression inBiofilmE. Strugeon 1,2 , M. Ploy 1,2,3 , S. Da Re 1,2 ; 1 Inserm, Limoges, France, 2 Univ. deLimoges, Limoges, France, 3 CHU, Limoges, France.C1-667 Mutator dnaQ Favors the Accumulation of a Double Mutationin an E.coli gyrA Mutant in One Step to Yield High-LevelFluoroquinolone ResistanceM. Petschulies, A. Heisig- Senior , P. Heisig; Univ. of Hamburg, Hamburg,Germany.C1-668 Mobile Element Tn1721 Associated to Resistance Genes andDisseminated in Clinical and Sewage SamplesL. C. Balsalobre, M. Dropa, D. E. Oliveira, G. Matté, M. Matté; Univ. ofSão Paulo, São Paulo, Brazil.C1-669 First Evidence of DNA Recombinant Activity of ISCR1A. P. Porto 1 , J. A. Ayala 2 , G. O. Gutkind 3 , J. A. Di Conza 1,3 ; 1 Univ. Nacionaldel Litoral, Santa Fe, Argentina, 2 Univ. Autónoma de Madrid, Madrid,Spain, 3 Univ. de Buenos Aires, Buenos Aires, Argentina.C1-670 Structural Variations in the Resistance Gene Regions of theIntegrative and Conjugative Element ICEPmu1 from BovinePasteurella multocida and Mannheimia haemolyticaG. B. Michael 1 , K. Kadlec 1 , M. T. Sweeney 2 , R. W. Murray 2 , J. L. Watts 2 ,S. P. Schwarz 1 ; 1 Inst. of Farm Animal Genetics (FLI), Neustadt-Mariensee,Germany, 2 Pfizer Animal Health, Kalamazoo, MI.C1-671 Role of Transcriptional Regulators of the MarR Family (MultipleAntibiotic Resistance) in Bacteroides fragilis Susceptibility toAntimicrobial Drugs and Oxydative StressL. A. Lobo 1 , N. L. P. Iorio 2 , F. L. Teixeira, BS 1 , D. N. S. Silva, BS 1 , E. O.Ferreira 1 , R. M. C. Domingues 1 ; 1 UFRJ, Rio de Janeiro, Brazil, 2 UFF, Rio deJaneiro, Brazil.C1-672 Effect of the Transcriptional Activators SoxS, RobA andRamA on the Expression of the Multidrug Efflux Pump AcrAB-TolC of Enterobacter cloacaeA. Perez 1 , M. Poza 1,2 , J. Aranda 1,2 , C. Latasa 3,4 , M. Tomas 1,2 , I. Lasa 3,4 ,G. Bou 1,2 ; 1 Hosp. A Coruña, A Coruña, Spain, 2 Univ. Hosp. A Coruña, ACoruña, Spain, 3 Lab. of Microbial Biofilms-CSIC, Pamplona, Spain, 4 Univ.of Pamplona, Pamplona, Spain.C1-673 Identification of Novel Antibacterials Inhibiting Biofilms in aBroad-Spectrum MannerK. Sambanthamoorthy, N. Pattabiraman, C. Luo; Walter Reed Army Inst.of Res., Silver Spring, MD.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------086(C1)Poster SessionResistance by Efflux/Quinolone ResistanceMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C1-674 Chemical Inhibition of Multidrug-Resistance EffluxAbolishes Biofilm Formation by Salmonella enterica SerovarTyphimuriumS. Baugh, L. J. V. Piddock, M. A. Webber; Univ. of Birmingham, Birmingham,United Kingdom.C1-675 Susceptibility of Tetracyclines to TN1721- and Plasmid RP1dTet(A) Resistance is Dependent on Expression Level and NotPrimary StructureC. Fyfe, J. A. Sutcliffe, T. H. Grossman; Tetraphase Pharmaceuticals, Watertown,MA.C1-676 Efflux Mediated Multiresistance in Clinical Isolates of AcinetobacterbaumanniiE. J. Yoon, P. Courvalin, C. Grillot-Courvalin; Inst. Pasteur, Paris, France.C1-677 Biofilm Regulator nuc in Staphylococus aureus is DifferentiallyRegulated and Expressed During In Vitro Antibiotic TreatmentW. Rose 1 , S. Shukla 2 , Z. Ye 2 ; 1 Univ. of Wisconsin, Madison, WI, 2 MarshfieldClinic, Marshfield, WI.C1-678 Putative Mechanism of Resistance Detection of Inquilinuslimosus by a Full Genome Sequencing ApproachM. Pino 1 , J. Di Conza 1 , S. Revale 2 , G. Gutkind 1 ; 1 Fac. Farm. y Bioq.-UBA,Buenos Aires, Argentina, 2 INDEAR, Rosario, Argentina.C1-679 First Identification of tet(31) among Tetracycline-ResistantPorcine Bordetella bronchisepticaK. Kadlec 1 , H. Kaspar, DVM 2 , J. Mankertz 2 , S. P. Schwarz 1 ; 1 Inst. of FarmAnimal Genetics (FLI), Neustadt-Mariensee, Germany, 2 Federal Office ofConsumer Protection and Food Safety (BVL), Berlin, Germany.90September 9-12 |

MONDAY SCIENTIFIC SESSIONSC1-680 Cumulative Resistance to the Novel Lpxc Inhibitor Chir-090in Pseudomonas aeruginosa: Interplay of Efflux and Non EffluxMechanismsA. K. Jones 1 , S. Barnes 2 , K. Suefuji 1 , L. Xie 1 , J. R. Walker 2 , C. R. Dean 1 ;1Novartis Inst. for Biomedical Res., Emeryville, CA, 2 Genomics Inst. of theNovartis Res. Fndn., San Diego, CA.C1-681 Ozenoxacin. Selection of Resistant Mutants of Gram-PositiveCocciY. López, Biologist 1 , M. Tato 2 , R. Cantón 2 , J. Vila 1 ; 1 Hosp. Clinic, Barcelona,Spain, 2 Ramón y Cajal Univ. Hosp., Madrid, Spain.C1-682 Ozenoxacin Impact of Mutations in the gyrA y parC Genes ofClinical Gram-Positive Cocci in the MICY. López 1 , M. Tato 2 , R. Cantón 2 , J. Vila 1 ; 1 Hosp. Clinic, Barcelona, Spain,2Ramón y Cajal Univ. Hosp., Madrid, Spain.C1-683 Prevalence and Molecular Characterization of Plasmid-MediatedQuinolone Resistance in Prospective Bacteremic ClinicalIsolates of Enterobacter spp. from SpainJ. Rodriguez-Martinez 1 , P. Díaz de Alba 1 , C. Ruiz de Alegría 2 , C. Martín-Gandul 3 , O. Gasch 4 , M. Cano 2 , F. Tubau 4 , J. Lepe 3 , R. Lara 5 , F. Rodriguez 5 ,J. Rodriguez-Baño 1 , L. Martinez-Martinez 2 , M. Jiménez-Mejías 3 ,A. Pascual 1 ; 1 Univ. of Seville, Seville, Spain, 2 UH Marques de Valdecilla,Santander, Spain, 3 UH Virgen del Rocio, Seville, Spain, 4 UH Bellvitge,Barcelona, Spain, 5 UH Reina Sofia, Cordoba, Spain.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------087(C2)Poster SessionDiverse Resistance Issues in EnterobacteriaceaeMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C2-684 Host Risk Factors and Efflux Pump Gene ExpressionsAmong E.coli Strains Isolated From Community-AcquiredUrinary Tract InfectionsF. Can 1 , O. Kurt Azap 2 , I. Dolapci 3 , A. Yesilkaya 2 , H. Arslan 2 , O.Ergonul 1 ; 1 Koc Univ., Istanbul, Turkey, 2 Baskent Univ., Ankara, Turkey,3Ankara Univ., Ankara, Turkey.C2-685 Antimicrobial Resistance and Virulence Markers of E. coliIsolated from Nosocomial Bloodstream Infection: A Study of theSCOPE Brazil ProjectA. C. Rochstroh, A. M. Doi, R. M. Silva, A. R. Marra, A. C. C. Pignatari;UNIFESP, Sao Paulo, Brazil.C2-686 Molecular Study of Escherichia coli Isolates from Outbreak ofInfections After Transrectal Ultrasound-Guided Prostate BiopsyN. Suwantarat 1 , S. Rudin 2 , D. Dumford 1 , S. Marshall 2 , A. M. Hujer 2 , K.M. Hujer 2 , R. A. Bonomo 2 , C. J. Donskey 2 ; 1 Case Western Reserve Univ.,Cleveland, OH, 2 Louis Stokes VA Med. Ctr., Cleveland, OH.C2-687 Temporal Trends in Antibiotic Resistance among E. coliST131 Isolates, 1968-2012B. Olesen 1,2 , F. Scheutz 2 , J. Frimodt-Møller 1 , B. Johnston 3 , D. S. Hansen 1 ,K. A. Krogfelt 2 , J. R. Johnson 3 ; 1 Hillerød Hosp., Hillerød, Denmark, 2 StatensSerum Inst., Copenhagen, Denmark, 3 VA Med. Ctr., Minneapolis, MN.C2-688 Regional Differences in Susceptibility of E. coli inCommunity-Acquired Versus Hospital-Associated Intra-AbdominalInfections: SMART 2010/2011R. Badal, S. Lob, S. Bouchillon, M. Hackel, D. Hoban; IHMA, Inc.,Schaumburg, IL.C2-689 Risk Factors for 3rd Generation Cephalosporin ResistantCommunity Onset E. coli Infections from Seven Centres in LowPrevalence CountriesB. A. Rogers 1,2 , P. R. Ingram 2,3 , N. Runnegar 2,4 , J. T. Freeman 2,5 , M. C.Pitman 2,6 , E. Athan 2,7 , S. Havers 1 , D. L. Paterson 1,2 ; 1 Univ. of Queensland,UQCCR, Brisbane, Australia, 2 The COOEE Study Group, ASID ClinicalRes. Network, Qld, Australia, 3 The Royal Perth Hosptial, Perth, Australia,4Princess Alexandra Hosp., Woolloongabba, Australia, 5 Auckland DistrictHlth. Board, Auckland, New Zealand, 6 The Royal Darwin Hosp., Tiwi,Australia, 7 Barwon Hlth., Geelong, Australia.C2-690 Molecular Epidemiology of Non-Nosocomial Klebsiellapneumoniae Bloodstream (KpB) InfectionsM. Cubero, I. Grau, R. Pallares, J. Ayats, M. Cisnal, J. Liñares, C. Ardanuy;Hosp. Univ. Bellvitge, L´Hospitalet de Llobregat (Barcelona), Spain.C2-691 New OXY-Variants from Klebisiella oxytoca (KOX) Bloodculture(BC) Clinical Isolates Collected in U.S.A. HospitalsM. Castanheira, L. M. Deshpande, R. E. Mendes, R. N. Jones; JMI Lab.,N Liberty, IA.C2-692 OqxAB, a Quinolone and Olaquindox Efflux Pump, isWidely Distributed Among Multidrug-Resistant (MDR)Klebsiella pneumoniae of Human Origin in the Northeast U.S.A.F. Perez 1 , S. Rudin 1 , S. Marshall 1 , L. Chen 2 , P. Coakley 3 , B. N. Kreiswirth2, D. van Duin 4 , D. L. Paterson 5 , R. A. Bonomo 1 ; 1 VAMC, Cleveland, OH,2UMDNJ, Newark, NJ, 3 CWRU, Cleveland, OH, 4 Cleveland Clinic, Cleveland,OH, 5 Univ. of Queensland, Brisbane, Australia.C2-693 First Detection of Klebsiella pneumoniae Isolates Harboringqnr Genes in JapanH. Okade 1,2 , S. Nakagawa 2 , N. Nomura 2 , J. Mitsuyama 2 , Y. Yamagishi 1 , H.Mikamo 1 ; 1 Aichi Med. Univ., Aichi, Japan, 2 Res. Lab., Toyama ChemicalCo., Ltd., Toyama, Japan.C2-694 Molecular Characterization of-Lactam/-Lactamase InhibitorCombinations (BL/BI) - Resistant Isolates from ColombiaL. J. Rojas 1 , A. Correa 1 , E. de La Cadena 1 , M. F. Mojica 1 , J. P. Quinn 2 ,R. A. Bonomo 3 , M. V. Villegas 1 , Colombian Nosocomial Resistance StudyGroup; 1 CIDEIM, Cali, Colombia, 2 AstraZeneca, Waltham, MA, 3 VAMCCleveland, Cleveland, OH.C2-695 Ceftriaxone Resistance among Salmonella Isolates fromHumans in the United States, 1996-2010J. L. Reynolds 1,2 , J. M. Whichard 1 , B. E. Karp 1 ; 1 CDC, Atlanta, GA,2Atlanta Res. and Ed. Fndn., Decatur, GA.C2-696 Quinolone Resistance Mechanisms and Molecular Epidemiologyof Salmonella sppC. Ballesté-Delpierre 1 , A. Fàbrega 1 , A. Dehn Lunn 2 , M. Solé 1 , M. Jiménezde Anta 1 , J. Vila 1 ; 1 CRESIB-Hosp. Clínic, UB, Barcelona, Spain, 2 Univ. ofSheffield, Sheffield, United Kingdom.Final Program91

Monday SCIENTIFIC SESSIONSC2-697 CTX-M-5-Coding Plasmids of Nosocomial SalmonellaTyphimurium Clone Circulating for a Long Time in Russia,Belarus, and KazakhstanV. Kozyreva 1 , E. Ilina 2 , A. Carattoli 3 , M. Edelstein 1 , R. Kozlov 1 ; 1 Inst. ofAntimicrobial Chemotherapy, Smolensk, Russian Federation, 2 Res. Inst. ofPhysical-Chemical Med., Moscow, Russian Federation, 3 Inst. Superiore diSanità, Rome, Italy.C2-698 Characterisation of Antimicrobial Resistance Patterns andIntegrons among Salmonella enterica serovar Enteritidis Isolates inTaiwan and Development of Macroarray for Their DetectionH. Tsen 1 , J. Pang 2,3 ; 1 Hung-Kuang Univ., Taichung, Taiwan, 2 Vanung Univ.,Tao-Yuan, Taiwan, 3 Vanung Univ., Tao Yuan, Taiwan.C2-699 A 3 Year Study of Changing Epidemiology, Seasonal Patterns,Antibiotic Resistance and Racial Prediliction of Shigella at QatarG. Wilson; Hamad Med. Corp., Doha, Qatar.C2-700 Prevalence of Plasmid-Mediated Quinolone ResistanceDeterminants among Oxyiminocephalosporin Resistant EnterobacteriaceaeG. Rincón 1,2 , M. Radice 1 , S. Sennati, D 3 , G. Santella 1 , L. Pallecchi 3 , G. M.Rossolini 3 , J. Di Conza 1,4 , G. Gutkind 1 ; 1 Fac de Farm UBA, Buenos Aires,Argentina, 2 Univ. Industrial de Santander, Santander, Colombia, 3 Univ. diSiena, Siena, Italy, 4 Univ. del Litoral, Santa Fe, Argentina.C2-701 Prevalence of Plasmid-Mediated Quinolone ResistanceMechanisms (PMQR) in ArgentinaE. Albornoz 1 , C. Lucero 1 , C. Rodriguez 2 , WHONET-Argentina Group, M.Galas 1 , D. Centrón 2 , A. Corso 1 , A. Petroni 1 ; 1 Serv Antimicrobianos, INEI-ANLIS Malbran, Buenos Aires, Argentina, 2 Fac de Med., Univ. de Bs As,Buenos Aires Argentina.C2-702 In Vitro Susceptibilities of E. coli and K. pneumoniae Isolatedfrom Patients with Intra-Abdominal Infections in China: Datafrom the Study for Monitoring Antimicrobial Resistance Trends(SMART) 2002-2011Y. Wang, Q. Yang, Y. Xu, SMART Study Group in China; Peking UnionMed. Coll. Hosp., Beijing, China.------------------------------------------------------------------------088(C2)Poster SessionFood, Animals and Environment Reservoirs for Gram-Negative OrganismsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C2-703 Molecular Analysis of Extended-Spectrum Beta-Lactamases(ESBLs) Gene Sequences of Bacteria on Retail Lettuce andRelatedness to Clinical IsolatesC. Muraleedharan 1 , N. Bhutani 1 , D. Talreja 1 , S. W. Rana 2 , S. K. Walia 3 , M.Sawani 4 , A. Kumar 2 , S. K. Walia 1 ; 1 Oakland Univ., Rochester, MI, 2 KEI,Wayne State Univ., Detroit, MI, 3 Henry Ford Helath System, Detroit, MI,4Crittenton Hosp. Med. Ctr., Rochester, MI.C2-704 Extended-Spectrum Beta-Lactamase (ESBL) ProducingGram-Negative Bacteria from Pets, Buffalos and Psittacines, BrazilL. Barbato, L. C. Melo, C. P. Oresco, N. N. Oliveira, J. A. P. Abreu, A. F. P.Castro, N. Lincopan; USP, São Paulo, Brazil.C2-705 Antimicrobial Susceptibility of Escherichia coli (Ec) fromCattle (Ca), Pigs (P) and Chickens (Ch) in 10 EU Countries(EASSA study)A. de Jong 1 , V. Thomas 1 , S. Simjee, Senior 1 , F. El Garch 1 , H. Moyaert 1 ,D. Rigaut 1 , M. Vallé 1 , K. Maher 2 , I. Morrissey 2 ; 1 EASSA Study Group,Brussels, Belgium, 2 Q B, Fordham, United Kingdom.C2-706 CTX-M E. coli is Common in Retail Chicken in Ireland but isNot Closely Linked to Human IsolatesC. Ludden 1 , A. Brennan 1 , S. Kelly 1 , E. Burke 2 , M. Cormican 1,2 , D. Morris 1 ;1Natl. Univ. of Ireland, Galway, Galway, Ireland, 2 Univ. Hosp. Galway,Galway, Ireland.C2-707 Characterization by pMLST of Plasmids Encoding SHV-12in Escherichia coli Isolates from Human and Animal Food Sourcesin the South of SpainL. López-Cerero 1 , P. Egea 1 , E. Torres 1 , M. Bellido 1 , J. Rodríguez-Baño 1 ,A. Pascual 1,2 ; 1 Univ. Hosp. Virgen Macarena, Seville, Spain, 2 Sch. of Med.,Seville, Spain.C2-708 Co-Selection May Explain High Rates of Ciprofloxacin ResistantEscherichia coli from Retail Poultry Reared Without PriorFluoroquinolone ExposureP. R. Ingram 1 , B. A. Rogers 2 , H. E. Sidjabat 2 , J. S. Gibson 3 , T. J. J. Inglis 1 ;1PathWest Lab., QEII Med. Ctr., Perth, Australia, 2 The Univ. of Queensland,UQCCR, Brisbane, Australia, 3 The Univ. of Queensland, Sch. of Vet. Sci.,Brisbane, Australia.C2-709 Antimicrobial Susceptibility of Salmonella enterica (Se) fromHealthy Cattle (Ca), Pigs (P) and Chickens (Ch) Across the EU:European Antimicrobial Susceptibility Surveillance in Animals(EASSA)I. Morrissey 1 , A. de Jong 2 , H. Moyaert 2 , F. El Garch 2 , P. Butty 2 , U. Klein 2 ,D. Rigaut 2 , S. Simjee 2 , V. Thomas 2 , M. Vallé 2 ; 1 Q B, Fordham, United Kingdom,2 EASSA Study Group, Brussels, Belgium.C2-710 Diversity of blaCMY-2 Carrying Plasmids from Bovine E. coliExposed to Antibiotic AgentsJ. L. Cottell 1 , N. Kanwar 2 , G. H. Loneragan 3 , H. M. Scott 2 , P. Boerlin 1 ;1Univ. of Guelph, Guelph, Canada, 2 Kansas State Univ., Manhattan, KS,3Texas Tech Univ., Lubbock, TX.C2-711 Detection of pO157-Free Escherichia coli Serotype O157 inSurface WaterZ. Hossain 1 , K. Mohsina 2 , M. Fakruddin 1 , K. R. Mahbub 1 , M. M. Ahmed 1 ;1Bangladesh Council of Sci. and Industrial Res., Dhaka, Bangladesh, 2 ShahjalalUniv. of Sci. and Tech., Sylhet, Bangladesh.C2-712 Characterization of Antimicrobial Resistance and Class 1 integronsin Escherichia coli Isolated from Shrimps and EnvironmentK. Changkaew 1 , F. Utrarachkij 2 , K. Siripanichgon 2 , C. Nakajima 1 , O.Suthienkul 2 , Y. Suzuki 1 ; 1 Hokkaido Univ., Sapporo, Japan, 2 Mahidol Univ.,Bangkok, Thailand.C2-713 Antimicrobial Resistance in Salmonella enterica SerovarsIsolated from Retail Meat: An UpdateR. Figueiredo 1 , A. Henriques 2 , R. Sereno 2 , N. Mendonça 1 , G. J. Da Silva 1 ;1CEF, Univ. Coimbra, Coimbra, Portugal, 2 ControlVet SA, Tondela, Portugal.C2-714 Seasonality and Geography Influence the Prevalence andResistance of Retail-Source CampylobacterI. Forrester 1 , E. Crarey 2 , P. McDermott 2 , H. Tate 2 ; 1 Univ. of Maryland,Baltimore, 2 U.S. FDA, Laurel.92September 9-12 |

MONDAY SCIENTIFIC SESSIONSC2-715 16S rRNA Sequencing in Characterizing SXT-PositiveVibrio owensii Isolated from CoralsT. Bhotra, S. K. Das, D. V. Singh; Inst. of Life Sci., Bhubaneswar, India.C2-716 Presence of blaKPC Genes in Enterobacteriaceae StrainsIsolated from Sewage Treatment Plants in BrazilWithdrawnC2-717 Environmental Cc258 KPC-2-Producing Klebsiellapneumoniae, BrazilR. Moura 1 , S. Oliveira 1 , K. Silva 1 , M. Pavez 1 , E. Hachich 2 , M. Sato 1 , E.Mamizuka 1 , A. Pestana 1 , N. Lincopan 1 ; 1 Univ. of São Paulo, São Paulo,Brazil, 2 CETESB, São Paulo, Brazil.------------------------------------------------------------------------089(C2)Poster SessionPseudomonas aeruginosa: An Overview of SurvellianceDataMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C2-718 Prevalence of GES-Lactamases in P. aeruginosa in Lima,PerúE. Gonzales 1 , P. Maritza 2 , M. Radice 3 , G. Gutkind 3 ; 1 Inst. Natl. de Saluddel Niño, Lima, Peru, 2 Univ. de Buenos Aires, Argentina, 3 Fac de Farm Univ.de Buenos Aires, Argentina.C2-719 New Integron Encompassing bla VIM-2, qnrVC1 and GenesEncoding Bacterial Group II Intron in Clonal Srains ofPseudomonas aeruginosaV. Dubois, L. Coulange, C. Andre, F. M’zali, C. Quentin-Noury; CNRS-Univ. de Bordeaux 2, Bordeaux, France.C2-720 Metallo--Lactamases (MBLs) in the Heartland of theUnited States: International Strain of VIM-2 ProducingPseudomonas aeruginosa (Pa) in a Community Hospital inNortheast Ohio (NEO)F. Perez 1 , S. M. Marshall 1 , A. J. Ray 2 , D. Dumford 2 , M. R. Jacobs 2 , R. A.Bonomo 1 ; 1 VAMC, Cleveland, OH, 2 CWRU, Cleveland, OH.C2-721 Pseudomonas aeruginosa in Pediatric Pneumonia: Activity ofPiperacillin-Tazobactam and Comparators: 2004-2011D. Hoban 1 , M. Hackel 1 , M. Renteria 1 , R. Badal 1 , S. Bouchillon 1 ,B. Johnson 1 , J. Johnson 1 , S. Hawser 2 ; 1 IHMA, Inc., Schaumburg, IL,2IHMA Europe Sàrl, Epalinges, Switzerland.C2-722 Impact of New CLSI Piperacillin/Tazobactam Breakpointson Reported Susceptibility of Pseudomonas aeruginosa in NorthAmerica - TEST 2009-2011S. Lob , S. Bouchillon , M. Hackel , D. Hoban , J. Johnson; IHMA, Inc.,Schaumburg, IL.C2-723 Comparison of Variable Number Tandem Repeat Analysiswith Pulsed-Field Gel Electrophoresis for Multidrug-ResistantPseudomonas aeruginosa Isolates from South AfricaWithdrawnC2-724 Response to Imipenem Plus MK-7655, a Novel -LactamaseInhibitor, in a Surveillance Study Population of P. aeruginosa fromSMART 2009K. Young 1 , M. Hackel 2 , C. Lascols 2 , S. Bouchillon 2 , R. Badal 2 ; 1 Merck Res.Lab., Kenilworth, NJ, 2 IHMA, Schaumburg, IL.C2-725 A Multi-Center Longitudinal Comparison of P. aeruginosaAntibiotic Resistance Profiles and Anatomical SitesL. E. Nielsen, P. McGann, R. Clifford, L. Preston, Y. Kwak, P. Waterman, E.Lesho; WRAIR, US Army, Silver Spring, MD.------------------------------------------------------------------------090(D)Poster SessionMALDI-ToF Mass Spectrometry and Identificationand Susceptibility TestingMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:D-726 Rapid Identification of Pathogens by MALDI-ToF MS inBlood Culture BottlesB. Rodriguez-Sanchez, C. Sanchez-Carrillo , A. Ruiz, M. Rodriguez-Creixems, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Univ. of Madrid.Spain., Madrid, Spain.D-727 Rapid Identification of Pathogens Directly from Blood CultureBottles by Bruker MALDI-ToF Mass Spectrometry SystemV. O. Rotimi 1 , W. Jamal 1 , R. Saleem 2 , A. Pazhoor 2 ; 1 Kuwait Univ., Safat,Kuwait, 2 Mubarak Hosp., Jabriya, Kuwait.D-728 Rapid Identification of Antibiotic (Beta-Lactam) Hydrolysisin Gram-Negative Bacteria Isolated from Blood Cultures UsingMALDI-ToF MSD. Kasper 1 , N. W. Anderson 1 , B. W. Buchan 1,2 , N. A. Ledeboer 1,2 ; 1 Med.Coll. of Wisconsin, Milwaukee, WI, 2 Dynacare Lab., Milwaukee, WI.D-729 Evaluation of Matrix-Assisted Laser-Desorption/IonizationTime-of-Flight Mass Spectrometry (MALDI-ToF MS) for theIdentification of Bacteria and Yeast in Clincial SpecimensS. Robichaud 1 , J. M. Blondeau 1 , L. David 2 , H. Deneer 1 , O. Larios 1 , S.Sanche 1 ; 1 Univ. of Saskatchewan, Saskatoon, Canada, 2 Saskatoon Hlth.Region, Saskatoon, Canada.D-730 Comparison of Vitek MS and MALDI Biotyper for RapidBacterial Identification by Matrix-Assisted Laser Desorption-Ionization-Time of Flight Mass Spectrometry (MALDI-ToFMS) in a Pediatric SettingP. Morency-Potvin 1,2 , F. Rallu 1 , M. Saint-Jean 1,2 , M. Carrier 2 , D. Sans 2 , A.Demers 1,2 , C. Laferrière 1,2 ; 1 Sainte-Justine Univ. Hosp., Montréal, Canada,2Univ. of Montreal, Montréal, Canada.D-731 Rapid Identification of Burkholderia cepacia Complex (Bcc)Species Using MALDI-ToF MSL. C. C. Fehlberg 1 , R. Cayô 1 , L. H. S. Andrade 1 , D. M. Assis 1 , R. H. V.Pereira 2 , L. Juliano 1 , A. C. Gales 1 , E. A. Marques 2 ; 1 UNIFESP, São Paulo,Brazil, 2 UERJ, Rio de Janeiro, Brazil.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.Final Program93

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------091(D)Poster SessionMycobacteria: Diagnostics and Susceptibility TestingMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:D-732 Use of RT-PCR for the Detection of Mycobacteriumtuberculosis Complex DNAM. Rowlinson 1 , S. R. Crowe 1 , Y. Lee 1 , P. Fiorella 1 , R. Farah 1 , M. Pedrosa 1 ,M. Salfinger 2 ; 1 Florida Dept. of Hlth., Jacksonville, FL, 2 Florida Dept. ofHlth., Tallahassee, FL.D-733 Comparative Evaluation of Conventional Methods andNested Polymerase Chain Reaction in the Diagnosis of Extra-Pulmonary TuberculosisS. Sharma; Sgrdimsar, Amritsar, India.D-734 Comparative Evaluation of Advansure MycobacteriaGenoblot Assay Kit for the Identification of NontuberculousMycobacteria to the Species LevelH. Bae, G. Ryu, E. Lee; Green Cross Reference Lab., Yongin, Korea, Republicof.D-735 Rapid Species Identification of Mycobacterium chelonae andMycobacterium abscessus Complex and Determination ofInducible Clarithromycin Resistance by High Resolution MeltAnalysis (HRM)M. J. Tuohy, G. S. Hall, G. W. Procop, S. M. Harrington; Cleveland Clinic,Cleveland, OH.D-736 Evaluation of the TREK MIC MicroTiter Plate Method forAntimicrobial Susceptibility Testing of Mycobacterium tuberculosisComplex IsolatesC. Tanner 1 , P. Miles 1 , M. Rowlinson 1 , S. Crowe 1 , D. Willis 1 , M. Salfinger 2 ;1Bureau of Lab., Florida Dept. of Hlth., Jacksonville, FL, 2 Bureau of Lab.,Florida Dept. of Hlth., Tallahassee, FL.D-737 Comparison of a Commercial MTB MIC Plate, Agar ProportionMethod, and DNA Sequence Analysis for Detection of Resistanceto Isoniazid, Rifampin, and Ethambutol in Mycobacteriumtuberculosis ComplexD. Sikes, B. Metchock; CDC, Atlanta, GA.D-738 Drug Susceptibility Testing and Genotypes of Mycobacteriumtuberculosis Isolated from Extra-Pulmonary Clinical Specimens ofBangladeshWithdrawnD-739 Conversion of CO to CO2 by CO Dehydrogenase as a HighlySelective Stable Isotope Breath Test Marker for TuberculosisDiagnosisS. Choi 1 , M. Maiga 2 , M. Maiga 2 , V. Atudorei 1 , Z. Sharp 1 , W. Bishai 2 , G.Timmins 1 ; 1 Univ. of New Mexico, Albuquerque, NM, 2 Johns Hopkins Hosp.,Baltimore, MD.D-740 Mycobacterial IGRA Variations in Long-Term TreatedPatients with TNF Blockers are not Associated with TuberculosisOutcomeI. Sauzullo 1 , R. Scrivo 1 , F. Mengoni 1 , R. Marocco 2 , G. Valesini 1 , V. Vullo 1 , C.M. Mastroianni 2 ; 1 Sapienza Univ., Rome, Italy, 2 Sapienza Univ., Latina, Italy.D-741 Diagnostic Usefulness of a T-Cell-Based Assay in Patientswith Miliary Tuberculosis (TB)Y. Lee, K. Park, S. Kim, S. Park, S. Lee, S. Choi, Y. Kim, J. Woo, S. Kim;Asan Med. Ctr., Seoul, Korea, Republic of.D-742 Diagnosis of Latent Tuberculosis in Subjects with DiscordantTST/IGRA ResultsI. Sauzullo 1 , A. Ermocida 1 , F. Mengoni 1 , R. Rossi 1 , M. Lichtner 2 , V. Vullo 1 ,C. M. Mastroianni 2 ; 1 Sapienza Univ., Rome, Italy, 2 Sapienza Univ., Latina, Italy.D-743 Extrapulmonary Tuberculosis: Epidemiological, Molecularand Circulating Cytokines MarkersJ. Fortun, P. Martin-Davila, E. Gomez-Mampaso, A. Vallejo, I. Barbolla,P. Wikman, J. Ortíz, E. Navas, D. Gijon, I. Gomez-Garcia, A. Gonzalez, J.Rubi, E. Pallares, S. Moreno; Ramon Y Cajal Hosp., Madrid, Spain.D-744 Approach to Latent Tuberculosis Among Occupational HealthProvidersC. VinnardE 1 , D. LinkinE 2 , A. Behrman 2 ; 1 Drexel Univ. Coll. of Med.,Philadelphia, PA, 2 Univ. of Pennsylvania, Philadelphia, PA.------------------------------------------------------------------------092(D)Poster SessionPhenotypic Susceptibility Testing MethodsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:D-745 Evaluation of Two Etest MBL Strips for Detection of Metallo-Carbapenemases in EnterobacteriaceaeD. Halimi 1 , D. Girlich 2 , P. Nordmann 2 , S. Rivat 1 , G.Durand1, R.Martelin 1 ,G. Zambardi 1 ; 1 bioMerieux, La Balme les Grottes, France, 2 Hosp. Bicetre,Paris, France.D-746 Screening of Epidemiologically Challenging CarbapenemaseProducers Pseudomonas aeruginosa (CP-PA) by Agar Dilution(AD), Vitek 2C and Phoenix Systems: Are Current BreakpointsEnough?F. Pasteran 1 , C. Lucero 1 , M. M. Peres 2 , L. Errecalde 3 , O. Veliz 1 ,M. Rapoport 1 , E. Tuduri 1 , A. Di Bella 4 , S. Kaufman 3 , D. Korbenfeld 2 ,A. Corso 1 ; 1 Antimicrobianos, INEI-ANLIS, Buenos Aires, Argentina, 2 BDDiagnostics Systems, Buenos Aires, Argentina, 3 Hosp. Fernandez, BuenosAires, Argentina, 4 Hosp. Posadas, Buenos Aires, Argentina.D-747 Unreliability of the New CLSI 2012 Breakpoints for Cefepimeand Carbapenems to Detect KPCsM. V. Villegas 1 , A. Correa 1 , E. De La Cadena 1 , J. J. Maya 1 , V. M. Blanco 1 ,L. J. Rojas 1 , M. F. Mojica 1 , R. Pacheco 1 , C. Hernandez 1 , M. E. Vallejo 1,2 ,J. P. Quinn 3 , Colombian Nosocomial Resistance Study Group; 1 CIDEIM,Cali, Colombia, 2 Univ. Pontificia Bolivariana, Medellin, Colombia, 3 Astra-Zeneca, Waltham, MA.94September 9-12 |

MONDAY SCIENTIFIC SESSIONSD-748 Evaluation of a New Eteststrip for KPC Detection inEnterobacteriaceaeD. Halimi 1 , D. Girlich 2 , P. Nordmann 2 , S. Rivat 1 , G.Durand 1 , R.Martelin 1 ,G. Zambardi 1 ; 1 bioMerieux, La Balme les Grottes, France, 2 Hosp. Bicetre,Paris, France.D-749 Quantification of Modified Hodge Test: A New Approach toPhenotypic Screening of KPCV. B. Ribeiro 1,2 , A. R. Linhares 1 , A. P. Zavascki 4 , A. L. Barth 1,2 ; 1 Univ. Federaldo Rio Grande do Sul, Porto Alegre, Brazil, 2 Hosp. de Clínicas de PortoAlegre, Porto Alegre, Brazil.D-750 Carbapenem-Resistant Enterobacteriaceae Detection andPrevention Practices, Michigan, 2012B. M. Brennan, J. R. Coyle, M. S. Boehme, P. Boinapally, J. L. Finks; MichiganDept. of Community Hlth., Lansing, MI.D-751 Comparison of Two Chromogenic Media and MacConkeyAgar with Carbapenem Disks for the Detection of Carpabenemase-ProducingGram Negative Rods in Simulated StoolSpecimensJ. Blackburn 1 , C. Tsimiklis 1 , V. Lavergne 1 , J. Pilotte 2 , S. Grenier 2 , A. Gilbert2 , B. Lefebvre 2 , M. Domingo 2 , C. Tremblay 2 , A. Bourgault 2 ; 1 Hosp. duSacré-Coeur de Montréal, Montréal, Canada, 2 Inst. Natl. de Santé Publique,Lab. de Santé Publique du Québec, Montréal, Canada.D-752 Performance of Ceftriaxone (CAX) Minimum InhibitoryConcentration (MIC) > 1 μg/ml for Detection of Extended-Spectrum-Lactamase (ESBL) Producing E. coli (EC) andK. pneumoniae (KP)N. K. Boyd 1,2 , K. S. Alvarez 1,2 , L. Byrd 1 , K. P. Bhavan 1,2 ; 1 Parkland Hlth.and Hosp. System, Dallas, TX, 2 Univ. of Texas Southwestern Med. Sch.,Dallas, TX.D-753 Rapid Detection of-Lactamase Hydrolyzing Extended-Spectrum Cephalosporins in Enterobacteriaceae Using the NewChromogenicLACTA TestM. Garcia-Castillo, M. Morosini, M. Tato, T. Curiao, D. Gijón, A. Valverde,P. Ruiz-Garbajosa, R. Canton; Hosp. Univ. Ramón y Cajal, Madrid, Spain.D-754 Implementation of the 2010 Clinical and Laboratory StandardsInstitute (CLSI) Guidelines: Effects on Antibiotic (Abx)Utilization in the Treatment of Presumed Extended-SpectrumBeta-Lactamase (ESBL)-Producing Enterobacteriaceae (EB)J. Curello, C. MacDougall; UCSF Med. Ctr., San Francisco, CA.D-755 Evaluation of Vitek 2 and MicroScan WalkAway for Extended-Spectrum ß-Lactamase-Producing Escherichia coli and Klebsiellapneumoniae Isolates against Cefepime, Cefotaxime and CeftazidimeW. Jang 1 , J. Yu 2 , K. Park 2 , Y. Park 2 ; 1 St. Mary Hosp., Seoul, Korea, Republicof, 2 Sch. of Med., The Catholic Univ. of Korea, Seoul, Korea, Republic of.D-756 Use of Combination Antibiograms to Determine EmpiricDouble-Coverage of Gram-Negative OrganismsJ. J. Taylor, P. Pancholi, J. Balada-Llasat; The Ohio State Univ. Wexner Med.Ctr., Columbus, OH.D-757 Impact of EUCAST Breakpoints on the Management ofInfections Caused by Pseudomonas aeruginosaP. Bonfanti, B. Pini, C. Molteni, L. Principe, I. Caramma, S. Bracco,F. Luzzaro; 1 A.Manzoni Hosp., Lecco, Italy.D-758 Use of Oxoid Paper Disks Until 14 Days After Opening of theCartridge in Disk Diffusion Antimicrobial Susceptibility TestingMethodM. Grare, A. Ayma, M. Auregan, N. Marty, C. Segonds; IFB, CHUToulouse Purpan, Toulouse, France.D-759 Disk Diffusion-Based Algorithm Improves Detection ofaac(6’)-Ib-crP. Andres, E. Albornoz, L. Guerriero, A. Corso, A. Petroni; INEI-ANLISMalbran, Bs As, Argentina.D-760 Development of Disk Diffusion Testing for KPI-10, a NovelFluoroquinolone (FQ) with Potent, Broad-Spectrum ActivityJ. Deane 1 , A. Simenauer 1 , Y. Ge 2 , P. Eckburg 2 , D. Sahm 1 ; 1 Eurofins,Chantilly, VA, 2 Kalidex Pharmaceuticals, Inc., Menlo Park, CA.D-761 Susceptibility of Multi-Drug Resistant Strains of Acinetobacterbaumannii to Colistin: A comparison of Disc Diffusion, AgarDilution, Etest, Broth Microtitre Dilution, Automated andTime-Kill MethodologiesL. Phee, M. Hornsey, D. Wareham; QMUL, London, United Kingdom.D-762 Development of a Disk Diffusion Assay for OritavancinA. Belley, F. F. Arhin, , I. Sarmiento, G. Moeck; The Med. Company, St-Laurent, Canada.D-763 Colistin MIC Testing: The Effect of Different Types ofMicrotitre Trays and Surfactant Tween80 in Broth MicrodilutionMethodM. S. Albur, K. E. Bowker, A. R. Noel, A. P. MacGowan; North BristolNHS Trust, Bristol, United Kingdom.D-764 Various Test Method Parameters Have Minimal Impact onIn Vitro Minimal Inhibitory Concentration (MIC) ResultsObtained with KPI-10 by Broth Microdilution TestingJ. Deane 1 , A. Simenauer 1 , Y. Ge 2 , P. B. Eckburg 3 , D. Sahm 1 ; 1 Eurofins,Chantilly, VA, 2 Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 3 Eurofins,Menlo Park, CA.D-765 Comparison of Two Gradient Diffusion Assays and ThreeTesting Devices for Determination of MICs of Tigecyclineagainst Multiresistant IsolatesJ. Calvo 1 , C. Rodríguez 1 , L. Guzmán-Gómez 1 , I. de Benito 2 , A. Campo 2 ,L. Martínez-Martínez 1 ; 1 HUM Valdecilla, Santander, Spain, 2 Hosp. Sierrallana,Santander, Spain.D-766 An Equivalency Study of the Commercially Prepared DriedMIC System Compared with the CLSI Broth MicrodilutionReference Method for GSK2251052D. Zollos 1 , C. Knapp 1 , S. Killian 1 , N. Holliday 1 , N. Scangarella-Oman 2 ;1Thermo Fisher Scientific, Cleveland, OH, 2 GlaxoSmithKline, Collegeville,PA.D-767 Broth Microdilution Quality Control Ranges for Testingthe Imipenem/MK-7655 Combination (IMK) against KeyOrganism GroupsJ. Deane 1 , A. Simenauer 1 , K. Young 2 , M. Motyl 2 , D. Sahm 1 ; 1 Eurofins,Chantilly, VA, 2 Merck & Co., Inc., Kenilworth, NJ.D-768 Quality Control Parameters for LFF571 Aerobic & AnaerobicMinimum Inhibitory Concentration (MIC) Susceptibility TestsM. M. Traczewski, S. D. Brown; The Clinical Microbiol. Inst., Wilsonville, OR.Final Program95

Monday SCIENTIFIC SESSIONSD-769 Ozenoxacin. Checkerboard Interaction Studies with OtherAntibacterials against Gram-Positive OrganismsI. Morrissey 1 , R. Janes 1 , J. Dallow 1 , A. Guglietta 2 , D. Gargallo-Viola 2 ;1Quotient Bioresearch, Ltd., Fordham, United Kingdom, 2 Ferrer, R&D Ctr.,Barcelona, Spain.D-770 Effect of Testing Methodology on In Vitro Activity of SodiumOxychloroseneA. H. Stock 1 , S. S. Utley 1 , S. C. Cheatham 1 , M. R. Fleming 2 , M. B. Kays3; 1 St. Francis Health, Indianapolis, IN, 2 Methodist Dallas Med. Ctr., Dallas,TX, 3 Purdue Univ., Indianapolis, IN.D-771 Multicenter Evaluation of Ceftaroline Etest AntimicrobialSusceptibility Test for EnterobacteriaceaeM. M. Traczewski 1 , S. D. Brown 1 , W. M. Dunne 2,3 , M. Tuohy 4 , G. S. Hall 5 ,R. Collins 2 ; 1 The Clinical Microbiol. Inst., Wilsonville, OR, 2 WashingtonUniv. Sch. of Med., St. Louis, MO, 3 bioMerieux, Inc, Durham, NC, 4 ClevelandClinic, Cleveland, OH, 5 Cleveland Clinic, Wilsonville, OR.D-772 Screening of Hematological Patients for Intestinal Colonizationwith Antibiotic-Resistant Enterobacteria is Helpful toPredict Susceptibility of Bacteremia IsolatesP. Woerther, J. Micol, B. Gachot, J. Bourhis, S. de Botton, E. Chachaty; Inst.Gustave Roussy, Villejuif, France.D-773 Antimicrobial Resistance of Klebsiella pneumoniae andStaphylococcus aureus at Sentinel Sites in South AfricaO. Perovic, A. Singh-Moodley, M. Smith, W. Lowman; Natl. Hlth. Lab.Service, Johannesburg, South Africa.D-774 Detection of Amp C Beta Lactamase Producing BacteriaIsolated from a Tertiary Care HospitalsA. Hassanil; Natl. Univ. of Scienecs and Tech., Army Med. Coll.,Rawalpindi, Pakistan.D-775 Etiology and Antimicrobial Susceptibility Patterns of AcuteUncomplicated Cystitis from Primary Care Settings in RwandaC. Muvunyi, F. Masaisa, L. Mutesa, A. Musemakweri; Natl. Univ. ofRwanda/Faculty, Butare, Rwanda.D-776 Prevalence and Antimicrobial Susceptibility Pattern ofPropionibacterium Species Isolated from Indian Patients withAcne VulgarisR. Chaudhry, R. Khan, N. Khanna; AIIMS, Delhi, India.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------093(E)Poster SessionCornucopia of In Vitro ActivityMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:E-777 TP-434 is Active In Vitro against Biofilms Formed by UropathogenicEscherichia coliW. O’ Brien, J. A. Sutcliffe, T. H. Grossman; Tetraphase Pharmaceuticals,Watertown, MA.E-778 Comparison of Tedizolid (TZD) In Vitro Activity with Thatof Other Key Gram Positive Agents against Recent Enterococcaland Streptococcal IsolatesJ. Deane 1 , A. Simenauer 1 , K. Bartizal 2 , K. Shaw 2 , D. F. Sahm 1 ; 1 Eurofins,Chantilly, VA, 2 Trius Therapeutics, San Diego, CA.E-779 In Vitro Activity of Plazomicin against Gram-Negative andGram-Positive Pathogens Isolated from Patients in CanadianHospitals in 2011: CANWARD Surveillance StudyG. G. Zhanel 1 , H. J. Adam 2 , M. Baxter 1 , A. Denisuik 1 , A. Walkty 2 , P. R.S. Lagace-Wiens 2 , F. Schweizer 1 , D. J. Hoban 2 , J. A. Karlowsky 2 ; 1 Univ. ofManitoba, Winnipeg, Canada, 2 Diagnostic Services of Manitoba, Winnipeg,Canada.E-780 A549 Cell Culture Supernatant Inactivates CarbapenemAntibioticsH. Takemura, S. Terakubo, N. Okamura, J. Shimada, H. Nakashima; St.Marianna Univ., Kawasaki, Japan.E-781 Antimicrobial Activity of the Fluoroketolide, Solithromycin(CEM-101), against Neisseria gonorrhoeaeJ. Mallegol 1 , P. Fernandes 2 , C. Seah 1 , C. Guyard 1 , R. G. Melano 1 ; 1 Publ.Hlth. Ontario Lab., Toronto, Canada, 2 Cempra Pharmaceuticals, Inc., ChapelHill, NC.E-782 In Vitro Interactions with Fractional Inhibitory Concentration(FIC) Indices between 0.5 and 4 are In Vivo Important: A Need toRevisit FIC Index CutoffsJ. Meletiadis 1 , A. Elefanti 1 , L. Zerva 1 , P. E. Verweij 2 , J. W. Mouton 2 ;1Attikon Univ. Gen. Hosp., Athens, Greece, 2 Radboud Univ. Med. Ctr.,Nijmegen, Netherlands.E-783 Does Pulmonary Surfactant Generally Affect AntimicrobialActivity?R. Schwameis, S. Strommer, RT, M. A. Zeitlinger, R. Sauermann; Med.Univ. of Vienna, Vienna, Austria.------------------------------------------------------------------------094(E)Poster SessionIn Vitro Activity against Multidrug-Resistant Gram-Negative BacteriaMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:E-784 In Vitro Activity of Dioctadecyldimethylammonium BromideBicelles (DDAb) and DDAb/Tigecycline against Oxacillinase-Producing Acinetobacter baumanniiP. R. Neves, M. Medeiros, E. Mamizuka, N. Lincopan; Univ.e de São Paulo,São Paulo, Brazil.E-785 An Evaluation of Polymyxin B (PB) and Tigecycline (TIG)Combinations against Acinetobacter baumannii (Ab)G. G. Rao 1 , N. S. Ly 1 , R. L. Nation 2 , A. Forrest 1 , J. B. Bulitta 1,2 , J. Li 2 ,B. T. Tsuji 1 ; 1 SUNY, Buffalo, NY, 2 Monash Univ., Melbourne, Australia.E-786 In Vitro and In Vivo Responses of Acinetobacter baumannii (Ab)Isolates to Colistin (COL) and Doripenem (DOR) FollowingPrevious ExposureL. M. Gillis, E. G. Press, M. H. Nguyen, C. J. Clancy , R. K. Shields; Univ.of Pittsburgh, Pittsburgh, PA.E-787 Minimal Inhibitory Concentrations (MICs) of Tigecyclineto Acinetobacter baumannii Vary Significantly as a Function ofTesting MethodD. Marchaim, O. Tzuman, K. Hayakawa, P. R. Lephart, J. M. Pogue, T.Lazarovitch, K. S. Kaye; Wayne State Univ., Detroit, MI.96September 9-12 |

MONDAY SCIENTIFIC SESSIONSE-788 Synergistic Activity of Polymyxin B Associated withVancomycin or Imipenem against OXA-143, OXA-23, OXA-58,and OXA-72-Producing Acinetobacter baumanniiM. Medeiros, N. Lincopan; Univ. de São Paulo, São Paulo, Brazil.E-789 Seeking Active Agents against KPC-Producing Acinetobacterbaumannii (KPCAB)K. S. Thomson 1 , I. E. Robledo 2 , G. J. Vázquez 2 ; 1 Creighton Univ. Sch.of Med., Omaha, NE, 2 Univ. Puerto Rico, San Juan, PR.E-790 In Vitro Activity of Tobramycin and Polymyxin E againstPseudomonas aeruginosa PAO1 and 25668K. M. Tarquinio 1,2 , K. L. Confreda 1 , K. L. LaPlante 3,4 ; 1 Rhode IslandHosp. Pediatric Critical Care Med., Providence, RI, 2 Brown Univ., Providence,RI, 3 Providence VA ID Res. Program, Providence, RI, 4 Univ. of RhodeIsland Coll. of Pharmacy, Kingston, RI.E-791 Amikacin (A) & Meropenem (M) & Polymyxin B (P) isBactericidal against Pandrug-Resistant (PDR) Pseudomonasaeruginosa (PA) & Suppress the Emergence of Resistance up to120 hours in a Hollow Fiber Infection Model (HFIM)T. P. Lim 1,2 , S. Sasikala 1 , W. Lee 1 , T. Y. Tan 3 , L. Y. Hsu 2 , T. T. Tan 1 , A.L. Kwa 1 ; 1 Singapore Gen. Hosp., Singapore, Singapore, 2 Natl. Univ. Hosp.System, Singapore, Singapore, 3 Changi Gen. Hosp., Singapore, Singapore.E-792 Porin Expression Predicts Responses of Carbapenemase-Producing Klebsiella pneumoniae (KPC) to the Combination ofDoripenem (DOR)+Ertapenem (ERT)+Colistin (COL) In VitroJ. H. Hong 1 , S. Cheng 2 , R. Shields 1 , Y. Doi 1 , L. Chen 3 , Y. Zhao 3 , B. N.Kreiswirth 3 , C. Clancy 1 , M. H. Nguyen 1 ; 1 Univ. of Pittsburgh Med. Ctr.,Pittsburgh, PA, 2 Univ. of Pittsburgh, Pittsburgh, PA, 3 Publ. Hlth. Res Inst.,Univ. of Med. & Den. of NJ, Newark, NJ.E-793 Bactericidal Activity of Multiple Combinations of Fosfomycinand Colistin against NDM-1 Producing EnterobacteriaceaeM. S. Albur, A. R. Noel, K. E. Bowker, A. P. MacGowan; North BristolNHS Trust, Bristol, United Kingdom.E-794 In Vitro Activity of Colistin Alone and in Combination withDoripenem against KPC-Producing K. pneumoniae IsolatesG. C. Lee 1,2 , D. S. Burgess 1,2 ; 1 Univ. of Texas Col. of Pharmacy, Austin,Texas, 2 UT Hlth. Sci. Ctr., San Antonio, Texas.E-795 Optimizing Polymyxin (POL) Combinations (Combos) with‘Old’ Antibiotics against NDM-Producing Klebsiella pneumoniae(Kp)H. J. Lee 1 , K. Davis 1 , C. Ku 1 , H. H. Yu 1 , A. Poudyal 1 , J. Jacob 1 , B. Y. Liu 2 ,J. Fu 2 , D. L. Paterson 3 , R. L. Nation 1 , J. Li 1 ; 1 Monash Inst. of PharmaceuticalSci., Monash Univ., Melbourne, Australia, 2 Monash Univ., Melbourne,Australia, 3 Univ. of Queensland Ctr. for Clin. Res., Brisbane, Australia.E-796 Synergistic Activity of Colistin (COL) Plus Rifampin (RIF)against COL-Resistant (R) and Susceptible (S) KPC-ProducingKlebsiella pneumoniae (KPC-KP) Clinical IsolatesE. Tagliaferri 1 , C. Tascini 1 , S. Flammini 1 , T. Giani 2 , A. Leonildi 1 , I. Ciullo 1 ,G. Rossolini 2 , F. Menichetti 1 ; 1 Azienda Ospedaliera Univ. Pisana, Pisa, Italy,2Univ. di Siena, Siena, Italy.E-797 In Vitro Activity of Daptomycin in Combination with Low-Dose Colistin Versus a Diverse Collection of Gram-NegativeBacterial PathogensL. Phee, M. Hornsey, D. Wareham; QMUL, London, United Kingdom.E-798 Novel Antibiotic Combinations with Enhanced AntibacterialEffect against ESBL- Producing E.coli and Klebsiella pneumoniaeR. A. Hickman, D. Hughes, C. Malmberg, O. Cars; Uppsala Univ., Uppsala,Sweden.E-799 In Vitro Activities of Tigecycline and Tigecycline Combinationsagainst KPC-Producing K. pneumoniae: ComparisonBetween the Checkerboard and Etest MethodsV. Papoutsaki, D. Lekkakou, I. Galani, M. Souli, L. Galani, I. Karaiskos, N.Vakalis, H. Giamarellou; Hygeia Hosp., Athens, Greece.E-800 Synergistic Effect of Aztreonam Combinations against VIMandNDM-Producing Klebsiella pneumoniaeT. Tängdén 1 , R. A. Hickman 1 , P. Forsberg 1 , C. G. Giske 2 , P. Lagerbäck 1 ,O. Cars 1 ; 1 Uppsala Univ., Uppsala, Sweden, 2 Karolinska Inst., Stockholm,Sweden.E-801 Potential Antiseptic Properties of DioctadecyldimethylammoniumBromide Cationic Bilayer Fragments (DDA-BF) againstCarbapenemase-Producing BacteriaE. B. Gaspar 1 , A. S. Rosetti 2 , H. G. Turano 2 , M. Medeiros 2 , P. R. Neves 2 ,N. Lincopan 2 ; 1 Embrapa, Bagé, Brazil, 2 São Paulo Univ., São Paulo, Brazil.E-802 The Effect of Urine, Lung Surfactant and Testing ParameterVariations on the In Vitro Activity of GSK2251052 and MeropenemL. M. Koeth 1 , J. DiFranco-Fisher 1 , N. E. Scangarella-Oman 2 ; 1 Lab. Specialists,Inc., Westlake, OH, 2 GlaxoSmithKline, Collegeville, PA.E-803 Comparative In Vitro Activity of Doripenem, Meropenem andImipenem in a Prospective Multi-Centre StudyM. J. B. Melchers, Other 1 , A. Voss 2 , J. A. Kluytmans 3 , C. van Mil 2 , J. W.Mouton 1 , the Design study group; 1 Radboud Univ. Nijmegen Med. Ctr, Nijmegen,Netherlands, 2 Canisius Wilhelmina Hosp., Nijmegen, Netherlands,3Amphia Hosp., Breda, Netherlands.E-804 Discrepancies Between Colistin (COL) MICs and Inhibitionof Acinetobacter (Ab) and Klebsiella (Kp) During Time-Kill Assays(TKA)R. K. Shields, C. J. Clancy , E. G. Press, J. Hong, C. A. Updike, M. H.Nguyen; Univ. of Pittsburgh, Pittsburgh, PA.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------095(E)Poster SessionIn Vitro Activity Versus AnaerobesMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:E-805 Patterns of Resistance in Bacteroides fragilis Group: Analysis ofPeriod 2010-2012 in a Teaching Hospital of Madrid (Spain)F. J. Candel, E. Baos, P. Merino, F. De la Torre, E. Culebras, J. J. Picazo;Hosp. Clinico San Carlos, Madrid, Spain.E-806 In Vitro Activity of Twelve Antianaerobic Agents against ClinicalVeillonella sp. Strains Isolated Over a 4-Year Period (2008-11)L. Alcalá , T. Peláez, P. Martín-Rabadán, E. Reigadas , E. Bouza; Hosp. GUGregorio Marañón, Univ. Complutense de Madrid., Madrid, Spain.Final Program97

Monday SCIENTIFIC SESSIONSE-807 Susceptibilities of Clostridium difficile to CB-183,315 andComparatorsL. Chesnel 1 , A. E. Crist, Jr 2 , R. M. Patti, JD 2 , D. R. Snydman 3 , J. Kishel 1 ;1Cubist Pharmaceuticals, Lexington, MA, 2 York Hosp., York, PA, 3 TuftsMed. Ctr., Boston, MA.E-808 In Vitro Activity of Cadazolid against 209 Toxigenic Isolates ofClostridium difficileD. W. Hecht 1,2 , D. N. Gerding 1,2 , J. R. Osmolski 1 , S. Sambol 1 , A. Cheknis,BA 2 ; 1 Loyola Univ. Med. Ctr., Maywood, IL, 2 Hines Veterans Admin.Hosp., Hines, IL.------------------------------------------------------------------------096(F)Poster SessionNew Antifungal AgentsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:F-809 Antifungal Activities of a Novel Arylamidine T-2307 againstAzole-Resistant Aspergillus Species, A. calidoustusK. Yamashita, E. Yamada, M. Kaeriyama, H. Nishikawa, N. Fujino, N. Nomura,J. Mitsuyama; Res. Lab., Toyama Chemical Co.,Ltd., Toyama, Japan.F-810 Antifungal Spectrum, In Vivo Efficacy and Structure ActivityRelationship of Ilicicolin HS. Singh, W. Liu, X. Li, T. Chen, A. Shafiee, D. Card, G. Abruzzo, A.Flattery, C. Gill, J. Thompson, M. Rosenbach, S. Dreikorn, V. Hornak, M.Meinz, R. Kelly, J. Onishi; Merck & Co., Inc., Rahway, NJ.F-811 Comparative In Vitro Activities of Fluconazole, Voriconazole,and MXP-4509 against 256 Candida Isolates from RomanianTertiary HospitalsM. Mares 1 , V. Nastasa 1 , R. Moraru 1 , B. Minea 2 , L. Miron 1 ; 1 Ion Ionescude la Brad Univ., IASI, Romania, 2 Petru Poni Inst. of MacromolecularChemistry, IASI, Romania.F-812 Sulphur Containing Acetamide, from an Endophytic FungusEmericella sp. Isolated From Azadirachta indicaS. Mittal 1,2 , S. Kumar 1 , S. Gowil 1 , D. Shrivastava 1 ; 1 Jaipur Natl Univ, Jaipur,India, 2 Amol Pharmaceuticals Pvt. Ltd., Jaipur, India.F-813 Biochemical Evaluation of Rtt109 Inhibitor as a PotentialAnti-Fungal AgentJ. Pupaibool, T. J. Kottom, A. H. Limper; Mayo Clinic, Rochester, MN.F-814 Milbemycins: Not Just Fungal ABC-Transporter InhibitorsWithdrawnF-815 Antifungal Properties of 2-Adamantanamine, a Potentiator ofAzole AntifungalsM. LaFleur 1,2 , L. Long 3 , M. Ghannoum 3 , J. North 4 , R. Lee 4 , K. Lewis2; 1 Arietis Corp., Boston, MA, 2 Northeastern Univ., Boston, MA, 3 CaseWestern Reserve Univ., Cleveland, OH, 4 St. Jude Children’s Res. Hosp.,Memphis, TN.F-816 Potent Fungicidal Activity of Bis-Amidine AntibioticsT. J. Opperman, S. M. Kwasny, S. Nguyen, J. D. Williams, N. P. Peet, T. L.Bowlin; Microbiotix, Inc., Worcester, MA.F-817 ASP9726, A Unique 2nd Generation Echinocandin (1),Discovery of a Novel In Vitro Marker Correlated with In VivoAnti-Aspergillus EfficacyT. Nakai, S. Matsumoto, S. Uchida, S. Takeda, S. Akamatsu, K. Maki;Astellas Pharma Inc., Tsukuba, Japan.F-818 ASP9726, A Unique 2nd Generation Echinocandin (2) -Synthesis and In Vitro ActivityH. Morikawa, A. Okada, M. Tomishima, N. Kayakiri, D. Barrett, S.Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki; AstellasPharma Inc., Tsukuba, Ibaraki, Japan.F-819 ASP9726, A Unique 2nd Generation Echinocandin (3) -In Vitro and In Vivo Activity against Aspergillus spp.S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki, A.Okada, N. Kayakiri, D. Barret; Astellas Pharma Inc.,, Tsukuba, Ibaraki, Japan.F-820 ASP9726, A Unique 2nd Generation Echinocandin (4) -In Vitro and In Vivo Activity against Candida spp.S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki, H.Morikawa, M. Tomishima, D. Barrett; Astellas Pharma Inc.,, Tsukuba,Ibaraki, Japan.F-821 ASP9726, a Unique 2nd Generation Echinocandin (5) -InVitro and In Vivo Activity of Combination Therapy with Voriconazoleagainst Aspergillus fumigatusS. Akamatsu, S. Matsumoto, S. Uchida, BS , T. Nakai, S. Takeda, K. Maki;Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.F-822 Evaluation of ASP9726 on Glucan Synthase Inhibition fromEchinocandin Susceptible and Resistant FungiP. Paderu 1 , C. Jiménez-Ortigosa 1 , S. Akamatsu 2 , S. Matsumoto 2 , D. Perlin 1 ;1Publ. Hlth. Res. Inst, Newark, NJ, 2 Astellas Pharma Inc., Ibaraki, Japan.F-823 Efficacy and Pharmacokinetics of ASP9726 in a Guinea PigModel of Invasive Pulmonary Aspergillosis (IPA)W. R. Kirkpatrick 1,2 , N. P. Wiederhold 3,1 , L. K. Najvar 1,2 , S. Matsumoto 4 ,R. A. Bocanegra 1,2 , T. F. Patterson 1,2 ; 1 UTHSCSA, San Antonio, TX,2STVHCS, San Antonio, TX, 3 Univ. of Texas, Austin, TX, 4 Astellas,Tsubuka, Japan.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------097(F)Poster SessionNew Antiviral AgentsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:F-824 Discovery of a Novel Antiviral against HSV-1 & HSV-2N. Kapoor 1 , R. Bhowmick 1 , H. Sivaramakrishnn 1 , S. Sharma 1 , B. M.Thomas 2 ; 1 Piramal Life Sci. Limited, Mumbai, India, 2 Piramal HealthcareLimited, Mumbai, India.F-825 New, Safe, Effective and Convenient Virucidal Agents UsingAmino AcidK. Tsujimoto 1 , K. Ikeda 2 , Y. Suzuki 2 , H. Yamasaki. 3 , M. Nishide 1 , M. Yoshida1 , T. Arakawa 4 , A. H. Koyama 1,3 ; 1 Shin-ai Women’s Jr. Coll., Wakayama,Japan, 2 Wakayama Med. Univ. Sch. Hlth. & Nursing Sci., Wakayama,Japan, 3 Wakayama Med. Univ. Grad. Sch. Med., Wakayama, Japan, 4 AllianceProtein Lab., Thousand Oaks, CA.98September 9-12 |

MONDAY SCIENTIFIC SESSIONSF-826 Identification and Analysis of Hepatitis C virus NS3 HelicaseInhibitors Using a Nucleic Acid Binding AssayS. Mukherjee, A. M. Hanson, J. Ndjomou, D. Bartczak, L. A. Arnold, andD. N. Frick; Univ. of Wisconsin, Milwaukee, WI.F-827 Identification of Novel Small Molecule Inhibitors against theNS3/4A Serine Protease of Hepatitis C Virus by High-ThroughputScreeningH. Lee, T. Zhu, Y. Zhang, K. Patel, L. Truong, A. Sarkar, H. Jeong, M. E.Johnson; Univ. of Illinois, Chicago, IL.F-828 Discovery of a New Series of Pan-Genotypic NS5b Inhibitorsfor Hepatitis C: The Indazole Amide Class of Site IV PolymeraseAntiviralsA. G. Draffan 1 , S. Bond 1 , J. Cianci 1 , B. Frey 1 , M. Frazetto 1 , R. Halim 1 , S.Hamilton 1 , M. Harding 1 , R. Hufton 1 , S. Jahangiri 1 , T. Jeynes 1 , M. Lilly 1 , B.Lin 1 , A. Luttick 1 , C. Morton 1,2 , T. Nero 2 , B. Pool 1 , M. Parker 2 , K. Porter 1 ,M. Pryor 1 , J. Thomas 1 , S. Tucker 1 , J. Wielens 2 , V. Wirth 1 ; 1 Biota ScientificManagement, Melbourne, Australia, 2 St. Vincent’s Inst. of Med. Res.,Melbourne, Australia.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------098(F)Poster SessionNew Approaches in Mycobacterial TherapyMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:F-829 Novo23: A Novel Antibiotic With Specific Activity againstMycobacterium TuberculosisE. Gavrish 1 , A. Peoples 2 , A. Spoering 2 , A. Bissell 1 , W. Millett 2 , L. Ling 2 ,D. Hughes 2 , K. Lewis 1 ; 1 Northeastern Univ., Boston, MA, 2 NovoBioticPharmaceuticals, LLC, Cambridge, MA.F-830 Enhanced Activity of 13C-Isoniazid Using Magnetic IsotopeEffectS. Choi 1 , R. Gupta 2 , L. Silks 3 , W. Bishai 2 , G. Timmins 1 ; 1 Univ. of NewMexico, Albuquerque, NM, 2 Johns Hopkins Hosp., Baltimore, 3 Los AlamosNatl. Lab., Los Alamos, NM.F-831 The Search for New Antimicrobial Agents against Mycobacteriumabscessus,M. A. De Groote 1 , S. Cho 2 , L. L. Klein 2 , S. G. Franzblau 2; 1 Colorado StateUniv., Fort Collins, CO, 2 Univ. of Illiniois at Chicago, Chicago, IL.F-832 Anti-Bacterial Activity and Postantibiotic Effect of NovelSpectinamide Analogs against Mycobacterium TuberculosisM. M. Butler 1 , D. F. Bruhn 2 , H. I. M. Boshoff 3 , J. Liu 2 , T. L. Bowlin 1 , R.E. Lee 2 ; 1 Microbiotix, Inc., Worcester, MA, 2 St. Jude Children’s Res. Hosp.,Memphis, TN, 3 NIAID, Bethesda, MD.F-833 Antimicrobial Activity of Five Essential Oils and TheirCompounds against Mycobacterium TuberculosisS. Andrade Ochoa, K. F. Chacon Vargas, L. R. Hernández Ochoa, L. M.Rodriguez Valdez, G. V. Nevarez Moorillón, B. R. Rivera Chavira; Univ.Autonoma de Chihuahua, Chihuahua, Mexico.F-834 Anti-Tuberculosis In Vitro Activity of the NitroimidazoleTBA-354S. Franzblau 1 , S. Cho 1 , Y. Wang 1 , Y. Lu 2 , B. Wang 2 , J. Xu 2 , K. Mdluli 3 ,A. M. Upton 3 , Z. Ma 3 ; 1 Inst. for Tuberculosis Res., Univ. of Illinois,Chicago, IL, 2 Beijing Tuberculosis and Thoracic Tumor Res. Inst., Beijing,China, 3 Global Alliance for TB Drug Dev., New York, NY.F-835 In Vivo Anti-Tuberculosis Activity of the NitroimidazoleTBA-354 against Acute and Chronic Murine TuberculosisS. G. Franzblau 1 , Y. Wang 1 , A. M. Upton 2 , K. Mdluli 2 , Z. Ma 2 ; 1 Inst. forTuberculosis Res., Univ. of Illinois, Chicago, IL, 2 Global Alliance for TBDrug Dev., New York, NY.F-836 Activity of the Nitroimidazole TBA-354 Alone and in a NovelDrug Regimen in Two Murine Models of TuberculosisE. Nuermberger 1 , K. Williams 1 , O. Amoabeng 1 , R. Tasneen 1 , A.Minkowski 1 , K. Mdluli 2 , A. M. Upton 2 , Z. Ma 2 ; 1 Johns Hopkins Univ.,Baltimore, 2 Global Alliance for TB Drug Dev., New York, NY.F-837 In Vitro and In Vivo Evaluation of the Phototoxic Potential ofthe Nitroimidazole TBA-354D. Severynse-Stevens 1 , A. M. Upton 2 , A. M. Shadiack 2 , Z. Ma 2 ; 1 RTIIntl., Research Triangle Park, NC, 2 Global Alliance for TB Drug Dev., NewYork, NY.F-838 TBA-354: Process Chemistry Optimization for Large ScaleAPI Production to Support IND-Enabling DevelopmentC. B. Cooper 1 , T. Kaneko 1 , Q. Li 2 , L. Zhang 2 , S. Liu 2 , Z. Ma 1 ; 1 GlobalAlliance for TB Drug Dev., New York, NY, 2 Shanghai ChemPartner,Shanghai, China.F-839 In Vitro Profiling of the Absorption, Distribution, Metabolismand Excretion (ADME) Properties of the Nitroimidazole TBA-354T. Yang 1 , E. Pauli 2 , A. M. Upton 1 , W. Wargin 3 , A. M. Shadiack 1 , Z. Ma 1 ;1Global Alliance for TB Drug Dev., New York, NY, 2 RTI Intl., ResearchTriangle Park, NC, 3 PK-PM Associates, Chapel Hill, NC.F-840 Preclinical Pharmacokinetic Studies of the NitroimidazoleTBA-354 in Mice, Rats and DogsT. Yang 1 , E. Pauli 2 , A. M. Upton 1 , W. Wargin 3 , A. M. Shadiack 1 , Z. Ma 1 ;1Global Alliance for TB Drug Dev., New York, NY, 2 RTI Intl., ResearchTriangle Par, NC, 3 PK-PM Associates, Chapel Hill, NC.------------------------------------------------------------------------099(F)Poster SessionTargeting the Bacterial Cell Wall: New Beta-Lactamsand Beta-Lactamase Inhibitor CombinationsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:F-841 In Vitro Activity of BAL30072 against Contemporary ClinicalIsolates of Gram-Negative Bacteria (GNB) from New York Cityincluding Multidrug-Resistant (MDR) IsolatesD. Landman , M. Singh, B. El-Imad, E. Miller, T. Win, J. Quale; SUNYDownstate Med. Ctr., Brooklyn, NY.Final Program99

Monday SCIENTIFIC SESSIONSF-842 Comparative Efficacy of BAL30072, Aztreonam, Meropenemand Ceftazidime and Effects of Dose Fractionation in a MurineThigh Infection ModelJ. K. Gould 1 , A. Sattar 1 , G. M. Daws 1 , L. J. Payne 1 , J. Spikermann 2 , W.Stubbings 2 , A. Schmitt-Hoffmann 2 , M. G. P. Page 2 , P. A. Warn 1 ; 1 EuprotecLtd. Manchester, United Kingdom, 2 Basilea Pharmaceutica Intl. Ltd. Basel,Switzerland.F-843 Broad Spectrum Cephalosporins with Urea-SubstitutedPyridinium Group at the C-3’ Position Exhibiting Potent Activityagainst Methicillin-Resistant Staphylococcus aureus and PseudomonasaeruginosaY. He, N. Yin, J. Romero, C. Abel, R. Busch, B. Wang, A. Pearson, P. Herradura,D. Keith, J. Rock, L. Chesnel, K. Cassidy C. Monahan, S. Zhang, J. Silverman,D. Alexander, C. Metcalf Y. Gu; Cubist Pharmaceuticals, Lexington, MA.F-844 Synthesis and Structure-Activity Relationships of Aminoalkyl-N’-(Pyridin-4-yl) Benzohydrazide-Derived Cephalosporins withBroad Spectrum Activity against Methicillin-Resistant Staphylococcusaureus and Pseudomonas aeruginosaJ. Romero, Y. He, N. Yin, C. Abel, R. Busch, B. Wang, A. Pearson, P. Herradura,F. Epie, D. Keith, J. Rock, L. Chesnel, K. Cassidy, C. Monahan, S.Zhang, J. Silverman, D. Alexander, C. Metcalf-, Y. Gu; Cubist Pharmaceuticals,Lexington, MA.F-845 Structure-Activity Relationship Studies of Novel Cephalosporinswith Substituted Pyrazolium Groups at the C-3’ Positionagainst Methicillin-Resistant Staphylococcus aureus and PseudomonasaeruginosaN. Yin 1 , Y. He 1 , J. Romero 1 , C. Abel 1 , R. Busch 1 , B. Wang 1 , A. Pearson 2 ,P. Herradura 3 , F. Epie 1 , D. Keith 1 , J. Rock 1 , L. Chesnel 1 , K. Cassidy 1 , C.Monahan 1 , Y. Li 1 , C. Chuong 1 , S. Zhang 1 , J. Silverman 1 , D. Alexander 1 ,C. Metcalf 1 , Y. Gu 1 ; 1 Cubist Pharmaceuticals, Lexington, MA, 2 BiotechGenerics LLC, Brooklyn, NY, 3 Genentech, San Francisco, CA.F-846 In Vivo Efficacy of CB-027 against Methicillin-ResistantStaphylococcus aureus, and Ceftazidime-Resistant Pseudomonasaeruginosa and Klebsiella pneumoniae Infections in MiceS. Zhang, L. I. Mortin, Y. Li, C. Chuong, H. Corkrey, C. Khang, A. Alsup,T. Li, A. Arya, Y. He, N. Yin, J. Rock, C. Abel, Y. Gu, D. Alexander, C.Metcalf, J. Silverman, C. Murphy; Cubist Pharmaceuticals, Lexington, MA.F-847 Versatile 6-(hydroxymethyl) Penicillanic Acid Sulfone(6-HM-sulfone) Derivatives as-Lactamase InhibitorsJ. D. Buynak 1 , M. Nottingham 1 , C. Bethel 2 , K. Papp-Wallace 2 , D.McLeod 1 , S. R. R. Pagadala 1 , M. Winkler 3 , R. A. Bonomo 2 ; 1 SMU, Dallas,TX, 2 VAMC, Cleveland, OH, 3 CWRU, Cleveland, OH.F-848 Discovery of RPX7009, a Broad-Spectrum Beta-LactamaseInhibitor with Utility vs. Class A Serine CarbapenemasesS. J. Hecker 1 , K. R. Reddy 1 , M. Totrov 2 , G. C. Hirst 1 , O. Lomovskaya 1 , D.C. Griffith 1 , P. King 1 , R. Tsivkovski 1 , D. Sun 1 , M. Sabet 1 , Z. Tarazi 1 , M. N.Dudley 1 ; 1 Rempex Pharmaceuticals, Inc., San Diego, CA, 2 Molsoft L.L.C.,San Diego, CA.F-849 Biochemical Characterization of the Beta-Lactamase InhibitorRPX7009O. Lomovskaya, R. Tsivkovsky, D. Sun, D. Griffith, S. J. Hecker M. N.Dudley; Rempex Pharmaceuticals, Inc, San Diego, CA.F-850 Microbiological Characterization of Beta-Lactamase InhibitorRPX7009O. Lomovskaya, P. King, D. Sun, D. C. Griffith, S. J. Hecker, M. N. Dudley;Rempex Pharmaceuticals, Inc, San Diego, CA.F-851 Pharmacokinetics of the New Beta-Lactamase InhibitorRPX7009 in Preclinical SpeciesD. C. Griffith, M. Sabet, Z. Tarazi, O. Lomovskaya S. J. Hecker, M. N.Dudley; Rempex Pharmaceuticals, San Diego, CA.F-852 Nonclinical Toxicology and Safety Profile of the Beta-LactamaseInhibitor RPX7009D. C. Griffith, M. Sabet, Z. Tarazi, BS , R. Tsivkovski, O. Lomovskaya, S. J.Hecker M. N. Dudley; Rempex Pharmaceuticals, San Diego, CA.F-853 Activity of RPX2003 - RPX7009 Combinations againstCarbapenem-Resistant EnterobacteriaceaeD. M. Livermore, S. Mushtaq, H. Dhanji; Hlth. Protection Agency, London,United Kingdom.F-854 In Vitro Activity of RPX2003/RPX7009, a Carbapenem Combinedwith a Serine-Lactamase Inhibitor against Anaerobic BacteriaE. J. C. Goldstein, D. M. Citron; R.M. Alden Res. Lab., Culver City, CA.F-855 Activity of Rpx2003/rpx7009 (RPX3/9), a Carbapenem Combinedwith a Novel-Lactamase Inhibitor (BLI) Tested againstClinical Isolates Producing Defined EnzymesM. Castanheira 1 , O. Lomovskaya 2 , P. R. Rhomberg 1 , R. N. Jones 1 ; 1 JMILab., N Liberty, IA, 2 Rempex Pharmaceuticals, San Diego, CA.F-856 Pre-Clinical Evaluation of a Carbapenem/-Lactamase InhibitorCombination (RPX2003/RPX7009) Tested against Serine-Carbapenemase-Producing PathogensM. Castanheira, H. K. Becker, P. R. Rhomberg, R. N. Jones; JMI Lab., NLiberty, IA.F-857 In Vivo Evaluation of a Novel Carbapenemase Inhibitor (CPI),Rpx7009, in Combination with the Carbapenem Rpx2003 against2 Kpc Producing K. pneumonia (KP) in a Neutropenic MurineThigh ModelA. Lepak, K. Marchillo, W. Craig, D. R. Andes; Univ. of Wisconsin, Madison,WI.F-858 In Vivo Efficacy of the Beta-Lactamase Inhibitor RPX7009Combined with the Carbapenem RPX2003 against KPC-Producing K. pneumoniaeM. Sabet, Z. Tarazi , O. Lomovskaya, S. J. Hecke, M. N. DudleyO, D. C.Griffith; Rempex Pharmaceuticals, San Diego, CA.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------100(G)Poster SessionImpact of Expanded Valent: Pneumococcal VaccinesMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:G-859 Lessons from Pneumococcal Conjugate Vaccines (PCV)Efficacy Trials against Community-Acquired Pneumonia (CAP)and Acute Otitis Media (AOM)F. L. P. Fierens, B. Hoet, W. P. Hausdorff; GlaxoSmithKline Biologicals,Wavre, Belgium.G-860 Cost-Effectiveness of 13-Valent Pneumococcal Vaccine in theAdult Swiss PopulationP. R. BlankBiology 1 , T. D. Szucs 2 ; 1 Univ. of Zurich, Zurich, Switzerland,2Univ. of Basel, Basel, Switzerland.100September 9-12 |

MONDAY SCIENTIFIC SESSIONSG-861 Impact of the Ten-Pneumococcal Conjugate Vaccine (PCV10)on Invasive Pneumococcal Infections of the Population Attendingat University Hospital in BrazilS. R. Santos 1 , L. F. Passadore 1 , E. H. Takagi 2 , C. M. Fujii 1 , A. E. Gilio 1 ,M. B. Martinez 2,1 ; 1 HU-USP, Sao Paulo, SP, Brazil, 2 FCF-USP, Sao Paulo,SP, Brazil.G-862 Impact of Pneumococcal Conjugate Vaccination on HospitalizationRates for S. pneumoniae Invasive Disease in US Children:1998-2009R. M. Mera 1 , L. A. Miller 2 , J. A. Suaya 2 , H. A. Madsen 2 , D. F. Sahm 3 ;1MSI, Washington, DC, 2 GlaxoSmithKline, Upper Providence, PA,3Eurofins Medinet, Chantilly, VA.G-863 Effects of three Years of Immunization with Higher ValentPneumococcal Conjugate Vaccines on Serotype Distributionsamong Reported IPD Cases in German Children and AdultsM. van der Linden 1 , R. von Kries 2 , M. Imöhl 1 ; 1 Inst. of Med. Microbiol.,Aachen, Germany, 2 Inst. of Social Pediatrics and Adolescent Med., Munich,Germany.G-864 Effect of 7-Valent and 13-Valent Pneumococcal ConjugateVaccines on Pneumococcal Meningitis in French Children Under2 yearsC. Levy 1 , E. Varon 2 , E. Bingen 3 , S. Béchet 4 , Groupe des pédiatres et microbiologistesde l’Observatoire National des Méningites, R. Cohen 1 ; 1 Activ/GPIP, Saint Maur des Fossés, France, 2 CNRP APHP and GPIP, Paris,France, 3 Denis Diderot Univ. and GPIP, Paris, France, 4 Activ, Saint Maur desFossés, France.G-865 Use of the 13-Valent Conjugate Vaccine has the Potentialto Eliminate Pilus Carrying Isolates as Causes of InvasivePneumococcal DiseaseS. I. Aguiar, J. Melo-Cristino, M. Ramirez; Faculdade de Medicina deLisboa, Lisboa, Portugal.G-866 Impact of Two Years of Non-Universal Pediatric Use of the13-Valent Conjugate Vaccine (PCV13) in PortugalS. Aguiar 1 , A. Horacio 1 , J. Diamantino-Miranda 1 , M. J. Brito 2 ,M. Ramirez 1 , J. Melo-Cristino 1 , Microbiology and Pediatric PneumococcalWorking Group; 1 Faculdade de Med. de Lisboa, Lisboa, Portugal, 2 CentroHosp. Lisboa Central, Lisboa, Portugal.G-867 Comparison of Serologic Responses to Primary Vaccinationwith 23-valent Pneumococcal Polysaccharide Vaccine vs 7-ValentPneumococcal Conjugate Vaccine in HIV-Infected Patients in theEra of Combination Antiretroviral TherapyJ. Yang, C. Lu, W. Liu, Y. Su, S. Chang, DSc , C. Hung ; Natl. Taiwan Univ.Hosp., Taipei, Taiwan.------------------------------------------------------------------------101(G)Poster SessionUpdates in VaccinesMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:G-868 Efficacy and Immunologic Mechanisms of NDV-3 Vaccine ina Murine Model of Methicillin-Resistant Staphylococcus aureus(MRSA) Skin / Skin Structure Infection (SSSI)M. Yeaman 1 , S. Filler 2 , S. Chaili 3 , K. Barr 2 , H. Wang 2 , D. Kupferwasser2, Y. Fu 2 , J. P. Hennessey, Jr. 4 , C. Schmidt 4 , J. Edwards, Jr. 2 , Y. Xiong 2 , A.Ibrahim 2 ; 1 UCLA Shool of Med. & LABioMed at Harbor-UCLA Med.Ctr., Torrance, CA, 2 LABioMed at Harbor-UCLA Med. Ctr., Torrance, CA,3Los Angeles Biomedical Res. Inst., Torrance, CA, 4 NovaDigm Therapeutics,Inc., Grand Forks, ND.G-869 Comparison of-Propiolactone and W 805EC Nanoemulsionfor Inactivation of RSV Nasal Vaccination in a Mouse ChallengeModelT. Hamouda 1 , V. Bitko 1 , A. Myc 2 , J. Simon 1 , P. E. Makidon 2 , D. M.Smith 2 , N. Lukacs 2 , A. Fattom 1,2 , J. R. Baker, Jr. 1,2 ; 1 NanoBio Corp, AnnArbor, MI, 2 Univ. of Mich., Ann Arbor, MI.G-870 Expression and Immune Response to Staphylococcus aureusVirulence Factors in Human DiseaseW. Rozemeijer 1 , P. Fink 2 , E. Rojas 2 , C. H. Jones 2 , D. Pavliakova 2 , P.Giardina 2 , E. Murphy 2 , P. Liberator 2 , Q. Jiang 2 , D. Q. Girgenti 2 , R. P. H.Peters 1 , P. Savelkoul 1 , K. U. Jansen 2 , A. S. Anderson 2 , J. Kluytmans 1 ; 1 VUUniv. Med. Ctr., Amsterdam, Netherlands, 2 Pfizer Vaccine Res., Pearl River,NY.G-871 Fully Human Monoclonal Antibody to IL-10R AugmentsHCV Antigen-Specific T Cell Responses In VitroP. Rogers, L. Liou, E. Rodriguez, R. Soloff, K. Tomizuka, K. Ohgami;Kyowa Hakko Kirin California, Inc., La Jolla, CA.G-872 Effectiveness of Influenza Vaccine on the Prevention ofHospitalization with Acute Lower Respiratory Infection andExacerbation of Chronic Cardiopulmonary Disease in KoreaDuring Year of 2010-2011Y. Seo 1 , K. Hong 1 , I. Kim 1 , J. Baek 2 , W. Choi 1 , J. Lee 3 , J. Song 1 , J. Lee 2 ,H. Cheong 1 , W. Kim 1 ; 1 Korea Univ. Coll. of Med., Seoul, Korea, Republicof, 2 Inha Univ. Coll. of Med., Incheon, Korea, Republic of, 3 Hallym Univ.Coll. of Med., Seoul, Korea, Republic of.G-873 Safety, Tolerability and Lack of Immunogenicity in a Phase 1Clinical Trial of TCN-032 (Anti-Influenza A mAb)E. Ramos 1 , J. Mitcham 1 , P. Chan-Hui 1 , M. Roberson 2 , M. Al-Ibrahim 2 ;1Theraclone Sci., Seattle, WA, 2 SNBL CPC, Baltimore.G-874 Cost-Effectiveness Analysis of Two Rotavirus Vaccines inArgentinaA. Urueña 1 , F. Virgilio, Economist 1 , M. Betelu, Economist 1 , T. Pippo,Economist 1 , N. Giglio 2 , A. Gentile 3 , M. Diosque 1 , S. García Giménez 4 ,C. Vizzotti 1 ; 1 Ministerio de Salud de la Nación, Buenos Aires, Argentina,2Hosp. de Niños Ricardo Gutierrez, Buenos Aires, Argentina, 3 Sociedad Argentinade Pediatría, Buenos Aires, Argentina, 4 Organización Panamericanade la Salud, Buenos Aires, Argentina.Final Program101

Monday SCIENTIFIC SESSIONSG-875 Protection against Experimental Aspergillosis by Heat-KilledYeast (HKY ) is not Antibody DependentV. Chen 1 , M. Martinez 1 , M. Liu 1,2,3 , H. Yun 1,3 , K. V. Clemons 1,2,3 , D. A.Stevens 1,2,3 ; 1 California Inst. for Med. Res., San Jose, CA, 2 Santa Clara Vly.Med. Ctr., San Jose, CA, 3 Stanford Univ., Stanford, CA.G-876 Genome-Wide Association Study Identifies Variants NearIFNW1 and IFNB1 Associated with Host Susceptibility to PneumococcalDiseaseT. Benfield 1 , M. Nørgaard 2 , M. Hollegaard 3 , L. N. Clausen 1 , H. T.Sørensen 2 , H. M. David 3 , H. B. Konradsen 3 , Z. B. Harboe 1 ; 1 CopenhagenUniv. Hosp., Hvidovre, Denmark, 2 Århus Univ., Århus, Denmark, 3 StatenSerum Inst., Copenhagen, Denmark.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------102(H)Poster SessionAntiretroviral Therapy Outcomes Including SelectPopulationsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:H-877 Long-Term (96 And 144 Week) Efficacy and Safety from theVerxve Trial Comparing Nevirapine Extended Release (NVP XR)400 Mg Once a Day (qd) to Nevirapine Immediate Release (NVPIR) 200 Mg Twice a Day (bid) in Combination with Emtricitabine/Tenofovirin Treatment-Naïve HIV-1 PatientsC. Brinson 1 , A. Quinson 2 , M. Drulak 2 , J. Gathe, Jr. 3 ; 1 Central Texas ClinicalRes.,, Austin, TX, 2 Boehringer Ingelheim, Ridgefield, CT, 3 TherapeuticConcepts, Houston, TX.H-878 Efficacy and Tolerability of Tenofovir/Emtricitabine VersusAbacavir/lamivudine Based Antiretroviral Treatment for NaïVeHIV-1 Infected Patients: A Mixed Treatment ComparisonJ. Félix 1 , B. Vandewalle 1 , S. Rabiais 1 , M. J. Silva 1 , D. Ferreira 1 , J. Almeida 1 ,E. Teófilo 2 ; 1 Exigo, Alhos Vedros, Portugal, 2 Centro Hosp. Lisboa Central,Hosp. dos Capuchos, Lisboa, Portugal.H-879 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad)Demonstrates Comparable Efficacy and Favorable Tolerability toEfavirenz/Emtricitabine/ Tenofovir DF in Patients 50 YearsG. J. Richmond 1 , P. Ruane 2 , W. Robbins, F 3 , U. Bredeek 4 , P. Shalit 5 , D.Hardy 6 , K. Workowski 7 , M. Rhee 8 , D. Piontkowsky, JD 8 ; 1 Gary RichmondMD PA, Fort Lauderdale, FL, 2 Peter Ruane MD Inc., Los Angeles, CA,3Value Hlth. MD, Orlando, FL, 4 Metropolis Med., San Francisco, CA,5Tribal Med, Seattle, WA, 6 Cedars-Sinai Med. Ctr., Los Angeles, CA,7Emory Clinic, Atlanta, GA, 8 Gilead Sci., Foster City, CA.H-880 Older Patients Showed Similar Efficacy and Safety ResultsCompared to Younger Participants Over 96 Weeks in the PhaseIII ECHO and THRIVE Trials of Treatment-Naive HIV-1-Infected Patients Treated with Rilpivirine or EfavirenzR. Ryan 1 , Y. Dayaram 2 , D. Schaible 2 , B. Coate 1 , D. Anderson 2 ; 1 JanssenRes. & Dev., Titusville, NJ, 2 Janssen Services, LLC, Titusville, NJ.H-881 Meta Analysis of Differences in Viral Suppression by Race inClinical TrialsC. Evans 1 , H. Kwakwa 2 , D. Spencer 3 , L. Temme 4 , I. Walker 4 , M. Rawlings 4 ;1AIDS ARMS, Dallas, TX, 2 Philadelphia Dept. of Publ. Health, Philadelphia,PA, 3 Univ. of Maryland Sch. of Med., Baltimore, MD, 4 Gilead Sci.,Inc., Foster City, CA.H-882 Gender Stratification Analysis of HIV-1 Infected PatientsReceiving Atazanavir (ATV) Compared to ATV/Ritonavir (RTV),Each in Combination with Abacavir/Lamivudine (ABC/3TC),after Initial Suppression with ABC/3TC + ATV/RTV Through144 Weeks on TherapyK. Squires 1 , B. Young 2 , L. Santiago 3 , R. Dretler 4 , S. Walmsley 5 , H. Zhao 6 ,B. Wine 6 , L. L. Ross 6 , M. Shaefer 7 ; 1 T. Jefferson Univ, Philadelphia, PA,2Univ. of Colorado, Denver, Colorado, 3 HOPE Clin Res, San Juan, PuertoRico, 4 ID Specialists of Atlanta, Decatur, GA, 5 Univ Hlth. Network, Toronto,Canada, 6 GlaxoSmithKline, Research Triangle Park, NC, 7 ViiV Healthcare,Research Triangle Park, NC.H-883 Efficacy and Use of PI vs EFV in Treatment Naive HIV+ Menand WomenJ. Patel 1 , B. Livak 2 , J. Cole 1 , S. Vibhakar 2 , B. Max 2 , K. Y. Smith 1 ; 1 RushUniv. Med. Ctr., Chicago, IL, 2 Ruth M. Rothstein Core Ctr., Chicago, IL.H-884 Safety and Efficacy of Once Daily Raltegravir to EnhanceAdherence and Efficacy of HAART in Vulnerable HIV-InfectedPatientsK. Stewart 1 , B. Conway 2 , H. Tossonian 2 ; 1 Univ. of Saskatchewan, Saskatoon,Canada, 2 Univ. of British Columbia, Vancouver, Canada.H-885 Safety & Efficacy of Raltegravir (RAL) Over 3 Years inPatients Co-Infected with HIV and Hepatitis B and/or C Virus(HBV/HCV)J. Rockstroh 1 , P. Sklar 2 , J. Zhao 2 , H. Teppler 2 , C. Harvey 2 , K. Strohmaier 2 ,R. Leavitt 2 , B. Nguyen 2 ; 1 Univ. of Bonn, Bonn, Germany, 2 Merck, WhitehouseStation, NJ.H-886 Virological Response to ARV in HIV-1 Group O InfectedPatientsC. Charpentier 1,2 , G. Unal 1 , P. Cappy 1 , M. Leoz 1 , E. Alessandri 1 , A.Depatureaux 1 , I. Gueit 1 , F. Damond 2 , J. Pavie 3 , F. Barin 4,5 , F. Simon 6 , J. C.Plantier 1 ; 1 CHU Charles Nicolle, Rouen, France, 2 Hôpital Bichat-ClaudeBernard, Paris, France, 3 Hosp. George Pompidou, Paris, France, 4 Hosp.Bretonneau, Tours, France, 5 Uni. François Rabelais, Tours, France, 6 HôpitalSaint-Louis, Paris, France.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------103(H)Poster SessionSafety and Toxicity of Antiretroviral TherapyMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:H-887 Prevalence and Risk Factors of Low Grade Proteinuria inHIV-Infected PatientsA. J. Zeder, R. Hilge, J. R. Bogner, U. Seybold; Ludwig-Maximilians-Univ.,Munich, Germany.102September 9-12 |

MONDAY SCIENTIFIC SESSIONSH-888 High Incidence of Renal Stones in HIV-Infected Patients onRitonavir-Boosted Atazanavir Than in Those on Other ProteaseInhibitors-Containing Antiretroviral TherapyY. Hamada 1 , T. Nishijima 1 , K. Watanabe 1 , H. Komatsu 2 , K. Tsukada 1 , H.Gatanaga 1 , Y. Kikuchi 1 , S. Oka 1 ; 1 AIDS clinical Ctr., Natl. Ctr. for GlobalHlth. and Med., Tokyo, Japan, 2 Saku Central Hosp., Nagano, Japan.H-889 High ATZ and DRV Urine Concentrations and Cristalluriain Asymptomatic Patients Receiving ATV and DRV-BasedRegimensV. de Lastours 1 , E. Silva 1 , M. Daudon 2 , R. Porcher 1 , H. Sauvageon 1 , J.Molina 1 ; 1 Saint-Louis Hosp., Paris, France, 2 Tenon Hosp., Paris, France.H-890 Single Nucleotide Polymorphisms in ABCC2 Predict Tenofovir-InducedKidney Tubular Dysfunction in Japanese Patientswith HIV Infection: A Pharmacogenetic StudyT. Nishijima 1 , H. Komatsu 2 , K. Higasa 3 , M. Takano, RN 1 , T. Hayashida1, K. Tsuchiya 1 , R. Yamada 3 , S. Oka 1 , H. Gatanaga 1 ; 1 Natl. Ctr. for GlobalHlth. and Med., Tokyo, Japan, 2 Saku Central Hosp., Saku, Japan, 3 KyotoUniv., Kyoto, Japan.H-891 Renal Safety Profile of Cobicistat-Boosted Elvitegravir orAtazanavir plus Emtricitabine/Tenofovir DF in HIV PatientsP. Benson 1 , C. Mayer, MO 2 , J. Morales Ramirez 3 , M. Rhee 4 ; 1 Be WellMed. Ctr., Berkley, MI, 2 St. Joseph’s Comprehensive Res. Inst., Tampa, FL,3Clin. Res. Puerto Rico, San Juan, Puerto Rico, 4 Gilead Sci., Foster City, CA.H-892 Cobicistat Does Not Affect the In Vitro Renal Transport orCytotoxicity of TenofovirK. Stray, R. Bam, G. Birkus, J. Hao , I. Lepist , S. Yant , A. Ray, T. Cihlar;Gilead Sci., Foster City, CA.H-893 Pharmacogenetic Aspects of HIV/AIDS and TuberculosisTreatments: Emphasis on Ugandan PopulationJ. Mukonzo 1,1 , J. Ogwal-Okeng 1 , P. Waako 2 , L. L. Gustafsson 3 , E. Aklillu 3 ;1Makerere Univ., Coll. of Hlth. Sci., Kampala, Uganda, 2 Makerere Univ.,College of Hlth. Sci., Uganda, 3 Karolinska Inst., Stockholm, Sweden.H-894 Impact of Seven Nucleotide Polymorphisms and Haplotypesof CYP2B6 on Plasma Efavirenz Level in HIV/TuberculosisCo-Infected Thai Patients Receiving RifampicinW. Manosuthi 1 , C. Sukasem 2 , A. Lueangniyomkul 1 , W. Mankatitham 1 ,S. Thongyen 1 , S. Nilkamhang 1 , S. Manosuthi 1 , S. Sungkanuparph 2 ;1Bamrasnaradura Infectious Dis. Inst., Ministry of Publ. Health, Nonthaburi,Thailand, 2 Faculty of Med. Ramathibodi Hosp., Mahidol Univ., Bangkok,Thailand.H-895 Prevalence of HLA-B*5701 Allele in HIV-Infected Subjectsin North America and Reductions in Risk for Development ofAbacavir Associated Hypersensitivity Reaction (ABC HSR)C. B. Small 1 , D. Wohl 2 , D. A. Margolis 3 , L. L. Ross 3 , B. Wine 3 , H. Zhao 3 ,M. S. Shaefer 4 ; 1 New York Med. Coll., Valhalla, NY, 2 AIDS Clin TrialsUnit, UNC CH, Chapel Hill, NC, 3 GlaxoSmithKline, Research TrianglePark, NC, 4 ViiV Healthcare, Research Triangle Park, NC.------------------------------------------------------------------------104(K)Poster SessionBlood Stream InfectionsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-896 Outcome of Appropriate Empiric Combination versusMonotherapy for Pseudomonas aeruginosa BacteremiaD. R. Bowers 1,2 , Y. X. Liew 3 , D. C. Lye 4,5 , A. L. Kwa 3 , L. Y. Hsu 5 , V.H. Tam 1,2,5 ; 1 St Luke’s Episcopal Hosp., Houston, TX, 2 Univ. of Houston,Houston, TX, 3 Singapore Gen Hosp., Singapore, Singapore, 4 Tan Tock SengHosp, Singapore, Singapore, 5 Natl. Univ. of Singapore, Singapore, Singapore.K-897 Clinical and Microbiological Characteristics of Helicobactercinaedi Bacteremia in JapanH. Araoka, M. Baba, H. Inagawa, M. Kimura, A. Yoneyama; ToranomonHosp., Tokyo, Japan.K-898 Inadequate Empiric Antibacterial Therapy (EAT) Affects theOutcome of High-Risk Hematological Patients (pts) with 126E.coli (Ec) Bacteremia (B)A. Micozzi, G. Colafigli, S. Santilli, D. Ballarò, C. Minotti, G. Gentile;Hematology, Rome, Italy.K-899 Risk Factors for Extensively Resistant Acinetobacterbaumannii Bacteremia Susceptible only to Polymyxin B: A Case-Case Control StudyT. M. Ng 1 , D. C. Lye 1 , C. B. Tengarm 2 ; 1 Tan Tock Seng Hosp., Singapore,Singapore, 2 Natl. Univ. of Singapore, Singapore, Singapore.K-900 Clinical Outcomes of Staphylococcus aureus Blood StreamInfections in Latin America: A Prospective Multicenter StudyC. Seas 1 , C. Garcia 1 , J. Zurita 2 , C. Alvarez 3 , M. Guzman 4 , J. Reyes 5 , C.Arias 5 , Latin America Working Group on Bacterial Resistance; 1 Hosp. Natl.Cayetano Heredia, Lima, Peru, 2 Hosp. Vozandes, Quito, Ecuador, 3 Hosp.San Ignacio, Bogota, Colombia, 4 Ctr. Med. de Caracas, Caracas, Venezuela,Bolivarian Republic of, 5 Univ. del Bosque, Bogota, Colombia.K-901 Outcomes Following Carbapenem Therapy for Klebsiella Bacteremia:An Assessment of the Updated Susceptibility BreakpointsL. R. Biehle 1,2 , E. B. Hirsch 3 , J. M. Cottreau 1,2 ; 1 Univ. of Houston, Houston, TX,2St. Luke’s Episcopal Hosp., Houston, TX, 3 Northeastern Univ., Boston, MA.K-902 Risk Factors Associated with Blood Stream Infection (BSI)Due to Extensively Drug-Resistant (XDR) Acinetobacterbaumannii (AB) in Immunocompromised PatientsI. K. Chalana, N. Davis, D. Marchaim, P. Johnson, R. Tansek, K. Chaudhry,N. Khandker, P. Lephart, J. Slim, J. Hothi, H. Ahmed, J. Pogue, J. J. Zhao,S. Dhar, A. O. Soubani, K. Hayakawa, A. Bhargava, K. S. Kaye, T. Chopra;Detroit Med. Ctr., Wayne State Univ., Detroit, MI.K-903 Clinical Impact of KPC Status and Appropriate Treatmentamong Enterobacteriaceae (EB) and Pseudomonas aeruginosa (Pae)in a Multicenter Matched Control Cohort Study in ColombiaR. Pacheco 1 , L. E. Osorio 2 , J. J. Maya 1 , V. M. Blanco 1 , A. Correa 1 , M. V.Villegas 1 ; 1 CIDEIM, Cali, Colombia, 2 Univ. del Valle, Cali, Colombia.Final Program103

Monday SCIENTIFIC SESSIONSK-904 Outbreak of Burkholderia cepacia Complex Bacteremia in aChemotherapy Day Care Unit Due to Intrinsic Contamination ofGranisetronT. Singhal, S. Shah, R. Naik; Kokilaben Dhirubhai Ambani Hosp. and Med.Res. Inst., Mumbai, India.K-905 Clinical Features of 119 Patients with Acinetobacter baumanniiSepticemiaX. Lu, P. Zou; West China Hosp. of Sichuan Univ., Chengdu, China.K-906 Outcomes Associated with Vancomycin Intermediate Staphylococcusaureus (VISA) Bloodstream Infections (BSI)K. E. Barber 1 , A. M. Casapao 2 , J. M. Pogue 1 , M. J. Rybak 2 ; 1 Detroit Med.Ctr., Detroit, MI, 2 Anti-Infective Res. Lab., Wayne State Univ., Detroit, MI.K-907 Assessment of Risk Factors Associated with Rapid Fatality inMethicillin-Resistant Staphylococcus aureus BacteremiaT. Kim 1 , H. Kim 2 , E. Kim 2 , S. Park 2 , Y. Lee 1 , S. Moon 1 , K. Park 1 , Y.Chong 1 , S. Kim 1 , S. Lee 1 , S. Choi 1 , J. Jeong 2 , J. Woo 1 , Y. Kim 1 ; 1 AsanMed. Ctr., Seoul, Korea, Republic of, 2 Asan Inst. of Life Sci., Seoul, Korea,Republic of.K-908 Burden of Nosocomial Staphylococcus aureus BloodstreamInfection in Korea: A Prospective Nationwide SurveyC. Kim 1,2 , A. Kim 2 , K. Song 1 , E. Kim 1 , H. Kim 1 , Y. Cho 3 , Y. Choi 4 , J. Park 5 ,B. Kim 6 , N. Kim 1 , K. Kim 7 , M. Oh 1 , Burden of Healthcare-associatedinfection Study Group; 1 Seoul Natl. Univ., Seoul, Korea, Republic of, 2 Natl.Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republicof, 3 Gachon Univ, Incheon, Korea, Republic of, 4 Ajou Univ., Suwon, Korea,Republic of, 5 Boramae Hosp., Seoul, Korea, Republic of, 6 Sangye-Paik Hosp.,Seoul, Korea, Republic of, 7 Pusan Natl. Univ., Pusan, Korea, Republic of.K-909 Early Experience with Ceftaroline fosamil Therapy at an AcademicHospital SystemA. M. Casapao 1 , K. E. Barber 2 , C. K. Wong 1 , L. M. Steinke 2 , R. P.Mynatt 2 , S. L. Davis 1 , K. S. Kaye 1 , J. M. Pogue 2 , M. J. Rybak 1 ; 1 WayneState Univ., Detroit, MI, 2 Detroit Med. Ctr., Detroit, MI.K-910 Pitt Bacteremia Score and APACHE II in Predicting 30-DayMortalityT. M. Ng, D. C. Lye; Tan Tock Seng Hosp., Singapore, Singapore.K-911 Epidemiology, Resistance Profile and Origin of Bacteremia inNon-Neutropenic Patients with Solid TumorM. Merad, E. Chachaty , B. Gachot, S. Antoun; Gustave Roussy Inst.,Villejuif, France.K-912 Methicillin-Resistant S. aureus (MRSA) USA600 Lab Characteristicsand Association to Patient Mortality in BloodstreamInfections (BSI) and PneumoniaD. Moreno, S. Arshad, M. B. Perri, A. Shoyinka, P. Hartman, M. J. Zervos;Henry Ford Hlth. System, Detroit, MI.K-913 Risk Factors for KPC-Producing Klebsiella pneumonia BacteremiaJ. L. L. Rocha 1 , F. F. Tuon 2 , P. Toledo 3 , L. M. Arend 4 , S. Penteado 2 , C. H.Dias 2 , T. M. Leite 2 , A. P. Zavascki 5 ; 1 Frischmann Aisengart/DASA Med.Diagnóstica, Curitiba, Brazil, 2 Hosp. Univ. Evangélico de Curitiba, Curitiba,Brazil, 3 Univ. Estadual de Ponta Grossa, Ponta Grossa, Brazil, 4 Lab. Centraldo Estado LACEN-PR, Curitiba, Brazil, 5 Hosp. de Clínicas de Porto Alegre,Curitiba, Brazil.K-914 Electronic All-Cause Bloodstream Infection Surveillance: AnAlternative to Time-Consuming Patient Chart AnalysisW. Zingg, M. Chraiti, D. Pittet, The HUG Infection Control Team; Univ. ofGeneva Hosp. and Faculty of Med., Geneva, Switzerland.K-915 Impact of a Guideline and Educational Intervention Programon the Treatment of Staphylococcus aureus Bacteremia at a LargeAcademic Medical CenterC. Nguyen 1 , J. Nguyen 1,2 , T. Tsukamoto 1,2 , C. Christensen 2,1 , B. Heintz ofClinical Pharmacy 2,1 ; 1 Univ. of California, San Francisco Sch. of Pharmacy,San Francisco, CA, 2 Univ. of California, Davis Med. Ctr., Sacramento, CA.K-916 Red Blood Cell Distribution Width is an Independent Predictorof Mortality in Patients with Gram-Negative BacteremiaN. Ku, H. Kim, H. Oh, Y. Kim-, M. Kim, J. Song, D. Oh, J. Ahn, S. Kim,S. Jeong, S. Han, C. Kim , Y. Song , J. Kim, J. Choi ; Yonsei Univ. Coll. ofMed., Seoul, Korea, Republic of.------------------------------------------------------------------------105(K)Poster SessionClostridium difficile InfectionsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-917 Assessing the Utility of Bedside Severity-of-illness Tools in theTreatment of Patients with Clostridium difficile InfectionsC. Garibotto , T. Doan; Long Island Jewish Med. Ctr., New Hyde Park, NY.K-918 Molecular and Clinical Characterization of Clostridium difficileInfections in a Japanese Teaching HospitalN. Mori, S. Yoshizawa, T. Saga, Y. Ishii, K. Tateda; Toho Univ. Faculty,Tokyo, Japan.K-919 Evaluation of Clinical Cure Rates of Clostridium difficile withDifferent Oral Vancomycin Dosing RegimensY. T. Garcia 1 , T. D. Kish 1,2 ; 1 James J. Peters VA Med. Ctr., Bronx, NY,2Arnold and Marie Schwartz Coll. of Pharmacy and Hlth. Sci., Long IslandUniv., Brooklyn, NY.K-920 Clinical Characteristics of Community-Associated VersusNon-Community-Associated Clostridium difficile Infection inHospitalized PatientsD. N. Shah 1,2 , V. R. K. Panchumarthi 3 , L. S. Al-Jashaami 3 , H. L. Koo 3,2,4 ,H. L. DuPont 3,2,1,4 , K. W. Garey 1,3,2 ; 1 Univ. of Houston, Houston, TX, 2 St.Luke’s Episcopal Hosp., Houston, TX, 3 Univ. of Texas Sch. of Publ. Health,Houston, TX, 4 Baylor Coll. of Med., Houston, TX.K-921 A Risk Index Based on Comorbid Conditions and DiseaseSeverity to Predict Mortality in Patients with Clostridium difficileInfectionD. N. Shah 1,2 , N. Bhatt 3 , E. Chen 3 , H. L. Koo 3,2,4 , H. L. DuPont 3,2,4,1 , K.W. Garey 1,2,3 ; 1 Univ. of Houston, Houston, TX, 2 St. Luke’s Episcopal Hosp.,Houston, TX, 3 Univ. of Texas Sch. of Publ. Health, Houston, TX, 4 BaylorColl. of Med., Houston, TX.K-922 Evaluation of Combination vs. Monotherapy for Clostridiumdifficile Infection (CDI)J. C. Njoku 1,2 , T. C. VanSchooneveld 1,2 , M. E. Rupp 1,2 , K. M. Olsen 1,2 , F.Qiu 2 , J. L. Meza 2 , E. D. Hermsen 1,2 ; 1 The Nebraska Med. Ctr., Omaha,NE, 2 Univ. of Nebraska Med. Ctr., Omaha, NE.K-923 Serum White Blood Cell Count of 15,000 Cells/mm3Predicts 30 Day All Cause Mortality Among HemodialysisPatients with Clostridium difficile InfectionA. A. Venugopal, S. Szpuna, L. B. Johnson; St John Hosp. and Med. Ctr.,Grosse Pointe Woods, MI.104September 9-12 |

MONDAY SCIENTIFIC SESSIONSK-924 Successful Treatment of Simulated Clostridium difficile Infectionin a Human Gut Model by Fidaxomycin After Vancomycin orMetronidazole FailureC. H. Chilton 1 , G. Crowther 1 , J. Freeman 1 , S. Todhunter 1 , S. Nicholson 1 ,C. Longshaw 2 , M. H. Wilcox 1 ; 1 Univ. of Leeds & Leeds Teaching Hosp.,Leeds, United Kingdom, 2 Astellas Phama Europe Ltd, Staines, UnitedKingdom.K-925 Clostridium difficile in Ready-to-Eat Raw Vegetables, FranceC. Eckert 1,2 , B. Burghoffer 1,2 , F. Barbut 1,2 ; 1 Natl. Reference Lab. for C.difficile, Saint-Antoine Hosp., AP-HP, Paris, France, 2 UPMC Univ Paris 06,Paris, France.K-926 Procalcitonin Levels Correlate with Severity in Cases ofClostridium difficile InfectionK. Rao, S. T. Walk, D. Micic, E. Chenoweth, L. Deng, MA Associate,R. Jain, I. Trivedi, M. Yu , C. Ring, V. B. Young , G. B. Huffnagle, D. M.Aronoff ; Univ. of Michigan, Ann Arbor, MI.K-927 Analysis of Sequential Isolates from Clostridium difficile Infectionsby MLVA SubtypingS. Taori 1,2 , A. Wroe 1 , K. Templeton 2 , A. Gibb 2 , I. Poxton 1 ; 1 Univ. of Edinburgh,Edinburgh, United Kingdom, 2 NHS Lothian, Edinburgh, UnitedKingdom.K-928 Evaluation of ATLAS Score in Predicting Clinical Cure andRecurrence of Clostridium difficile Infection (CDI)S. Jacobson 1 , D. Slain 2 ; West Virginia Univ., Morgantown, WV.K-929 Do Antibiotic Combinations with Rifampin for OsteoarticularInfections Protect against Clostridium difficile-Associated Colitis?C. Landelle , M. Schindler , W. Zingg , L. Pagani , I. Uckay, D. Pittet; Univ.of Geneva Hosp., Geneva, Switzerland.K-930 Case-Control Study of Community-Onset Clostridium difficileInfections in the NetherlandsM. Hensgens 1 , A. Demeulemeester 2 , O. Dekkers 1 , A. Buiting 3 , P. Bloembergen4 , B. van Benthem 5 , E. Kuijper 1 ; 1 LUMC, Leiden, Netherlands,2SHL, Breda, Netherlands, 3 Elisabeth Hosp., Tilburg, Netherlands, 4 Isala,Zwolle, Netherlands, 5 Natl. Inst. for Publ. Hlth. and the Environment,Bilthoven, Netherlands.K-931 Is There Any Correlation Between Microbiological Profile andthe Prognosis of Clostridium difficile Disease (CDD)?D. Rodriguez-Pardo, B. Almirante, R. Bartolomé, J. Vila, B. Mirelis, F.March, T. Cornejo, M. Español, M. Lung, A. Pahissa; Barcelona Clostridiumdifficile Project Study Group, Barcelona, Spain.K-932 Risk Factors Predictive of Recurrent C. difficile InfectionP. Ty 1 , A. Wong-Beringer 2,1 ; 1 Huntington Hosp., Pasadena, CA, 2 UnivSouthern California, Los Angeles, CA.K-933 Study on the Molecular Epidemiology and Antibiotic Resistanceof Clostridium difficile Isolates in Shijiazhuang of ChinaJ. Zhao 1 , J. Yang 1 , Y. Li 1 , S. Cui 2 , J. Li 1 , D. Shi 1 , W. Song 1 , H. Wei 1 , X.Liu 1 , C. Qiang 1 , Z. Li 1 , Q. Sun 1 ; 1 The Second Hosp. of Hebei Med. Univ.,Shijianzhuang, Hebei Province, China, 2 Chinese Natl. Inst. for the Controlof Pharmaceutical and Biological Products, Beijing, China.K-934 Comparison of Pulsed Xenon UV to Bleach for the Decontaminationof C. difficile from Surfaces in the Patient EnvironmentS. S. Ghantoji 1 , M. Stibich 2 , J. Stachowiak 2 , B. Tanner 3 , C. Perego 1 , S.Cantu 1 , R. F. Chemaly 1 ; 1 MD Anderson Cancer Ctr., Houston, TX, 2 XenexHealthcare Services, LLC, San Antonio, TX, 3 Antimicrobial Test Lab.,Austin, TX.K-935 Prevalence of Diarrhea Associated with Antibiotics Use in TwoConcentration Hospitals in MexicoR. FigueroaInfectious Disease Hosp., IMSS, Mexico, D.,F., Mexico.K-936 MLST Analysis Investigation of 104 Clostridium difficileIsolates from Various Areas and Hospitals of ChinaY. Cheng, Q. Yan, H. Zhou, C. Chen, R. Cen, W. Li, J. Lu; State Key Lab.for Infectious Disease Prevention and Control, Natl. Inst. for CommunicableDisease Control and Prevention, Chinese Ctr. for Disease Control andPrevention, Beijing, China.------------------------------------------------------------------------106(K)Poster SessionEndocarditisMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-937 In-Hospital and Long-Term Outcome of Left-Sided InfectiveEndocarditis (LSIE): The Influence of Methicillin-Resistant S.aureus Infection on PrognosisN. Fernández-Hidalgo, B. Almirante, P. Tornos, M. T. González-Alujas, A.M. Planes, M. Galiñanes, A. Pahissa; Hosp. Vall d’Hebron, Barcelona, Spain.K-938 Enterococcus faecalis Infective Endocarditis (EFIE): The Influenceof Ampicillin + Gentamicin (AG) vs Ampicillin + Ceftriaxone(AC) on OutcomeN. Fernández-Hidalgo, 1,2 , B. Almirante 1,2 , J. Gavaldà 1,2 , M. Gurgui 2 , C.Peña 2 , A. de Alarcón 2 , J. Ruiz 2 , M. Montejo 2 , N. Vallejo 2 , I. Vilacosta 2 , F.López-Medrano 2 , A. Plata 2 , J. López 2 , C. Hidalgo 2 , J. Gálvez 2 , J. M. Lomas 2 ,M. Falcone 3 , M. Noureddin 2 , X. Martínez-Lacasa 2 , A. Pahissa 1,2 ; 1 Hosp. Valld’Hebron, Barcelona, Spain, 2 Enterococcus Faecalis Infective EndocarditisStudy Group, Spain, 3 Enterococcus Faecalis Infective Endocarditis StudyGroup, Italy.K-939 Relationships Between Gender, Early Valve Surgery (EVS) andMortality in Patients with Infective Endocarditis (IE) Analyzed ina Multicenter CohortC. Chirouze, F. Alla, C. Selton-Suty, L. Schubel, T. Doco-Lecompte, M.Erpelding, X. Duval, B. Hoen; AEPEI, PARIS, France.K-940 The Clinical Impact of Routine Performance of PET/CT inPatients with Infectious Endocarditis (IE): Preliminary Results ofa Prospective Ongoing StudyM. Kestler, P. Muñoz, M. Rodriguez, F. Jimenez, A. Rotger, A. Marti, J.C. Alonso, J. Orcajo, E. Bouza; Hosp. G. U. Gregorio Marañon. Univ. ofMadrid, Madrid, Spain.K-941 Influence of the Timing of Cardiac Surgery on the Prognosisof Left-Sided Native Endocarditis: Prospective and MulticenterCohort study (GAMES)J. Gálvez-Acebal 1 , P. Muñoz 2 , J. M. Miró 3 , A. Alarcón 4 , L. Castelo 5 ,J. Ruiz 6 , A. Moreno 7 , M. Montejo 8 , J. Lomas 9 , S. Reus 10 , E. Bouza 11 ,GAMES; 1 Hosp. VMacarena, Seville, Spain, 2 Hosp. GMarañón, Madrid,Spain, 3 Hosp. Clinic, Barcelona, Spain, 4 Hosp. VRocío, Seville, Spain, 5 Hosp.JCanalejo, Coruña, Spain, 6 Hosp. VVictoria, Malaga, Spain, 7 Hosp. La Paz,Madrid, Spain, 8 Hosp. Cruces, Bilbao, Spain, 9 Hosp. JRJimenez, Huelva,Spain, 10 Hosp. Alicante, Alicante, Spain, 11 Hosp. GMarañón, Seville, Spain.Final Program105

Monday SCIENTIFIC SESSIONSK-942 Valve Surgery in Infective Endocarditis: Determinants ofIn-Hospital PrognosisM. Martinez-Selles 1 , A. Arnaiz 2 , P. Muñoz 1 , J. Ruiz 3 , M. Moreno 4 , J.Reguera 5 , J. Galvez 6 , J. Portu 7 , J. Oteo 8 , J. dela Torre 9 , E. Bouza- Prof 1 ,GAMES; 1 H G.U. Gregorio Marañón. Univ. of Madrid, Madrid, Spain,2Hosp. Valdecilla, Santander, Spain, 3 Hosp. V Victoria, Málaga, Spain, 4Hosp. La Paz, Madrid, Spain, 5 Hosp. Carlos Haya, Malaga, Spain, 6 Hosp. VMacarena, Seville, Spain, 7 Hosp. Txagorritxu, Barakaldo, Spain, 8 Hosp. SanPedro, La Rioja, Spain, 9 Hosp. Costa del Sol, Marbella, Spain.K-943 Short-Term and Long-Term Mortality Risk Factors in aProspective Cohort of 1000 Consecutive Infective Endocarditis inSpain (GAMES)P. Muñoz 1 , M. Fariñas 2 , A. Alarcón 3 , L. Castelo 4 , J. Miró 5 , M. Montejo 6 ,E. Navas 7 , R. Ivanova 8 , J. Paño 9 , A. Moreno 10 , C. Hidalgo-Tenorio 11 , M.Goenaga 12 , A. Plata 13 , M. Rodríguez 1 , E. Bouza 1 , GAMES; 1 Hosp. G.U.Gregorio Marañón. Univ. of Madrid, Madrid, Spain, 2 Hosp. Valdecilla,Santander, Spain, 3 Hosp.V del Rocío, Sevilla, Spain, 4 Hosp. Juan Canalejo,Coruña, Spain, 5 Hosp. Clinic, Barcelona, Spain, 6 Hosp. Cruces, Bilbao,Spain, 7 Hosp. Ramón y Cajal, Madrid, Spain, 8 Hosp. V Victoria, Málaga,Spain, 9 Hosp. La Paz, Madrid, Spain, 10 Hosp. Central Asturias, Oviedo,Spain, 11 H V Nieves, Granada, Spain, 12 Hosp. Donosti, San Sebastián,Spain, 13 Hosp. Carlos Haya, Málaga, Spain.K-944 Efficacy of Daptomycin in the Treatment of EnterococcalEndocarditis: A 5-Year PerspectiveI. Ceron, P. Muñoz, M. Marin, M. Rodríguez-Créixems, B. Pinilla, A.Segado, J. Roda, H. Rodríguez, M. Valerio, A. Fernandez-Cruz, A. Burillo,E. Bouza- ID prof, GAME; Hosp. G.U. Gregorio Marañón, Univ. of Madrid,Madrid, Spain.K-945 Changes in the Antibiotic Treatment of Enterococcus faecalisInfective Endocarditis (EF-IE) in the Last 15 YearsJ. M. Pericas, C. Cervera, A. del Río, C. García-De-La-Maria, Ph , A.Moreno, X. Castañeda, M. Almela, C. Falces, S. Ninot, Y. Armero, C. A.Mestres, D. Soy, J. M. Gatell, F. Marco, J. M. Miró, Hospital Clinic EndocarditisStudy Group; Hosp. Clinic - IDIBAPS, Barcelona, Spain.K-946 Evaluation of Population Analysis Profile Susceptibility (PAP)as a Predictor of Patient Outcomes with Methicillin-ResistantStaphylococcus aureus (MRSA) Infective Endocarditis (IE)A. M. Casapao, S. Patel , R. Kullar, S. L. Davis, M. J. Rybak; Wayne StateUniv., Anti-Infective Res. Lab., Detroit, MI.------------------------------------------------------------------------107(K)Poster SessionFungal InfectionsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-947 Candidaemia in Malaysia: Surprising Results from a NationalStudyQ. A. Nguyen 1,2 , D. J. E. Marriott 1 , Malaysian Candidaemia Study (MaCaS)Group; 1 St. Vincent’s Hosp. Sydney, Sydney, Australia, 2 Garvan Inst. of Med.Res., Sydney, Australia.K-948 Predictors of Poor Outcome in Candidemia: A Population-Based Surveillance for Candidemia in SpainM. Puig 1 , B. Padilla 2 , J. Garnacho 3 , R. Zaragoza 4 , P. Muñoz 2 , J. Aguado 5 ,M. Montejo 6 , B. Almirante 1 , CANDIPOP Project, GEIH-GEMI-COMED (SEIMC) and REIPI.; 1 Hosp. Vall d´Hebron, Barcelona, Spain,2Hosp. Gregorio Marañón, Madrid, Spain, 3 Hosp. Virgen del Rocio, Sevilla,Spain, 4 Hosp. Univ. Dr. Peset, Valencia, Spain, 5 Hosp. 12 de Octubre, Madrid,Spain, 6 Hosp. Cruces, Bilbao, Spain.K-949 Predictors of Candida sp. as a Causative Agent of Catheter-Related Bloodstream InfectionsM. Nagao, G. Hotta, M. Yamamoto, Y. Matsumura, A. Matsushima, Y. Ito,S. Takakura, S. Ichiyama; Kyoto Univ. Hosp., Kyoto, Japan.K-950 Candida Bloodstream Infections (BSI) in the Intensive CareUnit (ICU) Adult PatientsM. Puig 1 , J. Garnacho 2 , R. Zaragoza 3 , J. Pemán 4 , M. Valerio 5 , E. Martin-Mazuelos 6 , B. Almirante 1 , CANDIPOP Project, GEIH-GEMICOMEDand REIPI; 1 Hosp. Vall d´Hebron, Barcelona, Spain, 2 Hosp. Virgen delRocio, sevilla, Spain, 3 Hosp. Univ. Dr. Peset, Valencia, Spain, 4 Hosp. La Fe,Valencia, Spain, 5 Hosp. gregorio Marañon, Madrid, Spain, 6 Hosp. de Valme,Sevilla, Spain.K-951 Outcome and Risk Factors for Mortality in Critically IllPatients with Invasive Pulmonary AspergillosisS. Blot 1 , J. Rello 2 , G. Dimopoulos 3 , K. Vandewoude 1 , D. Vogelaers 1 ,and the AspICU Study Investigators; 1 Ghent Univ., Gent, Belgium, 2 Valld’hebron Univ. Hosp., Barcelona, Spain, 3 Athens Attikon Univ. Hosp.,Athens, Greece.------------------------------------------------------------------------108(K)Poster SessionInfluenzaMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-952 Hospital-Acquired Influenza in an Australian Sentinel SurveillanceSystemN. Macesic 1 , T. Kotsimbos 1,2 , P. M. Kelly 3 , A. C. Cheng 1,2 , FluCAN Investigators;1 Alfred Hlth., Melbourne, Australia, 2 Monash Univ., Melbourne,Australia, 3 Australian Natl. Univ., Canberra, Australia.K-953 Vaccination against Influenza at a European Pediatric CancerCenter: Immunization Rates and Attitudes among Staff MembersS. Jocham, A. Wiener, J. Groenefeld, A. Loecken, J. Kuehn, A. H. Groll;Univ. Hosp., Muenster, Germany.K-954 Nosocomial Outbreak of Seasonal Influenza in a GeriatricHospitalL. Pagani 1 , V. Sauvan 1 , A. Iten 1 , L. Kaiser 2 , S. Harbarth 1 , D. Pittet 1 ;1Infection Control Program, Geneva, Switzerland, 2 Lab. of Virology, Geneva,Switzerland.K-955 Risk For Death From Seasonal and Pandemic Influenza: ASystematic ReviewD. Mertz 1 , T. Kim 1 , J. Johnstone 1 , P. Lam 2 , M. Science 1 , S. P. Kuster 3 , S.A. Fadel 2 , D. Tran 2 , N. Bathnagar 1 , M. Loeb 1 ; 1 McMaster Univ., Hamilton,Canada, 2 Univ. of Toronto, Toronto, Canada, 3 Univ. Hosp. Zurich, Zurich,Switzerland.106September 9-12 |

MONDAY SCIENTIFIC SESSIONSK-956 Epidemic of Seasonal Influenza in an Internal MedicineServiceA. Iten, S. Manuel, L. Pagani, Y. Thomas, V. Camus, L. Kaiser, A. Perrier, D.Pittet; HUG, Geneva, Switzerland.------------------------------------------------------------------------109(L1)Poster SessionAn Update on TuberculosisMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:L1-957 Use of Fluoroquinolons in Tuberculosis Regimen in NorthernParis and Northern France, between 2004 and 2011M. Amsilli 1 , A. Blanc 2 , H. Ferrand 1 , E. Senneville 2 , E. Papy 1 , A. Vachée 3 ,R. Ruimy 1 , E. Bouvet 1 , X. Lemaire 4 , Y. Yazdanpanah 1,2 ; 1 Hosp. Bichat,Paris, France, 2 Hosp. Gustave Dron, Tourcoing, France, 3 Ctr. Hosp., Roubaix,France, 4 Ctr. Hosp., Douai, France.L1-958 Tolerance and Safety of Intravenous Streptomycin Therapy inPatients with TuberculosisR. Pérez Tanoira 1 , R. Fernández-Roblas 1 , F. Sánchez-Patán 2 , A. JiménezGirón 2 , J. Esteban Moreno 1 , M. Fernández Guerrero 1 ; 1 Fundación JiménezDíaz, Madrid, Spain, 2 Inst. of Food Sci. Res., Madrid, Spain.L1-959 Predictors of Non-Adherence to a Pharmacist-ManagedTreatment Program for Latent Tuberculosis Infection (LTBI)Among Homeless PopulationA. F. Adesanya 1 , A. Le 2 , L. Nelson 3 , J. Hirsch 2 , S. Lorentz 2 ; 1 ComprehensivePharm Services, Memphis, TN, 2 Univ. of California, San Diego, La Jolla,CA, 3 Univ. of Louisville Hosp., Louisville, KY.------------------------------------------------------------------------110(L1)Poster SessionZoonotic InfectionsMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:L1-960 Imaging Techniques (Radyograph, Scintigraphy and MagneticRezonance Imaging) in Brucellar Sacroiliitis Can be Used asa Criteria for a Follow-Up in the Termination of TreatmentA. Bilgeturk, H. C. Gul, A. Karakas, G. Mert, C. Artuk, C. P. Eyigun;Gulhane Military Med. Sch., Ankara, Turkey.L1-961 Brucella Melitensis (BM) Bacteremia in Adult HospitalizedPatients in Southern IsraelY. Glick, E. Levin, L. Saidel-Odes, F. Schlaeffer, K. Riesenberg; SorokaUniv. Med. Ctr. (SUMC) and Faculty of Hlth. Sci., Ben Gurion Univ. of theNegev, Beer Sheva, Israel.L1-962 Timing of Antibiotic and Surgical Treatment of Q-FeverEndocarditisY. Maor, A. Kogan, B. Orlov, H. Cohen, L. Sternik, A. Malachy, E. Raanani,G. Rahav; Sheba Med. Ctr., Tel Hashomer, Israel.L1-963 Chronic Q Fever: Clinical Data and OutcomeF. Laterza 1 , A. Elsendoorn 1 , S. Sunder 2 , G. Beraud 1 , G. Le Moal 1 , S.Edouard 3 , A. Riche 4 , M. Texereau 5 , D. Boutoille 6 , C. Godet 1 , F. Roblot 1 ,GERICCO; 1 Univ. Hosp., Poitiers, France, 2 Univ. Hosp., Tours, France,3Natl. Reference Ctr., Univ. Aix-Marseille, Marseille, France, 4 Gen. Hosp.,Angoulême, France, 5 General Hosp., Niort, France, 6 Univ. Hosp., Nantes,France.L1-964 Phylogeography of Francisella tularensis Subspecies Holarcticafrom the Country of TurkeyY. Ozsurekciship 1 , D. M. Wagner 2 , M. Celikship 1 , E. Karadag Oncelship 1 ,D. N. Birdsell 2 , A. J. Vogler 2 , P. Keim 2 , A. Ozkaya Parlakayship 1 , M. Ceyhan1 ; 1 Hacettepe Univ. Faculty of Med., Ankara, Turkey, 2 Northern ArizonaUniv., Arizona, AZ.L1-965 Diagnostic Value of FDG-PET/CT in Diagnosing VascularChronic Q-FeverJ. C. J. Hagenaars 1 , A. W. Vlake 1 , N. H. M. Renders 1 , A. S. van Petersen 2 ,M. G. L. de Jager-Leclercq 2 , F. L. Moll 3 , O. H. J. Koning 1 , P. C. Wever 1 ,C. J. Hoekstra 1 ; 1 Jeroen Bosch Hosp., Hertogenbosch, Netherlands, 2 Hosp.Bernhoven, Veghel/Oss, Netherlands, 3 Univ. Med. Ctr. Utrecht, Netherlands.------------------------------------------------------------------------111(M)Poster SessionExperimental MycologyMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:M-966 Polymorphism of Polyglutamine Proteins in Candida glabrataand Role in AdaptationT. D. Edlind, S. K. Katiyar; Drexel Univ. Coll. of Med., Philadelphia, PA.M-967 Histopathology Following Polyene or Echinocandin Treatmentof Infection with Candida tropicalis Strain Having UniqueEchinocandin-Resistant (ER) GenesJ. Schwartz 1 , H. Lee 2 , J. Olson 3 , D. Hahka 3 , N. Nguyen 3 , A. Ibrahim 2 , J.Adler-Moore 3 ; 1 Charles River, Davis, CA, 2 LA Biomed Res. Inst., Torrance,CA, 3 Cal Poly, Pomona, CA.M-968 Disruption of Candida albicans Mitochondrial Function byCaspofunginS. T. King, K. R. Stover , S. Ferguson, J. P. Hosler, J. D. Cleary; Univ. of MississippiMed. Ctr., Jackson, MS.M-969 Differential Expression of the Genes Encoding Erg11 andMultidrug Efflux Transporters in Fluconazole Resistant Isolatesof Non-Albicans Species of CandidaE. L. Berkow, K. S. Barker, K. M. Brown, P. D. Rogers; Univ. of TennesseeHlth. Sci. Ctr., Memphis, TN.M-970 Clinically-Derived Mutations in ERG11 Cause DecreasedFluconazole Susceptibility When Expressed in a SusceptibleStrain of C. albicansS. A. Flowers , K. S. Barker, P. D. Rogers; Univ. of Tennessee, Memphis, TN.M-971 Cas5, Upc2, and Rpn4 Influence the Fungistatic Activity ofFluconazole against Candida albicansE. M. Vasicek, E. L. Berkow, K. S. Barker, P. D. Rogers; Univ. of TennesseeHlth. Sci. Ctr., Memphis, TN.Final Program107

Monday SCIENTIFIC SESSIONSM-972 Hyperthermia Sensitizes Rhizopus oryzae (Ro) to Posaconazole(PCZ) and Itraconazole (ICZ) Action Through ApoptosisF. Shirazi 1 , M. Pontikos 1 , R. Lewis 1 , S. Achi 1 , T. Walsh 2 , N. Albert 1 , D.Kontoyiannis 1 ; 1 UT MD Anderson Cancer Ctr., Houston, TX, 2 CornellUniv., New York, NY.M-973 CBS Domain-Containing Proteins are Rhizopus oryzaeFerrioxamine ReceptorsM. Liu 1 , T. Ghebremariam 1 , C. Skory 2 , J. E. Edwards, Jr. 1 , A. S. Ibrahim 1 ;1Habor-UCLA Med. Ctr., Torrance, CA, 2 USDA, Peoria, IL.M-974 Thermokinetic Evaluation of Fluconazole, Caspofungin,Anidulafungin and Amphotericin B on Planktonic and BiofilmCandida spp. by MicrocalorimetryE. Maiolo 1 , F. Ulrika 1 , S. Dominique 2 , T. Andrej 1 ; 1 Univ. Hosp., Lausanne,Switzerland, 2 Inst. of Microbio. Lausanne, Switzerland.M-975 Mutational Analysis of a Major Multi-Drug TransporterCdr1p of Pathogenic Candida albicans Reveals Novel Insights intoDrug Binding and TransportM. Rawal Scholar, R. Prasad; Jawaharlal Nehru Univ., New Delhi, India.M-976 Impact of Iron Chelators on Growth and Expression ofIron-Related Genes of Cryptococcus SpeciesM. Chayakulkeeree, T. Tangkoskul Asistant, S. Tiengrim Associate, S.Onsomearng; Siriraj Hosp., Mahidol Univ., Bangkok, Thailand.M-977 The Antifungal Activity of an Abbreviated Regimen ofAmphotericin B Deoxycholate (DAmB) For CryptococcalMeningitis is Due to Persistence of Drug in the Brain RatherThan T-Cell RecruitmentJ. Livermore 1 , A. Sharp 1 , C. Walker 1 , W. Moser 1 , L. Gregson 1 , J. Goodwin1 , T. W. Felton 1 , S. J. Howard 1 , W. Mueller 1 , J. Perfect 2 , W. W. Hope1; 1 The Univ. of Manchester, Manchester, United Kingdom, 2 Duke Univ.,Durham, NC.M-978 Caspofungin Induces Apoptosis of Candida albicans atMinimum Inhibitory Concentration (MIC) and Causes Necrosisat > MICB. Hao 1 , S. Cheng 1 , C. Clancy 2 , M. Nguyen 1 ; 1 Univ. of Pittsburgh,Pittsburgh, PA, 2 Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA.M-979 Effects of Conditional Expression of Cell Wall Synthesis-Encoding Genes in C. albicans (CA) in a Toll-Deficient Model ofInvasive Candidiasis (IC)R. E. Lewis 1 , N. D. Albert 2 , K. Young 3 , C. M. Douglas 3 , D. P.Kontoyiannis 2; 1 Univ. of Houston Coll. of Pharmacy, Houston, TX, 2 TheUnvi. of Texas M.D. Anderson Cancer Ctr., Houston, TX, 3 Merck Res. Lab.,Kenilworth, NJ.M-980 Evaluation of Arasertaconazole Nitrate Efficacy in a VaginalCandidiasis Rat ModelF. Cabello, DVM , N. Marti, D. Gargallo, A. Guglietta; Res. and Dev. Ctr..Ferrer Internacional SA, Barcelona, Spain.M-981 Antifungal Activity, Plasma Pharmacokinetics and Safety ofSecond-Generation Echinocandin ASP9726 in ExperimentalPulmonary Aspergillosis in Persistently Neutropenic RabbitsV. Petraitis 1 , R. Petraitiene 1 , K. A. Such 2 , P. W. Moradi 1 , G. E. Strauss 1 , E.Petraityte 1 , S. Fleener 3 , S. Akamatsu 4 , S. Matsumoto 4 , T. J. Walsh, Transplantation1 ; 1 Weill Cornell Med. Coll. of Cornell Univ., New York, NY, 2 TheRockefeller Univ., Weill Cornell Med. Coll., and Mem. Sloan-KetteringCancer Ctr., New York, NY, 3 Covance Res. Products, Denver, PA, 4 AstellasPharma Inc., Tukuba, Ibaraki, Japan.M-982 P-Glycoprotein (Pgp) and Amphotericin B (AmB)M. Martinez 1 , V. Chen 1 , K. V. Clemons 1 , M. Johansen 1 , T. Blaschke 1 ,L. Zhu 2 , D. A. Stevens 1 ; 1 Stanford Univ., Stanford, CA, 2 Fudan Univ.,Shanghai, China.M-983 pH Signaling Inhibition in Candida albicans Leads toEnhanced Activity and Restore Fungicidal Effect of ErgosterolSynthesis InhibitorsS. Sahli 1 , S. Boulahfa 1 , M. Cornet 1,2 ; 1 Univ. Joseph Fourier, Grenoble,France, 2 CHU, Grenoble, France.M-984 In Vitro Immunopharmacodynamics of Cell Wall ActiveAntifungals against Candida albicans and Aspergillus fumigatusR. E. Lewis 1 , G. Liao 1 , K. Young 2 , C. M. Douglas 2 , D. P. Kontoyiannis 3 ;1Univ. of Houston Coll. of Pharmacy, Houston, TX, 2 Merck & Co, Kenilworth,NJ, 3 The Univ. of Texas M.D. Anderson Cancer Ctr., Houston, TX.M-985 Impaired Mitochondrial Function in Fluconazole (FLC)Heteroresistant Candida glabrataT. Finn 1 , A. Novikov 1 , O. Zimmerman 1 , Y. Paran 1 , N. Osherov 2 , R. Ben-Ami 1 ; 1 Tel Aviv Med. Ctr., Tel Aviv, Israel, 2 Tel Aviv Univ., Tel Aviv, Israel.M-986 Isolation and Characterization of Small Colony Variants ofPseudomonas aeruginosa from Monomicrobial and P. aeruginosa-Aspergillus fumigatus Mixed Microbial BiofilmsE. K. Manavathu, D. L. Vager, J. A. Vazquez; Henry Ford Hosp., Detroit, MI.M-987 A Tale of Two Biofilms: A Comparative Study of the Characteristicsand Antifungal Drug Susceptibilities of Submerged andSurface Biofilms of Aspergillus fumigatusE. K. Manavathu, D. L. Vager, J. A. Vazquez; Henry Ford Hosp., Detroit, MI.M-988 Efficacy and Dose-Response Relationships of LiposomalAmphotericin B (L-AmB) against Different Azole-Resistant Aspergillusfumigatus Isolates in a Non-Neutropenic Murine Modelof Disseminated AspergillosisS. Seyedmousavi 1,2 , W. J. G. Melchers 1,2 , J. W. Mouton 1,2 , P. E. Verweij 1,2 ;1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 NijmegenInst. for Infection, Inflammation and Immunity, Nijmegen, Netherlands.M-989 Pharmacodynamics of Anidulafungin (AFG) against ClinicalAspergillus fumigatus Isolates in a Non-Neutropenic MurineModel of Disseminated AspergillosisS. Seyedmousavi 1,2 , R. J. M. Brüggemann 1,2 , W. J. G. Melchers 1,2 , P. E.Verweij 1,2 , J. W. Mouton 1,2 ; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen,Netherlands, 2 Nijmegen Inst. for Infection, Inflammation and Immunity,Nijmegen, Netherlands.M-990 Global Transcriptome Profiling of Human Endothelial Cellsin Response to Infection with Non-Mutant Morphological Formsof Candida albicansC. S. Y. Lim 1,2 , Y. Tan 2 , R. Rosli 2 , H. Seow 2 , P. Chong 2 ; 1 UCSI Univ.,Cheras, Malaysia, 2 Univ. Putra Malaysia, Serdang, Malaysia.M-991 Itraconazole Induced Changes in Cardiac FunctionJ. D. Cleary, K. Stover , J. Farley; Univ. of Mississippi Med. Ctr., Jackson, MS.M-992 Drug Concentrations in Urine Following Single, Multipleor Intermittent Treatment with Increasing Doses of LiposomalAmphotericin B (LAmB) Versus Amphotericin B (Amp)N. Nguyen, J. A. Olson, J. Ruiz, J. Adler-Moore; Cal Poly Univ., Pomona, CA.108September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------112(P)Poster SessionGlobal Health, Parasitology and Travel MedicineMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:P-993 First Detection of Encephalitozoon Spp. Spores in Stools Free-Living Capybaras (Hydrochoerus Hydrochaeris)WithdrawnP-994 Serosurvey for Antibodies to Balamuthia mandrillaris in MississippiResidentsD. C. Sullivan, B. A. Chapman, H. H. Henderson, S. Molitorisz; Univ. ofMississippi Med. Ctr., Jackson, MS.P-995 Encephalitozoon and Enterocytozoon (Microsporidia) Sporesin Stool from Pigeons and Exotic BirdsWithdrawnP-996 Vaccination Status of Young Adults in FranceJ. Giraud 1 , C. Chubilleau 1 , S. Robin 1 , B. Bouffard 1 , M. Vivier-Darrigol2, C. Binet 3 , P. Ingrand 4 , F. Roblot 5 ; 1 Regional Hlth. Observatory, Poitiers,France, 2 Regional Hlth. Agency, Poitiers, France, 3 Natl. Service Agency,Paris, France, 4 Univ. of Med. and Pharmacy, Poitiers, France, 5 Univ. Hosp.,INSERM U1070, Poitiers, France.P-997 The Influence of TiO2 and ZnO Nanoparticles and UV Irradiationon Murine Macrophages Infectivity by Leishmania tropicaY. A. Yakubchyk, M. H. Rafailovich; SUNY Stony Brook, Stony Brook, NY.P-998 The Risk Areas of Malaria in Surin Province Thailand Usingthe Geographic Information SystemS. Kaewpitoon 1 , R. Rujiragul 2 , N. Ueng-arporn 1 , L. Matrakool 1 , A.Sathapollatchaphum 2 , W. Ratanasalink 2 , A. GnamNuan 2 , P. Saosri 2 , N.Kaewpitoon 1 ; 1 Inst. of Med., Suranaree Univ. of Tech., Muang NakhonRatchasima, Thailand, 2 Parasitic Disease Res. Unit, Inst. of Med., SuranareeUniv. of Tech., Muang Nakhon Ratchasima, Thailand.P-999 The Carcinogenic Human Liver Fluke: Current Status of Opisthorchisviverrini Metacercariae in Northeastern ThailandN. Kaewpitoon 1 , S. Kaewpitoon 1 , N. Ueng-arporn 1 , R. Rujiragul 1 , S.Churproong 1 , L. Matrakool 1 , S. Auiwatanagul 1 , B. Sripa 2 ; 1 Inst. of Med.,Suranaree Univ. of Tech., Muang Nakhon Ratchasima, Thailand, 2 Faculty ofMed., Khon Kaen Univ., Khon Kaen, Thailand.P-1000 Side Effects of Amphotericin B of Colloidal Dispersion in theTreatment of Cutaneous Leishmaniasis at the Central MilitaryHospitalC. E. Perez 1 , C. Morales 2 ; 1 Hosp. Militar Central, Bogotá, Colombia, 2 Hosp.Militar Central, Bogotá, Colombia.P-1001 Resurgence of Q Fever in Urban Areas, Israel 2000-2010N. Carmi-Oren 1 , A. Keysary 2 , S. Rzotkiewicz 2 , Y. Atiya-Nasagi 2 , M.Weinberger 1,3 ; 1 Assaf Harofeh Med. Ctr., Zerifin, Israel, 2 Israel Inst. forBiological Res. (IIBR), Ness Ziona, Israel, 3 Sackler Sch. of Med., Tel AvivUniv., Tel Aviv, Israel.P-1002 Antimicrobial Resistance and the Public Health InvolvementL. C. Balsalobre, M. Dropa, G. Matté, M. Matté; Univ. of São Paulo, SãoPaulo, Brazil.P-1003 Sepsis Does Not Require High End Antibiotics Always: AStudy from South IndiaP. Senthur Nambi, R. Gopalakrishnan, A. Ghafur, V. Ramasubramanian;Apollo Hosp., Chennai, India.P-1004 Melioidosis in India: Rare or Rarely Diagnosed?D. Sureshkumar, R. Gopalakrishnan, K. Abdul Ghafur, P. Vidyalakshmi, A.Tayade; Apollo Hosp., Tamilnadu, India.P-1005 Danish Travellers with Plasmodium ovale Curtisi and P. ovaleWallikeri after Visiting AfricaM. Chen 1 , P. Kjældgaard 1 , T. Christensen 2 , R. Legarth 2 , R. Legarth 2 , N.Kirkby 2 , L. Reinstrup 2 , G. Gomme 2 , J. A. L. Kurtzhals 2 ; 1 SonderjyllandHosp., Sonderborg, Denmark, 2 Rigshospital, Copenhagen, Denmark.P-1006 A Case of CNS Toxocariasis Presenting with MultipleSclerosis-Mimicking Recurrent EncephalomyelitisJ. S. Moon, S. Lee, K. Jung, K. Chu; Seoul Natl. Univ. Hosp., Seoul, Korea,Republic of.P-1007 In Vitro Effects of Galactofuranoside Derivatives onLeishmania donovaniM. Suleman 1 , J. Gangneux 2 , L. Legentil 3 , Y. Cabezas 3 , O. Sergent 1 ,V. Ferrières 3 , F. Robert-Gangneux 4 ; 1 INSERM U1085 IRSET, Rennes,France, 2 CHU Pontchaillou - INSERM U1085 IRSET, Rennes, France,3Ecole Supérieure de Chimie de Rennes, Rennes, France, 4 CHU Rennes -INSERM U1085 IRSET, Rennes, France.P-1008 Comparative Study of the Diagnosis Methods in HumanEchinococcosisL. M. Junie, IV, P. T. Ciobanca, N. Constantea; Univ. of Med. and Pharmacy,Cluj Napoca, Romania.P-1009 Evaluation of Risk Factors for Autochthonous Leptospirosisin AustriaC. Wallner 1 , H. Flick 1 , T. Valentin 1 , K. Seeber 1 , I. Zollner-Schwetz 1 , J.Wagner 1 , A. Grisold 1 , F. Allerberger 2 , R. Krause 1 , M. Hoenigl 1 ; 1 Med.Univ. of Graz, Austria, Graz, Austria, 2 AGES Austria, Vienna, Austria.P-1010 Impact of Use of Antibiotics on Pathogenic BacteriaSensibility of Layer and Broiler Chicken in NgaoundéréTown - CameroonK. S. Tanedjeu 1 , D. Bakari 2 , T. N. Leopold 2 , M. Carl 2 ; 1 Natl. Dairy Res.Inst., Karnal, India, 2 Univ. of Ngaoundere, Ngaoundere, Cameroon.P-1011 Comparison of Clinical Features of Q Fever in FrenchGuiana and in Metropolitan FranceS. Edouard 1 , M. Demar 2 , F. Djossou 2 , P. Addoud 2 , A. Mahamat 2 , D.Raoult 1 ; 1 Unité de Recherche Sur les Maladies Infectieuses et TropicalesÉmergentes URMITE, Marseille, France, 2 Dept. of Infectious and TropicalDiseases, Cayenne, Guyana.P-1012 Coxiella burnetii in Ruminant Bulk Tank Milk Samples inPortugalS. Anastacio 1,2 , C. Cruz, Lic 2 , D. Pessoa 2 , G. J. Da Silva 1 ; 1 CEF, Univ.Coimbra, Coimbra, Portugal, 2 Univ. Sch. Vasco da Gama, Coimbra, Portugal.P-1013 Efficacy of Liposomal Amphotericin B against Acute ChagasDisease in MiceM. Martinez 1 , V. Chen 1 , K. V. Clemons 1,2,3 , D. A. Stevens 1,2,3 ; 1 CaliforniaInst. for Med. Res., San Jose, CA, 2 Santa Clara Vly. Med. Ctr., San Jose, CA,3Stanford Univ., Stanford, CA.Final Program109

Monday SCIENTIFIC SESSIONSP-1014 Diagnosis of a Travel-Related Schistosoma haematobium-Schistosoma bovis Hybrid ClusterP. H. P. Soentjens 1,2 , L. Cnops 1 , T. Huyse 1,3 , D. De Vos 4 , C. P. Yansouni 1,5,6 ,M. Van Esbroeck 1 ; 1 Inst. of Tropical Med., Antwerp, Belgium, 2 MilitaryHosp. Queen Astrid, Brussels, Belgium, 3 Lab. of Biodiversity and EvolutionaryGenomics, Univ. of Leuven, Leuven, Belgium, 4 Lab. for Molecularand Cellular Technology, Military Hosp. Queen Astrid, Brussels, Belgium,5JD MacLean Ctr. for Tropical Diseases, McGill Univ., Montreal, Canada,6Div. of Infectious Diseases and Med. Microbiol., McGill Univ. Hlth. Ctr.,Montreal, Canada.P-1015 Hepatitis A Virus Circulation after Universal Single DoseVaccination in Argentinean ChildrenC. Vizzotti 1 , A. Gentile 2 , J. González, Virologist 3 , A. Rearte 1 , M. Ramonet 2 ,M. Cañero 2 , M. Pérez C. 1 , A. Urueña 1 , M. Diosque 1 , ArgentineanHepatitis A Working Group; 1 Ministerio de Salud de la Nación, BuenosAires, Argentina, 2 Sociedad Argentina de Pediatría, Buenos Aires Argentina,3INEI-ANLIS Dr. Carlos Malbrán, Buenos Aires, Argentina.P-1016 High Persistence of Protective Antibodies against Hepatitis AAfter Universal Single Dose Vaccination in ArgentinaC. Vizzotti 1 , A. Gentile 2 , J. González, Virologist 3 , A. Rearte 1 , M. Ramonet 2 ,M. Cañero V. 2 , M. Pérez C. 1 , A. Urueña 1 , M. Diosque 1 , Argentinean HepatitisA Working Group; 1 Ministerio de Salud de la Nación, Buenos Aires,Argentina, 2 Sociedad Argentina de Pediatría, Buenos Aires, Argentina, 3 INEIANLIS Dr. Carlos Malbrán, Buenos Aires, Argentina.P-1017 Safety of Ferric Carboxymaltose Treatment for ExperimentalMalariaJ. Kirchhoff , L. Maretty, J. A. L. Kurtzhals ; Copenhagen Univ. Hosp.,Copenhagen, Denmark.P-1018 Hydatid Disease in Cantabria (North of Spain)M. Gutiérrez-Cuadra, C. Amado, M. Cimas, C. Armiñanzas, M. C. Fariñas;Univ. Hosp. Marqués de Valdecilla, Santander, Spain.P-1019 5’ Methylthioadenosine Nucleosidase: A Novel Target forAntiparasitic Drug Development in Giardia intestinalis andEntamoeba histolytica InfectionsK. Cornell; Boise State Univ., Boise, ID.P-1020 Mucocutanea Leishmanisis (ml): An Important HealthProblem in all the WorldP. Merino, I. Gestoso, J. Picazo- Chief; Clínico San Carlos Hosp., Madrid,Spain.P-1021 Enhanced Norovirus Surveillance and DetectionCapability with a New Filter Card Sampling Method AboardU.S. Navy VesselsC. T. Coetzer 1 , S. J. Maier 1 , R. D. Hontz 1 , B. Espinosa 2 , N. Gregoricus 3 ,J. Vinje 3 , J. Dejli 1 ; 1 Navy Environmental and Preventive Med. Unit Two,Norfolk, VA, 2 Naval Med. Res. Ctr. BioDefense Res. Directorate, Frederick,3Natl. Calicivirus Lab., CDC, Atlanta, GA.P-1022 Low Serum Albumin in Rickettsial Infections in SouthernIsrael, 2009-2011L. Saidel-Odes, K. Riesenberg, A. Borer, R. Smolyakov, S. Novick,F. Schlaeffer; Soroka Univ. Med. Ctr. and Faculty of Hlth. Sci., Ben GurionUniv. of the Negev, Beer Sheva, Israel.P-1023 Epidemiology and Diagnosis of Meningitis, 2000 to 2009 atMiddlemore Hospital, Auckland, New ZealandS. McBride 1 , J. Fulke 1 , H. Giles 1 , M. Hobbs 2 , V. Sathyendran 2 , E.Thompson 3 , S. Taylor 1 , D. Holland 1 ; 1 Middlemore Hosp., Auckland, NewZealand, 2 Auckland City Hosp., Auckland, New Zealand, 3 North ShoreHosp., Auckland, New Zealand.P-1024 Trends in Colistin Use in 60 Countries, 2000-2010WithdrawnLate-breaker presentations are listed behind the Late-breaker tab of the Final Program.----------------------------------------------------------------------------------113(T)Poster SessionInfections in Transplant Recipients and Patients withMalignanciesMonday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:T-1025 Incidence, Risk Factors and Consequences of Severe NeutropeniaFollowing Orthotopic Liver TransplantationB. Alraddadi 1 , N. E. Nierenberg 1 , L. L. Price 1 , J. K. L. Chow 1 , R. J.Rohrer 1 , D. D. Poutsiaka 1 , J. T. Cooper 1 , R. B. Freeman 2 , D. R. Snydamn 1 ;1Tufts Med. Ctr., Boston, MA, 2 Dartmouth-Hitchcock Med. Ctr., Lebanon,NH.T-1026 A Prospective Study of Fever in Solid Organ TransplantRecipients (FEVERSOT)P. Muñoz 1,2,3 , A. Eworo 1 , I. Ramírez 1 , M. Valerio 1 , A. Burillo 1 , F. Anaya 1 ,M. Salcedo 1 , A. Villa 1 , E. Sarmiento 1 , P. Lopez-Roa 1 , E. Bouza 1,2,3 ,FEVERSOT; 1 H G.U. Gregorio Marañón, Univ. of Madrid, Madrid, Spain,2CIBERES, Madrid, Spain, 3 REIPI, Madrid, Spain.T-1027 Spectrum of Infections in Myeloma Patients Rreated Solelywith Lenalidomide Based Regimens and Autologous Stem CellTransplantationB. W. Teh, K. A. Thursky, R. Sedunary, A. Khot, M. A. Slavin, S. J.Harrison; Sonnenburg MacCallum Cancer Ctr, Melbourne, Australia.T-1028 Feasibility of Very Early Discharge of Febrile Neutropenia(FN) Patients (pts) Selected Using the Mascc Score: A BelgianStudyA. Georgala, A. Loizidou, T. Berghmans , M. Aoun, V. Van Laethem, L.Dubreucq, J. Klastersky, M. Paesmans; Inst. Jules Bordet, Bruxelles, Belgium.T-1029 A Retrospective Review of Clostridium difficile Treatment inAdult and Pediatric Intestinal Transplant PatientsS. N. Nevrekar 1 , L. A. Pote 1 , K. A. Doan 1 , A. P. Shah 2 , R. S. Mangus 2 , R.M. Vianna 2 , A. J. Tector 2 , S. A. Kubal 2 ; 1 Indiana Univ. Hlth., Indianapolis,IN, 2 IU Sch. of Med., Indianapolis, IN.T-1030 Risk Factors and Outcomes of Bacteremia Caused by Drug-Resistant ESKAPE Pathogens in Solid Organ Transplant (SOT)RecipientsM. Bodro 1 , N. Sabé 2 , C. Baliellas 2 , J. Roca 2 , J. Cruzado 2 , J. Carratalà 2 ; 1 IDI-BELL Biomedical Res. Inst., Barcelona, Spain, 2 Hosp. Univ. de Bellvitge,Barcelona, Spain.110September 9-12 |

MONDAY SCIENTIFIC SESSIONST-1031 Refractory KPC Carbapenemase-Producing Klebsiellapneumoniae Bacteremia is Tolerated by Solid Organ TransplantPatients (SOT Pts)C. Clancy 1 , R. K. Shields 2 , Y. Zhao 3 , L. Chen 3 , B. N. Kreiswirth 3 , E. J.Kwak 2 , F. Silveira 2 , K. Abu-Elmagd 2 , G. Costa 2 , M. Nguyen 2 ; 1 Univ. ofPittsburgh and VA Pittsburgh, Pittsburgh, PA, 2 Univ. of Pittsburgh, Pittsburgh,PA, 3 Publ. Hlth. Res. Ins., UMDNJ, Newark, NJ.T-1032 Comparison of Three Methods for Detection of Latent TB inSolid Organ Transplant CandidatesS. Kusne 1 , T. M. Seville 1 , H. R. Vikram 1 , Y. H. Chang 1 , A. E. McCullough 1 ,M. J. Binnicker 2 , J. E. Blair 1 ; 1 Mayo Clinic Arizona, Phoenix, AZ, 2 MayoClinic Rochester, Rochester, MN.T-1033 Prevalence and Epidemiology of Positive QuantiFERONamong Pre-Kidney Transplant RecipientsJ. Simkins, M. I. Morris; Univ. of Miami, Miller Sch. of Med., Miami, FL.T-1034 Epidemiology and Outcomes of Carbapenem-ResistantKlebsiella pneumoniae (CRKP) Bacteriuria in Renal Transplant(RT) RecipientsS. M. Pouch 1,2 , C. J. Kubin 1,2 , D. Tsapepas 1 , G. Dube 2 , M. Pereira 2 ;1NewYork-Presbyterian Hosp., New York, NY, 2 Columbia Univ. Med. Ctr.,New York, NY.T-1035 Extended Spectrum Beta Lactamase-Producing EnterobacteriaceaeAssociated Infections in Kidney Transplant Recipients: ACase-Control StudyE. Righi, M. Giannella, M. L. Balsamo, A. Colombo, D. Donati, A. Curto,N. Astuti, A. Tebini Project Leader, P. A. Grossi; Insubria Univ., Varese, Italy.T-1036 Epidemiology and Antimicrobial Resistance in Urine IsolatesAmong Renal Transplant Recipients Over a 10-Year PeriodC. J. Kubin 1,2 , S. M. Pouch 1 , D. Tsapepas 1 , G. Dube 2 , M. Pereira 2 ; 1 NewYork Presbyterian Hosp., New York, NY, 2 Columbia Univ., New York, NY.T-1037 Clinical and Molecular Epidemiologic Characterization ofMethicillin-Resistant Staphylococcus aureus (MRSA) InfectionsOccurring Early after Lung Transplant (LTx)M. Nguyen 1 , M. Shelton, BA 1 , R. K. Shields 1 , J. Marsh 1 , L. H. Harrison1 , E. J. Kwak 1 , F. Silveira 1 , Y. Toyoda 1 , N. Shigemura 1 , C. Bermudez,M.D. 2 , C. Clancy 2 ; 1 Univ. of Pittsburgh, Pittsburgh, PA, 2 Univ. of Pittsburghand VA Pittsburgh, Pittsburgh, PA.T-1038 Low Incidence of Bacterial Resistance and Mortality in theNew Era of Haematopoietic Stem Cell TransplantationL. Yañez, A. Bermudez, A. Insunza; Hosp. Univ. Marques De Valdecilla,Santander, Spain.T-1039 Vancomycin-Resistant Enterococcus (VRE) Bacteremia inImmunocompromised PatientsY. L. Song, J. I. Ito, B. Tegtmeier, S. S. Dadwal, J. Kriengkauykiat; City ofHope, Duarte, CA.T-1040 Risk Factors for Bacterial Infection After Liver Transplantation:A Retrospective Study in 195 Patients from Four Centers inCentral ItalyL. Tessitore, P. Piselli, M. Giannella, M. Antonini, L. Sollazzi, M. Dauri, F.Pugliese, V. Perilli, M. Polzoni, F. Ruperto, V. Puro, N. Petrosillo 2nd Division,on behalf of the NETWORK group; INMI L. Spallanzani, Rome, Italy.T-1041 Pneumonia after Solid Organ Transplantation: A MulticenterProspective StudyM. Giannella 1 , P. Munoz 1 , J. Martinez Alarcon 2 , P. Grossi 3 , E. Bouza 1 , onbehalf of the PISOT Study Group; 1 Hosp. Gregorio Maranon, Madrid, Spain,2Hosp. de Ciudad Real, Ciudad Real, Spain, 3 Univ. of Insubria, Varese, Italy.T-1042 Opsonophagocytic Activity of Pneumococcal Antibodies inVaccinated Patients with B-Cell MalignanciesJ. Karlsson 1,2 , H. Hogevik 3 , K. Andersson 2 , B. Andréasson 4 , C. Wennerås 2,5 ;1Infectious Diseases, Trollhättan/Uddevalla, Sweden, 2 Clinical Bacteriology,Göteborg, Sweden, 3 Dev., Trollhättan/Uddevalla, Sweden, 4 Hematology/InternalMed., Trollhättan/Uddevalla, Sweden, 5 Hematology and Coagulation,Göteborg, Sweden.T-1043 Incidence and Burden of Infection-Related Hospitalizationsamong Solid-Organ Transplant RecipientsB. Hamandi, A. Morillo, C. Rotstein, L. G. Singer, E. Renner, S. J. Kim, H.Ross, S. Husain; Univ. Hlth. Network, Toronto, Canada.T-1044 Infectious Complications of Central Venous Catheters inPatients Undergoing Hematopoietic Stem Cell TransplantationG. Martinho, R. Romanelli, G. Teixeira, J. Chaia, A. Macedo, W. Trindade ,V. Nobre; Univ. Federal de Minas Gerais, Belo Horizonte, Brazil.T-1045 Current Clinical Features and Outcomes of Early-Onset andLate-Onset Bloodstream Infection (BSI) in Hematopoietic StemCell Transplant (HSCT) RecipientsC. Gudiol 1 , C. Garcia-Vidal 1 , M. Cisnal 1 , M. Arnan 2 , I. Sánchez-Ortega 2 ,R. Duarte 2 , J. Carratalà 1 ; 1 Hosp. Univ. de Bellvitge, Barcelona, Spain, 2 Hosp.Duran i Reynals, Barcelona, Spain.T-1046 Surveillance Cultures (SC) and Microbiological Documentationof “Bad Bugs” Among Hematological Patients (HP) PresentingFebrile Neutropenia (FN)A. Georgala 1 , A. Dediste 2 , M. Paesmans 1 , M. Aoun 1 ; 1 Inst. Jules Bordet,Bruxelles, Belgium, 2 Lab. de la Porte de Hal CHU St Pierre-Inst. JulesBordet, Bruxelles, Belgium.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.Final Program111

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------114(G)Slide SessionVaccines: Innovations, Impact and SafetyMonday, 1:30 p.m.–4:00 p.m. ................... Room 121UAN: 0391-9999-12-086-L04-PModerators:Jan Bonhoeffer, MD - Assistant ProfessorInfectious Disease and Vaccines, Univ. Children’s Hosp., Basel, Switzerland.Penina Haber, MPH - EpidemiologistImmunization safety, CDC, Atlanta, GA.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Highlight new vaccine developments;> Provide updated information on vaccine impact and safety; and> Discuss the impact of newer vaccines.Presentations:1:30 p.m.G-1047 Antibody Persistence and the Effect of a Booster Dose Given5, 10 or 15 Years After Vaccination With a Recombinant HepatitisB VaccineV. Gilca, MD, PhD - Medical Epidemiologist 1,2,3 , N. Boulianne, MS - MedicalEpidemiologist 1,2,3 , M. Dionne, MD - Scientific Director 1,2,3 , P. D. Wals,MD, PhD - Medical Epidemiologist 1,2,3 , G. D. Serres, MD, PhD - MedicalEpidemiologist 1,2,3 ; 1 Quebec Publ. Hlth. Inst., Quebec, Canada, 2 Laval Univ.Res. Hosp. Ctr., Quebec, Canada, 3 Laval Univ., Quebec, Canada.1:45 p.m.G-1048 Safety and Immunogenicity of an Intramuscular BivalentNorovirus VLP VaccineJ. J. Treanor, MD - Prof Med 1 , S. E. Frey, MD - Prof Med 2 , R. Gormley,MD, PhD - Investigator 3 , R. L. Atmar, MD - Prof Med 4 , D. Topham,PhD - Prof Microbiol Immunol 1 , W. Chen, MD - Assist Prof Med 5 , J.Ferreira, ScM - Biostatistician 6 , R. Bargatze, PhD - CSO 7 , C. Richardson,PhD - VP R&D 8 , P. Mendelman, MD - CMO 8 ; 1 Univ. of Rochester,Rochester, NY, 2 St. Louis Univ. Sch. of Med., St. Louis, MO, 3 Navy Med.Res. Ctr., Silver Springs, MD, 4 Baylor Coll. of Med., Houston, TX, 5 Univ. ofMaryland Sch. of Med., Baltimore, MD, 6 Emmes Corporatiopn, Rockville,MD, 7 Ligocyte Pharmceuticals, Bozeman, MT, 8 Ligocyte Pharmaceuticals,Bozeman, MT.2:00 p.m.G-1049 Nasopharyngeal Carriage in Healthy Children Before andAfter 13-valent Pneumococcal Conjugate Vaccine ImplementationR. Cohen, MD - Pediatric Infectious Disease Specialist, Scientific Directorof a Research Institute on Pediatric Community-Acquired Infections(ACTIV) 1 , C. Levy, MD - Research MD 1 , E. Bingen, PhD - ProfessorMicrobiology 2 , S. Béchet, MSc - Biostatistician 1 , C. Bensoussan-Ambacher,MD - Pediatrician 3 , F. Corrard, MD - Pediatrician 1 , E. Varon, MD - Microbiologist4 ; 1 Activ, Saint Maur des Fossés, France, 2 Denis Diderot Univ.,Paris, France, 3 AFPA, Vence, France, 4 CNRP APHP, Paris, France.2:15 p.m.G-1050 Rapid Reduction in the Incidence of Culture-Positive NonsusceptibleStreptococcus pneumoniae (NSSP) Otitis Media (AOM)Following Introduction of Pneumococcal Conjugate Vaccines(PCVs) in Southern IsraelR. Dagan, MD - Professor, N. Givon-Lavi, PhD - Lecturer, E. Leibovitz,MD - Professor, S. Raiz, MD - Doctor, D. Greenberg, MD - Professor; Ben-Gurion Univ. of the Negev and Soroka Univ. Med. Ctr., Beer-Sheva, Israel.2:30 p.m.G-1051 Promoting Vaccination at Birth Improves Vaccination CoverageA. Gagneur, MD, PhD - Professor 1 , A. Farrands, Msc - Research Assistant 2 ,T. Lemaitre, Msc - Research Assistant 2 , G. Petit, MD, PhD - Professor 1 ;1Univ. of Sherbrooke, Sherbrooke, Canada, 2 Clinical Res. Ctr. CHU Sherbrooke,Sherbrooke, Canada.2:45 p.m.G-1052 Safety of Live Attenuated Influenza Vaccine in Adults: U.S.,Vaccine Adverse Event Reporting System (VAERS)P. Haber, MPH - Epidemilogist, P. Moro, MD - Medical Epidemilogist,K. Broder, MD - Medical Epidemilogist, P. Lewis, MSPH - Statistician, C.Vellozzi, MD, MPH - Medical Epidemilogist; CDC, Atlanta, GA.3:00 p.m.G-1053 Safety and Immunogenicity of a Recombinant Hemagglutinin(rHA) Pandemic H5N1 Influenza VaccineJ. J. Treanor, MD - Professor of Medicine 1 , R. Izikson, MD - Manager,Clinical Studies 2 , L. Dunkle, MD - Chief Medical Officer 3 , P. Patriarca,MD - Senior Consultant 4 , K. Goldenthal, MD - Consultant 5 , M. M. J. Cox,PhD - President and CEO 6 ; 1 Univ. of Rochester, Rochester, NY, 2 ProteinSci. Corp., Meriden, CT, 3 Protein Sci. Corp, Meriden, CT, 4 Biologics ConsultingGroup, Bethesda, MD, 5 Bethesda, MD, 6 Protein Sci., Meriden, CT.3:15 p.m.G-1054 Exposure to Antibody-Stimulating Proteins and Polysaccharidesin Vaccines and Risk of AutismF. DeStefano, MD - Medical Officer 1 , C. S. Price, MS - Statisticians 2 , E. S.Weintraub, MPH - Statistician 1 ; 1 CDC, Atlanta, GA, 2 Abt Associates Inc.,Bethesda, MD.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------115(M)Slide SessionSleuthing in MycologyMonday, 1:30 p.m.–4:00 p.m. ...... Esplanade Ballroom 310UAN: 0391-9999-12-087-L04-PModerators:John Perfect, MD - Interim ChiefDuke Univ. Med. Ctr., Durham, NC.Michail Lionakis, MD, ScD - Assistant Clinical InvestigatorNIAID, NIH, Bethesda, MD.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Discuss mechanisms of drug resistance;> Identify host and fungal responses to disease; and> Describe the impact of environment on fungal infections.112September 9-12 |

MONDAY SCIENTIFIC SESSIONSPresentations:1:30 p.m.M-1055 Cx3cr1 is Important for Host Defense against InvasiveCandidiasis (IC) in Mice and HumansM. S. Lionakis, MD - Assistant Clinical Investigator 1 , M. Swamydas,PhD - Research Associate 1 , B. G. Fischer, BS - Student 1 , T. Plantinga, PhD- Postdoc 2 , M. Jaeger, BS - Student 2 , M. D. Johnson, PharmD - AssistantProfessor 3 , J. R. Perfect, MD - Professor 3 , B. D. Alexander, MD - AssociateProfessor 3 , B. Kullberg, MD - Professor 2 , M. Netea, MD - Professor 2 , P. M.Murphy, MD - Chief 1 ; 1 NIH, Bethesda, MD, 2 Radboud Univ., Nijmegen,Netherlands, 3 Duke, Durham, NC.1:45 p.m.M-1056 Nanostring Analysis of Candida albicans Gene ExpressionDuring Intra-Abdominal Candidiasis (IAC) Provides Insightsinto Pathogenesis and Reveals Rewiring of Regulatory PathwaysS. Cheng, MD - Research Associate Professor 1 , C. Clancy, MD - AssociateProfessor 1 , A. P. Mitchell, PhD - Professor 2 , W. Xu, PhD - Fellow 1 , S.Fanning, PhD - Fellow 2 , N. Solis, MS - Research Associate 3 , S. Filler, MD- Professor 3 , M. Nguyen, MD - Professor 1 ; 1 Univ. of Pittsburgh, Pittsburgh,PA, 2 Carnegie Mellon Univ., Pittsburgh, PA, 3 UCLA, Los Angeles, CA.2:00 p.m.M-1057 Conditional Expression of Cell Wall Polysaccharide-EncodingGenes in C. albicans and A. fumigatus Reproduces ImmunopharmacologicEffects of Caspofungin and Nikkomycin Z ExposureR. E. Lewis, Pharm.D. - Professor 1 , G. Liao, PhD - Research Assistant 1 , K.Young, MS - Researcher 2 , C. M. Douglas, PhD - Researcher 2 , D. P. Kontoyiannis,M.D. - Professor 3 ; 1 Univ. of Houston Coll. of Pharmacy, Houston,TX, 2 Merck & Co, Kenilworth, NJ, 3 The Univ. of Texas M.D. AndersonCancer Ctr., Houston, TX.2:15 p.m.M-1058 Anidulafungin (ANF) Compared to Caspofungin (CAS) ina Non-Neutropenic Mouse Model of Invasive Candidiasis (IC)Caused by ANF-Susceptible (S) C. parapsilosis (C.p) Isolates withDifferent Degrees of In Vitro Non-Susceptibility (NS) to CAS:MIC Does Not Tell the Whole StoryD. Dimopoulou, MD - Research Fellow 1 , G. Hamilos, MD - AttendingPhysician 1 , G. Samonis, MD - Professor 1 , D. P. Kontoyiannis, MD, ScD,FACP - Professor 2 ; 1 Univ. Hosp. of Heraklion, Heraklion,Crete, Greece,2The Univ. of Texas MD Anderson Cancer Ctr., Houston, TX.2:30 p.m.M-1059 Candida glabrata Heteroresistance to Fluconazole is Associatedwith Aneuploidy and Chromosomal Translocations Involvingthe PDH1 GeneO. Zimmerman, MD- Physician 1 , A. Novikov, BSc - Research Assistant 1 ,T. Finn, MD- Physician 1 , Y. Paran, MD- Physician 1 , N. Osherov, PhD -Researcher 2 , R. Ben-Ami, MD- Physician 1 ; 1 Tel Aviv Sourasky Med. Ctr.,Tel Aviv, Israel, 2 Tel Aviv Univ., Tel Aviv, Israel.2:45 p.m.M-1060 Breath Volatile Organic Compound (VOC) Profiles for theDiagnosis of Invasive Aspergillosis (IA)S. Koo, MD - Physician 1,2 , H. R. Thomas, AB - Res Asst 1 , P. Rearden,PhD - Staff 3 , J. Comolli, PhD - Staff 3 , L. R. Baden, MD - Physician 1,2 , F.M. Marty, MD - Physician 1,2 ; 1 Brigham and Women’s Hosp., Boston, MA,2Harvard Med. Sch., Boston, MA, 3 Draper Lab., Cambridge, MA.3:00 p.m.M-1061 A Non-Echinocandin Compound Isolated from a MarineSponge Mediates its Antifungal Activity by Targeting the FungalCell WallS. Tripathi, PhD - Postdoctoral Associate, T. Xu, PhD - Postdoctoral Associate,Q. Feng, MS - Senior R & D Biologist, M. Jacob, PhD - ResearchScientist, W. Xu, PhD - Postdoctoral Associate, X. Li, PhD - Senior Scientist,A. Clark, PhD - Professor, A. Agarwal, PhD - Senior Scientist; Univ. ofMississippi, University, MS.3:15 p.m.M-1062 Unmasking the Contribution of Oral Mycobiome to theBiofilm Accretion-Endotrach Occlusion During MechanicalVentilation Using 18S DetectionM. Ghannoum, PhD - Professor 1 , C. Waters, MS - Lead Tech 2 , H. Motlagh,MPH - Research Associate 2 , A. Wilson, MD - Director 2 , J. Thomas,PhD - Professor 2 ; 1 Case Western Reserve, Cleveland, OH, 2 West VirginiaUniv., Morgantown, WV.3:30 p.m.M-1063 Neurological Disease After Mold Exposure, Immune Risks& Response to Biofilm-Focused Antifungal TherapyJ. F. Rini, MS, I. H. Grant, MD- Clinical Assistant Professor, Departmentof Family and Community Medicine; New York Med. Coll., Valhalla, NY.------------------------------------------------------------------------116(T)Slide SessionInfections in Transplant RecipientsMonday, 1:30 p.m.–4:00 p.m. ................... Room 120UAN: 0391-9999-12-088-L04-PModerators:Emily Blumberg, MD - Professor of MedicineUniv. of Pennsylvania, Philadelphia, PA.Shahid Husain, MD - Associate Professor of Medicine, Director of TransplantInfectious DiseasesUniv. of Toronto, Toronto, Canada.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Identify the impact of respiratory viruses on transplant recipient;> Review newer diagnostic strategies for diagnosing post-transplant infections;and> Recognize the impact of CMV on post-transplant outcome.Presentations:1:30 p.m.T-1064 Incidence of Viral Infections in Patients with Lung TransplantationP. Bridevaux, MD, MS - Dr 1 , J. Aubert, MD - Professor 2 , G. Wagner, RN- Research assistant 1 , L. Kaiser, MD - Professor 1 ; 1 Univ. Hosp. of Geneva,Geneva, Switzerland, 2 Ctr. Hosp. Univ. Vaudois, Lausanne, Switzerland.Final Program113

Monday SCIENTIFIC SESSIONS1:45 p.m.T-1065 Bronchiolitis obliterans following Respiratory Viral Infectionsin Allogeneic Hematopoietic Stem Cell Transplant RecipientsD. P. Shah, MD, MSPH - Pre-Doctoral Fellow, A. M. Alousi, MD - AssistantProfessor, L. Bashoura, MD - Associate Professor, P. K. Shah, MD,MSPH - Research Assistant, S. Mahajan, MD - Graduate Research Assistant,V. E. Mulanovich, MD - Assistant Professor, E. Ariza-Heredia, MD -Assistant Professor, R. F. Chemaly, MD, MPH, FACP - Associate Professor;MD Anderson Cancer Ctr., Houston, TX.2:00 p.m.T-1066 Histoplasmosis Following Solid Organ TransplantationM. A. Assi, MD - Clinical Associate Professor 1 , S. I. Martin, MD - AssistantProfessor 2 , D. R. Kaul, MD - Associate Professor 3 , M. S. Sandid, MD- Clinical Associate Professor 1 , L. J. Wheat, MD - President and Director 4 ;1Univ. of Kansas, Wichita, KS, 2 Ohio State Univ., Columbus, OH, 3 Univ. ofMichigan, Ann Arbor, MI, 4 MiraVista Diagnostics, Indianapolis, IN.2:15 p.m.T-1067 Utility of BAL Galactomannan (GM) and Culture Based Pre-Emptive Antifungal Therapy (PET) Strategy in Lung TransplantRecipients (LTRs)S. Husain, MD - Associate Professor of Medicine, L. Singer, MD - MedicalDirector, Toronto Lung Transplant Program, Y. Akinlolu, MSc - ClinicalResearch Coordinator, C. Chaparro, MD - Assistant Professor of Medicine,C. Rotstein, MD - Professor of Medicine, S. Keshavjee, MD - Director,Lung Transplant Program; Univ. Hlth. Network, Toronto, Canada.2:30 p.m.T-1068 Recurrent Clostridium difficile Infections (CDI) in SolidOrgan Transplant (SOT) RecipientsM. A. Yu, PharmD - Pharmacist, S. T. Walk, PhD - Research Investigator,M. Tupps, PharmD - Pharmacist, C. Ring, MS - Research Coord, T. Horwedel,PharmD - Pharmacist, D. M. Aronoff, MD - Physician, J. L. Nagel,PharmD - Pharmacist; Univ. of Michigan Hlth. System, Ann Arbor, MI.2:45 p.m.T-1069 Methicillin-Resistant S. aureus (MRSA) Screening andDecolonization is Highly Cost-Effective Among Lung TransplantRecipients (LTR) in a Simulation ModelC. Clancy, MD - Associate Professor 1 , R. K. Shields, PharmD - Professor 2 ,S. Bartsch, MS - Research Associate 2 , B. Lee, MD - Assistant Professor 2 , M.Nguyen, MD - Professor 1 ; 1 Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh,PA, 2 Univ. of Pittsburgh, Pittsburgh, PA.3:00 p.m.T-1070 An International Multicenter Performance Analysis of CMVViral Load TestsH. Hirsch, MD, MS, FAMH - Professor 1 , I. Lautenschlager, MD, PhD -Director 2 , B. A. Pinsky, MD, PhD - Director 3 , L. Cardeñoso, MD -Professor 4 , S. Aslam, BS - Research Biostatistician 5 , B. Cobb, PhD,FACMG - Director 5 , R. Vilchez, MD, PhD - Director 5 , A. Valsamakis,MD, PhD - Professor 6 ; 1 Univ. of Basel, Basel, Switzerland, 2 Helsinki Univ.Hosp., Univ. of Helsinki, Helsinki, Finland, 3 Stanford Univ., Palo Alto, CA,4Hosp. Univ. de la Princesa, Madrid, Spain, 5 Roche Molecular Systems, Inc.,Pleasanton, CA, 6 John Hopkins Univ., Baltimore, MD.3:15 p.m.T-1071 Influence of Cytomegalovirus (CMV) Disease in the Developmentof Cardiac Allograft Vasculopathy (CAV) in HeartTransplants Recipients (HTR) through the Application of theNew ISHLT (International Society of Heart Transplantation)Coronary Angiographic CriteriaA. García-Reyne, MD, PhD - Research Assistant, S. de Dios, MD - ResearchAssistant, A. Jurado, MD - Research Assistant, F. López-Medrano,MD, PhD - Research Assistant, R. San-Juan, MD, PhD - Research Assistant,M. Fernández-Ruiz, MD - Research Assistant, J. Origüen, MD -Research Assistant, M. Lizasoain, MD - Research Assistant, J. Aguado, MDPhD - Professor, J. Delgado, MD, PhD - Research Assistant, C. Lumbreras,MD, PhD - Research Assistant; Univ. Hosp. 12 Octubre, Madrid, Spain.3:30 p.m.T-1072 The Time Course of Development and Impact from ViralResistance against Ganciclovir in Cytomegalovirus InfectionComplicating Course after TransplantationC. D. Cunha-Bang, MD - Clinical Research Associate 1 , N. Kirkby, PhD- Consultant 2 , M. Sønderholm, MS - Research Assistant 1 , S. S. Sørensen,MD - Consultant 2 , H. Sengeløv, MD - Consultant 2 , M. Iversen, MD- Consultant 2 , A. Rasmussen, MD - Consultant 2 , F. Gustafson, MD -Consultant 2 , C. Frederiksen, PhD - Bioinformatic Scientist 1 , J. Kjær, MSc- IT Manager 1 , A. C. Lepri, PhD - Senior Lecturer 1 , J. D. Lundgren, MD- Professor 1 ; 1 Copenhagen HIV Programme, Copenhagen N, Denmark,2Rigshospitalet, Copenhagen N, Denmark.------------------------------------------------------------------------117(V)Slide SessionRespiratory Viruses and MeaslesMonday, 1:30 p.m.–4:00 p.m. ...... Esplanade Ballroom 309UAN: 0391-9999-12-089-L04-PModerators:Laurent Kaiser, MD - Professor, Head of the Laboratory of Clinical UrologyUniv. Hosp. of Geneva, Geneva, Switzerland.Guy Boivin, MDMicrobiology, Laval Univ., Sainte-Foy, Canada.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Evaluate incidence and impact of antiviral resistance of influenzainfection;> Identify which viruses are associated with pneumonia requiring ICUadmission; and> Review characteristics of current measles outbreak.Presentations:1:30 p.m.V-1073 Measles Outbreak in a University Hospital in ParisM. Caseris, MD- Doctor, N. Houhou, MD- Doctor, P. Longuet, MD-Doctor, R. Lepeule, MD- Doctor, C. Rioux, MD- Doctor, C. Choquet,MDD - Doctor, Y. Yazdanpanah, MD, PhD - Professor, P. Yeni, MD, PhD -Professor, V. Joly, MD- Doctor; CHU Bichat Claude Bernard, Paris, France.114September 9-12 |

MONDAY SCIENTIFIC SESSIONS1:45 p.m.V-1074 Viral Infection in Adult Patients with Severe Hospital-Acquired Pneumonia Requiring Intensive Care Unit AdmissionH. Hong, MD- Fellow 1 , Y. Lee, MD- Fellow 1 , S. Park, MD- Fellow 1 , S.Moon, MD- Fellow 1 , S. Park, MD- Professor 2 , O. Cho, MD- Professor 3 , S.Kim, MD- Professor 1 , H. Sung, MD- Professor 1 , S. Lee, MD- Professor 1 ,Y. Kim, MD- Professor 1 , J. Woo, MD- Professor 1 , S. Choi, MD- Professor1; 1 Asan Med. Ctr., Univ. of Ulsan Coll. of Med., Seoul, Korea, Republic of,2Dongguk Univ. Ilsan Hosp., Goyang, Korea, Republic of, 3 Gyeongsang Natl.Univ. Hosp., Jinju, Korea, Republic of.2:00 p.m.V-1075 Impact of RSV Infection in Patients with Lymphoma orMultiple Myeloma (MM): A Single Center StudyS. N. Mahajan, MD - Research Assistant 1 , S. S. Ghantoji, MD,M.P.H.- Research Assistant, D. J. Shah, MD, MPH. - Research Assistant, V. E.Mulanovich, M.D. - Assistant Professor, E. Ariza Heredia, MD - AssistantProfessor , R. F. Chemaly, MD, MPH, FACP - Associate Professor; M DAnderson Cancer Ctr., Houston, TX.2:15 p.m.V-1076 Four-Year Prospective Evaluation of Host and Viral FactorsAffecting Clinical Performance of a Rapid RSV Test in HospitalisedChildrenJ. Papenburg, MD - Graduate Student 1 , D. Buckeridge, MD - Professor 1 ,M. Ouakki, MSc - Statistician 2 , G. De Serres, MD - Professor 2 , G. Boivin,MD - Professor 2 ; 1 McGill Univ., Montreal, Canada, 2 Univ. Laval, Quebec,Canada.2:30 p.m.V-1077 Design of a Broadly Neutralizing Antibody TargetingInfluenza AZ. H. Shriver, PhD- Vice President, Research, K. Viswanathan, PhD -Principal Scientist; Visterra, Inc., Cambridge, MA.2:45 p.m.V-1078 Effects of Antiviral Treatment on Influenza-AssociatedComplications During the 2009-2010 Pandemic SeasonP. Spagnuolo 1 , M. Zhang 2 , S. Liu 2 , J. Liu 2 , Y. Xu 3 , J. Han 3 , L. Shi 2 ; 1 CaseWestern Reserve Univ., Cleveland, OH, 2 Tulane Univ., New Orleans, LA,3Genentech, Inc., South San Francisco, CA.3:00 p.m.V-1079 Evaluation of Pandemic Influenza A/H1N1 Virus MutationsConferring Resistance to ZanamivirM. A. Pizzorno, MS - PhD Candidate, Y. Abed, PhD - Professor, X. Bouhy,Technician - Technician, G. Boivin, MD, MS - Professor; Laval Univ. andCHUQ, Quebec, Canada.3:15 p.m.V-1080 Lack of Emergent Resistance to Oseltamivir Despite AntiviralEfficacy in Type B Influenza Patients in the First 3 Years of theInfluenza Resistance Information Study (IRIS)M. Schutten, C. Boucher 1 , R. Dutkowski 2 , K. Klumpp 2 , B. Lina 3 , A. Monto 4 ,A. Nist 2 , A. Osterhaus 1 , J. Nguyen-Van-Tam 5 , X. Tong 2 , R. J. Whitley 6 ;1Erasmus MC, Rotterdam, Netherlands, 2 Hoffmann-La Roche, Inc., Nutley,NJ, 3 Univ. of Lyon, Lyon, France, 4 Univ. of Michigan Sch. of Publ. Health,Ann Arbor, MI, 5 Univ. of Nottingham, Nottingham, United Kingdom, 6 Univ.of Alabama at Birmingham, AL.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------118(K)Interactive SymposiumEvidence-Based Infection Prevention and Control:Answering Key QuestionsMonday, 2:00 p.m.–4:00 p.m. ................... Room 104UAN: 0391-9999-12-090-L04-PConveners:Didier Pittet, MD - Professor of Medicine; Director, Infection ControlProgramme and WHO Collaborating Centre on Patient SafetyUniv. of Geneva Hosp., Geneva, Switzerland.John Conly, MD - Professor of Medicine, Microbiology, Immunology andInfectious DiseasesUniv. of Calgary, Calgary, Canada.Speakers:2:00 p.m.1081-1082 Effective Infection Prevention and Control Measures inEurope: An EU-Sponsored Meta-AnalysisAlison Holmes, MD, MPH - ProfessorImperial Coll., London, United Kingdom.Walter Zingg, MD - Senior RegistrarUniv. of Geneva Hosp. and Faculty of Med., Geneva, Switzerland.2:30 p.m.1083 Isolation for Respiratory Viruses: The Cochrane SystematicReview and OthersKlara M. Posfay-Barbe, MD - Head of Pediatric Infectious DiseasesUniv. of Geneva Hosp., Children’s Hosp. of Geneva, Geneva, Switzerland.3:00 p.m.1084 Aerosol-Generating Procedures: A Systematic ReviewJohn Conly, MD - Professor of Medicine, Microbiology, Immunology andInfectious DiseasesUniv. of Calgary, Calgary, Canada.3:30 p.m.1085 The Role of Environmental Disinfection: A Systematic ReviewWing Hong Seto, MD - Director, WHO Collaborating Centre for InfectionControlHosp. Authority, Hong Kong, China.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify the evidence base to determine which host, viral, or environmentalcharacteristics increase or decrease the risk of infection in healthcaresettings;> Analyze the efficacy of evidence-based management strategies used forkey healthcare-associated infection outbreaks;> Review evidence-based changes in the epidemiology of key outbreaks; and> Summarize lessons learned from key outbreaks and their direct impact oninfection control practices today.Intended Audience: Infection control physicians, infection control professionals,clinical laboratory personnel, microbiologists, and hospital epidemiologists.Level: Beginning/IntermediateFinal Program115

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------119(P)Interactive SymposiumClinical Problem Solving: Interactive Cases in Traveland Tropical MedicineMonday, 2:00 p.m.– 4:00 p.m. ................... Room 103UAN: 0391-9999-12-091-L04-PDeveloped in Cooperation with the American Society of Tropical Medicine andHygiene (ASTMH)Conveners:Kevin Kain, MD - Professor of MedicineUniv. of Toronto, Toronto, Canada.Alan J. Magill, MD - Program ManagerDefense Sci. Office (DSO), Defense Advanced Res. Programs Agency(DARPA), Arlington, VA.Speakers:2:00 p.m.Management Principles in NeurocyticercosisChristina M. Coyle, MD, MS - Professor of Clinical MedicineAlbert Einstein Coll. of Med., Bronx, NY.2:40 p.m.1086 Tropical DermatologyScott A. Norton, MD, MPH - Chief of DermatologyChildren’s Natl. Med. Ctr., Washington, DC.3:20 p.m.1087 Immigrants and VFRsRogelio López-Vélez, MD, DTM&H, PhD - Head Tropical MedicineRamón y Cajal Hosp., Madrid, Spain.Objectives: Upon completion of this Interactive Symposium Session, theparticipant should be able to:> Cite some of the latest significant literature of travelers medicine, parasitology,and tropical medicine;> Discuss the epidemiology of travelers’ illnesses; and> Identify issues in management and prevention of these illnesses.Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists,and general physicians.Level: Intermediate------------------------------------------------------------------------120SymposiumICAAC LiveMonday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 303ICAAC Live is a talk show that explores topics in infectious disease in acasual discussion format. Hosts Vincent Racaniello and Michael Schmidtwill be joined by William Bishai, John Brownstein, and Victor Nizet. We’lldiscuss the regulation of virulence factors in the pathogenesis of tuberculosis,the emerging role of social media in public health, and outside-the-boxapproaches to antibacterial therapy, such as targeting virulence factors orboosting innate immune function, with Streptococci and Staphylococci asthe primary models. The conversational style of ICAAC Live promotes easylearning without the distraction of visual presentations.Upon completion of this Symposium Session, the participant should be ableto:> Understand how social media tools such as HealthMap are playingincreasingly important roles in public health;> Identify how the expression of tuberculosis virulence factors is regulatedand how this impacts virulence; and> Become familiar with new approaches to antibacterial therapy that targetvirulence factors or boost innate immune function.Intended Audience: Clinician scientists or basic scientists involved inresearch on antimicrobial therapy or microbial virulence and epidemiologistsand public health officials.Course Level: IntermediateConveners:Vincent Racaniello, PhDColumbia Univ. Coll. of Physicians & Surgeons, New York, NY.Michael G. Schmidt, PhDMed. Univ. of South Carolina, Charleston, SC.Panelists:1087a John Brownstein, PhD - Associate ProfessorChildren’s Hosp. Boston & Harvard Med. Sch., Boston, MA.1087b William Bishai, MD, PhD - Director of K-RITHKwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV (K-RITH) and JohnsHopkins Ctr. for Tuberculosis Res., Durban, South Africa.1087c Victor Nizet, MD - ProfessorUniv. of California, San Diego Sch. of Med. and Skaggs Sch. of Pharmacy &Pharmaceutical Sci., La Jolla, CA.116September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------121(A)SymposiumAerosol Drug Delivery: Getting Anti-Infective Agentsto the LungMonday, 2:00 p.m.– 4:00 p.m. ................... Room 130UAN: 0391-9999-12-092-L04-PDeveloped in Cooperation with the Society of Infectious Diseases Pharmacists (SIDP)Conveners:Michael Dudley, PharmD - Senior Vice President of R&D and ChiefScientific OfficerRempex Pharmaceuticals, San Diego, CA.Larry H. Danziger, PharmD - Professor of Pharmacy and Professor ofPharmacy in MedicineUniv. of Illinois, Coll. of Pharmacy and Med., Chicago, IL.Speakers:2:00 p.m.1088 Considerations for Aerosol Delivery of Anti-Infective AgentsDavid E. Geller, MD - Associate ProfessorFlorida State Univ., Orlando, FL.2:30 p.m.1089 Pharmacokinetic/Pharmacodynamic Issues of Aerosol Anti-Infective AgentsMichael Dudley, PharmD - Senior Vice President of R&D and ChiefScientific OfficerRempex Pharmaceuticals, San Diego, CA.3:00 p.m.1090 Aerosolized Anti-Infective Agents for Cystic FibrosisPatrick A. Flume, MD - ProfessorMed. Univ. of South Carolina, Charleston, SC.3:30 p.m.1091 Ventilator-Associated Pneumonia: Can Aerosol Drug DeliveryHelp?Jean Chastre, MD - ProfessorUniv. Sch. of Med., Paris 6, Groupe Hosp. Pitié-Salpêtriére, Paris, France.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Recognize the advantages and disadvantages of devices used for aerosoldelivery of anti-infective agents;> Describe the pharmacokinetic/pharmacodynamic issues associated withaerosol delivery of drugs; and> Evaluate the role of aerosolized anti-infective agents in patients withpneumonia and cystic fibrosis.Intended Audience: Physicians, pharmacists, and microbiologists.Level: Intermediate------------------------------------------------------------------------122(B)SymposiumBacterial and Viral Infections in Patients Treated withNovel Biologic Agents: What Do I Need to Know?Monday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 300UAN: 0391-9999-12-093-L04-PConveners:Henry Masur, MDNIH, Bethesda, MD.Leonard H. Calarese, DO - ProfessorCleveland Clinic Lerner Coll. of Med., Cleveland, OH.Speakers:2:00 p.m.1092 Opportunistic Infections in Patients Treated with Anti-TNF AgentsDeborah Symmons, MD FFPH FRCP - ProfessorUniv. of Manchester, Manchester, United Kingdom.2:40 p.m.1093 Infections Associated with Non-Anti-TNF Biologic AgentsKathryn Dao, MD - Associate Director of Clinical RheumatologyBaylor Res. Inst., Dallas, TX.3:20 p.m.1094 Viral Infections (HBV, HCV, PML) and Biologic AgentsLeonard H. Calabrese, DO - ProfessorCleveland Clinic Lerner Coll. of Med., Cleveland, OH.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the mechanism of action of biologic therapies approved for thetreatment of rheumatologic, gastrointestinal, and dermatologic disease;> Assess the spectrum and risk of opportunistic infections in patientstreated with anti-TNF and non-anti-TNF biologic agents; and> Describe the effect of biologic agents on viral infections, including HBV,HCV, PML.Intended Audience: ID fellows, ID practitioners, pharmacists, immunologistsand basic researchers in immunology, virology, microbiology andmycology.Level: Intermediate/AdvancedFinal Program117

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------123(C2)SymposiumAntibiotic Combinations against Gram-Negatives inthe XDR Era: From Bench to BedsideMonday, 2:00 p.m.– 4:00 p.m. ................... Room 122UAN: 0391-9999-12-094-L04-PDeveloped in Cooperation with the European Society of Clinical Microbiologyand Infectious Diseases (ESCMID)Conveners:Jesús Rodríguez-Baño, MD, PhD - ProfessorHosp. Universitario Virgen Macarena and Univ. of Seville, Seville, Spain.Johann D. Pitout, MD - ProfessorUniv. of Calgary, Calgary, Canada.Speakers:2:00 p.m.1095 Truths and Half Truths About In Vitro Synergy against Gram-NegativesShawn Aaron, MD - ProfessorThe Ottawa Hosp. Res. Inst., Univ. of Ottawa, Ottawa, Canada.2:40 p.m.1096 Animal Modeling for Combined Therapy for Gram-NegativeInfections: A Critical AppraisalVincent H. Tam, PharmD - Associate ProfessorUniv. of Houston Coll. of Pharmacy, Houston, TX.3:20 p.m.1097 Combination Antibiotics and Outcome of Life-ThreateningBacterial Infections and Septic ShockAnand Kumar, MD - Associate ProfessorUniv. of Manitoba, Hlth. Sci. Ctr., Winnipeg, Canada.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Recommend when in vitro synergy-testing of antimicrobial agents isindicated for gram- negatives;> Examine the role of animal modeling for combination therapy for gramnegative infections; and> Describe if the combination of active antibiotics influences the outcome ofinfections due to multi-resistant gram-negative bacteria.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, clinical pathologists, medical technologists,and epidemiologists.Level: Intermediate------------------------------------------------------------------------124(D)SymposiumEpidemiology and Diagnosis of Febrile Illness in theEra of Global Climate ChangeMonday, 2:00 p.m.– 4:00 p.m. ................... Room 102UAN: 0391-9999-12-095-L04-PConveners:Megan E. Reller, MD, PhD, MPH - Assistant Professor of PathologyThe Johns Hopkins Univ. Sch. of Med., Baltimore, MD.Delia Enria, MD, MPH - DirectorInst. Nacional de Enfermedades Virales Humanas, Pergamino, Argentina.Speakers:2:00 p.m.1098 Do We Have Good Data on Dengue?Delia A. Enria, MD, MPH - DirectorInstituto Nacional de Enfermedades Virales Humanas, Pergamino, Argentina.2:20 p.m.1099 Challenges for the Detection of Malaria Infections in BothEndemic and Non-Endemic Countries at a Time of ChangingWeather PatternsColin J. Sutherland, PhD, MPH - Reader in ParasitologyLondon Sch. of Hygiene and Tropical Med., London, United Kingdom.2:40 p.m.1100 LeptospirosisAlbert I. Ko, MD - Associate Professor of Epidemiology and MedicineYale Sch. of Publ. Health, New Haven, CT.3:00 p.m.1101 Rickettsial and Ehrlichial InfectionsMegan E. Reller, MD, PhD - Assistant Professor of PathologyThe Johns Hopkins Univ. Sch. of Med., Baltimore, MD.3:40 p.m.1102 Therapeutic Targets for Chikungunya VirusMark Heise, PhD - Associate ProfessorUniv. of North Carolina, Chapel Hill, NC.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the global reach of dengue, malaria, rickettsial diseases, Chikungunyavirus and leptospirosis;> Recognize the clinical manifestations of each of the etiologies of febrileillness that are discussed; and> Assess the progress and limitations of diagnostic tests for each infectionor syndrome.Intended Audience: Infectious Diseases specialists, Microbiologists,Epidemiologists, and VirologistsLevel: Intermediate118September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------125(F)SymposiumAlternative Approaches to Inhibiting Gram-NegativeBacteriaMonday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 308UAN: 0391-9999-12-096-L04-PConveners:Malcolm G. P. Page, PhD - ProfessorBasilea Pharmaceutica, Basel, Switzerland.Donald Moir, PhD - Chief Scientific OfficerMicrobiotix, Inc., Worcester, MA.Speakers:2:00 p.m.1103 Small Molecule Inhibitors of Type III SecretionDonald Moir, PhD - Chief Scientific OfficerMicrobiotix, Inc., Worcester, MA.2:30 p.m.1104 SASP Delivery to Pseudomonas aeruginosaHeather Fairhead, PhD - CEOPhico Therapeutics Ltd., Cambridge, United Kingdom.3:00 p.m.1105 Alginate Oligosaccharides: OligoG for the Treatment ofBiofilmsEdvar J. Onsoyen, MSc, PhD - Chief Scientific Officer, R&D DirectorAlgiPharma AS, Sandvika, Norway.3:30 p.m.1106 From the Natural Antibiotic Protegrin to the ClinicalCandidate POL7080Glenn E. Dale, PhD - Head of Pre-Clinical DevelopmentPolyphor AG, Basel, Switzerland.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the important problems in treating infections caused by gramnegativebacterial pathogens;> Discuss the gaps in the antimicrobial spectrum of currently availabletherapeutic agents and the limitations of conventional drug discoveryapproaches; and> Identify and distinguish new approaches to the discovery of novel agentsacting against difficult to treat gram-negative bacteria.Intended Audience: Microbiologists working in academia and in thepharmaceutical industry.Level: Intermediate------------------------------------------------------------------------126(H)SymposiumCurrent Issues in HIV-Associated OpportunisticDiseasesMonday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 306UAN: 0391-9999-12-097-L02-PConveners:Jean-Michel G. Molina, MD - ProfessorSaint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, France.Richard E. Chaisson, MD - ProfessorJohn Hopkins Univ. Ctr. for Tuberculosis Res., Baltimore, MD.Speakers:2:00 p.m.1107 Diagnosis and Management of Castleman DiseaseEric Oksenhendler, MD - ProfessorUniv. of Paris Diderot, Paris, France.2:30 p.m.1108 Use of Antiretrovirals in Patients with Cryptococcal MeningitisDavid R. Boulware, MD, MPH - Distinguished Assistant ProfessorUniv of Minnesota, Minneapolis, MN.3:00 p.m.1109 Prevention and Treatment of Tuberculosis in HIV InfectedIndividualsRichard E. Chaisson, MD - ProfessorJohn Hopkins Univ. Ctr. for Tuberculosis Res., Baltimore, MD.3:30 p.m.1110 HIV and MalariaJohanna P. Daily, MD, MS - Associate Professor of Medicine andMicrobiology and ImmunologyAlbert Einstein Coll. of Med., Bronx, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss new data for the diagnosis and management of Castleman diseasein patients with HIV-infection;> Discuss the challenges of using antiretrovirals for the treatment of cryptococcalmeningitis;> Review current knowledge on the prophylaxis and management of tuberculosisin HIV-infection; and> Discuss the impact of HIV-infection on the incidence, clinical presentationand management of malaria.Intended Audience: HIV treating physicians, ID professionals, clinicalvirologists mycologists and parasitologists, primary care physicians, tropicalmedicine physicians, public health specialists and industry professionals.Level: Intermediate/AdvancedFinal Program119

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------127(L)SymposiumNew Issues in the Management of Multidrug-Resistant(MDR) EndocarditisMonday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 305UAN: 0391-9999-12-098-L04-PDeveloped in Cooperation with the Infectious Diseases Society of America (IDSA)Conveners:M. Lindsay Grayson, MD - ProfessorUniv. of Melbourne, Austin Hlth., Melbourne, Australia.Henry F. Chambers, MD - ProfessorSan Francisco Gen. Hosp., San Francisco, CA.Speakers:2:00 p.m.1111 MDR Staphylococcus aureus Endocarditis (MRSA, hVISA)Henry F. Chambers, MD - ProfessorSan Francisco Gen. Hosp., San Francisco, CA.2:30 p.m.1112 Endocarditis Due to VRE and Other Resistant EnterococciRobert C. Moellering, Jr., MD - Shields Warren-Mallinckrodt Professor ofMedical ResearchHarvard Med. Sch., Boston, MA.3:00 p.m.1113 MDR Gram-Negative EndocarditisDavid Paterson, PhD - Professor of MedicineUniv. of Queensland Ctr. for Clinicial Res., Brisbane, Australia.3:30 p.m.1114 Q Fever Endocarditis and Intravascular InfectionsCorine Delsing, MDUniv. Med. Ctr. St. Radbound, Radboud Univ. Nijmegen Med. Ctr.,Nijmegen, Netherlands.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe how to diagnose multidrug-resistant intravascular infections;> Assess how to effectively treat multidrug resistant endocarditis and intravascularinfections; and> Discuss the current development pathway for new agents and other approachesfor endocarditis.Intended Audience: Clinicians, scientists, researchers, and microbiologists.Level: All Levels------------------------------------------------------------------------128(M)SymposiumFungal Infections in High-Risk Groups: Current andFuture Strategies for ControlMonday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 302UAN: 0391-9999-12-099-L04-PDeveloped in Cooperation with the Mycology Study Group (MSG)Conveners:Tania C. Sorrell, MB BS, MD, FRACP - ProfessorUniv. of Sydney, Sydney, Australia.John Edwards, Jr., MD - Chief, Division of Infectious DiseasesHarbor UCLA Med. Ctr., Torrance, CA.Speakers:2:00 p.m.1115 Invasive candidiasis in ICU PatientsPhilippe Eggimann, MD - ProfessorCtr. Hosp. Univ. Vaudois, Lausanne, Switzerland.2:30 p.m.1116 Candidemia in Neonates: Focus on an Indian Neonatal ICUArunaloke Chakrabarti, MD - ProfessorPostgraduate Inst. of Med. Ed. & Res., Chandigarh, Chandigarh, India.3:00 p.m.1117 Candida Vaccination as a Therapeutic StrategyJohn Edwards, Jr., MDChief, Division of Infectious DiseasesHarbor UCLA Med. Ctr., Torrance, CA.3:30 p.m.1118 HIV-Treatment Issues in Cryptococcal MeningitisJeremy Day, MD PhD - DoctorOxford Univ. Clinical Research Unit, Hosp. for Tropical Diseases, Ho ChiMinh City, Viet Nam.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify risk groups for invasive fungal infection;> Assess variability in resources for antifungal management; and> Provide guidelines for success in care of invasive fungal infections.Intended Audience: ID clinicians and trainees.Level: Advanced120September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------129(K)Slide SessionStaphylococcus aureus: Tough Bug, Tough TreatmentMonday, 2:00 p.m.–4:00 p.m. ................... Room 132UAN: 0391-9999-12-100-L04-PModerators:Vance Fowler, Jr., MD - Professor with TenureDuke Univ., Durham, NC.John Jernigan, MD - Director, Office of Prevention Research and EvaluationCDC, Atlanta, GA.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Discuss the relationship between vancomycin MIC and clinical outcome;> Assess predictors and clinical success in the treatment of S.aureus infections;and> Assess predictors of success in treating MRSA pneumonia.Presentations:2:00 p.m.State-of-the-Art Minilecture1119 Update on S. aureus Epidemiology, Resistance, and TreatmentVance Fowler, Jr., MD - Professor with TenureDuke Univ., Durham, NC.2:30 p.m.K-1120 Predictors of Clinical Success Among a National VeteransAffairs (VA) Cohort with Methicillin-Resistant Staphylococcusaureus (MRSA) PneumoniaA. R. Caffrey, PhD, MS - Assistant Professor of Pharmacoepidemiology 1,2 ,L. A. Puzniak, PhD - Regional Research Specialist 3 , D. E. Myers, MPH -Outcomes Research Scientist 3 , K. L. LaPlante, PharmD - Associate Professor4,2; 1 Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI, 2 Univ. of RhodeIsland, Coll. of Pharmacy, Kingston, RI, 3 Pfizer, Inc., Collegeville, PA,4Providence VA ID Res. Program, Providence, RI.3:00 p.m.K-1122 Influence of Vancomycin (VAN) MIC on the Outcome ofCloxacillin-Treated Methicillin-Susceptible Staphylococcus aureus(MSSA) Left-Sided Infective Endocarditis (IE)C. Cervera, MD, PhD - Physician, X. Castañeda, MD - Physician, A. delRío, MD, PhD - Physician, C. García de la María, MD, PhD - Physician,D. Soy, MD, PhD - Physician, A. Moreno, MD, PhD - Physician, C. Falces,MD, PhD - Physician, Y. Armero, MD - Physician, J. Pericas, MD - Physician,M. Almela, MD, PhD - Physician, S. Ninot, MD, PhD - Physician, J.Pare, MD, PhD - Physician, C. Mestres, MD, PhD - Physician, J. Gatell,MD, PhD - Physician, F. Marco, MD, PhD - Physician, J. M. Miro, MD,PhD - Physician; Hosp. Clinic - IDIBAPS, Barcelona, Spain.3:15 p.m.K-1123 Clinical Outcomes in Patients with Heterogeneous Vancomycin-IntermediateStaphylococcus aureus (hVISA)A. M. Casapao, PharmD - Post-Doc Fellow 1 , S. N. Leonard, PharmD - Post-Doc Fellow 1 , S. L. Davis, PharmD - Assistant Professor 1 , T. P. Lodise, PharmD- Associate Professor 2 , N. Patel, PharmD - Assistant Professor 2 , D. A. Goff,PharmD - Associate Professor 3 , K. L. LaPlante, PharmD - Assistant Professor 4 ,B. A. Potoski, PharmD - Associate Professor 5 , M. J. Rybak, PharmD, MPH -Professsor 1 ; 1 Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI, 2 AlbanyColl. of Pharmacy, Albany, NY, 3 Ohio State Univ., Columbus, OH, 4 Univ. ofRhode Island, Providence, RI, 5 Univ. of Pittsburgh, Pittsburgh, PA.3:30 p.m.K-1125 Methicillin-Sensitive Staphylococcus aureus Outbreak in aNeonatal Ward: System Reengineering WarrantedY. Achermann, MD- ID Physician, K. Seidl, PhD - Research Assistant,S. Karrer, None - Infection Control Practitioner, A. Holzmann, None - LabTechnician, G. Senn, None - Lab Technician, A. Zinkernagel, MD, PhD, MS- ID Physician, A. Leone, MD - Physician on Neonatal Ward, H. Bucher, MD- Professor, H. Sax, MD - Professor; Univ. Hosp. Zurich, Zurich, Switzerland.2:45 p.m.K-1121 Daptomycin (DAP) Versus Vancomycin (VAN) for Methicillin-ResistantStaphylococcus aureus Bacteremia (MRSAB) withVAN MIC > 1 mg/L: A Matched Cohort StudyK. P. Murray, PharmD - Clinical Pharmacist 1 , J. J. Zhao, PharmD - ClinicalPharmacist Specialist 1 , S. L. Davis, PharmD - Assistant Professor 2 , K. S. Kaye,MD, MPH - Professor 1,3 , M. J. Rybak, PharmD, MPH - Professor 1,3,2 ; 1 DetroitMed. Ctr., Detroit, MI, 2 Anti-Infective Res. Lab., Eugene ApplebaumColl. of Pharmacy and Hlth. Sci., Detroit, MI, 3 Wayne State Univ. Sch. ofMed., Detroit, MI.Final Program121

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------130ICAAC LectureICAAC LectureMonday, 4:30 p.m.–5:30 p.m. ................... Room 103UAN: 0391-9999-12-101-L04-PConveners:M. Lindsay Grayson, MD - ProfessorUniv. of Melbourne, Austin Hlth., Melbourne, Australia.Craig E. Rubens, MD, PhD - Professor of Pediatrics & Global HealthUniv. of Washington and Seattle Children’s, Seattle, WA.In this session, attendees will gain a greater understanding regarding emergingnew issues related to fungal infections, new antibiotics, emerging antimicrobialresistance, and new laboratory diagnostic methods and approaches.Objectives: Upon completion of this Symposium Session, the participantshould have a greater understanding regarding emerging new issues related to:> The pathogenesis and management of fungal infections;> Emerging new technologies in the diagnosis of fungal disease;> The development of new classes of antifungal agents; and> The emergence of antimicrobial resistance.Intended Audience: Chines clinicians, scientists, researchers, microbiologists,virologists, pharmacists and public health physicians..Level: Beginning/intermediate.4:30 p.m.Award Presentations4:45 p.m.1126 Fungal Disease in the 21st CenturyArturo Casadevall, MD, PhD - Professor of Microbiology and Immunologyand Medicine; Chair, Department of Microbiology and ImmunologyAlbert Einstein Coll. of Med., Bronx, NY.Objectives: Upon completion of the ICAAC Lecture, the participant shouldhave a greater understanding regarding emerging new issues related to:> The pathogenesis and management of fungal infections;> Emerging new technologies in the diagnosis of fungal disease; and> The development of new classes of antifungal agents.Intended Audience: Clinicians, scientists, researchers, microbiologists,virologists, pharmacists and public health physicians.Level: All Levels------------------------------------------------------------------------130aSymposiumICAAC-Global Chinese Association of Clinical Microbiologyand Infectious Diseases (GCACMID) SymposiumMonday, 5:45 p.m. - 7:15 p.m.. . . . . . . . . . . . . . . . . . . Room 102UAN:Note: This session will be translated into MandarinConveners:M. Lindsay Grayson, MDUniv. of Melbourne, Austin Hlth., Melbourne, Australia.Wing Hong Seto, MDHosp. Authority, Hong Kong, China.Po Ren Hsueh, MDNatl. Taiwan Univ. Coll. of Med., Taipei, Taiwan.Speakers:5:50 p.m.1126a Current Global Epidemiology of Gram-Negative ResistanceRonald Jones, MDJMI Lab., North Liberty, IA.6:10 p.m.1126b New Quinolones: What’s on the Horizon?David C. Hooper, MDMassachusetts Gen. Hosp., Boston, MA.6:30 p.m.1126c Fungal Disease in the 21st CenturyArturo Casadevall, MD, PhDAlbert Einstein Coll. of Med. of Yeshiva Univ., Bronx, NY.6:50 p.m.1126d The Impact of Emerging New Diagnostic Laboratory Techniqueson Clinical Infectious DiseaseFranklin R. Cockerill, III,Mayo Clinic, Rochester, MN.122September 9-12 |

MONDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------131(A)Meet-the-ExpertsTop Papers in Anti-Infective and Antiretroviral PK/PDMonday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 310UAN: 0391-9999-12-102-L04-PDeveloped in Cooperation with the Society of Infectious Diseases Pharmacists (SIDP)Convener:Keith A. Rodvold, PharmD - ProfessorUniv. of Illinois at Chicago, Chicago, IL.Experts:1127 Johan W. Mouton, MD, PhD - ProfessorRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.1128 Courtney V. Fletcher, PharmD - Dean and ProfessorColl. of Pharmacy, Univ. of Nebraska Med. Ctr., Omaha, NE.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe the latest developments within the field of anti-infective PK/PD;> Describe the most recent findings of importance in anti-infective PK/PDand their consequences for dosing of such drugs; and> Identify the issues and difficulties in implementing recent PK/PD data inthe clinic.Intended Audience: Physicians, pharmacists, and microbiologists.Level: Beginning/Intermediate------------------------------------------------------------------------132(C2)Meet-the-ExpertsDetecting, Controlling, and Treating Carbapenemase-Producing EnterobacteriaceaeMonday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 302UAN: 0391-9999-12-103-L04-PExperts:1129 Rafael Canton, PhD - ProfessorHosp. Univ. Ramón y Cajal. Inst. Ramón y Cajal de Investigación Sanitaria(IRYCIS), Madrid, Spain.1130 David Landman, MD - Associate ProfessorSUNY Downstate Med. Ctr., Brooklyn, NY.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe which treatment options and control methods that are availablefor infections due to carbapenemase-producing Enterobacteriaceae;> Identify the changing epidemiology of carbapenemase-producingEnterobacteriaceae; and> Describe which control methods that are available to prevent infectionsdue to carbapenemase-producing Enterobacteriaceae.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, and epidemiologists.Level: Intermediate------------------------------------------------------------------------133(D)Meet-the-ExpertsMALDI-ToF and PCR/ESI Mass Spectrometry:Implementation and Impact on Patient CareMonday, 5:45 p.m.–7:00 p.m. ................... Room 121UAN: 0391-9999-12-104-L04-PExperts:1131 Nathan A. Ledeboer, PhD - Assistant Professor of PathologyMed. Coll. of Wisconsin, Milwaukee, WI.1132 Stefan Zimmermann, MD - Assistant Medical DirectorUniv. Klinikum, Heidelberg, Germany.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe how to implement mass spectrometry into the clinical microbiologylaboratory;> Discuss the impact of mass spectrometry methods on workflow and laboratorycosts; and> Assess the impact of MALDI-ToF mass spectrometry on patient care.Intended Audience: Clinical microbiologists, infection control practitioners,and infectious diseases physicians.Level: Intermediate------------------------------------------------------------------------134(H, V)Meet-the-ExpertsPrevention of Anal Cancer in HIV-Infection: FromEarly Detection to VaccinationMonday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 309UAN: 0391-9999-12-105-L02-PExperts:1133 Erna M. Kojic, MD - Assistant Professor of MedicineWarren Alpert Med. Sch. of Brown Univ., Providence, RI.1134 Joel Palefsky, MD - ProfessorUniv. of California, San Francisco, CA.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Identify risk factors for anal dysplasia in HIV infection;> Discuss the role of HPV vaccination in HIV infected persons; and> Discuss the role of HPV vaccine as a therapeutic intervention for anallesions.Intended Audience: HIV and HCV clinicians including MD, pharmacists,pharmacologists, physician extenders and other clinician, HIV and HCVclinical and translational scientists including those involved in all phases ofantiviral research.Level: Intermediate/AdvancedFinal Program123

Monday SCIENTIFIC SESSIONS------------------------------------------------------------------------136(K)Meet-the-ExpertsPreventing Line-Associated Bloodstream Infection:Which Measures are Essential?Monday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 308UAN: 0391-9999-12-107-L04-PExperts:1138 Dennis Maki, MD - Deputy Head, Div. of Infectious Diseases & HospitalEpidemiology, Head, Hosp. EpidemiologyUniv. of Wisconsin Sch. of Med. and Publ. Hlth., Madison, WI.1139 Andreas F. Widmer, MD, MS - Deputy Head of Div. Infectious Diseases& Hospital EpidemiologyUniv. Hosp., Basel, SwitzerlandObjectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Identify the most effective measures to prevent bloodstream infection;> Explain the importance of adhering to evidence-based practice recommendationsto prevent bloodstream infection; and> Discuss why a continuous monitoring of review of processes is essential tomaintain a low infection rate.Intended Audience: Infectious disease specialists, infection control professionals,hospital epidemiologists, and hospital administrators.Level: Beginning/Intermediate------------------------------------------------------------------------137(P)Meet-the-ExpertsControversies in Pre-Travel PreparationMonday, 5:45 p.m.–7:00 p.m. ................... Room 122UAN: 0391-9999-12-108-L04-PDeveloped in Cooperation with the American Society of Tropical Medicine andHygiene (ASTMH)Experts:1140 Michael D. Libman, MD - Associate ProfessorMicrobiology, McGill Univ., Montreal, Canada.1141a Lin Chen, MD - Assistant Clinical Professor of MedicineHarvard University, Cambridge, MA.Objectives: Upon completion of this Meet-the-Expert session, the participantshould be able to:> Cite some of the latest significant literature on travel medicine;> Discuss the epidemiology of travel related illnesses; and> Identify issues in prevention of these illnesses.Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists,and general physicians.Level: Intermediate------------------------------------------------------------------------138(V, H)Meet-the-ExpertsNew Strategies for Transplantation of HIV-InfectedIndividualsMonday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 300UAN: 0391-9999-12-109-L02-PExperts:1141 Linda Frassetto, MD - ProfessorUniv. of California, San Francisco, CA.1142 Elmi Muller, MBChB, MRCS(Ed), FCS(SA) - Medical DoctorUniv. of Cape Town, Groote Schuur Hosp., Cape Town, South Africa.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Analyze the impact of drug interactions (with a focus on antiretroviralsand immunosuppressants) on patient management;> Assess the safety of HIV infected donor organs in HIV infected transplantrecipients; and> Assess the pros and cons of solid organ transplantation in HIV-infectedpatients.Intended Audience: Physicians, pharmacists, and clinical microbiologists/virologists.Level: Intermediate124September 9-12 |

NOTESFinal Program125

NOTES126September 9-12 |

Tuesday Schedule at-a-Glance> 7:00 a.m. - 8:15 a.m.155 (P) Update on Drug Resistance in MalariaEsplanade Ballroom 310> 11:15 a.m. - 1:15 p.m.Meet-the-Experts138a (K) MDRO Control: What to Do WhenBasic Prevention Measures Don’t Work?Room 102139 (A) Intra- and Extracellular Activities ofAnti-Infective AgentsEsplanade Ballroom 310140 (C2, K) Clostridium difficile: TheManagement of Severe and RecurrentInfectionsEsplanade Ballroom 308141 (F) Too Few New Anti-Gram-NegativeAgents: How to Change the Landscape?Room 122142 (G) Healthy Mother, Healthy BabyEsplanade Ballroom 309143 (H) Management of AntiretroviralTherapy-Induced Bone ToxicityRoom 121144 (K) Antimicrobial Resistance andAntimicrobial Stewardship in Non-HospitalSettingsRoom 120> 8:30 a.m. - 10:30 a.m.Interactive Symposia145 (G) Interactive Cases in PediatricInfectious DiseasesRoom 103146 (M) Challenging Cases in MycologyRoom 104Symposia147 (A) Vancomycin: What Do We Know NowAbout Pharmacokinetics/Pharmacodynamics?Esplanade Ballroom 306148 (B) New Concepts in Tuberculosis:Pathogenesis, Diagnostics, Treatment, andPreventionEsplanade Ballroom 308149 (C1) Novel Techniques for the Diagnosticof the Emerging Antibiotic ResistancesEsplanade Ballroom 302150 (D) Antimicrobial Susceptibility UpdateRoom 120151 (E, C1) Laboratory Approaches forDetection, Characterization, and Reporting ofImportant Resistance Mechanisms in Gram-NegativesRoom 132152 (H) What’s New in Antiretroviral TherapyRoom 130153 (L) Dangerous Pets and Other AnimalsRoom 102154 (L, F) What Every Clinician Should KnowAbout Emerging New AntimicrobialsEsplanade Ballroom 305> 8:30 a.m. - 11:00 a.m.Slide Sessions156 (C1) Extended Spectrum-LactamasesRoom 121157 (C2) Carbapenemases Go GlobalEsplanade Ballroom 300158 (L1) New Insights in Bacterial MeningitisEsplanade Ballroom 309159 (M) Mycology for the BedsideRoom 122160 (V) Hepatitis and Herpes VirusesRoom 254> 11:15 a.m. - 12:15 p.m.Poster WalkNew Developments in TransplantationHalls A-C> 11:15 a.m. - 12:45 p.m.Symposia192 (B) Virulence Bags: Extracellular Vesiclesthat Modify Host-Pathogen InteractionsEsplanade Ballroom 302193 (K) Regional Approaches to Preventionof Healthcare-Associated AntimicrobialResistanceEsplanade Ballroom 300194 (L) Emerging and Current Challenges inInjecting Drug UsersRoom 102195 (V) Influenza: Beyond the HeadlinesRoom 130Slide Sessions196 (B) Novel Antibody Therapy of DifficultInfectionsEsplanade Ballroom 310197 (C1) Resistance in Staphylococcus aureusRoom 122198 (G) Global PediatricsEsplanade Ballroom 309199 (K) Bloodstream Infections: Catheters,Cultures and CountsRoom 121Poster Sessions161 (A) Clinical Pharmacology of Antiviraland Anti-Tuberculosis AgentsHalls A-C162 (A) Clinical Pharmacology of Novel Anti-Infective AgentsHalls A-C163 (A) Pharmacokinetics/Pharmacodynamicsof New and Old OxazolidinonesHalls A-C164 (B) Antimicrobial Therapy in AnimalModels IIHalls A-C165 (B) Microbial Determinants of VirulenceHalls A-C166 (C1) Resistance to Staphylococcus andOther Gram-PositiveHalls A-C167 (C2) Characterization of Streptococcuspneumoniae in the Era of Antibiotics andVaccinesHalls A-C168 (C2) Drug-Resistant MycobacteriumtuberculosisHalls A-C169 (C2) MRSA: A Bug with InternationalAppeal and Great SenseHalls A-C170 (D) Detection of Bacteremia andBiomarkers for SepsisHalls A-C171 (D) Diagnosis, Characterization andAntimicrobial Susceptibility Testing: Gram-Positive CocciHalls A-C172 (D) Molecular Methods for PathogenIdentification and Resistance DetectionHalls A-C173 (E) In Vitro Activity of Lipoglycopeptidesand Related CompoundsHalls A-C174 (E) In Vitro Activity VersusStaphylococcalHalls A-C175 (F) Antimicrobial Peptides andPeptidomimeticsHalls A-C176 (F) Compounds and Approaches forCombating Gram-Positive InfectionsHalls A-C177 (F) Novel Antimicrobial Approaches andAgentsHalls A-C178 (G3) PediatricsHalls A-CTuesday

Tuesday Schedule at-a-Glance continued…179 (H) HIV-I Pathogenesis and Predictorsof Antiretroviral Response in Treatment andPreventionHalls A-C180 (H) HIV-I Resistance, Tropism and NovelLaboratory MethodsHalls A-C181 (K) Extended-Spectrum-LactamaseEnterobacteriaceaeHalls A-C182 (K) MRSA InfectionsHalls A-C183 (K) Resistant Acinetobacter InfectionsHalls A-C184 (K) Resistant Gram-Negative InfectionsHalls A-C185 (K) Use of Vancomycin, Daptomycin and/or LinezolidHalls A-C186 (L1) Endocarditis and Other InvasiveInfectionsHalls A-C187 (L1) Meningitis and Central NervousSystem InfectionsHalls A-C188 (L1) Methicillin-Resistant Staphylococcusaureus: Clinical AspectsHalls A-C189 (L1) Novel Agents and Insights in Skinand Soft Tissue InfectionsHalls A-C190 (M) Clinical Mycology IHalls A-C191 (M) Clinical Mycology IIHalls A-C> 12:15 p.m. - 1:15 p.m.Poster WalkFungal Infections at the BedsideHalls A-C> 1:30 p.m. - 4:00 p.m.> 2:00 p.m. - 4:00 p.m.Interactive Symposium202 (H2, H3) Advances in HIV and HCVManagementRoom 103Symposia203 (C1) Bacterial Communication andResistanceEsplanade Ballroom 300204 (C2, K) Global Spread of AntimicrobialResistance: Mechanisms of Spread,Surveillance, and ControlRoom 121205 (E) Selecting Antibiotic ResistantMutants in the Laboratory: How Best toMimic the Real World?Esplanade Ballroom 302206 (F) Iron Transport and Homeostasis: AreThere Opportunities for New Drugs?Esplanade Ballroom 309207 (G) Hot Topics in Pediatric InfectiousDisease: 2012Room 122208 (K) Are Prevalence Surveys Still Useful forHealthcare-Associated Infection Surveillance?Esplanade Ballroom 305209 ID QuizEsplanade Ballroom 308210 (L1) Potluck: The Latest on FoodborneInfectionsRoom 132211 (P) Global Health as an AcademicDisciplineEsplanade Ballroom 310212 (V, G) Viruses and the Central NervousSystem: Diagnostic, Treatment and RecentOutbreaksRoom 130> 4:30 p.m. - 5:30 p.m.Cubist-ICAAC Award Lecture213 Cubist-ICAAC Award LectureRoom 103> 5:45 p.m. - 7:00 p.m.Meet-the-Experts214 (C1, C2) Top 10 -Lactamase Papers in2012Esplanade Ballroom 305215 (C2) Surveillance of AntimicrobialResistance: Potential Sources of BiasEsplanade Ballroom 309216 (F) Meeting the Challenge of Efflux fromGram-Negative BacteriaEsplanade Ballroom 302217 (K) Challenging Issues in PediatricInfection Prevention and ControlRoom 122218 (K) Issues in the Diagnosis andManagement of Prosthetic Joint InfectionsEsplanade Ballroom 310219 (M, D) How Can the Mycology Lab Workfor You?Room 121Slide Sessions200 (A) Maximizing PK/PD Modeling forDosing, Prevention of Resistance and ClinicalOutcomesRoom 102201 (D) Diverse Applications of MassSpectrometry in Clinical MicrobiologyRoom 120

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------138a(K)Meet-the-ExpertsMDRO Control: What to Do When Basic PreventionMeasures Don’t Work?Tuesday, 7:00 a.m.–8:15 a.m.. ................... Room 102UAN: 0391-9999-12-106-L04-PExperts:1142a Alexander J. Kallen, MD, MPH - Medical OfficerCDC, Atlanta, GA.1142b Po Ren Hsueh, MD - ProfessorNatl. Taiwan Univ. Hosp., Natl. Taiwan Univ. Coll. of Med., Taipei, Taiwan.1142c Paul A. Tambyah, MD - Assistant ProfessorNatl. Univ. Hosp., Singapore, Singapore.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discuss the basic preventive measures which are generally taken as thefirst tier measures;> Identify possible measures which are generally taken as the second tiermeasures; and> Assess the strengths and weaknesses of the different second tier measuresand when to apply them for the different MDROs.Intended Audience: ID specialists, infection control professionals, hospitalepidemiologists, and clinical microbiologists.Level: Intermediate----------------------------------------------------------------------------------139(A)Meet-the-ExpertsIntra- and Extracellular Activities of Anti-Infective AgentsTuesday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 310UAN: 0391-9999-12-110-L04-PDeveloped in Cooperation with the International Society of Anti-InfectivePharmacology (ISAP)Convener:Niels Frimodt-Møller, MD, DMSc - Professor, Senior ConsultantHvidovre Hosp., Copenhagen, Denmark.Experts:1143 Francoise Van Bambeke, PharmD, Ph, PharmD - ProfessorUniv. Catholique de Louvain, Brussels, Belgium.1144 Anne Sandberg-Schaal, PharmD, PhD - Post DocHvidovre Hosp., Copenhagen, Denmark.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe the importance of targeting both intra- and extracellularpathogens;> Describe the methodology available for estimating the intracellularpenetration and activity of antimicrobials; and> Identify the issues and difficulties in estimating the intracellular activityin vitro and in vivo of antimicrobials.Intended Audience: Physicians, pharmacists, and microbiologists.Level: Intermediate------------------------------------------------------------------------140(C2, K)Meet-the-ExpertsClostridium difficile: The Management of Severe andRecurrent InfectionsTuesday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 308UAN: 0391-9999-12-111-L04-PExperts:1145 Dale N. Gerding, MD - ProfessorLoyola Univ. Chicago Stritch Sch. of Med., Chicago, IL.1146 Thomas Louie, MD - ProfessorUniv. of Calgary, Calgary, Canada.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe which treatment options are available for recurrent Clostridiumdifficile infection;> Identify the changing epidemiology of Clostridium difficile associateddisease; and> Describe the management of severe infections due to Clostridium difficile.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, and epidemiologists.Level: Intermediate------------------------------------------------------------------------141(F)Meet-the-ExpertsToo Few New Anti-Gram-Negative Agents: How toChange the Landscape?Tuesday, 7:00 a.m.–8:15 a.m. .................... Room 122UAN: 0391-9999-12-112-L04-PConvener:Michael J. Pucci, PhD - Executive DirectorAchillion Pharmaceuticals, New Haven, CT.Experts:1147 Robert A. Stavenger; MD- Team LeaderGlaxoSmithKline, Collegeville, PA.1148 David Shlaes, MD, PhD - PresidentAnti-Infectives Consulting, Stonington, CT.1149 Otto Cars; MD, MPH- Professsor Infectious DiseasesUppsala University, Uppsala, Sweden.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Gain an understanding of the current environment for the development ofnew agents that target gram-negative pathogens;> Identify issues that have led to the current lack of new drugs to treatgram-negative bacterial infections; and> Discuss potential solutions to this crisis and understand their probabilitiesfor success.Final Program127

Tuesday SCIENTIFIC SESSIONSIntended Audience: Microbiologists, clinicians, and pharmaceutical andacademic scientists.Level: Intermediate------------------------------------------------------------------------142(G)Meet-the-ExpertsHealthy Mother, Healthy BabyTuesday, 7:00 a.m.–8:15 a.m. ....... Esplanade Ballroom 309UAN: 0391-9999-12-113-L04-PExperts:1150 Claire Thorne, PhD - LecturerUniv. Coll. London, London, United Kingdom.1151 Saad B. Omer, MBBS, MPH, PhD - Assistant ProfessorEmory Univ., Sch. of Publ. Hlth. & Med., Atlanta, GA.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Cite important recent advances in prevention of perinatal transmission ofHIV infection;> Discuss promising new strategies for prevention of influenza in pregnantwomen and young infants; and> Identify preventive strategies to the care of mothers and their infants.Intended Audience: Physicians, public health practitioners, epidemiologists,pharmacologists and all with an interest in maternal-infant health.Level: Beginning/Intermediate------------------------------------------------------------------------143(H)Meet-the-ExpertsManagement of Antiretroviral Therapy-Induced BoneToxicityTuesday, 7:00 a.m.–8:15 a.m. .................... Room 121UAN: 0391-9999-12-114-L04-PExperts:1152 Grace A. McComsey, MD - Professor of Medicine and PediatricsCase Western Reserve Univ. Sch. of Med., Cleveland, OH.1153 Pablo Tebas, MD - Professor of MedicineUniv. of Pennsylvania, Phhiladelphia, PA.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe bone complications resulting from HIV infection and its treatment;> Distinguish between osteoporosis and osteomalacia;> Discuss the role Vitamin D may play in the development of HIV associatedbone disease; and> Discuss the management of HIV associated bone disease.Intended Audience: HIV and HCV clinicians including MD, pharmacists,pharmacologists, physician extenders and other clinician, HIV and HCVclinical and translational scientists including those involved in all phases ofantiviral research.Level: Intermediate/Advanced------------------------------------------------------------------------144(K)Meet-the-ExpertsAntimicrobial Resistance and Antimicrobial Stewardshipin Non-Hospital SettingsTuesday, 7:00 a.m.–8:15 a.m. .................... Room 120UAN: 0391-9999-12-115-L04-PExperts:1154 L. Silvia Munoz-Price, MD - Associate Professor of MedicineJackson Mem. Hosp., Univ. of Miami, Miami, FL.1155 Maria Luisa Moro, MD - DoctorAgenzia Sanitaria e Sociale Regione Emilia-Romagna, Bologna, Italy.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Identify issues regarding antimicrobial resistance and antimicrobial stewardshipin non-hospital settings that are specific to these settings;> Identify resources that are helpful for addressing antimicrobial resistanceand antimicrobial stewardship in non-hospital settings; and> Identify one intervention they can use in their own practice.Intended Audience: Physicians involved in infection control, particularlythose working in non-hospital settings, physicians interested in controllingantimicrobial use in non-hospital settings, and microbiologists providingservices to non-hospital settings.Level: Beginning/Intermediate------------------------------------------------------------------------145(G)Interactive SymposiumInteractive Cases in Pediatric Infectious DiseasesTuesday, 8:30 a.m.–10:30 a.m. .................. Room 103UAN: 0391-9999-12-116-L04-PConveners:Jeffrey R. Starke, MD - ProfessorBaylor Coll. of Med., Houston, TX.Karina M. Butler, MB, DCh - ProfessorOur Lady’s Children’s Hosp. Crumlin, Dublin, Ireland.Panelists:1156 Carol J. Baker, MD - Professor of Pediatrics, Molecular Virology& MicrobiologyBaylor Coll. of Med., Houston, TX.1157 Mary Anne Jackson, MD - Professor of PediatricsChildren’s Mercy Hosp., Kansas City, MO.1158 David Isaacs, MD - Professor of Pediatric Infectious DiseasesThe Children’s Hosp. at Westmead, Westmead, Australia.1159 Anne Vergison, MD, PhD - Associate professorULB-HUDERF, Brussels, Belgium.1160 Pia S. Pannaraj, MD, MPH - Assistant Professor of PediatricsUniv. of Southern California, Children’s Hosp. Los Angeles, Los Angeles, CA.Objectives: Upon completion of this Interactive Symposium, the participantshould be able to:128September 9-12 |

TUESDAY SCIENTIFIC SESSIONS> Identify some common and not-so-common clinical manifestations ofimportant infectious diseases in childhood;> Cite medical evidence and current expert opinion in management andprevention of infections in childhood;> Assess and compare knowledge anonymously with peers; and> Recognize and identify unusual infectious diseases.Intended Audience: Infectious disease physicians and physician extenders,public health personnel, microbiologists, pharmacologists and researchers.Level: Intermediate------------------------------------------------------------------------146(M)Interactive SymposiumChallenging Cases in MycologyTuesday, 8:30 a.m.–10:30 a.m. .................. Room 104UAN: 0391-9999-12-117-L04-PConveners:Andrew Ullmann, MD - ProfessorKlinikum der Johannes, Mainz, Germany.Jack D. Sobel, MD - Professor, Immunology Microbiology and Chief, InfectiousDiseasesWayne State Univ. Sch. of Med., Detroit, MI.Speakers:8:30 a.m.1161 Management Guidelines and Real Life SituationsAndrew J. Ullmann, MD - ProfessorJulius-Maximilians Univ., Wuerzburg, Germany.9:00 a.m.1162 Conundrums in ManagementJack D. Sobel, MD - Professor, Immunology Microbiology and Chief, InfectiousDiseasesWayne State Univ. Sch. of Med., Detroit, MI.9:30 a.m.1163 A Difficult CasePatricia Muñoz, MD, PhD - ProfHosp. G.U. Gregorio Maranon, Madrid, Spain.10:00 a.m.1164 Australia: When the Human Petri Dish Serves an UnusualGuestDeborah J. E. Marriott, MBBS, BscMed, FRACP, FRCPA, MASM -ProfessorSt. Vincent’s Hosp., Sydney, Australia.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Manage complex cases;> Discuss the boundaries of diagnosis and treatment; and> Identify principles for the epidemiology and care of patients.Intended Audience: Clinicians and trainees.Level: Advanced------------------------------------------------------------------------147(A)SymposiumVancomycin: What Do We Know Now About Pharmacokinetics/Pharmacodynamics?Tuesday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 306UAN: 0391-9999-12-118-L04-PDeveloped in Cooperation with the Society of Infectious Diseases Pharmacists(SIDP)Conveners:Annie Wong-Beringer, PharmD - ProfessorUniv. of Southern California Sch. of Pharmacy, Los Angeles, CA.Keith A. Rodvold, PharmD - ProfessorUniv. of Illinois, Coll. of Pharmacy and Med., Chicago, IL.Speakers:8:30 a.m.1165 Pharmacokinetic/Pharmacodynamic In Vitro Models: Lessonsfrom Glycopeptide- and Lipopeptide-Resistant PathogensMichael J. Rybak, PharmD, MPH - Professor of Pharmacy & MedicineWayne State Univ. Coll. of Pharmacy & Hlth. Sci., Detroit, MI.9:00 a.m.1166 Do High MIC Values Influence Clinical Outcomes of Vancomycin?Natasha E. Holmes, MBBS (Hons) - PhD Research ScholarAustin Hlth., Dept. of Infectious Diseases, Heidelberg, Australia.9:30 a.m.1167 Vancomycin-Associated Nephrotoxicity: A Critical Appraisal ofRisk with High-Dose TherapyAnnie Wong-Beringer, PharmD - Associate ProfessorUniv. of Southern California Sch. of Pharmacy, Los Angeles, CA.10:00 a.m.1168 When to Change Methicillin-Resistant Staphylococcus aureusTherapy: Can Pharmacokinetic/Pharmacodynamic Indices Guidethe Decision?Vance Fowler, Jr., MD - Professor with TenureDuke Univ. Sch. of Med., Durham, NC.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe in vitro bactericidal activity of glycopeptide- and lipopeptideresistantpathogens;> Appraise whether high minimum inhibitory concentrations of vancomycininfluence clinical outcomes;> Evaluate the risks of vancomycin-associated nephrotoxicity with highdosetherapy; and> Recognize the role of pharmacokinetic-pharmacodynamic indices ofvancomycin.Intended Audience: Physicians, pharmacists, and microbiologists.Level: IntermediateFinal Program129

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------148(B)SymposiumNew Concepts in Tuberculosis: Pathogenesis, Diagnostics,Treatment, and PreventionTuesday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 308UAN: 0391-9999-12-119-L04-PConveners:John Chan, MD - ProfessorAlbert Einstein Coll. of Med., Bronx, NY.Warwick J. Britton, PhD, MBBS, FRACP, FRCP, FRCPA - BoschProfessor of Medicine and Professor of ImmunologyCentenary Inst. and Univ. of Sydney, Sydney, Australia.Speakers:8:30 a.m.1169 New Concepts in Tuberculosis DiagnosticsDavid Alland, MD - ProfessorNew Jersey Med. Sch. (UMDNJ), Newark, NJ.9:00 a.m.1170 Adaptive Immunity in Tuberculosis: Friend and FoeJoel Ernst, MD - Professor of Medicine, Pathology, and MicrobiologyNew York Univ., New York, NY.9:30 a.m.1171 New Approach to Tuberculosis Vaccine DesignWarwick J. Britton, PhD, MBBS, FRACP, FRCP, FRCPA - ProfessorCentenary Inst. and Univ. of Sydney, Sydney, Australia.10:00 a.m.1172 B Cells and Humoral Immunity in TuberculosisJohn Chan, MD - ProfessorAlbert Einstein Coll. of Med., Bronx, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the role of innate and adaptive immunity to pathogenesis ofTuberculosis;> Describe new findings relevant to Tuberculosis vaccine development; and> Incorporate new concepts for Tuberculosis diagnosis into future clinicalpractice.Intended Audience: ID clinicians, immunologists, microbiologists, anddiagnostic developers.Level: Intermediate/Advanced------------------------------------------------------------------------149(C1)SymposiumNovel Techniques for the Diagnostic of the EmergingAntibiotic ResistancesTuesday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 302UAN: 0391-9999-12-120-L04-PConveners:Jacques Schrenzel, MD - ProfessorGeneva Univ. Hosp., Geneva, Switzerland.Kenneth S. Thomson, PhD - ProfessorCreighton Univ., Omaha, NE.Speakers:8:30 a.m.1173 Molecular/Protein-Based Techniques for Detection ofResistance in Gram-NegativesKenneth Thomson, PhD - ProfessorCreighton Univ., Omaha, NE.9:00 a.m.1174 Molecular/Protein-Based Techniques for Diagnostic ofResistance in Gram-PositivesFrederic Laurent, PharmD, PhD - Associate ProfessorHospices Civils de Lyon, Croix Rousse Hosp., Lyon, France.9:30 a.m.1175 Point-of-Care TechnologiesMichel Drancourt, MD, PhD - ProfessorUniv. of Marseilles, Marseille, France.10:00 a.m.1176 Future TechniquesJacques Schrenzel, MD - ProfessorGeneva Univ. Hosp., Geneva, Switzerland.Objectives: Upon completion of this Symposium Session, participantsshould be able to:> Describe the molecular and protein-based techniques useful for diagnosticof emerging antibiotic resistances;> Discuss the development of future technologies for diagnostic of antibioticresistances; and> Identify the techniques that may be potentially implemented in a clinicallab.Intended Audience: ID physicians, pharmacists, scientists, and industryclinical microbiologists.Level: Intermediate130September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------150(D)SymposiumAntimicrobial Susceptibility UpdateTuesday, 8:30 a.m.–10:30 a.m. .................. Room 120UAN: 0391-9999-12-121-L04-PConveners:Jean B. Patel, PhD - Deputy Director, Office of Antimicrobial ResistanceCDC, Atlanta, GA.Rafael Canton, PhD - ProfessorHosp. Univ. Ramón y Cajal. Inst. Ramón y Cajal de Investigación Sanitaria(IRYCIS), Madrid, Spain.Speakers:8:30 a.m.1177 CLSI and EUCAST UpdateJean Patel, PhD, D(ABMM) - Deputy Director, Office of AntimicrobialResistanceCDC, Atlanta, GA.9:00 a.m.1178 New Challenges in Antimicrobial Susceptibility Testing inMultidrug-Resistant Gram-Negative RodsRafael Canton, PhD - ProfessorHosp. Univ. Ramón y Cajal. Inst. Ramón y Cajal de Investigación Sanitaria(IRYCIS), Madrid, Spain.9:30 a.m.1179 Antifungal Susceptibility Testing Update: Yeast and MoldsAnnette W. Fothergill, MA, MBA - Assistant ProfessorUniv. of Texas Hlth. Sci. Ctr., San Antonio, TX.10:00 a.m.1180 Antimicrobial Susceptibility Testing of Non-TuberculousMycobacteria and its Clinical RelevanceJakko van Ingen, MD, PhD - Resident in Clinical MicrobiologyRadboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Review current CLSI and EUCAST guidelines regarding antimicrobialsusceptibility testing;> Assess what clinicians should know about and when to request antimicrobialsusceptibility testing for clinical care; and> Review unsettled issues and pitfalls of current antimicrobial susceptibilitytesting, methods and their clinical application.Intended Audience: Clinical microbiologists, infection control practitioners,and infectious diseases physicians.Level: Intermediate------------------------------------------------------------------------151(E, C1)SymposiumLaboratory Approaches for Detection, Characterization,and Reporting of Important Resistance Mechanisms inGram-NegativesTuesday, 8:30 a.m.–10:30 a.m. .................. Room 132UAN: 0391-9999-12-122-L04-PConveners:Stephen G. Jenkins, PhD - Professor of Pathology and Laboratory MedicineNew York Presbyterian Hosp./Weill Cornell Med. Ctr., New York, NY.Melvin P. Weinstein, MD - Professor of Medicine and PathologyRobert Wood Johnson Med. Sch., New Brunswick, NJ.Speakers:8:30 a.m.1181 Current Global Epidemiology of Gram-Negative ResistanceRonald N. Jones, MD - President, CEOJMI Lab., North Liberty, IA.9:00 a.m.1182 Phenotypic Detection of Resistance Mechanisms in Multidrug-Resistant EnterobacteriaceaeAudrey N. Schuetz, MD - Assistant ProfessorWeill Cornell Med. Coll., New York, NY.9:30 a.m.1183 Molecular Detection and Characterization of ResistanceMechanisms in EnterobacteriaceaeAndrea Endimiani, MD, PhD - Clinical MicrobiologistUniv. of Bern, Bern, Switzerland.10:00 a.m.1184 Reporting Antimicrobial Susceptibility Testing Results forESBL and KPC-Producing Gram-NegativesDavid Paterson, PhD - Professor of MedicineUniv. of Queensland Ctr. for Clinical Res., Brisbane, Australia.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe various-lactamase mediated resistance mechanisms among theEnterobacteriaceae and other clinically important gram-negatives;> Explain regional, national, and global patterns of antimicrobial resistanceresulting from the various mechanisms described for various gram-negatives;> Recognize atypical antimicrobial susceptibility testing results with theEnterobacteriaceae for the parenteral cephalosporins and carbapenems thatshould lead to additional and/or confirmatory phenotypic and or moleculartesting; and> Develop an approach to educate the end users (clinicians and hospital epidemiologists)on the impact these resistance mechanisms on the reportingof antimicrobial susceptibility testing results.Intended Audience: Infectious disease physicians, clinical microbiologists,clinical pharmacists with expertise and interest in infectious diseases, andinfection control practitioners.Level: IntermediateFinal Program131

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------152(H)SymposiumWhat’s New in Antiretroviral TherapyTuesday, 8:30 a.m.–10:30 a.m. .................. Room 130UAN: 0391-9999-12-123-L04-PConveners:Roy M. Gulick, MD - Professor of MedicineWeill Cornell Med. Coll., New York, NY.Joseph Eron, Jr., MD - Professor of MedicineUniv. of North Carolina, Chapel Hill, NC.Speakers:8:30 a.m.1185 Antiretroviral Therapy 2012: What to Start?Joel E. Gallant, MD, MPH - Professor of Medicine & EpidemiologyJohns Hopkins Univ. Sch. of Med., Baltimore, MD.9:00 a.m.1186 New Antiretrovirals and Novel Strategies for the Treatment ofHIV-1 InfectionPatrick G. Yeni, MD - ProfessorHosp. Bichat-Claude Bernard and Xavier Bichat Med. Sch., Paris, France.9:30 a.m.1187 Pre-Exposure Prophylaxis (PrEP) for HIV-1: Where Have WeBeen and Where are We Going?Jared Baeten, MD, PhD - Associate ProfessorUniv. of Washington, Seattle, WA.10:00 a.m.1188 Top Papers in Antiretroviral Therapy: Including Key Presentationsfrom the 2012 International AIDS ConferenceRoy M. Gulick, MD - Professor of MedicineWeill Cornell Med. Coll., New York, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss several recommended initial antiretroviral regimens for the treatmentof HIV-1 infection and identify potential patient types for whichone regimen may be more suited than another;> Summarize information of new antiretroviral agents and antiretroviraltreatment strategies that are in development for the treatment of HIV-1infection;> Compare data from several large studies of pre-exposure prophylaxis studiesusing antiretrovirals for the prevention of HIV infection and considerwhich at risk individuals may benefit from PrEP for HIV prevention; and> Review the most important antiretroviral research studies that werepublished in 2012 or were presented at the 2012 International AIDSconference in Washington DC.Intended Audience: HIV clinicians including MD, pharmacists, pharmacologists,physician extenders and other clinician, HIV clinical and translationalscientists including those involved in all phases of antiretroviral research,virologists, and drug developers.Level: All Levels------------------------------------------------------------------------153(L)SymposiumDangerous Pets and Other AnimalsTuesday, 8:30 a.m.–10:30 a.m. .................. Room 102UAN: 0391-9999-12-124-L04-PConveners:Tara C. Smith, PhD - Assistant ProfessorEpidemiology, Univ. of Iowa, Iowa City, IA.David Aronoff, MD - Associate ProfessorUniv. of Michigan, Ann Arbor, MI.Speakers:8:30 a.m.1189 The Role of Bats in the Transmission of Dangerous ZoonoticVirusesLin-Fa Wang, PhD - ProfessorCSIRO Australian Animal Hlth. Lab., Geelong, Australia.9:00 a.m.1190 Microbe Hunting: New Approaches to Pathogen Surveillanceand DiscoveryW. I. Lipkin, MD - ProfessorColumbia Univ., New York, NY.9:30 a.m.1191 MRSA and AnimalsTara C. Smith, PhD - Assistant ProfessorUniv. of Iowa, Iowa City, IA.10:00 a.m.1192 Once Bitten, Twice Shy: Animal Bites and Infectious DiseasesDavid F. Looke, MD - Infectious Diseases Physician and Clinical MicrobiologistPrincess Alexandra Hosp., Univ. of Queensland, Brisbane, Australia.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss how to diagnose zoonotic infections;> Effectively treat infections related to animal bites; and> Identify new concepts regarding the epidemiology of newly recognizedzoonotic infections.Intended Audience: Clinicians, scientists, researchers, microbiologists, andpublic health physicians.Level: All Levels132September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------154(L, F)SymposiumWhat Every Clinician Should Know About EmergingNew AntimicrobialsTuesday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 305UAN: 0391-9999-12-125-L04-PConveners:M. Lindsay Grayson, MD - ProfessorUniv. of Melbourne, Austin Hlth., Melbourne, Australia.George M. Eliopoulos, MD - Professor of MedicineBeth Israel Deaconess Med. Ctr., Boston, MA.Speakers:8:30 a.m.1193 Fidaxomicin and Other Macrocyclic AntibioticsKathleen Mullane, DO, PharmD - Associate Professor of MedicineUniv. of Chicago, Chicago, IL.8:50 a.m.1194 New Oxazolidinones, Including Tedizolid (Torezolid, TR-700)George M. Eliopoulos, MD - Professor of MedicineBeth Israel Deaconess Med. Ctr., Boston, MA.9:10 a.m.1195 Ceftaroline: An UpdateHelen W. Boucher, MD, FACP - Associate ProfessorTufts Med. Ctr., Boston, MA.9:30 a.m.1196 New Beta-Lactam/Beta-Lactamase Combinations (IncludingAvibactam NKL104 and Tazobactam)David M. Livermore, PhD - ProfessorUniv. of East Anglia, Norwich, United Kingdom.9:50 a.m.1197 Plazomicin (ACHN-490) and Other NeoglycosidesKaren Bush, PhD - Adjunct ProfessorIndiana Univ., Bloomington, IN.10:10 a.m.Waiting for replacementObjectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the new emerging antimicrobial agents;> Recognize when these new agents may be of value in clinical practice;> Assess how to safely use these new agents; and> Identify the current development pathway for these new agents.Intended Audience: Clinicians, scientists, researchers, and microbiologists.Level: All Levels------------------------------------------------------------------------155(P)SymposiumUpdate on Drug Resistance in MalariaTuesday, 8:30 a.m.–10:30 a.m. ..... Esplanade Ballroom 310UAN: 0391-9999-12-126-L04-PConveners:Thomas E. Wellems, MD, PhD - Chief, LMVRNIAID, NIH, Bethesda, MD.Alan J. Magill, MD - Program ManagerDefense Sci. Office (DSO), Defense Advanced Res. Programs Agency(DARPA), Arlington, VA.Speakers:8:30 a.m.1199 What Can We Learn from the History of Resistance to Anti-Malarial Drugs?Thomas E. Wellems, MD, PhD - Chief, LMVRNIAID, NIH, Bethesda, MD.9:00 a.m.1200 Emerging Artemisinin Resistance in Plasmodium falciparumMalariaRick M. Fairhurst, MD, PhD - Clinical Tenure-Track InvestigatorNIAID, NIH, Bethesda, MD.9:30 a.m.1200a Selection of Malaria Parasites with Decreased Sensitivity toArtemisinin Partner DrugsPhilip J. Rosenthal, MD - ProfessorSan Francisco Gen. Hosp., San Francisco, CA.10:00 a.m.1201 Designing the Next Generation of Medicines for MalariaControl and EliminationTim Wells, PhD - Chief Scientific OfficerMed. for Malaria Venture, Geneva, Switzerland.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the current global distribution of genotypic and phenotypicmarkers associated with drug resistance to malaria;> Compare the difference between therapeutic failures and drug resistance;Recognize the technical and biologic difficulties in isolating and identifyingthe genetic correlates of acquired drug resistance in malaria; and> Interpret genotypic and phenotypic data acquired in the laboratory andapply to treatment recommendations.Intended Audience: Graduate students, MsC, and PhD, Public Health IDresidents and trainees, ID Fellows and MDS.Level: IntermediateFinal Program133

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------156(C1)Slide SessionExtended Spectrum-LactamasesTuesday, 8:30 a.m.–11:00 a.m. .................. Room 121UAN: 0391-9999-12-127-L04-PModerators:Patrice Nordmann, MD - ProfessorHosp. Bicetre, Le-Kremlin-Bicetre, France.Gian M. Rossolini, MD - Professor of Clinical MicrobiologySiena Univ. Hosp., Siena, Italy.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Identify current epidemiology trend in emerging ESBLs;> Discuss genetic vectors of ESBLs; and> Understand the factors contributing to the spread of ESBLs.Presentations:8:30 a.m.C1-1202 How to Detect Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: A New ParadigmP. Nordmann, MD, PhD - Professor, L. Poirel, PhD - Associate Researcher,L. Dortet, PharmD - Assistant Professor; Hosp. de Bicetre, Le KremlinBicetre, France.8:45 a.m.C1-1203 Complete Nucleotide Sequence of a F33: A-: B- TypeEpidemic Plasmid Carrying bla CTX-M-65, fosA3 and rmtB, SpreadingBoth in Pets and a Pig Farm in ChinaJ. Liu, PhD - Associate Professor, L. He, MD - Master, Z. Chen, BD -Professor; South China Agricultural Univ., Guangzhou, China.9:00 a.m.C1-1204 Role of Amino Acid Variation on Activity and Evolution ofCTX-M Family of-LactamasesB. Fryszczyn, BS - Graduate Student, T. Palzkill, PhD - Principal Investigator;Baylor Coll. of Med., Houston, TX.9:15 a.m.C1-1205 Epidemic I1-Type Plasmid Responsible for the Emergenceand Wide Dissemination of CTX-M-9 Group ESBLs in Escherichiacoli from the Intestinal Microbiota of Healthy Children in BoliviaE. Riccobono, MS - PhD Student 1 , L. Pallecchi, MD - Professor 1 , T. DiMaggio, MS - Technician 1 , V. Di Pilato, MS - PhD 1 , A. Mantella, MS -Professor 2 , C. Trigoso, MD - Professor 3 , A. Bartoloni, MD - Professor 2 ,G. M. Rossolini, MD - Professor 1 ; 1 Univ. of Siena, Siena, Italy, 2 Univ. ofFlorence, Florence, Italy, 3 Univ. Mayor de San Andrés, La Paz, Bolivia,Plurinational State of.9:30 a.m.C1-1206 Mutations in R220 In PER-2-Lactamase Resulting inA Decreased Susceptibility to Inhibitors Also Impact in theCatalytic Activity Towards SubstratesM. Ruggiero, PhD student - Fellow 1 , E. Sauvage, PhD - Researcher 2 , F.Troncoso, PhD - Researcher 1 , L. Curto, PhD - Researcher 1 , M. Galleni, PhD- Researcher 2 , P. Power, PhD - Researcher 1 , G. Gutkind, PhD - Researcher 1 ;1Fac. Farm. y Bioq - UBA, Buenos Aires, Argentina, 2 CIP, Univ. de Liège,Liege, Belgium.9:45 a.m.C1-1207 PER-2-Producing Enterobacter cloacae (PER-2-ECL): FirstReport in BrazilK. S. Nogueira, PhD - PhD 1 , L. C. C. Fehlberg, MS - PhD student 2 , R.Cayô, MS - PhD Student 2 , A. G. Nicoletti, MS - PhD Student 2 , J. K.Palmeiro, MS - PhD Student 1 , A. C. Gales, MD - MD 2 , L. M. Dalla-Costa,PhD - PhD 1 ; 1 UFPR, Curitiba, Brazil, 2 UNIFESP, São Paulo, Brazil.10:00 a.m.C1-1208 Plasmid Sequencing of Four blaCTX-M EncodingPlasmids, Including the Identification of a Novel blaCTX-M-32IncX1C. J. Boinett, MSc - PhD Student 1,2 , M. AbuOun, PhD - Research Scientist 1 ,M. J. Woodward, PhD - Professor of Human Gut Microbiome Studies 3 , M. F.Anjum, PhD - Senior Scientist 1 ; 1 Animal Hlth. and Vet. Lab. Agency, Surrey,United Kingdom, 2 Royal Holloway, Univ. of London, Surrey, United Kingdom,3 Reading Univ., Reading, United Kingdom.10:15 a.m.C1-1209 SHV-129: A Gateway to Global Suppressors (GSs) in theSHV-Lactamase FamilyM. L. Winkler, BA - Student 1 , A. M. Hujer, BS - Research Assistant 1 , C.Lascols, MS - Molecular Microbiologist 2 , M. Taracila, MS - Research Assistant 1 ,R. A. Bonomo, MD - Professor 3 ; 1 CWRU, Cleveland, OH, 2 IHMA, Schaumburg,IL, 3 CWRU, VAMC, Cleveland, OH.------------------------------------------------------------------------157(C2)Slide SessionCarbapenemases Go GlobalTuesday, 8:30 a.m.–11:00 a.m. ..... Esplanade Ballroom 300UAN: 0391-9999-12-128-L04-PModerators:Johann Pitout, MD – ProfessorUniv. of Calgary, Calgary, Canada.Jesús Rodríguez-Baño, MD, PhD – ProfessorHosp. Univ. Virgen Macarena, Seville, Spain.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Describe the molecular epidemiology of enterobacteria that producecarbapenemase;> Describe the virulence associated with enterobacteriaceae; and> Describe the worldwide emergence of enterobacteria carbapenemase.Presentations:8:30 a.m.C2-1210 Molecular Epidemiology and Virulence Factors of Carbapenemase-ProducingKlebsiella Pneumoniae (C-Kp), and FirstReport of bla OXA-48in the U.S.A.C. Lascols, Masters (MS) - Molecular Microbiologist 1 , M. Hackel, PhD -Lab Manager 1 , G. Peirano, PhD - Research Associate 2 , J. D. D. Pitout, MD -Professor 2 ; 1 IHMA, Schaumburg, IL, 2 Univ. of Calgary, Calgary, Canada.134September 9-12 |

TUESDAY SCIENTIFIC SESSIONS8:45 a.m.C2-1211 The Increasing Spread of KPC-Producing Klebsiellapneumoniae in Europe: Results from an Italian Nationwide SurveyT. Giani, PhD - PhD 1 , B. Pini, MD - MD 2 , F. Arena, MD - MD 1 , V.Conte, BS - St 1 , L. Pagani, PhD - Professor 3 , F. Luzzaro, MD - MD 2 , G.M. Rossolini, MD - Professor 1 ; 1 Univ. of Siena, Siena, Italy, 2 A. ManzoniHosp., Lecco, Italy, 3 Univ. of Pavia, Pavia, Italy.9:00 a.m.C2-1212 Outbreak of Klebsiella pneumoniae Carbapenemase-2- ProducingK. pneumoniae Sequence Type 11 in Taiwan, 2011C. Liu, MD - Visiting Staff 1 , C. Lee, MD - Visiting Staff 2 , C. Liao, MD -Visiting Staff 1 , W. Lee, MD - Visiting Staff 3 , Y. Liu, MD - Visiting Staff 4 ,J. Mu, PhD - Research Staff 5 , M. Lee, MD - Visiting Staff 6 , P. Hsueh, MD- Professor 7 ; 1 Far Eastern Mem. Hosp., New Taipei City, Taiwan, 2 MackayMem. Hosp., Taipei City, Taiwan, 3 Wan Fang Hosp., Taipei City, Taiwan,4Shuang Ho Hosp., Taipei Med. Univ. and Sch. of Med., New Taipei City,Taiwan, 5 Res. and Diagnostic Ctr., Ctr. for Disease Control, Taipei City, Taiwan,6 Chung Shan Med. Univ. Hosp., Taichung City, Taiwan, 7 Natl. TaiwanUniv. Hosp., Natl. Taiwan Univ. Coll. of Med., Taipei City, Taiwan.9:15 a.m.C2-1213 Surveillance and Enzyme Characterization of Carbapenem-Resistant Enterobacteriaceae (CRE) in an Indiana Health CareSetting (2009-2012)K. Bush, PhD - Professor 1 , T. Davis, MS - Student 1 , R. Lee, PhD -Lecturer 1,2 , R. Relich, PhD - Fellow 3 , G. A. Denys, PhD - Clinical Director,Microbiology 3 ; 1 Indiana Univ. Bloomington, Bloomington, IN, 2 Dow AgroSci., Indianapolis, IN, 3 Indiana Univ. Hlth., Indianapolis, IN.9:30 a.m.C2-1214 VIM-1-Producing Escherichia coli ST131 and Enterobactercloacae, Ontario, Canada, 2008-2011N. Tijet, PhD 1 , O. Lastovetska, MS 1 , G. MacMullin, MS 1 , C. Vermeiren,MS 2 , P. Wenzel, MS 3 , B. M. Willey, MS 4 , D. J. Farrell, PhD 1 , D. E. Low,MD 1 , S. N. Patel, PhD 1 , R. G. Melano, PhD 1 ; 1 Publ. Hlth. Ontario Lab.,Toronto, Canada, 2 Shared Hosp. Labs, Toronto, Canada, 3 Halton HealthcareServices, Oakville, Canada, 4 Mt Sinai Hosp., Toronto, Canada.9:45 a.m.C2-1215 Emergence of IMP-1 Producing Klebsiella pneumoniae in aTertiary Care Hospital in KoreaH. Yang, MD - Assistant Professor 1 , J. Yoo, PhD - Research Staff 2 , J. Chung,MD - Clinical Assistant Professor 3 , J. Park, MD - Assistant Professor 1 ; 1 KosinUniv. Coll. of Med., Busan, Korea, Republic of, 2 Korea NIH, Osong, Korea,Republic of, 3 Dongguk Univ. Ilsan Hosp., Goyang, Korea, Republic of.10:00 a.m.C2-1216 Clinical and Molecular Characterization of Carbapenemase-Resistant K. pneumoniae (KPC) Strains from a Tertiary CenterC. Clancy, MD - Associate Professor 1 , R. Shields, PharmD - Assistant Professor2 , J. Hong, MD - Fellow 2 , L. Chen, PhD - Research Associate 3 , Y. Zhao,PhD - Research Associate 3 , B. N. Kreiswirth, PhD - Professor 3 , S. Park, MD- Research Associate 3 , D. S. Perlin, MD - Professor 3 , Y. Doi, MD - AssistantProfessor 2 , E. Kwak, MD - Assistant Professor 2 , F. Silveira, MD - AssistantProfessor 1 , W. Pasculle, PhD - Director Microbiology 2 , M. Nguyen, MD -Professor 2 ; 1 Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA, 2 Univ. ofPittsburgh, Pittsburgh, PA, 3 Publ Hlth Res Ins, UMDNJ, Newark, NJ.10:15 a.m.C2-1217 Molecular Epidemiology of KPC-Producers Enterobacteriaceae(ETB) in Argentina: An update 2006-2012S. Gomez, D. Faccone, M. Raporport, L. Guerriero, P. Ceriana, A. Petroni,F. Pasteran, Argentinean Kpc-Group, A. Corso; INEI-ANLIS-MALBRAN,Buenos Aires, Argentina.10:30 a.m.C2-1218 Molecular Epidemiology of KPC-2-Producing Klebsiellapneumoniae in Brazil: Clonal Spread of CC11 (ST11, ST437, andST340) and Dispersion of blaKPC-2 Associated with Tn4401 “a”P. S. Pereira, MS- PhD Student, C. F. M. Araújo, BSc - Student, L. M. Seki,PhD - Researcher, A. D. Carvalho-Assef, PhD - Researcher, M. D. Asensi,PhD - Researcher, Brazilian KPC Study Group; Oswaldo Cruz Inst. - IOC-FIOCRUZ, Rio de Janeiro, Brazil.10:45 a.m.C2-1219 First Reported Case of New Delhi Metallo (NDM)Carbapenem-Positive Gene in Escherichia coli from CompanionAnimals in the United StatesB. W. Shaheen, DVM, MS, PhD - Post Doctoral Research Fellow 1 , R. Nayak,MS, PhD - Research Scientist 1 , D. M. Boothe, DVM, MS, PhD - Professor 2 ;1U.S. FDA, Jefferson, AR, 2 Auburn Univ., Auburn, AL.------------------------------------------------------------------------158(L1)Slide SessionNew Insights in Bacterial MeningitisTuesday, 8:30 a.m.–11:00 a.m. ..... Esplanade Ballroom 309UAN: 0391-9999-12-129-L04-PModerators:Petter Brandtzag, MD, PhD - ProfessorUniv. of Oslo, Oslo, Norway.Stefano Giulieri, MD - Service of Infectious DiseasesUniv. of Lausanne, Lausanne, Switzerland.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Improve clinical evaluation and management of patients with meningitis;> Critically evaluate information regarding the diagnosis and prognosis ofacute bacterial meningitis; and> Integrate new knowledge regarding cerebrospinal fluid analysis intoclinical decision making for patients with meningitis.Presentations:8:30 a.m.1220 State-of-the-Art MinilectureUpdate on Neisseria meningitidis: Pathogenesis and ManagementPetter Brandtzag, MD, PhD - ProfessorUniv. of Oslo, Oslo, Norway.9:00 a.m.L1-1221 Is CSF Lactate the Best Parameter for DiscriminatingBacterial from Viral Community-Acquired Meningitis?S. Giulieri, MD - Staff Physician, C. Chapuis, MD - Consultant, K. Jaton,PhD - Staff Microbiologist, J. Bille, MD - Professor, P. Meylan, MD -Professor, O. Manuel, MD - Staff Physician, O. Marchetti, MD - Professor;Univ. of Lausanne, Lausanne, Switzerland.Final Program135

Tuesday SCIENTIFIC SESSIONS9:15 a.m.L1-1222 Listeria monocytogenes Meningitis: Implementation ofAdjunctive Dexamethasone Therapy and Risk Factors forUnfavorable OutcomeM. M. Koopmans, BS - Student, M. C. Brouwer, MD, PhD - Neurologist,A. van der Ende, PhD - Medical Microbiologist, D. van de Beek, MD, PhD -Neurologist; Academic Med. Ctr., Amsterdam, The Netherlands.9:30 a.m.L1-1223 Delayed Cerebral Thrombosis in Bacterial Meningitis: AProspective Cohort StudyM. J. Lucas, MD - PhD student, M. C. Brouwer, MD, PhD - Neurologist, D.van de Beek, MD, PhD - Neurologist; Academic Med. Ctr., Amsterdam, TheNetherlands.9:45 a.m.L1-1224 Acute Community-Acquired Meningitis in the ICU: EarlyTreatment with Rifampicin is Associated with Lower MortalityC. Bretonnière, MD - Doctor 1 , M. Jozwiak, MD - Resident 1 , C. Giraud,MD - Doctor 2 , P. Beuret, MD - Doctor 3 , J. Trouillet, MD - Professor 4 , J.Teboul, MD - Professor 5 , J. Caillon, PharmD - Doctor 1 , G. Potel, MD -Professor 6 , D. Villers, MD - Professor 1 , D. Boutoille, MD - Professor 1 , C.Guitton, MD - Doctor 1 ; 1 CHU, Nantes, France, 2 CHU, Rouen, France, 3 CH,Roanne, France, 4 APHP-PSL, Paris, France, 5 APHP-BCT, Bicêtre, France,6Faculté de Med., Nantes, France.------------------------------------------------------------------------159(M)Slide SessionMycology for the BedsideTuesday, 8:30 a.m.–11:00 a.m. .................. Room 122UAN: 0391-9999-12-130-L04-PModerators:Tania Sorrell, MB, BS, MD, FRACP - ProfessorUniv. of Sydney, Westmead, Australia.Raoul Herbrecht, MD - ProfessorHosp. de Hautepierre, Strasbourg, France.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Identify specific aspects of clinical mycology;> Assess the impact of cost for fungal infections;> Discuss the epidemiology of fungal infections; and> Identify framing issues around guidelines and risk groups for fungal infections.Presentations:8:30 a.m.M-1225 Application of the 2008 Definitions for Invasive FungalDiseases to the Voriconazole vs Amphotericin B for Therapy ofInvasive Aspergillosis Trial: A Collaborative EORTC / MSGStudy (MSG 05)R. Herbrecht, MD - Professor 1 , T. F. Patterson, MD - Professor 2 , M. A. Slavin,MD - Professor 3 , O. Marchetti, MD - Professor 4 , J. Maertens, MD - Professor 5 ,H. T. Schlamm, MD - Medical Director 6 , J. P. Donnelly, PhD - Professor 7 , P. G.Pappas, MD - Professor 8 ; 1 CHU, Strasbourg, France, 2 UTHSC and STVHCS,San Antonio, TX, 3 Peter MacCallum Cancer Ctr., Melbourne, Australia,4CHUV/Univ., Lausanne, Switzerland, 5 UZ Gasthuisberg, K.U.Leuven, Leuven,Belgium, 6 Pfizer, New York, NY, 7 Radboud Univ Med Ctr, Nijmegen, Netherlands,8 Univ Alabama, Birmingham, AL.8:45 a.m.M-1226 Is Halo Sign the Earliest Sign of Pulmonary InvasiveAspergillosis (PIA)?K. Kyo, MD - Staff, T. Ochi, MD - Staff, T. Okatani, MD - Staff, M. Itagaki,MD - Staff, R. Imanaka, MD - Staff, Y. Katayama, MD - Staff, T. Kyo,MD - Chairman; Hiroshima Red Cross Atomic-Bomb Survivors Hosp.,Hiroshima, Japan.9:00 a.m.M-1227 Invasive Aspergillosis -Associated Immune ReconstitutionSyndrome in Lung Transplant RecipientsWithdrawn9:15 a.m.M-1228 Environmental Variables Associated with an Increased Riskof Invasive AspergillosisM. Labori, MD - Physician 1 , C. Garcia-Vidal, PhD - Physician 1 , M. Peghin,MD - Physician 2 , A. Moreno, PhD - Physician 3 , I. Ruiz, PhD - Physician 2 ,C. Cervera, PhD - Physician 3 , C. Gudiol, MD - Physician 1 , E. Rossello,MD - Physician 2 , J. Bellacasa, MD - Physician 3 , J. Ayats, MD - Physician 1 ,P. Barba, MD - Physician 2 , J. Carratalà, PhD - Professor 1 ; 1 Hosp. Bellvitge,Barcelona, Spain, 2 Hosp. VallHebron, Barcelona, Spain, 3 Hosp. Clinic,Barcelona, Spain.9:30 a.m.M-1229 Efficacy of Anidulafungin in 504 Patients with Invasive Candidiasis(IC) from a Pooled Clinical Trial DatabaseB. Kullberg, MD - Professor of Medicine 1 , U. Conte, PharmD - Clinician 2 , H.Schlamm, MD - Medical Development Lead 2 , P. Biswas, PhD - Statistician 2 ,R. Swanson, PhD - Clinical Development Lead 2 , M. Ruhnke, MD - Professorof Medicine 3 ; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands,2Pfizer Inc., New York, NY, 3 Charité Univ., Berlin, Germany.9:45 a.m.M-1230 Cost-of-Illness Analysis of Candidemia in Patients on theIntensive Care UnitS. Heimann, MS - Scientist, O. Cornely, Professor of Medicine - Scientist,H. Wisplinghoff, MD - Scientist, M. Vehreschild, MD - Scientist, B. Franke,data manager - Scientist, J. Glossmann, MD - Scientist, J. Vehreschild, MD -Scientist; Univ. Hosp. of Cologne, Köln, Germany.10:00 a.m.M-1231 Management Bundles for Invasive Candidiasis (IC): TheImpact of Compliance on Clinical Efficacy and MortalityY. Takesue, MD - Professor 1 , S. Takakura, MD - Associate Professor 1 , H.Mikamo, MD - Professor 1 , S. Oda, MD - Professor 1 , Y. Kitagawa, MD -Professor 1 , S. Kohno, MD - Professor 2 ; 1 ACTION Project Committee, Tokyo,Japan, 2 Mycoses Forum, Tokyo, Japan.10:15 a.m.M-1232 Antifungal Stewardship: A Bedside Intervention ApproachP. Muñoz, MD, PhD - ID Consultant, M. Valerio, MD - ID Consultant,B. Cáliz, PharmD - Pharmacist, C. Rodríguez, PharmD - Pharmacist, M.Sanjurjo, PharmD - Head of Pharmacy Dept, P. Escribano, PhD - Research, J.Guinea, PhD - Research, COMIC Study Group-PROMULGA, E. Reigadas,MD - Research, E. Bouza, MD, PhD - Head of Clin Microb and ID Dept;Hosp. Gen., Gregorio Marañón. Univ. of Madrid, Madrid, Spain.136September 9-12 |

TUESDAY SCIENTIFIC SESSIONS10:30 a.m.M-1233 Longitudinal Clinical Findings and Outcome amongCryptococcus gattii Patients in British ColumbiaP. Phillips, MD - Clinical Professor 1 , L. MacDougall, MSc - Epidemiologist 2 ,D. Thompson, PhD - Statistician 2 , E. Galanis, MD - Assistant Professor,Epidemiologist 2,3 ; 1 St. Paul’s Hosp., Univ. of British Columbia, Vancouver,Canada, 2 British Columbia Ctr. for Disease Control, Vancouver, Canada,3Univ. of British Columbia, Vancouver, Canada.10:45 a.m.M-1234 The Outcome of Invasive Fusariosis Has Improved in theLast DecadeM. Nucci, MD - Associate Professor 1 , M. Vehreschild, MD - Professor 2 , E.Velasco, MD - Clinician 3 , F. Queiroz-Telles, MD - Associate Professor 4 , B.Simoes, MD - Associate Professor 5 , C. A. Souza, MD - Professor of Medicine 6 ,S. Cesaro, MD - Professor 7 , N. Hamerschlak, MD - Clinician 8 , O. Cornely,MD - Professor 2 , E. Anaissie, MD - Professor of Medicine 9 ; 1 Federal Univ.of Rio de Janeiro, Rio de Janeiro, Brazil, 2 Univ. Hosp. Cologne, Cologne,Germany, 3 Natl. Cancer Inst., Rio de Janeiro, Brazil, 4 Federal Univ. of Parana,Curitiba, Brazil, 5 Univ. of Sao Paulo, Ribeirao Preto, Brazil, 6 State Univ. ofCampinas, Campinas, Brazil, 7 Azienda Ospedaliera Univ. Integrata, Verona,Italy, 8 Hosp. Albert Einstein, Sao Paulo, Brazil, 9 Univ. of Arkansas for Med.Sci., Little Rock, AR.------------------------------------------------------------------------160(V)Slide SessionHepatitis and Herpes VirusesTuesday, 8:30 a.m.–11:00 a.m. .................. Room 254UAN: 0391-9999-12-131-L04-PModerators:Paul D. Griffiths, MD, DSc - ProfessorUniv. Coll. Sch. of Med., London, United Kingdom.Vincent R. Racaniello, PhD - ProfessorColumbia Univ. Coll. of Physicians & Surgeons, New York, NY.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Evaluate prospects for CMV vaccine;> Review new treatments for Hepatitis; and> Describe epidemiology and clinical presentation of herpes virus infections.Presentations:8:30 a.m.1235 State-of-the-Art MinilectureCMV Vaccine: Is there a Future?Paul D. Griffiths, MD, DScUniv. Coll. London, London, United Kingdom.V-1236 Triple Therapy with TMC435, Peginterferon and Ribavirin inHCV Genotype 1 Infected Treatment Experienced Patients: TheASPIRE TrialWithdrawn9:00 a.m.V-1237 Prevalence of Naturally Occurring Hepatitis C Virus (HCV)Variants with Primary Resistance to the Direct-Acting Antivirals(DAA): Analysis of 722 Complete Genome Sequences and 307NS3/4A and NS5B Partial SequencesM. B. Kolarovic, Junior, Assitant - School of Medicine, A. E. Farinati, Sr.,MD - School of Medicine; Salvador Univ., Buenos Aires, Argentina.9:15 a.m.V-1238 Seroepidemiology of Hepatitis E Virus Infection AmongMen Who Have Sex with Men in TaiwanW. Liu, MS - Research Assistant 1 , C. Lu, MD - Attending Physician 2 , Z.Yang, MS - Student 3 , S. Chang, DSc - Associate Professor 3 , C. Hung, MD,MSc, PhD - Associate Professor 1 , P. Chen, MD, PhD - Professor 1 ; 1 Natl.Taiwan Univ. Hosp., Taipei, Taiwan, 2 Natl. Taiwan Univ. Hosp. Hsin-ChuBranch, Hsin-Chun, Taiwan, 3 Natl. Taiwan Univ. Coll. of Med., Taipei,Taiwan.9:30 a.m.V-1239 Comparison of Central Nervous System Infection in HerpesSimplex Virus Type 1 and Herpes Simplex Virus Type 2: the ClinicalManifestations and Cerebrospinal Fluid FindingsS. Moon, MD - ID Fellow 1,2 , Y. Lee, MD - ID Fellow 1 , H. Hong, MD -ID Fellow 1 , S. Park, MD - ID Fellow 1 , S. Park, MD - Professor 3 , K. Park,MD - Professor 1 , Y. Chong, MD - Professor 1 , S. Kim, MD - Professor 1 , H.Sung, MD - Professor 1 , S. Lee, MD - Professor 1 , Y. Kim, MD - Professor 1 ,J. Woo, MD - Professor 1 , S. Choi, MD - Professor 1 ; 1 Asan Med. Ctr., Univ.of Ulsan Coll. of Med., Seoul, Korea, Republic of, 2 Graduate Sch. of KyungHee Univ., Seoul, Korea, Republic of, 3 Dongguk Univ. Ilsan Hosp., Goyang,Korea, Republic of.9:45 a.m.V-1240 Varicella-Zoster Meningoencephalitis: 16 Years of Experiencein the Era of PCRI. Pelegrin, MD - Fellow, I. Oriol, MS - Intern, J. Niubó, PhD - consultant,S. Martinez-Yelamos, PhD - Consultant, J. Ariza, PhD - Professor, P. F-Viladrich, PhD - Professor, C. Cabellos, PhD - Consultant; Hosp. Universitaride Bellvitge, Barcelona, Spain.10:00 a.m.V-1241 Age-Specific Epstein-Barr Virus (EBV) Antibody (Ab)Prevalence and Risk Factors for Early Acquisition of InfectionL. M. Condon, MD - Attending Pediatrician 1 , M. D. Rabinovitch, MD -Attending Pediatrician 1 , L. E. Cederberg, MD - Attending Pediatrician 1 , R.V. Liebo, MD - Attending Pediatrician 1 , A. S. Delaney, MPH - Research Assistant2 , H. H. Balfour, jr, MD - Professor 2 ; 1 HealthPartners, Minneapolis-StPaul, MN, 2 Univ. of Minnesota, Minneapolis, MN.10:15 a.m.V-1242 Diabetic Critical Patients Have a Higher Risk of CytomegalovirusDiseaseP. López Roa, PharmD - Research Assistant 1 , M. Gónzalez del Vecchio, MD- Research Assistant 1 , P. Muñoz, PhD - Professor 2 , B. Padilla, MD - ResearchAssistant 1 , P. Catalán, PharmD - Research Assistant 1 , E. Bouza, PhD - Professor1 ; 1 Hosp. Gen. Univ. Gregorio Marañon. Univ. of Madrid., Madrid, Spain,2Hosp. Gen. Univ. Gregorio, Madrid, Spain.Final Program137

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALKTuesday, September 11 | 11:15 a.m. - 12:15 p.m. | Halls A-CNew Developments in TransplantationConvener:Emily A. Blumberg, MD - Professor of MedicinePerelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.Presentations:Refractory KPC Carbapenemase-Producing Klebsiella pneumoniaeBacteremia is Tolerated by Solid Organ TransplantPatients (SOT Pts)C. Clancy; Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA.Chronic High EBV Load Carriage Has Low Predictive Value toDetect Post-Transplant Lymphoproliferative Disorder (PTLD)in Solid-Organ Transplant RecipientsC. Gardiol; Univ. Hosp. Ctr. of Lausanne, Lausanne, Switzerland.Risk Factors and Outcomes of Bacteremia Caused by Drug-Resistant ESKAPE Pathogens in Solid Organ Transplant(SOT) RecipientsM. Bodro; IDIBELL Biomedical Res. Inst., Hosp.Llobregat. Barcelona,Spain.The Molecular Epidemiology of a Respiratory Syncytial VirusOutbreak Among Oncology and Hematopoietic Stem CellTransplant (HSCT) PatientsH. Y. Chu; Univ. of Washington, Seattle, WA.Diagnosis of Invasive Aspergillosis and Mucormycosis guidedby PCR Assays from Bronchoalveolar Lavage Fluid in AllogenicStem Cell RecipientsH. Lellek; Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany.Tuesday, September 11 | 12:15 p.m. - 1:15 p.m. | Halls A-CFungal Infections at the BedsideConvener:John Perfect, MD - Interim Chief, Division of Infectious Diseases andInternational HealthDuke Univ. Med. Ctr., Durham, NC.Presentations:The Clinical Course Following the Use of Corticosteroids forSymptomatic Relief of Primary Pulmonary Coccidioidomycosisin Immunocompetent PersonsN. Azadeh; Mayo Clinic Arizona, Phoenix, AZ.Effectiveness of Posaconazole Vs Fluconazole as AntifungalProphylaxis in Hematology-Oncology Patients at DukeUniversity Hospital (DUH) 2004-2010H. C. Kung; Duke Clinical Res. Inst., Durham, NC.Pilot Prospective Study of High Dose (10 mg/kg/d) LiposomalAmphotericin B (L-AmB) for the Initial Treatment of Mucormycosis:“AMBIZYGO” TrialF. Lanternier; Hosp. Necker Enfants malades, Paris, France; Inst. Pasteur,Paris, France.Systemic Candidiasis Increased Mortality in ICU InfectedPatients with CirrhosisH. Dupont; Pole d’Anesthesie-Reanimation, CHU d’Amiens, Amiens,France.The Tolerability of Amphotericin B Lipid Complex Formulationin Patients With Severe Infusion Reactions to LiposomalAmphotericin BD. Farmakiotis; MD Anderson Cancer Ctr., Houston, TX.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------161(A)Poster SessionClinical Pharmacology of Antiviral and Anti-TuberculosisAgentsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:A-1243 Pharmacokinetic/Pharmacodynamic Model for NeuraminidaseInhibitor Oseltamivir in the FerretK. Yang 1,2 , G. Rao 1,2 , M. Reddy 2 , C. Pamulapati 2 , B. M. Marathe 3 , E.A. Govorkova 3 , C. R. Rayner 2 , A. Forrest 1 ; 1 SUNY Buffalo, Buffalo, NY,2Roche, Nutley, NJ, 3 St. Jude Children’s Res. Hosp., Memphis, TN.A-1244 Population Pharmacokinetics (PPK) of Oseltamivir in Pediatricand Adult SubjectsM. A. Kamal 1 , S. A. Van Wart 2 , C. R. Rayner 1 , V. Subramoney 1 , D. K.Reynolds 2 , C. C. Bulik 2 , P. F. Smith 1 , S. M. Bhavnani 2 , A. Forrest 2 ;1Hoffman-LaRoche, Nutley, NJ, 2 ICPD, Latham, NY.A-1245 A Prospective, Open-Label Study of the Pharmacokinetics,Safety and Pharmacodynamics of Oseltamivir in Infants

TUESDAY SCIENTIFIC SESSIONSA-1248 Cytochrome P450 (CYP) Interactions with the HCV ProteaseInhibitor BI 201335 in Healthy VolunteersJ. P. Sabo 1 , A. D. Kashuba 2 , C. H. Ballow 3 , M. Haschke 4 , C. Yong 1 , T. R.MacGregor 1 , Y. Li 1 , J. Kort 1 ; 1 Boehringer Ingelheim Pharmaceuticals Inc,Ridgefield, CT, 2 Univ. of North Carolina, Chapel Hill, NC, 3 Buffalo ClinicalRes. Ctr., Buffalo, NY, 4 Univ. Hosp. Basel, Basel, Switzerland.A-1249 Lack of Pharmacokinetic (PK) Interaction BetweenRilpivirine and the Integrase Inhibitors Dolutegravir andS/GSK1265744S. L. Ford 1 , E. Gould 1 , S. Chen 1 , D. Margolis 1 , W. Spreen 1 , H. Crauwels 2 ,S. Piscitelli 1 ; 1 GlaxoSmithKline, Research Triangle Park, NC, 2 Janssen R&D,Beerse, Belgium.A-1250 Pharmacokinetics of Cobicistat-Boosted ElvitegravirAdministered in Combination with Methadone orBuprenorphine/NaloxoneR. D. Bruce 1 , P. Winkle 2 , J. Custodio 3 , X. Ying 4 , M. Rhee 3 , J. Andrews 3 ,B. P. Kearney 3 , S. Ramanathan 3 ; 1 Yale Univ., New Haven, CT, 2 AnaheimClinical Trials, Anaheim, CA, 3 Gilead Sci., Foster City, CA, 4 Gilead Biometrics,Foster City, CA.A-1251 Mid-Dosing Versus Trough Concentration of Atazanavirand the Risk of Hyperbilirubinemia and Virological OutcomeS. Lin 1,2 , C. Lu 3 , S. Chang 1 , Y. Chen 1 , C. Hung 2 ; 1 Natl. Taiwan Univ.,Taipei, Taiwan, 2 Natl. Taiwan Univ. Hosp., Taipei, Taiwan, 3 Natl. TaiwanUniv. Hosp., Hsinchu, Taiwan.A-1252 Comparing Raltegravir Genital Tract Distribution in HIV-Infected Men and WomenE. Dobson 1 , A. Luque 1 , F. Aslam 1 , R. DiCenzo 2,1 ; 1 Univ. of Rochester,Rochester, NY, 2 Albany Coll. of Pharmacy and Hlth. Sci., Albany, NY.A-1253 Raltegravir: Intra-Cellular Pharmacokinetics/PharmacodynamicsG. Kumar 1 , F. De Salvador-Guillouet 2 , J. Cottalorda 3 , R. Garraffo 4 , P.Roger 5 ; 1 Univ. of Nice Sophia Antipolis, Nice, France, 2 Hosp. L’Archet 1,Nice, France, 3 L’Archet 2, Nice, France, 4 Pasteur, Nice, France, 5 L’Archet 1,Nice, France.A-1254 Comparative Study of the Effects of Anti-TB Drugs andAnti-HIV Drugs on CYP3A4 and P-GlycoproteinY. Horita, N. Doi; Janpan Anti-Tuberculosis Assosiation, Res. Inst. of Tuberculosis,Tokyo, Japan.A-1255 Delamanid, a New Drug for Multidrug-Resistant Tuberculosis(MDR-TB), and Efavirenz Do Not Show Clinically RelevantDrug Interactions in Healthy SubjectsC. Petersen 1 , A. Paccaly 1 , J. Kim 1 , S. Roth 2 , R. Stoltz 3 , C. Wells 1 ; 1 OtsukaNovel Products and Otsuka Pharmaceutical Dev. and Commercialization,Rockville, 2 Otsuka Pharmaceutical Dev. and Commercialization, Rockville,3Covance Clinical Res., Evanston, IN.A-1256 Population Pharmacokinetics (PK) of TMC207 and its M2Metabolite with Efavirenz (EFV) Demonstrate Reduced ExposureE. Svensson 1 , K. E. Dooley 2 , F. Aweeka 3 , J. Park 4 , M. O. Karlsson 1 ; 1 UppsalaUniv., Uppsala, Sweden, 2 Johns Hopkins Univ. Sch. of Med., Baltimore,3Univ. of California, San Francisco, CA, 4 Harvard Sch. of Publ. Health,Boston, MA.A-1257 Whole Blood Mycobactericidal Activity (WBA) of Bedaquiline(BDQ, TMC207) Alone and in Combination with Rifampin(RIF) or Rifabutin (RBT) After Oral Dosing of Healthy VolunteersC. E. Good 1 , A. M. B. Healan 2 , J. L. Blumer 3 , S. A. Fulton 1,2 , M. R. Jacobs 1,2 ,K. Kreller 4 , R. A. Salata 1,2 , R. S. Wallis 5,2,2 ; 1 Univ. Hosp. Case Med. Ctr.Cleveland, OH, 2 Case Western Reserve Univ., Cleveland, OH, 3 Univ. Toledo,Toledo, OH, 4 Clin. RM, Hinckley, OH, 5 Pfizer, Groton, CT.A-1258 The Pharmacokinetics (PK) of Second Line Anti-TuberculosisAgents with and without TMC207, an InvestigationalAntimycobacterial Agent, in Patients with MDR-TBR. van Heeswijk 1 , A. Diacon 2 , A. Pym 3 , P. Meyvisch 1 , T. De Marez 4 , B.Dannemann 4 , R. Hoetelmans 1 ; 1 Janssen Infectious Diseases BVBA, Beerse,Belgium, 2 Stellenbosch Univ., Stellenbosch, South Africa, 3 Med. Res. Council,Durban, South Africa, 4 Janssen R&D LLC., Titusville, NJ.A-1259 Corrected QT Interval (QTcF) Prolongation in a Phase 2Open-Label Trial of TMC207 Plus Background Regimen (BR)as Treatment for MDR-TB: Effect of Co-Administration withClofazimine (CFZ)B. R. Dannemann 1 , N. Bakare 1 , T. De Marez 1 , N. Lounis 2 , R. van Heeswijk 2 ,P. Meyvisch 2 , M. Haxaire 2 , K. Andries 2 , D. Everitt 3 , A. Upton 4 ; 1 JanssenRes. & Dev., LLC., Raritan, NJ, 2 Janssen Infectious Diseases BVBA, Beerse,Belgium, 3 TB Alliance, New York, NY, 4 Discovery TB Alliance, New York, NY.A-1260 The Pharmacokinetics Of TMC207, an InvestigationalAntimycobacterial Agent, in Subjects with Moderate HepaticImpairmentR. van Heeswijk 1 , A. Vandevoorde 1 , P. Meyvisch 1 , T. De Marez 2 , B.Dannemann 2 , R. Hoetelmans 1 ; 1 Janssen Infectious Diseases BVBA, Beerse,Belgium, 2 Janssen R&D LLC, Titusville, NJ.A-1261 Pharmacokinetic/Pharmacodynamic (PK/PD) AnalysisEvaluating the Effects of Rifampin (RIF) and Linezolid (LZD),Alone and in Combination, against Mycobacterium tuberculosis(Mtb) in the Non-Replicating Persister (NRP) State Using Datafrom a Hollow-Fiber Infection Model (HFIM)O. O. Okusanya 1 , B. Xue 1 , T. Zhu 2 , P. H. van der Graaf 3 , C. C. Bulik 1 , S.M. Bhavnani 1 , P. G. Ambrose 1 , A. Forrest 1 ; 1 ICPD, Latham, NY, 2 Pfizer,Inc., Groton, CT, 3 Pfizer, Inc., Sandwich, United Kingdom.A-1262 Pharmacokinetic/Pharmacodynamic (PK/PD) AnalysisEvaluating the Effects of Rifampin (RIF), PNU-100480(Sutezolid, U-480), and its Metabolite PNU-101603 (U-603),Alone and in Combination, against Mycobacterium tuberculosis(Mtb) in the Non-Replicating Persister (NRP) State Using DataFrom a Hollow-Fiber Infection Model (HFIM)O. O. Okusanya 1 , B. Xue 1 , T. Zhu 2 , P. H. van der Graaf 3 , C. C. Bulik 1 , S.M. Bhavnani 1 , P. G. Ambrose 1 , A. Forrest 1 ; 1 ICPD, Latham, NY, 2 PfizerInc., Groton, CT, 3 Pfizer Inc., Sandwich, United Kingdom.A-1263 Pharmacokinetic/Pharmacodynamic (PK/PD) AnalysisEvaluating the Effects of Rifampin (RIF), Linezolid (LZD),PNU-100480 (Sutezolid, U-480), and its Metabolite PNU-101603(U-603), as Single Agents, against Mycobacterium tuberculosis(Mtb) in Log-Phase Growth Using Data from a Hollow-FiberInfection Model (HFIM)B. Xue 1 , O. O. Okusanya 1 , T. Zhu 2 , P. H. van der Graaf 3 , C. C. Bulik 1 , S. M.Bhavnani 1 , P. G. Ambrose 1 , A. Forrest 1 ; 1 ICPD, Latham, NY, 2 Pfizer, Inc.,Groton, CT, 3 Pfizer, Inc., Sandwich, United Kingdom.Final Program139

Tuesday SCIENTIFIC SESSIONSA-1264 PK and Bactericidal Activity in Sputum and Blood of PNU-100480 (Sutezolid, U-480) and its Major Metabolite (PNU-101603, U-603) in Patients with Pulmonary TBR. S. Wallis 1 , S. O. Friedrich 2 , A. H. Diacon 2 , R. Dawson 3 , A. Venter 2 , D.Paige 1 , T. Zhu 1 , A. Silvia 1 , J. Gobey 1 , C. Ellery 1 , Y. Zhang 1 ; 1 Pfizer, Groton,CT, 2 Stellenbosch Univ., Stellenbosch, South Africa, 3 Univ. Cape Town,Cape Town, South Africa.A-1265 Pharmacodynamics of PNU-100480 (U, Sutezolid), a NewOxazolidinone, in Combination with its Active Metabolite in theKilling of Mycobacterium tuberculosis (Mtb) in an In Vitro HollowFiber Infection Model (HFIM)A. Louie, D. Brown, K. Files, M. Swift, S. Fikes, G. Drusano; Univ. ofFlorida, Orlando, FL.A-1266 A New Mathematical Model for Anti-Infective Pharmacokinetics/Pharmacodynamics(PK/PD) which AccommodatesRandom MutationsA. Forrest 1,2 , O. O. Okusanya 1,2 , J. B. Bulitta 3 ; 1 SUNY Sch. of Pharmacy,Buffalo, NY, 2 ICPD, Latham, NY, 3 Monash Univ., Melbourne, Australia.A-1267 Tissue Distribution and Macrophages Uptake for NovelSpectinamide Drug Candidates against TuberculosisA. Trivedi 1 , D. Madhura 1 , J. Liu 2 , K. Kromke 1 , C. Rathi 1 , V. Loveless 1 , R.E. Lee 2 , B. Meibohm 1 ; 1 Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TN,2St. Jude Children’s Res. Hosp., Memphis, TN.A-1268 Increasing Rifampicin Dosage in the Treatment of MurineTuberculosis Allows Reduction of Therapy DurationG. J. de Knegt 1 , R. E. Aarnoutse 2 , M. T. Ten Kate 1 , M. J. Boeree 2 , D. vanSoolingen 3 , I. A. Bakker-Woudenberg 1 , J. E. M. de Steenwinkel 1 ; 1 ErasmusUniv. Med. Ctr., Rotterdam, Netherlands, 2 Radboud Univ. Nijmegen Med.Ctr., Nijmegen, Netherlands, 3 Natl. Inst. of Publ. Hlth. and the Environment,Bilthoven, Netherlands.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------162(A)Poster SessionClinical Pharmacology of Novel Anti-Infective AgentsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:A-1269 Population Pharmacokinetic (PPK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment (TA) Analysesfor Solithromycin (SOL, CEM-101) to Support Intravenous (IV)Dose Selection in Patients with Community-Acquired BacterialPneumonia (CABP)O. O. Okusanya 1 , S. M. Bhavnani 1 , A. Forrest 1 , C. C. Bulik 1 , D. Oldach 2 ,P. Fernandes 2 , P. G. Ambrose 1 ; 1 ICPD, Latham, NY, 2 Cempra Pharmaceuticals,Chapel Hill, NC.A-1270 Evaluation of the Pharmacokinetics/Pharmacodynamics(PK/PD) of GSK2251052 (GSK052) against Gram-NegativeBacilli (GNB) in a Murine-Thigh Infection ModelC. C. Bulik 1 , O. O. Okusanya 1 , S. M. Bhavnani 1 , A. Lepak 2 , A. Forrest 1 , P.G. Ambrose 1 , J. L. Hoover 3 , D. R. Andes 2 ; 1 ICPD, Latham, NY, 2 Univ. ofWisconsin, Madison, WI, 3 GlaxoSmithKline, Collegeville, PA.A-1271 Evaluation of the Pharmacokinetics/Pharmacodynamics(PK/PD) of GSK2251052 (GSK052) against Gram-NegativeBacilli (GNB) Using Data from a Neutropenic Murine-Pneumonia Infection ModelD. R. Andes 1 , O. O. Okusanya 2 , C. C. Bulik 2 , A. Lepak 1 , S. M. Bhavnani 2 ,A. Forrest 2 , J. L. Hoover 3 , P. G. Ambrose 2 ; 1 Univ. of Wisconsin, Madison,WI, 2 ICPD, Latham, NY, 3 GlaxoSmithKline, Collegeville, PA.A-1272 Pharmacokinetics and Safety of Oral GSK2251052, a Novel,Boron-Containing Antimicrobial, in Healthy SubjectsE. Dumont 1 , D. Tenero 1 , M. Barton 1 , J. Bianco 2 , S. Shakib 3 , M. Kurtinecz 1 ,P. Patel 4 , J. Tomayko 1 ; 1 GlaxoSmithKline, Philadelphia, PA, 2 GlaxoSmith-Kline, Abbotsford, Australia, 3 CMAX, Adelaide, Australia, 4 GlaxoSmith-Kline, RTP, NC.A-1273 Cadazolid, a Novel Antibiotic with Potent Activity againstClostridium difficile: Safety, Tolerability, and Pharmacokinetics inHealthy Subjects following Single and Multiple Oral DosesD. Baldoni 1 , M. Gutierrez 1 , J. Dingemanse 1 , W. Timmer 2 ; 1 Actelion PharmaceuticalsLtd., Allschwil, Switzerland, 2 Clinical Res. Services MannheimGmbH, Mannheim, Germany.A-1274 Mutant Prevention Concentration of Fidaxomicin forClostridium difficileJ. Seddon, F. Babakhani, P. Sears; Optimer Pharmaceuticals, San Diego, CA.A-1275 Pharmacokinetics/Pharmacodynamics (PK/PD) of PeptideDeformylase (PDF) Inhibitor GSK1322322 (GSK322) againstStreptococcus pneumoniae in a Mouse Pneumonia ModelJ. L. Hoover, R. J. Straub, S. J. Novick, O. J. Naderer, S. Rittenhouse; Glaxo-SmithKline, Collegeville, PA.A-1276 Intravenous (IV) First Time in Human Safety and Pharmacokineticsof GSK1322322 (GSK322), a Peptide DeformylaseInhibitor AntibacterialO. J. Naderer 1 , L. S. Jones 1 , J. Z. Zhu 2 , M. Kurtinecz 3 , E. F. Dumont 3 ;1GlaxoSmithKline, Research Triangle Park, NC, 2 GlaxoSmithKline, UpperMerion, PA, 3 GlaxoSmithKline, Upper Providence, PA.A-1277 Penetration of GSK1322322 (GSK322) into Epithelial LiningFluid (ELF) and Alveolar Macrophages (AM) as Determined byBronchoalveolar Lavage (BAL)O. J. Naderer 1 , K. A. Rodvold 2 , L. S. Jones 1 , J. Z. Zhu 3 , E. F. Dumont 4 ;1GlaxoSmithKline, Research Triangle Park, NC, 2 Univ. of Illinois at Chicago,IL, 3 GlaxoSmithKline, Upper Merion, PA, 4 GlaxoSmithKline, Upper Providence,PA.A-1278 The Monoclonal Antibody Panobacumab (KBPA101)Improves Pseudomonas aeruginosa (PA) Opsonophagocytosis byTHP-1 MonocytesH. Jacqmin, J. Buyck, P. M. Tulkens, F. Van Bambeke; Univ. Catholique deLouvain, Bruxelles, Belgium.A-1279 Optimizing Fosfomycin Dosing for Treatment of Pseudomonasaeruginosa Infections in Critically-Ill Patients Based onPharmacokinetics/Pharmacodynamics (PK/PD) TargetO. Asuphon 1 , P. Montakantikul 2 , J. Haungsaitong 2 , P. Sonthisombat 1 , P.Kiratisin 3 ; 1 Naresaun Univ., Pitsanulok, Thailand, 2 Mahidol Univ., Bangkok,Thailand, 3 Siriraj Hosp., Mahidol Univ., Bangkok, Thailand.140September 9-12 |

TUESDAY SCIENTIFIC SESSIONSA-1280 Tigecycline and Enterobacter Invasive Infections: PK/PDParameters Using Monte Carlo SimulationJ. Lepe 1 , C. Martín-Gandul 1 , J. Rodríguez-Martínez 2 , O. Gasch 3 , C. Ruiz deAlegría 4 , R. Lara 5 , C. Fernández-Mazarrasa 4 , F. Tubau 3 , F. Rodríguez-López 5 ,L. Martínez-Martínez 4 , M. Jiménez-Mejías 1 ; 1 Univ. Hosp. Virgen del Rocío,Sevilla, Spain, 2 Univ. Hosp. Virgen Macarena, Sevilla, Spain, 3 Univ. Hosp.Bellvitge, Barcelona, Spain, 4 Univ. Hosp. Marqués de Valdecillas, Santander,Spain, 5 Univ. Hosp. Reina Sofía, Córdoba, Spain.A-1281 Pharmacokinetics of [14c]-Labeled Omadacycline (PTK0796) in Healthy Male SubjectsH. Sun 1 , L. Ting 1 , J. Flarakos 1 , K. Dole 1 , J. Praestgaard 1 , S. J. Kovacs 1 , D.S. Stein 1 , G. Sunkara 1 , S. K. Tanaka 2 ; 1 Novartis, East Hanover, NJ, 2 ParatekPharmaceuticals, Boston, MA.A-1282 Pharmacokinetics of Omadacycline (PTK 0796) in Subjectswith Hepatic ImpairmentL. Ting 1 , S. J. Kovacs 1 , J. Praestgaard 1 , R. Maietta 2 , D. S. Stein 1 , G. Sunkara 1 ,M. P. Draper 3 , H. Sun 1 ; 1 NIBR, Novartis Pharmaceuticals, East Hanover,NJ, 2 NIBR, Novartis Pharmaceuticals, Cambridge, MA, 3 Paratek Pharamaceuticals,Boston, MA.A-1283 Pharmacokinetics and Safety of Morinidazole in Patientswith Moderate Impaired Hepatic Function Compared withHealthy VolunteersX. Wu, Z. Chen, J. Wu, G. Cao, J. Yu, Bachelor, Y. Shi, Y. Zhang, J. Zhang;Inst. of Antibiotics, Huashan Hosp., Fudan Univ., Shanghai, China.A-1284 Metabolism and Excretion of PMX-30063: A Novel Class ofAntibioticsB. Korczak, D. Liu, R. Scott; Polymedix, Radnor, PA.A-1285 Urinary Antibacterial Activity of BAL30072 against UropathogensAfter IV AdministrationF. M. E. Wagenlehner 1 , B. Blenk 2 , C. Wagenlehner 1 , H. Blenk 2 , K. G.Naber 3 ; 1 Justus Liebig Univ., Giessen, Germany, 2 Eukarion Inst., Nuernberg,Germany, 3 Tech. Univ., Munich, Germany.A-1286 Systemic Safety Profile of Solithromycin in Phase 1 & 2Clinical TrialsD. Oldach, B. Jamieson, K. Clark, K. Keedy, P. Fernandes; Cempra, Inc.,Chapel Hill, NC.------------------------------------------------------------------------163(A)Poster SessionPharmacokinetics/Pharmacodynamics of New and OldOxazolidinonesTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:A-1287 Pharmacokinetics (PK) of Intravenous (IV) Linezolid (LZD)in Moderately to Morbidly Obese AdultsA. A. Bhalodi, P. K. Papasavas, D. S. Tishler, D. P. Nicolau, J. L. Kuti;Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT.A-1288 Clinical Pharmacokinetic/Pharmacodynamic Profile ofLinezolid in Multidrug Resistant Gram Positive InfectionsH. Mikamo, Y. Yamagishi; Aichi Med. Univ., Aichi, Japan.A-1289 Radezolid Demonstrates Favorable Safety Compared toLinezolid in a Three-Month Rat Toxicology StudyC. Moore 1 , H. Dedhia 1 , E. Duffy 2 , J. Longcor 2 , E. Burak 2 , E. Bortolon 2 , D.Molstad 2 , Y. Wu 2 , H. Jing 2 , D. Li 2 , R. Hanselmann 2 , M. Reeve 2 , A. Marra 2 ;1Covance Lab., Chandler, AZ, 2 Rib-X Pharmaceuticals, New Haven, CT.A-1290 A Phase 1, Single and Multiple Ascending Intravenous (IV)Dose Study of Safety, and Pharmacokinetics (PK) of Radezolid(RDZ) in Healthy SubjectsL. E. Lawrence 1 , A. Marra 1 , J. Longcor 1 , R. Hoover 1 , M. Benedict 2 , C.Smith 2 , Y. Cai 2 , M. Medlock 2 ; 1 Rib-X Pharmaceuticals Inc., New Haven,CT, 2 PPD, Wilmington, NC.A-1291 Study of the Cellular Uptake and Subcellular Distributionof the Oxazolidinone Tedizolid (TZD) in Murine J774 Macrophages:Lack of Association with MitochondriaD. Das, A. Lambert, G. Muccioli, P. M. Tulkens, F. Van Bambeke; Univ.Catholique de Louvain, Bruxelles, Belgium.A-1292 Safety and Pharmacokinetics after Single Oral and IV Administrationof Tedizolid Phosphate in Adolescent PatientsK. A. Muñoz 1 , H. Dreskin 1 , J. Bradley 2 , A. Arrieta 3 , E. Capparelli 2 , R.Jacobs 4 , S. L. Minassian 1 , E. Fang 1 , P. Prokocimer 1 , S. Flanagan 1 ; 1 TriusTherapeutics, Inc., San Diego, CA, 2 UCSD, San Diego, CA, 3 CHOC,Orange, CA, 4 ACH, Little Rock, AR.A-1293 Safety and Pharmacokinetics of Single Oral Administrationof Tedizolid Phosphate in Healthy Elderly Subjects and AdultControl SubjectsH. J. Dreskin 1 , K. Muñoz 1 , E. Fang. 1 , S. L. Minassian 1 , D. Subich 2 , S. Flanagan1 , P. Prokocimer 1 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 Covance,Inc., Orlando, FL.A-1294 A Phase 1 Study of Intravenously Administered TedizolidPhosphate in Subjects with Advanced Renal ImpairmentS. Flanagan 1 , D. Morris 2 , T. Boyea 1 , H. Dreskin 1 , S. L. Minassian 1 , H.Alcorn, Jr 3 , T. Marbury 4 , M. Abdelhameed 2 , E. Fang 1 , P. Prokocimer 1 ;1Trius, San Diego, CA, 2 Covance, Madison, WI, 3 DaVita, Minneapolis, MN,4Orlando Clinical Res. Ctr., Orlando, FL.A-1295 A Phase 1 Study of Orally Administered Tedizolid Phosphatein Subjects with Moderate or Severe Hepatic ImpairmentT. Boyea 1 , H. Dreskin 1 , S. L. Minassian 1 , T. C. Marbury 2 , H. J. Alcorn, Jr 3 ,E. Fang 1 , P. Prokocimer 1 , S. Flanagan 1 ; 1 Trius Therapeutics, San Diego, CA,2Orlando Clinical Res. Ctr., Orlando, FL, 3 DaVita Clinical Res., Minneapolis,MN.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------164(B)Poster SessionAntimicrobial Therapy in Animal Models IITuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:B-1296 Insights into the Activity of Pyrazinamide in Immune-Competentand Immune-Deficient Murine Models of TuberculosisD. V. Almeida 1,2 , P. Converse 1 , S. Tyagi 1 , S. Li 1 , N. Ammerman 1,2 ,K. Wallengren 2 , J. Grosset 1,2 , W. Bishai 1,2 ; 1 Johns Hopkins Univ., Baltimore,2K-RITH, Univ. of KwaZulu-Natal, Durban, South Africa.Final Program141

Tuesday SCIENTIFIC SESSIONSB-1297 Effects of Recombinant Thrombomodulin in Combinationwith Antibiotics on a Murine Legionella Pneumonia ModelY. Morinaga, K. Yanagihara, N. Kaku, Y. Migiyama, Y. Harada, K. Nagaoka,K. Yamada, K. Izumikawa, H. Kakeya, Y. Yamamoto, S. Kohno; NagasakiUniv., Nagasaki, Japan.B-1298 Efficacy of Combination Therapy with Ciprofloxacin PlusCefotaxime against Vibrio vulnificus Sepsis in MiceH. Jang, S. Jung, K. Park, J. Shin, S. Kang; Chonnam Natl. Univ. Coll. ofMed., Gwang-Ju, Korea, Republic of.B-1299 Activity of Telavancin in Combination with Colistin in aGalleria mellonella Model of Acinetobacter baumannii InfectionM. Horsney 1 , L. Phee 1 , C. Longshaw 2 , D. Wareham 1 ; 1 QMUL, London,United Kingdom, 2 Astellas Europe, London, United Kingdom.B-1300 Activity of Tigecycline Combinations in ExperimentalInfections Caused by Nine KPC-Producing EnterobacteriaceaeClinical IsolatesG. Michail 1 , M. Labrou 1 , S. Manousaka 1 , A. Tsakris 2 , S. Pournaras 1 ; 1 Med.Sch., Univ. of Thessaly, Larissa, Greece, 2 Med. Sch., Univ. of Athens, Athens,Greece.B-1301 Efficacy of Solithromycin for Treatment of ExperimentalSyphilis InfectionB. J. Molini, L. C. Tantalo, S. L. Brandt, S. K. Sahi, C. M. Marra, S. A.Lukehart; Univ. of Washington, Seattle, WA.B-1302 Efficacy of Plazomicin against Yersinia pestis in a Murine-Aerosol Challenge Late-Treatment ModelH. S. Heine 1 , L. Chuvala 1 , R. Riggins 1 , G. Hurteau 1 , R. Cass 2 , R. Cirz 2 ;1Univ. of Florida, Gainesville, FL, 2 Achaogen Inc., San Francisco, CA.B-1303 In Vitro and In Vivo Activity of Modithromycin (EDP-420)against Neisseria gonorrhoeaeX. Luo 1 , L. T. Phan 1 , O. Jones-Nelson 2 , M. Pilligua-Lucas 2 , D. J. J. Simon 2 ,A. E. Jerse 2 , Y. S. Or 1 ; 1 ENANTA Pharmaceuticals, Inc., Watertown, MA,2Uniformed Services Univ., Bethesda.B-1304 Efficacy of a Novel Mechanism Antibacterial GSK2251052against Yersinia pestis in a Post-Exposure Prophylaxis Murine-Aerosol Challenge ModelH. S. Heine 1 , L. Chuvala 1 , R. Riggins 1 , G. Hurteau 1 , C. Jakielaszek 2 ; 1 Univ.Florida, Gainesville, FL, 2 GlaxoSmithKline, Collegeville, PA.B-1305 Colonization Characteristics of Quinolone-Resistant Escherichiacoli in the Faecal Microbiota of Healthy VolunteersV. de Lastours 1 , A. Bleibtreu 2 , F. Chau 1 , E. Denamur 2 , B. Fantin 3 ; 1 EA3964Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France, 2 UMR U772 Univ.Paris Diderot, Sorbonne Paris Cité, Paris, France, 3 EA3964 Univ. ParisDiderot, Sorbonne Paris Cité, Paris, France.B-1306 Clinical Impact of Aac(6’)-Ib-cr on Ciprofloxacin Treatmentin a Murine Model of Escherichia coli PyelonephritisT. Guillard 1 , E. Cambau 1 , F. Chau 1 , C. de Champs 2 , B. Fantin 1 ; 1 Univ ParisDiderot-Paris 7, Paris, France, 2 SFR CAP-Santé , URCA, Reims, France.B-1307 Mediation of the Development of Periodontitis by AminoguanidineP. Chang, Chang, L. Chong, S. Tsai; Natl. Univ. of Singapore, Singapore,Singapore.B-1308 GSK2251052, a Novel LeuRS Inhibitor, is Effective againstMultidrug-Resistant Pseudomonas aeruginosa in a Mouse PneumoniaModelJ. L. Hoover, C. Mininger, S. Rittenhouse; GlaxoSmithKline, Collegeville, PA.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------165(B)Poster SessionMicrobial Determinants of VirulenceTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:B-1309 Sequence Analysis of RepMP4 and RepMP2/3 Elementsof Mycoplasma pneumoniae P1 Gene During Four OutbreaksBetween 2000 and 2011J. Lee 1 , N. Yang 2 , K. Hong 2 , E. Choi 3 , H. Lee 3 ; 1 Kangwon Natl. Univ.Hosp., Chuncheon, Korea, Republic of, 2 Seoul Natl. Univ. Children’sHosp., Seoul, Korea, Republic of, 3 Coll. of Med., Seoul Natl. Univ., Seoul,Korea, Republic of.B-1310 Identification of Mycobacterium avium ssp hominissuis (MAH)Genes Related to the Formation of Microaggregates as PutativeTargets for Prevention of Lung InfectionL. Babrak, L. Bermudez; Oregon State Univ., Corvallis, OR.B-1311 Streptococcus pyogenes Protease, SpyCEP, Interrupts CXCNeutrophil Chemoattractant Signalling by Preventing CXCR1/2Receptor BindingJ. Goldblatt, E. Wise, J. Viney, N. Lynskey, C. Turner, R. Edwards, J. Pease,S. Sriskandan; Imperial, London, United Kingdom.B-1312 Toward a Functional Classification of Group A StreptococcusM ProteinP. R. Smeesters 1,2,3 , K. Sriprakash 3 , P. Dreze 1 , T. Vu, 3 , D. Bessen 4 , J. Guglielmini5 , A. Steer 2 , J. Carapetis 6 , L. Van Melderen 1 , D. McMillan 3 , M ProteinStudy Group; 1 Univ. Libre de Bruxelles, Charleroi, Belgium, 2 MurdochChildren Res. Inst., Melbourne, Australia, 3 Queensland Inst. for Med. Res.,Brisbane, Australia, 4 New York Med. Coll., New-York, NY, 5 Inst. Pasteur,Paris, France, 6 Menzies Sch. of Hlth. Res., Darwin, Australia.B-1313 A Framework for Streptococcal Superantigen Nomenclatureand Disease AssociationR. Commons 1 , P. R. Smeesters 2 , N. Curtis 3 ; 1 Royal Darwin Hosp., NorthernTerritory, Australia, 2 Murdoch Children’s Res. Inst., Parkville, Australia, 3 TheUniv. of Melbourne and Murdoch Children’s Res. Inst., Royal Children’sHosp. Melbourne, Parkville, Australia.B-1314 Genomic Comparison of Streptococcus mitis and StreptococcuspneumoniaeA. M. Mitchell 1 , A. Smith 2 , T. J. Mitchell 1 ; 1 Univ. of Birmingham, Birmingham,United Kingdom, 2 Univ. of Glasgow, Glasgow, United Kingdom.B-1315 Comparison of Bengal Bay Clone ST772 with BovineStaphylococcus aureus Isolates from IndiaG. Arakere 1 , B. Chakrakodi 1 , S. Prabhakara 1 , S. Isloor 2 , N. Hegde, 3 ; 1 Societyfor Innovation and Dev., Bangalore, India, 2 Vet. Coll., Bangalore, India, 3 EllaFndn., Hyderabad, India.142September 9-12 |

TUESDAY SCIENTIFIC SESSIONSB-1316 Potential New Staphylococcal Chromosome Cassette (SCC)and New LPXTG-Surface Protein Associated with the Transfer ofHuman Staphylococcus aureus CC8 to CattleG. Resch 1 , M. Stojanov 1 , O. Sakwinska 2 , P. Moreillon 1 ; 1 Univ. of Lausanne,Lausanne, Switzerland, 2 Nestlé Res. Ctr., Lausanne, Switzerland.B-1317 Alpha-Toxin Expression in Methicillin-Resistant Staphylococcusaureus (MRSA) is Not Associated with Cytotoxicity FollowingInvasion of Human Osteoblasts by MRSAJ. Ranfaing 1 , J. P. Rasigade 2,1 , S. Trouillet 1 , J. Etienne 2,1 , F. Vandenesch 2,1 ,F. Laurent 2,1 ; 1 Inserm U851, Lyon, France, 2 Hospices Civils de Lyon, Lyon,France.B-1318 Staphylococcus aureus Biofilm Formation Depends on MLSTLineage in Bone and Joint InfectionsG. G. Aubin. 1,2 , C. Lasserre 1,2 , N. Caroff 2 , D. Lepelletier 1,2 , A. Reynaud 1,2 ,J. Lavigne 3 , S. Corvec 1 ; 1 Nantes Univ. Hosp., Nantes, France, 2 Med. Sch.,Nantes, France, 3 Montpellier Univ., Nîmes, France.B-1319 Intra-Osteoblastic Persistence of Methicillin-SusceptibleStaphylococcus aureus (MSSA): An Adaptative Mechanism of Boneand Joint Infections (BJI) ChronicityF. Valour, J. Rasigade, S. Trouillet, J. Gagnaire, A. Bouaziz, M. Bès, H.Meugnier, S. Lustig, F. Vandenesch, T. Ferry, F. Laurent; Hospices Civils deLyon - INSERM U851, Lyon, France.B-1320 Increased Likelihood of Infective Endocarditis in Humansbut Attenuated Virulence of Clonal Complex 30 Genotype inStaphylococcus aureus is Associated with Distinct Genomic Architectureof its GenomeB. K. Sharma-Kuinkel 1 , V. G. Fowler, Jr. 1 , S. Ahn 1 , T. H. Rude 1 , E. F.Mongodin 2 , S. R. Gill 3 ; 1 Duke Univ., Durham, NC, 2 Univ. of Maryland Sch.of Med. - IGS, Baltimore, 3 Univ. of Rochester Sch. of Med. and Dentistry,Rochester, NY.B-1321 Antibiotic Resistance Due to Target Gene Mutations AffectingVirulence in Klebsiella pneumoniaeY. Tsai, L. Siu; Natl. Inst. of Infectious Diseases and Vaccinology, Natl. Hlth.Res. Inst., Miaoli, Taiwan.B-1322 Pertussis Fimbrial Proteins Mediate Adherence to PrimaryHuman Airway Epithelial Cells: A Model to Study B. pertussisFimbriae AdherenceC. P. Guevara 1 , T. Starner 1 , P. B. McCray, Jr 1 , J. Zabner 1 , F. R. Mooi 2 , D. P.Greenberg 3 , M. D. Decker 4 , O. G. Gomez-Duarte 4 ; 1 Univ. of Iowa Coll. ofMed., Iowa City, IA, 2 Ctr. for Infectious Disease Control, Bilthoven, Netherlands,3 Univ. of Pittsburgh Sch. of Med., Pittsburgh, PA, 4 Vanderbilt Univ.Sch. of Med., Nashville, TN.B-1323 Delineating the Magnitude of Virulence in KPC (+) OrganismsM. Griffith 1,2 , M. Malczynski 2 , G. Barajas 2 , C. Qi 2,3 , M. Scheetz 1,2 ; 1 MidwesternUniv., Downers Grove, IL, 2 Northwestern Mem. Hosp., Chicago, IL,3Northwestern Univ., Chicago, IL.B-1324 Sodium Salicylate Inhibited Hyper-Mucosity of KlebsiellaePneumoniae and Enhanced Leukocyte Phagocytosis and BactericidalActivityC. Lee; Kaohsiung Chang Gung Mem. Hosp., Kaohsiung, Taiwan.B-1325 Sialic Acid Involved in Hypermucoviscosity Phenotype andResistance to Phagocytosis of Klebsiella pneumoniae by NeutrophilsC. Lee; Kaohsiung Chang Gung Mem. Hosp., Kaohsiung, Taiwan.B-1326 Comparative Virulence of KPC (+) and KPC (-) Klebsiellapneumoniae in a Galleria mellonella ModelM. Griffith 1,2 , M. Advincula 1 , M. Malczynski 2 , G. Barajas 2 , C. Qi 2,3 , M.Scheetz 1,2 ; 1 Midwestern Univ., Downers Grove, IL, 2 Northwestern Mem.Hosp., Chicago, IL, 3 Northwestern Univ., Chicago, IL.B-1327 Relationship Between Resistance Mechanisms and PotentialVirulence in Acinetobacter spp. Strains Using the Caenorhabditiselegans ModelP. Espinal 1,2 , A. Pantel 2 , J. Lavigne 2 , J. Vila 1 ; 1 Univ. of Barcelona Hosp. Clinic,Barcelona, Spain, 2 INSERM, U1047, Montpellier 1 Univ., Nimes, France.B-1328 Comparison of Virulence Between Salmonella typhumuriumand S. choleraesuis by Proteomic and Cellular MicrobiologicalMethodsK. Huang 1 , K. Chien 1 , C. Chiu 1,2 ; 1 Chang Gung Univ., Tao-Yuan, Taiwan,2Chang Gung Children’s Hosp., Taoyuan, Taiwan.B-1329 Loss of Outer Membrane Protein A (OmpA) Affects the Fitnessand Virulence of Acinetobacter baumanniiY. Smani 1 , R. López-Rojas 1 , A. Fàbrega 2 , I. Roca 2 , J. Vila 2 , J. Pachón 1 ; 1 Inst.of Biomedicine of Seville, IBiS, Univ. Hosp. Virgen del Rocío, Seville, Spain,2Hosp. Clinic, Sch. of Med., Univ. of Barcelona, IDIBAPS, Barcelona, Spain.B-1330 Impact of Antibiotics on the Expression of the tra Genes andon the Host Innate Immune Gene Activity during SXT ElementBearing Aeromonas salmonicida Infection in Atlantic Salmon(Salmo salar L.)L. Cantas 1 , F. L. Roux 2 , D. Mazel 3 , H. Sørum 1 ; 1 Norwegian Sch. of Vet.Sci., Oslo, Norway, 2 IFREMER-UPMC Station Biologique de Roscoff,Roscoff, France, 3 Inst. Pasteur, Paris, France.B-1331 Molecular Epidemiology of Virulence Factor Genes in UropathogenicEscherichia coli from Hospitalized PatientsU. K. Frank 1 , K. Biehler 2 , L. Goldberg 2 ; 1 Heidelberg Univ. Hosp., Heidelberg,Germany, 2 Freiburg Univ. Hosp., Freiburg, Germany.B-1332 Comparison of Adhesin Genes Between Uropathogenic andIntestinal Commensal Escherichia coli StrainsX. Qin, X. Ye, D. Zhu, Y. Zhang, M. Wang; Huashan Hosp., Shanghai, China.B-1333 PA2226, a Novel Regulator of Quorum Sensing and Virulencein Pseudomonas aeruginosaT. Kohler 1 , H. Ouertatani-Sakouhi 2 , P. Cosson 2 , C. van Delden 1 ; 1 Univ.Hosp. Geneva, Geneva, Switzerland, 2 Univ. of Geneva, Geneva, Switzerland.B-1334 The Impact of Hypoxia on Infection of Pulmonary EpithelialCells by Pseudomonas aeruginosaB. Schaible 1 , S. McClean 2 , C. T. Taylor 1 , K. Schaffer 3 ; 1 Conway Inst., Univ.Coll. Dublin, Dublin, Ireland, 2 Inst. of Technology Tallaght, Dublin, Ireland,3St Vincent’s Univ. Hosp., Dublin, Ireland.B-1335 Acute Lung Injury Response to Pseudomonas aeruginosaInfection in an Murine Pneumonia Model: Impact of the Type IIISecretion SystemA. Broquet, C. Jacqueline, R. Cinotti, M. Davieau, C. Desessard, A. Roquilly,J. Caillon, G. Potel, K. Asehnoune; UPRES EA3826, Nantes, France.B-1336 Carbapenem Resistance is Not Associated with Virulence ofPseudomonas aeruginosa (PA) Using the Dictyostelium discoideum(Dd) Virulence ModelR. C. Fowler 1 , A. T. Weber 2 , N. D. Hanson 1 ; 1 Creighton Univ., Omaha, NE,2Univ. of Nebraska, Omaha, NE.Final Program143

Tuesday SCIENTIFIC SESSIONSB-1337 Impact of Ciprofloxacin (CIP) on the Expression of GenesInvolved in Pseudomonas aeruginosa (PA14) Persistence (P) in aRabbit Model of Catheter Associated Urinary Tract Infection(CAUTI)M. Etienne, E. Fiaux, M. David, J. Peltier, I. El Meouche, L. Gibert, J. Didi,M. Pestel-Carom, F. Caron; Rouen Univ. Hosp., Rouen, France.B-1338 Pseudomonas aeruginosa (PA14) Catheter-Associated UrinaryTract Infection (CAUTI) in Rabbit: A Model to Explore In VivoBacterial Persistence in Biofilm (B) InfectionsM. Etienne, M. David, E. Fiaux, J. Peltier, M. Pestel-Caron, F. Caron;Rouen Univ. Hosp., Rouen, France.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------166(C1)Poster SessionResistance to Staphylococcus and Other Gram-PositiveTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C1-1339 A Novel Staphylococcal Chromosomal Cassette ContainingfusC in Methicillin-Resistant Staphylococcus aureusY. T. Lin, H. J. Chen, L. J. Teng; Natl. Taiwan Univ. Med. Coll., Taipei City,Taiwan.C1-1340 A Unique IS1216V-Flanked Composite Mobile Elementfrom Enterococci is Distributed to ST59 Community-AcquiredMethicillin-Resistant Staphylococcus aureus in TaiwanW. C. Hung 1 , T. Takano 1 , Y. Iwao 1 , L. J. Teng 2 , T. Yamamoto 1 ; 1 NiigataUniv., Niigata, Japan, 2 Natl. Taiwan Univ., Taipei, Taiwan.C1-1341 Characterization of the Staphylococcus aureus MepA MultidrugEfflux Pump Using MutagenesisD. Patel 1 , S. M. Seo 2 , B. D. Schindler 2 , G. W. Kaatz 2,1 ; 1 Wayne State Univ.Sch. of Med., Detroit, MI, 2 John D. Dingell VA Med. Ctr., Detroit, MI.C1-1342 Rifampin Resistance in Propionibacterium acnes: In VitroEmergence and Molecular Characterization of Mutations in theRpoB GeneU. Furustrand Tafin 1 , A. Trampuz 1 , S. Corvec 2 ; 1 Univ. Hosp., Lausanne,Switzerland, 2 Univ. Hosp., Nantes, France.C1-1343 Streptococcus sanguinis Displaying a Cross ResistancePhenotype to Several Ribosomal RNA Targeting Agents,Including LinezolidR. E. Mendes 1 , L. M. Deshpande 1 , J. Kim 2 , D. Myers 2 , J. E. Ross 1 ,R. N. Jones 1 ; 1 JMI Lab., N Liberty, IA, 2 Hershey Med. Ctr, Hershey, PA.C1-1344 Structure of Vancomycin Resistance Bifunctional D,D-Dipeptidase/D,D-Carboxypeptidase VanXY from EnterococcusfaecalisD. Meziane-Cherif 1 , P. J. Stogios 2,3 , E. Evdokimova 2,3 , Z. Wawrzak 4 ,A. Savchenko 2,3 , P. Courvalin 1 ; 1 Inst. Pasteur, Paris, France, 2 Univ. ofToronto, Toronto, Canada, 3 Ctr. for Structural Genomics of InfectiousDiseases, Toronto, Canada, 4 Northwestern Univ., Chicago, IL.C1-1345 Mutations in the liaFSR System Avoid Bactericidal Killingof Daptomycin against EnterococciJ. M. Munita 1,2 , T. T. Tran 1,3 , D. Panesso 1,4 , L. Diaz 1,4 , J. Reyes 1,4 , B. E.Murray 1 , C. A. Arias 1,4 ; 1 Univ. of Texas Med. Sch., Houston, TX, 2 Univ. delDesarrollo Clinica Alemana Sch. of Med., Santiago, Chile, 3 Univ. of HoustonColl. of Pharm., Houston, TX, 4 Univ. El Bosque, Bogota, Colombia.C1-1346 Cadazolid, a Novel Quinolonyl-Oxazolidinone Antibioticwith Potent Activity against Clostridium difficile: In Vitro AntibacterialActivity and Propensity for Resistance DevelopmentH. H. Locher, P. Pfaff, S. Schroeder, J. Specklin, C. Hubschwerlen, W. Keck;Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.C1-1347 Cadazolid, a Novel Quinolonyl-Oxazolidinone Antibiotic:Mode of Action and Effect on Clostridium difficile Toxin and SporeFormationH. H. Locher, S. Schroeder, D. Ritz, A. Knezevic, C. Hubschwerlen, W.Keck; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.C1-1348 Characterization of Mobile erm(X) And mef(A) MacrolideResistance Genes in Rhodococcus equi Isolates from Pneumonic FoalsM. C. Roberts 1 , S. Giguere 2 , L. J. Berghaus 2 , N. D. Cohen 3 , D. No 1 , O. O.Soge 1 ; 1 Univ. of Washington, Seattle, WA, 2 Univ. of Georgia, Athens, GA,3Texas A & M Univ., College Station, TX.C1-1349 Characterization of a New VGA Gene Homologue inStaphylococcus sciuriC. Hot, N. Berthet, O. Chesneau; Inst. Pasteur, Paris, France.C1-1350 Analysis of a Multi-Resistance Plasmid from Methicillin-Resistant Staphylococcus epidermidis IsolatesS. Weiß, A. T. Feßler, K. Kadlec, S. P. Schwarz; Inst. of Farm Animal Genetics(FLI), Neustadt-Mariensee, Germany.C1-1351 Correlation of icaA and Regulatory Genes agr and sarAExpression in Staphylococcus aureus Following Antibiotic Exposurein a Drip-Flow Biofilm ModelS. K. Shukla 1 , Z. Ye 1 , W. Rose 2 ; 1 Marshfield Clin., Marshfield, WI, 2 Univ. ofWisconsin, Madison, WI.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------167(C2)Poster SessionCharacterization of Streptococcus pneumoniae in the Eraof Antibiotics and VaccinesTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C2-1352 In Vitro Activity Efficacy of Comparative Antimicrobialsagainst Streptococcus pneumoniae from Respiratory Tract Sourcesfrom Europe: France, Germany, Italy, Spain And Sweden 2010-2011D. Hoban, M. Hackel, R. Badal, S. Bouchillon, B. Johnson; IHMA, Inc.,Schaumburg, IL.C2-1353 Relationship Between Genetic Beta-Lactam Resistanceand Capsular Type or Clonal Complex of Isolates from InvasivePneumococcal Disease in JapanN. Chiba 1 , M. Shouji 2 , M. Morozumi 1 , K. Ubukata 1 ; 1 Kitasato Inst. for LifeSci., Tokyo, Japan, 2 Natl. Cancer Ctr. Hosp., Tokyo, Japan.144September 9-12 |

TUESDAY SCIENTIFIC SESSIONSC2-1354 Rapid Decrease in 7-Valent Conjugate Vaccine Coveragefor Invasive Pneumococcal Diseases (IPD) in Pediatric Patientsin JapanK. Ubukata 1 , N. Chiba 1 , M. Morozumi 1 , H. Sakata 2 , S. Iwata 3 ; 1 KitasatoInst. for Life Sci.,Kitasato Univ., Tokyo, Japan, 2 Asahikawa-Kosei Gen.Hosp., Asahikawa, Japan, 3 Keio Univ. Sch. of Med., Tokyo, Japan.C2-1355 Quinolone-Nonsusceptible Streptococcus pneumoniaeClinical Isolates in ChinaQ. Guo, P. Wang, F. Hu, D. Zhu, F. Yang, M. Wang; Huashan Hosp.,Shanghai, China.C2-1356 Laboratory Surveillance of Pneumococcal serotypes and AntimicrobialSusceptibility Before and After Pcv7 in Mexico Sireva2000-2011G. Echaniz-Aviles 1 , M. Carnalla-Barajas 1 , A. Soto-Noguerón 1 , M.Velazquez-Meza 1 , M. Sanchez-Alemán 1 , M. Hernández-Salgado 1 , F.Solórzano-Sánchez 2 , SIREVA-Mexico Network; 1 Inst. Nacional de SaludPubl., Cuernavaca, Morelos, Mexico, 2 Inst. Mexicano del Seguro Social,Mexico City, Mexico.C2-1357 S19A and Coverage of Pneumococcal Conjugate Vaccines inMexicoR. M. Hinojosa-Robles, M. J. De la Cruz-Váldez, P. A. Hernández-Rodríguez, C. Martínez-Longoria, L. Vera-Cabrera; Hosp. Univ., U.A.N.L.,Monterrey, Mexico.C2-1358 Characteristics of Invasive Pneumococci Collected fromAdults Prior 13-Valent Conjugated Vaccine (pcv13) Introductionin SpainC. Ardanuy 1 , J. Marimón 2 , E. Cercenado 3 , N. Larrosa 4 , D. Fontanals 5 , M.Quesada 6 , A. Fenoll 7 , E. Pérez-Trallero 2 , J. Liñares 1 ; 1 Hosp Univ. Bellvitge-IDIBELL, L’Hosp. de Llobregat, Spain, 2 Hosp. Univ. Donostia, Donostia,Spain, 3 Hosp. Univ. Gregorio Marañón, Madrid, Spain, 4 Hosp. Univ. Valld’Hebron, Barcelona, Spain, 5 Hosp. Parc Taulí, Sabadell, Spain, 6 Hosp.Germans Trias i Pujol, Badalona, Spain, 7 Ctr. Natl. Microbiologia-ISCIII,Majadahonda, Spain.C2-1359 Changes in Epidemiology of Invasive Strains of Streptococcuspneumoniae (Spn) in France Following Introduction of 13-ValentConjugate Vaccine (PCV13) 7 years after PCV7C. Janoir 1 , Reseau des Observatoires Regionaux du Pneumocoque, L. Gutmann1 , A. Lepoutre 2 , E. Varon 1 ; 1 AP-HP, Hosp. Europeen G-Pompidou- CNRP, Paris, France, 2 InVS, St Maurice, France.C2-1360 Multidrug-Resistance in the Most Prevalent Invasive Streptococcuspneumoniae (SPN) Serotypes (STs) Post PCV-13 Introductionin CanadaH. Adam 1,2,3 , M. Gilmour 4,2 , M. Baxter 2,3 , I. Martin 4 , L. Scharikow 2 ,K. Nichol 1,3 , W. Demczuk 4 , J. Embree 2 , D. Hoban 1,2,3 , G. G. Zhanel 2,3 ;1Diagnostic Services of Manitoba, Winnipeg, Canada, 2 Univ. of Manitoba,Winnipeg, Canada, 3 Canadian Antimicrobial Resistance Alliance (CARA),Winnipeg, Canada, 4 Natl. Microbiol. Lab., Winnipeg, Canada.C2-1361 Epidemiology of Serotype 19A Streptococcus pneumoniae inAdults Over the Past DecadeB. E. Gonzalez 1 , K. G. Hulten 2 , K. S. Sannes-Lowery 3 , C. Washington 3 , C.Chen 3 , S. Bajaksouzian 1 , A. R. Windau 1 , C. E. Good 1 , M. R. Jacobs 1 ; 1 CaseWestern Reserve U/U Hosp. Case Med Ctr, Cleveland, OH, 2 Baylor Coll. ofMed., Houston, TX, 3 AthoGen, Carlsbad, CA.C2-1362 Surveillance for Antimicrobial Resistance in Streptococcuspneumoniae, Canada, 1993-2011K. A. Green, A. McGeer, A. Plevneshi, S. Pong-Porter, K. Wong, D. E. Low,Canadian Bacterial Surveillance Network (CBSN); Mount Sinai Hosp.,Toronto, Canada.C2-1363 Lack of Impact of Infant PCV Vaccination on Rates of AdultInvasive Pneumococcal Disease in Ontario, CanadaK. Wong, A. McGeer, K. Green, A. Plevneshi, W. Rudnick, D. E. Low,Toronto Invasive Bacterial Diseases Network; Mount Sinai Hosp., Toronto,Canada.C2-1364 What will Happen to Antimicrobial Resistance in AdultInvasive Pneumococcal Disease in Canada after the Introductionof Infant PCV13 Vaccination?K. A. Green, A. McGeer, K. Wong, A. Plevneshi, S. Pong-Porter, W.Rudnick, D. E. Low, Canadian Bacterial Surveillance Network (CBSN);Mount Sinai Hosp., Toronto, Canada.C2-1365 Characterization of Spanish Isolates PresumptivelyIdentified as Atypical S. pneumoniaeD. Rolo 1 , A. S. Simões 1,2 , A. Domenecher 1 , A. Fenoll 3 , J. Liñares 1 , H. deLencastre 2,4 , C. Ardanuy 1 , R. Sá-Leão 1,2 ; 1 Hosp. Univ. Bellvitge, IDIBELL-CIBERES, Barcelona, Spain, 2 .ITQB/UNL, Oeiras, Portugal, 3 CNM-ISCIII, Madrid, Spain, 4 The Rockefeller Univ., New York, NY.C2-1366 Unique Pneumococcal Capsule Serotype of Serogroup 6J. Y. Baek 1 , K. S. Ko 2,1 , S. H. Kim 1 , C. I. Kang 3 , D. R. Chung 3,1 , K. R. Peck 3 ,J. H. Song 3,1 ; 1 APFID, Seoul, Korea, Republic of, 2 Sungkyunkwan Univ. Sch.of Med., Suwon, Korea, Republic of, 3 Samsung Med. Ctr., Seoul, Korea,Republic of.------------------------------------------------------------------------168(C2, P)Poster SessionDrug-Resistant Mycobacterium tuberculosisTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C2-1367 Investigation of Extensively Drug Resistance in MultidrugResistance Tuberculosis IsolatesB. Bektore 1 , T. Haznedaroglu 1 , O. Baylan 1 , M. Ozyurt 1 , N. Ozkutuk 2 , D.Satana 3 , C. Cavusoglu 4 , E. Seber 5 ; 1 Gulhane Military Med. Academy HaydarpasaTraining Hosp., Istanbul, Turkey, 2 Med. Sch. of Celal Bayar Univ.,Manisa, Turkey, 3 Istanbul Med. Sch. of Istanbul Univ., Istanbul, Turkey,4Med. Sch. of Ege Univ., Izmir, Turkey, 5 Taksim Tuberculosis Dispensary,Istanbul, Turkey.C2-1368 Drug Resistance Pattern and Genotypic Characteristics ofExtremely Drug-Resistant Tuberculosis Strains from NepalesePatientsA. Poudel 1 , C. Nakajima 1 , B. Maharjan 2 , B. D. Pandey 3 , Y. Suzuki 1,4 ; 1 HokkaidoUniv., Sapporo, Japan, 2 German Nepal Tuberculosis Project (GENET-UP), Kathmandu, Japan, 3 Sukraraj Tropical and Infectious Disease Hosp.,Kathmandu, Japan, 4 JST/JICA-SATREPS, Tokyo, Japan.Final Program145

Tuesday SCIENTIFIC SESSIONSC2-1369 Molecular Characterization of Multidrug-Resistant Mycobacteriumtuberculosis from Asian CountriesC. Nakajima 1 , Z. M. Rahim 2 , A. Tamaru 3 , B. D. Pandey 4 , B. Maharjan 5 ,K. S. Aye 6 , A. Poudel 1 , Y. Suzuki 1 ; 1 Hokkaido Univ. Res. Ctr. for ZoonosisControl, Sapporo, Japan, 2 ICDDR, B, Dhaka, Bangladesh, 3 Osaka PrefecturalInst. of Publ. Health, Osaka, Japan, 4 Sukraraj Tropical and InfectiousDisease Hosp., Kathmandu, Nepal, 5 GENETUP, Kathmandu, Nepal, 6 Dept.of Med. Res., Yangon, Myanmar.C2-1370 Phenotypic Resistance Profiles and Gene Mutations Associatedto Isoniazid and Rifampicin Resistance of Clinical Isolates ofMycobacterium tuberculosis from Guadalajara, MéxicoS. M. Flores-Treviño 1 , R. Morfin-Otero 2 , E. Rodriguez-Noriega 2 , G.Gonzalez 1 , Y. Hernandez 2 , N. Rodriguez 2 , E. Gonzalez-Diaz 2 , E. Garza-Gonzalez 1 ; 1 Univ. Autonoma de Nuevo Leon, San Nicolas de los Garza,Mexico, 2 Univ. de Guadalajara, Guadalajara, Mexico.C2-1371 Molecular Detection of Multidrug-Resistant Mycobacteriumtuberculosis among HIV/TB Co-Infected Patients in PortHarcourt, NigeriaO. K. Obunge 1 , N. Onyejepu 2 , P. Odeigah 2 ; 1 Univ. of Port Harcourt, PortHarcourt, Nigeria, 2 Univ. of Lagos, Lagos, Nigeria.C2-1372 Changing Epidemiology of Mycobacterium tuberculosisComplex (TB) Infections in a Tertiary Care Teaching Hospital inRiyadh Saudi Arabia: 8 Years Retrospective StudyA. M. M. Somily, Jr., T. Naeem, Jr., A. Kambal; King Saud Univ., Riyadh,Saudi Arabia.C2-1373 Diabetes Mellitus is Important as HIV for Development ofTuberculosis Control Programmes: Seven Years Experience in aMexican Teaching HospitalC. Emanuela 1 , M. Lichtner 1 , E. González Díaz 2 , M. Morfin Otero 2 , E.Rodriguez Noriega 3 , S. Savinelli 1 , H. Perez Gomez 4 , C. Mastroianni 1 , V.Vullo 1 ; 1 Sapienza Univ. of Rome, Roma, Italy, 2 Univ. de Guadalajara Mexico,Hosp. Civil de Guadalajara, “Fray Antonio Alcalde, Guadalajara, Mexico,3Univ. de Guadalajara Mexico, Hosp. Civil de Guadalajara, Fray AntonioAlcalde, Roma, Mexico, 4 Univ. de Guadalajara Mexico, Hosp. Civil de Guadalajara,Fray Antonio Alcalde, Guadalajara, Mexico.C2-1374 Tuberculosis Encephalitis in FranceE. Honnorat 1 , T. De Broucker 2 , A. Mailles 3 , J. Stahl 1 ; 1 Univ. I, Grenoble,France, 2 Hosp. Delafontaine, Saint-Denis, France, 3 French Public Hlth.Inst., Saint-Maurice, France.C2-1375 Outbreak of Mycobacterium abcessus subsp. boletti in RioGrande do Sul State, Southern BrazilL. S. Nunes 1 , C. M. Cardoso 2 , F. de Paris 3 , L. F. Baethgen 4 , M. O. Ribeiro 2 ,V. Farias 2 , M. G. Silva 5 , R. S. Duarte 5 , A. L. Barth 3,1 ; 1 Programa de PósGraduação Ciências Médicas , Univ. Federal do Rio Grande do Sul, PortoAlegre, Brazil, 2 Lab. Central de Saúde Pública/RS, Porto Alegre, Brazil,3Hosp. de Clinc. de Porto Alegre, Porto Alegre, Brazil, 4 Programa de PósGraduação em Patologia, Univ. Fedd de Ciências da Saúde de Porto Alegre,Porto Alegre, Brazil, 5 Univ. Fed. do Rio de Janeiro, Rio de Janeiro, Brazil.------------------------------------------------------------------------169(C2)Poster SessionMRSA: A Bug with International Appeal and GreatSenseTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:C2-1376 Displacement of the Brazilian Endemic Clone (BEC - SC-Cmec III) by a Pediatric Clone (SCCmec II) Causing Shift in theVancomycin MICs Among Methicillin-Resistant Staphylococcusaureus (MRSA) Isolated in BrazilE. A. M. Frigatto, C. G. Carvalhaes, B. Nonato, A. G. Souza, F. M. Inoue, V.G. S. Oliveira, R. Girardello, S. S. Andrade, A. M. O. Machado, A. C. Gales;UNIFESP, São Paulo, Brazil.C2-1377 Staphylococcus aureus International Clones Spread amongInpatients Attending in an University Hospital in Rio De Janeiro,BrazilF. Aguiar-Alves 1,2 , T. M. Costa 1,2 , N. Iorio 3,4 , M. C. Ferguson 1 , D. Caldeira 1 ,J. Carballito 1 , K. R. N. dos Santos 4 , S. Mondino 1 ; 1 UFF, Niteroi, Brazil, 2 FederalFluminense Univ., Niteroi, Brazil, 3 UFF, Rio de Janeiro, Brazil, 4 FederalUniv. of Rio de Janeiro, Rio de Janeiro, Brazil.C2-1378 Molecular Characterization of Methicillin Resistant Staphylococcusaureus from a Teaching Hospital in South West NigeriaM. A. Raji 1,2 , O. Ojemhen 2 , P. Basset 3 , D. Blanc 3 ; 1 Lagos State Univ. Coll. ofMed., Ikeja, Lagos State, Nigeria, 2 BT Hlth. Diagnostic Ctr., Ikeja, Nigeria,3CHUV, Lausanne, Switzerland.C2-1379 Continuing Evolution of USA300 (CMRSA10) Community-AssociatedMethicillin-Resistant Staphylococcus aureus(CA-MRSA) in Canadian Hospitals from 2007-2011K. A. Nichol 1 , H. J. Adam 1,2 , M. R. Mulvey 3,2 , M. McCracken 3 , M. Baxter 2 ,A. Onio 2 , D. J. Hoban 1,2 , G. G. Zhanel 2 , Canadian Antimicrobial ResistanceAlliance (CARA); 1 Diagnostic Services of Manitoba, Winnipeg, Canada,2Univ. of Manitoba, Winnipeg, Canada, 3 Natl. Microbiol. Lab., Winnipeg,Canada.C2-1380 Characterization of Community-Onset Methicillin-Resistant Staphylococcus aureus (COMRSA) Infections throughPopulation-Based Surveillance in CanadaG. Golding 1 , N. Vaid 2 , M. Gale-Rowe 2 , G. Jayaraman 2 , J. MacDonald 3 , L.Fang 2 , J. Njihia 2 , M. McCracken 1 , C. Archibald 2 , M. Mulvey 1 , T. Wong 2 ,J. Embil 4 , J. Conly 3 , COMRSA Pilot Group; 1 PHAC, Winnipeg, Canada,2PHAC, Ottawa, Canada, 3 Alberta Hlth. Services, Calgary, Canada, 4 Univ. ofManitoba, Winnipeg, Canada.C2-1381 Prospective Screening (S) for Vancomycin-IntermediateSusceptibility (VISA) and Heteroresistance (hVISA) amongMethicillin-Resistant Staphylococcus aureus (MRSA) IsolatesDirectly from Blood Culture (BC) BottlesS. Iyer, M. Sharma, L. B. Johnson, K. Riederer, S. Shemes, R. Khatib; StJohn Hosp. & Med. Ctr., Grosse Pointe Woods, MI.C2-1382 Characteristics of Staphylococcus aureus Nasal Carriage, ResistancePatterns and Genetic Lineages in Healthy German AdultsR. Köck 1 , P. Werner 2 , A. W. Friedrich 3 , C. Fegeler 2 , Prevalence of MultiresistantMicroorganisms (PMM)Study Group, K. Becker 1 ; 1 Univ. Hosp. ofMünster, Münster, Germany, 2 Univ. Heilbronn, Heilbronn, Germany, 3 Univ.Hosp. Groningen, Groningen, Netherlands.146September 9-12 |

TUESDAY SCIENTIFIC SESSIONSC2-1383 Staphylococcal Isolates of Nasal Carriers May ShareGenetic Resistance ElementsR. Chamon 1 , V. C. Salgueiro 1 , M. Seixas 1 , L. D. Falcão - 2 , H. C. C. Póvoa 2 ,K. R. N. dos Santos 1 , N. L. P. Iorio 2 ; 1 Rio de Janeiro Federal Univ., Rio deJaneiro, Brazil, 2 Fluminense Federal Univ., Rio de Janeiro, Brazil.C2-1384 Molecular Epidemiology of Staphylococcus aureus InfectionIsolates in IowaR. Nair 1 , S. Wardyn 2 , M. Quick 2 , J. Wu 2 , T. Smith 2 ; 1 Univ. of Iowa Coll. ofPubl. Health, Coralville, IA, 2 Univ. of Iowa, Coralville, IA.C2-1385 Diversity of SCCmec Elements in MRSA from RussiaV. V. Gostev 1 , A. E. Goncharov 2 , S. V. Sidorenko 1,2 ; 1 Res. Inst. of Children’sInfections, Saint Petersburg, Russian Federation, 2 I.I. Mechnikov North WestState Med. Univ., Saint- Petersburg, Russian Federation.C2-1386 Simultaneous Presence of SCCmec Types IV and VElements in a Clinical MRSA IsolateA. Romanov 1 , Y. Chernov 1 , M. Edelstein 1 , E. Moskvitina 2 , A. Dekhnich 1 ;1Inst. of Antimicrobial Chemotherapy, Smolensk, Russian Federation,2Federal Med. Biological Agency Clinical Hosp. No. 81, Seversk, RussianFederation.C2-1387 Methicillin-Resistant Staphylococcus aureus Carrying thePVL Gene with Reduced Sensibility to Vancomycin Isolated froma NewbornC. O. da Silva, R. C. Chamon, N. L. P. Iorio, F. S. Cavalcante, D. C. Ferreira,K. R. N. dos Santos; Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil.C2-1388 Molecular and Phenotypic Characters of Methicillin-ResistantStaphylococcus aureus Isolates from Patients with Empyema inCentral TaiwanW. Wang 1,2 , T. Chiueh 1 , S. Tsao 3 ; 1 Natl. Defense Med. Ctr., Taipei, Taiwan,2Fong-Yuan Hosp., Taichung, Taiwan, 3 Chung Shan Med. Univ. Hosp.,Taichung, Taiwan.C2-1389 Cefazolin High-Iinoculum Effect in Methicillin-SusceptibleS. aureus (MSSA) from South American (SA) HospitalsS. Rincon, 1 , J. Reyes 1 , L. P. Carvajal 1 , B. E. Murray, 2 , E. C. Nannini 3 , C. A.Arias 2 ; 1 Univ. El Bosque, Bogota, Colombia, 2 Univ. of Texas Med. Sch.at Houston, Houston, TX, 3 Univ. Nal de Rosario, Rosario, Argentina.C2-1390 Reversal of Vancomycin (VAN) MIC Creep in S. aureus (SA)Strains Isolated from BloodE. L. Palavecino, J. W. Johnson, J. C. Williamson; Wake Forest Sch. ofMed., Winston Salem, NC.C2-1391 Vancomycin Susceptibility in Methicillin-ResistantStaphylococcus aureus (MRSA) Over 10 Years: MIC DecreaseAfter a Transient CreepR. Khatib, M. Sharma, L. B. Johnson, K. Riederer, S. Shemes, S. Iyer;St. John Hosp. & Med. Ctr., Grosse Pointe Woods, MI.C2-1392 Low Prevalence of hVISA among S. aureus BloodstreamIsolates and No Evidence of MIC Creep in the Cologne MetropolitanAreaH. Seifert, D. Stefanik, A. Kaasch; Univ. of Cologne, Köln, Germany.C2-1393 A Plasmid-Borne System for Assessing the Excision andIntegration of Staphylococcal Cassette Chromosome Mec(SCCMec) Mediated By CcrA And CcrBL. Wang, G. Archer; Virginia Commonwealth Univ., Richmond, VA.C2-1394 High Level Mupirocin Resistance and In Vitro Activity ofFusidic Acid among Staphylococcus aureus Clinical IsolatesT. Hosbul, B. Bektore, M. Ozyurt; Gulhane Military Med. Academy, HaydarpasaTraining Hosp., Istanbul, Turkey.C2-1395 Accessory Gene Regulator (AGR) Function, rpoBMutations and Vancomycin (VA) Susceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Blood IsolatesM. Camoez, J. Sierra, F. Tubau, O. Gasch, M. Pujol, J. Liñares, R. Martín,M. Domínguez; Hosp. Univ. Bellvitge. UB. IDIBELL, Barcelona, Spain.C2-1396 Molecular Epidemiology of Community-Acquired MRSACausing Skin and Skin Structure Infections in ArgentinaS. Fernandez 1 , N. Gardella 1 , M. Lopez Furst 2 , L. De Vedia 3 ,M. Stryjewski 4 , M. Ganaha 5 , S. Prieto 6 , E. Carbone 7 , N. Lista 3 ,F. Rotrying 8 , M. Mollerach 1 ; 1 FFyB UBA, Caba, Argentina, 2 S. Mendez,Caba, Argentina, 3 Hosp. Muñiz, Caba Argentina, 4 CEMIC, Caba,Argentina, 5 Hosp. V Lopez y Planes, Buenos Aires, Argentina, 6 Hosp.NS de Luján, Buenos Aires, Argentina, 7 Hosp. Aeronáutico, Caba,Argentina, 8 Hosp. UAI, Caba, Argentina.C2-1397 Molecular Epidemiology of Community-Acquired MRSACausing Invasive Disease in Argentina in 2010 and 2011S. Fernandez 1 , N. Gardella 1 , S. Di Gregorio 1 , M. Lopez Furst 2 ,L. De Vedia 3 , M. Stryjewski 4 , C. Ganaha 5 , S. Prieto 6 , E. Carbone 7 , N.Lista 3 , F. Rotrying 8 , M. Mollerach 1 ; 1 UBA, Caba, Argentina, 2 S.Mendez,Caba, Argentina, 3 Hosp. Muñiz, Caba, Argentina, 4 CEMIC, Caba, Argentina,5 Hosp. V lopez y Planes, BA, Argentina, 6 Hosp. NS de Luján, BA,Argentina, 7 Hosp. Aeronautico, Caba, Argentina, 8 UAI, Caba, Argentina.C2-1398 Acute Bacterial Skin and Skin Structure Infections(Absssi) Caused by Community-Acquired Methicillin-ResistantStaphylococcus aureus: An Emerging Problem in ArgentinaA. Mykietiuk, P. Pessacq, M. Obed, B. Alcorta, G. Bertoni, P. Damico, E.Scaglione, J. Poggio, G. Guerrini, A. Calmaggi; HIGA ROSSI, La Plata,Argentina.C2-1399 Dynamics of the Emergence of Quinolone Resistance inStaphylococci from the Nasal Microbiota of Patients Treated byFluoroquinolonesA. Munier, V. de Lastours, F. Barbier, B. Fantin, R. Ruimy; EA3964 Univ.Paris Diderot, Paris, France.C2-1400 Distinct Frequency of Biofilm (BF)-Related Genes amongCiprofloxacin (CIP) Susceptible and Resistant S. epidermidis(SEPI) agr Types I (tI) and II (tII) Isolates from Endophthalmitis(END)P. J. Bispo 1 , D. Miller 2 ; 1 Federal Univ. of Sao Paulo, São Paulo, Brazil,2Bascom Palmer Eye Inst., Miami, FL.C2-1401 Microbiologic Features and Antimicrobial Susceptibilitiesof Linezolid Resistant Coagulase Negative StaphylococcalIsolates in a Tertiary CenterT. Kelesidis 1 , B. Gu 1 , S. Tsiodras 2 , R. Humphries 1 ; 1 UCLA, Los Angeles,CA, CA, 2 Univ. of Athens Med. Sch., Athens, Greece.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.Final Program147

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------170(D)Poster SessionDetection of Bacteremia and Biomarkers for SepsisTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:D-1402 Usefulness of Procalcitonin and C-Reactive Protein asDiagnostic Markers of Bacterial Infection in Febrile NeutropeniaM. Aimoto , H. Koh, M. Bingo , M. Yoshida, H. Okamura, T. Yoshimura, A. Inaba, S. Koh , S. Nanno , M. Nishimoto , Y. Hayashi , A. Hirose, M.Nakamae, K. Hagihara, Y. Terada, T. Nakane, H. Nakamae, , M. Hino;Graduate Sch. of Med., Osaka City Univ., Osaka, Japan.D-1403 Use of Monocyte Chemoattractant Protein 1-Alpha (MCP-1), Soluble Tumor Necrosis Factor Receptor Type 1 (sTNFR-1)and C-Reactive Protein (CRP) in the Prediction of Fever inNeutropenic PatientsA. V. Macedo, H. Bittencourt, A. S. Miranda, M. Marriel, V. C. S. Rocha, A.L. Teixeira, V. Nobre; Univ. Federal de Minas Gerais, Belo Horizonte, Brazil.D-1404 Soluble Urokinase Plasminogen Activator Receptor (suPAR)Levels May Predict Positive Blood Cultures in Systemic InflammatoryResponse SyndromeM. Hoenigl, R. B. Raggam, J. Wagner, A. J. Grisold, W. Krammer, K.Seeber, F. Prueller, E. Leitner, R. Krause; Med. Univ. of Graz, Austria, Graz,Austria.D-1405 Is Soluble Urokinase Plasminogen Activation Receptor(SUPAR) A Valuable Tool in the Follow-Up Febrile NeutropenicPatients with Hematological Malignancy?S. Kaya 1 , G. Yılmaz 1 , A. Mentese 2 , M. Sönmez 3 , A. Uzun Sümer 2 ,S. Sönmez Yıldırım 1 , &. Köksal 1 ; 1 Karadeniz Tech. Univ. Faculty of Med.,Trabzon, Turkey.D-1406 High Level of Autoantibody to Interferon-Gamma, a MajorCause of Acquired Cell-Mediated Immune Deficiency in Non-HIV Individuals in Northern ThailandP. Wongkulab, J. Wipasa, R. Chaiwarith, K. Supparatpinyo; Chiang MaiUniv., Chiang Mai, Thailand.D-1407 Serum Levels of Interferon Gamma in Patients withBrucellosis in a Saudi HospitalM. M. A. Abo-Shadi 1 , A. I. H. Al-Harbi 2 , E. Ballal 3 ; 1 Faculty of Sci.-TaibahUniv., Al-Madinah, Saudi Arabia, 2 Taibah Univ., AlMadinah AlMunawarah,Saudi Arabia, 3 Prince Sultan Armed Forces Hosp., AlMadinah AlMunawarah,Saudi Arabia.D-1408 Detection of Integrons in Blood Cultures: Predictive Valuefor Acquired Resistance to Antibiotics?O. Barraud 1,2,3 , D. Chainier 1,2,3 , J. Vignaud 3 , M. Ploy 1,2,3 ; 1 INSERM, Limoges,France, 2 Univ. Limoges, Limoges, France, 3 CHU Limoges, Limoges, France.D-1409 Comparison of Charcoal-Containing Aerobic and StandardAerobic Blood Culture Media: Comparing Yield and Time toDetectionG. N. Hartmeyer, T.Besser and R.B Dessau; Slagelse Sygehus ClinicalMicrobiol., Slagelse, Denmark.D-1410 Same-Day Blood Culture with Digital MicroscopyS. Metzger 1 , C. S. Price 2 , K. Hance 1 , D. Howson 1 ; 1 Accelr8, Denver, CO,2Denver Hlth. Med. Ctr., Denver, CO.D-1411 The Value of Adding Septifast to a Prediction Score forComplicated Bloodstream Infections Caused by Gram-PositiveBacteria or CandidaA. Fernandez-Cruz, M. Marín, M. Kestler, L. Alcalá, M. Rodríguez-Créixems, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.D-1412 Comparison of Conventional Blood Culture and Real-TimePCR of Culture Bottles and Whole Blood for Diagnostic ofBloodstream Infections in Pediatric Oncologic PatientsM. G. Quiles 1 , L. C. Menezes 1 , K. C. Bauab 1 , T. T. Rocchetti 1 , F. S.Palomo 1 , E. Gumpl 3 , F. Carlesse 2 , A. C. C. Pignatari 1 ,; 1 Federal Univ. ofSão Paulo, São Paulo, Brazil, 2 Inst. of Pediatric Oncology, GRAACC/IPO/UNIFESP, São Paulo, Brazil, 3 UNIFESP, São Paulo, Brazil.D-1413 Clinical Impact of Matrix-Assisted Laser Desorption/IonizationTime-of-Flight Mass Spectrometry (MALDI-ToF MS)Identifications from Positive Blood Cultures BottlesD. Martiny 1 , F. Debaugnies 1 , D. Gateff 2 , M. Gérard 2 , A. Dediste 1 , M.Chantrenne 1 , C. Martin 2 , D. Konopnicki 2 , M. Aoun 3 , A. Loizidou 3 , A.Georgala 3 , M. Hainaut 2 , O. Vandenberg 1 , S. Van Praet 2 ; 1 Saint-Pierre Univ.Hosp. and Jules Bordet Inst., Brussels, Belgium, 2 Saint-Pierre Univ. Hosp.,Brussels, Belgium, 3 Jules Bordet Inst., Brussels, Belgium.D-1414 Performance Characteristics of Rapid Prototype Immunoassaysfor the Detection of Staphylococcus aureus and Prediction ofSusceptibility Directly from Blood CulturesC. V. Larka, G. W. Svanas, L. Robertson, S. Elagin; Meridian Bioscience,Inc., Cincinnati, OH.D-1415 Rapid Detection of Staphylococcus aureus and Methicillin-Resistant S. aureus (MRSA) in Blood Cultures: Evaluation of theGenomEra MRSA/SA AssayE. Cercenado 1 , C. Sánchez-Carrillo 1 , M. Marín 1 , A. Vindel 2 , M. Rodríguez-Créixems1 , E. Bouza 1 ; 1 Hosp. Gen. Univ. Gregorio Marañón, Madrid,Spain, 2 Inst. de Salud Carlos III, Madrid, Spain.D-1416 Evaluation of a Microarray Based Assay for Rapid Detectionof Gram-Positive Organisms and Resistance Markers in PositiveBlood CulturesL. P. Samuel, R. J. Tibbetts, A. Agotesku, M. Fey, R. Hensley, F. A. Meier;Henry Ford Hlth. System, Detroit, MI.D-1417 Performance of the Nanosphere Verigene Gram-PositiveBlood Culture Nucleic Acid Test for Rapid Detection of S. aureus,S. epidermidis and mecA Directly from Positive Blood CulturesWithdrawnD-1418 Verification of a Commercial Signal Amplification Assay forRapid Identification of MRSA from Blood Culture BottlesG. A. Capraro; LSU Hlth. Sci. Ctr., Shreveport, LA.D-1419 Evaluation of Three Rapid Methods to Identify Staphylococcusaureus and Determine Cloxacillin Susceptibility Directly fromPositive Blood CultureS. Molinos, M. Quesada, L. Mateu, M. Colomer, C. Rodrigo, M. Gimenez;Hosp. Germans Trias i Pujol, Badalona, Spain.D-1420 Analysis of Sequential Time to Positivity of Blood CultureSamples among Patients with Persistent Staphylococcus aureusBacteremiaC. Liao; Far Eastern Mem. Hosp., New Taipei City, Taiwan.148September 9-12 |

TUESDAY SCIENTIFIC SESSIONSD-1421 Antimicrobial Resistance Profile of Salmonella Isolates fromTyphoid Fever Outbreak in Rwanda, May 2011I. M. Uwimana 1 , T. Mukankwiro 1 , N. Umulisa 2 , E. Habyarimana 3 , J. Flandin4 , O. Mukabayire 1 ; 1 RBC/IHDPC/Natl. Reference Lab., Kigali, Rwanda,2RBC/IHDPC/Malaria Div., Kigali, Rwanda, 3 Ruhengeri District Hosp.,Musanze, Rwanda, 4 Natl. Reference Lab., Kigali, Rwanda.D-1422 Importance of Appropriate Antibiotic Usage in the Clearanceof Acinetobacter baumannii BacteremiaY. Chuang 1 , S. Chang 1 , W. Wang 2 ; 1 Natl. Taiwan Univ. Hosp., Taipei, Taiwan,2 John A. Burns Sch. of Med., Univ. of Hawaii at Manoa, Honolulu, HI.D-1423 MALDI-ToF MS and Direct Antimicrobial SusceptibilityTesting from Positive Blood Cultures: Comparison of the Bactalertand Bactec SystemH. Wisplinghoff 1,2 , T. Hoppe 2 , A. Hamprecht 1 , U. Aurbach 2 ; 1 Univ. ofCologne, Cologne, Germany, 2 Dres. Wisplinghoff & Colleagues, Cologne,Germany.------------------------------------------------------------------------171(D)Poster SessionDiagnosis, Characterization and AntimicrobialSusceptibility Testing: Gram-Positive CocciTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:D-1424 Evaluation of a Cost Effective Broth and Selective AgarCombination for the Detection of MRSA and Staphylococcusaureus from Surveillance SpecimensE. L. Chan, D. Seales; Trinity Med. Ctr., Birmingham, AL.D-1425 Droplet Digital PCR for Detection of Methicillin-ResistantStaphylococcus aureus from Clinical SwabsD. C. Sullivan 1 , K. L. Kelley 1 , B. A. Chapman 1 , P. Belgrader 2 ; 1 Univ. of MississippiMed. Ctr., Jackson, MS, 2 BioRad Clin. Diag. Group, Hercules, CA.D-1426 Rapid Methicillin-Resistant Staphylococcus aureus (MRSA)Screening on Admission to Pediatric and Neonatal Intensive CareUnits in an Italian Pediatric HospitalR. Bandettini, M. Perotti, F. Risso, A. Moscatelli, M. Diana, L. Pescetto,L. Ricagni, E. Castagnola; Ist. G. Gaslni, Lab. Centrale, Genoa, Italy.D-1427 Evaluation of the Xpert Methicillin-Resistant Staphylococcusaureus (MRSA) Assay for Rapid Detection of Nasal Carriage ofMRSAWithdrawn.D-1428 A New Multiplex Pcr to Detect Sccmec Types in Methicillin-Resistant Staphylococcus aureus of Nasal CarriageF. S. Cavalcante, D. C. Ferreira, Y. C. Lyra, F. Monteiro, E. D. Abad, K. R.N. dos Santos; Univ. Federal do Rio de Janeiro, Rio de Janeiro, Brazil.D-1429 Phage Open-Reading Frames Typing Method for Methicillin-ResistantStaphylococcus aureus Outbreak Investigation inNeonatal Intensive Care UnitS. Matsushita, T. Shoji, K. Kinoshita, Y. Horikoshi; Tokyo MetropolitanChildren’s Med. Ctr., Tokyo, Japan.D-1430Automated System Fails to Detect an Unusual MacrolideResistance Phenotype among Methicillin-Resistant StaphylococcusaureusT. Hosbul 1 , B. Bozdogan 2 , T. Haznedaroglu 1 , M. Ozyurt 1 ; 1 Gulhane MilitaryMed. Academy, Haydarpasa Training Hosp., Istanbul, Turkey, 2 AdnanMenderes Univ. Faculty of Med., Aydin, Turkey, Aydin, Turkey.D-1431 Reduced Activity of Clindamycin against Various Streptococciwith Clindamycin-Inducible Resistance in the NeutropenicThigh Infection ModelA. J. Lepak 1 , W. A. Craig 1 , D. R. Andes 2 , K. Marchillo 3 , J. van Hecker 3 ;1Univ. of Wisconsin, Madison, WI, 2 Univ. of Wisconsin, William S MiddletonMem. VA Hosp., Madison, WI, 3 William S Middleton Mem. VA Hosp.,Madison, WI.D-1432 Use of DNA Microarray to Characterize Oxacillin-Susceptible,mecA-Positive Staphylococcus aureusK. A. Sharff 1 , S. Slaughter 2 , G. Forrest 3 , C. Pfeiffer 3 , S. Monecke 4 , R.Ehricht 5 , M. Oethinger 2 ; 1 Oregon Hlth. & Sci. Univ., Ptld, OR, 2 ProvidenceMed. Ctr., Portland, OR, 3 VA Med. Ctr., Portland, OR, 4 Inst. for Med.Microbiol. and Hygiene, Dresden, Germany, 5 Alere Technologies, Jena,Germany.D-1433 Comparison of Etest and Broth Microdilution (BMD) MICMethods for Testing Staphylococcus aureus (SA) and Streptococcusagalactiae (GBS) with CeftarolineD. J. Diekema 1 , J. H. Jorgensen 2 , M. A. Lewinski 3 , L. Boyken 1 , L. C.Fulcher 2 , M. L. McElmeel 2 , M. A. Tagarao 3 , J. A. Hindler 3 ; 1 Univ. of IowaHosp. and Clinics, Iowa City, IA, 2 Univ. of Texas Hlth. Sci. Ctr., San Antonio,TX, 3 UCLA Hlth. System, Los Angeles, CA.D-1434 Onsite hVISA Detection: One Hospital’s StoryM. Jeffres 1,21Roseman Univ. of Hlth. Sci., Henderson, NV, 2 Univ. of Nevada Sch. ofMed., Las Vegas, NV.D-1435 Prevalence and Relevance of Detecting Vancomycin Heteroresistanceamong Methicillin-Resistant Staphylococcus aureusBacteremiaV. Huang, S. Sambhara, C. Bishop, J. Attardo; Mercer Univ. Coll. of Pharmacyand Hlth. Sci., Atlanta, GA.D-1436 Increased Cell Wall Stiffness in Vancomycin-Resistant Staphylococcusaureus Measured by Atomic Force MicroscopyL. Rio Marques 1 , G. Longo 2 , S. Kasas 2 , A. Trampuz 1 , A. Bizzini 1 ; 1 Univ.Hosp. Lausanne, Lausanne, Switzerland, 2 Ecole Polytechnique FédéraleLausanne, Switzerland.D-1437 Hexaplex PCR Assay for Detection of Staphylococcus aureus,mecA, czrC, QacA/B and Pantone-Valentine Leucocidin Geneswith Simultaneous Discrimination from Coagulase NegativeStaphylococciS. Panda 1 , S. Kar 2 , R. Choudhury 1 , S. Sharma 2 , D. V. Singh 1 ; 1 Inst. of LifeSci., Bhubaneswar, India, 2 LV Prasad Eye Inst., Bhubaneswar, India.D-1438 The First Report of Daptomycin Susceptibility of 832 Strainsof Gram-Positive Cocci from an University Hospital in Japan(2009-2011)A. Yoshizumi 1 , M. Iwata 2 , H. Murakami 2 , S. Yumoto 2 , K. Yasui 2 ,C. Maehara 2 , S. Fukuzawa 2 , K. Enokizono 2 , A. Hikosaka 2 , Y. Ishii 1 ,K. Tateda 1 ; 1 Toho Univ., Tokyo Japan, 2 Toho Univ. Omori Med. Ctr.,Tokyo, Japan.Final Program149

Tuesday SCIENTIFIC SESSIONSD-1439 Staphylococcus aureus Enterotoxins Relevance in Atopic Dermatitis:Clinical, Immunological and Microbiological ParametersA. Rojo, A. Aguinaga, G. Gastaminza, J. R. Yustet, A. España; Clin. Univ.Navarra, Pamplona, Spain.D-1440 Staphylococcus aureus in Atopic Dermatitis: Different GenotypicProfile from Asymptomatic Atopic Carriers?A. Rojo 1 , A. Aguinaga 1 , S. Monecke 2 , G. Gastaminza 1 , J. R. Yuste 1 , A.España 1 ; 1 Clin. Univ. Navarra, Pamplona, Spain, 2 Ins. for Med. Microbiol. &Hyg., Jena, Germany.D-1441 Evaluation of the VITEK 2 AST-ST1 Card for AntibioticSusceptibility Testing of Oral, Group D, and Beta-HemolyticStreptococciR. Leclercq 1 , M. Auzou 1 , F. Garnier 2 , M. Ploy 2 , H. Poupet 3 , C. Poyart 3 ,V. Cattoir 1 ; 1 CHU Caen, Caen, France, 2 CHU Limoges, Limoges, France,3CHU Cochin, Paris, France.D-1442 Comparison of Surveillance Culture to Xpert vanA Assay forDetection of Vancomycin-Resistant EnterococciK. Gilhuley, D. Cianciminio-Bordelon, D. Reid, S. Tulumba, Y. Tang, N. E.Babady; Mem. Sloan-Kettering Cancer Ctr., New York, NY.D-1443 16S-23S Intergenic Spacer (ITS) Region Sequence Analysisand Species Identification of the Genera Aerococcus, Abiotrophia,Granulicatella, Gemella and LeuconostocD. Carkaci 1,2 , X. Nielsen, 1 , J. Christensen 1 ; 1 Slagelse Hosp, Slagelse, Denmark,2 Roskilde Univ., Roskilde, Denmark.D-1444 Identification of the Bovis Group Streptococci and the Valueof Sequence Analysis of the 16S-23S Intergenic Spacer RegionE. S. Marmolin 1 , G. N. Hartmeyer 2 , X. C. Nielsen 2 , R. Dargis 2 , E. Knudsen 1 ,M. N. Skov 1 , M. Kemp 1 , J. J. Christensen 2 , U. S. Justesen 1 ; 1 Odense Univ.Hosp., Odense C, Denmark, 2 Slagelse Hosp., Slagelse, Denmark.------------------------------------------------------------------------172(D)Poster SessionMolecular Methods for Pathogen Identification andResistance DetectionTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:D-1445 High Resolution Melting (HRM) Analysis Allows RapidDetection and Differentiation of bla KPCAlleles in Gram-NegativePathogensA. L. Roth, M. Kovarik, N. D. Hanson; Creighton Univ., Omaha, NE.D-1446 Fast Identification of KPC-Type Genes by PyrosequencingJ. Monteiro 1,2 , R. Widen 2 , A. C. Pignatari 1 , C. Kubasek 2 , A. C. Gales 1 , S.Silbert 2 ; 1 Federal Univ. of São Paulo, São Paulo, Brazil, 2 Tampa Gen. Hosp.,Tampa, FL.D-1447 Accreditation of Carbapenemase and ESBL Multiplex End-Point PCRs According to ISO15189P. Bogaerts, R. Rezende de Castro, Y. Glupczynski; CHU UCL Mont-Godinne, Yvoir, Belgium.D-1448 The Laboratory Diagnosis of Carbapenemase-ProducingEnterobacteriaceae (C-Ent)D. Doyle 1 , G. Peirano 2 , C. Lascols 3 , T. Lloyld 1 , D. Church 2 , J. Pitout 2 ;1Calgary Lab Services, Calgary, Canada, 2 Univ. of Calgary, Calgary, Canada,3IHMA, Inc, Schaumburg, IL.D-1449 Development of a Rapid Multiplex PCR Assay for EmergingCarbapenemases and CMY-2H. Briggs, M. Herrera, B. Wickes, J. Jorgensen; Univ. of Texas Hlth. Sci. Ctr.San Antonio, TX.D-1450 An Evaluation of Multiple Phenotypic Screening Methodsfor Klebsiella pneumoniae Carbapenemase (KPC)-ProducingEnterobacteriaceaeE. B. Hirsch 1 , K. T. Chang 2 , D. N. Francoeur 1 , K. R. Ledesma 2 , V. H.Tam 2,3 , T. M. Lasco 3 ; 1 Northeastern Univ., Boston, MA, 2 Univ. of Houston,Houston, TX, 3 St. Luke’s Episcopal Hosp., Houston, TX.D-1451 Development of Real-Time Multiplex PCR Assays forMetallo-Lactamases, Other Carbapenemases, AmpC andCTX-M ESBLsR. L. Swayne 1 , S. H. Aliyu 1 , M. J. Ellington 2 , N. Woodford 3 , M. D.Curran 4 ; 1 Cambridge Univ. Hosp. NHS Trust, Cambridge, United Kingdom,2Cambridge Microbiol. Lab Hlth. Protection Agency, Cambridge, UnitedKingdom, 3 Antibiotic Resistance Monitoring and Ref Lab, Hlth. ProtectionAgency, London, United Kingdom, 4 Cambridge Microbiol. Lab, Hlth.Protection Agency, Cambridge, United Kingdom.D-1452 Virulence Factor Gene cnf and-Lactamase Gene TEM areAssociated with an Increased Severity of Escherichia coli BloodStream InfectionsM. Mora-Rillo, N. Fernández-Romero, C. Navarro San Francisco, M. P.Romero-Gómez, J. R. Paño-Pardo, J. R. Arribas-López, J. Mingorance;Hosp. Univ. La Paz, IdiPAZ, Madrid, Spain.D-1453 Real-Time PCR For Detection of Blaoxa-48 Genes FromSpiked StoolsT. Naas, G. Cotellon, A. Ergani P. Nordmann; INSERM U914: EmergingResistance to Antibiotics, Le Kremlin Bicetre, France.D-1454 Rapid Detection of Common Bacterial Antibiotic ResistanceGenes Using a Set of Locked Nucleic Acid (lna)-BasedQuantitative PCR AssaysWithdrawnD-1455 A New OXA Variant from Achromobacter sp: A SpeciesSpecific MarkerM. Papalia 1 , M. Almuzara 1 , G. Traglia, Lic 2 , M. Ramírez 1 , A. Belmonte 2 ,A. Famiglietti 1 , C. Vay 1 , G. Gutkind 1 , M. Radice 1 ; 1 UBA, Buenos Aires,Argentina, 2 UNR, Rosario, Argentina.D-1456 New Lamp Method For Simple Screening of Plasmid-Mediated Quinolone Resistance Genes, qepAK. Yamane 1,2 , A. Horino 2 , S. Suzuki 2 , J. Wachino 2 , M. Matsui 2 , K. Shibayama 2 ,Y. Arakawa 3,2 ; 1 Kawasaki Med. Sch., Kurashiki, Japan, 2 Natl. Inst. of InfectiousDiseases, Tokyo, Japan, 3 Nagoya Univ. Graduate Sch. of Med., Nagoya,Japan.D-1457 Campylobacterosis; Changing Dynamics of Human InfectionWithdrawn150September 9-12 |

TUESDAY SCIENTIFIC SESSIONSD-1458 Chemotherapy-Induced Changes of the Intestinal MicrobiotaAnalyzed by High Throughput PyrosequencingE. Montassier 1 , E. Batard 1 , J. Hardouin 2 , J. Caillon 1 , T. Carton 3 , N. Caroff 1 ,T. Gastinne 1 , P. Moreau 1 , G. Potel 1 , M. De la Cochetière 2 , F. Le Vacon 3 ;1Ctr. Hosp. Univ. de Nantes, Nantes, France, 2 Faculté de Med. de Nantes,Nantes, France, 3 Biofortis Res., Nantes, France.D-1459 Pyrotyping: A Practical Genotyping Method Compatible toMultilocus Sequence Typing (MLST) by PyrosequencingT. Saga, N. Aoike, Y. Ishii, K. Tateda; Toho Univ., Tokyo, Japan.D-1460 Rapid Identification of Causative Bacteria from PositiveBlood Culture Samples by DNA PyrosequencingM. Yamada, K. Yanagihara, Y. Morinaga, S. Kohno, S. Kamihira; NagasakiUniv., Nagasaki, Japan.D-1461 A Novel TM-Mapping Method that Enables Identificationof Pathogenic Microorganisms Within 3 Hours after Samples areCollectedH. Niimi 1 , T. Ueno 1 , S. Hayashi 1 , M. Mori 2 , H. Tabata 3 , H. Minami 3 ,S. Saito 1 , I. Kitajima 1 ; 1 Toyama Univ. Hosp., Toyama, Japan, 2 IshikawaPrefectural Univ., Ishikawa, Japan, 3 Hokkaido Mitsui Chemicals Corp.,Hokkaido, Japan.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------173(E)Poster SessionIn Vitro Activity of Lipoglycopeptides and RelatedCompoundsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:E-1462 In Vitro Activity of Oritavancin against Gram-PositivePathogens Isolated in Canadian Hospitals in 2011J. A. Karlowsky 1,2 , H. Adam 1 , M. Baxter 2 , D. Hoban 1,2 , G. G. Zhanel 2 ;1Diagnostic Services of Manitoba, Winnipeg, Canada, 2 Univ. of Manitoba,Winnipeg, Canada.E-1463 A Multi-Site Study Comparing an 18-24h CommerciallyPrepared Dried MIC Susceptibility System to the CLSI BrothMicrodilution Method for Oritavancin Using Fastidious andNon-Fastidious Gram-Positive OrganismsN. M. Holliday 1 , D. Zollos 1 , C. C. Knapp 1 , S. B. Killian 1 , F. F. Arhin 2 ,G. Moeck 2 , J. M. Streit 3 , R. N. Jones 3 , R. R. Prochaska 3 , P. R. Rhomberg 3 ,L. Sykes 4 ; 1 TREK Diagnostic Systems, Cleveland, OH, 2 The Med. Company,Parsippany, NJ, 3 JMI Lab., North Liberty, IA, 4 Kaiser Permanente,Cleveland, OH.E-1464 Evaluating the Activity of Daptomycin (DAP) and Linezolid(LND) in Combination with Rifampin (RIF) or Gentamicin(GENT) on Enterococcus faecium in an In Vitro PharmacodynamicModel Using Simulated Endocardial Vegetations (SEV)M. K. Luther 1 , K. M. Babcock 1 , K. L. LaPlante 1,2 , A. R. Caffrey 1,3 ; 1 ProvidenceVA ID Res. Program, Providence, RI, 2 Univ. of Rhode Island, Kingston,RI, 3 Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI.E-1465 In Vitro Development of Daptomycin Resistance (DAP-R)After Exposure to DAP of Enterococcus faecalis (EF) BloodstreamIsolates from Patients with Infective Endocarditis (IE)C. Garcia-de-la-Maria, J. M. Pericas, A. del-Rio, Y. Armero, Biologist, X.Castañeda, C. Cervera, M. Almela, C. Falces, S. Ninot, C. A. Mestres, D.Soy, J. M. Gatell, A. Moreno, F. Marco, J. M. Miro, Hospital Clinic EndocarditisStudy Group; Hosp. Clinic - IDIBAPS, Barcelona, Spain.E-1466 Efficacy of Daptomycin (DAP) and Ceftaroline (CPT) inMethicillin- Resistant Staphylococcus aureus (MRSA)/ Candidaglabrata (CG) Polymicrobial BiofilmsJ. M. Rybak 1,2 , J. A. Vazquez 2 ; 1 Eugene Applebaum Coll. of Pharm. andHlth. Sci., Detroit, MI, 2 Henry Ford Hosp., Detroit, MI.E-1467 A Multi-Site Study Comparing an 18-24h CommerciallyPrepared Dried MIC Susceptibility System to the CLSI BrothMicrodilution Method for Dalbavancin Using Fastidious andNon-Fastidious Gram-Positive OrganismsS. B. Killian 1 , N. M. Holliday 1 , C. C. Knapp 1 , D. Zollos 1 , M. Dunne 2 , J.M. Streit 3 , R. N. Jones 3 , R. R. Prochaska 3 , P. R. Rhomberg 3 , L. Sykes 4 ;1TREK Diagnostic Systems, Cleveland, OH, 2 Durata Therapeutics, Inc.,Morristown, NJ, 3 JMI Lab., North Liberty, IA, 4 Kaiser Permanente, Cleveland,OH.E-1468 Telavancin in the Therapy of Experimental Aortic ValveEndocarditis in Rabbits Due to Daptomycin-NonsusceptibleMethicillin-Resistant Staphylococcus aureus (MRSA)Y. Q. Xiong 1,2 , W. A. Hady 1 , A. S. Bayer 1,2 , L. Chen 3 , S. Yang 1,2 ; 1 Harbor-UCLA, Torrance, CA, 2 David Geffen Sch. of Med. UCLA, Los Angeles,CA, 3 Publ. Hlth. Res. Inst. Tuberculosis Ctr., Newark, NJ.E-1469 Activity Of Telavancin (TLV), Daptomycin (DAP), Linezolid(LND), and Vancomycin (VAN) against Clinical HeterogeneousVancomycin-Intermediate Staphylococcus aureus (hVISA) in aSimulated In Vitro Pharmacodynamic (IVPD) Infection ModelM. K. Luther 1 , K. M. Babcock 1 , A. R. Caffrey 1,2 , K. L. LaPlante 1,2 ; 1 ProvidenceVA ID Res. Program, Providence, RI, 2 Univ. of Rhode Island Coll. ofPharmacy, Kingston, RI.E-1470 In Vitro Activity of Telavancin and Other Non-ß-Lactam Antibioticsin Methicillin Resistant Staphylococcus aureus (Hospital-Acquired MRSA versus Community-Acquired MRSA) in AustriaE. Leitner, G. Zarfel, G. Feierl, U. Wagner-Eibel, M. Gehrer, E. Marth, A.Grisold; Inst. of Hygiene, Microbio. and Environmental Med., Graz, Austria.------------------------------------------------------------------------174(E)Poster SessionIn Vitro Activity Versus StaphylococcalTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:E-1471 In Vitro Activity of Vancomycin, Linezolid and Tigecyclineagainst Methicillin-Resistant Staphylococcus aureus (MRSA)Bloodstream Isolates and Outcomes in Patients with MRSABacteremia of the Medical Hospital of Vienna From 2000-2011C. Forstner, C. Dungl, S. Tobudic, H. Burgmann; Med. Univ. of Vienna,Vienna, Austria.Final Program151

Tuesday SCIENTIFIC SESSIONSE-1472 Beta-Lactams (BL) Enhance Vancomycin KillingActivity against Clinical Methicillin-Resistant Staphylococcusaureus (MRSA) In VitroT. Dilworth, J. Sliwinski Candidate, K. Ryan Candidate, M. Dodd, R. C.Mercier; Univ. of New Mexico, Albuquerque, NM.E-1473 The Combination of Iron Chelation and Vancomycin isSynergistic against Staphylococcus aureus In VitroG. Luo, T. Ghebremariam, H. Lee, A. Bayer, A. S. Ibrahim; Harbor-UCLAMed. Ctr., Torrance, CA.E-1474 Activity of PMX-30063 against Drug Resistant StaphylococciR. Scott 1 , B. Korczak 1 , D. Jorgensen 1 , S. Hawser 2 , M. Hackel 3 , S. Bouchillon3 , Y. Xiong 4,5 , A. Bayer 5 ; 1 PolyMedix, Inc., Radnor, PA, 2 IHMA Europe,Epalinges, Switzerland, 3 IHMA, Inc., Schaumberg, IL, 4 LA Biomed Res.Inst, Torrance, CA, 5 Geffen Sch. of Med., Torrance, CA.E-1475 Ceftaroline Activity against Community Associated (CA) andHealthcare Associated (HA) Methicillin-Resistant Staphylococcusaureus (MRSA)WithdrawnE-1476 Daptomycin (D) & Tigecycline (T) is Bactericidal againsta High Inoculum of Methicillin-Resistant Staphylococcus aureus(MRSA) with Reduced Susceptibilities to Vancomycin (V) Up to120 Hours in a Hollow Fiber Infection Model (HFIM)T. P. Lim 1,2 , N. Tahir, Dip 1 , W. Lee 1 , S. Sasikala 1 , Y. Cai 1 , L. Y. Hsu 2 , T.Y. Tan 3 , A. L. Kwa 1 ; 1 Singapore Gen. Hosp., Singapore, Singapore, 2 Natl.Univ. Hosp. System, Singapore, Singapore, 3 Changi Gen. Hosp., Singapore,Singapore.E-1477 In Vitro Activity of Fosfomycin Alone and Combinationwith Trimethoprim/Sulfamethoxazole against Blood Isolates ofMethicillin-Susceptible and Methicillin-Resistant StaphylococcusaureusA. Leelarasamee, T. Yungyuen, U. Kijsinthopchai, P. Disthaporn, A.Leelaporn; Mahidol Univ., Bangkok, Thailand.E-1478 Combination of Daptomycin with-Lactams Increases theAntibacterial Efficacy against Clinically Relevant MRSA Strainsand Prevents Selection of Dap-Resistant DerivativesC. Singh, K. B. Plata, P. Chanda, S. Riosa, R. Rosato, A. Rosato; TheMethodist Res. Inst., Houston, TX.E-1479 In Vitro Activity Profile of Tedizolid (TZD) and Correlationswith Linezolid (LZD) Activity against Recent StaphylococcalIsolatesJ. Deane 1 , A. Simenauer 1 , K. Bartizal 2 , K. Shaw 2 , D. Sahm 1 ; 1 Eurofins,Chantilly, VA, 2 Trius Therapeutics, San Diego, CA.E-1480 Biofilm Multiple Combination Bactericidal Test (MCBT) onMethicillin-Resistant Staphylococcus aureus (MRSA) from Patientswith Cystic Fibrosis (CF)R. Saginur 1 , W. Ferris 2 , L. Hyde 2 , R. Slinger 2 , F. Chan 2 ; 1 The OttawaHosp., Civic Campus, Ottawa, Canada, 2 CHEO, Ottawa, Canada.E-1481 Vancomycin MIC Creep among Ocular Staphylococcus aureusIsolatesP. J. Bispo, A. C. Pignatari, A. L. Hofling-Lima; Federal Univ. of Sao Paulo,São Paulo, Brazil.E-1482 Seesaw Effect Between Daptomycin (DAP) and Macrolide-Lincosamide-Streptogramin (MLS) Resistance in MRSAA. D. Berti 1 , W. Rose 1 , G. Sakoulas 2 ; 1 Univ. Wisconsin-, Madison, WI,2Univ. California, San Diego, CA.E-1483 In Vitro Susceptibility and Tolerance of Staphylococcus aureusSmall Colony Variants to Beta-Lactam AntibioticsE. A. Idelevich 1 , A. Kriegeskorte 1 , C. von Eiff 1,2 , G. Peters 1 , K. Becker 1 ;1Univ. Hosp. Münster, Münster, Germany, 2 Pfizer Pharma GmbH, Berlin,Germany.E-1484 Retapamulin Activity against S. aureus Resistant to VariousAntimicrobial AgentsL. D. Saravolatz, Sr., J. Pawlak, S. Saravolatz, L. B. Johnson; St John Hosp.and Med. Ctr., Grosse Pointe Woods, MI.E-1485 Sequential Versus Simultaneous Exposure to CombinationTherapy for Methicillin-Resistant Staphylococcus aureus (mrsa)BiofilmsS. J. Bergman 1 , K. A. Luciano 2 , V. Sundareshan 2 ; 1 Southern Illinois Univ.Edwardsville, Springfield, IL, 2 Southern Illinois Univ., Springfield, IL.E-1486 Phylogenetic Analysis of Enoyl-ACP Reductase (ENR)Protein Sequences from 123 Bacterial Species and Demonstrationof Staphylococcal-Specific Inhibition by the FabI ENR InhibitorAFN-1252 Using Reference In Vitro Susceptibility TestingJ. A. Karlowsky 1 , N. Kaplan 2 , B. Hafkin 2 , D. J. Hoban 1 , G. G. Zhanel 1 ;1Univ. of Manitoba, Winnipeg, Canada, 2 Affinium Pharmaceuticals, Toronto,Canada.------------------------------------------------------------------------175(F)Poster SessionAntimicrobial Peptides and PeptidomimeticsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:F-1487 Antimicrobial Peptide Epidermicin Protects GalleriaMellonella Larvae from Experimental Infection with S. aureusT. Gibreel, M. Upton; Univ. of Manchester, Manchester, United Kingdom.F-1488 Antimicrobial Activity of Native Human Defensins HNP1-3Purified by a Biological Recycling ProcessL. Vossier 1 , F. Leon 1 , C. Bachelier 1 , H. Marchandin 2 , J. Coste 1 , C.Fournier-Wirth 1 ; 1 Etablissement Français du Sang Pyrénées Méditerranée,Montpellier, France, 2 UMR 5119 ECOSYM, Univ. Montpellier 1, Montpellier,France.F-1489 Novel Antimicrobial Peptides with Improved Bioavailabilityand Reduced CytotoxicityH. Kim, J. H. Jang, J. B. Yang, J. H. Cho; Gyeongsang Natl. Univ., Jinju,Korea, Republic of.F-1490 Determination of Structure-Activity Correlations for RationalDesign of Engineered Cationic Antimicrobial PeptidesJ. D. Steckbeck, B. Deslouches, J. K. Craigo, R. C. Montelaro; Univ. ofPittsburgh, Pittsburgh, PA.152September 9-12 |

TUESDAY SCIENTIFIC SESSIONSF-1491 Antimicrobial Activity of Two New Peptides (S2-P082090and S5-P082090) against Gram-Positive and -Negative Bacteria:Comparison with OmigananP. Maffia 1 , D. Faccone 2 , O. Veliz 2 , B. Bogado 1 , L. Semorile 1 , A. Corso 2 ;1Univ. Nacional de Quilmes, Buenos Aires, Argentina, 2 Antimicrobianos,Inst. Natl. de Enfermedades Infecciosas-ANLIS, Bueno Aires, Argentina.F-1492 Antimicrobial Activity Upon Planktonic Cells and BiofilmsOf PolyethyleneimineJ. Barros 1 , P. A. Ramalho 2 , C. Pina-Vaz 2 , A. G. Rodrigues 2 , I. Pina-Vaz 2 ;1Faculty of Dentistry, Porto, Portugal, 2 Faculty of Med., Porto, Portugal.F-1493 Small, Nonpeptidic Mimics of Host Defense Proteins ExhibitPotent Killing Activity against Gram-Positive and Gram-NegativeBiofilm CulturesR. W. Scott, M. Corrigan; PolyMedix, Inc., Radnor, PA.F-1494 Nonpeptidic Mimics of Host Defense Proteins as AntimicrobialAgents for E. coli O104:H4, Campylobacter spp. and OtherFoodborne PathogensR. Scott 1 , S. Mithal 1 , C. Chen 2 ; 1 PolyMedix, Inc., Radnor, PA, 2 USDAARS, Wyndmoor, PA.F-1495 Nonpeptidic Mimics of Host Defense Proteins as AntimicrobialAgents for Category A and B Biowarefare PathogensR. Scott 1 , S. Mithal 1 , C. L. Marchand, III 2 , S. Halasohoris 2 , L. Miller 2 ;1PolyMedix, Inc., Radnor, PA, 2 USAMRIID, Frederic, MD.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------176(F)Poster SessionCompounds and Approaches for Combating Gram-Positive InfectionsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:F-1496 M676, a Putative Inhibitor of Undecaprenyl PyrophosphateSynthase, Synergizes with-Lactam Antibiotics against MRSAL. Miesel 1 , J. Baysarowich 2 , A. Caron 3 , J. Huber 2 , M. Kavana 1 , J. Lafleur 3 ,P. T. Meinke 2 , D. B. Olsen 4 , R. E. Painter 1 , M. J. Salvatore 2 , M. Szymonifka2 , C. M. Tan 1 , S. T. Waddell 2 , H. Wang 1 , K. Young 1 , S. Singh 2 ; 1 MerckRes. Labs, Kenilworth, NJ, 2 Merck Res. Labs, Rahway, NJ, 3 Merck Res. Labs,Kirkland, Canada, 4 Merck Res. Labs, West Point, PA.F-1497 Antibacterial Spectrum of Oxazolidinone MRX-I: PotentActivity against Multidrug-Resistant Gram-Positive PathogensD. M. Zhu 1 , W. Wang 2 , Y. Q. Huang 3 , Y. Y. Zhang 1 ; 1 HuaShan Hosp.,Fudan Univ., Shanghai, China, 2 MicuRx Pharmaceuticals Inc., Hayward,CA, 3 MicuRx Pharmaceuticals Inc., Shanghai, CA.F-1498 Antimicrobial Profile of MRX-I: Resistance and Drug CombinationStudiesY. Li 1 , H. L. Wang 1 , Y. H. Xu 1 , W. Wang 2 , Y. Q. Huang 1 , Q. Wang 1 , J.Liu 2 ; 1 MicuRx Pharmaceuticals Inc., Shanghai, China, 2 MicuRx PharmaceuticalsInc., Hayward, CA.F-1499 Novel Oxazolidinone MRX-I is Efficacious in Mouse Modelsof Gram-Positive Bacterial InfectionsC. R. Li 1 , G. Q. Li 1 , X. X. Hu 1 , W. X. Zhang 1 , X. K. Wang 1 , J. Pang 1 , X.Lu 1 , Q. Q. Zhai 1 , H. Yuan 2 , M. F. Gordeev 3 , X. Y. Yang 1 , X. F. You 1 ; 1 Inst.of Medicinal Biotechnology, Chinese Academy of Med. Sci. & Peking UnionMed. Coll., Beijing, China, 2 MicuRx Pharmaceuticals Inc., Shanghai, China,3MicuRx Pharmaceuticals Inc., Hayward, CA.F-1500 Pre-Clinical Pharmacokinetics of MRX-I in Rodents and DogsX. Y. Chen 1 , Z. W. Gao 1 , H. Yuan 2 , Z. Y. Yuan 3 , D. F. Zhong 1 ; 1 ShanghaiInst. of Materia Medica, Chinese Academy of Sci., Shanghai, China,2MicuRx Pharmaceuticals Inc., Shanghai, China, 3 MicuRx PharmaceuticalsInc., Hayward, CA.F-1501 In Vitro Safety Study of MRX-I, a Safer OxazolidinoneAntibiotic AgentW. Wang 1 , Z. Wang 2 , Y. Chang 2 , H. Yuan 3 , Z. Y. Yuan 1 , J. L. Zhou 4 , D.F. Zhong 4 ; 1 MicuRx Pharmaceuticals Inc., Hayward, CA, 2 Natl. ShanghaiCtr. For Drug Safety Evaluation & Res., Shanghai, China, 3 MicuRx PharmaceuticalsInc., Shanghai, China, 4 Shanghai Inst. of Materia Medica, ChineseAcademy of Sci., Shanghai, China.F-1502 Single-Dose and Repeat-Dose Toxicity of MRX-I in RatY. L. Qiu 1 , J. Q. Jiang 1 , H. X. Huang 1 , C. H. Hsu 1 , J. Ma - 1 , H. Yuan 2 ,M. F. Gordeev 3 ; 1 Natl. Shanghai Ctr. For Drug Safety Evaluation & Res.,Shanghai, China, 2 MicuRx Pharmaceuticals Inc., Shanghai, China, 3 MicuRxPharmaceuticals Inc., Hayward, CA.F-1503 Single Oral Dose Pharmacokinetics of MRX-I in HealthySubjectsJ. Zhang 1 , X. J. Wu 1 , J. Huang 1 , J. C. Yu 1 , B. N. Guo 1 , G. Y. Cao 1 , J. F.Wu 1 , K. J. Zhang 2 , H. Yuan 3 , Z. Y. Yuan 4 , Y. G. Shi 1 , Y. Y. Zhang 1 ;1HuaShan Hosp., Fudan Univ., Shanghai, China, 2 Sun Yat-Sen Univ.,Guangzhou, China, 3 MicuRx Pharmaceuticals Inc., Shanghai, China,4MicuRx Pharmaceuticals Inc., Hayward, CA.F-1504 Hematological Effect and Pharmacokinetics of Multiple OralDose MRX-I in Healthy SubjectsJ. Zhang 1 , X. J. Wu 1 , J. Huang 1 , J. C. Yu 1 , B. N. Guo 1 , G. Y. Cao 1 , J. F.Wu 1 , H. Yuan 2 , Z. Y. Yuan 3 , Y. G. Shi 1 , Y. Y. Zhang 1 ; 1 HuaShan Hosp.,Fudan Univ., Shanghai, China, 2 MicuRx Pharmaceuticals Inc., Shanghai,China, 3 MicuRx Pharmaceuticals Inc., Hayward, CA.F-1505 Pikromycin Derivative of Solithromycin: Discussion of ActivityD. Pereira 1 , J. Li, P. Fernandes 1 , S. Matsa 1 ; 1 Cempra, Inc., Chapel Hill, NC,2Biolink, Morrisville, NC.F-1506 COT-303, A Novel Glycosylated Glycopeptide: I. In VitroActivity against Gram-Positive BacteriaH. Maki, H. Nakai, T. Hori, O. Yoshida, K. Matsui, Y. Yamano, J. Shimada;Shionogi & Co., Ltd., Osaka, Japan.F-1507 COT-303, A Novel Glycosylated Glycopeptide: II. In VivoEfficacy against Experimental Animal Infection ModelsH. Maki, R. Nakamur, M. Tsuji, O. Yoshida, K. Matsu, Y. Yamano,J. Shimada; Shionogi & Co., Ltd., Osaka, Japan.F-1508 Antimicrobial Spectrum and Biosynthesis of the New LipopeptideAntibiotic, PaenibacterinE. Huang 1 , Y. Guo 2 , A. E. Yousef 1 ; 1 The Ohio State Univ., Columbus, OH,2China Agricultural Univ., Beijing, China.Final Program153

Tuesday SCIENTIFIC SESSIONSF-1509 In Vitro Antimicrobial Activity and In Vivo Efficacy in aMouse Staphylococcal-Septicemia Model of Water-SolubleTripropeptin C AnalogsS. Hirosawa 1 , H. Hashizume 2 , Y. Kobayashi 1 , R. Watabe 1 , K. Inoue 2 , Y.Takahashi 2 , S. Harada 2 , S. Ohba 3 , T. Masuda 3 , R. Sawa 2 , Y. Takahashi 1 ,T. Miyake 1 , A. Nomotoector 2 , M. Shibasaki 2 ; 1 Inst. of Microbial Chemistry,Hiyoshi, Kanagawa, Japan, 2 Inst. of Microbial Chemistry, Tokyo, Japan, 3 Inst.of Microbial Chemistry, Numazu, Shizuoka, Japan.F-1510 Antimicrobial Activity of Six Seachaid Pharmaceuticals InvestigationalCompounds Tested against Gram-Positive StrainsR. E. Mendes 1 , D. J. Biedenbach 1 , A. A. Watters 1 , R. N. Jones 1 , R. G.Sherrill 2 , K. D. James 2 ; 1 JMI Lab., N Liberty, IA, 2 Seachaid Pharmaceuticals,Durham, NC.F-1511 Antimicrobial Activity and Spectrum of a Seachaid PharmaceuticalsInvestigational Compound (SP2078) Tested againstGram-Positive PathogensR. E. Mendes, P. R. Rhomberg, M. Konrardy, R. N. Jones; JMI Lab., NLiberty, IA.F-1512 Time-Kill and Post-Antibiotic-Effect Studies of a SeachaidPharmaceuticals Investigational Compound (SP2078) againstWildtype and Multidrug-Resistant PathogensR. E. Mendes, P. R. Rhomberg, D. M. Johnson, BS - MT, R. N. Jones; JMILab., N Liberty, IA.F-1513 Exploring Triazoles as Antimicrobials against Methicillin-Resistant Staphylococcus aureus (MRSA)M. O. Abreu 1,2 , B. L. A. Ferreira 2 , D. Gonzaga 3 , V. Ferreira 3 , H. C. Castro 2 ,F. A. Alves 1 ; 1 Programa de Pós Graduação - HUAP, Rio de Janeiro, Brazil,2LABiEMOL - Inst. de Biologia, Rio de Janeiro, Brazil, 3 Inst. de Química,Rio de Janeiro, Brazil.F-1514 CNH365.396, a Novel Marine-Derived Compound withPotent Activity against Methicillin-Resistant Staphylococcus aureus(MRSA)M. Hensler 1 , E. Soubih 1 , K. Jang 1 , W. Thienphrapa 1 , J. Locke 2 , M. Cunningham2 , B. Kwan 2 , S. Nam 1 , C. Kauffman 1 , D. Beatty 1 , K. J. Shaw 2 , V.Nizet 1 , W. Fenical 1 ; 1 Univ. Calif., San Diego, CA, 2 Trius Therapeutics, SanDiego, CA.F-1515 Antivirulence Agents against MRSA and Streptococcus pyogenesM. Shoham, G. Yu, B. Truitt, M. Pesho, V. Khodaverdian, L. Bollinger, A.Nash, R. Viswananthan; Case Western Reserve Univ., Cleveland, OH.F-1516 Killing and Lysis of Staphylococcus aureus and other Staphylococciby an Engineered EndolysinA. C. Fluit 1 , S. van Marm 1 , F. Eichenseher 2 , M. J. Loessner 2 , F. Pietersma 3 ,E. C. H. Boel 1 ; 1 Univ. Med. Ctr. Utrecht, Utrecht, Netherlands, 2 ETH Zurich,Switzerland, 3 Micreos BV, Wageningen, Netherlands.F-1517 Soluble High-Affinity T Cell Receptors for the Detectionand Treatment of Superantigen-Mediated Staphylococcal aureusDiseasesA. S. Chervin 1 , D. M. Mattis 2 , N. Wang 2 , W. Salgado-Pabon 3 , A. R.Spaulding 3 , O. N. Chuang-Smith 4 , L. M. Breshears 4 , M. L. Peterson 4 , A. R.Horswill 3 , C. L. Quinn 1 , P. M. Schlievert 3,1 , D. M. Kranz 2,1 ; 1 ImmuVen, Inc.,Champaign, IL, 2 Univ. of Illinois, Urbana, IL, 3 Univ. of Iowa, Iowa City, IA,4Univ. of Minnesota, Minneapolis, MN.F-1518 Novel Biopolymer SYN01 Wound Treatment Reduces MRSABiofilms in a Partial Thickness Porcine Wound Model and Modulatesthe Production of IL-8 in Human MacrophagesS. M. Townsend 1 , S. N. Garbers 1 , C. Perez 1 , J. Gil 2 , J. Valdes 2 , C. P. Smith 1 ,S. C. Davis 2 , S. M. Baker 1 , W. P. Wiesman 1 ; 1 Synedgen, Inc., Claremont, CA,2Univ. of Miami, Miami, FL.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------177(F)Poster SessionNovel Antimicrobial Approaches and AgentsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:F-1519 Activity of HPi1, a Novel Quinoxaline, against EnterotoxigenicBacteroides fragilisA. Hachmann, M. LaFleur, K. Lewis; Northeastern Univ., Boston, MA.F-1520 In Vitro Activity of Sodium Oxychlorosene against Multidrug-Resistant(MDR) PathogensA. H. Stock 1 , S. S. Utley 1 , S. C. Cheatham 1 , M. R. Fleming 2 , D. W. Smith 3 ,M. F. Wack 4 , M. B. Kays 5 ; 1 St. Francis Hlth., Indianapolis, IN, 2 MethodistDallas Med. Ctr., Dallas, TX, 3 Indiana Univ. Hlth. Methodist Hosp.,Indianapolis, IN, 4 Indiana Univ. Methodist Hosp., Indianapolis, IN, 5 PurdueUniv., Indianapolis, IN.F-1521 Anti-Staphylococcal and Anti-Enterococcal Activity of NovelProtein Synthesis Inhibitors from the RX-04 ProgramJ. M. Remy 1 , J. A. DeVito 1 , E. M. Duffy 1 , D. F. Sahm 2 ; 1 Rib-X Pharmaceuticals,Inc., New Haven, CT, 2 Eurofins Medinet, Chantilly, VA.F-1522 Antibacterial Activity of Novel RX-04 Compounds againstBiodefense PathogensJ. Hershfield 1 , L. Miller 1 , S. Halasohoris, N.A. 1 , C. Marchand, DVM 1 , J.Remy 2 , M. Leggio 2 , J. DeVito 2 , A. Marra 2 , A. Bhattacharjee 2 , Z. Kanyo 2 ,E. Duffy 2 ; 1 USAMRIID, Fort Detrick, 2 Rib-X Pharmaceuticals, Inc., NewHaven, CT.F-1523 Novel Ribosome Inhibitors are Efficacious in a Murine RespiratoryTract Infection Model Caused by Streptococcus pneumoniaeA. Rey 1 , C. DelGorge 1 , A. Marra 2 , E. Bortolon 2 , D. Molstad 2 , E. Duffy 2 ;1Sanofi Pharmaceuticals, Toulouse, France, 2 Rib-X Pharmaceuticals, NewHaven, CT.F-1524 In Vitro Activity of E-101, a Rapidly Bactericidal Myeloperoxidase(MPO)-Based Agent, against Key Bacterial PathogensJ. Deane 1 , A. Simenauer 1 , G. A. Denys 2 , P. O’Hanley 3 , J. T. Stephens 3 , D. F.Sahm 1 ; 1 Eurofins, Chantilly, VA, 2 Indiana Univ. Hlth. Path Lab, Indianapolis,IN, 3 Exoxemis, Inc., Little Rock, AR.F-1525 TP-271 is a Potent, Broad-Spectrum Fluorocycline withActivity against Community-Acquired Bacterial Respiratory andBiothreat PathogensT. H. Grossman 1 , C. Fyfe 1 , W. O’ Brien 1 , M. Hackel 2 , J. A. Sutcliffe 1 ;1Tetraphase Pharmaceuticals, Watertown, MA, 2 IHMA, Schaumburg, IL.F-1526 Novel 8-Heterocycle Substituted Tetracyclines are Potent andBroad Spectrum Antibacterial Agents with Oral BioavailabilityX. Xiao, Y. Deng, C. Sun, C. Chen, D. Hunt, R. Clark, C. Fyfe, W. O’Brien,T. Grossman, J. Sutcliffe; Tetraphase Pharmaceuticals, Watertown, MA.154September 9-12 |

TUESDAY SCIENTIFIC SESSIONSF-1527 In Vitro Synergy Studies with a Promising New Compound,the Tetra-para-Guanidinoethylcalix[4]areneM. Grare 1 , M. Mourer 1 , J. Regnouf-de-Vains 1 , R. E. Duval 1,2 ; 1 UMR 7565,Univ. de Lorraine CNRS, Nancy, France, 2 ABC Platform, Nancy, France.F-1528 In Vitro Activity of C-101 Solution, a New Eosinophil Peroxidase(EPO) Containing Enzyme System against Gram-Negativeand Gram-Positive PathogensG. A. Denys 1 , D. Shah 2 , D. F. Sahm 2 , R. C. Allen 3 , P. O’Hanley 4 , J. T.Stephens 4 ; 1 Indiana Univ. Hlth., Indianapolis, IN, 2 Eurofins, Chantilly, VA,3Creighton Univ. Med. Ctr., Omaha, NE, 4 Exoxemis, Inc., Little Rock, AR.F-1529 Identification of a Novel Anti-PcrV Antibody That BlocksType Three Secretion and Provides Superior Protection in Pseudomonasaeruginosa Animal Infection ModelsP. Warrener, R. Varkey, J. Zha, A. DiGiandomenico, M. Camara, P. Chowdury,B. Sellman, K. Stover; MedImmune LLC, Gaithersburg.F-1530 Disposition of MGB-BP-3, a New Class of AntibacterialAgent, after Oral Administration in a Hamster Model of SevereClostridium difficile Associated Diarrhoea (CDAD)M. Ravic 1 , C. Suckling 2 , I. Hunter 2 , C. Gemmell 3 , P. Warn 4 , A. Sattar 4 ,M. Saunders 5 ; 1 MGB Biopharma, Glasgow, United Kingdom, 2 Univ. ofStrathclyde, Glasgow, United Kingdom, 3 Univ. of Glasgow and Strathclyde,Glasgow, United Kingdom, 4 Euprotec, Manchester, United Kingdom, 5 Kuecept,Potters Bar, United Kingdom.F-1531 SRI-011225, a First-in-Class Bactericidal AntimicrobialActive against Drug-Resistant PathogensL. Jong, K. Mortelmans, C. Green, L. Hokama, T. Tran, D. Sahner; SRIIntl., Menlo Park, CA.F-1532 In Vitro Antimicrobial Effect of Diacetyl RheinS. Nguon 1,2 , J. Novakova 2 , L. Kokoska 2 ; 1 Royal Univ. of Agriculture, PhnomPenh, Cambodia, 2 Czech Univ. of Life Sci. Prague, Czech Republic.F-1533 Antibacterial and Antifungal Activity of 2-S-Nitrobenzyl-Substituted HalogenobenzimidazolesA. E. Laudy 1 , E. Swietochowska 1 , M. Kozlowska 2 , Z. Kazimierczuk. 2 , S.Tyski 1,3 ; 1 Med. Univ. of Warsaw, Warsaw, Poland, 2 Warsaw Univ. of Life Sci.,Warsaw, Poland, 3 Natl. Med.s Inst., Warsaw, Poland.F-1534 Computational Design of Staphylococcus aureus SrtA EnzymeInhibitorsA. H. Chan 1 , E. M. Weiner 1 , J. Wereszczynski 2 , J. A. McCammon 2 , R. T.Clubb 1 ; 1 Univ. of California, Los Angeles, Los Angeles, CA, 2 Univ. of California,San Diego, CA.F-1535 Identifying and Characterizing Inhibitors of Streptococcuspneumoniae Enda Using a Novel PicoGreen Nuclease AssayE. J. R. Peterson, D. Kireev, W. P. Janzen S. F. Singleton; Univ. of NorthCarolina, Chapel Hill, NC.F-1536 Screening for Broad Spectrum Antimicrobials with UnknownTargetsL. Fleck 1 , G. Casadei 2 , K. Lewis 1 ; 1 Northeastern Univ., Boston, MA, 2 TheLombardy and E. Romagna Zootechnic Inst., Parma, Italy.F-1537 Developing Synthetic Antibodies against Clostridium difficileToxins as a Potential TherapeuticS. Wong 1 , P. Papatheodorou 2 , T. Brummelkamp 3 , B. Nelson 1 , D. van Dyk,K. Aktories 2 , S. Sidhu 1 , J. Moffat 1 ; 1 Univ. of Toronto, Toronto, Canada, 2 Univ.of Freiburg, Freiburg, Germany, 3 Netherlands Cancer Inst., Amsterdam,Netherlands.F-1538 High-Throughput Screening for Novel Antimicrobial AgentsUsing a Whole Animal Infection ModelB. Fuchs 1 , Y. Kim 1 , J. Larkins-Ford 1 , A. Conery 1 , F. Ausubel 1 , E. Mylonakis2 ; 1 Massachusetts Gen. Hosp., Boston, MA, 2 Brown Univ., Providence, RI.F-1539 Inhibition of Cell Division Induced by External Guide SequencesTargeting ftszC. Davies Sala 1 , A. Soler Bistué 1,2 , L. Korprapun 1 , A. Zorreguieta 1 , M.Tolmasky 2 ; 1 Fundación Inst. Leloir IIBBA CONICET UBA, Buenos Aires,Argentina, 2 California State Univ. Fullerton, CA.F-1540 Residues of Phosphopantetheine Adenylyltransferase ThatDetermine Susceptibility to the Inhibitor N-Fmoc-L-glutamyl-D-histidine IsobutylamideA. R. Akin 1 , M. F. Hollis-Symynkywicz 2 , W. Shu 1 , K. Suefuji 1 , L. Xie 1 ,D. N. Chin 2 , B. A. Appleton 1 , C. J. Balibar 1 ; 1 Novartis Inst. BioMed. Res.,Emeryville, CA, 2 Novartis Inst. BioMed. Res., Cambridge, MA.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------178(G3)Poster SessionPediatricsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:G3-1541 Bacterial Meningitis and Pneumococcal Serotype Distributionin Children in CameroonA. Gervaix 1 , J. Taguebue 2 , B. Ninet Bescher 1 , J. Corbeil 3 , F. Raymond 3 ,G. Alcoba 1 , M. Kobela 2 ; 1 Univ. Hosp. of Geneva, Geneva, Switzerland,2Mother and Child Hosp. of Chantal Biya Fndn., Yaounde, Cameroon,3Univ. of Laval, Quebec, Canada.G3-1542 Outcomes of Invasive Meningococcal Disease in CanadaBetween 2002 and 2010M. Sadarangani 1,2 , S. A. Halperin 3 , W. Vaudry 4 , N. Le Saux 5 , R. Tsang 6 ,D. W. Scheifele 1 , J. A. Bettinger 1 , For the Canadian Immunization MonitoringProgram, ACTive (IMPACT); 1 Univ. of British Columbia, Vancouver,Canada, 2 Univ. of Oxford, Oxford, United Kingdom, 3 IWK Hlth. Ctr. &Dalhousie Univ., Halifax, Canada, 4 Univ. of Alberta, Edmonton, Canada,5Children’s Hosp. of Eastern Ontario, Ottawa, Canada, 6 Natl. Microbiol.Lab., Winnipeg, Canada.G3-1543 Epidemiology of Bacterial Meningitis in Greece, in the Eraof Conjugate Vaccines: A 7 Years Review 2005-2011T. Georgakopoulou 1 , D. Menegas 1 , G. Tzanakaki 2 , E. Pipa 1 , A. Vernardaki 1 ,P. Mavraganis 1 , M. Theodoridou. 1 , J. Kremastinou. 1 ; 1 Hellenic Ctr. forDisease Control & Prevention, Athens, Greece, 2 Nat. Meningitis Ref. Lab,Athens, Greece.G3-1544 Childhood Meningitis in the UK in the ConjugateVaccine EraM. Sadarangani 1,2 , L. Willis 1 , S. Kadambari 3 , D. F. Kelly 1 , P. T. Heath 3 ,S. Nadel 4 , A. J. Pollard 1 , For the UK Childhood Meningitis Study Group;1Univ. of Oxford, Oxford, United Kingdom, 2 Univ. of British Columbia,Vancouver, Canada, 3 St. George’s, Univ. of London, United Kingdom, 4 St.Mary’s Hosp., London, United Kingdom.Final Program155

Tuesday SCIENTIFIC SESSIONSG3-1545 Acute Childhood Encephalitis in Israel: Etiology,Epidemiology and Clinical CharacteristicsG. Grisaru 1 , N. Yanai 1 , S. Reif 1 , G. Paret 2 ; 1 Dana Children’s Hosp.Sourasky Med. Ctr., Tel-Aviv, Israel, 2 Safra Children’s Hosp., Tel-Aviv, Israel.G3-1546 The Betaherpesviruses in Children with CancerJ. Goldfarb 1 , N. Borges 2 , L. K. Gowans 1 , D. Kohn 3 , S. Worley 4 , B. Yen-Lieberman 1 , D. Lach 1 , L. Danziger-Isakov 1 , P. Pellett 5 ; 1 Cleveland ClinicChildren’s Hosp., Cleveland, OH, 2 Children’s Hosp. Pittsburgh, PA, 3 ClevelandClinic, Cleveland, OH, 4 Cleveland Clinic Biostatistics and Quanti,Cleveland, OH, 5 Wayne State Univ. Sch. of Med., Cleveland, OH.G3-1547 Bloodstream Infections at a European Pediatric CancerCenter: Trends in Epidemiology and Outcome between 2000and 2010M. Floeth, G. Lubritz, A. Tragiannidis, A. Kremer, G. Goletz, R. Koeck, K.Becker, A. H. Groll; Univ. Hosp., Muenster, Germany.G3-1548 Clinical and Epidemiological Aspects of Severe Form of theAcute Respiratory Infection at ChildrenZ. Djolbunova; Kyrgyz State Med. Academy Dept. of Child InfectiousDiseases, Bishkek, Kyrgyzstan.G3-1549 Influenza C Virus (ICV) Infection in Children Aged

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------179(H)Poster SessionHIV-I Pathogenesis and Predictors of AntiretroviralResponse in Treatment and PreventionTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:H-1564 CD4 Slope as a Predictor for Immunologic Recovery in AdvancedHuman Immunodeficiency Virus-Infected PatientsK. Kim 1 , J. Yi 2 , S. Lee 1 ; 1 Pusan Natl. Univ. Hosp., Busan, Korea, Republicof, 2 Pusan Natl. Univ. Yangsan Hosp., Yangsan, Gyeongsangnam-do, Korea,Republic of.H-1565 Factors Associated with Immune Discordance in HIV-InfectedPatients Receiving Antiretroviral Therapy with Complete ViralSuppressionP. Mingbunjerdsuk, N. Asdamongkol, S. Sungkanuparph; Faculty of Med.Ramathibodi Hosp., Mahidol Univ., Bangkok, Thailand.H-1566 Persistent Low-Level Viraemia in HIV-1-Infected Patients:Swiss HIV Cohort StudyN. Boillat Blanco 1 , K. Darling 1 , F. Schöni-Affolter 2 , H. Günthard 3 , R.Fulchini 4 , M. Rougemont 5 , E. Bernasconi 6 , D. Vuichard 7 , H. Furrer 8 , O.Clerc 1 , M. Cavassini 1 ; 1 Univ., Lausanne, Switzerland, 2 SHCS Data Ctr.,Lausanne, Switzerland, 3 Univ., Zurich, Switzerland, 4 Hosp., St. Gallen, Switzerland,5 Univ., Geneva, Switzerland, 6 Hosp., Lugano, Switzerland, 7 Univ.,Basel, Switzerland, 8 Univ., Bern, Switzerland.H-1567 CD4/CD8 Ratio Relations with Immune Activation, BacterialTranslocation and Latent HIV-1 Reservoir in Virally SuppressedHIV-Infected SubjectsS. Serrano-Villar 1 , C. Gutiérrez 1 , A. Vallejo 1 , B. Hernández-Novoa 1 ,L. Díaz 2 , M. Abad 1 , N. Madrid 1 , F. Dronda 1 , M. Muñoz-Fernández 2 , S.Moreno 1 ; 1 Hosp. Ramón y Cajal, Madrid, Spain, 2 Hosp. Gregorio Marañón,Madrid, Spain.H-1568 Only One Viral Strain is Circulating and Massively Fuels theViral Reservoir in Acute Primary HIV-1 InfectionA. Cheret 1 , C. Bacchus 2 , V. Avettand-Fenoël 1 , A. Mélard 1 , C. Blanc 3 , G. Nembot4 , C. Lascoux-Combes 5 , L. Meyer 4 , A. Samri 2 , B. Autran 2 , C. Rouzioux 1 ,OPTIPRIM ANRS Study Group; 1 EA 3620, Necker Hosp., Paris, France,2Cellular and Tissular Immunology Lab. INSERM UMR-S 945 Pitié-SalpêtrièreHosp., Paris, France, 3 Flow Cytometry Platform Hosp. Pitié-Salpêtrière, Paris,France, 4 Epidemiology and Publ. Hlth. Dept., Inserm U1018 Le Kremlin-Bicêtre,Paris, France, 5 Internal Med. Dept., Saint-Louis Hosp., Paris, France.H-1569 Identification of Glycosylation Sites That May Alter theBystander Apoptosis Activity of HIV-1 EnvR. T. C. Lee 1 , L. K. Lee 2 , A. Joshi 3 , O. T. Ng 2 , K. Y. Ng 2 , S. Maurer-Stroh 1 ,H. Garg 3 ; 1 Agency for Sci., Technology, and Res., Singapore, Singapore, 2 TanTock Seng Hosp., Singapore, Singapore, 3 Texas Tech Univ. Hlth. Sci. Ctr., ElPaso, TX.H-1570 Intracellular Tenofovir Concentrations are Associated withdATP and Lymphocyte Activation During A PK/PD Analysis inthe TDF2 StudyR. E. Haaland 1 , C. Dawson 1 , A. Holder 1 , C. P. Pau 1 , D. K. Smith 1 , T. M.Segolodi 1 , M. C. Thigpen 1 , L. A. Paxton 1 , T. L. Parsons 2 , C. W. Hendrix 2 ,C. E. Hart 1 ; 1 CDC, Atlanta, GA, 2 Johns Hopkins Univ., Baltimore.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------180(H)Poster SessionHIV-I Resistance, Tropism and Novel LaboratoryMethodsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:H-1571 A Diminution in Population HIV-1 Viral Load Correlateswith Declining Levels of Circulating HIV Drug ResistanceMutations in QuebecH. Charest 1 , R. Cantin. 1 , B. Brenner 2 , J. Routy 2 , J. Baril 3 , M. Klein 2 , B.Trottier 4 , M. Roger 5 , D. G. Murphy 1 , I. Hardy 5 , D. Moisi 2 , M. Couillard 1 ,M. A. Wainberg 2 , C. L. Tremblay 1,5 ; 1 INSPQ/LSPQ, Ste-Anne-de-Bellevue,Canada, 2 McGill Univ., Montréal, Canada, 3 Clinique du Quartier Latin,Montréal, Canada, 4 Clinique L’Actuel, Montréal, Canada, 5 CRCHUM,Montréal, Canada.H-1572 Antiretroviral Resistance Mutations Among AntiretroviralTreament-Naïve and Experienced Patients in KoreaM. KimYonsei Univ. Coll. of Med., Seoul, Korea, Seoul, Kosovo, Republic of.H-1573 Surveillance of HIV Drug Resistance Mutations in HIVPatients Receiving ARV’s, During the Last Two Years in PanamaJ. A. Castillo, G. Arteaga, C. González, Lic, Y. Mendoza, A. A. Martínez, J.M. Pascale; Inst. Conmemorativo Gorgas de Estudios de la Salud, Panama,Panama.H-1574 Genotypic Algorithm for Predicting Elvitegravir Susceptibility:Clinical Validation and Correlation with PhenotypeM. Haddad 1 , W. Huang 1 , M. Miller 2 , K. White 2 , A. Paquet 1 , M. Evans 1 ,C. Petropoulos 1 , J. Whitcomb 1 , L. Napolitano 1 ; 1 Monogram Biosciences,South San Francisco, CA, 2 Gilead Sci., Foster City, CA.H-1575 Determination of HIV-1 Coreceptor Tropism Using ProviralDNA in Women with Undetectable Viral LoadR. Baumann 1 , A. Rogers 1 , H. Hamdan 1 , W. Gao 2 , K. Anastos 2 , M. Young 3 ,W. A. Meyer 4 , R. Pesano 1 , R. Kagan 1 ; 1 Quest Diagnostics Nichols Inst.,San Juan Capistrano, CA, 2 Albert Einstein Coll. of Med., Bronx, NY,3Georgetown Univ., Washington DC, 4 Quest Diagnostics Baltimore, SanJuan Capistrano, CA.H-1576 Clinical Validation of Genotypic HIV Tropism Assessmentto Guide the Therapeutic Use of CCR5 AntagonistsE. Seclén 1 , V. Soriano 1 , M. M. González 1 , C. Sarriá 2 , L. Prósper 2 , M. J.Sepúlveda 3 , J. Sanz 4 , J. Arranz 4 , E. Poveda 1 ; 1 Hosp. Carlos III, Madrid,Spain, 2 Hosp. de la Princesa, Madrid, Spain, 3 Complejo Hosp. de Toledo,Madrid, Spain, 4 Hosp. Príncipe de Asturias, Madrid, Spain.H-1577 Implementation of an HIV Tropism Genotyping AssayR. Alonso, P. Garcia, E. Bouza; Hosp. Gral. Univ. Gregorio Marañón,Madrid, Spain.H-1578 The Impact of HIV-1 Tropism on Immunologic Progressionin Patients with Primary HIV-1 InfectionM. Tsai 1 , S. Chang, DSc 1 , C. Yang 2 , W. Liu 1 , C. Hung 1 , S. Chang 1 ; 1 Natl.Taiwan Univ. Hosp., Taipei, Taiwan, 2 Far Eastern Mem. Hosp., New TaipeiCity, Taiwan.Final Program157

Tuesday SCIENTIFIC SESSIONSH-1579 Tropism Correlates with Residual Viremia and Therapy butNot with Cellular HIV DNA During Successful Therapy in NaïvePatientsS. G. Parisi 1 , S. Andreis 1 , R. Scaggiante 1 , M. Cruciani 2 , R. Ferretto 3 , V.Manfrin 4 , L. Sarmati 5 , M. Basso 1 , M. Andreoni 5 , C. Mengoli 1 , G. Palù1; 1 Univ., Padova, Italy, 2 ULSS20, Verona, Italy, 3 Hosp, Schio, Italy, 4 Hosp.,Vicenza, Italy, 5 Univ, Roma, Italy.H-1580 Effect of Natural and HAART-Induced Viral Suppressionand Viral Breakthrough on Anti-HIV Antibody Proportion andAvidity in Individuals with Clade B HIV InfectionS. K. Wendel 1 , C. E. Mullis 2 , S. H. Eshleman. 2 , J. Blankson 2 , R. Moore 2 ,T. C. Quinn 1,2 , O. Laeyendecker 1,2 ; 1 NIAID, Baltimore, 2 JHU, Baltimore.H-1581 Digital Droplet (DD) qPCR Allows Quantitation of HIVProviral DNA in Aviremic HIV+ Subjects on HAART Treatedwith ZFN CCR5 Modified Autologous CD4 T-cells (SB-728-T)P. Tebas 1 , C. June 1 , D. Stein 2 , R. Mitsuyasu 3 , J. Lalezari 4 , S. Wang 5 , G.Lee 5 , M. Giedlin 5 , W. Tang 5 , D. Ando 5 ; 1 PENN, Philadelphia, PA, 2 AlbertEinstein Coll. of Med., Bronx, NY, 3 UCLA, Los Angeles, CA, 4 Quest Clin.Res., San Francisco, CA, 5 Sangamo BioSci., Richmond, CA.H-1582 Technical and Clinical Performance Evaluation of a Fourth-Generation HIV AssayY. Cho , J. Choi, H. Kim, G. Shin; Korea Univ. Med. Sch., Seoul, Korea,Republic of.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------181(K)Poster SessionExtended-Spectrum-Lactamase EnterobacteriaceaeTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-1583 Utility of a Clinical Risk-Factor Scoring Model in PredictingInfection with Extended-Spectrum-Lactamase (ESBL)-Producing Enterobacteriaceae Upon Hospital AdmissionS. Johnson 1,2 , R. Drew 1,2 , D. May 1,2 , D. Anderson 2 ; 1 Campbell Univ. Coll. ofPharmacy and Hlth. Sci., Buies Creek, NC, 2 Duke Univ. Hosp., Durham, NC.K-1584 ESBL Producing Escherichia coli and Klebsiella pneumoniae:Update From a Tertiary Care Lebanese Health Care SystemE. E. Azar 1 , E. Salem 2 , M. Jallad 2 , R. Nawfal 1 , J. Irani 2 , Z. Daoud 2 ; 1 SaintGeorge Hosp., Beirut, Lebanon, 2 Univ. of Balamand, Beirut, Lebanon.K-1585 Impact of Institutional Gram Negative (GN) Susceptibilitywith Use of Ertapenem as a First Line Treatment of InfectionsCaused by Extended Spectrum Beta-Lactamase (ESBL) ProducingEnterobacteriaceaeJ. Fong 1 , W. Huang 2 , E. Radigan 2 ; 1 Massachusetts Coll. of Pharmacy andHlth. Sci., Worcester, MA, 2 Univ. of Mass. Mem. Med. Ctr., Worcester, MA.K-1586 ESBL-Producing E.coli vs. Klebsiella spp. Infections:Differences in Epidemiology and OutcomesS. Voit 1,2 , R. Klevens 2 , P. Nieberg 1 , A. Wong-Beringer 2,1 ; 1 Huntington Hosp.,Pasadena, CA, 2 Univ. So California, Los Angeles, CA.K-1587 Risk Factors for Multidrug Resistance Among CommunityOnset Extended-Spectrum-Lactamase-Producing Escherichiacoli InfectionsS. Park 1 , C. Kang 1 , Y. Wi 2 , K. Huh 1 , S. Cho 1 , D. Chung 1 , K. Peck 1 , J. Song1; 1 Samsung Med. Ctr., Seoul, Korea, Republic of, 2 Samsung ChangwonHosp., Seoul, Korea, Republic of.K-1588 Risk Factors for Infection and Treatment Outcome ofExtended-Spectrum-Lactamase-Producing Escherichia coli andKlebsiella pneumoniae Bacteremia in Adult Cancer PatientsS. Park, C. Kang, S. Cho, D. Chung, K. Peck, J. Song; Samsung Med. Ctr.,Seoul, Korea, Republic of.K-1589 Differences Between Patients with Isolates of CTX-M TypeExtended-Spectrum-Lactamase (ESBL)-Producing Escherichiacoli Compared to Non-CTX-M Type ESBL-Producing E. coliK. Hayakawa 1 , S. Gattu 2 , D. Marchaim 1 , A. Bhargava 1 , M. Palla 1 , U. M.Gudur 1 , K. Alshabani 1 , P. Bathina 1 , S. Datla 1 , V. Kuchipudi 1 , S. Shahani 1 ,V. Upputuri 1 , J. A. Moshos, MT 1 , P. R. Lephart, 1 , K. Bush 2 , K. S. Kaye 1 ;1Detroit Med. Ctr. (DMC), Wayne State Univ., Detroit, MI, 2 Indiana Univ.,Bloomington, IN.K-1590 Piperacillin/Tazobactam is Not Associated with ReducedSurvival in Extended-Spectrum Beta-Lactamase-ProducingEnterobacteriaceae Bloodstream InfectionsN. F. Dewhurst 1,2 , S. M. Poutanen 3,4,2 , B. Hamandi 4,2 , L. Dresser 4,2 , M.Pitre 4 , A. Lin 4 , D. Lowe 4 ; 1 St. Michael’s Hosp., Toronto, Canada, 2 Univ. ofToronto, Toronto, Canada, 3 Mt. Sinai Hosp., Toronto, Canada, 4 Univ. Hlth.Network, Toronto, Canada.K-1591 Inadequate Antibiotic Therapy is Associated with DecreasedSurvival in Patients with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Bloodstream InfectionsN. F. Dewhurstt 1,2 , S. M. Poutanen 3,4,2 , B. Hamandi 4,2 , L. Dresser 4,2 , M.PitrePharm 4 , A. Lin 4 , D. Lowe 4 ; 1 St. Michael’s Hosp., Toronto, Canada,2Univ. of Toronto, Toronto, Canada, 3 Mt. Sinai Hosp., Toronto, Canada,4Univ. Hlth. Network, Toronto, Canada.K-1592 Costs of an E.coli Bacteremia in a German University HospitalR. Leistner, E. Meyer, F. Schwab, P. Dem, C. Sakellariou, S. Kruse, P.Gastmeier; Charité Univ. Med. Berlin, Inst. for Hygiene and EnvironmentalMed., Berlin, Germany.------------------------------------------------------------------------182(K)Poster SessionMRSA InfectionsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-1593 Reduction in Community-Onset Methicillin-ResistantStaphylococcus aureus in an Urban Canadian SettingA. Wilmer 1 , E. Lloyd-Smith 2 , M. Romney 3 , S. Champagne 3 , M. Hull 2 ;1Univ. of British Columbia, Vancouver, Canada, 2 St. Paul’s Hosp., Vancouver,Canada, 3 St. Paul’s Hosp., Vancouver, Canada.K-1594 Rapid Screening Tests for MRSA Did Not Decrease PostoperativeMRSA Infections in Patients with Inflammatory BowelDisease (IBD)Y. Takahashi, Y. Takesue, K. Ichiki, K. Nakajima, M. Uchino, H. Ikeuchi;Hyogo Coll. of Med., Nishinomiya, Japan.158September 9-12 |

TUESDAY SCIENTIFIC SESSIONSK-1595 Mupirocin Resistance in Methicillin-Resistant Staphylococcusaureus (MRSA) in Singapore General Hospital (SGH) Burns Unit(BU)J. Teo, A. L. Kwa, W. Lee, Y. Liew, T. H. Koh, S. S. Goh, M. L. Ling, C.Song, M. P. Chlebicki; Singapore Gen. Hosp., Sg, Singapore.K-1596 A Neonatal MRSA Outbreak Investigation Using RapidWhole Genome SequencingWithdrawnK-1597 End Stage Renal Disease (ESRD) Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Show NoIncreased Risk for Clinical FailureB. Bajoka 1 , S. Arshad 2 , D. Moreno 2 , A. Shoyinka 2 , M. J. Zervos 2,3 ; 1 MichiganState Univ., Sch. of Med., Lansing, MI, 2 Henry Ford Hosp., Detroit, MI,3Wayne State Univ., Sch. of Med., Detroit, MI.K-1598 Clinical Response at Day 3 of Initial Antibiotic Treatment inHospitalized Adult Patients with Acute Bacterial Skin and SkinStructure Infections: A Patient Chart Review Study within a USHealthcare SystemR. Adamson 1 , I. Lew 1 , S. Amara 1 , X. Huang 2 ; 1 Barnabas Health, SouthPlainfield, NJ, 2 Forest Res. Inst., Jersey City, NJ.K-1599 Molecular Epidemiology of Methicillin-ResistantStaphylococcus aureus in a Neonatal Intensive Care Unit in JapanM. Nagao, M. Kawai, G. Hotta, M. Yamamoto, Y. Matsumura, A. Matsushima,Y. Ito, S. Takakura, S. Ichiyama; Kyoto Univ. Hosp., Kyoto, Japan.K-1600 Comparative Epidemiology of Bacteremia Due to Methicillin-Resistant Staphylococcus aureus (MRSA) Between Older andYounger Adults: A Propensity Score AnalysisR. Kullar 1 , M. J. Rybak 2 , K. S. Kaye 3 ; 1 Wayne State Univ., Detroit, MI,2Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI, 3 Detroit Med.Ctr./Wayne State Univ., Detroit, MI.K-1601 Age and Pitt Score Predict Early Death in Methicillin-Resistant Staphylococcus aureus (MRSA) BacteremiaV. P. Martins 1 , D. Otero 1,2 , A. L. Ferreira 1 , A. G. Magalhães 1 , L. A.Mascarenhas 1,2 , F. L. Cardoso 1 , S. A. Nouér 1 ; 1 Univ. Federal do Rio deJaneiro, Rio de Janeiro, Brazil, 2 Inst. Natl. do Cancer, Rio de Janeiro, Brazil.------------------------------------------------------------------------183(K)Poster SessionResistant Acinetobacter InfectionsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-1602 Randomized Controlled Trial of Colistin (COL) vs. Colistinplus Fosfomycin (COL + FOS) for Infections Caused by Carbapenem-Resistant(CR) Acinetobacter baumanniiR. Sirijatuphat, P. Koomanachai, V. Thamlikitkul; Siriraj Hosp., Bangkok,Thailand.K-1603 Carbapenem-Resistant A. baumannii Bacteremia in OncologicIntensive Care UnitE. Abdala, L. P. G. Duarte, M. P. Freire, K. Y. Ibrahim, A. S. K. Magri, C. P.Garcia, L. C. Pierrotti, P. P. Gutierrez, F. Rossi, M. Bellesso, J. Pereira, L. A.Hajjar, P. M. Hoff; Inst. do Câncer do Estado de São Paulo da FMUSP, SãoPaulo, Brazil.K-1604 Patients Infected with Acinetobacter baumannii and Treatedwith Tigecycline: The Impact of Minimal Inhibitory Concentration(MIC) on Outcomes and the Role of Different Testing MethodsK. Hayakawa, D. Marchaim, P. Bathina, D. R. Abbadi, J. M. Pogue, A.Bhargava, P. R. Lephart, K. S. Kaye; Detroit Med. Ctr. (DMC), Wayne StateUniv., Detroit, MI, Detroit, MI.K-1605 Predictors of Treatment Failure in Patients Infected withResistant Acinetobacter baumannii (Ab) Treated with Colistin(COL) Plus Doripenem (DOR)L. M. Gillis, M. H. Nguyen, C. J. Clancy, R. K. Shields; Univ. of Pittsburgh,Pittsburgh, PA.K-1606 Carbapenem-Resistant Strains of Acinetobacter baumanniiIsolated from an Intensive Care Unit in Brazil: The Importanceof OXA-143 and OXA-23F. C. Neves 1 , W. T. Clemente 1 , N. Lincopan 2 , R. Romanelli 1 , L. F. Paiva 1 , L.A. Jesus 1 , V. Nobre 1 ; 1 Univ. Federal de Minas Gerais, Belo Horizonte, Brazil,2Univ. de São Paulo, São Paulo, Brazil.K-1607 Colistin with Carbapenem to Treat Extensively Drug ResistantA. baumannii (XDRAB) Bacteremia Achieved Better MicrobiologicalOutcomes Than Colistin with TigecyclineA. Cheng 1,2 , H. Sun 1 , Y. Chuang 1 , C. Yang 3 , C. Yang 4 , Y. C. Chen 1 , S.C. Chang 1 ; 1 NTUH, Taipei, Taiwan, 2 FEMH, New Taipei City, Taiwan,3FEMH, Taipei, Taiwan, 4 NTUH, Douliou, Taiwan.------------------------------------------------------------------------184(K)Poster SessionResistant Gram-Negative InfectionsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-1608 Prevalence of and Risk Factors for Biliary Carriage ofMultidrug-Resistant BacteriaE. Maseda 1 , G. Maggi 1 , R. Gomez-Gil 1 , G. Ruiz 1 , R. Madero 1 , L. Aguilar 2 ,F. Gilsanz 1 ; 1 Hosp. La Paz, Madrid, Spain, 2 Univ. Complutense, Madrid,Spain.K-1609 Incidence and Predictors of Bloodstream Infections AmongCarbapenem-Resistant Klebsiella pneumoniae CarriersS. Amit, T. Kotlovsky, H. Mishali, M. Shapiro, M. Schwaber, Y. Carmeli;Tel-Aviv Sourasky Med. Ctr., Tel-Aviv, Israel.K-1610 Bloodstream Infections Caused by Multidrug-ResistantProteus Mirabilis: Epidemiology, Risk Factors and Impact ofMultidrug ResistanceA. Korytny, K. Reisenberg, L. Saidel-Odes, F. Schlaeffer, A. Borer; SorokaUniv. Med. Ctr. and Faculty of Hlth. Sci., Ben Gurion Univ. of the Negev,Beer Sheva, Israel.Final Program159

Tuesday SCIENTIFIC SESSIONSK-1611 Impact of Isolation for Resistant Pathogens on BarcodeMedication Administration Technology UtilizationE. J. Ernst 1 , P. M. Polgreen 2 , B. Johannsson 3 , T. Naughton 3 , S. J. Johnson 1 ;1Univ. of Iowa Coll. of Pharm., Iowa City, IA, 2 Univ. of Iowa Carver Coll. ofMed., Iowa City, IA, 3 Univ. of Iowa Hosp. and Clinics, Iowa City, IA.K-1612 Prolongued Versus Bolus Meropenem Infusion Impact onMortalityR. Rodil, M. Landecho, J. Beunza, J. Azanza, J. del Pozo; Clinica Univ. deNavarra, Pamplona, Spain.K-1613 Delineation of Specific Antibiotic (Abx) Exposures asRisk Factors (RF) for Isolation of Carbapenem-ResistantEnterobacteriaceae (CRE): A Meta-AnalysisJ. Teo, Y. Cai, C. Lim, W. Lee, A. L. Kwa; Singapore Gen. Hosp.,Singapore, Singapore.K-1614 Quantifying the Magnitude of Clinical Virulence of KPCThrough Translational StudyM. Griffith 1,2 , M. Advincula 1 , M. Malczynski 2 , G. Barajas 2 , C. Qi 2,3 , M.Scheetz 1,2 ; 1 Midwestern Univ., Downers Grove, IL, 2 Northwestern Mem.Hosp., Chicago, IL, 3 Northwestern Univ., Chicago, IL.K-1615 Effect of Elevated Carbapenem MICs on Patient Mortalityin Gram-Negative Bloodstream InfectionsM. Griffith 1,2 , J. Wagner 1 , M. Advincula 1 , M. Scheetz 1,2 ; 1 Midwestern Univ.,Downers Grove, IL, 2 Northwestern Mem. Hosp., Chicago, IL.K-1616 Burkholderia cepacia Complex Isolated from Cystic FibrosisPatients: Identification, Epidemiology and ResistanceJ. Gonzalez-Lopez, P. Martinez de Salazar, M. T. Tórtola, A. Mirambell, A.Andreu, N. Larrosa, A. Ferrer; Hosp. Vall d’Hebron, Barcelona, Spain.K-1617 Selection of E.coli ST131 CTX-M-15 (E65) by CommonAntibiotics in the Mouse Intestinal Colonisation ModelF. B. Hertz, Hertz 1,2,3 , A. Loebner-Olesen 4 , F. Hansen 1 , A. M. Hammerum 5 ,N. Frimodt-Moeller 3 ; 1 Statens Serum Inst., RUC and HVH, Amager, Copenhagen,Denmark, 2 Roskilde Univ., Roskilde, Denmark, 3 Hvidovre Hosp.,Hvidovre, Denmark, 4 Roskilde Univ., Amager, Copenhagen, Denmark,5Statens Serum Inst., Amager, Copenhagen, Denmark.K-1618 The First Clinical Study on the New Beta Lactam-BetaLactamase Inhibitor Combination: Cefepime-TazobactamA. Ghafur, A. Tayade, K. Priyadarshini, K. Chandra; Apollo Hosp., Chennai,India.K-1619 Bacteremia Caused by Klebsiella pneumoniae Carbapenemase(KPC)-Producing Organisms: An Analysis of Attributable Mortalityand Risk Factors for RecurrenceN. Girometti 1 , R. E. Lewis 1 , F. Tumietto 1 , S. Ambretti 2 , M. Bartoletti 1 , P.Viale 1 ; 1 Clinic of Infectious Diseases - Sant’Orsola-Malpighi Hosp., Univ.of Bologna, Bologna, Italy, 2 Operative Unit of Microbiol. - Sant’Orsola-Malpighi Hosp., Univ. of Bologna, Bologna, Italy.K-1620 Factors Associated with the Development of Polymyxin BResistance in Klebsiella pneumoniaeS. R. Rosen 1 , C. J. Kubin 1 , K. Wright 1 , A. Lat 1 , E. Y. Furuya 2 , M. T. Yin 2 ;1NewYork, Presbyterian Hosp, New York, NY, 2 Columbia Univ., New York,NY.K-1621 Epidemiology and Clinical Features of Infections Caused byEscherichia coli Producing AmpC-Lactamases (EC-AmpC)V. Pascual 1 , G. Ortiz 2 , M. Simó 3 , N. Alonso 4 , M. C. Garcia 5 , M. Xercavins3, A. Rivera 4 , M. A. Morera 3 , E. Miró 4 , E. Espejo 5 , F. Navarro 4 , M.Gurgui 4 , J. Pérez 3 , M. Rodríguez-Carballeira 1 , J. Garau 1 , E. Calbo 1 ; 1 Hosp.Mútua de Terrassa, Barcelona, Spain, 2 Hosp. de Sant Pau, Barcelona, Spain,3Catlab, Barcelona, Spain, 4 Hosp. de Sant Pau, Barcelona, Spain, 5 Consorcide Terrassa, Barcelona, Spain.K-1622 The Changing Face of Carbapenem Resistance AmongGram-Negative Pathogens at a Tertiary CenterR. K. Shields, L. G. Clarke, C. J. Clancy, M. H. Nguyen; Univ. of Pittsburgh,Pittsburgh, PA.K-1623 Sonication: The Clue in the Diagnosis of the Source of aCarbapenem-Resistant Klebsiella pneumoniae Outbreak Related toa DuodenoscopeL. Falgueras, M. Espasa, I. Fernández, S. Capilla, M. Píriz, G. Navarro, I.Sanfeliu, D. Fontanals, F. Segura; Corporació Sanitària Parc Taulí. Inst. Univ.Parc-Taulí-UAB., Sabadell, Spain.K-1624 Impact of Multidrug Resistance on Prognosis in Pseudomonasaeruginosa BacteriemiaM. Montero, H. Knobel, R. Terrades, L. Sorlí, J. M. Nuñez, S. Grau, F.Alvarez Lerma, J. P. Horcajada, Ph D; Hosp. del Mar, Barcelona, Spain.K-1625 Transient Emergence of Carbapenemase-Producing Klebsiellapneumoniae ST379 in Central NJM. E. Rosenthal 1 , L. Chen 2 , A. Rojtman 1 , B. N. Kreiswirth 2 ; 1 Jersey ShoreUniv. Med. Ctr., Neptune, NJ, 2 Publ. Hlth. Res. Inst. UMDNJ, Newark, NJ.------------------------------------------------------------------------185(K)Poster SessionUse of Vancomycin, Daptomycin and/or LinezolidTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:K-1626 Creatine Phosphokinase (CPK) Elevations in Patients onDaptomycin With or Without a StatinJ. Mordino 1 , E. B. Hirsch 2,1 , M. Golik Mahoney 1 ; 1 Beth Israel DeaconessMed. Ctr., Boston, MA, 2 Northeastern Univ., Boston, MA.K-1627 Timing of Initial Therapeutic Drug Monitoring (TDM) inPatients with Impaired Renal Function Treated with Once DailyAdministration of Vancomycin (VCM)Y. Takahashi, Y. Takesue, K. Nakajima, T. Tsuchida, S. Takubo; Hyogo Coll.of Med., Nishinomiya, Japan.K-1628 Comparative Effectiveness of Linezolid and VancomycinStratified by Obesity Status among a National Veterans Affairs(VA) Cohort with Methicillin-Resistant Staphylococcus aureus(MRSA) PneumoniaA. R. Caffrey 1,2 , L. A. Puzniak 3 , D. E. Myers 3 , K. L. LaPlante 4,2 ; 1 Univ. ofRhode Island Coll. of Pharmacy, Kingston, RI, 2 Univ. of Rhode Island, Coll.of Pharmacy, Kingston, RI, 3 Pfizer, Inc., Collegeville, PA, 4 Providence VA IDRes. Program, Providence, RI.160September 9-12 |

TUESDAY SCIENTIFIC SESSIONSK-1629 A Randomized Controlled Trial to Evaluate a Strategy toPrevent Drug-Induced Nephrotoxicity in High-Risk Patients(STOP-NT)J. J. Carreno 1,2 , S. L. Davis 1,2 , R. M. Chambers 2 , J. A. Vazquez 2 ; 1 WayneState Univ. Coll. of Pharmacy, Detroit, MI, 2 Henry Ford Hosp., Detroit, MI.K-1630 Outcomes of Methicillin-Resistant Staphylococcus aureusBacteremia and Vancomycin Minimum Inhibitory Concentrationin Hemodialysis PatientsG. A. Patel, R. Sharma; State Univ. of New York Downstate Med. Ctr.,Brooklyn, NY.K-1631 Efficacy and Safety of Daptomycin (DAP) in the Treatment ofGram-Positive Infections in Patients with Renal ImpairmentR. Kullar 1 , I. McClellan 2 , M. Geriak 3 , G. Sakoulas 3 ; 1 Oregon State Univ.Oregon Hlth. & Sci. Univ, Portland, OR, 2 Oregon State Univ., Portland, OR,3Sharp Mem. Hosp., San Diego, CA.K-1632 Enterococcal Bloodstream Infection During NeutropenicFever: Impact of Vancomycin Resistance on MortalityS. Cho 1 , D. Lee 1 , J. Choi 1 , J. Kwon 2 , S. Kim 3 , S. Choi 1 , S. Park 1 , J. Choi 1 ,J. Yoo 1 ; 1 Coll. of Med., The Catholic Univ. of Korea, Seoul, Korea, Republicof, 2 Ilsan Hosp., Goyang-si Gyeonggi-do, Korea, Seoul, Korea, Republic of,3Coll. of Med., The Korea Univ. of Korea, Seoul, Korea, Republic of.K-1633 Cost-Effectiveness Analysis of Linezolid (LIN), Daptomycin(DAP) and Vancomycin (VAN) in Methicillin-Resistant Staphylococcusaureus (MRSA) Complicated Skin and Soft Tissue Infections(cSSTI) from a Spanish PerspectiveS. Grau 1 , M. M. Alonso-Socas 2 , J. Rodríguez-Baño 3 , A. Soriano 4 , M.Trikic 5 , M. De Salas-Cansado 5 ; 1 Hosp. del Mar, Barcelona, Spain, 2 Univ.Hosp. of Tenerife, Tenerife, Spain, 3 Hosp. Virgen de la Macarena, Sevilla,Spain, 4 Hosp. Clìnic, Barcelona, Spain, 5 Pfizer, Madrid, Spain.K-1634 Treatment and Outcomes of Patients with DaptomycinNon-Susceptible S. aureus Associated InfectionN. Fattouh, B. Ostrowsky, Y. Guo; Montefiore Med. Ctr., Bronx, NY.K-1635 Daptomycin (DAP) Outcomes in Patients (Pts) with SevereSepsis Due to Staphylococcal Bacteremia (SB) with Vancomycin(VAN) MICs of 2 mg/LK. Holloway, K. C. Lamp, H. Anderson, M. J. Yoon; Cubist Pharmaceuticals,Lexington, MA.K-1636 Daptomycin Resistance Following Vancomycin Failure inInvasive Methicillin-Resistant Staphylococcus aureus BacteremiaK. A. Bauer, J. Wong, J. Gaborcik Candidate, D. A. Goff; The Ohio StateUniv. Med. Ctr., Columbus, OH.------------------------------------------------------------------------186(L1)Poster SessionEndocarditis and Other Invasive InfectionsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:L1-1637 Endocarditis from Enterococcus faecalisA. R. Cremona, Losinno Juan, Ramirez Santiago, Blanco Miriam, CazzolaLaura, Firpo Soledad, Yebara Analia; Hosp. Italiano, La Plata, Argentina.L1-1638 Comparison of High Dose Daptomycin (DAP) and DoseOptimized Vancomycin (VAN) for MRSA Bacteremia andInfective Endocarditis (IE)S. L. Davis 1,2 , M. J. Rybak 1,3,4 , J. A. Vazquez 2,4 , E. Hershberger 5 , P. Bernardo 5 ,D. P. Levine 4,3 ; 1 Wayne State Univ. Coll. of Pharmacy, Detroit, MI, 2 HenryFord Hosp., Detroit, MI, 3 Detroit Med. Ctr., Detroit, MI, 4 Wayne StateUniv. Sch. of Med., Detroit, MI, 5 Cubist Pharmaceuticals, Lexington, MA.L1-1639 578 Endocarditis in French Region: Epidemiology,Mortality and CostS. Sunder 1 , S. Baron 1 , F. Bastides 1 , T. Prazuck 2 , Y. Guimard 3 , A. Valery 2 , M.Massot 3 , L. Bernard 1 ; 1 CHRU de Tours, Tours, France, 2 CHR d’Orléans,Orléans, France, 3 CH de Bourges, Bourges, France.L1-1640 Relation Between Specific Bacteria, EchocardiographicFindings, and Surgical Findings in Patients Undergoing CardiacSurgery Due to Infectious EndocarditisY. Maor, A. Akuka, D. Ben David, N. Keller G. Rahav; Sheba Med. Ctr., TelHashomer, Israel.L1-1641 Morbidity and Mortality Associated with Invasive PneumococcalDisease (IPD) Among Adults During a 3 Year Surveillancein BelgiumW. E. Peetermans 1 , J. Flamaing 1 , J. Verhaegen 1 , W. De Backer 2 , B. Delaere 3 ,P. Van Damme 2 , K. Van Herck 4 , Y. Van Laethem 5 , F. Surmont 6 ; 1 Univ. Hosp.Leuven, Leuven, Belgium, 2 Univ. of Antwerp, Edegem, Belgium, 3 CliniquesUniversitaires Mont-Godinne, Mont Godinne, Belgium, 4 Univ. of Ghent,Ghent, Belgium, 5 Univ. Hosp. St Pierre, Brussels, Belgium, 6 Pfizer, Brussels,Belgium.L1-1642 The Composition of the Intestinal Microbiota is a RiskFactor for Escherichia coli Post-Chemotherapy BacteremiaE. Montassier 1 , E. Batard 1 , J. Hardouin 2 , J. Caillon 1 , T. Carton 3 , N. Caroff 1 ,T. Gastinne 1 , P. Moreau 1 , G. Potel 1 , F. Le Vacon 3 , M. De la Cochetière 2 ;1Ctr. Hosp. Univ. de Nantes, Nantes, France, 2 Faculté de Med. de Nantes,Nantes, France, 3 Biofortis Res., Nantes, France.L1-1643 Clinical Relevance of Community-Acquired Severe Sepsisand Septic Shock in Adults: An Epidemiological Population-Based StudyJ. Almirall, L. Campins, J. Capdevila, J. Yebenes, R. Bisbal, A. Albis, E.Güell, J. Mendez, M. Serra; Consorci Sanitari del Maresme, MATARO,Spain.Final Program161

Tuesday SCIENTIFIC SESSIONSL1-1644 Beta-Haemolytic Streptococcal Infective Endocarditis(BHIE): Characteristics and Outcomes from a Large, Multi-National CohortN. Fernández-Hidalgo 1,2 , M. L. Aznar 1,2 , Z. A. Kanafani 3,4 , V. H. Chu 5 ,B. Almirante 1,2 ; 1 Hosp. Vall d’Hebron, Barcelona, Spain, 2 Intl. Collaborationon Endocarditis, ., Spain, 3 American Univ. of Beirut Med. Ctr., Beirut,Lebanon, 4 Intl. Collaboration on Endocarditis, Lebanon, 5 Duke Univ. Med.Ctr., Durham, NC.L1-1645 Stable Incidence but Increasing Severity of Community-Onset Boils and Abscesses Underlies Rising Hospital Admissionsin EnglandL. Shallcross, A. C. Hayward, A. M. Johnson, J. Rosenthal, I. Petersen; Univ.Coll. London, London, United Kingdom.L1-1646 Invasive Systemic Infection among Hospitalized DiabeticFoot Ulcer Patients Following DischargeS. Chen, J. Giurini, A. Karchmer; Beth Israel Deaconess Med. Ctr., Boston,MA.L1-1647 Comparison of Once Versus Twice Daily Dose of Amikacinin Neonatal Early SepsisM. Rezai; Mazandaran Univ. of Med. Sci., Sari, Iran, Islamic Republic of.------------------------------------------------------------------------187(L1)Poster SessionMeningitis and Central Nervous System InfectionsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:L1-1648 Bacterial Meningitis in Patients with Absent or DysfunctionalSpleenK. S. Adriani, M. C. Brouwer, A. van der Ende, D. van de Beek; AMC,Amsterdam, Netherlands.L1-1649 Specific Features in Encephalitis of Unknown Origin CanHelp Raising Aetiological HypothesisA. Mailles 1 , V. Vaillant 1 , J. Honnorat 2 , J. Stahl 3 ; 1 Inst. de Veille Sanitaire,Saint Maurice cedex, France, 2 Lyon’s Neuroscience Res. Ctr. Inserm UnitU1028 / CNRS 5292, Lyon, France, 3 Univ. I, Grenoble, France.L1-1650 Hospitalization for Central Nervous System Infectionamong Individuals With and Without End Stage Renal Disease:A Danish Population-Based StudyJ. D. Gunst, S. Jensen-Fangel, B. Jespersen, L. Østergaard, O. S. Søgaard;Infectious Disease, Aarhus Univ. Hosp., Denmark.L1-1651 A Patient with Meningitis Due to a Lipopolysaccharide-Deficient N. meningitidisJ. R. Piet 1 , A. Zariri 2 , F. Fransen 2 , K. Schipper 1 , P. van der Ley 2 , D. van deBeek 1 , A. van der Ende 1 ; 1 Academic Med. Ctr., Amsterdam, Netherlands,2Lab. of Vaccine Res., Bilthoven, Netherlands.L1-1653 Unusual Increase in Meningococcal Disease Associated withSerogroup C ST11/ET37 CC in Mexico CityL. E. Espinosa de los Montero 1,2 , L. V. Jimenez 3 , D. Gomez 3,4 , N. A. Matias 5 ,J. A. Vazquez 6 , R. Abad 6 , V. Medina 6 , Grupo Mexicano De Trabajo EnEnfermedad Meningococcica; 1 Hosp., Mexico City, Mexico, 2 Investigation,Hosp. Manuel GeA Gonzalez, Mexico, 3 Hosp. Infantil Federico Gomez,Mexico City, Mexico, 4 Hosp. Infantil de México, Distrito Federal, Mexico,5Med. Ctr., Mexico City, Mexico, 6 Inst. of Hlth. Carlos III, Majadahonda,Madrid, Spain.------------------------------------------------------------------------188(L1)Poster SessionMethicillin Resistant Staphylococcus aureus: ClinicalAspectsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:L1-1654 Changing Epidemiology of the Community-OnsetStaphylococcus aureus Bacteremia: 9-Years Experience in a Taiwan Emergency DepartmentS. Pan, S. Chen, J. Wang, S. Chang; Natl. Taiwan Univ. Hosp., Taipei,Taiwan.L1-1655 Early Concomitant Antimicrobial Therapy with Vancomycinin Combination with Gentamicin in Methicillin-ResistantStaphylococcus aureus (MRSA) Bacteremia: Clinical Failure andNephrotoxicity RatesS. Arshad 1 , D. Moreno 1 , A. Shoyinka 1 , M. J. Zervos 1,2 ; 1 Henry Ford Hosp.,Detroit, MI, 2 Wayne State Univ., Sch. of Med., Detroit, MI.L1-1656 Clinical Experience with Telavancin for Treatment ofMethicillin-Resistant Staphylococcus aureus (MRSA) BloodstreamInfectionB. Soltani, S. Chi, B. Laurence, C. Fernandes, B. Suh; Temple Univ. Hosp.,Philadelphia, PA.L1-1657 Clinical Manifestation and Molecular Characterization ofCommunity-Associated MRSA (CA-MRSA) in JapanT. Yamaguchi 1 , Y. Miura 2 , D. Kawamata 3 , M. Sagisaka 3 , T. Matsumoto 1 ;1Tokyo Med. Univ., Tokyo, Japan, 2 Bunkyo Gakuin Univ. Graduate Sch.,Tokyo, Japan, 3 Toda Central Med. Lab., Saitama, Japan.L1-1658 Is a High Vancomycin Mic Associated with Poor Prognosisin Methicillin-Susceptible Staphylococcus aureus Bacteremia?L. López-Cortés, C. Velasco, J. Gálvez-Acebal, M. del Toro, M. DeCueto, F. Caballero, A. Dominguez-Castellano, M. Muniain, Á. Pascual, J.Rodríguez-Baño; Hosp. Univ. Virgen Macarena, Seville, Spain.L1-1652 Intracranial Pressure Monitoring and Treatment ofCommunity-Acquired Bacterial Meningitis: A Ten YearRetrospective SurveyU. Hjort, U. Hjort, P. Christensen, P. Soerensen; Aalborg Hosp., AarhusUniv. Hosp., Aalborg, Denmark.162September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------189(L1)Poster SessionNovel Agents and Insights in Skin and Soft TissueInfectionsTuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:L1-1659 Initial Analysis of the CAPTURE Study: CeftarolineFosamil for the Treatment of Acute Bacterial Skin and SkinStructure Infections (ABSSSI) Including Special Risk GroupsP. Santos 1 , A. Davis 2 , A. Jandourek 3 , Y. Li 3 , H. Friedland 3 ; 1 Lakes RegionGen. Healthcare, Laconia, NH, 2 Provena United Samaritans Med. Ctr.,Danville, IL, 3 Cerexa, Inc., Oakland, CA.L1-1660 Microbiological Activity and Outcome of the PleuromutilinBC-3781 in a Clinical Phase 2 Trial in Acute Bacterial Skin andSkin Structure Infections (ABSSSI)S. Paukner 1 , Z. Ivezic-Schoenfeld 1 , K. J. Tack 2 , D. F. Sahm 3 , W. T. Prince 1 ;1Nabriva Therapeutics AG, Vienna, Austria, 2 n.a., Brighton, MI, 3 EurofinsMedinet Ltd, Chantilly, VA.L1-1661 Safety Among Hospitalized Patients Receiving CeftarolineFosamil (CPT-F) Treatment: A USA Retrospective Analysis of aLarge Hospital Claims Database Using ICD-9-CM CodesX. Huang, B.Pharm 1 , A. Jandourek 2 , S. Laussucq 2 ; 1 Forest Res. Inst., Inc.,Jersey City, NJ, 2 Cerexa, Inc, Oakland, CA.L1-1662 A Phase 2 Randomized, Double-Blinded, Dose-Ranging,Active Controlled Efficacy and Safety Evaluation of PMX-30063for the Treatment of Acute Skin & Skin Structure Infections(ABSSSI) Caused by Staphylococcus aureus (SA)D. Jorgensen, R. Scott, B. Korczak; PolyMedix, Inc., Radnor, PA.L1-1663 Results of a Phase 2 Study of Delafloxacin (DLX) Comparedto Vancomycin (VAN) and Linezolid (LNZ) in Acute BacterialSkin and Skin Structure Infections (ABSSSI)L. E. Lawrence 1 , J. Longcor 1 , S. Hopkins 1 , S. Green 2 , P. Mehra 2 , W. Sears 2 ,W. D. O’Riordan 2 , P. Manos 2 ; 1 Rib-X Pharmaceuticals Inc., New Haven,CT, 2 eStudySite, San Diego, CA.L1-1664 Safety Profile of Tedizolid Phosphate Compared to Linezolidin a Phase 3 ABSSSI StudyE. Fang 1 , C. De Anda 1 , A. Das 2 , P. Prokocimer 1 ; 1 Trius Therapeutics, SanDiego, CA, 2 Axistat, San Francisco, CA.L1-1665 Comparison of Investigator Assessed Clinical OutcomeOver Time of Tedizolid Phosphate vs Linezolid in a Phase 3 Studyin Patients with ABSSSIC. De Anda 1 , E. Fang 1 , S. Green 2 , P. Mehra 3 , P. Prokocimer 1 ; 1 TriusTherapeutics, San Diego, CA, 2 eStudySite, La Mesa, CA, 3 eStudySite,Chula Vista, CA.L1-1666 Inter-Country Differences in Microbiological Testing andDiagnoses for cSSTI in Hospitalized Patients: Results from theEuropean REACH StudyJ. Garau 1 , F. Blasi 2 , J. Medina 3 , M. Ávila 4 , K. McBride 5 , H. Ostermann 6 ;1Hosp. Univ. Mutua de Terrassa, Barcelona, Spain, 2 Univ. Degli Studi diMilano, Milan, Italy, 3 AstraZeneca, Madrid, Spain, 4 AstraZeneca Europe,Zaventem, Belgium, 5 Instat Services, Inc., Chatham, NJ, 6 Univ. Hosp.Munich, Munich, Germany.L1-1667 Skin Surface Temperature: An Objective Measure of Severityand Treatment Response in Acute Skin and Soft Tissue InfectionM. Montalto 1,2 , F. Davies 2 , N. Marijanovic 2 , A. Meads 3 ; 1 Epworth Hosp.,Richmond, Australia, 2 Royal Melbourne Hosp., Parkville, Australia, 3 PegasusHealth, Christchurch, New Zealand.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------190(M)Poster SessionClinical Mycology ITuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:M-1668 A Built-in Multiplex Protocol to Identify the OpportunisticFungal Pathogen Candida glabrataA. De Las Peñas, D. Barron, M. Cuellar, I. Castaño; Inst. Potosino de InvestigacionCientifica y Tecnologica, San Luis Potosi, San Luis Potosi, Mexico.M-1669 Clinical Characteristics of Candidemia in Adults withHematological Malignancy and Antimicrobial Susceptibilities ofthe Isolates at a Medical Center in Taiwan, 2001-2010H. Y. Tsai 1,2 , Chien-Yuan Chen, Shang-Yi Huang, Woei Tsay, Ming Yao,Jih-Luh Tang, Bo-Sheng Ko, Wen-Chien Chou, Hwei-Fang Tien, Po-RenHsueh; 1 Far Eastern Mem. Hosp., New Taipei City, Taiwan, 2 Far EasternMem. Hosp., New Taipei City, Taiwan.M-1670 Neurological, Visual, and MRI Brain Scan Findings in87 South African Patients with HIV-Associated CryptococcalMeningoencephalitisA. Loyse 1 , A. Moodley 2 , P. Rich 3 , W. Rae 4 , A. Iqbal 5 , A. Michowicz 6 ,L. Bishop 6 , D. Wilson 6 , T. S. Harrison 1 ; 1 St George’s Univ. of London,London, United Kingdom, 2 Grey’s Hosp., Pietermaritzburg, South Africa,3St George’s Hosp., London, United Kingdom, 4 Univ. of the Free State,Bloemfontein, South Africa, 5 Univ. of Kwazulu-Natal, Durban, South Africa,6Edendale Hosp., Pietermaritzburg, South Africa.M-1671 Cost-Effectiveness of Caspofungin vs LiposomalAmphotericin B for Empiric Therapy in TurkeyS. J. Turner 1 , E. Senol 2 , A. Kara 3 , D. Al-Badriyeh 4 , D. C. M. Kong 5 , E.C. Dinleyici 6 ; 1 Univ. at Buffalo, Buffalo, NY, 2 Gazi Univ., Ankara, Turkey,3Hacettepe Univ., Ankara, Turkey, 4 Qatar Univ., Doha, Qatar, 5 Monash Univ.,Melbourne, Australia, 6 Eskisehir Osmangazi Univ., Eskisehir, Turkey.M-1672 Pharmacoeconomics (PE) of Fluconazole (FLU) Versus (vs)Posaconazole (POS) vs Voriconazole (VOR) for Antifungal Prophylaxisin Acute Myeloid Leukemia (AML) Patients UndergoingConsolidation Chemotherapy (CON-C)WithdrawnM-1673 Urinary Biomarkers of Acute Renal Injury in Patients withCandiduriaM. Gutiérrez-Cuadra 1 , J. P. Horcajada 2 , B. A. Lavín 1 , J. A. Gómez-Gerique 1 , M. T. García-Unzueta 1 , M. C. Fariñas 1 ; 1 Univ. Hosp. Marqués deValdecilla, Santander, Spain, 2 Hosp. del Mar, Barcelona, Spain.Final Program163

Tuesday SCIENTIFIC SESSIONSM-1674 Detection of Multiple Candida Species in OropharyngealCandidiasis (OPC) Patients Using Real Time PCRM. L. Herrera 1 , N. P. Wiederhold 2,1 , W. R. Kirkpatrick 1,3 , M. Olivo 1,3 ,S. D. Westbrook 1,3 , D. K. Berg 1 , S. W. Redding 1 , T. F. Patterson 1,3 , B.L. Wickes 1 ; 1 UTHSCSA, San Antonio, TX, 2 Univ. of Texas, Austin, TX,3STVHCS, San Antonio, TX.M-1675 Fks Mutation is a Risk Factor for Failure of Echinocandin(EC) Therapy among Patients (pts) with Invasive Candidiasis (IC)Due to Candida glabrata (cg) but Not Other Candida SpeciesR. K. Shields, M. H. Nguyen, E. G. Press, BS, A. L. Kwa, C. J. Clancy;Univ. of Pittsburgh, Pittsburgh, PA.M-1676 Correlation between Circulating Fungal Biomarkers andClinical Outcome in Invasive AspergillosisD. Neofytos 1 , K. Mullane 2 , D. Fredricks 3 , B. Granwehr 4 , K. Marr 1 , N.Almyroudis 5 , D. Kontoyiannis 4 , J. Maertens 6 , R. Fox 7 , C. Douglas 7 , R. Iannone7 , A. Kauh 7 , R. Railkar 7 , N. Shire 7 ; 1 Johns Hopkins Univ., Baltimore,2Univ. of Chicago, Chicago, IL, 3 Fred Hutchinson Ctr., Seattle, WA, 4 Univ. ofTexas Anderson, Houston, TX, 5 Roswell Park Cancer Inst., SUNY, Buffalo,NY, 6 UZ Leuven, Gasthuisberg, Belgium, 7 Merck, Whitehouse Station, NJ.M-1677 Prevalence of Cryptococcal Antigenemia and Cost Effectivenessof Cryptococcal Screening in VietnamR. M. Smith 1 , T. A. Nguyen 2 , H. Ha 2 , P. Thang 2 , C. Thuy 3 , L. X. Truong 4 ,H. T. Bui 5 , T. H. Le 6 , B. Struminger 5 , M. McConnell 5 , R. N. Fanfair 1 ,B. Park 1 , J. R. Harris 1 ; 1 CDC, Atlanta, GA, 2 NIHE, Hanoi, Viet Nam,3NHTD, Hanoi, Viet Nam, 4 PI, HCMC, Viet Nam, 5 CDC, Hanoi, VietNam, 6 CDC, HCMC, Viet Nam.M-1678 Aspergillus RNA in the Blood of Patients is a PromisingAlternative Biomarker for Invasive AspergillosisY. Zhao 1 , P. Paderu 1 , R. Fox 2 , C. Douglas 2 , R. Railkar 2 , N. Shire 2 ,D. Perlin 1 ; 1 PHRI Ctr., UMDNJ, Newark, NJ, 2 Merck & Co., Inc., NorthWales, PA.M-1679 Absolute Lymphocyte Count (ALC) as a Prognostic Markerfor Outcome in Hematological Malignancy Patients with PulmonaryMucormycosisR. E. Lewis 1 , F. Sampsonas 2 , S. Georgiadou 2 , G. Chamilos 2 , D. P. Kontoyiannis2 ; 1 Univ. of Houston Coll. of Pharmacy, Houston, TX, 2 The Univ. ofTexas MD Anderson Cancer Ctr., Houston, TX.M-1680 Thermomyces lanuginosus Endocarditis and Review of EndocarditisDue to Rare MoldsS. Sivagnanam, S. Chen, C. Halliday, D. Packham; Ctr. for Infectious Diseasesand Microbiol., Sydney, Australia.M-1681 Epidemiology, Clinical Manifestations, Management andOutcome of 179 Cases of Aspergillus OsteomyelitisM. Gamaletsou 1,2 , M. Bueno 2 , B. Moriyama 3 , N. Sipsas 1 , D. Kontoyiannis 4 ,E. Roilides 5 , B. Brause 6,2 , T. J. Walsh 2 ; 1 Athens Univ. Med. Sch., Athens,Greece, 2 Cornell Univ. Med. Sch., New York, NY, 3 NIH, Bethesda, 4 MDAnderson Cancer Ctr., Houston, TX, 5 Aristotle Univ. Med. Sch., Thessaloniki,Greece, 6 Hosp. for Special Surgery, New York, NY.M-1682 Inter-Laboratory and Inter-Study Reproducibility of aLateral Flow Device (LFD) for the Detection of InvasivePulmonary Aspergillosis (IPA)N. P. Wiederhold 1,2 , L. K. Najvar 2,3 , R. A. Bocanegra 2,3 , W. R. Kirkpatrick 2,3 ,T. F. Patterson 2,3 , C. R. Thornton 4 ; 1 Univ. of Texas, Austin, TX, 2 UTHSC-SA, San Antonio, TX, 3 STVHCS, San Antonio, TX, 4 Univ. Exeter, Exeter,United Kingdom.M-1683 Efficacy of Anidulafungin in Patients with InvasiveCandidiasis (IC): Focus on Non-Albicans Candida sppU. Conte 1 , P. Hogan 1 , H. Schlamm 1 , P. Biswas 1 , B. Kullberg 2 , M. Ruhnke 3 ;1Pfizer Inc., New York, NY, 2 Radboud Univ. Nijmegen Med. Ctr., Nijmegen,Netherlands, 3 Charité Univ. Med., Berlin, Germany.M-1684 How Long Should Patients with Candidemia be Followed?P. Muñoz, M. Valerio, L. Córdova, M. Rodríguez-Creixéms, J. Guinea, P.Escribano, A. Fernández-Cruz, B. Cáliz, T. Peláez, E. Bouza, COMIC StudyGroup-PROMULGA; Hosp. Gen. Gregorio Marañón. Univ. of Madrid,Madrid, Spain.M-1685 Intra-Abdominal Candidiasis (IAC) is Under-Recognized,but is the Most Common Type of Invasive Candidiasis (IC) andResults in Poor OutcomesM. Nguyen 1 , C. Clancy 2 ; 1 Univ. of Pittsburgh, Pittsburgh, PA, 2 Univ. ofPittsburgh and VA Pittsburgh, Pittsburgh, PA.M-1686 Radical Surgery of Rhino-Orbito-Cerebral MucormycosisImpacts its PrognosisP. Vironneau 1 , F. Lanternier 2,3 , D. Garcia-Hermoso 3 , G. Morizot 3 , C. Elie 2 ,F. Dromer 3 , P. Herman 1 , R. Kania 1 , O. Lortholary 2,3 , French Mycosis StudyMycosis; 1 Hosp. Lariboisiere, Paris, France, 2 Hosp. Necker-Enfants Malades,Paris, France, 3 Inst. Pasteur, Paris, France.M-1687 Does Treatment Affect the Levels of Serum-D-Glucan(BD) in the Treatment of Invasive Candidiasis (IC)?K. Nakajima, Y. Takesue, K. Ichiki, T. Ueda, M. Komatsu, Y. Wada,T. Tsuchida, Y. Takahashi; Hyogo Coll. of Med., Nishinomiya, Japan.M-1688 Is it Feasible to Diagnose Catheter-Related Fungemiawithout Catheter Withdrawal?A. Fernandez-Cruz, P. Martín-Rabadán, M. Suárez, L. Rojas, M. Pérez, J.Guinea, M. Guembe, T. Peláez, C. Sánchez, E. Bouza, PROMULGA; Hosp.Gen. Univ. Gregorio Marañón, Madrid, Spain.M-1689 American Histoplasmosis in HIV-Infected Patients: A Studyof Prognostic Factors Associated with Early DeathWithdrawnM-1690 Earlier Diagnosis of Fusariosis with Aspergillus SerumGalactomannan TestingA. Varon, M. L. S. Chiganer, M. Garnica, H. Reis, M. Paixao, G. Barreiros,T. Akiti, S. A. Nouer, M. Nucci; Federal Univ. of Rio de Janeiro, Rio deJaneiro, Brazil.M-1691 Detection and Identification of Fungi Using the BroadFungal Assay on the PLEX-ID PCR-Electrospray IonizationMass Spectrometry (ESI-MS) SystemP. J. Simner, J. R. Uhl, L. Hall, M. M. Weber, R. C. Walchakt, N. L.Wengenack; Mayo Clinic, Rochester, MN.M-1692 Quantitative PCR Detection of Circulating DNA in Serumfor Early Diagnosis of MucormycosisL. Millon 1,2 , F. Grenouillet 1,2 , F. Larosa 1 , A. P. Bellanger 1,2 , F. Skana 1 , S.Rocchi 1,2 , J. Leroy 3 , E. Deconinck 1 ; 1 Univ. Hosp., Besancon, France, 2 UMRCNRS 6249, Besançon, France, 3 Univ. Hosp., Besancon, France.M-1693 An Evaluation of Four Commercial Assays for the Detectionof Cryptococcal AntigenJ. E. Bestrom, D. J. Jespersen, L. O. Rollins, M. J. Binnicker; Mayo Clinic,Rochester, MN.164September 9-12 |

TUESDAY SCIENTIFIC SESSIONSM-1694 Disseminated Histoplasmosis (DH) Before and After theImplementation of Urine Antigen Detection Elisa (UADE) in anHIV Clinic in GuatemalaB. Samayoa 1,2 , D. Mercado 1 , E. Argueta 1 , C. Scheel 3 , B. Guzman 1 , I.Amado 1 , B. Gomez 3 , R. Morales 1 , T. Chiller 3 , E. Arathoon 1 ; 1 Asociacionde Salud Integral, Guatemala, Guatemala, 2 Univ. de San Carlos, Guatemala,Guatemala, 3 CDC, Atlanta, GA.M-1695 Correlation of Circulating Human Blood RNA Biomarkersand Clinical Outcomes in an Observational Invasive Aspergillosis(IA) TrialN. J. Murgolo 1 , W. Ding 1 , J. Li 1 , R. A. Railkar 2 , R. L. Fox 2 , C. M.Douglas 3 , P. D. Mozley 3 , E. A. Kauh 4 , R. Iannone 2 , A. Loboda 3 , R.Cristescu 5 , N. Shire 2 ; 1 Merck Res. Lab., Kenilworth, NJ, 2 Merck Res. Lab.,North Wales, PA, 3 Merck Res. Lab., West Point, PA, 4 Merck Res. Lab.,Rahway, NJ, 5 Merck Res. Lab., Boston, MA.------------------------------------------------------------------------191(M)Poster SessionClinical Mycology IITuesday, 11:15 a.m.–1:15 p.m. ................... Halls A-CPresentations:M-1696 Factors Influencing Non-Albicans Candidemia: A Case-Case-Control StudyD. P. Kofteridis, A. Valachis, D. Dimopoulou, A. Christidou, A. Adrianaki,G. Giourgouli, S. Maraki, G. Samonis; Univ. Hosp. of Heraklion, Heraklion,Greece.M-1697 The Clinical Course Following the Use of Corticosteroids forSymptomatic Relief of Primary Pulmonary Coccidioidomycosis inImmunocompetent PersonsN. Azadeh, S. Kusne, H. Vikram, M. Seville, R. Orenstein, DO, J. E. Blair;Mayo Clin. Phoenix, AZ.M-1698 Systemic Candidiasis Increased Mortality in ICU InfectedPatients with CirrhosisH. Dupont, S. Huyard, N. Airapetian, F. Tinturier, M. Levrard, A. Seydi, Y.Mahjoub; Pole d’Anesthesie-Reanimation, CHU d’Amiens, Amiens, France.M-1699 Multicenter Evaluation of a Novel POC Assay for the Detectionof Cryptococcal Antigen in HIV-Infected PersonsD. Boulware 1 , D. Meya 2 , N. Longley 3 , N. Govender 4 , J. Jarvis 3 , B. Neary 5 ,K. Taseera 6 , T. Chiller 7 , T. Harrison 3 , S. Bauman 5 ; 1 Univ. of Minn., Minneapolis,MN, 2 Makerere Univ., Kampala, Uganda, 3 St. George’s Univ. ofLondon, London, United Kingdom, 4 NICD, Johannesburg, South Africa,5IMMY, Norman, OK, 6 Mbarara Univ of Sci and Tech, Mbarara, Uganda,7CDC, Atlanta, GA.M-1700 Fungal Intravascular Catheter Colonization withoutFungemia Should be Treated?Y. Meije, G. Fresco, P. Martín-Dávila, E. Loza, E. Gómez-GªPedrosa, J.Rodríguez, V. Pintado, J. Cobo, S. Moreno, J. Fortún; Hosp. Ramón y Cajal,Madrid, Spain.M-1701 Detection of (1,3)-Beta-D-Glucan in BronchoalveolarLavage Fluid for the Diagnosis of Invasive AspergillosisA. Atalay, G. Metan, A. N. Koc , L. G. Kaynar, H. Buyukoglan, I. Bozkurt,A. Yildirim, F. Elmali, B. Eser; Erciyes Univ., Kayseri, Turkey.M-1702 The Use of In Vitro Lymphocyte Activation Testing toDetermine the Prevalence of Immunity to Coccidioides AmongHealthy Arizona Residents without a History of SymptomaticCoccidioidomycosisJ. E. Blair 1 , Y. Ruiz 2 , S. Duffy 2 , T. Pitta 1 , D. Lake 2 ; 1 Mayo Clinic Arizona,Phoenix, AZ, 2 Arizona State Univ., Phoenix, AZ.M-1703 Effectiveness of Posaconazole vs Fluconazole as AntifungalProphylaxis in Hematology-Oncology Patients at Duke UniversityHospital (DUH) 2004-2010H. C. Kung 1 , M. D. Johnson 2 , R. H. Drew 2 , P. Saha-Chaudhuri 3 , J. R.Perfect 2 ; 1 Duke Clinical Res. Inst., Durham, NC, 2 Duke Univ. Med. Ctr.,Durham, NC, 3 Duke Univ. Sch. of Med., Durham, NC.M-1704 Evaluation of an Aspergillus PCR Assay in CerebrospinalFluid Samples of Immunocompromised Patients to DetectCerebral AspergillosisM. Reinwald 1 , M. Hummel 1 , B. Spiess, 1 , M. Duerken 1 , H. Bertz 2 , M.Barreto-Miranda 1 , W. K. Hofmann 1 , D. Buchheidt 1 ; 1 Mannheim Univ.Hosp., Mannheim, Germany, 2 Freiburg Univ. Hosp., Freiburg, Germany.M-1705 The Tolerability of Amphotericin B Lipid Complex Formulationin Patients with Severe Infusion Reactions to LiposomalAmphotericin BD. Farmakiotis, F. P. Tverdek D. Kontoyiannis; MD Anderson Cancer Ctr.,Houston, TX.M-1706 Development of Treatment Costs of Patients UndergoingRemission Induction Chemotherapy: A Historical ComparisonBefore and After Introduction of Posaconazole ProphylaxisS. Heimann, O. Cornely, H. Wisplinghoff, M. Vehreschild, B. Franke, J.Glossmann, J. Vehreschild; Univ. Hosp. of Cologne, Cologne, Germany.M-1707 Pilot Prospective Study of High Dose (10 mg/kg/d) LiposomalAmphotericin B (L-AmB) for the Initial Treatment ofMucormycosis: AMBIZYGO TrialF. Lanternier 1,2 , S. Poiree 1 , C. Elie 1 , P. Bakouboula 1 , P. Ribaud 3 , M. Wolff 4 ,E. Dannaoui 5 , R. Herbrecht 6 , D. Garcia-Hermoso 2 , O. Lortholary 1,2 ; 1 Hosp.Necker Enfants malades, Paris, France, 2 Inst. Pasteur, Paris, France, 3 Hosp.Saint Louis, Paris, France, 4 Hosp. Bichat, Paris, France, 5 Hosp. EuropeenGeorges Pompidou, Paris, France, 6 Hosp. Hautepierre, Paris, France.M-1708 Characterization of the Cellular Immune Responses toRhizopus oryzae and Impact on Immunotherapeutic Strategies inHematopoietic Stem Cell TransplantationT. Lehrnbecher 1 , L. Tramsen 1 , S. Perkhofer 2 , C. Lass-Flörl 3 , F. Roeger 1 , R.Schubert 1 , S. Schmidt 1 ; 1 Johann Wolfgang Goethe-Univ., Frankfurt, Germany,2 Univ. of Applied Sci. Tyrol, Innsbruck, Austria, 3 Univ. of Innsbruck,Innsbruck, Austria.M-1709 Efficacy of Anidulafungin in 105 Patients with Deep TissueCandidiasisU. Conte 1 , H. Schlamm 1 , P. Biswas 1 , B. Kullberg 2 , M. Ruhnke 3 ; 1 Pfizer Inc.,New York, NY, 2 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands,3 Charité Univ., Berlin, Germany.M-1710 Evaluation of Caspofungin Susceptibility Testing by the NewVITEK 2 AST-YS06 Yeast Card Using a Unique Collection ofFKS Wild Type and Hot Spot Mutant Isolates Including the FiveMost Common Candida SpeciesK. Astvad 1 , D. S. Perlin 2 , H. K. Johansen 1 , R. H. Jensen 3 , M. C. Arendrup 3 ;1Rigshospitalet, Copenhagen, Denmark, 2 Publ. Hlth. Res. Inst., Newark, NJ,3Statens Serum Inst., Copenhagen, Denmark.Final Program165

Tuesday SCIENTIFIC SESSIONSM-1711 MGCD290, an Oral Fungal Hos2 Inhibitor, Enhancesthe Antifungal Properties of Fluconazole following Multiple orSingle Oral Dose Administration in Pre- and Post-Infection SettingsJ. Besterman, D. T. Nguyen, H. Ste-Croix; MethylGene Inc, Montreal,Canada.M-1712 Examination of Rhodamine 6G Accumulation in Multi-Azoles Resistant Trichosporon asahii: Possible Role for Drug EffluxS. Toba; Oita Univ., Oita-Ken, Japan.M-1713 Effect of Combination Antimicrobial Therapy on C. albicans-S. aureus Polymicrobial BiofilmsA. Shoyinka 1 , N. Doyon-Reale 1 , M. P. Ponniah 1 , M. M. Harriot 1,2 , J. A.Vazquez 1 ; 1 Henry Ford Hlth. System, Detroit, MI, 2 Oakland Univ. WilliamBeaumont Sch. of Med., Rochester, MI.M-1714 Activity of MK-3118, a New Oral Glucan Synthase Inhibitor,Tested against Candida and Aspergillus spp. Using Two ReferenceBroth Microdilution (BMD) MethodsM. A. Pfaller 1 , S. A. Messer 1 , M. R. Motyl 2 , R. N. Jones 1 , M. Castanheira 1 ;1JMI Lab., N. Liberty, IA, 2 Merck Sharp & Dohme Corp, Kenilworth, NJ.M-1715 In Vitro Susceptibility of MK-3118 against Candida andAspergillus Species Including Echinocandin and Azole ResistantVariantsC. Jimenez-Ortigosa 1 , P. Paderu 1 , M. R. Motyl 2 , D. S. Perlin 1 ; 1 Publ. Hlth.Res. Inst., Newark, NJ, 2 Merck Sharp & Dohme Corp., Kenilworth, NJ.M-1716 Antimicrobial Monotherapy vs. Combination Therapy ofAspergillus fumigatus and Pseudomonas aeruginosa BiofilmsH. Zainah, E. Manavathu, D. Vager, J. A. Vazquez; Henry Ford Hosp.,Detroit, MI.M-1717 In Vitro Synergy of Polymyxin B and Fluconazole againstCandida glabrataG. A. Pankey, D. S. Ashcraft; Ochsner Clin. Fndn., New Orleans, LA.M-1718 Antifungal Activity of Arasertaconazole Nitrate againstFluconazole-Resistant StrainsN. Marti 1 , A. Gomez-Lopez 2 , D. Gargallo-Viola 1 , A. Guglietta 1 , M.Cuenca-Estrella 2 ; 1 Res. and Dev. Ctr. Ferrer Internacional SA, Barcelona,Spain, 2 Inst. Carlos III, Madrid, Spain.M-1719 Activity of Antifungals and Their Combinations againstAspergillus fumigatus and Aspergillus terreus by Isothermal MicrocalorimetryU. Furustrand Tafin, A. Trampuz; Univ. Hosp., Lausanne, Switzerland.M-1720 Species-Specific Differences in Susceptibilities of Biofilms ofLess Common Candida Bloodstream Isolates to EchinocandinsM. Simitsopoulou 1 , P. Peskova 1 , E. Tasina 1 , D. Kyrpitzi 1 , A. Velegraki 2 ,T. Walsh 3 , E. Roilides 1 ; 1 Aristotle Univ., Thessaloniki, Greece, 2 Univ. ofAthens, Athens, Greece, 3 Cornell Univ., New York, NY.------------------------------------------------------------------------192(B)SymposiumVirulence Bags: Extracellular Vesicles that ModifyHost-Pathogen InteractionsTuesday, 11:15 a.m.– 12:45 p.m. . . . Esplanade Ballroom 302UAN: 0391-9999-12-132-L04-PConveners:Joshua D. Nosanchuk, MD - Associate ProfessorAlbert Einstein Coll. of Med., Bronx, NY.Leonardo Nimrichter, PhD - ProfessorCidade Univ., Rio de Janeiro, Brazil.Speakers:11:15 a.m.1721 Fungal Extracellular Exosomes: Weapons or WeaknessLeonardo Nimrichter, PhD - ProfessorCidade Univ., Rio de Janeiro, Brazil.11:35 a.m.1722 Viral Hijacking of Host Cell Exosomes for CommunicationNancy Raab-Traub, PhD - Kenan ProfessorUniv. of North Carolina, Chapel Hill, NC.11:55 a.m.1723 Leishmania-Innate and Adaptive Immune Responses Dance toLeishmania ExosomesNeil Reiner, MD - Professor of Medicine, Microbiology and ImmunologyUniv. of British Columbia, Vancouver, Canada.12:15 p.m.1724 Gene Silencing by Exosomes: A Remarkable Mechanisms forSubverting Host Processes by PathogensJaap M. Middeldorp, PhDVU Univ. Med. Ctr., Amsterdam, Netherlands.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the processes of extracellular vesicle production/release;> Describe the components packaged within extracellular vesicles; and> Predict the impact of extracellular vesicles on microbial virulence.Intended Audience: Infectious diseases specialists, scientists and pharmacistsof all levels of training and experience; those interested in mechanisms ofmicrobial pathogenesis, cell communication, and host-pathogen interactions.Level: All Levels166September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------193(K)SymposiumRegional Approaches to Prevention of Healthcare-Associated Antimicrobial ResistanceTuesday, 11:15 a.m.–12:45 p.m. .... Esplanade Ballroom 300UAN: 0391-9999-12-133-L04-PConvener:John Jernigan, MD - Director, Office of Prevention Research and EvaluationCDC, Atlanta, GA.Speakers:11:15 a.m.1725 Sharing Patients Among Healthcare Facilities in a Region:Implications for Control of Multidrug-Resistant OrganismsSusan S. Huang, MD, MPH - Associate ProfessorUniv. of California Irvine Sch. of Med., Orange, CA.11:45 a.m.1726 Using Local Epidemiology to Guide Control Strategies forCarbapenem-Resistant EnterobacteriaceaeMary Hayden, MD - Director, Division of Clinical MIcrobiologyRush Univ. Med. Ctr., Rush Med. Coll., Chicago, IL.12:15 p.m.1727 Follow-Up on the National Carbapenem-Resistant EnterobacteriaceaeIntervention in IsraelMitchell J. Schwaber, MD, MSc - DirectorIsrael Ministry of Health, Tel Aviv, Israel.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the scientific rationale for the regional approach to prevention ofantimicrobial resistance;> Describe how certain healthcare facilities may serve as reservoirs of transmissionto other facilities in a region; and> Review the national experience with prevention of carbapenem-resistantEnterobacteriaceae in Israel.Intended Audience: Infectious diseases clinicians and scientists, publichealth officials interested in healthcare-associated antimicrobial resistanceand infection control.Level: Intermediate/Advanced------------------------------------------------------------------------194(L)SymposiumEmerging and Current Challenges in Injecting DrugUsersTuesday, 11:15 a.m.–12:45 p.m. ................. Room 102UAN: 0391-9999-12-134-L04-PConveners:Shiranee Sriskandan, MD, PhD - ProfessorImperial Coll., London, United Kingdom.Donald Levine, MD - Professor and Chief, Division of General InternalMedicineWayne State Univ., Detroit, MI.Speakers:11:15 a.m.1728 Wound Botulism in Injecting Drug UsersDuc J. Vugia, MD, MPH - Chief, Infectious Diseases BranchCalifornia Dept. of Pub. Hlth., Richmond, CA.11:45 a.m.1729 Anthrax in Heroin UsersTim J. Brooks, MA, MSc, FRCPath, FRSPH - Head of Rare & ImportedPathogens Department 1 , John Hood 2 , Colin Ramsay 2 ; 1 Hlth. ProtectionAgency, Porton Down, United Kingdom, 2 Ctr. for Emergency Preparedness& Response, Salisbury, United Kingdom.12:15 p.m.1730 Update on Endocarditis in Drug UsersDonald P. Levine, MD - Professor and Chief, Division of General InternalMedicineWayne State Univ., Detroit, MI.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify new threats to injecting drug users;> Identify how such infections may present; and> Identify treatment options available.Intended Audience: Infectious diseases physicians and medical microbiologists.Level: IntermediateFinal Program167

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------195(V)SymposiumInfluenza: Beyond the HeadlinesTuesday, 11:15 a.m.–12:45 p.m. ................. Room 130UAN: 0391-9999-12-135-L04-PConveners:Guy Boivin, MD - ProfessorLaval Univ., Quebec, Canada.Vincent Racaniello, PhD - ProfessorColumbia Univ., New York, NY.Speakers:11:15 a.m.1731 Host Genetics of Severe InfluenzaKenneth Baillie, BSc MRCP FRCA - Clinical LecturerThe Roslin Inst., Univ. of Edinburgh, Midlothian, United Kingdom.11:45 a.m.1732 H5N1 Influenza Viruses in Asia and Middle-East: Still a Threat?Malik Peiris, MBBS, PhD - ProfessorThe Univ. of Hong Kong, Hong Kong.12:15 p.m.1733 Emergence of an Animal-Origin Influenza A H3N2 Virus inthe USLyn Finelli, PhD - Lead, Influenza Surveillance and Outbreak Response,Influenza DivisionCDC, Atlanta, GA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the epidemiological features of selected influenza virus threats;> Assess the mechanisms responsible for severe influenza diseases;> Identify risk factors for severe influenza infections; and> Discuss potential therapeutic and prophylactic modalities for specificinfluenza variants.Intended Audience: Infectious diseases specialists, virologists, clinicalmicrobiologists, and pediatricians.Level: Intermediate/Advanced------------------------------------------------------------------------196(B)Slide SessionNovel Antibody Therapy of Difficult InfectionsTuesday, 11:15 a.m.–12:45 p.m. .... Esplanade Ballroom 310UAN: 0391-9999-12-136-L04-PModerators:Liise-anne Pirofski, MD - Chief, Division of Infectious Diseases, AlbertEinstein College of Medicine and Montefiore Medical CenterAlbert Einstein Coll. of Med., Bronx, NY.Arturo Casadevall, MD, PhD - Professor of Microbiology and Immunologyand Medicine; Chair, Department of Microbiology and ImmunologyAlbert Einstein Coll. of Med. of Yeshiva Univ., Bronx, NY.Objectives: Upon the completion of this Slide Session, the particpant shouldbe able to:> Define antibody therapy;> Discuss the rationale for use of antibody therapy;> Discuss mechanisms by which antibody therapies work; and> Discuss the pathogens for which antibody therapies are being developed.Presentations:11:15 a.m.B-1734 Controlling Pseudomonas aeruginosa Infections Using a NovelAnti-Psl/PcrV Multi-Specific Antibody ApproachA. DiGiandomenico, PhD - Scientist II, A. Keller, BS - Research AssociateII, C. Gao, PhD - Associate Scientist II, J. Hilliard, PhD - Scientist II, M.Camara, MS - Associate Scientist I, P. Warrener, MS - Scientist II, G. Rainey,PhD - Scientist II, C. Gao, PhD - Fellow, N. Dimasi, PhD - Senior Scientist,B. Sellman, PhD - Principal Scientist, C. Stover, PhD - Senior Director; Med-Immune, LLC, Gaithersburg, MD.11:30 a.m.B-1735 Efficacy of Human Intravenous Immunoglobulin (IVIG)for the Treatment of Lethal Necrotizing Pneumonia Caused byHypervirulent Community-Associated Methicillin-ResistantStaphylococcus aureusA. H. Duong, BS - Student 1 , C. Badiou, PhD - Researcher 2 , H. N. Le, BA- Student 1 , H. F. Chambers, MD - Professor 1 , B. A. Diep, PhD - AssistantProfessor 1 , G. Lina, MD - Professor 2 ; 1 Univ. California San Francisco, CA,2Univ. Lyon, Lyon, France.11:45 a.m.B-1736 Anti-Alpha Toxin mAb Reduces CA-MRSA Disease Severityan a Murine Dermonecrosis Model Through a Modulation of theInflammatory ResponseB. Sellman, PhD- Principal Scientist, C. Tkaczyk, PhD - Sr. Scientist, M.Hamilton, MS - Associate Scientist, A. Datta, MD - Pathologist, T. O’Day, BS- Statistician, L. Hua, PhD - Scientist, A. Barnes, BS - Associate Scientist, C.Stover, PhD - Sr. Director; MedImmune, LLC, Gaithersburg, MD.12:00 p.m.B-1737 Evaluation of Anti-Alpha Toxin mAb in Adjunctive Therapywith Vancomycin in a MRSA-Induced Mouse Pneumonia ModelJ. J. Hilliard, PhD- Scientist II, R. Zinsou, MS - Associate Scientist I, C.Tkaczyk, PhD - Senior Scientist, L. Hua, PhD - Scientist I, Y. Shi, BS - AssociateScientist I, L. Cheng, DVM - Pathologist, B. Sellman, PhD - PrincipalScientist, C. K. Stover, PhD - Senior Director; MedImmune, LLC, Gaithersburg,MD.12:15 p.m.B-1738 Improved Antibody Therapies for the Treatment ofClostridium difficile InfectionD. P. Humphreys, PhD - Director, A. Moore, PhD - Senior Scientist, N.Fisher, BSc - Scientist, B. MacKenzie, BSc - Scientist, J. Compson, BSc -Scientist, M. Oxbrow, BSc - Scientist, S. Cross, BSc - Senior Scientist, K.Tyson, PhD - Senior Scientist, D. Knight, BSc - Scientist, V. O’Dowd, BSc- Scientist, K. Herve, PhD - Scientist, D. Lightwood, PhD - Senior GroupLeader; UCB Pharma, Slough, United Kingdom.168September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------197(C1)Slide SessionResistance in Staphylococcus aureusTuesday, 11:15 a.m.–12:45 p.m. ................. Room 122UAN: 0391-9999-12-137-L04-PModerators:Frederic Laurent, MD, PhD - Associate ProfessorHopsices Civils de Lyon, Inserm U851, Lyon, France.Rodrigo E. Mendes, PhD - Associated DirectorJMI Lab., North Liberty, IA.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Discuss the emerging antibiotic resistance that’s in Staphylococcus aureus;> Discuss several biochemical based mechanisms of resistance; and> Understand impact of resistance mechanisms on therapeutic options forstaphylococcal infections.Presentations:11:15 a.m.C1-1739 Human Case of Invasive Osteitis: First Report of SevereInfection Due to a Methicillin-Resistant Staphylococcus aureusIsolate Carrying the Novel meca LGA251VariantO. Barraud, PharmD, PhD - Biologist 1,2,3 , F. Laurent, PharmD, PhD -Biologist 4,5 , B. François, MD - Clinician 1,3 , N. Hidri, MD - Biologist 1,3 , C.Martin, PharmD, PhD - Biologist 1,3 , M. Bes, Technician - Technician 4,5 , M.Clavel, MD - Clinician 3 , F. Garnier, PharmD, PhD - Biologist 1,3 , M. Ploy,PharmD, PhD - Professor 1,2 ; 1 INSERM, Limoges, France, 2 Univ. Limoges,Limoges, France, 3 CHU Limoges, Limoges, France, 4 INSERM, Lyon,France, 5 CNR Staphylocoques, Lyon, France.11:25 a.m.C1-1740 Low Prevalence of Cassette Chromosome Recombinases(ccr) Genes among Community-Associated MethicillinSusceptible Staphylococcus aureus (CA-MSSA)Withdrawn11:25 a.m.C1-1741 Biochemical Mechanisms of Sulfonamide Resistance inStaphylococcus aureusE. C. Griffith, Pharm D - GHS, R. E. Lee, PhD - Member; St. Jude,Memphis, TN.11:35 a.m.C1-1742 Thickened Cell Wall as a Mechanism for IncreasedTelavancin Minimum Inhibitory Concentration (MIC) inMethicillin-Resistant Staphylococcus aureus (MRSA)K. Ryan, PharmD Candidate - Research Assistant, S. Jett, PhD - Director,HSC EM Facility, R. C. Mercier, PharmD - Associate Professor; Univ. of NewMexico, Albuquerque, NM.11:45 a.m.C1-1743 Divergent Evolution of Methicillin-Resistant Staphylococcusaureus (MRSA) ST239 in a Patient with Persistent BacteremiaS. J. van Hal, MBChB, FRACP, FRCPA - Associate Professor 1,2 , J. A. Steen,PhD - Researcher 3,4 , I. B. Gosbell, PhD - Staff Specialist 1,5,2 , B. A. Espedido,PhD - Scientist 1,5 , M. A. Cooper, PhD - Professor 3 , S. M. Grimmond, PhD- Professor 3,4 , S. O. Jensen, PhD - Principal Scientist 1,5 ; 1 Antibiotic ResistanceMobile Elements Group, Sch. of Med., Univ. of Western Sydney, Sydney,Australia, 2 Liverpool Hosp., South West Sydney Local Hlth. District,Sydney, Australia, 3 Inst. for Molecular Bioscience, Univ. of Queensland, Brisbane,Australia, 4 Queensland Ctr. for Med. Genomics, Univ. of Queensland,Brisbane, Australia, 5 Ingham Inst. for Applied Med. Res., Sydney, Australia.11:55 a.m.C1-1744 Cell Membrane (CM) Lipid Profiles Correlate withDaptomycin (DAP) Resistance (R) in Methicillin-ResistantStaphylococcus aureus (MRSA)N. N. Mishra, PhD - Senior Research Associate 1 , A. Rubio, PhD - Scientist 2 ,A. S. Bayer, MD - Professor 1,3 ; 1 LA Biomedical Res. Inst. at Harbor UCLA,Torrance, CA, 2 Cubist Pharmaceuticals, Lexington, MA, 3 David Geffen Sch.of Med. UCLA, Los Angeles, CA.12:05 p.m.C1-1745 Analysis of cfr-Carrying Plasmids in Staphylococcus epidermidisand Staphylococcus aureus from Two Hospitals in OhioR. E. Mendes, PhD - Dir 1 , L. M. Deshpande, PhD - Res Scientist 1 , H. F.Bonilla, MD - Professor 2 , M. D. Huband, BS - Senior Principal Scientist 3 , R.N. Jones, MD - CEO 1 , J. P. Quinn, MD - Senior Advisor 3 ; 1 JMI Lab., NorthLiberty, IA, 2 UPMC Mercy, Pittsburgh, PA, 3 Pfizer Inc, Groton, CT.12:15 p.m.C1-1746 Dynamics of Excision of the Staphylococcal Cassette Chromosomemec (SCCmec) in Methicillin-Resistant Staphylococcusaureus (MRSA)M. Stojanov, Master of Science - PhD Student 1 , P. Moreillon, MD-PhD- Professor 1 , O. Sakwinska, PhD - Researcher 2 ; 1 UNIL, Lausanne Univ.,Lausanne, Switzerland, 2 Nestlé Res. Ctr., Lausanne, Switzerland.12:25 p.m.C1-1747 Expression of Multidrug Resistance Efflux Pump(MDR-EP) Genes in Clinical and Environmental Isolates ofStaphylococcus aureusB. D. Schindler, PhD - Postdoctoral Fellow 1 , C. Kosmidis, MD - Fellow 2 ,P. L. Jacinto, MD - Fellow 2 , D. Patel, MD - Fellow 2 , K. Bains, MD -Fellow 2 , S. M. Seo, MT - Laboratory Associate 1 , G. W. Kaatz, MD - Professorof Medicine 1 ; 1 John D. Dingell VA Med. Ctr., Detroit, MI, 2 Wayne StateUniv. Sch. of Med., Detroit, MI.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.Final Program169

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------198(G)Slide SessionGlobal PediatricsTuesday, 11:15 a.m.–12:45 p.m. .... Esplanade Ballroom 309UAN: 0391-9999-12-138-L04-PModerators:Karina M. Butler, MB, DCh - ProfessorOur Lady’s Children’s Hosp., Dublin, Ireland.Mike Sharland, MD - Professor of Paediatric Infectious DiseasesSt. George’s Hosp. and Med. Sch., London, United Kingdom.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Discuss current epidemiology of pediatric infectious diseases on a globalscale;> Discuss cutting-edge management issues in pediatric infections; and> Discuss aspects of the global impact of infections in children.Presentations:11:15 a.m.G-1748 Multiplication of Coxsackie Bs and Other Non PolioEnteroviruses on L20B Cell LineB. S. Oderinde, Mr, Masters in Medical Laborary Science (MMLS) -Lecturer 1,2 , M. M. Baba, PhD - Lecturer 1,2 , A. J. Williams, PhD - Microbiologist3 , D. N. Bukbuk, Masters - Lecturer 1 , M. J. Bamaiyi, BSc - Technician 2 ,M. T. Akinola, BSc - Technologist 2 , J. Dawurung, BSc- Technician 2 , H.Adamu, HND / AIMLT - Technologist 2 , T. Muhammed, Masters - Technologist2 ; 1 Univ. of Maiduguri , Maiduguri, Nigeria, 2 WHO Natl. Polio/ITB Lab., Univ. of Maiduguri Teaching Hosp., Maiduguri, Nigeria, 3 CDC,Atlanta, GA.11:30 a.m.G-1749 A Prospective Observational Study of the Safety andTolerability of Oseltamivir in Children Aged up to 24 MonthsB. Rath 1 , W. A. Blumentals 2 , M. K. Miller. 3 , K. A. Starzyk 4 , B. Tetiurka 5 ,M. Wollenhaupt 6 ; 1 Charite Univ. Med. Ctr., Berlin, Germany, 2 Hoffmann-LaRoche, Inc., Nutley, NJ, 3 Genentech, Inc., South San Francisco, CA, 4 Outcome,Cambridge, MA, 5 Niepubliczny Zaklad Opieki Zdrowotnej Salmed,Leczna, Poland, 6 F. Hoffmann, La Roche Ltd., Basel, Switzerland.11:45 a.m.G-1750 Appropriateness of Currently Recommended Antibiotics(AB) in Treatment of Late Onset Sepsis (LOS) in Five EuropeanCountriesI. Lutsar, MD, PhD - Professor, NeoMero Consortium; Univ. of Tartu,Tartu, Estonia.12:00 p.m.G-1751 Multicenter Study of the Burden of Invasive Neonatal GroupB Streptococcal DiseaseL. Rivera, MD - Professor 1 , X. Saez Llorenz, MD - Professor 2 , J. FerisIglesias, MD - Professor 3 , M. Ip, MD - Professor 4 , S. Saha, MD - Professor 5 ,P. Adrian, PhD - Senior Researcher 6 , I. Boudville, MD - Head Epidemiology,Region International 7 , M. C. Cunnington, PhD - Epidemiologist 8 , M.Kyaw, PhD - Associate Director 9 , K. Slobod, MD - Head, Bacterial AdvancedProgram 10 ; 1 Hosp. Nuestra Sra Altagracia, Santo Domingo, DominicanRepublic, 2 Hosp. del Nino, Panama City, Panama, 3 Hosp. Infantil Dr RobertReid, Santo Domingo, Dominican Republic, 4 Chinese Univ. of Hong Kong,Hong Kong, China, 5 Dhaka Shishu Hosp., Dhaka, Bangladesh, 6 Univ. ofWitwatersrand, Johannesberg, South Africa, 7 NVD, Singapore, Singapore,8Novartis Vaccines & Diagnostics, London, United Kingdom, 9 MedImmune,Washington, D.C., 10 NVD, Cambridge, MA.12:15 p.m.G-1752 Socioeconomic and Racial Disparities of Invasive Streptococcuspneumoniae Infection among Children in AtlantaJ. O. Spicer, MD, MPH - Medical Resident 1 , S. Thomas, MSPH - Epidemiologist2 , A. Holst, MPH - Epidemiologist 2 , W. Baughman, MSPH - EIPCoordinator 2,3 , M. M. Farley, MD - Professor 1,3 ; 1 Emory Univ. Sch. of Med.,Atlanta, GA, 2 Emerging Infections Program, Atlanta, GA, 3 VA Med. Ctr.,Decatur, GA.12:30 p.m.G-1753 Short Term Mortality Rates (STMRs), Long-Term MortalityRates (LTMRs), and Mortality Risk Factors (MRFs) among ChildrenPresenting with Community-Acquired Pneumonia (CAAP)in Southern IsraelD. Greenberg, MD - Professor 1 , N. Givon-Lavi, PhD - Lecturer 1 , S. Ben-Shimol, MD - Instructor 1 , J. Bar-Ziv, MD - Professor 2 , R. Dagan, MD -Professor 1 ; 1 Ben-Gurion Univ and Soroka Univ Med Ctr., Beer-Sheva, Israel,2Hadassah Univ Med Ctr., Jerusalem, Israel.------------------------------------------------------------------------199(K)Slide SessionBloodstream Infections: Catheters, Cultures andCountsTuesday, 11:15 a.m.–12:45 p.m. ................. Room 121UAN: 0391-9999-12-139-L04-PModerators:Loreen Herwaldt, MD - Professor, Hospital EpidemiologistUniv. of Iowa Coll. of Med., Iowa City, IA.Jean-Francois Timsit, MD, PhD - ProfessorCHVA Michallon, Univ. Joseph FowlerObjectives: Upon the completion of this Slide Session, the participantshould be able to:> Identify key epidemiologic characteristics of catheter-associated bloodstreaminfections;> Review the performance characteristics of electronic BSI surveillancemethodologies; and> Describe the potential effect of blood culturing practice on reportedbacteremia rates in children’s hospitals.170September 9-12 |

TUESDAY SCIENTIFIC SESSIONSPresentations:11:15 a.m.K-1754 Resistance Prevalence in Community-Acquired and Hospital-AcquiredBloodstream Infections in European ChildrenJ. A. Bielicki, MD, MPH - Research Fellow, T. Planche, MD - ConsultantMicrobiologist, M. Sharland, MD - Professor, ARPEC Project Group; St.George’s Univ., London, United Kingdom.11:30 a.m.K-1755 Evaluation of the Reporting Validity of CLABSI Data to aProvincial Surveillance ProgramP. S. Fontela, MD, PhD - Professor 1 , I. Rocher, M.Sc. - Conseillerère en SoinsInfirmiers 2 , R. W. Platt, PhD - Professor 1 , M. Pai, MD, PhD - Professor 1 , D.L. Buckeridge, MD, PhD - Professor 1 , C. Frenette, MD - Director of InfectionControl 1 , M. Dionne, MD - Scientific Director 2 , C. Quach, MD, M.Sc. -Professor 1 ; 1 McGill Univ., Montreal, Canada, 2 Inst. Natl. de Santé Publiquedu Québec, Montreal, Canada.11:45 a.m.K-1756 The Validation of a Novel Surveillance System for MonitoringBloodstream Infections in the Calgary Health RegionJ. R. Leal, Masters- Surveillance Analyst 1,2 , D. B. Gregson, MD - Professor2,1,3 , T. Ross, BSc - Data Analyst 3 , W. W. Flemons, MD - VP Quality,Safety and Health Information 1,2 , D. L. Church, MD, PhD - Professor 2,3 , K.B. Laupland, MD, MSc - Associate Professor 2,1,3 ; 1 Alberta Hlth. Services,Calgary, Canada, 2 Univ. of Calgary, Calgary, Canada, 3 Calgary Lab. Services,Calgary, Canada.12:00 p.m.K-1757 Randomized Controlled Trial of Chlorhexidine Dressingand Highly Adhesive Dressing for Preventing Catheter-RelatedInfections in the ICUJ. F. Timsit, MD, PhD - Head of the Medical Polyvalent ICU 1 , O. Mimoz,MD, PhD - Head of the Surgical ICU 2 , J. C. Lucet, MD, PhD - InfectionControl; Prevention 3 , DRESSING2 Study Group, France; 1 Univ. Hosp.Grenoble, Grenoble, France, 2 Univ. Hosp. Poitiers, Poitiers, France, 3 Univ.Hosp. Bichat, Paris, France.12:15 p.m.K-1758 Epidemiology and Outcome of Hospital-Acquired ParenteralNutrition Catheter-Related Bacteremia (PN-CRB)D. Rodriguez-Pardo, MD, PhD - Professor, B. Almirante, MD, PhD -Professor, N. Fernandez-Hidalgo, MD - Professor, C. Pigrau, MD, PhD- Professor, C. Ferrer, MS - Research Nurse, R. Sorde, MD - Research, A. M.Planes, MD,PhD - Professor, M. Palomar, MD,PhD - Professor, R. Burgos,MD, PhD - Professor, A. Pahissa, MD, PhD - Professor; Hosp. Univ. Valld’Hebron, Barcelona, Spain.12:30 p.m.K-1759 Variation in Paediatric Blood Culturing Strategies MayInfluence Reported Rates of Bacteraemia in European Children’sHospitalsJ. A. Bielicki, MD, MPH - Research Fellow, T. Planche, MD - ConsultantMicrobiologist, M. Sharland, MD - Professor, ARPEC Project Group; StGeorge’s Univ., London, United Kingdom.------------------------------------------------------------------------200(A)Slide SessionMaximizing PK/PD Modeling for Dosing, Preventionof Resistance and Clinical OutcomesTuesday, 1:30 p.m.–4:00 p.m. ................... Room 102UAN: 0391-9999-12-140-L04-PModerators:George L. Drusano, MD - DirectorOrdway Res. Inst., Albany, NY.William W. Hope - Professor of Therapeutics and Infectious DiseasesThe Univ. of Manchester, Manchester, United Kingdom.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Describe novel PK/PD modeling techniques;> Illustrate methods to evaluate clinical outocmes related to PK/PDparameters; and> Discuss the application of PK/PD parameters for prevention of resistance.Presentations:1:30 p.m.A-1760 A Threshold Concentration of Avibactam (AVI) Duringthe Pharmacokinetic Decline Phase, Below Which-LactamaseInhibition in Enterobacteriaceae Becomes IneffectiveW. Nichols, PhD - Director 1 , P. Levasseur, PhD - Microbiology Consultant 2 ,J. Li, PhD – Sr. Scientist 3 , S. Das, PhD – Sr. Scientist 4 ; 1 AstraZeneca,Waltham, MA, 2 AstraZeneca, Enghien les bains, France, 3 AstraZeneca,Wilmington, DE, 4 AstraZeneca, Alderley Park, United Kingdom.1:45 p.m.A-1761 Infusion Duration Impact on Cell Kill for Combination ofCeftaroline (CPT) & Avibactam (AVI) Against Two Klebsiella(KP) & One Enterobacter (EC) StrainsA. Louie, MD - Professor 1 , D. Bown, MS - Manager 1 , J. McCauley, BS -Tech 1 , J. Rodriguez, BS - Tech 1 , M. Swift, BS - Tech 1 , G. Williams, PhD- Employee 2 , G. L. Drusano, MD - Professor 1 ; 1 Univ. of Florida, Albany, NY,2Cerexa, Oakland, CA.2:00 p.m.A-1762 A Novel Mathematical Modeling Approach to Characterizethe Pharmacodynamics (PD) of Ceftolozane (TOL)/Tazobactam(TAZ), a-Lactam &-Lactamase Inhibitor (BLI) CombinationR. L. Soon, PhD - Fellow 1 , A. Forrest, PharmD - Research Professor 1 , J. B.Bulitta, PhD – Sr. Res. Fellow 2,1 , B. T. Tsuji, PharmD – Asst. Professor 1 ; 1 Univ.at Buffalo, Buffalo, NY, 2 Monash Univ., Melb, Australia.2:15 p.m.A-1763 A Semi-Mechanistic Pharmacokinetic/Pharmacodynamic(PK/PD) Model for MK-7655, a Novel Beta-Lactamase Inhibitor(BLI) for Use in Combination with Imipenem/CilastatinM. L. Rizk, PhD - Sr Research Pharmacokineticist 1 , G. F. Ahmed, BS - PhDCandidate 2 , K. Young, MS - Biology Lead 1 , M. Motyl, PhD - Biology Lead 1 ,J. Butterton, MD – Sr. Director 1 , F. Racine, AS - Biology Member 1 , J. Wu,PhD – Sr. Research Chemist 1 , C. Li, PhD - Research Fellow 1 , L. Wenning,PhD - Director 1 ; 1 Merck Sharp & Dohme Corp., Whitehouse Station, NJ,2Univ. of Minnesota, Minneapolis, MN.Final Program171

Tuesday SCIENTIFIC SESSIONS2:30 p.m.A-1764 External Evaluation of a Mechanism-Based PK/PD Model:Predicting Inoculum EffectsE. I. Nielsen, PhD - Assistant Professor, D. Khan, MSc - PhD Student, S.Cao, PhD - Researcher, U. Lustig, MSc - Assistant, D. Hughes, PhD - Professor, D. I. Andersson, PhD - Professor, L. E. Friberg, PhD - AssociateProfessor; Uppsala Univ., Uppsala, Sweden.2:45 p.m.A-1765 Impact of Administration of Piperacillin-Tazobactam byExtended Infusion on Emergence of Resistance in an In VitroHollow Fiber Infection Model (HFIM)T. Felton, MD - Clinical Research Fellow, L. O’Connor, MRes - MedicalStudent, J. Goodwin, BSc - Research Assistant, A. Sharp, BSc - ResearchAssistant, L. Gregson, BSc - Research Technician, J. Livermore, PhD - ResearchAssistant, S. Howard, PhD - Research Associate, W. Hope, MD, PhD -Professor; Univ. of Manchester, Manchester, United Kingdom.3:00 p.m.A-1766 Prolonged Infusion of Piperacillin-Tazobactam for theTreatment of Pseudomonas aeruginosa InfectionsG. Wu, PharMD - Clinical Pharmacy Coordinator, N. Saad, BS, PharmD -Associate Director of Clinical Pharmacy and Residency Program, T. Abraham, BS,MS,, PharmD - Director of Clinical Pharmacy and Residency Program; NewYork Methodist Hosp., Brooklyn, NY.3:15 p.m.A-1767 Appropriateness of Dosing Pre- and Post-Implementation ofExtended-Infusion Piperacillin/TazobactamM. Mendez, PharmD - Infectious Diseases Clinical Pharmacist, N. Lu,PharmD - Clinical Pharmacist, S. Anderson, PharmD - Trauma SurgeryClinical Pharmacist, S. Munyaradzi, MS - Clinical Decision Support Analyst;Community Regional Med. Ctr., Fresno, CA.3:30 p.m.A-1768 Vancomycin AUC24/MIC Ratio in Patients with ComplicatedBacteremia and Osteomyelitis Due to Methicillin-ResistantStaphylococcus aureusK. M. Gawronski, Pharm D - Specialty Practice Pharmacist 1 , J. E. Brown,PharmD, MS - Assistant Professor 2 , D. A. Goff, PharmD - Specialty PracticePharmacist Infectious Diseases 1 , K. A. Bauer, PharmD - Specialty Practice PharmacistInfectious Diseases 1 ; 1 The Ohio State Univ. Med. Ctr., Columbus, OH,2State Univ. of New York, Buffalo, NY.3:45 p.m.A-1769 Single Nucleotide Polymorphisms of ABCB1 Gene InfluenceDaptomycin Pharmacokinetics in Adult PatientsL. Baietto, Masters - PhD student, A. D’Avolio, BSc, MSc, SM - Researcher,F. G. De Rosa, MD - Associate Professor, J. Cusato, BSc, MSc - Biologist, S.Pace, BSc - Student, A. Calcagno, MD - Clinician, N. Pagani, MD - Clinician,C. Montrucchio, MD - Clinician, M. Simiele, BSc, MSc - PhD student,G. Di Perri, MD, DTM & H, PhD - Professor; Univ. of Turin, Turin, Italy.------------------------------------------------------------------------201(D)Slide SessionDiverse Applications of Mass Spectrometry in ClinicalMicrobiologyTuesday, 1:30 p.m.–4:00 p.m. ................... Room 120UAN: 0391-9999-12-141-L04-PModerator:Charlotte A. Gaydos, DrPH - ProfessorInfectious Diseases, Johns Hopkins Univ., Baltimore, MD.Objectives: Upon completion of this Slide Session, the participant should beable to:> Discuss techniques of mass spectrometry;> Review applications of mass spectrometry in clinical infectious diseasediagnostics; and> Discuss MALDI-ToF and PCR-ESI mass spectrometry applications inclinical microbology.Presentations:1:30 p.m.1770 State-of-the-Art MinilectureOverview of MALDI-ToF Mass SpectrometryNathan A. Ledeboer, MD - Assistant Professor of PathologyPathology, Med. Coll. of Wisconsin, Milwaukee, WI.1:50 p.m.1771 State-of-the-Art MinilectureOverview of PCR-ESI-Mass SpectrometryCharlotte A. Gaydos, DrPHUniv., Baltimore, MD.2:10 p.m.D-1772 Comparison between Matrix-Assisted Laser DesorptionIonization-Time of Flight Mass Spectrometry (MALDI-ToFMS) and Sequencing of 16S rRNA Gene for the Identification ofDifficult-to-Identify Bacterial StrainsB. Rodriguez-Sanchez, PhD - Researcher, C. Sanchez-Carrillo, PharmD -Researcher, E. Cercenado, PhD - Researcher, M. Marin, PhD - Researcher, A.Ruiz, PhD - Researcher, M. Rodriguez-Creixems, MD - Medical Doctor, E.Bouza, MD, PhD - Professor; Hosp. Gen. Univ. Gregorio Marañón. Univ.ofMadrid. Spain., Madrid, Spain.2:25 p.m.D-1773 Vitek-MS Mass Spectrometry is a New Accurate Techniquefor the Routine Identification of Clinical Strains of StreptococcuspneumoniaeP. D. Weber, PhD - Senior Microbiologist, M. Scotto, MS - Microbiology-Technician; BIO-VSM LAB Lab. of Clinical Microbiol., Vaires sur Marne,France.172September 9-12 |

TUESDAY SCIENTIFIC SESSIONS2:40 p.m.D-1774 Identification of Anaerobic Bacteria by Bruker BiotyperMatrix Assisted Laser Desorption Ionization-Time of FlightMass Spectrometry with On-Plate Formic Acid PreparationB. Schmitt, DO- Clinical Microbiology Fellow, S. Cunningham, MT -Development Technologist II, A. Dailey, MT - Clinical Lab Technologist, D.Gustafson, MT - Technical Specialist I, R. Patel, MD - Chair, Division ofClinical Microbiology; Mayo Clinic, Rochester, MN.2:55 p.m.D-1775 Use of MALDI-ToF to Characterize Different Clonal Complexesof Methicillin-Resistant Staphylococcus aureus (MRSA)J. M. Sierra, PhD - Researcher 1 , M. Camoez, MS - PhD Student 1 , I. Roca,PhD - Researcher 2 , J. Vila, PhD - Professor 2 , M. A. Dominguez, PhD - Faculty1 ; 1 Hosp. Belvitge. IDIBELL, Hospitalet, Spain, 2 Hosp. Clinic. CRESIB,Barcelona, Spain.3:10 p.m.D-1776 Rapid Identification of Mycobacterium tuberculosis ResistanceUsing PCR and Mass SpectrometryD. Florea, MD, PhD - Research Assist 1 , D. Otelea, MD, PhD - Researcher 2 ,A. Hristea, MD, PhD - Lecturer 3 , O. Moldovan, PhD - Biologist 4 , A. Macri,MD, PhD - Assistant Professor 4,5 , S. Paraschiv, PhD - Biologist 2 , C. Baicus,MD, PhD - Associate Professor 6,5 , A. Streinu-Cercel, MD , PhD - Professor2,5; 1 Natl. Inst. of Infectious Diseases, Bucharest, Romania, 2 Natl. Inst. ofInfectious Diseases Professor Dr Matei Bals, Bucharest, Romania, 3 Natl. Inst.of Infectious Diseases, Univ. of Med. and Pharmacy, Bucharest, Romania,4Marius Nasta Natl. Inst. of Pneumology, Bucharest, Romania, 5 Univ. ofMed. and Pharmacy, Bucharest, Romania, 6 Colentina Clinical Hosp., Bucharest,Romania.3:25 p.m.D-1777 Comparison of MALDI-ToF MS to Nucleic Acid Sequencingfor the Identification of Clinical Isolates of Mycobacterium sppK. M. Riebe, M(ASCP) - Head Technologist, Microbiology 1 , B. W. Buchan,PhD - Instructor 2 , M. Timke, PhD - Scientist 3 , M. Kostrzewa, PhD - Scientist3 , N. A. Ledeboer, PhD - Assistant Professor 2 ; 1 Dynacare Lab., Milwaukee,WI, 2 Med. Coll. of Wisconsin, Milwaukee, WI, 3 Bruker DaltonikGmbH, Bremen, Germany,.3:40 p.m.D-1778 PCR-Electrospray Ionization/Mass Spectrometry as a SingleTool for the Detection and Typing of Adenovirus in Routine ViralDiagnostics of Stem Cell Transplant PatientJ. Le Goff, PharmD, PhD - Associate Professor 1 , L. Feghoul, PharmD -Doctor 1 , J. Dalle, MD, PhD - Professor 2 , R. Peffault Delatour, MD, PhD- Associate Professor 1 , F. Simon, MD, PhD - Professor 1 ; 1 Univ. Paris Diderot,Hosp. Saint-Louis, Paris, France, 2 Univ. Paris Diderot, Hosp. Robert Debré,Paris, France.------------------------------------------------------------------------202(H2, H3)Interactive SymposiumAdvances in HIV and HCV ManagementTuesday, 2:00 p.m.–4:00 p.m. ................... Room 103UAN: 0391-9999-12-142-L02-PDeveloped in Cooperation with the International Antiviral Society-USA (IAS-USA)Speakers:2:00 p.m.1779 Update on Guidelines and Issues for Initiating AntiretroviralTherapy in HIV InfectionAnn C. Collier, MD - Professor of MedicineUniv. of Washington Sch. of Med., Seattle, WA.2:40 p.m.1780 Clinical Management of Antiretroviral Therapy-ExperiencedPatientPablo Tebas, MD - Professor of MedicineUniv. of Pennsylvania, Philadelphia, PA.3:20 p.m.1781 Clinical Management of HCV Infection: A New ParadigmDavid L. Wyles, MD - Associate ProfessorUniv. of California, San Diego, CA.Objectives: Upon completion of this Interactive Symposium Session, theparticipant should be able to:> Design, implement, and evaluate antiretroviral therapy in selected patients,including those who are pregnant, older, or treatment-experienced;> Design direct-acting antiviral regimens that effectively treat HCV infectionin HIV/HCV coinfected patients; and> Discuss the pros and cons of antiretroviral therapy initiation.Intended Audience: Infectious diseases physicians, HIV and HCV specialists,and other clinical decision makers who are actively involved in the medicalcare of people with HIV/AIDS and Hepatitis C virus (HCV).Level: AdvancedFinal Program173

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------203(C1)SymposiumBacterial Communication and ResistanceTuesday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 300UAN: 0391-9999-12-143-L04-PConveners:Patrice Courvalin, MD - ProfessorInst. Pasteur, Paris, France.Emmanuelle M. Charpentier, PhD - Assoc. ProfessorMIMS, Umea Univ., Umea, Sweden.Speakers:2:00 p.m.1782 Conjugative Transfer in Human CellsChristoph Dehio, PhD - ProfessorUniv. of Basel, Basel, Switzerland.2:30 p.m.1783 Bacterial Communication by NanotubesSigal Ben-Yehuda, PhD - ProfessorThe Hebrew Univ. of Jerusalem, Jerusalem, Israel.3:00 p.m.1784 Promiscuous Cryptic Resistance DeterminantsValerie W. Soo, PhD - Postdoctoral Research FellowMassey Univ., Auckland, New Zealand.3:30 p.m.1785 Transfer Limitations by CRISPRsEmmanuelle Charpentier, PhD - Associate ProfessorMIMS, Umea Univ., Umea, Sweden.Objectives: Upon completion of this Symposium Session, participantsshould be able to:> Assess the extent and limitations of resistance dissemination;> Identify the mechanisms of resistance spread recently elucidated; and> Identify the factors that favor dissemination of resistance.Intended Audience: ID physicians, pharmacists, scientists, and industryclinical microbiologists.Level: Advanced------------------------------------------------------------------------204(C2, K)SymposiumGlobal Spread of Antimicrobial Resistance: Mechanismsof Spread, Surveillance, and ControlTuesday, 2:00 p.m.–4:00 p.m. ................... Room 121UAN: 0391-9999-12-144-L04-PConveners:Didier Pittet, MD, MS - Professor of Medicine; Director, Infection ControlProgram and WHO Collaborating Centre on Patient SafetyUniv. of Geneva Hosp., Geneva, Switzerland.Jesús Rodríguez-Baño, MD, PhD - ProfessorHosp. Univ. Virgen Macarena and Univ. of Seville, Seville, Spain.Speakers:2:00 p.m.1786 Overview of Global Differences and Mechanisms for SpreadNeil Woodford, PhD, FRCPath - ProfessorHlth. Protection Agency, London, United Kingdom.2:30 p.m.1787 Building Capacity for Diagnosing Resistance Worldwide: AreWe Making Any Progress?Keith P. Klugman, MD, PhD - William H Foege Professor of Global HealthRollins Sch. of Publ. Hlth., Emory Univ., Atlanta, GA.3:00 p.m.1788 New Technologies: Towards Global Surveillance and Prediction?Hajo Grundmann, MD, PhD - ProfessorUniv. Med. Ctr. Groningen, Univ. of Groningen, Groningen, Netherlands.3:30 p.m.1789 Surveillance Spread and Control: Should We All Use the EuropeanModel?Dominique L. Monnet, PharmD, PhD ; ECDC, Stockholm, Sweden.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the global differences and mechanisms for spread of antimicrobialresistance;> Describe the progress on recognizing antimicrobial resistance on a worldwidebasis;> Review the role of new technologies in furthering or improving globalsurveillance; and> Evaluate the European model for antimicrobial surveillance and control.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, clinical pathologists, medical technologists,and epidemiologists.Level: Intermediate174September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------205(E)SymposiumSelecting Antibiotic Resistant Mutants in the Laboratory:How Best to Mimic the Real World?Tuesday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 302UAN: 0391-9999-12-145-L04-PConveners:Laura J. V. Piddock, PhD – ProfessorUniv. of Birmingham, Birmingham, United Kingdom.Joseph M. Blondeau, MSc, PhD - Head, Clinical MicrobiologyUniv. of Saskatchewan, Saskatoon, Canada.Speakers:2:00 p.m.1790 Selecting Resistant Bacteria in Liquid MediaRoy Kishony, PhD - ProfessorHarvard Med. Sch., Boston, MA.2:30 p.m.1791 Effect of Antioxidants and Oxygen Concentration on AntimicrobialLethality and ResistanceXilin Zhao, PhD - Assistant ProfessorUMDNJ, New Jersey Med. Sch., Newark, NJ.3:00 p.m.1792 Lethal and Non-Lethal Selection of Antibiotic ResistanceDan I. Andersson, PhD - ProfessorUppsala Univ., Uppsala, Sweden.3:30 p.m.1793 In Infection Models: Ensuring the Output Accurately Reflectsthe Population in the ModelDavid P. Nicolau, PharmD - Dir., Ctr for Anti-Infective Res. & Dev.Hartford Hosp., Hartford, CT.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the strategies and experimental techniques used to select antibioticresistant mutants that reflect those that can be selected by exposure toantibiotics in vivo;> Assess how to account for random mutation in ensuring statistical robustnessas it relates to mutation rates and frequency of mutations;> Discuss how reactive oxygen species may influence both mutation ratesand mechanisms of resistance; and> Ensure that in infection models the output accurately reflects the populationin the model.Intended Audience: Scientific and medical researchers, including postgraduatestudents.Level: Intermediate------------------------------------------------------------------------206(F)SymposiumIron Transport and Homeostasis: Are ThereOpportunities for New Drugs?Tuesday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 309UAN: 0391-9999-12-146-L04-PConveners:Malcolm G. P. Page, PhD - ProfessorBasilea Pharmaceutica, Basel, Switzerland.Marvin J. Miller, PhD - ProfessorUniv. of Notre Dame and PracticaChem, LLC, Notre Dame, IN.Speakers:2:00 p.m.1794 Utilizing Iron Assimilation Processes for the Development ofNew AntibioticsMarvin J. Miller, PhD - ProfessorUniv. of Notre Dame and PracticaChem, LLC, Notre Dame, IN.2:30 p.m.1795 Barriers and Possible Solutions to Iron Chelation Therapy forInfectionsBrad Spellberg, MD - Associate Professor of MedicineHarbor UCLA Med. Ctr., Torrance, CA.3:00 p.m.1796 Heme Aggregation Inhibitors as Anti-Malarial AgentsDavid W. Wright, PhD - Associate ProfessorVanderbilt Univ., Nashville, TN.3:30 p.m.1797 Siderophore-LactamsEric Desarbre, PhD - Medicinal ChemistBasilea Pharmaceutica Intl. Ltd, Basel, Switzerland.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the role of iron homeostasis in the growth of microbial pathogens,including bacteria, fungi and protozoa;> Identify and distinguish new approaches to the discovery of agents exploitingiron-uptake systems in bacteria; and> Recognize the potential pitfalls in application of iron chelators in antimicrobialchemotherapy.Intended Audience: Microbiologists working in academia and in the pharmaceuticalindustry.Level: IntermediateFinal Program175

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------207(G)SymposiumHot Topics in Pediatric Infectious Disease: 2012Tuesday, 2:00 p.m.–4:00 p.m. ................... Room 122UAN: 0391-9999-12-147-L04-PConveners:Carlo Giaquinto, MD - Medical Doctor PaediatricianAzienda Ospedaliera-Univ., Padova, Italy.Jeffrey R. Starke, MD - ProfessorBaylor Coll. of Med., Houston, TX.Speakers:2:00 p.m.1798 TB or not TB? New Diagnostics and Treatment forChildhood TBJeffrey R. Starke, MD - ProfessorBaylor Coll. of Med., Houston, TX.2:30 p.m.1799 New Insights into Shiga Toxin-Associated HUSMarina Morigi, PhD - Head, Laboratory of Cell Biology andXenotransplantationMario Negri Inst. for Pharmacological Res., Bergamo, Italy.3:00 p.m.1800 HBV and HCV Treatment in ChildrenGiuseppe Indolfi, MD, PhD - ConsultantMeyer Children’s Univ. Hosp., Florence, Italy.3:30 p.m.1801 Impact of Expanded Valent Pneumococcal VaccinesPia S. Pannaraj, MD, MPH - Assistant Professor of PediatricsUniv. of Southern California, Children’s Hosp. Los Angeles, Los Angeles,CA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss contemporary advances in pathogenesis, diagnosis and treatmentof key pediatric infectious diseases and their importance to child health;> Summarize the potential impact of implementation of scientific advancesto improve child health; and> Apply updated information to communication, decision-making andclinical practice.Intended Audience: Infectious disease physicians and physician extenders,clinical microbiologists, public health officials and pharmacologists.Level: Beginning/Intermediate------------------------------------------------------------------------208(K)SymposiumAre Prevalence Surveys Still Useful for Healthcare-Associated Infection Surveillance?Tuesday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 305UAN: 0391-9999-12-148-L04-PConveners:Wing Hong Seto, MD - Director, WHO Collaborating Centre for InfectionControlHosp. Authority, Hong Kong, China.Gary L. French, MD - ProfessorKing’s Coll., London, London, United Kingdom.Speakers:2:00 p.m.1802 Period vs Point Prevalence Surveys: What is the Difference?Walter Zingg, MD - Senior PhysicianUniv. of Geneva Hosp., Geneva, Switzerland.2:20 p.m.1803 Prevalence Surveys: New Insights From the UK ExperienceGary L. French, MD - ProfessorKing’s Coll., London, London, United Kingdom.2:40 p.m.1804 The Use of Prevalence Surveys in EuropeCarl Suetens, MD - Senior ExpertECDC, Stockholm, Sweden.3:00 p.m.1805 Prevalence Surveys in Asia-Pacific: Effective Tracking of CarePracticesBenjamin J. Cowling, PhD - Assistant ProfessorThe Univ. of Hong Kong, Hong Kong, Hong Kong.3:20 p.m.1806 New Prevalence Survey Tools from the CDCShelley Magill, MD, PhD - Medical OfficerCDC, Atlanta, GA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify the most recent utilizations of the prevalence survey in HAIsurveillance;> Discuss examples of effective application of the prevalence survey data inHAI surveillance; and> Identify the recent tools available to enhance the use of the prevalencesurvey.Intended Audience: ID specialists, infection control professionals, hospitalepidemiologists, and public health professionals.Level: Intermediate/Advanced176September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------209SymposiumID QuizTuesday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 308UAN: 0391-9999-12-149-L04-PConveners:Jonathan Cohen, MD - ProfessorBrighton and Sussex Med. Sch., Brighton, United Kingdom.Peter H. Gilligan, PhD - Professor, Pathology and Laboratory MedicineUniv. of North Carolina, Chapel Hill, NC.Speakers:1807 Vance Fowler, Jr., MD - Professor with TenureDuke Univ., Durham, NC.1808 Stephen Harbarth, MD - ProfessorUniv. of Geneva Hosp., Geneva, Switzerland.1809 Patricia Muñoz, MD, PhD - Professor of Infectious DiseasesHosp. Gregorio Marañón, Madrid, Spain.1810 David L. Paterson, MD, PhD - ProfessorUniv. of Queensland Ctr. for Clinicial Res., Brisbane, Australia.1811 Guy Thwaites, MD - Consultant in Infectious Diseases and MicrobiologyImperial Coll. London, United Kingdom.1812 Helen W. Boucher, MD FACP - Associate ProfessorTufts Med. Ctr., Boston, MA.1813 Wendy Armstrong, MD - Associate ProfessorInfectious Disease, Emory Univ., Atlanta, GA.1814 Yehuda Carmeli, MD - ProfessorTel-Aviv Med. Ctr., Tel-Aviv, Israel.1815 Ajit P. Limaye, MD - ProfessorUniv. of Washington, Seattle, WA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Identify common and uncommon clinical manifestations of importantinfectious diseases;> Discuss important concepts in clinical microbiology; and> Discuss recent developments and emerging clinical problems in ID andclinical microbiology.Intended Audience: Clinicians, scientists, researchers, microbiologists,pharmacists, and public health physicians.Level: All levels------------------------------------------------------------------------210(L1)SymposiumPotluck: The Latest on Foodborne InfectionsTuesday, 2:00 p.m.–4:00 p.m. ................... Room 132UAN: 0391-9999-12-150-L04-PConveners:Hoonmo L. Koo, MD, MPH - Assistant ProfessorBaylor Coll. of Med., Houston, TX.Jakob P. Cramer, MD, MSC - Head Research Unit PhysicianUniv. Med. Ctr., Hamburg, Germany.Speakers:2:00 p.m.1816 Listeriosis: From Milk to MelonsBenjamin Silk, PhD - Staff EpidemiologistCDC, Atlanta, GA.2:20 p.m.1817 Noroviruses: More Than a Cruise Ship VirusHoonmo L. Koo, MD, MPH - Assistant ProfessorBaylor Coll. of Med., Houston, TX.2:40 p.m.1818 Salmonellosis: Recent Multistate Outbreak InvestigationsCasey Barton Behravesh, MS, DVM, DrPH, DACVPM - Deputy BranchChief, Outbreak Response and Prevention BranchCDC, Atlanta, GA.3:00 p.m.1819 Parasitic Infections in the Water SupplyJulia W. Gargano, PhD - EpidemiologistCDC, NCEZID, Atlanta, GA.3:20 p.m.1820 E. coli: Pathogenesis and Treatment of EHEC/HUSJakob P. Cramer, MD, MSC - Head Research Unit PhysicianUniv. Med. Ctr., Hamburg, Germany.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Define possible foodborne infections in patients presenting with gastroenteritis;> Differentiate among the common etiologies of food-related infectiousdiseases; and> Summarize new information about the diagnosis and management offoodborne infectious diseases.Intended Audience: Healthcare providers and investigators with an interestin foodborne infections.Level: IntermediateFinal Program177

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------211(P)SymposiumGlobal Health as an Academic DisciplineTuesday, 2:00 p.m.–4:00 p.m. ...... Esplanade Ballroom 310UAN: 0391-9999-12-151-L04-PDeveloped in Cooperation with the American Society of Tropical Medicine andHygiene (ASTMH)Conveners:Kevin Kain, MD - Professor of MedicineUniv. of Toronto, Toronto, Canada.Alan J. Magill, MD - Program ManagerDefense Advanced Res. Programs Agency (DARPA), Arlington, VA.Speakers:2:00 p.m.1821 Academic Institutions and Career Development in GlobalHealthJudith N. Wasserheit, MD, MDH - ProfessorUniv. of Washington, Seattle, WA.2:20 p.m.1822 CDC and Public Health Careers in Global HealthMartin Cetron, MD - Director, DGMQCDC, Atlanta, GA.2:40 p.m.1823 Uniformed Services Career Paths in Global HealthPhil Coyne, Jr., MD, MSPH - Assistant Professor, Tropical Public HealthUniformed Services Univ. of Hlth. Sci., Bethesda, MD.3:00 p.m.1824 Foundations and Opportunities in Global HealthRegina Rabinovich, MD, MPH - Director, Department of Infectious Diseasesand Tropical MedicineBill and Melinda Gates Fndn., Seattle, WA.3:20 p.m.1825 European Perspective on Global Health Training and CareerPathsJohanna P. Daily, MD, MS - Associate Professor of Medicine and Microbiologyand ImmunologyAlbert Einstein Coll. of Med., Bronx, NY.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Assess the opportunities for pursuing an academic career in global health;> Discuss how to access resources and opportunities for further training inglobal health; and> Access websites and literature relevant to academic training and professionalcareer development in global health.Intended Audience: Graduate students, MSc and PhD public health, IDresidents and trainees, and ID fellows and MDs.Level: Beginning------------------------------------------------------------------------212(V, G)SymposiumViruses and the Central Nervous System: Diagnostic,Treatment and Recent OutbreaksTuesday, 2:00 p.m.–4:00 p.m. ................... Room 130UAN: 0391-9999-12-152-L04-PConveners:Laurent Kaiser, MD - Professor, Head of the Laboratory of Clinical VirologyUniv. Hosp. of Geneva, Geneva, Switzerland.Morven S. Edwards, MD - ProfessorBaylor Coll. of Med., Houston, TX.Speakers:2:00 p.m.1826 VZV CNS ComplicationsAnne Gershon, MD - ProfessorColumbia Univ. Med. Ctr., New York, NY.2:30 p.m.1827 HHV6 Encephalitis in Immunocompetent and in ImmunocompromisedHostsDanielle M. Zerr, MD, MPH - ProfessorUniv. of Washington and Seattle Children’s Hosp., Seattle, WA.3:00 p.m.1828 HSV Central Nervous System Infection in Neonates and Children:Diagnostic and Treatment MonitoringDavid W. Kimberlin, MD - Professor of PediatricsUniv. of Alabama, Birmingham, AL.3:30 p.m.1829 Enterovirus 71 and Brainstem Encephalitis in AsiaMong How Ooi, MRCP, PhD - Consultant PaediatricianSarawak Gen. Hosp., Sarawak, Malaysia.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe clinical features of medically important herpes viruses and associatedmeningo-encephalitis;> Describe the potential advantages and limitation of available diagnosticprocedures;> Discuss the role of the different treatment options; and> Describe the role of emerging enteroviruses.Intended Audience: ID physicians and specialists, clinical microbiologists,epidemiologist.Level: Intermediate/Advanced178September 9-12 |

TUESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------213Cubist-ICAAC Award LectureCubist-ICAAC Award LectureTuesday, 4:30 p.m.–5:30 p.m. ................... Room 103Conveners:M. Lindsay Grayson, MD - ProfessorUniv. of Melbourne, Austin Hlth., Melbourne, Australia.Craig E. Rubens, MD, PhD - Professor of Pediatrics & Global HealthUniv. of Washington and Seattle Children’s, Seattle, WA.Award Lecturer:1830 Antiviral Chemotherapy: Astonishing Progress and FormidablePushback - The Ying and Yang of Host-Viral InteractionsLawrence Corey, MD - Professor, President, DirectorFred Hutchinson Cancer Res. Ctr., Seattle, WA.------------------------------------------------------------------------214(C1, C2)Meet-the-ExpertsTop 10 ß-Lactamase Papers in 2012Tuesday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 305UAN: 0391-9999-12-153-L04-PConveners:Robert A. Bonomo, MD - ProfessorLouis Stokes Cleveland Dep. of VA Med. Ctr., Cleveland, OH.Karen Bush, PhD - Adjunct ProfessorIndiana Univ., Bloomington, IN.Experts:1831 Robert A. Bonomo, MD - ProfessorLouis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH.1832 Karen Bush, PhD - Adjunct ProfessorIndiana Univ., Bloomington, IN.1832a Timothy G. Palzkill; PhD - ProfessorBaylor College of Medicine, Houston, TX.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discuss the changing epidemiology of beta-lactamase mediated resistance;> Recite the novel beta-lactamases that are described; and> Identify the new mechanistic developments in the fields of beta-lactamaseenzymology and inhibitors.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, epidemiologists.Level: Intermediate------------------------------------------------------------------------215(C2)Meet-the-ExpertsSurveillance of Antimicrobial Resistance: PotentialSources of BiasTuesday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 309UAN: 0391-9999-12-154-L04-PExperts:1833 Mitchell J. Schwaber, MD, MSc - DirectorNatl. Ctr. for Infection Control, Israel Ministry of Health, Tel Aviv, Israel.1834 Kevin B. Laupland, MD - Associate ProfessorUniv. of Calgary, Calgary, Canada.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe which methods can be use to overcome bias in surveillance forantimicrobial resistance;> Identify the prevalence and rate data for the epidemiological interpretationof antimicrobial resistance studies; and> Identify potential bias in surveillance for antimicrobial resistance.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, and epidemiologists.Level: Intermediate------------------------------------------------------------------------216(F)Meet-the-ExpertsMeeting the Challenge of Efflux from Gram-NegativeBacteriaTuesday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 302UAN: 0391-9999-12-155-L04-PConvener:Malcolm G. P. Page, PhD - ProfessorBasilea Pharmaceutica, Basel, Switzerland.Experts:1835 Hiroshi Nikaido, MD - Professor EmeritusUniv. of California Berkeley, Berkeley, CA.1836 Klaas M. Pos, PhD - ProfessorGoethe Univ. Frankfurt, Frankfurt, Germany.1837 Olga Lomovskaya, PhD - Vice President, BiologyRempex Pharmaceuticals, Inc., San Diego, CA.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe the role of efflux in the resistance of microbial pathogens,especially Gram-negative bacteria;> Describe the mechanism of RND-type efflux pumps; and> Identify and distinguish new approaches to the discovery of agents actingagainst efflux systems in bacteria.Intended Audience: Microbiologists working in academia and in thepharmaceutical industry.Level: AdvancedFinal Program179

Tuesday SCIENTIFIC SESSIONS------------------------------------------------------------------------217(K)Meet-the-ExpertsChallenging Issues in Pediatric Infection Preventionand ControlTuesday, 5:45 p.m.–7:00 p.m. ................... Room 122UAN: 0391-9999-12-156-L04-PExperts:1838 Walter Zingg, MD - Senior PhysicianUniv. of Geneva Hosp., Geneva, Switzerland.1839 Lisa Saiman, MD, MPH - Professor of Clinical PediatricsColumbia Univ. Med. Ctr., New York, NY.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discuss the epidemiology of healthcare-associated infections in neonataland pediatric patients;> Describe effective strategies for the prevention and control of infection inpediatric care settings; and> Describe the best evidence-based strategies to apply in the pediatric setting.Intended Audience: ID specialists, infection control professionals, hospitalepidemiologists, public health professionals, hospital administrators, pediatricinfectious diseases and infection control experts.Level: Beginning/Intermediate------------------------------------------------------------------------218(K)Meet-the-ExpertsIssues in the Diagnosis and Management of ProstheticJoint InfectionsTuesday, 5:45 p.m.–7:00 p.m. ...... Esplanade Ballroom 310UAN: 0391-9999-12-157-L04-PExperts:1840 Andrej Trampuz, MD - Assistant ProfessorInfectious Diesases, Univ. Hosp. Lausanne, Lausanne, Switzerland.1841 Adolf W. Karchmer, MD - Professor of Medicine, Harvard Medical SchoolBeth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discuss the latest understanding of the pathogenesis of prosthetic jointinfection;> Identify the advantages and disadvantages of various diagnostic strategies;and> Assess optimal operative and non-operative management strategies forprosthetic joint infections.Intended Audience: Practicing clinicians who are often called upon to managepatients with prosthetic joint infections.Level: Intermediate/Advanced------------------------------------------------------------------------219(M, D)Meet-the-ExpertsHow Can the Mycology Lab Work for You?Tuesday, 5:45 p.m.–7:00 p.m. ................... Room 121UAN: 0391-9999-12-158-L04-PExperts:1842 Maiken C. Arendrup, MD, PhD - Head of Unit of MycologyStatens Serum Inst., Copenhagen, Denmark.1843 Sean Zhang, PhD - Director, Mycology Laboratory/Assistant ProfessorJohns Hopkins Hosp., Johns Hopkins Sch. of Med., Baltimore, MD.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Determine when antifungal susceptibility testing is useful in clinicalpractice and the likely impact of introducing new antifungal susceptibilitybreakpoints in the diagnostic laboratory;> Recognize the advantages and pitfalls of in-house nucleic acid testing forfungal identification; and> Evaluate the cost-effectiveness and clinical use of multiplexed bacterialand fungal assays.Intended Audience: Mycology researchers, ID physicians and trainees.Level: Intermediate----------------------------------------------------------------------------------220(C2)Meet-the-ExpertsAnaerobes and Surveillance: Neglected or Not?Wednesday, 7:00 a.m.–8:15 a.m. . . . Esplanade Ballroom 302UAN: 0391-9999-12-159-L04-PExperts:1844 Ellie J. C. Goldstein, MD - Clinical Professor of MedicineUCLA David Geffen Sch. of Med., Santa Monica, CA.1845 David W. Hecht, MD, MS - Professor and Chair, Department of MedicineLoyola Univ. Med. Ctr., Chicago, IL.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe which mechanisms, species and antibiotics are the most appropriateto include for anaerobe surveillance studies;> Discuss when and the most appropriate method(s) that should be used toperform antimicrobial susceptibility testing on anaerobes; and> Describe the most appropriate method(s) that should be used for antimicrobialsusceptibility testing on anaerobes.Intended Audience: Clinical microbiologists, infectious disease physicians,infection control practitioners, and epidemiologists.Level: Intermediate180September 9-12 |

NOTESFinal Program181

NOTES182September 9-12 |

Wednesday Schedule at-a-Glance> 7:00 a.m. - 8:15 a.m.Meet-the-Experts220 (C2) Anaerobes and Surveillance:Neglected or Not?Esplanade Ballroom 302221 (D) Optimal Diagnostic Testing forClostridium difficile in Clinical PracticeEsplanade Ballroom 310222 (H) Can We Safely Simplify AntiretroviralTherapy in Treatment-Experienced Patients?Esplanade Ballroom 300223 (K) Environmental Cleaning andInfection PreventionRoom 120224 (M) Fungal Infections of the CentralNervous SystemRoom 121> 8:00 a.m. - 9:00 a.m.Plenary Session225 The Use of Social Media and NewTechnologies in HealthcareRoom 130> 9:15 a.m. - 11:15 a.m.Interactive Symposium226 (D) Challenges in the Diagnosis andClinical Interpretation of Infections withGram-Positive RodsRoom 104Symposia227 (A) Use of Pharmacokinetics/Pharmacodynamics for Risk Reduction ofAdverse EventsRoom 103228 (C1) Resistance in S. aureus Beyond MecAEsplanade Ballroom 302229 (F) New Approaches in the Treatment ofFungal InfectionsEsplanade Ballroom 309230 (G, B) Interplay between Pathogen andHost: From Immune Deficiency to InfectiousDiseaseRoom 122231 (K) A Multifaceted Approach toPreventing Surgical Site InfectionsRoom 121234 (P) Best Practices for Serologic Testing inSelected Parasitic DiseasesRoom 254235 (V) Recognizing and Managing AntiviralResistanceRoom 120Poster Sessions240 (A) Antifungals: Improving PK/PD andSafetyHalls A-C241 (A) Toxicokinetics and PK/PD of New andOld FluoroquinolonesHalls A-C242 (C1) Mechanisms of Resistance to NovelCompoundsHalls A-C243 (C2) Antimicrobial Resistance ofMiscellaneous BacteriaHalls A-C244 (C2) Streptococcus and EnterococusHalls A-C245 (E) In Vitro Activity for MycobacteriaHalls A-C246 (F) New Ways with Old Friends:Repurposing and Novel FormulationsHalls A-C247 (F) Novel Inhibitors of Bacterial GyrB/ParE Topoisomerase SubunitsHalls A-C248 (F) Quinolones and BeyondHalls A-C249 (F) Targeting Gram-Negative PathogensHalls A-C250 (K) Bone InfectionsHalls A-C251 (K) Hand HygieneHalls A-C252 (K) Vascular Catheter and Device RelatedInfectionsHalls A-C253 (K) Ventilator-Associated PneumoniaHalls A-C254 (L1) Bone and Joint InfectionsHalls A-C255 (L2) Urinary Tract InfectionHalls A-C> 9:15 a.m. - 11:45 a.m.Slide Sessions236 (C2) Acinetobacter: Challenges andContinued EmergenceRoom 132237 (C2) MRSA: Pervasive, Persistent, andPathogenicEsplanade Ballroom 305238 (H) Common Pathogens: Still a Problemin HIV-IRoom 102239 (K) Antimicrobial Stewardship: Perils ofPrescribingEsplanade Ballroom 310Wednesday232 (L1, G) What’s New with Pneumococcus?Esplanade Ballroom 308233 (M) Controversies in Clinical MycologyEsplanade Ballroom 300

Notes

WEDNESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------221(D)Meet-the-ExpertsOptimal Diagnostic Testing for Clostridium difficile inClinical PracticeWednesday, 7:00 a.m.–8:15 a.m. . . . Esplanade Ballroom 310UAN: 0391-9999-12-160-L04-PExperts:1846 Mark H. Wilcox, MD - ProfessorLeeds Teaching Hosp. NHS Trust, Leeds, United Kingdom.1847 Vivian G. Loo, MD, MSc - Associate ProfessorMcGill Univ. Hlth. Ctr., Montreal, Canada.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Describe the strengths and weaknesses of current methods for C. difficiletesting; Evaluate data presented on comparative methods for C. difficiledetection; and> Discuss the impact of molecular testing on C. difficile prevalence andinfection control practice.Intended Audience: Microbiologists, infection control practitioners, infectiousdiseases physicians.Level: Intermediate------------------------------------------------------------------------222(H)Meet-the-ExpertsCan We Safely Simplify Antiretroviral Therapy inTreatment-Experienced Patients?Wednesday, 7:00 a.m.–8:15 a.m. . . . Esplanade Ballroom 300UAN: 0391-9999-12-161-L04-PExperts:1848 Pedro Cahn, MD, PhD - Senior ScientistFundación Huesped, Buenos Aires, Argentina.1849 Sharon L. Walmsley, MD, MSc, FRCPC - Professor of MedicineUniv. Hlth. Network, Toronto, Canada.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discuss several potential scenarios in which patients suppressed oneffective but complicated antiretroviral therapy can have their regimensimplified without compromising the success of the treatment regimen;> Summarize information on new agents and new assays that may increaseour ability to simplify antiretroviral therapy even in patients who haveextensive previous treatment experience;> Assess the potential risks and benefits of therapy simplification for specificpatient types; and> Evaluate the role of new fixed dose combination tablets in simplificationof successful but cumbersome or complex regimens in treatment experiencedpatients.Intended Audience: HIV clinicians including MD, pharmacists, pharmacologists,physician extenders and other clinician, HIV clinical and translationalscientists including those involved in all phases of antiretroviral research,virologists, and drug developers.Level: All Levels------------------------------------------------------------------------223(K)Meet-the-ExpertsEnvironmental Cleaning and Infection PreventionWednesday, 7:00 a.m.–8:15 a.m. ................ Room 120UAN: 0391-9999-12-162-L04-PExperts:1850 John M. Boyce, MD - Hospital EpidemiologistHosp. of Saint Raphael, New Haven, CT.1851 Markus Dettenkofer, MD - ProfessorUniv. Freiburg, Freiburg, Germany.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Discuss the evidence linking environmental contamination and HAIs;> Identify methods that assess environmental cleaning; and> Identify one intervention they can use in their own practice.Intended Audience: Physicians involved in infection prevention and control,microbiologists working in infection prevention and control or supportinginfection prevention and control efforts and interested in the association ofenvironmental contamination and HAIs.Level: All Levels------------------------------------------------------------------------224(M)Meet-the-ExpertsFungal Infections of the Central Nervous SystemWednesday, 7:00 a.m.–8:15 a.m. ................ Room 121UAN: 0391-9999-12-163-L04-PExperts:1852 David A. Stevens, MD - ProfessorStanford Univ. and Sta. Clara Valley Med. Ctr., San Jose and Stanford, CA.1853 Thomas Walsh, MD - Director Transplantation in Oncology InfectiousDiseases ProgramWeill Cornell Med. Coll., Cornell Univ., New York, NY.Objectives: Upon completion of this Meet-the-Experts Session, the participantshould be able to:> Generate an appropriate differential diagnosis, diagnostic workup andmanagement plan for CNS fungal infections;> Recognize the importance of travel history and underlying co-morbiditiesin predicting the likelihood of a fungal cause of CNS infections; and> Apply principles of PK/PD and an evidence-based approach tomanagement.Intended Audience: Mycology researchers, ID physicians, and trainees.Level: IntermediateFinal Program183

Wednesday SCIENTIFIC SESSIONS------------------------------------------------------------------------225Plenary SessionThe Use of Social Media and New Technologies inHealthcareWednesday, 8:00 a.m.–9:00 a.m. .................Room 130UAN: 0391-9999-12-164-L04-PConveners:Vincent Racaniello, PhD - ProfessorColumbia Univ., New York, NY.David Aronoff, MD - Associate ProfessorUniv. of Michigan, Ann Arbor, MI.Speakers:8:00 a.m.1854 Novel Approaches to Spatial Modelling of Infectious DiseaseTransmissionNeil M. Ferguson, DPhil, MA - Head of Department and ProfessorImperial Coll. London, London, United Kingdom.8:30 a.m.1855 The Emerging Role of Social Media in Public HealthJohn Brownstein, PhD - Associate ProfessorChildren’s Hosp. Boston & Harvard Med. Sch., Boston, MA.Objectives: Upon completion of this Plenary Session, the participant shouldhave a greater understanding regarding emerging new technologies and theiruse in:> Mapping and modeling infectious diseases, especially outbreaks;> Planning and designing effective public health interventions;> Monitoring infectious diseases outbreaks; and> Improving health care communications.Intended Audience: Clinicians, scientists, researchers, microbiologists,virologists, pharmacists and public health physicians.Level: All Levels------------------------------------------------------------------------226(D)Interactive SymposiumChallenges in the Diagnosis and Clinical Interpretationof Infections with Gram-Positive RodsWednesday, 9:15 a.m.–11:15 a.m. ................Room 104UAN: 0391-9999-12-165-L04-PConveners:Guido Funke, MD - ProfessorGartner and Colleagues Lab., Ravensburg, Germany.Patricia S. Conville, MS - Scientific ReviewerFDA, Silver Spring, MD.Speakers:9:15 a.m.1856 CorynebacteriaGuido Funke, MD - ProfessorGaertner and Colleagues Lab., Ravensburg, Germany.9:45 a.m.1857 Non-Tuberculous MycobacteriaChristine Y. Turenne, PhD - Director of BacteriologySaskatchewan Disease Control Lab., Regina, Canada.10:15 a.m.1858 Branching Out: Insight into Current Nocardia ChallengesPatricia S. Conville, MS - Scientific ReviewerFDA, Silver Spring, MD.10:45 a.m.1859 Diagnosis, Identification and Susceptibility Testing of Gordonia& TsukamurellaBarbara A. Brown-Elliott, MS, MT (ASCP) - Research Assistant Professor/Supervisor Mycobacteria/Nocardia LaboratoryUniv. of Texas Hlth. Sci. Ctr. at Tyler, Tyler, TX.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the broad range of infections caused by the aerobic Actinomycetes;> Discuss the importance of accurate diagnosis of the various genera withinthis group;> Develop an approach to the diagnosis of the important pathogens; and> Identify the new technologies for identification of the aerobic grampositiverods.Intended Audience: Clinical microbiologists, infection control practitioners,and infectious diseases physicians.Level: Intermediate184September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------227(A)SymposiumUse of Pharmacokinetics/Pharmacodynamics for RiskReduction of Adverse EventsWednesday, 9:15 a.m.–11:15 a.m. ................Room 103UAN: 0391-9999-12-166-L04-PDeveloped in Cooperation with the International Society of Anti-Infective Pharmacology(ISAP)Conveners:Sujata M. Bhavnani, PharmD, MS - Vice-President, Translational MedicineInst. for Clin. Pharmacodynamics, Latham, NY.Paul M. Tulkens, MD - ProfessorUniv. of Catholique de Louvain, Brussels, Belgium.Speakers:9:15 a.m.1860 Hepatic Safety of AntibioticsPaul M. Tulkens, MD - ProfessorUniv. Catholique de Louvain, Brussels, Belgium.9:45 a.m.1861 Pharmacodynamic Modeling the Risk of Myelosuppressionwith LinezolidAlan Forrest, PharmD - Research Professor; Senior Director,PharmacometricsSUNYBuffalo Sch. of Pharmacy, SUNY-Buffalo; Inst. of Clin.Pharmacodynamics, Buffalo and Albany, NY.10:15 a.m.1862 Daptomycin Exposure and the Probability of Creatine PhosphokinaseElevationsSujata M. Bhavnani, PharmD, MS - Vice President, Translational MedicineInst. for Clinical Pharmacodynamics, Latham, NY.10:45 a.m.1863 Case-Control Studies on the Safety of Timethoprim-SulfamethoxazoleTony Antoniou, PharmD - Clinical Pharmacy Specialist, Assistant ProfessorUniv. of Toronto, St. Michael’s Hosp., Toronto, Canada.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe in hepatic safety issues associated with commonly usedantibiotics;> Appraise the use pharmacodynamic modeling to assess adverse eventsassociated with antibiotics;> Assess the relationships between antibiotic exposure and the probability ofadverse events; and> Recognize trimethoprim-sulfamethoxazole induced adverse events in variouspatient populations.Intended Audience: Physicians, pharmacists, and microbiologists.Level: Intermediate------------------------------------------------------------------------228(C1)SymposiumResistance in S. aureus Beyond MecAWednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 302UAN: 0391-9999-12-167-L04-PConveners:Patricia Bradford, PhD - Vice President, Discovery BiologyAstraZeneca Pharmaceuticals, Waltham, MA.Jared A. Silverman, PhD - Sr. Vice President of BiologyCubist Pharmaceuticals, Lexington, MA.Speakers:9:15 a.m.1864 Cfr-Mediated Resistance to Linezolid and Other AntibioticsKaren J. Shaw, PhD - Sr. V. P. BiologyTrius Therapeutics, San Diego, CA.9:45 a.m.1865 Vga-Mediated Antimicrobial ResistanceStefan Schwarz, DVM - ProfessorInst. of Farm Animal Genetics (FLI), Neustadt-Mariensee, Germany.10:15 a.m.1866 Co-Evolution of Daptomycin Resistance with Resistance toHost Defense PeptidesArnold Bayer, MD - Professor of MedicineUCLA Sch. of Med., LA Biomedical Res. Inst., Torrance, CA.10:45 a.m.1867 Staphylococcal Resistance to Anti-MRSA CephalosporinsHenry F. Chambers, MD - ProfessorUCSF, San Francisco, CA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Recognize novel mechanisms of resistance affecting new anti-staphylococcalantibiotics;> Describe the mechanisms by which these genes cause resistance; and> Identify the spread of these resistance mechanisms.Intended Audience: Physicians and microbiologists.Level: IntermediateFinal Program185

Wednesday SCIENTIFIC SESSIONS------------------------------------------------------------------------229(F)SymposiumNew Approaches in the Treatment of Fungal InfectionsWednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 309UAN: 0391-9999-12-168-L04-PConveners:Michael J. Pucci, PhD - Executive DirectorAchillion Pharmaceuticals, New Haven, CT.Eleftherios Mylonakis, MD, PhD - Associate Professor of MedicineHarvard Med. Sch. and Mass. Gen. Hosp., Boston, MA.Speakers:9:15 a.m.1868 Antifungal Drug Discovery Through the Study of InvertebrateModel HostsEleftherios Mylonakis, MD, PhD - Associate ProfessorHarvard Med. Sch., Mass. Gen. Hosp., Boston, MA.9:45 a.m.1869 Screening for New Antifungal AgentsDerek Law, PhD - Head of MicrobiologyF2G Ltd., Manchester, United Kingdom.10:15 a.m.1870 Role for Inhibition of Hsp90 Function in the Treatment ofFungal InfectionsStephanie Diezmann, PhD - Post-doctoral FellowUniv. of Toronto, Toronto, Canada.10:45 a.m.1871 A Novel Class of Orally Active Antifungal Beta-1,3-D-GlucanSynthase InhibitorsTodd A. Black, PhD – Director, Site LeadMerck Res. Labs., Kenilworth, NJ.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the role of iron homeostasis in the growth of microbialpathogens, including bacteria, fungi and protozoa;> Identify and distinguish new approaches to the discovery of agentsexploiting iron-uptake systems in bacteria; and> Recognize the potential pitfalls in application of iron chelators inanti-microbial chemotherapy.Intended Audience: Microbiologists working in academia and in thepharmaceutical industry.Level: Intermediate------------------------------------------------------------------------230(G, B)SymposiumInterplay Between Pathogen and Host: From ImmuneDeficiency to Infectious DiseaseWednesday, 9:15 a.m.–11:15 a.m. ................Room 122UAN: 0391-9999-12-169-L04-PConveners:Carlo Giaquinto, MD - Medical Doctor PediatricianAzienda Ospedaliera Univ., Padova, Italy.Nigel J. Klein, MD, PhD - Professor of Infection and ImmunityInst. of Child Health, Univ. Coll. London, London, United Kingdom.Speakers:9:15 a.m.1872 Immune Activation in HIV InfectionAndrew Prendergast, MA, DPhil, MRCPCH - Senior Lecturer in PediatricInfection and ImmunityQueen Mary, Univ. of London, London, United Kingdom.9:45 a.m.1873 Immune Reconstitution Following Treatment of ImmunodeficienciesNigel J. Klein, MD, PhD - Professor of Infection and ImmunityInst. of Child Health, London, United Kingdom.10:15 a.m.1874 New Insights into Meningitis PathogenesisKwang Sik Kim, MD - Professor and DirectorJohns Hopkins Sch. of Med., Baltimore, MD.10:45 a.m.1875 Fungal Infection in the Immunodeficient HostEmmanuel Roilides, MD - ProfessorAristotle Univ. Sch. of Med., Thessaloniki, Greece.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss how immune activation adds to the challenges of treatmentand prevention of HIV infection;> Discuss new insights into immune reconstitution following treatmentof immunodeficiencies;> Apply new insights into meningitis pathogenesis to evaluation andmanagement of patients with meningitis; and> Identify advances in fungal infection pathogenesis in the immunodeficienthost.Intended Audience: Physician scientists, infectious disease clinicians,clinical microbiologists, clinical virologists, pharmacologists and those withan interest in the pathogenesis and treatment of infectious diseases.Level: Intermediate186September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------231(K)SymposiumA Multifaceted Approach to Preventing Surgical SiteInfectionsWednesday, 9:15 a.m.–11:15 a.m. ................Room 121UAN: 0391-9999-12-170-L04-PDeveloped in Cooperation with the Surgical Infection Society (SIS)Conveners:Jan Kluytmans, MD, PhD - ProfessorAmphia Hosp., Breda, Netherlands.E. Patchen Dellinger, MD - ProfessorUniv. of Washington, Seattle, WA.Speakers:9:15 a.m.1876 Implementing a Bundle Strategy to Prevent Surgical Site InfectionsJan Kluytmans, MD, PhD - ProfessorAmphia Hosp., Breda, Netherlands.9:45 a.m.1877 Meta-Analysis of Studies Evaluating Preoperative Screeningfor S. aureus, Decolonization of Carriers, and PerioperativeAntimicrobial ProphylaxisMarin Schweizer, PhD - Assistant ProfessorCarver Coll. of Med., Iowa City, IA.10:15 a.m.1878 Should Perioperative Prophylaxis for Non-AbdominalProcedures Include Coverage for Gram-Negative Organismsand Data from the Swiss National Surveillance System?Andreas Widmer, MD, MS - Deputy Head of Div. Infectious Diseases &Hospital EpidemiologyUniv. Hosp., Basel, Switzerland.10:45 a.m.1879 The New ASHP/SHEA/IDSA/SIS Guidelines for SurgicalProphylaxisE. Patchen Dellinger, MD - Professor of SurgeryUniv. of Washington, Seattle, WA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss pros and cons of including specific interventions in a bundle toprevent SSIs;> Discuss the evidence supporting screening patients undergoing cardiac ororthopedic procedures for Staphylococcus aureus;> Discuss the evidence addressing whether perioperative prophylaxis fornon-abdominal procedures should include coverage for gram-negativeorganisms; and> Discuss important changes in the ASHP/SHEA/IDSA/SIS guidelinesfor perioperative antimicrobial prophylaxis.Intended Audience: Clinical microbiologists, especially those whose laboratoriesmay be asked to process preoperative screening tests for S. aureus;infectious disease physicians; physicians and microbiologists involved ininfection prevention.Level: All Levels------------------------------------------------------------------------232(L1, G)SymposiumWhat’s New with Pneumococcus?Wednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 308UAN: 0391-9999-12-171-L04-PConveners:Keith P. Klugman, MD, PhD - William F. Foege Professor of Global HealthRollins Sch. of Publ. Hlth., Emory Univ., Atlanta, GA.Patrick G. P. Charles, MBBS, PhD - Infectious Diseases PhysicianAustin Hlth., Heidelberg VIC, Australia.Speakers:9:15 a.m.1880 What is the Clinical Impact of Penicillin Non-Susceptibility onTreatment Outcomes for Meningitis and Invasive PneumococcalDisease?Keith P. Klugman, MD, PhD - William H. Foege Professor of Global HealthRollins Sch. of Publ. Health, Emory Univ., Atlanta, GA.9:35 a.m.1881 Extensive Genomic Diversity and Plasticity amongStreptococcus pneumonia StrainsN. Luisa Hiller, PhD; Ctr. for Genomic Sciences, Allegheny Gen. Hosp.,Pittsburgh, PA.9:55 a.m.1882 Does Penicillin Non-Susceptibility Really Matter When itComes to Treating Pneumonia?Patrick G. P. Charles, MBBS, PhD - Infectious Diseases PhysicianAustin Hlth., Heidelberg VIC, Australia.10:15 a.m.1883 The Clinical Impact of Emerging Macrolide and QuinoloneResistance in North AmericaThomas J. Marrie, MD - ProfessorDalhousie Univ., Halifax, Canada.10:45 a.m.1884 How Has the New Polyvalent Pneumococcal Vaccine AlteredPatterns of Clinical Disease?Peter R. Paradiso, PhD - Vaccine ConsultantParadiso Biologics Consulting, Radnor, PA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Describe the impact of antimicrobial resistance to the management of S.pneumoniae infections;> Improve their clinical care of patients at risk for and infected with pneumococcus;> Critically analyze recent data regarding the global spread of antimicrobialresistance in pneumococcus; and> Define the impact of vaccination on global patterns of clinical disease.Intended Audience: Clinicians and investigators interested in pneumococcalinfections.Level: IntermediateFinal Program187

Wednesday SCIENTIFIC SESSIONS------------------------------------------------------------------------233(M)SymposiumControversies in Clinical MycologyWednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 300UAN: 0391-9999-12-172-L04-PDeveloped in Cooperation with the Mycology Study Groug (MSG) and EuropeanOrganisation for Research and Treatment of Cancer (EORTC-IDG)Conveners:John Perfect, MD - Interim Chief, Division of Infectious Diseases and InternationalHealthDuke Univ. Med. Ctr., Durham, NC.J.P. Donnelly, MD – Coordinator Studies Supportive CareRadboud Univ. Nijmegen Med. Ctr., Nijmegan Inst. for Infection, Nijmegen,Netherlands.Speakers:9:15 a.m.1885 Fungal Biomarkers and How to Use ThemElias Anaissie, MD - Infectious Disease PhysicianUniv. of Cincinnati, Cincinnati, OH..9:45 a.m.1886 Do We Really Know How to Dose AntifungalsWilliam Hope, MD, PhD - Professor of Therapeutics and Infectious DiseasesThe Univ. of Liverpool, Liverpool, United Kingdom.10:15 a.m.1887 Fungal Infections and Diagnostic Guidelines: What is Rightand What is StrongJ.P. Donnelly, PhD - Coordinator Studies Supportive CareRadboud Univ. Nijmegen Med. Ctr., Nijmegan Inst. for Infection, Nijmegen,Netherlands.10:45 a.m.1888 How Does the Clinical Mycologist Fit Into AntimicrobialStewardshipGraeme Forrest, MD - Assistant Professor of Medicine, Division of InfectiousDiseases VAMCPortland VA Med. Ctr., Portland, OR.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the use of biomarkers;> Identify the importance of dosing antifungals;> Assess guidelines and their limitations; and> Describe issues around antifungal stewardship.Intended Audience: Clinicians, clinical microbiologists, trainees, andpharmacists.Level: Advanced------------------------------------------------------------------------234(P)SymposiumBest Practices for Serologic Testing in Selected ParasiticDiseasesWednesday, 9:15 a.m.–11:15 a.m. ................Room 254UAN: 0391-9999-12-173-L04-PConveners:Alan J. Magill, MD - Associate ProfessorUniformed Services Univ. of the Hlth. Sci., Bethesda, MD.Patricia P. Wilkins, PhD - Chief, Reference Diagnostics LaboratoryCDC, Atlanta, GA.Speakers:9:15 a.m.1889 The Serologic Diagnosis of NeurocysticercosisHector H. Garcia, MD, PhD - ProfessorUniv. Peruana Cayetano Heredia and Inst. de Ciencias Neurologicas, Lima,Peru.9:45 a.m.1890 The Serologic Assessment of Filarial InfectionsThomas B. Nutman, MD - Head, Helminth Immunology SectionNIAID, NIH, Bethesda, MD.10:15 a.m.1891 The Serologic Diagnosis of StrongyloidiasisJay S. Keystone, MD, MSc (CTM), FRCPC - ProfessorToronto Gen. Hosp., Toronto, Canada.10:45 a.m.1892 The CDC Reference Laboratory and Serologic DiagnosisPatricia P. Wilkins, PhD - Chief, Reference Diagnostics LaboratoryCDC, Atlanta, GA.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Update the clinical community on the appropriate use of currently availableserologic testing for the diagnosis of three major infectious diseasesusing a case-based interactive format;> Discuss the advantages and limitations of serologic testing in the diagnosisand management of neurocysticercosis, schistosomiasis, and strongyloidiasis;and> Describe the reference capabilities for the CDC DPDM to support clinicians.Intended Audience: Clinical microbiologists, parasitologists, pathologists,researchers, public health and epidemiologists, quality improvement professionalsand infectious disease physicians.Level: Intermediate188September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------235(V)SymposiumRecognizing and Managing Antiviral ResistanceWednesday, 9:15 a.m.–11:15 a.m. ................Room 120UAN: 0391-9999-12-174-L04-PConveners:Guy Boivin, MD - Professor of MicrobiologyLaval Univ., Quebec, Canada.Joseph Eron, Jr., MD - Professor of MedicineUniv. of North Carolina, Chapel Hill, NC.Speakers:9:15 a.m.1893 Management of HIV Resistance: New PerspectivesIan Frank, MD - Professor of MedicineUniv. of Pennsylvania, Philadelphia, PA.9:45 a.m.1894 CMV: When to Think About Resistance and When to SwitchTherapy?Sunwen Chou, MD - Professor of MedicineOregon Hlth. and Sci. Univ., Portland, OR.10:15 a.m.1895 Influenza: How Resistance Emerges and the Role of CombinationTherapyMaria Zambon, PhD - Director, Reference Microbiology ServicesHlth. Protection Agency, London, United Kingdom.10:45 a.m.1896 How to Avoid Resistance When Treating Hepatitis BLorne Tyrrell, MD/PhD - Professor and Director of the Li Ka Shing Instituteof VirologyUniv. of Alberta, Edmonton, Canada.Objectives: Upon completion of this Symposium Session, the participantshould be able to:> Discuss the increasing problem of antiviral resistance;> Identify risk factors for selecting for drug-resistant viruses;> Discuss the consequences of drug-resistant infections; and> Propose potential alternate therapeutic strategies.Intended Audience: enteral infectious diseases specialists, HIV specialists,virologists, clinical microbiologists, and epidemiologists.Level: Intermediate/Advanced------------------------------------------------------------------------236(C2)Slide SessionAcinetobacter: Challenges and Continued EmergenceWednesday, 9:15 a.m.–11:45 a.m. ................Room 132UAN: 0391-9999-12-175-L04-PModerators:Jordi Vila, MD, PhD - Head of the Department of Clinical MicrobiologyHosp. Clinic, Barcelona, Spain.Robert A. Bonomo, MD - ProfessorLouis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Discuss the world wide dissemination of A. baumannii;> Identify information about predominant clones of A. baumannii;> Discuss the present challenge for antimicrobial treatment of Acinetobacterinfections; and> Discuss genetic elements related to resistance.Presentations:9:15 a.m.C2-1897 Carbapenem-Resistant Acinetobacter baumannii: An ItalianNationwide ProblemF. Luzzaro, Doctor - Doctor 1 , R. Migliavacca, PhD - Research 2 , S. Bracco,PhD student - Doctor 1 , A. Piazza, PhD Student - Doctor 2 , E. Nucleo,PhD - Research 2 , G. Rossolini, Professor - Professor 3 , L. Pagani, Professor ofClinical Microbiology - Professor 2 ; 1 A. Manzoni Hosp., Lecco, Italy, 2 Univ. ofPavia, Pavia, Italy, 3 Univ. of Siena, Siena, Italy.9:30 a.m.C2-1898 Prevalence of Multidrug-Resistant Acinetobacter baumanniiin Southwest Nigeria Tertiary HospitalsW. E. Ike, MS - Doctoral Student 1 , B. A. Adeniyi, PhD - Professor 1 , O. O.Soge, PhD - Research Scientist 2 ; 1 Univ. of Ibadan, Ibadan, Nigeria, 2 Univ. ofWashington, Seattle, WA.9:45 a.m.C2-1899 Spread of Carbapenem-Resistant Acinetobacter baumanniiGlobal Clone II in Asian CountriesD. H. Kim, MS - Graduate Student 1 , J. Y. Choi, MS - Research Assistant 1 ,S. H. Kim, PhD - Project Manager 2 , D. R. Chung, MD - Professor 3,2 , J. H.Song, MD, PhD - Professor 3,2 , K. S. Ko, PhD - Professor 1,2 ; 1 SungkyunkwanUniv. Sch. of Med., Suwon, Korea, Republic of, 2 APFID, Seoul, Korea, Republicof, 3 Sungkyunkwan Univ. Sch. of Med., Seoul, Korea, Republic of.10:00 a.m.C2-1900 Carbapenem Resistant in Acinetobacter baumannii: AnEmerging Problem in IsraelP. Espinal, MS - Research 1 , M. Kasma, MS - Research 2 , Y. Lerman, MD -Research 2 , Y. Carmeli, PhD - Professor 2 , J. Vila, PhD - Professor 1 ; 1 Univ. ofBarcelona, Hosp. Clinic, Barcelona, Spain, 2 Sourasky Med. Ctr., Tel Aviv, Israel.Final Program189

Wednesday SCIENTIFIC SESSIONS10:15 a.m.C2-1901 Molecular Identification and Characterization of AcinetobacterSpecies Causing Bacteremia at a Japanese Tertiary HospitalS. Endo, MD - Assistant Professor, M. Sasano, MS - Research Assistant, H.Yano, MD - Lecture, H. Kanamori, MD - Assistant Professor, S. Inomata, MD- Assistant Professor, N. Ishibashi, MD - Assistant Professor, T. Aoyagi, MD -Assistant Professor, M. Hatta, MD - Assistant Professor, Y. Gu, MD - AssistantProfessor, M. Yamada, MD - Assistant Professor, K. Tokuda, MD - Lecture, M.Kitagawa, MS - Assistant Professor, H. Kunishima, MD - Associate Professor,M. Kaku, MD - Professor; Tohoku Univ., Sendai, Japan.10:30 a.m.C2-1902 First Outbreak of Multiresistant Acinetobacter baumanniiProducing the Carbapenemase OXA 23 in SpainM. Merino, MSc - PhD Student, M. Poza, PhD - Researcher, M. J. Barba,CLT - Lab Assistant, S. Rumbo-Feal, MSc - PhD Student, A. Fernandez,MSc - PhD Student, M. Tomás, PhD - PhD Researcher, G. Bou, PhD -Professor; Univ. La Coruña, La Coruña, Spain.10:45 a.m.C2-1903 Clinical and Microbiological Characteristics of BloodstreamInfection Caused by Acinetobacter baumannii ComplexH. Lee, MD, MS - Attending Doctor and Lecturer, S. Wu, Bachelor -Research Assistant, C. Chen, PhD - Assistant Professor, C. Chiu, MD, PhD -Professor; Chang Gung Mem. Hosp., Taoyuan, Taiwan.11:00 a.m.C2-1904 Application of Pyrosequencing Assay for Rapid Detectionof Epidemic Clonal Lineage of Acinetobacter baumanniiM. Matsui, PhD - Reseacher 1 , S. Suzuki, MD, PhD - Senior Researcher 1 , K.Shibayama, MD, PhD - Director 1 , Y. Arakawa, MD, PhD - Professor 2 ; 1 Natl.Inst. of Infectious Diseases, Japan, Tokyo, Japan, 2 Nagoya Univ. GraduateSch. of Med., Aichi, Japan.11:15 a.m.C2-1905 High Prevalence of OXA-23-Producing Carbapenem-Resistant Acinetobacter baumannii Among Hospitals from PortoAlegre, BrazilJ. Barin, PharmD - Researcher 1 , B. L. Heineck, Biomedicine Student -Research Assistant 1 , A. F. Martins, Ph.D. - Professor 2 , A. P. Zavascki, PhD-Researcher 3,1 ; 1 Univ. Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2 Ctr.Univ. Metodista, IPA, Porto Alegre, Brazil, 3 Hosp. de Clinc. de Porto Alegre,Porto Alegre, Brazil.------------------------------------------------------------------------237(C2)Slide SessionMRSA: Pervasive, Persistent, and PathogenicWednesday, 9:15 a.m.–11:45 a.m. . . Esplanade Ballroom 305UAN: 0391-9999-12-176-L04-PModerators:Emil P. Lesho, DO - Co-Founder and Director, MRSNWalter Reed Army Inst. of Res., Silver Spring, MD.Usha Stiefel, Stiefel, MD - Chief, Infectious Diseases SectionCleveland VA Med. Ctr., Cleveland Heights, OH.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Discuss hot topics in molecular epidemiology of MRSA;> Identify the clonal shifts in MRSA around the world;> Assess resistance epidemiology; and> Describe details about MRSA in animals as reservoirs.Presentations:9:15 a.m.C2-1906 Agr Function and Mortality in Nosocomial Pneumonia Dueto Methicillin-Resistant Staphylococcus aureusD. S. Smyth, PhD – Research 1 , M. Wible, MS – Research 2 , R. E. Mendes,PhD – Director 3 , A. Labella, MD – Research 1 , J. M. Kafer, BS – Research 1 , V.J. Torres, PhD – Professor 1 , R. P. Novick, MD – Professor 1 , B. Shopsin, MD,PhD – Professor 1 ; 1 Dept. of Med. and Microbiol., New York, NY, 2 PfizerInc., Collegeville, PA, 3 JMI Lab., North Liberty, IA.9:30 a.m.C2-1907 Emergence of Different Lineages of MRSA Type IV and IISubstituting the BEC in Bloodstream Infections in Two BrazilianHospitalsR. C. Chamon, BA - Master Student, V. C. Salgueiro, BA - Master Student,S. S. Ribeiro, Graduate Student - Graduate Student, F. S. Cavalcante, MD- PhD Student, N. L. P. Iorio, PhD - Research, K. R. N. dos Santos, PhD -Professor; Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil.9:45 a.m.C2-1908 Epidemiology of CA-MRSA in Auckland, New Zealand:Emergence of ST5-IV as the Dominant CA-MRSA CloneD. A. Williamson, MD - Clinical Research Fellow 1 , S. A. Roberts, MD -Clinical Microbiologist 2 , S. R. Ritchie, MD PhD - Senior Lecturer 1 , J. D.Fraser, PhD - Professor 1 , G. Coombs, MS - Principal Scientist 3 , H. Heffernan,MS - Senior Scientist 4 ; 1 Univ. of Auckland, Auckland, New Zealand,2Auckland District Hlth. Board, Auckland, New Zealand, 3 AustralianCollaborating Ctr. for Enterococcus and Staphylococcus Species (ACCESS)Typing and Res., Perth, Australia, 4 Inst. of Environmental Sci. and Res.,Wellington, New Zealand.190September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS10:00 a.m.C2-1909 MRSA USA300 Variant has Replaced the Chilean Clone inLatin American HospitalsJ. Reyes, MA - Professor 1,2 , C. A. Arias, MD, MS, PhD - Professor 1,2 , S.Rincon, MS - Professor 1 , L. P. Carvajal, BSc - Research 1 , N. Rojas, BSc -Research 1 , G. Ibarra, Medical Student - Research Assistant 1 , C. Garcia, MD,PhD - Physician 3 , C. A. Alvarez, MD - Physician 4 , M. Guzman, MD - Physician5 , C. Seas, MD, MS - Physician 3 , E. Gotuzzo, MD - Physician 3 , LatinAmerican Working Group on Bacterial Resistance; 1 Univ. El Bosque, Bogotá,Colombia, 2 Univ. of Texas Med. Sch., Houston, TX, 3 Hosp. Nal CayetanoHeredia, Lima, Peru, 4 Hosp. San Ignacio, Bogotá, Colombia, 5 Ctr. Med. deCaracas, Caracas, Venezuela, Bolivarian Republic of.10:15 a.m.C2-1910 New Patterns of Methicillin-Resistant Staphylococcus aureus(MRSA) Clones in the Community and Hospital Setting, Argentina2009C. Sola, PhD 1 , A. Egea, MD 1 , R. Lamberghini, MD 2 , H. Paganini, MD 3 ,P. Gagetti, MD 4 , D. Faccone, PhD 4 , C. Lucero, MD 4 , M. Galas, MD 4 ,CA-MRSA Argentina Group, J. L. Bocco, PhD, A. Corso, MD 4 ; 1 CIBICI–CONICET. Fac. Cs. Químicas, UNC, Córdoba, Argentina, 2 Hosp. G. Rawson,Córdoba, Argentina, 3 Hosp. Dr. J. Garrahan, Buenos Aires, Argentina,4Antimicrobianos, INEI-ANLIS, Buenos Aires, Argentina.10:30 a.m.C2-1911 Molecular Epidemiology of Healthcare-AssociatedMethicillin-Resistant Staphylococcus aureus (HA-MRSA) Isolatedfrom Adult Patients in RussiaY. Chernov, MD - Research Assistant, A. Romanov, MD - Research Assistant,M. Edelstein, MD, PhD - Research Assistant, A. Dekhnich, MD, MSc,PhD - Research Assistant; Inst. of Antimicrobial Chemotherapy, Smolensk,Russian Federation.10:45 a.m.C2-1912 Carriage of Staphylococcus aureus CC398 Among LivestockWorkers and Household Members in NCJ. Rinsky, MPH - Student 1 , M. Nadimpalli, MS - Student 1 , D. Hall, ProgramManager 2 , D. Baron-Hall, Executive Director 2 , J. Stewart, PhD, MS - AssistantProfessor 1 , S. Wing, PhD - Associate Professor 1 , C. Heaney, PhD, MS -Assistant Professor 3 ; 1 UNC, Chapel Hill, NC, 2 REACH, Warsaw, NC, 3 JHU,Baltimore, MD.11:00 a.m.C2-1913 Prevalence and Characteristics of Methcillin-ResistantStaphylococcus aureus Recovered from Raw Meats in Korea, 2010-2011H. Nam, PhD - Researcher, S. Lim, PhD - Researcher, G. Jang, MS - Researcher,M. Chae, MS - Researcher, S. Kim, MS - Researcher, S. Jung, PhD- Researcher; Animal, Plant, and Fisheries Quarantine and Inspection Agency,Anyang, Republic of Korea, Anyang, Korea, Republic of.11:15 a.m.C2-1914 Distribution of qacA/B And mupA Genes in Clinical Isolatesof Methicillin-Resistant Staphylococcus aureusM. Milillo, BSc - Research Assistant, R. Quintero, MS - Research Assistant, Y.Kwak, MS - Lab Manager, A. Mueller, BSc - Research Assistant, P. Waterman,MD - Deputy Director, P. McGann, PhD - Senior Microbiologist, E. Lesho,DO - Director; MRSN, WRAIR, Silver Spring, MD.11:30 a.m.C2-1915 Oxacillin and Vancomycin Resistance Profile of Staphylococcusaureus Strains Isolated from Medical StudentsI. A. Mendez, MA - Professor, D. F. Holguin, Student - Student, D. P.Pachon, MS - Professor, F. J. Africano, Student - Student, I. M. Gonzalez,Student - Student, N. A. Rojas, MS - Professor; Sch. of Med., Univ. Militar,Bogota, Colombia.------------------------------------------------------------------------238(H)Slide SessionCommon Pathogens: Still a Problem in HIV-IWednesday, 9:15 a.m.–11:45 a.m. ................Room 102UAN: 0391-9999-12-177-L02-PModerators:Sharon L. Walmsley, MD, MSc, FRCPC - Professor of MedicineUniv. of Toronto, Toronto, Canada.Judith Aberg, MD - Professor of Medicine; Director Division of InfectiousDiseases and ImmunologyNew York Univ., Bellevue Hosp. Ctr, New York, NY.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Assesses the effect of HIV clinical malfunctions of common pathogens;> Discuss the utility of interferon gamma release assay HIV infection; and> Identify the impact of HSV-2 infection on HIVPresentations:9:15 a.m.H-1916 Incidence and Risk Factors for Invasive Pneumococcal Diseasein HIV Infected and Uninfected Individuals in DenmarkZ. B. Harboe, MD – Doctor 1 , M. V. Larsen, MD – Doctor 2 , S. Ladelund,MS - Statistician 2 , G. Kronborg, MD - Doctor 2 , R. Skov, MD - Doctor 3 , H.Konradsen, MD - Doctor 3 , N. Obel, MD - Doctor 4 , C. Shade, MD - Doctor 5 ,J. Gerstoft, MD - Doctor 4 , T. L. V. Benfield, MD - Doctor 2 ; 1 Statens SerumInst., Hvidovre Hosp., Copenhagen, Denmark, 2 Hvidovre Hosp., Copenhagen,Denmark, 3 Statens Serum Inst., Copenhagen, Denmark, 4 Rigshospitalet,Copenhagen, Denmark, 5 Aarhus Univ. Hosp., Aarhus, Denmark.9:30 a.m.H-1917 Comparison of the QuantiFERON TB Gold In-Tube Assaywith Tuberculin Skin Test for the Diagnosis of Latent TuberculosisInfection Among HIV Infected ChildrenR. M. Viani, MD - Associate Professor 1 , M. R. Araneta, PhD - AssociateProfessor 1 , G. Lopez, MD - Associate Professor 2 , S. A. Spector, MD - Professor 1 ;1Univ. of California, La Jolla, CA, 2 Tijuana Gen. Hosp., Tijuana, Mexico.9:45 a.m.H-1918 Reversion and Conversion of Interferon-Gamma ReleaseAssay Results in HIV-1-Infected IndividualsM. C. Aichelburg, MD - Resident, F. Breitenecker, MD - Resident, T.Reiberger, MD - Associate Professor, A. Makristathis, MD - Associate Professor,A. Rieger, MD - Associate Professor; Med. Univ. of Vienna, Vienna, Austria.Final Program191

Wednesday SCIENTIFIC SESSIONS10:00 a.m.H-1919 Six Year Follow Up of 590 Danish HIV Infected PatientsScreened for Tuberculosis InfectionCopenhagen Soborg, MD,PhD - R 1 , M. Ruhwald, MD, PhD - R 2 , P.Andersen, MD - C 3 , P. Ravn, MD,PhD - C 4 ; 1 Copenhagen Univ. Hosp.,Hvidovre, Copenhagen, Denmark, 2 Copenhagen Univ. Hosp., Hvidovre,Copenhagen, Denmark, 3 SSI, Copenhagen, Denmark, 4 Cph Univ. Hosp.,Hillerod, Copenhagen, Denmark.10:15 a.m.H-1920 No Impact of Suppressive Antiretroviral Therapy onMucosal Shedding of Herpes Simplex Virus Types 1 and 2 inHIV Co-Infected AdultsD. H. S. Tan, MD - Clinician Scientist, J. M. Raboud, PhD - AssociateProfessor, R. Kaul, MD PhD - Associate Professor, S. L. Walmsley, MD MSc -Professor; Univ. of Toronto, Toronto, Canada.10:30 a.m.H-1921 Risk Factors in the Progression of Low Grade IntraepithelialNeoplasia (LGAIN) to High Grade Intraepithelial Neoplasia(HGAIN) in a Cohort of HIV-MSMC. Hidalgo Tenorio, MD, PhD - Staff of Infectious Disease Unit, M. RiveroRodriguez, MD - Staff of Infectious Disease Unit, C. Gil Anguita, MD -Research Assitant of Infectious Disease Unit, A. Concha, MD, PhD - Chef ofPathology Anatomy Service, M. Lopez del Hierro, MD, PhD - Staff of GeneralService, P. Palma, MD, PhD - Staff of General Surgery Service, I. Segura, MD,PhD - Staff of General Surgery Service, M. Lopez Ruz, MD, PhD - Chef ofInfectious Disease Unit, R. Javier, MD, PhD - Staff of Infectious Disease Unit,C. Garcia Vallecillos, Chem. - Research Assitant of Infectious Disease Unit, J.Pasquau Liaño, MD - Staff of Infectious Disease Unit; M. Álvarez, MD - Staffof Infectious Disease Unit, C. Diéguez, MD - Staff of Infectious Disease Unit,Univ. Hosp Virgen de las Nieves, Granada, Spain.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------239(K)Slide SessionAntimicrobial Stewardship: Perils of PrescribingWednesday, 9:15 a.m.–11:45 a.m. . . Esplanade Ballroom 310UAN: 0391-9999-12-178-L04-PModerator:Neil O. Fishman, MDInfectious Diseases, Univ. of Pennsylvania Med. Ctr., Philadelphia, PA.Objectives: Upon the completion of this Slide Session, the participantshould be able to:> Identify the central components of a successful antimicrobial stewardshipprogram;> Describe the relative role of measuring procalcitonin levels to guidetherapy in patients with malignancies; and> Discuss demographic factors associated with antimicrobial consumptionin Denmark.Presentations:9:15 a.m.1922 State-of-the-Art MinilectureNeil O. Fishman, MDUniv. of Pennsylvania Med. Ctr., Philadelphia, PA.9:45 a.m.K-1923 Impact of a Comprehensive Antimicrobial Stewardship Program(ASP) on Antimicrobial Usage (AU) at a Large CommunityHospitalD. Patel, Pharm D - Clinical Pharmacy Specialist, Infectious Diseases 1,2 , V.Velmahos, MD - Medical Director, Antimicrobial Stewardship Program 2 , C. A.Ewing, MD - Chairman, Department of Pathology 2 , C. MacDougall, PharmD - Associate Professor of Clinical Pharmacy 3 ; 1 Comprehensive Pharmacy Services,Memphis, TN, 2 John F. Kennedy Med. Ctr., Edison, NJ, 3 UCSF Sch.of Pharmacy, San Francisco, CA.10:0 a.m.K-1924 High Impact of an Educational Antimicrobial StewardshipProgram on Prescribing Practice in a Tertiary Hospital CentreJ. M. Cisneros, PhD - Assistant, M. Gil-Navarro, MD - Assistant, O.Net, PhD - Assistant, F. Jiménez-Parrila, MD - Assistant, J. Cano, MD- Assistant, E. Cordero, PhD - Assistant, J. Lepe, PhD - Assistant, M. J.Rodríguez-Hernández, PhD - Assistant, J. A. Márquez, MD - Assistant, M.Aguilar-Guisado, PhD - Assistant, R. Amaya, PhD - Assistant, C. Ferrándiz,MD - Assistant, J. Garnacho-Montero, PhD - Assistant, J. Palomino, PhD -Assistant, E. Jiménez-Mejías, PhD - Assistant, M. Herrero, MD - Assistant,A. Gutiérrez, MD - Assistant, J. Molina, MD - Assistant; Hosp. Univ. Virgendel Rocio, Sevilla, Spain.10:15 a.m.K-1925 Increased Antimicrobial Consumption in Denmark 2001 to2010: Association with Demographic FactorsK. Kuhn, PhD- Scientist, A. Hammerum, PhD- Head of Section, U. Jensen,MD - Scientist; Statens Serum Inst. Copenhagen, Denmark.10:30 a.m.K-1926 Early Antibiotic Discontinuation (E-DC) is Not Associatedwith Increased Mortality in Patients with Clinically SuspectedVentilator Associated Pneumonia (VAP) and Negative QuantitativeBronchoalveolar Lavage (BAL) CulturesK. Raman, PharmD - PGY2 1,2 , M. D. Nailor, PharmD - Ass. Prof. 2,1 , D. P.Nicolau, PharmD – Dir. 3 , J. Aslanzadeh, PhD - Dir. 1 , J. L. Kuti, PharmD -Ass. Dir. 3 ; 1 Hartford Hosp., Hartford, CT, 2 Univ. of CT, Storrs, CT, 3 Ctr. forAnti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT.10:45 a.m.K-1927 Appropriateness of Antimicrobial Use in HospitalizedPatients with Positive Urine CulturesS. J. Celetti, MSc - Student, A. Brooks, PharmD - Pharmacist, P. Delanghe,BSc - Student, D. Mertz, MD MSc - Physician; Hamilton Hlth. Sci., Hamilton,Canada.192September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------240(A)Poster SessionAntifungals: Improving PK/PD and SafetyWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:A-1928 Pharmacokinetic Rationale for Alternate Dosing Strategiesof Anidulafungin in Hematological PatientsR. J. M. Brüggemann 1 , W. J. F. Van der Velden 1 , A. Colbers 1 , C. A. J.Knibbe 2 , V. J. C. Lempers 1 , D. M. Burger 1 , N. M. A. Blijlevens 1 , J. P.Donnelly 1 ; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands,2Sint Antonius Ziekenhuis, Nieuwegein, Netherlands.A-1929 Pharmacodynamic (PD) Evaluation of 3 Echinocandins (E)against C. glabrata (CG) with and without Fks Mutations in theNeutropenic Disseminated Candidiasis ModelA. Lepak 1 , M. Castanheira 2 , M. Pfaller 3 , D. Diekema 3 , D. R. Andes 1 ;1Univ. of Wisconsin, Madison, WI, 2 JMI, North Liberty, IA, 3 Univ. of Iowa,Madison, IA.A-1930 In Vivo Pharmacodynamic (PD) Evaluation of CombinationTriazole (T) and Echinocandin (E) Therapy against Susceptibleand Resistant A. fumigatus (AF)A. Lepak 1 , D. R. Andes 1 , A. Forrest 2 ; 1 Univ. of Wisconsin, Madison, WI,2ICPD, Latham, NY.A-1931 Isavuconazole (ISA) Pharmacodynamic (PD) Target Determinationfor C. albicans (CA) in an In Vivo Neutropenic MurineModel of Invasive Candidiasis (IC)A. Lepak, K. Marchillo, J. Cabezas, D. R. Andes; Univ. of Wisconsin,Madison, WI.A-1932 Pharmacodynamic (PD) of Posaconazole (P) in a MurineInvasive Pulmonary Aspergillosis (IPA) Model against Wild Typeand Cyp51 Mutant IsolatesA. Lepak, K. Marchillo, J. VanHecker, D. R. Andes; Univ. of Wisconsin,Madison, WI.A-1933 Intrapulmonary Penetration of Posaconazole in ImmunosuppressedMice Receiving Oral Prophylactic RegimensS. Seyedmousavi 1,2 , R. J. M. Brüggemann 1,2 , W. J. G. Melchers 1,2 , P. E.Verweij 1,2 , J. W. Mouton 1,2 ; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen,Netherlands, 2 Nijmegen Inst. for Infection, Inflammation and Immunity,Nijmegen, Netherlands.A-1934 Phase 1B Study of the Pharmacokinetics and Safety ofPosaconazole (POS) Solid Oral Tablet in Patients at Risk forInvasive Fungal Infection (IFI)R. F. Duarte 1 , J. López Jiménez 2 , O. A. Cornely 3 , L. Ma 4 , M. P. S. vanIersel 5 , H. Waskins 6 ; 1 Catalan Inst. Oncol, Barcelona, Spain, 2 Hosp Ramony Cajal, Madrid, Spain, 3 Univ. Hosp. Cologne, Cologne, Germany, 4 Merck,Titusville, NJ, 5 MSD, Oss, Netherlands, 6 Merck, Whitehouse Station, NJ.A-1935 Effect of Concomitant Medications Affecting Gastric pH andMotility on Posaconazole (POS) Tablet Pharmacokinetics (PK)W. K. Kraft 1 , P. Chang 1 , M. P. S. van Iersel 2 , H. Waskin 3 , G. Krishna 3 ,W. Kersemaekers 2 ; 1 Thomas Jefferson Univ., Philadelphia, PA, 2 Merck, Oss,Netherlands, 3 Merck, Whitehouse Station, NJ.A-1936 Effect of Multiple Doses of Isavuconazole on the Pharmacokineticsof CYP3A4 Substrate Midazolam in Healthy VolunteersA. Desai, N. Zadeikis, H. Pearlman, D. Kowalski, R. Townsend; AstellasPharma Global Dev., Deerfield, IL.A-1937 Influence of CYP2C19 and ABCB1 Genetic Polymorphismson Voriconazole Levels in Haematological PatientsL. Baietto, A. D’Avolio, J. Cusato, C. Marra, M. Simiele, F. G. De Rosa, G.Di Perri; Univ. of Turin, Turin, Italy.A-1938 An In Vitro Pharmacokinetic/Pharmacodynamic ModelPredicts In Vivo Outcome of Voriconazole Treatment againstAspergillus fumigatus Isolates with Reduced Azole SusceptibilityM. Siopi 1 , E. Mavridou 2 , A. Elefanti 1 , P. E. Verweij 2 , J. W. Mouton 2 , J. Meletiadis1 ; 1 Attikon Univ. Gen. Hosp., Athens, Greece, 2 Radboud Univ. Med.Ctr., Nijmegen, Netherlands.A-1939 In Vitro Evaluation of the Efficacy of Voriconazole (VOR)in Combination with Amphotericin B (AMB) against Aspergillusfumigatus (AFM) Using a Novel Pharmacokinetic/Pharmacodynamic(PK/PD) ModelM. Siopi, A. Elefanti, N. Siafakas, L. Zerva, J. Meletiadis; Attikon Univ.Gen. Hosp., Athens, Greece.A-1940 Effect of Delay Exposure and Supra/Sub-MIC Concentrationsof Amphotericin B to Aspergillus Conidial, Hyphal andMycelial GrowthK. Krompa, N. Siafakas, L. Zerva, J. Meletiadis; Attikon Univ. Gen. Hosp.,Athens, Greece.A-1941 Safety, Tolerance and Adverse Events of Treatment withLipozomal Amphotericin B in Pediatric PatientsE. Karadag Oncel, A. Kara, Y. Ozsurekci, M. Celik, A. Ozkaya Parlakay, A.Cengiz, M. Ceyhan; Hacettepe Univ., Ankara, Turkey.A-1942 Pharmacokinetics (PK) and Pharmacodynamics (PD) ofLiposomal Amphotericin B (LAmB) and Flucytosine (5FC)against Cryptococcus neoformans in a Murine Model of CryptococcalMeningitisL. O’Connor, J. Livermore, A. Sharp, J. Goodwin, T. W. Felton, S. J. Howard,W. W. Hope; The Univ. of Manchester, Manchester, United Kingdom.A-1943 Pharmacokinetics and Pharmacodynamics of Fluconazolein a Murine Model of Cryptococcal Meningitis With Bridging toHumans: High Dosages are Required for Near-Maximal AntifungalActivityA. Sudan, J. Livermore, S. Howard, Z. Al-Nakeeb A. Sharp, J. Goodwin, L.Gregson, T. Wilkinson P. A. Warn, T. W. Felton, W. W. Hope; The Univ. ofManchester, Manchester, United Kingdom.A-1944 Pharmacokinetics and Pharmacodynamics of LiposomalAmphotericin B (LAmB) for Cryptococcal Meningitis: A SingleHigh Dose of Liposomal Amphotericin B is as Efficacious asDaily Dosing RegimensJ. Livermore 1 , L. O’Connor 1 , A. Sharp 1 , L. Gregson 1 , J. Goodwin 1 , P.Warn 1 , T. Felton 1 , J. A. Schwartz 2 , S. Howard 1 , W. W. Hope 1 ; 1 The Univ.of Manchester, Manchester, United Kingdom, 2 Charles River Lab., Davis, CA.Final Program193

Wednesday SCIENTIFIC SESSIONSA-1945 Standardization of a Murine Model of Systemic Candida albicansInfection to Study Therapeutic Equivalence (TE) of Fluconazole(FCZ) GenericsJ. M. Gonzalez, M. Agudelo, L. M. Leiva, C. A. Rodriguez, O. Vesga; Univ.of Antioquia, Medellin, Colombia.A-1946 Maximal Use PK Study of Luliconazole Solution 10% inSubjects with OnychomycosisA. Tavakkol 1 , T. Jones 2 ; 1 Topica Pharmaceuticals, Los Altos, CA, 2 J & SStudies, Inc., College Station, TX.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------241(A)Poster SessionToxicokinetics and PK/PD of New and OldFluoroquinolonesWednesday, 9:15 a.m.–11:15 a.m. .........................Halls A-CPresentations:A-1947 In Vivo Pharmacodynamic (PD) Characterization of a NewFluoroquinolone (FQ) Antibiotic, Kpi-10, against Gram-Positive(GP) and Gram-Negative (GN) BacteriaA. Lepak, K. Marchillo, J. Cabezas, W. Craig, D. R. Andes; Univ. of Wisconsin,Madison, WI.A-1948 Systemic Exposure Profile and Tissue Penetration (Lung,Kidney, Bone Marrow, and Gallblader) of KPI-10 in Rabbits AfterIntravenous AdministrationC. Jacqueline 1 , V. Le Mabecque 1 , C. Desessard 2 , A. F. Miegeville 1 , Y. Ge3, G. Potel 1 , J. Caillon 1 ; 1 UPRES EA 3826, Nantes, France, 2 Atlangram,Nantes, France, 3 Kalidex Pharmaceuticals Inc., Menlo Park, CA.A-1949 Absorption, Excretion, Tissue Distribution, and ProteinBinding of KPI-10, a New Broad-Spectrum FluoroquinoloneY. Ge 1 , P. B. Eckburg 1 , J. Enoru 2 , E. Solon 3 ; 1 Kalidex Pharmaceuticals, Inc.,Menlo Park, CA, 2 Ricerca Biosciences, LLC, Concord, OH, 3 QPS, LLC,Newark, DE.A-1950 In Vitro and In Vivo Metabolism of KPI-10, a New Broad-Spectrum FluoroquinoloneY. Ge 1 , P. B. Eckburg 1 , V. Jiang 1 , J. Enoru 2 , R. Mc Clanahan 2 , W. De Maio2, D. Johnson 3 , A. Kousba 3 ; 1 Kalidex Pharmaceuticals, Inc., Menlo Park,CA, 2 Ricerca Biosciences, LLC, Concord, OH, 3 MicroConstants, Inc., SanDiego, CA.A-1951 Effect of KPI-10, a Novel, Broad-Spectrum Fluoroquinolone,on the Activity of Cytochrome P450 Isoenzymes in HumanHepatocytesJ. Ge 1 , P. B. Eckburg 1 , J. Enoru 2 , W. DeMaio 2 ; 1 Kalidex Pharmaceuticals,Inc., Menlo Park, CA, 2 Ricerca Biosciences, LLC, Concord, OH.A-1952 Safety & Pharmacokinetics of KPI-10, a NovelFluoroquinolone, in Healthy Adults Receiving Single DoseOral AdministrationsP. B. Eckburg 1 , Y. Ge 1 , V. Jiang 1 , T. Kilfoil 2 , G. H. Talbot 3 ; 1 KalidexPharmaceuticals, Inc., Menlo Park, CA, 2 InClin, Inc., Los Altos, CA, 3 TalbotAdvisors LLC, Anna Maria, FL.A-1953 Permeability and Pharmacokinetics (PK) of Intravenous (IV)and Oral (PO) KPI-10, a Novel Broad-Spectrum Fluoroquinolone(FQ)Y. Ge 1 , P. B. Eckburg 1 , V. Jiang 1 , D. Freeman 2 , A. Kousba 3 ; 1 KalidexPharmaceuticals, Inc., Menlo Park, CA, 2 Ricerca Biosciences, LLC, Concord,OH, 3 MicroConstants, Inc., San Diego, CA.A-1954 Repeat-Dose Toxicity and Toxicokinetics (TK) of Oral KPI-10, a Novel Fluoroquinolone, in Rats and DogsP. B. Eckburg 1 , Y. Ge 1 , L. Donald 2 ; 1 Kalidex Pharmaceuticals, Inc., MenloPark, CA, 2 Intertek Cantox, Hoover, AL.A-1955 Lack of In Vitro or In Vivo Phototoxicity Associated withKPI-10, a New Broad-Spectrum FluoroquinoloneP. B. Eckburg 1 , Y. Ge 1 , K. Yasuhiro 2 , D. B. Learn 3 ; 1 Kalidex Pharmaceuticals,Inc., Menlo Park, CA, 2 Wakunaga Pharmaceutical Co., Ltd., Hiroshima,Japan, 3 Charles River Lab., Horsham, PA.A-1956 Metabolism and Mass Balance of Delafloxacin in HealthyHuman Volunteers Following Intravenous AdministrationA. McEwen 1 , L. Lawrence 2 , S. Wood 1 , G. Ford 1 , J. Longcor 2 , D. Li 2 , M.Reeve 2 , R. Hoover 2 ; 1 Quotient Bioresearch, Rushden, United Kingdom,2Rib-X Pharmaceuticals, New Haven, CT.A-1957 Pharmacokinetics (PK) of Delafloxacin (DLX), Vancomycin(VAN), and Linezolid (LNZ) in a Phase 2 Exploratory Study inSubjects with Acute Bacterial Skin and Skin Structure Infections(ABSSSI)R. Hoover 1 , L. Lawrence 1 , J. Longcor 1 , J. Greenfield 2 ; 1 Rib-X Pharmaceuticals,New Haven, CT, 2 PharmaNet/i3, The Woodlands, TX.A-1958 A Thorough Phase 1 QTc Study of Delafloxacin (DLX)Compared with Placebo and Moxifloxacin (MXF)L. E. Lawrence 1 , M. Benedict 2 , M. Medlock 2 , J. Litwin 3 , M. Thorn 4 , S.Hopkins 1 , J. Longcor 1 ; 1 Rib-X Pharmaceuticals Inc., New Haven, CT, 2 PPDPhase 1 Clinic, Austin, TX, 3 ERT, Philadelphia, PA, 4 Statistical Resources,Chapel Hill, NC.A-1959 Comparison of Postantibiotic Effects of Finafloxacin andOther FluoroquinolonesC. Y. Goh 1 , S. B. Ng 1 , M. J. Everett 1 , A. Vente 2 ; 1 MerLion PharmaceuticalsPte Ltd, Singapore, Singapore, 2 MerLion Pharmaceuticals GmbH, Berlin,Germany.A-1960 A Phase I Study to Determine Safety, Tolerability andPharmacokinetics (PK) of Intravenous Doses of Finafloxacin HCl(FIN) in Healthy SubjectsM. Lückermann, L. Mooney, H. Patel, C. Fischer, S. Wohlert, A. Vente;MerLion Pharmaceuticals GmbH, Berlin, Germany.A-1961 Population Pharmacokinetic (PPK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment (TA) Analyses toSupport JNJ-Q2 Dose Selection for Patients with Acute BacterialSkin and Skin Structure Infections (ABSSSI)S. A. Van Wart 1 , M. Melhem 1 , J. M. Davenport 2 , P. G. Ambrose 1 , S. M.Bhavnani 1 , D. R. Andes 3 , W. A. Craig 3 , G. F. Mc Intyre 2 , C. M. Rubino 1 ;1ICPD, Latham, NY, 2 Furiex Pharmaceuticals, Morrisville, NC, 3 Univ. ofWisconsin, Madison, WI.194September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONSA-1962 Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis forEfficacy of JNJ-Q2 Using Phase 2 Data from Patients with AcuteBacterial Skin and Skin Structure Infections (ABSSSI)S. M. Bhavnani 1 , J. P. Hammel 1 , S. A. Van Wart 1 , M. Melhem 1 , C. M.Rubino 1 , J. M. Davenport 2 , G. F. Mc Intyre 2 , P. G. Ambrose 1 ; 1 ICPD,Latham, NY, 2 Furiex Pharmaceuticals, Morrisville, NC.A-1963 Decrease of Levofloxacin Fecal Concentrations in ExperimentalDogs Using DAV132, an Oral Adsorbent Delivered to theIleum/ColonS. Sayah-Jeanne 1 , E. Chachaty 2 , T. Nguyen 3,4 , V. Augustin 1 , J. de Gunzburg1 , F. Mentré 3,4 , A. Andremont 5,6 ; 1 Da Volterra, Paris, France, 2 InstitutGustave-Roussy, Villejuif, France, 3 UMR738 INSERM, Paris, France, 4 Univ.Paris Diderot, Paris, France, 5 EA 3964 Univ. Paris Diderot, Paris, France,6Hosp. Bichat, AP-HP, Paris, France.A-1964 Levofloxacin (LVX) Penetration into Epithelial Lining Fluid(ELF) Differs Between Infected and Uninfected PatientsJ. L. Kuti, D. P. Nicolau; Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp.,Hartford, CT.A-1965 Ciprofloxacin (CIP) PK/PD in Experimental Urinary TractInfection (UTI) Depends on Time>MIC and not AUC24/MICL. Jakobsen 1,2 , K. S. Jensen 1 , C. Vingsbo Lundberg 1 , N. Frimodt-Møller 1,2,3 ; 1 Statens Serum Inst., Copenhagen, Denmark, 2 Hvidovre Hosp.,Hvidovre, Denmark, 3 Hvidovre Univ. Hosp., Hvidovre, Denmark.A-1966 External Evaluation of a Mechanism-Based PKPD Model:Predicting In Vitro Resistance Selection in Competition ExperimentsD. Khan, P. Lagerbäck, E. Gullberg, S. Cao, C. Malmberg, O. Cars, D.Hughes, D. I. Andersson, E. I. Nielsen, L. E. Friberg; Uppsala Univ.,Uppsala, Sweden.A-1967 Testing the Mutant Selection Window Hypothesis withFluoroquinolone-Exposed Escherichia coli in an in Vitro DynamicModel: Examination of Alternative Predictors of ResistanceA. A. Firsov 1 , E. N. Strukova 1 , D. S. Shlykova 1 , Y. A. Portnoy 1 , S. A.Dovzhenko 1 , M. B. Kobrin 1 , S. H. Zinner 2 ; 1 Gause Inst. of New Antibiotics,Moscow, Russian Federation, 2 Mount Auburn Hosp., Cambridge, MA.A-1968 Pharmaceutical Equivalence (PE), Therapeutic Equivalence(TE), and Resistance (R) Selection of 5 Generic Products ofCiprofloxacin (CIP) Compared with the Innovator againstPseudomonas aeruginosaC. A. Rodriguez, M. Agudelo, J. A. Perez, J. M. Gonzalez, O. Vesga; Univ.of Antioquia, Medellin, Colombia.------------------------------------------------------------------------242(C1)Poster SessionMechanisms of Resistance to Novel CompoundsWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:C1-1969 Structure of Plusbacin Bound to Bacterial Cell WallsS. Kim 1 , R. D. O’Connor 2 , M. Singh 2 , C. Cao 3 , M. VanNiewenhze 3 , J.Schaefer 2 ; 1 Baylor Univ., Waco, TX, 2 Washington Univ., St. Louis, MO,3Indiana Univ., Bloomington, IN.C1-1970 Dynamics and Mechanisms of Resistance Development toCeftazidime, Meropenem and Ceftolozane/Tazobactam in Wild-Type and Mutator P.aeruginosa StrainsG. Cabot, X. Mulet, B. Moyà, L. Zamorano., C. Juan, A. Oliver; Hosp. SonEspases, Palma de Mallorca, Spain.C1-1971 Single- and Multistep Resistance Selection with the PleuromutilinAntibiotic BC-3781S. Paukner 1 , C. L. Clark, 2 , Z. Ivezic-Schoenfeld 1 , K. Kosowska-Shick 2 ;1Nabriva Therapeutics AG, Vienna, Austria, 2 Hershey Med. Ctr., Hershey, PA.C1-1972 Resistance Mechanism to Antisense Peptide-PhosphorodiamidateMorpholino OligomersB. L. Geller 1 , K. A. Reese 1 , G. M. Mitev 1 , V. Mullen 1 , K. R. Pomraning 1 , R.C. Johnson 1 , P. L. Iversen 2 , M. Freitag 1 ; 1 Oregon State Univ., Corvallis, OR,2AVI BioPharma, Inc., Corvallis, OR.C1-1973 Activity of the EF-G Inhibitor Argyrin B in Key GramNegative Pathogens: Spectrum and ResistanceA. L. Woods, A. K. Jones, R. E. Caughlan, C. R. Dean; Novartis Inst. forBiomedical Res., Emeryville, CA.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------243(C2)Poster SessionAntimicrobial Resistance of Miscellaneous BacteriaWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:C2-1974 Oropharyngeal Colonization by Non-Typable HaemophilusInfluenzae (NTHi) among Healthy Children Attending DayCare CentersS. Marti 1 , C. Puig 1 , A. Fleites 2 , L. Calatayud 1 , C. Ardanuy 1 , J. Liñares 1 ;1Hosp. Univ. Bellvitge, Barcelona, Spain, 2 Hosp. Central, Oviedo, Spain.C2-1975 Genetic Diversity of ftsI Gene in-Lactamase Non-Producing Ampicillin Resistant and-Lactamase ProducingAmoxicillin-Clavulanic Acid Resistant Haemophilus influenzaeStrains Isolated from the Nasopharyngeal Carriage of Children inSouth KoreaC. Park 1 , J. Kang 1 , K. Kim 2 , D. Lee 1 , J. Lee 1 , H. Kwon 1 , E. Choi 1 ; 1 TheCatholic Univ. of Korea, Seoul, Korea, Republic of, 2 Ewha Univ., Seoul,Korea, Republic of.Final Program195

Wednesday SCIENTIFIC SESSIONSC2-1976 Population-Based Surveillance of Haemophilus influenzaeAntimicrobial Resistance in the United StatesWithdrawnC2-1977 An Outbreak of Macrolide-Resistant Mycoplasma pneumoniae(MRMP) Infection in 2011 Among Japanese ChildrenT. Okada 1,2 , M. Morozumi 2 , T. Tajima 3 , M. Hasegawa 4 , N. Chiba 2 , S. Iwata 5 ,K. Ubukata 2 ; 1 Natl. Hosp. Organization Tokyo Med. Ctr., Tokyo, Japan,2Kitasato Inst. for Life Sci., Kitasato Univ., Tokyo, Japan, 3 Hakujikai Mem.Hosp., Tokyo, Japan, 4 Nihon Univ. Sch. of Med., Tokyo, Japan, 5 Keio Univ.Sch. of Med., Tokyo, Japan.C2-1978 Increasing Prevalence of Macrolide-Resistance of Mycoplasmapneumoniae Pneumonia in Korea, 2000-2011N. Yang 1 , K. Hong 1 , S. Lee 2 , J. Lee 3,4 , Y. Ahn 5 , J. Lee 6 , E. Choi 1 , H. Lee 1 ;1Seoul Natl. Univ. Hosp., Seoul, Korea, Republic of, 2 Clinical Res. Inst.,Seoul Natl. Univ. Hosp., Seoul, Korea, Republic of, 3 Seoul Natl. Univ., Seoul,Korea, Republic of, 4 Seoul Natl. Univ. Bundang Hosp., Seongnam, Korea,Republic of, 5 Seoul Eulji Hosp., Seoul, Korea, Republic of, 6 Kangwon Natl.Univ. Hosp., Seoul, Korea, Republic of.C2-1979 Characterisation of Antibiotic Resistant Determinants inMoraxella osloensis, an Opportunistic Human PathogenL. M. Bishop 1 , Muriel T. Mafura, Theresa Hunt, A. P. Roberts 2 , M. F.Anjum 3 ; 1 Animal Hlth. Vet. Lab. Agency, Weybridge, United Kingdom,2Eastman Dental Inst., Univ. Coll. London, London, United Kingdom,3Animal Hlth. Vet. Lab. Agency, Weybridge, United Kingdom.C2-1980 Antimicrobial Susceptibility and Genetic Diversity of 55Turkish Bacillus Anthracis StrainsM. Ortatatli 1 , A. Karagoz 2 , D. Percin 3 , L. Kenar 1 , S. Kilic 2 , R. Durmaz 2 ;1GATA, Ankara, Turkey, 2 RSNPHA, Ankara, Turkey, 3 Erciyes Univ. Facultyof Med., Kayseri, Turkey.C2-1981 Antimicrobial Resistance Profile and Relatedness of cagAGene with Enhanced Metronidazole and Quinolone Resistancean Helicobacter pyloriA. Khan 1 , A. Farooqui 2 , H. Manzoor 3 , S. S. Akhter 3 , M. S. Qureshy 3 , S.U. Kazmi 1 ; 1 Univ. of Karachi, Karachi, Pakistan, 2 Intl. Inst. of Infection andImmunity, Shantou, China, 3 Civil Hosp., Karachi, Pakistan.C2-1982 Ciprofloxacin Resistance in Neisseria meningitidis Serogroupa Isolated from Invasive Meningococcal Meningitis from 2005 to2012 in Delhi, IndiaS. Dwivedi 1 , B. K. Das 1 , A. Kapil 1 , S. Sood 1 , R. Chaudhry 1 , M. Deb 2 , D.Nair 2 , S. Gupta 3 ; 1 AIIMS, Delhi, India, 2 VMMC and Safdarjung Hosp.,Delhi, India, 3 Natl. Ctr. for Disease control, Delhi, India.C2-1983 Identification of Antibiotic Resistance Genes in the HumanMicroflora Using 2 Different ApproachesM. Anjum 1 , R. Card 1 , P. Warburton 2 , E. Allan 2 , P. Mullany 2 ; 1 AnimalHlth. and Vet. Lab. Agency, Surrey, United Kingdom, 2 Univ. Coll. London,London, United Kingdom.------------------------------------------------------------------------244(C2)Poster SessionStreptococcus and EnterococusWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:C2-1984 Characterization of vanA type-Vancomycin-SusceptibleEnterococcus faeciumY. Jung, Y. Lee, S. Lee; KCDC, ChungCheongbuk-do, Korea, Republic of.C2-1985 Low Prevalence of Inc18-like vanA Plasmid AmongProspectively-Collected Vancomycin-Resistant EnterococcusIsolates from Detroit Medical CenterE. T. Martin 1 , A. M. Casapao 1 , J. McRoberts 1 , C. Archer 1 , K. Kaye 1,2 , M. J.Rybak 1,2 ; 1 Wayne State Univ., Detroit, MI, 2 Detroit Med Ctr, Detroit, MI.C2-1986 Diversity of Multiple Antibiotic Resistant Enterococci fromBroiler Chicken Fed Antimicrobial Supplemented DietsM. S. Diarra 1 , H. Rempel 1 , J. Champagne 2 , L. Masson 2 , E. Topp 3 ; 1 PacificAgri-Food Res. Ctr., Agassiz, Canada, 2 Natl. Res. Council of Canada,Montreal, Canada, 3 Southern Crop Protection and Food Res. Ctr., London,Canada.C2-1987 Conjugative Plasmids Carrying the Multiresistance Genecfr in Enterococcus faecalis and Enterococcus thailandicus from Swineand Farm EnvironmentY. Wang 1 , Y. Liu 1 , S. Schwarz 2 , C. Wu 1 , Z. Shen 3 , Q. Zhang 3 , J. Shen 1 ;1China Agricultural Univ., Beijing, China, 2 Inst. of Farm Animal Genetics,FLI, Neustadt-Mariensee, Germany, 3 Iowa State Univ., Ames, IA.C2-1988 Phenotypical and Genotypical Surveillance of Macrolideand Lincosamide Resistance in Group B Streptococcus in BelgiumJ. Descy, Y. Ackermans, R. Boreux, C. Meex, L. Remont, G. RodriguezCuns, P. Melin; Natl. Reference Lab. for Group B Streptococci, Univ. Hosp.,Leige, Belgium.C2-1989 Current Status of Group B Streptococci (GBS) in JapanPenicillin-Resistant GBS is Emerging in Japan?T. Ohno 1 , H. Sawamura 1 , A. Yamada 1 , I. Koita 1 , H. Suematsu 1 , N. Nagano 2 ,M. Toyama 2 , Y. Nagano 2 , K. Kimura 3 , Y. Arakawa 3 , Y. Yamagishi 1 ,H. Mikamo 1 ; 1 Aichi Med. Univ., Aichi, Japan, 2 Natl. Inst. of InfectiousDiseases, Tokyo, Japan, 3 Nagoya Univ., Aichi, Japan.C2-1990 Characteristics of Capsular and Multilocus SequenceTypes of Streptococcus agalactiae from Neonatal InvasiveInfections in JapanK. Ubukata 1 , M. Morozumi 1 , N. Chiba 1 , T. Wajima 1 , H. Sakata 2 , S. Iwata 3 ;1Kitasato Inst. for Life Sci., Kitasato Univ., Tokyo, Japan, 2 Asahikawa-KoseiGen. Hosp., Asahikawa, Japan, 3 Keio Univ. Sch. of Med., Tokyo, Japan.C2-1991 Change in the Prevalent emm Type and Increase in MacrolideResistance among Streptococcus pyogenes Isolated fromInvasive Infections in JapanT. Wajima, M. Morozumi, N. Chiba, K. Ubukata; Kitasato Inst. for LifeSci., Kitasato Univ., Minato-ku, Japan.196September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------245(E)Poster SessionIn Vitro Activity for MycobacteriaWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:E-1992 In Vitro Activities of PNU-100480 and Linezolid againstMycobacterium tuberculosis (MTB) Isolates with Different Degreesof Anti-Tuberculosis Drug ResistanceC. W. Yip 1 , K. M. Kam 1 , T. K. Lam 1 , C. Y. Chan 2 , W. W. Yew 2 ; 1 Publ. Hlth.Lab. Ctr., Dept. of Hlth., Kln, Hong Kong, 2 The Chinese Univ. of HongKong, NT, Hong Kong.E-1993 Clinical Doses of PNU-100480 (U, Sutezolid) Plus Rifampin(R) Synergistically Kills Mycobacterium tuberculosis (Mtb) whileLinezolid (L) Plus R Does NotA. Louie, D. Brown, M. Swift, K. Files, S. Fikes, G. Drusano; Univ. ofFlorida, Orlando, FL.E-1994 Multidrug Resistance Among Newly Diagnosed TuberculosisPatients in Cross River State, NigeriaA. E. Asuquo 1 , B. P. Thumamo 1 , L. N. Abia-Bassey 1 , N. O. Umoh 2 , M. B.Idasa 3 , F. O. Eko 4 ; 1 Univ. of Calabar, Calabar, Nigeria, 2 Ministry of Hlth.,Uyo, Nigeria, 3 Univ. of Calabar Teaching Hosp., Calabar, Nigeria, 4 MorehouseSch. of Med., Atlanta, GA.E-1995 In Vitro Activities of Tedizolid Compared to Linezolidagainst Mycobacterium fortuitumM. H. Cynamon, M. Sklaney; VA Med. Ctr., Syracuse, NY.------------------------------------------------------------------------246(F)Poster SessionNew Ways with Old Friends: Repurposing and NovelFormulationsWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:F-1996 Non-Steroidal Anti-Inflammatory Drugs: AntimicrobialActivity and Influence on Efflux Mediated Resistance to Antibioticsof Gram-Negative RodsA. E. Laudy, J. Kalbarczyk, S. Tyski; Med. Univ. of Warsaw, Warsaw, Poland.F-1997 Antibacterial Spectrum and Structure-Activity Relationshipof Tomatidine AnalogsI. Guay, F. Chagnon, G. Mitchell, K. Bouarab, É. Marsault, F. Malouin;Univ. de Sherbrooke, Sherbrooke, Canada.F-1998 Tomatidine is Bactericidal against Staphylococcus aureus in Co-Culture with Pseudomonas aeruginosa Strains Producing HQNOS. Boulanger, G. Mitchell, E. Frost, É. Marsault, K. Bouarab, F. Malouin;Univ. de Sherbrooke, Sherbrooke, Canada.F-1999 Re-Purposing the Non-Steroidal Anti-Inflammatory DrugDiflunisal to Target Methicillin-Resistant Staphylococcus aureus(MRSA)A. Salvioni 1 , N. Haste 1 , W. Thienphrapa 1 , V. Khodaverdian 2 , G. Yu 2 , M.Shoham 2 , V. Nizet 1 , M. Hensler 1 ; 1 Univ. Calif. San Diego, La Jolla, CA,2Case Western Reserve Univ., Cleveland, OH.F-2000 Benzamil Hydrochloride Has Antifungal Activity againstCandida albicans Biofilms In VitroM. Jahng 1 , H. S. Rane 1,2 , S. M. Bernardo 1,2 , S. A. Lee 1,2 ; 1 New Mexico VAHealthcare System, Albuquerque, NM, 2 Univ. of New Mexico, Albuquerque,NM.F-2001 Silver Nanoparticles: Antibacterial Potential and ApplicationsG. C. Cotton, M. G. Baron, R. A. Dixon; Univ. of Lincoln, Lincoln, UnitedKingdom.F-2002 In Vivo Activity and Pharmacokinetics of Gold Nanoparticlesagainst Multidrug-Resistant Gram-Negative BacteriaY. Zhao 1 , F. Long 1 , X. You 2 , W. Zhang 1 , X. Jiang 1 ; 1 Natl. Ctr. for Nanoscienceand Technology, Beijing, China, 2 Peking Union Med. Coll., Beijing,China.F-2003 Orally Administered DAV131, a Formulated Oral Adsorbent,Inhibits Establishment of Intestinal Colonization by Beta-Lactamine Resistant Klebsiella pneumoniae in Mice Treated byCefotaximeN. Grall 1,2 , N. Ducrot 1 , M. Laurent 1 , S. Sayah-Jeanne 3 , E. Chachaty 4 , T.Nguyen 2 , J. De Gunzburg 3 , A. Andremont 1,2 ; 1 Bichat Hosp., Paris, France,2Univ. Paris Diderot, Paris, France, 3 Da Volterra, Paris, France, 4 Inst. GustaveRoussy, Villejuif, France.F-2004 Enhancing Activity of Tigecycline to Metallo-Beta-Lactamse-ProducingPseudomonas aeruginosa by Using DDA Bicelles:Synergistic Activity and Physico-Chemical BehaviorJ. Aliaga, H. Turano, N. Lincopan; Univ. de São Paulo, São Paulo, Brazil.F-2005 In Vitro Inhibition of Clostridium perfringens Epsilon ToxinUsing Beta-Cyclodextrin Derivatives Provides a Potential Strategyfor Therapeutic DevelopmentM. Boley 1 , T. Robinson 2 , L. Jicsinszky 2 , V. Karginov 2 , K. Langenbach 1 ;1ATCC, Manassas, VA, 2 Innovative Biologics, Herndon, VA.F-2006 Development of an In Vitro Pharmacokinetic/PharmacodynamicModel for Studying Novel Nanoantibiotics: Dextrin-Colistin ConjugatesE. Azzopardi, E. Ferguson, D. Thomas; Cardiff Univ., Cardiff, United Kingdom.F-2007 Use of Small-Angle Neutron Scattering to Investigate theMechanism of Action of Bioresponsive Dextrin-Colistin ConjugatesE. Ferguson 1 , J. Roberts 1 , R. Schweins 2 , D. Thomas 1 , P. Griffiths 1 ; 1 CardiffUniv., Cardiff, United Kingdom, 2 Institut Laue-Langevin, Grenoble, France.F-2008 Comparative In Vitro Toxicity of Colistin, CMS and Dextrin-Colistin ConjugatesE. Ferguson, J. Roberts, D. Thomas; Cardiff Univ., Cardiff, United Kingdom.F-2009 Dihomo-Linolenic Acid (DGLA) Enhances the AntimicrobialEfficacy of Benzoyl PeroxideJ. Rowe, D. Coughlan, M. Manku, J. Climax; Dignity Sci., Dublin, Ireland.Final Program197

Wednesday SCIENTIFIC SESSIONSF-2010 Antimicrobial Activity of EDTA Containing Nanoemulsionson MDR Acinetobacter baumanniiK. Ramalingam 1 , Y. Y. Hwang 2 , V. Lee 1 , A. Rene 2 ; 1 Univ. of Texas Hlth.Sci. Ctr., San Antonio, TX, 2 Naval Med. Res. Unit, San Antonio, TX.F-2011 Antibacterial Activity of Daptomycin and Vancomycin-LoadedPolymeric Particulate Systems for Bone Infections TreatmentI. S. Ferreira 1 , B. Betrisey 2 , A. Bettencourt 1 , A. J. Almeida 1 , A. Trampuz 2 ;1Univ. of Lisbon, Lisbon, Portugal, 2 Univ. Hosp., Lausanne, Switzerland.F-2012 Glyceryl Trinitrate (GTN) is Useful as a Novel Non-AntibioticCatheter Lock for the Prevention of Intraluminal CatheterBiofilm ColonisationJ. Rosenblatt, R. Y. Hachem, T. Dvorak, A. Chaftari, M. Alshuabi, I. I. Raad;U.T.M.D. Anderson Cancer Ctr., Houston, TX.F-2013 Augmenting Antibiotic-Coated Catheters (CVC) Activityagainst Bacterial Biofilm Adherence by Impregnating the Cvcwith VerapamilJ. A. Mohamed, A. Chaftari, R. Y. Hachem, M. Alshuaibi, I. I. Raad;U.T.M.D. Anderson Cancer Ctr., Houston, TX.F-2014 Pathogenesis and Prevention of Ventilator-Associated Pneumonia(VAP): An in Vitro Model Using Antimicrobial-CoatedEndotracheal Tube (ETT)J. Rosenblatt, R. Y. Hachem, R. Reitzel, A. Chaftari, I. I. Raad; U.T.M.D.Anderson Cancer Ctr., Houston, TX.F-2015 Barrier-Forming Oral Formulation Containing CetylpyridiniumChloride (fCPC) Exhibits Potent Activity against OralPathogensJ. Chandra 1 , P. K. Mukherjee 1 , F. Esper 2 , A. M. Ghannoum 3 , B. Sokol 3 , R.A. Salata 2 , M. A. Ghannoum 4 ; 1 Case Western Reserve Univ., Cleveland, OH,2Univ. Hosp. Case Med. Ctr., Cleveland, OH, 3 Oasis Consumer HealthcareLLC, Cleveland, OH, 4 Univ. Hosp. Case Med. Ctr. and Case WesternReserve Univ., Cleveland, OH.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------247(F)Poster SessionNovel Inhibitors of Bacterial GyrB/ParE TopoisomeraseSubunitsWednesday, 9:15 a.m.–11:15 a.m. .........................Halls A-CPresentations:F-2016 In Vitro and In Vivo Biology of Benzothiazole Urea-Based,Dual-Targeting DNA Supercoiling Inhibitors for the Treatmentof Bacterial InfectionsJ. T. Palmer 1 , S. Barker 2 , J. M. Bennett 2 , J. Berry 2 , M. Blair 1 , L. G.Czaplewski 2 , I. Collins 2 , D. Davies 2 , D. J. Haydon 2 , P. Lancett 2 , A. Logan 2 ,C. J. Lunniss 1 , C. Morton 1 , G. R. W. Pitt 1 , D. Offermann 1 , L. Offermann 1 ,S. Pommier 2 , D. Price 2 , N. Stokes 2 , H. Thomaides-Brears 2 , S. P. Tucker 1 ;1Biota Scientific Management, Notting Hill, Australia, 2 Biota Europe, Begbroke,United Kingdom.F-2017 Antibacterial Agents Targeting DNA Gyrase B andTopoisomerase IV: Discovery of a New Class by Structure-BasedDrug DesignX. Li 1 , L. W. Tari 1 , D. Bensen 1 , M. Trzoss 1 , T. Lam 1 , J. Zhang 1 , Z. Chen 1 ,S. J. Lee 1 , M. Cunningham 1 , K. Nelson 1 , V. Brown-Driver 1 , M. Stidham 1 ,T. Nguyen 2 , F. Lightstone 2 , K. Shaw 1 , J. Finn 1 ; 1 Trius Therapeutics, Inc.,San Diego, CA, 2 Lawrence Livermore Natl. Lab., Livermore, CA.F-2018 Antibacterial Agents Targeting DNA Gyrase B and TopoisomeraseIV: Optimization of Gram-Negative AntibacterialActivity and Drug PropertiesJ. Finn 1 , M. Trzoss 1 , X. Li 1 , D. Bensen 1 , T. Lam 1 , J. Zhang 1 , Z. Chen 1 , S.Lee 1 , M. Cunningham 1 , K. Nelson 1 , A. Castellano 1 , B. Kwan 1 , M. Stidham 1 ,V. Brown-Driver, T. Nguyen 2 , F. Lightstone 2 , S. Wong 2 , K. J. Shaw 1 , L. W.Tari 1 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 Lawrence Livermore Natl.Lab., Livermore, CA.F-2018a Antibacterial Agents Targeting DNA Gyrase B and TopoisomeraseIV: Design of Compounds with Broad-Spectrum Gram-Negative Antibacterial ActivityL. Tar 1 , D. Bensen 1 , M. Trzoss 1 , X. Li 1 , T. Lam 1 , J. Zhang 1 , Z. Chen 1 , S. Lee 1 ,M. Cunningham 1 , K. Nelson 1 , M. Stidham 1 , V. Brown-Driver 1 , T. Nguyen 2 ,F. Lightstone 2 , S. Wong 2 , K. J. Shaw 1 , J. Finn 1 ; 1 Trius Therapeutics, SanDiego, CA, 2 Lawrence Livermore Natl. Lab., Livermore, CA.F-2019 Potent Activity of Novel Gyrase/Topoisomerase Inhibitorsagainst Gram-Negative and Gram-Positive Pathogens withImportant Resistance PhenotypesC. M. Pillar, L. Stapert, M. Marchak, D. L. Shinabarger; Micromyx, LLC,Kalamazoo, MI.F-2020 Microbiological Profile of Novel Inhibitors of DNA Gyraseand Topoisomerase IV against Gram-Negative PathogensK. Nelson, A. Castellano, S. Farkas, V. Brown-Driver, K. J. Shaw; TriusTherapeutics, San Diego, CA.F-2021 In Vitro Activity of Novel Gyrase Inhibitor Antimicrobialsagainst Clinical Pseudomonas aeruginosa IsolatesP. R. Tessier, D. P. Nicolau; Hartford Hosp., Hartford, CT.F-2022 Antimicrobial Activity and In Vivo Efficacy of Novel GyrB/ParE Inhibitors versus Burkholderia pseudomalleiV. Driver 1 , N. Podnecky 2 , N. Marlenee 2 , R. Bowen 2 , X. Li 1 , K. J. Shaw 1 ,H. P. Schweizer 2 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 Colorado StateUniv., Fort Collins, CO.F-2023 Broad Spectrum Activity of Novel, Dual Targeting Inhibitorsof Bacterial DNA Gyrase and Topoisomerase IV against BiodefensePathogensK. Montgomery 1 , G. Vanier 1 , K. Nelson 2 , V. Brown-Driver 2 , K. J. Shaw 2 ,P. J. Jackson 1 ; 1 Lawrence Livermore Natl. Lab., Livermore, CA, 2 TriusTherapeutics, Inc., San Diego, CA.F-2024 Advanced Microbiological Profile of New DNA Gyrase/Topoisomerase IV InhibitorsV. Brown-Driver, A. Castellano, K. Nelson, X. Li, T. Lam, M. Trzoss,J. Zhang, Z. Chen S. Lee, K. J. Shaw, J. Finn; Trius Therapeutics, SanDiego, CA.F-2025 Selection and Characterization of E. coli Mutants withReduced Susceptibility to Novel DNA Gyrase/TopoisomeraseIV InhibitorsA. Castellano, J. Locke, S. Farkus, V. Brown-Driver, K. J. Shaw; TriusTherapeutics, Inc., San Diego, CA.198September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONSF-2026 Comparative Pharmacokinetics of Novel Inhibitors of DNAGyrase/Topoisomerase IVV. Ong, V. Brown-Driver, C. L. Hall, G. W. Hough, K. Nelson; TriusTherapeutics, Inc., San Diego, CA.F-2027 Use of Microdosing and Accelerator Mass Spectrometry toEvaluate the Pharmacokinetics of a Novel GyrB/ParE InhibitorM. A. Malfatti 1 , V. Lao 1 , K. W. Turteltaub 1 , C. L. Hall 2 , V. S. Ong 2 ;1Lawrence Livermore Natl. Lab., Livermore, CA, 2 Trius Therapeutics, Inc.,San Diego, CA.F-2028 Activity of Novel, Dual Targeting Inhibitors of BacterialDNA Gyrase and Topoisomerase IV in Murine Infection ModelsT. M. Murphy 1 , M. A. Blair 1 , S. Little 1 , A. M. Slee 1 , V. Brown-Driver 2 , K. J.Shaw 2 ; 1 ViviSource Lab., Inc, Waltham, MA, 2 Trius Therapeutics, Inc., SanDiego, CA.F-2029 In Vitro Activity and Pharmacodynamic (PD) Evaluation ofDual Targeting Inhibitors of Bacterial DNA Gyrase and TopoisomeraseIV (DTIs) against Extracellular and Intracellular Formsof Ciprofloxacin-Susceptible (CIPS) and Ciprofloxacin-Resistant(CIPR) Pseudomonas aeruginosa (PA) and Staphylococcus aureus (SA)J. M. Buyck 1 , S. Lemaire 1 , D. Pierard 2 , F. Van Bambeke 1 , P. M. Tulkens 1 ;1Univ. Catholique de Louvain, Bruxelles, Belgium, 2 Vrije Univ. Brussel,Bruxelles, Belgium.------------------------------------------------------------------------248(F)Poster SessionQuinolones and BeyondWednesday, 9:15 a.m.–11:15 a.m. ................ Halls A-CPresentations:F-2030 Ev-035: Novel 2-Pyridone Based Topoisomerase Inhibitorswith Broad-Spectrum Activity against MDR Pathogens, IncludingQuinolone ResistanceJ. Heim, P. Roussel, D. Milligan, S. Goldman; Evolva, Reinach, Switzerland.F-2031 Ev-035: Synthesis and In Vitro Antibacterial Activity of aNew Series of 2-Pyridone Based Topoisomerase InhibitorsP. Roussel, G. Liu, D. Milligan, S. Goldman, J. Heim; Evolva SA, Reinach,Switzerland.F-2032 Ev-035: In Vitro ADMET, Mouse PK and Efficacy in MurineInfection Models of a New Orally Available Class of AntibioticsG. Salerno, J. Heim, S. Goldman, D. Milligan, P. Roussel; Evolva, Reinach,Switzerland.F-2033 EV-035: Potent Antibiotic Series against Biothreat AgentBurkholderia pseudomalleiS. Goldman 1 , G. Salerno 1 , D. Milligan 1 , P. Roussel 1 , N. Marlenee 2 , R.Bowen 2 , N. Podnecky 2 , H. P. Schweizer 2 , J. Heim 1 ; 1 Evolva, Reinach,Switzerland, 2 Colorado State Univ., Fort Collins, CO.F-2034 Activity and Pharmacokinetics of Clinafloxacin for Bovineand Swine Respiratory DiseaseM. T. Sweeney, R. Quesnell, R. Tiwari, M. LeMay, C. Benner, J. Watts;Pfizer, Kalamazoo, MI.F-2035 DS-8587, a New Generation of Broad Spectrum Quinolone:Pharmacodynamic and Therapeutic Efficacy in Animal InfectionModelsY. Kurosaka, S. Uoyama, C. Ishii, K. Hoshino; Daiichi Sankyo Co., Ltd.,Tokyo, Japan.F-2036 DS-8587, a New Generation of Broad Spectrum Quinolone:In Vitro Antibacterial Activities against Chinese Clinical IsolatesD. Zhu 1 , Y. Kurosaka 2 , K. Hoshino 2 ; 1 Huashan Hosp., Fudan Univ.,Shanghai, China, 2 Daiichi Sankyo, Co., Ltd., Tokyo, Japan.F-2037 DS-8587, a New Generation of Broad Spectrum Quinolone:Antibacterial Spectrum and its In Vitro Activities against ClinicalIsolates in JapanM. Chiba, K. Fujikawa, R. Okumura, K. Yuichi, K. Hoshino; DaiichiSankyo, Co., Ltd., Tokyo, Japan.F-2038 DS-8587, a New Generation of Broad Spectrum Quinolone:Mode of Action and Frequency of Resistant Mutants of MajorPathogensR. Okumura, Y. Onodera, M. Chiba, K. Fujikawa, K. Hoshino; DaiichiSankyo, Co. Ltd., Tokyo, Japan.F-2039 DS-8587, a New Generation of Broad Spectrum Quinolone:In Vitro Antibacterial Activities against A. baumanniiS. Higuchi 1,2 , Y. Onodera 1 , M. Chiba 1 , K. Hoshino 1 , N. Gotoh 2 ; 1 DaiichiSankyo, Co. Ltd., Tokyo, Japan, 2 Kyoto Pharmaceutical Univ., Kyoto, Japan.F-2040 DS-8587, a New Generation of Broad Spectrum Quinolone:In Vitro Antibacterial Activity against Japanese Clinical Isolatesof ESBL Producing Escherichia coliY. Ishii 1 , M. Chiba 2 , K. Hoshino 2 , K. Tateda 1 ; 1 Toho Univ. Sch. of Med.,Tokyo, Japan, 2 Daiichi Sankyo, Co., Ltd., Tokyo, Japan.F-2041 DS-8587, a New Generation of Broad Spectrum Quinolone:Nonclinical and Clinical Pharmacokinetic ProfilesN. Kobayashi 1 , T. Shimizu 1 , K. Toyama 1 , E. Kamiyama 1 , E. Suzuki 1 , T.Abiko 1 , H. Fukase 2 , T. Tokui 1 , T. Izumi 1 ; 1 Daiichi Sankyo, Co. Ltd., Tokyo,Japan, 2 CPC Clinical Trial Hosp., Kagoshima, Japan.F-2042 DS-8587, a New Generation of Broad Spectrum Quinolone:Safety Profile in Preclinical StudiesH. Miida, Y. Tsuchiya, S. Itoh, K. Noritake, T. Ishizaka, W. Takasaki; DaiichiSankyo, Co. Ltd., Shizuoka, Japan.F-2043 DS-8587, a New Generation of Broad Spectrum Quinolone:Pharmacodynamics and In Vivo Efficacy against AcinetobactorbaumanniiM. Pandya 1 , T. K. Barman 1 , E. P. M. Rao 1 , M. Kumar 1 , S. Singhal 1 , D.J. Upadhyay 1 , Y. Kurosaka 2 , S. Uoyama 2 , C. Ishii 2 , K. Hoshino 2 ; 1 DaiichiSankyo Life Sci. Res. Ctr. Gurgaon, India, 2 Daiichi Sankyo, Co. Ltd., Tokyo,Japan.F-2044 DS-8587, a New Generation of Broad Spectrum Quinolone:In Vitro Antibacterial Activity against Clinical Isolates fromPostoperative Intraabdominal Infections (IAIs)Y. Takesue 1 , M. Chiba 2 , K. Hoshino 2 ; 1 Hyogo Coll. of Med., Nishinomiya,Japan, 2 Daiichi Sankyo, Co. Ltd., Tokyo, Japan.Final Program199

Wednesday SCIENTIFIC SESSIONSF-2045 DS-8587, a New Generation of Broad Spectrum Quinolone:In Vitro Antibacterial Activity against 9 Major Anaerobic Speciesof Japanese Clinical IsolatesH. Mikamo 1 , Y. Yamagishi 1 , H. Suematsu 1 , H. Sawamura 1 , M. Chiba 2 , R.Okumura 2 , K. Hoshino 2 ; 1 Aichi Med. Univ., Aichi, Japan, 2 Daiichi Sankyo,Co. Ltd., Tokyo, Japan.F-2046 In Vitro Activity of KPI-10 against Clinically ImportantGram-Negative BacteriaJ. Deane 1 , A. Simenauer 1 , Y. Ge 2 , P. B. Eckburg 2 , D. Sahm 1 ; 1 Eurofins,Chantilly, VA, 2 Kalidex Pharmaceuticals, Inc., Menlo Park, CA.F-2047 In Vitro Activity of KPI-10 against Clinically ImportantGram-Positive BacteriaJ. Deane 1 , A. Simenauer 1 , Y. Ge 2 , P. Eckburg 2 , D. Sahm 1 ; 1 Eurofins, Chantilly,VA, 2 Kalidex Pharmaceuticals Inc., Menlo Park, CA.F-2048 Activity of Novel Fluoroquinolone, KPI-10, vs. Multidrug-Resistant Bacteria, Including those with NDM-1 CarbapenemaseD. M. Livermore, M. Warner, S. Mushtaq; Hlth. Protection Agency, London,United Kingdom.F-2049 In Vitro Activity and DNA Gyrase Inhibitory Activity ofKPI-10, a Novel Fluoroquinolone (FQ), against Quinolone-Susceptible (QS) and Quinolone-Resistant (QR) E. coliD. Kazamori, K. Sugimoto, Diploma, H. Aoi, K. Itoh, Y. Kuramoto, A.Yazaki; Wakunaga Pharmaceutical Co. Ltd., Hiroshima, Japan.F-2050 In Vitro Activity of KPI-10 Tested against a GlobalCollection of Acinetobacter spp. Including Multidrug-Resistant(MDR) StrainsR. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones;JMI Lab., N Liberty, IA.F-2051 KPI-10 In Vitro Activity Tested against Pathogens CommonlyAssociated with Community-Acquired Bacterial Pneumonia(CABP) InfectionsR. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones;JMI Lab., N Liberty, IA.F-2052 KPI-10, a Novel Flouroquinolone (FQ) Tested againstNeisseria gonorrhoeae Including Ciprofloxacin Non-Susceptible(CIP-NS) and Penicillin Non-Susceptible (PEN-NS) StrainsR. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones;JMI Lab., N Liberty, IA.F-2053 In Vitro Activity of KPI-10 Tested against PathogensCommonly Associated with Urinary Tract infections (UTIs)R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones;JMI Lab., N Liberty, IA.F-2054 Activity of KPI-10 against Highly Resistant E. coli andK. pneumoniae from Various CountriesM. A. Habeeb 1 , P. Eckburg 2 , J. Ge 3 , C. G. Giske 4 ; 1 Natl. Inst. for Biotechnologyand Genetic Engineering (NIBGE), Faisalabad, Pakistan, 2 KalidexPharmaceutical Inc, Menlo Park, CA, 3 Kalidex Pharmaceuticals, Menlo Park,CA, 4 Karolinska Inst., Stockholm, Sweden.F-2055 In Vivo Activity of KPI-10, a Novel Fluoroquinolone (FQ),in Mouse Systemic and Local Infection Models Caused byMultidrug- and FQ-Resistant PathogensH. Amano, H. Aoi, K. Sakata, K. Inokuma, D. Kazamori, K. Itoh, Y.Kuramoto, A. Yazaki; Wakunaga Pharmaceutical Co. Ltd., Akitakata, Japan.F-2056 50% Effective Dose (ED50) Determination of KPI-10 forTreating Sepsis in Mice Due to Quinolone-Susceptible (QS) andQuinolone-Resistant (QR) Nosocomial Pathogens: Comparisonwith Ciprofloxacin (CIP)C. Jacqueline 1 , M. Davieau 1 , C. Desessard 2 , A. F. Miegeville 1 , Y. Ge 3 , G.Potel 1 , J. Caillon 1 ; 1 UPRES EA 3826, Nantes, France, 2 Atlangram, Nantes,France, 3 Kalidex Pharmaceuticals Inc, Menlo Park, CA.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------249(F)Poster SessionTargeting Gram-Negative PathogensWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:F-2057 FimH Antagonists: A Selective and Highly Effective NovelTherapeutic Approach for the Treatment of Urinary Tract InfectionB. Ernst, D. Abgottspon, M. Scharenberg, X. Jiang, O. Schwardt; Inst. ofMolecular Pharmacy, Basel, Switzerland.F-2058 N-Chlorotaurine, a Long-Lived Endogenous Oxidant, InactivatesShiga Toxin 2 of Enterohemorrhagic Escherichia coliM. Nagl 1 , C. Eitzinger 1 , S. Ehrlenbach 1 , H. Lindner 1 , L. Kremser 1 , W.Gottardi 1 , D. Orth 1 , D. Debabov 2 , M. Anderson 2 ; 1 Innsbruck Med. Univ.,Innsbruck, Austria, 2 Novabay, Emeryville, CA.F-2059 Activity of Novel Pyrrolocytosine Agents against Multidrugand Carbapenem Resistant Klebsiella pneumoniaeM. R. Jacobs 1 , S. Bajaksouzian 1 , A. R. Windau 1 , A. N. Foster 1 , K. M. Hujer 2 ,R. A. Bonomo 2 ; 1 CWRU/Univ. Hosp, Cleveland, OH, 2 CWRU,VAMC,Cleveland, OH.F-2060 Antimicrobial Activity and Synergistic Effect of SyntheticPeptides against Antibiotic Resistant Pseudomonas aeruginosafrom Gallbladder Bile of Acute Cholecystitis PatientsJ. Chae 1 , B. Son 2 , Y. Park 3 , W. Choe 1 , S. Ahn 2 , S. Kim 2 , Y. Jo 2 , Y. Park 2 ; 1 Lab.Med., Eulji Univ. Coll. of Med., Eulji-Gen. Hosp., Seoul, Korea, Republicof, 2 Internal Med., Eulji Univ. Coll. of Med., Eulji-Gen. Hosp., Seoul,Korea, Republic of, 3 Biotechnology and Res. Ctr. for Proteineous Materials(RCPM), Chosun Univ., Kwangju, Korea, Republic of.F-2061 Rational Design of Engineered Antimicrobial PeptidesConsisting Exclusively of Arginine and TryptophanB. Deslouches, J. D. Steckbeck, J. K. Craigo, R. C. Montelaro; Univ. ofPittsburgh, Pittsburgh, PA.F-2062 OligoG, a Novel Antimicrobial Alginate Oligosaccharide,Impedes Biofilm Development by Inhibition of Bacterial MotilityC. Emanuel 1 , S. Khan 1 , K. E. Hill 1 , E. Onsøyen 2 , R. Myrvold 2 , A. Dessen 2 ,D. W. Thomas 1 ; 1 Cardiff Univ., Cardiff, United Kingdom, 2 Algipharma AS,Sandvika, Norway.F-2063 Nanoscale Characterisation of the Interaction of AlginateOligosaccharide Nanomedicines with the Bacterial Cell Surfaceof Pseudomonas aeruginosaL. C. Powell 1,2 , M. F. Pritchard 1,2 , S. Khan 1 , C. Wright 2 , E. Onsøyen 3 , R.Myrvold 3 , K. E. Hill 1 , D. W. Thomas 1 ; 1 Cardiff Univ., Cardiff, UnitedKingdom, 2 Swansea Univ., Swansea, United Kingdom, 3 Algipharma AS,Sandvika, Norway.200September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONSF-2064 Modification and Rheological Properties of PseudomonalBiofilms and Cystic Fibrosis SputumM. F. Pritchard 1,2 , L. C. Powell 1,2 , S. Khan 1 , A. Sowedan 2 , C. J. Wright 2 ,K. Hawkins 2 , I. J. Doull 1 , E. Onsøyen 3 , R. Myrvold 3 , K. E. Hill 1 , D. W.Thomas 1 ; 1 Cardiff Univ., Cardiff, United Kingdom, 2 Swansea Univ.,Swansea, United Kingdom, 3 Algipharma AS, Sandvika, Norway.F-2065 SASP: In Vitro Characterisation of PT3.33 for the Treatmentof Multidrug-Resistant Pseudomonas aeruginosaS. Baines 1 , M. Knetchel 2 , C. Pillar 2 , D. Shinabarger 2 , A. Wilkinson 1 ,H. Fairhead 1 ; 1 Phico Therapeutics Ltd, Cambridge, United Kingdom,2Micromyx, Kalamazoo, MI.F-2066 SASP: Efficacy against Pseudomonas aeruginosa in a MurinePneumonia ModelJ. Gould 1 , L. Payne 1 , P. Warn 1 , A. Wilkinson 2 , H. Fairhead 2 ; 1 EuprotecLtd., Manchester, United Kingdom, 2 Phico Therapeutics Ltd., Cambridge,United Kingdom.F-2067 Activity of FAB001 in Combination with AntimicrobialAgents against Acinetobacter baumanniiC. Soulama-Mouze 1 , C. Zampaloni 2 , F. Monti 2 , C. Siegmund 2 , S. Hawser 2 ;1FAB Pharma, Paris, France, 2 IHMA Europe Sàrl, Epalinges, Switzerland.F-2068 Mastoparan Analog, (mast-1) an Antimicrobial Peptide Activeagainst Pan-Resistant A. baumanniiX. Vila-Farrés 1 , M. Teixidó 2 , E. Giralt 2 , J. Vila 1 ; 1 CRESIB, Barcelona, Spain,2IRB, Barcelona, Spain.F-2069 Dual Inhibitors of Biofilm Formation and Beta-LactamResistanceC. Melander; North Carolina State Univ., Raleigh, NC.F-2070 A Novel Inhaled Anti-Infective Agent (NB-401) for CFLung Infections: Estimating In Vivo Airway Surface LiquidConcentrations in HumansC. F. Lange 1 , S. I. Gracon 2 , J. R. Baker, Jr 2 ; 1 Univ. of Alberta, Edmonton,Canada, 2 NanoBio Corp., Ann Arbor, MI.F-2071 Quorum Sensing Inhibition of Chromobacterium violaceumby Caffeoylquinic Acid- and Flavanol-Rich Fractions fromManuka PropolisA. T. Gemiarto, E. W. C. Chan, C. S. Y. Lim; UCSI Univ., Kuala Lumpur,Malaysia.F-2072 Structural Studies, SAR Analyses, and Antibacterial Testingof a New Class of F. tularensis Enoyl Reductase (FabI) InhibitorsS. Mehboob 1 , J. Song 2 , P. Su 1 , K. Hevener 1 , T. Boci 1 , J. Deng 1 , M.Ghassemi 1 , Y. Zhang 1 , B. Santarsiero 1 , H. Jeong 1 , J. L. Cook 1 , A. K.Ghosh 2 , M. E. Johnson 1 ; 1 Univ. of Illinois Chicago, IL, 2 Purdue Univ.,West Lafayette, IN.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------250(K)Poster SessionBone InfectionsWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:K-2073 Characteristics of Septic Arthritis: A Retrospective StudyOver 11 YearsL. N. Walti 1 , L. Meyer 2 , T. Hugle 2 , A. Trampuz 1 ; 1 Univ. Hosp., Lausanne,Switzerland, 2 Univ. Hosp., Basel, Switzerland.K-2074 Prognostic Factors of Calcaneal OsteomyelitisA. Merlet, F. Dauchy, C. Cazanave, H. Dutronc, B. de Barbeyrac, D.Chauveaux, R. Weigert, M. Dupon; Univ. Hosp. Pellegrin, Bordeaux, France.K-2075 Epidemiology of Adverse Events Associated with ProlongedAntibiotic Therapy for Osteoarticular InfectionsA. Iten, M. Schindler, W. Zingg, L. Pagani, I. Uckay, D. Pittet; HUG,Geneva, Switzerland.K-2076 Etiology and Choice of Empirical Antibiotics of PyogenicSpondylodiscitis in Patients with Invasive Spinal ProceduresK. Kim 1 , J. Koh 1 , J. Yi 2 , S. Lee 1 ; 1 Pusan Natl. Univ. Hosp., Busan, Korea,Republic of, 2 Pusan Natl. Univ. Yangsan Hosp., Busan, Korea, Republic of.K-2077 Long-Term Oral Suppressive Antibiotic Therapy in Boneand Joint InfectionsG. Fresco, C. Javier, Y. Meije, J. Rodríguez, V. Pintado, S. Alonso, P. Martín-Dávila, J. Fortún; Hosp. Ramon Y Cajal, Madrid, Spain.K-2078 Experience with Daptomycin (DAP) for Treatment ofDevice-Associated Osteomyelitis (DAO)E. D. Hermsen 1 , L. Mendez-Vigo 1 , E. F. Berbari 2 , T. Chung 1 , M. J. Yoon 1 ,K. C. Lamp 1 ; 1 Cubist Pharmaceuticals, Lexington, MA, 2 Mayo Clinic,Rochester, MN.K-2079 Gram-Negative Pyogenic Vertebral Osteomyelitis: Is MoreDifficult to Manage?O. Cho, Y. Suh, I. Bae, S. Kim; Gyeongsang Natl. Univ. Hosp., Jinju, Korea,Republic of.------------------------------------------------------------------------251(K)Poster SessionHand HygieneWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:K-2080 Hand Hygiene Compliance in ICU: Explanation by Socio-Anthropological ObservationM. Surska 1 , A. Melbörde Kelmere 2 , G. Freijs 2 , V. Skultans 3 , A. Luse 1 , K.Sedlinieks 1 , U. Dumpis 2 ; 1 Riga Stradins Univ., Riga, Latvia, 2 Stradins Univ.Hosp., Riga, Latvia, 3 Univ. of Bristol, Bristol, United Kingdom.K-2081 Validation of a User-Centered Infotainment Board Game inInfection-Control and Hand HygieneWithdrawnFinal Program201

Wednesday SCIENTIFIC SESSIONSK-2082 Novel Water Based Method of Impregnating Exam Gloveswith Gendine AntisepticR. Reitzel, J. Rosenblatt, R. Y. Hachem, I. I. Raad; U.T.M.D. AndersonCancer Ctr., Houston, TX.K-2083 Tracking the Progress of Hand Hygiene Indicators in HealthcareFacilities WorldwideB. Allegranzi 1 , A. Gayet-Ageron 2 , H. Sax 3 , S. Bagheri Nejad 1 , A.Stewardson 2 , D. Pittet 2 ; 1 WHO, Geneva, Switzerland, 2 Univ. of GenevaHosp., Geneva, Switzerland, 3 Univ. Hosp. of Zurich, Zurich, Switzerland.K-2084 Infection Control Practices in a University Hospital DentalClinic: Do Dentists Follow the Recommendations?U. K. Frank 1 , U. Haegele 2 ; 1 Heidelberg Univ. Hosp., Heidelberg, Germany,2Freiburg Univ. Dental Clinic, Freiburg, Germany.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.------------------------------------------------------------------------252(K)Poster SessionVascular Catheter and Device Related InfectionsWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:K-2085 Daptomycin (Dapto) with or without 25% Ethanol Comparedto Combinations of Minocycline (Mino), EDTA, and 25% Ethanol(ETOH) against Biofilm Producing MRSA or MRSE IsolatesK. M. Mullane, D.O., R. Estes, J. Theusch, A. Beck, D. L. Pitrak; Univ. ofChicago, Chicago, IL.K-2086 Non-Central Line Related Laboratory Confirmed BloodstreamInfection (LCBI)M. M. De Vries, P. Mancos; Methodist Hosp., Gary, IN.K-2087 Prospective Study of Clinical Outcome After a TotallyImplantable Venous Access Port-Related Infection in OncologyD. Lebeaux, B. Larroque, J. Gellen-Dautremer, V. Leflon-Guibout, C.Dreyer, S. Bialek, A. Froissart, O. Hentic, C. Tessier, V. Zarrouk, B. Fantin;Hosp. Beaujon, Clichy, France.K-2088 Sustained Reduction of Catheter-Related Infections AfterIntroduction of Chlorhexidine (CHX)-Impregnated DressingsP. Eggimann, C. Joseph, M. Thévenin, P. Voirol, G. Zanetti, J. Revelly, Y.Que; Ctr. Hosp. Univ. Vaudois (CHUV), Lausanne, Switzerland.K-2089 Outcome and Predictive Factors of Treatment Failure inStaphylococcal Vascular Graft Infection (SVGI): Impact ofRifampin (RIF)L. Legout 1 , E. Senneville 1 , M. Valette 1 , C. Rouyer 1 , M. Massongo 1 , P.Delia 1 , B. Sarraz-Bournet 1 , S. Haulon 2 , O. Leroy 1 ; 1 Dron Hosp., Tourcoing,France, 2 Univ. Hosp. of Lille, Lille, France.K-2090 Catheter-Related Bloodstream Infections Caused by UnusualMicroorganismsE. Reigadas, M. Rodríguez-Créixems, C. Sánchez-Carrillo, P. Martín-Rabadán, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.K-2091 Hospital-Wide Objective Measurement of the Adequacy inthe Number of Vascular Catheters and Catheter Lumens as a Toolfor the Reduction of Catheter-Related BacteremiaA. Carretero, D. Díaz, C. Fuentes, J. González, M. Fernández-Ruiz, A.García-Reyne, J. Origüen, R. San Juan, M. Lizasoain, C. Lumbreras, J.Aguado, F. López-Medrano; Univ. Hosp. 12 de Octubre, Madrid, Spain.K-2092 Persistent Catheter-Related Staphylococcus aureus Bacteremiaafter Catheter Removal and Initiation of Appropriate AntimicrobialTherapy: Incidence, Risk Factors, and OutcomesK. Park, Y. Chong, S. Kim, S. Lee, S. Choi, J. Jeong, J. Woo, Y. Kim; AsanMed. Cencer, Seoul, Korea, Republic of.K-2093 Endoluminal Catheter Colonization Surveillance CulturesReduce Catheter-Related Bloodstream Infections (CRBSI) inHemodialysisP. Brañas, E. Morales, F. Rios, F. Sanz, E. Gutierrez, N. Quintanilla, M.Sanchez, M. A. Orellana, J. Otero, F. Chaves; Hosp. 12 de Octubre, Madrid,Spain.K-2094 Staphylococcus epidermidis LPXTG Surface Protein SesC isAssociated with Device-Related InfectionsM. Shahrooei, L. Khodaparast, L. Khodaparast, J. Van Eldere; KULeuven,Leuven, Belgium.K-2095 Daptomycin is Effective as First Line Treatment of Catheter-Related Bacteraemia: Results from The EUCORE StudyP. Nikolaidis 1 , M. Allen 2 , A. Robb 3 , A. Beiras-Fernandez 4 , R. Utili 5 , B.Gragera 6 , A. Gonzalez-Ruiz 7 , N. Kröger 8 , K. Bouylout 9 , R. Pathan 10 , R.Chaves 9 ; 1 Div. of Internal Med., Thessaloniki, Greece, 2 Novartis, Frimley,United Kingdom, 3 Camberley, Newcastle upon Tyne, United Kingdom,4Univ. of Munich, Munich, Germany, 5 Monaldi, Napoli, Italy, 6 Hosp. Univ.Vall d’Hebron, Barcelona, Spain, 7 Darent Valley Hosp., Dartford, UnitedKingdom, 8 Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany, 9 Novartis,Basel, Switzerland, 10 Novartis, HYD, India.K-2096 Efficacy of a Novel Gendine Coated Peripherally InsertedCentral Venous Catheters (picc) against Multidrug-ResistantPathogensJ. A. Mohamed, R. Y. Hachem, A. Chaftari, Y. Jiang, I. I. Raad; U.T.M.D.Anderson Cancer Ctr., Houston, TX.K-2097 In Vivo Activity of Antibiofilm/Antimicrobial-TreatedCentral Venous Catheters against Colonization and Device-AssociatedInfectionM. D. Mansouri, R. O. Darouiche; Baylor Coll. of Med., Houston, TX.K-2098 Targeting Biofilm Eradication in Totally Implanted CentralVenous Ports by Lock Solutions in an In Vitro Dynamic Model ofBiofilm FormationL. Olivier 1 , C. Aumeran 1 , O. Traore 1 , C. Forestier 2 ; 1 CHU Clermont-Ferrand, Clermont-Ferrand, France, 2 Univ. Blaise Pascal, Clermont-Ferrand,France.202September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS------------------------------------------------------------------------253(K)Poster SessionVentilator- Associated PneumoniaWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:K-2099 Meta-Analysis of Linezolid vs. Glycopeptide for Treatmentof Proven Methicillin-Resistant Staphylococcus aureus (MRSA)Nosocomial Pneumonia (NP)WithdrawnK-2100 Comparative Patterns of Drug Regimens in Antipsychotic-Receiving Geriatric Patients with Nosocomial PneumoniaJ. Westphal 1 , F. Jehl 2 , C. Nonnenmacher 3 ; 1 Regional Agency for Hlth.,Paris, France, 2 Univ. Lab. for Microbiol., Strasbourg, France, 3 Hosp. Ctr.,Strasbourg-Brumath, France.K-2101 The Systematic Application of Intermitent Aspiration ofSubglottic Secretions (IASS) in a Major Heart Surgery (MHS)-Intensive Care Unit is Feasible and Cost-EffectiveM. Perez Granda; Hosp. Gral Univ. Gregorio Marañon, Madrid, Spain.------------------------------------------------------------------------254(L1)Poster SessionBone and Joint InfectionsWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:L1-2102 Streptococcal Vertebral Osteomyelitis (SVO): MultipleFaces for the Same DiseaseO. Murillo 1 , A. Roset 1 , B. Sobrino 2 , J. Lora 1 , R. Verdaguer 1 , E. Jimenez-Mejias 3 , J. Nolla 1 , J. Colmenero 2 , J. Ariza 1 ; 1 Hosp. Bellvitge, Barcelona,Spain, 2 Hosp. Carlos Haya, Malaga, Spain, 3 Hosp. Virgen Rocio, Sevilla,Spain.L1-2103 Which Duration of Decubitus in Vertebral Osteomyelitis?G. Gras 1 , D. Mulleman 1 , H. Harrabi 1 , K. Fevre 1 , M. Dupon 2 , B. Marchou3 , C. Marcelli 4 , L. Bernard 1 ; 1 CHRU de Tours, Tours, France, 2 CHU deBordeaux, Bordeaux, France, 3 CHU de Toulouse, Toulouse, France, 4 CHU deCaen, Caen, France.L1-2104 Vertebral Osteomyelitis Without Bacteremia: How to ObtainMicrobiological Diagnosis?R. Buzele 1 , G. Gras 1 , J. J. Parienti 2 , F. Debiais 3 , A. Dinh 4 , C. Marcelli 2 , M.Dupon 5 , F. Roblot 3 , L. Bernard 1 ; 1 CHRU de Tours, Tours, France, 2 CHU deCaen, Caen, France, 3 CHU de Poitiers, Poitiers, France, 4 AP-HP, Garches,France, 5 CHU de Bordeaux, Bordeaux, France.L1-2105 Daptomycin Versus Comparator for Treatment of ProstheticJoint Infection (PJI): Prevalence and Susceptibility of InfectingStaphylococciG. M. Thorne, S. Rege, S. Yankelev, C. Gupta, D. Anastasiou, J. Steenbergen,E. Campanaro; Cubist Pharmaceuticals, Lexington, MA.L1-2106 Efficacy of Clindamycin in Combination with Rifampin orFluoroquinolones for Therapy in Staphylococcal OsteoarticularInfectionsC. Saroufim, Y. El-Samad, F. Brazier., B. Brunschweiler, B. Canarelli, Y.Douadi, JP Lanoix. E. Justinien, JL Schmit; Amiens Univ. Hosp., Amiens,France.------------------------------------------------------------------------255(L2)Poster SessionUrinary Tract InfectionWednesday, 9:15 a.m.–11:15 a.m. ................Halls A-CPresentations:L2-2107 Surveillance of Antimicrobial Susceptibility of Aerobic andFacultative Gram-Negative Bacilli Isolated from Patients withUrinary-Tract Infections in China: The 2010-2011 Study forMonitoring Antimicrobial Resistance Trends (SMART)Q. Yang 1 , H. Zhang 1 , Y. Wang 1 , M. Chen 1 , R. E. Badal 2 , Y. Xu 1 ; 1 PekingUnion Med. Coll. Hosp., Beijing, China, 2 Intl. Hlth. Management Associates,Schaumburg, IL.L2-2108 Prevalence and Risk Factors (RF) of Extended-Spectrum-Lactamases (ESBLs) Producing E. coli (EC) in CommunityOnset (CO) Urinary Tract Infections (UTI)J. J. Maya 1 , A. Correa 1 , R. Pacheco 1 , V. M. Blanco 1 , H. Vargas 2 , A. Y. Celis 2 ,C. M. Montoya 3 , M. Garzón 3 , F. Rosso 4 , L. Matta 5 , M. E. Vallejo 1,6 ,M. V. Villegas 1 ; 1 CIDEIM, Cali, Colombia, 2 Secret. Distr. Salud, Bogotá,Colombia, 3 H. El Tunal, Bogotá, Colombia, 4 Fund. Clin. Valle del Lili, Cali,Colombia, 5 Corp. Comfenalco Valle – Univ. Libre., Cali, Colombia, 6 Univ.Pontificia Bolivariana, Medellín, Colombia.L2-2109 Hospital Epidemiology of Urinary Tract Infections/ColonizationsDue to ESBL-Producing Escherichia coliR. Lepeule, V. Leflon, D. Vanjak, J. R. Zahar, M. Lafaurie, C. Besson, A.Lefort; Groupe des Référents en Infectiologie d’Ile de France (GRIF), Paris,France.L2-2110 Risk Factors of Bacteremia in Urinary Tract InfectionsA. Lalueza, N. Bermejo, R. García, O. Jiménez, B. Ponce, S. Bermejo, F.López-Medrano, A. G-Reyne, J. Aguado; Hosp. Madrid, Spain.L2-2111 Standardized, Low-Dose Daptomycin is Effective for theTreatment of Urinary Tract InfectionsM. Moaddab, H. R. Palmer, K. Putney; St. Luke’s Episcopal Hosp.,Houston, TX.L2-2112 A Micro-Patterned Surface Reduces Microbial ColonizationAssociated with Catheter-Associated Urinary Tract InfectionWithdrawnL2-2113 Increased ESBL Prevalence with Time in Escherichia coliand Klebsiella spp from >50.000 Samples from the Community of aLarge City as a Function of Age, Sex, and LocationJ. L. L. Rocha 1,2 , F. F. Tuon 3 , J. R. Johnson 4 ; 1 Frischmann Aisengart/DASAMed. Diagnóstica, Curitiba, Brazil, 2 Hosp. VITA, Curitiba, Brazil, 3 Hosp.Univ. Evangélico, Curitiba, Brazil, 4 VA Med. Ctr. and Univ. of Minnesota,Minneapolis, MN.Final Program203

Wednesday SCIENTIFIC SESSIONSL2-2114 Prospective Study of Asymptomatic Bacteriuria in FemalePatients with Autoimmune Rheumatic DiseasesS. Georgiadou, M. Gamaletsou, I. Mpanaka, A. Vlachou, V. Syriou, G.Kaltsas, M. Tektonidou, M. Manoussakis, N. Sipsas; Natl. and KapodistrianUniv. of Athens, Athens, Greece.L2-2115 Economic Evaluation of Ceftibuten in the Treatment ofUncomplicated Infection of Urinary Tract in MexicoM. V. Blandon 1 , A. Reyes 2 ; 1 Merck Sharp & Dohme, Mexico, Mexico,2Hosp. Infantil de Mexico Federico Gomez, Mexico, Mexico.L2-2116 Selecting Empiric Treatment for Urinary Tract InfectionsDue to Multidrug-Resistant EnterobacteriaceaeT. Khawcharoenporn 1 , S. Vasoo 2 , K. Singh 2 ; 1 Thammasat Univ.,Pathumthani, Thailand, 2 Rush Univ. Med. Ctr., Chicago, IL.L2-2117 Empirical Therapy for Severe Urinary Tract Infection (UTI)in an Era of Increasing ESBL-Producing Community-AcquiredEnterobacteriaceae: A Model-Based Estimation of EffectivenessJ. J. Parienti 1,2 , J. C. Lucet 2 , A. Lefort 3 , E. Casalino 2 , L. Armand-Lebèvre 2 ,M. Wolff 2 , F. Caron 4 , R. Leclercq 1 , Y. Yazdanpanah 2 ; 1 Côte de Nacre Univ.,Caen, France, 2 CHU Bichat, Paris, France, 3 Beaujon, Paris, France, 4 CHURouen, Rouen, France.L2-2118 National Trends in Antibiotic Prescribing for UncomplicatedCystitis in WomenJ. C. McGregor 1 , M. R. Elman 1 , C. Dent 2 , D. T. Bearden 1 ; 1 Oregon StateUniv., Oregon Hlth. & Sci. Univ., Portland, OR, 2 Oregon Publ. Hlth. Div.,Portland, OR.Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.204September 9-12 |

NOTESFinal Program205

NOTES206 September 9-12 |

NotesIndices

Notes

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberAAarnoutse, R. E. .................161, A-1268Aaron, S. ......................... 123, 1095Abad, E. D. .....................171, D-1428Abad, M. .............H-222, 019; H-1567, 179Abad, R. ......................L1-1653, 187Abadir, D. ......................A-1245, 161Abbadi, D. R. ...................K-1604, 183Abdala, E. ......................K-1603, 183Abdel Hady, W. ...................B-646, 084Abdel Hardy, W. ........ B-654, 084; B-655, 084Abdel-Massih, R. ................. T-364, 029Abdelhameed, M. ................A-1294, 163Abdelraouf, K. ..........A-025, 004; A-028, 004;.............................A-029, 004;Abdul Ghafur, K. ........P-565, 075; P-1004, 112Abdul-Jabbar, A. ..................K-261, 023Abed, Y. ........................V-1079, 117Abel, C. ...............F-843, 099; F-844, 099;....................F-845, 099; F-846, 099Abel, S. .........................K-238, 020Abel zur Wiesch, P. ................K-238, 020Abgottspon, D. .................. F-2057, 249Abia-Bassey, L. N. ................E-1994, 245Abiko, T. ....................... F-2041, 248Abildskov, K. M. ..................A-026, 004Ablah, E. .......................L1-284, 025Abo-Shadi, M. M. ................D-1407, 170Abraham, T. .....................A-1766, 200Abreu, J. A. .....................C2-704, 088Abreu, M. O. .................... F-1513, 176Abruzzo, G. ...................... F-810, 096Abu-Elmagd, K. ................. T-1031, 113Abu Oun, M. ...................C1-1208, 156Achermann, Y. ...................K-1125, 129Achi, S. .........................M-972, 111Ackermann, G. ...................D-179, 013Ackermans, Y. ..................C2-1988, 244Acosta, F. ........................B-649, 084Adam, H. J. ..........C2-103, 009; C2-135, 010;........C2-149, 010; E-194, 015; 169; E-779,.......E-191, 015; E-200, 015; C2-1360, 167;................C2-1379, 093; E-1462, 173Adams-Haduch, J. M. .............C2-112, 009Adams-Sapper, S. ................C2-110, 009Adamson, R. ....................K-1598, 182Adamu, H. ......................G-1748, 198Addoud, P. ...................... P-1011, 112Adelson, M. E. ................... P-563, 075Adeniyi, B. A. ..................C2-1898, 236Ader, F. .........................T-360, 029Adesanya, A. F. ..................L1-959, 109Adler, A. .............C2-109, 009; K-557, 074Adler, F. .......................G3-1560, 178Adler, H. .......................C2-082, 007Adler-Moore, J. ........M-967, 111; M-992, 111Adler-Shohet, F. ................G3-1561, 178Adrian, P. .......................G-1751, 198Adrian, P. V.. . . . . . . . . . . . . . . . . . . . . . D-172, 013Adrianaki, A. ....................M-1696, 191Adriani, K. S. ...................L1-1648, 187Advincula, M. ........B-1326, 165; K-1614, 184;............................K-1615, 184Aebi, S. ........................C2-116, 009Aerts, L. ......................... V-399, 030Africano, F. J. ...................C2-1915, 237Agarwal, A. .....................M-1061, 115Aggarwal, S. .....................A-618, 082Agotesku, A. ....................D-1416, 170Aguado, J. M. ..........T-340, 029; T-359, 029;.......K-948, 107; T-1071, 116; K-2091, 252;...........................L2-2110, 255Agudelo, M. .........A-1945, 240; A-1968, 241Aguiar, B.. . . . . . . . . . . . . . . . . . . . . . . C2-716, 088Aguiar, S. I. ............G-865, 100; G-866, 100Aguiar-Alves, F. .................C2-1377, 169Aguilar, L. ......................K-1608, 184Aguilar-Guisado, M. ..............K-1924, 239Aguinaga, A. .........D-1439, 171; D-1440, 171Ahmed, G. F. ....................A-1763, 200Ahmed, H. ......................K-902, 104Ahmed, M. M. ..................C2-711, 088Ahmed-Bentley, J. .................K-561, 074Ahn, J. ................H-230, 019; K-916, 104Ahn, S.. . . . . . . . . . . . . . B-1320, 165; F-2060, 249Ahn, Y. .......................C2-1978, 243Aibinu, I. .......................C2-108, 009AIC246 Study Team, .............. T-356, 029Aichelburg, M. C. ................H-1918, 238Aimoto, M. .....................D-1402, 170Ainoda, Y. .......................M-326, 028Airapetian, N. ...................M-1698, 191Ait Oufella, H. ...................D-173, 013Akamatsu, S. ...........F-817, 096; F-818, 096;.........F-819, 096; F-820, 096; F-821, 096;...................F-822, 096; M-981, 111Akhter, S. S.. . . . . . . . . . . . . . . . . . . . C2-1981, 243Akin, A. R. ..................... F-1540, 177Akinlolu, Y. ..................... T-1067, 116Akinola, M. T. ...................G-1748, 198Akins, R. L. ......................A-604, 082Akiti, T. ........................M-1690, 190Akkoyunlu, Y. ....................V-379, 030Aklillu, E. .......................H-893, 103Aktories, K. ..................... F-1537, 177Akuka, A. .....................L1-1640, 186Al Hubail, M. ...................C1-071, 006Al Naiemi, N. ...................C2-104, 009Al Sweih, N. ....................C1-071, 006Al-Badriyeh, D. ..................M-1671, 190Al-Buridi, R. S. ...................K-242, 020Al-Ghafri, S. S. ..................C2-079, 007Al-Harbi, A. I.. . . . . . . . . . . . . . . . . . . D-1407, 170Al-Hattali, H. S. .................C2-079, 007Al-Ibrahim, M. ...................G-873, 101Al-Jashaami, L. S. .................K-920, 105Al-Nakeeb, Z. ...................A-1943, 240Alam, M. J. ........... D-158, 011; M-316, 028Alarcón, A. ............K-941, 106; K-943, 106Alastruey-Izquierdo, A. .............M-321, 028Albert, N. D. ..........M-972, 111; M-979, 111Alberto Delgado-Iribarren ..........M-312, 028Albis, A. ......................L1-1643, 186Albornoz, E. ..........C2-701, 087; D-759, 092Albrecht, M. ....................L1-284, 025Albrich, W. C. ....................D-172, 013Albur, M. S. ............D-763, 092; E-793, 094Alcalá, L. .............M-322, 028; K-470, 048;...................E-806, 095; D-1411, 170Alcántar-Curiel, M. D. ............C2-113, 009Alcoba, G. .....................G3-1541, 178Alcorn, H. J. .........A-1294, 163; A-1295, 163Alcorta, B. .....................C2-1398, 169Alenezi, O. ......................V-371, 030Alessandri, E. ....................H-886, 102Alexander, B. D. .........408, 034; M-1055, 115Alexander, D. ...........F-843, 099; F-844, 099;....................F-845, 099; F-846, 099Alfandari, S.. . . . . . . . . . . . . . . . . . . . . . K-237, 020Alhadab, A. ......................A-643, 083Aliaga, J. ....................... F-2004, 246Alier, A. .........................K-258, 022Aliyu, S. H. ..........L1-288, 025; D-1451, 172Alla, F. ..........................K-939, 106Allada, G. .......................A-643, 083Allan, E. ......................C2-1983, 243Alland, D. ........................ 1169, 148Allegranzi, B. ............ 483, 053; K-2083, 251Allen, M. .......................K-2095, 252Allen, R. C. ..................... F-1528, 177Allen, U. D. ........................ 494, 059Allerberger, F. ................... P-1009, 112Allibardi, S. ......................D-159, 011Final Program207

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberAlluri, K. C. .....................C2-096, 008Almeida, A. J. ................... F-2011, 246Almeida, D. V. ...................B-1296, 164Almeida, J. .......................H-878, 102Almela, M. ............A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129; E-1465, 173Almirall, J. .....................L1-1643, 186Almirante, B. ...........K-931, 105; K-937, 106;.........K-938, 106; K-948, 107; K-950, 107;................L1-1644, 186; K-1758, 199Almuzara, M. ........C1-074, 006; D-1455, 172Almyroudis, N. ..................M-1676, 190Alonso, J. C. .....................K-940, 106Alonso, N. ......................K-1621, 184Alonso, R. ......................H-1577, 180Alonso, S. ......................K-2077, 250Alonso-Socas, M. M. .............K-1633, 185Alousi, A. M. .................... T-1065, 116Alpizar, W. A. ....................B-663, 084Alraddadi, B. .................... T-1025, 113Alshabani, K. ..........K-272, 024; K-1589, 181Alshuabi, M. .................... F-2012, 246Alshuaibi, M. .................... F-2013, 246Alsup, A. ........................ F-846, 099Alvarez, C. A. ........K-900, 104; C2-1909, 237Alvarez, F. .......................V-376, 030Alvarez, K. S. .....................D-752, 092Alvarez, M. ...........M-321, 028; M-323, 028Álvarez, M. .....................H-1921, 238Alvarez Lerma, F. ................K-1624, 184Alvarez-Perez, S. ..................K-470, 048Álvarez-Pérez, S. ..................M-322, 028Alves, C. ........................H-227, 019Alves, F. A. ..................... F-1513, 176Alves, M. ........................D-176, 013Amado, C. ...................... P-1018, 112Amado, I. .......................M-1694, 190Amador, G. ......................B-653, 084Amano, H. ...................... F-2055, 248Amara, S. .......................K-1598, 182Amaya, R. ......................K-1924, 239Ambretti, S. .....................K-1619, 184Ambrose, P. G. .......A-1261, 161; A-1262, 161;......A-1263, 161; A-1269, 162; A-1270, 162;......A-1271, 162; A-1961, 241; A-1962, 241;.............................A-620, 082Ambrosi, X. ......................B-054, 005Amigues, I. ...................... T-361, 029Amini, R. ........................V-389, 030Amit, S. ........................K-1609, 184Ammerman, N. ..................B-1296, 164Amoabeng, O. .................... F-836, 098Amsilli, M. .....................L1-957, 109Anaissie, E. ............M-1234, 159; 1885, 233Ananda-Rajah, M. .................M-315, 028Anastacio, S. .................... P-1012, 112Anastasiou, D. ..................L1-2105, 254Anastos, K. .....................H-1575, 180Anaya, F. ....................... T-1026, 113Andersen, L. P. ...................B-663, 084Andersen, P. .....................H-1919, 238Anderson, A. S. ...........575, 077; G-870, 101Anderson, D. .....................H-880, 102Anderson, D. A. .................... 427, 039Anderson, D. ....................K-1583, 181Anderson, D. J. ..................C2-117, 009Anderson, E. .....................A-636, 083Anderson, H. ....................K-1635, 185Anderson, M. ..........T-362, 029; F-2058, 249Anderson, N. W. ..................D-728, 090Anderson, S. ....................A-1767, 200Andersson, D. I. ........A-1764, 200; 1792, 205;............................A-1966, 241Andersson, K. ................... T-1042, 113Andes, D. R. ....413, 035; 857, 099; A-1270, 162;....F-A-1271, 162; D-1431, 171;A-1929, 240;......A-1930, 240; A-1931, 240; A-1932, 240;.................A-1947, 241; A-1961, 241Ando, D. .............H-1581, 180; H-553, 073Andrade, L. N. ..................C2-086, 008Andrade, L. H. ...................D-731, 090Andrade, S. S. ..................C2-1376, 169Andrade Ochoa, S. ................ F-833, 098Andre, C. ............ C2-091, 008; D-184, 014;............................C2-719, 089Andréasson, B. ................... T-1042, 113Andreis, S. ......................H-1579, 180Andrej, T. ........................M-974, 111Andremont, A. ....... A-1963, 241; F-2003, 246Andreoletti, L. ....................V-387, 030Andreoni, M. ....................H-1579, 180Andreou, A. ......................K-562, 074Andrés, A. ....................... T-359, 029Andres, P. ........................D-759, 092Andreu, A. ...........L2-303, 027; K-1616, 184Andrews, D. ..........L1-287, 025; K-561, 074Andrews, J. .....................A-1250, 161Andries, K. .....................A-1259, 161Angus, P. ........................ T-369, 029Ani, C. ..........................H-228, 019Anjum, M. .....................C2-1983, 243Anjum, M. F. .........K-236, 020; C1-1208, 156;........................... C2-1979, 243ANRSFORMVAC Study Group .....V-375, 030Antonelli, G. .....................V-393, 030Antoniadou, A. .........K-245, 021; K-246, 021Antonini, M. .................... T-1040, 113Antoniou, T. ...................... 1863, 227Antonopoulou, A. .................K-245, 021Antoun, S. .......................K-911, 104Aoi, H. ...............F-2049, 248; F-2055, 248Aoike, N. .......................D-1459, 172Aoun, M. ............T-1028, 113; D-1413, 170;............................ T-1046, 113Aoyagi, T.. . . . . . . . . . . C2-114, 009; C2-1901, 236Apodaka, A. ......................K-263, 023Appleton, B. A. .................. F-1540, 177Aquino, A. .....................G3-1563, 178Araci, J. .........................A-637, 083Aracil, B. .......................C1-593, 081Arakawa, T. ...................... F-825, 097Arakawa, Y. ........ D-1456, 172; C2-1904, 236;...........................C2-1989, 244Arakere, G. .....................B-1315, 165Aranda, J. .......................C1-672, 085Araneta, M. R.. . . . . . . . . . . . . . . . . . . H-1917, 238Aranzamendi, M. ................C2-105, 009Araoka, H. .......................K-897, 104Arathoon, E. ....................M-1694, 190Araújo, C. F. ...................C2-1218, 157Arauz, A. B. ......................H-220, 019Archer, C. .....................C2-1985, 244Archer, G. .....................C2-1393, 169Archibald, C. ...................C2-1380, 169Ardanuy, C. .........C2-690, 087; C2-1358, 167;...............C2-1365, 167; C2-1974, 243Ardic, N. .......................D-1427, 171Arena, F. ......................C2-1211, 157Arend, L. M. .....................K-913, 104Arendrup, M. C. ........ M-318, 028; 1842, 219;............................M-1710, 191Argentinean Hepatitis A Working Group,..................P-1015, 112; P-1016, 112Argentinean KPC-Group, .. .......C2-1217, 157Argueta, E. .....................M-1694, 190Arhin, F. F. .......... C2-128, 010; D-762, 092;............................E-1463, 173Ariano, R. .............A-639, 083; A-040, 004Arias, C. ........................K-900, 104Arias, C. A. ........C1-1345, 166; C2-1389, 169;...........................C2-1909, 237Ariza, J. .....K-254, 022; B-647, 084; B-658, 084;................ V-1240, 160; L1-2102, 254Ariza-Heredia, E. ..... T-1065, 116; V-1075, 117Armaganidis, A. ........K-245, 021; K-246, 021Armand-Lebèvre, L. . . . A-021, 003; L2-2117, 255208September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberArmero, Y. .............A-610, 082; B-648, 084;.......K-945, 106; E-1465, 173; K-1122, 129Armiñanzas, C. .................. P-1018, 112Armstrong, W.. . . . . . . . . . . . . . . . . . . . . 1813, 209Arnaiz, A. .......................K-942, 106Arnan, M. ...................... T-1045, 113Aronoff, D. M. ...................K-926, 105;............................ T-1068, 116Arnold, L. ....................... F-826, 097ARPEC project group . . K-1754, 199; K-1759, 199Arpin, C. .......................C2-091, 008Arranz, J. .......................H-1576, 180Arrazola, P. ...................... T-359, 029Arribas-López, J. R. ..............D-1452, 172Arrieta, A. C. ....... A-1292, 163; G3-1560, 178;...........................G3-1561, 178Arshad, S. ............K-912, 104; K-1597, 182;...........................L1-1655, 188Arslan, H. ......................C2-684, 087Arteaga, G. .....................H-1573, 180Artuk, C. .......................L1-960, 110Arvas, G. ........................V-379, 030Arya, A. ......................... F-846, 099Arya, G. .......................G3-1562, 178Arzate, P. ......................G3-1563, 178Asahata, S. .......................M-326, 028Asami, T. ........................A-038, 004Asante-Appiah, E. .................H-551, 073Asdamongkol, N. .................H-1565, 179Asehnoune, K. ..........B-051, 005; B-054, 005;.................. B-651, 084; B-1335, 165Asensi, M. D. ..................C2-1218, 157Ashcraft, D. S. ...................M-1717, 191Ashouri, N. ....................G3-1561, 178Ashwini, C. ...................... P-564, 075Aslam, F. .......................A-1252, 161Aslam, S. ..............T-355, 029; T-1070, 116Aslan, T.. . . . . . . . . . . . . . . . . . . . . . . . . V-379, 030Aslanzadeh, J. ...................K-1926, 239AspICU Study Investigators .........K-951, 107ASP Team (SGH). ................K-235, 020Asshouri, N. ...................G3-1560, 178Assi, M. A. .......... L1-284, 025; T-1066, 116Assis, D. M. ......................D-731, 090Astuti, N. ....................... T-1035, 113Astvad, K. ......................M-1710, 191Asuphon, O. ....................A-1279, 162Asuquo, A. E. ...................E-1994, 245Atalay, A. .......................M-1701, 191Athan, E. .......................C2-689, 087Atiya-Nasagi, Y. ................. P-1001, 112Atmar, R. L. ....................G-1048, 114Attardo, J. ......................D-1435, 171Atudorei, V. ......................D-739, 091Aubert, J. ....................... T-1064, 116Aubin, G. G. ..........K-255, 022; B-1318, 165Augostini, P. ..................... P-563, 075Augustin, V. .....................A-1963, 241Auiwatanagul, S. .................. P-999, 112Aumeran, C. ....................K-2098, 252Aurbach, U. .....................D-1423, 170Auregan, M. .....................D-758, 092Ausubel, F. ...................... F-1538, 177Autran, B. ......................H-1568, 179Auzou, M. ......................D-1441, 171Avery, R. ............M-337, 028; M-1227, 159Avettand-Fenoël, V. ...............H-1568, 179Ávila, M. ........... L1-290, 026; L1-1666, 189Aweeka, F. ......................A-1256, 161Ayala, J. A. ......................C1-669, 085Ayats, J. . . C2-690, 087; M-329, 028; M-1228, 159Aye, K. S. ......................C2-1369, 168Aylin, P. .........................K-260, 023Ayma, A. ........................D-758, 092Azadeh, N. .....................M-1697, 191Azanza, J. .......................K-1612, 184Azar, E. E. ......................K-1584, 181Aznar, M. L. ...................L1-1644, 186Azoulay, E. ...................... P-568, 075Azzopardi, E. .................... F-2006, 246BB. Brunschweiler ................L1-2106, 254B. Canarelli ....................L1-2106, 254Baalbaki, R. ......................K-250, 022Baba, K. A. .....................C2-101, 009Baba, M. M. ....................G-1748, 198Baba, M. ........................K-897, 104Babady, N. E. ....................D-1442, 171Babakhani, F. ....................A-1274, 162Babcock, K. M. ........K-233, 020; E-1464, 173;............................E-1469, 173Babrak, L. ......................B-1310, 165Bacchus, C. .....................H-1568, 179Bachelier, C. .................... F-1488, 175Back, K. R. .....................L1-294, 026Badal, R. ............C2-100, 009; C2-120, 009;......C2-143, 010; C2-144, 010; C2-148, 010;......C2-688, 087; C2-721, 089; C2-724, 089;...............C2-1352, 167; L2-2107, 255Baddley, J. W. ...................... 489, 056Baden, L. R. ....................M-1060, 115Bader, O. ........................M-335, 028Badiou, C. ......................B-1735, 196Bae, H.. . . . . . . . . . . . . . . . . . . . . . . . . . D-734, 091Bae, I. .........................K-2079, 250Baek, J. ..........................G-872, 101Baek, J. Y. .....................C2-1366, 167Baeten, J. ......................... 1187, 152Baethgen, L. F. .................C2-1375, 168Baggi, E. ..........G3-1549, 178; G3-1553, 178Bagheri Nejad, S. .................K-2083, 251Bahma, J. ........................ T-364, 029Baicus, C.. . . . . . . . . . . . . . . . . . . . . . . D-1776, 201Baietto, L. ...........A-1769, 200; A-1937, 240Baines, S. ............. B-662, 084; F-2065, 249Bains, K. ......................C1-1747, 197Bajaksouzian, S. ......C2-092, 008; C2-1361, 167;............................ F-2059, 249Bajoka, B. ......................K-1597, 182Bakare, N. ......................A-1259, 161Bakari, D. ...................... P-1010, 112Baker, C. J. ................ 525, 067; 1156, 145Baker, J. R. ............G-869, 101; F-2070, 249Baker, M. G. ...................G3-1555, 178Baker, S. M. ..................... F-1518, 176Bakker-Woudenberg, I. A. ..........B-058, 005;............................A-1268, 161Bakouboula, P. ...................M-1707, 191Balada-LLasat, J. .................D-1417, 170Balada-Llasat, J. ...................D-756, 092Balakrishnan, I. ..................C2-081, 007Balansay-Ames, M. ................V-383, 030Balbaaki, R. ......................K-251, 022Baldoni, D. .....................A-1273, 162Balfour, H. H. ...................V-1241, 160Balibar, C. J. ..................... F-1540, 177Balic, N. ........................L2-306, 027Baliellas, C. ..................... T-1030, 113Ballal, E. .......................D-1407, 170Ballarò, D. .......................K-898, 104Ballen, K. ........................ T-354, 029Ballesté-Delpierre, C. .............C2-696, 087Ballow, C. H. ....................A-1248, 161Balsalobre, L. C. ......C1-668, 085; C2-106, 009Balsamo, M. L. .................. T-1035, 113Balzaretti, M. ....................C2-094, 008Bam, R. .........................H-892, 103Bamaiyi, M. J. ...................G-1748, 198Bamford, C. .....................C2-723, 089Bandara, K. .....................K-2081, 251Bandettini, R. ...................D-1426, 171Final Program209

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberBanevicius, M. ....................A-633, 083Bani-Hashemi, T. .................B-661, 084Bankowski, M. J. ..................D-155, 011Baos, E. .........................E-805, 095Bar-Ziv, J. ......................G-1753, 198Barajas, G. B-1323, 165; B-1326, 165; K-1614, 184Baraniak, A. .....................C2-109, 009Barauna, I. .......................K-257, 022Barba, M. J. ....................C2-1902, 236Barba, P. ........................M-1228, 159Barbato, L. ......................C2-704, 088Barber, K. E. ...........K-906, 104; K-909, 104Barberà, M. .....................L2-303, 027Barbier, F. .....................C2-1399, 169Barbolla, I. .......................D-743, 091Barbut, F. ....D-154, 011; D-157, 011; K-925, 105Bargatze, R. .....................G-1048, 114Baril, J. .........................H-1571, 180Barin, F. .........................H-886, 102Barin, J. .......................C2-1905, 236Barker, K. S. ...........M-969, 111; M-970, 111;.............................M-971, 111Barker, S. ....................... F-2016, 247Barla, G. S. ......................E-196, 015Barman, T. K. ................... F-2043, 248Barnes, A. ......................B-1736, 196Barnes, S. .......................C1-680, 086Baron, M. G. .................... F-2001, 246Baron, S. ......................L1-1639, 186Baron-Hall, D. .................C2-1912, 237Barr, K. .........................G-868, 101Barrailler, S. ......................A-638, 083Barraud, O. .........D-1408, 170; C1-1739, 197Barreiros, G. ....................M-1690, 190Barreto-Miranda, M. ..............M-1704, 191Barrett, D. ....F-818, 096; F-819, 096; F-820, 096Barrios, H. ...........C1-067, 006; C1-069, 006Barron, A. E. ....................... 436, 041Barron, D. ......................M-1668, 190Barron, M. ...........M-337, 028; M-1227, 159Barros, J. ....................... F-1492, 175Barry, M. ......................... 1821, 211Barth, A. L. ..........D-749, 092; C2-1375, 168Bartizal, K. ............E-778, 093; E-1479, 174Bartczak, D. ...................... F-826, 097Bartoletti, M. ....................K-1619, 184Bartolomé, R. ....................K-931, 105Bartoloni, A. ...................C1-1205, 156Barton, M. ......................A-1272, 162Barton Behravesh, C.. . . . . . . . . . . . . . . . 1818, 210Bartsch, S. ...................... T-1069, 116Baruchel, A. ...................... T-363, 029Bashoura, L. .................... T-1065, 116Basset, P. ......................C2-1378, 169Bassetti, M. ......................M-317, 028Basso, M. .............H-216, 018; H-1579, 180Bastides, F. ...........D-176, 013; L1-1639, 186Basustaoglu, A. C. ................D-1427, 171Batard, E. ...........L1-285, 025; L1-283, 025;................D-1458, 172; L1-1642, 186Bathina, P. ............K-272, 024; K-1589, 181;............................K-1604, 183Bathnagar, N.. . . . . . . . . . . . . . . . . . . . . K-955, 108Bauab, K. C. ....................D-1412, 170Baudel, J. ........................D-173, 013Bauer, J. .........................A-598, 082Bauer, K. A. ..........K-1636, 185; A-1768, 200Baugh, S. .......................C1-674, 086Baughman, W. ...................G-1752, 198Bauman, S. .....................M-1699, 191Baumann, D. P. ...................K-252, 022Baumann, H. ..................... T-347, 029Baumann, R. ....................H-1575, 180Baumler, A. ........................ 416, 036Baxter, M. ...........C2-103, 009; C2-135, 010;.......E-191, 015; E-779, 093; C2-1360, 167;................C2-1379, 169; E-1462, 173Bayer, A. . . . E-1473, 174; E-1474, 174; 1866, 228Bayer, A. S. ............B-646, 084; B-654, 084;......B-655, 084; C1-1744, 197; E-1468, 173Baylan, O. .....................C2-1367, 168Baysarowich, J. ................... F-1496, 176Baziaka, F. .......................K-562, 074Beall, B. ........................... 517, 065Bearden, D. T. ..................L2-2118, 255Beatty, D. ....................... F-1514, 176Beaudoin, M. .....................A-632, 083Bebrova, E. ...................... T-344, 029Beceiro, A. ......................C1-593, 081Béchet, S. .............G-1049, 114; G-864, 100Beck, A. ........................K-2085, 252Becker, H. K. ..................... F-856, 099Becker, K. .............A-596, 082; A-597, 082;......A-599, 082; C2-1382, 169; E-1483, 174;...........................G3-1547, 178Bedford, B. .....................A-1247, 161Bedir, O. .......................D-1427, 171Bedos, J. P. .......................K-237, 020Behle, T. F. .......................A-027, 004Behrman, A. .....................D-744, 091Beigi, R. ........................... 453, 045Beilke, M. A. .....................D-153, 011Beiras-Fernandez, A. ..............K-2095, 252Bekele, Y. ........................D-181, 013Bektore, B. .........C2-1367, 168; C2-1394, 169Belgrader, P. .....................D-1425, 171Bellacasa, J. .....................M-1228, 159Bellanger, A. P. ..................M-1692, 190Bellesso, M. .....................K-1603, 183Belley, A. ........................D-762, 092Belli, D. C. ....................G3-1556, 178Bellido, M. ......................C2-707, 088Bellos, N. ........................H-555, 073Belmonte, A. ....................D-1455, 172Ben David, D. ..................L1-1640, 186Ben-Ami, R. .........M-985, 111; M-1059, 115Ben-David, D. ....................K-557, 074Ben-Shimol, S. ..................G-1753, 198Ben-Yehuda, S. .................... 1783, 203Benedict, M. .........A-1290, 163; A-1958, 241Benfield, T. ...........G-876, 101; H-1916, 238Benito, N. ............C2-111, 009; K-256, 022Benner, C. ...................... F-2034, 248Bennett, J. M. ................... F-2016, 247Bens, C. .........................M-334, 028Bensen, D. ...........F-2017, 247; F-2018, 247;........................... F-2018a, 247Benson, P. .......................H-891, 103Bensoussan-Ambacher, C. ..........G-1049, 114Bentley, S. D. ....................... 518, 065Beranger, R. W. ...................K-257, 022Berard, X. .......................D-164, 012Beraud, G. ............A-039, 004; L1-963, 110Berbari, E. F. ....................K-2078, 250Berendt, A. R. ...................... 538, 070Berg, D. K. .....................M-1674, 190Berg, R. M. ......................B-055, 005Berg, T. ........................V-1236, 160Bergen, P. ........................A-024, 004Berger, C.. . . . . . . . . . . . . . . . . . . . . . . . T-343, 029Berghaus, L. J. ..................C1-1348, 166Berghmans, T. ................... T-1028, 113Bergman, S. J. ...................E-1485, 174Berkow, E. L. ..........M-969, 111; M-971, 111Berkowitz, L. .....................K-241, 020Berktas, M. ......................V-379, 030Bermejo, N. ....................L2-2110, 255Bermejo, S. ....................L2-2110, 255Bermudez, A. .................... T-1038, 113Bermudez, C. ...........T-364, 029; T-1037, 113Bermudez, L. ....................B-1310, 165Bernard, E. ......................B-052, 005210September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberBernard, L. ...........D-176, 013; D-177, 013;....L1-1639, 186; L1-2103, 254; L1-2104, 254Bernardo, P. ....................L1-1638, 186Bernardo, S. M. .................. F-2000, 246Bernasconi, E. ...................H-1566, 179Berry, J. ........................ F-2016, 247Bertaina, C. ....................G3-1559, 178Berthet, N. .....................C1-1349, 166Berti, A. D. .....................E-1482, 174Bertoldi, M. B. ..................C2-087, 008Bertoni, G. .....................C2-1398, 169Bertuccio, P. .....................L2-304, 027Bertz, H. .......................M-1704, 191Bertz, R. J. ......................A-1247, 161Berven, S. .......................K-261, 023Bès, M. ............B-1319, 165; C1-1739, 197Bessen, D. ......................B-1312, 165Besser, T. .......................D-1409, 170Besson, C. .....................L2-2109, 255Besterman, J. ....................M-1711, 191Bestrom, J. E. ....................M-1693, 190Betelu, M. .......................G-874, 101Bethel, C. R. .........C1-463, 047; C1-590, 081;............................. F-847, 099Betrisey, B. ...................... F-2011, 246Betsuyaku, T. .....................A-038, 004Bettencourt, A. .................. F-2011, 246Bettinger, J. A. ..................G3-1542, 178Bettiol, M. ......................C2-084, 008Beumont-Mauviel, M. .............V-1236, 160Beunza, J. .......................K-1612, 184Beuret, P. ......................L1-1224, 158Bevilacqua, S. ....................L2-302, 027Beyda, N. D. .....................M-316, 028Bhalla, P. ........................T-345, 029Bhalodi, A. A. ..........A-020, 003; A-625, 083;..................A-630, 083; A-1287, 163Bharadwaj, S. .....................K-236, 020Bhargava, A. .........C2-096, 008; L2-306, 027;.......K-902, 104; K-1589, 181; K-1604, 183Bhatt, N. ........................K-921, 105Bhattacharjee, A. ................. F-1522, 177Bhavan, K. P. .....................D-752, 092Bhavnani, S. M. ........A-620, 082; A-1244, 161;......A-1261, 161; A-1262, 161; A-1263, 161;......A-1269, 162; A-1270, 162; A-1271, 162;........ 1862, 227; A-1961, 241; A-1962, 241Bhotra, T. .......................C2-715, 088Bhowmick, R. .................... F-824, 097Bhutani, N. .....................C2-703, 088Bialek, R. ........................ T-347, 029Bialek, S. .......................K-2087, 252Bianco, J. .......................A-1272, 162Bias, T. E. .......................K-241, 020Bidet, P. .......................G3-1554, 178Biedenbach, D. J. ......C2-123, 010; C2-145, 010;...... F-1510, 176; F-2050, 248; F-2051, 248;..................F-2052, 248; F-2053, 248Biehle, L. R. .....................K-901, 104Biehler, K. ......................B-1331, 165Biek, D. .........................A-625, 083Bielicki, J. .....................G3-1559, 178Bielicki, J. A. .........K-1754, 199; K-1759, 199Bilgeturk, A. ....................L1-960, 110Billaud, G. ....................... T-360, 029Bille, J. ........................L1-1221, 158Binet, C. ........................ P-996, 112Bingen, E. ...........G-864, 100; G-1049, 114;...........................G3-1554, 178Bingo, M. ......................D-1402, 170Binnicker, M. J. ........D-174, 013; T-1032, 113;............................M-1693, 190Birdsell, D. N. ...................L1-964, 110Birkmann, A. ..................... V-391, 030Birkus, G. .......................H-892, 103Biron, C. ........................ P-566, 075Bisbal, R. ......................L1-1643, 186Bishai, W. . . D-739, 091; F-830, 098; B-1296, 164Bishai, W. R. ..............533, 069; 1087b, 120Bishop, C. ......................D-1435, 171Bishop, L. ......................M-1670, 190Bishop, L. M. ..................C2-1979, 243Bisi-Johnson, M. A.. . . . . . . . . . . . . . . C2-101, 009Bispo, P. J. ..........C2-1400, 169; E-1481, 174Bissell, A. ........................ F-829, 098Biswas, P. ...........M-1229, 159; M-1683, 190;............................M-1709, 191Bitko, V. .........................G-869, 101Bittencourt, H. ..................D-1403, 170Biver, E. .........................H-231, 019Bizzini, A. ............B-649, 084; D-1436, 171Björkman, S. .....................A-033, 004Black, T. A. ....................... 1871, 229Blackburn, J. .....................D-751, 092Blair, J. E. .......... T-1032, 113; M-1697, 191;............................M-1702, 191Blair, M. ....................... F-2016, 247Blair, M. A. ..................... F-2028, 247Blair, P.. . . . . . . . . . . . . . . . . . . . . . . . . . V-383, 030Blanc, A. .......................L1-957, 109Blanc, C. .......................H-1568, 179Blanc, D. ......................C2-1378, 169Blanco, J. L. ......................K-470, 048Blanco, V. M. .......... D-747, 092; K-903, 104;...........................L2-2108, 255Blandino, G. ....................C1-594, 081Blandon, M. V. .................L2-2115, 255Blanes, M. ....................... T-340, 029Blank, P. R. ......................G-860, 100Blankson, J. .....................H-1580, 180Blaschke, T. ......................M-982, 111Blasi, F. ............L1- L1-290, 026; 1666, 189Bleibtreu, A. .......... B-660, 084; B-1305, 164Blenk, B. .......................A-1285, 162Blenk, H. .......................A-1285, 162Blijlevens, N. M. .................A-1928, 240Block, L. ........................K-247, 022Bloembergen, P. ...................K-930, 105Blondeau, J. M. ...................D-729, 090Blot, S. ..........................K-951, 107Blumentals, W. A. ................G-1749, 198Blumer, J. L. ....................A-1257, 161Blyth, C. C. ......................M-313, 028Bo-Sheng Ko ....................M-1669, 190Bocanegra, R. A. ........B-650, 084; F-823, 096;............................M-1682, 190Bocco, J. L. ....................C2-1910, 237Boci, T. ........................ F-2072, 249Bodro, M. ...................... T-1030, 113Boeckh, M. ...................... T-353, 029Boehme, M. S. ....................D-750, 092Boel, E. C. ...................... F-1516, 176Boelman, K. J. ....................D-170, 012Boeree, M. J. ....................A-1268, 161Boerlin, P. ......................C2-710, 088Bogado, B. ...................... F-1491, 175Bogaerts, P. .....................D-1447, 172Boggian, K. ...................... T-343, 029Boggild, A. ........................ 404, 033Bogner, J. R. .....................H-887, 103Boibieux, A. ............K-249, 022; K-253, 022Boillat Blanco, N. ................H-1566, 179Boinapally, P. .....................D-750, 092Boinett, C. J. ...................C1-1208, 156Boisson, M. ......................A-037, 004Boivin, G. .............V-392, 030; V-399, 030;................. V-1076, 117; V-1079, 117Boley, M. ....................... F-2005, 246Bollinger, L. ..................... F-1515, 176Bologna, R. ......................B-045, 005Bond, S. ......................... F-828, 097Bonfanti, P. ......................D-757, 092Bonfietti, L. X.. . . . . . . . . . . . . . . . . . . .M-311, 028Bonfillon, C. .....................K-560, 074Final Program211

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberBonhoeffer, J. ....................... 528, 067Bonhoeffer, S. ....................K-238, 020Boniatti, M. M. ...................A-027, 004Bonilla, H. F. ...................C1-1745, 197Bonnin, R. ......................C1-071, 006Bonomo, R. A.. . . . . . . .C1-076, 006; C2-092, 008;......C1-460, 047; C1-463, 047; C1-464, 047;......C1-467, 047; C1-590, 081; C2-686, 087;......C2-692, 087; C2-694, 087; C2-720, 089;........F-847, 099; 1831, 214; C1-1209, 156;............................ F-2059, 249Boon, L. .........................B-058, 005Boone, J. H. ............D-162, 011; D-163, 011Booth, M. P. ....................C1-465, 047Boothe, D. M. ..................C2-1219, 157Bordi, R. ........................H-553, 073Borens, O. .............K-250, 022; K-251, 022Borer, A. .............H-232, 019; M-339, 028;................. P-1022, 112; K-1610, 184Boreux, R. .....................C2-1988, 244Borgert, S. .......................K-274, 024Borges, N. .....................G3-1546, 178Borovkova, N. ...................L2-310, 027Bortolon, E. .......... A-1289, 163; F-1523, 177Bosari, S. .......................L2-304, 027Boshoff, H. I. ..................... F-832, 098Bosis, S. .......................G3-1553, 178Botelho-Nevers, E. ................ P-566, 075Bou, G. ..............C1-070, 006; T-340, 029;........T-368, 029; K-559, 074; C1-593, 081;................C1-672, 085; C2-1902, 236Bouarab, K. ...........F-1997, 246; F-1998, 246Bouaziz, A. . K-249, 022; K-253, 022; B-1319, 165Bouchami, O. ..................C1-1740, 197Bouchara, J. P. ....................M-332, 028Bouchene, S. .....................A-033, 004Boucher, C. .....................V-1080, 117Boucher, H. W. ............1195, 154; 1812, 209Bouchillon, S. ........C2-099, 009; C2-100, 009;.....C2-120, 009; C2-133, 010; C2-1352, 167;......C2-140, 010; C2-141, 010; C2-143, 010;......C2-144, 010; C2-147, 010; C2-148, 010;......C2-150, 010; C2-688, 087; C2-721, 089;......C2-722, 089; C2-724, 089; E-1474, 174Boudville, I. .....................G-1751, 198Bouffard, B. ...................... P-996, 112Bouhy, X. .......................V-1079, 117Boulahfa, S. ......................M-983, 111Boulanger, S. .................... F-1998, 246Bouler, J. ........................B-653, 084Boulianne, N.. . . . . . . . . . V-389, 030; G-1047, 114Boulware, D. ....................M-1699, 191Boulware, D. R. .................... 1108, 126Bourgault, A. .....................D-751, 092Bourhis, J. .......................D-772, 092Boussiotis, V. A. .................. T-354, 029Boutoille, D. ........ L1-963, 110; L1-1224, 158Bouvet, D. .............D-176, 013; D-177, 013Bouvet, E. ............ V-375, 030; L1-957, 109Bouylout, K. ....................K-2095, 252Bouza, E. ............C2-127, 010; C2-130, 010;....... C2-142, 010; D-166, 012; K-263, 023;....... M-322, 028; K-470, 048; D-726, 090;.........E-806, 095; K-940, 106; K-941, 106;.........K-942, 106; K-943, 106; K-944, 106;......T-1026, 113; T-1041, 113; M-1232, 159;..... V-1242, 160; D-1411, 170; D-1415, 170;.... H-1577, 180; M-1684, 190; M-1688, 190;.................D-1772, 201; K-2090, 252Bowden, R. ......................K-474, 048Bowen, R. ............F-2022, 247; F-2033, 248Bowers, D. R. ....................K-896, 104Bowker, K. E. ..........A-628, 083; A-629, 083;. . A-631, 083; A-642, 083; D-763, 092; E-793,094Bowlin, T. L. ............F-816, 096; F-832, 098Bown, D. .......................A-1761, 200Boyce, J. M. ....................... 1850, 223Boyd, D. A. .....................C2-085, 008Boyd, N. K. ......................D-752, 092Boyea, T. ............A-1294, 163; A-1295, 163Boyken, L. ......................D-1433, 171Boyle, F. ........................C2-122, 009Bozdogan, B. ....................D-1430, 171Bozic, K. ........................K-247, 022Bozkurt, I. ......................M-1701, 191Bracco, S. ............D-757, 092; C2-1897, 236Bradley, J. .......................A-1292, 163Brañas, P. .......................K-2093, 252Brandt, S. L. ....................B-1301, 164Brause, B.. . . . . . . . . . . . . . . . . . . . . . .M-1681, 190Bravetti, P. ......................L2-302, 027Brazier, F. ......................L1-2106, 254Brazilian KPC Study Group .......C2-1218, 157Bredeek, U. ......................H-879, 102Breitenecker, F. ..................H-1918, 238Brennan, A. .....................C2-706, 088Brennan, B. M. ...................D-750, 092Brenner, B. ......................H-1571, 180Brentzos, G.. . . . . . . . . . . . . . . . . . . . . . B-043, 005Breshears, L. M. ................. F-1517, 176Bretonnière, C. .................L1-1224, 158Bridevaux, P. .................... T-1064, 116Brielmaier, B. .....................K-279, 024Briggs, H. ......................D-1449, 172Brink, A. .......................... 421, 037Brinson, C. ......................H-877, 102Brisse, S. .......................C2-088, 008Brito, M. J. .......................G-866, 100Britton, W. J. ...................... 1171, 148Broder, K. ......................G-1052, 114Brodner, A. H. ...................C1-588, 081Broge Jr. T. A. .................... T-354, 029Brooks, A. ......................K-1927, 239Brooks, T. J. ....................... 1729, 194Brophy, A. .......................A-618, 082Broquet, A. ............B-051, 005; B-054, 005;..................B-651, 084; B-1335, 165Brossier, C. ......................K-560, 074Broun, E. ........................A-026, 004Brouwer, M. C. .................L1-1223, 158;............... L1-1222, 158; L1-1648, 187Brown, D. . A-011, 003; A-1265, 161; E-1993, 245Brown, J. ....A-605, 082; A-615, 082; A-617, 082Brown, J. E. .....................A-1768, 200Brown, K. .............A-615, 082; A-617, 082Brown, K. M. .....................M-969, 111Brown, M. .......................A-618, 082Brown, N. G. ....................C1-462, 047Brown, S. D. . E-188, 015; D-768, 092; D-771, 092Brown-Driver, V. ......F-2017, 247; F-2018, 247;..... F-2018a, 247; F-2020, 247; F-2023, 247;...... F-2024, 247; F-2025, 247; F-2026, 247;............................ F-2028, 247Brownstein, J. ............1087a, 120; 1855, 225Bru, J. ...........................K-237, 020Bruce, R. D. .....................A-1250, 161Brüggemann, R. J. .....M-989, 111; A-1928, 240;............................ A-1933, 240Bruhn, D. F. ...................... F-832, 098Brummelkamp, T. ................ F-1537, 177Brundage, T. ..................... T-358, 029Bruneel, F. ............. P-568, 075; P-570, 075Brzostek, J.. . . . . . . . . . . . . . . . . . . . . . A-1245, 161BSAC Working Party on Resistance Surveillance,............................C2-152, 010Buchan, B. W. .........D-1777, 201; D-728, 090Bucher, H. ......................K-1125, 129Buchheidt, D. ........M-335, 028; M-1704, 191Buckeridge, D. L. .....V-1076, 117; K-1755, 199Bueno, M. ......................M-1681, 190Bui, H. T. .......................M-1677, 190Bui, T. ..........................T-351, 029Buiting, A. .......................K-930, 105Bukbuk, D. N. ...................G-1748, 198Bulik, C. C. ...........A-620, 082; A-1244, 161;......A-1261, 161; A-1262, 161; A-1263, 161;......A-1269, 162; A-1270, 162; A-1271, 162212September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberBulitta, J. B. ............A-011, 003; A-024, 004;........A-031, 004; E-785, 094; A-1266, 161;............................A-1762, 200Bunce, C. P. .....................L1-286, 025Burak, E. .......................A-1289, 163Burchardt, A. .....................T-341, 029Burden of Healthcare-associated infection StudyGroup, .......................K-908, 104Burger, D. M. ...................A-1928, 240Burgess, D. S. ....................E-794, 094Burghoffer, B. ....................K-925, 105Bürgisser, P. ......................D-184, 014Burgmann, H. ...................E-1471, 174Burgos, R. ......................K-1758, 199Burillo, A. ............ K-944, 106; T-1026, 113Burke, E. .......................C2-706, 088Burke, E. E. ......................B-661, 084Burkett, A. .....................G3-1552, 178Burman, M. K. ...................D-170, 012Burns, K. .......................C2-088, 008Burton, M. .............D-185, 014; V-374, 030Burucoa, C. ......................A-039, 004Busch, R. .....F-843, 099; F-844, 099; F-845, 099Bush, K. ..............C2-1213, 157; 1197, 154;................... K-1589, 181; 1832, 214Buskila, D. .......................H-232, 019Bustamante, B. ...................M-311, 028Buteau, C. .......................V-376, 030Butler, M. M.. . . . . . . . . . . . . . . . . . . . . F-832, 098Butterfield, J. M. ..................A-606, 082Butterton, J. ............A-009, 003; A-010, 003;............................A-1763, 200Butty, P. ........................C2-709, 088Buyck, J. ............. A-1278, 162; F-2029, 247Buynak, J. D. ..................... F-847, 099Buyukoglan, H. ..................M-1701, 191Buzea, M. ......................C2-110, 009Buzele, R. .....................L1-2104, 254Byrd, L. .........................D-752, 092CCA-MRSA Argentina Group ......C2-1910, 237Caballero, A. ....................L1-289, 026Caballero, F. ....................L1-1658, 188Cabello, F. .......................M-980, 111Cabellos, C. . B-647, 084; B-658, 084; V-1240, 160Cabezas, J. ...........A-1931, 240; A-1947, 241Cabezas, Y. ..................... P-1007, 112Cabo, J. .........................B-647, 084Cabo, X. .........................K-254, 022Cabot, G. ......................C1-1970, 242Caffrey, A. R. ..........K-233, 020; K-1120, 129;......E-1464, 173; E-1469, 173; K-1628, 185Cahn, P. .......................... 1848, 222Cai, Y. .....E-195, 015; K-235, 020; A-1290, 163;.................E-1476, 174; K-1613, 184Caillon, J. ..............B-051, 005; B-054, 005;.......C2-080, 007; E-203, 016; L1-283, 025;.......B-651, 084; B-653, 084; L1-1224, 158;.....B-1335, 165; D-1458, 172; L1-1642, 186;................. A-1948, 241; F-2056, 248Calabrese, L. H. .................... 1094, 122Calábria, P. ..............P-993, 112; P-995, 112Calabrò, M. ......................D-159, 011Calatayud, L. ...................C2-1974, 243Calbo, E. .......................K-1621, 184Calcagno, A. ....................A-1769, 200Caldeira, D. ....................C2-1377, 169Cáliz, B. ............M-1232, 159; M-1684, 190Callebaut, C. .....................H-552, 073Calmaggi, A. ...................C2-1398, 169Caltagirone, M. ..................C2-094, 008Calvo, J. ..............C2-105, 009; D-765, 092Camara, M. .......... F-1529, 177; B-1734, 196Cambau, E. .....................B-1306, 164Camilotti, J. .....................C2-087, 008Camoez, M. .........C2-1395, 169; D-1775, 201Campanaro, E. ..................L1-2105, 254Campbell, A. P. ................... T-353, 029Campeau, L. .....................H-551, 073Campins, L. ....................L1-1643, 186Campo, A. .......................D-765, 092Camúñez, F.. . . . . . . . . . . . . . . . . . . . . . D-166, 012Camus, V. .......................K-956, 108Can, F. .........................C2-684, 087Canadian Antimicrobial Resistance Alliance(CARA), ........C2-135, 010; C2-1379, 169Canadian Bacterial Surveillance Network (CBSN),...............C2-1362, 167; C2-1364, 167Canadian Immunization MonitoringProgram,ACTive (IMPACT), . . . G3-1542, 178Candel, F. J. ......................E-805, 095CANDIPOP Project, GEIH-GEMICOMED(SEIMC) and REIPI. ............K-948, 107CANDIPOP Project, GEIH-GEMICOMEDand REIPI, ....................K-950, 107Canellini, G. .....................D-184, 014Cañero, M. ..................... P-1015, 112Cañero V. M. .................... P-1016, 112Cano, J. ........................K-1924, 239Cano, M. ............C2-105, 009; C1-683, 086Cantas, L. ......................B-1330, 165Cantin, R. ......................H-1571, 180Cantón, R. ............C2-111, 009; E-205, 016;......C1-681, 086; C1-682, 086; D-753, 092;......................1129, 132; 1178, 150Cantu, S. ........................K-934, 105Cao, C. .......................C1-1969, 242Cao, G. Y. ............F-1503, 176; F-1504, 176Cao, G. ........................A-1283, 162Cao, S. ..............A-1764, 200; A-1966, 241Capdevila, J. ....................L1-1643, 186Capilla, S. ......................K-1623, 184Capobianchi, A. ...................V-393, 030Capparelli, E. ....................A-1292, 163Cappy, P. ........................H-886, 102Capraro, G. A. ...................D-1418, 170Caramma, I. ......................D-757, 092Carapetis, J. .....................B-1312, 165Caratozzolo, A. .................G3-1552, 178Carattoli, A. .....................C2-697, 087Carballito, J. ....................C2-1377, 169Carbone, E. ........C2-1396, 169; C2-1397, 169Card, D. ......................... F-810, 096Card, R. .......................C2-1983, 243Cardenas, A. ....................C1-462, 047Cardeñoso, L. ..........T-355, 029; T-1070, 116Cardone, K. E. ....................A-606, 082Cardoso, C. M. .................C2-1375, 168Cardoso, F. L. ...................K-1601, 182Carijó, J. H. ......................K-257, 022Carkaci, D. .....................D-1443, 171Carl, M. ........................ P-1010, 112Carlesse, F. ......................D-1412, 170Carman, R. ......................D-163, 011Carman, R. J. .....................D-162, 011Carmeli, Y. ...........C2-109, 009; K-557, 074;....... K-1609, 184; 1814, 209; C2-1900, 236Carmi-Oren, N. .................. P-1001, 112Carmichael, A. J. .................L1-288, 025Carnalla-Barajas, M. .............C2-1356, 167Caroff, N. ............C2-080, 007; K-255, 022;.....B-1318, 165; D-1458, 172; L1-1642, 186Caron, A. ....................... F-1496, 176Caron, F. ............B-1337, 165; B-1338, 165;...........................L2-2117, 255Carrat, F. ..............D-173, 013; V-387, 030Carratalà, J. ...........D-180, 013; L1-293, 026;...... L1-295, 026; L1-298, 026; M-329, 028;....... T-340, 029; T-1030, 113; T-1045, 113;............................M-1228, 159Carreno, J. J.. . . . . . . . . . . K-240, 020; K-1629, 185Carretero, A. ....................K-2091, 252Carrier, M. .......................D-730, 090Final Program213

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberCars, O. .....A-030, 004; E-798, 094; E-800, 094;................... 1149, 141; A-1966, 241Carton, T. ..........D-1458, 172; L1-1642, 186Carvajal, L. P. ......C2-1389, 169; C2-1909, 237Carvalhaes, C. G. ...............C2-1376, 169Carvalho, R. A. ..................C2-716, 088Carvalho-Assef, A. D. ............C2-1218, 157Casadei, G. ..................... F-1536, 177Casadevall, A. ..................... 1126, 130Casado, J. L. ...........H-217, 018; H-222, 019Casalino, E. ....................L2-2117, 255Casapao, A. M. .........K-275, 024; K-906, 104;........K-909, 104; K-946, 106; K-1123, 129;...........................C2-1985, 244Casari, E. .............C2-094, 008; D-159, 011Casper, C. ....................... T-353, 029Caseris, M. .....................V-1073, 117Cass, R. ..............A-042, 004; B-1302, 164Cassidy, K. ....F-843, 099; F-844, 099; F-845, 099Castagnola, E. ...................D-1426, 171Castañeda, X. ...........A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129; E-1465, 173Castanheira, M. ........E-189, 015; M-330, 028;.......C1-594, 081; C2-691, 087; F-855, 099;.......F-856, 099; M-1714, 191; A-1929, 240Castaño, I. ......................M-1668, 190Castel, A. D. .....................H-213, 017Castellano, A. ........F-2018, 247; F-2020, 247;..................F-2024, 247; F-2025, 247Castells, L. ....................... T-368, 029Castelo, L. .............K-941, 106; K-943, 106Castillo, J. A. ....................H-1573, 180Castro, A. F. .....................C2-704, 088Castro, H. C. .................... F-1513, 176Catalan, J. C. ....................C1-067, 006Catalán, P. ......................V-1242, 160Cattamanchi, A. .................... 530, 068Cattelan, C. ......................K-250, 022Cattoir, V. ............B-660, 084; D-1441, 171Cauchon, E. ......................H-551, 073Caughlan, R. E. .................C1-1973, 242Caumes, E. ................ 402, 033; 493, 058Cavalcante, F. S. .... C2-1387, 169; D-1428, 171;...........................C2-1907, 237Cavassini, M. ..........D-184, 014; H-1566, 179Cavedon, L. ......................M-315, 028Cavusoglu, C. ..................C2-1367, 168Cayô, R. .............D-731, 090; C1-1207, 156Cazanave, C. ....................K-2074, 250Ceccoli, C. .....................G3-1552, 178Cederberg, L. E. .................V-1241, 160Celetti, S. J. .....................K-1927, 239Celik, M. ............L1-964, 110; A-1941, 240Celis, A. Y. ....................L2-2108, 255Cellot, S. ........................V-376, 030Cen, R. .........................K-936, 105Cengiz, A. ......................A-1941, 240Centrón, D. ..........C1-074, 006; C2-701, 087Cercenado, E. ........C2-111, 009; C2-127, 010;......C2-130, 010; C2-142, 010; C1-593, 081;.....C2-1358, 167; D-1415, 170; D-1772, 201Cerf, C. .........................A-035, 004Ceriana, P. .....................C2-1217, 157Ceron, I. ........................K-944, 106Cerqueiro, C. ...................G3-1552, 178Cervera, C. ............A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129;E-1465, 173;............................M-1228, 159Cervera, T. .......................K-263, 023Cesaro, S. .......................M-1234, 159Cetron, M. ........................ 1822, 211Cevenini, R. ......................E-207, 016Ceyhan, M. ..........L1-964, 110; A-1941, 240Chachaty, E. .......... D-772, 092; K-911, 104;................. A-1963, 241; F-2003, 246Chacon Vargas, K. F. ............... F-833, 098Chae, J. ........................ F-2060, 249Chae, M. ......................C2-1913, 237Chaftari, A. ..........F-2012, 246; F-2013, 246;................. F-2014, 246; K-2096, 252Chagnon, F. ..................... F-1997, 246Chaia, J. ........................ T-1044, 113Chaili, S. ........................G-868, 101Chainier, D. .....................D-1408, 170Chaiprasert, A. ...................M-336, 028Chaisson, R. E. .................... 1109, 126Chaiwarith, R. ...................D-1406, 170Chakrabarti, A. ..........M-332, 028; 1116, 128Chakrakodi, B. ..................B-1315, 165Chalana, I. K. ....................K-902, 104Chambers, H. F. ........B-1735, 196; 1111, 127;.............................. 1867, 228Chambers, R. M. .......K-240, 020; K-1629, 185Chamilos, G. ....................M-1679, 190Chamon, R. ........C2-1383, 169; C2-1387, 169;...........................C2-1907, 237Champagne, J. ..................C2-1986, 244Champagne, S. ........D-161, 011; K-1593, 182Champlin, R. ..................... T-356, 029Chan, A. H. ..................... F-1534, 177Chan, C. Y. .....................E-1992, 245Chan, E. L. .....................D-1424, 171Chan, E. W. .................... F-2071, 249Chan, F. ........................E-1480, 174Chan, J. .......................... 1172, 148Chan, M. ........................A-614, 082Chan, P. ..............A-616, 082; A-1247, 161Chan-Hui, P. .....................G-873, 101Chan-Tompkins, N. H. .............A-619, 082Chanda, P. ......................E-1478, 174Chandorkar, G. ...................A-641, 083Chandra, J. ...................... F-2015, 246Chandra, K. ...........K-236, 020; K-1618, 184Chandran, A. U. ..................K-561, 074Chang, I. .......................A-1247, 161Chang, K. T. ....................D-1450, 172Chang, P. ............B-1307, 164; A-1935, 240Chang, S. ............ C2-097, 008; H-215, 018;........H-218, 018; H-221, 019; H-226, 019;......K-270, 024; H-1578, 180; L1-1654, 188Chang, S. C. ..........K-266, 023; K-1607, 183Chang, S. .............H-215, 018; H-218, 018;.......L2-309, 027; G-867, 100; V-1238, 160;......A-1251, 161; D-1422, 170; H-1578, 180Chang, Y. ....................... F-1501, 176Chang, Y. H. .................... T-1032, 113Chang, Y. .......................... 426, 038Changkaew, K.. . . . . . . . . . . . . . . . . . . C2-712, 088Chantrenne, M. ..................D-1413, 170Chaparro, C. .................... T-1067, 116Chapman, A. L. ..................L1-287, 025Chapman, B. A. ........P-994, 112; D-1425, 171Chappey, C. .....................A-1245, 161Chapplain, J. .....................K-267, 023Chapuis, C. ....................L1-1221, 158Charest, H. ...........V-389, 030; H-1571, 180Charles, P. G. ...................... 1882, 232Charlier, P. ......................C1-459, 047Charoin-Pannier, A. ..............A-1245, 161Charpentier, C. ...................H-886, 102Charpentier, E. .................... 1785, 203Chastre, J. ........................ 1091, 121Chaturvedula, A. ..................A-611, 082Chau, F. . . . B-660, 084; B-1305, 164; B-1306, 164Chaudhry, K. .....................K-902, 104Chaudhry, R. .........D-776, 092; C2-1982, 243Chaussade, H. ....................D-177, 013Chauveaux, D. ...................K-2074, 250Chavda, K. D. ...................C1-589, 081Chaves, F. ......................K-2093, 252Chaves, R. ......................K-2095, 252Chayakulkeeree, M. ................M-976, 111Cheatham, S. C. .......A-017, 003; L1-282, 025;..................D-770, 092; F-1520, 177Cheknis, A. ......................E-808, 095214September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberChemaly, R. F. ..........T-356, 029; K-934, 105;................. T-1065, 116; V-1075, 117Chen, C. .............K-936, 105; F-1526, 177;.... F-1494, 175; C2-1903, 236; C2-1361, 167Chen, E. ............G3-1550, 178; K-921, 105Chen, H. ........................K-243, 021Chen, H. J. ....................C1-1339, 166Chen, K. ........................B-057, 005Chen, L. ............C1-589, 081; C2-692, 087;......E-792, 094; C2-1216, 157; E-1468, 173;.........K-1625, 184; T-1031, 113; 1141, 137Chen, L. F.. . . . . . . . . . . . . . . . . . . . . . C2-117, 009Chen, M. .............B-663, 084; P-1005, 112;...........................L2-2107, 255Chen, P. ........................V-1238, 160Chen, S. ........................M-1680, 190Chen, S. C. ......................M-313, 028Chen, S. ...........L1-1646, 186; L1-1654, 188;............................A-1249, 161Chen, T. ......................... F-810, 096Chen, V.. . . .G-875, 101; M-982, 111; P-1013, 112Chen, W. .......................G-1048, 114Chen, X. Y. ..................... F-1500, 176Chen, Y. ..............C2-097, 008; K-270, 024;............................A-1251, 161Chen, Y. C. ............K-266, 023; A-640, 083;............................K-1607, 183Chen, Z. ...........C1-1203, 156; A-1283, 162;......F-2017, 247; F-2018, 247; F-2018a, 247;............................ F-2024, 247Cheng, A. C. ...........K-558, 074; K-952, 108Cheng, A. ............K-266, 023; K-1607, 183Cheng, L. ......................B-1737, 196Cheng, S. . . E-792, 094; M-978, 111; M-1056, 115Cheng, Y. ........................K-936, 105Chenoweth, E. ....................K-926, 105Cheong, H. ......................G-872, 101Cheret, A. ......................H-1568, 179Chernov, Y. ........C2-1386, 169; C2-1911, 237Cherot, J. ........................ T-363, 029Chervin, A. S. ................... F-1517, 176Chesneau, O. ...................C1-1349, 166Chesnel, L. ............E-807, 095; F-843, 099;....................F-844, 099; F-845, 099Chesson, M. .....................A-611, 082Chi, S. ........................L1-1656, 188Chiba, M. ...........F-2037, 248; F-2038, 248;...... F-2039, 248; F-2040, 248; F-2044, 248;............................ F-2045, 248Chiba, N. ..........C2-1353, 167; C2-1354, 167;. . .C2-1990, 244; C2-1991, 244; C2-1977, 243;Chidiac, C. ............K-249, 022; K-253, 022Chien, K. .......................B-1328, 165Chien-Yuan Chen ................M-1669, 190Chiganer, M. L. ..................M-1690, 190Chiller, T. ...........M-1694, 190; M-1699, 191Chilton, C. H. ..........K-474, 048; K-924, 105Chin, D. N. ..................... F-1540, 177Chin, T. .........................H-229, 019Chindamporn, A. .................M-336, 028Ching, P. ........................K-243, 021Chirouze, C. .....................K-939, 106Chittick, G. ...................... T-362, 029Chiu, C. ............B-1328, 165; C2-1903, 236Chiueh, T. .....................C2-1388, 169Chlebicki, M. P. ........K-235, 020; K-1595, 182Cho, J. ..........................D-182, 014Cho, J. H. ...................... F-1489, 175Cho, O. .............V-1074, 117; K-2079, 250Cho, S. ................ F-831, 098; F-834, 098Cho, S. Y. ......................C2-137, 010Cho, S. . . . K-1587, 181; K-1588, 181; K-1632, 185Cho, Y. ..............K-908, 104; H-1582, 180Choe, W. ....................... F-2060, 249Choi, D. ........................L1-294, 026Choi, E. ..............D-182, 014; B-1309, 165;...............C2-1975, 243; C2-1978, 243Choi, J. ........................K-1632, 185Choi, J. Y. .....................C2-1899, 236Choi, J. .............. H-230, 019; K-916, 104;.................H-1582, 180; K-1632, 185Choi, S. .... T-366, 029; D-739, 091; D-741, 091;........F-830, 098; K-907, 104; V-1074, 117;...... V-1239, 160; K-1632, 185; K-2092, 252Choi, W. ........................G-872, 101Choi, Y. .........................K-908, 104Chong, L. ......................B-1307, 164Chong, P. ........................M-990, 111Chong, Y. . K-907, 104; V-1239, 160; K-2092, 252Choong, K. .....................L2-307, 027Chopra, K. ....................... T-364, 029Chopra, T. ............C2-096, 008; K-902, 104Choquet, C. .....................V-1073, 117Chotikanatis, K.. . . . . . . . . . . . . . . . . . . E-206, 016Chou, S. .......................... 1894, 235Choudhury, R. ...................D-1437, 171Choulaki, C. .....................B-043, 005Chow, D. S. ......................A-025, 004Chow, H. ........................B-053, 005Chow, J. K. ..................... T-1025, 113Chowdury, P. .................... F-1529, 177Chraiti, M. ......................K-914, 104Chrenkova, V. ....................T-344, 029Christensen, C. ...................K-915, 104Christensen, J. J. .................D-1444, 171Christensen, J. ...................D-1443, 171Christensen, T. ................... P-1005, 112Christensen, P. ..................L1-1652, 187Christiansen, K. ..................E-1475, 174Christidou, A. ...................M-1696, 191Chu, H. Y. .......................T-353, 029Chu, K. ........................ P-1006, 112Chu, V. H. .....................L1-1644, 186Chuang, Y. ........... K-266, 023; D-1422, 170;............................K-1607, 183Chuang-Smith, O. N. ............. F-1517, 176Chubilleau, C. .................... P-996, 112Chuck, S. K. .....................H-556, 073Chukwuemeka, A. .................K-260, 023Chung, C. ......................C2-089, 008Chung, C. E. .....................A-017, 003Chung, D. ....................... T-361, 029Chung, D. R. ........C2-137, 010; C2-1366, 167;...........................C2-1899, 236Chung, D. ...........K-1587, 181; K-1588, 181Chung, J. ......................C2-1215, 157Chung, K. .....................L2-2112, 255Chung, P. .......................K-1634, 185Chung, R. T. .....................V-377, 030Chung, T. .............K-277, 024; K-2078, 250Chuong, C. .............F-845, 099; F-846, 099Church, D.. . . . . . . . . . . . . . 496, 060; D-1448, 172Church, D. L. ...................K-1756, 199Churproong, S. ................... P-999, 112Chuvala, L. .......... B-1302, 164; B-1304, 164Cianci, J. ........................ F-828, 097Cianciminio-Bordelon, D. ..........D-1442, 171Ciccaglioni, A. ....................D-165, 012Ciesielczuk, H. ..................C2-102, 009Cieslak, P. R. ..................... T-345, 029Cihlar, T. ........................H-892, 103Cimas, M. ...................... P-1018, 112Cinotti, R. ............ B-054, 005; B-1335, 165Ciobanca, P. T. ................... P-1008, 112Cirz, R. ....A-041, 004; A-042, 004; B-1302, 164Cisnal, M. ........... C2-690, 087; T-1045, 113Cisneros, J. M. ...................K-1924, 239Cisneros, J. ....................... T-340, 029Citron, D. M. .................... F-854, 099Ciullo, I. ........................E-796, 094Clancy, C. .............T-348, 029; T-364, 029;....... E-792, 094; M-978, 111; T-1031, 113;..... T-1037, 113; M-1056, 115; T-1069, 116;................C2-1216, 157; M-1685, 190Final Program215

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberClancy, C. J. ............T-346, 029; E-786, 094;.......E-804, 094; K-1605, 183; K-1622, 184;............................M-1675, 190Clark, A. .......................M-1061, 115Clark, C. L. ....................C1-1971, 242Clark, K. .......................A-1286, 162Clark, R. .............H-228, 019; F-1526, 177Clarke, L. G. ....................K-1622, 184Clausen, L. N. ....................G-876, 101Clavel, M. .....................C1-1739, 197Cleary, J. D. ...........M-968, 111; M-991, 111Clemente, W. T. .................K-1606, 183Clemons, K. V. ........G-875, 101; M-982, 111;............................ P-1013, 112Clerc, O. .......................H-1566, 179Clifford, R. .....................C2-725, 089Climax, J. ....................... F-2009, 246Clinch, B. ......................A-1245, 161Clubb, R. T. ..................... F-1534, 177Cnops, L. ....................... P-1014, 112Coakley, P. ......................C2-692, 087Coate, B. ........................H-880, 102Cobb, B. ..............T-355, 029; T-1070, 116Cobo, J. .............M-323, 028; M-1700, 191Cobos, N. ......................C1-075, 006Cockerill, F. R. ..................... 006, 002Coelho, C. .....................C1-1740, 197Coen, P. .........................D-160, 011Coetzer, C. T. ................... P-1021, 112Coggle, S. V. ....................L1-288, 025Cohen, C. .......................H-211, 017Cohen, H. ......................L1-962, 110Cohen, N. D. ...................C1-1348, 166Cohen, R. ............G-864, 100; G-1049, 114Colafigli, G. ......................K-898, 104Colbers, A.. . . . . . . . . . . . . . . . . . . . . . A-1928, 240Cole, J. ..........................H-883, 102Coll, P. ..........................K-256, 022Collier, A. C. ...................... 1779, 202Collins, A. R. .....................B-059, 005Collins, C. ......................C2-088, 008Collins, I. ....................... F-2016, 247Collins, R. .......................D-771, 092Colmenero, J. ...................L1-2102, 254Colombian Nosocomial Resistance Study Group,..................C2-694, 087; D-747, 092Colombo, A. .................... T-1035, 113Colomer, M. ....................D-1419, 170Comer, G. ......................... 492, 057COMIC Study Group-PROMULGA................M-1232, 159; M-1684, 190Commons, R. ...................B-1313, 165Comolli, J. ......................M-1060, 115Compson, J. .....................B-1738, 196COMRSA Pilot Group ...........C2-1380, 169Concha, A. .....................H-1921, 238Condon, L. M. .................. V-1241, 160Conen, A. ......................C2-082, 007Conery, A. ...................... F-1538, 177Confreda, K. L. ...................E-790, 094Conklin, B. C. ...................C1-073, 006Conly, J. .............. 1084, 118; C2-1380, 169Consolo, S. ....................G3-1549, 178Constantea, N. ................... P-1008, 112Conte, U. ...........M-1229, 159; M-1683, 190;............................M-1709, 191Conte, V. ......................C2-1211, 157Converse, P. .....................B-1296, 164Conville, P. S. ....................... 1858, 22Conway, B. ............V-371, 030; H-884, 102Cook, A. M. ....................L1-286, 025Cook, J. L. ...................... F-2072, 249Coombs, G. ....................C2-1908, 237Coon, R. ........................V-383, 030Cooper, D. ......................... 575, 077Cooper, B. S. ....................... 571, 076Cooper, C. B. ..................... F-838, 098Cooper, J. T. ..................... T-1025, 113Cooper, M. A. .......C1-062, 006; C1-1743, 197Corbeil, J.. . . . . . . . . . . . . . . . . . . . . . G3-1541, 178Corbin, V. ....................... P-566, 075Cordero, E. .....................K-1924, 239Córdoba, S. ......................M-327, 028Córdova, L. .....................M-1684, 190Corey, K. E. ......................V-377, 030Corey, L. ......................... 1830, 213Corkrey, H. ...................... F-846, 099Cormican, M. ........C2-088, 008; C2-119, 009;.................C2-122, 009; C2-706, 088Cornejo, P. ......................C1-067, 006Cornejo, T. .......................K-931, 105Cornell, K. ...................... P-1019, 112Cornely, O. A. ........M-338, 028; M-1230, 159;. . . . . M-1234, 159; M-1706, 191; A-1934, 240Cornet, M. .......................M-983, 111Corrah, T. ......................L1-288, 025Corrard, F. ......................G-1049, 114Correa, A. ........... C2-694, 087; D-747, 092;.................K-903, 104; L2-2108, 255Corrigan, M. .................... F-1493, 175Corso, A. ............C2-084, 008; C2-701, 087;......D-746, 092; D-759, 092; C2-1217, 157;. . . . . . . . . . . . . . . . F-1491, 175; C2-1910, 237;Cortet, B. ........................H-231, 019Corvec, S. ............C2-080, 007; K-255, 022;. . . . . . . . . . . . . . . . B-1318, 165; C1-1342, 166Cosgrove, S. E. ...................K-275, 024Cosson, P. ......................B-1333, 165Costa, G. ....................... T-1031, 113Costa, T. M. ....................C2-1377, 169Coste, J. ........................ F-1488, 175Cotellon, G. .....................D-1453, 172Cottagnoud, M. ...................B-649, 084Cottagnoud, P. ....................B-649, 084Cottalorda, J. ....................A-1253, 161Cottell, J. L. .....................C2-710, 088Cotton, F. .......................A-637, 083Cotton, G. C. ................... F-2001, 246Cottreau, J. M. ....................K-901, 104Couet, W. .............A-033, 004; A-036, 004;........... A-035, 004; A-037, 004; 502, 061Couffignal, C. ....................A-021, 003Coughlan, D. .................... F-2009, 246Couillard, M. ....................H-1571, 180Coulange, L. .........C2-091, 008; C2-719, 089Courvalin, P. .........C1-458, 047; C1-676, 086;...........................C1-1344, 166Couture, C. ......................V-399, 030Couzigou, C. .....................K-234, 020Cowling, B. J. ..................... 1805, 208Cox, M. M. .....................G-1053, 114Coyle, C. M. ..............406, 033; 1085a, 199Coyle, J. R. .......................D-750, 092Coyne, P. .................1823, 211; 493a, 058Craig, W. .............F-857, 099; D-1431, 171;.................A-1947, 241; A-1961, 241Craigo, J. K. ...........F-1490, 175; F-2061, 249Crandon, J. L. ..........A-013, 003; A-014, 003;. . A-015, 003; A-625, 083; A-630, 083; A-633,083Crank, C. W. ...........K-275, 024; K-278, 024Crarey, E. .......................C2-714, 088Crauwels, H. ....................A-1249, 161Creech, C. B. ....................... 490, 056Creely, D. ........................E-197, 015Cremers, S. ......................A-026, 004Cremet, L. ......................C2-080, 007Crémieux, A. .....................B-645, 084Cremona, A. R. .................L1-1637, 186Crespo, M. ....................... T-364, 029Crist, A. E. ......................E-807, 095Cristescu, R. ....................M-1695, 190Crofoot, G. ......................H-555, 073Crook, D. ........................D-160, 011Cross, S. ........................B-1738, 196216September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberCrowe, S. ........................D-736, 091Crowe, S. R. .....................D-732, 091Crowther, G. ...........B-662, 084; K-924, 105Cruciani, M. ..........H-216, 018; H-1579, 180Cruz, C. ........................ P-1012, 112Cruzado, J. ...................... T-1030, 113Cubero, M. .....................C2-690, 087Cuellar, M. .....................M-1668, 190Cuenca-Estrella, M. ....M-321, 028; M-327, 028;........................... M-1718, 191Cuervo, G. .......................M-329, 028Cuevas, O. ......................C2-130, 010Cuhaci, B. .......................A-618, 082Cui, S. ..........................K-933, 105Culebras, E. ......................E-805, 095Cunha-Bang, C. D. ............... T-1072, 116Cunningham, M. ......F-1514, 176; F-2017, 247;.................F-2018, 247; F-2018a, 247Cunningham, S. .................D-1774, 201Cunnington, M. C. ...............G-1751, 198Curello, J. ........................D-754, 092Curfs, I. .........................M-334, 028Curiao, T. ........................D-753, 092Curlier, E. ....................... P-566, 075Curran, M. D. ...................D-1451, 172Curtis, N. .......................B-1313, 165Curto, A. ....................... T-1035, 113Curto, L. ......................C1-1206, 156Cusato, J. ............A-1769, 200; A-1937, 240Custodio, J. .....................A-1250, 161Cutler, C. ........................ T-354, 029Cynamon, M. H. .................E-1995, 245Czaplewski, L. G. ................ F-2016, 247DD’Abramo, A. ....................D-165, 012D’Abrera, V. .....................K-265, 023D’Avolio, A. .........A-1769, 200; A-1937, 240D’Hondt, R. E. ...................A-011, 003Da Re, S. .......................C1-666, 085Da Silva, C. O. .................C2-1387, 169Da Silva, G. J. ........C2-713, 088; P-1012, 112Dadwal, S. .............T-349, 029; T-350, 029;...................T-351, 029; T-1039, 113Dagan, R. ...........G-1050, 114; G-1753, 198Dahoumane, R. ...................D-173, 013Dailey, A. L. ..........D-170, 012; D-1774, 201Daily, J. P. ........................ 1110, 126Dalarosa, M. G. ...................A-027, 004Dale, G. E. ....................... 1106, 125Daleno, C. .....................G3-1549, 178Dalla-Costa, L. M. . . . C2-087, 008; C1-1207, 156Dalle, D. ........................K-272, 024Dalle, J. ..............T-363, 029; D-1778, 201Dallow, J. ....E-204, 016; E-210, 016; D-769, 092Damiani, C. ......................M-333, 028Damico, P. .....................C2-1398, 169Damond, F. ......................H-886, 102Dangel, M. ......................D-167, 012Danieli, E. .....................G3-1553, 178Daniels, K. R. ...................L1-297, 026Danish Fungaemia Study Group ......M-318, 028Dannaoui, E. ....................M-1707, 191Dannemann, B. .......A-1258, 161; A-1259, 161;............................A-1260, 161Dantas, G. ......................... 432, 040Danziger-Isakov, L. ..............G3-1546, 178Dao, K. .......................... 1093, 122Daoud, Z. ......................K-1584, 181Dargis, R. ......................D-1444, 171Darini, A. C. ....................C2-086, 008Darling, K. E. ....................D-184, 014Darling, K. ......................H-1566, 179Darouiche, R. O. .................K-2097, 252Das, A. ........................L1-1664, 189Das, B. K. .....................C2-1982, 243Das, D. ........................A-1291, 163Das, S. .....A-1760, 200; A-634, 083; A-635, 083Das, S. K. .......................C2-715, 088Datla, S. .............C2-096, 008; K-1589, 181Datta, A. .......................B-1736, 196Dauchy, F. A. ..........K-248, 022; K-2074, 250Daudon, M. ......................H-889, 103Dauri, M. ....................... T-1040, 113Davenport, J. M. ......A-1961, 241; A-1962, 241David, H. M. .....................G-876, 101David, L. ........................D-729, 090David, M. ........... B-1337, 165; B-1338, 165Davido, B. .......................B-645, 084Davieau, M. ............E-203, 016; B-651, 084;................. B-1335, 165; F-2056, 248Davies, D. ...................... F-2016, 247Davies, F. ......................L1-1667, 189Davies, K. A. .....................D-160, 011Davies, T. A. ....................C1-594, 081Davies Sala, C.. . . . . . . . . . . . . . . . . . . F-1539, 177Davis, A. ......................L1-1659, 189Davis, K. ..............H-211, 017; E-795, 094Davis, M. M. ....................... 504, 062Davis, N. ........................K-902, 104Davis, S. C. ..................... F-1518, 176Davis, S. L. ............K-240, 020; K-275, 024;........K-909, 104; K-946, 106; K-1121, 129;.....K-1123, 129; K-1629, 185; L1-1638, 186Davis, T. .......................C2-1213, 157Daws, G. M. ..................... F-842, 099Dawson, C. .....................H-1570, 179Dawson, R. .....................A-1264, 161Dawurung, J. ....................G-1748, 198Day, J. ........................... 1118, 128Dayaram, Y. ......................H-880, 102De Alarcón, A. ...................K-938, 106De Anda, C. ....... L1-1664, 189; L1-1665, 189De Backer, W. ..................L1-1641, 186De Barbeyrac, B. .......K-248, 022; K-2074, 250De Benito, I. .....................D-765, 092De Botton, S. .....................D-772, 092De Broucker, T. .................C2-1374, 168De Champs, C. ..................B-1306, 164De Colsa, A. ...................G3-1563, 178De Cueto, M. ...................C2-111, 009De Cueto, M. ..................L1-1658, 188De Dios, S. ..................... T-1071, 116De Gialluly, C. ....................D-176, 013De Greeff, S. C. ...................D-183, 014De Groote, M. A. ................. F-831, 098De Gunzburg, J. .................A-1963, 241De Gunzburg, J. ................. F-2003, 246De Hoog, S. ......................M-338, 028De Jager-Leclercq, M. G. ..........L1-965, 110De Jong, A. ..........C2-705, 088; C2-709, 088De Knegt, G. J. ........B-058, 005; A-1268, 161De la Cadena, E. .......C2-694, 087; D-747, 092De la Cochetière, M. . . D-1458, 172; L1-1642, 186De la Cruz-Váldez, M. J. ..........C2-1357, 167De la Torre, F. ....................E-805, 095De Lamballerie, X. ................V-387, 030De Las Peñas, A. .................M-1668, 190De Lastours, V. ........H-889, 103; H-219, 019;................B-1305, 164; C2-1399, 169De Lencastre, H. ....C2-1365, 167; C1-1740, 197De Luca, C. ......................D-159, 011De Maio, W. ....................A-1950, 241De Marco, B. ..................... T-357, 029De Marez, T. .........A-1258, 161; A-1259, 161;............................A-1260, 161De Melker, H. E. ..................D-183, 014De Moraes-Pinto, M. I. ..........G3-1557, 178De Paris, F. ....................C2-1375, 168De Rosa, F. G. ........A-1769, 200; A-1937, 240De Salas-Cansado, M. .............K-1633, 185De Salvador-Guillouet, F. ..........A-1253, 161Final Program217

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberDe Serres, G. .......... V-389, 030; V-1076, 117De Steenwinkel, J. E. ..............A-1268, 161De Vedia, L. .......C2-1396, 169; C2-1397, 169De Vos, D. ...................... P-1014, 112De Vries, M. M. .................K-2086, 252Dean, C. R. .........C1-680, 086; C1-1973, 242Deane, J. .............A-008, 003; C2-125, 010;.......C2-128, 010; C2-134, 010; E-208, 016;........D-760, 092; D-764, 092; D-767, 092;.......E-778, 093; E-1479, 174; F-1524, 177;..................F-2046, 248; F-2047, 248Deb, M. .......................C2-1982, 243Debabov, D. ..................... F-2058, 249Debaugnies, F. ...................D-1413, 170DeBess, E. E.. . . . . . . . . . . . . . . . . . . . . T-345, 029Debiais, F. .....................L1-2104, 254Decker, M. D. ...................B-1322, 165Deconinck, E. ...................M-1692, 190Dedhia, H. ......................A-1289, 163Dediste, A. ...........T-1046, 113; D-1413, 170Deeks, S. ........................H-553, 073Deenen, R.. . . . . . . . . . . . . . . . . . . . . . C1-588, 081Dehio, C. ......................... 1782, 203Dehn Lunn, A. ..................C2-696, 087Dejli, J. ......................... P-1021, 112Dekhnich, A. .......C2-1386, 169; C2-1911, 237Dekkers, O. ............K-472, 048; K-930, 105Del Palacio, M. ...................H-222, 019Del Pozo, J. .....................K-1612, 184Del Río, A. ...........K-945, 106; K-1122, 129Del Toro, M. ...................L1-1658, 188Del-Rio, A. . A-610, 082; B-648, 084; E-1465, 173Dela Torre, J. .....................K-942, 106Delabre, R. M. .................... V-387, 030Delaere, B. .....................L1-1641, 186Delaney, A. S. ...................V-1241, 160Delanghe, P. .....................K-1927, 239Delgado, J. ...................... T-1071, 116Del Gorge, C. ................... F-1523, 177Delia, P. ........................K-2089, 252Dellinger, E. ...................... 1879, 231Delmée, M. ......................D-156, 011Dem, P. ........................K-1592, 181DeMaio, W. .....................A-1951, 241Demar, M. ...................... P-1011, 112Demczuk, W. ...................C2-1360, 167DeMena, A. ....................G3-1552, 178Demers, A. ......................D-730, 090Demeulemeester, A. ...............K-930, 105Denamur, E. ....................B-1305, 164Deneer, H. .......................D-729, 090Deng, J. ........................ F-2072, 249Deng, L. ........................K-926, 105Deng, W. ......................G3-1562, 178Deng, Y.. . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177Denis, O. ..............A-597, 082; A-598, 082Denisuik, A. .........C2-103, 009; C2-135, 010;. . . . . . . . C2-149, 010; E-194, 015; E-779, 093Denmark, R. ....................L1-300, 026Denning, D. ........................ 457, 046Dent, C. .......................L2-2118, 255Denys, G. A. ........C2-1213, 157; F-1524, 177;............................ F-1528, 177Depatureaux, A. ...................H-886, 102DePestel, D. D. ...................K-276, 024Deprez, G. .......................A-637, 083Desai, A. .......................A-1936, 240Desarbre, E. ....................... 1797, 206Descy, J. .......................C2-1988, 244Desessard, C. ...........E-203, 016; B-653, 084;......B-1335, 165; A-1948, 241; F-2056, 248Deshpande, L. M. .....C1-594, 081; C2-691, 087;...............C1-1343, 166; C1-1745, 197Deslouches, B. .........F-1490, 175; F-2061, 249Dessau, R.B. ....................D-1409, 170Dessen, A. ...................... F-2062, 249DeStefano, F. ....................G-1054, 114Dettenkofer, M. .................... 1851, 223DeVito, J. A. ..........F-1521, 177; F-1522, 177Dewhurst, N. F. .......K-1590, 181; K-1591, 181Dhanji, H. ....................... F-853, 099Dhar, S. .........................K-902, 104Di Bella, A. ......................D-746, 092Di Conza, J. ..........C1-466, 047; C1-678, 086;. . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-700, 087Di Conza, J. A. ..................C1-669, 085Diéguez, C. .....................H-1921, 238Di Gregorio, S. .................C2-1397, 169Di Maggio, T. ..................C1-1205, 156Di Perri, G. ..........A-1769, 200; A-1937, 240Di Pilato, V. ....................C1-1205, 156Diacon, A. ...........A-1258, 161; A-1264, 161Diamantino-Miranda, J. ............G-866, 100Diana, M. ......................D-1426, 171Diarra, M. S. ...................C2-1986, 244Dias, C. H. ......................K-913, 104Díaz, D. ........................K-2091, 252Díaz, L. ........................H-1567, 179Diaz, L. .......................C1-1345, 166Díaz de Alba, P. ..................C1-683, 086DiCenzo, R. ....................A-1252, 161Didi, J. .........................B-1337, 165Diebolt, E. . ......................H-228, 019Diekema, D. ........ C2-126, 010; D-1433, 171;............................A-1929, 240Diep, B. A.. . . . . . . . . . . . B-645, 084; B-1735, 196Dieterich, D. T. ..................... 585, 080Diezmann, S. ...................... 1870, 229DiFranco-Fisher, J. ................E-802, 094DiGiandomenico, A. . . . F-1529, 177; B-1734, 196Dilworth, T. .....................E-1472, 174Dimasi, N. ......................B-1734, 196Dimopoulos, G. ...................K-951, 107Dimopoulou, D. ......B-043, 005; M-1058, 115;........................... M-1696, 191Dina, J.. . . . . . . . . . . . . . . . . . . . . . . . . . D-178, 013Dinelli, M. I. ...................G3-1557, 178Ding, W. .......................M-1695, 190Dingemanse, J. ...................A-1273, 162Dinh, A. ............ P-566, 075; L1-2104, 254Dinleyici, E. C. ..................M-1671, 190Dionne, M. ..........G-1047, 114; K-1755, 199Diosque, M. ...........G-874, 101; P-1015, 112;. . . . . . . . . . . . . . . . . . . . . . . . . . . . .P-1016, 112Diot, P.. . . . . . . . . . . . . . . . . . . . . . . . . . A-036, 004DiPersio, J. .......................D-163, 011DiStefano, D. ....................H-551, 073Disthaporn, P. ...................E-1477, 174Diviti, S. .......................C2-096, 008Dixit, V. .........................V-373, 030Dixon, R. A. .................... F-2001, 246Djamdjian, L. ...................C1-072, 006Djikeng, A. ......................H-214, 018Djolbunova, Z.. . . . . . . . . . . . . . . . . . G3-1548, 178Djossou, F. ...................... P-1011, 112Djuidje Ngounoue, M. .............H-214, 018Doan, K. A. ..................... T-1029, 113Doan, T. .........................K-917, 105Dobson, E. .....................A-1252, 161Doco-Lecompte, T. ................K-939, 106Dodd, M. .......................E-1472, 174Doerholt, K. ...................G3-1559, 178Doern, G. ......................C2-126, 010Dohrn, C. ......................C2-126, 010Doi, A. M. ......................C2-685, 087Doi, N. ........................A-1254, 161Doi, Y. .......001, 001; C2-112, 009; E-792, 094;. . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1216, 157Doit, C. ......................... T-363, 029Dolande, M. .....................M-327, 028Dolapci, I. ......................C2-684, 087Dole, K. ........................A-1281, 162Dolivet, G. ......................L2-302, 027218September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberDomenech, A. ..................C2-1365, 167Domingo, J. D. .................G3-1551, 178Domingo, M. .....................D-751, 092Domingues, R. M. ................C1-671, 085Dominguez, M. A. ...............D-1775, 201Domínguez, M. .................C2-1395, 169Dominguez, W. .................G3-1563, 178Dominguez-Castellano, A. ........L1-1658, 188Dominique, S. ....................M-974, 111Donald, L. ......................A-1954, 241Donald, R. ......................... 575, 077Donati, D. ...................... T-1035, 113Donati, M. .......................E-207, 016Donay, J. ........................H-219, 019Donnellan, M. ....................K-469, 048Donnelly, J. P. ........M-1225, 159; A-1928, 240Donnelly, J. ....................... 1887, 233Donnio, P. .......................K-267, 023Donskey, C. J. ...................C2-686, 087Dooley, K. E. ....................A-1256, 161Dorca, J. ..............D-180, 013; L1-293, 026;................. L1-295, 026; L1-298, 026Dorronzoro, A. ...................E-202, 015Dortet, L. ...........C1-078, 006; C1-587, 081;. . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1202, 156Dos Santos, A. M. ...............G3-1557, 178Dos Santos, K. R. . . . C2-1387, 169; D-1428, 171;. . . C2-1377, 169; C2-1383, 169; C2-1907, 237Dotan, I. ........................H-232, 019Douadi, Y. .....................L1-2106, 254Douglas, C. M. ..................M-979, 111;.................M-984, 111; M-1057, 115Douglas, C. .........M-1676, 190; M-1678, 190Douglas, C. M. ..................M-1695, 190Doull, I. J. ...................... F-2064, 249Douville-Fradet, M. ...............V-389, 030Dovgan, E. V. ...................L1-299, 026Dovzhenko, S. A. .................A-1967, 241Doyle, D. .......................D-1448, 172Doyon-Reale, N. .................M-1713, 191Draffan, A. G. .................... F-828, 097Drancourt, M. ..................... 1175, 149Draper, M. P. ....................A-1282, 162Drawz, S. M. ....................C1-463, 047Dreikorn, S. ...................... F-810, 096Drescher, M. .....................V-398, 030Dreskin, H. ..........A-1292, 163; A-1293, 163;.................A-1294, 163; A-1295, 163Dresser, L. ...........K-1590, 181; K-1591, 181DRESSING2 Study Group, France . . K-1757, 199Dretler, R. .......................H-882, 102Drew, R. ............K-1583, 181; M-1703, 191Drews, S. J. ......................V-386, 030Dreyer, C. ......................K-2087, 252Dreze, P. .......................B-1312, 165Driver, V. ....................... F-2022, 247Droggari, M. .....................K-245, 021Dromer, F. ......................M-1686, 190Dronda, F. ............H-217, 018; H-1567, 179Dropa, M. ...........C2-106, 009; C1-668, 085;............................ P-1002, 112Drouot, E. ....................... V-392, 030Droz, S. ........................C2-116, 009Drulak, M. .......................H-877, 102Drusano, G. ............A-041, 004; A-042, 004;.................A-1265, 161; E-1993, 245Drusano, G. L. ........A-011, 003; A-1761, 200Duarte, L. P. ....................K-1603, 183Duarte, R. ...................... T-1045, 113Duarte, R. F. ....................A-1934, 240Duarte, R. S. ...................C2-1375, 168Dube, G. .............T-1034, 113; T-1036, 113Dubois, V. ......................C2-719, 089Dubreucq, L. .................... T-1028, 113Dubuque, J. ......................V-389, 030Duchene, E. .....................L1-283, 025Ducrot, N. ...................... F-2003, 246Dudley, M. ....................... 1089, 121Dudley, M. N. ..........F-849, 099; F-850, 099;F-851, 099; F-852, 099; F-858, 099; F-848, 099Duerken, M. ....................M-1704, 191Duffy, E. ............A-1289, 163; F-1521, 177;..................F-1522, 177; F-1523, 177Duffy, S. .......................M-1702, 191Dumford, D. .........C2-686, 087; C2-720, 089Dumkow, L. E. ...................K-240, 020Dumont, E. F. ........A-1272, 162; A-1276, 162;............................A-1277, 162Dumpis, U. .....................K-2080, 251Duncan, F. .......................V-371, 030Dungl, C.. . . . . . . . . . . . . . . . . . . . . . . E-1471, 174Dunkle, L. ......................G-1053, 114Dunne, M. ............C2-134, 010; K-239, 020;..................A-623, 082; E-1467, 173Dunne, W. M. ....................D-771, 092Duong, A. H. ...................B-1735, 196Dupon, M.. . . . . . . . . . . .K-248, 022; K-2074, 250;............... L1-2103, 254; L1-2104, 254DuPont, H. L. ..........K-920, 105; K-921, 105Dupont, H. .....................M-1698, 191Durand, G. ............D-745, 092; D-748, 092Durica, G. .......................A-644, 083Durmaz, R. ....................C2-1980, 243Dutch Mica Study Group ...........M-334, 028Dutkowski, R. ...................V-1080, 117Dutronc, H. ...........K-248, 022; K-2074, 250Duval, R. E. ..................... F-1527, 177Duval, X. ........................K-939, 106Dvorak, T. ...................... F-2012, 246Dwivedi, S. ....................C2-1982, 243Dworkin, J. ......................K-233, 020Dwyer, D. E. ....................... 498, 060Dyer, J. ..........................K-265, 023EEbrahimi, R. .....................H-556, 073Echaniz-Aviles, G. ..............C2-1356, 167Echenagusia, A. ...................D-166, 012Echenagusia, M. ..................D-166, 012Eckburg, P. B. ......... E-207, 016; D-760, 092;...... D-764, 092; A-1949, 241; A-1950, 241;......A-1951, 241; A-1952, 241; A-1953, 241;......A-1954, 241; A-1955, 241; F-2046, 248;..................F-2047, 248; F-2054, 248Eckert, C. . . .K-925, 105; D-154, 011; D-157, 011Edder, P. ........................K-560, 074Edelstein, M. ........C2-1386, 169; C2-697, 087;...........................C2-1911, 237Edlind, T. D. .....................M-966, 111Edouard, S. .......... L1-963, 110; P-1011, 112Edwards, J. ........................ 1117, 128Edwards, K. M. ............. 002, 001; 527, 067Edwards, R. .....................B-1311, 165Edwards, Jr. J. E. ....... G-868, 101; M-973, 111Eells, S. J. .............. B-654, 084; B-655, 084Efstathiou, P. .....................K-245, 021Egard, M. ......................L1-291, 026Egea, A. .......................C2-1910, 237Egea, P. ........................C2-707, 088Eggimann, P. ........... 1115, 128; K-2088, 252Ehninger, G. ..................... T-356, 029Ehricht, R. ......................D-1432, 171Ehrlenbach, S. ................... F-2058, 249Eichenseher, F.. . . . . . . . . . . . . . . . . . . F-1516, 176Eitzinger, C. .................... F-2058, 249Eko, F. O. ......................E-1994, 245Ektare, V. ........................K-239, 020El Garch, F. ..........C2-705, 088; C2-709, 088El Lakkis, I. .....................L1-284, 025El Meouche, I. ...................B-1337, 165El-Imad, B. ...................... F-841, 099El-Mahdy, T. S. ..................C1-077, 006El-Moamly, A. ...................V-378, 030El-Samad, V. ...................L1-2106, 254Final Program219

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberElagin, S. .......................D-1414, 170Elders, P. J. ......................C2-104, 009Elefanti, A. ...........E-782, 093; A-1938, 240;............................A-1939, 240Eley, T. .........................A-1247, 161Elie, C. ............M-1686, 190; M-1707, 191Eliopoulos, G. M. .................. 1194, 154Ellery, C. .......................A-1264, 161Ellington, M. J. ..................D-1451, 172Elmali, F. .......................M-1701, 191Elman, M. R.. . . . . . . . . . . . . . . . . . . L2-2118, 255Elsendoorn, A.. . . . . . . . . A-039, 004; L1-963, 110Elvers, B. ........................D-183, 014Emanuel, C.. . . . . . . . . . . . . . . . . . . . . F-2062, 249Emanuela, C. ...................C2-1373, 168Embil, J. .......................C2-1380, 169Embree, J. .....................C2-1360, 167Endimiani, A. .......... C2-116, 009; 1183, 151Endo, S. ............C2-114, 009; C2-1901, 236Englund, J. ....................... T-353, 029Englund, J. A. ...................... 441, 042Enokizono, K. ...................D-1438, 171Enoru, J. ............A-1949, 241; A-1950, 241;. . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1951, 241Enria, D. A. ....................... 1098, 124Entenza, J. .......................B-046, 005Epie, F. ................F-844, 099; F-845, 099Erb, S. ..........................D-167, 012Ergani, A. ......................D-1453, 172Ergonul, O. .....................C2-684, 087Ermocida, A. .....................D-742, 091Ernst, B. ....................... F-2057, 249Ernst, E. J. ......................K-1611, 184Ernst, F. R. .....................L1-292, 026Ernst, J. .......................... 1170, 148Eron, J. .........................H-229, 019Erpelding, M. ....................K-939, 106Errecalde, L. .....................D-746, 092Escribano, P. ........M-1232, 159; M-1684, 190Eser, B. ........................M-1701, 191Eshleman, S. H.. . . . . . . . . . . . . . . . . . H-1580, 180España, A. ...........D-1439, 171; D-1440, 171Español, M. ......................K-931, 105Espasa, M. ......................K-1623, 184Espedido, B. A. ......C1-062, 006; C1-1743, 197Espejo, E. ......................K-1621, 184Esper, F. ...............V-385, 030; F-2015, 246Espinal, P. ..........B-1327, 165; C2-1900, 236Espinosa, B. ..................... P-1021, 112Espinosa de los Monteros, L. E. ....L1-1653, 187Espinosa-Silva, Y. .................H-228, 019Esposito, S. .........L2-304, 027; G3-1549, 178;...............G3-1551, 178; G3-1553, 178Esteban Moreno, J. ...............L1-958, 109Esterly, J. ........................K-271, 024Estes, R.. . . . . . . . . . . . . . . . . . . . . . . . K-2085, 252Etienne, J. ......................B-1317, 165Etienne, M. .......... B-1337, 165; B-1338, 165Euba, G. ........................K-254, 022Evans, C. ........................H-881, 102Evans, M. ......................H-1574, 180Evdokimova, E. ......C1-458, 047; C1-1344, 166Everett, M. J. ....................A-1959, 241Everitt, D. ......................A-1259, 161Ewing, C. A. ....................K-1923, 239Eworo, A. ...................... T-1026, 113Eyigun, C. P. ....................L1-960, 110Eyre, D. W. ......................K-474, 048Ezdon, D. .......................A-618, 082FF-Viladrich, P. ...................V-1240, 160Fabre, T. .........................K-248, 022Fàbrega, A. ..........C2-696, 087; B-1329, 165Faccone, D. .........C2-084, 008; C2-1217, 157;................ F-1491, 175; C2-1910, 237Fadel, S. A. ......................K-955, 108Fairfax, M. ......................L2-306, 027Fairhead, H. ............1104, 125; F-2065, 249;. . . . . . . . . . . . . . . . . . . . . . . . . . . . .F-2066, 249Fairhurst, R. M. .................... 1200, 155Fairley, C. K. ....................L2-301, 027Faix, D. .........................V-383, 030Fakkas Fernández, M. ..............D-169, 012Fakruddin, M. ...................C2-711, 088Falcão, L. D. ...................C2-1383, 169Falces, C. ..............A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129; E-1465, 173Falci, D. R. ......................A-027, 004Falcone, M. ......................K-938, 106Falgueras, L. ....................K-1623, 184Fallo, A. .......................G3-1552, 178Falup-Pecurariu, O. ..............G3-1551, 178Famiglietti, A. ...................D-1455, 172Famure, O. ....................... T-365, 029Fanfair, R. N. ....................M-1677, 190Fang, E. .............A-1292, 163; A-1293, 163;.................A-1294, 163; A-1295, 163;............... L1-1664, 189; L1-1665, 189Fang, L. .......................C2-1380, 169Fanning, S.. . . . . . . . . . . . . . . . . . . . . .M-1056, 115Fantin, B. .....433, 040; B-660, 084; B-1305, 164;.....B-1306, 164; C2-1399, 169; K-2087, 252Farah, R. ........................D-732, 091Faria, N. A. ....................C1-1740, 197Faria-Ramos, I. ...................M-320, 028Farias, V. ......................C2-1375, 168Fariñas, M. ......................K-943, 106Fariñas, M. C. ........D-169, 012; M-1673, 190;............................ P-1018, 112Fariñas-Alvarez, C. ................D-169, 012Farinati, A. E. ......... E-202, 015; V-1237, 160Farinha, S. .......................M-320, 028Farkas, S. ....................... F-2020, 247Farkus, S. ....................... F-2025, 247Farley, J. .........................M-991, 111Farley, M. M. ....................G-1752, 198Farmakiotis, D. ..................M-1705, 191Farnsworth, A. ...................L2-301, 027Farnum, C. ......................A-018, 003Farooqui, A. ....................C2-1981, 243Farrands, A. .....................G-1051, 114Farrell, D. J. ..........C2-089, 008; C2-090, 008;................C2-145, 010; C2-1214, 157Fathima, S. ...................... V-386, 030Fatima, K. .......................H-228, 019Fattom, A. .......................G-869, 101Fattouh, N. .....................K-1634, 185Faure, E. ..............B-050, 005; B-060, 005Faure, K. .............. B-050, 005; B-060, 005Fawley, W. N. ....................K-474, 048Fedler, K. A. .....................E-193, 015Fedyakina, I. .....................V-388, 030Fegeler, C. .....................C2-1382, 169Feghoul, L. ...........T-363, 029; D-1778, 201Fehlberg, L. C. .......D-731, 090; C1-1207, 156Feierl, G. .......................E-1470, 173Félix, J. ..........................H-878, 102Felton, T. W. .........M-977, 111; A-1765, 200;......A-1942, 240; A-1943, 240; A-1944, 240Feng, M. ........................H-551, 073Feng, Q. ........................M-1061, 115Fenical, W.. . . . . . . . . . . . . . . . . . . . . . F-1514, 176Fenoll, A. ..........C2-1358, 167; C2-1365, 167Fentaw, D. S. .....................D-181, 013Ferenci, P. ......................V-1236, 160Ferguson, E.. . . . . . . . . . F-2006, 246; F-2007, 246;............................ F-2008, 246Ferguson, M. C.. . . . . . . . . . . . . . . . . C2-1377, 169Ferguson, N. M. ................... 1854, 225Ferguson, S. ......................M-968, 111Feris Iglesias, J. ..................G-1751, 198220September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberFernandes, C. ...................L1-1656, 188Fernandes, P. ..........E-781, 093; A-1286, 162;.................A-1269, 162; F-1505, 176;Fernández, A. ...................C1-593, 081Fernandez, A. ........C1-070, 006; L1-289, 026;...........................C2-1902, 236Fernández, I. ....................K-1623, 184Fernandez, P. .....................K-559, 074Fernandez, S. .......C2-1396, 169; C2-1397, 169Fernández Guerrero, M. ...........L1-958, 109Fernandez-Cruz, A. ................K-944, 106;.....D-1411, 170; M-1684, 190; M-1688, 190Fernández-Hidalgo, N. .............K-937, 106;......K-938, 106; L1-1644, 186; K-1758, 199Fernández-Mazarrasa, C. ..........A-1280, 162Fernández-Roblas, R. .............L1-958, 109Fernández-Romero, N. ............D-1452, 172Fernández-Ruiz, M. ....M-329, 028; T-359, 029;................. T-1071, 116; K-2091, 252Fernández-Sabé, N. ................ T-368, 029Fernandez-Sampedro, M. ...........D-169, 012Ferrand, H. .....................L1-957, 109Ferrándiz, C. ....................K-1924, 239Ferrario, A. ...........D-159, 011; K-1601, 182Ferreira, B. L. ................... F-1513, 176Ferreira, D. C. .......C2-1387, 169; D-1428, 171Ferreira, D. ......................H-878, 102Ferreira, E. O. ...................C1-671, 085Ferreira, I. S. .................... F-2011, 246Ferreira, J. ......................G-1048, 114Ferreira, V. ...................... F-1513, 176Ferrer, A. .......................K-1616, 184Ferrer, C. .......................K-1758, 199Ferretto, R. .....................H-1579, 180Ferrières, V. ..................... P-1007, 112Ferris, R. ........................H-550, 073Ferris, W. .......................E-1480, 174Ferry, T. ....B-1319, 165; K-249, 022; K-253, 022Feßler, A. T. ....................C1-1350, 166Feversot ........................ T-1026, 113Fevre, K. ......................L1-2103, 254Fey, M. .........................D-1416, 170Fiaux, E. ............ B-1337, 165; B-1338, 165Fick, J. .........................C1-665, 085Fielding, R. ......................V-396, 030Fierens, F. L. .....................G-859, 100Fiett, J. .........................C2-109, 009Figueiredo, P. .....................H-227, 019Figueiredo, R. ...................C2-713, 088Figueroa, C. ...................... T-361, 029Figueroa, R. ......................K-935, 105Fikes, S. ...............A-041, 004; A-042, 004;.................A-1265, 161; E-1993, 245Files, K. .............A-1265, 161; E-1993, 245Filler, S. ....B-650, 084,G-868, 101; M-1056, 115FILPOP Study Group .............M-321, 028Fine, A. .........................T-342, 029Finelli, L. ......................... 1733, 195Fink, P. .........................G-870, 101Finks, J. L. .......................D-750, 092Finn, J. ............. F-2017, 247; F-2018a, 247;..................F-2018, 247; F-2024, 247Finn, T. .............M-985, 111; M-1059, 115Fiorella, P. .......................D-732, 091Firsov, A. A. ....................A-1967, 241Fischer, B. G. ....................M-1055, 115Fischer, C. ......................A-1960, 241Fischer, G. .......................M-338, 028Fischetti, V. A. ....................B-659, 084Fiscon, M. .......................H-216, 018Fish, D. N. ......................... 475, 049Fisher, M. .......................H-556, 073Fisher, N. .......................B-1738, 196Fishman, J. A. ...................... 410, 034Fitzgibbons, L. N. ................. T-345, 029Flach, C. .......................C1-665, 085Flahault, A. ......................V-387, 030Flamaing, J. ....................L1-1641, 186Flamm, J. ........................H-556, 073Flamm, R. K. .........C2-123, 010; C2-124, 010;.....C2-129, 010; C2-131, 010; C2-132, 010;......C2-136, 010; C2-138, 010; C2-139, 010;.......C2-145, 010; C2-146, 010; E-186, 015;......... E-187, 015; E-189, 015; E-193, 015;..................E-199, 015; F-2050, 248;.......F-2051, 248; F-2052, 248; F-2053, 248Flammini, S. .....................E-796, 094Flanagan, S. ..........A-1292, 163; A-1293, 163;.................A-1294, 163; A-1295, 163Flandin, J. ......................D-1421, 170Flarakos, J. ......................A-1281, 162Flattery, A. ....................... F-810, 096Flecher, E. .......................K-267, 023Fleck, L. ....................... F-1536, 177Fleener, S. .......................M-981, 111Fleites, A. .....................C2-1974, 243Fleming, M. R. ........A-017, 003; F-1520, 177;..................L1-282, 025; D-770, 092Flemons, W. W. .................K-1756, 199Fletcher, C. V. ..................... 1128, 131Flexner, C. W. ...................... 481, 052Flick, H. ............. V-398, 030; P-1009, 112Floeth, M. .....................G3-1547, 178Florea, D.. . . . . . . . . . . . . . . . . . . . . . . D-1776, 201Flores-Treviño, S. M. ............C2-1370, 168Flowers, S. A. ....................M-970, 111FluCAN Investigators ..............K-952, 108Fluit, A. C. ..................... F-1516, 176Flume, P. A. ....................... 1090, 121Foà, R. ..........................V-393, 030Fong, J. ........................K-1585, 181Fontanals, D. ........K-1623, 184; C2-1358, 167Fontela, P. S. ....................K-1755, 199Force, E. ........................B-658, 084Ford, G. ........................A-1956, 241Ford, S. L. ......................A-1249, 161Forestier, C. .....................K-2098, 252Formighieri, M. S. ................C2-087, 008Forrest, A. .............A-012, 003; A-016, 003;........ A-024, 004; A-027, 004; A-031, 004;.........E-201, 015;A-605, 082; A-620, 082;........A-644, 083; E-785, 094; A-1243, 161;......A-1244, 161; A-1261, 161; A-1262, 161;......A-1263, 161; A-1266, 161; A-1269, 162;......A-1270, 162; A-1271, 162; A-1762, 200;................... 1861, 227; A-1930, 240Forrest, G. . . . T-345, 029; D-1432, 171; 1888, 233Forrester, I. .....................C2-714, 088Forsberg, P. ......................E-800, 094Forstner, C. .....................E-1471, 174Fortún, J. ............. M-323, 028; T-340, 029;...... D-743, 091; K-2077, 250; M-1700, 191Fossali, E. .....................G3-1549, 178Fossler, M. J. .....................A-611, 082Foster, A. N. .................... F-2059, 249Foster, G. F. .....................V-1236, 160Fothergill, A. W. ................... 1179, 150Foucrier, A. ......................A-021, 003Fournier-Wirth, C. ............... F-1488, 175Fowler, R. C. ....................B-1336, 165Fowler, V. ......B-1320, 165; 1168, 147; 1808, 209Fox, R. .............M-1676, 190; M-1678, 190Fox, R. L. .......................M-1695, 190Fragaki, M. ......................B-043, 005Fraimow, H. S. ...................C1-589, 081Fraisse, T. ........................ P-566, 075Fralich, T. ........................H-556, 073Franco, M. .......................K-256, 022Francoeur, D. N. .................D-1450, 172Francois, P. ......................... 425, 038François, B. ....................C1-1739, 197Frank, I. .......................... 1893, 235Frank, U. K. ..........B-1331, 165; K-2084, 251Franke, B. ..........M-1230, 159; M-1706, 191Fransen, F. .....................L1-1651, 187Franzblau, S. ..................... F-834, 098Final Program221

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberFranzblau, S. G. ......... F-831, 098; F-835, 098Fraser, J. D. ....................C2-1908, 237Frassetto, L. ....................... 1141, 138Frazetto, M. ...................... F-828, 097Frederiksen, C. .................. T-1072, 116Fredricks, D. ....................M-1676, 190Freeman, D. .....................A-1953, 241Freeman, J. . . . K-474, 048; B-662, 084; K-924, 105Freeman, J. T. ....................C2-689, 087Freeman, R. B. ................... T-1025, 113Frei, C. R. ......................L1-297, 026Frei, R. ...............C2-082, 007; D-167, 012Freijs, G. .......................K-2080, 251Freire, M. P. .....................K-1603, 183Freitag, M. .....................C1-1972, 242French, D. .......................K-561, 074French, G. L. ...................... 1803, 208French Mycosis Study Mycosis ......M-1686, 190Frenette, C. .....................K-1755, 199Frere, J. .......................G3-1554, 178Fresco, G. ...........M-323, 028; M-1700, 191;............................K-2077, 250Frey, B. .......................... F-828, 097Frey, S. E. ......................G-1048, 114Friaes, A. .......................C2-151, 010Frías-Mendivil, M. ...............C2-113, 009Friberg, L. E. ...........A-032, 004; A-033, 004;.................A-1764, 200; A-1966, 241Frick, D. N. ............ V-370, 030; F-826, 097Fried, M. W. ....................V-1236, 160Friedland, H. ...................L1-1659, 189Friedland, I. ......................A-641, 083Friedrich, A. W.. . . . . . . . . . . . . . . . . C2-1382, 169Friedrich, S. O. ..................A-1264, 161Frigatto, E. A. ..................C2-1376, 169Friis-Moeller, A. ..................B-663, 084Frimat, B. .......................A-638, 083Frimodt-Moeller, N. ..............K-1617, 184Frimodt-Møller, J. ................C2-687, 087Frimodt-Møller, N. ...............A-1965, 241Fritsch, E. .......................K-560, 074Froissart, A. .....................K-2087, 252Frost, E. ........................ F-1998, 246Fryszczyn, B. ...................C1-1204, 156Fu, J. ...........................E-795, 094Fu, Y. ...........................G-868, 101Fuchs, B. ....................... F-1538, 177Fuchs, C. .......................L1-291, 026Fuentes, C.. . . . . . . . . . . . . . . . . . . . . . K-2091, 252Fujii, C. M. ......................G-861, 100Fujikawa, K. ...........F-2037, 248; F-2038, 248Fujino, N. ....................... F-809, 096Fujita, T. ........................M-326, 028Fujiwara, H. ......................A-038, 004Fujiwara, T. ......................H-550, 073Fukase, H. ...................... F-2041, 248Fukuzawa, S. ....................D-1438, 171Fulcher, L. C. ....................D-1433, 171Fulchini, R. .....................H-1566, 179Fulke, J. ........................ P-1023, 112Fulton, S. A. ....................A-1257, 161Funatsu, Y. .......................A-038, 004Funke, G. ......................... 1856, 226Furrer, H. .......................H-1566, 179Furustrand Tafin, U. . .C1-1342, 166; M-1719, 191Furuya, E. Y. ....................K-1620, 184Fux, C. A. ......................C2-082, 007Fyfe, C. .............C1-675, 086; F-1525, 177;............................ F-1526, 177GG-Reyne, A. ...................L2-2110, 255Gaardbo, J. C. ....................B-055, 005Gabastou, J. ......................M-327, 028Gaborcik, J. .....................K-1636, 185Gachot, B. .............D-772, 092; K-911, 104Gagetti, P. .....................C2-1910, 237Gagnaire, J. .....................B-1319, 165Gagneur, A. .....................G-1051, 114Galani, I. ........................E-799, 094Galani, L. .............K-562, 074; E-799, 094Galanis, E. ......................M-1233, 159Galas, M. ...........C2-701, 087; C2-1910, 237Galbois, A. .......................D-173, 013Gale-Rowe, M. .................C2-1380, 169Gales, A. C. ..............420, 037; D-731, 090;....C1-1207, 156; C2-1376, 169; D-1446, 172Galicia, A. ......................C1-069, 006Galiñanes, M. ....................K-937, 106Gallagher, J. C. ...................K-277, 024Gallagher, L. .....................V-371, 030Gallant, J. .......................... 003, 001Gallant, J. E. ...................... 1185, 152Galleni, M. .........C1-459, 047; C1-1206, 156Gallien, S. ....................... P-566, 075Gallo, R. L. ........................ 522, 066Gálvez, J. ..............K-938, 106; K-942, 106Gálvez-Acebal, J. ......K-941, 106; L1-1658, 188Gama, B. ............C2-127, 010; C2-130, 010;..................C2-142, 010; M-322, 028Gamaletsou, M. ......M-1681, 190; L2-2114, 255GAMES ....K-941, 106; K-942, 106; K-943, 106;.............................K-944, 106Gan, J. .........................A-1246, 161Gan, V. C. ....................... P-567, 075Ganaha, C. ....................C2-1397, 169Ganaha, M. ....................C2-1396, 169Gandhi, T. .......................H-225, 019Gane, E. .......................V-1236, 160Gangneux, F. .....................M-333, 028Gangneux, J. .....................M-333, 028Gangneux, J. .................... P-1007, 112Gao, C. ............. B-1734, 196; B-1734, 196Gao, W. ........................H-1575, 180Gao, X. .........................K-269, 023Gao, Z. W. ..................... F-1500, 176Garau, J. .............L1-290, 026; K-1621, 184;...........................L1-1666, 189Garber, J. ........................A-643, 083Garbers, S. N. ................... F-1518, 176Garcia, C. P. .....................K-1603, 183Garcia, C. ...........C2-1909, 237; K-900, 104Garcia, H. H. ...................... 1889, 234Garcia, L. G. ...........A-596, 082; A-597, 082;. . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-599, 082Garcia, M. C.. . . . . . . . . . . . . . . . . . . . K-1621, 184Garcia, M. E. .....................K-470, 048Garcia, P. .......................H-1577, 180García, R. .....................L2-2110, 255Garcia, Y. T. ......................K-919, 105Garcia Alvarez, L. .................K-260, 023Garcia de la Maria, C. ....A-610, 082; B-645, 084;....... B-648, 084; K-945, 106; K-1122, 129;............................E-1465, 173Garcia de la Puente, S. ............G3-1563, 178García Giménez, S. ................G-874, 101Garcia Vallecillos, C. ..............H-1921, 238Garcia-Castillo, M. ................D-753, 092Garcia-Hermoso, D. . . M-1686, 190; M-1707, 191García-Reyne, A. .......T-368, 029; T-1071, 116;............................ K-2091, 252Garcia-Somoza, D. .... L1-293, 026; L1-295, 026García-Unzueta, M. T. ............M-1673, 190Garcia-Vidal, C. .......D-180, 013; L1-293, 026;...... L1-295, 026; L1-298, 026; M-329, 028;.................T-1045, 113; M-1228, 159Gardella, N. ........C2-1396, 169; C2-1397, 169Gardiol, C. .......................T-352, 029Garey, K. W. ..........D-158, 011; M-316, 028;. . . . . . . . . . . .476, 049; K-920, 105; K-921, 105Garg, H. .......................H-1569, 179Gargallo-Viola, D. .......E-204, 016; E-205, 016;........E-210, 016; D-769, 092; M-980, 111;............................M-1718, 191222September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberGargano, J. W. ..................... 1819, 210Garibotto, C. .....................K-917, 105Garland, S. M. ...................L2-301, 027Garnacho, J. ............K-948, 107; K-950, 107Garnacho-Montero, J. .............K-1924, 239Garnica, M. .....................M-1690, 190Garnier, F. ..........D-1441, 171; C1-1739, 197Garraffo, R. .....................A-1253, 161Garrigós, C. ............ B-647, 084; B-658, 084Garza-Gonzalez, E. ..............C2-1370, 168Garza-Ramos, U.. . . . . . C1-067, 006; C1-069, 006Garzón, M. ....................L2-2108, 255Garzoni, C. ...................... T-343, 029Gasch, O. ............C1-683, 086; A-1280, 162;...........................C2-1395, 169Gaspar, E. B. .....................E-801, 094Gaspar, G. G. ...................C2-086, 008Gastaminza, G. .......D-1439, 171; D-1440, 171Gastinne, T. .........D-1458, 172; L1-1642, 186Gastmeier, P. ....................K-1592, 181Gatanaga, H. ..........H-223, 019; H-224, 019;...................H-888, 103; H-890, 103Gateff, D. ......................D-1413, 170Gatell, J. M. ............A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129; E-1465, 173Gathe, J. .........................H-877, 102Gatti, B. ........................C2-084, 008Gattu, S. .......................K-1589, 181Gaustad, P. .......................M-332, 028Gauthier, N.. . . . . . . . . . . . . . . . . . . . . . A-638, 083Gautier, H. ......................B-653, 084Gauzit, R. .......................K-237, 020Gavaldà, J. .......................K-938, 106Gavaldá, J. ....................... T-340, 029Gavaldà, J. ..............T-359, 029; T-368, 029Gavrish, E. ...................... F-829, 098Gawronski, K. M. ................A-1768, 200Gayathri, R. ...................... T-367, 029Gayet-Ageron, A. ................K-2083, 251Gayoso, C. .......................K-559, 074Gayosso-Vázquez, C. .............C2-113, 009Gaytan, J. .......................C1-067, 006Gazzard, B. ......................H-556, 073Ge, J. ............... A-1951, 241; F-2054, 248Ge, Y.. . . . . . .E-203, 016; E-207, 016; D-760, 092;...... D-764, 092; A-1948, 241; A-1949, 241;......A-1950, 241; A-1952, 241; A-1953, 241;......A-1954, 241; A-1955, 241; F-2046, 248;..................F-2047, 248; F-2056, 248Geerlings, S. E. ..................... 542, 071Gehrer, M. ......................E-1470, 173Gellen-Dautremer, J. ..............K-2087, 252Geller, B. L. ....................C1-1972, 242Geller, D. E. ...................... 1088, 121Gemiarto, A. T. .................. F-2071, 249Gemmell, C. .................... F-1530, 177Gentile, A. ............G-874, 101; P-1015, 112;. . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1016, 112Gentile, G. ............. V-393, 030; K-898, 104Georgakopoulou, T. ..............G3-1543, 178Georgala, A. .........T-1028, 113; T-1046, 113;........................... D-1413, 170;Georgiadou, S. .......M-1679, 190; L2-2114, 255Gérard, M. ......................D-1413, 170Gerding, D. N. K-471, 048; E-808, 095; 1145, 140Gerdts, V. ......................... 523, 066Geriak, M. ......................K-1631, 185Gericco ........................L1-963, 110Gershon, A. ....................... 1826, 212Gerstoft, J. ......................H-1916, 238Gervaix, A. ....................G3-1541, 178Gestoso, I. ...................... P-1020, 112Getachew, T. .....................D-181, 013Geyer, C. .......................C2-115, 009Ghafur, A. .............K-236, 020; P-564, 075;................. P-1003, 112; K-1618, 184Ghanem, K. G. ..................... 478, 050Ghannoum, A. M. ...... V-385, 030; F-2015, 246Ghannoum, M. .........V-385, 030; F-815, 096;.................M-1062, 115; F-2015, 246Ghantoji, S. S. .........K-934, 105; V-1075, 117Ghassemi, M. ................... F-2072, 249Ghebremariam, T. ......B-650, 084; M-973, 111;. . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1473, 174Ghebremedhin, B. ................C2-108, 009Ghosh, A. K. .................... F-2072, 249Ghossein, C. .....................A-636, 083Ghout, I. ........................B-645, 084Giamarellou, H. .........K-245, 021; K-246, 021;. . . . . . . . . . . . . . . . . . . K-562, 074; E-799, 094Giani, T. .............E-796, 094; C2-1211, 157Giannella, M. ........T-1035, 113; T-1040, 113;. . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1041, 113Giardina, P. ......................G-870, 101Gibb, A. .........................K-927, 105Gibbons, H. S. ........C1-064, 006; C1-592, 081Gibert, L. .......................B-1337, 165Gibot, S. ........................ P-570, 075Gibreel, T. ...................... F-1487, 175Gibson, J. S. .....................C2-708, 088Giddey, M. ............ B-046, 005; B-659, 084Giedlin, M. ...........H-553, 073; H-1581, 180Giglio, N. ........................G-874, 101Giguere, S. .....................C1-1348, 166Gijon, D. ..............D-743, 091; D-753, 092Gijón, P. .........................K-263, 023Gil, C. .........................L1-289, 026Gil, J. .......................... F-1518, 176Gil Anguita, C. ..................H-1921, 238Gil-Navarro, M. .................K-1924, 239Gilbert, A. .......................D-751, 092Gilca, R. ........................V-389, 030Gilca, V. ........................G-1047, 114Giles, H. ....................... P-1023, 112Gilhuley, K. .....................D-1442, 171Gilio, A. E. ......................G-861, 100Gilis, L. ......................... T-360, 029Gill, C.. . . . . . . . . . . . . . . . . . . . . . . . . . F-810, 096Gill, S. R. .......................B-1320, 165Gillis, L. M. ...........E-786, 094; K-1605, 183Gillman, J. .......................T-357, 029Gilmour, M. ...................C2-1360, 167Gilsanz, F. ......................K-1608, 184Gimenez, M. ....................D-1419, 170Giourgouli, G. ...................M-1696, 191Giraffa, G. ......................... 431, 040Giralt, E. ....................... F-2068, 249Girardello, R. ...................C2-1376, 169Giraud, C. .....................L1-1224, 158Giraud, J. ........................ P-996, 112Giraudeau, C. ...................C2-080, 007Girgenti, D. .............. K-259, 023; 575, 077Girgenti, D. Q. ...................G-870, 101Girlich, D. .............D-745, 092; D-748, 092Girmenia, C. .....................V-393, 030Girometti, N. ....................K-1619, 184Giske, C. . . C2-107, 009; E-800, 094; F-2054, 248Giulieri, S. .....................L1-1221, 158Giurini, J. ......................L1-1646, 186Givon-Lavi, N. .......G-1050, 114; G-1753, 198Glick, Y. .......................L1-961, 110Glossmann, J.. . . . . . . . M-1230, 159; M-1706, 191Glupczynski, Y. ..................D-1447, 172GnamNuan, A. ................... P-998, 112Gniadkowski, M. .................C2-109, 009Gobey, J. .......................A-1264, 161Gobin, P. ....A-035, 004; A-036, 004; A-037, 004Godet, C. .............A-039, 004; L1-963, 110Godkin, S. ..............T-358, 029; T-362, 029Goenaga, M. .....................K-943, 106Goering, R. V. ....................K-469, 048Goetghebeur, M. ..................K-473, 048Goff, D. A. ...........K-275, 024; K-1123, 129;.................K-1636, 185; A-1768, 200Final Program223

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberGoffinet, N. .....................L1-285, 025Goh, C. Y. ......................A-1959, 241Goh, S. S. ......................K-1595, 182Golan, A. ........................M-339, 028Gold, J. .........................A-643, 083Gold, L. .........................T-349, 029Goldberg, L. ....................B-1331, 165Goldblatt, J. .....................B-1311, 165Goldenthal, K. ...................G-1053, 114Goldfarb, J. ....................G3-1546, 178Golding, G. ....................C2-1380, 169Goldman, S. .........F-2030, 248; F-2031, 248;..................F-2032, 248; F-2033, 248Goldstein, B. P. ..................C2-134, 010Goldstein, E. J. K-471, 048; F-854, 099; 1844, 220Goletz, G. .....................G3-1547, 178Golik Mahoney, M. ...............K-1626, 185Gomez, B. ......................M-1694, 190Gomez, D. .....................L1-1653, 187Gómez, J. .......................C2-111, 009Gomez, S. ..........C2-084, 008; C2-1217, 157Gomez-Duarte, O. G. .............B-1322, 165Gómez-GªPedrosa, E. .............M-1700, 191Gomez-Garcia, I. .................D-743, 091Gómez-García de la Pedrosa, E. ......M-323, 028Gómez-Gerique, J. A. .............M-1673, 190Gomez-Gil, R. ..................K-1608, 184Gomez-Lopez, A. ................M-1718, 191Gomez-Mampaso, E. ..............D-743, 091Gómez-Román, J. .................D-169, 012Gomme, G. ..................... P-1005, 112Goncharov, A. E. ................C2-1385, 169Gonzaga, D. .................... F-1513, 176Gonzales, E. ....................C2-718, 089Gonzalez, A. .....................D-743, 091Gonzalez, B. E. .................C2-1361, 167González, C. ....................H-1573, 180González, E. .....................H-220, 019Gonzalez, G. ...................C2-1370, 168Gonzalez, I. M. .................C2-1915, 237Gonzalez, J. M. .......A-1945, 240; A-1968, 241González, J. ..........P-1015, 112; P-1016, 112;............................K-2091, 252González, M. M. .................H-1576, 180Gonzalez, M. M. .................C1-461, 047Gonzalez, N. ...................G3-1563, 178Gonzalez, R. ....................C1-067, 006Gónzalez del Vecchio, M. ..........V-1242, 160González Díaz, E. ...............C2-1373, 168González-Alujas, M. T. .............K-937, 106Gonzalez-Diaz, E. ...............C2-1370, 168Gonzalez-Lopez, J. ....L2-303, 027; K-1616, 184Gonzalez-Ruiz, A. ................K-2095, 252Goo, T. ..........................D-155, 011Good, C. E. .........A-1257, 161; C2-1361, 167Goodwin, J. ..........M-977, 111; A-1765, 200;. . . . . . A-1942, 240; A-1943, 240; A-1944, 240Goorhuis, A. .....................K-472, 048Goossens, H. ........C2-109, 009; G3-1559, 178Gopalakrishnan, R. .....P-564, 075; P-1003, 112;............................ P-1004, 112Gordeev, M. F. .........F-1499, 176; F-1502, 176Gormley, R. .....................G-1048, 114Gosbell, I. B. ........C1-062, 006; C1-1743, 197Gose, S. ........................L2-308, 027Gosset, P. ........................B-050, 005Gostev, V. V. ...................C2-1385, 169Gotoh, N. ...................... F-2039, 248Gottardi, W. .................... F-2058, 249Gottlieb, D. J. ...................... 547, 072Gotuzzo, E. ....................C2-1909, 237Goudeau, A. ...........D-176, 013; D-177, 013Gould, E. ............A-1246, 161; A-1249, 161Gould, I. M. ....................... 579, 078Gould, J. ....................... F-2066, 249Gould, J. K. ...................... F-842, 099Goulielmos, G. ...................B-043, 005Gouliouris, T. ....................L1-288, 025Govender, N. ....................M-1699, 191Govorkova, E. A. .................A-1243, 161Gowans, L. K. ..................G3-1546, 178Gowil, S. ........................ F-812, 096Grabe, D. W. .....................A-606, 082GRCn°2 EPIDIFF ................D-154, 011Gracon, S. I. .................... F-2070, 249Graeden, E. ...................... V-396, 030Gragera, B. .....................K-2095, 252Graham, H. ......................H-556, 073Grall, N. ....................... F-2003, 246Gramegna, M. ...................L2-304, 027Grant, I. H. .....................M-1063, 115Granwehr, B. ....................M-1676, 190Grare, M. .............D-758, 092; F-1527, 177Gras, G. .............D-177, 013; L1-2103, 254;...........................L1-2104, 254Gras-Le Guen, C. ................L1-285, 025Grattard, F. ......................D-178, 013Grau, I. ........................C2-690, 087Grau, S. .............K-1624, 184; K-1633, 185Gravett, M. G. ...................... 454, 045Grayson, L. ...................... T-369, 029Green, C. ....................... F-1531, 177Green, K. ......................C2-1363, 167Green, K. A. .......C2-1362, 167; C2-1364, 167Green, M. ......................E-1475, 174Green, S. .......... L1-1663, 189; L1-1665, 189Greenberg, D. ...... G-1050, 114; G3-1551, 178;. . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1753, 198Greenberg, D. P. .................B-1322, 165Greenfield, J. ....................A-1957, 241Grégoire, N. ............A-035, 004; A-036, 004;.............................A-037, 004Gregoricus, N. ................... P-1021, 112Gregory, D. ...................... T-369, 029Gregson, D. B. ...................K-1756, 199Gregson, L. ..........M-977, 111; A-1765, 200;.................A-1943, 240; A-1944, 240Grenet, D. .......................A-035, 004Grenier, S. .......................D-751, 092Grenouillet, F. ...................M-1692, 190Grif, K. .........................M-332, 028Griffith, D. C. ..........F-848, 099; F-849, 099;.........F-850, 099; F-851, 099; F-852, 099;............................. F-858, 099Griffith, E. C. ..................C1-1741, 197Griffith, M. ............K-271, 024; A-636, 083;.................B-1323, 165; B-1326, 165;.................K-1614, 184; K-1615, 184Griffiths, P. ..............495, 059; F-2007, 246Grillot-Courvalin, C. .............C1-676, 086Grimard, D. ......................V-389, 030Grimmond, S. M. ....C1-062, 006; C1-1743, 197Grisaru, G. ....................G3-1545, 178Grisold, A. ...........P-1009, 112; E-1470, 173;............................D-1404, 170Groenefeld, J. .....................K-953, 108Groll, A. H. ..........K-953, 108; G3-1547, 178Gross, U. ........................M-335, 028Grosset, J. ......................B-1296, 164Grossi, P. .............T-1035, 113; T-1041, 113Grossman, T. .................... F-1526, 177Grossman, T. H. .......C1-675, 086; E-777, 093;............................ F-1525, 177Groupe des Pédiatres et Microbiologistes del’Observatoire National des Méningites,.............................G-864, 100Grulich, A. E. ...................L2-301, 027Grundmann, H. .................... 1788, 204Grupo Mexicano De Trabajo En EnfermedadMeningococcica ..............L1-1653, 187Gu, A. M. .......................K-268, 023Gu, B. ........................C2-1401, 169Gu, X. .........................C2-083, 008Gu, Y. ...... F-843, 099; F-844, 099; F-845, 099;......F-846, 099; C2-114, 009; C2-1901, 236224September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberGuay, I. ........................ F-1997, 246Gubbay, J. .....................G3-1562, 178Gudiol, C. ........... M-329, 028; T-1045, 113;............................M-1228, 159Gudiol, F.. . . . . . . . . . . . .D-180, 013; L1-298, 026;................. L1-293, 026; L1-295, 026Gudur, U. M. ..........K-272, 024; K-1589, 181Gueit, I. .........................H-886, 102Güell, E. ......................L1-1643, 186Guembe, M. ......... D-166, 012; M-1688, 190Guenthard, H. F. ..................V-384, 030Guerriero, L. .........D-759, 092; C2-1217, 157Guerrini, G. ....................C2-1398, 169Guerry, S. ......................L2-308, 027Guery, B. .............. B-050, 005; B-060, 005Guevara, C. P. ...................B-1322, 165Guglielmini, J. ...................B-1312, 165Guglietta, A. ...........E-204, 016; E-205, 016;........E-210, 016; D-769, 092; M-980, 111;............................M-1718, 191Guidet, B. .......................D-173, 013Guillard, T. .....................B-1306, 164Guillet, J. .......................L2-302, 027Guimard, Y. ....................L1-1639, 186Guinea, J. ...........M-1232, 159; M-1684, 190;............................M-1688, 190Guinea-Ortega, J. V. ...............M-332, 028Guiot, P. .......................L1-291, 026Guitton, C. ....................L1-1224, 158Gul, H. C. ......................L1-960, 110Gulick, R. M. ..................... 1188, 152Gullberg, E. .....................A-1966, 241Gumpl, E. ......................D-1412, 170Gunst, J. D. ....................L1-1650, 187Günthard, H. ....................H-1566, 179Guo, B. N. ............A-640, 083; F-1503, 176;............................ F-1504, 176Guo, Q. .......................C2-1355, 167Guo, X. .........................B-047, 005Guo, Y. ............. F-1508, 176; K-1634, 185Gupta, C. ......................L1-2105, 254Gupta, R. ........................ F-830, 098Gupta, S. ......................C2-1982, 243Gurevich, J. ......................B-045, 005Gurevitch, A. S. ..................L1-299, 026Gurgui, M. ............K-256, 022; T-340, 029;..................K-938, 106; K-1621, 184Gustafson, D. .........D-170, 012; D-1774, 201Gustafson, F. .................... T-1072, 116Gustafsson, L. L. ..................H-893, 103Gutiérrez, A. ....................K-1924, 239Gutiérrez, C. ....................H-1567, 179Gutierrez, E. ....................K-2093, 252Gutierrez, M. ..........A-009, 003; A-1273, 162Gutierrez, P. P. ...................K-1603, 183Gutiérrez-Cuadra, M. . . P-1018, 112; M-1673, 190Gutkind, G. ..........C1-459, 047; C1-466, 047;......C1-678, 086; C1-669, 085; C2-700, 087;.....C2-718, 089; C1-1206, 156; D-1455, 172Gutmann, L. ...................C2-1359, 167Guyard, C. .......................E-781, 093Guyer, B. ........................H-556, 073Guzman, B. .....................M-1694, 190Guzman, M. .........K-900, 104; C2-1909, 237Guzmán-Gómez, L. ...............D-765, 092Gygax, S. E. ...................... P-563, 075Gyssens, I. C.. . . . . . . . . . . . . . . . . . . . . B-044, 005HHa, H. .........................M-1677, 190Haaland, R. E. ...................H-1570, 179Haas, P. J. ........................M-334, 028Habeeb, M. A. ................... F-2054, 248Haber, P. .......................G-1052, 114Habyarimana, E. .................D-1421, 170Hachem, R. Y. ........F-2012, 246; F-2013, 246;...... F-2014, 246; K-2082, 251; K-2096, 252Hachich, E. .....................C2-717, 088Hachmann, A. ................... F-1519, 177Hackel, M. ...........C2-099, 009; C2-100, 009;......C2-120, 009; C2-143, 010; C2-141, 010;......C2-144, 010; C2-147, 010; C2-148, 010;......C2-150, 010; C2-688, 087; C2-721, 089;. . . . . C2-722, 089; C2-724, 089; C2-1210, 157;. . . . . .C2-1352, 167; E-1474, 174; F-1525, 177Hackstein, H. .................... T-341, 029Haddad, M. .....................H-1574, 180Hady, W. A. .....................E-1468, 173Haegele, U. .....................K-2084, 251Hafkin, B. ......................E-1486, 174Hagenaars, J. C. ..................L1-965, 110Hagihara, K. ....................D-1402, 170Hagihara, M. ...........A-014, 003; A-022, 003;...................A-023, 004; M-328, 028Hahka, D. .......................M-967, 111Hai Consortium ..................K-469, 048Haider, S. .......................C2-096, 008Haihara, M. ......................A-015, 003Hainaut, M. .....................D-1413, 170Hajjar, L. A. .....................K-1603, 183Hakyemez, I. .....................V-379, 030Halac, U. ........................V-376, 030Halasohoris, S. .........F-1495, 175; F-1522, 177Hale, D. .........................K-558, 074Halim, R. ........................ F-828, 097Halimi, D. .............D-745, 092; D-748, 092Hall, A. D. .............A-601, 082; A-602, 082Hall, C. L. ............F-2026, 247; F-2027, 247Hall, D. .......................C2-1912, 237Hall, G. S. .............D-735, 091; D-771, 092Hall, L. ........................M-1691, 190Halliday, C. .....................M-1680, 190Hallin, M. .......................A-598, 082Halperin, S. A.. . . . . . . . . . . . . . . . . . G3-1542, 178Hamada, Y. ......................H-888, 103Hamandi, B. .........T-1043, 113; K-1590, 181;............................K-1591, 181Hamdan, H. ....................H-1575, 180Hamelin, M. .....................V-399, 030Hamerschlak, N. .................M-1234, 159Hamilos, G. .....................M-1058, 115Hamilton, M. ...................B-1736, 196Hamilton, S. ..................... F-828, 097Hammel, J. P. ....................A-1962, 241Hammerschlag, M. R. ..............E-206, 016Hammerum, A. ..................K-1925, 239Hammerum, A. M. ...............K-1617, 184Hammond, S. .................... T-354, 029Hamouda, T. .....................G-869, 101Hamprecht, A. ........ M-338, 028; D-1423, 170Han, D. ......................... T-366, 029Han, J. .............V-1078, 117; G3-1550, 178Han, S. ...............H-230, 019; K-916, 104Hanahoe, B. ..........C2-119, 009; C2-122, 009Hance, K. .......................D-1410, 170Hancock, R. ........................ 521, 066Handiwala, L. ....................V-397, 030Hangartner, L. ....................V-384, 030Hannan, T. J. ....................... 509, 063Hanselmann, R. ..................A-1289, 163Hansen, D. S. ...................C2-687, 087Hansen, F. ......................K-1617, 184Hanson, A. ...................... F-826, 097Hanson, N. D. ........C1-077, 006; C2-115, 009;. . . . . . . . . . . . . . . . . B-1336, 165; D-1445, 172Hao, B. .........................M-978, 111Hao, J. ..........................H-892, 103Harada, S. ...................... F-1509, 176Harada, Y. .............B-048, 005; B-049, 005;. . . . . . . . . . . . . . . . . . .B-657, 084; B-1297, 164Harbarth, S. .... K-560, 074; 572, 076; K-954, 108Harboe, Z. B.. . . . . . . . . .G-876, 101; H-1916, 238Harding, M. ..................... F-828, 097Hardouin, J. .........L1-1642, 186; D-1458, 172Hardy, D. ........................H-879, 102Final Program225

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberHardy, I.. . . . . . . . . . . . . . . . . . . . . . . . H-1571, 180Harrabi, H. ....................L1-2103, 254Harrell, L. .......................K-471, 048Harrington, S. M. .................D-735, 091Harriot, M. .....................M-1713, 191Harris, A. D. ....................C2-095, 008Harris, J. R. .....................M-1677, 190Harrison, L. H. .................. T-1037, 113Harrison, S. J. ................... T-1027, 113Harrison, T. S. ...................M-1670, 190Harrison, T. .....................M-1699, 191Hart, C. E. ......................H-1570, 179Hartling, H. J. ....................B-055, 005Hartman, P. ......................K-912, 104Hartmeyer, G. N. .....D-1409, 170; D-1444, 171Harvey, C. .......................H-885, 102Haschke, M. ....................A-1248, 161Hasegawa, M. ..................C2-1977, 243Hasegawa, N. .....................A-038, 004Hashizume, H. .................. F-1509, 176Hassan, A. .............D-171, 012; D-774, 092Hasse, B. K. ........................ 543, 071Haste, N. ....................... F-1999, 246Hatta, M. ...........C2-114, 009; C2-1901, 236Hattori, T. ......................C2-101, 009Haulon, S. ......................K-2089, 252Hausdorff, W. P. ..................G-859, 100Havers, S. ......................C2-689, 087Havlichek, D. ....................A-018, 003Hawkey, P. ......................C2-115, 009Hawkins, K. ..................... F-2064, 249Hawkins, K. R. ...................D-174, 013Hawser, S. ...........C2-120, 009; C2-133, 010;. . . . . . C2-140, 010; C2-143, 010; C2-721, 089;................. E-1474, 174; F-2067, 249Haxaire, M. .....................A-1259, 161Hayakawa, K.. . . . . . . . . .A-034, 004; C2-096, 008;.........K-262, 023; K-272, 024; E-787, 094;.......K-902, 104; K-1589, 181; K-1604, 183Hayashi, S. ......................D-1461, 172Hayashi, Y. .....................D-1402, 170Hayashida, T. .....................H-890, 103Hayden, M. ....................... 1726, 193Haydon, D. J. .................... F-2016, 247Hayward, A. C. .................L1-1645, 186Hazen, R. .......................H-550, 073Haznedaroglu, T. .....C2-1367, 168; D-1430, 171Hazuda, D. ......................H-551, 073He, B. .........................A-1247, 161He, J. .......A-025, 004; A-028, 004; A-029, 004He, L. ........................C1-1203, 156He, Y. ...... F-843, 099; F-844, 099; F-845, 099;............................. F-846, 099Healan, A. M. ...................A-1257, 161Heaney, C. .....................C2-1912, 237Heath, P. T. ....................G3-1544, 178Heble, D. E. .....................A-612, 082Hecht, D. W. ............ E-808, 095; 1845, 220Hecker, S. J. ............F-848, 099; F-849, 099;......... F-850, 099; F-851, 099; F-852, 099;............................. F-858, 099Heffernan, H. ..................C2-1908, 237Hegde, N. ......................B-1315, 165Heilmann, K. ....................C2-126, 010Heim, J. .............F-2030, 248; F-2031, 248;..................F-2032, 248; F-2033, 248Heimann, S. ........M-1230, 159; M-1706, 191Heine, H. S. .......... B-1302, 164; B-1304, 164Heine, R. .......................... 455, 045Heineck, B. L. ..................C2-1905, 236Heintz, B. .......................K-915, 104Heise, M. ......................... 1102, 124Heisig, A. ......................C1-667, 085Heisig, P. .......................C1-667, 085Henderson, C. ...................L2-307, 027Henderson, H. H. ................. P-994, 112Hendrix, C. W. ..................H-1570, 179Hennessey, Jr. J. P. .................G-868, 101Henrich, B. .....................C1-588, 081Henriet, A. ......................A-036, 004Henriques, A. ...................C2-713, 088Hensgens, M. ..........K-472, 048; K-930, 105Hensler, M. .......... F-1514, 176; F-1999, 246Hensley, R. .....................D-1416, 170Hentic, O. ......................K-2087, 252Herbrecht, R. ........M-1225, 159; M-1707, 191Herman, P. ......................M-1686, 190Herman, R. .....................C1-459, 047Hermida, J. ......................H-217, 018Hermsen, E. D. ........K-2078, 250; K-922, 105Hernandez, C. ....................D-747, 092Hernandez, Y. ..................C2-1370, 168Hernández Ochoa, L. R. ............ F-833, 098Hernández-Novoa, B. .............H-1567, 179Hernández-Rodríguez, P. A. .......C2-1357, 167Hernández-Salgado, M. ..........C2-1356, 167Herradura, P. . . F-843, 099; F-844, 099; F-845, 099Herrera, M. .....................D-1449, 172Herrera, M. L. ...................M-1674, 190Herrero, M. .....................K-1924, 239Hershberger, E. .......A-641, 083; L1-1638, 186Hershfield, J. .................... F-1522, 177Hertz, F. B. .....................K-1617, 184Herve, K. .......................B-1738, 196Herwaldt, B. L. ..................... 450, 044Herwaldt, L. ....................... 486, 054Hester, J. ........................ T-361, 029Heuer, O. ......................... 1789, 204Hevener, K. ..................... F-2072, 249Heymann, D. ....................... 004, 001Hezode, C. .....................V-1236, 160Hickey, A. J. ........................ 437, 041Hickey, R. .......................A-618, 082Hickman, R. A. .........E-798, 094; E-800, 094Hicks, C. ........................H-229, 019Hidalgo, C. ......................K-938, 106Hidalgo Tenorio, C. .....L1-289, 026; K-943, 106;........................... H-1921, 238Hidri, N. ......................C1-1739, 197Higasa, K. .......................H-890, 103Higgins, P. G. ...................C1-070, 006Higgs, C. ........................H-212, 017Higuchi, S.. . . . . . . . . . . . . . . . . . . . . . F-2039, 248Hikosaka, A. ....................D-1438, 171Hilbert, D. W. .................... P-563, 075Hilge, R. ........................H-887, 103Hill, D. R. ......................... 405, 033Hill, K. E. ...........F-2062, 249; F-2063, 249;............................ F-2064, 249Hilliard, J. ......................B-1734, 196Hilliard, J. J. .....................B-1737, 196Hillman, R. J. ...................L2-301, 027Hilty, M. .......................C2-116, 009Hindler, J. A. ....................D-1433, 171Hingwe, A. .....................C2-112, 009Hino, M. .......................D-1402, 170Hinojosa-Robles, R. M. ..........C2-1357, 167Hirai, Y. .........................M-326, 028Hirakata, Y. .....................C2-114, 009Hirosawa, S. .................... F-1509, 176Hirose, A. ......................D-1402, 170Hirsch, E. B. ......... K-901, 104; D-1450, 172;............................K-1626, 185Hirsch, H. . . .T-343, 029; T-355, 029; T-1070, 116Hirsch, J. .......................L1-959, 109Hirschfield, G. ...................V-1236, 160Hirst, G. C. ...................... F-848, 099Hites, M. C. .....................A-637, 083Hjort, U. ......................L1-1652, 187Hoban, D. ..C2-100, 009; C2-120, 009; C2-141, 010;...... C2-143, 010; C2-144, 010; C2-147, 010;.......C2-148, 010; C2-149, 010; E-191, 015;......C2-688, 087; C2-721, 089; C2-722, 089;.....C2-1352, 167; C2-1360, 167; E-1462, 173226September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberHoban, D. J. ...........E-194, 015; E-200, 015;.................C2-103, 009; C2-135, 010;......E-779, 093; C2-1379, 169; E-1486, 174Hobbs, M. ...................... P-1023, 112Hoekstra, C. J. ...................L1-965, 110Hoen, B. ........................K-939, 106Hoenigl, M. ...........V-398, 030; P-1009, 112;. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1404, 170Hoet, B. .........................G-859, 100Hoetelmans, R. .......A-1258, 161; A-1260, 161Hoff, P. M.. . . . . . . . . . . . . . . . . . . . . . K-1603, 183Hoffmeyer, P. ...........K-249, 022; K-253, 022Hofling-Lima, A. L. ..............E-1481, 174Hofmann, P. .....................K-248, 022Hofmann, W. K. ......M-335, 028; M-1704, 191Hogan, P. .......................M-1683, 190Hogevik, H. ..................... T-1042, 113Hokama, L. ..................... F-1531, 177Holden, P. N. ...........A-024, 004; E-201, 015Holder, A. ......................H-1570, 179Holguin, D. F. ..................C2-1915, 237Holland, D. ..................... P-1023, 112Hollegaard, M. ...................G-876, 101Holliday, N. ...........D-766, 092; E-1463, 173;............................E-1467, 173Hollis-Symynkywicz, M. F. ......... F-1540, 177Holloway, K. ....................K-1635, 185Holmes, A. ............. K-260, 023; 1081, 118Holmes, N. E. ..................... 1166, 147Holst, A. .......................G-1752, 198Holtzer, C. .......................H-212, 017Holzmann, A. ...................K-1125, 129Hong, H. . . .T-366, 029; V-1074, 117; V-1239, 160Hong, J. .............C2-1216, 157; E-804, 094Hong, J. H. ......................E-792, 094Hong, K. . G-872, 101; B-1309, 165; C2-1978, 243Hönigl, M.. . . . . . . . . . . . . . . . . . . . . . . V-395, 030Honnorat, E. ...................C2-1374, 168Honnorat, J. ....................L1-1649, 187Hontz, R. D. .................... P-1021, 112Hood, J. .......................... 1729, 194Hook, E. W. .....................D-185, 014Hooper, D. C. .............. 515, 064; 580, 078Hoopes, J. D. ..................... V-383, 030Hooton, T. M. ...................... 511, 063Hoover, J. L. .........A-1270, 162; A-1271, 162;.................A-1275, 162; B-1308, 164Hoover, R. ...........A-1290, 163; A-1956, 241;............................A-1957, 241Hope, R. .......................C2-102, 009Hope, W. ..............A-1765, 200; 1886, 233Hope, W. W. ............ 411, 035; M-977, 111;......A-1942, 240; A-1943, 240; A-1944, 240Hopkins, S. ..........E-208, 016; L1-1663, 189;. . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1958, 241Hopman, J. ......................K-244, 021Hoppe, T. .......................D-1423, 170Horacio, A. ......................G-866, 100Horan, J. ........................A-026, 004Horcajada, J. P.. . . . . . . . .C2-111, 009; K-258, 022;.................K-1624, 184; M-1673, 190Hori, T. ........................ F-1506, 176Horikoshi, Y. ....................D-1429, 171Horino, A. ......................D-1456, 172Horita, Y. .......................A-1254, 161Hornak, V. ....................... F-810, 096Hornsey, M. ............D-761, 092; E-797, 094Horsney, M. .....................B-1299, 164Horswill, A. R. ........ B-646, 084; F-1517, 176Horton, L. B. ....................C1-462, 047Horwedel, T. .................... T-1068, 116Hosbul, T. ..........C2-1394, 169; D-1430, 171Hose, A. ........................D-155, 011Hoshino, K. ..........F-2035, 248; F-2036, 248;...... F-2037, 248; F-2038, 248; F-2039, 248;...... F-2040, 248; F-2043, 248; F-2044, 248;............................ F-2045, 248Hosler, J. P. ......................M-968, 111Hospital Clinic Endocarditis Study Group,...................A-610, 082; B-648, 084;..................K-945, 106; E-1465, 173Hossain, Z. .....................C2-711, 088Hot, C. .......................C1-1349, 166Hothi, J. .........................K-902, 104Hotta, G. .............K-949, 107; K-1599, 182Houbraken, J. ....................M-332, 028Hough, G. W. ................... F-2026, 247Houhou, N. .....................V-1073, 117Housman, S. T. .........A-022, 003; A-023, 004Houze, S. ........................ P-570, 075How Ooi, M. ...................... 1829, 212Howard, S. ...........A-1765, 200; A-1943, 240;............................A-1944, 240Howard, S. J. ..........M-335, 028; M-977, 111;. . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1942, 240Howard, W. J. ...................C2-112, 009Howson, D. .....................D-1410, 170Hristea, A. ...........C2-110, 009; D-1776, 201Hryniewicz, W. ..................C2-109, 009Hsu, C. H. ...................... F-1502, 176Hsu, L. Y. .............E-791, 094; K-896, 104;..................E-1476, 174; E-195, 015Hsueh, P. ............. 1136, 135; C2-1212, 157Hu, B. ..........................K-269, 023Hu, F. ........................C2-1355, 167Hu, M. ................A-028, 004; A-029, 004Hu, S. ..........................K-261, 023Hu, X. X. ....................... F-1499, 176Hua, L. . . . V-383, 030; B-1736, 196; B-1737, 196Huang, C. .......................A-613, 082Huang, E. ...................... F-1508, 176Huang, H. X. .................... F-1502, 176Huang, J. .............F-1503, 176; F-1504, 176Huang, K. ......................B-1328, 165Huang, S. S. ....................... 1725, 193Huang, V. ............A-609, 082; D-1435, 171Huang, W. ...........H-1574, 180; K-1585, 181Huang, X. ...........L1-292, 026; K-1598, 182;...........................L1-1661, 189Huang, Y. Q. ..........F-1497, 176; F-1498, 176Huangsaitong, J. .................A-1279, 162Hubacek, P. ...................... T-344, 029Huband, M. D. .................C1-1745, 197Huber, J. ....................... F-1496, 176Hubschwerlen, C. . . . C1-1346, 166; C1-1347, 166Huffnagle, G. B. ..................K-926, 105Hufton, R. ....................... F-828, 097Hughes, D. ............E-798, 094; F-829, 098;.................A-1764, 200; A-1966, 241Hughes, M. ......................V-383, 030Hugle, T. .......................K-2073, 250Huh, K. .............C2-137, 010; K-1587, 181Huisse, M. G. .................... P-570, 075Hujer, A. M. .........C2-092, 008; C2-686, 087;...........................C1-1209, 156Hujer, K. M. ......... C2-686, 087; F-2059, 249Hull, C. M. ...................... V-397, 030Hull, M.. . . . . . . . . . . . . . . . . . . . . . . . K-1593, 182Hulten, K. G. ..................C2-1361, 167Hultgren, S. J. ...................... 512, 063Humar, A. ......................... 409, 034Hummel, M. ....................M-1704, 191Humphreys, D. P. ................B-1738, 196Humphries, R. ........K-280, 024; C2-1401, 169Hung, C. ............ A-1251, 161; G-867, 100;........H-215, 018; H-218, 018; H-221, 019;.......H-226, 019; L2-309, 027; V-1238, 160;............................H-1578, 180Hung, W. C. ...................C1-1340, 166Hunstad, D. A. ...................A-612, 082Hunt, D. ....................... F-1526, 177Hunter, I. ....................... F-1530, 177Hurteau, G. .......... B-1302, 164; B-1304, 164Hurwitz, J. L. ....................V-382, 030Husain, S. . .M-337, 028; T-365, 029; T-1043, 113;.................T-1067, 116; M-1227, 159Final Program227

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberHuyard, S. ......................M-1698, 191Huyse, T. ....................... P-1014, 112Hwang, Y. Y. .................... F-2010, 246Hwei-Fang Tien, ................M-1669, 190Hyde, L. .......................E-1480, 174IIacovides, H. .....................A-613, 082Iannetta, M. ......................D-165, 012Iannone, R. .........M-1676, 190; M-1695, 190Ibarra, G. ......................C2-1909, 237Ibrahim, A. ............B-650, 084; G-868, 101;.......M-973, 111; M-967, 111; E-1473, 174;Ibrahim, K. Y. ...................K-1603, 183Ichiki, K. ............K-1594, 182; M-1687, 190Ichiyama, S. ...........K-949, 107; K-1599, 182Ichki, K. ...............A-607, 082; A-608, 082Icyeza, E. R. .....................D-156, 011Idasa, M. B. .....................E-1994, 245Idelevich, E. A. ..................E-1483, 174Ierino, F. ........................ T-369, 029Iglesias, C. ......................C2-142, 010Ike, W. E. .....................C2-1898, 236Ikeda, K. ........................ F-825, 097Ikeuchi, H. .....................K-1594, 182Ilina, E. ........................C2-697, 087Imamura, Y. ......................V-380, 030Imanaka, R. .....................M-1226, 159Imöhl, M. .......................G-863, 100Imperial, M. ....................C2-085, 008Inaba, A. .......................D-1402, 170Inagawa, H. ......................K-897, 104Indolfi, G. ........................ 1800, 207Inglis, T. J. ......................C2-708, 088Ingram, P. R. .........C2-689, 087; C2-708, 088Ingrand, P. ....................... P-996, 112Inokuma, K. ..................... F-2055, 248Inomata, S. .........C2-114, 009; C2-1901, 236Inoue, F. M. ....................C2-1376, 169Inoue, K. ....................... F-1509, 176Insunza, A. ..................... T-1038, 113Ioana, M. ........................B-044, 005Ioannidis, I. ......................K-562, 074Ion, M. ........................C2-110, 009Iorga, B. I. ...........C1-066, 006; C1-072, 006Iori, A. ..........................V-393, 030Iorio, N. .......................C2-1377, 169Iorio, N. L. .........C1-671, 085; C2-1383, 169;. . . . . . . . . . . . . . . C2-1387, 169; C2-1907, 237Ip, M.. . . . . . . . . . . . . . . . . . . . . . . . . . G-1751, 198Iqbal, A. ........................M-1670, 190Irani, J. .........................K-1584, 181Ireland, C. E. ...........A-600, 082; A-603, 082Isaacs, D. ......................... 1158, 145Isendahl, J. ......................C2-107, 009Ishibashi, N. ........C2-114, 009; C2-1901, 236Ishibashi, T. ......................A-019, 003Ishihara, M. ............A-607, 082; A-608, 082Ishii, C. ..............F-2035, 248; F-2043, 248Ishii, Y. ..............C1-077, 006; K-918, 105;......D-1438, 171; D-1459, 172; F-2040, 248Ishizaka, T. ...................... F-2042, 248Isloor, S. ........................B-1315, 165Itagaki, M. ......................M-1226, 159Iten, A. ....K-954, 108; K-956, 108; K-2075, 250Ito, J. ....... T-349, 029; T-350, 029; T-351, 029;............................ T-1039, 113Ito, Y. ................K-949, 107; K-1599, 182Itoh, K. ..............F-2049, 248; F-2055, 248Itoh, S. ......................... F-2042, 248ITUBRAS-GEIH-SEIMC Group . . C2-111, 009Ivanova, R. .......................K-943, 106Iversen, M.. . . . . . . . . . . . . . . . . . . . . . T-1072, 116Iversen, P. L. ...................C1-1972, 242Ivezic-Schoenfeld, Z. .............C1-1971, 242;...........................L1-1660, 189Iwanaga, N. ......................V-380, 030Iwao, Y. .......................C1-1340, 166Iwata, M. .......................D-1438, 171Iwata, S. .............A-038, 004; C2-1354, 167;...............C2-1977, 243; C2-1990, 244Iyer, S. ............C2-1381, 169; C2-1391, 169Izdebski, R. .....................C2-109, 009Izikson, R. ......................G-1053, 114Izquierdo, M. .....................K-263, 023Izumi, T. ....................... F-2041, 248Izumikawa, K. ..........B-049, 005; V-380, 030;........ V-400, 030; B-657, 084; B-1297, 164JJaber, M. J. ....................... V-376, 030Jacinto, P. L. ....................C1-1747, 197Jackson, M. ....................... 1157, 145Jackson, P. J. ..................... F-2023, 247Jacob, J. T. .......................A-611, 082Jacob, J. ...............A-027, 004; E-795, 094Jacob, M. .......................M-1061, 115Jacobs, F. ........................A-637, 083Jacobs, J. .........................M-311, 028Jacobs, M. R. .........C2-092, 008; C2-720, 089;.....A-1257, 161; C2-1361, 167; F-2059, 249Jacobs, R. .......................A-1292, 163Jacobson, I. .....................V-1236, 160Jacobson, S. ......................K-928, 105Jacobus, N. V. ....................K-471, 048Jacoby, G. A. ....................... 513, 064Jacqmin, H. .....................A-1278, 162Jacqueline, C. ...........B-051, 005; B-054, 005;.........E-203, 016; B-651, 084; B-653, 084;...... B-1335, 165; A-1948, 241; F-2056, 248Jaeger, M. .......................M-1055, 115Jahangiri, S. ...................... F-828, 097Jahng, M. ....................... F-2000, 246Jain, A. ..........................V-373, 030Jain, R. ..........................K-926, 105Jakielaszek, C. ...................B-1304, 164Jakobsen, L. .....................A-1965, 241Jakubowski, A. .................... T-361, 029Jallad, M. .......................K-1584, 181Jamal, A. J. .......................T-365, 029Jamal, W. .............C2-121, 009; D-727, 090Jambeih, R. .....................L1-284, 025James, K. D. ..................... F-1510, 176Jamieson, B. .....................A-1286, 162Jandourek, A. ....... L1-1659, 189; L1-1661, 189Janes, R. .....E-204, 016; E-210, 016; D-769, 092Jang, G. .......................C2-1913, 237Jang, H. ........................B-1298, 164Jang, J. H. ...................... F-1489, 175Jang, K. ........................ F-1514, 176Jang, W. .........................D-755, 092Janoir, C. ......................C2-1359, 167Jansen, K. ..........................575, 077Jansen, K. U. ...........D-172, 013; G-870, 101Janzen, W. P. .................... F-1535, 177Janzon, A. ......................C1-665, 085Japan Trichosporonosis Study Group . .M-324, 028Jarillo-Quijada, M. D. .............C2-113, 009Jarvis, J. ........................M-1699, 191Jaton, K. .......................L1-1221, 158Javier, C. .......................K-2077, 250Javier, R. ............L1-289, 026; H-1921, 238Jayaraman, G. ..................C2-1380, 169Jayasekara, N.. . . . . . . . . . . . . . . . . . . . K-2081, 251Jayasundara, K. ..................K-2081, 251Jayawickrema, S. .................K-2081, 251Jaydev, F. ........................K-272, 024Jeffres, M. ......................D-1434, 171Jehl, F. .........................K-2100, 253Jeng, A. .........................A-616, 082Jenkins, S. G. .....................K-471, 048Jensen, K. S. .....................A-1965, 241228September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberJensen, R. H. ....................M-1710, 191Jensen, S. O. ...................C1-1743, 197Jensen, U. .......................K-1925, 239Jensen-Fangel, S. ................L1-1650, 187Jenson, S. O. ....................C1-062, 006Jeong, H. ..............F-827, 097; F-2072, 249Jeong, J. ..............K-907, 104; K-2092, 252Jeong, S. ...............H-230, 019; K-916, 104Jerse, A. E. ......................B-1303, 164Jespersen, B. ....................L1-1650, 187Jespersen, D. J. ...................M-1693, 190Jesus, L. A. ......................K-1606, 183Jett, S. ........................C1-1742, 197Jeynes, T. ........................ F-828, 097Ji, D. ...........................H-226, 019Jia, L. ...........................K-268, 023Jian, Z. .........................C2-083, 008Jiang, H. ........................H-554, 073Jiang, J. Q. ...................... F-1502, 176Jiang, Q.. . . . . . . . . . . . . . . . . . . . . . . . . G-870, 101Jiang, V. . . A-1950, 241; A-1952, 241; A-1953, 241Jiang, X. ..............F-2002, 246; F-2057, 249Jiang, Y. ........................K-2096, 252Jicsinszky, L. .................... F-2005, 246Jih-Luh Tang ....................M-1669, 190Jimenez, F. .......................K-940, 106Jimenez, L. V. ..................L1-1653, 187Jiménez, O. ....................L2-2110, 255Jiménez de Anta, M. ..............C2-696, 087Jiménez Girón, A. ................L1-958, 109Jiménez-Mejías, E. . . . K-1924, 239; L1-2102, 254Jiménez-Mejías, M. ....C1-683, 086; A-1280, 162Jiménez-Ortigosa, C. ....F-822, 096; M-1715, 191Jiménez-Parrila, F. ................K-1924, 239Jin, F. ..........................L2-301, 027Jin, R. H. ........................H-554, 073Jing, H. ........................A-1289, 163J.L. Schmit ....................L1-2106, 254Jo, Y. .......................... F-2060, 249Jocham, S. .......................K-953, 108Joffe, A. M. ......................K-561, 074Johannsson, B. ...................K-1611, 184Johansen, H. K. ..................M-1710, 191Johansen, M. .....................M-982, 111Johns, B. ........................H-550, 073Johnson, A. ..........C2-100, 009; C2-120, 009Johnson, A. M. .................L1-1645, 186Johnson, B. ..........C2-099, 009; C2-144, 010;......C2-147, 010; C2-148, 010; C2-150, 010;................C2-721, 089; C2-1352, 167Johnson, D. M. .................. F-1512, 176Johnson, D. .....................A-1950, 241Johnson, J. ...........C2-099, 009; C2-141, 010;.................C2-143, 010; C2-147, 010;.................C2-721, 089; C2-722, 089Johnson, J. R. ........C2-687, 087; L2-2113, 255Johnson, J. K. ....................C2-095, 008Johnson, J. W. ..................C2-1390, 169Johnson, L. E. ...................C2-112, 009Johnson, L. B. ........K-923, 105; C2-1381, 169;................ C2-1391, 169; E-1484, 174Johnson, L. ...................... T-348, 029Johnson, M. D. ......M-1055, 115; M-1703, 191Johnson, M. E. .........F-827, 097; F-2072, 249Johnson, P. .......................K-902, 104Johnson, R. C. ..................C1-1972, 242Johnson, S. J. ....................K-1611, 184Johnson, S. ......................K-1583, 181Johnson, S. J. .....................K-471, 048Johnston, B. .....................C2-687, 087Johnstone, J. ......................K-955, 108Joly, V. .........................V-1073, 117Jones, A. K. .........C1-680, 086; C1-1973, 242Jones, B. .........................V-382, 030Jones, C. H. ......................G-870, 101Jones, L. S. ...........A-1276, 162; A-1277, 162Jones, M. E. ......................M-331, 028Jones, R. N. ..........C2-123, 010; C2-124, 010;......C2-129, 010; C2-131, 010; C2-132, 010;......C2-136, 010; C2-138, 010; C2-139, 010;.......C2-145, 010; C2-146, 010; E-186, 015;.........E-187, 015; E-189, 015; E-193, 015;.......E-199, 015; M-330, 028; C1-594, 081;........C2-691, 087; F-855, 099; F-856, 099;....... 1181, 151; C1-1343, 166; E-1463, 173;.......E-1467, 173;F-1510, 176; F-1511, 176;.... F-1512, 176; M-1714, 191; C1-1745, 197;.................F-2050, 248; F-2051, 248;..................F-2052, 248; F-2053, 248Jones, T. ........................A-1946, 240Jones-Nelson, O. .................B-1303, 164Jong, L. ........................ F-1531, 177Joo, J. ...........................A-616, 082Joosten, L. A. .....................B-044, 005Jordán, M. .......................K-256, 022Jorgensen, D. ........ E-1474, 174; L1-1662, 189Jorgensen, J. H. ...... C2-112, 009; D-1433, 171;............................D-1449, 172José M. Aguado ...................M-312, 028Joseph, C. ......................K-2088, 252Joshi, A. ........................H-1569, 179Jost, G. ..........................D-168, 012Jozwiak, M. ....................L1-1224, 158Juan, C. .......................C1-1970, 242Juenke, J. M. .....................A-017, 003Juliano, L. .......................D-731, 090Jumes, P. ..............A-009, 003; A-010, 003June, C. ........................H-1581, 180June, C. M. .....................C1-467, 047Jung, K. ........................ P-1006, 112Jung, S. ............B-1298, 164; C2-1913, 237Jung, Y. .......................C2-1984, 244Junie, L. M. ..................... P-1008, 112Jurado, A. ....................... T-1071, 116Justesen, U. S. ...................D-1444, 171Justinien, E. ....................L1-2106, 254Juve, R. ........................L2-303, 027KKaasch, A. .....................C2-1392, 169Kaatz, G. W. .........A-627, 083; C1-1341, 166;...........................C1-1747, 197Kabickova, E. ..................... T-344, 029Kadambari, S. ..................G3-1544, 178Kadlec, K. ...........C1-670, 085; C1-679, 086;...........................C1-1350, 166;Kadota, J. ........................M-324, 028Kaeriyama, M. .................... F-809, 096Kaewpitoon, N. ......... P-998, 112; P-999, 112Kaewpitoon, S. ......... P-998, 112; P-999, 112Kafer, J. M. ....................C2-1906, 237Kagan, R. .......................H-1575, 180Kahandawaarachchi, I. ............K-2081, 251Kahl, B. C. . . . A-597, 082; A-599, 082; A-596, 082Kaiser, C. ........................H-229, 019Kaiser, L. ..............K-954, 108; K-956, 108;................T-1064, 116; G3-1556, 178;Kajihara, T. ......................V-380, 030Kajiwara, C. ......................B-056, 005Kakeya, H. .............B-049, 005; V-380, 030;.........V-400, 030; B-657, 084; B-1297, 164Kakis, A. ........................K-247, 022Kaku, M. ...........C2-114, 009; C2-1901, 236Kaku, N. ............. B-657, 084; B-1297, 164Kakuta, R. ......................C2-114, 009Kalbarczyk, J. .................... F-1996, 246Kallen, A. J. ....................... 1135, 135Kalra, A. ........................A-018, 003Kaltsas, G. .....................L2-2114, 255Kam, K. M. .....................E-1992, 245Kam, T. C. ......................L1-286, 025Kamal, M. A. ....................A-1244, 161Kamar, N. ......................... 586, 080Kambal, A. ....................C2-1372, 168Kamihira, S. .....................D-1460, 172Final Program229

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberKamiyama, E. ................... F-2041, 248Kanafani, Z. A. .................L1-1644, 186Kanagaratnam, B. ................C2-122, 009Kanamori, H. ........C2-114, 009; C2-1901, 236Kandoussi, H. ...................A-1247, 161Kaneko, T. ....................... F-838, 098Kang, C. I. ..........C2-137, 010; C2-1366, 167;.................K-1587, 181; K-1588, 181Kang, J. .......................C2-1975, 243Kang, S. ........................B-1298, 164Kania, R. .......................M-1686, 190Kanwar, N. ......................C2-710, 088Kanyo, Z. ....................... F-1522, 177Kapil, A. ......................C2-1982, 243Kaplan, N. ......................E-1486, 174Kapoor, N. ....................... F-824, 097Kaptue, L. .......................H-214, 018Kar, S. .........................D-1437, 171Kara, A. .............M-1671, 190; A-1941, 240Kara, L. .........................V-375, 030Karadag Oncel, E. .....L1-964, 110; A-1941, 240Karagoz, A. ....................C2-1980, 243Karaiskos, I. ............K-562, 074; E-799, 094Karakas, A. .....................L1-960, 110Karchmer, A. W. ........541, 070; L1-1646, 186;.............................. 1841, 218Karginov, V. ..................... F-2005, 246Karlowsky, J. A. .......C2-135, 010; C2-149, 010;.........E-191, 015; E-200, 015; E-779, 093;.................E-1462, 173; E-1486, 174;Karlsson, J. ...................... T-1042, 113Karlsson, M. O. ........A-033, 004; A-1256, 161Karp, B. E. ......................C2-695, 087Karrer, S. .......................K-1125, 129Karthaus, M. .....................M-338, 028Kasas, S. ........................D-1436, 171Kashuba, A. D. ..................A-1248, 161Kasma, M. .....................C2-1900, 236Kaspar, H. ......................C1-679, 086Kasper, D. .......................D-728, 090Katayama, Y. ....................M-1226, 159Katiyar, S. K. .....................M-966, 111Katsouda, E. .....................K-562, 074Katsube, T. .......................A-019, 003Kauffman, C. A. ..........491, 057; F-1514, 176Kaufman, S. ......................D-746, 092Kauh, A. .......................M-1676, 190Kauh, E. A. .....................M-1695, 190Kaul, D. R. ..................... T-1066, 116Kaul, R. ........................H-1920, 238Kavana, M. ..................... F-1496, 176Kawai, M. ......................K-1599, 182Kawamata, D. ..................L1-1657, 188Kawasuji, T. ......................H-550, 073Kawasumi, N. ....................M-328, 028Kaya, B. .........................V-379, 030Kaya, S. ........................D-1405, 170Kayakiri, N. .............F-818, 096; F-819, 096Kaye, K. ....C2-096, 008; 501, 061; C2-1985, 244Kaye, K. S. .............A-034, 004; K-262, 023;.........K-272, 024; E-787, 094; K-902, 104;...........K-909, K-1121, 129; K-1589, 181;.............K-1604, 183; 104; K-1600, 182Kaynar, L. G. ....................M-1701, 191Kays, M. B. ........... A-017, 003; D-770, 092;............................ F-1520, 177Kazamori, D. ..........F-2049, 248; F-2055, 248Kazimierczuk, Z. ................. F-1533, 177Kazma, M. ......................C2-109, 009Kazmi, S. U. ...................C2-1981, 243Kearney, B. P. ....................A-1250, 161Keck, W. ..........C1-1346, 166; C1-1347, 166Keedy, K. .......................A-1286, 162Keel, R. A. .......................A-020, 003Keiger, A. .......................C2-117, 009Keim, P. ........................L1-964, 110Keitel, W. A. ....................... 576, 077Keith, D. .....F-843, 099; F-844, 099; F-845, 099Kelchlin, P. A. ..........A-024, 004; E-201, 015Kelesidis, T. ..........K-280, 024; C2-1401, 169Keller, A. .......................B-1734, 196Keller, N. ......................L1-1640, 186Kelley, K. L. .....................D-1425, 171Kelly, D. F. .....................G3-1544, 178Kelly, P. M. ......................K-952, 108Kelly, R. ......................... F-810, 096Kelly, S. ........................C2-706, 088Kemp, M. ......................D-1444, 171Kenar, L. ......................C2-1980, 243Kenfak-Foguena, A. ...............D-184, 014Kennon, J. .......................K-558, 074Kerff, F. .............C1-593, 081; C1-459, 047Kerkering, T. M. ..................D-162, 011Kersemaekers, W. ................A-1935, 240Keshavjee, S. .................... T-1067, 116Keslova, P. ....................... T-344, 029Kessler, H. .......................V-398, 030Kestler, M. .............K-263, 023; K-940, 106;............................D-1411, 170Keysary, A. ...................... P-1001, 112Keystone, J. S. ..................... 1891, 234Khachatryan, A. ...................K-239, 020Khan, A. ......................C2-1981, 243Khan, D. ............A-1764, 200; A-1966, 241Khan, R. ........................D-776, 092Khan, S. . . . F-2062, 249; F-2063, 249; F-2064, 249Khandker, N. .....................K-902, 104Khang, C. ....................... F-846, 099Khanna, N. ......................D-776, 092Khatib, R. .........C2-1381, 169; C2-1391, 169Khatri, J. K. ......................K-272, 024Khawcharoenporn, T. ............L2-2116, 255Khodaparast, L. ..................K-2094, 252Khodaverdian, V. .......F-1515, 176; F-1999, 246Khot, A. ........................ T-1027, 113Kidney, A. ......................C2-152, 010Kijsinthopchai, U. ................E-1477, 174Kikuchi, Y. . . H-888, 103; H-223, 019; H-224, 019Kilayko, M. C. ...................C2-112, 009Kilfoil, T. .......................A-1952, 241Kilic, A. . . . D-158, 011; M-316, 028; D-1427, 171Kilic, S. .......................C2-1980, 243Killian, S. ........................D-766, 092Killian, S. B. .........E-1463, 173; E-1467, 173Kim, A. .........................K-908, 104Kim, B. .........................K-908, 104Kim, C. .....H-230, 019; K-908, 104; K-916, 104Kim, D. H. ....................C2-1899, 236Kim, E. ...............K-907, 104; K-908, 104Kim, H. .... H-230, 019; K-907, 104; K-908, 104;....... K-916, 104; F-1489, 175; H-1582, 180Kim, I. ..........................G-872, 101Kim, J. .............A-1255, 161; C1-1343, 166Kim, J. S. ........................ T-365, 029Kim, J. ................H-230, 019; K-916, 104Kim, K. .....K-908, 104; H-1564, 179; 1874, 230;. . . . . . . . . . . . . . . . C2-1975, 243; K-2076, 250Kim, M. J. ......................L1-294, 026Kim, M. ....H-230, 019; K-916, 104; H-1572, 180Kim, N. .........................K-908, 104Kim, S. J. ....................... T-1043, 113Kim, S. .............. K-1632, 185; F-2060, 249Kim, S. H. .........C2-1366, 167; C2-1899, 236Kim, S. ..... H-230, 019; T-366, 029; D-741, 091;. . . . . . . . K-907, 104; K-916, 104; V-1074, 117;. . . . V-1239, 160; C2-1913, 237; C1-1969, 242;.................K-2092, 252; K-2079, 250Kim, T. ................K-907, 104; K-955, 108Kim, W. ...............D-155, 011; G-872, 101Kim, Y. S. ......................L1-294, 026Kim, Y. .....H-230, 019; T-366, 029; V-372, 030;........ D-741, 091; K-907, 104; K-916, 104;......V-1074, 117; V-1239, 160; F-1538, 177;............................K-2092, 252230September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberKimberlin, D. W. ................... 1828, 212Kimura, K. .....................C2-1989, 244Kimura, M. ......................K-897, 104Kimura, S. .......................B-056, 005Kinder, C. .......................H-555, 073King, P. ................F-848, 099; F-850, 099King, S. T. .......................M-968, 111Kinoshita, K. ....................D-1429, 171Kipnis, E. .............. B-050, 005; B-060, 005Kiratisin, P. .....................A-1279, 162Kirchhoff, J. ..................... P-1017, 112Kireev, D. ....................... F-1535, 177Kirkby, N. ............P-1005, 112; T-1072, 116Kirkpatrick, W. R. .......B-650, 084; F-823, 096;................M-1674, 190; M-1682, 190Kish, T. D. .......................K-919, 105Kishel, J. ..............E-807, 095; K-277, 024Kishony, R. ....................... 1790, 205Kissoon, M. ......................K-281, 024Kitagawa, M. ........C2-114, 009; C2-1901, 236Kitagawa, Y. .....................M-1231, 159Kitajima, I. ......................D-1461, 172Kitano, M. .......................V-380, 030Kitzis, M. D. .....................K-234, 020Kjældgaard, P. ................... P-1005, 112Kjær, J. ......................... T-1072, 116Klaassen, C. H. ........M-332, 028; M-334, 028Klastersky, J. ..................... T-1028, 113Klein, L. L. ...................... F-831, 098Klein, M. .......................H-1571, 180Klein, N. J. ........................ 1873, 230Klein, S. ........................C2-093, 008Klein, U. .......................C2-709, 088Klevens, R.. . . . . . . . . . . . . . . . . . . . . . K-1586, 181Klinker, K. .......................K-274, 024Klose, H. ........................ T-347, 029Kluge, S. ........................ T-347, 029Klugman, K. P. ...........D-172, 013; 1787, 204;.............................. 1880, 232Klumpp, K. ..........A-1245, 161; V-1080, 117Kluytmans, J. A.. . . . . . . . E-803, 094; G-870, 101;.............................. 1876, 231Knapp, C. . D-766, 092; E-1463, 173; E-1467, 173Knebel, W. .......................A-634, 083Knechtel, M. ..........A-008, 003; F-2065, 249Knezevic, A. ...................C1-1347, 166Knibbe, C. A. ...................A-1928, 240Knight, D. ......................B-1738, 196Knobel, H. ......................K-1624, 184Knoderer, C. A. .................G3-1558, 178Knudsen, E. .....................D-1444, 171Ko, A. I. .......................... 1100, 124Ko, K. S. ..........C2-1366, 167; C2-1899, 236Kobayashi, M. ....................H-550, 073Kobayashi, N. ................... F-2041, 248Kobayashi, T. .....................H-223, 019Kobayashi, Y. .................... F-1509, 176Kobela, M. .....................G3-1541, 178Kobrin, M. B. ...................A-1967, 241Koc, A. N. ......................M-1701, 191Köck, R. .......................C2-1382, 169Koeck, R. ......................G3-1547, 178Koenig, W. .....................C2-108, 009Koeth, L. M. .....................E-802, 094Kofteridis, D. P. ........B-043, 005; M-1696, 191Kogan, A. ......................L1-962, 110Koh, H. ........................D-1402, 170Koh, J. .........................K-2076, 250Koh, S. .........................D-1402, 170Koh, T. H. ............E-195, 015; K-1595, 182Kohler, I. ........................ V-384, 030Kohler, T. .......................B-1333, 165Kohlhoff, S. A. ...................E-206, 016Kohn, D. ......................G3-1546, 178Kohno, S. ..............B-048, 005; B-049, 005;........L1-296, 026; V-380, 030; V-400, 030;...... B-657, 084; M-1231, 159; B-1297, 164;........................... D-1460, 172;Köhrer, K. ......................C1-588, 081Koita, I. .......................C2-1989, 244Kojic, E. M. ....................... 1133, 134Kokoska, L. ..................... F-1532, 177Köksal .........................D-1405, 170Koksal, I. ........................V-394, 030Kolarovic, M. B. ................. V-1237, 160Koll, B. S. ......................... 573, 076Kolli, R. ......................... V-370, 030Kolling, G. L. ....................B-047, 005Komastu, M. ...........A-607, 082; A-608, 082;............................M-1687, 190Komatsu, H. ...........H-888, 103; H-890, 103Komp Lindgren, P. ................A-030, 004Konda, K. ......................L1-284, 025Kong, C. J. ......................L2-308, 027Kong, D. C. ...........K-558, 074; M-1671, 190Koning, O. H. ...................L1-965, 110Konishi, H. ......................M-326, 028Konopnicki, D. ..................D-1413, 170Konradsen, H. ...................H-1916, 238Konradsen, H. B. ..................G-876, 101Konrardy, M. .................... F-1511, 176Konrardy, M. L. .......F-2050, 248; F-2051, 248;. . . . . . . . . . . . . . . . . . F-2052, 248; F-2053, 248Kontoyiannis, D. .......M-972, 111; M-979, 111;.....M-984, 111; M-1057, 115; M-1058, 115;.....M-1676, 190; M-1681, 190; M-1705, 191Koo, H. L. .... K-920, 105; K-921, 105; 1817, 210Koo, S. .........................M-1060, 115Koomanachai, P. .................K-1602, 183Koopmans, M. M. ...............L1-1222, 158Koralnik, I. J. ..................... T-354, 029Korbenfeld, D. ....................D-746, 092Korczak, B. ..........A-1284, 162; E-1474, 174;...........................L1-1662, 189Korean Network for Study on Infectious Diseases(KONSID), ..................C2-137, 010Korprapun, L. ................... F-1539, 177Kort, J. .........................A-1248, 161Korytny, A. .....................K-1610, 184Kosmidis, C. ...................C1-1747, 197Kosowska-Shick, K. ..............C1-1971, 242Kostrzewa, M. ...................D-1777, 201Kotlovsky, T. .........C2-109, 009; K-1609, 184Kotra, H. ........................K-262, 023Kotsimbos, T. .....................K-952, 108Kottom, T. J. ..................... F-813, 096Koup, R. .......................... 577, 077Kousba, A. ...........A-1950, 241; A-1953, 241Kouyos, R. D. ....................K-238, 020Kovacs, S. J. ..........A-1281, 162; A-1282, 162Kovanda, L. L. ....................M-331, 028Kovarik, M. .....................D-1445, 172Kowalski, D. ....................A-1936, 240Koyama, A. H. .................... F-825, 097Koyamatsu, T. ....................D-155, 011Kozlov, R. ......................C2-697, 087Kozlowska, M. ................... F-1533, 177Kozyreva, V. .....................C2-697, 087Kraft, W. K. .....................A-1935, 240Kralidis, G. ...................... T-343, 029Krammer, W. ....................D-1404, 170Kranz, D. M. .................... F-1517, 176Krause, P. J. ........................ 448, 044Krause, R. .............V-395, 030; V-398, 030;.................P-1009, 112; D-1404, 170Kreiswirth, B.,N. ......C1-589, 081; C2-692, 087;. . . . . . . . . . . . . . . . . . E-792, 094; T-1031, 113;................C2-1216, 157; K-1625, 184Kreller, K. ......................A-1257, 161Kremastinou, J. .................G3-1543, 178Kremer, A. .....................G3-1547, 178Kremser, L. ..................... F-2058, 249Krepps, M. D. ........C1-064, 006; C1-592, 081Final Program231

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberKriegeskorte, A. ..................E-1483, 174Kriengkauykiat, J. .......T-349, 029; T-350, 029;. . . . . . . . . . . . . . . . . . . T-351, 029; T-1039, 113Krishna, G. .....................A-1935, 240Kristiansson, E. ..................C1-665, 085Kristoffersson, A. N. ...............A-032, 004Kröger, N. ............ T-347, 029; K-2095, 252Krogfelt, K. A. ...................C2-687, 087Kromke, K. .....................A-1267, 161Krompa, K. .....................A-1940, 240Kronborg, G. ....................H-1916, 238Kruse, S. .......................K-1592, 181Ku, C. ................A-031, 004; E-795, 094Ku, N. ................H-230, 019; K-916, 104Kubal, S. A. ..................... T-1029, 113Kubasek, C. .....................D-1446, 172Kubin, C. J. ...........A-026, 004; T-1034, 113;. . . . . . . . . . . . . . . . . .T-1036, 113; K-1620, 184Kuchipudi, V. .........C2-096, 008; K-1589, 181Kuehn, J. ........................K-953, 108Kuhn, K. .......................K-1925, 239Kuijper, E. .............K-472, 048; K-930, 105Kulawy, R. .......................A-011, 003Kulhanek, G. .....................A-018, 003Kullar, R. ..............K-275, 024; A-643, 083;. . . . . . . K-946, 106; K-1600, 182; K-1631, 185Kullberg, B. ........... M-1055, 115; 1114, 127;....M-1229, 159; M-1683, 190; M-1709, 191;Kumar, A. .............C2-703, 088; 1097, 123Kumar, D. .......................E-196, 015Kumar, G. ............B-052, 005; A-1253, 161Kumar, M. ...................... F-2043, 248Kumar, S. ........................ F-812, 096Kunapuli, A. .....................H-225, 019Kung, H. C. .....................M-1703, 191Kunishima, H. .......C2-114, 009; C2-1901, 236Kunze, M. .......................D-179, 013Kupferwasser, D. ..................G-868, 101Kuramoto, Y. ..........F-2049, 248; F-2055, 248Kurosaka, Y. ..........F-2035, 248; F-2036, 248;............................ F-2043, 248Kurt Azap, O. ...................C2-684, 087Kurtinecz, M. ........A-1272, 162; A-1276, 162Kurtzhals, J. A. ....... P-1005, 112; P-1017, 112Kushima, H. .....................M-324, 028Kusne, S. ............T-1032, 113; M-1697, 191Kuster, S. P. ......................K-955, 108Kuti, J. L. ..............A-018, 003; A-020, 003;....... A-022, 003; A-023, 004; A-1287, 163;.................K-1926, 239; A-1964, 241Kuypers, J. ....................... T-353, 029Kwa, A. L. .............E-195, 015; K-235, 020;........E-791, 094; K-896, 104; E-1476, 174;......K-1595, 182; K-1613, 184; M-1675, 190Kwak, E. J. .............T-346, 029; T-364, 029;......T-1031, 113; T-1037, 113; C2-1216, 157Kwak, Y. ...........C2-725, 089; C2-1914, 237Kwakwa, H. ......................H-881, 102Kwan, B. .............F-1514, 176; F-2018, 247Kwasny, S. M. .................... F-816, 096Kwon, D. B. .....................C1-595, 081Kwon, H. ......................C2-1975, 243Kwon, J. ........................K-1632, 185Kyaw, M. .......................G-1751, 198Kyo, K. .........................M-1226, 159Kyo, T. .........................M-1226, 159Kyrpitzi, D. .....................M-1720, 191LLabella, A. .....................C2-1906, 237Labori, M. ...........L1-293, 026; L1-295, 026;............................M-1228, 159Labrou, M. .....................B-1300, 164Lach, D. .......................G3-1546, 178Ladelund, S. ....................H-1916, 238Laerum, O. D. ....................B-663, 084Laeyendecker, O. .................H-1580, 180Lafaurie, M. ....................L2-2109, 255Laferrière, C. .....................D-730, 090Lafleur, J. ....................... F-1496, 176LaFleur, M. ........... F-815, 096; F-1519, 177Lagacé-Wiens, P. ......C2-103, 009; C2-135, 010;. . . . . . . . C2-149, 010; E-191, 015; E-194, 015;...................E-200, 015; E-779, 093Lagerbäck, P. ..........E-800, 094; A-1966, 241Lagioia, M. ......................D-159, 011Lagousi, T. .....................G3-1551, 178Lai, M.. . . . . . . . . . . . . . . . . . . . . . . . . . H-551, 073Lajoie, V. ........................V-389, 030Lake, D. ........................M-1702, 191Lakshmi, V. P. ....................K-236, 020Lalande, V. .............D-154, 011; D-157, 011Lalezari, J. ............H-553, 073; H-1581, 180Lalueza, A. ....................L2-2110, 255Lam, P. .........................K-955, 108Lam, T. .............F-2017, 247; F-2018, 247;. . . . . . . . . . . . . . . . . F-2018a, 247; F-2024, 247Lam, T. K. ......................E-1992, 245Laman, J. D. .....................B-058, 005LaMarche, M. ....................B-664, 084Lamberghini, R. ................C2-1910, 237Lambert, A. .....................A-1291, 163Lammens, C. ....................C2-109, 009Lamp, K. C. ...........K-276, 024; K-1635, 185;............................K-2078, 250Lancett, P. ...................... F-2016, 247Landecho, M. ...................K-1612, 184Landelle, C. ......................K-929, 105Landersdorfer, C. B. .....A-011, 003; A-027, 004Landman, D. ............ F-841, 099; 1130, 132Landon, E. .......................K-279, 024Landron, C. ......................A-039, 004Landry, M. L. ...................... 430, 039Lange, C. F. ..................... F-2070, 249Langenbach, K. .................. F-2005, 246Langner-Wegscheider, B. ...........V-395, 030Lanoix, J.P. .....................L1-2106, 254Lanternier, F. ........M-1686, 190; M-1707, 191Lao, V. ......................... F-2027, 247Laouénan, C. .....................A-021, 003Lapidus, N. ......................V-387, 030LaPlante, K. L. .........K-233, 020; E-790, 094;......K-1120, 129; K-1123, 129; E-1464, 173;................. E-1469, 173; K-1628, 185Lara, A. .......................G3-1563, 178Lara, R. . . . T-368, 029; C1-683, 086; A-1280, 162Lardeux, M. ......................D-178, 013Larios, O.. . . . . . . . . . . . . . . . . . . . . . . . D-729, 090Larka, C. V. .....................D-1414, 170Larkins-Ford, J. .................. F-1538, 177Larosa, F. .......................M-1692, 190Larroque, B. .....................K-2087, 252Larrosa, N. ..........C2-1358, 167; K-1616, 184Larsen, M. V. ....................H-1916, 238Larsson, D. G. ...................C1-665, 085LaRue, H. ......................D-1417, 170Lasa, I. .........................C1-672, 085Lasco, T. M. ...........D-158, 011; M-316, 028;............................D-1450, 172Lascols, C. .......... D-1448, 172; C2-724, 089;...............C1-1209, 156; C2-1210, 157Lascoux-Combes, C. ..............H-1568, 179Laser, L. .........................K-238, 020Lass Floerl, C. .........M-332, 028; M-337, 028;................M-1227, 159; M-1708, 191Lasserre, C. ...........K-255, 022; B-1318, 165Lassetter, K. ......................A-010, 003Lastovetska, O. ......C2-089, 008; C2-1214, 157Lat, A. .........................K-1620, 184Latasa, C.. . . . . . . . . . . . . . . . . . . . . . . C1-672, 085Laterza, F. ......................L1-963, 110Latin America Working Group on BacterialResistance .....................K-900, 104232September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberLatin American Working Group on BacterialResistance ...................C2-1909, 237Laudy, A. E.. . . . . . . . . . .F-1533, 177; F-1996, 246Launay, O. ....................... V-375, 030Laupland, K. B. ......... K-1756, 199; 1834, 215Laurence, B.. . . . . . . . . . . . . . . . . . . . L1-1656, 188Laurent, F. .............1174, 149; B-1317, 165;................B-1319, 165; C1-1739, 197Laurent, M. ..................... F-2003, 246Laurent, V. ....................... P-568, 075Laussucq, S. ....................L1-1661, 189Lauten, M. .......................M-335, 028Lautenbach, E. ..................... 487, 055Lautenschlager, I. .......T-355, 029; T-1070, 116Lauzon, D.. . . . . . . . . . . . . . . . . . . . . . . V-389, 030Lavergne, V. ......................D-751, 092Lavigne, J. ............K-255, 022; B-1318, 165;............................B-1327, 165Lavín, B. A. .....................M-1673, 190Lavoie, L. .......................K-473, 048Law, D. .......................... 1869, 229Lawrence, L. .........A-1956, 241; A-1957, 241Lawrence, L. E. ........E-208, 016; A-1290, 163;. . . . . . . . . . . . . . . . L1-1663, 189; A-1958, 241Lawson, C. ......................A-040, 004Lawson-Ayayi, S. ..................K-248, 022Laxminarayan, R. ................ P-1024, 112Lazarovitch, T. ....................E-787, 094Le, A.. . . . . . . . . . . . . . . . . . . . . . . . . . L1-959, 109Le, B. M. ........................ T-357, 029Le, H. N. .......................B-1735, 196Le, T. H. .......................M-1677, 190Le Gal, S. .......................M-333, 028Le Goff, J. ............T-363, 029; D-1778, 201Le Joubioux, A. ...................A-638, 083Le Mabecque, V. .......B-653, 084; A-1948, 241Le Moal, G. ...........A-039, 004; L1-963, 110Le Saux, N. ....................G3-1542, 178Le Strat, Y. ......................V-375, 030Le Vacon, F. .........D-1458, 172; L1-1642, 186Leakey, A. .............E-204, 016; E-210, 016Leal, J. R. .......................K-1756, 199Learn, D. B. .....................A-1955, 241Leavitt, R. .......................H-885, 102Lebeaux, D. .....................K-2087, 252LeClaire, A. ......................D-155, 011Leclercq, R. .........D-1441, 171; L2-2117, 255Lecompte, T. ..................... T-343, 029Ledeboer, N. A. ..........D-728, 090; 1131, 133;............................D-1777, 201Ledergerber, B. ...................V-384, 030Ledesma, K. R. .........A-025, 004; A-028, 004;..................A-029, 004; D-1450, 172Lee, A. ..........................A-616, 082Lee, B. ................V-386, 030; T-1069, 116Lee, C. . . B-1324, 165; B-1325, 165; C2-1212, 157Lee, D. .............K-1632, 185; C2-1975, 243Lee, E. ..........................D-734, 091Lee, F. .......................... T-357, 029Lee, G.. . . . . . . . . . . . . . .H-553, 073; H-1581, 180Lee, G. C. .......................E-794, 094Lee, H. .......................C2-1903, 236Lee, H. J. ..............A-031, 004; E-795, 094Lee, H. ....... F-827, 097; M-967, 111; B-1309,............E-1473, 174; 165; C2-1978, 243Lee, J.. . . . . . . . . . . . . . . . . . . . . . . . . . . G-872, 101Lee, J. J. .............C1-068, 006; C1-595, 081Lee, J.. . . . . D-182, 014; G-872, 101; B-1309, 165;. . . C2-1978, 243; C2-1978, 243; C2-1975, 243Lee, J. H. ............C1-068, 006; C1-595, 081Lee, K. ...............H-218, 018; H-221, 019;...................H-226, 019; V-372, 030Lee, L. K. ......................H-1569, 179Lee, M. .......................C2-1212, 157Lee, N. Y. ......................C2-137, 010Lee, R. T. .......................H-1569, 179Lee, R. .......................... F-815, 096Lee, R. E. ..........A-1267, 161; C1-1741, 197;............................. F-832, 098Lee, R. ........................C2-1213, 157Lee, S. ..............F-2018, 247; F-2018a, 247Lee, S. J. ....................... F-2017, 247Lee, S. A. ....................... F-2000, 246Lee, S. H. ...........C1-068, 006; C1-595, 081Lee, S. ......T-366, 029; D-741, 091; K-907, 104;. . . . . . P-1006, 112; V-1074, 117; V-1239, 160;. . . H-1564, 179; C2-1978, 243; C2-1984, 244;...... F-2024, 247; K-2076, 250; K-2092, 252Lee, V. ......................... F-2010, 246Lee, W. ...............E-195, 015; V-372, 030;......E-791, 094; C2-1212, 157; E-1476, 174;................. K-1595, 182; K-1613, 184Lee, Y. J. ........................T-361, 029Lee, Y. ..... T-366, 029; D-732, 091; D-741, 091;..................K-907, 104; V-1074, 117;................V-1239, 160; C2-1984, 244Leeds, J. .........................B-664, 084Leelaporn, A. ....................E-1477, 174Leelarasamee, A. .................E-1477, 174Lefebvre, B. ...........C2-085, 008; D-751, 092Leflon, V. ......................L2-2109, 255Leflon-Guibout, V. ...............K-2087, 252Lefort, A. ............B-660, 084; L2-2109, 255;...........................L2-2117, 255Legarth, R. ..................... P-1005, 112Legentil, L. ..................... P-1007, 112Leggio, M. ...................... F-1522, 177Legoff, J. ........................D-178, 013Legout, L. ......................K-2089, 252Leguerrier, A. ....................K-267, 023Lehner, B. ......................C2-093, 008Lehoux, D. ......................A-620, 082Lehrnbecher, T. ..................M-1708, 191Leib, S. .........................B-649, 084Leibovitz, E. ......... M-339, 028; G-1050, 114Leistner, R. .....................K-1592, 181Leite, T. M. ......................K-913, 104Leitner, E. ...........D-1404, 170; E-1470, 173Leiva, L. M. .....................A-1945, 240Lekkakou, D. .....................E-799, 094Lellek, H. .......................T-347, 029Lemaire, N. ......................A-638, 083Lemaire, S. . A-596, 082; A-599, 082; F-2029, 247Lemaire, X. .....................L1-957, 109Lemaitre, T. .....................G-1051, 114LeMay, M. ...................... F-2034, 248Lemeunier, L. ....................H-231, 019Lempers, V. J. ...................A-1928, 240Len, O. .........................T-368, 029Leneva, I. A. ..................... V-388, 030Leo, Y. ................ P-569, 075; P-567, 075Leon, F. ........................ F-1488, 175Leonard, D. A. ..................C1-467, 047Leonard, S. N. .........A-622, 082; K-1123, 129Leone, A. .......................K-1125, 129Leonildi, A. ......................E-796, 094Leopold, T. N. ................... P-1010, 112Leoz, M. ........................H-886, 102Lepak, A. .............F-857, 099; A-1270, 162;......A-1271, 162; A-1929, 240; A-1930, 240;..... A-1931, 240; A-1932, 240; A-1947, 241Lepak, A. J. .....................D-1431, 171Lepe, J. . . C1-683, 086; A-1280, 162; K-1924, 239Lepelletier, D. .........K-255, 022; B-1318, 165Lepeule, R. ......... V-1073, 117; L2-2109, 255Lephart, P. ............K-902, 104; L2-306, 027Lephart, P. R. ..........K-262, 023; K-272, 024;........T-367, 029; E-787, 094; K-1589, 181;............................K-1604, 183Lepist, I. ........................H-892, 103Lepoutre, A. ...................C2-1359, 167Lepri, A. C. ..................... T-1072, 116Lerman, Y. ..........C2-109, 009; C2-1900, 236Leroy, J. ........................M-1692, 190Leroy, O. .......................K-2089, 252Final Program233

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberLeruez, M. .......................V-387, 030Lesho, E. ...........C2-725, 089; C2-1914, 237Leung, V. ........................D-161, 011Levasseur, P. .....................A-1760, 200Levin, E. .......................L1-961, 110Levine, D. P. .........K-275, 024; L1-1638, 186;.............................. 1730, 194Levitt, P. S. .....................C1-464, 047Levrard, M. .....................M-1698, 191Levy, C. ..............G-864, 100; G-1049, 114Lévy, S. .........................V-375, 030Lévy-Bruhl, D. ...................V-375, 030Lew, D. ...............K-249, 022; K-253, 022Lew, I. .........................K-1598, 182Lewinski, M. A. .................D-1433, 171Lewis, J. S. ......................C2-112, 009Lewis, K. ..............F-815, 096; F-829, 098;..................F-1519, 177; F-1536, 177Lewis, P. .......................G-1052, 114Lewis, R. E. ..........M-984, 111; M-1057, 115;............................M-1679, 190Lewis, R. ................414, 035; M-972, 111Lewis, R. E. ...........M-979, 111; K-1619, 184Li, C. R. ....................... F-1499, 176Li, C. ..........................A-1763, 200Li, D. ...............A-1289, 163; A-1956, 241Li, G. Q. ....................... F-1499, 176Li, H. ..........................C2-083, 008Li, J. ........A-024, 004; A-027, 004; A-031, 004;...........500, 061; A-634, 083; A-635, 083;.........E-785, 094; E-795, 094; K-933, 105;......F-1505, 176; M-1695, 190; A-1760, 200Li, K. ...........................V-370, 030Li, Q. ................F-838, 098; D-1454, 172Li, S. ..........................B-1296, 164Li, T. ........................... F-846, 099Li, W. ................K-268, 023; K-936, 105Li, X. ..... A-009, 003; F-810, 096; M-1061, 115;..... F-2017, 247; F-2018, 247; F-2018a, 247;................. F-2022, 247; F-2024, 247;Li, Y. .....C2-083, 008; C2-083, 008; T-365, 029;.........F-845, 099; F-846, 099; K-933, 105;..... A-1248, 161; F-1498, 176; L1-1659, 189Li, Z. ...........................K-933, 105Liao, C. ............C2-1212, 157; D-1420, 170Liao, G. .............M-984, 111; M-1057, 115Liappis, A. P. .....................H-213, 017Liberator, P. ..............575, 077; G-870, 101Libman, M. D. ............ 403, 033; 1140, 137Lichtner, M. .........D-742, 091; C2-1373, 168Liebenstein, T. ....................A-621, 082Liebo, R. V. .....................V-1241, 160Liew, Y. X. .......................K-896, 104Liew, Y. ........................K-1595, 182Lightstone, F.. . . . . . . . . F-2017, 247; F-2018, 247;........................... F-2018a, 247Lightwood, D. ...................B-1738, 196Liguori, S. .....................G3-1554, 178Lilly, M. ......................... F-828, 097Lim, C. H. ......................L1-294, 026Lim, C. ........................K-1613, 184Lim, C. J. ........................K-558, 074Lim, C. S. ............M-990, 111; F-2071, 249Lim, S. ........................C2-1913, 237Lim, T. P. . . . E-195, 015; E-791, 094; E-1476, 174Lim, W. P. .......................A-614, 082Limaye, A. P. .............. 1815, 209; 407, 034Limper, A. H. .................... F-813, 096Lin, A. ..............K-1590, 181; K-1591, 181Lin, B. .......................... F-828, 097Lin, C. .........................C2-097, 008Lin, S. .........................A-1251, 161Lin, T. ..........................V-397, 030Lin, Y. T. ......................C1-1339, 166Lina, B. ........................V-1080, 117Lina, G. ........................B-1735, 196Liñares, J. .............B-658, 084; C2-690, 087;...............C2-1358, 167; C2-1365, 167;...............C2-1395, 169; C2-1974, 243Lincopan, N. .........C2-106, 009; C2-704, 088;.......C2-716, 088; C2-717, 088; E-784, 094;........E-788, 094; E-801, 094; K-1606, 183;............................ F-2004, 246Lindner, H. ..................... F-2058, 249Ling, L. ......................... F-829, 098Ling, M. L. .....................K-1595, 182Linhares, A. R. ...................D-749, 092Linkin, D. .......................D-744, 091Lionakis, M. ....................... 548, 072Lionakis, M. S. ..................M-1055, 115Liou, L. .........................G-871, 101Lipkin, C. B. ....................L1-292, 026Lipkin, W. I. ...................... 1190, 153Lipsky, B. A. ....................... 540, 070Lischka, P. ....................... T-356, 029Lista, N. ...........C2-1396, 169; C2-1397, 169Little, S. ........................ F-2028, 247Litwin, J. .......................A-1958, 241Liu, B. Y. ........................E-795, 094Liu, C. ....K-247, 022; K-261, 023; C2-1212, 157Liu, D. .........................A-1284, 162Liu, E. M. ......................C1-065, 006Liu, G. ......................... F-2031, 248Liu, J. ....F-832, 098; V-1078, 117; C1-1203, 156;.....A-1267, 161; F-1498, 176; G3-1550, 178Liu, M. .............. G-875, 101; M-973, 111Liu, S. . . . F-838, 098; V-1078, 117; G3-1550, 178Liu, W. ....A-041, 004; A-042, 004; C2-083, 008;.......H-215, 018; H-218, 018; L2-309, 027;........F-810, 096; G-867, 100; V-1238, 160;............................H-1578, 180Liu, X. ..........................K-933, 105Liu, Y. ...............A-010, 003; C2-083, 008;...............C2-1212, 157; C2-1987, 244Livak, B. ........................H-883, 102Livermore, D. M. .......E-192, 015; F-853, 099;................... 1196, 154; F-2048, 248Livermore, J. .........M-977, 111; A-1765, 200;......A-1942, 240; A-1943, 240; A-1944, 240Livshiz-Riven, I. ..................M-339, 028Lizasoain, M. ......... T-1071, 116; K-2091, 252Lloyd, T. ........................K-561, 074Lloyd-Smith, E. .......K-1593, 182; D-161, 011Lloyld, T. .......................D-1448, 172Lo, S. ...............C2-089, 008; C2-090, 008Lob, S. ..............C2-100, 009; C2-141, 010;.................C2-688, 087; C2-722, 089Lobo, L. A. .....................C1-671, 085Loboda, A.. . . . . . . . . . . . . . . . . . . . . .M-1695, 190Locher, H. H. ......C1-1346, 166; C1-1347, 166Lock, J. L. ......................L1-286, 025Locke, J. ..............F-1514, 176; F-2025, 247Lodise, T. P. . A-020, 003; A-606, 082; K-1123, 129Loeb, M. ........................K-955, 108Loebner-Olesen, A. ...............K-1617, 184Loecken, A. ......................K-953, 108Loessner, M. J. ................... F-1516, 176Logan, A.. . . . . . . . . . . . . . . . . . . . . . . F-2016, 247Lohse, A. W. ...................... 1820, 210Loizidou, A. .........T-1028, 113; D-1413, 170Loman, N. J. ....................... 424, 038Lomas, J. M. .....................K-938, 106Lomas, J. ........................K-941, 106Lomovskaya, O. .........F-855, 099; F-848, 099;......... F-849, 099; F-850, 099; F-851, 099;...........F-852, 099; F-858, 099; 1837, 216Loneragan, G. H. ................C2-710, 088Long, F. ........................ F-2002, 246Long, L. ......................... F-815, 096Longcor, J. ............E-208, 016; A-1289, 163;.....A-1290, 163; L1-1663, 189; A-1956, 241;.................A-1957, 241; A-1958, 241Longley, N. .....................M-1699, 191Longo, G. ......................D-1436, 171Longshaw, C. ..........K-924, 105; B-1299, 164Longuet, P. .....................V-1073, 117Loo, A. .........................A-636, 083Loo, V. G. ........................ 1847, 221234September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberLooke, D. F. ....................... 1192, 153Lopez, E. ......................G3-1552, 178Lopez, G. ......................H-1917, 238López, J.. . . . . . . . . . . . . . . . . . . . . . . . . K-938, 106López, Y. .............E-205, 016; C1-681, 086;............................C1-682, 086Lopez del Hierro, M. .............H-1921, 238Lopez Furst, M. .....C2-1396, 169; C2-1397, 169López Jiménez, J. .................A-1934, 240Lopez Ruz, M. ..................H-1921, 238López-Cerero, L. .................C2-707, 088López-Contreras, J. ................K-256, 022López-Cortés, L. ................L1-1658, 188López-Medrano, F. ......T-359, 029; K-938, 106;..... T-1071, 116; K-2091, 252; L2-2110, 255Lopez-Roa, P. .........T-1026, 113; V-1242, 160López-Rojas, R. ..................B-1329, 165López-Vélez, R.. . . . . . . . . . . . . . . . . . . . 1087, 119Lora, J. ........................L1-2102, 254Lora-Tamayo, J. .........K-254, 022; B-647, 084Lorentz, S. ......................L1-959, 109Lorenzo, I. G. ...................C1-067, 006Loriau, J. ........................K-234, 020Lortholary, O. .......M-1686, 190; M-1707, 191Losinno Juan, Ramirez Santiago, Blanco Miriam,Cazzola Laura, Firpo Soledad, Yebara Analia,...........................L1-1637, 186Lou, Y. .........................A-1246, 161Loughborough, A. .................K-281, 024Louie, A. ....A-011, 003; A-041, 004; A-042, 004;. . . . . . A-1265, 161; A-1761, 200; E-1993, 245Louie, T. ......................... 1146, 140Lounis, N. ......................A-1259, 161Loveless, V. .....................A-1267, 161Low, D. E. ...........C2-089, 008; C2-090, 008;.....K-281, 024; C2-1214, 157; C2-1363, 167;. . . . . . . . . . . . . . . C2-1362, 167; C2-1364, 167Low, D. .......................G3-1562, 178Lowe, D. ............K-1590, 181; K-1591, 181Lowman, W. .....................D-773, 092Loyse, A. .......................M-1670, 190Loza, E. .............M-323, 028; M-1700, 191Lu, C. ....G-867, 100; V-1238, 160; A-1251, 161Lu, J. ...........................K-936, 105Lu, M. ..........................H-551, 073Lu, N. .........................A-1767, 200Lu, R. J. .........................H-554, 073Lu, X. ............... K-905, 104; F-1499, 176Lu, Y. ........................... F-834, 098Lubritz, G.. . . . . . . . . . . . . . . . . . . . . G3-1547, 178Lucas, E. ......................G3-1563, 178Lucas, M. J. ....................L1-1223, 158Lucero, C. ........... C2-701, 087; D-746, 092;...........................C2-1910, 237Lucet, J. C.. . . . . . . . . . K-1757, 199; L2-2117, 255Luciano, K. A. ...................E-1485, 174Lückermann, M. .................A-1960, 241Ludden, C. ..........C2-119, 009; C2-122, 009;............................C2-706, 088Lueangniyomkul, A. ...............H-894, 103Luisa Moro, M. .................... 1155, 144Lukacs, N. .......................G-869, 101Lukehart, S. A. ..................B-1301, 164Lumbreras, C. .........T-359, 029; T-1071, 116;. . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2091, 252Lundgren, J. D. .................. T-1072, 116Lung, M. ........................K-931, 105Lunniss, C. J. .................... F-2016, 247Luo, C. ........................C1-673, 085Luo, G. ..............B-650, 084; E-1473, 174Luo, R. ........................L1-292, 026Luo, X.. . . . . . . . . . . . . . . . . . . . . . . . . B-1303, 164Luque, A. .......................A-1252, 161Luse, A. ........................K-2080, 251Lustig, S. . . . K-249, 022; K-253, 022; B-1319, 165Lustig, U. .......................A-1764, 200Luther, M. K. ........E-1464, 173; E-1469, 173Lutsar, I. ...........G3-1559, 178; G-1750, 198Luttick, A. ....................... F-828, 097Luzzaro, F. .......... D-757, 092; C2-1211, 157;. . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1897, 236Ly, N. S. .....A-016, 003; A-024, 004; E-785, 094Lye, D. C. . . . P-567, 075; P-569, 075; A-614, 082;.........K-896, 104; K-899, 104; K-910, 104Lyerly, D. M. ...........D-162, 011; D-163, 011Lynch, D. T.. . . . . . . . . . . . . . . . . . . . . . D-170, 012Lynskey, N. .....................B-1311, 165Lyon, G. M. ..........M-337, 028; M-1227, 159Lyon, K. C. ....................G3-1558, 178Lyra, Y. C. ......................D-1428, 171MM Protein Study Group ...........B-1312, 165M’zali, F. . . C2-091, 008; D-164, 012; C2-719, 089Ma, J. .......................... F-1502, 176Ma, L. .........................A-1934, 240Ma, Z. ...... F-834, 098; F-835, 098; F-836, 098;......... F-837, 098; F-838, 098; F-839, 098;............................. F-840, 098MacDonald, J. ..................C2-1380, 169MacDonald, N. C. .................K-240, 020MacDougall, C. ........D-754, 092; K-1923, 239MacDougall, L. ..................M-1233, 159Macedo, A. ..........T-1044, 113; D-1403, 170Macesic, N. ......................K-952, 108MacGowan, A. P. .......A-628, 083; A-629, 083;........ A-631, 083; A-642, 083; D-763, 092;.............................E-793, 094MacGregor, T. R. .................A-1248, 161Machado, A. M. ................C2-1376, 169Machalek, D. A. .................L2-301, 027MacKenzie, B. ...................B-1738, 196MacKenzie, C. R. ................C1-588, 081Mackenzie, R. ..................G3-1562, 178Mackey, J. ......................L1-284, 025Macmullin, G. ..................G3-1562, 178MacMullin, G. .................C2-1214, 157MacNeill, M. ....................C2-090, 008Macri, A. .......................D-1776, 201Madero, R.. . . . . . . . . . . . . . . . . . . . . . K-1608, 184Madhi, S. A. .....................D-172, 013Madhura, D. ....................A-1267, 161Madrid, N. ......................H-1567, 179Madsen, H. A. ....................G-862, 100Maehara, C. .....................D-1438, 171Maertens, J. .........M-1225, 159; M-1676, 190Maffia, P. ....................... F-1491, 175Magalhães, A. G. .................K-1601, 182Magarian Blander, J. ................. 417, 036Maggi, G. ......................K-1608, 184Magill, S. ......................... 1806, 208Magri, A. S. .....................K-1603, 183Magulick, J. P. ...................L1-297, 026Mahajan, S. ...........T-1065, 116; V-1075, 117Mahamat, A. .................... P-1011, 112Maharjan, B. .......C2-1368, 168; C2-1369, 168Mahbub, K. R. ...................C2-711, 088Maher, K.. . . . . . . . . . . . . . . . . . . . . . . C2-705, 088Mahjoub, Y. .....................M-1698, 191Mahoney, A. D. ..................... 531, 068Maia, J. .........................M-320, 028Maier, S. J. ...................... P-1021, 112Maietta, R. .....................A-1282, 162Maiga, M. .......................D-739, 091Maillart, E. ......................A-637, 083Mailles, A. .........C2-1374, 168; L1-1649, 187Maiolo, E. .......................M-974, 111Maki, D. ......................... 1138, 136Maki, H. ............ F-1506, 176; F-1507, 176Maki, K. ..............F-817, 096; F-818, 096;..........F-819, 096; F-820, 096; F-821, 096Makidon, P. E. ....................G-869, 101Makristathis, A. ..................H-1918, 238Malachy, A. .....................L1-962, 110Final Program235

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberMalagnino, V. ....................D-165, 012Malani, P. N. ....................... 488, 055Malaysian Candidaemia Study (MaCaS) Group,.............................K-947, 107Malczynski, M. .......B-1323, 165; B-1326, 165;............................K-1614, 184Malfatti, M. A. .................. F-2027, 247Malhotra, M. K. ..................K-240, 020Malhotra-Kumar, S. ..............C2-109, 009Mallegol, J. ......................E-781, 093Malmberg, C. .........E-798, 094; A-1966, 241Malouin, F. ...........F-1997, 246; F-1998, 246Mamizuka, E. .........C2-717, 088; E-784, 094Manavathu, E. ...................M-1716, 191Manavathu, E. K. ......M-986, 111; M-987, 111Manca, N. ......................L2-304, 027Manca, S. ........................K-561, 074Mancos, P. ......................K-2086, 252Mändar, R. .....................L2-310, 027Mandrekar, J. N. ........D-170, 012; B-652, 084Manfrin, V. .....................H-1579, 180Mangano, A. .....................B-045, 005Mangin, E. ......................A-010, 003Mangus, R. S. ................... T-1029, 113Manjuba, C. .....................C2-107, 009Mankatitham, W. .................H-894, 103Mankertz, J. .....................C1-679, 086Manku, M. ..................... F-2009, 246Manoharan, A. ...................E-196, 015Manonelles, G. .................G3-1552, 178Manos, P. ......................L1-1663, 189Manosuthi, S. ....................H-894, 103Manosuthi, W. ...................H-894, 103Manousaka, S. ...................B-1300, 164Manoussakis, M. ................L2-2114, 255Mansi, I. A. .....................L1-297, 026Mansouri, M. D. .................K-2097, 252Mantella, A. ....................C1-1205, 156Manuel, O. .T-343, 029; T-352, 029; L1-1221, 158Manuel, S. .......................K-956, 108Manzoor, H. ...................C2-1981, 243Manzur, A. ......................M-329, 028Maor, Y. ............ L1-962, 110; L1-1640, 186Maraki, S. ......................M-1696, 191Marathe, B. M. ..................A-1243, 161Marathe, N. .....................C1-665, 085Marbury, T. A-010, 003; A-1294, 163; A-1295, 163Marcelli, C. ........ L1-2103, 254; L1-2104, 254March, F. ........................K-931, 105Marchaim, D. .........A-034, 004; C2-096, 008;.........K-262, 023; K-272, 024; T-367, 029;........E-787, 094; K-902, 104; K-1589, 181;............................K-1604, 183Marchak, M. .................... F-2019, 247Marchand, C. L. .......F-1495, 175; F-1522, 177Marchand, S. ...........A-036, 004; A-037, 004Marchandin, H. .................. F-1488, 175Marchetti, O. ........L1-1221, 158; M-1225, 159Marchillo, K. ..........F-857, 099; D-1431, 171;......A-1931, 240; A-1932, 240; A-1947, 241Marchou, B. ....................L1-2103, 254Marco, F. ..............A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129; E-1465, 173Marcus, G. .......................T-367, 029Mardekian, J. .....................K-259, 023Mares, M. ....................... F-811, 096Maretty, L. ...................... P-1017, 112Margolis, D. ..........H-895, 103; A-1249, 161Margolskee, D. ................... T-358, 029Margot, N. .......................H-552, 073Mariani, L. ......................D-168, 012Maricela Valerio ..................M-312, 028Marijanovic, N. .................L1-1667, 189Marimón, J. ....................C2-1358, 167Marín, M. ...........C2-127, 010; C2-130, 010;......C2-142, 010; D-1411, 170; D-1415, 170Marin, M. . . K-470, 048; K-944, 106; D-1772, 201Mario Fernández-Ruiz .............M-312, 028Marlenee, N. ..........F-2022, 247; F-2033, 248Marmolin, E. S. ..................D-1444, 171Marocco, R. ......................D-740, 091Marques, E. A. ...................D-731, 090Márquez, J. A. ...................K-1924, 239Marr, K. ........................M-1676, 190Marra, A. R. ....................C2-685, 087Marra, A. ............A-1289, 163; A-1290, 163;. . . . . . . . . . . . . . . . . .F-1522, 177; F-1523, 177Marra, C. M. ....................B-1301, 164Marra, C. .......................A-1937, 240Marrie, T. J. ....................... 1883, 232Marriel, M. .....................D-1403, 170Marriott, D. J. ........... K-947, 107; 1164, 146Marsault, É. ...........F-1997, 246; F-1998, 246Marsh, J. ....................... T-1037, 113Marshall, S. ..........C2-686, 087; C2-692, 087Marshall, S. M. ..................C2-720, 089Marshall, S. H. .......C2-092, 008; C1-590, 081Martelin, R. ............D-745, 092; D-748, 092Marth, E. .......................E-1470, 173Marti, A. ........................K-940, 106Marti, N. ............M-980, 111; M-1718, 191Marti, S. ......................C2-1974, 243Martin, C. ..........D-1413, 170; C1-1739, 197Martin, E. T. .........K-272, 024; C2-1985, 244Martin, I. ......................C2-1360, 167Martín, J. ........................H-217, 018Martín, R. .....................C2-1395, 169Martin, S. I. ..................... T-1066, 116Maritza, P. ......................C2-718, 089Martin-Davila, P. .......M-323, 028; D-743, 091;.................M-1700, 191; K-2077, 250Martín-Gandul, C. ....C1-683, 086; A-1280, 162Martin-Lopez, A. .................K-470, 048Martin-Mazuelos, E. ...............K-950, 107Martín-Rabadán, P. ..... D-166, 012; E-806, 095;................ M-1688, 190; K-2090, 252Martínez, A. A. ..................H-1573, 180Martinez, D. .....................M-315, 028Martínez, E. ....................... 446, 043Martínez, G. .....................M-327, 028Martínez, J. .....................C1-075, 006Martinez, M. ..........G-875, 101; M-982, 111;............................ P-1013, 112Martinez, M. B. ...................G-861, 100Martinez, R. ....................C2-086, 008Martinez, S. ......................K-258, 022Martinez Alarcon, J. .............. T-1041, 113Martinez de Salazar, P. ............K-1616, 184Martínez-Lacasa, X. ...............K-938, 106Martinez-Leyva, G. ..............G3-1563, 178Martínez-Longoria, C. ...........C2-1357, 167Martínez-Martínez, L. ............C2-105, 009;..........C2-111, 009; D-169, 012; 516, 064;.......C1-683, 086; D-765, 092; A-1280, 162Martinez-Selles, M. ................K-942, 106Martinez-Yelamos, S. .............V-1240, 160Martinho, G. .................... T-1044, 113Martins, A. F. ..................C2-1905, 236Martins, M. A. ...................M-311, 028Martins, V. P. ....................K-1601, 182Martiny, D. .....................D-1413, 170Marty, F. M. ..........T-354, 029; M-1060, 115Marty, N. ........................D-758, 092Maryland MDRO Prevention Collaborative,............................C2-095, 008Masaisa, F. .......................D-775, 092Masarwa, S. ......................K-557, 074Mascara, G. P. ....................A-619, 082Mascarenhas, L. A. ...............K-1601, 182Mascellino, M. T. ..................D-165, 012Maseda, E. ......................K-1608, 184Mason, K. L. .....................B-661, 084Massias, L. .............A-021, 003; B-645, 084236September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberMasson, L. .....................C2-1986, 244Massongo, M. ...................K-2089, 252Massot, M. ....................L1-1639, 186Mastroianni, C. M. ............... D-165, 012;...................D-740, 091; D-742, 091Mastroianni, C. .................C2-1373, 168Masuda, T. ...................... F-1509, 176Mataseje, L. F. ...................C2-085, 008Mateos, J. ........................K-559, 074Mateu, L. .......................D-1419, 170Mathai, D. .......................E-196, 015Matheron, S. ..................... P-570, 075Matias, N. A. ...................L1-1653, 187Matos, J. A. ......................K-257, 022Matrakool, L. ...........P-998, 112; P-999, 112Matsa, S. ....................... F-1505, 176Matsui, K. ............F-1506, 176; F-1507, 176Matsui, M. ..........D-1456, 172; C2-1904, 236Matsumoto, S. ..........F-817, 096; F-818, 096;......... F-819, 096; F-820, 096; F-821, 096;.........F-822, 096; F-823, 096; M-981, 111Matsumoto, T. ..................L1-1657, 188Matsumura, Y. .........K-949, 107; K-1599, 182Matsuo, Y. .......................A-019, 003Matsushima, A. ........K-949, 107; K-1599, 182Matsushita, S. ...................D-1429, 171Matta, L. ......................L2-2108, 255Matte, G. R. .........C2-106, 009; C1-668, 085;.................C2-716, 088; P-1002, 112Matte, M. H. .........C2-106, 009; C1-668, 085;.................C2-716, 088; P-1002, 112Mattis, D. M. ................... F-1517, 176Maurer-Stroh, S. .................H-1569, 179Maury, E. ........................D-173, 013Maury, N. .......................K-560, 074Mavraganis, P. ..................G3-1543, 178Mavridou, E. ....................A-1938, 240Mavrou, I. .......................K-245, 021Max, B. .........................H-883, 102May, D. ........................K-1583, 181May, R. .......................L2-2112, 255May, T. .........................L2-302, 027May-Hadford, J. ..................V-386, 030Maya, J. J. ............ D-747, 092; K-903, 104;...........................L2-2108, 255Mayer, C. ........................H-891, 103Mayhew, A. .......... L1-287, 025; L1-288, 025Mazel, D. .......................B-1330, 165Mc Clanahan, R. .................A-1950, 241Mc Garry, E. ....................C2-119, 009Mc Intyre, G. F. .......A-1961, 241; A-1962, 241McBride, K. ......... L1-290, 026; L1-1666, 189McBride, S. ..................... P-1023, 112McCabe, I. .......................K-260, 023McCammon, J. A. ................ F-1534, 177McCauley, J. ....................A-1761, 200McClean, S. .....................B-1334, 165McClellan, I. ....................K-1631, 185McComsey, G. A. .................. 1152, 143McConnell, M. ..................M-1677, 190McCormick, D. ......... T-356, 029; V-391, 030McCoy, C. .......................D-163, 011McCracken, M. .....C2-1379, 169; C2-1380, 169McCray, P. B. ....................B-1322, 165McCullough, A. E. ............... T-1032, 113McDermott, L. A. .................K-471, 048McDermott, P. ...................C2-714, 088McElmeel, M. L. .................D-1433, 171McEwen, A. ....................A-1956, 241McGann, P. .........C2-725, 089; C2-1914, 237McGeer, A. ..........K-281, 024; C2-1362, 167;...............C2-1363, 167; C2-1364, 167McGill, R. L. .....................A-619, 082McGregor, J. C. .................L2-2118, 255McIntosh, S. D. ...................H-213, 017McKenney, D. ....................B-664, 084McKinnell, J. A. ........B-654, 084; B-655, 084McKinnell, J. .....................A-042, 004McLellan, D. G. ..................K-265, 023McLeod, D. ...................... F-847, 099McLin, V. A. ...................G3-1556, 178McMillan, D. ...................B-1312, 165McRoberts, J. P. .......A-602, 082; C2-1985, 244Mdluli, K. ....F-834, 098; F-835, 098; F-836, 098Meads, A. .....................L1-1667, 189Mear, J. .........................B-060, 005Méar, J. B. .......................B-050, 005Medeiros, M. ...........E-784, 094; E-788, 094;.............................E-801, 094Mediavilla, J. R. ..................C1-589, 081Medina, J. .......... L1-290, 026; L1-1666, 189Medina, V. .....................L1-1653, 187Medlock, M. .........A-1290, 163; A-1958, 241Meex, C. ......................C2-1988, 244Mehboob, S. .................... F-2072, 249Mehra, P. .......... L1-1663, 189; L1-1665, 189Mehtar, S. ......................... 484, 053Meibohm, B. ....................A-1267, 161Meier, F. A. .....................D-1416, 170Meije, Y. .............M-323, 028; T-340, 029;.................M-1700, 191; K-2077, 250Meini, M. R. ....................C1-461, 047Meinke, P. T. .................... F-1496, 176Meinz, M. ....................... F-810, 096Meis, J. F. .............M-332, 028; M-334, 028Mejstrikova, E. ................... T-344, 029Melander, C. .................... F-2069, 249Melano, R. G. ........C2-089, 008; C2-090, 008;......C1-589, 081; E-781, 093; C2-1214, 157Mélard, A. ......................H-1568, 179Melbarde-Kelmere, A. .............K-2080, 251Melchers, M. J. .........E-190, 015; E-198, 015;.............................E-803, 094Melchers, W. J. ........M-319, 028; M-988, 111;..................M-989, 111; A-1933, 240Meletiadis, J. ..........E-782, 093; A-1938, 240;.................A-1939, 240; A-1940, 240Melhem, M. .....................M-327, 028Melhem, M. S. ...................M-311, 028Melhem, M. .........A-1961, 241; A-1962, 241Melin, P. ......................C2-1988, 244Mellado, E. ......................M-321, 028Melo, L. C. .....................C2-704, 088Melo-Cristino, J. ...... C2-151, 010; G-866, 100;.............................G-865, 100Mena, A. ........................A-011, 003Mendelman, P. ...................G-1048, 114Mendes, R. E. ........C2-132, 010; C2-139, 010;.....C2-691, 087; C1-1343, 166; F-1510, 176;.....F-1511, 176; F-1512, 176; C1-1745, 197;...........................C2-1906, 237Mendez, I. A. ..................C2-1915, 237Méndez, J. .......................K-559, 074Mendez, J. .....................L1-1643, 186Mendez, M. .....................A-1767, 200Mendez-Vigo, L. .................K-2078, 250Mendonça, N. ...................C2-713, 088Mendoza, Y. ....................H-1573, 180Menegas, D. ...................G3-1543, 178Menezes, L. C. ..................D-1412, 170Mengoli, C. ...........H-216, 018; H-1579, 180Mengoni, F. ............D-740, 091; D-742, 091Menichetti, F. ....................E-796, 094Mentese, A. ...........V-394, 030; D-1405, 170Mentré, F. ............A-021, 003; A-1963, 241Mera, R. M. ......................G-862, 100Merad, M. .......................K-911, 104Mercado, D. .....................M-1694, 190Mercier, R. C. .......E-1472, 174; C1-1742, 197Mercuri, P. ......................C1-459, 047Meriem, S. .............K-250, 022; K-251, 022Merin, C. .......................L1-289, 026Merino, I. ......................C2-111, 009Merino, M. ....................C2-1902, 236Merino, P. ............ E-805, 095; P-1020, 112Final Program237

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberMerkier, A. K. ...................C1-074, 006Merlet, A. ......................K-2074, 250Merlin, J. .......................L2-302, 027Mert, G. .......................L1-960, 110Mertz, D. .............K-955, 108; K-1927, 239Meshay, M. ......................A-618, 082Mesquita, N. M. ..................K-257, 022Messaritakis, I.. . . . . . . . . . . . . . . . . . . . B-043, 005Messer, S. A. .........M-1714, 191; M-330, 028Mestres, C. A. ..........A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129; E-1465, 173Metan, G. ......................M-1701, 191Metcalf, C.. . . . . . . . . . . . . F-843, 099; F-844, 099;....................F-845, 099; F-846, 099Metchock, B. .....................D-737, 091Metzger, S. .....................D-1410, 170Meugnier, H. ....................B-1319, 165Meya, D. .......................M-1699, 191Meyer, E. .......................K-1592, 181Meyer, L. ............H-1568, 179; K-2073, 250Meyer, W. .......................M-336, 028Meyer, W. A. ....................H-1575, 180Meyers, J. ........................H-211, 017Meylan, P. . .T-343, 029; T-352, 029; L1-1221, 158Meyvisch, P. ..........A-1259, 161; A-1258, 161;............................A-1260, 161Meza, A. .......................C1-069, 006Meza, J. L. .......................K-922, 105Meziane-Cherif, D. . . . C1-458, 047; C1-1344, 166Michael, G. B. ...................C1-670, 085Michail, G. .....................B-1300, 164Michallet, M. ..................... T-360, 029Michelet, C. ......................K-267, 023Michowicz, A. ...................M-1670, 190Micic, D. ........................K-926, 105Micol, J. .........................D-772, 092Micozzi, A. ............V-393, 030; K-898, 104Microbiology and Pediatric PneumococcalWorking Group. . . . . . . . . . . . . . . . . G-866, 100Middeldorp, J. M. .................. 1724, 192Miegeville, A. F. .......B-653, 084; A-1948, 241;. . . . . . . . . . . . . . . . . . . . . . . . . . . . .F-2056, 248Miesel, L.. . . . . . . . . . . . . . . . . . . . . . . F-1496, 176Migiyama, Y. ...........B-048, 005; B-049, 005;.................. B-657, 084; B-1297, 164Migliavacca, R. ......C2-094, 008; C2-1897, 236Miida, H. ....................... F-2042, 248Mikamo, H. ..............L2-305, M-325, 028;.............M-328, 028; 027; C2-693, 087;....M-1231, 159; A-1288, 163; C2-1989, 244;............................ F-2045, 248Milanelo, L. .............P-993, 112; P-995, 112Miles, P. .........................D-736, 091Milillo, M. .....................C2-1914, 237Miller, A. .......................... 575, 077Miller, B. ........................A-641, 083Miller, D. ......................C2-1400, 169Miller, E. ........................ F-841, 099Miller, L. A. ......................G-862, 100Miller, L. .............F-1495, 175; F-1522, 177Miller, M. K. ....................G-1749, 198Miller, M. J. ....................... 1794, 206Miller, M. ............H-552, 073; H-551, 073;............................H-1574, 180Miller, T. E. ...................... P-563, 075Millett, W. ....................... F-829, 098Milligan, D. ..........F-2030, 248; F-2031, 248;..................F-2032, 248; F-2033, 248Millon, L. ......................M-1692, 190Mimoz, O. . . A-035, 004; A-037, 004; K-1757, 199Min, W. J. .......................H-554, 073Minami, H. .....................D-1461, 172Minassian, S. L. .......A-1292, 163; A-1293, 163;.................A-1294, 163; A-1295, 163Minea, B. ........................ F-811, 096Minenza, N. ....................C2-723, 089Ming Yao .......................M-1669, 190Mingbunjerdsuk, P. ...............H-1565, 179Mingorance, J. ...................D-1452, 172Mininger, C. ....................B-1308, 164Minkowski, A. .................... F-836, 098Minodier, P. ....................G3-1554, 178Minotti, C. ......................K-898, 104Miquelarena, A. ...................E-202, 015Mira, J. P. ...............P-568, 075; P-570, 075Miragaia, M. ...................C1-1740, 197Mirambell, A. ...................K-1616, 184Miranda, A. S. ...................D-1403, 170Miranda, I. M. ....................M-320, 028Mireia Puig ......................M-312, 028Mirelis, B. .......................K-931, 105Miro, E. ........................C1-593, 081Miró, E. ........................K-1621, 184Miró, J. .........................K-943, 106Miro, J. M. .............A-610, 082; B-645, 084;.........B-648, 084; K-941, 106; K-945, 106;.................K-1122, 129; E-1465, 173Miron, L. ........................ F-811, 096Mischnik, A. ....................C2-093, 008Mishali, H. .....................K-1609, 184Mishra, N. N. ..................C1-1744, 197Misset, B.. . . . . . . . . . . . . . . . . . . . . . . . K-234, 020Mitcham, J. ......................G-873, 101Mitchell, A. P. ...................M-1056, 115Mitchell, A. M. ..................B-1314, 165Mitchell, G. ...........F-1997, 246; F-1998, 246Mitchell, J. .......................A-618, 082Mitchell, J. D. ...................... 536, 069Mitchell, R. .....................L2-306, 027Mitchell, T. J. ............ 519, 065; B-1314, 165Mitev, G. M. ...................C1-1972, 242Mithal, S. ............ F-1494, 175; F-1495, 175Mitsuyama, J. ..........C2-693, 087; F-809, 096Mitsuyasu, R. ..........H-553, 073; H-1581, 180Mittal, S. ........................ F-812, 096Miura, Y. ......................L1-1657, 188Miyairi, I.. . . . . . . . . . . . . . . . . . . . . . . . D-175, 013Miyake, T. ...................... F-1509, 176Miyata, I. ........................D-175, 013Miyazaki, T. ......................V-380, 030Mizushima, D. ....................H-224, 019Moaddab, M. ...................L2-2111, 255Moeck, G. ............C2-128, 010; A-620, 082;..................D-762, 092; E-1463, 173Moellering, Jr. R. C. ................ 1112, 127Moffat, J. ....................... F-1537, 177Mohamed, J. A. ....... F-2013, 246; K-2096, 252Mohazabnia, P. ................... T-357, 029Mohin, S. ........................K-272, 024Mohsina, K. .....................C2-711, 088Moir, D. .......................... 1103, 125Moise, P. A. ......................K-276, 024Moisi, D. .......................H-1571, 180Mojica, M. F. .........C1-590, 081; C2-694, 087;.............................D-747, 092Mok, S. .........................A-611, 082Moldovan, O. ...................D-1776, 201Molero, L. ........... L1-293, 026; L1-295, 026Molina, J. . . .H-219, 019; H-889, 103; K-1924, 239Molini, B. J. .....................B-1301, 164Molinos, S. .....................D-1419, 170Molitorisz, S. ..................... P-994, 112Moll, F. L. ......................L1-965, 110Moller, K. .......................B-055, 005Mollerach, M. ......C2-1396, 169; C2-1397, 169Molstad, D. .......... A-1289, 163; F-1523, 177Molteni, C. ......................D-757, 092Mommeja-Marin, H. .....T-358, 029; T-362, 029Monaco, A. ......................B-045, 005Monahan, C. . . F-843, 099; F-844, 099; F-845, 099Mondino, S. ....................C2-1377, 169Monecke, S. ..........D-1432, 171; D-1440, 171Mongodin, E. F. .................B-1320, 165Monllau, J. .......................K-256, 022238September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberMonnet, D. L. ..................... 1789, 204Montakantikul, P. ................A-1279, 162Montalto, M. ...................L1-1667, 189Montassier, E. ........L1-283, 025; L1-285, 025;................D-1458, 172; L1-1642, 186Monteiro, F. .....................D-1428, 171Monteiro, J. .....................D-1446, 172Montejo, M. ...........T-340, 029; T-368, 029;K-938, 106; K-941, 106; K-943, 106; K-948, 107Montelaro, R. C. .......F-1490, 175; F-2061, 249Montero, M. ....................K-1624, 184Montgomery, K. ................. F-2023, 247Monti, F. ............C2-133, 010; C2-140, 010;............................ F-2067, 249Montinaro, V. ...................L2-304, 027Monto, A. ......................V-1080, 117Montoya, C. M. .................L2-2108, 255Montoya, J. G. ........M-337, 028; M-1227, 159Montrucchio, C. .................A-1769, 200Moodley, A. .....................M-1670, 190Mooi, F. R. ...........D-183, 014; B-1322, 165Moon, J. S. ...................... P-1006, 112Moon, S. ..............T-366, 029; K-907, 104;. . . . . . . . . . . . . . . . . .V-1074, 117; V-1239, 160Mooney, L. .....................A-1960, 241Moore, A. ......................B-1738, 196Moore, C. ......................A-1289, 163Moore, E. ......................C1-665, 085Moore, R. ......................H-1580, 180Mootien, J. Y. ...................L1-291, 026Mora-Rillo, M. ..................D-1452, 172Moradi, P. W. ....................M-981, 111Moradpour, D. ....................D-184, 014Morales, C. ..................... P-1000, 112Morales, E. .....................K-2093, 252Morales, J. M. .................... T-359, 029Morales, R. .....................M-1694, 190Morales Ramirez, J. ................H-891, 103Moraru, R. ....................... F-811, 096Mordechai, E. .................... P-563, 075Mordino, J. .....................K-1626, 185Moreau, P. ..........D-1458, 172; L1-1642, 186Moreillon, P. ..........B-046, 005; B-1316, 165;...........................C1-1746, 197Morency-Potvin, P. ................D-730, 090Moreno, A. ...........H-217, 018; H-222, 019;.........T-340, 029; A-610, 082; B-648, 084;........ K-943, 106; K-941, 106; K-945, 106;. . . . . . K-1122, 129; M-1228, 159; E-1465, 173Moreno, D. ...........K-912, 104; K-1597, 182;. . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1655, 188Moreno, M. ......................K-942, 106Moreno, S. ............H-217, 018; H-222, 019;. . . . . . . M-323, 028; D-743, 091; H-1567, 179;............................M-1700, 191Moreno-Bofarull, A. ...............E-205, 016Morera, M. A. ...................K-1621, 184Morfin, R. ......................C1-067, 006Morfin Otero, M. ...............C2-1373, 168Morfin-Otero, R. ................C2-1370, 168Mori, M. .......................D-1461, 172Mori, N. ........................K-918, 105Moriarty, S. R. ....................A-623, 082Morigi, M. ........................ 1799, 207Morikawa, H. .......... F-818, 096; F-820, 096Morillo, A. ...................... T-1043, 113Morinaga, Y. ...........B-048, 005; B-049, 005;.......B-657, 084; B-1297, 164; D-1460, 172Moriyama, B. ....................M-1681, 190Morizot, G. .....................M-1686, 190Moro, P. ........................G-1052, 114Morobe, I. ......................C2-101, 009Morosini, M. ...........E-205, 016; D-753, 092Morozumi, M. ......C2-1353, 167; C2-1354, 167;. . .C2-1990, 244; C2-1991, 244l; C2-1977, 243Morrill, H. J. .....................K-233, 020Morris, D. ...........C2-088, 008; C2-119, 009;......C2-122, 009; C2-706, 088; A-1294, 163Morris, M. I. .................... T-1033, 113Morrissey, I. ............E-204, 016; E-210, 016;.......C2-705, 088; C2-709, 088; D-769, 092Mortelmans, K. .................. F-1531, 177Mortensen, E. M. ................L1-297, 026Mortin, L. I. ..................... F-846, 099Morton, C. ............F-828, 097; F-2016, 247MOSAR WP5 & WP2 Study Groups,............................C2-109, 009Moscatelli, A. ...................D-1426, 171Moser, W. .......................M-977, 111Moshos, J. ............K-262, 023; K-1589, 181Moskvitina, E. ..................C2-1386, 169Moss, R. .............. V-381, 030; V-382, 030Motlagh, H. .....................M-1062, 115Motyl, M. R. ........M-1714, 191; M-1715, 191Motyl, M. . . A-008, 003; D-767, 092; A-1763, 200Moundipa, P. F. ...................H-214, 018Moura, R. ......................C2-717, 088Mourer, M. ..................... F-1527, 177Mouton, J. W. ..........B-044, 005; E-190, 015;........E-198, 015; M-332, 028; A-624, 083;........E-782, 093; E-803, 094; M-988, 111;........ M-989, 111; 1127, 131; A-1933, 240;............................A-1938, 240Moyà, B. ......................C1-1970, 242Moyaert, H. ..........C2-705, 088; C2-709, 088Mozley, P. D. ....................M-1695, 190Mpanaka, I. ....................L2-2114, 255Mu, J. .........................C2-1212, 157Muccioli, G. ....................A-1291, 163Mueller, A.. . . . . . . . . . . . . . . . . . . . . C2-1914, 237Mueller, B. A. ....................A-606, 082Mueller, N. ...................... T-343, 029Mueller, W. ......................M-977, 111Muhammed, T. ..................G-1748, 198Mühlemann, K. ..................C2-116, 009Mukabayire, O. ..................D-1421, 170Mukankwiro, T. ..................D-1421, 170Mukherjee, P. K. ....... V-385, 030; F-2015, 246Mukherjee, S. .......... V-370, 030; F-826, 097Mukhi, S. ........................V-386, 030Mukonzo, J. ......................H-893, 103Mulanovich, V. E. ..... T-1065, 116; V-1075, 117Mulet, X. ......................C1-1970, 242Mullane, K. M. ........ 1193, 154; M-1676, 190;............................K-2085, 252Mullany, P. .....................C2-1983, 243Mulleman, D. ..................L1-2103, 254Mullen, V. .....................C1-1972, 242Muller, A. E. .....................A-624, 083Muller, E. ........................ 1142, 138Muller-Serieys, C. .................B-645, 084Mullis, C. E. ....................H-1580, 180Mulvey, M. ..........C2-085, 008; C2-103, 009;...............C2-1379, 169; C2-1380, 169Munar, M. .......................A-643, 083Muniain, M. ...................L1-1658, 188Munier, A. ...........H-219, 019; C2-1399, 169Munita, J. M. ...................C1-1345, 166Muñoz, K. A. .........A-1292, 163; A-1293, 163Muñoz, P. . . .K-940, 106; K-941, 106; K-942, 106;. . . . . . . . K-943, 106; K-944, 106; K-948, 107;......T-1026, 113; T-1041, 113; M-1232, 159;............................M-1684, 190Muñoz, P. ..............T-340, 029; 1163, 146;................... V-1242, 160; 1809, 209Muñoz-Fernández, M. ............H-1567, 179Munoz-Price, L. ................... 1154, 144Munyaradzi, S. ..................A-1767, 200Muppavarapu, K. .......C2-096, 008; K-272, 024Murakami, H. ...................D-1438, 171Muraleedharan, C. ................C2-703, 088Murgolo, N. J. ...................M-1695, 190Muriel T. Mafura, Theresa Hunt ....C2-1979, 243Murillo, O. ............K-254, 022; B-647, 084;...........................L1-2102, 254Murphy, C. ...................... F-846, 099Murphy, D. G. ...................H-1571, 180Final Program239

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberMurphy, E. ......................G-870, 101Murphy, P. M. .........B-057, 005; M-1055, 115Murphy, T. M. ................... F-2028, 247Murray, B. E. .......C1-1345, 166; C2-1389, 169Murray, K. P. ....................K-1121, 129Murray, R. W. ...................C1-670, 085Musemakweri, A. .................D-775, 092Mushtaq, S. ...........C2-152, 010; E-192, 015;...................F-853, 099; F-2048, 248Mutesa, L. .......................D-775, 092Muthusamy, A. ...................K-262, 023Mutters, N. T. ...................C2-093, 008Muvunyi, C. .....................D-775, 092Myc, A. .........................G-869, 101Myers, C. ........................V-383, 030Myers, D. ......................C1-1343, 166Myers, D. E. .........K-1120, 129; K-1628, 185Mykietiuk, A. ........M-329, 028; C2-1398, 169Mylonakis, E. .......... F-1538, 177; 1868, 229Mynatt, R. P. .....................K-909, 104Myrvold, R. ..........F-2062, 249; F-2063, 249;............................ F-2064, 249NNaas, T. .............C1-066, 006; C1-072, 006;............................D-1453, 172Naber, K. G. ....................A-1285, 162Nacache, F. .....................C2-716, 088Nacy, C. A. ........................ 435, 041Nadel, S. ......................G3-1544, 178Naderer, O. J. .........A-1275, 162; A-1276, 162;............................A-1277, 162Nadimpalli, M. .................C2-1912, 237Naeem, T. .....................C2-1372, 168Nagano, N. ....................C2-1989, 244Nagano, Y. .....................C2-1989, 244Nagao, M. ............K-949, 107; K-1599, 182Nagaoka, K. ............B-048, 005; B-049, 005;.................. B-657, 084; B-1297, 164Nagashima, M. ..................L1-296, 026Nagel, J. ..............H-225, 019; T-1068, 116Nagl, M. ....................... F-2058, 249Nahmgunn, H. ...................A-038, 004Naik, R. ...............K-264, 023; K-904, 104Nailor, M. D. ....................K-1926, 239Nair, D. .......................C2-1982, 243Nair, R. .......................C2-1384, 169Najvar, L. K. ...........B-650, 084; F-823, 096;............................M-1682, 190Nakagawa, S. ....................C2-693, 087Nakai, H. ....................... F-1506, 176Nakai, T. .... F-817, 096; F-818, 096; F-819, 096;....................F-820, 096; F-821, 096Nakajima, C. ........C2-712, 088; C2-1368, 168;...........................C2-1369, 168Nakajima, K. ...........A-607, 082; A-608, 082;......K-1594, 182; K-1627, 185; M-1687, 190Nakamae, H. ....................D-1402, 170Nakamae, M. ....................D-1402, 170Nakamura, R. ................... F-1507, 176Nakamura, S. .....................V-380, 030Nakane, T. ......................D-1402, 170Nakashima, H. ....................E-780, 093Nam, H. ......................C2-1913, 237Nam, S. ........................ F-1514, 176Nannini, E. C. ..................C2-1389, 169Nanno, S. .......................D-1402, 170Napolitano, L. ...................H-1574, 180Napravnik, S. .....................H-229, 019Narbey, D. ......................L1-291, 026Nardell, E. ......................... 529, 068Nardi, S. ........................H-216, 018Nash, A. ........................ F-1515, 176Nast, C. C. .......................B-646, 084Nastasa, V. ....................... F-811, 096Nath, G. ........................V-373, 030Nation, R. L. ...........A-024, 004; A-027, 004;.........A-031, 004; E-785, 094; E-795, 094Nauclér, P. ......................C2-107, 009Naughton, T. ....................K-1611, 184Navarro, F. ...........C1-593, 081; K-1621, 184Navarro, G. .....................K-1623, 184Navarro San Francisco, C. ..........D-1452, 172Navas, D. .......................L1-285, 025Navas, E. ....H-217, 018; D-743, 091; K-943, 106Navon-Venezia, S. .................K-557, 074Nawfal, R. ......................K-1584, 181Nayak, R. ......................C2-1219, 157Naylor, C. .......................B-047, 005Ndjomou, J. ......................V-370, 030Ndzerem, E. .....................H-212, 017Neary, B. .......................M-1699, 191Neely, M. ........................A-636, 083Nelson, B. ...................... F-1537, 177Nelson, K. ...........F-2017, 247; F-2018, 247;..... F-2018a, 247; F-2020, 247; F-2023, 247;..................F-2024, 247; F-2026, 247Nelson, L. ......................L1-959, 109Nelson, M. P. .....................A-612, 082Nelson-Piercy, C.. . . . . . . . . . . . . . . . . . . . 452, 045Nembot, G. .....................H-1568, 179Neofytos, D. ....................M-1676, 190NeoMero Consortium .............G-1750, 198Nero, T. ......................... F-828, 097Net, O. .........................K-1924, 239Netea, M. G. ..........B-044, 005, M-1055, 115NETWORK Group .............. T-1040, 113Neuzil, K. M. ....................... 526, 067Nevarez Moorillón, G. V. ........... F-833, 098Neves, F. C. .....................K-1606, 183Neves, P. R. ............E-784, 094; E-801, 094Nevez, G. ........................M-333, 028Nevrekar, S. N. .................. T-1029, 113Newland, J. G. ...................... 479, 051Newton, D. W. ..................... 497, 060Neyret, P. ..............K-249, 022; K-253, 022Ndjomou, J. ...................... F-826, 097Ng, K. Y. .......................H-1569, 179Ng, K. ..........................K-561, 074Ng, O. T. .......................H-1569, 179Ng, S. B. .......................A-1959, 241Ng, T. M. ....A-614, 082; K-899, 104; K-910, 104Ngamskulrungroj, P. ...............M-336, 028Nguon, S. ....................... F-1532, 177Nguyen, B. .............D-165, 012; H-885, 102Nguyen, C. ......................K-915, 104Nguyen, D. T. ...................M-1711, 191Nguyen, J. .......................V-383, 030Nguyen, J. C. .....................K-234, 020Nguyen, J. .......................K-915, 104Nguyen, M. H. .........T-346, 029; E-786, 094;........E-792, 094; E-804, 094; K-1605, 183;.................K-1622, 184; M-1675, 190Nguyen, M. ........... T-364, 029; M-978, 111;......T-1031, 113; T-1037, 113; M-1056, 115;.....T-1069, 116; C2-1216, 157; M-1685, 190Nguyen, N. ...........M-967, 111; M-992, 111Nguyen, Q. A. ....................K-947, 107Nguyen, S. ....................... F-816, 096Nguyen, T. ...........A-1963, 241; F-2003, 246;......F-2017, 247; F-2018, 247; F-2018a, 247Nguyen, T. A. ...................M-1677, 190Nguyen-Van-Tam, J. ..............V-1080, 117NIAID Influenza Research Collaboration,.............................V-383, 030Nica, M. .......................C2-110, 009Nicco, E. ........................M-317, 028Nichol, G. .......................H-553, 073Nichol, K. ..........C2-135, 010; C2-1379, 169Nichol, K. .....................C2-1360, 167Nicholls, D. L. ..........A-628, 083; A-629, 083;...................A-631, 083; A-642, 083Nichols, A. .......................K-247, 022Nichols, K. R. ..................G3-1558, 178240September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberNichols, W. ............A-632, 083; A-634, 083;..................A-635, 083; A-1760, 200Nichols, W. W. ...................E-187, 015Nicholson, B. ....................C2-117, 009Nicholson, S. .....................K-924, 105Nickerson, E. ....................L1-288, 025Nicol, M. .......................C2-723, 089Nicolas-Chanoine, M. ................ 510, 063Nicolau, D. P. ...........A-013, 003; A-014, 003;........ A-015, 003; A-018, 003; A-020, 003;.......... A-022, 003; A-023, 004; 539, 070;........ A-625, 083; A-630, 083; A-633, 083;....... A-1287, 163; 1793, 205; K-1926, 239;................. A-1964, 241; F-2021, 247Nicoletti, A. G. .................C1-1207, 156Nicoletti, G. .....................C1-594, 081Nicolle, L. E. ....................... 544, 071Nieberg, P. ......................K-1586, 181Nielsen, E. I. .........A-1764, 200; A-1966, 241Nielsen, L. E. ....................C2-725, 089Nielsen, X. ...........D-1443, 171; D-1444, 171Nierenberg, N. E. ................ T-1025, 113Nieves, D. J. ........G3-1560, 178; G3-1561, 178Niimi, H. .......................D-1461, 172Nikaido, H. ....................... 1835, 216Nikitin, I. .......................V-1236, 160Nikolaidis, P. ....................K-2095, 252Nilkamhang, S. ...................H-894, 103Nimrichter, L. ..................... 1721, 192Ninet Bescher, B. ................G3-1541, 178Ninot, S. ....A-610, 082; B-648, 084; K-945, 106;. . . . . . . . . . . . . . . . . K-1122, 129; E-1465, 173Niranjan, V. .....................A-1245, 161Nishide, M. ...................... F-825, 097Nishijima, K. .....................H-223, 019Nishijima, T. H-224, 019; H-888, 103; H-890, 103Nishikawa, H. .................... F-809, 096Nishimoto, M. ...................D-1402, 170Nishimura, M. ....................B-056, 005Nist, A. ........................V-1080, 117Niubó, J. .......................V-1240, 160Nizet, V.. . . . . . .418, 036; 1087c, 120; F-1514, 176;............................ F-1999, 246Njihia, J.. . . . . . . . . . . . . . . . . . . . . . . C2-1380, 169Njoku, J. C. ......................K-922, 105No, D. ........................C1-1348, 166Nobre, V. ............T-1044, 113; D-1403, 170;............................K-1606, 183Noel, A. R. ............A-628, 083; A-629, 083;........ A-631, 083; A-642, 083; D-763, 092;.............................E-793, 094Nogueira, K. S. .................C1-1207, 156Nolan, T. ........................ F-851, 099Nolla, J. .......................L1-2102, 254Nomoto, A. ..................... F-1509, 176Nomura, N. ...........C2-693, 087; F-809, 096Nonato, B. .....................C2-1376, 169Nonnenmacher, C. ...............K-2100, 253Nordmann, P.. . . . . . . . . .A-042, 004; C1-061, 006;......C1-063, 006; C1-066, 006; C1-071, 006;......C1-072, 006; C1-078, 006; C1-465, 047;...... C1-587, 081; C1-591, 081; D-745, 092;......D-748, 092; C1-1202, 156; D-1453, 172Nørgaard, M. .....................G-876, 101Noritake, K. ..................... F-2042, 248North, J. ......................... F-815, 096Norton, S. A. ...................... 1086, 119Nosanchuk, J. ....................... 549, 072Notermans, D. ....................D-183, 014Nottingham, M. .................. F-847, 099Nouch, S. ........................V-371, 030Nouér, S. A. ..........K-1601, 182; M-1690, 190Noureddine, M. ...................K-938, 106Noury, P. .......................C2-091, 008Nouwen, J. L.. . . . . . . . . . . . . . . . . . . . . B-058, 005Novack, V. .......................H-232, 019Novakova, J. ..................... F-1532, 177Novick, R. P. ...................C2-1906, 237Novick, S. ...................... P-1022, 112Novick, S. J. .....................A-1275, 162Novikov, A. ..........M-985, 111; M-1059, 115Nucci, M. ............M-329, 028; M-1234, 159;............................M-1690, 190Nucleo, E. ..........C2-094, 008; C2-1897, 236Nuermberger, E. .................. F-836, 098Nukaga, M. ..........C1-076, 006; C1-460, 047Nunes, L. S. ....................C2-1375, 168Nuñez, J. M. ....................K-1624, 184Nutman, T. B. ..................... 1890, 234Nyberg, J. ........................A-032, 004Nyc, O. ......................... T-344, 029OO’Brien, W. ...........E-777, 093; F-1525, 177;............................ F-1526, 177O’Connor, L. .........A-1765, 200; A-1942, 240;............................A-1944, 240O’Connor, R. D. ................C1-1969, 242O’Day, T. .......................B-1736, 196O’Dowd, V. .....................B-1738, 196O’Hanley, P. ...........F-1524, 177; F-1528, 177O’Riordan, W. D. ...............L1-1663, 189Obed, M. ......................C2-1398, 169Obel, N. ........................H-1916, 238Obi, C. L. ......................C2-101, 009Obunge, O. K. ..................C2-1371, 168Ochi, T. ........................M-1226, 159Oda, K. ......................... V-390, 030Oda, S. .........................M-1231, 159Odeigah, P. ....................C2-1371, 168Oderinde, B. S. ..................G-1748, 198Odugbemi, T. ....................C2-108, 009Oelschlaeger, P. ..................C1-065, 006Oethinger, M. ...................D-1432, 171Offenstadt, G. ....................D-173, 013Offermann, D. ................... F-2016, 247Offermann, L. ................... F-2016, 247Ogwal-Okeng, J. ..................H-893, 103Oh, D. ................H-230, 019; K-916, 104Oh, H. ..........................K-916, 104Oh, M. ..........................K-908, 104Ohba, S. ........................ F-1509, 176Ohgami, K. ......................G-871, 101Ohno, T. ......................C2-1989, 244Ohuchi, N. .....................C1-460, 047Ojemhen, O. ........C2-121, 009; C2-1378, 169Ojielska, M. ...................... P-566, 075Oka, S. .....H-223, 019; H-224, 019; H-888, 103;.............................H-890, 103Okada, A. ..............F-818, 096; F-819, 096Okada, K. .......................M-326, 028Okada, T. ......................C2-1977, 243Okade, H. ......................C2-693, 087Okamura, H. ....................D-1402, 170Okamura, N. .....................E-780, 093Okatani, T. ......................M-1226, 159Oksenhendler, E. ................... 1107, 126Okumura, R. .........F-2037, 248; F-2038, 248;............................ F-2045, 248Okusanya, O. O. .......A-620, 082; A-1261, 161;......A-1262, 161; A-1263, 161; A-1266, 161;......A-1269, 162; A-1270, 162; A-1271, 162Olaru, I. D. .....................C2-110, 009Oldach, D. ...........A-1286, 162; A-1269, 162Olesen, B. ......................C2-687, 087Olin, J. T. ........................V-397, 030Oliva, A. ........................D-165, 012Oliveira, D. E. ...................C1-668, 085Oliveira, L. G. ..................G3-1557, 178Oliveira, N. N. ...................C2-704, 088Oliveira, S. ......................C2-717, 088Oliveira, V. G. ..................C2-1376, 169Oliver, A. .............C1-593, 081; A-011, 003;...........................C1-1970, 242Olivier, L. ......................K-2098, 252Final Program241

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberOlivo, M. .......................M-1674, 190Olsen, D. B. ..................... F-1496, 176Olsen, K. M. .....................K-922, 105Olson, J. A. ...........M-992, 111; M-967, 111Olyaei, A. .......................A-643, 083Omer, S. B. ....................... 1151, 142ONERBA .......................K-237, 020Ong, A. T. .......................M-313, 028Ong, V. ..............F-2026, 247; F-2027, 247Onio, A. .......................C2-1379, 169Onishi, J. ........................ F-810, 096Ono, E. .......................G3-1557, 178Onodera, Y. ...........F-2038, 248; F-2039, 248Onsomearng, S. ...................M-976, 111Onsøyen, E. ............1105, 125; F-2062, 249;. . . . . . . . . . . . . . . . . . F-2063, 249; F-2064, 249Onufrak, N. ............A-615, 082; A-617, 082Onyejepu, N. ...................C2-1371, 168Oosting, M. ......................B-044, 005Opperman, T. J. ................... F-816, 096OPTIPRIM ANRS Study Group . . . H-1568, 179Or, Y. S. ........................B-1303, 164Oramasionwu, C. U. ..............L1-297, 026Orcajo, J. ........................K-940, 106Orellana, M. A. ..................K-2093, 252Orenstein, R. ....................M-1697, 191Oresco, C. P. ....................C2-704, 088Origüen, J. ........... T-1071, 116; K-2091, 252Oriol, I. ........................V-1240, 160Orlando, G. .....................L2-304, 027Orlov, B. .......................L1-962, 110Ortatatli, M. ...................C2-1980, 243Orth, D. ........................ F-2058, 249Ortiz, G. .......................K-1621, 184Ortíz, J. .........................D-743, 091Osherov, N. ..........M-985, 111; M-1059, 115Osmolski, J. R. ....................E-808, 095Osorio, L. E. .....................K-903, 104Østergaard, L. ..................L1-1650, 187Osterhaus, A. ....................V-1080, 117Ostermann, H. ...... L1-290, 026; L1-1666, 189Ostrowsky, B. ....................K-1634, 185Otelea, D. ......................D-1776, 201Oteo, J. ..............C1-593, 081; K-942, 106Otero, D. .......................K-1601, 182Otero, J. ........................K-2093, 252Otvagin, I. V. ....................L1-299, 026Ouachée, M. ..................... T-363, 029Ouakki, M. .....................V-1076, 117Ouertatani-Sakouhi, H. ...........B-1333, 165Ovbiagele, B. .....................H-228, 019Ovetchkine, P. ..................G3-1554, 178Oxbrow, M. .....................B-1738, 196Ozkaya Parlakay, A. ....L1-964, 110; A-1941, 240Ozkutuk, N.. . . . . . . . . . . . . . . . . . . . C2-1367, 168Ozsurekci, Y. .........L1-964, 110; A-1941, 240Ozyurt, M. ........C2-1367, 168; C2-1394, 169;. . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1430, 171PPaccaly, A. ......................A-1255, 161Pace, S. ........................A-1769, 200Pacheco, R. ........... D-747, 092; K-903, 104;...........................L2-2108, 255Pachon, D. P. ...................C2-1915, 237Pachón, J. .......................B-1329, 165Packham, D. ....................M-1680, 190Paderu, P. ............ F-822, 096; M-1678, 190;............................M-1715, 191Padilla, B. ............K-948, 107; V-1242, 160Paesmans, M. ..........T-1028, 113; T-1046, 113Pagadala, S. R. .................... F-847, 099Pagani, L. . .C2-094, 008; K-929, 105; K-954, 108;.....K-956, 108; C2-1211, 157; C2-1897, 236;............................K-2075, 250Pagani, N. ......................A-1769, 200Paganini, H. ....................C2-1910, 237Page, M. G. ...................... F-842, 099Pahissa, A. . . . T-340, 029; T-368, 029; K-931, 105;........K-937, 106; K-938, 106; K-1758, 199Pai, M. .........................K-1755, 199Paige, D. .......................A-1264, 161Painter, R. E. .................... F-1496, 176Painter, T.. . . . . . . . . . . . . . . . . . . . . . . L2-306, 027Painter, W. ..............T-358, 029; T-362, 029Paiva, L. F. ......................K-1606, 183Paixao, M. ......................M-1690, 190Pajot, O. ........................A-021, 003Palavecino, E. L. ................C2-1390, 169Palefsky, J. ........................ 1134, 134Palella, F. ........................H-556, 073Palla, M. .............K-262, 023; K-1589, 181Pallares, E. .......................D-743, 091Pallarés, M. .....................C2-111, 009Pallares, R. ......................C2-690, 087Pallecchi, L. .........C2-700, 087; C1-1205, 156Pallen, M. J. ........................ 423, 038Palma, P. .......................H-1921, 238Palmeiro, J. K. .......C2-087, 008; C1-1207, 156Palmer, H. R. ...................L2-2111, 255Palmer, J. T. ..................... F-2016, 247Palomar, M. .....................K-1758, 199Palomino, J. .....................K-1924, 239Palomo, F. S. ....................D-1412, 170Palù, G. ..............H-216, 018; H-1579, 180Palzkill, T. G. ........C1-462, 047; C1-1204, 156Pamulapati, C. ...................A-1243, 161Pan, S. ..............K-270, 024; L1-1654, 188Panagea, T. .......................K-246, 021Pancholi, P. ......................D-756, 092Panchumarthi, V. R. ...............K-920, 105Panda, S. .......................D-1437, 171Pandey, B. D. .......C2-1369, 168; C2-1368, 168Pandori, M. .....................L2-308, 027Pandya, M. ..................... F-2043, 248Panesso, D. ....................C1-1345, 166Pang, J. .............. F-1499, 176; C2-698, 087Pankey, G. A. ....................M-1717, 191Pannaraj, P. S. .............1160, 145; 1801, 207Paño, J. ..........................K-943, 106Paño-Pardo, J. R. .................D-1452, 172Pantel, A. .......................B-1327, 165Papadakis, J. ......................B-043, 005Papadomichelakis, E. ...............K-245, 021Papalia, M.. . . . . . . . . . . C1-074, 006; D-1455, 172Papanicolaou, G. ........ T-361, 029; T-362, 029Papasavas, P. K. ..................A-1287, 163Papatheodorou, P. ................ F-1537, 177Papenburg, J. .................... V-1076, 117Papoutsaki, V. ....................E-799, 094Papp-Wallace, K. M. . . .C1-076, 006; C1-460, 047;. . . . . . . C1-463, 047; C1-464, 047; F-847, 099Pappas, P. G. ............546, 072; M-1225, 159Papy, E. ........................L1-957, 109Paquet, A. ......................H-1574, 180Paradiso, P. R. ..................... 1884, 232Paran, Y. ............M-985, 111; M-1059, 115Paranhos-Baccala, G. ..............D-172, 013Paraschiv, S. .....................D-1776, 201Pare, J. .........................K-1122, 129Paret, G. ......................G3-1545, 178Parienti, J. J. ........ L1-2104, 254; L2-2117, 255Parisi, S. G. ...........H-216, 018; H-1579, 180Park, B. ........................M-1677, 190Park, C. .......................C2-1975, 243Park, H. ......................... T-366, 029Park, J. .... T-366, 029; K-908, 104;C2-1215, 157;. . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1256, 161Park, K. . . . D-755, 092; D-741, 091; K-2092, 252;....... K-907, 104; V-1239, 160; B-1298, 164Park, S. ............. V-1074, 117; V-1239, 160Park, S. Y. ......................C2-137, 010242September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberPark, S. .....T-366, 029; D-741, 091; K-907, 104;.....V-1074, 117; V-1239, 160; C2-1216, 157;...... K-1587, 181; K-1588, 181; K-1632, 185Park, Y. . . . D-755, 092; C2-112, 009; F-2060, 249Parker, M. ....................... F-828, 097Parquin, F. .......................A-035, 004Parsons, T. L. ....................H-1570, 179Pascale, J. M. ....................H-1573, 180Pascual, A. ...........C1-683, 086; C2-707, 088;...........................L1-1658, 188Pascual, M. ...................... T-352, 029Pascual, V. ......................K-1621, 184Pasculle, W. ....................C2-1216, 157Paskalis, H. ......................K-562, 074Pasqualotto, A. C. .....M-337, 028; M-1227, 159Pasquau Liaño, J. ......L1-289, 026; H-1921, 238Passadore, L. F. ...................G-861, 100Passet, V. .......................C2-088, 008Pasteran, F. .......... C2-084, 008; D-746, 092;...........................C2-1217, 157Patel, D. .............T-367, 029; C1-1341, 166;................C1-1747, 197; K-1923, 239Patel, G. A. .....................K-1630, 185Patel, H.. . . . . . . . . . . . . . . . . . . . . . . . A-1960, 241Patel, J. .................H-883, 102; 1177, 150Patel, K. ......................... F-827, 097Patel, N. ..............A-606, 082; K-1123, 129Patel, P. .............A-1246, 161; A-1272, 162Patel, R. .....D-170, 012; K-471, 048; B-652, 084;............................D-1774, 201Patel, S. .........................K-281, 024Patel, S. N. ...........C2-089, 008; C2-090, 008;...........................C2-1214, 157Patel, S. .........................K-946, 106Paterson, D. ...............1113, 127; 1184, 151Paterson, D. L.. . . . . . . .C2-112, 009; C2-689, 087;......... C2-692, 087; E-795, 094; 1810, 209Pathan, R. ......................K-2095, 252Patriarca, P. .....................G-1053, 114Patricia Muñoz ...................M-312, 028Pattabiraman, N. .................C1-673, 085Patterson, T. F. ............456, 046; B-650, 084;......F-823, 096; M-1225, 159; M-1674, 190;............................M-1682, 190Patti, R. M. ......................E-807, 095Pau, C. P. .......................H-1570, 179Paukner, S. .........L1-1660, 189; C1-1971, 242Pauli, E. ............... F-839, 098; F-840, 098Pavell, A. M. .....................K-278, 024Pavez, M. .......................C2-717, 088Pavie, J. .........................H-886, 102Pavliakova, D. ....................G-870, 101Pavlovic, J. ....................... T-369, 029Pawlak, J. .......................E-1484, 174Paxton, L. A. ....................H-1570, 179Payne, L. J. .............F-842, 099; F-2066, 249Paz, C. .........................L2-303, 027Pazhoor, A. ......................D-727, 090Pean, Y. .........................K-237, 020Pearce, D. D. .....................H-228, 019Pearlman, H. ....................A-1936, 240Pearson, A.. . . . F-843, 099; F-844, 099; F-845, 099Pearson, J. ......................E-1475, 174Pease, J. ........................B-1311, 165Peck, K. R. ..........C2-1366, 167; C2-137, 010;.................K-1587, 181; K-1588, 181Pedrero, S. .......................K-254, 022Pedrosa, M. ......................D-732, 091Peet, N. P. ....................... F-816, 096Peetermans, W. E. ...............L1-1641, 186Peffault Delatour, R. ..............D-1778, 201Pegg, K. M. .....................C1-065, 006Peghin, M. ......................M-1228, 159Peirano, G. ...........K-561, 074; C2-1210, 157;. . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1448, 172Peiris, M. ......................... 1732, 195Peláez, T. . . . M-321, 028; K-470, 048; E-806, 095;................M-1684, 190; M-1688, 190Peleg, A. Y. ......................K-558, 074Pelegrín, I. .......................B-658, 084Pelegrin, I. ...................... V-1240, 160Pellett, P. ......................G3-1546, 178Peltier, J. ............. B-1337, 165; B-1338, 165Pemán, J. . . . M-321, 028; M-329, 028; K-950, 107Peña, C. .........................K-938, 106Peng, H. Y. ......................H-554, 073Peng, L. F. .......................V-377, 030Peng, W. .......................C2-083, 008Penman, A. ......................D-185, 014Penteado, S. ......................K-913, 104Peoples, A. ....................... F-829, 098Peppercorn, A. ...................A-1246, 161Percin, D. ......................C2-1980, 243Perego, C. .......................K-934, 105Pereira, D. ...................... F-1505, 176Pereira, J. .......................K-1603, 183Pereira, M. ............T-1034, 113; T-1036, 113Pereira, P. S. ....................C2-1218, 157Pereira, R. H. .....................D-731, 090Peres, M. M. .....................D-746, 092Perez, A. .......................C1-672, 085Perez, C. E. ..................... P-1000, 112Perez, C. ....................... F-1518, 176Perez, F. . . C2-092, 008; C2-692, 087; C2-720, 089Perez, G. ........................B-045, 005Perez, J. A. ......................A-1968, 241Pérez, J. .............. T-340, 029; K-1621, 184Pérez, M. .......................M-1688, 190Pérez C. M. ...........P-1015, 112; P-1016, 112Perez Gomez, H. ................C2-1373, 168Perez Granda, M. ................K-2101, 253Pérez Tanoira, R. .................L1-958, 109Pérez-Elías, M. .........H-217, 018; H-222, 019Pérez-Llarena, F. ......C1-070, 006; C1-593, 081Pérez-Trallero, E. ...............C2-1358, 167Perfect, J. ............M-977, 111; M-1055, 115;............................M-1703, 191Pericas, J. M. ...........A-610, 082; B-648, 084;.......K-945, 106; K-1122, 129; E-1465, 173Perilli, V. ....................... T-1040, 113Perin, S. ......................... P-566, 075Périn-Dureau, F. ..................A-035, 004Perkhofer, S. ....................M-1708, 191Perkins, M. ........................ 534, 069Perlin, D. S. ..........F-822, 096; C2-1216, 157;.....M-1678, 190; M-1710, 191; M-1715, 191Perotti, M. ......................D-1426, 171Perovic, O. .......................D-773, 092Perreten, V. .....................C2-116, 009Perri, M. B. ......................K-912, 104Perrier, A. .......................K-956, 108Perrone, R. ......................A-1247, 161Persing, D. H. ....................K-469, 048Pesano, R. ......................H-1575, 180Pescetto, L. .....................D-1426, 171Pesho, M. ....................... F-1515, 176Peskova, P. ......................M-1720, 191Pessacq, P. .....................C2-1398, 169Pessoa, D. ...................... P-1012, 112Pestana, A. ......................C2-717, 088Pestel-Caron, M. ...... B-1337, 165; B-1338, 165Peters, G. .......................E-1483, 174Peters, R. P. ......................G-870, 101Petersen, C. .....................A-1255, 161Petersen, I. .....................L1-1645, 186Peterson, E. J. ................... F-1535, 177Peterson, M. L. .................. F-1517, 176Petit, G. ........................G-1051, 114Peto, T. E. .......................K-474, 048Petraitiene, R. ....................M-981, 111Petraitis, V. ......................M-981, 111Petraityte, E. .....................M-981, 111Petri, W. A. .............. B-047, 005; 507, 062Petrikkos, G. ...........K-245, 021; K-246, 021Final Program243

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberPetroni, A. ...........C2-084, 008; C2-701, 087;.................D-759, 092; C2-1217, 157Petropoulos, C. ..................H-1574, 180Petrosillo, N. .................... T-1040, 113Petschulies, M. ..................C1-667, 085Pettit, N. ........................K-279, 024Peves Rios, W. ..................G3-1553, 178Pfaff, P. ...........C1-1346, 166; C1-1347, 166Pfaller, M. ......................A-1929, 240Pfaller, M. A. .........M-330, 028; M-1714, 191Pfeffer, K. ......................C1-588, 081Pfeiffer, C. ......................D-1432, 171Phan, L. T. ......................B-1303, 164Phee, L. ....D-761, 092; E-797, 094; B-1299, 164Phillips, P. ......................M-1233, 159Piazza, A. ...........C2-094, 008; C2-1897, 236Picazo, J. J. ............ E-805, 095; P-1020, 112Piddock, L. J. ....................C1-674, 086Pierard, D. ...................... F-2029, 247Pierrotti, L. C. ...................K-1603, 183Piet, J. R. ......................L1-1651, 187Pietersma, F. .................... F-1516, 176Pignatari, A. C. ...... C2-685, 087; D-1412, 170;................ D-1446, 172; E-1481, 174Pigrau, C. ......................K-1758, 199Pilewski, J. ....................... T-364, 029Pillai, D. ......................G3-1562, 178Pillar, C.. . . A-008, 003; F-2019, 247; F-2065, 249Pillet, S. .........................D-178, 013Pilligua-Lucas, M. ................B-1303, 164Pilotte, J. ........................D-751, 092Pina-Vaz, C. ..........M-320, 028; F-1492, 175Pina-Vaz, I. ..................... F-1492, 175Pinho, M. D. ....................C2-151, 010Pini, B. .............. D-757, 092 C2-1211, 157Pinilla, B. ........................K-944, 106Pino, M. ............C1-466, 047; C1-678, 086Pinsky, B. A. ...........T-355, 029; T-1070, 116Pintado, V. M-323, 028; M-1700, 191; K-2077, 250Piontkowsky, D. ...................H-879, 102Pipa, E. .......................G3-1543, 178Pippo, T. ........................G-874, 101Piret, J. ..........................V-392, 030Píriz, M. .......................K-1623, 184Pisano, J. ........................K-279, 024Piscitelli, S. .....................A-1249, 161Piselli, P. ....................... T-1040, 113PISOT study group ............... T-1041, 113Pitman, M. C. ...................C2-689, 087Pitout, J. D. ..........K-561, 074; C2-1210, 157;..............................D-1448, 172Pitrak, D. L. ....................K-2085, 252Pitre, M. ............K-1590, 181; K-1591, 181Pitt, G. R. ...................... F-2016, 247Pitta, T. ........................M-1702, 191Pittet, D. ....K-560, 074; K-914, 104; K-929, 105;........K-954, 108; K-956, 108; K-2075, 250;............................K-2083, 251Pittet, L. F. ....................G3-1556, 178Pizzorno, M. A. .................. V-1079, 117Planche, T. D. ........ D-160, 011; K-1754, 199;............................K-1759, 199Planes, A. M. ..........K-937, 106; K-1758, 199Plantier, J. C. .....................H-886, 102Plantinga, T. S. ........B-044, 005; M-1055, 115Plata, A. ...............K-938, 106; K-943, 106Plata, K. B. .....................E-1478, 174Platt, R. W. .....................K-1755, 199Playford, E. G. ...................M-313, 028Plevneshi, A. .......C2-1362, 167; C2-1363, 167;...........................C2-1364, 167Plouzeau, C. .....................A-039, 004Plovsing, R. P. ....................B-055, 005Ploy, M. ............ C1-666, 085; D-1408, 170;................D-1441, 171; C1-1739, 197Po-Ren Hsueh ...................M-1669, 190Pockros, P. J. ....................V-1236, 160Podczervinski, S. .................. T-353, 029Podnecky, N. ..........F-2022, 247; F-2033, 248Poggio, J. ......................C2-1398, 169Pogue, J. M. ............A-034, 004; K-272, 024;.........E-787, 094; K-902, 104; K-906, 104;..................K-909, 104; K-1604, 183Poinhos, R. ......................H-227, 019Poiree, S. .......................M-1707, 191Poirel, L. ............C1-061, 006; C1-063, 006;......C1-071, 006; C1-078, 006; C1-465, 047;.........C1-587, 081; C1-591, 081; 514, 064;...........................C1-1202, 156Poirier, A. .......................V-389, 030Polgreen, P. M. ..................K-1611, 184Polisetty, R. ......................A-618, 082Politikos, I.. . . . . . . . . . . . . . . . . . . . . . . T-354, 029Pollard, A. J. ...........440, 042; G3-1544, 178Polzoni, M. ..................... T-1040, 113Pomar, V. ........................K-256, 022Pommier, S. ..................... F-2016, 247Pomraning, K. R. ................C1-1972, 242Ponce, B. ......................L2-2110, 255Pong, S. .......................G3-1562, 178Pong-Porter, S. .....C2-1362, 167; C2-1364, 167Ponniah, M. P. ...................M-1713, 191Pontikos, M. .....................M-972, 111Pool, B. ......................... F-828, 097Poonwan, N. .....................M-336, 028Popoiu, M. ......................C2-110, 009Poppen, P. J. ......................H-213, 017Porcher, R. .............H-219, 019; H-889, 103Porter, K. ........................ F-828, 097Portillo, M. E. ....................K-258, 022Portinari, R. ...................... T-357, 029Portnoy, Y. A. ...................A-1967, 241Porto, A. P.. . . . . . . . . . . . . . . . . . . . . . C1-669, 085Portu, J. .........................K-942, 106Pos, K. M. ........................ 1836, 216Posfay-Barbe, K. M. ....G3-1556, 178; 1083, 118Poskly, B. .......................C2-112, 009Postelnick, M. ....................K-271, 024Pote, L. A. ...................... T-1029, 113Potel, G. ....B-051, 005; B-054, 005; E-203, 016;.......L1-283, 025; L1-285, 025; B-651, 084;......B-653, 084; L1-1224, 158; B-1335, 165;.....D-1458, 172; L1-1642, 186; A-1948, 241;............................ F-2056, 248Potoski, B. A. ..........K-275, 024; K-1123, 129Potron, A. C1-061, 006; C1-063, 006; C1-591, 081Pouch, S. M. ..........T-1034, 113; T-1036, 113Poudel, A. .........C2-1368, 168; C2-1369, 168Poudyal, A. ......................E-795, 094Poulakou, G. .....................K-245, 021Poulsen, S. D. ....................B-055, 005Poupet, H. ......................D-1441, 171Pournaras, S. ....................B-1300, 164Poutanen, S. M. ........K-281, 024; K-1590, 181;............................K-1591, 181Poutsiaka, D. D.. . . . . . . . . . . . . . . . . . T-1025, 113Poveda, E. ......................H-1576, 180Póvoa, H. C. ...................C2-1383, 169Powderly, B. ....................... 1807, 209Powell, L. C. ..........F-2063, 249; F-2064, 249Power, P. ............C1-459, 047; C1-466, 047;...........................C1-1206, 156Powers, R. A. ....................C1-467, 047Poxton, I. ........................K-927, 105Poyart, C. .......................D-1441, 171Poynten, I. M. ...................L2-301, 027Poza, M. ...........C1-672, 085; C2-1902, 236Pozzetto, B. ......................D-178, 013Prabhakara, S. ...................B-1315, 165Praestgaard, J. .........B-664, 084; A-1281, 162;. . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1282, 162Pranatharthi, C. ................... T-367, 029Prasad, R. .......................M-975, 111Prattes, J. ........................V-398, 030Prazuck, T. .....................L1-1639, 186Prendergast, A. .................... 1872, 230244September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberPrentice, A. M. ..................... 505, 062Press, E. G. .E-786, 094; E-804, 094; M-1675, 190Press, R. A. ......................K-273, 024Preston, L. ......................C2-725, 089Prevalence of Multiresistant Microorganisms(PMM)Study Group ...........C2-1382, 169Prevots, R. .......................M-314, 028Price, C. S. ...........G-1054, 114; D-1410, 170Price, D. ........................ F-2016, 247Price, L. L. ...................... T-1025, 113Prieto, S. ..........C2-1396, 169; C2-1397, 169Prince, W. T. ...................L1-1660, 189Principe, L. ......................D-757, 092Principi, N. ........G3-1549, 178; G3-1553, 178Pritchard, M. F. ........F-2063, 249; F-2064, 249Pritt, B. S. ...............D-174, 013; 447, 044Priyadarshini, K. .................K-1618, 184Prochaska, R. R. ......E-1463, 173; E-1467, 173Procop, G. W. ....................D-735, 091Proctor, R. A. ...........A-596, 082; A-597, 082;.............................A-599, 082Prokocimer, P. ........A-1292, 163; A-1293, 163;.....A-1294, 163; A-1295, 163; L1-1664, 189;...........................L1-1665, 189PROMULGA ...................M-1688, 190Prósper, L. ......................H-1576, 180Prueller, F. ......................D-1404, 170Pryor, M. ........................ F-828, 097Puchades, F. ......................M-329, 028Pugh, M. V. .....................L1-297, 026Pugliese, F. ...................... T-1040, 113Puig, C. .......................C2-1974, 243Puig, L. .........................K-258, 022Puig, M. .....T-368, 029; K-948, 107; K-950, 107Puimé, A.. . . . . . . . . . . . . . . . . . . . . . . .M-327, 028Pujol, M. ............K-254, 022; C2-1395, 169Pulluru, H. .......................A-034, 004Punab, M. ......................L2-310, 027Punt, N. .........................A-624, 083Pupaibool, J. ..................... F-813, 096Puro, V. ........................ T-1040, 113Putney, K. .....................L2-2111, 255Puzniak, L. A. ........K-1120, 129; K-1628, 185Pym, A. ........................A-1258, 161Pyrgos, V. ........................M-314, 028QQi, C. .... B-1323, 165; B-1326, 165; K-1614, 184Qiang, C. ........................K-933, 105Qin, X. .........................B-1332, 165Qiu, F. ..........................K-922, 105Qiu, Y. L. ....................... F-1502, 176Quach, C. ......................K-1755, 199Quale, J. ......................... F-841, 099Que, Y. A. ............B-046, 005; K-2088, 252Queiroz-Telles, F. ................M-1234, 159Quelet, S. ........................V-375, 030Quentin, C. .....................C2-091, 008Quentin, R. ......................D-176, 013Quentin-Noury, C. ...............C2-719, 089Quereda, C. ......................H-217, 018Quesada, M. ........C2-1358, 167; D-1419, 170Quesnell, R. ..................... F-2034, 248Quick, M. .....................C2-1384, 169Quiles, M. G. ...................D-1412, 170Quinart, A. ......................D-164, 012Quinn, C. L. .................... F-1517, 176Quinn, J. P. .......... C2-694, 087; D-747, 092;...........................C1-1745, 197Quinn, T. C. ....................H-1580, 180Quinson, A. ......................H-877, 102Quintanilla, N. ..................K-2093, 252Quintero, R. ...................C2-1914, 237Quinteros, M. G. ..................E-202, 015Quintiliani, R. ....................A-020, 003Qureshy, M. S. ..................C2-1981, 243RRaab-Traub, N. .................... 1722, 192Raad, I. I. ............F-2012, 246; F-2013, 246;...... F-2014, 246; K-2082, 251; K-2096, 252Raanani, E. .....................L1-962, 110Rabaud, C. ............. K-237, 020; P-566, 075Rabiais, S. .......................H-878, 102Rabinovich, R. ..................... 1824, 211Rabinovitch, M. D. ...............V-1241, 160Raboud, J. M. ...................H-1920, 238Racine, F. .......................A-1763, 200Radice, M. ...........C1-074, 006; C2-700, 087;.................C2-718, 089; D-1455, 172Radigan, E. .....................K-1585, 181Rae, W. ........................M-1670, 190Rafailovich, M. H. ................. P-997, 112Rafalskiy, V. V. ...................L1-299, 026Raffay, A. .......................C2-079, 007Raggam, R. B. .........V-398, 030; D-1404, 170Raghubir, N. ....................C2-150, 010Rahav, G. ........... L1-962, 110; L1-1640, 186Rahim, Z. M. ..................C2-1369, 168Rahman, M. .....................H-228, 019Railkar, R. ..........M-1676, 190; M-1678, 190;............................M-1695, 190Rainey, G. ......................B-1734, 196Raiz, S. ........................G-1050, 114Raji, M. A. ..........C2-121, 009; C2-1378, 169Rajuri, S. D. ......................K-272, 024Rallu, F. .............D-730, 090; G3-1554, 178Ramalho, P. A. ................... F-1492, 175Ramalingam, K. .................. F-2010, 246Raman, K. ......................K-1926, 239Ramanathan, S. ..................A-1250, 161Ramasubramanian, V. ....P-564, 075; P-565, 075;............................ P-1003, 112Rambaud, C. .....................D-157, 011Ramírez, I. ...................... T-1026, 113Ramirez, M.. . . . . . . . . .C1-074, 006; C2-151, 010;.............................G-866, 100Ramírez, M.. . . . . . . . . . .G-865, 100; D-1455, 172Ramonet, M. ..........P-1015, 112; P-1016, 112Ramos, A. ....................... T-340, 029Ramos, E. .......................G-873, 101Ramphal, R.. . . . . . . . . . . . . . . . . . . . . . K-274, 024Ramsay, C. ........................ 1729, 194Rana, S. W. .....................C2-703, 088Rane, H. S. ..................... F-2000, 246Ranfaing, J. .....................B-1317, 165Rao, E. P. ....................... F-2043, 248Rao, G. G. .............A-016, 003; A-024, 004;..................A-1243, 161; E-785, 094Rao, K. ..........................K-926, 105Raoult, D. ...............P-1011, 112; 449, 044Rapoport, M. ..........C2-084, 008; D-746, 092Raporport, M. ..................C2-1217, 157Rasigade, J. P. ......... B-1317, 165; B-1319, 165Rasmussen, A. ................... T-1072, 116Ratanasalink, W. .................. P-998, 112Rath, B. .............A-1245, 161; G-1749, 198Rath, P. M. ......................M-335, 028Rathi, C. .......................A-1267, 161Ravic, M. ....................... F-1530, 177Ravn, P. ........................H-1919, 238Rawal, M. .......................M-975, 111Rawlings, M. .....................H-881, 102Rawte, P. .......................C2-090, 008Ray, A. J. .............C2-720, 089; H-892, 103Raymond, F. ...................G3-1541, 178Rayner, C. R. .........A-1245, 161; A-1243, 161;............................A-1244, 161Rearden, P. ......................M-1060, 115Rearte, A. ............P-1015, 112; P-1016, 112Redding, S. W. ..................M-1674, 190Final Program245

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberReddy, K. R. ..................... F-848, 099Reddy, M. ......................A-1243, 161Reddy, S. ......................L2-2112, 255Reese, K. A. ....................C1-1972, 242Reeve, M. ...........A-1956, 241; A-1289, 163Rege, S. .......................L1-2105, 254Regnouf-de-Vains, J. .............. F-1527, 177Reguera, J. .......................K-942, 106Reiberger, T. ....................H-1918, 238Reid, D. ........................D-1442, 171Reif, S. ........................G3-1545, 178Reigadas, E. ..........E-806, 095; M-1232, 159;............................K-2090, 252Reimnitz, P. ......................B-044, 005Reiner, N. ........................ 1723, 192Reingold, A. ....................... 532, 068Reinstrup, L. .................... P-1005, 112Reinwald, M. .........M-335, 028; M-1704, 191Reis, H. ........................M-1690, 190Reisenberg, K. ...................K-1610, 184Reitzel, R. ...........F-2012, 246; F-2014, 246;............................K-2082, 251Relich, R. ......................C2-1213, 157Reller, M. E. ...................... 1101, 124Rello, J. .........................K-951, 107Remont, L. ....................C2-1988, 244Rempel, H. ....................C2-1986, 244Remy, J. M. ...........F-1521, 177; F-1522, 177Renders, N. H. ..................L1-965, 110Rene, A. ........................ F-2010, 246Renner, E. ...................... T-1043, 113Renteria, M. .........C2-099, 009; C2-150, 010;............................C2-721, 089Renzi, G. ........................K-560, 074Repetto, V. ......................C2-094, 008Resch, G. .............B-659, 084; B-1316, 165Reseau des Observatoires Regionaux du Pneumocoque.......................C2-1359, 167Ressina, S. ......................C1-588, 081Reuland, E. A. ...................C2-104, 009Reus, S. .........................K-941, 106Revale, S. .......................C1-678, 086Revelly, J. .......................K-2088, 252Revest, M. .......................K-267, 023Rey, A. ......................... F-1523, 177Reyes, A. ......................L2-2115, 255Reyes, J. .............K-900, 104; C1-1345, 166;...............C2-1389, 169; C2-1909, 237Reyna, F. .......................C1-067, 006Reynaud, A. ...........C2-080, 007; K-255, 022;. . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1318, 165Reynolds, D. K. ..................A-1244, 161Reynolds, J. L. ...................C2-695, 087Reynolds, R. ....................C2-152, 010Rezai, M. ......................L1-1647, 186Rezende de Castro, R. .............D-1447, 172Rhéaume, C. .....................V-399, 030Rhee, M. ..............T-350, 029; H-555, 073;........H-879, 102; H-891, 103; A-1250, 161Rhomberg, P. R. ......C2-124, 010; C2-131, 010;........C2-146, 010; E-193, 015; F-855, 099;. . . . . . . F-856, 099; E-1463, 173; E-1467, 173;..................F-1511, 176; F-1512, 176Riahi, F. ........................C2-126, 010Ribaud, P. ......................M-1707, 191Ribeiro, M. O. ..................C2-1375, 168Ribeiro, S. S. ...................C2-1907, 237Ribeiro, V. B. .....................D-749, 092Ribera, A. .......................K-254, 022Ricagni, L. ......................D-1426, 171Ricardo, E. .......................M-320, 028Riccobono, E. ..................C1-1205, 156Rice, C. M. ........................ 005, 002Rich, P. ........................M-1670, 190Richard, M. ............ T-356, 029; V-391, 030Richardson, C. ...................G-1048, 114Richaud, C. ......................B-660, 084Riche, A. .......................L1-963, 110Richmond, G. J. ...................H-879, 102Richter, S. S. .........C2-112, 009; C2-126, 010Riebe, K. M. ....................D-1777, 201Riederer, K. ........C2-1381, 169; C2-1391, 169Rieger, A. .......................H-1918, 238Riesenberg, K. ........ H-232, 019; L1-961, 110;. . . . . . . . . . . . . . . . . . . . . . . . . . . . .P-1022, 112Rigassio-Radler, D. ...............L1-300, 026Rigaut, D. ...........C2-705, 088; C2-709, 088Riggins, R. ........... B-1302, 164; B-1304, 164Riggs, M. ........................A-634, 083Righi, E. .............M-317, 028; T-1035, 113Rijnsburger, M. C. ................C2-104, 009Rijs, T. ..........................M-319, 028Riley, L. W. .....................C2-110, 009Rincón, G. ..........C2-700, 087; C2-1389, 169;...........................C2-1909, 237Ring, C. .............. K-926, 105; T-1068, 116Rini, J. F. .......................M-1063, 115Rinsky, J. ......................C2-1912, 237Rio Marques, L. .................D-1436, 171Rios, F. .........................K-2093, 252Riosa, S. ........................E-1478, 174Rioux, C. .......................V-1073, 117Risso, F. ........................D-1426, 171Ritchie, G. .......................D-161, 011Ritchie, S. R. .......G3-1555, 178; C2-1908, 237Riteau, B. ........................V-399, 030Rittenhouse, S. .......A-1275, 162; B-1308, 164Ritz, D. .......................C1-1347, 166Rivas, N. ......................G3-1552, 178Rivat, S. ...............D-745, 092; D-748, 092Rivera, A. .......................K-1621, 184Rivera, J. I. ......................C2-112, 009Rivera, L. .......................G-1751, 198Rivera Chavira, B. R. ............... F-833, 098Rivero Rodriguez, M. .............H-1921, 238Rizk, M. ........................A-008, 003Rizk, M. L. . A-009, 003; A-010, 003; A-1763, 200Rizzardini, G. ...................L2-304, 027RLN ...........................M-327, 028Robb, A. .......................K-2095, 252Robbins, W. ......................H-879, 102Roberson, M. .....................G-873, 101Robert, J. ........................K-237, 020Robert-Gangneux, F. .............. P-1007, 112Roberts, A. P. ...................C2-1979, 243Roberts, J. ...........L2-301, 027; F-2007, 246;............................ F-2008, 246Roberts, M. C. ..................C1-1348, 166Roberts, S. A. ......G3-1555, 178; C2-1908, 237Robertson, L. ....................D-1414, 170Robichaud, S. ....................D-729, 090Robin, S. ........................ P-996, 112Robinson, T. .................... F-2005, 246Robledo, I. E. ....................E-789, 094Roblot, F. .............A-039, 004; L1-963, 110;................. P-996, 112; L1-2104, 254Robson, J. M. ....................L2-307, 027Roca, I. . . C1-075, 006; B-1329, 165; D-1775, 201Roca, J. ........................ T-1030, 113Rocchetti, T. T. ..................D-1412, 170Rocchi, S. ......................M-1692, 190Rocha, J. L. ...........C2-087, 008; K-913, 104;. . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2113, 255Rocha, V. C. ....................D-1403, 170Rocher, I. .......................K-1755, 199Rochstroh, A. C. .................C2-685, 087Rock, J. A. ......................L1-294, 026Rock, J. ..... F-843, 099; F-844, 099; F-845, 099;............................. F-846, 099Rockstroh, J. .....................H-885, 102Roda, J. .........................K-944, 106Rodgers, M. A. ...................V-377, 030Rodier, M. ....................... T-363, 029Rodil, R. .......................K-1612, 184Rodkey, E. ......................C1-463, 047246September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberRodrigo, C. .....................D-1419, 170Rodrigues, A. G. .......M-320, 028; F-1492, 175Rodrigues, A. ....................C2-107, 009Rodrigues, C. ....................... 419, 037Rodrigues, F. ...................G3-1551, 178Rodriguez, C. A. ......A-1945, 240; A-1968, 241Rodríguez, C. ...................M-1232, 159Rodriguez, C. ...................C2-701, 087Rodríguez, C. ....................D-765, 092Rodriguez, E. ..........C1-067, 006; G-871, 101Rodriguez, F. ....................C1-683, 086Rodríguez, H. ....................K-944, 106Rodriguez, J. ....................A-1761, 200Rodríguez, J. .........M-1700, 191; K-2077, 250Rodriguez, N. ..................C2-1370, 168Rodríguez, V. ....................C1-067, 006Rodriguez Cuns, G. ..............C2-1988, 244Rodriguez Noriega, E. ............C2-1373, 168Rodriguez Valdez, L. M. ............ F-833, 098Rodriguez-Baño, J. . . . C1-683, 086; C2-707, 088l................K-1633, 185; L1-1658, 188Rodríguez-Carballeira, M. .........K-1621, 184Rodríguez-Créixems, M. ...........C2-127, 010;........ D-726, 090; K-943, 106; K-940, 106;...... K-944, 106; D-1411, 170; D-1415, 170;..... M-1684, 190; D-1772, 201; K-2090, 252Rodriguez-French, A. ..............H-220, 019Rodríguez-Hernández, M. J. ........K-1924, 239Rodríguez-López, F. ..............A-1280, 162Rodríguez-Martínez, J. . C1-683, 086; A-1280, 162Rodriguez-Noriega, E. ...........C2-1370, 168Rodriguez-Pardo, D. ....K-931, 105; K-1758, 199Rodríguez-Rosales, G. ..............D-166, 012Rodriguez-Sanchez, B. . .D-726, 090; D-1772, 201Rodríguez-Tudela, J. ...............M-327, 028Rodvold, K. A. ...................A-1277, 162Roeger, F. .......................M-1708, 191Roger, M.. . . . . . . . . . . . . . . . . . . . . . . H-1571, 180Roger, P. ..............A-1253, 161; B-052, 005Rogers, A. ......................H-1575, 180Rogers, B. A. .........C2-689, 087; C2-708, 088Rogers, L. M. ....................B-661, 084Rogers, P. D. ..........M-969, 111; M-970, 111;.............................M-971, 111Rogers, P. ........................G-871, 101Rohde, H. ....................... T-347, 029Rohrer, R. J. ..................... T-1025, 113Roig, G. ........................L2-303, 027Roilides, E. .........M-1681, 190; M-1720, 191;.............................. 1875, 230Rojas, E. ........................G-870, 101Rojas, L. J. ............C2-694, 087; D-747, 092Rojas, L. .......................M-1688, 190Rojas, N. ..........C2-1909, 237; C2-1915, 237Rojo, A. .............D-1439, 171; D-1440, 171Rojtman, A. .....................K-1625, 184Rollins, L. O. ....................M-1693, 190Rolo, D. .......................C2-1365, 167Rolo, J. ........................C1-1740, 197Rolston, K. V. ....................K-252, 022Román, E. ......................C2-105, 009Romanelli, R. ......... T-1044, 113; K-1606, 183Romanov, A. .......C2-1386, 169; C2-1911, 237Romero, F. .......................M-322, 028Romero, J. ....F-843, 099; F-844, 099; F-845, 099Romero-Gómez, M. P. ............D-1452, 172Romney, M. ...........D-161, 011; K-1593, 182Rondinaud, E. ........C1-063, 006; C1-591, 081Ronit, A. ........................B-055, 005Roques, P. ....................... T-363, 029Roquilly, A. ............B-051, 005; B-054, 005;.................. B-651, 084; B-1335, 165Rosato, A. ......................E-1478, 174Rosato, R. ......................E-1478, 174Rose, W. ..............A-621, 082; A-626, 083;.....C1-677, 086; C1-1351, 166; E-1482, 174Rosen, S. R. .....................K-1620, 184Rosenbach, M. .................... F-810, 096Rosenblatt, J. .........F-2012, 246; F-2014, 246;............................K-2082, 251Rosenblatt, J. E. ...................D-170, 012Rosenthal, J. ....................L1-1645, 186Rosenthal, M. E. .................K-1625, 184Roset, A. ......................L1-2102, 254Rosetti, A. S. .....................E-801, 094Rosli, R. .........................M-990, 111Ross, H. ........................ T-1043, 113Ross, J. E. ..........C2-139, 010; C1-1343, 166Ross, L. L. .............H-882, 102; H-895, 103Ross, T. ........................K-1756, 199Rossello, E. .....................M-1228, 159Rossi, F. ........................K-1603, 183Rossi, R. ........................D-742, 091Rosso, F. ......................L2-2108, 255Rossolini, G. M. .......C2-700, 087; E-796, 094;. . . C1-1205, 156; C2-1211, 157; C2-1897, 236Rotger, A. .......................K-940, 106Roth, A. L. .....................D-1445, 172Roth, S. ........................A-1255, 161Rotimi, O. ......................C2-121, 009Rotimi, V. ............C1-071, 006; D-727, 090Rotrying, F. ........C2-1396, 169; C2-1397, 169Rotstein, C. ...........T-1043, 113; T-1067, 116Rougemont, M. ..................H-1566, 179Round, J. .......................... 415, 036Rousseau, C. .....................V-376, 030Roussel, P. ...........F-2030, 248; F-2031, 248;..................F-2032, 248; F-2033, 248Routy, J. ........................H-1571, 180Roux, F. L. ......................B-1330, 165Rouyer, C. ......................K-2089, 252Rouzioux, C. ....................H-1568, 179Rowe, J. ........................ F-2009, 246Rowlinson, M. ..........D-732, 091; D-736, 091Roy, C. .......................... P-568, 075Rozemeijer, W. ...................G-870, 101Ruane, P. ..............H-556, 073; H-879, 102Rubi, J. ..........................D-743, 091Rubino, C. M. ........A-1961, 241; A-1962, 241Rubinovitch, B. ...................K-557, 074Rubinstein, E. ............ 578, 078; A-639, 083Rubio, A. ......................C1-1744, 197Rucinski, S. L. ....................D-170, 012Rude, T. H. .....................B-1320, 165Rudin, S. . C2-092, 008; C2-686, 087; C2-692, 087Rudnick, W. .......C2-1363, 167; C2-1364, 167Ruebsamen-Schaeff, H. . . . T-356, 029; V-391, 030Ruggiero, M. ........C1-466, 047; C1-1206, 156Ruhnke, M. .........M-1229, 159; M-1683, 190;............................M-1709, 191Ruhwald, M. ....................H-1919, 238Ruimy, R. ...........L1-957, 109; C2-1399, 169Ruiz, A. ..............D-726, 090; D-1772, 201Ruiz, B. ........................C2-105, 009Ruiz, G. ........................K-1608, 184Ruiz, I. .........................M-1228, 159Ruiz, J. ......K-938, 106; K-941, 106; K-942, 106;............................ M-992, 111Ruiz, S. ........................C2-092, 008Ruiz, Y. ........................M-1702, 191Ruiz de Alegría, C. ....C1-683, 086; A-1280, 162Ruiz-Camps, I. ...................M-312, 028Ruiz-Garbajosa, P. ......C2-111, 009; D-753, 092Rujiragul, R. ............P-998, 112; P-999, 112Rumbo-Feal, S. .................C2-1902, 236Rummel, M. ..................... T-341, 029Runnegar, N. ....................C2-689, 087Ruperto, F. ...................... T-1040, 113Rupp, M. E. ......................K-922, 105Rutgersson, C. ...................C1-665, 085Ruvinsky, S. D. ...................B-045, 005Ryan, K. ............E-1472, 174; C1-1742, 197Ryan, R. .........................H-880, 102Rybak, J. M. .....................E-1466, 173Final Program247

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberRybak, M.,J. ............K-272, 024; K-275, 024;........ A-600, 082; A-601, 082; A-602, 082;........ A-603, 082; A-626, 083; A-627, 083;.........K-906, 104; K-909, 104; K-946, 106;......K-1121, 129; K-1123, 129; K-1600, 182;...... L1-1638, 186; 1165, 147; C2-1985, 244Ryu, G. .........................D-734, 091Rzotkiewicz, S. .................. P-1001, 112SSá-Leão, R. ....................C2-1365, 167Saad, N. ........................A-1766, 200Sabé, N. ........................ T-1030, 113Sabet, M. .... F-848, 099; F-851, 099; F-852, 099;............................. F-858, 099Sabo, J. P. .......................A-1248, 161Sadarangani, M. ....G3-1542, 178; G3-1544, 178Sader, H. S. ..........C2-123, 010; C2-124, 010;......C2-129, 010; C2-131, 010; C2-132, 010;......C2-136, 010; C2-138, 010; C2-145, 010;........C2-146, 010; E-186, 015; E-189, 015;.........E-187, 015; E-193, 015; E-199, 015;...... F-2050, 248; F-2051, 248; F-2052, 248;............................F-2053, 248;Saez Llorenz, X. .................G-1751, 198Safdar, A. ........................K-273, 024Saga, T. ..............K-918, 105; D-1459, 172Sagermann, M. ...................B-053, 005Saginur, R. ......................E-1480, 174Sagisaka, M. ...................L1-1657, 188Saha, S. ........................G-1751, 198Saha-Chaudhuri, P. ...............M-1703, 191Sahi, S. K. ......................B-1301, 164Sahli, S. .........................M-983, 111Sahm, D. .............A-008, 003; C2-125, 010;.......C2-128, 010; C2-134, 010; E-208, 016;........D-760, 092; D-764, 092; D-767, 092;.......E-778, 093; G-862, 100; L1-1660, 189;......E-1479, 174; F-1524, 177; F-1521, 177;.......F-1528, 177; F-2046, 248; F-2047, 248Sahner, D. ...................... F-1531, 177Saidel-Odes, L. ....... H-232, 019; L1-961, 110;................. P-1022, 112; K-1610, 184Saiman, L. ........................ 1839, 217Saint-Jean, M. ....................D-730, 090Saito, S. ........................D-1461, 172Sakata, H. .........C2-1354, 167; C2-1990, 244Sakata, K.. . . . . . . . . . . . . . . . . . . . . . . F-2055, 248Sakellariou, C. ...................K-1592, 181Sakoulas, G. ............K-275, 024; A-601, 082;.......A-626, 083; E-1482, 174; K-1631, 185Sakwinska, O. .......B-1316, 165; C1-1746, 197Salama, N. N. ....................A-606, 082Salas-Venero, C. ..................D-169, 012Salata, R. A. ...........V-385, 030; A-1257, 161;............................ F-2015, 246Salcedo, M. ..................... T-1026, 113Saleem, R. .......................D-727, 090Saleh-Mghir, A.. . . . . . . . . . . . . . . . . . . B-645, 084Salem, E. .......................K-1584, 181Salerno, G. ............F-2032, 248; F-2033, 248Salez, N. ........................V-387, 030Salfinger, M. ...........D-732, 091; D-736, 091Salgado-Pabon, W. ............... F-1517, 176Salgueiro, V. C. .....C2-1383, 169; C2-1907, 237Salimnia, A. .....................L2-306, 027Salimnia, H. ....................L2-306, 027Salstrom, S. ......................D-163, 011Saltigeral, P. ....................G3-1563, 178Salvado, M. ......................K-258, 022Salvatore, M. J. .................. F-1496, 176Salvioni, A. ..................... F-1999, 246Samayoa, B. .....................M-1694, 190Sambanthamoorthy, K. ............C1-673, 085Sambhara, S. ....................D-1435, 171Sambol, S. .......................E-808, 095Samonis, G. ..........B-043, 005; M-1058, 115;............................M-1696, 191Sampsonas, F. ...................M-1679, 190Samri, A. .......................H-1568, 179Samson, R. A. ....................M-332, 028Samuel, L. P. ....................D-1416, 170San Juan, R. .....................K-2091, 252San Miguel, A. ...................D-164, 012San Roman, M. D. ................A-024, 004San-Juan, R. .................... T-1071, 116Sanche, S. .......................D-729, 090Sánchez, A. ..........C1-067, 006; C1-069, 006Sánchez, C. .....................M-1688, 190Sanchez, I. ......................L1-289, 026Sanchez, M. .....................K-2093, 252Sanchez-Alemán, M. .............C2-1356, 167Sánchez-Carrillo, C. . . . C2-127, 010; D-726, 090;......D-1415, 170; D-1772, 201; K-2090, 252Sánchez-Ortega, I. ............... T-1045, 113Sánchez-Patán, F. ................L1-958, 109Sánchez-Sousa, A. .................M-323, 028Sandberg-Schaal, A. ................ 1144, 139Sanders, R. L. .......... V-381, 030; V-382, 030Sandid, M. ............L1-284, 025; T-1066, 116Sandri, A. M. .....................A-027, 004Sanfeliu, I. ......................K-1623, 184Sanguinetti, M. ................... F-814, 096Sanjuan-Padrón, L. ...............C2-113, 009Sanjurjo, M. .....................M-1232, 159Sannes-Lowery, K. S. ............C2-1361, 167Sans, D. .........................D-730, 090Santalucía, M. ....................E-202, 015Santarsiero, B. ................... F-2072, 249Santella, G. .....................C2-700, 087Santiago, C. .....................L1-289, 026Santiago, L. ......................H-882, 102Santilli, S. .............V-393, 030; K-898, 104Santos, A. .......................H-227, 019Santos, M. .......................H-227, 019Santos, P. ......................L1-1659, 189Santos, R. ........... L1-287, 025; L1-288, 025Santos, S. R. .....................G-861, 100Santos-Preciado, J. I. ..............C2-113, 009Sanz, F. ........................K-2093, 252Sanz, J. .........................H-1576, 180Saosri, P. ........................ P-998, 112Saravolatz, L. D. .................E-1484, 174Saravolatz, S. ....................E-1484, 174Sarkar, A. ........................ F-827, 097Sarmati, L. ......................H-1579, 180Sarmento, A. .....................H-227, 019Sarmiento, E. .................... T-1026, 113Sarmiento, I. .....................D-762, 092Saroufim, C. ...................L1-2106, 254Sarraz-Bournet, B. ................K-2089, 252Sarriá, C. .......................H-1576, 180Sasano, M. .....................C2-1901, 236Sasikala, S. . . E-195, 015; E-791, 094; E-1476, 174Sass, N. .......................G3-1557, 178Satana, D. .....................C2-1367, 168Sathapollatchaphum, A. ............ P-998, 112Sathyendran, V. .................. P-1023, 112Sato, A. .........................H-550, 073Sato, J. L. ......................G3-1557, 178Sato, M. ........................C2-717, 088Sattar, A. ..............F-842, 099; F-1530, 177Satyanarayana, G. .................T-354, 029Satzke, C. ......................... 520, 065Sauermann, R. ....................E-783, 093Saunders, M. .................... F-1530, 177Sauvage, E. .........C1-459, 047; C1-1206, 156Sauvageon, H. ....................H-889, 103Sauvan, V. .......................K-954, 108Sauzullo, I. .............D-740, 091; D-742, 091Savard, R. .......................V-389, 030Savchenko, A. .......C1-458, 047; C1-1344, 166Savelkoul, P. ...........C2-104, 009; G-870, 101Savinelli, S. ....................C2-1373, 168Sawa, R. ........................ F-1509, 176248September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberSawamura, H. ....... C2-1989, 244; F-2045, 248Sawani, M. .....................C2-703, 088Sax, H. ..............K-1125, 129; K-2083, 251Sayah-Jeanne, S. ...... A-1963, 241; F-2003, 246Scaggiante, R. ...................H-1579, 180Scaglione, E. ...................C2-1398, 169Scala, A. .......................G3-1549, 178Scangarella-Oman, N. ....D-766, 092; E-802, 094Schaefer, E. A. ....................V-377, 030Schaefer, J. .....................C1-1969, 242Schaffer, K. .....................B-1334, 165Schaible, B. .....................B-1334, 165Schaible, D. ......................H-880, 102Scharenberg, M. ................. F-2057, 249Scharikow, L. ...................C2-1360, 167Scharmen, A. .....................A-018, 003Scheel, C. .......................M-1694, 190Scheetz, M. ...........A-636, 083; B-1323, 165;......B-1326, 165; K-1614, 184; K-1615, 184Scheifele, D. W. .................G3-1542, 178Schellekens, J. F. ..................D-183, 014Scherrer, A. U. ....................V-384, 030Scheutz, F. ......................C2-687, 087Schindler, B. D. .....C1-1341, 166; C1-1747, 197Schindler, M. ..........K-929, 105; K-2075, 250Schipper, K. ....................L1-1651, 187Schlaeffer, F. ......... H-232, 019; L1-961, 110;................. P-1022, 112; K-1610, 184Schlamm, H. ........M-1225, 159; M-1229, 159;................M-1683, 190; M-1709, 191Schlecht, H. P. ....................A-618, 082Schlievert, P. M.. . . . . . . . . . . . . . . . . . F-1517, 176Schmaltz, C. A. ...................K-257, 022Schmidt, C. ......................G-868, 101Schmidt, S. .....................M-1708, 191Schmidt, S. S. ....................B-652, 084Schmitt, B.. . . . . . . . . . . . . . . . . . . . . . D-1774, 201Schmitt-Hoffmann, A. ............. F-842, 099Schnegg, A. ......................D-184, 014Schoenen, F. J. ....................V-370, 030Schöni-Affolter, F. ................H-1566, 179Schonning, K. ....................B-663, 084Schrengenberger, K. ................D-167, 012Schrenzel, J. ............. K-560, 074; 1176, 149Schroeder, S. .......C1-1346, 166; C1-1347, 166Schubel, L. .......................K-939, 106Schubert, R. .....................M-1708, 191Schuck, V. .......................A-632, 083Schuetz, A. N. ..................... 1182, 151Schurtz, G. ......................B-050, 005Schutten, M. .................... V-1080, 117Schwab, F. ......................K-1592, 181Schwaber, M. J. ........K-557, 074; K-1609, 184;......................1727, 193; 1833, 215Schwameis, R. ....................E-783, 093Schwardt, O. .................... F-2057, 249Schwartz, J. A. .........M-967, 111; A-1944, 240Schwarz, S. P.. . . . . . . . .C1-670, 085; C1-679, 086;...... C1-1350, 166; 1865, 228; C2-1987, 244Schweins, R. .................... F-2007, 246Schweizer, F. ..........C2-135, 010; E-779, 093Schweizer, H. P. ........F-2022, 247; F-2033, 248Schweizer, M. ..................... 1877, 231Science, M. ......................K-955, 108Scott, H. M. ....................C2-710, 088Scott, R. .....524, 066; A-1284, 162; E-1474, 174;...... F-1494, 175; F-1495, 175; F-1493, 175;...........................L1-1662, 189Scotto, M. ......................D-1773, 201Scrivo, R. ........................D-740, 091Scully, I. ........................... 575, 077Seah, C. .........................E-781, 093Seales, D. .......................D-1424, 171Sears, P. ........................A-1274, 162Sears, W. ......................L1-1663, 189Seas, C. .............K-900, 104; C2-1909, 237Seber, E. ......................C2-1367, 168Seclén, E. .......................H-1576, 180Secor, W. E. ...................... P-563, 075Seddon, J.. . . . . . . . . . . . . . . . . . . . . . . A-1274, 162Sedlacek, P. ...................... T-344, 029Sedlinieks, K. ....................K-2080, 251Sedunary, R. .................... T-1027, 113Seeber, K. . . V-398, 030; P-1009, 112; D-1404, 170Segado, A. .......................K-944, 106Segner, R. E. .....................D-170, 012Segolodi, T. M. ..................H-1570, 179Segonds, C. ......................D-758, 092Segreti, J. ........................K-275, 024Segura, F. .......................K-1623, 184Segura, I. .......................H-1921, 238Seidl, K. ..............B-646, 084; K-1125, 129Seifarth, W. ......................M-335, 028Seifert, H. ............A-030, 004; C1-070, 006;...........................C2-1392, 169Seitz, A. E. ......................M-314, 028Seixas, M. .....................C2-1383, 169Sekaly, R. ........................H-553, 073Seki, L. M.. . . . . . . . . . . . . . . . . . . . . C2-1218, 157Seki, M. ............... V-380, 030; V-400, 030Seki, T. ..........................H-550, 073Selenge, B. ......................C1-068, 006Sellman, B. ..........F-1529, 177; B-1734, 196;................. B-1736, 196; B-1737, 196Selton-Suty, C. ...................K-939, 106Semorile, L. ..................... F-1491, 175Sen, L. ..........................B-045, 005Sengeløv, H. .................... T-1072, 116Senn, G. .......................K-1125, 129Sennati, S. ......................C2-700, 087Senneville, E. ......... H-231, 019; L1-957, 109;............................K-2089, 252Senol, E. .......................M-1671, 190Senthur Nambi, P. ...... P-564, 075; P-1003, 112Seo, S. M. .........C1-1341, 166; C1-1747, 197Seo, Y. ..........................G-872, 101Seoung, S. K. ....................L1-294, 026Seow, H. ........................M-990, 111Sepúlveda, M. J. ..................H-1576, 180Sereno, R. ......................C2-713, 088Sergent, O. ..................... P-1007, 112Serra, J. ........................L2-303, 027Serra, M. ......................L1-1643, 186Serrano-Villar, S. .......H-217, 018; H-1567, 179Serres, G. D. ....................G-1047, 114Seto, W. ................ K-243, 021; 1085, 118Severynse-Stevens, D. .............. F-837, 098Seville, M. ......................M-1697, 191Seville, T. M. .................... T-1032, 113Seward, J. F. ........................ 442, 042Sexton, D. J. .....................C2-117, 009Seybold, U. ......................H-887, 103Seydi, A. .......................M-1698, 191Seyedmousavi, S. .......M-989, 111; M-988, 111;............................A-1933, 240Sfair, S. ........................C2-087, 008Sferrazza, S. ....................G3-1553, 178Shade, C. .......................H-1916, 238Shadiack, A. M. .........F-837, 098; F-839, 098;............................. F-840, 098Shaefer, M. ............H-882, 102; H-895, 103Shafiee, A. ....................... F-810, 096Shafran, S. D. ...................... 401, 033Shah, A. P. ...................... T-1029, 113Shah, D. N. . . D-158, 011; K-920, 105; K-921, 105Shah, D. J. ......................V-1075, 117Shah, D. P. ...................... T-1065, 116Shah, D.. . . . . . . . . . . . . . . . . . . . . . . . F-1528, 177Shah, P. K. ...................... T-1065, 116Shah, S. .........................K-904, 104Shahani, S. ......................K-1589, 181Shaheen, B. W. .................C2-1219, 157Shahrooei, M. ...................K-2094, 252Final Program249

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberShakib, S. .......................A-1272, 162Shalit, P. .........................H-879, 102Shallcross, L. ...................L1-1645, 186Shamblaw, D. ..........H-555, 073; H-556, 073Shang-Yi Huang .................M-1669, 190Shani, E. ........................M-339, 028Shannon, S. K. ....................D-170, 012Shapiro, M. .....................K-1609, 184Sharff, K. A. ....................D-1432, 171Sharland, M. ...........480, 051; G3-1559, 178;.................K-1754, 199; K-1759, 199Sharma, M. ........C2-1381, 169; C2-1391, 169Sharma, R. ......................K-1630, 185Sharma, S. . . D-733, 091; F-824, 097; D-1437, 171Sharma-Kuinkel, B. K. ............B-1320, 165Shapiro, M. .....................K-1609, 184Sharp, A. ............M-977, 111; A-1942, 240;......A-1943, 240; A-1944, 240; A-1765, 200Sharp, Z. ........................D-739, 091Shaw, E. ........................C2-111, 009Shaw, K. ..............E-778, 093; E-1479, 174;........ F-1514, 176; 1864, 228; F-2017, 247;......F-2018, 247; F-2018a, 247; F-2020, 247;...... F-2022, 247; F-2023, 247; F-2024, 247;..................F-2025, 247; F-2028, 247Shelton, E. ....................... T-369, 029Shelton, M. ..................... T-1037, 113Shemes, S. .........C2-1381, 169; C2-1391, 169Shen, J. .......................C2-1987, 244Shen, Z. .......................C2-1987, 244Sherrill, R. G. ................... F-1510, 176Sheth, P. M. .....................C2-089, 008Shetty, N. ........................D-160, 011Shi, D. ..........................K-933, 105Shi, L. .............G3-1550, 178; V-1078, 117Shi, Y. G. . . .A-640, 083; F-1503, 176; F-1504, 176Shi, Y. ..............A-1283, 162; B-1737, 196Shibasaki, M. .................... F-1509, 176Shibayama, K. .......D-1456, 172; C2-1904, 236Shibue, Y. .......................B-056, 005Shields, R. .............T-346, 029; T-348, 029;.........E-792, 094; E-786, 094; E-804, 094;.......T-1031, 113; T-1037, 113; T-1069, 116;.....C2-1216, 157; K-1605, 183; K-1622, 184;............................M-1675, 190Shigemura, N. ..........T-1037, 113; T-364, 029Shimada, J. . .E-780, 093; F-1506, 176; F-1507, 176Shimizu, T. ..................... F-2041, 248Shin, G. ........................H-1582, 180Shin, J. .........................B-1298, 164Shinabarger, D. ........A-008, 003; F-2065, 249;Shirazi, F. ........................M-972, 111Shire, N. M-1676, 190; M-1678, 190; M-1695, 190Shlaes, D. ......................... 1148, 141Shlykova, D. S. ..................A-1967, 241Shoham, M. ...........F-1515, 176; F-1999, 246Shoji, T. ........................D-1429, 171Shopsin, B. ....................C2-1906, 237Short, E. ........................K-271, 024Shortridge, D. ....................E-197, 015Shouche, Y. .....................C1-665, 085Shouji, M. .....................C2-1353, 167Shoyinka, A. ..........K-912, 104; K-1597, 182;................L1-1655, 188; M-1713, 191Shrivastava, D. .................... F-812, 096Shriver, Z. H.. . . . . . . . . . . . . . . . . . . . V-1077, 117Shu, W. ........................ F-1540, 177Shubert, C. ......................E-197, 015Shukla, S. K. ..........V-373, 030; C1-677, 086;...........................C1-1351, 166Shulman, S. T. ...................... 582, 079Shultz, J. ........................K-274, 024Shutt, K. A. .....................C2-112, 009Siafakas, N. ..........A-1939, 240; A-1940, 240Sidhu, M. .......................D-172, 013Sidhu, S. ....................... F-1537, 177Sidjabat, H. E. ...................C2-708, 088Sidorenko, S. V. .................C2-1385, 169Siebert, H. ......................C2-090, 008Siegmund, C. .................... F-2067, 249Siegrist, C. .....................G3-1556, 178Sierra, J. ............C2-1395, 169; D-1775, 201Sikes, D. ........................D-737, 091Silbert, S. .......................D-1446, 172Silk, B. ........................... 1816, 210Silks, L. ......................... F-830, 098Silva, D. N. .....................C1-671, 085Silva, E. .........................H-889, 103Silva, K. ........................C2-717, 088Silva, M. J. .......................H-878, 102Silva, M. G. ....................C2-1375, 168Silva, R. M. .....................C2-685, 087Silva-Costa, C. ..................C2-151, 010Silva-Sanchez, J. ......C1-067, 006; C1-069, 006Silveira, F. ...........T-364, 029; C2-1216, 157;..................T-1031, 113; T-1037, 113Silver, S. .........................H-213, 017Silverman, J.. . . . . . . . . . . . F-843, 099; F-844, 099;....................F-845, 099; F-846, 099Silvia, A. .......................A-1264, 161SIMA-P Study Group ............. P-570, 075Simenauer, A. ........C2-125, 010; C2-128, 010;.......C2-134, 010; D-760, 092; D-764, 092;........D-767, 092; E-1479, 174; E-778, 093;.......F-1524, 177; F-2046, 248; F-2047, 248Simiele, M. ..........A-1769, 200; A-1937, 240Simitsopoulou, M. ................M-1720, 191Simjee, S. ............C2-705, 088; C2-709, 088Simkins, J. ...................... T-1033, 113Simner, P. ............C2-103, 009; M-1691, 190Simó, G. ........................D-166, 012Simó, M. .......................K-1621, 184Simões, A. S. ...................C2-1365, 167Simoes, B. ......................M-1234, 159Simon, D. J. .....................B-1303, 164Simon, F. . . . T-363, 029; H-886, 102; D-1778, 201Simon, J. ........................G-869, 101Simoneau, E. .....................V-389, 030Simpson, R. ......................A-619, 082Sims, K. ........................A-1247, 161Singer, L. G. ..........T-1043, 113; T-1067, 116Singh, C. .......................E-1478, 174Singh, D. V. ..........C2-715, 088; D-1437, 171Singh, J. ...........G3-1560, 178; G3-1561, 178Singh, K. S. ..........K-278, 024; L2-2116, 255Singh, M.. . B-656, 084; F-841, 099; C1-1969, 242Singh, N. ............M-337, 028; M-1227, 159Singh, S. ............. F-810, 096; F-1496, 176Singh-Moodley, A. ................D-773, 092Singhal, S. ...................... F-2043, 248Singhal, T. .............K-264, 023; K-904, 104Singleton, S. F.. . . . . . . . . . . . . . . . . . . F-1535, 177Siopi, M. ............A-1938, 240; A-1939, 240Sipsas, N. ...........M-1681, 190; L2-2114, 255SIREVA-Mexico Network ........C2-1356, 167Sirijatuphat, R. ..................K-1602, 183Siripanichgon, K. .................C2-712, 088SITIP Lyme Disease Study Group, G3-1553, 178Siu, L. .........................B-1321, 165Sivagnanam, S. ..................M-1680, 190Sivaramakrishnn, H. ............... F-824, 097Skalweit, M. J. ...................C1-073, 006Skana, F. .......................M-1692, 190Sklaney, M. .....................E-1995, 245Sklar, P. .........................H-885, 102Skory, C. ........................M-973, 111Skov, M. N. .....................D-1444, 171Skov, R. ........................H-1916, 238Skultans, V. .....................K-2080, 251Slain, D. .........................K-928, 105Slaughter, J. ......................E-197, 015Slaughter, S. .....................D-1432, 171Slavin, M. A. ......... M-315, 028; T-1027, 113;............................M-1225, 159Slee, A. M. ...................... F-2028, 247250September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberSlim, J. ..........................K-902, 104Slinger, R. ......................E-1480, 174Sliwinski, J. .....................E-1472, 174Slobod, K. ......................G-1751, 198Small, C. B. ......................H-895, 103Smani, Y. .......................B-1329, 165Smart, J. I. .......................M-331, 028SMART Study Group in China .....C2-702, 087Smeesters, P. R. ....... B-1312, 165; B-1313, 165Smelhaus, V. ..................... T-344, 029Smith, A. .......................B-1314, 165Smith, C. P. ..................... F-1518, 176Smith, C. .............A-018, 003; A-1290, 163Smith, D. W. .................... F-1520, 177Smith, D. K. ....................H-1570, 179Smith, D. M. .....................G-869, 101Smith, K. Y. ......................H-883, 102Smith, M. .......................D-773, 092Smith, M. I. ........................ 506, 062Smith, P. F. .....................A-1244, 161Smith, R. M. ....................M-1677, 190Smith, T. ......................C2-1384, 169Smith, T. C. ....................... 1191, 153Smith, T. J. ......................L1-300, 026Smollan, G. ......................K-557, 074Smolyakov, R. .........H-232, 019; P-1022, 112Smyth, D. S. ...................C2-1906, 237Snelders, E. ......................M-319, 028Snydman, D. R. .........K-471, 048; E-807, 095;............................ T-1025, 113Sobel, J. D. ............. 1162, 146; L2-306, 027Soborg, C. ......................H-1919, 238Sobrino, B. .....................L1-2102, 254Soentjens, P. H. .................. P-1014, 112Soerensen, P. ...................L1-1652, 187Søgaard, O. S. ..................L1-1650, 187Soge, O. O. ........C1-1348, 166; C2-1898, 236Sohnle, P. ........................D-153, 011Sokol, B. ....................... F-2015, 246Sola, C. .......................C2-1910, 237Solé, M. .............C1-075, 006; C2-696, 087Soler Bistué, A. .................. F-1539, 177Solis, N. ........................M-1056, 115Sollazzi, L. ...................... T-1040, 113Soloff, R. ........................G-871, 101Solon, E. .......................A-1949, 241Solórzano-Sánchez, F. ............C2-1356, 167Soltani, B. .....................L1-1656, 188Somily, A. M. ..................C2-1372, 168Son, B. ......................... F-2060, 249Son, T. .......................... T-361, 029Sønderholm, M. ................. T-1072, 116Song, C. ........................K-1595, 182Song, J. H. .........C2-1366, 167; C2-1899, 236Song, J. .............K-1588, 181; K-1587, 181Song, J. H. ......................C2-137, 010Song, J. ....H-230, 019; G-872, 101; K-916, 104;............................ F-2072, 249Song, K. .........................K-908, 104Song, W. ........................K-933, 105Song, Y. L. ...................... T-1039, 113Song, Y. ...............H-230, 019; K-916, 104Sönmez, M. .....................D-1405, 170Sönmez Yıldırım, S. ...............D-1405, 170Sonthisombat, P. .................A-1279, 162Soo, V. W. ........................ 1784, 203Sood, S. .......................C2-1982, 243Soon, R. L. ............A-016, 003; A-024, 004;........E-201, 015; A-605, 082; A-1762, 200Sorbello, A. ...................... T-342, 029Sorde, R. .......................K-1758, 199Sordelli, N. ....................G3-1552, 178Sordillo, E. ......................C2-112, 009Sørensen, H. T. ...................G-876, 101Sørensen, S. S. ................... T-1072, 116Soriano, A. ......................K-1633, 185Soriano, V. ..............482, 052; H-1576, 180Sorlí, L. ..............K-258, 022; K-1624, 184Sorrell, T. C. .....................M-313, 028Sørum, H. ......................B-1330, 165Sotier, M. ........................B-660, 084Soto-Noguerón, A. ..............C2-1356, 167Sotorrio, V. .....................L1-289, 026Soubani, A. O. ....................K-902, 104Soubih, E. ...................... F-1514, 176Soulama-Mouze, C. .............. F-2067, 249Souli, M. ....E-799, 094; K-245, 021; K-246, 021Souza, A. G. ...................C2-1376, 169Souza, C. A. ....................M-1234, 159Sowedan, A.. . . . . . . . . . . . . . . . . . . . . F-2064, 249Soy, D. ......A-610, 082; B-648, 084; K-945, 106;. . . . . . . . . . . . . . . . . K-1122, 129; E-1465, 173Spagnuolo, P. ........V-1078, 117; G3-1550, 178Spalla, M. ......................C2-094, 008SPANC Research Team ...........L2-301, 027Spaulding, A. R. ................. F-1517, 176Specklin, J. .....................C1-1346, 166Spector, S. A. ....................H-1917, 238Spellberg, B. ...................... 1795, 206Spelman, D. ......................K-558, 074Spencer, D. ......................H-881, 102Spencer, J. . .....................C1-465, 047Spicer, J. O. .....................G-1752, 198Spiess, B. ............M-335, 028; M-1704, 191Spigelman, M. ...................... 537, 069Spikermann, J. .................... F-842, 099SPILF ..........................K-237, 020Spiro, D. ........................H-214, 018Spoering, A. ...................... F-829, 098Spoulou, V. ....................G3-1551, 178Spreen, W. ......................A-1249, 161Sprenger, C. R. ...................A-623, 082Spudich, S. S. ...................... 444, 043Squassi, I. ......................G3-1552, 178Squires, K. .......................H-882, 102Sripa, B. ......................... P-999, 112Sriprakash, K. ...................B-1312, 165Sriskandan, S. ...................B-1311, 165Srivastava, M. .................... V-373, 030Stachowiak, J. ....................K-934, 105Stahl, J. . P-566, 075; C2-1374, 168; L1-1649, 187Stapert, L. ...................... F-2019, 247Staphylococcus Study Group ........C2-130, 010Stappers, M. H. ...................B-044, 005Starke, J. R. ....................... 1798, 207Starner, T. ......................B-1322, 165Stary, J.. . . . . . . . . . . . . . . . . . . . . . . . . . T-344, 029Starzyk, K. A. ...................G-1749, 198STCS ........................... T-343, 029Ste-Croix, H. ....................M-1711, 191Steckbeck, J. D. ........F-1490, 175; F-2061, 249Steckelberg, J. M. .................B-652, 084Stecken, L. .......................D-164, 012Steed, M. E. . A-600, 082; A-603, 082; A-627, 083Steen, J. A. ..........C1-062, 006; C1-1743, 197Steenbergen, J. ..................L1-2105, 254Steer, A. ................ 583, 079; B-1312, 165Steering Comittee ................. P-566, 075Stefanik, D. ....................C2-1392, 169Stein, D. S. ..........A-1281, 162; A-1282, 162Stein, D. .......................H-1581, 180Stein, G. E. ......................A-018, 003Steinhouse, K. ....................V-396, 030Steinke, L. M. ....................K-909, 104Stepan, G. .......................H-552, 073Stephens, J. T. .........F-1524, 177; F-1528, 177Stephens, J. ......................K-239, 020Sternik, L. ......................L1-962, 110Stevens, D. A. .........G-875, 101; M-982, 111;....................P-1013, 112; 1852, 224Stevens, V. .............A-615, 082; A-617, 082Final Program251

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberStewardson, A. ........K-560, 074; K-2083, 251Stewart, J. .....................C2-1912, 237Stewart, K. .......................H-884, 102Stibich, M. .......................K-934, 105Stidham, M. .........F-2017, 247; F-2018, 247;F-2018a, 247Stilwell, M. G. ...................C2-136, 010Stoch, S. A. ......................A-009, 003Stock, A. H. ...........D-770, 092; F-1520, 177Stock, P. ........................... 443, 043Stoelben, S. ............ T-356, 029; V-391, 030Stogios, P. J. .........C1-458, 047; C1-1344, 166Stojanov, M. ........B-1316, 165; C1-1746, 197Stokes, N. ...................... F-2016, 247Stoltz, R. .......................A-1255, 161Stover, C. ............ B-1734, 196; B-1736, 196Stover, C. K. ....................B-1737, 196Stover, K. .............M-991, 111; M-968, 111Stover, K. ....................... F-1529, 177Straub, R. J. .....................A-1275, 162Strauss, G. E. .....................M-981, 111Stray, K. .........................H-892, 103Streinu-Cercel, A. ................D-1776, 201Streit, J. M. ............E-186, 015; E-199, 015;.................E-1463, 173; E-1467, 173Strohmaier, K. ....................H-885, 102Strommer, S. .....................E-783, 093Strugeon, E. .....................C1-666, 085Strukova, E. N. ..................A-1967, 241Struminger, B. ...................M-1677, 190Strutton, D. ......................K-259, 023Stryjewski, M. ......C2-1396, 169; C2-1397, 169Stubbings, W. .................... F-842, 099Su, P. .......................... F-2072, 249Su, Y. .................G-867, 100; H-218, 018Suarez, J. ............M-337, 028; M-1227, 159Suárez, M. ......................M-1688, 190Suaya, J. A. ......................G-862, 100Subich, D. ......................A-1293, 163Subramoney, V. ..................A-1244, 161Such, K. A. ......................M-981, 111Suckling, C. ..................... F-1530, 177Sudan, A. .......................A-1943, 240Suefuji, K. ........... C1-680, 086; F-1540, 177Suematsu, H. ........ C2-1989, 244; F-2045, 248Suetens, C.. . . . . . . . . . . . . . . .1789, 204; 1804, 208Sugimoto, K. .................... F-2049, 248Sugita, T. ........................M-328, 028Sugumar, M. .....................E-196, 015Suh, B. ........................L1-1656, 188Suh, Y. .........................K-2079, 250Sukasem, C. ......................H-894, 103Suleman, M. .................... P-1007, 112Sullivan, D. C. ..........V-374, 030; P-994, 112;............................D-1425, 171Sumillera, M. .....................D-169, 012Sun, C.. . . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177Sun, D. ......F-848, 099; F-849, 099; F-850, 099Sun, H. . . .K-266, 023; A-1281, 162; A-1282, 162;............................K-1607, 183Sun, Q. .........................K-933, 105Sundaragiri, P. R. ..................K-272, 024Sundareshan, V. ..................E-1485, 174Sunder, S. ............D-176, 013; D-177, 013;................ L1-963, 110; L1-1639, 186Sundsmo, J. S. ....................B-053, 005Sunesara, I. ......................D-185, 014Sung, H. . . .T-366, 029; V-1074, 117; V-1239, 160Sungkanuparph, S. .....H-894, 103; H-1565, 179Sunkara, G. ..........A-1281, 162; A-1282, 162Suominen, H. ....................M-315, 028Supparatpinyo, K. ................D-1406, 170Supple, M. E. ....................A-622, 082Sureshkumar, D. ....... P-565, 075; P-1004, 112Surgers, L. .......................D-154, 011Surin, R. ........................A-637, 083Surmont, F. ....................L1-1641, 186Surska, M. ......................K-2080, 251Sutcliffe, J. A. .........C1-675, 086; E-777, 093;..................F-1525, 177; F-1526, 177Sutherland, C. J. ................... 1099, 124Suthienkul, O. ...................C2-712, 088Suwantarat, N. ...................C2-686, 087Suzuki, E. ...................... F-2041, 248Suzuki, S. ...........D-1456, 172; C2-1904, 236Suzuki, Y. ............C2-712, 088; F-825, 097;. . . . . . . . . . . . . . . C2-1368, 168; C2-1369, 168Svanas, G. W. ...................D-1414, 170Svanborg, C. M. .................... 508, 063Svensson, E.. . . . . . . . . . . . . . . . . . . . . A-1256, 161Sverdlov, O. .....................A-1247, 161Swamydas, M. ...................M-1055, 115Swanson, R. .....................M-1229, 159Swayne, R. L. ...................D-1451, 172Sweeney, M. T. .......C1-670, 085; F-2034, 248Swiatlo, E. .......................D-185, 014Swietochowska, E. ................ F-1533, 177Swift, M. ............A-1265, 161; A-1761, 200;. . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1993, 245Swigart, W. E. ...................L1-286, 025Swyers, L. ......................D-1417, 170Sykes, L. ............E-1463, 173; E-1467, 173Symmons, D. ...................... 1092, 122Syriou, V. ......................L2-2114, 255Syrogiannopoulos, G. ............G3-1551, 178Szeszs, M. W. ....................M-311, 028Szpunar, S. .......................K-923, 105Sztark, F. ........................D-164, 012Szucs, T. D. ......................G-860, 100Szymonifka, M. .................. F-1496, 176TTabata, H. ......................D-1461, 172Tabone, T. ......................L2-301, 027Tabrizi, S. N. ....................L2-301, 027Taccone, F. S. .....................A-637, 083Tack, K. J. .....................L1-1660, 189Tagarao, M. A.. . . . . . . . . . . . . . . . . . . D-1433, 171Tagliaferri, E. .....................E-796, 094Taguebue, J. ....................G3-1541, 178Tahir, N. .............E-195, 015; E-1476, 174Tailor, F. ..............C2-103, 009; E-194, 015Taishi, T. ........................H-550, 073Tajima, T. ......................C2-1977, 243Takagi, E. H. .....................G-861, 100Takahashi, Y. ...........A-607, 082; A-608, 082;......F-1509, 176; K-1594, 182; K-1627, 185;............................M-1687, 190Takakura, S. ..........K-949, 107; M-1231, 159;............................K-1599, 182Takano, M. ......................H-890, 103Takano, T. .....................C1-1340, 166Takasaki, W. .................... F-2042, 248Takeda, S. . . . F-817, 096; F-818, 096; F-819, 096;....................F-820, 096; F-821, 096Takemoto, S. ...........K-247, 022; K-261, 023Takemura, H.. . . . . . . . . . . . . . . . . . . . . E-780, 093Takesue, Y. .............A-607, 082; A-608, 082;.....M-1231, 159; K-1594, 182; K-1627, 185;................ M-1687, 190; F-2044, 248Takubo, S. ......................K-1627, 185Talbot, G. H. ....................A-1952, 241Talreja, D. ......................C2-703, 088Tam, V. H. .............A-025, 004; A-028, 004;...........A-029, 004; 503, 061; A-614, 082;.........K-896, 104; 1096, 123; D-1450, 172Tamaru, A.. . . . . . . . . . . . . . . . . . . . . C2-1369, 168Tamayo-Legorreta, E. M. ..........C1-069, 006Tambyah, P. A. .................... 1137, 135Tan, C. M. ...................... F-1496, 176Tan, D. H. ......................H-1920, 238Tan, M. .........................D-163, 011Tan, S. .......................... T-354, 029Tan, T. Y. . . . E-195, 015; E-791, 094; E-1476, 174252September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberTan, T. T. ..............E-195, 015; E-791, 094Tan, Y. ..........................M-990, 111Tanaka, A. ....................... V-380, 030Tanaka, S. K. ....................A-1281, 162Tanedjeu, K. S. .................. P-1010, 112Tang, W. .......................H-1581, 180Tang, W. W. .....................H-553, 073Tang, Y. ........................D-1442, 171Tängdén, T. ......................E-800, 094Tangkoskul, T. ....................M-976, 111Tankovic, J. ......................D-173, 013Tanner, B. .......................K-934, 105Tanner, C. .......................D-736, 091Tansek, R. .............K-262, 023; K-902, 104Tantalo, L. C. ...................B-1301, 164Tanudra, M. A. ...................A-632, 083Tanzi, E. .......................L2-304, 027Taori, S. .........................K-927, 105Tapiero, B. .....................G3-1554, 178Taraboulos-Klein, T. ...............M-339, 028Taracila, M. .........C1-463, 047; C1-1209, 156Taracila, M. A. ...................C1-590, 081Taramasso, L.. . . . . . . . . . . . . . . . . . . . .M-317, 028Tarazi, Z. ..............F-848, 099; F-851, 099;....................F-852, 099; F-858, 099Tari, L. W. ...........F-2017, 247; F-2018, 247;........................... F-2018a, 247Tarquinio, K. M. ..................E-790, 094Tascini, C. .......................E-796, 094Taseera, K. ......................M-1699, 191Tashiro, T. .......................V-380, 030Tasina, E. .......................M-1720, 191Tasneen, R. ...................... F-836, 098Tate, H. ........................C2-714, 088Tateda, K. ............B-056, 005; C1-077, 006;.......L1-296, 026; K-918, 105; D-1438, 171;.................D-1459, 172; F-2040, 248Tato, M. ..............E-205, 016; C1-681, 086;..................C1-682, 086; D-753, 092Tattevin, P. .......................B-645, 084Tavakkol, A. ....................A-1946, 240Tavares, P. .......................M-320, 028Tawa, P. .........................H-551, 073Tayade, A. ............P-565, 075; P-1004, 112;. . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1618, 184Taylor, C. T. .....................B-1334, 165Taylor, J. J. .......................D-756, 092Taylor, S. ....................... P-1023, 112Tebas, P. .... H-556, 073; 1153, 143; H-1581, 180;.............................. 1780, 202Tebini, A. ....................... T-1035, 113Teboul, J. ......................L1-1224, 158Tector, A. J. ..................... T-1029, 113Tedone, N. ....................... T-360, 029Tegtmeier, B. ...........T-349, 029; T-350, 029;...................T-351, 029; T-1039, 113Teh, B. W. ...................... T-1027, 113Teixeira, A. L. ...................D-1403, 170Teixeira, F. L. ....................C1-671, 085Teixeira, G. ..................... T-1044, 113Teixidó, M. ..................... F-2068, 249Tektonidou, M. .................L2-2114, 255Telles, J. .........................D-172, 013Temme, L. .......................H-881, 102Templeton, D. J. .................L2-301, 027Templeton, K. ....................K-927, 105Ten Kate, M. T. ........B-058, 005; A-1268, 161Tenero, D. ......................A-1272, 162Teng, C. B. ......................K-899, 104Teng, L. J. .........C1-1339, 166; C1-1340, 166Tenover, F. C. ....................K-469, 048Teo, J. ...............K-1595, 182; K-1613, 184Teófilo, E. .......................H-878, 102Teperman, L. W. ..................K-273, 024Teppler, H.. . . . . . . . . . . . . . . . . . . . . . . H-885, 102Terada, Y.. . . . . . . . . . . . . . . . . . . . . . . D-1402, 170Terakubo, S. ......................E-780, 093Terrades, R. .....................K-1624, 184Terranova, L. ...................G3-1553, 178Terrault, N. ........................ 584, 080Tersen, I. ........................K-234, 020Teruya, K. .......................H-224, 019Tessier, C. ......................K-2087, 252Tessier, P. R. ..................... F-2021, 247Tessitore, L. ..................... T-1040, 113Testro, A. ........................ T-369, 029Tetiurka, B. .....................G-1749, 198Teunis, P. ........................D-183, 014Texereau, M. ....................L1-963, 110Thamlikitkul, V. .......E-209, 016; K-1602, 183Thang, P. .......................M-1677, 190Tharpe, W. ...................... T-357, 029The Canadian Antimicrobial Resistance Alliance(CARA) ......................E-194, 015The Design Study Group ...........E-803, 094The Fungiscope ECMM/ISHAM Working Group,.............................M-338, 028The HUG Infection Control Team ....K-914, 104Theiler, G. .......................V-395, 030Thein, T. .............. P-567, 075; P-569, 075Theodoridou, M. ................G3-1543, 178Theusch, J. ......................K-2085, 252Thévenin, M. ....................K-2088, 252Thienphrapa, W. .......F-1514, 176; F-1999, 246Thigpen, M. C. ..................H-1570, 179Thom, K. A. ....................C2-095, 008Thomaides-Brears, H. ............. F-2016, 247Thomas, B. M. ................... F-824, 097Thomas, C. ......................K-260, 023Thomas, D. ..........F-2006, 246; F-2007, 246;............................ F-2008, 246Thomas, D. W. .......F-2062, 249; F-2063, 249;............................ F-2064, 249Thomas, H. R. ...................M-1060, 115Thomas, J. ............F-828, 097; M-1062, 115Thomas, S.. . . . . . . . . . . . . . . . . . . . . . G-1752, 198Thomas, T. A. ....................A-026, 004Thomas, V. ..........C2-705, 088; C2-709, 088Thomas, Y. ......................K-956, 108Thompson, D. ...................M-1233, 159Thompson, E. ................... P-1023, 112Thompson, J. ..................... F-810, 096Thomson, K. ...................... 1173, 149Thomson, K. S. ...................E-789, 094Thongyen, S. .....................H-894, 103Thorn, M. ......................A-1958, 241Thorne, C. ........................ 1150, 142Thorne, G. M. ..................L1-2105, 254Thornton, C. R.. . . . . . . . . . . . . . . . . .M-1682, 190Thumamo, B. P. ..................E-1994, 245Thuot, A. ........................V-389, 030Thursky, K. ...........M-315, 028; T-1027, 113Thuy, C. ........................M-1677, 190Thwaites, G. .............. 499, 060; 1811, 209Thys, Y. .........................B-044, 005Tian, Y. .........................H-552, 073Tibbetts, R. J. ...................D-1416, 170Ticchioni, M.. . . . . . . . . . . . . . . . . . . . . B-052, 005Tickler, I. A. .....................K-469, 048Tiengrim, S. ...........E-209, 016; M-976, 111Tierno, P. M. .....................K-273, 024Tijet, N. . C2-089, 008; C2-090, 008; C2-1214, 157Timke, M. ......................D-1777, 201Timmer, W. .....................A-1273, 162Timmins, G. ...........D-739, 091; F-830, 098Timmler, B. ......................V-391, 030Timsit, J. F. . . . P-568, 075; 574, 076; K-1757, 199Tinelli, M. .....................L2-304, 027Ting, L. .............A-1281, 162; A-1282, 162Tinturier, F. .....................M-1698, 191Tipton, M. .......................H-229, 019Tisdel, N. L. .....................D-158, 011Tishler, D. S. ....................A-1287, 163Tisi, G. ........................L2-304, 027Final Program253

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberTiwari, R. ...................... F-2034, 248Tjoeng, C. .......................V-381, 030Tkaczyk, C. .......... B-1736, 196; B-1737, 196Tkhilaishvili, T. ...................K-251, 022Toba, S. .............M-324, 028; M-1712, 191Tobudic, S. ......................E-1471, 174Todhunter, S. ...........B-662, 084; K-924, 105Tokimatsu, I. .....................M-324, 028Tokuda, K. ..........C2-114, 009; C2-1901, 236Tokui, T. ....................... F-2041, 248Toledano, R. .....................H-232, 019Toledo, P. ........................K-913, 104Toleman, M. A. .......C1-064, 006; C1-592, 081Tolmasky, M. .................... F-1539, 177Tomas, M. K-559, 074; C1-672, 085; C2-1902, 236Tomaselli, S. G. .........A-628, 083; A-629, 083;...................A-631, 083; A-642, 083Tomasz, A. ........................ 1881, 232Tomatis, P. E.. . . . . . . . . . . . . . . . . . . . C1-461, 047Tomayko, J. .....................A-1272, 162Tomishima, M. ..........F-818, 096; F-820, 096Tomizuka, K. .....................G-871, 101Tong, X. .............A-1245, 161; V-1080, 117Topham, D. .....................G-1048, 114Topp, E. .......................C2-1986, 244Toran, J. .........................E-202, 015Torelli, G. .......................V-393, 030Torelli, R. ........................ F-814, 096Tornos, P. ........................K-937, 106Torok, M. E. ......... L1-287, 025; L1-288, 025Toronto Invasive Bacterial Diseases Network,...........................C2-1363, 167Torre-Cisneros, J. ................. T-340, 029Torres, E. .......................C2-707, 088Torres, V. J. ....................C2-1906, 237Torresi, J. ........................ T-369, 029Tortajada, M. ...................G3-1551, 178Tórtola, M. T. ...................K-1616, 184Tosini, W. .......................V-375, 030Tossonian, H. ..........V-371, 030; H-884, 102Totet, A. ........................M-333, 028Totrov, M. ....................... F-848, 099Totsuka, K. ......................M-326, 028Totty, H. R. ......................D-162, 011Touger-Decker, R. ................L1-300, 026Tovilo, K. ........................V-398, 030Townsend, R. ....................A-1936, 240Townsend, S. M. ................. F-1518, 176Toyama, K. ..................... F-2041, 248Toyama, M. ....................C2-1989, 244Toyoda, Y. .............T-1037, 113; T-364, 029Traczewski, M. M.. . . . . . E-188, 015; D-768, 092;.............................D-771, 092Tragiannidis, A. .................G3-1547, 178Traglia, G. ...........C1-074, 006; D-1455, 172Trampuz, A.. . . . . . . . . . . D-168, 012; K-250, 022;..... K-251, 022; C1-1342, 166; D-1436, 171;........M-1719, 191; 1840, 218; F-2011, 246;............................K-2073, 250Tramsen, L. .....................M-1708, 191Tran, D. .........................K-955, 108Tran, M. ........................A-018, 003Tran, T. ........................ F-1531, 177Tran, T. T. .....................C1-1345, 166Trang, M.. . . . . . . . . . . . . . . . . . . . . . . . A-012, 003Traore, O. ......................K-2098, 252Trautner, B. W. ..................... 545, 071Treanor, J. J. ..........G-1048, 114; G-1053, 114Tremblay, C. .....................D-751, 092Tremblay, C. L. ..................H-1571, 180Trevillyan, J. ......................T-369, 029Trigoso, C. .....................C1-1205, 156Trikic, M. ......................K-1633, 185Trindade, W. .................... T-1044, 113Tripathi, S. ......................M-1061, 115Trivedi, A. ......................A-1267, 161Trivedi, I. ........................K-926, 105Trojani, C. .......................B-052, 005Troncoso, F. ....................C1-1206, 156Trottier, B. ......................H-1571, 180Trouillet, J. .....................L1-1224, 158Trouillet, S. .......... B-1317, 165; B-1319, 165Truitt, B. ....................... F-1515, 176Truong, L. ....................... F-827, 097Truong, L. X. ....................M-1677, 190Trustman, N. .....................K-241, 020Truu, J. .........................L2-310, 027Trzoss, M. ...........F-2017, 247; F-2018, 247;.................F-2018a, 247; F-2024, 247Tsai, H. Y. ......................M-1669, 190Tsai, M. ..............H-1578, 180; H-221, 019Tsai, S. .........................B-1307, 164Tsai, Y. .........................B-1321, 165Tsakris, A. ......................B-1300, 164Tsang, R. ......................G3-1542, 178Tsao, S. .......................C2-1388, 169Tsapepas, D. ..........T-1034, 113; T-1036, 113Tse, B. Y. .......................C2-081, 007Tsen, H. ........................C2-698, 087Tsimiklis, C. .....................D-751, 092Tsiodras, S. ..........K-280, 024; C2-1401, 169Tsivkovski, R. ..........F-848, 099; F-849, 099;............................. F-852, 099Tsuchida, T. ............A-607, 082; A-608, 082;.................K-1627, 185; M-1687, 190Tsuchiya, K. ......................H-890, 103Tsuchiya, Y. ..................... F-2042, 248Tsuji, B. T. .............A-016, 003; A-024, 004;.........A-031, 004; E-201, 015;A-605, 082;..................E-785, 094; A-1762, 200Tsuji, M. .............A-019, 003; F-1507, 176Tsujimoto, K. ..................... F-825, 097Tsukada, K. ............H-224, 019; H-888, 103Tsukamoto, T. ....................K-915, 104Tubach, F. ..............P-568, 075; P-570, 075Tubau, F. ....K-254, 022; B-647, 084; B-658, 084;.....C1-683, 086; A-1280, 162; C2-1395, 169Tucker, S. ........................ F-828, 097Tucker, S. P. ..................... F-2016, 247Tuduri, E. .......................D-746, 092Tulkens, P. M. ..........A-596, 082; A-597, 082;....... A-598, 082; A-599, 082; A-1278, 162;.........A-1291, 163; 1860, 227; F-2029, 247Tulliano, G. ......................K-273, 024Tulumba, S. .....................D-1442, 171Tumietto, F. .....................K-1619, 184Tuohy, M. J. ............D-735, 091; D-771, 092Tuon, F. F. ............C2-087, 008; K-913, 104;...........................L2-2113, 255Tupps, M. ...................... T-1068, 116Turano, H. G. ......... E-801, 094; F-2004, 246Turenne, C. Y. ..................... 1857, 226Turlej-Rogacka, A. ...............C2-107, 009Turner, C. ......................B-1311, 165Turner, S. J. ...........A-605, 082; M-1671, 190Turteltaub, K. W. ................. F-2027, 247Tverdek, F. P. ....................M-1705, 191Ty, P. ...........................K-932, 105Tyagi, S. ........................B-1296, 164Tyring, S. K. .....................V-397, 030Tyrrell, L. ......................... 1896, 235Tyski, S. ..............F-1533, 177; F-1996, 246Tyson, K. .......................B-1738, 196Tzanakaki, G. ..................G3-1543, 178Tzuman, O. ......................E-787, 094UUbukata, K. ........C2-1353, 167; C2-1354, 167;. . C2-1977, 243; C2-1990, 244; C2-1991, 244Uchida, S. .............F-817, 096; F-818, 096;..........F-819, 096; F-820, 096; F-821, 096Uchino, M. .....................K-1594, 182Uçkay, I. .....K-249, 022; K-929, 105; K-253, 022;............................ K-2075, 250Ueda, T. ....A-607, 082; A-608, 082; M-1687, 190254September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberUeng-Arporn, N. .........P-998, 112; P-999, 112Ueno, T. ........................D-1461, 172Uhl, J. R. .......................M-1691, 190UK Childhood Meningitis Study Group,...........................G3-1544, 178Ullmann, A. J. ..................... 1161, 146Ullum, H. .......................B-055, 005Ulrika, F. ........................M-974, 111Umeh, O. ........................A-641, 083Umejiburu, U. ...................C2-121, 009Ummels, L. ......................K-244, 021Umoh, N. O. ....................E-1994, 245Umulisa, N. .....................D-1421, 170Unal, G. .........................H-886, 102Underwood, M. ...................H-550, 073Uoyama, S.. . . . . . . . . . . .F-2035, 248; F-2043, 248Upadhyay, D. J. .................. F-2043, 248Updike, C. A. ....................E-804, 094Upputuri, V. .....................K-1589, 181Upton, A. .......................A-1259, 161Upton, A. M. .............438, 041; F-834, 098;......... F-835, 098; F-836, 098; F-837, 098;....................F-839, 098; F-840, 098Upton, M. ...................... F-1487, 175Urban, C. ..............A-014, 003; A-015, 003Urbancic, K. ...................... T-369, 029Urueña, A. ............G-874, 101; P-1015, 112;............................ P-1016, 112Usonis, V. ......................G3-1551, 178Utili, R. ........................K-2095, 252Utley, S. S. . L1-282, 025; D-770, 092; F-1520, 177Utrarachkij, F. ...................C2-712, 088Uwimana, I. M. ..................D-1421, 170Uzun Sümer, A. ..................D-1405, 170VVabret, A.. . . . . . . . . . . . . . . . . . . . . . . . D-178, 013Vachée, A. ......................L1-957, 109Vager, D. L. ...........M-986, 111; M-987, 111;............................M-1716, 191Vaid, N. .......................C2-1380, 169Vaillant, V. .....................L1-1649, 187Vaishnav, R. ......................K-242, 020Vakalis, N. .......................E-799, 094Valachis, A. ...........B-043, 005; M-1696, 191Valdes, J. ....................... F-1518, 176Vale Silva, L. ..................... F-814, 096Valentin, T. ............V-395, 030; V-398, 030;.................P-1009, 112; D-1404, 170Valerio, M. .............K-944, 106; K-950, 107;..... T-1026, 113; M-1232, 159; M-1684, 190Valery, A. ......................L1-1639, 186Valesini, G. ......................D-740, 091Valette, M. ......................K-2089, 252Valhidate Study Group ............L2-304, 027Vallé, M. ............C2-705, 088; C2-709, 088Vallejo, A. ............H-222, 019; D-743, 091;............................H-1567, 179Vallejo, M. E. .........D-747, 092; L2-2108, 255Vallejo, N. .......................K-938, 106Vallier, B. C. ....................C1-467, 047Valour, F. .......................B-1319, 165Valsamakis, A. ............429, 039; T-1070, 116Valverde, A. ......................D-753, 092Van Bambeke, F. ........A-596, 082; A-597, 082;..........A-598, 082; A-599, 082; 1143, 139;......A-1278, 162; A-1291, 163; F-2029, 247Van Benthem, B. ........K-472, 048; K-930, 105Van Broeck, J. ....................D-156, 011Van Caeseele, P. ..................C2-085, 008Van Damme, P. .................L1-1641, 186Van de Beek, D. .....L1-1222, 158; L1-1223, 158;............... L1-1648, 187; L1-1651, 187Van de Vegt, D. ...................K-244, 021Van Delden, C. ........ T-343, 029; B-1333, 165Van den Akker, F. ................C1-463, 047Van den Berg, S. ..................B-058, 005Van der Ende, A. ....L1-1222, 158; L1-1648, 187;...........................L1-1651, 187Van der Graaf, P. H. ..............A-1261, 161;.................A-1262, 161; A-1263, 161Van der Ley, P. ..................L1-1651, 187Van der Linden, M. ................G-863, 100Van der Velden, W. J.. . . . . . . . . . . . . . A-1928, 240Van Duin, D. ....................C2-692, 087Van Dyk, D. .................... F-1537, 177Van Eldere, J. ....................K-2094, 252Van Esbroeck, M. ................ P-1014, 112Van Grunderbeeck, N. ..............A-638, 083Van Hal, S. J. ........C1-062, 006; C1-1743, 197Van Heeswijk, R. ......A-1258, 161; A-1259, 161;............................A-1260, 161Van Herck, K. ..................L1-1641, 186Van Iersel, M. P. ......A-1934, 240; A-1935, 240Van Ingen, J. ...................... 1180, 150Van Keulen, M. ..................C2-104, 009Van Laethem, V. ................. T-1028, 113Van Laethem, Y. ................L1-1641, 186Van Lunzen, J. ....................H-556, 073Van Marm, S. ................... F-1516, 176Van Melderen, L. .................B-1312, 165Van Mil, C. . . E-190, 015; E-198, 015; E-803, 094Van Petersen, A. S. ...............L1-965, 110Van Praet, S. ....................D-1413, 170Van Soolingen, D. ................A-1268, 161Van Wart, S. A. .......A-1244, 161; A-1961, 241;............................ A-1962, 241Vandenberg, O. ..................D-1413, 170Vandenbroucke-Grauls, C. M. ......C2-104, 009Vandenesch, F. ........ B-1317, 165; B-1319, 165Vander, K. .......................V-398, 030Vandevoorde, A. .................A-1260, 161Vandevoorde, C. ..................A-621, 082Vandewalle, B. ....................H-878, 102Vandewoude, K. ...................K-951, 107VanHecker, J. .........A-1932, 240; D-1431, 171Vanier, G.. . . . . . . . . . . . . . . . . . . . . . . F-2023, 247Vanjak, D. .....................L2-2109, 255VanNiewenhze, M. ..............C1-1969, 242VanSchooneveld, T. C.. . . . . . . . . . . . . . K-922, 105VanScoy, B. . . A-011, 003; A-041, 004; A-042, 004Vanstone, G. L. ..................C2-081, 007Vargas, H. .....................L2-2108, 255Vargas-Shiraishi, O.. .G3-1560, 178; G3-1561, 178Varkey, R. ...................... F-1529, 177Varon, A. .......................M-1690, 190Varon, E. .............H-219, 019; G-864, 100;. . . . . . . . . . . . . . . . C2-1359, 167; G-1049, 114Varona-Bobadilla, H. J. ............C2-113, 009Vasaikar, S. D. ...................C2-101, 009Vasicek, E. M. ....................M-971, 111Vasoo, S. ......................L2-2116, 255Vaudaux, C. ......................K-560, 074Vaudry, W. .....................G3-1542, 178Vay, C. ..............C1-074, 006; D-1455, 172Vázquez, G. J. ....................E-789, 094Vazquez, J. A. .........M-986, 111; M-987, 111;.....E-1466, 173; K-1629, 185; L1-1638, 186;....L1-1653, 187; M-1713, 191; M-1716, 191Vazquez, L. .....................C1-067, 006Vázquez, M. ....................C1-067, 006Vehreschild, J. ........M-338, 028; M-1230, 159;............................M-1706, 191Vehreschild, M. J. .....M-338, 028; M-1230, 159;................ M-1234, 159; M-1706, 191Velasco, C. .....................L1-1658, 188Velasco, E. ......................M-1234, 159Velazquez-Meza, M. .............C2-1356, 167Velegraki, A. ....................M-1720, 191Veliz, O. . . . C2-084, 008; D-746, 092; F-1491, 175Vellozzi, C. .....................G-1052, 114Velmahos, V. ....................K-1923, 239Veloso, T. R. ......................B-046, 005Vema-Varapu, C. .................A-1247, 161Vente, A. ............A-1959, 241; A-1960, 241Final Program255

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberVenter, A. .......................A-1264, 161Venugopal, A. A. ..................K-923, 105Venugopalan, V. ...................K-241, 020Vera-Cabrera, L. ................C2-1357, 167Verbrugh, H. A. ...................B-058, 005Verdaguer, R. ...................L1-2102, 254Verdijk, R. M. ....................B-058, 005Verduin, K. ......................M-334, 028Vergidis, P. .......................B-652, 084Vergison, A. ............... 439, 042; 1159, 145Verhaegen, J. ...................L1-1641, 186Verhoeven, P. O. ..................D-178, 013Vermeiren, C. ..................C2-1214, 157Vernardaki, A. ..................G3-1543, 178Vernet, G. .......................D-172, 013Versporten, A. ..................G3-1559, 178Versteeg, D. ......................M-319, 028Verweij, P. E. ..........M-319, 028; E-782, 093;.......M-988, 111; M-989, 111; A-1933, 240;............................A-1938, 240Vesga, O. ............A-1945, 240; A-1968, 241Veuthey, M. ............K-250, 022; K-251, 022Veverka, M. M. .................G3-1558, 178Viale, P. ........................K-1619, 184Viana, P. O. ....................G3-1557, 178Viani, R. M. ....................H-1917, 238Vianna, R. M. ................... T-1029, 113Viasus, D. ............D-180, 013; L1-293, 026;................. L1-295, 026; L1-298, 026Vibhakar, S. ......................H-883, 102Vidal, B. ........................K-234, 020Vidyalakshmi, P. ........P-564, 075; P-565, 075;............................ P-1004, 112Viget, N. ........................H-231, 019Vignaud, J. ......................D-1408, 170Vikram, H. ..........T-1032, 113; M-1697, 191Vila, A. J. .......................C1-461, 047Vila, J. ....C1-075, 006; E-205, 016; C1-681, 086;.......C1-682, 086; C2-696, 087; K-931, 105;......B-1327, 165; B-1329, 165; D-1775, 201;................ C2-1900, 236; F-2068, 249Vila-Farrés, X. ................... F-2068, 249Vilacosta, I. ......................K-938, 106Vilchez, R. .............T-355, 029; T-1070, 116Villa, A. ........................ T-1026, 113Villareal, V. A. .................... V-377, 030Villegas, M. V. ........C2-092, 008; C1-590, 081;....... C2-694, 087; D-747, 092; K-903, 104;...........................L2-2108, 255Villers, D. .....................L1-1224, 158Vincent, W. ......................K-241, 020Vindel, A. ......................D-1415, 170Viney, J. ........................B-1311, 165Vingsbo Lundberg, C. .............A-1965, 241Vinje, J. ........................ P-1021, 112Vinnard, C. ......................D-744, 091Viola, G. M. .....................K-252, 022Virgilio, F. .......................G-874, 101Virmaux, M. .....................M-333, 028Vironneau, P. ....................M-1686, 190Viscidi, R. ....................... T-354, 029Viscoli, C. .......................M-317, 028Vishwanathan, K. .................A-632, 083Viswananthan, R. ................ F-1515, 176Viswanathan, K. .................V-1077, 117Vitali, L. .......................C2-086, 008Viu, D. .........................L2-303, 027Vivas, M. ..............B-647, 084; B-658, 084Vivier-Darrigol, M. ................ P-996, 112Vizzotti, C. ...........G-874, 101; P-1015, 112;............................ P-1016, 112Vlachou, A. ....................L2-2114, 255Vlake, A. W. ....................L1-965, 110Vogelaers, D. .....................K-951, 107Vogler, A. J. .....................L1-964, 110Voirol, P. .......................K-2088, 252Voit, S. .........................K-1586, 181Volkow, P. ......................C1-067, 006Von Eiff, C. .....................E-1483, 174Von Kries, R. .....................G-863, 100Von Sonnenburg, F. ................. 1825, 211Voss, A. ....... 485, 054; K-244, 021; E-803, 094Vossier, L. ...................... F-1488, 175Vouillamoz, J. ........... B-046, 005; B-659, 084Vu, T. ..........................B-1312, 165Vu-Cantero, D. ................... T-343, 029Vugia, D. J. ....................... 1728, 194Vuichard, D. ....................H-1566, 179Vullo, V. ..............D-165, 012; D-740, 091;.................D-742, 091; C2-1373, 168WWaako, P. ........................H-893, 103Wachino, J. .....................D-1456, 172Wack, M. F. ..................... F-1520, 177Wada, Y. ..............A-607, 082; A-608, 082;............................M-1687, 190Waddell, S. T. ................... F-1496, 176Wagener, M. .........M-337, 028; M-1227, 159Wagenlehner, C. .................A-1285, 162Wagenlehner, F. M. ...............A-1285, 162Wagner, D. M. ...................L1-964, 110Wagner, G. ..................... T-1064, 116Wagner, J. . . .A-009, 003; A-010, 003; V-398, 030;. . . . . . P-1009, 112; D-1404, 170; K-1615, 184Wagner, M. ......................K-473, 048Wagner-Eibel, U. ................E-1470, 173Wahlers, K. ......................M-338, 028Wainaina, J. N. ...................D-153, 011Wainberg, M. A. .................H-1571, 180Wajima, T. ...........A-019, 003; C2-1990, 244;...........................C2-1991, 244Walchak, R. C. ..................M-1691, 190Walia, S. K. .....................C2-703, 088Walk, S. T. ............ K-926, 105; T-1068, 116Walker, C. .......................M-977, 111Walker, I. ........................H-881, 102Walker, J. R. .....................C1-680, 086Walkty, A. ...........C2-135, 010; C2-149, 010;.........E-191, 015; E-200, 015; E-779, 093Wallace, C. J. ....................C1-590, 081Wallace, R. J. ...................... 1859, 226Wallengren, K. ...................B-1296, 164Wallis, R. S. ..........A-1257, 161; A-1264, 161Wallner, C. ..................... P-1009, 112Walmsley, S. .....................H-882, 102Walmsley, S. L. .........1849, 222; H-1920, 238Wals, P. D. ......................G-1047, 114Walsh, C. T. ........................ 007, 002Walsh, T. .............M-972, 111; M-981, 111;. . . . . . . . . . . . . . . . . . . M-1681, 190; 1853, 224Walsh, T. .......................M-1720, 191Walsh, T. R. ..........C1-064, 006; C1-592, 081Walti, L. N. ........... D-168, 012; K-250, 022;..................K-251, 022; K-2073, 250Wang, B. .... F-834, 098; F-843, 099; F-844, 099;............................. F-845, 099Wang, C. J. ......................H-554, 073Wang, H. L. .................... F-1498, 176Wang, H. .............G-868, 101; F-1496, 176Wang, J. . . . A-027, 004; A-031, 004; C2-097, 008;. . . . . . . . . . . . . . . . . K-270, 024; L1-1654, 188Wang, L. ............. 1189, 153; C2-1393, 169Wang, M. X. .....................H-554, 073Wang, M. G. .....................A-640, 083Wang, M. ..........B-1332, 165; C2-1355, 167Wang, N. ....................... F-1517, 176Wang, P.. . . . . . . . . . . . . . . . . . . . . . . C2-1355, 167Wang, Q. ....................... F-1498, 176Wang, S. . . .K-278, 024; H-553, 073; H-1581, 180Wang, W. ......... C2-1388, 169; D-1422, 170;.......F-1497, 176; F-1498, 176; F-1501, 176Wang, X. K. ..................... F-1499, 176256September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberWang, Y. . . . K-268, 023; C2-702, 087; F-834, 098;..... F-835, 098; C2-1987, 244; L2-2107, 255Wang, Z. ....................... F-1501, 176Warburton, P. ..................C2-1983, 243Ward, D. ........................H-555, 073Wardyn, S. .....................C2-1384, 169Wareham, D. ......... C2-102, 009; D-761, 092;. . . . . . . . . . . . . . . . . . E-797, 094; B-1299, 164Wargin, W. .............F-839, 098; F-840, 098Warn, P. ..............F-842, 099; F-1530, 177;. . . . . . A-1943, 240; A-1944, 240; F-2066, 249Warner, M. ........... E-192, 015; F-2048, 248Warrener, P. .......... F-1529, 177; B-1734, 196Washington, C. .................C2-1361, 167Waskin, H. .....................A-1935, 240Waskins, H. .....................A-1934, 240Watabe, R. ...................... F-1509, 176Watanabe, K. ...........H-223, 019; H-888, 103Waterman, P. ........C2-725, 089; C2-1914, 237Waters, C. ......................M-1062, 115Watson, S. .......................K-265, 023Watters, A. A. ................... F-1510, 176Watts, J. ........................ F-2034, 248Watts, J. L. ......................C1-670, 085Wawrzak, Z. ...................C1-1344, 166Webber, M. A. ...................C1-674, 086Weber, A. T. .....................B-1336, 165Weber, M. M. ...................M-1691, 190Weber, P. D. .....................D-1773, 201Wei, H. .........................K-933, 105Wei, X.. . . . . . . . . . . . . . . . . . . . . . . . . A-1250, 161Weigert, R. .....................K-2074, 250Weinberger, M. .................. P-1001, 112Weiner, E. M. ................... F-1534, 177Weintraub, E. S. .................G-1054, 114Weiser, M. ....................... T-343, 029Weiss, P. .........................B-653, 084Weiß, S. .......................C1-1350, 166Weissman, S. ....................C2-115, 009Weist, K. ......................... 1789, 204Wellems, T. E. ..................... 1199, 155Weller, S. .......................A-1246, 161Wells, C. .......................A-1255, 161Wells, T. .......................... 1201, 155Wen-Chien Chou ................M-1669, 190Wendel, A. F. ....................C1-588, 081Wendel, S. K. ....................H-1580, 180Wengenack, N. L. ................M-1691, 190Wennerås, C. .................... T-1042, 113Wenning, L. ....................A-1763, 200Wenzel, P. .....................C2-1214, 157Wereszczynski, J. ................. F-1534, 177Werner, P. .....................C2-1382, 169Werth, B. J. ............A-600, 082; A-602, 082;.........A-603, 082; A-626, 083; A-627, 083Wertheim, H. F. ................. P-1024, 112Wessels, M. ........................ 581, 079Westbrook, S. D. .................M-1674, 190Westphal, J. .....................K-2100, 253Wever, P. C. .....................L1-965, 110Weyer, K. .......................... 535, 069Wheat, L. J. ..................... T-1066, 116Whichard, J. M. ..................C2-695, 087Whitcomb, J. ....................H-1574, 180White, K. .............H-556, 073; H-1574, 180White, P. ........................K-277, 024Whitlam, J. ...................... T-369, 029Whitley, R. J. ....................V-1080, 117WHONET-Argentina Group ......C2-701, 087Wi, Y. .........................K-1587, 181Wible, M. .....................C2-1906, 237Wickes, B. ......................D-1449, 172Wickes, B. L. ....................M-1674, 190Wickham, K. .....................D-163, 011Widen, R. ......................D-1446, 172Widmer, A. F. ........ C2-082, 007; D-167, 012;......................1139, 136; 1878, 231Wiederhold, N. P. .........412, 035; B-650, 084;. . . . . . .F-823, 096; M-1674, 190; M-1682, 190Wielens, J. ....................... F-828, 097Wiener, A. .......................K-953, 108Wienzek-Lischka, S. ............... T-341, 029Wiesman, W. P. .................. F-1518, 176Wikman, P. ......................D-743, 091Wilcox, M. ........... D-160, 011; K-474, 048;.......... B-662, 084; K-924, 105; 1846, 221Wildhaber, B. E. ................G3-1556, 178Wilkins, P. P. ...................... 1892, 234Wilkinson, A. .........F-2065, 249; F-2066, 249Wilkinson, T. ....................A-1943, 240Will, S. .........................M-335, 028Willey, B. .............C2-085, 008; K-281, 024;...........................C2-1214, 157Williams, A. J. ...................G-1748, 198Williams, A. .....................B-664, 084Williams, G. ...........A-630, 083; A-631, 083;............................A-1761, 200Williams, J. D. .................... F-816, 096Williams, K. ..................... F-836, 098Williamson, D. A. . . . G3-1555, 178; C2-1908, 237Williamson, J. C. ................C2-1390, 169Williamson, P. R. ..................M-314, 028Willis, D. ........................D-736, 091Willis, L. ......................G3-1544, 178Wilmer, A. ............D-161, 011; K-1593, 182Wilson, A. N. ....................K-262, 023Wilson, A. ......................M-1062, 115Wilson, A. C. ..................G3-1558, 178Wilson, D. ......................M-1670, 190Wilson, G. ......................C2-699, 087Wilson, L. E. ....................C2-095, 008Win, T. ......................... F-841, 099Windau, A. R. ....... C2-1361, 167; F-2059, 249Windsor, H. ......................E-207, 016Wine, B. ..............H-882, 102; H-895, 103Wing, S. ......................C2-1912, 237Winkle, P. ......................A-1250, 161Winkler, M. ...................... F-847, 099Winkler, M. L. ......C1-463, 047; C1-1209, 156Winner, J. .......................D-153, 011Winthrop, K. L. ................... T-345, 029Wipasa, J.. . . . . . . . . . . . . . . . . . . . . . . D-1406, 170Wirth, V. ........................ F-828, 097Wise, E. ........................B-1311, 165Wiskirchen, D. E. .................A-013, 003Wisniewski, T. ....................D-153, 011Wisplinghoff, H. .....M-1230, 159; D-1423, 170;. . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1706, 191Witmer, M. ......................H-551, 073Woei Tsay ......................M-1669, 190Woerther, P. ......................D-772, 092Wohl, D. ........................H-895, 103Wohlert, S. .....................A-1960, 241Wolfe, A. ........................K-561, 074Wolff, F. .........................A-637, 083Wolff, M. ....A-021, 003; P-568, 075; P-570, 075;. . . . . . . . . . . . . . . . M-1707, 191; L2-2117, 255Wolfhagen, M. ...................M-334, 028Wollenberg, L. ....................A-016, 003Wollenhaupt, M. ......A-1245, 161; G-1749, 198Wong, A. ........................K-243, 021Wong, C. K. .....................K-909, 104Wong, J. ........................K-1636, 185Wong, J. G. ...................... P-567, 075Wong, K. ..........C2-1362, 167; C2-1363, 167;...........................C2-1364, 167Wong, S. ............F-1537, 177; F-2018, 247;........................... F-2018a, 247Wong, T. ............D-161, 011; C2-1380, 169Wong-Beringer, A. .......K-932, 105; 1167, 147;. . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1586, 181Wongkulab, P. ...................D-1406, 170Woo, J. ......D-741, 091; T-366, 029; K-907, 104;. . . . . . V-1074, 117; V-1239, 160; K-2092, 252Wood, S. .......................A-1956, 241Final Program257

Author INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberWoodford, N. ....... C2-102, 009; D-1451, 172;.............................. 1786, 204Woods, A. L. ...................C1-1973, 242Woods, C. W. ...................C2-117, 009Woodward, M. J. ................C1-1208, 156Workowski, K. ....445, 043; 477, 050; H-879, 102Worley, S. .....................G3-1546, 178Wormser, G. P. ..................... 451, 044Wren, M. ........................D-160, 011Wright, C. ............F-2063, 249; F-2064, 249Wright, D. W. ..................... 1796, 206Wright, G. ......................... 434, 040Wright, K. ......................K-1620, 184Wroe, A. ........................K-927, 105Wu, C. ........................C2-1987, 244Wu, G. .........................A-1766, 200Wu, H. .........................H-554, 073Wu, J. F. ..............F-1503, 176; F-1504, 176Wu, J. . . . C2-118, 009; C2-1384, 169; A-1763, 200Wu, J. F. .........................A-640, 083Wu, J. ..........................A-1283, 162Wu, P. .........................L2-309, 027Wu, S. ........................C2-1903, 236Wu, U. .........................C2-097, 008Wu, X. J. . . .A-640, 083; F-1503, 176; F-1504, 176Wu, X. ....C1-068, 006; C1-595, 081 A-1283, 162Wu, Y. .........................A-1289, 163Wyles, D. L. ...................... 1781, 202XXercavins, M. .........C2-111, 009; K-1621, 184Xerinda, S. .......................H-227, 019Xiao, X. ........................ F-1526, 177Xiao, Y. ........................... 422, 037Xie, D. ..........................H-554, 073Xie, L. .............. C1-680, 086; F-1540, 177Xie, Y. ..........................H-554, 073Xiong, Y. .............G-868, 101; E-1474, 174Xiong, Y. Q. ............B-646, 084; B-654, 084;..................B-655, 084; E-1468, 173Xu, H. ..........................K-268, 023Xu, J. ........................... F-834, 098Xu, T. ..........................M-1061, 115Xu, W. .............M-1056, 115; M-1061, 115Xu, Y. ..............V-1078, 117; G3-1550, 178Xu, Y. H. ....................... F-1498, 176Xu, Y. ..............C2-702, 087; L2-2107, 255Xue, B. . . . A-1261, 161; A-1262, 161; A-1263, 161Xue, M. .........................K-239, 020YYılmaz, G. ......................D-1405, 170Yakubchyk, Y. A. .................. P-997, 112Yamada, A. ....................C2-1989, 244Yamada, E. ....................... F-809, 096Yamada, K. ............B-048, 005; B-049, 005;.................. B-657, 084; B-1297, 164Yamada, M. ......... C2-114, 009; D-1460, 172;...........................C2-1901, 236Yamada, R. ......................H-890, 103Yamagishi, Y. .........L2-305, 027; M-325, 028;......M-328, 028; C2-693, 087; A-1288, 163;................ C2-1989, 244; F-2045, 248Yamaguchi, K. ....................B-056, 005Yamaguchi, T. ..................L1-1657, 188Yamamoto, M. .........K-949, 107; K-1599, 182Yamamoto, T. ...................C1-1340, 166Yamamoto, Y. ..........B-049, 005; V-380, 030;.................. B-657, 084; B-1297, 164Yamane, K. .....................D-1456, 172Yamano, Y. ............F-1506, 176; F-1507, 176Yamasaki, H. ..................... F-825, 097Yamashita, K. ..................... F-809, 096Yan, J.. . . . . . . . . . . . . . . . . . . . . . . . . . C2-118, 009Yan, Q. ..........................K-936, 105Yan, Y. ..........................H-551, 073Yanagihara, K. ..........B-048, 005; B-049, 005;........V-380, 030; B-657, 084; B-1297, 164;............................D-1460, 172Yanai, N. ......................G3-1545, 178Yañez, L. ....................... T-1038, 113Yang, C. .............C2-097, 008; L2-309, 027;.................H-1578, 180; K-1607, 183Yang, F. .......................C2-1355, 167Yang, H. .......................C2-1215, 157Yang, J. ................H-221, 019; G-867, 100Yang, J. B. ...................... F-1489, 175Yang, J. ..........................K-933, 105Yang, K. ..............A-016, 003; A-1243, 161Yang, L. .........................H-229, 019Yang, N. ............B-1309, 165; C2-1978, 243Yang, P. L. .......................V-377, 030Yang, Q. ............C2-702, 087; L2-2107, 255Yang, S. ........................E-1468, 173Yang, T. ............... F-839, 098; F-840, 098Yang, X. Y. ...................... F-1499, 176Yang, Z. ..............H-215, 018; V-1238, 160Yankelev, S. ....................L1-2105, 254Yano, H. ............C2-114, 009; C2-1901, 236Yansouni, C. P. ................... P-1014, 112Yant, S. .........................H-892, 103Yao, C. ..........................H-554, 073Yapar, M. ........................D-158, 011Yasuhiro, K. .....................A-1955, 241Yasui, K. ........................D-1438, 171Yau, C. ..........................K-243, 021Yazaki, A.. . . . . . . . . . . . .F-2049, 248; F-2055, 248Yazdanpanah, Y. ......L1-957, 109; V-1073, 117;...........................L2-2117, 255Ye, X. Y. .........................A-640, 083Ye, X. ..........................B-1332, 165Ye, Z. ..............C1-677, 086; C1-1351, 166Yeaman, M. ......................G-868, 101Yeang, M. ....................... P-569, 075Yebenes, J. .....................L1-1643, 186Yen-Lieberman, B. ..............G3-1546, 178Yeni, P. .........................V-1073, 117Yeni, P. G. ........................ 1186, 152Yesilkaya, A. ....................C2-684, 087Yew, W. W. .....................E-1992, 245Yi, J. ................H-1564, 179; K-2076, 250Yildirim, A. .....................M-1701, 191Yilmaz, G. ....................... V-394, 030Yilmaz, H. .......................V-394, 030Yilmaz, S. ......................D-1427, 171Yin, M. T. ............A-026, 004; K-1620, 184Yin, N. ...... F-843, 099; F-844, 099; F-845, 099;............................. F-846, 099Yin, X. .........................A-1250, 161Yip, C. W. ......................E-1992, 245Yoneyama, A. .....................K-897, 104Yong, C. ........................A-1248, 161Yoo, J.. . . . . . . . . . . . . . C2-1215, 157; K-1632, 185Yoon, B. .........................H-213, 017Yoon, E. J. ......................C1-676, 086Yoon, M. J. ............K-276, 024; K-1635, 185;K-2078, 250Yoshida, M. ...........F-825, 097; D-1402, 170Yoshida, O. ...........F-1506, 176; F-1507, 176Yoshimura, T. ....................D-1402, 170Yoshinaga, T. .....................H-550, 073Yoshizawa, S. .....................K-918, 105Yoshizumi, A. ........C1-077, 006; D-1438, 171You, X. F. ....................... F-1499, 176You, X. ......................... F-2002, 246Young, B. ........................H-882, 102Young, C. ........................D-185, 014Young, K. .............A-008, 003; C2-724, 089;....... D-767, 092; M-979, 111; M-984, 111;......M-1057, 115; F-1496, 176; A-1763, 200Young, M. ......................H-1575, 180Young, V. B. ......................K-926, 105258September 9-12 |

AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberYousef, A. E. .................... F-1508, 176Yu, G. ...............F-1999, 246; F-1515, 176Yu, H. H. ........................E-795, 094Yu, H. ..........................K-259, 023Yu, J. C. . . . .A-640, 083; F-1503, 176; F-1504, 176Yu, J. ................D-755, 092; A-1283, 162Yu, M. ..........................K-926, 105Yu, M. A. ....................... T-1068, 116Yuan, H. ............F-1499, 176; F-1500, 176;. . . . . . .F-1501, 176; F-1502, 176; F-1503, 176;............................ F-1504, 176Yuan, Z. Y. ...........F-1500, 176; F-1501, 176;..................F-1503, 176; F-1504, 176Yuichi, K. ....................... F-2037, 248Yumoto, S. ......................D-1438, 171Yun, H. .........................G-875, 101Yung, C.. . . . . . . . . . . . . . . .P-567, 075; P-569, 075Yung, S. C.. . . . . . . . . . . . . . . . . . . . . . . B-057, 005Yungyuen, T. ....................E-1477, 174Yuste, J. R. ...........D-1439, 171; D-1440, 171ZZabner, J. .......................B-1322, 165Zadeikis, N. .....................A-1936, 240Zahar, J. R. ....................L2-2109, 255Zainah, H. ......................M-1716, 191Zaiss, N. H. ......................D-179, 013Zambardi, G. .E-197, 015; D-745, 092; D-748, 092Zambon, M. ...................... 1895, 235Zamorano, L. ........C1-593, 081; C1-1970, 242Zampaloni, C. ........C2-133, 010; C2-140, 010;............................ F-2067, 249Zampiero, A. ...................G3-1553, 178Zander, E. ......................C1-070, 006Zanetti, G. ......................K-2088, 252Zapico, S. ........................M-321, 028Zaragoza, R. ...........K-948, 107; K-950, 107Zarfel, G. .......................E-1470, 173Zariri, A. ......................L1-1651, 187Zarrouk, V. .....................K-2087, 252Zavascki, A. P. ......... A-027, 004; D-749, 092;.................K-913, 104; C2-1905, 236Zeder, A. J. ......................H-887, 103Zeidan, J. ........................H-553, 073Zeitlinger, M. A. ..................E-783, 093Zelenitsky, S. . A-040, 004; A-613, 082; A-639, 083Zerr, D. M. ....................... 1827, 212Zerva, L. . . E-782, 093; A-1939, 240; A-1940, 240Zervos, M. .......................K-276, 024Zervos, M. J. ...........A-609, 082; K-912, 104;................K-1597, 182; L1-1655, 188Zeuzem, S.. . . . . . . . . . . . . . . . . . . . . . V-1236, 160Zha, J. ......................... F-1529, 177Zhai, L. .........................B-663, 084Zhai, Q. Q. ..................... F-1499, 176Zhanel, G. .............A-040, 004; A-639, 083Zhanel, G. G. ........C2-103, 009; C2-135, 010;........C2-149, 010; E-191, 015; E-194, 015;.......E-200, 015; E-779, 093; C2-1360, 167;..... C2-1379, 169; E-1462, 173; E-1486, 174Zhang, H. .....................L2-2107, 255Zhang, J. .............A-640, 083; F-1503, 176;...... F-1504, 176; F-2017, 247; F-2018, 247;......F-2018a, 247; A-1283, 162; F-2024, 247Zhang, K. J. ..................... F-1503, 176Zhang, L. ........................ F-838, 098Zhang, M. ..........V-1078, 117; G3-1550, 178Zhang, Q. .....................C2-1987, 244Zhang, S. .... F-843, 099; F-844, 099; F-845, 099;.................... F-846, 099; 1843, 219Zhang, T. ........................H-554, 073Zhang, W. X. .................... F-1499, 176Zhang, W. ...................... F-2002, 246Zhang, Y. Y. ..........F-1497, 176; F-1503, 176;............................ F-1504, 176Zhang, Y. .............F-827, 097; A-1264, 161;................. B-1332, 165; F-2072, 249Zhang, Y. Y. ......................A-640, 083Zhang, Y. .......................A-1283, 162Zhao, H. ..............H-882, 102; H-895, 103Zhao, H. X. ......................H-554, 073Zhao, J. ...............H-885, 102; K-933, 105Zhao, J. J. ..............K-262, 023; K-275, 024;..................K-902, 104; K-1121, 129Zhao, L. ........................C2-095, 008Zhao, P. .........................D-172, 013Zhao, X. .......................... 1791, 205Zhao, Y. ..............E-792, 094; T-1031, 113;.....C2-1216, 157; M-1678, 190; F-2002, 246Zhong, D. F. ..........F-1500, 176; F-1501, 176Zhou, D. ..............A-634, 083; A-635, 083Zhou, H. ........................K-936, 105Zhou, J. L. ...................... F-1501, 176Zhou, Q. ........................K-269, 023Zhou, Y. J. .......................A-640, 083Zhu, D. M. ..................... F-1497, 176Zhu, D. ............B-1332, 165; C2-1355, 167;............................ F-2036, 248Zhu, J. Z. ............A-1276, 162; A-1277, 162Zhu, L. .........................M-982, 111Zhu, Q. .........................K-268, 023Zhu, T. ....F-827, 097; A-1261, 161; A-1262, 161;. . . . . . . . . . . . . . . . . A-1263, 161; A-1264, 161Zimmerman, O. ......M-985, 111; M-1059, 115Zimmermann, H. ....... T-356, 029; V-391, 030Zimmermann, S. ........C2-093, 008; 1132, 133Zingg, W. ....K-914, 104; K-929, 105; 1082, 118;.......... 1802, 208; 1838, 217; K-2075, 250Zinkernagel, A. ..................K-1125, 129Zinner, S. H. ....................A-1967, 241Zinsou, R. ......................B-1737, 196Ziochos, H. .....................C1-062, 006Zito, E. ........................... 575, 077Zollner-Schwetz, I. ......V-395, 030; V-398, 030;. . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1009, 112Zollos, D.. . . . . . . . . . . . D-766, 092; E-1463, 173;............................E-1467, 173Zorreguieta, A. .................. F-1539, 177Zou, P. ..........................K-905, 104Zoulim, F. ......................... 428, 039Zuerenko, G. .....................A-008, 003Zurita, J. ........................K-900, 104Zurita, S. ........................M-327, 028Final Program259

NOTES260September 9-12 |

KEYWORD INDEX13-valent Pneumococcal Conjugate Vaccine......................... G-864, G-104913C-isonizid .........................F-83016S rRNA methylase .................C1-120316S-23S rRNA gene ..................D-144316S-rRNA ...........................D-74318S rRNA ......................... M-10622-pyridone ......F-2030, F-2031, F-2032, F-2033AA549 ...............................E-780AAC(6’)-Ib-cr .........D-759, C2-700, B-1306abacavir ...................... H-882, H-895AbaR .............................C2-1899ABC transporter ..................... M-975abdominal ......................... M-1685abdominal prosthetic aortic graft ..........K-263ABSSSI .....C2-1396, K-1598, L1-1663, A-1957accessory gene regulator. . . . . . . . . . . . . . . C2-1395accident and emergency .................K-242ACH490 ...........................B-1302Achromobacter ........................D-1455Achromobacter xylosoxidans ..............C1-074Acinetobacter A-030, B-049, C1-071, E-789, F-2039Acinetobacter baumannii . . . A-024, C1-069, D-171,.......K-559, C1-676, E-784, E-786, E-785,. . E-787, E-788, F-841, K-899, K-902, K-905,. . . B-1327, B-1329, D-1422, K-1602, K-1604,.........K-1605, K-1606, K-1607, C2-1897,......C2-1898, C2-1899, C2-1902, C2-1903,. . C2-1904, C2-1905, F-2010, F-2043, F-2067Acinetobacter baumannii multidrug-resistant.................................E-202Acinetobacter spp. .............. C1-458, C2-1901acne .........................D-776, F-2009activation ............................B-052active surveillance ...................L1-1641activity ................F-1510, F-1511, F-1512acute respiratory infection .............G3-1548acute bacterial skin and skin structure infections.........................A-1961, A-1962acute HIV ..........................H-1568acute illness severity ....................K-910acute laryngitis .......................L1-299acute myocardial infarction ..............H-228acyclovir 5%/ hydrocortisone 1% cream .....V-397adenosine deaminase ...................D-182adenovirus ....................D-1778, T-363adequacy ...........................K-2091adherence .........H-211, H-212, P-565, H-884,........................B-1322, C2-1400adhesin ............................B-1332adjusted dosage .......................A-610ADME ......................F-839, A-1267adolescent ..........................A-1292adsorbent ...........................A-1963adult ................... M-322, P-566, K-956AdvanSureTM Mycobacteria GenoBlot Assay.................................D-734adverse drug effects ..................L1-1661adverse event . .L1-284, G-1052, L1-1664, K-2075aetiology ..........................L1-1649affirm test ..........................L2-306AFM ..............................D-1436AFN-1252 ..........................E-1486Africa ..............................C2-107Africa Middle East ...................C2-150age ....................H-556, H-880, H-879AGR .............................C2-1906agricultural azole antifungals ............ M-320AIC316 .............................V-391AIDS ........................H-220, A-1253airsamplers ...........................K-244albumin ......................D-180, P-1022algorithm ...........................L1-286alliaceus ............................ M-321allogeneic hematopoietic stem cell transplantation.................................T-360alpha toxin ..........................B-1736alternate dosing strategies ..............A-1928AmBisome ..........................P-1013Amikacin ..........................L1-1647Aminoglycoside resistance ...............A-042Aminoglycosides .........A-038, C1-458, E-779Amp C beta lactamase producing bacteria . .D-774Amp C Etest .........................D-774AmpC ................C2-079, C2-103, F-855AmpC -lactamases ..................C2-082amphotericin B .........H-220, M-977, M-982,...........M-992, M-1225, A-1939, A-1940Amphotericin B colloidal dispersion ......P-1000Ampicillin ...........................K-274Ampicillin + Ceftriaxone ................K-938Ampicillin + Gentamicin ................K-938Ampicillin plus Ceftriaxone .............K-945anaerobes ...............B-048, C1-671, F-854,.........................D-1774, F-2045ANAEROBIC QC ....................E-188anal ...............................L2-301anal intraepitelial neoplasia .............H-1921anidulafungin ......... M-311, M-989, M-1229,........................M-1683, M-1709animal ............................. M-991animal efficacy ................. F-842, F-1523animal model ...........G-875, M-980, P-1013,....B-1307, D-1431, A-1948, F-2035, F-2043,.........................F-2056, K-2097antagonism ..........................E-782anthropology ........................K-2080anti-influenzal agents ..................V-388anti-M2e mAb .......................G-873anti-MRSA antibiotics . . A-038, E-1466, E-1472,................................ F-1514anti-phagocytosis .....................B-1325anti-staphylococcal ....................B-656anti-TNF ............................D-740anti-tuberculosis treatment .............A-1264antibacterial ......A-628, A-642, D-768, F-1497,. . . . F-1498, F-1499, F-1501, F-1502, F-1503,....F-1504, F-1515, F-1527, F-1528, L1-1662antibacterial activity .....F-1488, F-1533, F-2044,......................... F-2045, F-2062antibacterial combination ........E-793, E-1485antibacterial mode of action ............F-2062antibacterial time-kill activity E-783, E-789, E-804antibio-resistance .....................P-1010antibiofilm ..........................C1-673antibiogram . . . L1-282, D-756, D-1441, C2-1980antibioresistance ......................K-470antibiotic ......L1-287, L1-288, F-2030, F-2031,......................... F-2032, F-2033antibiotic combinations .................A-030antibiotic consumption . . . K-234, L1-285, K-1595antibiotic resistance ....C1-065, C2-106, C2-152,....B-654, C1-666, C1-467, C2-684, C2-725,. . . G-866, P-1002, P-1024, G-1050, C1-1204,........C2-1399, D-1451, K-1636, C1-1972,...............C2-1979, C2-1986, L2-2117antibiotic resistance genes .......C1-074, D-1454antibiotic susceptibility . . . D-756, D-771, E-1480antibiotic use . . . K-1613, K-237, L2-2118, P-1024antibiotics ...... L1-291, A-638, K-935, B-1330,....F-1500, K-1591, G-1750, F-2003, K-2075antibiotics resistance .........C2-1353, C2-1401antibody ........ P-994, P-1016, V-1077, B-1738antibody response ....................H-1580antibody-dependent enhancement .......B-1734antifungal ........ M-317, M-331, F-810, F-816,........F-818, F-819, F-820, M-976, M-982,. . . M-983, M-1061, M-1714, A-1930, A-1936antifungal activity ..............M-974, F-1533antifungal agent .......................F-809antifungal combination therapy ......... M-1711antifungal combinations .............. M-1719antifungal drug response prediction ...... M-1695antifungal drugs ......................A-1946antifungal prophylaxis ................ M-1711Final Program261

Keyword INDEXantifungal stewardship ................ M-1232antifungal surveillance ................. M-330antifungal susceptibility ..........M-318, M-971antifungal susceptibility testing .......... M-311antifungal therapy .....M-338, M-1063, G3-1559antifungals ....................T-349, M-1232antigen ............................ M-1693antigen antibody combination assay ......H-1582antigen expression .....................G-870antigenemia ..........................T-355antimicrobial .......... C2-706, F-810, A-1284,.........................F-2001, K-2097antimicrobial activity .....F-1492, F-1532, F-1996antimicrobial agents ........K-252, F-825, F-831,.............F-833, P-1019, F-2010, F-2061antimicrobial coated endotracheal ........F-2014antimicrobial consumption .............K-1925antimicrobial peptide ......B-656, F-829, F-1487,............F-1489, F-1490, F-2060, F-2068antimicrobial resistance ......... C2-137, K-280,....L2-308, K-558, C2-698, C2-705, C2-709,...........C2-713, D-750, D-775, C2-1362,........ C2-1364, D-1449, G3-1562, K-1924antimicrobial stewardship ........ K-233, K-241,.........................K-1923, K-1924antimicrobial stewardship program ........K-235antimicrobial susceptibility ....... D-181, E-209,...............C2-1356, C2-1978, L2-2107antimicrobial susceptibility testing ....... D-736,. D-754, D-755, D-765, D-766, E-802, E-806,.........C2-1360, D-1423, D-1441, E-1463,.........................E-1467, F-2021antimicrobial therapy ............K-272, K-1927antimicrobial utilization ...............K-1923antimicrobials ........L1-299, F-1513, M-1696antiretroviral drugs ....................H-894antiretroviral therapy ......H-211, H-225, H-886,............................... H-1565antisense ...........................F-1539antisense antibiotic ..................C1-1972antiseptic ...........................F-2058antiviral ..........T-367, V-377, V-382, A-1246antiviral activity .......................F-824antiviral therapy .......................V-373anxiety ..............................H-232apo E ...............................V-372apoptosis .....................M-972, M-978arasertaconazole ...............M-980, M-1718arbovirus ...................... P-567, P-569Argentina. . . . . G-874, P-1015, P-1016, C2-1217,.......................C2-1398, C2-1910argyrin ............................C1-1973ART-naïve patients, ART experienced patients................................H-1572aseptic failure .........................K-258Asia/Pacific rim ......................C2-689ASP9726 ............................F-822Aspergillosis ....F-823, G-875, M-981, M-1060,. M-1225, M-1226, M-1676, M-1701, M-1704Aspergillus ........M-319, M-330, M-337, T-343,.........T-347, F-817, F-818, F-819, F-821,.........M-1227, M-1681, M-1714, A-1930,.........................A-1932, A-1940Aspergillus calidoustus ...................F-809Aspergillus fumigatus ......M-335, M-987, M-989,.................A-1938, M-1716, M-1719Aspergillus terreus ..................... M-332Asplenia ...........................L1-1648assessment ..........................K-2083Asunaprevir .........................A-1247Asymptomatic bacteriuria. . . . . . . . . . . . . . . L2-2114Atazanavir .......H-882, H-888, H-889, A-1251Atlantic salmon innate immunity ........B-1330ATLAS .............................K-928atopic dermatitis ..............D-1439, D-1440ATP-binding cassette ................C1-1349AUC/MIC .........................A-1768Austria .............................P-1009authochtonous .......................P-1009autoantibody ........................D-1406autoimmune rheumatic diseases ........L2-2114automation ..........................D-727avibactam .........E-190, E-194, A-633, A-634,..........................A-635, A-1760Azadirachta indica .....................F-812Azithromycin ........................L1-296Azithromycin extended release formulation . .V-400azole .................M-319, F-815, M-1711azole resistance . . . M-334, F-814, M-988, M-969B-D-glucan ........................ M-1687-lactamase inhibitor ...................F-855-lactams ...........................E-1478-lactams resistance mechanisms .......C1-1970B-cell malignancies ...................T-1042B. pseudomallei ........................F-2022BAC libraries .......................C2-1983Bacillus anthracis ......................C2-1980bacteremia .....B-058, C2-110, C2-127, C2-152,....... K-241, K-248, K-272, K-276, L1-297,.......B-650, C2-690, D-772, K-897, K-898,. K-899, K-901, K-909, K-913, K-915, L1-961,....T-1030, T-1031, T-1039, T-1045, D-1419,. . . K-1592, K-1597, K-1601, K-1619, K-1624,.K-1630, K-1635, L1-1638, L1-1642, L1-1658,. .K-1759, C2-1901, K-2086, K-2091, L2-2110bacteria ............................C2-711bacteria resistance .....................K-911bacterial ...........................L1-1221bacterial identification ....D-729, D-730, D-1461bacterial infection .....C2-1384, K-2075, T-1040bacterial meningitis ..........L1-1222, L1-1223,.......L1-1224, G3-1543, L1-1648, L1-1652bacterial resistance ....................A-1967bacterial topoisomerases ........F-2017, F-2018abactericidal ............F-1514, F-1516, F-1531bactericidal activity .............E-210, A-1264Bacteroides ..........................C2-140Bacteroides spp. ........................E-805bactobilia ...........................K-1608BAL30072 ..........................A-1285bariatric surgery .......................K-265barrier ....................... F-2015, V-385BC-3781 ..................C1-1971, L1-1660benzamil hydrochloride ................F-2000beta lactam i .........................E-196beta-cyclodextrin .....................F-2005beta-glucan ........................ M-1701beta-hemolytic streptococci ......E-778, L1-1644beta-lactam .........................C1-460beta-lactam resistance ..........C1-463, F-2069beta-lactam/beta-lactamase inhibitor .....C2-694beta-lactamase ............... C1-065, C1-076,C2-079, C1-460, C1-462, C1-463, C1-464, C1-466, D-753, F-847, D-1449, C1-1204, C1-1209,C2-1902beta-lactamase inhibitor ......... A-008, A-009,........ A-010, E-189, E-190, E-198, E-199,. . .C2-724,F-847, F-848, F-849, F-850, F-851,.......F-852, F-853, F-858, A-1761, A-1763beta-lactams. . . . . . . . . . . . . . . . . . . F-842, C2-149Betaherpesviruses ...................G3-1546biliary endoscopy .....................K-1608binary toxin ..........................K-933bioavailability ........................A-1247biodefense ................... F-1522, F-1525biodistribution .......................A-1267biofilm ..........B-057, D-171, A-598, C1-666,.....C1-673, C1-674, C1-677, E-777, E-790,.....M-974, M-986, M-987, B-1318, B-1337,. . . B-1338, C1-1351, F-1492, F-1493, F-1518,. . M-1713, M-1716, M-1720, F-2000, F-2013,........... F-2062, F-2064, F-2069, K-2094biomarkers .......P-570, D-163, K-926, D-1403,................ H-1567, M-1673, M-1676biosynthesis .........................F-1508biowarfare Pathogen ..................F-1495bis-amidine ..........................F-816BK virus ....................... T-354, T-360BKV IgG ............................T-361BKV viruria ..........................T-361blood ...............................V-393262September 9-12 |

KEYWORD INDEXblood culture .....D-727, D-728, K-911, D-1408,..........D-1413, D-1414, D-1416, D-1417,.........................D-1423, K-1759blood stream infection and pneumonia .....K-912bloodstream infection ....K-271, P-569, C2-685,....... D-726, K-896, K-900, K-914, T-1045,. . K-1123, D-1412, G3-1547, K-1590, K-1591,. . K-1609, K-1610, K-1615, L1-1656, K-1756,...............................C2-1907blurred vision .........................V-395board game .........................K-2081Bolivia ............................C1-1205bolus infusion .......................K-1612bone and joint infection .........B-1319, K-2076bone cell invasion. . . . . . . . . . . . . . . . . . . . . B-1319bone infection ........................B-052bone mineral density ...................H-231booster doses ........................G-1047bordetell pertussis ....................B-1322Bordetella pertussis ...................G3-1563Borrelia burgdorferi ....................G3-1553bovine .............................B-1315bovine respiratory disease .......C1-670, F-2034bovis group streptococci. . . . . . . . . . . . . . . . D-1444Brazil ...............C2-106, C2-716, C1-1207breakpoints ..........................D-746breast infection .......................K-252broad spectrum ................E-191, F-1536broad spectrum antibacterial agents .......F-2017broad-spectrum antimicrobial ...........F-2019broad-spectrum beta-lactams ............A-637broad-spectrum cephalosporin ...........F-843broiler and layer chicken ...............P-1010broiler chicken ......................C2-1986Bronchial epithelial cells ................A-597Bronchoalveolar lavage . .A-1277, M-1701, K-1926brucella ............................L1-961brucellosis ..........................L1-960BSI ...............................D-1452bundle ............................ M-1231Buprenorphine. . . . . . . . . . . . . . . . . . . . . . . A-1250Burkholderia .....C1-460, K-904, K-1616, F-2033Burkholderia cepacia complex ...............D-731Burkhlolderia pseudomallei ...............P-1004Cc-di-GMP ..........................C1-673C-reactive protein ....................D-1402C. albicans .....................M-970, A-1945C. difficile–associated disease .............B-663C. glabrata ............................ M-323C. parapsilosis ................ M-1058, M-1684CA-MRSA ......... B-056, C2-1379, C2-1398,.......................L1-1654, L1-1657CABP ...............C2-146, A-1286, F-1525CAD ...............................H-229Cadazolid ..... B-662, E-808, A-1273, C1-1346,...............................C1-1347Caenorhabditis elegans ...........B-1327, F-1538cagA .............................C2-1981calcaneal ...........................K-2074Campylobacter .................C2-714, D-1457Canada .....................C2-085, C2-090cancer .......K-953, V-1075, G3-1546, G3-1547Candida . . . M-330, F-814, K-949, M-978, M-979,........M-1056, M-1229, M-1231, M-1674,........M-1675, M-1683, M-1685, M-1700,.........M-1709, M-1718, M-1720, A-1931Candida albicans ........ B-050, M-968, M-971,.......... M-990, M-1696, M-1713, F-2000Candida glabrata .........M-316, F-822, M-985,. .M-1059, E-1466, M-1668, M-1717, A-1929Candida parapsilosis ................... M-326Candida spp. .....M-325, M-339, F-820, K-943,..................M-969, M-974, M-1715Candida tropicalis ...................... M-967candidemia ............M-311, M-312, M-313,...... M-317, M-323, M-325, M-329, T-349,.....K-947, K-948, K-950, M-1230, M-1684,............................... M-1700candidiasis ...........M-980, M-1055, M-1229,........................M-1683, M-1709candiduria ......................... M-1673CAP .......................L1-290, L1-294capsular types ...............C2-1354, C2-1990capybara .............................P-993carbapenem ......C1-071, E-193, K-234, K-237,.......L1-289, C1-595, E-780, E-803, F-853,..................K-901, K-1615, C2-1899carbapenem resistance . . . C2-096, D-751, T-1034,................B-1336, C2-1897, C2-1901carbapenem-hydrolyzing Class D -lactamase................................C1-068carbapenem-resistant Enterobacteriaceae.............C2-092, C2-095, K-234, D-750,................C2-1211, C2-1215, K-1613carbapenem-resistant Klebsiella pneumoniae.......A-014, K-557, E-792, K-1609, K-1623carbapenem/beta-lactamase inhibitor ......F-856carbapenemase ........C1-061, C1-063, C1-067,. . . C1-069, C1-070, C1-078, C2-083, C2-084,. . . C2-085, C2-088, C2-093, C2-097, C2-118,. . . C2-121, C1-464, C1-587, C1-588, C1-591,. . D-745, D-746, D-748, E-800, F-849, F-850,.........D-1447, D-1453, D-1448, C2-1213,................C2-1216, C2-1905, F-2054carbapenems ........................C1-594carbon monoxide ......................F-830carbon monoxide dehydrogenase ..........D-739carcinogenic Human Liver Fluke .........P-999cardiac allograft vasculopathy ...........T-1071cardiac device infections ................D-165cardiovascular .......................C2-140cardiovascular disease ..................H-230carriage ...........................C2-1912case-control study .................... M-313caspofungin ...........M-968, M-978, M-1671cassette chromosome recombinases (ccr) . . C1-1740catheter ............................K-2091catheter related infection ....... K-1757, K-2088,..................K-2090, K-2097, K-2098catheter tip colonization ................D-167catheter-related bacteremia ......K-1758, K-2095catheter-related bloodstream infection .....K-948,...........K-949, M-1688, K-1757, K-2087,.........................K-2090, K-2093Cationic antimicrobial peptides ..........F-2061cationic peptide ......................F-1491CAUTI ...........................L2-2112CAZ-AVI ....................A-632, A-1760CB-183,315 ..........................E-807CC11 .............................C2-1218CCHF ..............................V-394CCR5/CXCR4 ......................H-1577ccrAB ............................C2-1393CDAD ............C1-1346, C1-1347, F-1530cefazolin ....................A-609, C2-1389cefepime .....................C1-073, D-747cefepime-tazobactam ............E-196, K-1618cefoperazone/sulbactam .................A-640ceftaroline ........A-625, A-627, A-629, A-630,.....A-631, C2-126, C2-127, C2-130, E-188,...................D-771, K-909, D-1433ceftaroline fosamil ...................L1-1661ceftaroline-avibactam ..................E-191ceftazidime ......C1-076, E-190, A-631, A-633,.....................A-634, A-635, A-636ceftazidime-avibactam ..................E-187ceftobiprole ...................A-624, A-624aceftolozane ........ E-198, E-200, E-201, A-641,........................A-1762, C1-1970ceftriaxone ...........................A-613ceftriaxone resistance ..................C2-695cell defense ..........................A-599cell division .........................F-1539cell fractionation .....................A-1291cell wall .................... C1-1969, M-984cell wall stiffness .....................D-1436cell wall thickness ...................C1-1742cellular immunity .................... M-1708CEM-101 ...........................E-781central line associated infection ..........K-2085central line-associated blood stream infection..........................K-914, T-1044Final Program263

Keyword INDEXcentral nervous system infection ........L1-1650central venous catheter .........T-1044, K-2092cephalosporin .........C2-123, C2-124, C2-129,...... C2-131, E-199, L2-308, D-755, F-844,.........................F-845, L1-1659cephamycinase .......................C1-075cerebral .............................P-568cerebrospinal fluid ...... D-168, P-1023, M-1704cervical cancer .......................L2-302cetylpyridinium chloride .........V-385, F-2015cfr ...............................C1-1745cfr gene ...........................C2-1987chagas’ disease .......................P-1013characteristics .......................K-2073charcoal ............................F-2003charcoal-containin blood media .........D-1409chart review .........................L1-292chemokine ...........................B-057chemokine receptor .................. M-1055chemotherapy .......................D-1458chicken ............................C2-714child ..............................G3-1556childhood ..........................G3-1555children ......... V-390, G-864, K-953, V-1076,......G3-1542, G3-1545, G3-1547, G3-1551,........G3-1552, G3-1559, G-1749, A-1941,...............................C2-1974Chinese clinical isolates ................F-2036Chlamydia trachomatis ....E-206, L2-305, L2-309Chlamydophila ........................E-207chlorhexidine .......................C2-1914chlorine .............................K-243Chromobacterium violaceum .............F-2071chromogenic test ......................D-753chronic cardiopulmonary disease ..........G-872chronic kidney disease ..................K-235chronic liver disease ....................V-373chronic Q-fever ......................L1-965Ciprofloxacin .........C2-714, A-1968, C2-1982Ciprofloxacin PK/PD .................A-1965Ciprofloxacin resistance ................C2-686circulating DNA .................... M-1692CLABSI ...........................K-1755class 1 integron ........C1-666, C2-712, C2-719class C beta-lactamase .................C1-073class D beta-lactamase ..........C1-074, C1-467class D carbapenemase ................C1-595clavulanic acid ......................C1-1206clearing device ...................... M-1062Clinafloxacin ........................F-2034Clindamycin ................D-1431, L1-2106clinical and environmental isolates .......C1-668clinical characteristics ..................K-920clinical epidemiology ..... K-259, M-312, M-313,...................D-161, H-887, M-1702clinical features .......................K-905clinical impact ....................... M-320clinical isolates .......................F-2037clinical presentation ....................V-398clinical samples ...................... M-335clinical studies ...............K-1618, L1-1659clinical trial . . . .L1-299, H-877, V-1236, A-1272,.................A-1285, F-2041, L1-1660Clofazimine .........................A-1259clonal complex ......................C2-1361clonal complex 30 ....................B-1320clonal set ...........................C2-690clonal virus ..........................H-1568clonality ............................K-1606clones ......................C2-117, C2-1910Clostridium difficile ........D-153, D-154, D-156,. D-157, D-158, D-159, D-162, D-163, K-469,. . K-470, K-471, K-472, K-473, K-474, B-662,. . B-664, E-807, E-808, K-919, K-922, K-924,. . K-925, K-926, K-929, K-930, K-931, K-932,....... K-933, K-934, K-935, K-936, T-1029,.................A-1274, C1-1347, F-1530Clostridium difficile infection ........D-155, D-160,........D-161, K-917, K-918, K-920, K-921,....................K-923, K-928, T-1068Clostridium difficile toxin .. K-918, F-1537, B-1738Clostridium perfringens ................F-2005cloxacillin plus vancomycin ..............B-648CLSI ...............................D-752CLSI 2012 breakpoints .................D-747CMI .............................L1-1658CMV ............. D-174, T-340, T-356, T-358CMV resistance ......................T-1072CMX001 ............................T-362CMY ..............................C1-075CMY-2 ............................C2-710co-infection ..........................V-386co-localization ......................C1-1350co-receptor tropism ...................H-1575co-selection ...........C1-670, C2-708, C1-135coagulase negative staphylococci .........C2-1399Cobicistat ...........................H-892Coccidioidomycosis ...........M-1697, M-1702Coenzyme A ........................F-1540cohort .............................T-1043cohort study ..........................V-387coli ................................C2-102colistin .....A-031, A-032, A-033, A-034, A-035,. . A-036, A-037, K-562, D-761, E-793, E-796,......E-797, E-804, P-1024, B-1299, K-1602,...................F-2006, F-2007, F-2008colistin combinations ..... E-786, E-792, K-1605,................................K-1607colonization ....C2-096, D-166, K-560, C2-1974,...............................L2-2112colonization resistance .................F-2003colorectal cancer .....................F-1519combination .... A-031, B-1298, E-1482, A-1930,.........................A-1944, F-2067combination therapy ...... E-195, V-388, A-601,........A-626, D-756, E-791, E-795, F-821,..........................K-922, E-1476commensal bacteria ..................C2-1399commensal enterobacteria ..............B-1305community. . . . . . . . . . . .K-930, C2-112, C2-1380community hospitals ...........C2-117, K-1923community onset infections .............T-1041community-acquired ..................C2-082community-acquired bacterial pneumonia..................C2-145, L1-292, A-1269community-acquired ESBL-E ..........C2-104community-acquired infections ..........K-1754community-acquired pneumonia ......... D-180,.................L1-291, L1-298, G3-1549community-associated ..........K-920, C2-1908community-onset .....K-1587, L1-1645, L2-2113companion animals ..................C2-1219comparative effectiveness ...............K-1628complicated bloodstream infections. . . . . . . D-1411complicated skin and skin structure infections.................................B-044complications ........................V-1078conjugate vaccine ....................G3-1543conjugated vaccines ....................G-865conjugative plasmid ..................C2-1987contamination ........................K-904continuous infusion ....................A-614contributable mortality .................K-921copper ..............................K-245corals ..............................C2-715corticosteroids ...................... M-1697cost-effectiveness .........D-153, G-860, G-874,........................D-1424, M-1671cost-effectiveness analysis ..............K-1633cost-of-illness-analysis ................ M-1230costs ...................... M-1706, L2-2115Cotrimoxazole .......................K-2077Coxiella burnetti .......................P-1012Coxsackie Bs ........................G-1748Cpl-1 ...............................B-659CR-Acinetobacter baumannii ...........C2-1900Creatine phosphokinase ...............K-1626creep .............................C2-1376critical care. . . . . . . . . . . . . . . . . . . . . . . . . . . A-037critically ill patients ............A-027, L1-1224cross infection .......................K-1754cross protection .......................B-053264September 9-12 |

KEYWORD INDEXCryptococcal antigen (CrAg) .......... M-1699Cryptococcal meningitis ........H-220, M-1670Cryptococcosis. . . . . . . . M-336, M-1233, M-1677,............................... M-1699Cryptococcus .....M-331, M-976, M-977, M-1693,..................A-1942, A-1943, A-1944Cryptococcus gattii ...............T-345, M-1233Cryptococcus neoformans ................ M-314crystal structure ......................C1-465cSSTI ............................L1-1666CTX-M ......C1-072, C2-108, C2-113, C2-116,........C2-119, C2-704, C1-1204, C1-1205,................................K-1589CTX-M expression ...................C2-115CTX-M-15 .........................C2-110CTX-M-2 ..........................C2-106CTX-M-5 ..........................C2-697CTXM ............................D-1451culture .......................D-174, E-1994curli ...............................C1-674cutaneous leishmaniasis ................P-1000CVC ..............................F-2013CXCL8 ............................B-1311cyclic peptide ........................F-1509cystic fibrosis ...........A-035, A-036, C2-080,..... A-597, A-643, E-1480, K-1616, F-2063,......................... F-2064, F-2070Cytochromes P450 .....A-1248, A-1254, A-1951Cytokines ........B-055, B-056, B-058, B-1307Cytomegalovirus ....H-224, T-355, T-362, T-365,........ T-366, T-368, T-369, V-393, T-1070,......................... T-1071, V-1242Cytotoxin ...........................B-1317DDalbavancin ............C2-138, A-623, E-1467Daptomycin .......K-275, K-276, K-278, K-279,. .K-280, A-598, A-600, A-601, A-602, A-603,. . A-604, A-605, A-606, B-649, B-653, B-654,. B-658, B-659, B-660, E-797, K-944, K-1121,. C2-1392, C1-1345, D-1438, E-1464, E-1465,. . . E-1468, E-1469, E-1476, E-1478, E-1482,. . L1-1638, K-1626, K-1631, K-1634, K-1635,. . K-1636, C1-1744, F-2011, K-2078, K-2085,.........K-2095, K-2098, L1-2105, L2-2111Daptomycin and p-glicoprotein .........A-1769Daptomycin non-susceptibility .........C1-1743Daptomycin nonsusceptible ..............A-626Daptomycin pharmacogenomic ..........A-1769Daptomycin pharmacokinetic ...........A-1769Darunavir ...........................H-889DAS181 ......................V-381, V-382day 3 clinical response .................K-1598day 4 clinical Response ................L1-292de-escalation ..................K-271, L1-283decision rule ..........................K-917decolonization .................K-267, T-1069Dectin-1 .......................... M-1057Decubitus .........................L1-2103defined daily dose .................... M-326Delafloxacin .... E-208, A-598, L1-1663, A-1956,.........................A-1957, A-1958Delamanid ..........................A-1255delayed cerebral thrombosis ............L1-1223demography .........................K-1925dental medicine ......................K-2084depression ...........................H-232Dermatophytes ......................A-1946dessication ...........................K-559device-associated infections ..............K-252dexamethasone .....................L1-1222diabetes ...........................C2-1373diabetic foot ........................L1-1646diacetyl rhein ........................F-1532diagnosis ........ D-154, D-156, D-157, D-165,.......D-166, D-176, D-177, D-183, D-185,....D-741, P-1005, T-1026, M-1690, M-1692diagnosis of schistosome hybdrid cluster . . . P-1014diagnostic ...........................D-160diagnostic methods ...........M-1060, M-1694diagnostic performance ................D-1425diagnostic tests ................L1-298, D-169dialysis ..............................A-617diarrhea .......................K-469, K-935difficult-to-identify bacteria ............D-1772Dihydropteroate synthase .............. M-333Dioctacecyldimethylammonium bromide . . .E-784,.................................E-801Dioctadecyldimethylammonium bromide bicelles................................F-2004direct-acting antivirals .................V-1237direct-testing .........................D-164disease severity ........................D-163disinfectant ..........................F-825disk conservation ......................D-758disk diffusion .................. D-760, D-762disk diffusion method ..................D-758DNA binding ........................F-826DNA gyrase. . . . .F-2018, F-2023, F-2026, F-2027DNA gyrase, topoisomerase IV ..........F-2028DNA microarray ......................K-255DNA schistososome detection ..........P-1014DNA synthesis inhibitor ...............F-2019DNA-Microarray ....................D-1440dnaQ ..............................C1-667Dolutegravir ........................A-1249doripenem ........A-013, A-014, A-015, A-016,........A-017, A-018, A-019, A-020, A-024,....................E-786, E-803, K-1605dose ................................A-615dose selection .........................A-029dosing ..............................A-638double umbilical cord blood transplant .....T-354doxycycline .........................P-1003drosophila .......................... M-979drug distribution .....................F-2026drug interactions .....................A-1935drug regimen ........................K-2100drug resistance . .F-1531, H-1574, L1-1654, E-1994drug resistance testing .....V-374, D-737, D-1776drug resistance, bacterial ...............K-1754drug susceptibilities ................... M-987drug-drug interaction ..........A-1248, A-1254DS-8587 ......F-2035, F-2036, F-2037, F-2038,.... F-2039, F-2040, F-2041, F-2042, F-2043,......................... F-2044, F-2045duration .............................A-615Dutch community ....................C2-104Ee-test ...............................D-164E. coli .........C2-100, C2-103, C2-687, C2-688,.....C2-702, C2-710, C2-712, K-898D-1452,.....K-1586, F-2025, F-2040, F-2049, F-2057E. coli AmpC infection ................K-1621early sepsis .........................L1-1647Easter and Western Europe .............C2-141Eastern Europe ...............C2-136, C2-143EBV surveillance ......................T-352Echinocandin ..... M-323, F-817, F-818, F-819,.....F-821, F-823, M-981, M-1058, M-1675,.................M-1720, A-1928, A-1929Echinocandin resistance ............... M-967Echinocandin susceptibility ............ M-1710Echinococcus .........................P-1018ECHO and THRIVE ..................H-880Echocardiography ...................L1-1640ECOFF .............................E-187economic evaluation ............K-239, K-1592EDP-420 ...........................B-1303Efavirenz ............. H-883, A-1255, A-1256Effective dose .......................F-2056effectiveness ..........................G-872efficacy ...........H-555, B-664, F-817, F-2016efficacy and safety ....................K-1631efficacy and tolerability .................H-878efflux .......C1-675, C1-680, C2-696, C1-1341,...............................C1-1747efflux inhibitor .......................C1-674Final Program265

Keyword INDEXefflux inhibitors .......................F-814efflux pumps . . . C1-672, C2-684, C2-692, F-1996elderly .............................A-1293electronic surveillance .................K-1756elisa ........................D-183, M-1694elongation factor G ..................C1-1973Elvitegravir .........................A-1250Elvitegravir/Cobicistat/Emtricitabine/TenofovirDF ...............................H-879embolism ..........................L1-1637emergence of drug resistance ............C2-094emergency department .........L1-285, L1-286Emericella sp ..........................F-812Empyema ..........................C2-148Encephalitis ........ V-1239, C2-1374, G3-1545,...............................L1-1649end stage renal disease . . . K-235, K-1597, L1-1650EndA ..............................F-1535Endocarditis ..... A-039, K-277, K-937, L1-962,........ L1-963, D-1411, L1-1637, L1-1638,........L1-1639, L1-1640, L1-1644, M-1680Endocarditis and biofilms ...............B-646Endolysin ..........................F-1516Endotracheal tube ................... M-1062engineered antimicrobial peptides ........F-2061enhanced combination effect .............E-798Enoyl reductase ......................F-2072Enterobacter. . . . . . . . . . . . . . . . . . . C1-683, A-1280Enterobacter species ...................C2-105enterobacteria ........................D-759Enterobacteriaceae ...... C2-079, C2-083, C2-084,. . . C2-090, C2-093, C2-096, C2-097, C2-152,.......E-191, E-195, C1-587, A-629, A-630,.....C1-672, C2-694, C2-704, D-745, D-748,........D-749, D-771, D-772, K-901, K-903,........T-1035, C1-1202, C2-1214, D-1448,........................F-2053, L2-2116Enterobacteriaceae species ................E-798Enterococci ....E-778, K-944, C1-1345, C2-1986Enterococcus ........K-273, K-274, K-275, K-277,..........................K-278, K-1632Enterococcus faecalis ........K-938, K-945, E-1465,...............................L1-1637Enterococcus faecium ....................B-660Enterococcus spp. .....................C2-1987Enterococcus .........................E-1464Enterotoxigenic Bacteroides fragilis. . . . . . . . F-1519Enterotoxins ........................D-1439environment ........................C2-716environment disinfectant ................K-243environmental .......................C2-717environmental colonization ........K-245, K-246environmental decontamination ..........K-934environmental factors ................ M-1228enzyme immunoassay .........D-1407, M-1693enzyme mechanism ..................C1-1344Eosinophil peroxidase .................F-1528epidemic ............................T-363epidemic plasmid ....................C1-1205epidemiologic trends ..................C2-725epidemiology .........C2-083, C2-095, C2-105,......H-213, K-257, L1-293, L2-307, M-314,.....M-318, M-327, M-336, K-472, C2-699,. K-908, K-930, K-947, P-994, P-1001, P-1012,. . V-1241, G3-1543, K-1593, K-1616, K-1621,. K-1622, L1-1639, L1-1645, G-1751, K-1758,....... D-1775, C2-1905, C2-1908, C2-1985Epithelial lining fluid. . . . .A-025, A-1277, A-1933Epsilon toxin ........................F-2005Epstein-Barr virus ....................V-1241Ergosterol .......................... M-970Erm41 ..............................D-735Ertapenem ..............A-013, A-014, K-1585ESBL. . . . . . . . C1-071, C2-100, C2-101, C2-103,. . . C2-108, C2-109, C2-105, C2-107, C2-112,......C2-114, C2-147, E-186, E-194, E-196,. . . C1-462, C2-691, C2-701, C2-704, C2-718,........D-752, D-773, E-798, E-803, F-855,....... T-1035, C1-1202, C1-1207, C1-1208,. . . D-1447, K-1583, K-1584, K-1586, K-1590,.........................K-1591, F-2054ESBL enterobacteria ..................C2-117ESBL-producing Enterobacteriaceae ........K-560,........... D-754, D-755, K-1585, L2-2113ESBL-producing Escherichia coli ........ C2-689,. . . K-1587, K-1589, K-1592, K-1617, L2-2109Escherichia ..........................C2-102Escherichia coli ........C1-075, C2-080, C2-094,.....C2-111, C2-113, C2-114, E-197, E-201,. . L1-283, C2-685, C2-686, C2-1219, B-1305,..........F-1540, K-1588, A-1965, L2-2108ESKAPE pathogens ............K-233, T-1030essential oils ..........................F-833Etest .......... D-765, E-799, D-1433, K-1604Ethanol ............................K-2098Etiology ...........................G3-1544Eucast ..............................D-757Europe ......L1-290, C2-147, C2-1352, L1-1666evaluation .....................P-567, K-910evolution .................... C1-461, M-966exam gloves .........................K-2082excision ...........................C1-1746exotic birds. . . . . . . . . . . . . . . . . . . . . . . . . . . P-995experimental endocarditis ........ A-610, B-645,...........................B-648, K-943experimental meningitis ................B-649exposure ............................A-1934exposure-response ....................A-1933extended spectrum cephalosporins ........D-753extended infusion .......A-643, A-1766, A-1767extended spectrum beta lactamase ........C2-121extended-spectrum beta-lactamase ...... C2-118,.........C2-703, C1-1203, K-1588, L2-2108extended-spectrum cephalosporins .......C1-590FFAB001 ............................F-2067FabI ...............................E-1486familial predeliction ...................C2-699fatty acid ...........................F-2009FDG-PET/CT ......................L1-965Febrile neutropenia .....T-1028, T-1046, D-1402,.........................D-1403, D-1405fecal ...............................A-1963Ferrioxamine ........................ M-973FIC ................................E-203FIC index ...........................E-782Fidaxomicin ......K-471, K-473, K-932, A-1274,...............................C1-1346Fimbriae ...........................B-1322FimH antagonists ....................F-2057Finafloxacin ..................A-1959, A-1960first-line therapy .....................K-2095FKS mutations ..............M-1675, M-1710FKS1 .............................. M-979Flouroketolide .......................A-1286Fluconazole ......F-811, M-970, M-971, M-985,.........................A-1943, A-1945Fluconazole resistant ................. M-1059Fluorocycline .........................E-777Fluoroquinolone ....... C2-125, E-209, C1-665,.....C2-708, D-760, D-764, L1-957, A-1949,. . . A-1951, A-1952, A-1953, A-1954, A-1955,....A-1957, A-1959, A-1960, F-2037, F-2038,.... F-2046, F-2047, F-2048, F-2049, F-2054,................................F-2055Fluoroquinolone resistance .... C1-667, C2-1355,...............................C2-1400Fluroketolide ........................F-1505food ................................K-925food chain ..........................C2-707food contamination ....................K-560food of animal origin ..................C2-713foodborne pathegon ...................F-1494foreign body osteomyelitis ...............B-652foreign-body infection ..................B-647Foscavir .............................T-358Fosfomycin ....A-602, B-647, C1-1203, C2-087,............E-793, A-1279, E-1477, K-1602FQs ..................F-2050, F-2051, F-2052Francisella tularensis .............L1-964, F-2072French guiana .......................P-1011ftsI mutations ......................C2-1975full genome sequence ..................C1-678Fungaemia .......................... M-318266September 9-12 |

KEYWORD INDEXfungal ...............M-327, M-1688, M-1691fungal diseases ...................... M-1063fungal infections ......... M-338, T-343, T-345,.........................M-1060, T-1066Fungemia-fungicidal ...................F-816Furanoside ..........................P-1007Fusariosis ...................M-1234, M-1690fusC ..............................C1-1339fusidic acid .........................C1-1339fusidic acid resistance .................C2-1394fusion ...............................H-554GGalactomannan .......T-1067, M-1226, M-1690Galleria mellonella ......B-1323, B-1326, K-1614Ganciclovir ..........................T-358gastric band ..........................K-265Gastroenteritis .......................D-1457gastrointestinal illness .................P-1021GDH ...............................D-157Genadine antiseptic ...................K-2082gender stratification ....................H-882gene ...............................C2-101gene regulation .......C1-671, C1-676, C1-677,...............................C1-1351generic antibiotics .....................B-645genetic ..............................G-876genetic elements ......................H-894genetic identification ..................D-1460genetic resistance elements ............C2-1383genetic variation .....................B-1309GeneXpert ..........................D-1427GenomEra ..........................D-1415genomics .....................K-474, H-1569genotypes ..........................C2-1358genotypic algorithm ...................H-1574genotypic resistance ....................H-215genotypic tools .......................H-1576genotyping ...................H-214, C2-1980Gentamicin ..........................A-039geographic information system ...........P-998geriatrics ............................K-954Germany ............................G-863GES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-718Ghrelin .............................V-394GIM-1 ............................C1-588global suppressor ....................C1-1209glucan synthase enzyme .................F-822glucan synthesis ..................... M-1057Glutamate dehydrogenase ...............D-156Glyceryl trinitrate ....................F-2012Glycopeptides .........F-1506, F-1507, F-1510,......................... F-1511, F-1512gold nanoparticle .....................F-2002Gonorrhea ..........................F-2052grafts ...............................D-164gram-negative ......... A-040, C2-150, F-1522,.........................F-2023, K-2079gram negative bacilli ...... K-561, E-802, K-896,.........................A-1270, A-1271gram-negative antibacterial agents ...... F-2018agram-negative bacteremia ...............K-916gram-negative bacteria .........C2-151, D-766,............ K-897, F-2002, F-2046, F-2069gram-positive ................ C2-132, C2-133,...........C2-138, F-1497, F-1498, F-1499,............F-1500, F-1501, F-1503, F-1521gram-positive cocci ............D-1433, D-1438gram-positive organisms . .C2-134, C2-151, F-2047group B streptococci .........C2-1988, C2-1989group B streptococcus ..................G-1751growth curves .......................A-1940GS-7340 ............................H-552GSK1322322 .................A-1276, A-1277GSK2251052 .......... E-802, A-1270, A-1271,.........................A-1272, B-1304guidelines ...........................L1-298gyrA ..............................C2-696Gyrase ................F-2016, F-2024, F-2025Gyrase B .................... F-2020, F-2022Gyrase inhibitor. . . . . . . . . . . . . . . F-2021, F-2029HH. influenzae .......................C2-1975H1N1 2009 ..........................B-045H1N1 influenza .......................V-398HA-MRSA ........................C2-1379HAART ............................H-230Haemophilus spp. .......................C2-145halogenobenzimidazoles .................F-1533hamster .....................F-1530, B-1738hand hygiene ................C2-1915, K-2083handwashing compliance ...............K-2080HBV vaccine .........................V-375HCMV .............................V-392HCV .........................V-370, V-371HCV infection .......................V-372health related quality of life .............L1-300healthcare ..........................C2-122healthcare-associated infection .... K-245, K-246,K-947healthcare-associated infections ..........K-2084healthcare-associated pneumonia ........K-2100healthy children ......................G-1049heart failure ......................... M-991heart transplant ................ T-364, T-1071helicase-primase ......................V-391Helicobacter ................... M-328, K-897Helicobacter pylori .....................C2-1981hematologic disease ...................D-1403hematological malignancy ............. M-1669hematology ..........................K-898hematopoietic cell transplantation . . . T-362, T-1065hematopoietic stem cell transplant . .V-393, T-1045hematopoietic stem cell transplantation ....T-367,......................... T-1038, T-1044Hemodialysis ......A-606, A-618, A-636, K-923,................................K-1630Hemodialysis catheter .................K-2093Hemorrhagic cystitis ...................T-360hepatic .............................A-1295hepatic impairment ...................A-1260hepatitis .............................H-885hepatitis A vaccination ..........P-1015 P-1016Hepatitis B .............V-374, V-379, G-1047Hepatitis B virus ................H-218, V-373Hepatitis C . . B-053, T-364, V-379, F-828, A-1248Hepatitis C virus . . . D-185, H-215, T-368, V-377,.......F-826, F-827, G-871, V-1236, V-1237Hepatitis E ..........................V-376Hepatitis E virus ...............D-184, V-1238hepatotoxicity ........................H-221herpes simplex virus ........D-185, T-342, T-367,...................F-824, V-1239, H-1920hetero-VISA ........................D-1434heterocycle ..........................F-1526heterogeneous macrolide resistance .......D-1430heteroresistance ...............M-985, D-1435heterosubtypic antibodies ...............V-384Hexaplex PCR .......................D-1437HHV-6 ..................... T-351¸G3-1546high level mupirocin resistance .........C2-1394high resolution melt. . . . . . . . . . . . . . . . . . . .D-735high throughput screening . . F-827, F-831, F-1536high-inoculum effect .................C2-1389high-throughput compound screening ....F-1535histone acetyltransferase ................F-813histopathology ....................... M-967histoplasma ........................ M-1694HIV ......H-212, H-213, H-219, H-225, H-227,.......H-228, H-231, H-232, H-550, H-552,.......H-554, M-336, V-371, H-877, H-883,.........A-1253, C2-1373, H-1567, H-1570,.........H-1577, H-1580, H-1581, H-1582,..........H-1916, H-1919, H-1920, H-1921HIV co-receptor .....................H-1569HIV complications ....................H-887HIV drug mutation ...................H-1572Final Program267

Keyword INDEXHIV infection ....H-224, H-229, H-230, A-1252HIV infections/complications ..... H-217, H-888HIV infections/immunology .............H-553HIV low-level viremia .................H-1566HIV testing ................. H-1571, H-1581HIV therapy .....H-553, H-556, H-884, H-894,........................ H-1565, H-1579HIV tropism ........................H-1576HIV undetectability ..................H-1566HIV-1 ...................... H-1917, H-885HIV-1 resistance .....................H-1571HIV-1 treatment ......................H-878HIV-1 tropism ......................H-1579HIV-1 viral load .....................H-1579HIV-O .............................H-886HIV-positive .........................H-556HIV/AIDS ......... H-1564, M-1677, M-1699HIV/AIDS-TB .......................H-893HIV/HCV co-infection .........H-214, H-216,.......................... H-217, H-884HLA testing .........................H-895hMPV ..............................V-386hollow-fiber model ....................A-632homeless ...........................L1-959homosexual men ..............L2-301, V-1238hospital .......................H-213, P-566hospital acquired infection (HAI) . . K-238, K-908,.....................K-952, K-927, K-936hospital health workers .................D-744hospital-acquired MRSA .............C2-1911hospital-acquired pneumonia ......B-054, A-640hospitalization .......... H-211, L1-290, V-389,........G3-1551, K-1598, L1-1661, L1-1666hospitalization cost ....................D-159host defense ..........................B-651host defense protein ............E-1474, F-1493,......................... F-1494, F-1495host responses ......... B-051, B-1335, M-1708housekeeping .........................V-383HPV .......................L2-304, H-1921HPV 16 ............................L2-302HPV infection .......................L2-304HPV prevention .....................L2-304HRM ..............................D-1445HSCT ..............................T-361HSV ..............................L2-307HSV-shedding. . . . . . . . . . . . . . . . . . . . . . . . V-391human .............................B-1315human ADME ......................A-1956human alpha-defensins 1-3 .............F-1488human blood biomarkers .............. M-1695human immunodeficiency virus ...........H-223human immunodeficiency virus type 1 ....H-1918human metapneumovirus ...............V-399human papillomavirus (HPV). ..........L2-301human pharmacokinetics ...............A-1273human-use antibiotics ..........C2-705, C2-709hVISA ..............K-1123, C2-1381, E-1469hVISA/VISA/VRSA ....A-626, A-627, C1-1743Hydatid disease ......................P-1018hydrazide ............................F-844hydrochoerus hydrochaeris ..............P-993hyperbilirubinemia ...................A-1251hypermucoviscosity phenotype ..........B-1324hypermutant .........................A-011hypersensitivity .......................H-895hyperthermia ........................ M-972hypoxia ............................B-1334IICU ..........C2-144, H-227, M-1698, K-2088ICU mortality ........................K-951ICU patients ........................V-1242identification . . . D-727, D-1410, D-1444, D-1777identification of mycobacteria to the species . .D-734IGRA ....................... D-740, D-742IL-10R .............................G-871Ilicicolin H ..........................F-810imaging .............................P-568imaging techniques ...................L1-960imipenem ........A-009, A-021, C1-070, E-192,................................C2-724imipenem-sulbactam sinergy .............E-202Imipenem/MK-7655 ...................D-767immune memory .....................G-1047immune response ........B-055, H-222, G-1054,........................ H-1565, H-1567immunization ..................B-046, V-384immunization status ...................P-996immunoassay .........................D-184immunocompromised ..................T-349immunocompromised host ........T-344, V-376immunocompromised patients .....V-397, K-902immunogenicity .......................G-867immunologic progression. . . . . . . . . . . . . . .H-1578immunological failure .................H-1564immunology .........................B-661immunomodulation ........B-048, B-050, B-657,................................B-1297immunopharmacology ................. M-984immunosuppressor exposure ...........G3-1557IMP-1 ............................C2-1215IMP-27 ............................C2-090IMP-36 ............................C1-067impaired hepatic function ..............A-1283implantable port device ................K-2087improved bioavailability ................F-1489in vitro ............... E-1995, F-1510, F-1512in vitro activity ..........F-1506, F-2019, F-2049in vitro antifungal susceptibility ......... M-1669in vitro model ................A-1967, F-2014in vitro PK/PD model ......A-022, A-023, A-621in vitro susceptibility ............D-770, F-1520in vitro time-kill curve .................A-1764in vivo .......................B-664, K-1617in vivo efficacy .......... B-656, F-1507, F-2055in-hospital mortality ...................H-228inactivation ..........................E-780Inc I1 ..............................C2-707incidence ......K-273, T-344, C2-1363, L1-1643incompatibility types ..................C1-589India .... C1-063, C2-099, K-236, P-564, P-565,.........................P-1004, K-1618Indian S.aureus .......................B-1315inducible-resistance ...................D-1431infants .....................A-1245, G3-1561infection. . . . . . . . K-263, T-1026, T-1027, T-1043,...............................C2-1380infection control ........D-155, D-751, D-1442,.........................K-1611, K-2081infection model ......................F-1487infectious disease ......................P-564infective endocarditis ...... K-939, K-940, K-941,.......K-942, K-944, K-945, K-946, K-1122,..................E-1464, E-1465, F-1517inflammation ........................B-1307inflammatory bowel disease .............F-1519influenza ....V-380, V-384, V-385, V-389, V-390,.......V-400, K-952, K-955, K-956, G-1053,.........V-1079, A-1243, A-1246, G3-1549,...............................G3-1550influenza A ...................G-873, V-1077influenza A virus H1N1 subtype ..........V-387influenza A viruses. . . . . . . . . . . . . . . . . . . . . V-388influenza H1N1 .....................G3-1548influenza like illness ....................V-398influenza vaccine . . T-359, G-872, K-953, G-1052informatics .......................... M-315infusion duration .....................A-1761INH ...............................L1-959inhibition ...........................C1-066inhibitor .....F-813, F-826, F-857, V-370, F-2016inhibitor resistant phenotype ............C2-694injection drug users ....................V-371innate immunity ................B-054, B-059inoculum ............................K-253inoculum effect ......................A-1764Inquilinus limosus ..............C1-466, C1-678insertion sequence ....................C1-064268September 9-12 |

KEYWORD INDEXintegrase ............................H-550integrase inhibitor ....................A-1252integrase mutations ...................H-1574integrative and conjugative element. . . . . . . C1-670integron ..............C1-068, C2-101, D-1408intensive care unit ........ A-021, K-270, K-950,........................ M-1230, K-2080interactions ..........................D-769interferon .................... H-216, D-1407interferon- release assay ................D-744interferon-gamma ....................D-1406interferon-gamma release assay . . . D-741, H-1918interferon-γ release assay ..............H-1919intergenus transfer ....................C1-679internalization .......................B-1334interventional study ....................V-375intestinal microbiota ..........D-1458, L1-1642intra-abdominal ...............C2-100, C2-141intra-abdominal candidiasis ............ M-1056intra-abdominal infection .......C2-702, F-2044intracellular .........................F-2029intracellular activity ....................E-781intracellular infection ...................A-596intracranial pressure ..................L1-1652intraluminal catheter biofilm ............F-2012intravenous .........................A-1276intravenous immunoglobulin ............B-1735invasive aspergillosis . . . M-988, M-1226, M-1228,................M-1678, M-1682, M-1695invasive candidiasis .................. M-1687invasive fungal disease ..................T-344invasive fungal infection .........M-315, K-951,........................M-1232, M-1703invasive infection . . . . L1-1646, C1-1739, C2-1991invasive pneumococcal disease . . C2-1353, C2-1354invasive pneumococcal infections .........G-861invasive pulmonary aspergillosis ..........K-951invasive streptococcal infections ........G3-1554invasive zygomycosis .................. M-973IPAF ...............................B-060IPD ................................G-863IPDM ..............................A-613iron ...............................P-1017iron chelator ........................ M-976IS1216V-flanked composite mobile element...............................C1-1340IS6110 sequence ......................D-733IS91-like elements ....................C1-669ISAba1 ............................C1-070isavuconazole ....M-331, M-332, A-1931, A-1936ISCR1 .............................C1-669ISCR1 .............................C2-693isolation ............................K-1611Israel .......................C2-099, L1-961Italy .......................C1-594, C2-1211Itraconazole ......................... M-991ITS region ...........................D-734ITS region sequence analysis ............D-1443JJapan ...............................H-223JNJ-Q2 .....................A-1961, A-1962KK. oxytoca ...........................C2-691K. pneumoniae ........C2-108, C2-120, C2-702,.........................B-1324, B-1325kidney transplant .....................T-1036kidney transplant recipients .............T-1035kidney transplantation ..................T-359kidney tubular dysfunction ..............H-890kinetics ...........................C1-1206kirby – Bauer’s disk diffusion .............D-181Klebsiella .......A-041, A-042, C1-061, C2-1216,................................K-1586Klebsiella oxytoca .....................C1-593Klebsiella pneumoniae . . . C1-062, C2-086, C2-087,. . . C2-088, C2-091, C2-690, C2-692, C2-693,........C2-717, E-800, F-841, F-846, K-913,..........T-1034, C2-1215, B-1321, K-1588,.........................K-1620, F-2059Klebsiella pneumoniae carbapenemase-2 . . . C2-1212Klebsiella pneumoniae-producing Carbapenemase.........................K-1619, K-1625Klebsiella producing carbapenemase ......B-1323,................................K-1614KPC .........A-013, C1-066, C2-086, C2-089,.C1-589, D-747, D-748, D-749, E-789, E-796,. . F-849, F-850, F-856, F-857, K-903, T-1031,. . C2-1213, D-1445, D-1446, D-1450, F-2059KPC Carbapenemases . . . A-015, C2-087, C2-094,.........E-192, E-794, F-848, F-851, F-852,..............F-853, F-858, K-913, B-1300KPC carrier .........................C2-095KPC Klebsiella pneumoniae ..............B-1326KPC spread ..................C2-092, C2-716KPC-2 ......................C1-464, C2-717KPC-producing K. pneumoniae ..........C2-1218KPC-type .........................C2-1211KPI-10 .......E-207, A-1949, A-1950, A-1951,....A-1952, A-1953, A-1954, A-1955, F-2048LL20B ..............................G-1748laboratory detection ...................D-1448lactate ............................L1-1221Lactococcus lactis .....................B-046Lactoferrin ...........................D-162LAMP .............................D-1456latent tuberculosis ....................T-1032latent tuberculosis infection .......D-744, T-1033,................................H-1917lateral flow device ................... M-1682Latin America ......................C2-1909Legionella pneumonia ...........L1-293, L1-295Legionella pneumophila .................B-1297Leishmania .........................P-1007Leishmaniasis ..........H-222, P-1007, P-1020Lenalidomide .......................T-1027Leptospirosis ........................P-1009Letermovir ...........................T-356lettuce .............................C2-703Levofloxacin ...........B-649, A-1963, A-1964Lincosamides .......................C1-1349Linezolid ......B-655, C2-139, C2-142, K-1120,..........A-1261, A-1263, A-1287, A-1288,........ C1-1343, E-1471, E-1479, C1-1745,Linezolid resistant ...................C2-1401Lipid formulations of Amphotericin B . . . M-1705lipids .......................V-377, C1-1744lipoglycopeptide. . . . . . . . .C2-132, C2-134, A-621lipopolysaccharide ...................L1-1651liposomal Amphotericin B ......M-988, A-1941,........................M-1671, M-1707Listeria monocytogenes ..........F-1997, L1-1222liver cirrhosis ....................... M-1698liver transplant ........................T-368liver transplantation ...........T-1040, G3-1556livestock and poultry ...........C2-705, C2-709loading dose ..........................A-607locked nucleic acid (LNA). .............D-1454long-acting ..........................H-554long-term care facilities ...........K-557, K-558long-term functional outcome ..........L1-2103long-term oral suprressive antibiotic therapy................................K-2077LpxC ..............................C1-680LPXTG-protein .....................B-1316LTBI ..............................L1-959lung ..........................B-060, B-651lung transplant ...........A-035, M-337, T-364,.... M-1227, T-1037, T-1064, T-1067, T-1069Lyme disease .......................G3-1553lymphocyte ........................ M-1679lytA real-time PCR ....................D-172MM. fortuitum .........................E-1995Final Program269

Keyword INDEXM. tuberculosis ................D-733, C2-1368macroarray ..........................C2-698macrolide ..............B-048, B-049, C2-1988Macrolide resistance .... L1-296, D-175, B-1301,...............................C2-1977Macrolide resistance genes ............C1-1348Macrophage ....B-661, M-984, M-1055, M-1057magnetic isotope effect .................F-830magnetic resonance imaging ........... M-1670MAKI ............................ M-1700Malaria ....P-568, P-570, P-998, P-1005, P-1017Malaria guidelines .....................P-565MALDI-ToF . . . D-726, D-728, D-731, D-1423,.........................D-1772, D-1777MALDI-ToF MS .......D-729, D-730, D-1773,.........................D-1774, D-1775Manuka propolis .....................F-2071Maraviroc ..........................H-1576marker ..............................D-743mass sequencing .....................L2-310mass spectrometry .....D-1413, M-1691, D-1776mathematical modeling ..........V-396, A-1966MBL ........................B-045, C1-590MDR ..............................F-2030MDR acinetobacter .......A-022, A-023, K-562,.................................K-902MDR TB ...........................A-1259measles. . . . . . . . . . . . . . . . . . . . . . . P-566, V-1073meat ..............................C2-1913mecA gene ..........................D-1437mecA variant .......................C1-1739mechanicstic model ...................A-1763mechanism of action .....F-824, M-1061, F-2007mechanism-based inhibitors ............C1-459mechanism-based models / dr ............A-011mediatinitis ..........................K-267medical education ............C2-1915, K-2081medication therapy management ..........H-212mef(A), erm(X) .....................C1-1348Melioidosis .........................P-1004Meningitis .....B-658, M-977, P-1023, L1-1221,........V-1239, G3-1541, G3-1544, A-1942,.........................A-1943, A-1944Meningococcal .....................G3-1542Meningococcal disease ...............L1-1653Meningoencephalitis ........... P-1006, V-1240Meropenem ...................A-012, K-1612metabolism . . .A-1281, A-1284, A-1950, C2-1979metabolites .........................A-1950Metallo-beta-lactamase ........ C1-065, C1-077,..........C1-461, C1-465, C1-588, C1-593,.................. C1-594, D-745, D-1451Metallo-carbapenemase ................C2-091Methadone .........................A-1250Methicillin resistant ...................T-1037Methicillin-sensitive Staphylococcus aureus . . K-1125Methicillin-susceptible Staphylococcus aureus...........A-609, B-1319, C2-1389, K-1122Metronidazole ................. P-563, P-1019Metronidazole and vancomycin ...........K-922Mexico ....................L1-1653, L2-2115MHT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .D-749MIC ..........D-736, K-907, F-1508, M-1715,............F-2020, F-2024, F-2036, F-2047MIC creep ..................C2-1390, E-1481MIC determination ....................D-761MIC testing .......E-804, D-763, D-764, D-766,...................D-768, E-1463, E-1467Micafungin ............M-326, M-328, M-334,.......................G3-1560, G3-1561mice infections .......................B-1300micro-pattern ......................L2-2112microarray .......... D-1416, D-1432, C2-1983microbiological diagnosis ..............L1-2104microbiology .........................K-261microbiology laboratory .................D-729microcalorimetry .................... M-1719microdosing .........................F-2027microparticles .......................F-2011microRNA ...........................B-059microsporidia ................... P-993, P-995microtitre tray ........................D-763midazolam ..........................A-1936mimic ........ E-1474, F-1493, F-1494, F-1495minimum inhibitory concentration ........D-737Minocycline .........................C2-133Mitochondria .......................A-1291Mitochondrial function ................ M-968mixed species biofilm ..................E-1466mixed treatment comparison .............H-878MK-1439 ...........................H-551MK-3118 ..................M-1714, M-1715MK-7655 ...........................E-192MLST ...............K-936, D-1459, C2-1904MLST epidemiology .................C2-1353mode of action .......................F-2038model host ..........................F-1538modeling ...........................F-2070modified hodge test ...................D-1450molds .......................M-321, M-1680molecular characterization .............C2-1378molecular diagnostics .....D-155, D-732, D-1418,........................D-1419, M-1668molecular epidemiology ........D-161, C2-1216,.......B-1309, C2-1377, C2-1384, C2-1396,. . C2-1397, H-1571, K-1599, K-1625, C2-1911molecular typing . .....L2-309, C2-1210, B-1312,...............................C2-1388monoclonal .........................B-1736monoclonal antibody ..... T-342, G-871, A-1278,..................F-1529, B-1734, B-1737Monosulfactam ........... E-193, F-841, F-842monte carlo ..........................A-605Monte Carlo simulation . . . A-012, A-016, A-019,...................A-624a, A-644, A-1280Moraxella osloensis. . . . . . . . . . . . . . . . . . . . . C2-1979Morinidazole ........................A-1283Morpholino ........................C1-1972morphology switching ................. M-990mortality ........C2-097, D-160, H-227, K-254,....... K-472, K-912, K-923, K-955, K-1603,............... L1-1639, L1-1643, G-1753mortality risk factors ...... K-896, K-907, K-942,.....................K-943, K-948, K-950mortality-morbidity ............H-229, L1-1641Mouse ............................ M-1056mouse lung infection model ............F-2028mouse model . . . . V-399, B-663, M-1058, A-1275,................................B-1308mRNA half life ......................C2-115MRSA ........B-057, C2-123, C2-124, C2-127,.....C2-129, C2-130, C2-131, E-186, E-208,........A-596, A-605, A-608, A-622, B-646,.......B-647, B-650, B-653, C1-677, D-773,. . F-843, F-846, G-868, K-900, K-907, K-946,. . T-1069, A-1290, B-1317, C1-1351, C2-1377,......C2-1378, C2-1379, C2-1380, C2-1382,......C2-1385, C2-1383, C2-1386, C2-1388,. C2-1396, C2-1397, D-1415, D-1424, D-1426,. . D-1429, D-1435, D-1425, D-1427, D-1434,. . . E-1462, E-1470, E-1472, E-1473, E-1476,. . . E-1471, E-1477, E-1480, E-1482, E-1484,....E-1485, F-1496, F-1506, F-1507, F-1509,....F-1518, F-1521, K-1593, K-1594, K-1595,. . . K-1597, K-1599, K-1601, K-1634, K-1627,.......L1-1646, L1-1654, L1-1655, L1-1656,........L1-1657, L1-1665, B-1737, C1-1739,......C1-1742, C1-1743, C1-1744, C1-1746,.......D-1775, C2-1907, C2-1908, C2-1910,....... C2-1912, C2-1913, C2-1914, F-2001,.........................F-2032, K-2076MRSA bacteremia ....K-1121, C2-1391, D-1418,..................K-1600, K-1636, A-1768MRSA complicated skin and soft tissue infections................................K-1633MRSA diagnosis ..............D-1414, D-1432MRSA pneumonia ............K-1120, K-1628MRSA treatment. . . . . . . .F-1515, F-1517, F-1999MRX-I .......F-1497, F-1498, F-1499, F-1500,............F-1501, F-1502, F-1503, F-1504MSSA ..............................A-613MSSA and MRSA ....................B-648Mucin ..............................B-049Mucocutanea ........................P-1020Mucormycosis .........T-347, M-1679, M-1686,................M-1692, M-1707, M-1708Mucositis ...........................D-1458270September 9-12 |

KEYWORD INDEXmulti-azole resistance ................ M-1712multi-drug resistant pathogens . . . . D-770, F-1520multi-locus sequence typing . . . C2-114, G3-1562,...............................C2-1991multi-resistant ........................K-561multi-resistant TB ...................C2-1367multidisciplinar professionals. . . . . . . . . . . . P-1002multidrug cross-resistance .............. M-320multidrug efflux ......................C1-676multidrug resistance ......C2-149, E-195, M-975,........C1-1340, C2-1369, K-1587, K-1610,..........K-1624, C2-1898, F-2055, K-2096multidrug-resistant Acinetobacter spp ......K-1607multidrug-resistant bacteria ....... K-246, E-801,.........................F-1527, K-1608multidrug-resistant gram-negative C1-062, F-2018multidrug-resistant gram-negative bacilli . . . K-558multifaceted prevention program ..........K-240,.........................K-1629, K-2088Multilocus sequence typing .............C2-118multiple antibiotic resistance ............C1-671multiplex PCR .........D-178, D-1432, M-1668multiplex real time PCR .............. M-1674multiplex real-time PCR ...............D-1449multiplication .......................G-1748mupirocin ..........................E-1484mupirocin resistance ..........K-1595, C2-1914murine model ........................B-660murine tuberculosis ...................A-1268mutant prevention concentration .........A-1274mutants ..................... M-333, C1-681mutation ..........................C1-1343mutations ........... C1-682, C2-1370, H-1573MXP-4509 ..........................F-811Mycobacteria ........................D-1777Mycobacterial infections ................K-265Mycobacterium .............C2-1370, C2-1375Mycobacterium abscessus ..................K-266Mycobacterium avium .................B-1310Mycobacterium chelonae-abscessus complex D-735Mycobacterium massiliense ................K-266Mycobacterium tuberculosis .........D-736, F-829,..... F-832, F-833, A-1257, A-1261, A-1262,. . A-1263, C2-1369, C2-1371, D-1776, E-1994Mycobacterium tuberculosis complex ....... D-732,.........................D-737, C2-1367Mycoplasma ...................D-176, E-207Mycoplasma pneumoniae ..........D-175, B-1309,.......................C2-1977, C2-1978Myeloma ...........................T-1027Myeloperoxidase .....................F-1524NN. meningitidis serogroup .............L1-1653Nanoantibiotic ..........F-2006, F-2007, F-2008Nanoemulsion ..........G-869, F-2010, F-2070nanoparticle ..........................P-997nanosphere. . . . . . . . . . . . . . . . . . . . . . . . . . D-1417nasal carriers .......................C2-1383nasal colonization ...................C2-1377Nasopharyngeal .......................V-383Nasopharyngeal carriage .......G-1049, C2-1975nationwide matched cohort study .......L1-1650native antimicrobial peptide ............F-1488natural product .......................F-829natural products .......................F-825natural resistance .....................V-1237NDM ..............................K-561NDM-1 .......C1-064, C2-091,C1-592, F-2048NDM-2 ...........................C2-1900NDM-producing ......................E-795NDV-3 .............................G-868nebulisation ....................A-036, A-037necrotizing pneumonia ................B-1735neglected tropical diseases ...............P-569Neisseria gonorrhoeae. . . . . . . . . . . .L2-303, L2-308,..........................E-781, B-1303Neisseria meningitidis ......... C2-1982, L1-1651nemonoxacin .........................E-206neonatal ............................G-1751neonatal intensive care unit ......K-1125, K-1599neonatal invasive infection .............C2-1990neonate immunity ...................G3-1557neonates ............................ M-339neonatology .........................G-1750Nepal .............................C2-1368Nephropathia epidemica ................V-395Nephrotoxicity . . . A-034, A-616, A-617, G3-1558,........................K-1629, L1-1655nested polymerase chain reaction .........D-733Neuraminidase inhibitor ................V-390Neuropsychology .....................G-1054Neurosugical& onco ...................K-236Neurotoxicosis ......................G3-1548Neutropenia ......A-018, H-217, T-1025, K-1632Neutropenic fever ....................T-1038Nevirapine extended release .............H-877new Delhi metallo--lactamase .........C2-1219new OXA variant .....................D-1455newborn ...........................C2-1387Ngaoundere-Cameroon ................P-1010NICU ......................M-339, D-1429Nitroimidazole .....F-834, F-835, F-837, F-838,.................................F-840NK cells .............................B-051non-albicans Candida spp ............. M-1696non-critically ill .......................A-637non-fermenter ................ F-2050, F-2053non-immunosuppressed ...............V-1242non-nucleoside reverse transcriptase inhibitor.................................H-551non-ß-lactams .......................E-1470Nontuberculous mycobacteria ............F-831norovirus ....................P-1021, G-1048North America ...............C2-144, C2-722Northeastern Thailand .................P-999nosocomial infection ...................K-956nosocomial meningitis ..................K-562nosocomial pneumonia ................A-624anovel gendine ........................K-2096novel non-antibiotic catheter lock ........F-2012novel scaffold ................. F-1514, F-2018NS3 ................................V-370NS3/4A protease ......................F-827NS5b polymerase. . . . . . . . . . . . . . . . . . . . . . F-828NSAID ............................F-1996NTHi ............................C2-1974nursery .............................G-1051NXL104 ...............C2-149, E-194, A-630OO25b:ST131 .................C2-119, C2-122obesity ...........A-017, A-612, A-637, A-638,.........................A-1287, K-1628older adults .........................K-1600OLT ..............................T-1025Omadacycline ................A-1281, A-1282omega loop .........................C1-072Omiganan ..........................F-1491OmpA .............................B-1329once daily dose ......................L1-1647Oncohematological patients ............ M-312oncology .....................T-353, K-1603oncology patients ..............D-1412, K-2087Ontario, Canada ....................C2-1214Onychomycosis ......................A-1946OPAT .............................L1-284operation room .......................K-244Opisthorchis viverrini ....................P-999opportunistic infection ...........H-222, T-342Opsonophagocytosis ...........T-1042, A-1278optimal design ........................A-032oral pathogens .......................F-2015oral treatment .......................T-1028Final Program271

Keyword INDEXoritavancin ......C2-128, A-620, D-762, E-1462,................................E-1463Oropharyngeal ........................V-383Oropharyngeal candidiasis .......F-815, M-1674Oropharyngeal squamous cell carcinoma . . L2-302oseltamivir ....A-1243, A-1244, A-1245, G-1749,................................V-1080Oseltamivir phosphate ..................V-400Osteoarticular infection . K-929, M-1681, L1-2106Osteomyelitis . . . B-653, B-1317, A-1768, K-2074,........................K-2078, L1-2102Osteoporosis .........................H-231otitis media .........................G-1050otitis media ..........................D-181Otomycosis ......................... M-322outbreak . . .T-353, K-904, K-954, V-1073, K-1125,........C2-1375, D-1421, K-1623, C2-1902outcome .........M-317, M-324, D-180, K-931,................G3-1542, K-1601, C2-1906outpatient .....K-239, L1-287, L1-288, L2-2118OXA-143 ..........................K-1606OXA-163 ..........................C2-084OXA-210 ..........................C1-068OXA-23 ..........................C2-1900OXA-239 ..........................C1-069OXA-240 ..........................C1-595OXA-48 .....C1-061, C1-063, C1-066, C2-093,................................C1-591OXA-48-like ........................D-1453Oxacillinases .........................E-788Oxazolidinone . . . B-651, E-778, A-1289, A-1290,..................A-1291, E-1479, F-1502Ozenoxacin ...... E-204, E-205, E-210, C1-681,..........................C1-682, D-769PP-glycoprotein ....................... M-982P. aeruginosa .....A-632, C2-718, B-1308, F-2060PA-824 .............................F-836PAE ...............................F-2024paediatric infections ....................G-859Paenibacterin ........................F-1508Palivizumab ..........................T-357pandemic influenza ...................V-1078pandrug resistance ..............E-791, F-2068Parainfluenza .........................V-382parasite infections .............. P-997, P-1006parasites ................ P-994, P-997, P-1019parenteral nutrition ...................K-1758pathogen ...........................D-1457pathogenesis .................B-1310, B-1329pathogenomics .......................B-1314pathogens ..........................F-1524pattern recognition receptors .............B-044PBPK model .........................A-033PCR ........... D-173, D-174, D-176, D-177,....T-347, C1-665, D-1415, D-1425, D-1445,.................D-1447, K-1594, M-1704PCR ESI TOF Mass spectrometry .......D-1778PCR multiplex .......................D-1428PCR-ribotypin .......................K-933PCV10 vaccine .......................G-861PCV13. . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1364PCV7 ............................C2-1354PDH1 ............................ M-1059pediatric ..........A-019, B-045, M-322, V-376,.........A-612, A-1244, G3-1544, G3-1558,......................G3-1560, C2-1977pediatric infections ...................G-1752pediatric population ..................G3-1550PEI ...............................F-1492penicillin ..........................C2-1989peptide Deformylase ..................A-1276peptide structure and function ...........F-1490PER-2 ............................C1-1207peramivir ............................V-380percutaneous needle biopsy ............L1-2104performance evaluation ................H-1582peripheral line .......................K-2086peritonitis ......................... M-1685persistence ...................B-1337, B-1338persistent bacteremia ...........D-1420, K-2092persistent candidemia ................ M-1669pertussis .....................D-183, G3-1563PET/CT ............................K-940phage display ........................F-1537phage open-reading frames typing method................................D-1429pharmacodynamics .......A-025, A-030, A-041,....... A-624, A-642, A-629, A-631, M-989,. . . A-1762, A-1765, A-1931, A-1932, A-1942,.........................A-1947, A-1967pharmacokinetic .........A-025, A-628, H-893,..................A-1252, A-1928, A-1948pharmacokinetic/Pharmacodynamic (PK/PD)......A-038, A-606, A-620, A-1243, A-1269,. . . A-1270, A-1271, A-1275, A-1288, B-1308,....A-1760, A-1763, A-1961, A-1962, F-2035pharmacokinetics .........A-009, A-010, A-017,. .A-018, A-026, A-027, A-618, A-640, A-634,.... A-641, M-992, A-1245, A-1256, A-1258,. . . A-1260, A-1272, A-1279, A-1282, A-1283,. . . A-1949, A-1952, A-1953, A-1956, A-1960,...................F-2026, F-2027, F-2041pharmacy driven ......................K-241phase 2 ..............................V-381phase II ............................L1-294phase II clinical trial .................L1-1662phase-1 .............................G-873phenotypes. . . . . . . . . . . . . . . . . . . . . . . . . C2-1388phenylboronic acid. . . . . . . . . . . . . . . . . . . . D-1450phorbol myristate acetate ................A-599Phosphopantetheine adenylyltransferase . . . F-1540phototoxicity ........................A-1955phylogenetic analysis ...................H-214phylogeography ......................L1-964physiopathology. . . . . . . . . . . . . . . . . . . . . . . P-570PICC ..............................K-2096pigeons .............................P-995pikromycin ..........................F-1505pilus ................................G-865Piperacillin/tazobactam .... E-197, K-242, A-643,...........A-644, C2-721, C2-722, K-1590,.........................A-1766, A-1767PK/PD modeling ........A-012, A-636, A-644,..................A-1266, A-1764, F-2006PK/PD target attainment .........A-040, A-639PK/PD-index-effect relationship .........A-624plasmid ......C1-064, C1-591, C1-679, C2-697,.........C2-703, C2-711, C1-1208, C1-1745plasmid epidemiology .................C2-092plasmid-mediated ....................C2-082plasmid-mediated AmpC ..............C2-081plasmid-mediated quinolone resistance . . . . D-1456plasmids .....................C1-592, C2-710Plazomicin ........A-041, A-042, E-779, B-1302Plazomycin ..........................A-040Pleuromutilin. . . . . . . . . . . . . . . L1-1660, C1-1971Plex-ID ........................... M-1691Plusbacin ..........................C1-1969PML ...............................T-341PMQR ....... C1-683, C2-700, C2-701, D-759PMX30063 ..........A-1284, E-1474, L1-1662Pneumococcal bacteremia ...............G-862Pneumococcal resistance ................G-861Pneumococcal conjugate vaccine . . . G-859, G-860,.............G-863, G-866, G-867, G-1050Pneumococcal disease . . . G-859, G-876, L1-1641,................................H-1916Pneumococcal meningitis ...............G-864Pneumococcal pneumonia ........ D-172, G-862Pneumococcal polysaccharide vaccine ......G-867Pneumococcal surveillance ............C2-1364Pneumococcal vaccine .........T-1042, C2-1357Pneumococci ...............C2-1365, C2-1366Pneumococcus .......B-1314, C2-1356, C2-1362Pneumocystis jirovecii ................... M-333Pneumocystis jirovecii pneumonia .... H-221, H-226Pneumonia. . . . . . C2-146, D-173, H-226, L1-289,.......... L1-297, A-641, T-1041, G3-1551,. . .B-1737, G-1753, C2-1906, F-2066, K-2101PNU-100480 ..........A-1264, A-1265, E-1993PNU-100480 (Sutezolid) .......A-1262, A-1263272September 9-12 |

KEYWORD INDEXPNU100480 ........................E-1992point mutation ......................C2-1984Polyene+azole combination .............A-1939Polymerase chain reaction (PCR) .........T-355Polymyxin ...........................E-795Polymyxin B ......A-023, A-024, A-026, A-027,.....A-028, C2-086, E-785, K-1620, M-1717Polymyxin E .........................E-790population ..........................L2-303population analysis ............C2-1387, E-197population pharmacodynamic analysis .....A-016population pharmacokinetics ...... A-020, A-021,..... A-611, A-619, A-1244, A-1287, A-1964porin ...............................E-792Posaconazole .....T-346, T-350, A-1932, A-1933,..........A-1934, A-1935, M-1703, M-1706post-antibiotic effect ......A-008, F-832, A-1959poultrry ............................C2-706pre-emptive therapy. . . . . . . . . . . . . . . . . . . T-1067pre-exposure prophylaxis ...............H-1570pre-kidney transplant recipients .........T-1033prediction model .....................K-1583predictive performance .................A-614predictive tools. . . . . . . . . . . . . . . . . . . . . . . . K-910predictive value ......................D-1408predictor of mortality. . . . . . . . . . . . . . . . . . . K-916predictors of clinical success ............K-1120preemptive therapy ....................H-224preemptive treatment ...................T-366prescribing pattern .....................K-242prevalence ....C2-104, C2-107, C2-692, D-1434,.......................C2-1897, C2-1913prevention ...................K-2084, K-2101prevention programme .........K-1757, K-2093primary care settings ...................D-775primary HIV infection ................H-1578primary infection .................... M-1697probiotics ...........................L1-300procalcitonin ..................K-926, D-1402prognosis ........K-254, K-937, K-939, M-1679prognostic ..........................K-2074prognostic factors .....................P-567prolonged infusion ....................K-1612propensity score ......................K-1600Prophylaxis ....K-261, T-1038, M-1703, M-1706Propionibacterium ......................D-776Propionibacterium acnes .........D-170, C1-1342prospective study .................... M-1707prostate biopsy .......................C2-686prosthesis infection ...................K-2077prosthetic joint infection .........D-169, K-248,. . K-249, K-250, K-251, K-253, K-254, K-256,............K-257, K-258, K-2078, L1-2105prosthetic-related infection .......K-255, B-1318protease inhibitor .........H-215, H-883, H-888protease-activated receptor ..............V-399protein design .......................V-1077Proteomics ...........................K-559Proteus Mirabilis .....................K-1610Proviral DNA .......................H-1575Pseudomonas ....B-060, C1-465, D-746, A-1765,.................C1-1973, F-2064, F-2066Pseudomonas aeruginosa .... A-008, A-015, B-050,......B-051, C1-067, C1-078, A-633, A-639,. . . C1-680, C2-719, C2-720, C2-721, C2-722,.....C2-723, C2-724, C2-725, D-757, E-790,. . .E-193, E-199, E-791, F-843, F-846, K-903,....M-986, A-1278, B-1333, B-1334, B-1335,. . . . B-1336, B-1337, B-1338, F-1529, K-1624,.........M-1716, A-1766, B-1734, C1-1970,.....F-1998, F-2004, F-2021, F-2063, F-2065Pseudomonas aeruginosa ...............PTK 0796.........................A-1281, A-1282public health epidemiology .......C2-695, D-750public health interventions ..............G-860public health involvement ..............P-1002pulmonary complication ................H-226pulmonary penetration ................A-1964pulse-field gel electrophoresis ...........C2-723pulsed xenon ultraviolet .................K-934Puumala virus ........................V-395PVL ..............................L1-1657Pyelonephritis .......................B-1306Pyogenic spondylodiscitis ..............K-2076Pyrazinamide ........................B-1296Pyrazolium ..........................F-845Pyrosequence ........................D-1460Pyrosequencing ...... D-1446, D-1459, C2-1904Pyrrolocytosine ......................F-2059QQ fever ........L1-962, L1-963, P-1001, P-1011,................................P-1012qepA ..............................D-1456QNR ................C1-683, C2-693, C2-700QNRgenes ..........................C1-665qPCR .............................D-1453QTc ...............................A-1958quad ................................H-879quality control ................. D-767, D-768QuantiFERON ......................T-1033QuantiFERON-TB Gold In-Tube .......H-1917quantitative PCR (qPCR) ..............D-1454quantitative real time PCR .............D-1422Quinolone ........E-203, E-206, E-208, B-1298,. . . L1-1663, A-1947, A-1948, A-1958, F-2056Quinolone resistance . . . C2-696, C2-701, B-1305,................................B-1306Quinolone resistance-determining region . C2-1355Quinolones ........................C2-1981Quorum sensing ........M-990, B-1333, F-2071Rrabbit .............................. M-981race ................................H-881Radezolid. . . . . . . . . . . . . . . . . . . . C2-142, A-1290rainfall .............................L1-293Raltegravir ....................H-885, A-1253rapid ..............................D-1410rapid detection ........C1-078, C1-587 C1-1202rapid diagnostic ......................D-1461rapid test ...........................D-1426RDW. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-916reactivation ..........................T-351reactive oxygen species ..................A-599readmission ..........................K-240ready-to-eat raw vegetables ..............K-925real time PCR ........................D-159real time-RT-PCR ...................T-1064real-time multiplex PCR ...............D-1411real-time PCR ....C2-081, D-158, D-175, D-179,...........P-1005, T-1070, D-1412, D-1442recA gene ............................D-731recombinant .........................G-1053recombinant virus .....................V-392recombinase activity ...................C1-669recovery ............................H-1564recurrence .......K-924, K-932, T-1068, K-1619recurrent .......................... M-1684recurrent CDI ........................K-927recurrent herpes simplex labialis ..........V-397reduced cytotoxicity ...................F-1489regional antibiogram ...................K-233registry ............................. M-338regulation .................... C1-672, M-966rejection .............................T-359renal ...................T-365, H-891, A-1294renal dysfunction ......................A-607renal elimination ......................A-028renal function. . . . . . . . . . . . . . . . . . . . . . . . . A-635renal impairment .........A-029, A-621, H-887,..........................H-889, K-1631renal injury ........................ M-1673renal insufficiency .....................A-010renal replacement therapy ...............A-619renal transplant ..............T-1034, G3-1557renal transport ........................H-892renal uptake ..........................A-028Final Program273

Keyword INDEXrepeat testing .........................D-153reproducibility ........................D-758reservoir ............................H-1568residential-care ......................C2-119resistance ..... C2-080, C2-102, C2-122, C2-135,.....C2-136, K-238, K-278, L2-303, M-319,.......M-321, M-327, M-335, V-381, V-392,.......C1-461, P-563, A-604, A-628, A-642,.....C1-681, C2-706, C2-708, D-776, E-779,......E-805, F-857, T-1036, V-1079, V-1080,......C1-1208, C1-1341, C1-1342, C1-1345,......C2-1357, C2-1359, C2-1370, C2-1371,. . . D-1416, D-1421, F-1526, H-1573, K-1615,. .K-1620, K-1622, K-1634, M-1718, C1-1741,. . . A-1765, K-1925, A-1929, A-1938, A-1968,.......C2-1982, C2-1983, C2-1988, C2-1989resistance development .................A-011resistance Frequency ..................F-2025resistance genes .............C1-1350, C2-1903resistance mechanisms .................D-1430resistance mutation ....................H-218resistance selection ......A-600, A-1966, C1-1971resistant . C2-125, V-394, C1-682, F-820,C2-1978resistant Acinetobacter baumannii .........K-1603resistant microorganisms .........D-772, T-1046resistant pathogens ...................K-1611respiratory .....................D-177, V-386respiratory infections .....D-179, T-1065, F-1523,................................F-2051respiratory syncytial virus ...............T-353respiratory tract infection .............G3-1549respiratory viruses ............. V-389, M-1228retapamulin .........................E-1484retrospective analysis ..........V-1078, G3-1550RGM .............................C2-1375rhodamine 6G ...................... M-1712Rhodococcus ..........................C1-1348Ribavirin .....................H-216, V-1075ribosome ..........................C1-1343ribotype 027 .........................K-924Rickettsia conorii ......................P-1022Rickettsia typhi .......................P-1022Rifabutin ...........................A-1257Rifampicin ...........................K-929Rifampicin Dosage ...................A-1268Rifampin ..... B-652, L1-1224, A-1261, A-1262,................C1-1342, K-2089, L1-2106Rilpivirine ....................A-1249, H-880risk factors ........ K-263, V-387, K-949, K-955,.....K-899, T-1040, K-1583, K-1613, K-1621,........G-1753, C2-1903, H-1916, L2-2110,risk index ............................K-921Rituximab ...........................T-341RNA biomarker ..................... M-1678rnase P .............................F-1539rotavirus vaccine ......................G-874rpoB mutations .....................C2-1395RPX2003 ............................F-854RSV ............T-357, G-869, V-1075, V-1076RT-PCR ..........................G3-1563Rtt109 ..............................F-813RX-04 ...................... F-1521, F-1522SS. aureus infection .....................G-870S. pneoumoniae ................L1-1648, F-2028S. pyogenes ............................E-1462S/GSK1265744 ................H-550, A-1249Sacroiliitis ..........................L1-960safety ..........H-555, H-891, L1-957, P-1017,.......A-1289, G3-1560, G3-1561, G-1749,.........................A-1934, A-1941safety pharmacology ..................F-2042Salmonella .....C2-695, C2-697, C2-713, D-1421,................................B-1328Salmonella enteritidis ...................C2-698salvage therapy .......................H-1566sampling bias ........................K-1759SAR .......................... F-844, F-845SASP ....................... F-2065, F-2066SCCmec . . .B-1316, C2-1385, C2-1393, C1-1746SCCmec type ...............C2-1386, D-1428Scedosporium ........................T-348Schistosomiasis ......................P-1014score ...............................L1-295screening ....................T-1039, M-1677screening methods ..............D-751, P-1008scrub typhus ...................D-182, P-1003SCV ..........................A-596, A-597second-line therapy ..................C2-1367secondary pneumococcal pneumonia .......V-380secretions subglottic ...................K-2101see-saw effect ..................A-627, E-1478select agents .........................F-2023selection ............................K-1617semi-synthesis .......................F-1509semiquantitative roll-plate method ........D-167Sentry .............................C2-691Sepsis . . .B-055, L1-286, L1-289, P-1003, D-1413,. . D-1461, K-1635, L1-1643, G-1750, L2-2117Septic arthritis .......................K-2073Septicaemia .........................D-1404Septicemia ...........................K-905sequence type 11 ....................C2-1212serial testing performance ..............H-1918Serine-carbapenemase ............E-189, F-856seroepidemiology .....................V-1238serology ............................P-1008seroprevalence ...........D-184, V-379, V-1241serotype 19A ...............C2-1357, C2-1361serotypes . . . H-219, C2-1356, C2-1358, C2-1359,...... C2-1360, C2-1363, C2-1366, G3-1541Serratia marescens ....................C2-085serum levels ..........................T-350severe hospital-acquired pneumonia ......V-1074severity ............................L1-1667sexual intercourse .....................L2-310sexually transmitted infection ...........L2-309Shigella .............................C2-699shoulder .............................D-170SHV-12 ............................C2-707Sialic acid. . . . . . . . . . . . . . . . . . . . . . . . . . . B-1325signaling ........................... M-983SILAC .............................B-1328silver nanoparticles ...................F-2001simulation human pharmacokinetics .......A-022single nucleotide polymorphisms . . .B-044, H-890Sinusitis ........................... M-1686SIRS ..............................D-1404Sitafloxacin .........................L2-305site-directed mutagenesis ..............C1-1206skin and skin structure infections ....... C2-134,...............................C2-1398skin and soft tissue infections . . . K-239, G3-1555,...............................L1-1667skin infection .......L1-1659, L1-1664, L1-1665skin structure infections ................C2-123small colony variants ........... M-986, E-1483smallpox .............................V-396SMART ....................C2-120, C2-688smear positive ......................C2-1372Socioeconomic disparities ..............G-1752sodium oxychlorosene ...........D-770, F-1520sodium salicylate .....................B-1324softgel .............................A-1247solid organ transplant .....T-345, T-366, T-1026,......................... T-1066, T-1068solid organ transplantation .............T-1041solid tumor ..........................K-911solid-state NMR ....................C1-1969Solithromycin . . A-1269, A-1286, B-1301, F-1505Sonication .......D-165, D-167, D-168, K-1623Sortase .............................F-1534SOT ...............................T-340southwest Nigeria ...........C2-1378, C2-1898SP2078 ............................F-1511spa type ...........................C2-1382Spain ..............................P-1018sparse sampling schedule ................A-032specie specific marker .................D-1455274September 9-12 |

KEYWORD INDEXspecies identification ..................D-1443Spectinamides .......................A-1267Spectinomycin ........................F-832spectrum of activity ....................D-760spine SSI ............................K-261spread ............................C2-1212spread of resistance genes ..............C1-668sputum ..............................D-172SpyCEP ............................B-1311SSI ....................K-247, K-262, K-1594ST131 .......C2-110, C2-111, C2-112, C2-115,...........C2-116, C2-687, K-1584, F-2040ST258 ............................C2-1217ST59 CA-MRSA ...................C1-1340stable isotope .........................D-739Staphylococcal cassette chromosomal mec . . C1-1740Staphylococci . . C2-130, C2-1393, D-1441, L1-2105Staphylococcus ......... B-1314, D-1417, E-1479,........................F-1516, L1-2102Staphylococcus aureus ........B-043, B-046, B-058,.......C2-126, K-249, K-253, K-259, K-267,. . A-620, A-625, B-650, B-657, D-762, E-783,. . K-900, K-906, K-908, K-909, K-915, K-937,. . .T-1037, B-1316, B-1318, B-1320, C1-1339,......C1-1341, C2-1376, C2-1381, C2-1382,......C2-1384, C2-1390, C2-1391, C2-1394,. . D-1414, D-1419, D-1420, D-1428, D-1430,. . .D-1439, D-1440, D-1459, E-1468, E-1483,....E-1486, F-1487, F-1513, F-1534, F-1538,.......G3-1555, L1-1645, L1-1658, M-1713,........ B-1735, B-1736, C1-1740, C1-1741,......C1-1747, C2-1909, C2-1912, C2-1915,...................F-1997, F-1998, F-2029Staphylococcus aureus - ST398 .............K-255Staphylococcus aureus bacteremia ..........K-2092Staphylococcus epidermidis ...............K-2094Staphylococcus spp. .....C2-128, C2-1401, D-1437,.........................K-2085, K-2089statins ............... L1-297, M-329, K-1626STD ..............................B-1303stem cell transplantation .........T-363, D-1778stewardship ......H-225, K-1926, K-240, L1-282stochastic mutations ..................A-1266stool toxin ...........................D-162strain type ...........................K-931strain typing ................... M-316, K-469Streptococcus agalactiae ................C2-1990Streptococcus pneumoniae .........C2-145, C2-146,H-219, L1-296, B-658, G-862, G-865, G-866,.......A-1275, C2-1352, C2-1355, C2-1358,......C2-1359, C2-1360, C2-1361, C2-1363,. . . C2-1365, C2-1366, F-1535, G3-1541, G3-Streptococcus pseudopneumoniae ..........C2-1365Streptococcus pyogenes .....B-661, B-1311, B-1312,...............................C2-1991Streptococcus viridans .................L1-1640Streptococcus ...........................B-1313streptogramins ......................C1-1349Streptomycin .................L1-958, B-1321structural characterization ..............C1-467structure ............................C1-462structure-activity relationship ...........F-1490structure-based drug design ......F-2017, F-2018astructure-function .............C1-076, C1-458subspecialty ..........................P-564substrate specificity ................... M-975Sulfonamide .......................C1-1741sulphur contaning acetamide as anticandidal agent.................................F-812suPAR ......................D-1404, D-1405Superantigens ................B-1313, F-1517superficial culture .................... M-1688suppression ..........................H-881surface properties .....................F-2063surfactant ............................E-783surgery ...........K-939, K-941, K-942, L1-962surgical infection ..........K-256, K-259, K-262surgical management ................. M-1686surgical prophylaxis ..............K-236, K-247surgical site infection (SSI) ........K-266, K-269surgical wound ........................K-262surgical wound infection ................K-268surveillance . . . C2-089, C2-124, C2-125, C2-126,. . . C2-129, C2-131, C2-132, C2-135, C2-136,.....C2-137, C2-138, C2-139, E-204, K-237,.......M-315, D-773, K-914, K-952, P-1021,. .C2-1213, C2-1362, D-1424, H-1573, K-1755surveillance cultures ...................F-1524susceptibility .........C2-688, C2-120, C2-135,........E-200, L1-282, K-471, E-808, F-854,...........G-876, D-1410, E-1483, E-1992susceptibility testing .............E-205, D-728Sutezolid ....................A-1265, E-1993sutures ..............................K-269swine respiratory disease ...............F-2034Switzerland .........................C2-116SXT ...............................C2-715SXT transfer ........................B-1330syndromic diagnosis. . . . . . . . . . . . . . . . . . . .D-178synergism ............................E-796synergist ............................F-1496synergistic effects ......................E-788synergy. . . . . A-031, A-622, E-782, E-799, E-800,........... F-815, E-1472, L1-1655, F-2009synergy studies ..........E-797, B-1299, F-1527,.........................M-1717, F-2060synovial fluid ........................K-2073synthesis ............................F-838synthetic antibodies ...................F-1537Syphilis ............................B-1301systematic review ......................A-034systemic candidiasis . ................. M-1698TT-2307 ..............................F-809T-lymphocytes ........................B-052target .............................. M-983target surveillance .....................K-268target trough level .....................A-608Tazobactam ...... C1-073, E-198, E-200, E-201,................................A-1762TB ................................A-1254TB/HIV ..........................C2-1371TBA-354 .... F-834, F-835, F-836, F-837, F-838,........................... F-839, F-840TDM ..............................K-1627Tecovirimat ..........................V-396Tedizolid .....C2-142, A-1292, A-1293, A-1294,.........A-1295, L1-1664, L1-1665, E-1995Teicoplanin ....................A-607, A-608Telavancin ..... A-622, B-1299, E-1468, E-1469,................E-1470, L1-1656, C1-1742temporal trends ......................C2-687Tenofovir ........H-218, H-890, H-892, H-1570Tenofovir Prodrug .....................H-552TEST .............................C2-148Tetracycline .........................F-1526Tetracycline Resistance ................C1-675Tetracycline resistance genes ............C2-712Thailand ............................P-998therapeutic ..........................L1-958therapeutic drug monitoring ....... T-346, T-350therapeutic equivalence .........A-1945, A-1968therapy ................ L1-287, L1-288, T-341Thermomyces lanuginosus ............... M-1680thorough QT/QTc study ................A-623three dimensional extract test, ............D-774tick transmitted disease ...............G3-1553Tigecycline ..........C2-099, C2-133, C2-140,. . . C2-141, C2-143, C2-144, C2-147, C2-148,......C2-150, B-652, C2-721, D-765, E-784,.....E-785, E-799, A-1280, C2-1352, F-2004Tigecycline combinations ..............B-1300Tigecycline MIC ...............E-787, K-1604Tigecycline resistance ...........C2-151, E-787time-killing assay ................E-202, D-761time kill ............................F-2022time to detection .....................D-1409time to positivity of blood culture ........D-1420time-kill curves .......................E-203time-kill study ........................E-794tissue culture plate .....................D-171TLA-2 .............................C1-072Final Program275

Keyword INDEXTMC207 .....A-1256, A-1257, A-1258, A-1259,................................A-1260Tn1721 transposon ...................C1-668Tn4401 ............C1-589, C2-1217, C2-1218tolerability ..........................A-1273tolerance .......................... M-1705toll like receptor agonist ................B-054Tomatidine .................. F-1997, F-1998Topical microbicide ...................F-1528Topoisomerase ................C1-667, F-2039Topoisomerase inhibitors ...............F-2031totally implantable venous access ports .....D-166toxicity ......................A-1954, F-2008toxicology ..........................F-2042toxin. . . . . . . . . . . . . . . . . . . . . . . .M-1063, F-1999toxin genes ...........................D-158Toxoplasma gondii ......................H-223TP-271 ............................F-1525TR-701 FA .........................A-1292TR-701FA. . . . . . . . . . . .A-1293, A-1294, A-1295TR/L98H mutation .................. M-334trans-enamine .......................C1-459transmission .........................C2-109transplant ....K-273, M-337, T-348, T-351, T-357,..................T-1029, T-1031, M-1227transplantation ...... T-343, T-346, T-352, T-356,......T-365, T-1030, T-1032, T-1043, T-1072transposon ..........................C1-679treatment .........D-154, K-250, K-251, K-256,.................. K-917, M-1234, V-1236treatment failure ......................K-249treatment strategy .....................K-238triazoles ............................F-1513Trichomonas vaginalis ....................P-563Trichosporon asahii .................... M-1712trichosporonemia ..................... M-324trimethoprim/sulfametoxazole. . . . . .H-221, A-603tropism .................... H-1577, H-1578TST ......................... D-740, D-742Tuberculosis ...... D-739, D-741, D-742, D-743,. . . F-834, F-835, F-836, F-837, F-839, F-840,. . . L1-957, L1-958, A-1255, A-1258, A-1265,.......B-1296, C2-1372, C2-1373, C2-1374,......... G3-1552, E-1992, E-1993, H-1919Tularemia ...........................F-1531Turkey .............................L1-964Tween80 ............................D-763type 2 diabetes ........................B-043type B influenza ......................V-1080type-three secretion ...................F-1529typing ............................C1-1747UU-480 .............................A-1266Uganda .............................H-893ultrasonography ......................P-1008uncomplicated cystitis ..................D-775unusual microorganisms ...............K-2090upper respiratory infection ..............L1-300UppS ..............................F-1496urinary ............................L2-2111urinary tract infections .................C2-113urinary bactericidal activity (UBT) .......A-1285urinary screening .....................K-1927urinary tract infection .... C2-111, K-274, K-280,....L1-283, C2-684, C2-689, T-1036, B-1331,.........B-1332, A-1965, L2-2107, L2-2108,.......L2-2110, L2-2113, L2-2115, L2-2116,.......................L2-2117, L2-2118urinary tract infections/colonizations ....L2-2109urine concentrations .................. M-992uropathogenic E. coli .....E-777, B-1331, B-1332USA100 pvl+ .......................C2-1907USA300 .....................B-056, C2-1909USA600 MRSA ......................K-912UTI ........................F-2057, K-1927Vvaccination ...........................P-996vaccination coverage ............P-996, G-1051vaccination promotion .................G-1051vaccine . . . B-053, G-868, G-869, G-875, G-1048,G-1053, G-1054, K-2094vaccine acceptability ...................V-375vaccine development ...................G-870vaccine safety ........................G-1052vaginal co-infections ..................L2-306vaginal microbiota ....................L2-310vaginitis ............................L2-306Valganciclovir ................. T-369, T-1025validation ...........................K-1756vanA gene ...................K-281, C2-1985vanA-type .........................C2-1984Vancomycin ......C2-128, K-247, K-473, A-609,. .A-610, A-611, A-612, A-614, A-616, A-617,. . A-618, A-619, B-645, B-646, B-659, E-807,. . K-906, , K-919, K-1123, C2-1376, C2-1390,. . C2-1395, D-1435, E-1473, E-1477, E-1481,..........G3-1558, K-1627, K-1629, K-1630Vancomycin MIC ..... K-946, K-1122, C2-1391,.................C2-1392, E-1471, E-1485Vancomycin MIC creep ........K-1121, C2-1392Vancomycin nephrotoxicity ..............A-615Vancomycin-Resistent Enterococci (VRE) . . .K-272,. . K-275, K-277, K-279, K-281, A-600, A-601,.... A-602, B-655, T-1039, C1-1344, D-1436,.................D-1442, K-1632, C2-1985Vancomycin-susceptible Enterococcus faecium.................................C2-1984VAP ...............................K-1926variable number tandem repeat ..........C2-723Varicella vaccine. . . . . . . . . . . . . . . . . . . . . G3-1554Varicella zoster virus vaccine ...........G3-1556Varicella-zoster virus ..................V-1240Vascular graft infection ................K-2089Veillonella ............................E-806Ventilator associated pneumonia .........F-2014Verapamil ..........................F-2013Vertebral osteomyelitis ........K-2079, L1-2103,...............................L1-2104Vibrio owensii .........................C2-715Vibrio vulnificus .......................B-1298VIM-1 ............................C2-1214VIM-2 carbapenemase ................C2-719VIM-28 ............................C1-077VIM-type metallo-beta-lactamase .......C2-720viral diagnostics ......................V-1076viral infection ............B-059, K-954, V-1074viral load ....................H-1575, T-1070viral loads ............................V-372viral suppression .....................H-1580viridans group streptococci ..............A-604virological failure .....................T-1072virological outcome ...................A-1251virological response ....................H-886virtual screening ......................F-1534virulence .....C2-1210, B-1310, B-1321, B-1323,....B-1326, B-1327, B-1328, B-1333, B-1336,.........................F-1515, K-1614virulence factor ........C2-685, B-1312, B-1331,........B-1335, C2-1400, D-1452, G3-1554,......................... F-1999, F-2058virus ................. T-1064, T-1065, V-1073virus like particle .....................G-1048VISA ........A-603, K-906, C2-1381, C2-1387,................................E-1473visual symptoms ..................... M-1670vitamin D receptor ....................B-043VITEK 2 .......................... M-1710Voriconazole ....M-324, F-811, A-1938, A-1939,........................M-1225, M-1234Voriconazole P-Glycoprotein ...........A-1937Voriconazole pharmacogenomics .........A-1937Voriconazole therapeutic drug monitoring . A-1937VRE .......K-270, K-276, K-281, B-654, B-655VRE colonization .....................K-271VZV ..............................L2-307276September 9-12 |

KEYWORD INDEXWwater ..............................C2-711water based method ...................K-2082whole genome sequencing .......C1-062, B-1320,...............................L1-1651whole genomes ......................C1-592wound ......................C2-143, F-1518XX-ray crystallography. . . . . . . . . . . . . . . . . . C1-459X-ray structure ...............C1-463, C1-1344XDR-TB ..........................C2-1368YY. pestis ..............................B-1302yeast ............................... M-966Yersinia pestis ........................B-1304yield ...............................D-1409young adult ........................C2-1372ZZabofloxacin ........................L1-294Zanamivir ...................V-1079, A-1246Zoonosis ....................L1-963, P-1001Zygomycosis ........................ M-973Final Program277

NOTES278September 9-12 |

ORAL SESSIONSICAAC 2012Program GridSpecial Sessions and Lectures> Sunday AM> Sunday PM> Monday PM> Tuesday PM> Wednesday AMInteractive IDFellows Session001 Infectious Diseases101: For FellowsAge 18-88Room 1047:00 a.m. - 9:00 a.m.002 Opening KeynoteSessionHall E9:30 a.m. - 11:30 a.m.031 Literature ReviewRoom 1031:45 p.m. - 3:45 p.m.Poster SummarySession032 Early NewAntimicrobial AgentsRoom 1041:45 p.m. - 3:45 p.m.120 ICAAC LiveThis Week in Microbiologywith Vincent RacanielloEsplanade Ballroom 3032:00 p.m. - 4:00 p.m.130 ICAAC LectureRoom 1034:30 p.m. - 5:30 p.m.Symposium130a ICAAC-GCAC-MID SymposiumRoom 1025:45 p.m. - 7:15 p.m.209 ID QuizEsplanade Ballroom 3082:00 p.m. - 4:00 p.m.213 Cubist-ICAACAward LectureRoom 1034:30 p.m. - 5:30 p.m.Plenary Session225 The Use of SocialMedia and NewTechnologies inHealthcareRoom 1308:00 a.m. - 9:00 a.mFinal Program279

Program Grid Oral SessionsOral Sessions- Category AAntimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMSymposiumMeet-the-ExpertsSymposiumMeet-the-ExpertsSlide SessionSymposium035 PharmacodynamicsofAntifungal AgentsEsplanade Ballroom 3064:00 p.m. - 6:00 p.m.049 Surgical Prophylaxis:DosageRecommendations,Tissue Penetration,and PharmacokineticConsiderationsEsplanade Ballroom 3057:00 a.m. - 8:15 a.m.121 Aerosol DrugDelivery: GettingAnti-InfectiveAgents to the LungRoom 1302:00 p.m. - 4:00 p.m.Meet-the-Experts139 Intra- andExtracellularActivities of Anti-Infective AgentsEsplanade Ballroom 3107:00 a.m. - 8:15 a.m.Symposium200 Maximizing PK/PD Modeling forDosing, Preventionof Resistance andClinical OutcomesRoom 1021:30 p.m. - 4:00 p.m.227 Use of Pharmacokinetics/PharmacodynamicsforRisk Reduction ofAdverse EventsRoom 1039:15 a.m. - 11:15 a.m.Meet-the-Experts061 TargetingGram-NegativeSuperbugs withPolymyxins: FromLab-Bench toBedsideEsplanade Ballroom 3058:30 a.m. - 10:30 a.m.131 Top Papersin Anti-Infectiveand AntiretroviralPK/PDEsplanade Ballroom 3105:45 p.m. - 7:00 p.m.147 Vancomycin:What Do WeKnow Now AboutPharmacokinetics/Pharmacodynamics?Esplanade Ballroom 3068:30 a.m. - 10:30 a.m.Oral Sessions- Category BTherapy in Animal Models, Pathogenesis of Infectious Diseases, Molecular Basis for Pathogenicity, and Host Defenses> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM > Wednesday AMSymposiumSymposiumSymposiumSymposium036 Microbial FactorsModulatingHost Responses:New FrontiersEsplanade Ballroom 3094:00 p.m. - 6:00 p.m.062 Malnutrition,Microbiome &Mucosal ImmunityEsplanade Ballroom 3088:30 a.m. - 10:30 a.m.Symposium063 Pathogenesis,Diagnosis andTreatment ofUrinary TractInfectionRoom 1308:30 a.m. - 10:30 a.m.122 Bacterial andViral Infections inPatients Treatedwith Novel BiologicAgents: What DoI Need to Know?Esplanade Ballroom 3002:00 p.m. - 4:00 p.m.148 New Conceptsin Tuberculosis:Pathogenesis, Diagnostics,Treatment,and PreventionEsplanade Ballroom 3088:30 a.m. - 10:30 a.m.Symposium192 VirulenceBags: ExtracellularVesicles that ModifyHost-PathogenInteractionsEsplanade Ballroom 30211:15 a.m. - 12:45 p.m.Slide Session196 Novel AntibodyTherapy of DifficultInfectionsEsplanade Ballroom 31011:15 a.m. - 12:45 p.m.280September 9-12 |

ORAL SESSIONSOral Sessions- Cateogry C1Antibacterials: Mechanisms of Action, Biochemistry and Genetics of Resistance (Antibacterial, not Viral or Fungal)> Sunday PM> Monday AM> Monday PM > Tuesday AM> Tuesday PM> Wednesday AMSymposiumSymposiumSymposiumSymposiumSymposium037 MultidrugResistance inEmerging CountriesEsplanade Ballroom 3024:00 p.m. - 6:00 p.m.Slide Session064 Plasmid-Mediated QuinoloneResistanceEsplanade Ballroom 3028:30 a.m. - 10:30 a.m.Slide Session149 Novel Techniquesfor theDiagnostic of theEmerging AntibioticResistancesEsplanade Ballroom 3028:30 a.m. - 10:30 a.m.203 BacterialCommunicationand ResistanceEsplanade Ballroom 3002:00 p.m. - 4:00 p.m.Meet-the-Experts228 Resistance inBeyond MecAEsplanade Ballroom 3029:15 a.m. - 11:15 a.m.047 Structure/FunctionEsplanade Ballroom 3004:00 p.m. - 6:30 p.m.081 Carbapenemasein Enterobacteriaceaeand P. aeruginosaRoom 12211:15 a.m. - 12:45 p.m.Slide Session156 Extended Spectrum-LactamasesRoom 1218:30 a.m. - 11:00 a.m.214 Top 10-Lactamase Papersin 2012Esplanade Ballroom 3055:45 p.m. - 7:00 p.m.Slide Session197 Resistance inStaphylococcus aureusRoom 12211:15 a.m. - 12:45 p.m.Oral Sessions- Category C2Antibacterials: Surveys and/or Molecular Epidemiology of Resistance and Resistance Genes, Strains or Serotypes (Bacterial,not Viral or Fungal Resistance)> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMSymposiumSymposiumSymposiumMeet-the-ExpertsSymposiumMeet-the-Experts038 Whole GenomeSequencing andMolecular Epidemiology:The NewFrontier?Esplanade Ballroom 3084:00 p.m. - 6:00 p.m.065 PopulationDynamics inStreptococcuspneumoniaeEsplanade Ballroom 3108:30 a.m. - 10:30 a.m.123 Antibiotic CombinationsagainstGram-Negatives inthe XDR Era: FromBench to BedsideRoom 1222:00 p.m. - 4:00 p.m.Meet-the-Experts132 Detecting,Controlling, andTreating Carbapenemase-ProducingEnterobacteriaceaeEsplanade Ballroom 3025:45 p.m. - 7:00 p.m.140 : The Managementof Severe andRecurrent InfectionsEsplanade Ballroom 3087:00 a.m. - 8:15 a.m.Slide Session157 CarbapenemasesGo GlobalEsplanade Ballroom 3008:30 a.m. - 11:00 a.m.204 Global Spreadof AntimicrobialResistance: Mechanismsof Spread,Surveillance, andControlRoom 1212:00 p.m. - 4:00 p.m.Meet-the-Experts215 Surveillance ofAntimicrobial Resistance:PotentialSources of BiasEsplanade Ballroom 3095:45 p.m. - 7:00 p.m.220 Anaerobesand Surveillance:Neglected or Not?Esplanade Ballroom 3027:00 a.m. - 8:15 a.m.Slide Session236 Acinetobacter:Challenges andContinuedEmergenceRoom 1329:15 a.m. - 11:45 a.m.Slide Session237 MRSA:Pervasive,Persistent, andPathogenicEsplanade Ballroom 3059:15 a.m. - 11:45 a.m.Final Program281

Program Grid Oral SessionsOral Sessions- Category DLaboratory Tests for Diagnosing Infections; Methods for Antibacterial Susceptibility Testing> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMSymposiumMeet-the-ExpertsSymposiumSymposiumSlide SessionMeet-the-Experts039 Best Practices:Diagnosis of ViralCauses of HepatitisEsplanade Ballroom 3054:00 p.m. - 6:00 p.m.050 Syphilis Diagnostics:TraditionalVersus “New” AlgorithmRoom 1227:00 a.m. - 8:15 a.m.InteractiveSymposium060 Cases in ClinicalMicrobiologyRoom 1038:30 a.m. - 10:30 a.m.124 Epidemiologyand Diagnosis ofFebrile Illness inthe Era of GlobalClimate ChangeRoom 1022:00 p.m. - 4:00 p.m.Meet-the-Experts133 MALDI-ToFand PCR/ESI MassSpectrometry:Implementation andImpact on PatientCareRoom 1215:45 p.m. - 7:00 p.m.150 AntimicrobialSusceptibilityUpdateRoom 1208:30 a.m. - 10:30 a.m.201 Diverse Applicationsof MassSpectrometry inClinical MicrobiologyRoom 1201:30 p.m. - 4:00 p.m.221 Optimal DiagnosticTesting forClostridium difficilein Clinical PracticeEsplanade Ballroom 3107:00 a.m. - 8:15 a.m.InteractiveSymposium226 Challenges inthe Diagnosis andClinical Interpretationof Infectionswith Gram-PositiveRodsRoom 1049:15 a.m. - 11:15 a.mOral Sessions- Category EIn Vitro Antibacterial Susceptibility Studies and Drug-Combination Interactions> Sunday PM> Monday AM > Monday PM > Tuesday AM> Tuesday PM> Wednesday AMSymposiumSymposiumSymposium040 Origins andEcology of AntibioticResistanceEsplanade Ballroom 3104:00 p.m. - 6:00 p.m.151 Laboratory Approachesfor Detection,Characterization,and Reportingof Important ResistanceMechanismsin Gram-NegativesRoom 1328:30 a.m. - 10:30 a.m.205 SelectingAntibiotic ResistantMutants in theLaboratory: HowBest to Mimic theReal World?Esplanade Ballroom 3022:00 p.m. - 4:00 p.m.282September 9-12 |

ORAL SESSIONSOral Sessions-Category FNew Antimicrobial Agents (i.e. pre-US IND or prior to the start of any clinical therapeutic studies)and New Research Technologies> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMSymposiumSymposiumSymposiumMeet-the-ExpertsSymposiumSymposium041 New Treatmentsfor MycobacteriumtuberculosisInfectionsRoom 1224:00 p.m. - 6:00 p.m.066 Host Defense(Antimicrobial)Peptides: MajorPlayers in Healthand NovelTherapeuticsEsplanade Ballroom 3008:30 a.m. - 10:30 a.m.125 AlternativeApproaches toInhibiting Gram-Negative BacteriaEsplanade Ballroom 3082:00 p.m. - 4:00 p.m.141 Too FewNew Anti-Gram-Negative Agents:How to Change theLandscape?Room 1227:00 a.m. - 8:15 a.m.206 Iron Transportand Homeostasis:Are ThereOpportunities forNew Drugs?Esplanade Ballroom 3092:00 p.m. - 4:00 p.m.Meet-the-Experts229 New Approachesin the Treatment ofFungal InfectionsEsplanade Ballroom 3099:15 a.m. - 11:15 a.m216 Meeting theChallenge of Effluxfrom Gram-NegativeBacteriaEsplanade Ballroom 3025:45 p.m. - 7:00 p.m.Oral Sessions- Category GAdult and Pediatric Vaccine Studies and Pediatric Infections> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMSymposiumMeet-the-ExpertsSlide SessionMeet-the-ExpertsSymposiumSymposium042 VaccineConquests andChallengesRoom 1204:00 p.m. - 6:00 p.m.051 AntibioticShortages, AntibioticStewardshipand the Sick ChildEsplanade Ballroom 3097:00 a.m. - 8:15 a.m.Symposium067 Hot Topics inVaccinesRoom 1208:30 a.m. - 10:30 a.m.114 Vaccines:Innovations,Impact and SafetyRoom 1211:30 p.m. - 4:00 p.m.142 Healthy Mother,Healthy BabyEsplanade Ballroom 3097:00 a.m. - 8:15 a.m.Interactive Symposium145 InteractiveCases in PediatricInfectious DiseasesRoom 1038:30 a.m. - 10:30 a.m.207 Hot Topics inPediatric InfectiousDisease: 2012Room 1222:00 p.m. - 4:00 p.m.230 Interplaybetween Pathogenand Host: FromImmuneDeficiency toInfectious DiseaseRoom 1229:15 a.m. - 11:15 a.m.Symposium077 VaccineInnovationsEsplanade Ballroom 30511:15 a.m. - 12:45 p.m.Slide Session198 GlobalPediatricsEsplanade Ballroom 30911:15 a.m. - 12:45 p.m.Final Program283

Program Grid Oral SessionsOral Sessions- Category HHIV/AIDS and Other Retroviruses, Including Resistance> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM > Wednesday AMSymposiumMeet-the-ExpertsSymposiumMeet-the-ExpertsMeet-the-Experts043 Update on HIV-AssociatedCo-MorbiditiesRoom 1214:00 p.m. - 6:00 p.m.052 How Do ITreat HCV in HIV/HCV Co-InfectedPatients?Room 1217:00 a.m. - 8:15 a.m.Slide Session073 New AntiretroviralTherapy:Bench to BedsideRoom 1048:30 a.m. - 11:00 a.m.126 Current Issuesin HIV-AssociatedOpportunisticDiseasesEsplanade Ballroom 3062:00 p.m. - 4:00 p.m.Meet-the-Experts134 Preventionof Anal Cancer inHIV-Infection:From Early Detectionto VaccinationEsplanade Ballroom 3095:45 p.m. - 7:00 p.m.143 Managementof AntiretroviralTherapy-InducedBone ToxicityRoom 1217:00 a.m. - 8:15 a.m.Symposium152 What’s Newin AntiretroviralTherapyRoom 1308:30 a.m. - 10:30 a.m.222 Can WeSafely SimplifyAntiretroviralTherapy inTreatment-ExperiencedPatients?Esplanade Ballroom 3007:00 a.m. - 8:15 a.m.Slide Session238 CommonPathogens: Still aProblem in HIV-IRoom 1029:15 a.m. - 11:45 a.m.Oral Sessions- Category H2Antiretroviral Agents for Treatment and Prevention Including Preclinical and All Phases of Clinical Trials and Resistance> Sunday PM > Monday AM > Monday PM > Tuesday AM > Tuesday PMInteractiveSymposium202 Advances inHIV and HCVManagementRoom 1032:00 p.m. - 4:00 p.m.> Wednesday AM284September 9-12 |

ORAL SESSIONSOral Sessions- Cateogry KHealthcare-Associated and Surgical Infections and Clinical Epidemiology> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMSlide Session048 Difficulties ofClostridium difficileRoom 2544:00 p.m. - 6:30 p.m.Meet-the-Experts053 InfectionPrevention andControl in Lowand-Middle-Resource SettingsEsplanade Ballroom 3087:00 a.m. - 8:15 a.m.Meet-the-Experts054 Top Papersin InfectionPrevention andControl, 2011-2012Room 1207:00 a.m. - 8:15 a.m.Symposium068 PreventingSpread ofM. tuberculosis inHealthcareFacilitiesRoom 1228:30a.m. - 10:30 a.m.Slide Session074 Multidrug-ResistantOrganisms andCatheter-RelatedInfectionsRoom 2548:30 a.m. - 11:00 a.m.InteractiveSymposiumInteractiveSymposium118 Evidence-BasedInfection Preventionand Control:Answering KeyQuestionsRoom 1042:00 p.m. - 4:00 p.m.Slide Session129 Staphylococcusaureus: Tough Bug,Tough TreatmentRoom 1322:00 p.m. - 4:00 p.m.Meet-the-Experts136 PreventingLine-AssociatedBloodstream Infection:Which Measuresare Essential?Esplanade Ballroom 3085:45 p.m. - 7:00 p.m.Meet-the-Experts138a MDROControl: What toDo When BasicPreventionMeasures Don’tWork?Room 1027:00 a.m. - 8:15 a.m.Meet-the-Experts144 AntimicrobialResistance andAntimicrobialStewardship in Non-Hospital SettingsRoom 1207:00 a.m. - 8:15 a.m.Symposium193 RegionalApproaches toPrevention ofHealthcare-AssociatedAntimicrobialResistanceEsplanade Ballroom 30011:15 a.m. - 12:45 p.m.Slide Session199 BloodstreamInfections:Catheters, Culturesand CountsRoom 12111:15 a.m. - 12:45 p.m.Symposium208 Are PrevalenceSurveys Still Usefulfor Healthcare-Associated InfectionSurveillance?Esplanade Ballroom 3052:00 p.m. - 4:00 p.m.Meet-the-Experts217 ChallengingIssues in PediatricInfection Preventionand ControlRoom 1225:45 p.m. - 7:00p.m.Meet-the-Experts218 Issues in theDiagnosis andManagement ofProsthetic JointInfectionsEsplanade Ballroom 3105:45 p.m. - 7:00 p.m.Meet-the-Experts223 EnvironmentalCleaning andInfectionPreventionRoom 1207:00 a.m. - 8:15 a.m.Symposium231 A MultifacetedApproach toPreventing SurgicalSite InfectionsRoom 1219:15 a.m. - 11:15 a.m.Slide Session239 AntimicrobialStewardship: Perilsof PrescribingEsplanade Ballroom 3109:15 a.m. - 11:45 a.m076 Challenges inInfection ControlRoom 10411:15 a.m. - 12:45 p.m.Final Program285

Program Grid Oral SessionsOral Sessions- Category LClinical Treatment and Outcome Trials Involving Adult Community-Acquired Infections, Including Obstetrical-Gynecologicaland Sexually Transmitted Infections> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM > Wednesday AMSymposiumMeet-the-ExpertsSymposiumSymposium044 An Updateon Novel andImportantTickborneDiseasesRoom 1024:00 p.m. - 6:00 p.m.055 ChallengingInfections in OlderAdultsEsplanade Ballroom 3107:00 a.m. - 8:15 a.m.Symposium069 New Issues inthe Management ofMDR/XDR TBEsplanade Ballroom 3068:30 a.m. - 10:30 a.m.Symposium078 50 Years ofFluoroquinolones:Past, Present andFutureRoom 13211:15 a.m. - 12:45 p.m.Symposium127 New Issues inthe Managementof Multidrug-Resistant (MDR)EndocarditisEsplanade Ballroom 3052:00 p.m. - 4:00 p.m.153 Dangerous Petsand Other AnimalsRoom 1028:30 a.m. - 10:30 a.m.Symposium154 What EveryClinician ShouldKnow AboutEmerging NewAntimicrobialsEsplanade Ballroom 3058:30 a.m. - 10:30 a.m.Symposium194 Emerging andCurrent Challengesin Injecting DrugUsersRoom 10211:15 a.m. - 12:45 p.m.079 An Updateon StreptococcalPharyngitis andRheumatic FeverEsplanade Ballroom 30211:15 a.m. - 12:45 p.m.Oral Sessions- Category L1Clinical Trials of Adults with Community-Acquired Infections> Sunday PM > Monday AM> Tuesday AM> Tuesday PM> Wednesday AM> Wednesday PMMeet-the-ExpertsSlide SessionSymposiumSymposiumSymposium056 Difficult toManage CutaneousInfections in Adultsand ChildrenEsplanade Ballroom 3027:00 a.m. - 8:15 a.m.158 New Insights inBacterial MeningitisEsplanade Ballroom 3098:30 a.m. - 11:00 a.m.210 Potluck: TheLatest on FoodborneInfectionsRoom 1322:00 p.m. - 4:00 p.m.232 What’s Newwith Pneumococcus?Esplanade Ballroom 3089:15 a.m. - 11:15 a.m.045 An Update onPerinatal InfectionsRoom 1304:00 p.m. - 6:00 p.m.Symposium070 New Insightsin Diabetic FootInfections andOsteomyelitisRoom 1218:30 a.m. - 10:30 a.m.286September 9-12 |

ORAL SESSIONSOral Sessions- Category L2STD, Urinary Tract and Ob-Gyn Infections> Sunday PM > Monday AMSymposium071 An Update onthe Treatment andPrevention of UTIsRoom 1028:30 a.m. - 10:30 a.m> Monday PM > Tuesday AM > Tuesday PM > Wednesday AMOral Sessions- Category MMycology, Including Resistance and Mechanisms of Action of Antifungals> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMSymposium046 Mycology 2012:Top PapersRoom 1324:00 p.m. - 6:00 p.m.Meet-the-Experts057 FungalInfectionsInvolving the EyeRoom 1027:00 a.m. - 8:15 a.m.Symposium072 Research inMycology: HotTopicsRoom 1328:30 a.m. - 10:30 a.m.Slide Session115 Sleuthing inMycologyEsplanade Ballroom 3101:30p.m. - 4:00 p.m.Symposium128 FungalInfections inHigh-Risk Groups:Current and FutureStrategies forControlEsplanade Ballroom 3022:00 p.m. - 4:00 p.m.InteractiveSymposium146 ChallengingCases in MycologyRoom 1048:30 a.m. - 10:30 a.m.Slide Session159 Mycology forthe BedsideRoom 1228:30 a.m. -1:00 a.m.Meet-the-Experts219 How Can theMycology Lab Workfor You?Room 1215:45p.m. -7:00 p.m.Meet-the-Experts224 FungalInfections ofthe CentralNervous SystemRoom 1217:00 a.m. - 8:15 a.m.Symposium233 Controversies inClinical MycologyEsplanade Ballroom 3009:15 a.m. - 11:15 a.m.Final Program287

Program Grid Oral SessionsOral Sessions- Category PGlobal Health, Travel Medicine and Parasitology> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMInteractiveSymposium033 What’s HotWhere it’s Hot:Interactive Cases inTropical MedicineRoom 1034:00 p.m. - 6:00 p.m.Meet-the-Experts058 Top Ten Papersin Travel andTropical MedicineEsplanade Ballroom 3067:00 a.m. - 8:15 a.m.Slide Session075 Parasitology,Global Health andTravel MedicineEsplanade Ballroom 3098:30 a.m. - 11:00 a.m.InteractiveSymposium119 ClinicalProblem Solving:Interactive Cases inTravel and TropicalMedicineRoom 1032:00 p.m. - 4:00 p.m.Meet-the-Experts137 Controversies inPre-Travel PreparationRoom 1225:45 p.m. - 7:00 p.m.Symposium155 Update onDrug Resistancein MalariaEsplanade Ballroom 3108:30 a.m. - 10:30 a.m.Symposium211 Global Healthas an AcademicDisciplineEsplanade Ballroom 3102:00 p.m. - 4:00 p.m.Symposium234 Best Practicesfor Serologic Testingin Selected ParasiticDiseasesRoom 2549:15 a.m. - 11:15 a.m.Oral Sessions- Category TTransplantation Infectious Diseases> Sunday PM > Monday AM > Monday PMSlide Session116 Infectionsin TransplantRecipientsRoom 1201:30 p.m. - 4:00 p.m.> Tuesday AM > Tuesday PM > Wednesday AMOral Sessions- Category VVirology (Non-HIV), Including Resistance, and Non-HIV Viral Opportunistic Infections in HIV-Infected Patients> Sunday PM> Monday AM> Monday PM> Tuesday AM> Tuesday PM> Wednesday AMInteractiveSymposium034 Transplantationand the IDPhysician:ManagementStrategies for the21st CenturyRoom 1044:00 p.m. - 6:00 p.m.Meet-the-Experts059 PersistentHerpes VirusViremia: WhatDoes it Mean?Esplanade Ballroom 3007:00 a.m. - 8:15 a.m.Symposium080 Hot Topics inViral HepatitisRoom 13011:15 a.m. - 12:45 p.m.Slide Session117 RespiratoryViruses and MeaslesEsplanade Ballroom 3091:30 p.m. - 4:00 p.m.Meet-the-Experts138 New Strategiesfor Transplantationof HIV InfectedIndividualsEsplanade Ballroom 3005:45 p.m. - 7:00 p.m.Slide Session160 Hepatitis andHerpes VirusesRoom 2548:30 a.m. - 11:00 a.m.Symposium195 Influenza:Beyond theHeadlinesRoom 13011:15 a.m. - 12:45 p.m.Symposium212 Viruses and theCentral NervousSystem: Diagnostic,Treatment andRecent OutbreaksRoom 1302:00 p.m. - 4:00 p.m.Symposium235 Recognizingand Managing AntiviralResistanceRoom 1209:15 a.m. - 11:15 a.m.288September 9-12 |

POSTER SESSIONSPoster Session- Category AAntimicrobial Pharmacokinetics, Pharmacodynamics and General PharmacologySunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.Halls A-C003 PK/PD of CarbapenemsWith or Without Beta-LactamaseInhibitors004 Polymyxins andAminoglycosides: OptimizingPK/PD and Dosing082 Glycopeptides andLipopeptides: What’s New inPK/PD and Safety083 Improving Pharmacodynamicsof Beta-Lactams andBeta-Lactamase Inhibitors161 Clinical Pharmacologyof Antiviral and Anti-Tuberculosis Agents162 Clinical Pharmacology ofNovel Anti-Infective Agents163 Pharmacokinetics/Pharmacodynamics ofNew and Old Oxazolidinones240 Antifungals: ImprovingPK/PD and Safety241 Toxicokinetics and PK/PD ofNew and Old FluoroquinolonesPoster Session- Category BTherapy in Animal Models, Pathogenesis of Infectious Diseases, Molecular Basis for Pathogenicity, and Host DefensesSunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.005 Immune Response toMicrobial Infection084 Antimicrobial Therapy inAnimal Models I164 Antimicrobial Therapy inAnimal Models II165 Microbial Determinantsof VirulencePoster Session- Category C1Antibacterials: Mechanisms of Action, Biochemistry and Genetics of Resistance (Antibacterial, not Viral or Fungal)Sunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.Halls A-C006 Carbapenemases andExpanded Spectrum -Lactamases: Enterobacteriaceae,S. aeruginosa, A. bumannii085 Genetics and Resistance086 Resistance by Efflux/Quinolone Resistance166 Resistance to Staphylococcusand Other Gram-Positive242 Mechanisms of Resistanceto Novel CompoundsPoster Session- Category C2Antibacterials: Surveys and/or Molecular Epidemiology of Resistance and Resistance Genes, Strains or Serotypes (Bacterial,not Viral or Fungal Resistance)Sunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.Halls A-C007 AmpCs: Not Going Away!008 Carbapenemases: Will TheyEver End!009 ESBLs: Still Relevant087 Diverse Resistance Issuesin Enterobacteriaceae088 Food, Animals andEnvironment Reservoirs forGram-Negative Organisms167 Characterization ofStreptococcus pneumoniae in theEra of Antibiotics and Vaccines168 Drug-ResistantMycobacterium tuberculosis243 Antimicrobial Resistance ofMiscellaneous Bacteria244 Streptococcus and Enterococus010 Multi-Center SurveillanceStudies089 Pseudomonas aeruginosa: AnOverview of Survelliance Data169 MRSA: A Bug with InternationalAppeal and Great SenseFinal Program289

Program Grid Poster SessionsPoster Session- Category DLaboratory Tests for Diagnosing Infections; Methods for Antibacterial Susceptibility TestingSunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.011 Clostridium difficileDiagnosticss012 Diagnosis of Infections ofImplantable Devices and Biofilms013 Diagnosis of RespiratoryTract Infections014 Serologic Methods forDetection of Infectious Diseases090 MALDI-ToF Mass Spectrometryand Identification andSusceptibility Testing091 Mycobacteria: Diagnosticsand Susceptibility Testing092 Phenotypic SusceptibilityTesting Methods170 Detection of Bacteremia andBiomarkers for Sepsis171 Diagnosis, Characterizationand Antimicrobial SusceptibilityTesting: Gram-Positive Cocci172 Molecular Methods forPathogen Identification andResistance DetectionPoster Session- Category EIn Vitro Antibacterial Susceptibility Studies and Drug-Combination InteractionsSunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.Halls A-C015 In Vitro Activity of Beta-Lactamase InhibitorCombinations016 In Vitro Activity ofFluoroquinolones093 Cornucopia of In VitroActivity094 In Vitro Activity AgainstMultidrug-Resistant Gram-Negative Bacteria173 In Vitro Activity ofLipoglycopeptides and RelatedCompounds174 In Vitro Activity VersusStaphylococcal245 In Vitro Activity forMycobacteria095 In Vitro Activity VersusAnaerobesPoster Session- Category FNew Antimicrobial Agents (i.e. pre-US IND or prior to the start of any clinical therapeutic studies)and New Research TechnologiesSunday 11:30 a.m. - 1:30 p.m.Monday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.Halls A-C096 New Antifungal Agents097 New Antiviral Agents098 New Approaches in MycobacterialTherapy099 Targeting the Bacterial CellWall: New Beta-Lactams andBeta-Lactamase Inhibitor Combinations175 Antimicrobial Peptides andPeptidomimetics176 Compounds and Approachesfor Combating Gram-PositiveInfections177 Novel AntimicrobialApproaches and Agents246 New Ways with OldFriends: Repurposing andNovel Formulations247 Novel Inhibitors ofBacterial GyrB/ParETopoisomerase Subunits248 Quinolones and Beyond249 Targeting Gram-NegativePathogens290September 9-12 |

POSTER SESSIONSPoster Session- Category GAdult and Pediatric Vaccine Studies and Pediatric InfectionSunday 11:30 a.m. - 1:30 p.m.Monday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Wednesday 9:15 a.m. - 11:15 a.m.100 Impact of Expanded Valent:Pneumococcal Vaccines101 Updates in VaccinesPoster Session- Category G3Studies Relating to Aspects of Pediatric InfectionsSunday 11:30 a.m. - 1:30 p.m. Monday 11:15 a.m. - 1:15 p.m. Tuesday 11:15 a.m. - 1:15 p.m.Halls A-C178 PediatricsWednesday 9:15 a.m. - 11:15 a.m.Poster Session- Category HHIV/AIDS and Other Retroviruses, Including ResistanceSunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.017 Adherence to HIVTherapy and Care018 Hepatitis B and CCoinfection in HIV019 Opportunistic Infectionsand Co-Morbid Conditionsin HIV-I102 Antiretroviral TherapyOutcomes Including SelectPopulations103 Safety and Toxicity ofAntiretroviral Therapy179 HIV-I Pathogenesis andPredictors of AntiretroviralResponse in Treatment andPrevention180 HIV-I Resistance, Tropismand Novel Laboratory MethodsPoster Session- Category KHealthcare-Associated and Surgical Infections and Clinical EpidemiologySunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.Halls A-C020 Antibiotic Stewardshipand Usage021 Infection Control andthe Environment022 Prosthetic Joint Infections023 Surgical Site Infections024 Vancomyoin-ResistantEnterococci104 Blood Stream Infections105 Clostridium difficile Infections106 Endocarditis107 Fungal Infections108 Influenza181 Extended-Spectrum-Lactamase Enterobacteriaceae182 MRSA Infections183 Resistant AcinetobacterInfections184 Resistant Gram-NegativeInfections185 Use of Vancomycin,Daptomycin and/or Linezolid250 Bone Infections251 Hand Hygiene252 Vascular Catheter andDevice Related Infections253 Ventilator-AssociatedPneumoniaFinal Program291

Program Grid Poster SessionsPoster Session- Category L1Clinical Trials of Adults with Community-Acquired InfectionsSunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.Halls A-C025 Antimicrobial Stewardshipand OPAT026 Respiratory Tract Infection109 An Update on Tuberculosis110 Zoonotic Infections186 Endocarditis and Other InvasiveInfections187 Meningitis and Central NervousSystem Infections254 Bone and Joint Infections188 Methicillin-Resistant Staphylococcusaureus: Clinical Aspects189 Novel Agents and Insights inSkin and Soft Tissue InfectionsPoster Session- Category L2STD, Urinary Tract and Ob-Gyn InfectionsSunday 11:30 a.m. - 1:30 p.m.Halls A-C027 Studies in Sexually TransmittedInfectionMonday 11:15 a.m. - 1:15 p.m. Tuesday 11:15 a.m. - 1:15 p.m. Wednesday 9:15 a.m. - 11:15 a.m.Halls A-C255 Urinary Tract InfectionPoster Session- Category MMycology, Including Resistance and Mechanisms of Action of AntifungalsSunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Halls A-CWednesday 9:15 a.m. - 11:15 a.m.028 Fungal Epidemiology111 Experimental Mycology190 Clinical Mycology I191 Clinical Mycology II292September 9-12 |

POSTER SESSIONSPoster Session- Category PGlobal Health, Travel Medicine and ParasitologySunday 11:30 a.m. - 1:30 p.m.Monday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Wednesday 9:15 a.m. - 11:15 a.m.112 Global Health, Parasitologyand Travel MedicinePoster Session- Category TTransplantation Infectious DiseasesSunday 11:30 a.m. - 1:30 p.m.Halls A-CMonday 11:15 a.m. - 1:15 p.m.Halls A-CTuesday 11:15 a.m. - 1:15 p.m.Wednesday 9:15 a.m. - 11:15 a.m.029 Infections in TransplantRecipients: Viruses and Fungi113 Infections in TransplantRecipients and Patients withMalignanciesPoster Session- Category VVirology (Non-HIV), Including Resistance, and Non-HIV Viral Opportunistic Infections in HIV-Infected PatientsSunday 11:30 a.m. - 1:30 p.m.Halls A-C030 Non-HIV VirologyMonday 11:15 a.m. - 1:15 p.m. Tuesday 11:15 a.m. - 1:15 p.m. Wednesday 9:15 a.m. - 11:15 a.m.Final Program293

NOTES294September 9-12 |

NotesLate-breakers

Notes

LATE-BREAKER SCIENTIFIC SESSIONS003 (A)Poster SessionPK/PD of Carbapenems With or Without Beta-LactamaseInhibitorsSunday, 11:30 AM - 1:30 PM ..................... Halls A-CPresentation:A-022a Efficacy of Humanized Carbapenem Exposures against NewDelhi Metallo-Beta-Lactamase (NDM-1) Producing Enterobacteriaceaein a Murine Infection ModelD. E. Wiskirchen 1 , P. Nordmann 2 , J. L. Crandon 3 , D. P. Nicolau 3 ; 1 Univ.of St. Joseph, Sch. of Pharm., Hartford, CT, 2 Hosp. Bicetre, Paris, France,3Anti-Infect. Res. & Devel., Hartford Hosp., Hartford, CT.------------------------------------------------------------------------005 (B)Poster SessionImmune Response to Microbial InfectionSunday, 11:30 AM - 1:30 PM ..................... Halls A-CPresentations:B-060a TPA Alu I/D SNP Associates with Bacterial OsteomyelitisE. Valle-Garay 1 , A. H. Montes 1 , V. Carcaba 2 , J. A. Carton 2 , V.Asensi 2 ; 1 Oviedo Univ. Med. Sch., Oviedo, Spain, 2 Hosp. Univ. Central deAsturias, Oviedo Univ. Med Sch., Oviedo, Spain.B-060b Epithelial Innate Immune Response to Acinetobacter baumanniiChallenge: Why Some are More Vulnerable to Infection?Z. Feng 1 , X. Jia 1 , M. Adams 2 , R. A. Bonomo 3 , A. Weinberg 1 ; 1 Sch. ofDental Med., Case Western Reserve Univ., Cleveland, OH, 2 Sch. of Med.,Case Western Reserve Univ., Cleveland, OH, 3 Louis Stokes Cleveland Dept.of VA Med. Ctr., Cleveland, OH.B-060c Serum Annexin A2 Levels in Acute BrucellosisN. Aktug Demir 1 , S. Ozcimen 2 , S. Sumer 3 , A. Arpaci 4 , O. Ural 5 , A. C.Inkaya 6 ; 1 State Hosp. of Adiyaman, Adiyaman, Turkey, 2 Numune StateHosp., Konya, Turkey, 3 Selcuk Univ. Selcuklu Faculty of Med., Konya,Turkey, 4 Adiyaman Univ. Faculty of Med., Adiyaman, Turkey, 5 Selcuk Univ.Selcuku Faculty of Med., Konya, Turkey, 6 Hacettepe Univ. Faculty of Med.,Ankara, Turkey.------------------------------------------------------------------------008 (C2)Poster SessionCarbapenemases: Will They Ever End!Sunday, 11:30 AM - 1:30 PM ..................... Halls A-CPresentations:C2-097a Detection of Carbapenem-Resistant Providencia rettgeriProducing Metallo-ß-Lactamase NDM-1 in MexicoH. Barrios 1 , E. Garza-González 2 , E. Tamayo 1 , U. Garza-Ramos 1 , J. M.Llaca-Díaz 2 , A. Camacho-Ortiz 2 , S. Guzmán-López 3 , J. Silva-Sánchez 1 ;1INSP, Cuernavaca, Mexico, 2 Hosp. Univ. Dr. JE González, Monterrey,Mexico, Fac. de Medicina, UANL, Monterrey, Mexico.C2-097b First Identification of OXA-48 Carbapenemase-ProducingEnterobacteriaceae (CPE) in the United StatesA. J. Mathers 1 , K. Hazen 2 , A. Yeh 1 , J. Carroll 1 , H. Cox 1 , C. Sifri 1 ; 1 Univ. ofVirginia, Charlottesville, VA, 2 Duke, Durham, NC.------------------------------------------------------------------------009 (C2)Poster SessionESBLs: Still RelevantSunday, 11:30 AM - 1:30 PM ..................... Halls A-CPresentations:C2-121a Emergence of bla CTX-MResistance Determinants in theBovine E. coli Reservoir, Northwest United StatesM. A. Davis, L. Jones, N. Suthar, D. V. Meyers, W. Sischo, T. E. Besser;Washington State Univ., Pullman, WA.C2-121b CMY2 and CTXM15 Producing Salmonella Typhi, IndiaN. Taneja 1 , S. B. Appannanavar 1 , A. Kumar 1 , G. Verma 1 , Y. Kumar 2 ;1Postgraduate Inst. of Med. Ed. and Res., Chandigarh, India, 2 CRI Kasauli,Kasauli, India.------------------------------------------------------------------------026 (C2)Poster SessionRespiratory Tract InfectionSunday, 11:30 AM - 1:30 PM ..................... Halls A-CPresentations:L1-300a Severe Community-Acquired Pneumonia Requiring IntensiveCare Unit AdmissionH. Erdem 1 , H. Turkan 2 , A. Cilli 3 , L. Gorenek 1 , O. Oncul 1 , CAP in theICU Study Group; 1 GATA Haydarpasa Hosp., Istanbul, Turkey, 2 GATAHosp., Ankara, Turkey, 3 Akdeniz Univ., Sch. of Med., Antalya, Turkey.L1-300b Ceftaroline Fosamil (CPT-F) Use Patterns in HospitalizedAdult Patients with Community-Acquired Bacterial Pneumonia(CABP): A Retrospective Analysis of a Large U.S. HospitalDatabaseX. Huang 1 , E. Beresford 1 , H. D. Friedland 2 ; 1 Forest Res. Inst., Inc., JerseyCity, NJ, 2 Cerexa Inc., Oakland, CA.L1-300c Community-Acquired Pneumonia (CABP) Due to Methicillin-ResistantStaphyloccus aureus (MRSA) and Treatment withCeftaroline: Experience from the CAPTURE StudyA. Jandourek 1 , A. Cunningham 2 , G. Udeani 3 , Y. Li 1 , H. Friedland 1 ;1Cerexa, Inc., Oakland, CA, 2 Covenant Med. Ctr., Lubbock, TX,3Christus Spohn Hosp., Corpus Christi, TX.Final Program295

Late-Breaker SCIENTIFIC SESSIONS------------------------------------------------------------------------029 (T) (V)Poster SessionInfections in Transplant Recipients: Viruses and FungiSunday, 11:30 AM - 1:30 PM ..................... Halls A-CPresentations:T-369a Evaluation of Novel Program Aimed at Screening Solid OrganTransplant Recipients for Emerging CMV InfectionC. D. Cunha-Bang, S. S. Sørensen, H. Sengeløv, M. Iversen, F. Gustafsson,A. Rasmussen, N. Kirkby, J. Kjær, R. S. Brandt, C. Matthews, L. Peters, O.Kirk, J. Hilsted, J. Grarup, J. D. Lundgren, MATCH Program Study Group;Rigshospitalet, Copenhagen, Denmark.T-369b Risk Factors for Adenovirus Infection and Disease in PediatricHematopoietic Stem Cell Transplant PatientsL. Feghoul 1 , J. Dalle 2 , S. Chevret 1 , M. Ouachée 1 , M. Fahd 2 , A. Baruchel2, F. Simon 1 , J. Le Goff 1 ; 1 Univ Paris Diderot, Hosp. Saint-Louis, Paris,France, 2 Univ. Paris Diderot, Hosp. Robert Debré, Paris, France.------------------------------------------------------------------------030 (V)Poster SessionNon HIV VirologySunday, 11:30 AM - 1:30 PM ..................... Halls A-CPresentations:V-400a Method Development and Improvement of Human Papillomavirus(HPV) Detection and GenotypingS. F. Ambaye; Orebro Univ., Orebro, Sweden.V-400b Characterization of a Monoclonal Antibody Specific toMonkeypox Ortholog of A27L Protein: Specificity is Conferred bya Single Amino Acid Difference Within the Heparin Binding SiteL. Hughes 1 , J. Goldstein 1 , J. Pohl 1 , J. W. Hooper 2 , M. S. Keckler 1 , M.Townsend 1 , D. Bagarozzi 1 , I. Damon 1 , K. Karem 1 ; 1 CDC, Atlanta, GA,2USAMRIID, Frederick, MD.V-400c Hepatitis C Virus (HCV) Induces Epidermal Growth FactorReceptor (EGFR) Activation via CD81 Binding for Viral Internalizationand EntryJ. Diao, H. Pantua, H. Ngu, L. Komuves, L. Diehl, G. Schaefer, S. Kapadia;Genentech, San Francisco, CA.V-400d Prior Receipt of 2008-09 Trivalent Inactivated Influenza VaccineIncreases Pandemic H1N1 Severity in Ferrets: RandomizedDouble-Blind Placebo-Controlled ExperimentD. M. Skowronski 1 , M. E. Hamelin 2 , G. De Serres 3 , N. Z. Janjua 1 , G. Li1, X. Bouhy 2 , C. Couture 4 , S. Lavigne 4 , G. Boivin 2 ; 1 BC Ctr. for DiseaseControl, Vancouver, Canada, 2 Ctr. Hosp. Univ. de Québec, Québec, Canada,3Inst. Natl. de Santé Publique du Québec, Québec, Canada, 4 Inst. Univ. deCardiologie et Pneumologie de Québec, Québec, Canada.V-400e A Cell Based High-Throughput Screening Approach for theDiscovery of New Inhibitors of Respiratory Syncytial VirusW. Severson 1 , D. Chung 1 , B. Moore 2 , D. S. Matharu 3 , J. E. Golden 3 , C.Maddox 2 , L. Rasmussen 2 , M. I. Sosa 4 , S. Ananthan 2 , E. White 2 , C. Jonsson1 ; 1 Univ. of Louisville, Louisville, KY, 2 Southern Res. Inst., Birmingham,AL, 3 Univ. of Kansas, Lawrence, KS, 4 Southern Res. Inst., Birmingham, KY.V-400f The Role of Glycosylation in HCV Resistance to BroadlyNeutralizing AntibodiesH. Pantua, J. Diao, M. Ultsch, M. Hazen, K. Takeda, S. Date, T. K. Cheung,Q. Phung, P. Hass, D. Arnott, J. Hongo, R. Kelley, C. Eigenbrot, S. Kapadia;Genentech, South San Francisco, CA.------------------------------------------------------------------------073 (H)Slide SessionNew Antiretroviral Therapy: Bench to BedsideMonday, 8:30 AM - 11:00 AM .................. Room 104Presentations:H-556a Discovery of a Novel HIV-1 Nucleotide Competing RTInhibitor SeriesS. Tremblay, BSc - Research Associate, A. Pelletier, MSc - Research Associate,M. Ribadeneira, PhD - Associate Director, C. Sturino, PhD - Associate Director,S. Mason, PhD - Associate Director, L. Lamorte, PhD - Research Scientist,R. Bethell, PhD - Vice President, D. Rajotte, PhD - Senior Principal Scientist;Boehringer Ingelheim Ltd., R&D, Laval, Canada.H-556b Dolutegravir (DTG; S/GSK1349572) + Abacavir/LamivudineOnce Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz:48-Week Results - SINGLE (ING114467)S. Walmsley, MD - Professor of Medicine 1 , A. Antela, MD - Doctor 2 , N.Clumeck, MD - Professor 3 , D. Duiculescu, MD - Doctor 4 , A. Eberhard, MD- Doctor 5 , F. Gutiérrez, MD - Doctor 6 , L. Hocqueloux, MD - Doctor 7 , F.Maggiolo, MD - Doctor 8 , U. Sandkovsky, MD - Assistant Professor of Medicine9 , C. Granier, DESS - Manager, Statistics 10 , B. Wynne, MD - PhysicianProject Leader 10 , K. Pappa, PharmD - Clinical Investigation Leader 10 ; 1 UnivHlth. Network, Toronto, Canada, 2 Hosp. Clin. Univ., Santiago de Compostela,Spain, 3 Ctr. Hosp. Univ. Saint-Pierre, Brussels, Belgium, 4 InfectiousTropical Diseases Hosp., Bucharest, Romania, 5 MVZ Karlsplatz HIV Res.,Clin. Care Ctr., Munich, Germany, 6 Hosp. Univ. de Elche, Alicante, Spain,7Ctr. Hosp. Regional d’Orléans, Orléans, France, 8 Antiviral Therapy UnitOspedali Riuniti, Bergamo, Italy, 9 Univ. Nebraska Med Ctr., Omaha, NE,10GlaxoSmith-Kline, Research Triangle Park, NC.H-556c Simplification to Abacavir/Lamivudine (ABC/3TC) +Atazanavir (ATV) from Tenofovir/Emtricitabine (TDF/FTC)+ ATV/Ritonavir (RTV, /r) Maintains Viral Suppression andImproves Bone BiomarkersD. Wohl, MD - Associate Professor 1 , L. Bhatti, MD - Director HIV/HepCClin. 2 , C. B. Small, MD - Associate Professor 3 , H. Edelstein, MD - AssociateProfessor 4 , H. Zhao, PhD – Manager Stats 5 , D. A. Margolis, MD – ClinicalDivision Director 5 , L. L. Ross, MS - Senior Invest 5 , M. S. Shaefer, PharmD- Director Medical Affairs NA 6 ; 1 AIDS Clin. Trials Unit, UNC CH, ChapelHill, NC, 2 AIDS Healthcare Fndn., Beverly Hills, CA, 3 New York Med.Coll., Vahalla, NY, 4 Alameda County Med. Ctr., Oakland, CA, 5 GlaxoSmithKline,Research Triangle Park, NC, 6 ViiV Healthcare, Research TrianglePark, NC.296September 9-12 |

LATE-BREAKER SCIENTIFIC SESSIONS------------------------------------------------------------------------074 (K)Slide SessionMultidrug-Resistant Organisms and Catheter-RelatedInfectionsMonday, 8:30 AM - 11:00 AM .................. Room 254Presentations:K-562a Peptide Nucleic Acid Fluorescence In Situ Hybridization(PNA FISH) Screening for Detection of Central Venous CatheterRelated Bloodstream Infections in Patients Undergoing HemodialysisJ. Wagner, MD - Research Assistant, G. Schilcher, MD - Research Assistant,M. Hönigl, MD - Research Assistant, T. Valentin, MD - Research Assistant, W.Ribitsch, MD - Research Assistant, I. Zollner-Schwetz, MD - Assoc. Prof., J.Horina, MD - Professor, A. Rosenkranz, MD - Professor, R. Krause, MD -Professor; Med. Univ. Graz, Graz, Austria.K-562b One-Step 2% Chlorhexidine in 70% Isopropyl Alcohol(CHX-OH) Compared to 4-Step Povidone Iodine (PVI) Scrub,Rinse, Dry and 5% PVI-OH for Preventing Central Line-AssociatedBloodstream Infection (CLABSI)J. J. Parienti, MD, PhD - Physician, A. Seguin, MD - Physician, B. Sauneuf,MD - Physician, N. Terzi, MD - Physician, X. Valette, MD - Physician, R.Masson, MD - Physician, C. Daubin, MD - Physician, J. Dutheil, MS - ResearchAssistant, F. Fournel, MS - Research Assistant, F. Chaillot, MS - ResearchAssistant, V. Cattoir, MD, PhD - Physician, D. du Cheyron, MD, PhD -Physician; CHU Caen, Caen, France.K-562c First Evidence of a Hospital-Wide Multidisciplinary andMultimodal Intervention Program to Reduce Central VenousCatheter (CVC) Related Bloodstream Infections (CRBSI)W. Zingg, MD - Senior Registrar, B. Walder, MD - Senior Registrar, V.Cartier, MD - Senior Registrar, S. Touveneau, RN - Nurse, M. Theriault,RN - Senior Registrar, D. Pittet, MD, MS - Professor; Univ. of Geneva Hosp.,Geneva, Switzerland.------------------------------------------------------------------------085 (C1)Poster SessionGenetics and ResistanceMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:C1-673a Debunking the Myth of the Bifunctional Aminoglycoside(6’) Acetyltransferase Ie/Aminoglycoside (2”) PhosphotransferaseIa EnzymeH. Frase, M. Toth, N. T. Antunes, S. B. Vakulenko; The Univ. of NotreDame, Notre Dame, IN.------------------------------------------------------------------------086 (C1)Poster SessionResistance by Efflux/Quinolone ResistanceMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:C1-683a Structural Determinants of QnrS1 ResistanceM. M. Tavio 1 , G. A. Jacoby 2 , D. C. Hooper 1 ; 1 Massachusetts Gen. Hosp.,Boston, MA, 2 Lahey Clinic, Burlington, MA.------------------------------------------------------------------------090 (D)Poster SessionMALDI-ToF Mass Spectrometry and Identificationand Susceptibility TestingMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:D-731a Detection of SPM-1-Producing Pseudomonas aeruginosa (Pa)and CHDL-Producing Acinetobacter baumannii (Acb) Using LiquidChromatography Mass Spectrometry (LCMS) and MALDI-ToF MSC. G. Carvalhaes, R. Cayô, D. M. Assis, E. R. Martins, L. Juliano Neto, M.A. Juliano, A. C. Gales; UNIFESP, Sao Paulo, Brazil.D-731b Species-Specific Bacteriophage Amplification for EnhancedMALDI-ToF MS Bacterial DiagnosticsC. R. Cox, C. R. McAlpin, K. J. Voorhees; Colorado Sch. of Mines, Golden,CO.D-731c MALDI-ToF-MS Based Typing of Multidrug-ResistantKlebsiella pneumoniae Isolates for Advanced Microbial SourceTrackingL. Putignani 1 , A. Karger, F. Di Girolamo 1 , B. Bettin 2 , A. Masotti 1 , F. DelChierico 1 , A. Carattoli 3 , M. P. Balice 4 , M. Ballardini 4 , P. Bernaschi 4,1 , E.Bordi 4 , D. Capozzi 4 , M. Carletti 1,4 , A. Giordano 4 , S. Maiorano 4 , M. Meledandri4 , G. Parisi 4 , A. Tamburro 4 , A. Tarasi 4 , A. Capone 5,4 , N. Petrosillo5,4; 1 Bambino Gesù Children’s Hosp., IRCCS, Italy, Rome, Italy, 2 FederalRes. Inst. for Animal Hlth., Riems, Germany, Riems, Germany, 3 Publ. Hlth.Inst., Rome, Italy, Rome, Italy, 4 SEERBIO, Rome, Italy, 5 Spallanzani Hosp.,Rome, Italy.------------------------------------------------------------------------092 (D)Poster SessionPhenotypic Susceptibility Testing MethodsMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:D-776a ESBL/AmpC Co-Detection Simplified: A New Look at anExisting ESBL Detection TechniqueK. De, I. R. Kaur, N. P. Singh; Univ. Coll. of Med. Sci., Delhi, India.Final Program297

Late-Breaker SCIENTIFIC SESSIONSD-776b Comparison of Phenotypic Screening Methods for Detectionof Extended-Spectrum -Lactamase Producers among Pediatricswith Bloodstream Infections in a Saudi HospitalM. A. Abo-Shadi, A. A. Al-Johani; Faculty of Sci.-Taibah Univ., Al-Madinah,Saudi Arabia.D-776c Efflux Detection in Meropenem (MEM) Resistant Pseudomonas(P.) aeruginosa IsolatesC. A. Thoms-Rodriguez 1 , A. M. Nicholson 1 , N. Christian 1 , B. M. Willey 2 ,T. Mazzulli; Deputy Chief Microbiologist 2,3 ; 1 The Univ. of the West Indies,KGN, Jamaica, 2 Mount Sinai Hosp., Toronto, Canada, 3 The Univ. of Toronto,Toronto, Canada.------------------------------------------------------------------------094 (E)Poster SessionIn Vitro Activity against Multidrug-Resistant Gram-Negative BacteriaMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:E-804a In Vitro Activity of Plazomicin against Molecularly CharacterizedESBL-, AmpC-, and KPC-Producing Escherichia coli (EC)and Klebsiella pneumoniae (KPN) Obtained Across Canada: 2007- June 2012A. Denisuik 1 , H. J. Adam 1,2 , A. J. Walkty 1,2 , P. Lagacé-Wiens 1,2 , J. A.Karlowsky 1,2 , D. J. Hoban 1,2 , G. G. Zhanel 1 ; 1 Univ. of Manitoba, Winnipeg,Canada, 2 Diagnostic Services of Manitoba, Winnipeg, Canada.------------------------------------------------------------------------096 (F)Poster SessionNew Antifungal AgentsMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:F-823a Antifungal Activity of Aldimines Derived from 2-Aminophenolagainst Cryptococcus neoformans and Cryptococcus gattiiT. F. F. Magalhães, D. L. da Silva, C. M. da Silva, C. V. B. Martins, L. J.Nogueira, A. de Fátima, M. A. R. Stoianoff, J. A. G. Ferreira; Univ. Fed.de Minas Gerais, Belo Horizonte, Brazil.------------------------------------------------------------------------097 (F)Poster SessionNew Antiviral AgentsMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:F-828a AVI-7288 Provides Significant Survival Benefit WhenAdministered up to Four Days After Marburg Virus Infection inCynomolgus MacaquesP. L. Iversen 1 , T. K. Warren 2 , J. Wells 2 , J. Charleston 1 , A. C. Shurtleff 2 ,P. Sazani 1 , R. Davies 1 , L. Welch 2 , N. L. Garza 2 , A. Heald 1 , S. Bavari 2 ;1Sarepta Therapeutics., Cambridge, MA, 2 USAMRIID, Fredrick, MD.------------------------------------------------------------------------099 (F)Poster SessionTargeting the Bacterial Cell Wall: New Beta-Lactamsand Beta-Lactamase Inhibitor CombinationsMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:F-858a Time-Dependent Inhibition of NDM-1, VIM-2, & IMP-1Metallo--Lactamases By 3-(4-Chloromethylstyryl)-(6r,7r)-7-(Phenylacetamido)-Ceph-3-EM-4-Carboxylic AcidL. D. Sutton 1 , S. Yu 1 , A. Vosbeek 1 , M. Aitha 2 , M. W. Crowder 2 ; 1 SopharmiaInc., St. Joseph, MO, 2 Miami Univ., Oxford, OH.------------------------------------------------------------------------101 (C2)Poster SessionUpdates in VaccinesMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:G-876a Effectiveness of the Pneumococcal Haemophilus InfluenzaeProtein D Conjugate Vaccine (PHiD-CV10) against OutpatientAntimicrobial Prescriptions: FinIP TrialA. A. Palmu 1 , J. Jokinen 2 , H. Nieminen 1 , E. Ruokokoski 2 , T. Puumalainen 3 ,T. M. Kilpi 2 ; 1 Natl. Inst. for Hlth. and Welfare, Tampere, Finland, 2 Natl.Inst. for Hlth. and Welfare, Helsinki, Finland, 3 GlaxoSmithKline Vaccines,Espoo, Finland.G-876b Greater Risk of Measles with Earlier Age of 1st Dose in AdolescentsWho Received Two Pediatric Doses of Vaccine BeginningFrom 12 Months of Age: Further Evidence from QuebecG. De Serres 1 , F. Defay 1 , N. Boulianne 1 , M. Landry 2 , M. Ouakki 1 , N.Brousseau 3 , B. J. Ward 4 , D. M. Skowronski 5 ; 1 Inst. Natl. de Santé Publiquedu Québec, Québec, Canada, 2 MSSS, Montréal, Canada, 3 ASSS Mauricie etCtr. du Québec, Trois-Rivières, Canada, 4 McGill Univ., Montréal, Canada,5BCCDC, Vancouver, Canada.------------------------------------------------------------------------102 (H)Poster SessionAntiretroviral Therapy Outcomes Including SelectPopulationsMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:H-886a 18 Month Efficacy and Safety of the New WHO Option B+Regimen in the Prevention Breast Feeding Transmission of HIV-1in ZambiaM. Ngoma 1 , A. Misir 2 , W. Mutale 1 , R. Pilon 3 , M. S. Silverman 4 ; 1 Univ. ofZambia, Lusaka, Zambia, 2 Univ. of Ottawa, Ottawa, Canada, 3 Hlth. Canada,Ottawa, Canada, 4 Univ. of Toronto, Ajax, Canada.298September 9-12 |

LATE-BREAKER SCIENTIFIC SESSIONS------------------------------------------------------------------------112 (P)Poster SessionGlobal Health, Parasitology and Travel MedicineMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:P-1023a Adult Respiratory Distress Syndrome Secondary to BabesiosisP. Singh, N. Kaur, S. Cherian; SUNY Upstate Med. Univ., Syracuse, NY.------------------------------------------------------------------------113 (T)Poster SessionInfections in Transplant Recipients and Patients withMalignanciesMonday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:T-1046a Evaluation of the Effect of Number of Transplantations onTigecycline Susceptibility Patterns in Enterococcal Blood Isolatesfrom Hematopoetic Stem Cell Transplant (HSCT) Recipients: A5-yr Restrospective Study of 400 HSCT Recipients (2007-2011)S. K. Apewokin 1 , A. Pande 1 , S. Zainab 1 , A. Restrepo 1 , N. Ahmad 2 , M.Grazziutti 1 ; 1 Univ, of Arkansas for Med Sci., Little Rock, AR, 2 Univ ofArkansas for Med. Sci., Little Rock, AR.T-1046b Fidaxomicin in the Treatment of Clostridium difficile-AssociatedDiarrhea (CDAD) in Transplant RecipientsY. Dubrovskaya, D. S. Clutter, M. Merl, J. Zain, L. Teperman, R. Press, A.Safdar; NYU Langone Med. Ctr., New York, NY.------------------------------------------------------------------------114 (C2)Slide SessionVaccines: Innovations, Impact and SafetyMonday, 1:30 PM - 4:00 PM .................... Room 121Presentations:G-1054a Effectiveness of the 10-Valent Pneumococcal Non-TypeableHaemophilus influenzae Protein D Conjugate Vaccine againstAcute Otitis MediaT. Vesikari, MD - Professor 1 , A. Forstén, MD - Head of Study Clinics, PhysicianCoordinator 1 , I. Seppä, MD - Clinical Investigator 1 , T. Puumalainen,MD - Head of Medical Affairs 2 , A. Soininen, PhD - Senior CRA 2 , P. Lommel,MS - Manager Bio-Statistician 3 , M. Hezareh, PhD - Clinical DevelopmentManager 3 , M. Moreira, MD - Clinical Development Manager 3 , D.Borys, MD - Director Clinical Development 3 , L. Schuerman, MD - ClinicalDevelopment Manager 3 ; 1 Univ. of Tampere, Tampere, Finland, 2 GlaxoSmith-Kline, Espoo, Finland, 3 GlaxoSmithKline Vaccines, Wavre, Belgium.G-1054b Incidence of Invasive Pneumococcal Disease in ChildrenDeclines Further Following PCV13 IntroductionS. I. Pelton, MD - Professor of Pediatrics and Epidemiology 1 , I. Yildirim,MD - Research Scholar 1 , K. Hsu, MD - Assistant Professor of Pediatrics 1 , A.Silverio, BA - Research Associate 2 , and MA DPH; 1 BUSM, Boston, MA,2BMC, Boston, MA.------------------------------------------------------------------------117 (V)Slide SessionRespiratory Viruses and MeaslesMonday, 1:30 PM - 4:00 PM ....... Esplanade Ballroom 309Presentation:V-1080a Anti-Viral Treatment of Influenza in Infants Under 1 Yearof AgeM. O. Loveless, MD, MHA - Virology Medical Director 1 , P. Spagnuolo 2 , M.Zhang 3 , S. Liu 3 , J. Liu 3 , Y. Xu 1 , E. Chen 1 , J. Han 1 , L. Shi 3 ; 1 Genentech, Inc.,South San Francisco, CA, 2 Case Western Reserve Univ., Cleveland, OH,3Sch. of Publ. Hlth. and Tropical Med., Tulane Univ., New Orleans, LA.------------------------------------------------------------------------160 (V)Slide SessionHepatitis and Herpes VirusesTuesday, 8:30 AM - 11:00 AM .................. Room 254Presentation:V-1242a Age-Specific Prevalence of Epstein-Barr Virus (EBV) Antibody(Ab) in U.S. Children: Results from the National Health andNutrition Examination Surveys (NHANES) 2003-2010H. H. Balfour, Jr, MD - Professor 1 , F. Sifakis, MPH, PhD - Director,Epidemiology ID, Vaccines 2 , J. A. Sliman, MD - Associate Medical Director 2 ,J. A. Knight, BA - Associate Scientist 1 , D. O. Schmeling, BS - Scientist 1 , W.Thomas, PhD - Associate Professor 1 ; 1 Univ. of Minnesota, Minneapolis, MN,2MedImmune, LLC, Gaithersburg, MD.Final Program299

Late-Breaker SCIENTIFIC SESSIONS------------------------------------------------------------------------161 (A)Poster SessionClinical Pharmacology of Antiviral and Anti-TuberculosisAgentsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:A-1268a Long Half-Life is a Key Feature for High Potency ofAIC316 against HSV-2J. T. Schiffer 1 , A. Wald 1 , D. McCormick 2 , B. Timmler 2 , H. Rubsamen-Schaeff 2 , A. Birkmann 2 ; 1 Fred Hutchinson Cancer Res. Ctr., Seattle, WA,2Aicuris, Wuppertal, Germany.A-1268b First Single Intravenous Dose Escalation Data in Volunteersfor Letermovir: A Novel Anti-Human CytomegalovirusDrug Entering Phase 3D. Kropeit 1 , J. Scheuenpflug 1 , K. Erb-Zohar 2 , H. Stobernack 1 , D.McCormick 3 , M. Richard, MD - CMO 1 , H. Zimmermann 1 , H.Rübsamen-Schaeff 1 ; 1 AiCuris, Wuppertal, Germany, 2 Clinphase, Hanau,Germany, 3 DMPK Solutions Ltd., Nottingham, United Kingdom.A-1268c Investigation of the Effect of Oral Letermovir Administration;A Novel Anti-Human Cytomegalovirus Drug EnteringPhase 3, on the Pharmacokinetics of a Single Oral Dose of P-GP(MDR1) Substrate Digoxin in VolunteersJ. Scheuenpflug 1 , D. Kropeit 1 , K. Erb-Zohar 2 , J. G. W. Theis 3 , H. Stobernack1 , D. McCormick 4 , M. Richard 1 , H. Zimmermann 1 , H. Rübsamen-Schaeff 1 ; 1 AiCuris, Wuppertal, Germany, 2 Clinphase, Hanau, Germany,3InHeCon, Bergisch Gladbach, Germany, 4 DMPK Solutions Ltd, Nottingham,United Kingdom.A-1268d The Blood Bactericidal Activity of PNU-100480 (Sutezolid,U-480) and its Major Active Metabolite PNU-101603 (U-603) inPatients with Pulmonary TB: Insight from PK/PD ModelingT. Zhu, G. Nucci, R. S. Wallis; Pfizer Inc., Groton, CT.------------------------------------------------------------------------163 (A)Poster SessionPharmacokinetics/Pharmacodynamics of New and OldOxazolidinonesTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:A-1295a Lack of MAO Inhibition by Tedizolid Phosphate in Clinicaland Nonclinical StudiesS. Flanagan, S. Minassian, E. Fang, K. Bartizal, P. Prokocimer; Trius Therapeutics,San Diego, CA.------------------------------------------------------------------------164 (B)Poster SessionAntimicrobial Therapy in Animal Models IITuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:B-1308a Efficacy of Intravenous Plazomicin in the African GreenMonkey (AGM) Inhalational Plague ModelW. Mega 1 , R. Cirz 2 , R. Cass 2 , N. Reyes 2 , M. Valderas 1 , R. Sherwood 1 ;1LRRI, Albuquerque, NM, 2 Achaogen, Inc., South San Francisco, CA.------------------------------------------------------------------------165 (B)Poster SessionMicrobial Determinants of VirulenceTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:B-1338a Development of Anthrax in a Macaque Model after Ingestionof Bacillus anthracis SporesZ. Llewellyn 1 , N. Richardson-Harman 2 , J. Mann 1 , R. May 1 , B. Yamamoto 1 ,J. Toomey 1 , J. Boydston 1 , D. Karaolis 3 , S. Cendrowski 3 ; 1 Southern Res.Inst., Birmingham, AL, 2 Alpha StatConsult, Damascus, MD, 3 Natl. BiodefenseAnalysis and Countermeasures Ctr., Frederick, MD.------------------------------------------------------------------------166 (C1)Poster SessionResistance to Staphylococcus and Other Gram-PositiveTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:C1-1351a Meca-Independent High-Level, Beta-Lactam Resistancein Staphylococcus aureus Strains Passaged in Ceftobiprole andCeftarolineL. Chan, H. Chambers; Univ. of California, San Francisco, CA.C1-1351b Whole-Genome Analysis of a Daptomycin-SusceptibleEnterococcus faecium and its Daptomycin-Resistant Variant ArisingDuring TherapyT. T. Tran 1,2 , D. Panesso 1,3 , H. Gao 4 , J. H. Roh 1 , J. M. Munita 1,5 , J. Reyes 1,3 ,L. Diaz 1,3 , E. A. Lobos 4 , Y. Shamoo 6 , N. N. Mishra 7,8 , A. S. Bayer 7,8 , B.E. Murray 1 , G. M. Weinstock 4 , C. A. Arias 1,3 ; 1 Univ. of Texas Med. Sch.,Houston, TX, 2 Univ. of Houston Coll. of Pharm., Houston, TX, 3 Univ. ElBosque, Bogota, Colombia, 4 Washington Univ., St. Louis, MO, 5 Univ. delDesarrollo Sch. of Med., Santiago, Chile, 6 Rice Univ., Houston, TX, 7 LABiomedical Res Inst. at Harbor - UCLA, Torrance, CA, 8 Geffen Sch. ofMed. UCLA, Los Angeles, CA.300September 9-12 |

LATE-BREAKER SCIENTIFIC SESSIONS------------------------------------------------------------------------169 (C2)Poster SessionMRSA: A Bug with International Appeal and Great SenseTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:C2-1401a The Molecular Characteristic of Methicillin-ResistantStaphylococcus aureus Isolated from Children in Shanghai, ChinaJ. H. Cao, G. H. Li, X. G. Xu, D. M. Zhu; Huashan Hosp. Fudan Univ.,Shanghai, China.C2-1401b Spread of USA300-Like MRSA Colonization in a PostpartumMaternal and Neonatal Care Center in KoreaM. Ji, H. Sung, E. A. Kim, M. Kim; Univ. Ulsan and Asan Med. Ctr., Seoul,Korea, Republic of.------------------------------------------------------------------------172 (D)Poster SessionMolecular Methods for Pathogen Identification andResistance DetectionTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:D-1461a Evaluation of the First and Unique Commercial MolecularAssay Able to Identify Staphylococcus aureus Harboring the NewMecC Gene as Well as the Classical MecA Gene in Cultures andClinical MaterialsJ. Tasse 1 , A. Kearns 2 , A. Larsen 3 , G. Edwards 4 , B. Pichon 2 , R. Skov 3 , F.Laurent 1 ; 1 French Natl. Reference Ctr. for Staphylococci, Hospices Civils deLyon, Lyon, France, 2 Hlth. Protection Agency, London, United Kingdom,3Serum Staten Inst., Copenhagen, Denmark, 4 Scottish MRSA ReferenceLab., NHS Greater Glasgow and Clyde, Stobhill Hosp., Glasgow, UnitedKingdom.------------------------------------------------------------------------175 (F)Poster SessionAntimicrobial Peptides and PeptidomimeticsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:F-1495a In Vivo Activity of Novel Aggregating Peptide in StaphylococcalSepsis and Abscess InfectionN. G. Bednarska 1 , I. Vogel 1 , F. Rousseau 2 , J. Schymkowitz 2 , J. Van Eldere 3 ;1KU Leuven, Leuven, Belgium, 2 VIB SWITCH Lab., KU Leuven, Leuven,Belgium, 3 UZ Leuven, Leuven, Belgium.F-1495b Exploring the Inhibitory Potential of Antimicrobial PeptideLL-37 and its Fragments, that Prevent Biofilm Formation ofMultidrug-Resistant A. baumanniiX. Feng, K. Sambanthamoorthy, D. V. Zurawski, C. Paranavitana; WalterReed Army Inst. of Res., Silver Spring, MD.------------------------------------------------------------------------176 (F)Poster SessionCompounds and Approaches for Combating Gram-Positive InfectionsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:F-1518a New Mechanism of Action for Macrolide and Ketolide Antibioticsis to Reduce Fidelity of TranslationP. Gupta, N. Vazquez-Laslop, A. Mankin; Univ. of Illinois, Chicago, IL.------------------------------------------------------------------------177 (F)Poster SessionNovel Antimicrobial Approaches and AgentsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:F-1540a High Throughput Screening Method for Drugs againstBacterial Persisters Based on FluorescenceJ. Kim, Y. Joo, D. Cho, P. Heo, D. Kweon; Sungkyunkwan Univ., Suwon,Korea, Republic of.F-1540b Nanoscale Analysis of the Effects of a New Antibacterial,Cx1, on a Multidrug-Resistant Pseudomonas aeruginosaC. Formosa 1,2,3 , M. Grare 4 , R. E. Duval 3,5 , E. Dague 1,2 ; 1 CNRS, LAAS,Toulouse, France, 2 Univ. de Toulouse; UPS, INSA, INP, ISAE; UT1, UTM,LAAS, ITAV, Toulouse, France, 3 SRSMC, UMR 7565, Univ. de Lorraine -CNRS, Nancy, France, 4 Lab. de Bactériologie-Hygiène, IFB, CHU ToulousePurpan, Toulouse, France, 5 ABC Platform, Nancy, France.F-1540c A Phase I, Double-Blind, Randomised, Placebo-Controlled,Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokineticsof Single and Multiple Doses of NVB302 AdministeredOrally to Healthy VolunteersS. Febbraro 1 , A. Hancock 2 , A. Boyd 3 , M. J. Dawson 2 ; 1 Simbec Res.Limited, Merthyr Tydfil, United Kingdom, 2 Novacta Biosystems Limited,Welwyn Garden City, United Kingdom, 3 Boyd Consulting Limited, Crewe,United Kingdom.------------------------------------------------------------------------178 (G3)Poster SessionPediatricsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:G3-1563a Evaluation of Viral Coinfections in Hospitalized andNon-Hospitalized Children with Respiratory Infections UsingMicroarraysS. Kouni 1 , P. Karakitsos 2 , A. Chranioti 2 , M. Theodoridou Papagrigoriou 1 ,A. Michos 1 ; 1 Univ. of Athens, Aghia Sophia Children’s Hosp., Athens,Greece, 2 Univ. Hosp. Attikon, Athens, Greece.Final Program301

Late-Breaker SCIENTIFIC SESSIONSG3-1563b Prophylactic Valacyclovir to Prevent Outbreaks ofPrimary Herpes Gladiatorum at a 28-Day Wrestling Camp:A 10 Year ReviewJ. Anderson; Boynton Hlth. Service, Univ. of Minnesota, Minneapolis, MN.------------------------------------------------------------------------179 (H)Poster SessionHIV-I Pathogenesis and Predictors of AntiretroviralResponse in Treatment and PreventionTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:H-1570a Poor CD4+ T-Cell Restoration Linked to Residual HIV-1Reverse Transcription Under Anti-Retroviral TherapyK. C. Psomas 1,2 , C. Mettling 3 , J. Reynes 1 , P. Corbeau 2 ; 1 Infectious DiseasesDept., Univ. Hosp. of Montpellier, Montpellier, France, 2 Inst. of HumanGenetics, CNRS UPR 1142, Montpellier, France, 3 Inst. of Human GeneticsCNRS UPR 1142, Montpellier, France.H-1570b The CD4/CD8 Ratio as a Marker of T-Cell Activation/Exhaustion in HIV-Infected Children and Young Adults on Anti-Retroviral TherapyT. Sainz 1 , S. Serrano-Villar 2 , L. Díaz 1 , M. González-Tomé 3 , M. Mellado 4 ,J. Ramos 5 , S. Moreno 1 , M. Muñoz-Fernández 1 ; 1 Hosp. Gregorio Marañón,Madrid, Spain, 2 Hosp. Ramón y Cajal, Madrid, Spain, 3 Hosp. Doce deOctubre, Madrid, Spain, 4 Hosp. Carlos III, Madrid, Spain, 5 Hosp. de Getafe,Madrid, Spain.H-1570c HIV Impairs Human Alveolar Macrophage Innate ImmuneFunctionsH. C. Mwandumba 1,2 , K. C. Jambo 1 , D. Banda 1 , R. S. Heyderman 1,2 , D.G. Russell 3 ; 1 Malawi-Liverpool-Wellcome Trust Clinical Res. Programme,Blantyre, Malawi, 2 Liverpool Sch. of Tropical Med., Liverpool, United Kingdom,3 Cornell Univ., Ithaca, NY.H-1570d Elimination of HIV-1 Infected Cells by Radiolabeled Antibodyto GP41 in a Human Blood Brain Barrier ModelA. McFarren 1 , D. Tsukrov 2 , D. Williams 2 , L. Lopez 2 , S. Kitchen 3 , M.Gorny 4 , S. Zolla-Pazner 4 , A. Morgenstern 5 , F. Bruchertseifer 5 , A. Casadevall2 , J. Berman 2 , E. Dadachova 2 ; 1 Children’s Hosp. at Montefiore, Bronx,NY, 2 Albert Einstein Coll. of Med., Bronx, NY, 3 UCLA David Geffen Sch.of Med., Los Angeles, CA, 4 NYU, New York, NY, 5 Inst. for TransuraniumElements, Karlsruhe, Germany.H-1570e Killing of ART-Treated HIV-Infected Human Lymphocytesby RadioimmunotherapyD. I. Tsukrov 1 , A. McFarren 2 , D. Williams 1 , L. Lopez 1 , S. Kitchen 3 , M.Gorny 4 , S. Zolla-Pazner 4 , A. Morgenstern 5 , F. Bruchertseifer 5 , J. Berman 1 ,A. Casadevall 1 , E. Dadachova 1 ; 1 Albert Einstein Coll. of Med., Bronx, NY,2Children’s Hosp. at Montefiore, Bronx, NY, 3 UCLA David Geffen Sch. ofMed., Los Angeles, CA, 4 NYU, New York, NY, 5 Inst. for Transuranium Elements,Karlsruhe, Germany.H-1570f Prevalence of HIV-1 Seminal Shedding in HIV-1 InfectedMen Who Have Sex with Men (MSM) and Association with theSize of Intracellular HIV-1 Reservoir (ANRS EP49)J. Ghosn 1 , A. Delobelle 2 , M. Leruez-Ville 3 , C. Beaudoux 2 , L. Mascard 3 , A.Canestri 1 , R. Landman 4 , D. Zucman 5 , D. Ponscarme 6 , A. Rami 7 , J. Viard 8 ,B. Spire 9 , H. Lecuyer 3 , D. Costagliola 2 , C. Rouzioux, PharmD 3 , M. Suzan-Monti 9 ; 1 Bicetre Hosp., Paris, France, 2 INSERM UPMC UMR S943, Paris,France, 3 Necker Hosp., Paris, France, 4 Bicaht Hosp., Paris, France, 5 FochHosp., Suresnes, France, 6 St. Louis Hosp., Paris, France, 7 Lariboisiere Hosp.,Paris, France, 8 Hotel Dieu Hosp., Paris, France, 9 INSERM UMR S912,Marseille, France.------------------------------------------------------------------------180 (H)Poster SessionHIV-I Resistance, Tropism and Novel LaboratoryMethodsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:H-1582a Use of Next-Generation Sequencing Platforms to DetermineHIV-1 Coreceptor TropismM. E. Quinones-Mateu 1,2 , J. Archer 3 , J. Weber 4 , R. Gibson 2 , E. Paxinos 5 ,E. Arts 2 , D. L. Robertson 3 , L. Mimms 6 ; 1 UHCMC, Cleveland, OH,2CWRU, Cleveland, OH, 3 Univ. of Manchester, Manchester, United Kingdom,4 Inst. of Organic Chemistry and Biochemistry, Prague, Czech Republic,5Pacific Biosciences, Menlo Park, CA, 6 Quidel, San Diego, CA.H-1582b Evaluation of a Prototype Instrument-Free, Point of CareTest for the Measurement of CD4+ T-Cells in Management ofHIV InfectionD. A. Anderson 1 , S. Crowe 1 , M. Garcia 1 , N. Barnes 1 , A. Landay 2 , T.Denny 3 ; 1 Burnet Inst., Melbourne, Australia, 2 Rush Univ., Chicago, IL,3Duke Univ., Durham, NC.------------------------------------------------------------------------186 (C2)Poster SessionEndocarditis and Other Invasive InfectionsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentation:L1-1647a Efficacy and Safety of TP-434 versus Ertapenem in ComplicatedIntra-Abdominal Infection (cIAI)P. Horn 1 , G. Cesnauskas 2 , M. Ramesh 3 , S. Walpole 1 , J. Sutcliffe 1 ,J. Solomkin 4 ; 1 Tetraphase Pharmaceuticals, Watertown, MA, 2 Kaunas Hosp.,Kaunas, Lithuania, 3 Victoria Hosp., Bangalore, India, 4 Univ. Cincinnati,Cincinnati, OH.302September 9-12 |

LATE-BREAKER SCIENTIFIC SESSIONS------------------------------------------------------------------------189 (C2)Poster SessionNovel Agents and Insights in Skin and Soft TissueInfectionsTuesday, 11:15 AM - 1:15 PM .................... Halls A-CPresentations:L1-1667a Ceftaroline (CPT) Fosamil Real World Use Patterns inHospitalized Adult Patients with Acute Bacterial Skin and SkinStructure Infection (ABSSSI): A Retrospective Analysis of aLarge US Hospital DatabaseX. Huang 1 , S. Chen 1 , E. Beresford 1 , H. D. Friedland 2 ; 1 Forest Res. Inst.,Inc., Jersey City, NJ, 2 Cerexa Inc., Oakland, CA.L1-1667b Effect of a Single Prior Dose Short Acting Antibiotic onClinical Efficacy in a Phase 2b Exploratory Study of Delafloxacin(DLX) Compared to Vancomycin (VAN) and Linezolid (LNZ) inAdults with Acute Bacterial Skin and Skin Structure Infections(ABSSSI)J. Longcor, L. Lawrence, S. Hopkins, E. Duffy; Rib-X Pharmaceuticals, Inc.,New Haven, CT.L1-1667c Objective Measures of Clinical Efficacy in a Phase 2bExploratory Study of Delafloxacin Compared to Vancomycin andLinezolid in Adults with Acute Bacterial Skin and Skin StructureInfections (ABSSSI)J. Longcor, L. Lawrence, S. Hopkins; Rib-X Pharmaceuticals, Inc., NewHaven, CT.------------------------------------------------------------------------197 (C1)Slide SessionResistance in Staphylococcus aureusTuesday, 11:15 AM - 12:45 PM ................. Room 122Presentation:C1-1747a Identification of Novel Factors Affecting Methicillin-Resistanceand the Cell Wall Stress Stimulon in Staphylococcus aureusV. Dengler, MA or MS - PhD candidate 1 , M. M. Senn, PhD - Postdoc 1 ,C. Quiblier, MS - PhD Candidate 1 , B. Berger-Bächi, PhD - Professor 1 , N.McCallum, PhD - Postdoc 1,2 ; 1 Univ. of Zurich, Zurich, Switzerland, 2 Univ. ofSydney, Sydney, Australia.------------------------------------------------------------------------238 (H)Slide SessionCommon Pathogens: Still a Problem in HIV-IWednesday, 9:15 AM - 11:45 AM ............... Room 102Presentation:H-1921a HIV/HCV Coinfected and HCV Monoinfected PatientsHave Similar Early HCV Viral Kinetics with the Potent HCVNucleotide Polymerase Inhibitor Sofosbuvir (SOF)M. Rodriguez-Torres, MD - Principle Investigator 1 , M. Gonzales, MD -Investigator 1 , J. Rodriguez, PhD - Investigator 1 , S. Rossi, PharmD - SeniorDirector, Clinical Research 2 , G. Shen, PhD - Manager, Biostatistics 2 , A.Mathias, PhD - Director, Clinical Pharmacology 2 , B. Symonds, PharmD - VicePresident, Clinical Research 2 ; 1 Fundacion de Investigacion de Diego, San Juan,PR, 2 Gilead Sci., Foster City, CA.------------------------------------------------------------------------240 (A)Poster SessionAntifungals: Improving PK/PD and SafetyWednesday, 9:15 AM - 11:15 AM ................ Halls A-CPresentation:A-1946a Phase 1B Study of the Pharmacokinetics (PK) and Safetyof Posaconazole (POS) IV in Patients (Pts) at Risk for InvasiveFungal Infection (IFI)J. Maertens 1 , O. Cornely 2 , A. Ullmann 3 , W. Heinz 4 , G. Krishna 5 , M.Caceres 5 , N. Kartsonis 5 , H. Waskin 5 , M. N. Robertson 5 ; 1 Univ. Hosp.Gasthuisberg, Leuven, Belgium, 2 Univ. Hosp. Cologne, Cologne, Germany,3Johannes Gutenberg Univ., Mainz, Germany, 4 Julius-Maximilians-Univ.Würzburg, Würzburg, Germany, 5 Merck, Whitehouse Station, NJ.Final Program303

Late-Breaker SCIENTIFIC SESSIONS------------------------------------------------------------------------242 (C1)Poster SessionMechanisms of Resistance to Novel CompoundsWednesday, 9:15 AM - 11:15 AM ................ Halls A-CPresentation:C1-1973a Identification of the Antibiotic TA Binding Pocket in TypeII Signal Peptidase and Target Based Producer Strain ResistanceY. Xiao, D. Wall; Univ. of Wyoming, Laramie, WY.------------------------------------------------------------------------246 (F)Poster SessionNew Ways with Old Friends: Repurposing and NovelFormulationsWednesday, 9:15 AM - 11:15 AM ................ Halls A-CPresentations:F-2015a Rescuing Obsolete Antibiotics: Structural Basis of Inhibitionof Aminoglycoside-Modifying Enzymes by Protein KinaseInhibitorsP. J. Stogios 1 , E. Evdokimova 1 , P. Spanogiannopoulos 2 , N. Todorovic 2 ,A. Capretta 2 , G. D. Wright 2 , A. Savchenko 1 ; 1 Univ. of Toronto, Toronto,Canada, 2 McMaster Univ., Hamilton, Canada.F-2015b NanoDisk-Amphotericin B is Superior to Liposomal AmphotericinB in a Murine Model of Disseminated AspergillosisB. L. Burgess 1,2 , Y. He 2 , B. Luo 1 , R. O. Ryan 1,2 , S. F. Carroll 1 , T. M. Forte,PhD - Staff Scientist 1,2 , M. N. Oda 1,2 ; 1 Lypro Biosciences, Berkeley, CA,2Children’s Hosp. Oakland, Oakland, CA.------------------------------------------------------------------------248 (F)Poster SessionQuinolones and BeyondWednesday, 9:15 AM - 11:15 AM ................ Halls A-CPresentations:F-2056a DS-8587, a New Generation of Broad Spectrum Quinolone:In Vivo Anti-Anaerobe Activity in a New Murine Model of LiverAbscess Due to Fusobacterium necrophorum Via Injection intoCaudal VeinK. Nagaoka 1 , K. Yanagihara 1 , Y. Kurosaka 2 , K. Hoshino 2 , S. Kohno 1 ;1Nagasaki Univ. Graduate Sch. of Biomedical Sci., Nagasaki, Japan, 2 DaiichiSankyo, Co., Ltd., Tokyo, Japan.F-2056b DS-8587, a New Generation of Broad Spectrum Quinolones:In Vitro Antibacterial Activity against Clinical Isolatesfrom Aspiration PneumoniaJ. Fujita 1 , F. Higa 1 , I. Nakasone 1 , N. Yamane 1 , M. Chiba 2 , R. Okumura 2 ,K. Hoshino 2 ; 1 Univ. of the Ryukyus, Okinawa, Japan, 2 Daiichi Sankyo, Co.,Ltd., Tokyo, Japan.------------------------------------------------------------------------249 (F)Poster SessionTargeting Gram-Negative PathogensWednesday, 9:15 AM - 11:15 AM ................ Halls A-CPresentations:F-2072a Pharmacodynamic Assessments of RX-P873 against Klebsiellapneumoniae Using the Murine Thigh Infection ModelL. Lamb, J. L. Crandon, D. P. Nicolau; Ctr. for Anti-Infect. Res. & Dev.,Hartford Hosp., Hartford, CT.F-2072b Identification and Characterization of Small-moleculeInhibitors of Escherichia coli RecBCD DNA Repair Enzyme Usinga Transcreener Adenosine 5’-O-Diphosphate AssayM. A. Chapman 1 , G. R. Smith 2 , S. F. Singleton 1 ; 1 Univ. of North Carolinaat Chapel Hill, Chapel Hill, NC, 2 Fred Hutchinson Cancer Res. Ctr., Seattle,WA.------------------------------------------------------------------------251 (K)Poster SessionHand HygieneWednesday, 9:15 AM - 11:15 AM ................ Halls A-CPresentation:K-2084a Hand Hygiene Compliance (HHC) Results Using Before-After (B-A) Auditing Appear Inaccurate Compared to the WHO5 Moments Auditing Tool (5M) in Intense Care SettingsK. Ryan 1 , P. L. Russo 1 , D. Williams 1 , K. Heard 1 , K. Bellis 1 , S. Havers 1 ,M. L. Grayson 1,2 ; 1 Hand Hygiene Australia, Victoria, Australia, 2 Univ. ofMelbourne, Melbourne, Australia.------------------------------------------------------------------------255 (L2)Poster SessionUrinary Tract InfectionWednesday, 9:15 AM - 11:15 AM ................ Halls A-CPresentations:L2-2118a Plazomicin Safety and Efficacy in Patients with ComplicatedUrinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)V. Riddle 1 , D. Cebrik 2 , E. Armstrong 3 , R. Cass 3 , T. Clobes 3 , K. Hillan 3 ;1Ind. Consultant, Crofton, MD, 2 Axistat, San Francisco, CA, 3 Achaogen Inc.,S. San Francisco, CA.L2-2118b A Multi-Faceted Intervention to Reduce Rates of Catheter-AssociatedUrinary Tract Infections in a Resource-LimitedSettingL. G. Tillekeratne 1 , D. R. Linkin 1,2 , M. Obino 3 , A. Omar 3 , M. Wanjiku 3 ,D. Holtzman 1 , J. Cohn 1,2 ; 1 Hosp. of the Univ. of Pennsylvania, Philadelphia,PA, 2 Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA, 3 Sch.of Med., Univ. of Nairobi, Nairobi, Kenya.304September 9-12 |

LATE-BREAKER AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberAAbo-Shadi, M. A. ................D-776b, 092Adam, H. J. ..................... E-804a, 094Adams, M. ......................B-060b, 005Ahmad, N. ..................... T-1046a, 113Aitha, M. ....................... F-858a, 099Aktug Demir, N. ................. B-060c, 005Al-Johani, A. A. .................D-776b, 092Ambaye, S. F. .................... V-400a, 030Ananthan, S. .................... V-400e, 030And Ma Dph, ..................G-1054b, 114Anderson, B. J.. . . . . . . . . . . . . . . . . G3-1563b, 178Anderson, D. A. ................H-1582b, 180Antela, A. ......................H-556b, 073Antunes, N. T. ..................C1-673a, 085Apewokin, S. K. ................. T-1046a, 113Appannanavar, S. B. .............C2-121b, 009Archer, J. ......................H-1582a, 180Arias, C. A. ...................C1-1351b, 166Armstrong, E. ................. L2-2118a, 255Arnott, D. .......................V-400f, 030Arpaci, A. ...................... B-060c, 005Arts, E. .......................H-1582a, 180Asensi, V. ....................... B-060a, 005Assis, D. M. .....................D-731a, 090BBagarozzi, D. .................... V-400b, 030Balfour, H. H. .................. V-1242a, 160Balice, M. P. .....................D-731c, 090Ballardini, M. ...................D-731c, 090Banda, D. ......................H-1570c, 179Barnes, N. .....................H-1582b, 180Barrios, H. .....................C2-097a, 008Bartizal, K. .....................A-1295a, 163Baruchel, A. ..................... T-369b, 029Bavari, S. ....................... F-828a, 097Bayer, A. S. ...................C1-1351b, 166Beaudoux, C. ...................H-1570f, 179Bednarska, N. G. ................ F-1495a, 175Bellis, K. ......................K-2084a, 251Beresford, E. .................. L1-1667a, 189Beresford, E. ...................L1-300b, 026Berger-Bächi, B. ...............C1-1747a, 197Berman, J. .........H-1570d, 179, H-1570e, 179Bernaschi, P. ....................D-731c, 090Besser, T. E. ....................C2-121a, 009Bethell, R. ......................H-556a, 073Bettin, B. .......................D-731c, 090Bhatti, L. .......................H-556c, 073Birkmann, A. ...................A-1268a, 161Boivin, G. ......................V-400d, 030Bonomo, R. A.. . . . . . . . . . . . . . . . . . . B-060b, 005Bordi, E. .......................D-731c, 090Borys, D. ......................G-1054a, 114Bouhy, X. .......................V-400d, 030Boulianne, N.. . . . . . . . . . . . . . . . . . . . G-876b, 101Boyd, A. ....................... F-1540d, 177Boydston, J. .................... B-1338a, 165Brandt, R. S. .................... T-369a, 029Brousseau, N. ....................G-876b, 101Bruchertseifer, F. ....H-1570d, 179, H-1570e, 179Bruno, D. ...................... T-1072a, 116Burgess, B. L. .................. F-2015b, 246CCaceres, M. ....................A-1946a, 240Camacho-Ortiz, A. ..............C2-097a, 008Canestri, A. ....................H-1570f, 179Cao, J. H. .....................C2-1401a, 169Cap In The Icu Study Group, . ..... L1-300a, 026Capone, A.. . . . . . . . . . . . . . . . . . . . . . D-731c, 090Capozzi, D. .....................D-731c, 090Capretta, A. .................... F-2015a, 246Carattoli, A. .....................D-731c, 090Carcaba, V. ..................... B-060a, 005Carletti, M. .....................D-731c, 090Carroll, J. ......................C2-097b, 008Carroll, S. F.. . . . . . . . . . . . . . . . . . . . F-2015b, 246Cartier, V. ......................K-562c, 074Carton, J. A. .................... B-060a, 005Carvalhaes, C. G. ................D-731a, 090Casadevall, A. ......H-1570d, 179, H-1570e, 179Cass, R. ....................... B-1308a, 164Cass, R. ...................... L2-2118a, 255Cattoir, V. ......................K-562b, 074Cayô, R. ........................D-731a, 090Cebrik, D. .................... L2-2118a, 255Cendrowski, S.. . . . . . . . . . . . . . . . . . B-1338a, 165Cesnauskas, G. ................ L1-1647a, 186Chaillot, F. ......................K-562b, 074Chambers, H. .................C1-1351a, 166Chan, L. .....................C1-1351a, 166Chapman, M. A. ................ F-2072b, 249Charleston, J. .................... F-828a, 097Chen, E. ...................... V-1080a, 117Chen, S. ...................... L1-1667a, 189Cherian, S. ..................... P-1023a, 112Cheung, T. K. ....................V-400f, 030Chevret, S. ...................... T-369b, 029Chiba, M. ..................... F-2056b, 248Cho, D. ....................... F-1540a, 177Chranioti, A. ..................G3-1563a, 178Christian, N. ....................D-776c, 092Chung, D. ...................... V-400e, 030Cilli, A. ....................... L1-300a, 026Cirz, R. ....................... B-1308a, 164Clobes, T. ..................... L2-2118a, 255Clumeck, N. ....................H-556b, 073Clutter, D. S. ...................T-1046b, 113Cohn, J. ...................... L2-2118b, 255Corbeau, P. ....................H-1570a, 179Cornely, O. ....................A-1946a, 240Costagliola, D. ..................H-1570f, 179Couture, C. .....................V-400d, 030Cox, C. R. ......................D-731b, 090Cox, H. .......................C2-097b, 008Crandon, J. L. ...................A-022a, 003Crandon, J. L. .................. F-2072a, 249Crowder, M. W. ................. F-858a, 099Crowe, S. ......................H-1582b, 180Cunha-Bang, C. D. ............... T-369a, 029Cunningham, A. ................ L1-300c, 026DDa Silva, C. M. .................. F-823a, 096Da Silva, D. L. ................... F-823a, 096Di az, L. .......................H-1570b, 179Dadachova, E. ......H-1570d, 179, H-1570e, 179Dague, E. .......................F-1540c, 177Dalle, J. ........................ T-369b, 029Damon, I. ......................V-400b, 030Date, S. .........................V-400f, 030Daubin, C. ......................K-562b, 074Davies, R. ...................... F-828a, 097Davis, M. A. ...................C2-121a, 009Dawson, M. J. ..................F-1540d, 177De, K. .........................D-776a, 092de Fátima, A. .................... F-823a, 096De Serres, G. .........G-876b, 101, V-400d, 030Defay, F. ........................G-876b, 101Del Chierico, F. ..................D-731c, 090Delobelle, A. ...................H-1570f, 179Dengler, V. ....................C1-1747a, 197Denisuik, A. ....................E-804a, 094Denny, T. ......................H-1582b, 180Final Program339

Late-Breaker AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberDi Girolamo, F. ..................D-731c, 090Diao, J. ...............V-400c, 030, V-400f, 030Diaz, L. ......................C1-1351b, 166Diehl, L. ....................... V-400c, 030Dijkshoorn, L. .................C2-1905a, 236Du Cheyron, D. .................K-562b, 074Dubrovskaya, Y. ................. T-1046b, 113Duffy, E. .....................L1-1667b, 189Duiculescu, D. ...................H-556b, 073Durso, R. ...................... F-1540b, 177Dutheil, J. ......................K-562b, 074Duval, R. E. .................... F-1540c, 177EEberhard, A. ....................H-556b, 073Edelstein, H. ....................H-556c, 073Edwards, G. ....................D-1461a, 172Eigenbrot, C. .....................V-400f, 030Erb-Zohar, K. ......A-1268b, 161, A-1268c, 161Erdem, H. ..................... L1-300a, 026Evdokimova, E. ................. F-2015a, 246FFahd, M. ....................... T-369b, 029Fang, E. .......................A-1295a, 163Febbraro, S. .................... F-1540d, 177Feghoul, L. ..................... T-369b, 029Feng, X. ....................... F-1495b, 175Feng, Z. ........................B-060b, 005Ferreira, J. A. .................... F-823a, 096Fishetti, V. A. .................. F-1540b, 177Flanagan, S. ....................A-1295a, 163Formosa, C. .....................F-1540c, 177Forstén, A. .....................G-1054a, 114Forte, T. M. .................... F-2015b, 246Fournel, F. ......................K-562b, 074Frase, H. ......................C1-673a, 085Friedland, H. D. ............... L1-1667a, 189Friedland, H. D. .....L1-300b, 026, L1-300c, 026Fujita, J. ....................... F-2056b, 248GGales, A. C. .....................D-731a, 090Gao, H. ......................C1-1351b, 166Garcia, M. .....................H-1582b, 180Garcia-Reyne, A. ................ T-1072a, 116Garza, N. L. .................... F-828a, 097Garza-González, E. ..............C2-097a, 008Garza-Ramos, U.. . . . . . . . . . . . . . . . C2-097a, 008Ghosn, J. ......................H-1570f, 179Gibson, R. .....................H-1582a, 180Giordano, A. ....................D-731c, 090Golden, J. E. .................... V-400e, 030Goldstein, J. ..................... V-400b, 030González-Tomé, M. .............H-1570b, 179Gonzales, M. ...................H-1921a, 238Gorenek, L. .................... L1-300a, 026Gorny, M. .........H-1570d, 179, H-1570e, 179Granier, C. ......................H-556b, 073Grare, M. .......................F-1540c, 177Grarup, J. ....................... T-369a, 029Grayson, M. L. .................K-2084a, 251Grazziutti, M. .................. T-1046a, 113Gupta, P. ...................... F-1518a, 176Gustafsson, F. ................... T-369a, 029Gutiérrez, F.. . . . . . . . . . . . . . . . . . . . . H-556b, 073Guzmán-López, S. ..............C2-097a, 008HHönigl, M.. . . . . . . . . . . . . . . . . . . . . . K-562a, 074Hamelin, M. E. ..................V-400d, 030Han, J. ........................ V-1080a, 117Hancock, A.. . . . . . . . . . . . . . . . . . . . F-1540d, 177Hass, P. .........................V-400f, 030Havers, S. .....................K-2084a, 251Hazen, K. .....................C2-097b, 008Hazen, M. .......................V-400f, 030He, Y. ........................ F-2015b, 246Heald, A. ....................... F-828a, 097Heard, K. ......................K-2084a, 251Heinz, W. .....................A-1946a, 240Heo, P. ........................ F-1540a, 177Heyderman, R. S. ...............H-1570c, 179Hezareh, M. ...................G-1054a, 114Higa, F. ....................... F-2056b, 248Hillan, K. ..................... L2-2118a, 255Hilsted, J. ....................... T-369a, 029Hoban, D. J. .................... E-804a, 094Hocqueloux, L. ..................H-556b, 073Holtzman, D. .................L2-2118b, 255Hongo, J. ........................V-400f, 030Hooper, D. C. ..................C1-683a, 086Hooper, J. W. ....................V-400b, 030Hopkins, S. .......L1-1667b, 189, L1-1667c, 189Horina, J. .......................K-562a, 074Horn, P. ...................... L1-1647a, 186Hoshino, K. .........F-2056a, 248, F-2056b, 248Hsu, K. .......................G-1054b, 114Huang, D. B. ................... F-1540b, 177Huang, X. .....................L1-300b, 026Huang, X. .................... L1-1667a, 189Hughes, L. ...................... V-400b, 030IInkaya, A. C. .................... B-060c, 005Iversen, M.. . . . . . . . . . . . . . . . . . . . . . T-369a, 029Iversen, P. L. .................... F-828a, 097JJacoby, G. A. ...................C1-683a, 086Jambo, K. C. ...................H-1570c, 179Jandourek, A. ................... L1-300c, 026Janjua, N. Z. ....................V-400d, 030Ji, M. ........................C2-1401b, 169Jia, X. ..........................B-060b, 005John, G. ....................... T-1072a, 116Jokinen, J. ......................G-876a, 101Jones, L. .......................C2-121a, 009Jonsson, C. ...................... V-400e, 030Joo, Y. ........................ F-1540a, 177Juliano, M. A. ...................D-731a, 090Juliano Neto, L. ..................D-731a, 090KKapadia, S. ...................... V-400c, 030Kapadia, S. .......................V-400f, 030Karakitsos, P. ..................G3-1563a, 178Karaolis, D. .................... B-1338a, 165Karem, K. ......................V-400b, 030Karger, A. ......................D-731c, 090Karlowsky, J. A. .................. E-804a, 094Kartsonis, N. ...................A-1946a, 240Kaur, I. R. ......................D-776a, 092Kaur, N. ....................... P-1023a, 112Kearns, A. .....................D-1461a, 172Keckler, M. S. ...................V-400b, 030Kelley, R. ........................V-400f, 030Khan, B. ...................... F-1540b, 177Kilpi, T. M. .....................G-876a, 101Kim, E. A. ....................C2-1401b, 169Kim, J. ........................ F-1540a, 177Kim, M. ......................C2-1401b, 169Kirk, O. ........................ T-369a, 029340September 9-12 |

LATE-BREAKER AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberKirkby, N. ...................... T-369a, 029Kitchen, S. .........H-1570d, 179, H-1570e, 179Kjær, J. ......................... T-369a, 029Knight, J. A. ................... V-1242a, 160Kohno, S. ...................... F-2056a, 248Komuves, L.. . . . . . . . . . . . . . . . . . . . . V-400c, 030Kouni, S. .....................G3-1563a, 178Krause, R. ......................K-562a, 074Krishna, G. ....................A-1946a, 240Kropeit, D. .........A-1268b, 161, A-1268c, 161Kumar, A. .....................C2-121b, 009Kumar, Y. ......................C2-121b, 009Kurosaka, Y. .................... F-2056a, 248Kweon, D. ..................... F-1540a, 177LLagacé-Wiens, P. ................. E-804a, 094Lamb, L. ...................... F-2072a, 249Lamorte, L. .....................H-556a, 073Landay, A. .....................H-1582b, 180Landman, R. ...................H-1570f, 179Landry, M. ......................G-876b, 101Larsen, A. .....................D-1461a, 172Lattes, R. ...................... T-1072a, 116Laurent, F. .....................D-1461a, 172Lavigne, S. ......................V-400d, 030Law, C. ....................... F-1540b, 177Lawrence, L. ......L1-1667b, 189, L1-1667c, 189Le Goff, J. ......................T-369b, 029Lecuyer, H. ....................H-1570f, 179Lee, H. ....................... F-1540b, 177Leruez-Ville, M. ................H-1570f, 179Li, G. H. .....................C2-1401a, 169Li, G. ..........................V-400d, 030Li, Y. ......................... L1-300c, 026Linkin, D. R. .................. L2-2118b, 255Liu, J. ......................... V-1080a, 117Liu, S. ........................ V-1080a, 117Llaca-Díaz, J. M. ................C2-097a, 008Llewellyn, Z. ................... B-1338a, 165Lobos, E. A. ..................C1-1351b, 166Lommel, P. ....................G-1054a, 114Longcor, J. ....................L1-1667b, 189Longcor, J. .................... L1-1667c, 189Lopez, L. ..........H-1570d, 179, H-1570e, 179Loveless, M. O . ................ V-1080a, 117Lundgren, J. D. .................. T-369a, 029Luo, B. ........................ F-2015b, 246MMaddox, C. ..................... V-400e, 030Maertens, J. ....................A-1946a, 240Magalhães, T. F. .................. F-823a, 096Maggiolo, F. .....................H-556b, 073Maiorano, S. ....................D-731c, 090Mankin, A. .................... F-1518a, 176Mann, J. ....................... B-1338a, 165Margolis, D. A. ..................H-556c, 073Martins, C. V. ................... F-823a, 096Martins, E. R. ...................D-731a, 090Mascard, L. ....................H-1570f, 179Mason, S. .......................H-556a, 073Masotti, A. .....................D-731c, 090Masson, R. ......................K-562b, 074Match Program Study Group . ...... T-369a, 029Matharu, D. S. ................... V-400e, 030Mathers, A. J. ..................C2-097b, 008Mathias, A. ....................H-1921a, 238Matthews, C. .................... T-369a, 029May, R. ....................... B-1338a, 165Mazzulli, T. .....................D-776c, 092McAlpin, C. R. ..................D-731b, 090McCallum, N. .................C1-1747a, 197McCormick, D. .....A-1268a, 161, A-1268b, 161,...........................A-1268c, 161McFarren, A. ...... H-1570d, 179, H-1570e, 179,...........................H-1570d, 179Mega, W. ...................... B-1308a, 164Meledandri, M. ..................D-731c, 090Mellado, M. ....................H-1570b, 179Merl, M. ...................... T-1046b, 113Metan, G. ....................C2-1905a, 236Mettling, C. ....................H-1570a, 179Meyers, D. V. ...................C2-121a, 009Michos, A. ....................G3-1563a, 178Mimms, L.. . . . . . . . . . . . . . . . . . . . . H-1582a, 180Minassian, S. ...................A-1295a, 163Mishra, N. N. .................C1-1351b, 166Misir, A. .......................H-886a, 102Montejo, M. ................... T-1072a, 116Montes, A. H. ................... B-060a, 005Moore, B. ...................... V-400e, 030Moreira, M. ....................G-1054a, 114Moreno, S. .....................H-1570b, 179Morgenstern, A. ....H-1570d, 179, H-1570e, 179Muñoz-Fernández, M. ...........H-1570b, 179Munita, J. M. ..................C1-1351b, 166Munoz, P. ..................... T-1072a, 116Murray, B. E. ..................C1-1351b, 166Mutale, W. .....................H-886a, 102Mwandumba, H. C. .............H-1570c, 179NNagaoka, K. .................... F-2056a, 248Nakasone, I. .................... F-2056b, 248Ngoma, M. .....................H-886a, 102Ngu, H. ........................ V-400c, 030Nicholson, A. M. .................D-776c, 092Nicolau, D. P. ....................A-022a, 003Nicolau, D. P. ................... F-2072a, 249Nieminen, H.. . . . . . . . . . . . . . . . . . . . G-876a, 101Nogueira, L. J. ................... F-823a, 096Nordmann, P.. . . . . . . . . . . . . . . . . . . . A-022a, 003Nucci, G. ......................A-1268d, 161OObino, M. .................... L2-2118b, 255Oda, M. N. .................... F-2015b, 246Okumura, R. ................... F-2056b, 248Omar, A. .....................L2-2118b, 255Oncul, O. ...................... L1-300a, 026Ouachée, M. .................... T-369b, 029Ouakki, M. .....................G-876b, 101Ozcimen, S. ..................... B-060c, 005PPalmu, A. A. ....................G-876a, 101Pande, A. ...................... T-1046a, 113Panesso, D. ...................C1-1351b, 166Pantua, H. ...................... V-400c, 030Pantua, H. .......................V-400f, 030Pappa, K. .......................H-556b, 073Paranavitana, C. ................. F-1495b, 175Parienti, J. ......................K-562b, 074Parisi, G. .......................D-731c, 090Paton, B. ......................A-1946a, 240Paxinos, E. .....................H-1582a, 180Pelletier, A. .....................H-556a, 073Pelton, S. I. ....................G-1054b, 114Peters, L. ....................... T-369a, 029Petrosillo, N. ....................D-731c, 090Phung, Q. .......................V-400f, 030Pichon, B. .....................D-1461a, 172Pilon, R. .......................H-886a, 102Pittet, D. .......................K-562c, 074Pohl, J. ......................... V-400b, 030Final Program341

Late-Breaker AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberPonscarme, D. ..................H-1570f, 179Press, R. ....................... T-1046b, 113Prokocimer, P. ..................A-1295a, 163Psomas, K. C. ..................H-1570a, 179Putignani, L. ....................D-731c, 090Puumalainen, T. ......G-1054a, 114, G-876a, 101QQuiblier, C. ...................C1-1747a, 197Quinones-Mateu, M. E. ..........H-1582a, 180RRübsamen-Schaeff, H. ...........A-1268b, 161,...........................A-1268c, 161Rajotte, D. ......................H-556a, 073Ramesh, M. ................... L1-1647a, 186Rami, A. ......................H-1570f, 179Ramos, J. ......................H-1570b, 179Rasmussen, A. ................... T-369a, 029Rasmussen, L. ................... V-400e, 030Restrepo, A. .................... T-1046a, 113Reyes, J. ......................C1-1351b, 166Reyes, N. ...................... B-1308a, 164Reynes, J. ......................H-1570a, 179Ribadeneira, M. ..................H-556a, 073Ribitsch, W. .....................K-562a, 074Richard, M. ........A-1268b, 161, A-1268c, 161Richardson-Harman, N. .......... B-1338a, 165Riddle, V. ..................... L2-2118a, 255Robertson, D. L. ................H-1582a, 180Robertson, M. N. ...............A-1946a, 240Rodriguez, J. ...................H-1921a, 238Rodriguez-Torres, M. ............H-1921a, 238Roh, J. H. ....................C1-1351b, 166Rosenkranz, A. ..................K-562a, 074Ross, L. L. ......................H-556c, 073Rossi, S. .......................H-1921a, 238Rousseau, F. .................... F-1495a, 175Rouzioux, C. ...................H-1570f, 179Rubsamen-Schaeff, H. ...........A-1268a, 161Ruokokoski, E. ..................G-876a, 101Russell, D. G. ..................H-1570c, 179Russo, P. L. ....................K-2084a, 251Ryan, K. .......................K-2084a, 251Ryan, R. O. .................... F-2015b, 246SSørensen, S. S. ................... T-369a, 029Safdar, A. ...................... T-1046b, 113Sainz, T. .......................H-1570b, 179Sambanthamoorthy, K. ........... F-1495b, 175Sandkovsky, U. ..................H-556b, 073Sariguzel, F. M. ................C2-1905a, 236Sauneuf, B. .....................K-562b, 074Sauve, K. ...................... F-1540b, 177Savchenko, A. .................. F-2015a, 246Sazani, P. ....................... F-828a, 097Schaefer, G. ..................... V-400c, 030Scheuenpflug, J. .....A-1268b, 161, A-1268c, 161Schiffer, J. T. ...................A-1268a, 161Schilcher, G. ....................K-562a, 074Schmeling, D. O. ................ V-1242a, 160Schneider, B. ................... F-1540b, 177Schuch, R. ..................... F-1540b, 177Schuerman, L. ..................G-1054a, 114Schymkowitz, J. ................. F-1495a, 175Seguin, A. ......................K-562b, 074Sengeløv, H. .................... T-369a, 029Senn, M. M. ..................C1-1747a, 197Seppã, I. .......................G-1054a, 114Serrano-Villar, S. ................H-1570b, 179Severson, W. .................... V-400e, 030Shaefer, M. S. ...................H-556c, 073Shamoo, Y. ...................C1-1351b, 166Shen, G. ......................H-1921a, 238Sherwood, R. ................... B-1308a, 164Shi, L. ........................ V-1080a, 117Shurtleff, A. C. .................. F-828a, 097Sifakis, F. ...................... V-1242a, 160Sifri, C. .......................C2-097b, 008Silva-Sánchez, J. ................C2-097a, 008Silverio, A. .....................G-1054b, 114Silverman, M. S. .................H-886a, 102Simon, F. ....................... T-369b, 029Singh, N. P. .....................D-776a, 092Singh, N. ...................... T-1072a, 116Singh, P. ....................... P-1023a, 112Singleton, S. F.. . . . . . . . . . . . . . . . . . F-2072b, 249Sischo, W. .....................C2-121a, 009Skov, R. .......................D-1461a, 172Skowronski, D. M. ...............G-876b, 101Skowronski, D. M. ...............V-400d, 030Sliman, J. A.. . . . . . . . . . . . . . . . . . . . V-1242a, 160Small, C. B. .....................H-556c, 073Smith, G. R. ................... F-2072b, 249Soininen, A. ....................G-1054a, 114Solomkin, J. ................... L1-1647a, 186Sosa, M. I. ...................... V-400e, 030Spagnuolo, P. ................... V-1080a, 117Spanogiannopoulos, P. ............ F-2015a, 246Spire, B. .......................H-1570f, 179Stobernack, H. ......A-1268b, 161, A-1268c, 161Stogios, P. J. .................... F-2015a, 246Stoianoff, M. A.. . . . . . . . . . . . . . . . . . F-823a, 096Sturino, C. ......................H-556a, 073Sumer, S. ....................... B-060c, 005Sumerkan, B. ..................C2-1905a, 236Sung, H. .....................C2-1401b, 169Sutcliffe, J. .................... L1-1647a, 186Suthar, N. .....................C2-121a, 009Sutton, L. D. .................... F-858a, 099Suzan-Monti, M. ...............H-1570f, 179Symonds, B. ....................H-1921a, 238TTakeda, K. .......................V-400f, 030Tamayo, E. .....................C2-097a, 008Tamburro, A. ....................D-731c, 090Taneja, N. .....................C2-121b, 009Tarasi, A. .......................D-731c, 090Tasse, J. .......................D-1461a, 172Tavio, M. M. ...................C1-683a, 086Teperman, L. ................... T-1046b, 113Terzi, N. .......................K-562b, 074Theis, J. G. ....................A-1268c, 161Theodoridou Papagrigoriou, M. . . . G3-1563a, 178Theriault, M. ....................K-562c, 074Thomas, W. .................... V-1242a, 160Thoms-Rodriguez, C. A. ...........D-776c, 092Tillekeratne, L. G. ..............L2-2118b, 255Timmler, B. ....................A-1268a, 161Todorovic, N. ................... F-2015a, 246Toomey, J. ..................... B-1338a, 165Torre Cisneros, J. ................ T-1072a, 116Toth, M. ......................C1-673a, 085Touveneau, S. ...................K-562c, 074Townsend, M. ...................V-400b, 030Tran, T. T. ....................C1-1351b, 166Tremblay, S. .....................H-556a, 073Tsukrov, D. I. ...................H-1570e, 179Tsukrov, D. ....................H-1570d, 179Turkan, H. ..................... L1-300a, 026342September 9-12 |

LATE-BREAKER AUTHOR INDEXAuthor Presentation Number Author Presentation Number Author Presentation NumberUUdeani, G. ..................... L1-300c, 026Ullmann, A. ....................A-1946a, 240Ultsch, M. .......................V-400f, 030Ural, O. ........................ B-060c, 005VVakulenko, S. B. ................C1-673a, 085Valderas, M. .................... B-1308a, 164Valentin, T. .....................K-562a, 074Valette, X. ......................K-562b, 074Valle-Garay, E. .................. B-060a, 005Van Der Reijden, T. .............C2-1905a, 236Van Eldere, J. ................... F-1495a, 175Vazquez-Laslop, N. .............. F-1518a, 176Verma, G. .....................C2-121b, 009Vesikari, T. .....................G-1054a, 114Viard, J. .......................H-1570f, 179Vogel, I. ....................... F-1495a, 175Voorhees, K. J. ...................D-731b, 090Vosbeek, A. ..................... F-858a, 099WWagner, J. ......................K-562a, 074Wald, A. ......................A-1268a, 161Walder, B. ......................K-562c, 074Walkty, A. J. ..................... E-804a, 094Wall, D. ......................C1-1973a, 242Wallis, R. S. ....................A-1268d, 161Walmsley, S. ....................H-556b, 073Walpole, S. ................... L1-1647a, 186Wanjiku, M. ..................L2-2118b, 255Ward, B. J. ......................G-876b, 101Warren, T. K. .................... F-828a, 097Waskin, H. ....................A-1946a, 240Weber, J. ......................H-1582a, 180Weinberg, A. ....................B-060b, 005Weinstock, G. M. ..............C1-1351b, 166Welch, L. ....................... F-828a, 097Wells, J. ........................ F-828a, 097White, E. ....................... V-400e, 030Willey, B. M. ....................D-776c, 092Williams, D. ...... H-1570d, 179, H-1570e, 179,...........................K-2084a, 251Wiskirchen, D. E. ................A-022a, 003Wittekind, M. .................. F-1540b, 177Wohl, D. .......................H-556c, 073Wright, G. D. .................. F-2015a, 246Wynne, B. ......................H-556b, 073XXiao, Y. ......................C1-1973a, 242Xu, X. G. .....................C2-1401a, 169Xu, Y. ......................... V-1080a, 117YYamamoto, B. .................. B-1338a, 165Yamane, N. .................... F-2056b, 248Yanagihara, K. .................. F-2056a, 248Yeh, A. ........................C2-097b, 008Yildirim, I. .....................G-1054b, 114Yu, S. .......................... F-858a, 099ZZain, J. ........................ T-1046b, 113Zainab, S. ..................... T-1046a, 113Zhanel, G. G. ................... E-804a, 094Zhang, M. ..................... V-1080a, 117Zhao, H. .......................H-556c, 073Zhu, D. M. ...................C2-1401a, 169Zhu, T. ........................A-1268d, 161Zimmermann, H. . . . A-1268b, 161, A-1268c, 161Zingg, W. ......................K-562c, 074Zolla-Pazner, S. .....H-1570d, 179, H-1570e, 179Zollner-Schwetz, I. ...............K-562a, 074Zucman, D. ....................H-1570f, 179Zurawski, D. V. ................. F-1495b, 175Final Program343

NOTES344September 9-12 |

LATE-BREAKER KEYWORD INDEX22-aminophenol . ..................... F-823aAaac(6’)-aph(2’’) ......................C1-673aabacavir, H-556cAbacavir/Lamivudine ................ H-556bABSSSI ..........................L1-1667aAcinetobacter baumannii ......C2-1905a, F-1495bacute otitis media ................... G-1054aadenovirus ..........................T-369badult respiratory distress syndrome ...... P-1023aAfrican green monkey ................B-1308aaggregation ........................ F-1495aalcohol ............................ K-2084aaminoglycosides .....L2-2118a, F-2015a, C1-673aAmpC ............................ D-776aamphotericin B ..................... F-2015bAnnexin A2 ......................... B-060canthrax ............................B-1338aantianaerobic activity ................. F-2056aantibacterial activity .................. F-1495aantibacterial mode of action ........... F-1540cantibiotic ......................... L1-1667cantibiotic resistance . . .F-2072b, C1-673a, F-2015aantibiotic TA ......................C1-1973aantibiotic .........................L1-1667bantibody ............................ V-400fantifungal ........................... F-823aantimicrobial .......................F-1540bantimicrobial therapy ................. G-876aantiretroviral therapy , H-1570eantiviral ...........A-1268b, A-1268c, H-1921aantiviral treatment ...................A-1268aanti-virals .......................... V-1080aaspiration pneumonia ................F-2056batomic force microscopy .............. F-1540cAVI-7288 .......................... F-828aBbabesiosis .......................... P-1023abacteremia .........................F-1540bbacterial persistence .................. F-1540abacteriophage amplification .............D-731bbeta-lactam resistance ...............C1-1351abiomarker ..........................H-556cbloodstream infections .................D-776bboronic acid .........................D-776abrain ............................ H-1570dbreast feeding. . . . . . . . . . . . . . . . . . . . . . . . H-886aBrucellosis ..........................B-060cCCAP .............................L1-300aCarbapenemases ....................C2-097aCarbapenem-Resistant Klebsiella pneumoniae...............................C2-097bcatheter ............................K-562acatheter-related bloodstream infection ....K-562ccattle .............................C2-121aCCR5 antagonists ...................H-1582aCD4/CD8 ratio .....................H-1570bceftaroline fosamil .......... L1-1667a, L1-300bcell wall stress stimulon ..............C1-1747acentral catheter infection ...............K-562bcephalosporin ....................... L1-300cchildren ...........................G-1054bchlorexidine .........................K-562bcIAI .............................L1-1647aclass B metallo beta-lactamase ........... F-858aclinical data .......................L1-1667bclinical results ..................... L1-1667cclinical trial ....................... L1-1647aClostridium difficile infection . . . T-1046b, F-1540dCMV .....................A-1268b, A-1268cCMY-2 ...........................C2-121bcoinfection ............... G3-1563a, H-1921acommunity-acquired bacterial pneumonia. . . L1-300bcommunity-acquired pneumonia ........ L1-300ccommunity-associated MRSA ........C2-1401bconjugated vaccines ...................G-876aCRBSI .............................K-562aCryptococcus infections ................. F-823aCTX-M ...........................C2-121aCTX-M-15 ........................C2-121bcUTI ............................L2-2118aCytomegalovirus ..................... T-369aDDaptomycin .......................C1-1351bdeep sequencing .................... H-1582adefensin ............................B-060bdolutegravir .........................H-556bdoripenem ..........................A-022aDS-8587 ..........................F-2056bEE. coli ..............................E-804aefficacy ............................G-1054aFinal Programefflux ..............................D-776cemergence .........................C2-121aenterococcus ....................... T-1046aEnterococcus faecium .................C1-1351bepidemiology ......................G3-1563aEpithelia ...........................B-060bEpstein-Barr virus ................... V-1242aertapenem ..........................A-022aESBL. . . . . . . . . . . . . . . . . . . . . . . D-776a, E-804aextended-spectrum-lactamase .........D-776bFfidelity ............................ F-1518afluoro-quinolone .................... F-2056afluoroquinolone ....................L1-1667bframeshift ......................... F-1518aGgastrointestinal . ....................B-1338aHhand hygiene .......................K-2084aHCV ............... H-1921a, V-400c , V-400fhealthcare-associated infection . . K-562c, L2-2118bhemodialysis ........................K-562aherpes gladiatorum .................G3-1563bherpes simplex virus ..................A-1268ahigh throughput screening ............. F-1540ahigh-throughput compound screening . . . F-2072bHIV ...............H-1570d, H-556a, H-886aHIV coreceptor tropism ..............H-1582aHIV infection ......................H-1570cHIV Infections/immunology . . .H-1570a, H-1582bHIV testing ........................H-1570aHIV therapy ........................H-556aHIV viral load ......................H-1570fHIV/AIDS ........................H-1570ehospital database ....................L1-300bhospitalization .....................L1-1667ahuman alveolar macrophages ...........H-1570cIICU ..............................L1-300aimmunoactivation ...................H-1570bimmunosenescence ..................H-1570binfants ............................ V-1080ainfection control ....................K-2084ainfluenza .......................... V-1080ainfluenza A .........................V-400d345

Late-Breaker KEYWORD INDEXinfluenza vaccine .....................V-400dinnate immunity .....................B-060bintravenous ........................A-1946ainvasive aspergillosis .................F-2015binvasive Pneumococcal disease .........G-1054bKKlebsiella pneumoniae ................. F-2072aKlebsiella pneumoniae MDR .............D-731cLLinezolid ..........................A-1295aLL-37, LL-30, LL-20 ................F-1495bLspA ............................C1-1973aMMALDI-ToF MS bacterial diagnostics . . . D-731bMAO .............................A-1295aMarburg virus ....................... F-828amathematical modeling ...............A-1268aMeasles ........................... G-876bmecA .............................D-1461amecC .............................D-1461amechanism. . . . . . . . . . . . . . . . . . . . . . . . . . V-400cmetallo-ß-lactamases .................. F-858amethicillin resistance ................C1-1747amethicillin-resistant Staphylococcus aureus...................... C2-1401a, L1-300cMIC, Biofilm ......................F-1495bmicroarrays .......................G3-1563aMOA ............................C1-1973amolecular characteristic ..............C2-1401amolecular epidemiology .............. C2-1905amonkeypox .........................V-400bmonoclonal antibody ..................V-400bMS MALDI-ToF ................... D-731cmultidrug-resistant gram-negative ...... F-1540cmultifaceted prevention program .........K-562cmultiple sequencing primers ............V-400amurine model ...................... F-2056aMycobacterium tuberculosis .............A-1268dNnanoparticle ........................F-2015bNDM-1 .................... C2-097a, A-022aNHP .............................B-1338anon-fermentative bacilli. . . . . . . . . . . . . . . . D-731aNVB302 ..........................F-1540dobjective end points . ................ L1-1667cOoption B+ ...........................H-886aosteomyelitis ........................B-060aoutbreak ............................G-876bOXA-48 ..........................C2-097bOXA-like enzymes .................C2-1905aOXA-type ..........................D-731aPpaediatrics ..........................D-776bPanton-Valentine leukocidin ..........C2-1401bpathogenesis ................. B-060a, V-400cPCV13. . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1054bpediatric ............................T-369bpersister inhibitors ................... F-1540apharmacokinetic ....A-1268b, A-1268c, A-1946aPhase-1 ...........................F-1540dPK/PD ...........................A-1268dplague ............................B-1308aplasmid epidemiology ................C2-097bPlazomicin ..........B-1308a, E-804a, L2-2118apneumococcal conjugate vaccine ........G-1054apneumococci ........................G-876aPNU-100480 .......................A-1268dpoint-of-care .......................H-1582bPosaconazole .......................A-1946aPovidone Iodine ......................K-562bproteolytic function ..................H-1570cProvidencia rettgeri ...................C2-097apyrosequencing ......................V-400aQQnrS1 . ...........................C1-683aRradioimmunotherapy ........ H-1570d, H-1570eRecBCD ..........................F-2072bresistance ...................D-776c, C1-683aresistance selection ..................C1-1351arespiratory syncytial virus ..............V-400ereverse-transcriptase ..................H-556arifampin ........................... T-1072aRX-P873 .......................... F-2072aSSalmonella typhi .....................C2-121bscreening ........................... T-369asemen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1570fsepsis ............................. F-1495aseroepidemiology .................... V-1242asexual transmission ..................H-1570fSPM ..............................D-731aSpondylitis ..........................B-060cStaphylococcus aureus .........C1-1747a, D-1461a,...................... F-1540b, C1-1351astem cell transplantation ........T-369b, T-1046aStreptococcus milleri group ..............F-2056bstructure-activity relationship ..........C1-683astructure-function .............F-2015a, V-400fsulfonylpyrrolidine ....................V-400eSwine Influenza ......................V-400dTTedizolid ..........................A-1295atenofovir ...........................H-556ctherapeutic .......................... F-828aTP-434 ..........................L1-1647aTPA polymorphism ...................B-060atranslation ......................... F-1518atransplant .................. T-1072a, T-1046btransplantation ....................... T-369atreatment ..........................T-1046btreatment-nieve ......................H-556btuberculosis ........................ T-1072aTurkey ............................L1-300aTygecycline ........................ T-1046atype-specific real-time PCR ............V-400atyping .............................D-731cUurinary tract infection . ..............L2-2118bVvaccine effectiveness ..................G-876bvalacyclovir .......................G3-1563bVIM-type Metallo-Beta-Lactamase ...... F-858avirus binding ........................V-400bWwrestling . ........................G3-1563b346September 9-12 |

NOTESFinal Program347

NOTES348September 9-12 |

NOTESFinal Program349

NOTES350September 9-12 |

NEW LEVELS OF LEARNING WITHICAAC: The Digital Video LibraryFeatures Over 200 Hours of ICAAC 2012 Presentations◗ Full-motion videos, PDF slides and MP3 audioof many sessions◗ Convenient online and mobile viewing —iPad ® , iPhone ® and Android devices◗ CME credits above what you can earn at theconference◗ Portable DVD-ROM for on-the-go access**DVD-ROM will ship 6 weeks after the meetingSPECIAL DISCOUNTS WITHONSITE PURCHASE!■ South Lobby Virtual Meeting Booth■ Exhibit Hall Booth #1115www.icaac.org/dvl

Save the Date!